

```
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-7772

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 815 GAGAGAGGAGGAGCTGG 830
Db 17 GAGAGCAGAGCTGG 2

RESULT 125
US-09-480-017-8/c
; Sequence 8, Application US/09480017
; Patent No. 6388067
; GENERAL INFORMATION:
; APPLICANT: Yu, Su-May
; APPLICANT: Tong, Wu-Fu
; TITLE OF INVENTION: RICE CYSTEINE PROTEINASE GENE PROMOTER
; FILE REFERENCE: 08919-038001
; CURRENT APPLICATION NUMBER: US/09/480,017
; CURRENT FILING DATE: 2000-01-10
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthesized primer
US-09-480-017-8

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 699 TGGAGAGTGAGCGCGA 714
Db 17 TGGAGGCTGAGGGCGA 2

RESULT 126
US-09-474-432B-478
; Sequence 478, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleotides
; FILE REFERENCE: MEHB00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; CURRENT FILING DATE: 1999-12-19
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 478
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-478

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 92;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 512 CTGCGGGAGGTGGAGC 527
Db 1 CUGCGGGAGCGCAGC 16

RESULT 128
US-09-371-772B-479
; Sequence 479, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MEHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; LENGTH: 17
```

```
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-478

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 92;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 263 CTGCACCTGCCTTCAG 278
Db 1 CUCUCUGCCUUCAG 16

RESULT 127
US-09-474-432B-605
; Sequence 605, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleotides
; FILE REFERENCE: MEHB00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; CURRENT FILING DATE: 1999-12-19
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 605
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-605

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 92;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 512 CTGCGGGAGGTGGAGC 527
Db 1 CUGCGGGAGCGCAGC 16

RESULT 128
US-09-371-772B-479
; Sequence 479, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MEHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; LENGTH: 17
```

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1934:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-1934

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 92;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 875 AACCATCAAGCA 890
Db 1 AACUACCUAAGCA 16

RESULT 123
US-08-584-040-7615
Sequence 7615, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
TITLE OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974

FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 7615:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-7615
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 92;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 875 AACCATCAAGCA 890
Db 1 AACUACCUAAGCA 16

RESULT 124
US-08-584-040-7772/c
Sequence 7772, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
TITLE OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 7772:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs

RESULT 120

US-09-071-845-1868
 ; Sequence 1868, Application US/09071845
 ; Patent No. 6132967
 ; GENERAL INFORMATION:
 ; APPLICANT: Susan Grimm
 ; APPLICANT: Dan T. Stinchcomb
 ; APPLICANT: James McSwiggen
 ; APPLICANT: Sean Sullivan
 ; APPLICANT: Kenneth G. Draper
 ; TITLE OF INVENTION: RIBOZYME TREATMENT OF
 ; TITLE OF INVENTION: DISEASES OR CONDITIONS
 ; TITLE OF INVENTION: RELATED TO LEVELS OF
 ; TITLE OF INVENTION: INTRACELLULAR ADHESION
 ; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
 ; NUMBER OF SEQUENCES: 2390
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Lyon & Lyon
 ; STREET: 633 West Fifth Street
 ; STREET: Suite 4700
 ; CITY: Los Angeles
 ; STATE: California
 ; COUNTRY: U.S.A.
 ; ZIP: 90071-2066

COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 MEDIUM TYPE: storage
 COMPUTER: IBM Compatible
 OPERATING SYSTEM: IBM P.C. DOS 5.0
 SOFTWARE: Word Perfect 5.1
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/071,845
 FILING DATE:
 CLASSIFICATION:
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US/08/292,620
 FILING DATE: August 17, 1994
 APPLICATION NUMBER: 08/008,895
 FILING DATE: January 19, 1993
 APPLICATION NUMBER: 07/989,849
 FILING DATE: December 7, 1992
 ATTORNEY/AGENT INFORMATION:
 NAME: Warburg, Richard J.
 REGISTRATION NUMBER: 32,327
 REFERENCE/DOCKET NUMBER: 208/149
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (213) 489-1600
 TELEFAX: (213) 955-0440
 TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 1868:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 17 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 US-09-071-845-1868

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 75.0%; Pred. No. 92;
 Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 461 GAGAGACTCGGCTGG 476
 ||||| :|||:
 Db 1 GAGAACCCGCGCCUGG 16

RESULT 121

US-08-881-450A-6
 ; Sequence 6, Application US/08881450A
 ; Patent No. 6274310
 ; GENERAL INFORMATION:

APPLICANT: Habener, J.F. and Scoffers, D.A.
 TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DETECTING
 TITLE OF INVENTION: PANCREATIC DISEASE
 NUMBER OF SEQUENCES: 24
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Banner & Witcoff, Inc.
 STREET: One Financial Center
 CITY: Boston
 STATE: Massachusetts
 COUNTRY: USA
 ZIP: 02111
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: WordPerfect 6.1
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/881,450A
 FILING DATE: June 24, 1997
 CLASSIFICATION: 435
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER:
 FILING DATE:
 ATTORNEY/AGENT INFORMATION:
 NAME: Kathleen M. Williams
 REGISTRATION NUMBER: 34,380
 REFERENCE/DOCKET NUMBER: 11275/7823
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 617-345-9100
 TELEFAX: 617-345-9111
 INFORMATION FOR SEQ ID NO: 6:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 17 nucleotides
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: other nucleic acid
 FEATURE:
 NAME/KEY: primer S17b
 US-08-881-450A-6

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 92;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 680 AGCGAGCAGCGCGGC 695
 ||||| :|||:
 Db 1 AGCGAGCAGCGGAGGC 16

RESULT 122

US-08-584-040-1934
 ; Sequence 1934, Application US/08584040
 ; Patent No. 6346398

GENERAL INFORMATION:
 APPLICANT: Pavco, Pamela
 APPLICANT: McSwiggen, James
 APPLICANT: Stinchcomb, Dan T.
 APPLICANT: Escobedo, Jaime
 TITLE OF INVENTION: METHOD AND REAGENT FOR THE
 TITLE OF INVENTION: TREATMENT OF DISEASES OR
 TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
 TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
 TITLE OF INVENTION: GROWTH FACTOR
 NUMBER OF SEQUENCES: 8502
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Lyon & Lyon
 STREET: 633 West Fifth Street
 STREET: Suite 4700
 CITY: Los Angeles
 STATE: California
 COUNTRY: U.S.A.
 ZIP: 90071-2066

SEQUENCE CHARACTERISTICS:
 LENGTH: 17 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 US-09-071-845-1790

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 75.0%; Pred. No. 92;
 Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 461 GAGAGACTCGGCTGG 476
 ||||| :|||||:
 Db 1 GAGAACCCGCGCCUGG 16

RESULT 118
 US-09-071-845-1801
 ; Sequence 1801, Application US/09071845
 ; Patent No. 6132967
 ; GENERAL INFORMATION:
 ; APPLICANT: Susan Grimm
 ; APPLICANT: Dan T. Stinchcomb
 ; APPLICANT: James McSwiggen
 ; APPLICANT: Sean Sullivan
 ; APPLICANT: Kenneth G. Draper
 ; TITLE OF INVENTION: RIBOZYME TREATMENT OF
 ; TITLE OF INVENTION: DISEASES OR CONDITIONS
 ; TITLE OF INVENTION: RELATED TO LEVELS OF
 ; TITLE OF INVENTION: INTRACELLULAR ADHESION
 ; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
 ; NUMBER OF SEQUENCES: 2390
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Lyon & Lyon
 ; STREET: 633 West Fifth Street
 ; STREET: Suite 4700
 ; CITY: Los Angeles
 ; STATE: California
 ; COUNTRY: U.S.A.
 ; ZIP: 90071-2066
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 ; MEDIUM TYPE: storage
 ; COMPUTER: IBM Compatible
 ; OPERATING SYSTEM: IBM P.C. DOS 5.0
 ; SOFTWARE: Word Perfect 5.1
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/09/071.845
 ; FILING DATE:
 ; CLASSIFICATION:
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/292.620
 ; FILING DATE: August 17, 1994
 ; APPLICATION NUMBER: 08/008.895
 ; FILING DATE: January 19, 1993
 ; APPLICATION NUMBER: 07/989.849
 ; FILING DATE: December 7, 1992
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Warburg, Richard J.
 ; REGISTRATION NUMBER: 32,327
 ; REFERENCE/DOCKET NUMBER: 208/149
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (213) 489-1600
 ; TELEFAX: (213) 955-0440
 ; TELEX: 67-3510
 ; INFORMATION FOR SEQ ID NO: 1801:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 17 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; US-09-071-845-1801

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 75.0%; Pred. No. 92;
 Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
 Qy 461 GAGAGACTCGGCTGG 476
 ||||| :|||||:
 Db 1 GAGAACCCGCGCCUGG 16

RESULT 119
 US-09-071-845-1823
 ; Sequence 1823, Application US/09071845
 ; Patent No. 6132967
 ; GENERAL INFORMATION:
 ; APPLICANT: Susan Grimm
 ; APPLICANT: Dan T. Stinchcomb
 ; APPLICANT: James McSwiggen
 ; APPLICANT: Sean Sullivan
 ; APPLICANT: Kenneth G. Draper
 ; TITLE OF INVENTION: RIBOZYME TREATMENT OF
 ; TITLE OF INVENTION: DISEASES OR CONDITIONS
 ; TITLE OF INVENTION: RELATED TO LEVELS OF
 ; TITLE OF INVENTION: INTRACELLULAR ADHESION
 ; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
 ; NUMBER OF SEQUENCES: 2390
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Lyon & Lyon
 ; STREET: 633 West Fifth Street
 ; STREET: Suite 4700
 ; CITY: Los Angeles
 ; STATE: California
 ; COUNTRY: U.S.A.
 ; ZIP: 90071-2066
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 ; MEDIUM TYPE: storage
 ; COMPUTER: IBM Compatible
 ; OPERATING SYSTEM: IBM P.C. DOS 5.0
 ; SOFTWARE: Word Perfect 5.1
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/09/071.845
 ; FILING DATE:
 ; CLASSIFICATION:
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/292.620
 ; FILING DATE: August 17, 1994
 ; APPLICATION NUMBER: 08/008.895
 ; FILING DATE: January 19, 1993
 ; APPLICATION NUMBER: 07/989.849
 ; FILING DATE: December 7, 1992
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Warburg, Richard J.
 ; REGISTRATION NUMBER: 32,327
 ; REFERENCE/DOCKET NUMBER: 208/149
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (213) 489-1600
 ; TELEFAX: (213) 955-0440
 ; TELEX: 67-3510
 ; INFORMATION FOR SEQ ID NO: 1823:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 17 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; US-09-071-845-1823

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 75.0%; Pred. No. 92;
 Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
 Qy 461 GAGAGACTCGGCTGG 476
 ||||| :|||||:
 Db 1 GAGAACCCGCGCCUGG 16

```
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1868:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-292-620A-1868

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 92;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 461 GAGAGACTCGGCTGG 476
Db 1 GAGAACCCGCGCCUGG 16

RESULT 116
US-09-071-845-1639
; Sequence 1639, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1790:

two

; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1639:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-071-845-1639

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 92;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 461 GAGAGACTCGGCTGG 476
Db 1 GAGAACCCGCGCCUGG 16

RESULT 117
US-09-071-845-1790
; Sequence 1790, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1790:
```

```

COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
PRIOR APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1801:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-292-620A-1801

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 92;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 461 GAGAGACTCGGCTGG 476
||| |:|||:|
1 GAGAACCTCGGCCUGG 16

DB

RESULT 114
US-08-292-620A-1823
; Sequence 1823, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOSOME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0

```

APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435

PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1639:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-292-620A-1639

two

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 92;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 461 GAGAGACTCGGCTGG 476
Db 1 GAGAACCCGCGCCUGG 16

RESULT 112

US-08-292-620A-1790
Sequence 1790, Application US/08292620A
Patent No. 5837542
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)

NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1790:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-292-620A-1790

two

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 92;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 461 GAGAGACTCGGCTGG 476
Db 1 GAGAACCCGCGCCUGG 16

RESULT 113

US-08-292-620A-1801
Sequence 1801, Application US/08292620A
Patent No. 5837542
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California

Matches	11	Conservative	3	Mismatches	2	Indels	0	Gaps	0
---------	----	--------------	---	------------	---	--------	---	------	---

Qy 843 TGGCCTATCACCAGCT 858
:|:|:|:|:|:|:
pb 2 UGGCCUGCCACCAGCU 17

```

RESULT 109
US-08-373-124A-176/c
; Sequence 176, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071

```

```

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14: Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

Qy 405 AGAGGGAGGAGAAGGA 420
||| ||| ||| ||| |||
Db 17 AGAAGGAGGAGGAGGA 2

RESULT 110
US-08-435-628-176/c

Sequence 176, Application US/08435628
Patent No. 5817796
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITILE OF INVENTION: TREATMENT OF RESTENOSIS AND
TITILE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,628
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/373,124
FILING DATE: January 13, 1995
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 176:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-628-176

```
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14: Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

Qy 405 AGAGGAGGAGGA 420
||| ||||| |||||
Db 17 AGAAGGAGGAGGA 2

RESULT 111
US-08-292-620A-1639
; Sequence 1639, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen

```
Db      13 CACCAGCTCTCC 1
|||||
RESULT 106
US-09-572-891-18/c
; Sequence 18, Application US/09572891
; Patent No. 6566064
; GENERAL INFORMATION:
; APPLICANT: SHIRAKI, MASATAKA
; APPLICANT: OUCHI, YASUYOSHI
; APPLICANT: HOSOI, TAKAYUKI
; APPLICANT: KUSABA, NOBUTAKA
; APPLICANT: BABA, TOSHIKI
; APPLICANT: YOSHIDA, HIROSHI
; TITLE OF INVENTION: METHOD FOR ANTICIPATING SENSITIVITY TO MEDICINE FOR
; FILE REFERENCE: NISS-051
; CURRENT APPLICATION NUMBER: US/09/572,891
; CURRENT FILING DATE: 2000-05-18
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 18
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Located on the 19th chromosome; a part of the base sequence
US-09-572-891-18

Query Match      1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 84;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

US-09-572-891-18
373 CTGCAGGAGCTTCTG 388
|||||
Db      16 CTGCCAGGCGCTCTG 1

RESULT 107
US-09-155-885A-242/c
; Sequence 242, Application US/09155885A
; Patent No. 6709812
; GENERAL INFORMATION:
; APPLICANT: STUYVER, LIEVEN
; APPLICANT: ROSSAU, RUDI
; APPLICANT: MAERTENS, GEERT
; TITLE OF INVENTION: METHOD FOR TYPING AND DETECTING HBV
; NUMBER OF SEQUENCES: 313
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NIXON & VANDERHYE P.C.
; STREET: 1100 NORTH GLEBE ROAD
; CITY: ARLINGTON
; STATE: VIRGINIA
; COUNTRY: U.S.A.
; ZIP: 22201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/155,885A
; FILING DATE: 08-Oct-1998
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/EP97/02002
; FILING DATE: 21-APR-1997
; APPLICATION NUMBER: EP 96870053.4
; FILING DATE: 19-APR-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: SADOFF, B.J.

Db      13 CACCAGCTCTCC 1
|||||
RESULT 108
US-08-435-350-44
; Sequence 44, Application US/08435350
; Patent No. 5599704
; GENERAL INFORMATION:
; APPLICANT: James D. Thompson
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: TREATMENT OF BREAST CANCER
; NUMBER OF SEQUENCES: 118
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 611 West Sixth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,350
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/936,531
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 197/245
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 44:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-350-44

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 92;
```

```

/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/435,628
/ FILING DATE: 05-MAY-1995
/ CLASSIFICATION: 514
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/373,124
/ FILING DATE: January 13, 1995
/ APPLICATION NUMBER: 08/245,466
/ FILING DATE: May 18, 1994
/ APPLICATION NUMBER: 08/192,943
/ FILING DATE: February 7, 1994
/ APPLICATION NUMBER: 07/987,132
/ FILING DATE: December 7, 1992
/ APPLICATION NUMBER: 07/936,422
/ FILING DATE: August 26, 1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 209/035
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 182:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-435-628-182

```

```

Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 85;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 409 GGAGGAGAGGAG 421
Db 15 GGAGGAGAGGAG 3

```

```

RESULT 104
US-09-866-108A-7242
/ Sequence 7242, Application US/09866108A
/ Patent No. 6686188
/ GENERAL INFORMATION:
/ APPLICANT: GU, Yizhong
/ APPLICANT: JI, Yonggang
/ APPLICANT: PENN, Sharron G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
/ FILE REFERENCE: AEOMICA-7
/ CURRENT APPLICATION NUMBER: US/09/866,108A
/ CURRENT FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668

```

```

/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00663
/ PRIOR FILING DATE: 2001-01-30
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 15755
/ SOFTWARE: Aecomica Sequence Listing Engine
/ Patent No. 6686188
/ SEQ ID NO 7242
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
/ US-09-866-108A-7242

```

```

Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 85;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 697 GCTGGAGAGTGAG 709
Db 5 GCTGGAGAGTGAG 17

```

```

RESULT 105
US-09-866-108A-8974/c
/ Sequence 8974, Application US/09866108A
/ Patent No. 6686188
/ GENERAL INFORMATION:
/ APPLICANT: GU, Yizhong
/ APPLICANT: JI, Yonggang
/ APPLICANT: PENN, Sharron G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
/ FILE REFERENCE: AEOMICA-7
/ CURRENT APPLICATION NUMBER: US/09/866,108A
/ CURRENT FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00663
/ PRIOR FILING DATE: 2001-01-30
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 15755
/ SOFTWARE: Aecomica Sequence Listing Engine
/ Patent No. 6686188
/ SEQ ID NO 8974
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
/ US-09-866-108A-8974

```

```

Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 85;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 851 CACGAGCTCTCC 863

```



```

; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.
; ZIP: 90071
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 182:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
; US-08-373-124A-182

```

```

Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 85;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 409 GGAGGAGAGGAG 421
Db 15 GGAGGAGAGGAG 3

```

```

RESULT 102
US-08-628-180/c
; Sequence 180, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.
; ZIP: 90071

```

```

; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 180:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
; US-08-435-628-180

```

```

Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 85;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 409 GGAGGAGAGGAG 421
Db 16 GGAGGAGAGGAG 4

```

```

RESULT 103
US-08-435-628-182/c
; Sequence 182, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.
; ZIP: 90071
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1

```

```
US-09-685-664B-3805/c
; Sequence 3805, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MH800-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3805
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-09-685-664B-3805

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 73;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 696 AGCTGGAGAGTGAGC 710
Db 16 AGCTGGAGAGTGAGC 2

RESULT 99
US-09-811-286-11
; Sequence 11, Application US/09811286
; Patent No. 6586183
; GENERAL INFORMATION:
; APPLICANT: Drysdale, Connie M
; APPLICANT: Judson, Richard S
; APPLICANT: Liggett, Stephen B
; APPLICANT: Nandabalan, Krishnan
; APPLICANT: Stack, Catherine B
; APPLICANT: Stephens, J. Claiborne
; TITLE OF INVENTION: Association of beta2-adrenergic receptor haplotypes
; TITLE OF INVENTION: with drug response
; FILE REFERENCE: MWH-0303US1
; CURRENT APPLICATION NUMBER: US/09/811,286
; CURRENT FILING DATE: 2001-03-16
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-811-286-11

Query Match 1.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 70;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 196 CAGTGGTGCCCG 208
Db 3 CAGTGGTGCCCG 15

RESULT 100
US-08-373-124A-180/c
; Sequence 180, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 180:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-373-124A-180

Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 85;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 409 GGAGGAGAGGAG 421
Db 16 GGAGGAGAGGAG 4

RESULT 101
US-08-373-124A-182/c
; Sequence 182, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
```

```
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8419
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-8419

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 73;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 489 TGAAGAGCGCAGAGG 503
Db 3 TGAAGAGCGCAGAGG 17

RESULT 96
US-09-866-108A-8420
; Sequence 8420, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8419
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-8419

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 73;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 489 TGAAGAGCGCAGAGG 503
Db 3 TGAAGAGCGCAGAGG 17
```

```
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8420
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-8420

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 73;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 489 TGAAGAGCGCAGAGG 503
Db 2 TGAAGAGCGCAGAGG 16

RESULT 97
US-09-866-108A-8969/c
; Sequence 8969, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8969
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-8969

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 73;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 852 ACCAGCTCTTCCAAG 866
Db 17 ACCAGCTCTTCCATG 3

RESULT 98
```

; Patent No. 6686188
; SEQ ID NO 7248
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7248

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 73;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 699 TGGAGAGTGCAGCGG 713
|||||
Db 1 TGGAGAGTGCAGCGG 15

RESULT 93

US-09-866-108A-7448
; Sequence 7448, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.

; SOFTWARE: Aecomica Sequence Listing Engine
; NUMBER OF SEQ ID NOS: 15755
; Patent No. 6686188
; SEQ ID NO 7448
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7448

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 73;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 412 GGAGAGGAGTTCCT 426
|||||
Db 3 GGAGAGGAGTTCCT 17

RESULT 94

US-09-866-108A-7452

; Sequence 7452, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.

; SOFTWARE: Aecomica Sequence Listing Engine
; NUMBER OF SEQ ID NOS: 15755
; Patent No. 6686188
; SEQ ID NO 7452
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7452

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 73;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 414 AGAAGGAGTTCCTCA 428
|||||
Db 1 AGAAGGAGTTCCTCA 15

RESULT 95

US-09-866-108A-8419
; Sequence 8419, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 73;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

RESULT 94

US-09-866-108A-7452

; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6824
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6824

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 73;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 266 CACCTGCCTTCAGAA 280
Db 16 CACCTGCCTTCAGAA 2

RESULT 91
US-09-866-108A-6825/C
; Sequence 6825, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6824
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6824

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 73;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 266 CACCTGCCTTCAGAA 280
Db 16 CACCTGCCTTCAGAA 2

RESULT 92
US-09-866-108A-7248
; Sequence 7248, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine

REFERENCE/DOCKET NUMBER: 218/064
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 8022:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-8022

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 73;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 696 AGCTGAGAGTGAGC 710
DB 16 AGCTGAGAGGAGC 2

RESULT 87
US-09-474-432B-657/c
Sequence 657, Application US/09474432B
Patent No. 6528640
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Beigelman, Leo
APPLICANT: Burgin, Alex
APPLICANT: Beaudry, Amber
APPLICANT: Karpeisky, Alex
APPLICANT: Adamic, Jasenka
APPLICANT: Sweedler, David
APPLICANT: Zinnen, Shawn
TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleotides
FILE REFERENCE: MEH800-831-B (247/276)
CURRENT APPLICATION NUMBER: US/09/474,432B
CURRENT FILING DATE: 1999-12-19
PRIOR APPLICATION NUMBER: US 60/064,866
PRIOR FILING DATE: 1997-11-05
PRIOR APPLICATION NUMBER: US 60/084,727
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: US 09/186,675
PRIOR FILING DATE: 1998-11-04
PRIOR APPLICATION NUMBER: US 09/301,511
PRIOR FILING DATE: 1999-04-28
NUMBER OF SEQ ID NOS: 1526
SOFTWARE: PatentIn version 3.0
SEQ ID NO 657
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-474-432B-657

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 73;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 642 AGGAATGCCAGGCTC 656
DB 16 AGAATGCCAGGCTC 2

RESULT 88
US-09-371-772B-3805/c
Sequence 3805, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggan, Jim
APPLICANT: Stinchcomb, Dan

APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 8022:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-8022

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 73;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 696 AGCTGAGAGTGAGC 710
DB 16 AGCTGAGAGGAGC 2

RESULT 89
US-09-476-387-656/c
Sequence 656, Application US/09476387
Patent No. 6617438
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Beigelman, Leo
APPLICANT: Beaudry, Amber
APPLICANT: Karpeisky, Alex
APPLICANT: Adamic, Jasenka Matulic
APPLICANT: Sweedler, Dave
APPLICANT: Zinnen, Shawn
TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleotides
FILE REFERENCE: MEH800-831-C (249/073)
CURRENT APPLICATION NUMBER: US/09/476,387
CURRENT FILING DATE: 2001-04-04
PRIOR APPLICATION NUMBER: 09/474,432
PRIOR FILING DATE: 1999-12-29
PRIOR APPLICATION NUMBER: 09/301,511
PRIOR FILING DATE: 1999-04-28
PRIOR APPLICATION NUMBER: 09/186,675
PRIOR FILING DATE: 1998-11-04
PRIOR APPLICATION NUMBER: 60/083,727
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/064,866
PRIOR FILING DATE: 1997-11-05
NUMBER OF SEQ ID NOS: 1524
SOFTWARE: PatentIn version 3.0
SEQ ID NO 656
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-476-387-656

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 73;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 642 AGGAATGCCAGGCTC 656
DB 16 AGAATGCCAGGCTC 2

RESULT 90
US-09-866-108A-6824/c
Sequence 6824, Application US/09866108A

APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOSOME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
CITY: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071,845
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1619:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-1619

Query Match 1.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 80.0%; Pred. No. 66;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 304 GCGCTGCTGGAGGA 318
|||:|||||
Db 1 GCGCUGCCUGGUGGA 15

RESULT 85
US-08-345-264A-1/C
Sequence 1, Application US/08345264A
Patent No. 5660983
GENERAL INFORMATION:
APPLICANT: Charles S. Levings
APPLICANT: Ralph Dewey
TITLE OF INVENTION: STERILITY FACTOR
NUMBER OF SEQUENCES: 4
CORRESPONDENCE ADDRESS:
ADDRESSEE: Jeff Lloyd
STREET: 2421 N.W. 41st Street, Suite A-1
CITY: Gainesville
STATE: FL
COUNTRY: USA
ZIP: 32606

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/345,264A
FILING DATE: 23-NOV-1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Lloyd, Jeff
REGISTRATION NUMBER: 35,589
REFERENCE/DOCKET NUMBER: 08/345,264
TELEPHONE: 352-375-8100
TELEFAX: 352-372-5800
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-345-264A-1

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 73;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 754 GCGCATGCAGGGCCA 768
|||:|||||
Db 17 GCTCATGCAGGGCCA 3

RESULT 86
US-08-584-040-8022/c
Sequence 8022, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
TITLE OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327

/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: FastSEQ Version 1.5
/ CURRENT APPLICATION DATA: US/09/038,073
/ APPLICATION NUMBER: 09/038,073
/ FILING DATE:
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 09/585,684
/ FILING DATE:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 218/078
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 821:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-09-038-073-821

Query Match 1.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 59;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 579 CCCAGGTGAGTCCT 593
Db 15 CCCAGGTGAGTCCT 1

RESULT 82
US-09-275-850-18
/ Sequence 18, Application US/09275850A
/ Patent No. 6261774
/ GENERAL INFORMATION:
/ APPLICANT: Pagratis, Nikos
/ APPLICANT: Gold, Larry
/ APPLICANT: Shtatland, Timur
/ APPLICANT: Javornik, Brenda
/ TITLE OF INVENTION: Truncation SELEX Method
/ FILE REFERENCE: NEX 79
/ CURRENT APPLICATION NUMBER: US/09/275,850A
/ CURRENT FILING DATE: 1999-03-24
/ NUMBER OF SEQ ID NOS: 351
/ SOFTWARE: PatentIn Ver. 2.0
/ SEQ ID NO 18
/ LENGTH: 15
/ TYPE: RNA
/ ORGANISM: E. coli
/ US-09-275-850-18

Query Match 1.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 59;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 720 TGCAGCAGCAGCACA 734
Db 1 UGCAGCAGCAGCACA 15

RESULT 83
US-08-292-620A-1619

/ Sequence 1619, Application US/08292620A
/ Patent No. 5837542
/ GENERAL INFORMATION:
/ APPLICANT: Susan Grimm
/ APPLICANT: Dan T. Stinchcomb
/ APPLICANT: James McSwiggen
/ APPLICANT: Sean Sullivan
/ APPLICANT: Kenneth G. Draper
/ TITLE OF INVENTION: RIBOZYME TREATMENT OF
/ DISEASES OR CONDITIONS
/ TITLE OF INVENTION: RELATED TO LEVELS OF
/ INTRACELLULAR ADHESION
/ TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
/ NUMBER OF SEQUENCES: 2390
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ STREET: Suite 4700
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071-2066
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: Word Perfect 5.1
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/292,620A
/ FILING DATE: August 17, 1994
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ PRIOR APPLICATION DATA: including application
/ PRIOR APPLICATION DATA: described below:
/ APPLICATION NUMBER: 08/008,895
/ FILING DATE: January 19, 1993
/ APPLICATION NUMBER: 07/989,849
/ FILING DATE: December 7, 1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard J.
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 208/149
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 1619:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 16 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-292-620A-1619

Query Match 1.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 80.0%; Pred. No. 66;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 304 GCGCTGCGCTGGAGGA 318
Db 1 GCGCUGCUGGUGGA 15

RESULT 84
US-09-071-845-1619
/ Sequence 1619, Application US/09071845
/ Patent No. 6132967
/ GENERAL INFORMATION:
/ APPLICANT: Susan Grimm
/ APPLICANT: Dan T. Stinchcomb
/ APPLICANT: James McSwiggen
/ APPLICANT: Sean Sullivan


```

; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-347-613C-38

Query Match      1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 69;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      826 GCTGGCCCGAGTTCAGG 842
Db      1 GCTGGCCCGAGTTCAGG 17

RESULT 73
US-09-662-183A-38
; Sequence 38, Application US/09662183A
; Patent No. 6734284
; GENERAL INFORMATION:
; APPLICANT: Johansen, Teit E.
; APPLICANT: Blom, Nikolaj
; APPLICANT: Hansen, Claus
; TITLE OF INVENTION: No. 6734284el Neurotrophic Factors
; FILE REFERENCE: 19313-001 DIV
; CURRENT APPLICATION NUMBER: US/09/662,183A
; CURRENT FILING DATE: 2000-09-14
; PRIOR APPLICATION NUMBER: DANISH 1998 00904
; PRIOR FILING DATE: 1998-07-06
; PRIOR APPLICATION NUMBER: USSN 60/092,229
; PRIOR FILING DATE: 1998-07-09
; PRIOR APPLICATION NUMBER: DANISH 1998 01048
; PRIOR FILING DATE: 1998-08-19
; PRIOR APPLICATION NUMBER: USSN 60/097,774
; PRIOR FILING DATE: 1998-08-25
; PRIOR APPLICATION NUMBER: DANISH 1998 01260
; PRIOR FILING DATE: 1998-10-05
; PRIOR APPLICATION NUMBER: USSN 60/103,908
; PRIOR FILING DATE: 1998-10-13
; PRIOR APPLICATION NUMBER: DANISH 1998 01265
; PRIOR FILING DATE: 1998-10-06
; PRIOR APPLICATION NUMBER: 09/347,613
; PRIOR FILING DATE: 2000-07-02
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 38
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-662-183A-38

Query Match      1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 69;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      826 GCTGGCCCGAGTTCAGG 842
Db      1 GCTGGCCCGAGTTCAGG 17

RESULT 74
US-09-685-664B-3980/c
; Sequence 3980, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related

```

```

; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3980
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Mus musculus
US-09-685-664B-3980

Query Match      1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 69;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      688 GGCGCGCGAGCTGGAGA 704
Db      18 GGCGCGCGAGCTGTAGA 2

RESULT 75
US-09-396-196G-13872/c
; Sequence 13872, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 13872
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-396-196G-13872

Query Match      1.8%; Score 13.8; DB 1; Length 25;
Best Local Similarity 72.0%; Pred. No. 1.1e+02;
Matches 18; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY      823 GAAGCTGGCCCGAGTTCAGGTGCC 847
Db      25 GCAGCTGGCCCGAGTTCAGGTGCC 1

RESULT 76
US-09-142-078-44
; Sequence 44, Application US/09142078
; Patent No. 6172041
; GENERAL INFORMATION:
; APPLICANT: McCabe, R. Tyler
; APPLICANT: Zhou, Li-Ming
; APPLICANT: Layer, Richard T.
; TITLE OF INVENTION: Use of Conantokins
; NUMBER OF SEQUENCES: 71
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Rothwell, Figg, Ernst & Kurz, P.C.
; STREET: 555 Thirteenth Street, N.W., Suite 701-E
; CITY: Washington

```

SEQ ID NO 384
LENGTH: 18
TYPE: DNA
ORGANISM: Homo Sapiens
FEATURE:
NAME/KEY: misc feature
LOCATION: 1..18
OTHER INFORMATION: downstream amplification primer for SEQ 190, SEQ 267, SEQ 191, SE

US-09-218-207-384

Query Match 1.8%; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.2%; Pred. No. 69;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 372 GCTGCGAGGAGCTTCTG 388
DB 2 GCTGAGAGGAGCTTTG 18

RESULT 70

US-08-584-040-8322/c

Sequence 8322, Application US/08584040

Patent No. 6346398

GENERAL INFORMATION:

APPLICANT: Pavco, Pamela

APPLICANT: McSwiggen, James

APPLICANT: Stinchcomb, Dan T.

APPLICANT: Escobedo, Jaime

TITLE OF INVENTION: METHOD AND REAGENT FOR THE

TITLE OF INVENTION: TREATMENT OF DISEASES OR

TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS

TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL

TITLE OF INVENTION: GROWTH FACTOR

NUMBER OF SEQUENCES: 8502

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

STREET: Suite 4700

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071-2066

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/584,040

FILING DATE: January 11, 1996

CLASSIFICATION: 514

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/005,974

FILING DATE: October 26, 1995

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 218/064

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 8322:

SEQUENCE CHARACTERISTICS:

LENGTH: 18 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-584-040-8322

Query Match

Best Local Similarity 1.8%; Score 13.8; DB 1; Length 18;

88.2%; Pred. No. 69;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 688 GCGCGGCGAGCTGGAGA 704
DB 18 GGCCCGGCGAGCTGTAGA 2

RESULT 71

US-09-371-772B-3980/c

Sequence 3980, Application US/09371772B

Patent No. 6586127

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.

APPLICANT: Pavco, Pam

APPLICANT: McSwiggen, Jim

APPLICANT: Stinchcomb, Dan

APPLICANT: Escobedo, Jaime

TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel

TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor

FILE REFERENCE: MHB00.876-J (237/198)

CURRENT APPLICATION NUMBER: US/09/371,772B

CURRENT FILING DATE: 1999-08-10

PRIOR APPLICATION NUMBER: US 60/005,974

PRIOR FILING DATE: 1995-10-26

PRIOR APPLICATION NUMBER: US 08/584,040

PRIOR FILING DATE: 1996-01-08

NUMBER OF SEQ ID NOS: 14225

SOFTWARE: PatentIn version 3.0

SEQ ID NO 3980

LENGTH: 18

TYPE: RNA

ORGANISM: Mus sp.

US-09-371-772B-3980

Query Match

Best Local Similarity 1.8%; Score 13.8; DB 1; Length 18;

88.2%; Pred. No. 69;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 688 GCGCGGCGAGCTGGAGA 704
DB 18 GGCCCGGCGAGCTGTAGA 2

RESULT 72

US-09-347-613C-38

Sequence 38, Application US/09347613C

Patent No. 6593133

GENERAL INFORMATION:

APPLICANT: Johansen, Teit E.

APPLICANT: Blom, Nikolaj

APPLICANT: Hansen, Claus

TITLE OF INVENTION: No. 6593133el Neurotrophic Factors

FILE REFERENCE: Neurosearch 19313-001

CURRENT APPLICATION NUMBER: US/09/347,613C

CURRENT FILING DATE: 1999-07-02

PRIOR APPLICATION NUMBER: DANISH 1998 00904

PRIOR FILING DATE: 1998-07-06

PRIOR APPLICATION NUMBER: USSN 60/092,229

PRIOR FILING DATE: 1998-07-09

PRIOR APPLICATION NUMBER: DANISH 1998 01048

PRIOR FILING DATE: 1998-08-19

PRIOR APPLICATION NUMBER: USSN 60/097,774

PRIOR FILING DATE: 1998-08-25

PRIOR APPLICATION NUMBER: DANISH 1998 01260

PRIOR FILING DATE: 1998-10-05

PRIOR APPLICATION NUMBER: USSN 60/103,908

PRIOR FILING DATE: 1998-10-13

PRIOR APPLICATION NUMBER: DANISH 1998 01265

PRIOR FILING DATE: 1998-10-06

NUMBER OF SEQ ID NOS: 43

SOFTWARE: PatentIn Ver. 2.1

SEQ ID NO 38

LENGTH: 18

```
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/106,038A
; FILING DATE: June 26, 1998
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Laurel Spear Bernstein
; REGISTRATION NUMBER: 37,280
; REFERENCE/DOCKET NUMBER: RTS-0004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (760) 931-9200
; TELEFAX: (760) 603-3820
; INFORMATION FOR SEQ ID NO: 74:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-106-038A-74
```

```
Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 69;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 302 CAGCGCTGCTGGAGGA 318
Db 17 CTGGGCTGCTGGAGGA 1
```

RESULT 66

```
US-09-143-212-57
; Sequence 57, Application US/09/143212B
; Patent No. 6077672
```

GENERAL INFORMATION:

```
; APPLICANT: Brett P. Monia and Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF TRADD EXPRESSION
; FILE REFERENCE: RTS-0005
; CURRENT APPLICATION NUMBER: US/09/143,212B
; CURRENT FILING DATE: 1998-08-28
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 57
```

```
; LENGTH: 18
; TYPE: DNA
```

```
; ORGANISM: Artificial Sequence
```

FEATURE:

```
; OTHER INFORMATION: Antisense Oligonucleotide
```

```
US-09-143-212-57
```

```
Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 69;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 795 AGCGCCAGCGCCCTCG 811
Db 2 AGCGCCCGCAGCCTCG 18
```

RESULT 67

```
US-08-872-917-1/c
```

```
; Sequence 1, Application US/08872917
; Patent No. 6096549
```

GENERAL INFORMATION:

```
; APPLICANT: PELICIC, Vladimir
; APPLICANT: REVRAT, Jean-Marc
; APPLICANT: GICQUEL, Brigitte
; TITLE OF INVENTION: METHOD OF SELECTION OF ALLELIC EXCHANGE MUTANTS
; FILE REFERENCE: 03495-0148-01
; CURRENT APPLICATION NUMBER: US/08/872,917
; CURRENT FILING DATE: 1997-07-11
; EARLIER APPLICATION NUMBER: 08/661,658
; EARLIER FILING DATE: 1996-06-11
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
```

```
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Mycobacterium sp.
US-08-872-917-1
```

```
Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 69;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 810 CGGAGGAGGAGGAGGAG 826
Db 17 CGGAGGAGGAGGAGGAG 1
```

RESULT 68

```
US-09-338-907-384
; Sequence 384, Application US/09338907
; Patent No. 6265546
```

GENERAL INFORMATION:

```
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Ilya, Chumakov
; APPLICANT: Bougueleret, Lydie
; TITLE OF INVENTION: PROSTATE CANCER GENE
; FILE REFERENCE: GENSET.18CF1CP
; CURRENT APPLICATION NUMBER: US/09/338,907
; CURRENT FILING DATE: 1999-06-23
; EARLIER APPLICATION NUMBER: 08/996,306
; EARLIER FILING DATE: 1997-12-22
; EARLIER APPLICATION NUMBER: 60/099,658
; EARLIER FILING DATE: 1998-09-09
; EARLIER APPLICATION NUMBER: 09/218,207
; EARLIER FILING DATE: 1998-12-22
; NUMBER OF SEQ ID NOS: 578
; SOFTWARE: Patent.pm
; SEQ ID NO 384
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; NAME/KEY: misc feature
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer for SEQ 190, SEQ 267, SEQ 191, SE
```

```
US-09-338-907-384
```

```
Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 69;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 372 GCTGCGAGGAGCTTCTG 388
Db 2 GCTGAGAGGAGCTTTTG 18
```

RESULT 69

```
US-09-218-207-384
```

```
; Sequence 384, Application US/09218207
; Patent No. 6346381
```

GENERAL INFORMATION:

```
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Ilya, Chumakov
; APPLICANT: Bougueleret, Lydie
; TITLE OF INVENTION: Prostate cancer gene
; FILE REFERENCE: GENSET.018CP1
; CURRENT APPLICATION NUMBER: US/09/218,207
; CURRENT FILING DATE: 1998-12-22
; EARLIER APPLICATION NUMBER: 08/996,306
; EARLIER FILING DATE: 1997-12-22
; EARLIER APPLICATION NUMBER: 60/099,658
; EARLIER FILING DATE: 1998-09-09
; NUMBER OF SEQ ID NOS: 578
; SOFTWARE: Patent.pm
```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8422
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8422

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 490 GAAGAGCGACAGGAGC 506
Db 1 GAAGAGCGACAGGTGC 17

RESULT 63
US-09-685-664B-2829/c
; Sequence 2829. Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Strinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Endothelial Growth Factor Receptor
; FILE REFERENCE: MEHB00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 2829
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-09-685-664B-2829

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 457 GGTGAGAGACTCGGCC 473
Db 17 GGTAGACAGACTCGGCC 1

RESULT 64
US-08-470-124-56/c
; Sequence 56. Application US/08470124
; Patent No. 5849481
; GENERAL INFORMATION:
```

```
; APPLICANT: Urdea, Michael S.
; APPLICANT: Horn, Thomas
; APPLICANT: Chang, Chu-An
; APPLICANT: Warner, Brian
; APPLICANT: Fultz, Timothy J.
; TITLE OF INVENTION: LARGE COMB-TYPE BRANCHED POLYNUCLEOTIDES
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Morrison & Foerster
; STREET: 545 Middlefield Road, Suite 200
; CITY: Menlo Park
; STATE: California
; COUNTRY: USA
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/470,124
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/813,588
; FILING DATE: 23 December 1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Clotti, Thomas E.
; REGISTRATION NUMBER: 21,013
; REFERENCE/DOCKET NUMBER: 22300-20104.20
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-813-5600
; TELEFAX: 415-327-2951
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 56:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-470-124-56

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 69;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 867 AATACGACAACCAATC 883
Db 17 AGTAGACAACCAATC 1

RESULT 65
US-09-106-038A-74/c
; Sequence 74. Application US/09106038A
; Patent No. 6007995
; GENERAL INFORMATION:
; APPLICANT: Brenda F. Baker and Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF TNFRI
; NUMBER OF SEQUENCES: 91
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Isis Pharmaceuticals, Inc.
; STREET: 2292 Faraday Avenue
; CITY: Carlsbad
; STATE: CA
; COUNTRY: U.S.A.
; ZIP: 92008
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: Windows NT
; SOFTWARE: Microsoft Word 97
```

US-09-866-108A-7698

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 827 CTGGCCCGAGTGCAGGT 843
Db 17 CTGGCCCGAGTGCAGGT 1

RESULT 60

US-09-866-108A-7813

; Sequence 7813, Application US/09866108A

; Patent No. 6686188

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108A

; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663

; PRIOR FILING DATE: 2001-01-30

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755

; SOFTWARE: Aeomica Sequence Listing Engine

; Patent No. 6686188

; SEQ ID NO 7813

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-866-108A-7813

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 493 GAGCGAAGGAGCAGG 509
Db 1 GAAGCAAGGAGCAGG 17

RESULT 61

US-09-866-108A-8421

; Sequence 8421, Application US/09866108A

; Patent No. 6686188

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8421
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8421

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 489 TGAAGAGCGCAGAGGAG 505
Db 1 TGAAGAGCGCAGAGGAG 17

RESULT 62

US-09-866-108A-8422

; Sequence 8422, Application US/09866108A

; Patent No. 6686188

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108A

; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

US-09-371-772B-4771

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 62;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 874 CAACACATCAAGAGCA 890
|||||:|||||
Db 1 CAACUACCUAAGAGCA 17

RESULT 57

US-09-371-772B-6804/c
; Sequence 6804, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MH800,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6804
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6804

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 337 TGCCATCCGCAGAGCA 353
|||||:|||||
Db 17 TGCCATCCTGCTGAGCA 1

RESULT 58

US-09-866-108A-6823/c
; Sequence 6823, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7698
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens

; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6823
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6823

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 266 CACCTGCCTTCAGACA 282
|||||:|||||
Db 17 CACCTGCCTTGAGAAAA 1

RESULT 59

US-09-866-108A-7698/c
; Sequence 7698, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7698
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens


```

; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/0035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 184:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-435-628-184

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 405 AGAGGGAGGAGGAGGAG 421
Db 17 AGGAGGAGGAGGAGGAG 1

RESULT 54
US-08-584-040-5992/c
; Sequence 592, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 5992:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single

```

```

; TOPOLOGY: linear
; US-08-584-040-5992

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 457 GGTGGAGAGACTCGGCC 473
Db 17 GGTAGACAGACTCGGCC 1

RESULT 55
US-09-371-772B-2829/c
; Sequence 2829, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR FILING DATE: 1995-10-26
; PRIOR FILING DATE: 1995-10-26
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2829
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
; US-09-371-772B-2829

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 457 GGTGGAGAGACTCGGCC 473
Db 17 GGTAGACAGACTCGGCC 1

RESULT 56
US-09-371-772B-4771
; Sequence 4771, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR FILING DATE: 1995-10-26
; PRIOR FILING DATE: 1995-10-26
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4771
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens

```

US-09-866-108A-8973

Query Match 1.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 58;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 851 CACCACTCTTCCA 864
DB 14 CACCACTCTTCCA 1

RESULT 51

US-09-205-143-42/c
; Sequence 42, Application US/09205143
; Patent No. 6107091
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-16 EXPRESSION
; FILE REFERENCE: RTS-0032
; CURRENT APPLICATION NUMBER: US/09/205,143
; CURRENT FILING DATE: 1998-12-03
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 42
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-205-143-42

Query Match 1.9%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 308 TGCCTGGAGGAGAA 321
DB 14 TGCCTGGAGGAGAA 1

RESULT 52

US-08-373-124A-184/c
; Sequence 184, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943

; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 184:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-373-124A-184

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 405 AGAGGAGGAGGAGGAG 421
DB 17 AGAGGAGGAGGAGGAG 1

RESULT 53

US-08-435-628-184/c
; Sequence 184, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:

```
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7243
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7243

Query Match 1.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 58;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 697 GCTGGAGAGTGAGC 710
Db 4 GCTGGAGAGTGAGC 17

RESULT 49
US-09-866-108A-8972/c
; Sequence 8972, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7243
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7243
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8972
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8972

Query Match 1.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 58;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 851 CACCAGCTCTTCCA 864
Db 15 CACCAGCTCTTCCA 2

RESULT 50
US-09-866-108A-8973/c
; Sequence 8973, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8973
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8973
```

```

; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 10970
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer 99-23427 for SEQ 3105, in complement
US-09-422-978-10970

Query Match
Best Local Similarity 1.9%; Score 14.4; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 811 GCAGGAGAGAGGAG 826
DB 17 GAGAGAGAGATGAG 2

RESULT 46
US-08-690-734A-61
; Sequence 61, Application US/08690734A
; Patent No. 5871920
; GENERAL INFORMATION:
; APPLICANT: Page, David C.
; APPLICANT: Reijo, Renee
; TITLE OF INVENTION: DAZ: A GENE ASSOCIATED WITH AZOOSPERMIA
; NUMBER OF SEQUENCES: 96
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
; STREET: Two Militia Drive
; CITY: Lexington
; STATE: Massachusetts
; COUNTRY: US
; ZIP: 02173
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/690,734A
; FILING DATE: 31-JUL-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/310,429
; FILING DATE: 22-SEP-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Granahan, Patricia
; REGISTRATION NUMBER: 32,227
; REFERENCE/DOCKET NUMBER: WH194-07A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 861-6240
; TELEFAX: (617) 861-9540
; INFORMATION FOR SEQ ID NO: 61:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-690-734A-61

Query Match
Best Local Similarity 1.9%; Score 14.4; DB 1; Length 19;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

US-09-422-978-10970
; Sequence 61, Application US/08742185
; Patent No. 6020476
; GENERAL INFORMATION:
; APPLICANT: Page, David C.
; APPLICANT: Reijo, Renee
; APPLICANT: Saxena, Richa
; APPLICANT: Hawkins, Trevor
; APPLICANT: Reeve, Mary Pat
; TITLE OF INVENTION: DAZ: A GENE FAMILY ASSOCIATED WITH AZOOSPERMIA
; NUMBER OF SEQUENCES: 102
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
; STREET: Two Militia Drive
; CITY: Lexington
; STATE: Massachusetts
; COUNTRY: US
; ZIP: 02173
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/742,185
; FILING DATE: 30-OCT-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/690,734
; FILING DATE: 31-JUL-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/310,429
; FILING DATE: 22-SEP-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Granahan, Patricia
; REGISTRATION NUMBER: 32,227
; REFERENCE/DOCKET NUMBER: WH194-07A2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 861-6240
; TELEFAX: (617) 861-9540
; INFORMATION FOR SEQ ID NO: 61:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-742-185-61

Query Match
Best Local Similarity 1.9%; Score 14.4; DB 1; Length 19;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 526 GCACCTGAAGAGATGC 541
DB 1 GCACCTGAAGAGCTGC 16

RESULT 47
US-08-742-185-61
; Sequence 61, Application US/08742185
; Patent No. 6020476
; GENERAL INFORMATION:
; APPLICANT: Page, David C.
; APPLICANT: Reijo, Renee
; APPLICANT: Saxena, Richa
; APPLICANT: Hawkins, Trevor
; APPLICANT: Reeve, Mary Pat
; TITLE OF INVENTION: DAZ: A GENE FAMILY ASSOCIATED WITH AZOOSPERMIA
; NUMBER OF SEQUENCES: 102
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
; STREET: Two Militia Drive
; CITY: Lexington
; STATE: Massachusetts
; COUNTRY: US
; ZIP: 02173
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/742,185
; FILING DATE: 30-OCT-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/690,734
; FILING DATE: 31-JUL-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/310,429
; FILING DATE: 22-SEP-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Granahan, Patricia
; REGISTRATION NUMBER: 32,227
; REFERENCE/DOCKET NUMBER: WH194-07A2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 861-6240
; TELEFAX: (617) 861-9540
; INFORMATION FOR SEQ ID NO: 61:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-742-185-61

Query Match
Best Local Similarity 1.9%; Score 14.4; DB 1; Length 19;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 526 GCACCTGAAGAGATGC 541
DB 1 GCACCTGAAGAGCTGC 16

RESULT 48
US-09-866-108A-7243
; Sequence 7243, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
```

```

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 526 GCACCTGAAGAGATGC 541
DB 1 GCACCTGAAGAGCTGC 16

RESULT 47
US-08-742-185-61
; Sequence 61, Application US/08742185
; Patent No. 6020476
; GENERAL INFORMATION:
; APPLICANT: Page, David C.
; APPLICANT: Reijo, Renee
; APPLICANT: Saxena, Richa
; APPLICANT: Hawkins, Trevor
; APPLICANT: Reeve, Mary Pat
; TITLE OF INVENTION: DAZ: A GENE FAMILY ASSOCIATED WITH AZOOSPERMIA
; NUMBER OF SEQUENCES: 102
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
; STREET: Two Militia Drive
; CITY: Lexington
; STATE: Massachusetts
; COUNTRY: US
; ZIP: 02173
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/742,185
; FILING DATE: 30-OCT-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/690,734
; FILING DATE: 31-JUL-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/310,429
; FILING DATE: 22-SEP-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Granahan, Patricia
; REGISTRATION NUMBER: 32,227
; REFERENCE/DOCKET NUMBER: WH194-07A2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 861-6240
; TELEFAX: (617) 861-9540
; INFORMATION FOR SEQ ID NO: 61:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-742-185-61

Query Match
Best Local Similarity 1.9%; Score 14.4; DB 1; Length 19;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 526 GCACCTGAAGAGATGC 541
DB 1 GCACCTGAAGAGCTGC 16

RESULT 48
US-09-866-108A-7243
; Sequence 7243, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
```

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8971
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8971

Query Match      1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 49;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      851 CACCAGCTCTCCAAAG 866
Db      16 CACCAGCTCTCCATG 1

RESULT 43
US-08-585-684B-2688/c
; Sequence 2688, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: January 16, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2688:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-585-684B-2688

Query Match      1.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 54;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```
Db      2  GGAGACGAGTTCCTC 17

RESULT 40
US-09-866-108A-7451
; Sequence 7451, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7451
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7451

Query Match      1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 49;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      413  GGAGACGAGTTCCTCA 428
Db      1  GAGACGAGTTCCTCA 16

RESULT 41
US-09-866-108A-8970/c
; Sequence 8970, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
```

```
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8970
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8970

Query Match      1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 49;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      851  CACCAGCTCTTCCAG 866
Db      17  CACCAGCTCTTCCATG 2

RESULT 42
US-09-866-108A-8971/c
; Sequence 8971, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
```

```
RESULT 37
US-09-422-978-8682
; Sequence 8682, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSSET 020CP1
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 8682
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer 99-17522 for SEQ 817, in compleme
US-09-422-978-8682
Query Match 2.0%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 46;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 492 AGAGGAGAGGAGGAGG 509
Db 1 AGAGGAGAGGAGGAGG 18

RESULT 38
US-09-866-108A-7247
; Sequence 7247, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7449
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7449
Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 49;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 412 GGAGAGGAGGAGGAGG 427
Db 1 GGAGAGGAGGAGGAGG 16
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7247
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7247
Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 49;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 698 CTGGAGAGTGAGCGG 713
Db 1 CTGGAGAGTGAGCGG 16

RESULT 39
US-09-866-108A-7449
; Sequence 7449, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7449
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7449
Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 49;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 412 GGAGAGGAGGAGGAGG 427
Db 1 GGAGAGGAGGAGGAGG 16
```

	Best Local Similarity	100.0%;	Pred. No. 43;	
	Matches	15; Conservative	0; Mismatches	0; Indels
	Gaps	0;		
Qy	719 CTGCAGCAGCAGCAC	733		
Db	17 CTGCAGCAGCAGCAC	3		
RESULT 35	US-09-045-301-3/c			
	; Sequence 3, Application US/09045301A			
	; Patent No. 6265388			
	; GENERAL INFORMATION:			
	; APPLICANT: Fett, James W.			
	; APPLICANT: Olson, Karen A.			
	; TITLE OF INVENTION: Antisense Inhibition of Angiogenin Expression			
	; FILE REFERENCE: 10498/05286			
	; CURRENT APPLICATION NUMBER: US/09/045,301A			
	; CURRENT FILING DATE: 1998-03-20			
	; EARLIER APPLICATION NUMBER: 60/041182			
	; EARLIER FILING DATE: 1997-03-21			
	; NUMBER OF SEQ ID NOS: 10			
	; SOFTWARE: PatentIn Ver. 2.0			
	; SEQ ID NO 3			
	; LENGTH: 18			
	; TYPE: DNA			
	; ORGANISM: Artificial Sequence			
	; FEATURE:			
	; OTHER INFORMATION: Description of Artificial Sequence:			
	; OTHER INFORMATION: phosphorothioate oligodeoxynucleotide			
US-09-045-301-3				
Query Match	2.0%;	Score 14.8; DB 1; Length 18;		
Best Local Similarity	88.9%;	Pred. No. 46;		
Matches	16; Conservative	0; Mismatches	2; Indels	0; Gaps
Qy	845 GCCTATCACCAGCTCTTC	862		
Db	18 GCCCATCACCATCTCTTC	1		
RESULT 36	US-09-045-301-4			
	; Sequence 4, Application US/09045301A			
	; Patent No. 6265388			
	; GENERAL INFORMATION:			
	; APPLICANT: Fett, James W.			
	; APPLICANT: Olson, Karen A.			
	; TITLE OF INVENTION: Antisense Inhibition of Angiogenin Expression			
	; FILE REFERENCE: 10498/05286			
	; CURRENT APPLICATION NUMBER: US/09/045,301A			
	; CURRENT FILING DATE: 1998-03-20			
	; EARLIER APPLICATION NUMBER: 60/041182			
	; EARLIER FILING DATE: 1997-03-21			
	; NUMBER OF SEQ ID NOS: 10			
	; SOFTWARE: PatentIn Ver. 2.0			
	; SEQ ID NO 4			
	; LENGTH: 18			
	; TYPE: DNA			
	; ORGANISM: Artificial Sequence			
	; FEATURE:			
	; OTHER INFORMATION: Description of Artificial Sequence:			
	; OTHER INFORMATION: phosphorothioate oligodeoxynucleotide			
US-09-045-301-4				
Query Match	2.0%;	Score 14.8; DB 1; Length 18;		
Best Local Similarity	88.9%;	Pred. No. 46;		
Matches	16; Conservative	0; Mismatches	2; Indels	0; Gaps
Qy	845 GCCTATCACCAGCTCTTC	862		
Db	18 GCCCATCACCATCTCTTC	18		


```
Db      1 CTGCTTCAGACAG 15

RESULT 31
US-09-866-108A-7244
; Sequence 7244, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A6OMICA-7
; CURRENT APPLICATION NUMBER: US/09/866.108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: A6omica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7244
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7245

Query Match      2.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      697 GCTGGAGAGTGAGCG 711
Db      2 GCTGGAGAGTGAGCG 16

RESULT 32
US-08-585-684B-2687/c
; Sequence 2687, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: January 16, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:

Query Match      2.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      697 GCTGGAGAGTGAGCG 711
Db      3 GCTGGAGAGTGAGCG 17

RESULT 32
US-09-866-108A-7245
; Sequence 7245, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A6OMICA-7
; CURRENT APPLICATION NUMBER: US/09/866.108A
```

```

; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows
; SOFTWARE: FASTSEQ for Windows Version 2.0b
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/081,385
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/964,747
; FILING DATE: 05-NOV-1997
; APPLICATION NUMBER: 60/030,761
; FILING DATE: 06-NOV-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Wu, Frank
; REGISTRATION NUMBER: 41,386
; REFERENCE/DOCKET NUMBER: 22000-20577.21
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-813-5600
; TELEFAX: 650-494-0792
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 131:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-081-385-131

```

```

Query Match      2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 47;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

QY 471 GCCTGGAGAGCTCGATCTG 490
Db 1 GCCTGGAGAGCCGACTG 20

```

```

RESULT 28
US-09-608-088-16
; Sequence 16, Application US/09608088
; Patent No. 6680368
; GENERAL INFORMATION:
; APPLICANT: Mosselman, Sietse
; APPLICANT: Dijkema, Rein
; TITLE OF INVENTION: No. 6680368el Estrogen Receptor
; FILE REFERENCE: O/96193 US/D1
; CURRENT APPLICATION NUMBER: US/09/608,088
; CURRENT FILING DATE: 2000-06-30
; PRIOR APPLICATION NUMBER: US 08/826,361
; PRIOR FILING DATE: 1997-03-26
; PRIOR APPLICATION NUMBER: EP 96203284.3
; PRIOR FILING DATE: 1996-11-22
; PRIOR APPLICATION NUMBER: EP 96200820.7
; PRIOR FILING DATE: 1996-03-26
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-608-088-16

```

```

Query Match      2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 47;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

QY 822 GGAAGCTGGCCCGATGCGAG 841
Db 1 GGAAGCTGGCTCACTGCTG 20

```

```

RESULT 29
US-09-711-288-16
; Sequence 16, Application US/09711288
; Patent No. 6713270
; GENERAL INFORMATION:
; APPLICANT: Mosselman, Sietse
; APPLICANT: Dijkema, Rein
; TITLE OF INVENTION: No. 6713270el Estrogen Receptor
; FILE REFERENCE: O/96193 US/D2
; CURRENT APPLICATION NUMBER: US/09/711,288
; CURRENT FILING DATE: 2000-11-13
; PRIOR APPLICATION NUMBER: US 08/826,361
; PRIOR FILING DATE: 1997-03-26
; PRIOR APPLICATION NUMBER: EP 96203284.3
; PRIOR FILING DATE: 1996-11-22
; PRIOR APPLICATION NUMBER: EP 96200820.7
; PRIOR FILING DATE: 1996-03-26
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-711-288-16

```

```

Query Match      2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 47;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

QY 822 GGAAGCTGGCCCGATGCGAG 841
Db 1 GGAAGCTGGCTCACTGCTG 20

```

```

RESULT 30
US-09-863-049B-62
; Sequence 62, Application US/09863049B
; Patent No. 6824972
; GENERAL INFORMATION:
; APPLICANT: Kenwick, Sue J.
; APPLICANT: Nelson, David L.
; APPLICANT: Aradhya, Swaroop
; APPLICANT: D'Urso, Michele
; APPLICANT: Koffendin, Hayley
; APPLICANT: Munnich, Arnold
; APPLICANT: Smahi, Asmaa
; APPLICANT: Israel, Alain
; APPLICANT: Poustka, Annemarie
; APPLICANT: Lewis, Richard A
; APPLICANT: Levy, Moise
; APPLICANT: Heiss, Nina
; TITLE OF INVENTION: Diagnosis and Treatment of Medical Conditions Associated with Defe
; FILE REFERENCE: HO-P01961US1
; CURRENT APPLICATION NUMBER: US/09/863,049B
; CURRENT FILING DATE: 2001-05-22
; PRIOR APPLICATION NUMBER: US 60/206,223
; PRIOR FILING DATE: 2000-05-22
; NUMBER OF SEQ ID NOS: 79
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 62
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Human
US-09-863-049B-62

```

```

Query Match      2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 269 CTGCCTTCAGACAG 283
|||||

```

RESULT 25

```

: Sequence 131, Application US/090081395
: Patent No. 6593456
: GENERAL INFORMATION:
: APPLICANT: Gatanaga, T.
: APPLICANT: Granager, G.A.
: TITLE OF INVENTION: Factors Alter
: TITLE OF INVENTION: Factor Recepto
: TITLE OF INVENTION: of Use Thereo
: NUMBER OF SEQUENCES: 154
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: MORRISON & FOERSTER
: STREET: 755 PAGE MILL ROAD
: CITY: Palo Alto
: STATE: CA
: COUNTRY: USA

```

TITLE OF INVENTION: Factors Altering Tumor Necrosis
 TITLE OF INVENTION: Factor Receptor Releasing Enzyme Activity, and Methods
 TITLE OF INVENTION: of Use Thereof
 NUMBER OF SEQUENCES: 154
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: MORRISON & FORSTER
 STREET: 755 PAGE MILL ROAD
 CITY: Palo Alto
 STATE: CA
 COUNTRY: USA

GENERAL INFORMATION:
APPLICANT: SHERIDAN, PATRICK J.
APPLICANT: GAGNE, JULIO C.
APPLICANT: ANDERSON, MARY L.
APPLICANT: LUTKE, DOUGLAS N.
TITLE OF INVENTION: METHOD FOR DETECTING OLIGONUCLEOTIDES BY
TITLE OF INVENTION: ENZYME INHIBITION ASSAY
NUMBER OF SEQUENCES: 5
CORRESPONDENCE ADDRESS:
ADDRESSEE: CHIRON CORPORATION
STREET: 4560 HORTON STREET
CITY: EMERYVILLE
STATE: CALIFORNIA
COUNTRY: UNITED STATES
ZIP: 94608
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/472,756
FILING DATE: 07-JUN-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: GOLDMAN ESQ., KENNETH M.
REGISTRATION NUMBER: 34,174
REFERENCE/DOCKET NUMBER: 1014.001
TELEPHONE: (510) 601-2719
TELEFAX: (510) 655-3542
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: misc_feature
LOCATION: 19
OTHER INFORMATION: /standard_name=
OTHER INFORMATION: "N4-(6-aminocaproyl-2-aminoethyl)cytosine"
US-08-472-756-1

Query Match 2.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 40;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 867 AATACGACCAACCATC 883
Db 2 AGTAGACCAACCATC 18

RESULT 21
US-08-610-955-1
Sequence 1, Application US/08610955
Patent No. 5853974
GENERAL INFORMATION:
APPLICANT: SHERIDAN, PATRICK J.
APPLICANT: GAGNE, JULIO C.
APPLICANT: ANDERSON, MARY L.
APPLICANT: LUTKE, DOUGLAS N.
TITLE OF INVENTION: METHOD FOR DETECTING OLIGONUCLEOTIDES BY
TITLE OF INVENTION: ENZYME INHIBITION ASSAY
NUMBER OF SEQUENCES: 5
CORRESPONDENCE ADDRESS:
ADDRESSEE: CHIRON CORPORATION
STREET: 4560 HORTON STREET
CITY: EMERYVILLE
STATE: CALIFORNIA
COUNTRY: UNITED STATES
ZIP: 94608

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/610,955
FILING DATE: 05-MAR-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/472,756
FILING DATE: 07-JUN-1995
ATTORNEY/AGENT INFORMATION:
NAME: GOLDMAN ESQ., KENNETH M.
REGISTRATION NUMBER: 34,174
REFERENCE/DOCKET NUMBER: 1014.001
TELEPHONE: (510) 601-2719
TELEFAX: (510) 655-3542
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: misc_feature
LOCATION: 19
OTHER INFORMATION: /standard_name=
OTHER INFORMATION: "N4-(6-aminocaproyl-2-aminoethyl)cytosine"
US-08-610-955-1

Query Match 2.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 40;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 867 AATACGACCAACCATC 883
Db 2 AGTAGACCAACCATC 18

RESULT 22
US-09-732-199A-18
Sequence 18, Application US/09732199A
Patent No. 6379960
GENERAL INFORMATION:
APPLICANT: Ian Popoff
APPLICANT: Jacqueline Wyatt
TITLE OF INVENTION: ANTISENSE MODULATION OF DAMAGE-SPECIFIC DNA BINDING PROTEIN 2, PAGE 1
TITLE OF INVENTION: EXPRESSION
FILE REFERENCE: RTS-0214
CURRENT APPLICATION NUMBER: US/09/732,199A
CURRENT FILING DATE: 2000-12-06
NUMBER OF SEQ ID NOS: 57
SEQ ID NO 18
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-732-199A-18

Query Match 2.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 43;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 815 GAGAAGAGGAAGCTGSC 831
Db 3 GAGTAGAGGAAGCTGCG 19

RESULT 23

;; NUMBER OF SEQUENCES: 8
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Lappin & Kusmer
;; STREET: 200 State Street
;; CITY: Boston
;; STATE: MA
;; COUNTRY: USA
;; ZIP: 02109
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: PatentIn Release #1.0, Version #1.30
;; CURRENT APPLICATION DATA: US/08/532,979
;; FILING DATE:
;; CLASSIFICATION: 536
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Kerner, Ann-Louise
;; REGISTRATION NUMBER: 33,523
;; REFERENCE/DOCKET NUMBER: HYZ-050
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 617-330-1300
;; TELEFAX: 617-330-1311
;; INFORMATION FOR SEQ ID NO: 7:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 18 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA/RNA
;; HYPOTHETICAL: NO
;; ANTI-SENSE: YES
;; US-08-532-979-7

Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 36;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 677 GCCAGCGGAGGCGGCG 693
Db 18 GCCAGCGGAGGCGGCG 2

RESULT 18
US-09-115-566-32
; Sequence 32, Application US/09115566
; Patent No. 6232462
; GENERAL INFORMATION:
; APPLICANT: COLLINS, MARK L.
; APPLICANT: HORN, THOMAS
; APPLICANT: SHERIDAN, PATRICK E.
; APPLICANT: WARNER, BRIAN D.
; APPLICANT: URDEA, MICHAEL S.
; TITLE OF INVENTION: REDUCTION OF NONSPECIFIC HYBRIDIZATION
; NUMBER OF SEQUENCES: 35
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CHRION CORPORATION, INTELLECTUAL PROPERTY -
; STREET: P.O. BOX 8097
; CITY: EMERYVILLE
; STATE: CALIFORNIA
; COUNTRY: UNITED STATES OF AMERICA
; ZIP: 94662-8097
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/115,566
; FILING DATE:

;; CLASSIFICATION:
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US/08/794,153
;; FILING DATE: 03-FEB-1997
;; APPLICATION NUMBER: US 08/298,073
;; FILING DATE: 30-AUG-1994
;; ATTORNEY/AGENT INFORMATION:
;; NAME: GOLDMAN, KENNETH M.
;; REGISTRATION NUMBER: 34,174
;; REFERENCE/DOCKET NUMBER: 0974.001
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (510) 601-2719
;; TELEFAX: (510) 655-3542
;; INFORMATION FOR SEQ ID NO: 32:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 18 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA (genomic)
;; US-09-115-566-32

Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 36;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 867 AATACGACACACATC 883
Db 2 AGTACGACACACATC 18

RESULT 19
US-09-146-157-3
; Sequence 3, Application US/09146157
; Patent No. 6465175
; GENERAL INFORMATION:
; APPLICANT: HORN, Thomas
; APPLICANT: SCHROEDER, Hartmut R.
; APPLICANT: WARNER, Brian D.
; APPLICANT: FISS, Ellen
; APPLICANT: SELLS, Todd
; APPLICANT: LAW, Say-Jong
; TITLE OF INVENTION: OLIGONUCLEOTIDE PROBES BEARING QUENCHABLE FLUORESCENT LABELS,
; FILE OF INVENTION: AND METHODS OF USE THEREOF
; FILE REFERENCE: 1411.002
; CURRENT APPLICATION NUMBER: US/09/146,157
; CURRENT FILING DATE: 1998-09-03
; EARLIER APPLICATION NUMBER: 60/057,810
; EARLIER FILING DATE: 1997-09-04
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: This information
; OTHER INFORMATION: is not available.
US-09-146-157-3

Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 36;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 867 AATACGACACACATC 883
Db 2 AGTACGACACACATC 18

RESULT 20
US-08-472-756-1
; Sequence 1, Application US/08472756
; Patent No. 5780227

SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/794,153
FILING DATE: 03-FEB-1997
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/298,073
FILING DATE: 30-AUG-1994
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: GOLDMAN, KENNETH M.
REGISTRATION NUMBER: 34,174
REFERENCE/DOCKET NUMBER: 0974.001
TELECOMMUNICATION INFORMATION:
TELEPHONE: (510) 601-2719
TELEFAX: (510) 655-3542
INFORMATION FOR SEQ ID NO: 32:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-794-153-32

Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 36;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 867 AATACGACACACATC 883
Db 2 AGTACGACACACATC 18
|||||

RESULT 15
US-08-532-979-2/c
Sequence 2, Application US/08532979
Patent No. 5969117
GENERAL INFORMATION:
APPLICANT: Agrawal, Sudhir
TITLE OF INVENTION: MODIFIED PROTEIN KINASE A-SPECIFIC
TITLE OF INVENTION: OLIGONUCLEOTIDES AND METHODS OF THEIR USE
NUMBER OF SEQUENCES: 8
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Lappin & Kusmer
STREET: 200 State Street
CITY: Boston
STATE: MA
COUNTRY: USA
ZIP: 02109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/532,979
FILING DATE:
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Kerner, Ann-Louise
REGISTRATION NUMBER: 33,523
REFERENCE/DOCKET NUMBER: HYZ-050
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-330-1300
TELEFAX: 617-330-1311
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA

HYPOTHEITICAL: NO
ANTI-SENSE: YES
US-08-532-979-2
Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 36;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 677 GCCAGCGAGGAGCGCG 693
Db 18 GCCAGCGAGGAGCGCG 2
|||||
RESULT 16
US-08-532-979-5/c
Sequence 5, Application US/08532979
Patent No. 5969117
GENERAL INFORMATION:
APPLICANT: Agrawal, Sudhir
TITLE OF INVENTION: MODIFIED PROTEIN KINASE A-SPECIFIC
TITLE OF INVENTION: OLIGONUCLEOTIDES AND METHODS OF THEIR USE
NUMBER OF SEQUENCES: 8
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Lappin & Kusmer
STREET: 200 State Street
CITY: Boston
STATE: MA
COUNTRY: USA
ZIP: 02109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/532,979
FILING DATE:
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Kerner, Ann-Louise
REGISTRATION NUMBER: 33,523
REFERENCE/DOCKET NUMBER: HYZ-050
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-330-1300
TELEFAX: 617-330-1311
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA/RNA
HYPOTHEITICAL: NO
ANTI-SENSE: YES
US-08-532-979-5

Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 36;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGAGGAGCGCG 693
Db 18 GCCAGCGAGGAGCGCG 2
|||||

RESULT 17
US-08-532-979-7/c
Sequence 7, Application US/08532979
Patent No. 5969117
GENERAL INFORMATION:
APPLICANT: Agrawal, Sudhir
TITLE OF INVENTION: MODIFIED PROTEIN KINASE A-SPECIFIC
TITLE OF INVENTION: OLIGONUCLEOTIDES AND METHODS OF THEIR USE

US-09-866-108A-7246

Query Match 2.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 33;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 697 GCTGGAGAGTCAGCGG 713
Db 1 GCTGGAGAGTCAGCGG 17

RESULT 12

US-09-866-108A-7450
; Sequence 7450, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David R.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7450
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7450

Query Match 2.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 33;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 412 GGAGAGGAGTTCCTCA 428
Db 1 GGAGAGGAGTTCCTCA 17

RESULT 13

US-08-298-073-32
; Sequence 32, Application US/08298073
; Patent No. 5681702
; GENERAL INFORMATION:
; APPLICANT: COLLINS, MARK L.
; APPLICANT: HORN, THOMAS

; APPLICANT: SHERIDAN, PATRICK E.
; APPLICANT: WARNER, BRIAN D.
; APPLICANT: URDEA, MICHAEL S.
; TITLE OF INVENTION: REDUCTION OF NONSPECIFIC HYBRIDIZATION
; TITLE OF INVENTION: BY USING NOVEL, BASE-PAIRING SCHEMES
; NUMBER OF SEQUENCES: 35
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CHRION CORPORATION, INTELLECTUAL PROPERTY -
; ADDRESS: R440
; STREET: P.O. BOX 8097
; CITY: EMERYVILLE
; STATE: CALIFORNIA
; COUNTRY: UNITED STATES OF AMERICA
; ZIP: 94662-8097
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/298,073
; FILING DATE: 30-AUG-1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: GOLDMAN, KENNETH M.
; REGISTRATION NUMBER: 34,174
; REFERENCE/DOCKET NUMBER: 0974.001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (510) 601-2719
; TELEFAX: (510) 655-3542
; INFORMATION FOR SEQ ID NO: 32:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-298-073-32

Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 36;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 867 AATACGACACCATC 883
Db 2 AGTACGACACCATC 18

RESULT 14

US-08-794-153-32
; Sequence 32, Application US/08794153
; Patent No. 5780610
; GENERAL INFORMATION:
; APPLICANT: COLLINS, MARK L.
; APPLICANT: HORN, THOMAS
; APPLICANT: SHERIDAN, PATRICK E.
; APPLICANT: WARNER, BRIAN D.
; APPLICANT: URDEA, MICHAEL S.
; TITLE OF INVENTION: REDUCTION OF NONSPECIFIC HYBRIDIZATION
; TITLE OF INVENTION: BY USING NOVEL, BASE-PAIRING SCHEMES
; NUMBER OF SEQUENCES: 35
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CHRION CORPORATION, INTELLECTUAL PROPERTY -
; ADDRESS: R440
; STREET: P.O. BOX 8097
; CITY: EMERYVILLE
; STATE: CALIFORNIA
; COUNTRY: UNITED STATES OF AMERICA
; ZIP: 94662-8097
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS

```
RESULT 9
US-08-098-942C-16/c
; Sequence 16, Application US/08098942C
; Patent No. 6410322
; GENERAL INFORMATION:
; APPLICANT: Robinson, Gregory S.
; TITLE OF INVENTION: Antisense Oligonucleotides That
; TITLE OF INVENTION: Inhibit VEGF Expression
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Michael S. Greenfield
; STREET: 10 S. Wacker Drive Suite 3000
; CITY: Chicago
; STATE: Illinois
; COUNTRY: U.S.A.
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/098,942C
; FILING DATE: July 27, 1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Greenfield, Michael S.
; REGISTRATION NUMBER: 37,142
; REFERENCE/DOCKET NUMBER: 93,538
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312)715-1000
; TELEFAX: (312)715-1234
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; HYPOTHEICAL: YES
; ANTI-SENSE: YES
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: 1..20
; OTHER INFORMATION: /note="phosphorothioate
; OTHER INFORMATION: internucleotide linkages"
US-08-098-942C-16

Query Match 2.1%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 37;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

US-08-098-942C-16
QY 696 AGCTGGAGAGTGAGCGGA 714
| | | | | | | | | | | | | | | |
Db 19 AGCCGGAGAGGGAGCGGA 1

RESULT 10
US-10-083-720A-10
; Sequence 10, Application US/10083720A
; Patent No. 6797813
; GENERAL INFORMATION:
; APPLICANT: de Waal Malefyt, Rene
; APPLICANT: Fickenscher, Helmut
; APPLICANT: Fleckenstein, Bernhard
; APPLICANT: Knappe, Andrea
; TITLE OF INVENTION: MAMMALIAN CYTOKINE; RELATED REAGENTS
; FILE REFERENCE: DX0644KBK
; CURRENT APPLICATION NUMBER: US/10/083,720A
; CURRENT FILING DATE: 2002-02-28
; PRIOR APPLICATION NUMBER: 09/363,993
; PRIOR FILING DATE: 1999-07-29
; PRIOR APPLICATION NUMBER: 08/934,959
; PRIOR FILING DATE: 1997-09-22
```

```
; PRIOR APPLICATION NUMBER: 60/345,690
; PRIOR FILING DATE: 2002-01-03
; PRIOR APPLICATION NUMBER: 60/302,176
; PRIOR FILING DATE: 2001-06-28
; PRIOR APPLICATION NUMBER: 60/027,368
; PRIOR FILING DATE: 1996-09-23
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 10
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: IL-10 forward.
; NAME/KEY: misc feature
; LOCATION: (1)..(21)
; OTHER INFORMATION: IL-10 forward.
US-10-083-720A-10

Query Match 2.1%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

US-10-083-720A-10
QY 325 AGAGTCCGAGATGCATC 343
| | | | | | | | | | | | | | | |
Db 2 AGATCTCCGAGATGCCTC 20

RESULT 11
US-09-866-108A-7246
; Sequence 7246, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aemica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7246
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
```


;; FILE REFERENCE: HO-P01961US1
;; CURRENT APPLICATION NUMBER: US/09/863.049B
;; CURRENT FILING DATE: 2001-05-22
;; PRIOR APPLICATION NUMBER: US 60/206,223
;; PRIOR FILING DATE: 2000-05-22
;; NUMBER OF SEQ ID NOS: 79
;; SOFTWARE: PatentIn version 3.1
;; SEQ ID NO 63
;; LENGTH: 25
;; TYPE: DNA
;; ORGANISM: Human
US-09-863-049B-63

Query Match 2.6%; Score 19.4; DB 1; Length 25;
Best Local Similarity 95.2%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 263 CTGCACCTGCCTTCAGAACAG 283
||| ||||| ||||| ||||| |||||
Db 5 CTTACACCTGCCTTCAGAACAG 25

RESULT 6

US-08-745-269-5/c
; Sequence 5, Application US/08745269
; Patent No. 5763183
; GENERAL INFORMATION:
; APPLICANT: Pesonen, Ullamari
; APPLICANT: Koulu, Markku
; APPLICANT: Linnoila, Markku
; APPLICANT: Goldman, David
; APPLICANT: Virkkunen, Matti
; TITLE OF INVENTION: OF THE 5HT7 SEROTONIN RECEPTOR
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRES:
; ADDRESSEE: Knobbe, Martens, Olson and Bear
; STREET: 620 Newport Center Drive 16th Floor
; CITY: Newport Beach
; STATE: CA
; COUNTRY: USA
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/745,269
; FILING DATE: 08-NOV-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/006,394
; FILING DATE: 09-NOV-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Fuller, Michael L
; REGISTRATION NUMBER: 36,516
; REFERENCE/DOCKET NUMBER: NIH126.001A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619-235-8550
; TELEFAX: 619-235-0176
; TELEX:
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-745-269-5

Query Match 2.1%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 34;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 441 AGGAGGCCAGGAACCTGGT 459
||||| ||||| ||||| ||||| |||||
Db 19 AGGAGGCCAGGAACCTGGT 1

RESULT 7

US-09-232-468A-10
; Sequence 10, Application US/09232468A
; Patent No. 6207165
; GENERAL INFORMATION:
; APPLICANT: AUDONNET et al.
; TITLE OF INVENTION: POLYNUCLEOTIDE VACCINE FORMULA AGAINST PORCINE
; FILE REFERENCE: 454313-2230
; CURRENT APPLICATION NUMBER: US/09/232,468A
; CURRENT FILING DATE: 1999-01-05
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Aujeszky's Disease Virus (NIA3 Strain)
US-09-232-468A-10

Query Match 2.1%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 34;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 372 GCTGCGAGGAGCTTCTGCA 390
||||| ||||| ||||| ||||| |||||
Db 1 GCTGCGAGGAGCTTCTGCA 19

RESULT 8

US-09-784-984B-8
; Sequence 8, Application US/09784984B
; Patent No. 6576243
; GENERAL INFORMATION:
; APPLICANT: Merial Ltd.
; APPLICANT: Audonnet, Jean-Christophe
; APPLICANT: Bouchardon, Annabelle
; APPLICANT: Baudu, Philippe
; APPLICANT: Riviere, Michael
; TITLE OF INVENTION: Polynucleotide Vaccine Formula Against Porcine Reproductive and
; FILE REFERENCE: 454313-2230.1
; CURRENT APPLICATION NUMBER: US/09/784,984B
; CURRENT FILING DATE: 2001-02-16
; PRIOR APPLICATION NUMBER: FR 96/09338
; PRIOR FILING DATE: 1996-07-19
; PRIOR APPLICATION NUMBER: PCT/FR97/01313
; PRIOR FILING DATE: 1997-07-15
; PRIOR APPLICATION NUMBER: US 6,207,165
; PRIOR FILING DATE: 2001-03-27
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Pseudorabies virus
US-09-784-984B-8

Query Match 2.1%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 34;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 372 GCTGCGAGGAGCTTCTGCA 390
||||| ||||| ||||| ||||| |||||
Db 1 GCTGCGAGGAGCTTCTGCA 19

;
; LOCATION: (1)..(22)
; OTHER INFORMATION:
US-09-863-049B-61

Query Match 2.9%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 3.2;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 344 CGGCAGAGCAACAGATTCTGC 365
|||
Db 1 CGGCAGAGCAACAGATTCTGC 22

RESULT 2

US-09-863-049B-53/c
; Sequence 53, Application US/09863049B
; Patent No. 6824972
; GENERAL INFORMATION:
; APPLICANT: Kenrick, Sue J.
; APPLICANT: Nelson, David L.
; APPLICANT: Aradhya, Swaroop
; APPLICANT: D'Urso, Michele
; APPLICANT: Woffendin, Hayley
; APPLICANT: Munnich, Arnold
; APPLICANT: Smahi, Asmae
; APPLICANT: Israel, Alain
; APPLICANT: Poustka, Annemarie
; APPLICANT: Lewis, Richard A
; APPLICANT: Levy, Moise
; APPLICANT: Heiss, Nina
; TITLE OF INVENTION: Diagnosis and Treatment of Medical Conditions Associated with Def
; FILE REFERENCE: NFKAPPA B (NF-kB) Activation
; CURRENT APPLICATION NUMBER: US/09/863,049B
; CURRENT FILING DATE: 2001-05-22
; PRIOR APPLICATION NUMBER: US 60/206,223
; PRIOR FILING DATE: 2000-05-22
; NUMBER OF SEQ ID NOS: 79
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 53
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Human
US-09-863-049B-53

Query Match 2.6%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 6.9;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 645 AATGCCAGGCTCTGGAGGGT 664
|||
Db 20 AATGCCAGGCTCTGGAGGGT 1

RESULT 3

US-09-396-196G-13872
; Sequence 13872, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 13872
; LENGTH: 25

;
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-396-196G-13872

Query Match 2.6%; Score 19.8; DB 1; Length 25;
Best Local Similarity 91.3%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 733 CAGCGTCAGGTGGACCACTGC 755
|||
Db 3 CAACGTGCAGGTGGCCCACTGC 25

RESULT 4

US-09-863-049B-55/c
; Sequence 55, Application US/09863049B
; Patent No. 6824972
; GENERAL INFORMATION:
; APPLICANT: Kenrick, Sue J.
; APPLICANT: Nelson, David L.
; APPLICANT: Aradhya, Swaroop
; APPLICANT: D'Urso, Michele
; APPLICANT: Woffendin, Hayley
; APPLICANT: Munnich, Arnold
; APPLICANT: Smahi, Asmae
; APPLICANT: Israel, Alain
; APPLICANT: Poustka, Annemarie
; APPLICANT: Lewis, Richard A
; APPLICANT: Levy, Moise
; APPLICANT: Heiss, Nina
; TITLE OF INVENTION: Diagnosis and Treatment of Medical Conditions Associated with Defe
; FILE REFERENCE: NFKAPPA B (NF-kB) Activation
; CURRENT APPLICATION NUMBER: US/09/863,049B
; CURRENT FILING DATE: 2001-05-22
; PRIOR APPLICATION NUMBER: US 60/206,223
; PRIOR FILING DATE: 2000-05-22
; NUMBER OF SEQ ID NOS: 79
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 55
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Human
US-09-863-049B-55

Query Match 2.6%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 8.9;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 473 CTGGAGAGCTCGATCTGAAG 493
|||
Db 21 CTCGAGAGCTCGATCTGAAG 1

RESULT 5

US-09-863-049B-63
; Sequence 63, Application US/09863049B
; Patent No. 6824972
; GENERAL INFORMATION:
; APPLICANT: Kenrick, Sue J.
; APPLICANT: Nelson, David L.
; APPLICANT: Aradhya, Swaroop
; APPLICANT: D'Urso, Michele
; APPLICANT: Woffendin, Hayley
; APPLICANT: Munnich, Arnold
; APPLICANT: Smahi, Asmae
; APPLICANT: Israel, Alain
; APPLICANT: Poustka, Annemarie
; APPLICANT: Lewis, Richard A
; APPLICANT: Levy, Moise
; APPLICANT: Heiss, Nina
; TITLE OF INVENTION: NFKAPPA B (NF-kB) Activation

c 107	12.8	1.7	16	1	US-09-155-885A-242	Sequence 242, App	c 180	12	1.6	12	1	US-08-626-953-9	Sequence 9, Appli
c 108	12.8	1.7	17	1	US-08-435-350-44	Sequence 44, Appl	c 181	12	1.6	12	1	US-08-455-231-9	Sequence 9, Appli
c 109	12.8	1.7	17	1	US-08-373-124A-176	Sequence 176, App	c 182	12	1.6	12	1	US-08-455-552A-9	Sequence 9, Appli
c 110	12.8	1.7	17	1	US-08-435-628-176	Sequence 176, App	c 183	12	1.6	12	1	US-09-235-375-9	Sequence 9, Appli
c 111	12.8	1.7	17	1	US-08-232-620A-1639	Sequence 1639, Ap	c 184	12	1.6	14	1	US-09-213-834B-6	Sequence 6, Appli
c 112	12.8	1.7	17	1	US-08-292-620A-1790	Sequence 1790, Ap	c 185	12	1.6	14	1	US-09-213-834B-7	Sequence 7, Appli
c 113	12.8	1.7	17	1	US-08-292-620A-1801	Sequence 1801, Ap	c 186	12	1.6	15	1	US-08-319-492B-16	Sequence 16, Appl
c 114	12.8	1.7	17	1	US-08-292-620A-1823	Sequence 1823, Ap	c 187	12	1.6	15	1	US-08-588-595-1	Sequence 1, Appli
c 115	12.8	1.7	17	1	US-08-292-620A-1868	Sequence 1868, Ap	c 188	12	1.6	15	1	US-09-180-437-104	Sequence 104, App
c 116	12.8	1.7	17	1	US-09-071-845-1639	Sequence 1639, Ap	c 189	12	1.6	15	1	US-09-163-485-13	Sequence 13, Appl
c 117	12.8	1.7	17	1	US-09-071-845-1790	Sequence 1790, Ap	c 190	12	1.6	15	1	US-09-081-646-177	Sequence 177, App
c 118	12.8	1.7	17	1	US-09-071-845-1801	Sequence 1801, Ap	c 191	12	1.6	15	1	US-09-081-646-177	Sequence 177, App
c 119	12.8	1.7	17	1	US-09-071-845-1823	Sequence 1823, Ap	c 192	12	1.6	16	1	US-08-705-477E-49	Sequence 49, Appl
c 120	12.8	1.7	17	1	US-09-071-845-1868	Sequence 1868, Ap	c 193	12	1.6	16	1	US-09-917-907-1	Sequence 1, Appli
c 121	12.8	1.7	17	1	US-08-881-450A-6	Sequence 6, Appli	c 194	12	1.6	16	1	US-09-667-327-5	Sequence 5, Appli
c 122	12.8	1.7	17	1	US-08-584-040-1934	Sequence 1934, Ap	c 195	12	1.6	16	1	US-09-930-251-1	Sequence 1, Appli
c 123	12.8	1.7	17	1	US-08-584-040-7615	Sequence 7615, Ap	c 196	11.8	1.6	15	1	US-08-182-968A-139	Sequence 139, App
c 124	12.8	1.7	17	1	US-08-584-040-7772	Sequence 7772, Ap	c 197	11.8	1.6	15	1	US-08-100-465-7	Sequence 7, Appli
c 125	12.8	1.7	17	1	US-09-480-017-8	Sequence 8, Appli	c 198	11.8	1.6	15	1	US-08-291-932A-296	Sequence 296, App
c 126	12.8	1.7	17	1	US-09-474-432B-478	Sequence 478, App	c 199	11.8	1.6	15	1	US-08-292-620A-35	Sequence 35, Appl
c 127	12.8	1.7	17	1	US-09-474-432B-605	Sequence 605, App	c 200	11.8	1.6	15	1	US-08-292-620A-176	Sequence 176, App
c 128	12.8	1.7	17	1	US-09-371-772B-479	Sequence 479, App	c 201	11.8	1.6	15	1	US-08-774-306A-139	Sequence 139, App
c 129	12.8	1.7	17	1	US-09-371-772B-3556	Sequence 3556, Ap	c 202	11.8	1.6	15	1	US-09-064-156A-139	Sequence 139, App
c 130	12.8	1.7	17	1	US-09-371-772B-4770	Sequence 4770, Ap	c 203	11.8	1.6	15	1	US-09-071-845-35	Sequence 35, Appl
c 131	12.8	1.7	17	1	US-09-476-387-477	Sequence 477, App	c 204	11.8	1.6	15	1	US-09-071-845-176	Sequence 176, App
c 132	12.8	1.7	17	1	US-09-476-387-604	Sequence 604, App	c 205	11.8	1.6	15	1	US-09-232-468A-9	Sequence 9, Appli
c 133	12.8	1.7	17	1	US-09-866-108A-354	Sequence 354, App	c 206	11.8	1.6	15	1	US-09-275-850-21	Sequence 21, Appl
c 134	12.8	1.7	17	1	US-09-866-108A-355	Sequence 355, App	c 207	11.8	1.6	15	1	US-09-081-646-429	Sequence 429, App
c 135	12.8	1.7	17	1	US-09-866-108A-672	Sequence 672, App	c 208	11.8	1.6	15	1	US-09-081-646-468	Sequence 468, App
c 136	12.8	1.7	17	1	US-09-866-108A-673	Sequence 673, App	c 209	11.8	1.6	15	1	US-09-474-432B-194	Sequence 194, App
c 137	12.8	1.7	17	1	US-09-866-108A-1523	Sequence 1523, Ap	c 210	11.8	1.6	15	1	US-09-784-984B-7	Sequence 7, Appli
c 138	12.8	1.7	17	1	US-09-866-108A-1524	Sequence 1524, Ap	c 211	11.8	1.6	15	1	US-09-476-387-194	Sequence 194, App
c 139	12.8	1.7	17	1	US-09-866-108A-1720	Sequence 1720, Ap	c 212	11.8	1.6	15	1	5182195-58	Patent No. 5182195
c 140	12.8	1.7	17	1	US-09-866-108A-1721	Sequence 1721, Ap	c 213	11.8	1.6	15	1	5182195-58	Patent No. 5182195
c 141	12.8	1.7	17	1	US-09-866-108A-1996	Sequence 1996, Ap							
c 142	12.8	1.7	17	1	US-09-866-108A-1997	Sequence 1997, Ap							
c 143	12.8	1.7	17	1	US-09-866-108A-6822	Sequence 6822, Ap							
c 144	12.8	1.7	17	1	US-09-866-108A-6890	Sequence 6890, Ap							
c 145	12.8	1.7	17	1	US-09-866-108A-6891	Sequence 6891, Ap							
c 146	12.8	1.7	17	1	US-09-866-108A-7677	Sequence 7677, Ap							
c 147	12.8	1.7	17	1	US-09-866-108A-7678	Sequence 7678, Ap							
c 148	12.8	1.7	17	1	US-09-866-108A-7697	Sequence 7697, Ap							
c 149	12.8	1.7	17	1	US-09-866-108A-7699	Sequence 7699, Ap							
c 150	12.8	1.7	17	1	US-09-866-108A-7812	Sequence 7812, Ap							
c 151	12.8	1.7	17	1	US-09-866-108A-7814	Sequence 7814, Ap							
c 152	12.8	1.7	17	1	US-09-866-108A-8033	Sequence 8033, Ap							
c 153	12.8	1.7	17	1	US-09-866-108A-8034	Sequence 8034, Ap							
c 154	12.8	1.7	17	1	US-09-866-108A-8043	Sequence 8043, Ap							
c 155	12.8	1.7	17	1	US-09-866-108A-8423	Sequence 8423, Ap							
c 156	12.8	1.7	17	1	US-09-404-312-648	Sequence 648, App							
c 157	12.8	1.7	17	1	US-09-685-664B-479	Sequence 479, App							
c 158	12.8	1.7	17	1	US-09-685-664B-3556	Sequence 3556, Ap							
c 159	12.8	1.7	17	1	5240847-22	Patent No. 5240847							
c 160	12.4	1.6	14	1	US-08-390-850-5	Sequence 5, Appli							
c 161	12.4	1.6	14	1	US-08-435-634-5	Sequence 5, Appli							
c 162	12.4	1.6	15	1	US-08-319-492B-129	Sequence 129, App							
c 163	12.4	1.6	15	1	US-08-307-682B-18	Sequence 18, Appl							
c 164	12.4	1.6	15	1	US-08-585-684B-820	Sequence 820, App							
c 165	12.4	1.6	15	1	US-08-585-684B-885	Sequence 885, App							
c 166	12.4	1.6	15	1	US-08-585-684B-886	Sequence 886, App							
c 167	12.4	1.6	15	1	US-09-038-073-820	Sequence 820, App							
c 168	12.4	1.6	15	1	US-09-038-073-885	Sequence 885, App							
c 169	12.4	1.6	15	1	US-09-038-073-886	Sequence 886, App							
c 170	12.4	1.6	15	1	US-09-180-437-182	Sequence 182, App							
c 171	12.4	1.6	15	1	US-09-475-947A-304	Sequence 304, App							
c 172	12.4	1.6	16	1	US-08-911-894-13	Sequence 13, Appl							
c 173	12.4	1.6	16	1	US-08-911-894-14	Sequence 14, Appl							
c 174	12.4	1.6	16	1	US-09-509-565-38	Sequence 38, Appl							
c 175	12.4	1.6	16	1	US-09-060-299-445	Sequence 445, App							
c 176	12.4	1.6	16	1	US-09-402-923A-445	Sequence 445, App							
c 177	12.4	1.6	16	1	US-09-371-772B-5656	Sequence 5656, Ap							
c 178	12.4	1.6	16	1	US-09-544-398B-121	Sequence 121, App							
c 179	12.4	1.6	12	1	US-09-543-771B-121	Sequence 121, App							
					US-07-891-962-9	Sequence 9, Appli							

ALIGNMENTS

RESULT 1

US-09-863-049B-61
; Sequence 61, Application US/09863049B

; Patent No. 6824972
; GENERAL INFORMATION:
; APPLICANT: Kenwick, Sue J.
; APPLICANT: Nelson, David L.
; APPLICANT: Aradhya, Swaroop
; APPLICANT: D'Urso, Michele
; APPLICANT: Woffendin, Hayley
; APPLICANT: Munnich, Arnold
; APPLICANT: Smahi, Asmaa
; APPLICANT: Israel, Alain
; APPLICANT: Poustka, Annemarie
; APPLICANT: Lewis, Richard A
; APPLICANT: Levy, Moise
; APPLICANT: Heiss, Nina
; TITLE OF INVENTION: Diagnosis and Treatment of Medical Conditions Associated with Defect
; FILE REFERENCE: HO-P01961US1
; CURRENT APPLICATION NUMBER: US/09/863, 049B
; CURRENT FILING DATE: 2001-05-22
; PRIOR APPLICATION NUMBER: US 60/206,223
; PRIOR FILING DATE: 2000-05-22
; NUMBER OF SEQ ID NOS: 79
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 61
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
; FEATURE:
; NAME/KEY: misc_feature

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 8, 2005, 08:49:16 ; Search time 2 seconds
(without alignments)
2.698 Million cell updates/sec

Title: US-10-628-841-3

Perfect score: 755

Sequence: 1 tctggaagagccaactgtgt.....tgggcagtgcggaagcga.755

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 0.5

Searched: 212 seqs, 3574 residues

Total number of hits satisfying chosen parameters: 424

Minimum DB seq length: 8

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 213 summaries

Database : fetch3rni.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
1	22	2.9	22	1	US-09-863-049B-61
2	20	2.6	21	1	US-09-863-049B-53
3	19.8	2.6	25	1	US-09-396-196G-13872
4	19.4	2.6	21	1	US-09-863-049B-55
5	19.4	2.6	25	1	US-09-863-049B-63
6	15.8	2.1	19	1	US-08-745-269-5
7	15.8	2.1	19	1	US-09-232-468A-10
8	15.8	2.1	19	1	US-09-784-984B-8
9	15.8	2.1	20	1	US-08-098-942C-16
10	15.8	2.1	21	1	US-10-083-720A-10
11	15.4	2.0	17	1	US-09-866-108A-7246
12	15.4	2.0	17	1	US-09-866-108A-7450
13	15.4	2.0	18	1	US-08-298-073-32
14	15.4	2.0	18	1	US-08-794-153-32
15	15.4	2.0	18	1	US-08-532-979-2
16	15.4	2.0	18	1	US-08-532-979-5
17	15.4	2.0	18	1	US-08-532-979-7
18	15.4	2.0	18	1	US-09-115-566-32
19	15.4	2.0	18	1	US-09-146-157-3
20	15.4	2.0	19	1	US-08-472-756-1
21	15.4	2.0	19	1	US-08-610-955-1
22	15.4	2.0	20	1	US-09-732-199A-18
23	15.4	2.0	20	1	US-09-863-049B-13
24	15.2	2.0	20	1	US-09-180-783-3
25	15.2	2.0	20	1	US-09-467-082-47
26	15.2	2.0	20	1	US-09-658-679A-61
27	15.2	2.0	20	1	US-09-081-385-131
28	15.2	2.0	20	1	US-09-608-088-16
29	15.2	2.0	20	1	US-09-711-288-16
30	15	2.0	15	1	US-09-863-049B-62
31	15	2.0	17	1	US-09-866-108A-7244
32	15	2.0	17	1	US-09-866-108A-7245
33	15	2.0	18	1	US-08-585-684B-2687

1	US-09-038-073-2687	18	2.0	15	C 34
1	US-09-045-301-3	18	2.0	14.8	C 35
1	US-09-045-301-4	18	2.0	14.8	C 36
1	US-09-422-978-8682	18	2.0	14.8	C 37
1	US-09-866-108A-7247	17	1.9	14.4	C 38
1	US-09-866-108A-7449	17	1.9	14.4	C 39
1	US-09-866-108A-7451	17	1.9	14.4	C 40
1	US-09-866-108A-8970	17	1.9	14.4	C 41
1	US-09-866-108A-8971	17	1.9	14.4	C 42
1	US-08-585-684B-2688	18	1.9	14.4	C 43
1	US-09-038-073-2688	18	1.9	14.4	C 44
1	US-09-422-978-10970	18	1.9	14.4	C 45
1	US-08-690-734A-61	19	1.9	14.4	C 46
1	US-08-742-185-61	19	1.9	14.4	C 47
1	US-09-866-108A-7243	17	1.9	14	C 48
1	US-09-866-108A-8972	17	1.9	14	C 49
1	US-09-866-108A-8973	17	1.9	14	C 50
1	US-09-205-143-42	18	1.9	14	C 51
1	US-08-373-124A-184	17	1.8	13.8	C 52
1	US-08-435-628-184	17	1.8	13.8	C 53
1	US-08-584-040-5982	17	1.8	13.8	C 54
1	US-09-371-772B-2829	17	1.8	13.8	C 55
1	US-09-371-772B-4771	17	1.8	13.8	C 56
1	US-09-371-772B-6804	17	1.8	13.8	C 57
1	US-09-866-108A-6823	17	1.8	13.8	C 58
1	US-09-866-108A-7698	17	1.8	13.8	C 59
1	US-09-866-108A-7813	17	1.8	13.8	C 60
1	US-09-866-108A-8421	17	1.8	13.8	C 61
1	US-09-866-108A-8422	17	1.8	13.8	C 62
1	US-09-685-664B-2829	17	1.8	13.8	C 63
1	US-08-470-124-56	18	1.8	13.8	C 64
1	US-09-106-038A-74	18	1.8	13.8	C 65
1	US-09-143-212-57	18	1.8	13.8	C 66
1	US-08-872-917-1	18	1.8	13.8	C 67
1	US-09-338-907-384	18	1.8	13.8	C 68
1	US-09-218-207-384	18	1.8	13.8	C 69
1	US-08-584-040-8322	18	1.8	13.8	C 70
1	US-09-371-772B-3980	18	1.8	13.8	C 71
1	US-09-347-613C-38	18	1.8	13.8	C 72
1	US-09-662-183A-38	18	1.8	13.8	C 73
1	US-09-685-664B-3980	18	1.8	13.8	C 74
1	US-09-396-196G-13872	25	1.8	13.8	C 75
1	US-09-142-078-44	17	1.8	13.6	C 76
1	US-09-357-141-44	17	1.8	13.6	C 77
1	US-09-533-889-44	17	1.8	13.6	C 78
1	US-09-142-080-44	17	1.8	13.6	C 79
1	US-08-585-684B-821	15	1.8	13.4	C 80
1	US-09-038-073-821	15	1.8	13.4	C 81
1	US-09-275-850-18	15	1.8	13.4	C 82
1	US-08-292-620A-1619	16	1.8	13.4	C 83
1	US-09-071-845-1619	16	1.8	13.4	C 84
1	US-08-345-264A-1	17	1.8	13.4	C 85
1	US-08-584-040-8022	17	1.8	13.4	C 86
1	US-09-474-432B-657	17	1.8	13.4	C 87
1	US-09-371-772B-3805	17	1.8	13.4	C 88
1	US-09-476-387-656	17	1.8	13.4	C 89
1	US-09-866-108A-6824	17	1.8	13.4	C 90
1	US-09-866-108A-7248	17	1.8	13.4	C 91
1	US-09-866-108A-7448	17	1.8	13.4	C 92
1	US-09-866-108A-7452	17	1.8	13.4	C 93
1	US-09-866-108A-8419	17	1.8	13.4	C 94
1	US-09-866-108A-8420	17	1.8	13.4	C 95
1	US-09-866-108A-8969	17	1.8	13.4	C 96
1	US-09-685-664B-3805	17	1.8	13.4	C 97
1	US-09-811-286-11	15	1.8	13	C 98
1	US-08-373-124A-180	17	1.7	13	C 100
1	US-08-373-124A-182	17	1.7	13	C 101
1	US-08-435-628-180	17	1.7	13	C 102
1	US-08-435-628-182	17	1.7	13	C 103
1	US-09-866-108A-7242	17	1.7	13	C 104
1	US-09-866-108A-8974	17	1.7	13	C 105
1	US-09-572-891-18	16	1.7	12.8	C 106

Sequence 2687, Ap
Sequence 3, Appli
Sequence 4, Appli
Sequence 8682, Ap
Sequence 7247, Ap
Sequence 7449, Ap
Sequence 7451, Ap
Sequence 8970, Ap
Sequence 8971, Ap
Sequence 2688, Ap
Sequence 2688, Ap
Sequence 10970, A
Sequence 61, Appl
Sequence 61, Appl
Sequence 7243, Ap
Sequence 8972, Ap
Sequence 8973, Ap
Sequence 42, Appl
Sequence 184, Ap
Sequence 184, App
Sequence 5992, Ap
Sequence 2829, Ap
Sequence 4771, Ap
Sequence 6804, Ap
Sequence 6823, Ap
Sequence 7698, Ap
Sequence 7813, Ap
Sequence 8421, Ap
Sequence 8422, Ap
Sequence 2829, Ap
Sequence 56, Appl
Sequence 74, Appl
Sequence 57, Appl
Sequence 1, Appl
Sequence 384, Ap
Sequence 384, Ap
Sequence 8322, Ap
Sequence 3980, Ap
Sequence 38, Appl
Sequence 38, Appl
Sequence 13872, A
Sequence 44, Appl
Sequence 44, Appl
Sequence 44, Appl
Sequence 44, Appl
Sequence 821, Ap
Sequence 821, Ap
Sequence 18, Appl
Sequence 1619, Ap
Sequence 1619, Ap
Sequence 1, Appl
Sequence 8022, Ap
Sequence 657, App
Sequence 3805, Ap
Sequence 656, App
Sequence 6824, Ap
Sequence 6825, Ap
Sequence 7248, Ap
Sequence 7448, Ap
Sequence 7452, Ap
Sequence 8419, Ap
Sequence 8420, Ap
Sequence 8969, Ap
Sequence 3805, Ap
Sequence 11, Appl
Sequence 180, App
Sequence 182, App
Sequence 180, App
Sequence 180, App
Sequence 7242, Ap
Sequence 8974, Ap
Sequence 18, Appl

THIS PAGE BLANK (USPTO)

SCORE OVER LENGTH SEARCHES

Attached is a score over length search. This search was developed to overcome limitations in most standard search systems which favor large sequences with high scoring, but lesser overall identity over smaller sequences with higher overall identity. This search is especially useful for relatively small nucleic acid or polypeptide target sequences (antisense, fragments, probes, primers, RNAi, epitopes, haptens, etc.) claimed functionally via a form of hybridization and/or identity language and having defined upper and lower polynucleotide and or polypeptide length limits.

The score over length search is performed by first running the query sequence using examiner-specified identity and polynucleotide or protein length limit parameters, and saving 65,000 hits and 0 alignments from each desired database. The resulting output is reformatted using a Microsoft Word macro and is imported into Excel. The summary table data are then sorted by the ratio of score of each hit sequence divided by its length and the accession numbers for all hits below the examiner's desired score over length parameters are deleted. The remaining accession numbers are used to pull the corresponding sequences from the databases into subdatabases enriched for good hits and the query sequence is re-run against these subdatabases to yield the final results.

The score over length cutoff for this search is 75.

Examiner Please Note: This cover sheet should be included when submitting results to be scanned.

```

; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 479
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-479

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 875 AACCATCATCAAGACGA 890
DB 1 AACUACCUCAAGACGA 16

RESULT 129
US-09-371-772B-3556/c
; Sequence 3556, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3556
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-3556

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 815 GAGAGAGGAGGAGCTGG 830
DB 17 GAGAGAGGAGGAGCTGG 2

RESULT 130
US-09-371-772B-4770
; Sequence 4770, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08

```

```

; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4770
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4770

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 874 CAACCATCATCAAGACG 889
DB 2 CAACUACCUCAAGACG 17

RESULT 131
US-09-476-387-477
; Sequence 477, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Zinzen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
; FILE REFERENCE: MBH00-831-C (249/073)
; CURRENT APPLICATION NUMBER: US/09/476,387
; CURRENT FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 477
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-476-387-477

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 263 CTGCACCTGCCTTCAG 278
DB 1 CUCCUCCUGCCUUCAG 16

RESULT 132
US-09-476-387-604
; Sequence 604, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Zinzen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot

```

```
; FILE REFERENCE: MEHB00-831-C (249/073)
; CURRENT APPLICATION NUMBER: US/09/476,387
; CURRENT FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 604
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-476-387-604
```

```
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 92;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 512 CTGCGGAGGTGGAGC 527
Db 1 CUGCGGAGGCGCAGC 16
```

```
RESULT 133
US-09-866-108A-354/c
; Sequence 354, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aecomica Sequence Listing Engine
; NUMBER OF SEQ ID NOS: 15755
; Patent No. 6686188
; SEQ ID NO 354
; LENGTH: 17
; TYPE: DNA
```

```
; ORGANISM: Homo sapiens
US-09-866-108A-354
```

```
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 482 CTCGATCTGAAGAGGC 497
Db 17 CTCGTTCTGGAGAGGC 2
```

```
RESULT 134
US-09-866-108A-355/c
; Sequence 355, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aecomica Sequence Listing Engine
; NUMBER OF SEQ ID NOS: 15755
; Patent No. 6686188
; SEQ ID NO 355
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-355
```

```
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 482 CTCGATCTGAAGAGGC 497
Db 16 CTCGTTCTGGAGAGGC 1
```

```
RESULT 135
US-09-866-108A-672/c
; Sequence 672, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
```



```
/ APPLICANT: JI, Yonggang
/ APPLICANT: PENN, Sharron G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
/ FILE REFERENCE: AEOMICA-7
/ CURRENT APPLICATION NUMBER: US/09/866,108A
/ CURRENT FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00663
/ PRIOR FILING DATE: 2001-01-30
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 15755
/ SOFTWARE: Aecomica Sequence Listing Engine
/ Patent No. 6686188
/ SEQ ID NO 672
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
/ US-09-866-108A-672

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 233 GAAGAGTCTCTCTGG 248
DB 17 GATGAGTCTCTCTGG 2

RESULT 136
US-09-866-108A-673/c
/ Sequence 673, Application US/09866108A
/ Patent No. 6686188
/ GENERAL INFORMATION:
/ APPLICANT: GU, Yizhong
/ APPLICANT: JI, Yonggang
/ APPLICANT: PENN, Sharron G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
/ FILE REFERENCE: AEOMICA-7
/ CURRENT APPLICATION NUMBER: US/09/866,108A
/ CURRENT FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 15755
/ SOFTWARE: Aecomica Sequence Listing Engine
/ Patent No. 6686188
/ SEQ ID NO 672
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
/ US-09-866-108A-672
```

```
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00663
/ PRIOR FILING DATE: 2001-01-30
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 15755
/ SOFTWARE: Aecomica Sequence Listing Engine
/ Patent No. 6686188
/ SEQ ID NO 673
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
/ US-09-866-108A-673

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 233 GAAGAGTCTCTCTGG 248
DB 16 GATGAGTCTCTCTGG 1

RESULT 137
US-09-866-108A-1523/c
/ Sequence 1523, Application US/09866108A
/ Patent No. 6686188
/ GENERAL INFORMATION:
/ APPLICANT: GU, Yizhong
/ APPLICANT: JI, Yonggang
/ APPLICANT: PENN, Sharron G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
/ FILE REFERENCE: AEOMICA-7
/ CURRENT APPLICATION NUMBER: US/09/866,108A
/ CURRENT FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 15755
/ SOFTWARE: Aecomica Sequence Listing Engine
/ Patent No. 6686188
/ SEQ ID NO 1523
/ LENGTH: 17
```

```
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1523

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      846 CCTATCACCAGCTCTT 861
Db      17 CCCATCACCCTGCTT 2

RESULT 138
US-09-866-108A-1524/c
; Sequence 1524, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1524
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1720

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      392 TTCCAGCCAGCCAGCA 407
Db      17 TTCTGAGCCAGCCAGA 2

RESULT 140
US-09-866-108A-1721/c
; Sequence 1721, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666

; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1524

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      846 CCTATCACCAGCTCTT 861
Db      16 CCCATCACCCTGCTT 1

RESULT 139
US-09-866-108A-1720/c
; Sequence 1720, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aemica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1721
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1721

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 392 TTCCAGCCGAGCCAGA 407
DB 16 TTCTGAGCCGAGCCAGA 1

RESULT 141
US-09-866-108A-1996/c
; Sequence 1996, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aemica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1996

; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1996

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 309 GCCTGAGGAGCAATCA 324
DB 17 GCCTGAGGAGCAATCA 2

RESULT 142
US-09-866-108A-1997/c
; Sequence 1997, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aemica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1997
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1997

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 309 GCCTGAGGAGCAATCA 324
DB 16 GCCTGAGGAGCAATCA 1

RESULT 143
US-09-866-108A-6822/c
; Sequence 6822, Application US/09866108A
; Patent No. 6686188

GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aeomica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 6822
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-6822

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 267 ACCTGCCTTCAGACA 282
Db 17 ACCTGCCTTGAGAAA 2

RESULT 144
US-09-866-108A-6890/C
Sequence 6890, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27

PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aeomica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 6890
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-6890

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 306 GCTGCCTTGAGAGAA 321
Db 17 GCCTGCCTTGAGAGAA 2

RESULT 145
US-09-866-108A-6891/C
Sequence 6891, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aeomica Sequence Listing Engine
Patent No. 6686188

; SEQ ID NO 6891
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6891

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 306 GCTGCTGGAGGAGAA 321
Db 16 GCCGCTGGAAGAA 1

RESULT 146

US-09-866-108A-7677
; Sequence 7677, Application US/09866108A

; Patent No. 6686188

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108A

; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663

; PRIOR FILING DATE: 2001-01-30

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755

; SOFTWARE: Aeomica Sequence Listing Engine

; Patent No. 6686188

; SEQ ID NO 7677

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-866-108A-7677

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 490 GAAGAGCGAAGAG 505
Db 2 GAAGAGCGAAGAG 17

RESULT 147

US-09-866-108A-7678

; Sequence 7678, Application US/09866108A

; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755

; SOFTWARE: Aeomica Sequence Listing Engine

; Patent No. 6686188

; SEQ ID NO 7678

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-866-108A-7678

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 490 GAAGAGCGAAGAG 505
Db 1 GAAGAGCGAAGAG 16

RESULT 148

US-09-866-108A-7697/c

; Sequence 7697, Application US/09866108A

; Patent No. 6686188

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108A

; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

```
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7697
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7697

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      828 TGGCCAGTGTGCAGGT 843
      ||| ||| ||| ||| |||
Db      17 TGGCCAGTGTGCAGGT 2

RESULT 149
US-09-866-108A-7699/c
; Sequence 7699, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7697
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7697

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      828 TGGCCAGTGTGCAGGT 843
      ||| ||| ||| ||| |||
Db      17 TGGCCAGTGTGCAGGT 2

RESULT 149
US-09-866-108A-7699/c
; Sequence 7699, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7697
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7697
```

```
; Patent No. 6686188
; SEQ ID NO 7699
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7699

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      827 CTGGCCAGTGTGCAGG 842
      ||| ||| ||| ||| |||
Db      16 CTGGCCAGTGTGCAGG 1

RESULT 150
US-09-866-108A-7812
; Sequence 7812, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7812
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7812

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      493 GAGGCAGAGGAGCAG 508
      ||| ||| ||| ||| |||
Db      2 GAAGCAAAAGGAGCAG 17

RESULT 151
US-09-866-108A-7814
```

; Sequence 7814, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7814
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7814

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 494 AGCAGAAGAGCAGG 509
DB 1 AAGCAAAAGAGCAGG 16
|||||

RESULT 152
US-09-866-108A-8033
; Sequence 8033, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8033
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8033

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 696 AGCTGAGAGTGAGCG 711
DB 2 AGCTGAGAGTGAGCG 17
|||||

RESULT 153
US-09-866-108A-8034
; Sequence 8034, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755

; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8034
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8034

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 696 AGCTGGAGAGTGACG 711
Db 1 AGCTGGAGATCGACG 16

RESULT 154

US-09-866-108A-8423
; Sequence 8423, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108A

; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663

; PRIOR FILING DATE: 2001-01-30

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755

; SOFTWARE: Aeomica Sequence Listing Engine

; Patent No. 6686188

; SEQ ID NO 8423

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-866-108A-8423

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 491 AAGAGCGAAGGAGC 506
Db 1 AAGAGCGAAGGAGC 16

RESULT 155

US-09-404-912-648
; Sequence 648, Application US/09404912
; Patent No. 6703228
; GENERAL INFORMATION:

; APPLICANT: John Landers
; APPLICANT: David Houseman
; APPLICANT: Barbara Jordan
; APPLICANT: Alain Charest

; TITLE OF INVENTION: Methods and Products Related to

; FILE REFERENCE: M0656/7045 (HCL/MAT)

; CURRENT APPLICATION NUMBER: US/09/404,912

; CURRENT FILING DATE: 1999-09-24

; PRIOR APPLICATION NUMBER: US 60/101,757

; PRIOR FILING DATE: 1998-09-25

; PRIOR APPLICATION NUMBER: PCT/US99/22283

; PRIOR FILING DATE: 1999-09-24

; NUMBER OF SEQ ID NOS: 691

; SOFTWARE: FastSeq for Windows Version 3.0

; SEQ ID NO 648

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo Sapiens

US-09-404-912-648

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 397 AGCGAGCGAGGAG 412
Db 1 AGCGAGCTAGAGGAG 16

RESULT 156

US-09-685-664B-479

; Sequence 479, Application US/09685664B

; Patent No. 6818447

; GENERAL INFORMATION:

; APPLICANT: Ribozyne Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam

; APPLICANT: McSwiggen, Jim

; APPLICANT: Stinchcomb, Dan

; APPLICANT: Escobedo, Jaime

; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related

; FILE REFERENCE: MBH00-876-K (400/021)

; CURRENT APPLICATION NUMBER: US/09/685,664B

; CURRENT FILING DATE: 2000-10-10

; PRIOR APPLICATION NUMBER: US 60/005,974

; PRIOR FILING DATE: 1995-10-26

; PRIOR APPLICATION NUMBER: US 08/584,040

; PRIOR FILING DATE: 1996-01-08

; PRIOR APPLICATION NUMBER: US 09/371,772

; PRIOR FILING DATE: 1999-08-10

; NUMBER OF SEQ ID NOS: 8231

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 479

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-09-685-664B-479

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 92;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 875 AACCCATCAAGCA 890
Db 1 AACUACCAAGCA 16

RESULT 157


```

US-09-685-664B-3556/c
; Sequence 3556, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Endothelial Growth Factor Receptor
; FILE REFERENCE: MEH800-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3556
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-09-685-664B-3556

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 815 GAGAGGAGGAAGCTGG 830
DB 17 GAGAGCAGAGCTGG 2

RESULT 158
5240847-22
; Patent No. 5240847
; APPLICANT: HECKL, KONRAD; SPEVAK, WALTER; OSTERMANN, ELINBOURG;
; ZOPHEL, ANDREAS; KRISTEK, EDELTRAUD; MAURER-FOG, INGRID;
; WITCHE-CASTANON, MARIA J.; STRATOWA, CHRISTIAN; HAUPTMANN, RUDOLF
; TITLE OF INVENTION: HUMAN MANGANESE SUPEROXIDE DISMUTASE
; (HMN-SOD)
; NUMBER OF SEQUENCES: 34
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/167,261
; FILING DATE: 11-MAR-1988
; SEQ ID NO: 22
; LENGTH: 17
5240847-22

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 182 GAGATGTCGAGCCCA 197
DB 2 GAGATGTTACAGCCCA 17

RESULT 159
US-08-390-850-5/c
; Sequence 5, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John T.
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:

```

```

; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Fast-SEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/390,850
; FILING DATE: February 17, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5612215ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-390-850-5

Query Match 1.6%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 79;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 380 GAGCTTCTGCATTT 393
DB 14 GAACTTCTGCATTT 1

RESULT 160
US-08-435-634-5/c
; Sequence 5, Application US/08435634
; Patent No. 5731295
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John T.
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:

```

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,634
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/390,850
FILING DATE: February 17, 1995
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5731295ember 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-634-5

Query Match 1.6%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 79;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 380 GAGCTTCTGCATTT 393
Db 14 GAACCTTCTGCATTT 1

RESULT 161
US-08-319-492B-129/c
Sequence 129, Application US/08319492B
Patent No. 5616488
GENERAL INFORMATION:
APPLICANT: Sullivan, Sean M.
APPLICANT: Draper, Kenneth G.
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF IL-5
NUMBER OF SEQUENCES: 751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/319,492B
FILING DATE: October 7, 1994

PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/276
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 129:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-319-492B-129

Query Match 1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 88;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 308 TGCCTGGAGGAGAA 321
Db 14 TGCCTGGAGGAGAA 1

RESULT 162
US-08-307-682B-18/c
Sequence 18, Application US/08307682B
Patent No. 5665580
GENERAL INFORMATION:
APPLICANT: Crooke, Stanley T., Mirabelli,
APPLICANT: Christopher K., Ecker, David J., Cowsett, Lex M.
TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE
TITLE OF INVENTION: INHIBITION OF PAPILLOMAVIRUS TRANSFORMED CELLS
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Jane Massey Licata, Esq.
STREET: 210 Lake Drive East, Suite 201
CITY: Cherry Hill
STATE: NJ
COUNTRY: USA
ZIP: 08002
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
COMPUTER: IBM 486
OPERATING SYSTEM: WINDOWS FOR WORKGROUPS
SOFTWARE: WORDPERFECT 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/307,682B
FILING DATE: October 14, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 860,925
FILING DATE: March 31, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US90/07067
FILING DATE: December 3, 1990
APPLICATION NUMBER: 445,195
FILING DATE: December 4, 1989
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata, Esquire
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISIS-1049
TELECOMMUNICATION INFORMATION:
TELEPHONE: (609) 779-2400

```

; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; ANTI-SENSE: yes
US-08-307-682B-18

Query Match 1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 88;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 404 CAGAGGGAGGAGAA 417
Db 14 CAGAGGTAGGAGAA 1

RESULT 163
US-08-585-684B-820/c
; Sequence 820, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: January 16, 1996
; PRIOR APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 885:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-585-684B-885

Query Match 1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 88;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 273 CTTGAGAACAGGC 286
Db 15 CTTGAGAAAGGC 2

RESULT 165
US-08-585-684B-886/c
; Sequence 886, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: January 16, 1996
; PRIOR APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 820:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-585-684B-820

Query Match 1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 88;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 580 CCAGGTGACGTCT 593
Db 580 CCAGGTGACGTCT 593
```

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 886:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-886

Query Match 1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 88;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 273 CTTGAGAACAGGGC 286
Db 14 CTTGAGAAAGGC 1

RESULT 166
US-09-038-073-820/c
Sequence 820, Application US/09038073
Patent No. 6194150
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwiggen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 820:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-820

Query Match 1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 88;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 580 CCAGGTGAGTCCT 593
Db 15 CCAGGTGAAGTCCT 2

RESULT 167
US-09-038-073-885/c
Sequence 885, Application US/09038073
Patent No. 6194150
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwiggen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 885:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single

```

;
; TOPOLOGY: linear
; US-09-038-073-885
;
; Query Match
; Best Local Similarity 1.6%; Score 12.4; DB 1; Length 15;
; Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
;
; QY 273 CTTCAGAACAGGC 286
; Db 15 CTTCAGAAAGGC 2
;
; RESULT 168
; US-09-038-073-886/c
; Sequence 886, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 886:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-038-073-886
;
; Query Match
; Best Local Similarity 1.6%; Score 12.4; DB 1; Length 15;
; Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
;
; QY 273 CTTCAGAACAGGC 286
; Db 14 CTTCAGAAAGGC 1
;
; RESULT 169
; US-09-180-437-182/c
; Sequence 182, Application US/09180437
; Patent No. 6251873
;

```

```

;
; GENERAL INFORMATION:
; APPLICANT: FUKUSAKO, Shioji
; APPLICANT: MORISAWA, Yoshifumi
; APPLICANT: KUSUYAMA, Takeshi
; TITLE OF INVENTION: Antisense Compounds to CD14
; FILE REFERENCE: 1110-209P
; CURRENT APPLICATION NUMBER: US/09/180,437
; CURRENT FILING DATE: 1998-11-06
; EARLIER APPLICATION NUMBER: PCT/JP98/00953
; EARLIER FILING DATE: 1998-03-09
; EARLIER APPLICATION NUMBER: 09-053518 JAPAN
; EARLIER FILING DATE: 1997-03-07
; NUMBER OF SEQ ID NOS: 289
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 182
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:other nucleic
; OTHER INFORMATION: acid
; US-09-180-437-182
;
; Query Match
; Best Local Similarity 1.6%; Score 12.4; DB 1; Length 15;
; Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
;
; QY 325 AGAGCTCCGAGATG 338
; Db 14 AGCGTCCGAGATG 1
;
; RESULT 170
; US-09-475-947A-304
; Sequence 304, Application US/09475947A
; Patent No. 6472154
; GENERAL INFORMATION:
; APPLICANT: Garner, Harold R.
; APPLICANT: Wren, Jonathan D.
; APPLICANT: Minna, John D.
; TITLE OF INVENTION: Polymorphic Repeats in Human Genes
; FILE REFERENCE: UTS0667
; CURRENT APPLICATION NUMBER: US/09/475,947A
; CURRENT FILING DATE: 1999-12-31
; NUMBER OF SEQ ID NOS: 346
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 304
; LENGTH: 15
; TYPE: DNA
; ORGANISM: human
; US-09-475-947A-304
;
; Query Match
; Best Local Similarity 1.6%; Score 12.4; DB 1; Length 15;
; Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
;
; QY 719 CTGACGACGACGCA 732
; Db 1 CAGCAGCAGCAGCA 14
;
; RESULT 171
; US-08-911-894-13/c
; Sequence 13, Application US/08911894
; Patent No. 6030830
; GENERAL INFORMATION:
; APPLICANT: Saxon, Andrew
; APPLICANT: Zhang, Ke
; APPLICANT: Fujieda, Shigeharu
; TITLE OF INVENTION: IMMUNOGLOBULIN TRANS-SPICED TRANSCRIPTS
; TITLE OF INVENTION: AND USES THEREOF
; NUMBER OF SEQUENCES: 90
; CORRESPONDENCE ADDRESS:
;

```

ADDRESSEE: Akin, Gump, Strauss, Hauer & Feld
STREET: 816 Congress Avenue, Suite 1900
CITY: Austin
STATE: Texas
COUNTRY: USA
ZIP: 78701
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/911,894
FILING DATE: Concurrently Herewith
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/023,579
FILING DATE: 19-AUG-1996
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Mayfield, Denise L.
REGISTRATION NUMBER: 33,732
REFERENCE/DOCKET NUMBER: 43496.0006
TELEPHONE: (512) 499-6200
TELEFAX: (512) 499-6290
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-911-894-13

Query Match 1.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 98;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 773 GTGGAGGCGCGCT 786
Db 15 GTGGAGGCGCTCGCT 2

RESULT 172
US-08-911-894-14
Sequence 14, Application US/08911894
Patent No. 6030830
GENERAL INFORMATION:
APPLICANT: Saxon, Andrew
APPLICANT: Zhang, Ke
TITLE OF INVENTION: IMMUNOGLOBULIN TRANS-SPLICED TRANSCRIPTS
TITLE OF INVENTION: AND USES THEREOF
NUMBER OF SEQUENCES: 90
CORRESPONDENCE ADDRESS:
ADDRESSEE: Akin, Gump, Strauss, Hauer & Feld
STREET: 816 Congress Avenue, Suite 1900
CITY: Austin
STATE: Texas
COUNTRY: USA
ZIP: 78701
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/911,894
FILING DATE: Concurrently Herewith
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/023,579
FILING DATE: 19-AUG-1996

CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Mayfield, Denise L.
REGISTRATION NUMBER: 33,732
REFERENCE/DOCKET NUMBER: 43496.0006
TELEPHONE: (512) 499-6200
TELEFAX: (512) 499-6290
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-911-894-14

Query Match 1.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 98;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 773 GTGGAGGCGCGCT 786
Db 2 GTGGAGGCGCTCGCT 15

RESULT 173
US-09-509-565-38
Sequence 38, Application US/09509565
Patent No. 6399340
GENERAL INFORMATION:
APPLICANT: SAITO, YOSHIMASA
APPLICANT: NOGUCHI, YUJI
APPLICANT: YOSHIKAWA, KOJI
APPLICANT: SOEDA, SHINSUKE
TITLE OF INVENTION: PLASMID VECTORS
FILE REFERENCE: 0018-1105-OPCT
CURRENT APPLICATION NUMBER: US/09/509,565
CURRENT FILING DATE: 2000-06-23
PRIOR APPLICATION NUMBER: PCT/JP9804611
PRIOR FILING DATE: 1998-10-13
PRIOR APPLICATION NUMBER: JP9/303395
PRIOR FILING DATE: 1997-10-16
NUMBER OF SEQ ID NOS: 42
SOFTWARE: PatentIn version 3.0
SEQ ID NO 38
LENGTH: 16
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
NAME/KEY: misc feature
OTHER INFORMATION: Description of Artificial Sequence: synthetic DNA
US-09-509-565-38

Query Match 1.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 98;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 741 AGGTGACCAGCTG 754
Db 1 AGGTGACCAGCTG 14

RESULT 174
US-09-060-299-445/c
Sequence 445, Application US/09060299
Patent No. 6545137
GENERAL INFORMATION:
APPLICANT: Todd, John A
APPLICANT: Hess, John W
APPLICANT: Caskey, Charles T
APPLICANT: Cox, Roger D
APPLICANT: Gerhold, David
APPLICANT: Hammond, Holly

```

; APPLICANT: Hey, Patricia
; APPLICANT: Kawaguchi, Yoshihiko
; APPLICANT: Merriman, Tony R
; APPLICANT: Metzker, Michael L
; TITLE OF INVENTION: No. 6545137el Receptor
; NUMBER OF SEQUENCES: 455
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Nixon and Vanderhye
; STREET: 1100 No. 6545137th Glebe Road, Eighth Floor
; CITY: Arlington
; STATE: Virginia
; COUNTRY: US
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/060,299
; FILING DATE: 15-APR-1998
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/043,553
; FILING DATE: 15-APR-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/048,740
; FILING DATE: 05-JUN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: B.J.Sadoff
; REGISTRATION NUMBER: 36,663
; REFERENCE/DOCKET NUMBER: 620-35
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703)816-4100
; TELEFAX: (703)816-4100
; INFORMATION FOR SEQ ID NO: 445:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; US-09-060-299-445

Query Match 1.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 98;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 508 GGCTCTGGCGGAGG 521
Db 14 GGCTCTGGCGGAGG 1

RESULT 175
US-09-402-923A-445/c
; Sequence 445, Application US/09402923A
; Patent No. 6555654
; GENERAL INFORMATION:
; APPLICANT: Todd, John A
; APPLICANT: Hees, John W
; APPLICANT: Caskey, Charles T
; APPLICANT: Cox, Roger D
; APPLICANT: Gerhold, David
; APPLICANT: Hammond, Holly
; APPLICANT: Hey, Patricia
; APPLICANT: Kawaguchi, Yoshihiko
; APPLICANT: Merriman, Tony R
; APPLICANT: Metzker, Michael L
; TITLE OF INVENTION: No. 6555654el LDL-Receptor
; NUMBER OF SEQUENCES: 455
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Nixon and Vanderhye
; STREET: 1100 No. 6555654th Glebe Road, Eighth Floor
; CITY: Arlington
; STATE: Virginia

```

```

; COUNTRY: US
; ZIP: VA 22201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/402,923A
; FILING DATE: 14-Feb-2001
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/GB98/01102
; FILING DATE: 15-APR-1998
; APPLICATION NUMBER: US 60/043,553
; FILING DATE: 15-APR-1997
; APPLICATION NUMBER: US 60/048,740
; FILING DATE: 05-JUN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: B.J.Sadoff
; REGISTRATION NUMBER: 36,663
; REFERENCE/DOCKET NUMBER: 620-81
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703)816-4091
; TELEFAX: (703)816-4100
; INFORMATION FOR SEQ ID NO: 445:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 445:
; US-09-402-923A-445

Query Match 1.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 98;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 508 GGCTCTGGCGGAGG 521
Db 14 GGCTCTGGCGGAGG 1

RESULT 176
US-09-371-772B-5656/c
; Sequence 5656, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: MCSwiggan, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5656
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-371-772B-5656

Query Match 1.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 98;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

Qy 705 GTGAGCGCGAGCG 718
|||||
Db 16 GTGAGCGCGAGCG 3

RESULT 177
US-09-544-398B-121/c
; Sequence 121, Application US/09544398B
; Patent No. 6770461
; GENERAL INFORMATION:
; APPLICANT: Carulli, John P.
; APPLICANT: Little, Randall D.
; APPLICANT: Recker, Robert R.
; APPLICANT: Johnson, Mark L.
; TITLE OF INVENTION: High bone mass gene of 11q13.3
; FILE REFERENCE: 032796-013
; CURRENT APPLICATION NUMBER: US/09/544,398B
; CURRENT FILING DATE: 2002-06-10
; PRIOR APPLICATION NUMBER: US 09/229,319
; PRIOR FILING DATE: 1999-01-13
; PRIOR APPLICATION NUMBER: US 60/071,449
; PRIOR FILING DATE: 1998-01-13
; PRIOR APPLICATION NUMBER: US 60/105,511
; PRIOR FILING DATE: 1998-10-23
; NUMBER OF SEQ ID NOS: 641
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 121
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-544-398B-121

Query Match 1.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 98;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 462 AGAGACTGGCGCTG 475
|||||
Db 14 AGAGACTGGCGCTG 1

RESULT 178
US-09-543-771B-121/c
; Sequence 121, Application US/09543771B
; Patent No. 6780609
; GENERAL INFORMATION:
; APPLICANT: Carulli, John P.
; APPLICANT: Little, Randall D.
; APPLICANT: Recker, Robert R.
; APPLICANT: Johnson, Mark L.
; TITLE OF INVENTION: High bone mass gene of 11q13.3
; FILE REFERENCE: 032796-014
; CURRENT APPLICATION NUMBER: US/09/543,771B
; CURRENT FILING DATE: 2000-04-05
; PRIOR APPLICATION NUMBER: US 09/229,319
; PRIOR FILING DATE: 1999-01-13
; PRIOR APPLICATION NUMBER: US 60/071,449
; PRIOR FILING DATE: 1998-01-13
; PRIOR APPLICATION NUMBER: US 60/105,511
; PRIOR FILING DATE: 1998-10-23
; NUMBER OF SEQ ID NOS: 641
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 121
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-543-771B-121

Query Match 1.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 98;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 462 AGAGACTGGCGCTG 475

Db 14 AGAGACTGGCGCTG 1
|||||

RESULT 179
US-07-891-962-9/c
; Sequence 9, Application US/07891962
; Patent No. 5587308
; GENERAL INFORMATION:
; APPLICANT: Carter, Barrie J.
; APPLICANT: Flotte, Terence
; APPLICANT: Afione, Sandra
; APPLICANT: Solow, Rikki
; TITLE OF INVENTION: MODIFIED ADENO-ASSOCIATED VIRUS VECTOR
; TITLE OF INVENTION: CAPABLE OF EXPRESSION FROM A NOVEL PROMOTER
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NEEDLE & ROSENBERG
; STREET: 133 Carnegie Way, N.W., Suite 400
; CITY: Atlanta
; STATE: Georgia
; COUNTRY: USA
; ZIP: 30303
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/891,962
; FILING DATE: 19920602
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Periyman, David G.
; REGISTRATION NUMBER: 33,438
; REFERENCE/DOCKET NUMBER: 1414.012
; TELEPHONE: (404) 688-0770
; TELEFAX: (404) 688-9880
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-07-891-962-9

Query Match 1.6%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 668 GCCCGGGCGGCC 679
|||||
Db 12 GCCCGGGCGGCC 1

RESULT 180
US-08-626-953-9/c
; Sequence 9, Application US/08626953
; Patent No. 5866696
; GENERAL INFORMATION:
; APPLICANT: Carter, Barrie J.
; APPLICANT: Flotte, Terence
; APPLICANT: Afione, Sandra
; APPLICANT: Solow, Rikki
; TITLE OF INVENTION: MODIFIED ADENO-ASSOCIATED VIRUS VECTOR
; TITLE OF INVENTION: CAPABLE OF EXPRESSION FROM A NOVEL PROMOTER
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NEEDLE & ROSENBERG
; STREET: 133 Carnegie Way, N.W., Suite 400
; CITY: Atlanta

STATE: Georgia
COUNTRY: USA
ZIP: 30303
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/626,953
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA: 07/891,962
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Perryman, David G.
REGISTRATION NUMBER: 33,438
REFERENCE/DOCKET NUMBER: 1414.012
TELEPHONE: (404) 688-0770
TELEFAX: (404) 688-9880
INFORMATION FOR SEQ ID NO: 9:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-626-953-9

Query Match 1.6%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 668 GCCCGGGCGGCC 679
DB 12 GCCCGGGCGGCC 1

RESULT 181
US-08-455-231-9/c
Sequence 9, Application US/08455231
Patent No. 5989540
GENERAL INFORMATION:
APPLICANT: Carter, Barrie J.
APPLICANT: Flotte, Terence
APPLICANT: Afione, Sandra
APPLICANT: Solow, Rikki
TITLE OF INVENTION: MODIFIED ADENO-ASSOCIATED VIRUS VECTOR
NUMBER OF SEQUENCES: 13
CORRESPONDENCE ADDRESS:
ADDRESSEE: NEEDLE & ROSENBERG
STREET: 133 Carnegie Way, N.W., Suite 400
CITY: Atlanta
STATE: Georgia
COUNTRY: USA
ZIP: 30303
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,231
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA: 07/891,962
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Perryman, David G.

REGISTRATION NUMBER: 33,438
REFERENCE/DOCKET NUMBER: 1414.012
TELEPHONE: (404) 688-0770
TELEFAX: (404) 688-9880
INFORMATION FOR SEQ ID NO: 9:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-455-231-9

Query Match 1.6%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 668 GCCCGGGCGGCC 679
DB 12 GCCCGGGCGGCC 1

RESULT 182
US-08-455-552A-9/c
Sequence 9, Application US/08455552A
Patent No. 5990279
GENERAL INFORMATION:
APPLICANT: Carter, Barrie J.
APPLICANT: Flotte, Terence
APPLICANT: Afione, Sandra
APPLICANT: Solow, Rikki
TITLE OF INVENTION: MODIFIED ADENO-ASSOCIATED VIRUS VECTOR
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESS:
ADDRESSEE: NEEDLE & ROSENBERG
STREET: 127 Peachtree Street, Suite 1200
CITY: Atlanta
STATE: Georgia
COUNTRY: USA
ZIP: 30303
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,552A
FILING DATE: 31 May 1995
CLASSIFICATION: 530
ATTORNEY/AGENT INFORMATION:
NAME: Perryman, David G.
REGISTRATION NUMBER: 33,438
REFERENCE/DOCKET NUMBER: 20094.0152
TELEPHONE: (404) 688-0770
TELEFAX: (404) 688-9880
INFORMATION FOR SEQ ID NO: 9:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-455-552A-9

Query Match 1.6%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 668 GCCCGGGCGGCC 679
DB 12 GCCCGGGCGGCC 1

```
Db      12 GCCCGGGCGGCC 1

RESULT 183
US-09-235-375-9/c
; Sequence 9, Application US/09233375
; Patent No. 6165781
; GENERAL INFORMATION:
; APPLICANT: Carter, Barrie J.
;             Florite, Terence
;             Afione, Sandra
;             Solow, Rikki
; TITLE OF INVENTION: MODIFIED ADENO-ASSOCIATED VIRUS VECTOR
; CAPABLE OF EXPRESSION FROM A NOVEL PROMOTER
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NEEDLE & ROSENBERG
; STREET: 133 Carnegie Way, N.W., Suite 400
; CITY: Atlanta
; STATE: Georgia
; COUNTRY: USA
; ZIP: 30303
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/235.375
; FILING DATE: 21-Jan-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/626,953
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Perryman, David G.
; REGISTRATION NUMBER: 33,438
; REFERENCE/DOCKET NUMBER: 1414.012
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (404) 688-0770
; TELEFAX: (404) 688-9880
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-09-235-375-9

Query Match      1.6%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      668 GCCCGGGCGGCC 679
        |||||
Db      12 GCCCGGGCGGCC 1

RESULT 184
US-09-213-834B-6
; Sequence 6, Application US/09213834B
; Patent No. 6825011
; GENERAL INFORMATION:
; APPLICANT: Romantchikov, Yuri
; TITLE OF INVENTION: IMPROVED METHODS FOR INSERTION OF
; FILE REFERENCE: 11639/1
; CURRENT APPLICATION NUMBER: US/09/213,834B
; CURRENT FILING DATE: 1998-12-17
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSEQ for Windows Version 4.0
; OPERATING SYSTEM: IBM P.C. DOS 5.0
```

```
; SEQ ID NO 6
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cloning Vector
US-09-213-834B-6

Query Match      1.6%; Score 12; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 92;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      668 GCCCGGGCGGCC 679
        |||||
Db      1 GCCCGGGCGGCC 12

RESULT 185
US-09-213-834B-7
; Sequence 7, Application US/09213834B
; Patent No. 6825011
; GENERAL INFORMATION:
; APPLICANT: Romantchikov, Yuri
; TITLE OF INVENTION: IMPROVED METHODS FOR INSERTION OF
; FILE REFERENCE: 11639/1
; CURRENT APPLICATION NUMBER: US/09/213,834B
; CURRENT FILING DATE: 1998-12-17
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cloning Vector
US-09-213-834B-7

Query Match      1.6%; Score 12; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 92;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      668 GCCCGGGCGGCC 679
        |||||
Db      1 GCCCGGGCGGCC 12

RESULT 186
US-08-319-492B-16
; Sequence 16, Application US/08319492B
; Patent No. 5616488
; GENERAL INFORMATION:
; APPLICANT: Sullivan, Sean M.
; APPLICANT: Draper, Kenneth G.
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS
; NUMBER OF SEQUENCES: 751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
```

```

; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/319,492B
; FILING DATE: October 7, 1994
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/276
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-319-492B-16

Query Match 1.6%; Score 12; DB 1; Length 15;
Best Local Similarity 50.0%; Pred. No. 1e+02;
Matches 6; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 382 GCTTCGTGCAUUT 393
Db 4 GCUCUGCAUU 15

RESULT 187
US-08-588-595-1/c
; Sequence 1, Application US/08588595
; Patent No. 5958769
; GENERAL INFORMATION:
; APPLICANT: Roberts, James M.
; APPLICANT: Coats, Steven R.
; APPLICANT: Fero, Matthew L.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR MEDIATING
; TITLE OF INVENTION: CELL CYCLE PROGRESSION
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew
; STREET: One Market Plaza, Steuart Street Tower
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94105-1492
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/588,595
; FILING DATE: 18-JAN-1996
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W.
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 14538A-19
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs

```

```

; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleotide
; US-08-588-595-1

Query Match 1.6%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 607 GCAGGAGAGCCA 618
Db 12 GCAGGAGAGCCA 1

RESULT 188
US-09-180-437-104
; Sequence 104, Application US/09180437
; Patent No. 6251873
; GENERAL INFORMATION:
; APPLICANT: FUKUSAKO, Shioji
; APPLICANT: MORISAWA, Yoshifumi
; APPLICANT: KUSUYAMA, Takeshi
; TITLE OF INVENTION: Antisense Compounds to CD14
; FILE REFERENCE: 1110-209P
; CURRENT APPLICATION NUMBER: US/09/180,437
; CURRENT FILING DATE: 1998-11-06
; EARLIER APPLICATION NUMBER: PCT/JP98/00953
; EARLIER FILING DATE: 1998-03-09
; EARLIER APPLICATION NUMBER: 09-053518 JAPAN
; EARLIER FILING DATE: 1997-03-07
; NUMBER OF SEQ ID NOS: 289
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 104
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:other nucleic
; OTHER INFORMATION: acid
; US-09-180-437-104

Query Match 1.6%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 721 GCAGCAGCAGCA 732
Db 2 GCAGCAGCAGCA 13

RESULT 189
US-09-163-485-13/c
; Sequence 13, Application US/09163485
; Patent No. 6277571
; GENERAL INFORMATION:
; APPLICANT: FILLMORE, HELEN
; APPLICANT: BROADUS, WILLIAM
; APPLICANT: GILLIES, GEORGE
; TITLE OF INVENTION: SEQUENTIAL CONSENSUS REGION-DIRECTED AMPLIFICATION OF
; TITLE OF INVENTION: KNOWN AND NOVEL MEMBERS OF GENE FAMILIES
; FILE REFERENCE: VCUIP4B
; CURRENT APPLICATION NUMBER: US/09/163,485
; CURRENT FILING DATE: 1998-08-30
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 13
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide, consensus sequence from human

```

; OTHER INFORMATION: matrix metalloproteinases
US-09-163-485-13

Query Match 1.6%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 721 GCAGCAGCAGCA 732
Db 13 GCAGCAGCAGCA 2
|||||

RESULT 190

US-09-081-646-177

; Sequence 177, Application US/09081646

; Patent No. 6333152

; GENERAL INFORMATION:

; APPLICANT: Kinzler, Kenneth

; APPLICANT: Vogelstein, Bert

; APPLICANT: Zhang, Lin

; APPLICANT: Zhou, Wei

; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and

; FILE REFERENCE: 01107.74664

; CURRENT APPLICATION NUMBER: US/09/081,646

; CURRENT FILING DATE: 1998-05-20

; EARLIER APPLICATION NUMBER: 60/047,352

; EARLIER FILING DATE: 1997-05-21

; NUMBER OF SEQ ID NOS: 871

; SOFTWARE: FastSeq for Windows Version 3.0

; SEQ ID NO 177

; LENGTH: 15

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-081-646-177

Query Match

Best Local Similarity 1.6%; Score 12; DB 1; Length 15;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 249 GGAAGCCAGCCA 260
Db 4 GGAAGCCAGCCA 15
|||||

RESULT 191

US-08-705-477E-49

; Sequence 49, Application US/08705477E

; Patent No. 6569432

; GENERAL INFORMATION:

; APPLICANT: Israeli, Ron S

; APPLICANT: Heston, Warren D.W.

; APPLICANT: Fair, William R.

; APPLICANT: Overfelli, Ouathak

; APPLICANT: Pinto, John

; TITLE OF INVENTION: PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND USES THEREOF

; FILE REFERENCE: 1769/41426-G

; CURRENT APPLICATION NUMBER: US/08/705,477E

; CURRENT FILING DATE: 1996-08-29

; NUMBER OF SEQ ID NOS: 128

; SOFTWARE: PatentIn version 3.1

; SEQ ID NO 49

; LENGTH: 15

; TYPE: DNA

; ORGANISM: Homo sapiens

US-08-705-477E-49

Query Match

Best Local Similarity 1.6%; Score 12; DB 1; Length 15;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 641 AAGGAATGCCAG 652
|||||

Db 1 AAGGAATGCCAG 12

RESULT 192

US-09-079-839-1/c

; Sequence 1, Application US/09079839

; Patent No. 6048726

; GENERAL INFORMATION:

; APPLICANT: Weltman, Joel K.

; APPLICANT: Karim, Aftab S.

; TITLE OF INVENTION: INHIBITION OF EOSINOPHILIC INFLAMMATION

; FILE REFERENCE: 09998/002001

; CURRENT APPLICATION NUMBER: US/09/079,839

; CURRENT FILING DATE: 1998-05-15

; NUMBER OF SEQ ID NOS: 2

; SOFTWARE: FastSeq for Windows Version 3.0

; SEQ ID NO 1

; LENGTH: 16

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-079-839-1

Query Match

Best Local Similarity 1.6%; Score 12; DB 1; Length 16;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 382 GCTTCTGCAATT 393
Db 16 GCTTCTGCAATT 5
|||||

RESULT 193

US-09-917-907-1

; Sequence 1, Application US/09917907

; Patent No. 6653466

; GENERAL INFORMATION:

; APPLICANT: Matsuo, Masafumi

; TITLE OF INVENTION: Pharmaceutical Composition for Treatment of Muscular Dystrophy

; FILE REFERENCE: P21305

; CURRENT APPLICATION NUMBER: US/09/917,907

; CURRENT FILING DATE: 2001-07-31

; PRIOR APPLICATION NUMBER: 09/563,260

; PRIOR FILING DATE: 2000-05-01

; PRIOR APPLICATION NUMBER: JP 140930/99

; PRIOR FILING DATE: 1999-05-21

; NUMBER OF SEQ ID NOS: 2

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 1

; LENGTH: 16

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-917-907-1

Query Match

Best Local Similarity 1.6%; Score 12; DB 1; Length 16;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 536 AGATGCCAGCAG 547
Db 4 AGATGCCAGCAG 15
|||||

RESULT 194

US-09-667-327-5

; Sequence 5, Application US/09667327

; Patent No. 6653467

; GENERAL INFORMATION:

; APPLICANT: JCR Pharmaceuticals Co., Ltd.

; TITLE OF INVENTION: Medicament for Treatment of Duchenne Muscular Dystrophy

; FILE REFERENCE: GP34

; CURRENT APPLICATION NUMBER: US/09/667,327

; CURRENT FILING DATE: 2000-09-22

; NUMBER OF SEQ ID NOS: 6

```
; SEQ ID NO 5
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-667-327-5

Query Match      1.6%; Score 12; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      536 AGATGCCAGCAG 547
Db      4 AGATGCCAGCAG 15

RESULT 195
US-09-930-251-1
; Sequence 1, Application US/09930251
; Patent No. 6727355
; GENERAL INFORMATION:
; APPLICANT: Matsuo, Masafumi; Kamel, Shoichiro
; TITLE OF INVENTION: Pharmaceutical Composition for Treatment of Duchenne Muscular Dystrophy
; FILE REFERENCE: P21360
; CURRENT APPLICATION NUMBER: US/09/930,251
; CURRENT FILING DATE: 2001-08-16
; PRIOR APPLICATION NUMBER: JP2000-256547
; PRIOR FILING DATE: 2000-08-25
; NUMBER OF SEQ ID NOS: 19
; SEQ ID NO 1
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-930-251-1

Query Match      1.6%; Score 12; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      536 AGATGCCAGCAG 547
Db      4 AGATGCCAGCAG 15

RESULT 196
US-08-182-968A-139/C
; Sequence 139, Application US/08182968A
; Patent No. 5610054
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 497
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/182,968A
; FILING DATE: 13-JANUARY-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/882,888
; FILING DATE: 14-MAY-1992
```

```
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 205/277
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 139:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-182-968A-139

Query Match      1.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      511 TCTGCGGAGGTGGA 525
Db      15 TCTGATGGAGGTGGA 1

RESULT 197
US-08-100-465-7
; Sequence 7, Application US/08100465
; Patent No. 5610137
; GENERAL INFORMATION:
; APPLICANT: TOWNES, TIM M., ET AL.
; TITLE OF INVENTION: TRANSGENIC, CROSS-LINKED
; TITLE OF INVENTION: HEMOGLOBIN
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM PS/2 Model 502 or 55SX
; OPERATING SYSTEM: IBM P.C. DOS (Version 3.30)
; SOFTWARE: WordPerfect (Version 5.0)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/100,465
; FILING DATE: 30-JUL-1993
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/630,825
; FILING DATE: DECEMBER 20, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: CLARK, PAUL T.
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 004005
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-5070
; TELEFAX: (617) 542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-100-465-7

Query Match      1.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

Qy 260 ATGCTGCACCTGCT 274
||| ||||| ||
Db 1 ATGCTGCACCTGACT 15

RESULT 198

US-08-291-932A-296/c
; Sequence 296, Application US/08291932A
; Patent No. 5658780

GENERAL INFORMATION:

; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth G.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: NF-KB
; NUMBER OF SEQUENCES: 830

CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066

COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/291,932A
; FILING DATE: August 15, 1994
; CLASSIFICATION: 514

PRIOR APPLICATION DATA:

; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:

; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/157
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 296:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

Query Match 1.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 243 CTCTGGGGAAGCAG 257
||| ||||| |||
Db 15 CTCTGGGAGGGCAG 1

RESULT 199

US-08-292-620A-35
; Sequence 35, Application US/08292620A
; Patent No. 5837542

GENERAL INFORMATION:

; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390

CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066

COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435

PRIOR APPLICATION DATA:

; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:

; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 35:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-292-620A-35

Query Match 1.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 60.0%; Pred. No. 1.1e+02;
Matches 9; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 416 AAGGAGTCTCATG 430
||| ||||| :|:|:
Db 1 AAGGAGUGCUCCUG 15

RESULT 200

US-08-292-620A-176/c
; Sequence 176, Application US/08292620A
; Patent No. 5837542

GENERAL INFORMATION:

; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS

two

Two

;; TITLE OF INVENTION: RELATED TO LEVELS OF
;; TITLE OF INVENTION: INTRACELLULAR ADHESION
;; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
;; NUMBER OF SEQUENCES: 2390
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Lyon & Lyon
;; STREET: 633 West Fifth Street
;; CITY: Los Angeles
;; STATE: California
;; COUNTRY: U.S.A.
;; ZIP: 90071-2066
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/292,620A
;; FILING DATE: August 17, 1994
;; CLASSIFICATION: 435
;; PRIOR APPLICATION DATA: including application
;; PRIOR APPLICATION DATA: described below:
;; APPLICATION NUMBER: 08/008,895
;; FILING DATE: January 19, 1993
;; APPLICATION NUMBER: 07/989,849
;; FILING DATE: December 7, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 208/149
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 176:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-292-620A-176

Query Match 1.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 553 GGCTGAGGACAAAGGC 567
DB 15 GACTGAGGACAAATGC 1

RESULT 201
US-08-774-306A-139/c
; Sequence 139, Application US/08774306A
; Patent No. 5869253
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 497
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:

;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/774,306A
;; FILING DATE: December 26, 1996
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/182,968
;; FILING DATE: January 13, 1994
;; APPLICATION NUMBER: 07/882,888
;; FILING DATE: May 14, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 223/227
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 139:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-774-306A-139

Query Match 1.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 511 TCTGGCGGAGGTGGA 525
DB 15 TCTGATGGAGGTGGA 1

RESULT 202
US-09-064-156A-139/c
; Sequence 139, Application US/09064156A
; Patent No. 6132966
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 498
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/064,156A
; FILING DATE: April 21, 1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/774,306
; FILING DATE: December 26, 1996
; APPLICATION NUMBER: 08/182,968
; FILING DATE: January 13, 1994
; APPLICATION NUMBER: 07/882,888
; FILING DATE: May 14, 1992
; ATTORNEY/AGENT INFORMATION:

```
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 234/083
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 139:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-064-156A-139

Query Match 1.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 511 TCTGCGGAGGTGGA 525
Db 15 TCTGATGGAGGTGGA 1

RESULT 203
US-09-071-845-35
; Sequence 35, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 176:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-071-845-176
```

```
; INFORMATION FOR SEQ ID NO: 35:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-071-845-35

Query Match 1.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 60.0%; Pred. No. 1.1e+02;
Matches 9; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 416 AAGGAGTCTCTCATG 430
Db 1 AAGGAGUGUCUCCUG 15

RESULT 204
US-09-071-845-176/c
; Sequence 176, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 176:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-071-845-176
```


Query Match 1.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 553 GGCTGAGGACAAGGC 567
| | | | | | | | | | | | | | |
Db 15 GACTGAGGACAATGC 1

RESULT 205

US-09-232-468A-9/c
; Sequence 9, Application US/09232468A
; Patent No. 6207165
; GENERAL INFORMATION:
; APPLICANT: AUDONNET et al.
; TITLE OF INVENTION: POLYNUCLEOTIDE VACCINE FORMULA AGAINST PORCINE
; TITLE OF INVENTION: REPRODUCTIVE AND RESPIRATORY PATHOLOGIES
; FILE REFERENCE: 454313-2230
; CURRENT APPLICATION NUMBER: US/09/232,468A
; CURRENT FILING DATE: 1999-01-05
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 9
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Aujeszky's Disease Virus (NIA3 Strain)
US-09-232-468A-9

Query Match 1.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 372 GCTGCGAGGAGTTC 386
| | | | | | | | | | | | | | |
Db 15 GCTGCGAGGAGCATC 1

RESULT 206

US-09-275-850-21
; Sequence 21, Application US/09275850A
; Patent No. 6261774
; GENERAL INFORMATION:
; APPLICANT: Pagratis, Nikos
; APPLICANT: Gold, Larry
; APPLICANT: Shtatland, Timur
; APPLICANT: Javornik, Brenda
; TITLE OF INVENTION: Truncation SELEX Method
; FILE REFERENCE: NEX 79
; CURRENT APPLICATION NUMBER: US/09/275,850A
; CURRENT FILING DATE: 1999-03-24
; NUMBER OF SEQ ID NOS: 351
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 21
; LENGTH: 15
; TYPE: RNA
; ORGANISM: E. coli
US-09-275-850-21

Query Match 1.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.1e+02;
Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 720 TGCAGCAGCAGCACCA 734
| | | | | | | | | | | | | | |
Db 1 UGCAGCAACAGCGCA 15

RESULT 207

US-09-081-646-429/c
; Sequence 429, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:

; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 429
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-429

Query Match 1.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 324 AAGAGCTCGAGATG 338
| | | | | | | | | | | | | | |
Db 15 AACAGCTCGACATG 1

RESULT 208

US-09-081-646-468
; Sequence 468, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 468
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-468

Query Match 1.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 259 CATGCTGCACCTGCC 273
| | | | | | | | | | | | | | |
Db 1 CATGCTGCACCTCCC 15

RESULT 209

US-09-474-432B-194
; Sequence 194, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David

```
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
; FILE REFERENCE: MHB00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; CURRENT FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 194
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-194

Query Match          1.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 60.0%; Pred. No. 1.1e+02;
Matches 9; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY      264 TGCACCTGCCTTCAG 278
Db      : |||:||||:
          1 UCCUCCUGCCUUCAG 15

RESULT 210
US-09-784-984B-7/c
; Sequence 7, Application US/09784984B
; Patent No. 6576243
; GENERAL INFORMATION:
; APPLICANT: Merial Ltd.
; APPLICANT: Audonnet, Jean-Christophe
; APPLICANT: Bouchardon, Annabelle
; APPLICANT: Baudu, Philippe
; APPLICANT: Riviere, Michael
; TITLE OF INVENTION: Polynucleotide Vaccine Formula Against Porcine Reproductive and
; FILE REFERENCE: 454313-2230.1
; CURRENT APPLICATION NUMBER: US/09/784,984B
; CURRENT FILING DATE: 2001-02-16
; PRIOR APPLICATION NUMBER: FR 96/09338
; PRIOR FILING DATE: 1996-07-19
; PRIOR APPLICATION NUMBER: PCT/FR97/01313
; PRIOR FILING DATE: 1997-07-15
; PRIOR APPLICATION NUMBER: US 6,207,165
; PRIOR FILING DATE: 2001-03-27
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Aujeszky's Disease Virus (NIA3 Strain)
US-09-784-984B-7

Query Match          1.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      372 GCTCGGAGGAGCTTC 386
Db      : |||||:||||:
          15 GCTCGGAGGAGCATC 1

RESULT 211
US-09-476-387-194
; Sequence 194, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
```

```
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
; FILE REFERENCE: MHB00-831-C (249/073)
; CURRENT APPLICATION NUMBER: US/09/476,387
; CURRENT FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 194
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-476-387-194

Query Match          1.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 60.0%; Pred. No. 1.1e+02;
Matches 9; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY      264 TGCACCTGCCTTCAG 278
Db      : |||:||||:
          1 UCCUCCUGCCUUCAG 15

RESULT 212
5182195-58
; Patent No. 5182195
; APPLICANT: NAKAHAMA, KAZUO;KAISHO, YOSHIHIKO;YOSHIMURA, KOJI
; TITLE OF INVENTION: METHOD FOR INCREASING USING PROTEASE
; DEFICIENT YEASTS
; NUMBER OF SEQUENCES: 71
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/269,140
; FILING DATE: 09-NOV-1988
; SEQ ID NO:58:
; LENGTH: 15
5182195-58

Query Match          1.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      612 AGAGCCAGAGTCGCT 626
Db      : |||||:||||:
          1 AGAGCCTGGCTCGCT 15

RESULT 213
5182195-58
; Patent No. 5182195
; APPLICANT: NAKAHAMA, KAZUO;KAISHO, YOSHIHIKO;YOSHIMURA, KOJI
; TITLE OF INVENTION: METHOD FOR INCREASING USING PROTEASE
; DEFICIENT YEASTS
; NUMBER OF SEQUENCES: 71
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/269,140
; FILING DATE: 09-NOV-1988
; SEQ ID NO:58:
; LENGTH: 15
```

5182195-58

Query Match 1.6%; Score 11.8; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 1.1e+02;
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 612 AGAGCCAGAGTCGCT 626
 |||||
 Db 1 AGAGCCTGGGTCGCT 15

Search completed: April 8, 2005, 08:49:19
 Job time : 3 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 8, 2005, 08:45:15 ; Search time 8 Seconds
(without alignments)
3.726 Million cell updates/sec

Title: US-10-628-841-3

Perfect score: 755

Sequence: 1 tctggaagagccaactgtgt.....tgggcagtgagcggaagcga 755

Scoring table: IDENTITY NUC

Gapop 10_0 , Gapext 0.5

Searched: 1138 seqs, 19741 residues

Total number of hits satisfying chosen parameters: 2276

Minimum DB seq length: 8

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 1138 summaries

Database : fetchrng.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	29	3.8	29	ADA44708	PCR probe for ampl
2	27	3.6	27	ADSL7882	Human IKKGv2.1 D
3	23	3.0	23	ADG29527	IKKG siNA-target R
4	23	3.0	23	ADG29528	IKKG siNA-target R
5	22	2.9	22	ACD23070	Human NEMO exon 3
6	21	2.8	21	ADA13786	Short interfering
7	21	2.8	21	ADAL3787	Short interfering
8	21	2.8	21	ADAL3791	Short interfering
9	21	2.8	21	ADN75886	Human IKKGgamma sir
10	21	2.8	21	ADN75896	Human IKKGgamma sir
11	20	2.6	20	ADA44738	Antisense oligonuc
12	20	2.6	20	ADA44746	Antisense oligonuc
13	20	2.6	20	ADA44751	Antisense oligonuc
14	20	2.6	20	ADA44756	Antisense oligonuc
15	20	2.6	20	ADA44750	Antisense oligonuc
16	20	2.6	20	ADA44719	Antisense oligonuc
17	20	2.6	20	ADA44732	Antisense oligonuc
18	20	2.6	20	ADA44733	Antisense oligonuc
19	20	2.6	20	ADA44739	Antisense oligonuc
20	20	2.6	20	ADA44742	Antisense oligonuc
21	20	2.6	20	ADA44728	Antisense oligonuc
22	20	2.6	20	ADA44744	Antisense oligonuc
23	20	2.6	20	ADA44707	PCR primer for amp
24	20	2.6	20	ADA44718	Antisense oligonuc
25	20	2.6	20	ADA44734	Antisense oligonuc
26	20	2.6	20	ADA44747	Antisense oligonuc
27	20	2.6	20	ADA44730	Antisense oligonuc
28	20	2.6	20	ADA44733	Antisense oligonuc
29	20	2.6	20	ADA44741	Antisense oligonuc
30	20	2.6	20	ADA44724	Antisense oligonuc
31	20	2.6	20	ADA44727	Antisense oligonuc
32	20	2.6	20	ADA44720	Antisense oligonuc
33	20	2.6	20	ADA44740	Antisense oligonuc

C 34	20	2.6	20	1	ADA44725	Antisense oligonuc
C 35	20	2.6	20	1	ADA44731	Antisense oligonuc
C 36	20	2.6	20	1	ADA44745	Antisense oligonuc
C 37	20	2.6	20	1	ADA44723	Antisense oligonuc
C 38	20	2.6	20	1	ADA44748	Antisense oligonuc
C 39	20	2.6	20	1	ADA44721	Antisense oligonuc
C 40	20	2.6	20	1	ADA44737	Antisense oligonuc
C 41	20	2.6	20	1	ADA44749	Antisense oligonuc
C 42	20	2.6	20	1	ADA44735	Antisense oligonuc
C 43	20	2.6	20	1	ADA44743	Antisense oligonuc
C 44	20	2.6	20	1	ADA44729	Antisense oligonuc
C 45	20	2.6	20	1	ADA44736	Antisense oligonuc
C 46	20	2.6	21	1	ACD23062	Human NEMO gene RT
C 47	20	2.6	21	1	ADAL3795	Short interfering
C 48	20	2.6	23	1	ADG30046	IKKG-targeted siNA
C 49	19.4	2.6	21	1	ACD23064	Human NEMO gene RT
C 50	19.4	2.6	21	1	ADA13790	Short interfering
C 51	19.4	2.6	21	1	ADG30050	IKKG-targeted siNA
C 52	19.4	2.6	21	1	ADN75891	Human IKKGgamma sir
C 53	19.4	2.6	23	1	ADG30045	IKKG-targeted siNA
C 54	19.4	2.6	25	1	ACD23072	Human NEMO gene mu
C 55	19	2.5	19	1	ADN75887	IKK.2 associated s
C 56	19	2.5	19	1	ADN75888	IKK.2 associated s
C 57	19	2.5	19	1	ADN75892	IKK.3 associated s
C 58	19	2.5	19	1	ADN75883	IKK.1 associated s
C 59	19	2.5	19	1	ADN75893	IKK.3 associated s
C 60	19	2.5	19	1	ADN75882	IKK.1 associated s
C 61	19	2.5	19	1	ADN75898	IKK.4 associated s
C 62	19	2.5	19	1	ADN75897	IKK.4 associated s
C 63	19	2.5	21	1	ADAL3794	Short interfering
C 64	19	2.5	21	1	ADG30049	IKKG-targeted siNA
C 65	19	2.5	21	1	ADN75900	IKK.4 associated s
C 66	19	2.5	21	1	ADN75884	IKK.1 associated s
C 67	19	2.5	21	1	ADN75894	IKK.3 associated s
C 68	19	2.5	21	1	ADN75890	IKK.2 associated s
C 69	19	2.5	21	1	ADN75881	Human IKKGgamma sir
C 70	19	2.5	21	1	ADN75899	IKK.4 associated s
C 71	19	2.5	21	1	ADN75885	IKK.1 associated s
C 72	19	2.5	21	1	ADN75889	IKK.2 associated s
C 73	19	2.5	21	1	ADN75895	IKK.3 associated s
C 74	18.4	2.4	20	1	ADJ46760	Human KIAA1531 ant
C 75	18.4	2.4	20	1	ADG31926	Cyclin-dependent k
C 76	17	2.3	17	1	ADL47533	Human IKK-gamma su
C 77	17	2.3	17	1	ADL47537	Human IKK-gamma su
C 78	17	2.3	17	1	ADL47549	Human IKK-gamma su
C 79	17	2.3	17	1	ADL47744	Human IKK-gamma su
C 80	17	2.3	17	1	ADL47762	Human IKK-gamma su
C 81	17	2.3	17	1	ADL47788	Human IKK-gamma su
C 82	17	2.3	17	1	ADL47794	Human IKK-gamma su
C 83	17	2.3	17	1	ADL47821	Human IKK-gamma su
C 84	17	2.3	17	1	ADL47839	Human IKK-gamma su
C 85	17	2.3	17	1	ADL47841	Human IKK-gamma su
C 86	17	2.3	17	1	ADL47859	Human IKK-gamma su
C 87	17	2.3	17	1	ADL48207	Human IKK-gamma su
C 88	17	2.3	17	1	ADL48222	Human IKK-gamma su
C 89	17	2.3	17	1	ADL48232	Human IKK-gamma su
C 90	17	2.3	17	1	ADL48266	Human IKK-gamma su
C 91	17	2.3	17	1	ADL48275	Human IKK-gamma su
C 92	17	2.3	17	1	ADL48280	Human IKK-gamma su
C 93	17	2.3	17	1	ADL48291	Human IKK-gamma su
C 94	17	2.3	17	1	ADL48312	Human IKK-gamma su
C 95	17	2.3	17	1	ADL48482	Human IKK-gamma su
C 96	17	2.3	17	1	ADL48559	Human IKK-gamma su
C 97	17	2.3	17	1	ADL48564	Human IKK-gamma su
C 98	17	2.3	17	1	ADL48578	Human IKK-gamma su
C 99	17	2.3	17	1	ADL48600	Human IKK-gamma su
C 100	17	2.3	17	1	ADL48606	Human IKK-gamma su
C 101	17	2.3	17	1	ADL48617	Human IKK-gamma su
C 102	17	2.3	17	1	ADL48628	Human IKK-gamma su
C 103	17	2.3	17	1	ADL48630	Human IKK-gamma su
C 104	17	2.3	17	1	ADL48632	Human IKK-gamma su
C 105	17	2.3	17	1	ADL48653	Human IKK-gamma su
C 106	17	2.3	17	1	ADL48657	Human IKK-gamma su

253	17	2.3	17	1	ADL48485	Human	IKK-gamma	su	326	17	2.3	17	1	ADL48669	Human	IKK-gamma	su
254	17	2.3	17	1	ADL48485	Human	IKK-gamma	su	327	17	2.3	17	1	ADL48684	Human	IKK-gamma	su
255	17	2.3	17	1	ADL48589	Human	IKK-gamma	su	328	17	2.3	17	1	ADL48697	Human	IKK-gamma	su
256	17	2.3	17	1	ADL48644	Human	IKK-gamma	su	329	17	2.3	17	1	ADL47523	Human	IKK-gamma	su
257	17	2.3	17	1	ADL48654	Human	IKK-gamma	su	330	17	2.3	17	1	ADL47739	Human	IKK-gamma	su
258	17	2.3	17	1	ADL48666	Human	IKK-gamma	su	331	17	2.3	17	1	ADL47747	Human	IKK-gamma	su
259	17	2.3	17	1	ADL48699	Human	IKK-gamma	su	332	17	2.3	17	1	ADL47779	Human	IKK-gamma	su
260	17	2.3	17	1	ADL47959	Human	IKK-gamma	su	333	17	2.3	17	1	ADL47798	Human	IKK-gamma	su
261	17	2.3	17	1	ADL47761	Human	IKK-gamma	su	334	17	2.3	17	1	ADL47808	Human	IKK-gamma	su
262	17	2.3	17	1	ADL47781	Human	IKK-gamma	su	335	17	2.3	17	1	ADL47827	Human	IKK-gamma	su
263	17	2.3	17	1	ADL47782	Human	IKK-gamma	su	336	17	2.3	17	1	ADL47844	Human	IKK-gamma	su
264	17	2.3	17	1	ADL47785	Human	IKK-gamma	su	337	17	2.3	17	1	ADL47884	Human	IKK-gamma	su
265	17	2.3	17	1	ADL47815	Human	IKK-gamma	su	338	17	2.3	17	1	ADL47887	Human	IKK-gamma	su
266	17	2.3	17	1	ADL47825	Human	IKK-gamma	su	339	17	2.3	17	1	ADL48221	Human	IKK-gamma	su
267	17	2.3	17	1	ADL47829	Human	IKK-gamma	su	340	17	2.3	17	1	ADL48242	Human	IKK-gamma	su
268	17	2.3	17	1	ADL47838	Human	IKK-gamma	su	341	17	2.3	17	1	ADL48243	Human	IKK-gamma	su
269	17	2.3	17	1	ADL47848	Human	IKK-gamma	su	342	17	2.3	17	1	ADL48246	Human	IKK-gamma	su
270	17	2.3	17	1	ADL47853	Human	IKK-gamma	su	343	17	2.3	17	1	ADL48267	Human	IKK-gamma	su
271	17	2.3	17	1	ADL47856	Human	IKK-gamma	su	344	17	2.3	17	1	ADL48281	Human	IKK-gamma	su
272	17	2.3	17	1	ADL47868	Human	IKK-gamma	su	345	17	2.3	17	1	ADL48284	Human	IKK-gamma	su
273	17	2.3	17	1	ADL47888	Human	IKK-gamma	su	346	17	2.3	17	1	ADL48290	Human	IKK-gamma	su
274	17	2.3	17	1	ADL48235	Human	IKK-gamma	su	347	17	2.3	17	1	ADL48297	Human	IKK-gamma	su
275	17	2.3	17	1	ADL48237	Human	IKK-gamma	su	348	17	2.3	17	1	ADL48311	Human	IKK-gamma	su
276	17	2.3	17	1	ADL48244	Human	IKK-gamma	su	349	17	2.3	17	1	ADL48488	Human	IKK-gamma	su
277	17	2.3	17	1	ADL48259	Human	IKK-gamma	su	350	17	2.3	17	1	ADL48572	Human	IKK-gamma	su
278	17	2.3	17	1	ADL48271	Human	IKK-gamma	su	351	17	2.3	17	1	ADL48588	Human	IKK-gamma	su
279	17	2.3	17	1	ADL48332	Human	IKK-gamma	su	352	17	2.3	17	1	ADL48591	Human	IKK-gamma	su
280	17	2.3	17	1	ADL48474	Human	IKK-gamma	su	353	17	2.3	17	1	ADL48602	Human	IKK-gamma	su
281	17	2.3	17	1	ADL48565	Human	IKK-gamma	su	354	17	2.3	17	1	ADL48608	Human	IKK-gamma	su
282	17	2.3	17	1	ADL48601	Human	IKK-gamma	su	355	17	2.3	17	1	ADL48615	Human	IKK-gamma	su
283	17	2.3	17	1	ADL48609	Human	IKK-gamma	su	356	17	2.3	17	1	ADL48634	Human	IKK-gamma	su
284	17	2.3	17	1	ADL48620	Human	IKK-gamma	su	357	17	2.3	17	1	ADL48637	Human	IKK-gamma	su
285	17	2.3	17	1	ADL48623	Human	IKK-gamma	su	358	17	2.3	17	1	ADL48648	Human	IKK-gamma	su
286	17	2.3	17	1	ADL48639	Human	IKK-gamma	su	359	17	2.3	17	1	ADL48658	Human	IKK-gamma	su
287	17	2.3	17	1	ADL48660	Human	IKK-gamma	su	360	17	2.3	17	1	ADL48667	Human	IKK-gamma	su
288	17	2.3	17	1	ADL48660	Human	IKK-gamma	su	361	17	2.3	17	1	ADL48677	Human	IKK-gamma	su
289	17	2.3	17	1	ADL48662	Human	IKK-gamma	su	362	17	2.3	17	1	ADL48690	Human	IKK-gamma	su
290	17	2.3	17	1	ADL48703	Human	IKK-gamma	su	363	17	2.3	17	1	ADL47547	Human	IKK-gamma	su
291	17	2.3	17	1	ADL47513	Human	IKK-gamma	su	364	17	2.3	17	1	ADL47556	Human	IKK-gamma	su
292	17	2.3	17	1	ADL47517	Human	IKK-gamma	su	365	17	2.3	17	1	ADL47557	Human	IKK-gamma	su
293	17	2.3	17	1	ADL47542	Human	IKK-gamma	su	366	17	2.3	17	1	ADL47743	Human	IKK-gamma	su
294	17	2.3	17	1	ADL47544	Human	IKK-gamma	su	367	17	2.3	17	1	ADL47754	Human	IKK-gamma	su
295	17	2.3	17	1	ADL47546	Human	IKK-gamma	su	368	17	2.3	17	1	ADL47775	Human	IKK-gamma	su
296	17	2.3	17	1	ADL47550	Human	IKK-gamma	su	369	17	2.3	17	1	ADL47784	Human	IKK-gamma	su
297	17	2.3	17	1	ADL47740	Human	IKK-gamma	su	370	17	2.3	17	1	ADL47786	Human	IKK-gamma	su
298	17	2.3	17	1	ADL47741	Human	IKK-gamma	su	371	17	2.3	17	1	ADL47799	Human	IKK-gamma	su
299	17	2.3	17	1	ADL47763	Human	IKK-gamma	su	372	17	2.3	17	1	ADL47814	Human	IKK-gamma	su
300	17	2.3	17	1	ADL47772	Human	IKK-gamma	su	373	17	2.3	17	1	ADL47869	Human	IKK-gamma	su
301	17	2.3	17	1	ADL47802	Human	IKK-gamma	su	374	17	2.3	17	1	ADL47892	Human	IKK-gamma	su
302	17	2.3	17	1	ADL48209	Human	IKK-gamma	su	375	17	2.3	17	1	ADL48223	Human	IKK-gamma	su
303	17	2.3	17	1	ADL47846	Human	IKK-gamma	su	376	17	2.3	17	1	ADL48229	Human	IKK-gamma	su
304	17	2.3	17	1	ADL47852	Human	IKK-gamma	su	377	17	2.3	17	1	ADL48230	Human	IKK-gamma	su
305	17	2.3	17	1	ADL47861	Human	IKK-gamma	su	378	17	2.3	17	1	ADL48231	Human	IKK-gamma	su
306	17	2.3	17	1	ADL47863	Human	IKK-gamma	su	379	17	2.3	17	1	ADL48262	Human	IKK-gamma	su
307	17	2.3	17	1	ADL47874	Human	IKK-gamma	su	380	17	2.3	17	1	ADL48276	Human	IKK-gamma	su
308	17	2.3	17	1	ADL48209	Human	IKK-gamma	su	381	17	2.3	17	1	ADL48286	Human	IKK-gamma	su
309	17	2.3	17	1	ADL48228	Human	IKK-gamma	su	382	17	2.3	17	1	ADL48292	Human	IKK-gamma	su
310	17	2.3	17	1	ADL48247	Human	IKK-gamma	su	383	17	2.3	17	1	ADL48305	Human	IKK-gamma	su
311	17	2.3	17	1	ADL48257	Human	IKK-gamma	su	384	17	2.3	17	1	ADL48566	Human	IKK-gamma	su
312	17	2.3	17	1	ADL48334	Human	IKK-gamma	su	385	17	2.3	17	1	ADL48567	Human	IKK-gamma	su
313	17	2.3	17	1	ADL48563	Human	IKK-gamma	su	386	17	2.3	17	1	ADL48568	Human	IKK-gamma	su
314	17	2.3	17	1	ADL48579	Human	IKK-gamma	su	387	17	2.3	17	1	ADL48577	Human	IKK-gamma	su
315	17	2.3	17	1	ADL48595	Human	IKK-gamma	su	388	17	2.3	17	1	ADL48586	Human	IKK-gamma	su
316	17	2.3	17	1	ADL48604	Human	IKK-gamma	su	389	17	2.3	17	1	ADL48603	Human	IKK-gamma	su
317	17	2.3	17	1	ADL48607	Human	IKK-gamma	su	390	17	2.3	17	1	ADL48612	Human	IKK-gamma	su
318	17	2.3	17	1	ADL48613	Human	IKK-gamma	su	391	17	2.3	17	1	ADL48629	Human	IKK-gamma	su
319	17	2.3	17	1	ADL48616	Human	IKK-gamma	su	392	17	2.3	17	1	ADL48631	Human	IKK-gamma	su
320	17	2.3	17	1	ADL48621	Human	IKK-gamma	su	393	17	2.3	17	1	ADL48661	Human	IKK-gamma	su
321	17	2.3	17	1	ADL48622	Human	IKK-gamma	su	394	17	2.3	17	1	ADL48674	Human	IKK-gamma	su
322	17	2.3	17	1	ADL48624	Human	IKK-gamma	su	395	17	2.3	17	1	ADL48679	Human	IKK-gamma	su
323	17	2.3	17	1	ADL48627	Human	IKK-gamma	su	396	17	2.3	17	1	ADL48693	Human	IKK-gamma	su
324	17	2.3	17	1	ADL48664	Human	IKK-gamma	su	397	17	2.3	17	1	ADL48707	Human	IKK-gamma	su
325	17	2.3	17	1	ADL48668	Human	IKK-gamma	su	398	17	2.3	17	1	ADL47515	Human	IKK-gamma	su

c 691	15	2.0	20	1	ADO46267	Human oligonucleot	764	13.8	1.8	17	1	ADF62162	Human PCCP1 DNA fr
c 692	14.8	2.0	18	1	AAV60911	Angiogenin antisense	765	13.8	1.8	17	1	ADF64121	Human PCCP1 DNA fr
c 693	14.8	2.0	18	1	AAV60919	Angiogenin sense o	c 766	13.8	1.8	17	1	ADM09541	Human NOGO recepto
c 694	14.8	2.0	18	1	AAZ77049	PCR primer for the	c 767	13.8	1.8	17	1	ADL48763	Human IKK-gamma su
c 695	14.8	2.0	18	1	AAZ74326	Human biallelic ma	c 768	13.8	1.8	17	1	ADL49424	Human PKR substrat
c 696	14.8	2.0	19	1	AAZ33146	Treponema pallidum	c 769	13.8	1.8	17	1	ADL46635	Human NOGO recepto
c 697	14.8	2.0	19	1	ABN84784	Primer useful for	c 770	13.8	1.8	17	1	ADL51771	Human PKR substr
c 698	14.8	2.0	19	1	ABL31391	Human HLA genotypi	c 771	13.8	1.8	17	1	ADL49425	Human PKR substrat
c 699	14.8	2.0	19	1	ADF36747	Human VEGFR2 short	c 772	13.8	1.8	17	1	ADL87094	HCV DNzyme substr
c 700	14.8	2.0	19	1	ADF37071	Human VEGFR2 short	c 773	13.8	1.8	17	1	ACN69921	Human GMPLP-1 prob
c 701	14.8	2.0	19	1	ADN75338	Human CD45 CR regi	c 774	13.8	1.8	17	1	ACN70796	Human GMPLP-1 prob
c 702	14.8	2.0	19	1	ADR75637	Human apolipoprote	c 775	13.8	1.8	17	1	ACN70911	Human GMPLP-1 prob
c 703	14.8	2.0	19	1	ADR78255	Human apolipoprote	c 776	13.8	1.8	17	1	ACN71520	Human GMPLP-1 prob
c 704	14.4	1.9	17	1	ABN07457	Human GMPLP-1 17-m	c 777	13.8	1.8	17	1	ACN71519	Human GMPLP-1 prob
c 705	14.4	1.9	17	1	ABN07459	Human GMPLP-1 17-m	c 778	13.8	1.8	18	1	AAZ75572	Mouse flt-1 VEGF r
c 706	14.4	1.9	17	1	ABN07255	Human GMPLP-1 17-m	c 779	13.8	1.8	18	1	AAZ74250	Estn9 primer R1.
c 707	14.4	1.9	17	1	ABN08979	Human GMPLP-1 17-m	c 780	13.8	1.8	18	1	AAV07833	Segment of branch
c 708	14.4	1.9	17	1	ABN08978	Human GMPLP-1 17-m	c 781	13.8	1.8	18	1	AAZ36676	PCR primer for mar
c 709	14.4	1.9	17	1	ACD59504	HCV DNzyme substr	c 782	13.8	1.8	18	1	AAZ20075	PCR primer for hum
c 710	14.4	1.9	17	1	ACN70345	Human GMPLP-1 prob	c 783	13.8	1.8	18	1	AAV83062	Oligonucleotide fo
c 711	14.4	1.9	17	1	ACN70547	Human GMPLP-1 prob	c 784	13.8	1.8	18	1	AAZ01227	PCR primer for PGI
c 712	14.4	1.9	17	1	ACN72068	Human GMPLP-1 prob	c 785	13.8	1.8	18	1	AAZ48548	Human TNFR1 mRNA i
c 713	14.4	1.9	17	1	ACN70549	Human GMPLP-1 prob	c 786	13.8	1.8	18	1	AAZ74709	Sequencing primer
c 714	14.4	1.9	17	1	ACN72069	Human GMPLP-1 prob	c 787	13.8	1.8	18	1	AAZ93487	TRADD antisense ol
c 715	14.4	1.9	18	1	AAZ67194	Human CD40 hairpin	c 788	13.8	1.8	18	1	AAH56090	Human SCN3A PCR-SS
c 716	14.4	1.9	18	1	AAZ76614	Human biallelic ma	c 789	13.8	1.8	18	1	AAF89332	Sample member cius
c 717	14.4	1.9	18	1	AAH75205	Human inducible NO	c 790	13.8	1.8	18	1	ABT13201	Fanconi anaemia FA
c 718	14.4	1.9	18	1	AAZ55767	Fluorogenic probe	c 791	13.8	1.8	18	1	ABT05044	TNFR1 expression m
c 719	14.4	1.9	18	1	ADD94303	Mouse HUI77/HUIV26	c 792	13.8	1.8	18	1	ABT11916	Neublastin DNA rel
c 720	14.4	1.9	19	1	AAZ02688	Human papilloma vi	c 793	13.8	1.8	18	1	ADC42438	FANCD2 PCR primer
c 721	14.4	1.9	19	1	AAZ02696	Human papilloma vi	c 794	13.8	1.8	18	1	ABX34421	PCR primer #2 for
c 722	14.4	1.9	19	1	AAZ01486	Primer STS sy240 r	c 795	13.8	1.8	18	1	ACA58246	Human familial bip
c 723	14.4	1.9	19	1	AAZ92545	Human Y-specific S	c 796	13.8	1.8	18	1	ADL71979	CENP-A DNA amplify
c 724	14.4	1.9	15	1	AAZ35047	HPV ORF-Ec target	c 797	13.8	1.8	18	1	ADP47488	Intelligent PCR pr
c 725	14.4	1.9	17	1	ABN08981	Human GMPLP-1 17-m	c 798	13.8	1.8	18	1	ADQ059846	Human TNFR1 antise
c 726	14.4	1.9	17	1	ABN07261	Human GMPLP-1 17-m	c 799	13.8	1.8	18	1	ADRO6076	Novel mutant prote
c 727	14.4	1.9	17	1	ABN08980	Human GMPLP-1 17-m	c 800	13.8	1.8	18	1	ADT00917	Allele specific pr
c 728	14.4	1.9	17	1	ACC53301	Human tumour suppr	c 801	13.8	1.8	18	1	ADR74661	Probe for Conus ge
c 729	14.4	1.9	17	1	ACN70341	Human GMPLP-1 prob	c 802	13.6	1.8	17	1	AAV20512	Probe for Conus ge
c 730	14.4	1.9	17	1	ACN72070	Human GMPLP-1 prob	c 803	13.6	1.8	17	1	AAV17129	Probe used to isol
c 731	14.4	1.9	17	1	ACN72071	Human GMPLP-1 prob	c 804	13.6	1.8	17	1	AAV165365	Microsatellite seq
c 732	14.4	1.9	18	1	AAA48792	Human G-alpha-16 a	c 805	13.4	1.8	15	1	AAQ33752	Ap(a) mRNA (nt. p
c 733	13.8	1.8	17	1	AAZ81047	Human C-myb hamme	c 806	13.4	1.8	15	1	AAZ37567	Mouse B7-1 hammerh
c 734	13.8	1.8	17	1	AAZ73242	Mouse flt-1 VEGF r	c 807	13.4	1.8	15	1	AAZ65327	Substrate for ham
c 735	13.8	1.8	17	1	AAZ01997	Hammerhead ribozym	c 808	13.4	1.8	15	1	AAZ64153	E. coli nuok RNAMO
c 736	13.8	1.8	17	1	AAZ01998	Hammerhead ribozym	c 809	13.4	1.8	15	1	ACG69823	IGFBP2 oligonucleo
c 737	13.8	1.8	17	1	ABA80609	POE mutation corr	c 810	13.4	1.8	15	1	AAZ45430	IGFBP2 oligonucleo
c 738	13.8	1.8	17	1	ABA80608	POE mutation corr	c 811	13.4	1.8	15	1	AAZ45429	IGFBP3 oligonucleo
c 739	13.8	1.8	17	1	ABN08430	Human GMPLP-1 17-m	c 812	13.4	1.8	15	1	AAZ47286	Hepatitis C virus
c 740	13.8	1.8	17	1	ABN07706	Human GMPLP-1 17-m	c 813	13.4	1.8	15	1	ABX01206	Allele specific pr
c 741	13.8	1.8	17	1	ABN07821	Human GMPLP-1 17-m	c 814	13.4	1.8	15	1	ADR74748	Rat ICAM hairpin r
c 742	13.8	1.8	17	1	ABN06831	Human GMPLP-1 17-m	c 815	13.4	1.8	16	1	AAZ53413	Human NOV4 forward
c 743	13.8	1.8	17	1	ABN08429	Human GMPLP-1 17-m	c 816	13.4	1.8	16	1	ACF06258	Klebsiella oxytoca
c 744	13.8	1.8	17	1	ABV89590	Human POSHLI scann	c 817	13.4	1.8	16	1	ADN01434	DNA probe 1 specif
c 745	13.8	1.8	17	1	ABL31574	Human HLA genotypi	c 818	13.4	1.8	17	1	AAZ93742	Mouse flt-1 VEGF r
c 746	13.8	1.8	17	1	ABK56107	Human CLCA1 gene e	c 819	13.4	1.8	17	1	AAZ75272	Human GMPLP-1 17-m
c 747	13.8	1.8	17	1	ACN08336	WNV minus strand I	c 820	13.4	1.8	17	1	ABN07456	Human GMPLP-1 17-m
c 748	13.8	1.8	17	1	ACN10740	WNV minus strand I	c 821	13.4	1.8	17	1	ABN07256	Human GMPLP-1 17-m
c 749	13.8	1.8	17	1	ACN06511	WNV Amberzyme subs	c 822	13.4	1.8	17	1	ABN08977	Human GMPLP-1 17-m
c 750	13.8	1.8	17	1	ACN06512	WNV Amberzyme subs	c 823	13.4	1.8	17	1	ABN06832	Human GMPLP-1 17-m
c 751	13.8	1.8	17	1	ACN14467	WNV minus strand A	c 824	13.4	1.8	17	1	ABN08427	Human GMPLP-1 17-m
c 752	13.8	1.8	17	1	ACN10741	WNV minus strand I	c 825	13.4	1.8	17	1	ABN08428	Human GMPLP-1 17-m
c 753	13.8	1.8	17	1	ACN02935	WNV inozyme substr	c 826	13.4	1.8	17	1	ABN06833	Human GMPLP-1 17-m
c 754	13.8	1.8	17	1	ACA06363	NFKB sub-unit modu	c 827	13.4	1.8	17	1	ABN07460	Human GMPLP-1 17-m
c 755	13.8	1.8	17	1	ACA08234	Necrosis factor ka	c 828	13.4	1.8	17	1	ABK25615	Stress tolerance c
c 756	13.8	1.8	17	1	ADA99740	Human MD23 scannin	c 829	13.4	1.8	17	1	ABK25616	Stress tolerance c
c 757	13.8	1.8	17	1	ADA99741	Human MD23 scannin	c 830	13.4	1.8	17	1	ACN06513	WNV Amberzyme subs
c 758	13.8	1.8	17	1	ACD65432	HCV minus strand D	c 831	13.4	1.8	17	1	ACN08335	WNV minus strand H
c 759	13.8	1.8	17	1	ADB40151	Tumour suppression	c 832	13.4	1.8	17	1	ACN10739	Tumour suppression
c 760	13.8	1.8	17	1	ADB40733	Tumour suppression	c 833	13.4	1.8	17	1	ACN10739	Tumour suppression
c 761	13.8	1.8	17	1	ADF64209	Human PCCP1 DNA fr	c 834	13.4	1.8	17	1	ACA07656	NFKB sub-unit modu
c 762	13.8	1.8	17	1	ADF62167	Human PCCP1 DNA fr	c 835	13.4	1.8	17	1	ACA06305	NFKB sub-unit modu
c 763	13.8	1.8	17	1	ADF64208	Human PCCP1 DNA fr	c 836	13.4	1.8	17	1	ABZ64849	Human HER2 DNzyme

837	13.4	1.8	17	1	ACD63165	HCV minus strand D	c 910	12.8	1.7	16	1	ADD20502	Oreochromis niloti
838	13.4	1.8	17	1	ADB45030	Tumour suppression	c 911	12.8	1.7	16	1	ACD43260	Nucleotide sequenc
839	13.4	1.8	17	1	ADF62873	Human PCCP1 DNA fr	c 912	12.8	1.7	16	1	ACR06457	IMAGE:2631676 mRNA
840	13.4	1.8	17	1	ADL511393	Human tumour suppr	c 913	12.8	1.7	16	1	ADR06458	Unigene cluster EN
841	13.4	1.8	17	1	ADL511625	Human PTGDR substr	c 914	12.8	1.7	17	1	AAR052083	Breast cancer spec
842	13.4	1.8	17	1	ADL511956	Human PTGDR substr	c 915	12.8	1.7	17	1	AAT533562	Rat ICAM hammerhea
843	13.4	1.8	17	1	ADL821333	Human ER+ breast c	c 916	12.8	1.7	17	1	AAT53584	Rat ICAM hammerhea
844	13.4	1.8	17	1	ADL821556	Human ER+ breast c	c 917	12.8	1.7	17	1	AAT53620	Rat ICAM hammerhea
845	13.4	1.8	17	1	ADL85947	HCV DNazyme substr	c 918	12.8	1.7	17	1	AAT53439	Rat ICAM hammerhea
846	13.4	1.8	17	1	ADN443307	Mutant cell identi	c 919	12.8	1.7	17	1	AAT53627	Rat ICAM hammerhea
847	13.4	1.8	17	1	ADN443306	Mutant cell identi	c 920	12.8	1.7	17	1	AAT04961	Antimicrobial prot
848	13.4	1.8	17	1	ACN69922	Human GMPLP-1 prob	c 921	12.8	1.7	17	1	AAT81043	Human c-myb hamme
849	13.4	1.8	17	1	ACN70550	Human GMPLP-1 prob	c 922	12.8	1.7	17	1	AA669184	Human fit1 VEGF re
850	13.4	1.8	17	1	ACN71517	Human GMPLP-1 prob	c 923	12.8	1.7	17	1	AA675022	Mouse fit-1 VEGF r
851	13.4	1.8	17	1	ACN69923	Human GMPLP-1 prob	c 924	12.8	1.7	17	1	AA674865	Mouse fit-1 VEGF r
852	13.4	1.8	17	1	ACN72067	Human GMPLP-1 prob	c 925	12.8	1.7	17	1	AAV17893	Primer used to con
853	13.4	1.8	17	1	ACN71518	Human GMPLP-1 prob	c 926	12.8	1.7	17	1	AAV96651	Potato citrate syn
854	13.4	1.8	17	1	ACN70346	Human GMPLP-1 prob	c 927	12.8	1.7	17	1	AAA20387	Integrin alpha 6 s
855	13.4	1.8	17	1	ACN70546	Human PKR subestrat	c 928	12.8	1.7	17	1	AAA17439	Human fit1 VEGF re
856	13	1.7	13	1	ABF30519	Oligonucleotide SE	c 929	12.8	1.7	17	1	AAA22723	Integrin subunit b
857	13	1.7	13	1	ABF29699	Oligonucleotide SE	c 930	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
858	13	1.7	13	1	ABF29698	Oligonucleotide SE	c 931	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
859	13	1.7	13	1	ABF30518	Oligonucleotide SE	c 932	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
860	13	1.7	13	1	ADJ50821	Human PKR subestrat	c 933	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
861	13	1.7	13	1	ADJ50820	Human PKR subestrat	c 934	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
862	13	1.7	13	1	ADJ50850	Human PKR subestrat	c 935	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
863	13	1.7	13	1	ADJ50850	Human PKR subestrat	c 936	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
864	13	1.7	13	1	ADJ50850	Human PKR subestrat	c 937	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
865	13	1.7	13	1	ADJ50848	Human PKR subestrat	c 938	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
866	13	1.7	13	1	ADJ50848	Human PKR subestrat	c 939	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
867	13	1.7	13	1	ADJ50848	Human PKR subestrat	c 940	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
868	13	1.7	13	1	ADJ50848	Human PKR subestrat	c 941	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
869	13	1.7	13	1	ADJ50848	Human PKR subestrat	c 942	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
870	13	1.7	13	1	ADJ50848	Human PKR subestrat	c 943	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
871	13	1.7	13	1	AA678357	Human CHM1 allele	c 944	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
872	13	1.7	13	1	AA678357	IGFBP3 oligonucleo	c 945	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
873	13	1.7	13	1	AA678357	IGFBP3 oligonucleo	c 946	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
874	13	1.7	13	1	AA678357	IGFBP3 oligonucleo	c 947	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
875	13	1.7	13	1	AA678357	IGFBP3 oligonucleo	c 948	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
876	13	1.7	13	1	AA678357	IGFBP3 oligonucleo	c 949	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
877	13	1.7	13	1	AA678357	IGFBP3 oligonucleo	c 950	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
878	13	1.7	13	1	AA678357	IGFBP3 oligonucleo	c 951	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
879	13	1.7	13	1	AA678357	IGFBP3 oligonucleo	c 952	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
880	13	1.7	13	1	AA678357	IGFBP3 oligonucleo	c 953	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
881	13	1.7	13	1	AA678357	IGFBP3 oligonucleo	c 954	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
882	13	1.7	13	1	AA678357	IGFBP3 oligonucleo	c 955	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
883	13	1.7	13	1	AA678357	IGFBP3 oligonucleo	c 956	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
884	13	1.7	13	1	AA678357	IGFBP3 oligonucleo	c 957	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
885	13	1.7	13	1	AA678357	IGFBP3 oligonucleo	c 958	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
886	13	1.7	13	1	AA678357	IGFBP3 oligonucleo	c 959	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
887	13	1.7	13	1	AA678357	IGFBP3 oligonucleo	c 960	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
888	13	1.7	13	1	AA678357	IGFBP3 oligonucleo	c 961	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
889	13	1.7	13	1	AA678357	IGFBP3 oligonucleo	c 962	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
890	13	1.7	13	1	AA678357	IGFBP3 oligonucleo	c 963	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
891	13	1.7	13	1	AA678357	IGFBP3 oligonucleo	c 964	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
892	13	1.7	13	1	AA678357	IGFBP3 oligonucleo	c 965	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
893	13	1.7	13	1	AA678357	IGFBP3 oligonucleo	c 966	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
894	13	1.7	13	1	AA678357	IGFBP3 oligonucleo	c 967	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
895	13	1.7	13	1	AA678357	IGFBP3 oligonucleo	c 968	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
896	13	1.7	13	1	AA678357	IGFBP3 oligonucleo	c 969	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
897	13	1.7	13	1	AA678357	IGFBP3 oligonucleo	c 970	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
898	13	1.7	13	1	AA678357	IGFBP3 oligonucleo	c 971	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
899	13	1.7	13	1	AA678357	IGFBP3 oligonucleo	c 972	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
900	12.8	1.7	16	1	AA678357	IGFBP3 oligonucleo	c 973	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
901	12.8	1.7	16	1	AA678357	IGFBP3 oligonucleo	c 974	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
902	12.8	1.7	16	1	AA678357	IGFBP3 oligonucleo	c 975	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
903	12.8	1.7	16	1	AA678357	IGFBP3 oligonucleo	c 976	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
904	12.8	1.7	16	1	AA678357	IGFBP3 oligonucleo	c 977	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
905	12.8	1.7	16	1	AA678357	IGFBP3 oligonucleo	c 978	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
906	12.8	1.7	16	1	AA678357	IGFBP3 oligonucleo	c 979	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
907	12.8	1.7	16	1	AA678357	IGFBP3 oligonucleo	c 980	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
908	12.8	1.7	16	1	AA678357	IGFBP3 oligonucleo	c 981	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G
909	12.8	1.7	16	1	AA678357	IGFBP3 oligonucleo	c 982	12.8	1.7	17	1	AA678357	Human BRCA2 C2192G

c 983	12.8	1.7	17	1	ABQ63786	Human KTOM1a port1	1056	12.8	1.7	17	1	ADF62166	Human PCCP1 DNA fr
c 984	12.8	1.7	17	1	ABK26264	Increased starch p	1057	12.8	1.7	17	1	ADF64207	Human PCCP1 DNA fr
c 985	12.8	1.7	17	1	ABK26263	Increased starch p	1058	12.8	1.7	17	1	ADF62161	Human PCCP1 DNA fr
c 986	12.8	1.7	17	1	ABK19193	Human ERG Amberzym	1059	12.8	1.7	17	1	ADF62163	Human PCCP1 DNA fr
c 987	12.8	1.7	17	1	ABK18809	Human ERG DNAzyme	1060	12.8	1.7	17	1	ADF64120	Human PCCP1 DNA fr
c 988	12.8	1.7	17	1	ABK19192	Human ERG Amberzym	1061	12.8	1.7	17	1	ADF64122	Human PCCP1 DNA fr
c 989	12.8	1.7	17	1	ABK18227	Human ERG hammerhe	1062	12.8	1.7	17	1	ADF62168	Human PCCP1 DNA fr
c 990	12.8	1.7	17	1	ABK18227	Human ERG hammerhe	1063	12.8	1.7	17	1	ADF64210	Human PCCP1 DNA fr
c 991	12.8	1.7	17	1	ABK18149	Human ERG hammerhe	1064	12.8	1.7	17	1	ADF87667	Single nucleotide
c 992	12.8	1.7	17	1	ABK18826	Human ERG DNAzyme	1065	12.8	1.7	17	1	AD149767	Human tumour suppr
c 993	12.8	1.7	17	1	ABV90334	Human POSHL1 scann	1066	12.8	1.7	17	1	AD151254	Human tumour suppr
c 994	12.8	1.7	17	1	ABV89595	Human POSHL1 scann	1067	12.8	1.7	17	1	AD149316	Human tumour suppr
c 995	12.8	1.7	17	1	ABV89594	Human POSHL1 scann	1068	12.8	1.7	17	1	ACC54048	Human tumour suppr
c 996	12.8	1.7	17	1	ABV89339	Human POSHL1 scann	1069	12.8	1.7	17	1	ACC54057	Human tumour suppr
c 997	12.8	1.7	17	1	ABV90333	Human POSHL1 scann	1070	12.8	1.7	17	1	AD146532	Human NOGO recepto
c 998	12.8	1.7	17	1	ABV89591	Human POSHL1 scann	1071	12.8	1.7	17	1	AD149918	Human PKR substrat
c 999	12.8	1.7	17	1	ABV89592	Human POSHL1 scann	1072	12.8	1.7	17	1	AD151337	Human PTGDR substr
c 1000	12.8	1.7	17	1	ABV89589	Human POSHL1 scann	1073	12.8	1.7	17	1	AD147063	Human NOGO recepto
c 1001	12.8	1.7	17	1	ABV89593	Human POSHL1 scann	1074	12.8	1.7	17	1	AD148356	Human IKK-gamma su
c 1002	12.8	1.7	17	1	ABV89338	Human POSHL1 scann	1075	12.8	1.7	17	1	AD148356	Human IKK-gamma su
c 1003	12.8	1.7	17	1	ABK56982	Human C1CAL gene e	1076	12.8	1.7	17	1	AD148354	Human IKK-gamma su
c 1004	12.8	1.7	17	1	ACN06154	WNV Amberzyme subs	1077	12.8	1.7	17	1	AD151141	Human IKK-gamma su
c1005	12.8	1.7	17	1	ACN10742	WNV minus strand I	1078	12.8	1.7	17	1	AD151504	Human PTGDR substr
c 1006	12.8	1.7	17	1	ACN12591	WNV minus strand Z	1079	12.8	1.7	17	1	AD146486	Human NOGO recepto
c 1007	12.8	1.7	17	1	ACN05002	WNV DNAzyme substr	1080	12.8	1.7	17	1	AD148057	Human IKK-gamma su
c 1008	12.8	1.7	17	1	ACN06034	WNV Amberzyme subs	1081	12.8	1.7	17	1	AD148768	Human IKK-gamma su
c 1009	12.8	1.7	17	1	ACN04476	WNV Zinzyne substr	1082	12.8	1.7	17	1	AD148354	Human IKK-gamma su
c1010	12.8	1.7	17	1	ACN02936	WNV inozyme substr	1083	12.8	1.7	17	1	AD148766	Human IKK-gamma su
c1011	12.8	1.7	17	1	ACN07596	WNV minus strand H	1084	12.8	1.7	17	1	AD147943	Human IKK-gamma su
c1012	12.8	1.7	17	1	ACN14468	WNV minus strand A	1085	12.8	1.7	17	1	AD148357	Human NOGO recepto
c1013	12.8	1.7	17	1	ACN02562	WNV inozyme substr	1086	12.8	1.7	17	1	AD146662	Human IKK-gamma su
c1014	12.8	1.7	17	1	ACN08730	WNV inozyme substr	1087	12.8	1.7	17	1	AD148764	Human NOGO recepto
c1015	12.8	1.7	17	1	ACN11414	WNV minus strand I	1088	12.8	1.7	17	1	AD147162	Human IKK-gamma su
c1016	12.8	1.7	17	1	ACN12508	WNV minus strand Z	1089	12.8	1.7	17	1	AD148783	Human PTGDR substr
c1017	12.8	1.7	17	1	ACN08869	WNV minus strand H	1090	12.8	1.7	17	1	AD151594	Human PTGDR substr
c1018	12.8	1.7	17	1	ACN14466	WNV minus strand A	1091	12.8	1.7	17	1	AD151909	Human NOGO recepto
c1019	12.8	1.7	17	1	ACN04405	WNV Zinzyne substr	1092	12.8	1.7	17	1	AD146834	Human PTGDR substr
c1020	12.8	1.7	17	1	ACN02934	WNV inozyme substr	1093	12.8	1.7	17	1	AD150988	Human PTGDR substr
c1021	12.8	1.7	17	1	ACN09764	WNV minus strand I	1094	12.8	1.7	17	1	AD151681	Human NOGO recepto
c1022	12.8	1.7	17	1	ACN03270	WNV inozyme substr	1095	12.8	1.7	17	1	AD146479	Human NOGO recepto
c1023	12.8	1.7	17	1	ACN07198	WNV Amberzyme subs	1096	12.8	1.7	17	1	AD146479	Human IKK-gamma su
c1024	12.8	1.7	17	1	ABT35838	Tumour suppression	1097	12.8	1.7	17	1	AD148516	Human GR1D mRNA su
c1025	12.8	1.7	17	1	ABT36928	Tumour suppression	1098	12.8	1.7	17	1	AD148516	Human GR1D mRNA su
c1026	12.8	1.7	17	1	ABT37923	NFKB sub-unit modu	1099	12.8	1.7	17	1	AD148516	Human GR1D mRNA su
c1027	12.8	1.7	17	1	ACA07771	NFKB sub-unit modu	1100	12.8	1.7	17	1	AD148516	Human GR1D mRNA su
c1028	12.8	1.7	17	1	ACA07785	NFKB sub-unit modu	1101	12.8	1.7	17	1	AD148516	Human GR1D mRNA su
c1029	12.8	1.7	17	1	ACA08935	NFKB sub-unit modu	1102	12.8	1.7	17	1	AD148516	Human GR1D mRNA su
c1030	12.8	1.7	17	1	ACA07770	NFKB sub-unit modu	1103	12.8	1.7	17	1	AD148516	Human GR1D mRNA su
c1031	12.8	1.7	17	1	ACA06585	NFKB sub-unit modu	1104	12.8	1.7	17	1	AD148516	Human GR1D mRNA su
c1032	12.8	1.7	17	1	ACA06586	NFKB sub-unit modu	1105	12.8	1.7	17	1	AD148516	Human GR1D mRNA su
c1033	12.8	1.7	17	1	ADA99742	Human MD23 scannin	1106	12.8	1.7	17	1	AD148516	Human GR1D mRNA su
c1034	12.8	1.7	17	1	ADA99743	Human MD23 scannin	1107	12.8	1.7	17	1	AD148516	Human GR1D mRNA su
c1035	12.8	1.7	17	1	ABZ65413	Human HER2 DNAzyme	1108	12.8	1.7	17	1	AD148516	Human GR1D mRNA su
c1036	12.8	1.7	17	1	ABZ61885	Human H-Ras DNAzym	1109	12.8	1.7	17	1	AD148516	Human GR1D mRNA su
c1037	12.8	1.7	17	1	ABZ61923	Human H-Ras DNAzyme	1110	12.8	1.7	17	1	AD148516	Human GR1D mRNA su
c1038	12.8	1.7	17	1	ABZ64678	Human HER2 DNAzyme	1111	12.8	1.7	17	1	AD148516	Human GR1D mRNA su
c1039	12.8	1.7	17	1	ACD51596	HBV hammerhead rib	1112	12.8	1.7	17	1	AD148516	Human GR1D mRNA su
c1040	12.8	1.7	17	1	ACD64419	HBV minus strand D	1113	12.8	1.7	17	1	AD148516	Human GR1D mRNA su
c1041	12.8	1.7	17	1	ACD63931	HBV inozyme substr	1114	12.8	1.7	17	1	AD148516	Human GR1D mRNA su
c1042	12.8	1.7	17	1	ACD53095	HBV inozyme substr	1115	12.8	1.7	17	1	AD148516	Human GR1D mRNA su
c1043	12.8	1.7	17	1	ACD53033	HBV inozyme substr	1116	12.8	1.7	17	1	AD148516	Human GR1D mRNA su
c1044	12.8	1.7	17	1	ACD57181	Human HER2 DNAzyme	1117	12.8	1.7	17	1	AD148516	Human GR1D mRNA su
c1045	12.8	1.7	17	1	ACC66800	Murine oligonucleo	1118	12.8	1.7	17	1	AD148516	Human GR1D mRNA su
c1046	12.8	1.7	17	1	ACC66750	Murine oligonucleo	1119	12.8	1.7	17	1	AD148516	Human GR1D mRNA su
c1047	12.8	1.7	17	1	ADB43036	Tumour suppression	1120	12.8	1.7	17	1	AD148516	Human GR1D mRNA su
c1048	12.8	1.7	17	1	ADB43479	Tumour suppression	1121	12.8	1.7	17	1	AD148516	Human GR1D mRNA su
c1049	12.8	1.7	17	1	ADB42794	Tumour suppression	1122	12.8	1.7	17	1	AD148516	Human GR1D mRNA su
c1050	12.8	1.7	17	1	ADC03749	Human Na/H exchange	1123	12.8	1.7	17	1	AD148516	Human GR1D mRNA su
c1051	12.8	1.7	17	1	ADC04990	Human Na/H exchange	1124	12.8	1.7	17	1	AD148516	Human GR1D mRNA su
c1052	12.8	1.7	17	1	ADC04989	Human Na/H exchange	1125	12.8	1.7	17	1	AD148516	Human GR1D mRNA su
c1053	12.8	1.7	17	1	ADC03750	Human Na/H exchange	1126	12.8	1.7	17	1	AD148516	Human GR1D mRNA su
c1054	12.8	1.7	17	1	ADB44625	Tumour suppression	1127	12.8	1.7	17	1	AD148516	Human GR1D mRNA su
c1055	12.8	1.7	17	1	ADC35279	MaSpII silk protei	1128	12.8	1.7	17	1	AD148516	Human GR1D mRNA su

1129 12.8 1.7 17 1 ACN71132 Human GMLP-1 prob
 c1130 12.8 1.7 17 1 ACN65095 Human GMLP-1 prob
 1131 12.8 1.7 17 1 ACN71131 Human GMLP-1 prob
 c1132 12.8 1.7 17 1 ACN63770 Human GMLP-1 prob
 1133 12.8 1.7 17 1 ACN70776 Human GMLP-1 prob
 1134 12.8 1.7 17 1 ACN70910 Human GMLP-1 prob
 c1135 12.8 1.7 17 1 ACN63453 Human GMLP-1 prob
 1136 12.8 1.7 17 1 ACN70775 Human GMLP-1 prob
 c1137 12.8 1.7 17 1 ACN69988 Human GMLP-1 prob
 c1138 12.8 1.7 17 1 ADR74662 Allele specific pr

ALIGNMENTS

RESULT 1
 ADA44708
 ID ADA44708 standard; DNA; 29 BP.
 XX
 AC ADA44708;
 XX
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE PCR probe for amplifying human inhibitor-kappa B kinase-gamma #SEQ ID 6.
 XX
 KW Antisense oligonucleotide; cytostatic; immunosuppressive;
 KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
 KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; PCR;
 KW probe; ss.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note="modified by addition of FAM fluorescent reporter
 FT dye"
 FT 29
 FT modified_base b
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note="modified by addition of TAMRA quencher dye"
 FT
 XX WO2003031576-A2.
 XX
 XX 17-APR-2003.
 XX
 XX 03-OCT-2002; 2002WO-US031809.
 XX
 XX 06-OCT-2001; 2001US-00972607.
 XX
 XX (ISIS-) ISIS PHARM INC.
 XX
 XX Monia BP, Wyatt JR;
 XX
 XX WPI; 2003-457242/43.
 XX
 XX New compound having sequence targeted to nucleic acid encoding inhibitor-
 XX kappa B kinase-gamma, useful for preparing composition for treating e.g.,
 XX cancer, or inflammatory or autoimmune disorder.
 XX
 XX Example 13; Page 74; 106pp; English.
 XX
 XX The invention relates to an antisense compound that is targeted to a
 XX nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
 XX hybridising to the nucleic acid encoding inhibitor-kappa B kinase-gamma
 XX and inhibiting its expression. Compounds of the invention are antisense
 XX oligonucleotides comprising at least one modified internucleoside
 XX linkage, which is a phosphorothioate linkage, at least one modified sugar
 XX moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
 XX modified nucleobase, which is a 5-methylcytosine. Preferably, the
 XX antisense oligonucleotide is a chimeric oligonucleotide. The compound of
 XX the invention is useful for preparing a composition for treating a

CC hyperproliferative disorder e.g., cancer, or an autoimmune or
 CC inflammatory disorder. The methods are useful for inhibiting the
 CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
 CC treating an animal having a disease or condition associated with
 CC inhibitor-kappa B kinase-gamma. The current sequence represents a PCR
 CC probe used in an example from the invention to detect human inhibitor-
 CC kappa B kinase-gamma DNA.
 XX
 SQ Sequence 29 BP; 7 A; 4 C; 11 G; 7 T; 0 U; 0 Other;
 Query Match 3.8%; Score 29; DB 1; Length 29;
 Best Local Similarity 100.0%; Pred. No. 12;
 Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 162 TCTGGAAGAGCCCACTGTGTGAGATGGTG 190
 Db 1 TCTGGAAGAGCCCACTGTGTGAGATGGTG 29
 RESULT 2
 ADS17882/c
 ID ADS17882 standard; DNA; 27 BP.
 XX
 AC ADS17882;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Human IKKBSv2.1 DNA specific 3' reverse RT-PCR primer.
 XX
 KW Human; kappa light polypeptide inhibitor; gene enhancer; IKKKG;
 KW I-kappa-B-kinase-gamma; IKK; I-kappa-B-kinase; rheumatoid arthritis;
 KW lupus; AIDS; acquired immunodeficiency syndrome; influenza; septic shock;
 KW atherosclerosis; oncogenesis; apoptosis; antirheumatic; antiarthritic;
 KW dermatological; antiinflammatory; immunosuppressive; virucide; anti-HIV;
 KW antibacterial; antiarteriosclerotic; cytostatic; kinase inhibitor;
 KW RT-PCR; reverse transcription; primer; IKKGS2.1; ss.
 XX
 OS Homo sapiens.
 XX
 XX US2004175797-A1.
 XX
 XX 09-SEP-2004.
 PD
 XX 03-MAR-2004; 2004US-00792063.
 PF
 XX 04-MAR-2003; 2003US-0452293P.
 PR
 XX (JOHN/) JOHNSON J M.
 PA (GARR/) GARRETT-ENGELE P W.
 PA (KANZ/) KAN Z.
 XX
 XX Johnson JM, Garrett-Engle PW, Kan Z;
 PI WPI; 2004-634849/61.
 DR
 XX
 XX New splice variant isoforms of inhibitor of kappa light polypeptide gene
 XX enhancer in B cells, useful for treating arthritis, lupus, HIV, septic
 XX shock and atherosclerosis.
 PT
 XX Example 3; SEQ ID NO 24; 27pp; English.
 PS
 XX
 XX The present invention relates to a polypeptides and nucleic acids
 XX encoding four novel splice variant isoforms of human inhibitor of kappa
 XX light polypeptide gene enhancer in B cells, kinase of, I-kappa-B-kinase-
 XX gamma (IKKKG or IKK (I-kappa-B-kinase)-gamma). The invention is useful
 XX for treatment of diseases or conditions associated with aberrant
 XX expression or activity of the IKKKG polypeptide, such as rheumatoid
 XX arthritis, lupus, human immunodeficiency virus (HIV)-acquired
 XX immunodeficiency syndrome (AIDS), influenza, septic shock,
 XX atherosclerosis, oncogenesis and apoptosis. The present sequence is the
 XX human IKKBSv2.1 DNA specific reverse transcription (RT)-PCR primer. This
 XX sequence is used in the exemplification of the invention.

SQ Sequence 23 BP; 7 A; 3 C; 8 G; 0 T; 5 U; 0 Other;
 Query Match 3.0%; Score 23; DB 1; Length 23;
 Best Local Similarity 78.3%; Pred. No. 56;
 Matches 18; Conservative 5; Mismatches 0; Gaps 0

QY 164 TCGAAGAGCCCAACTGTGTGAGAT 186
 :|||||:|||||:|||||:|||||:
 Db 1 UGGAAGAGCCCAACUGUGUGAGAU 23

RESULT 4
 ADG29528
 ID ADG29528 standard; RNA; 23 BP.
 AC
 XX ADG29528;
 AC
 XX
 DT 26-FEB-2004 (first entry)
 XX
 XX IKKG siNA-target RNA - SEQ ID 94.
 DE
 XX double-stranded short interfering nucleic acid; siNA;
 XX antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
 KW anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
 KW Alzheimer's; Parkinson's; epilepsy; dementia; Huntington's;
 KW amyotrophic lateral sclerosis; gene therapy; target; ss; IKKG.
 KW
 XX Unidentified.
 OS
 XX W02003074654-A2.
 PN
 XX 12-SEP-2003.
 PD
 XX
 XX 20-FEB-2003; 2003WO-US005028.
 PF
 XX
 XX 20-FEB-2002; 2002US-0358580P.
 PR
 PR 11-MAR-2002; 2002US-0363124P.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 XX
 XX (STRN-) SIRNA THERAPEUTICS INC.
 PA
 XX Mcswiggen J, Beigelman L, Chowrira B, Payco P, Fosnaugh K;
 PI Jamison S, Usman N, Thompson J;
 PI
 XX WPI; 2003-731676/69.
 DR
 XX
 PT New double-stranded short interfering nucleic acid molecule, useful for
 PT down-regulating the expression of an endogenous mammalian target gene or
 PT for treating diseases that respond to modulation of gene expression or
 PT activity.
 PT
 XX
 XX Example 24; SEQ ID NO 94; 593pp; English.
 PS
 XX The invention relates to a double-stranded short interfering nucleic acid
 CC (siNA) molecule that down-regulates expression of an endogenous mammalian
 CC target gene comprising one or more chemical modifications and each strand
 CC of the double-stranded siNA comprises about 21 nucleotides. The siNA of
 CC the invention demonstrates antiarteriosclerotic, neuroprotective, and
 CC nootropic, antiparkinsonian and anticonvulsant activities and may be
 CC useful for down-regulating the expression of an endogenous mammalian
 CC target gene and therefore in the treatment of any disease or condition
 CC that responds to modulation of gene expression or activity in a cell,
 CC tissue or organism. The disease or condition may include pulmonary
 CC diseases such as restenosis, atherosclerosis, Alzheimer's disease,
 CC Parkinson's disease, epilepsy, dementia, Huntington's disease or
 CC amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
 CC gene therapy applications. The current sequence is that of the siNA.
 CC target DNA of the invention.
 CC

Example 4: Page 135; 204pp; English.

XX		The present invention describes a double-stranded short interfering nucleic acid (siNA) that downregulates expression of a target gene, where the siNA molecule comprises no ribonucleotides and each strand of the double-stranded siNA comprises about 21 nucleotides. Also described: (1) a siNA molecule that inhibits expression of target RNA; (2) a siNA molecule that inhibits replication of a virus and optionally does not require presence of a ribonucleotide for inhibition; (3) a siNA molecule that inhibits expression of a target gene and does not require presence of a ribonucleotide for inhibition; (4) a siNA molecule that inhibits expression of a target gene by mediating RNA interference; and (5) a method for modulating expression of a gene in a cell using siNA molecules. siNA's can have virucide, anti-HIV, hepatotropic, anti-inflammatory, plant antiviral, vasotropic, neuroprotective, cytotstatic, cardiovascular, immunosuppressive, respiratory, nephrotropic and endocrine activities. The siNA's are useful for downregulating expression of target genes, inhibiting expression of target RNA, and inhibiting replication of a virus. siNA molecules can be used: (a) for therapy of any disorder that responds to modulation of gene expression, especially animal and plant viral infections, specifically hepatitis B or C; HIV; herpes simplex; cytomegalovirus; human papilloma; respiratory syncytial or influenza viruses, and also many other diseases such as restenosis, neurodegeneration, cancers, and cardiovascular, neurological, prion, inflammatory, autoimmune, pulmonary, renal, liver, mitochondrial, endocrine or reproductive diseases; and (b) for diagnosis, target validation, genomic discovery, genetic engineering, pharmacogenomics and analysis of gene function. Chemical modification of siNA molecules improves interfering activity; stability; cellular uptake; binding affinity and/or mediates increased polymerase activity. siNA may be designed to target many related genes containing a conserved sequence. The present sequence represents a siNA oligonucleotide sequence, which is used in the exemplification of the present invention.
XX		Sequence 21 BP; 4 A; 4 C; 6 G; 2 T; 5 U; 0 Other;
XX		Query Match 2.8%; Score 21; DB 1; Length 21;
XX		Best Local Similarity 76.2%; Pred. No. 90;
XX		Matches 16; Conservative 5; Mismatches 0; Indels 0; Gaps 0
Qy	418 GGAGTTCCTCATGTGCAAGTT 438 :: :: ::	
Dd	1 GGAGUCCUCAUGGCAAGTT 21 :: :: ::	
RESULT 7		
ADAL3787/c		
ID	ADAL3787 standard; RNA; 21 BP.	
AC	ADAL3787;	
XX		
XX	20-NOV-2003 (first entry)	
XX		
DE	Short interfering nucleic acid (siNA) oligonucleotide SEQ ID NO:124.	
XX		
KW	double-stranded short interfering nucleic acid;	
KW	short interfering nucleic acid; siNA; expression; replication;	
KW	inhibition; RNA interference; virucide; anti-HIV; hepatotropic;	
KW	anti-inflammatory; plant; antiviral; vasotropic; neuroprotective;	
KW	cytostatic; cardiovascular; immunosuppressive; respiratory; nephrotropic;	
KW	endocrine; viral infection; hepatitis B; hepatitis C; HIV;	
KW	herpes simplex; cytomegalovirus; human papillomavirus;	
KW	respiratory syncytial virus; influenza virus; restenosis;	
KW	neurodegeneration; cancer; neurological; prion; inflammatory; autoimmune;	
KW	pulmonary; renal; liver; mitochondrial; reproductive disease;	
KW	chemical modification; ss.	
OS	Synthetic.	
XX		
FN	WO2003070918-A2.	
XX		
PD	28-AUG-2003.	
PF	20-FEB-2003; 2003WO-US005346.	

XX	20-FEB-2002; 2002US-0358580P.
PR	11-MAR-2002; 2002US-0363124P.
PR	06-JUN-2002; 2002US-0386782P.
PR	29-AUG-2002; 2002US-0406784P.
PR	05-SEP-2002; 2002US-0408378P.
PR	09-SEP-2002; 2002US-0409293P.
PR	15-JAN-2003; 2003US-0440129P.
XX	(RIBO-) RIBOZYME PHARM INC.
XX	McSwiggen J, Beigelman L, Macejak D, Zinnen S, Pavco P;
XX	Morrissey D, Fornaugh K, Mokler V, Jamison S;
XX	WPI; 2003-689785/65.
DR	New short interfering nucleic acid containing no ribonucleotides, useful
PT	e.g. for treating viral infection, downregulates expression of target
PT	gene or RNA.
XX	
XX	Example 4; Page 135; 204pp; English.
XX	The present invention describes a double-stranded short interfering
CC	nucleic acid (siNA) that downregulates expression of a target gene, where
CC	the siNA molecule comprises no ribonucleotides and each strand of the
CC	double-stranded siNA comprises about 21 nucleotides. Also described: (1)
CC	a siNA molecule that inhibits expression of target RNA; (2) a siNA
CC	molecule that inhibits replication of a virus and optionally does not
CC	require presence of a ribonucleotide for inhibition; (3) a siNA molecule
CC	that inhibits expression of a target gene and does not require presence
CC	of a ribonucleotide for inhibition; (4) a siNA molecule that inhibits
CC	expression of a target gene by mediating RNA interference; and (5) a
CC	method for modulating expression of a gene in a cell using siNA
CC	molecules. siNA's can have virucide, anti-HIV, hepatotropic,
CC	antiinflammatory, plant antiviral, vasotropic, respiratory, nephrotropic
CC	cytostatic, cardiovascular, immunosuppressive, respiratory, nephrotropic
CC	and endocrine activities. The siNA's are useful for downregulating
CC	expression of target genes, inhibiting expression of target RNA, and
CC	inhibiting replication of a virus. siNA molecules can be used: (a) for
CC	therapy of any disorder that responds to modulation of gene expression,
CC	especially animal and plant viral infections, specifically hepatitis B or
CC	C; HIV; herpes simplex; cytomegalo; human papilloma; respiratory
CC	cystical or influenza viruses, and also many other diseases such as
CC	restenosis, neurodegeneration, cancers, and cardiovascular, neurological,
CC	pilon, inflammatory, autoimmune, pulmonary, renal, liver, mitochondrial,
CC	endocrine or reproductive diseases; and (b) for diagnosis, target
CC	validation, genomic discovery, genetic engineering, pharmacogenomics and
CC	analysis of gene function. Chemical modification of siNA molecules
CC	improves interfering activity; stability; cellular uptake; binding
CC	affinity and/or mediates increased polymerase activity. siNA may be
CC	designed to target many related genes containing a conserved sequence.
CC	The present sequence represents a siNA oligonucleotide sequence, which is
CC	used in the exemplification of the present invention.
XX	
SQ	Sequence 21 BP; 5 A; 6 C; 4 G; 2 T; 4 U; 0 Other;
	Query Match 2.8%; Score 21; DB 1; Length 21;
	Best Local Similarity 100.0%; Pred. No. 90;
	Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0
OY	416 AAGGAGTTCCTCATGTGCAAG 436 Db 21 AAGGAGTTCCTCATGTGCAAG 1
RESULT 8	
ID	ADAL3791/c
ID	ADAL3791 standard; RNA; 21 BP.
XX	
AC	ADAL3791;
XX	
DT	20-NOV-2003 (first entry)
XX	


```

RESULT 12
ADA44746/c
ID ADA44746 standard; DNA; 20 BP.
XX
AC ADA44746;
XX
DT 20-NOV-2003 (first entry)
XX
DE Antisense oligonucleotide #ISIS 115418 #SEQ ID 44.
XX
KW Antisense oligonucleotide; cytostatic; immunosuppressive;
KW antinflammatory; gene therapy; hyperproliferative disorder; cancer;
KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages, all cytosines are 5-
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN WO2003031576-A2.
XX
PD 17-APR-2003.
XX
PF 03-OCT-2002; 2002WO-US031809.
XX
PR 06-OCT-2001; 2001US-00972607.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Wyatt JR;
XX
WPI; 2003-457242/43.
XX
PS New compound having sequence targeted to nucleic acid encoding inhibitor-
XX kappa B kinase-gamma, useful for preparing composition for treating e.g.,
XX cancer, or inflammatory or autoimmune disorder.
XX
PS Claim 3; Page 77; 106pp; English.
XX
CC The invention relates to an antisense compound that is targeted to a
XX nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
XX hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
XX and inhibiting its expression. Compounds of the invention are antisense
XX oligonucleotides comprising at least one modified internucleoside
XX linkage, which is a phosphorothioate linkage, at least one modified sugar
XX moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
XX modified nucleobase, which is a 5-methylcytosine. Preferably, the
XX antisense oligonucleotide is a chimeric oligonucleotide. The compound of
XX the invention is useful for preparing a composition for treating a
XX hyperproliferative disorder e.g., cancer, or an autoimmune or
XX inflammatory disorder. The methods are useful for inhibiting the
XX expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
XX treating an animal having a disease or condition associated with
XX inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
XX represent antisense oligonucleotides for the inhibition of human
XX inhibitor-kappa B kinase-gamma mRNA levels.
XX
SQ Sequence 20 BP; 4 A; 7 C; 6 G; 3 T; 0 U; 0 Other;

```

```

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 830 GCCCAGTTGCAGGTGGCCTA 849
DB 20 GCCCAGTTGCAGGTGGCCTA 1

RESULT 13
ADA44751/c
ID ADA44751 standard; DNA; 20 BP.
XX
AC ADA44751;
XX
DT 20-NOV-2003 (first entry)
XX
DE Antisense oligonucleotide #ISIS 115423 #SEQ ID 49.
XX
KW Antisense oligonucleotide; cytostatic; immunosuppressive;
KW antinflammatory; gene therapy; hyperproliferative disorder; cancer;
KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages, all cytosines are 5-
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN WO2003031576-A2.
XX
PD 17-APR-2003.
XX
PF 03-OCT-2002; 2002WO-US031809.
XX
PR 06-OCT-2001; 2001US-00972607.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Wyatt JR;
XX
WPI; 2003-457242/43.
XX
PS New compound having sequence targeted to nucleic acid encoding inhibitor-
XX kappa B kinase-gamma, useful for preparing composition for treating e.g.,
XX cancer, or inflammatory or autoimmune disorder.
XX
PS Example 15; Page 77; 106pp; English.
XX
CC The invention relates to an antisense compound that is targeted to a
XX nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
XX hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
XX and inhibiting its expression. Compounds of the invention are antisense
XX oligonucleotides comprising at least one modified internucleoside
XX linkage, which is a phosphorothioate linkage, at least one modified sugar
XX moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
XX modified nucleobase, which is a 5-methylcytosine. Preferably, the
XX antisense oligonucleotide is a chimeric oligonucleotide. The compound of
XX the invention is useful for preparing a composition for treating a
XX hyperproliferative disorder e.g., cancer, or an autoimmune or
XX inflammatory disorder. The methods are useful for inhibiting the

```

CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
 CC treating an animal having a disease or condition associated with
 CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
 CC represent antisense oligonucleotides for the inhibition of human
 CC inhibitor-kappa B kinase-gamma mRNA levels.
 XX
 SQ Sequence 20 BP; 2 A; 10 C; 3 G; 5 T; 0 U; 0 Other;
 Query Match 2.6%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 897 TGGCAGTGGCGGAGCGA 916
 Db 20 TGGCAGTGGCGGAGCGA 1
 RESULT 14
 ADA44726/C
 ID ADA44726 standard; DNA; 20 BP.
 XX
 AC ADA44726;
 XX
 XX 20-NOV-2003 (first entry)
 DE Antisense oligonucleotide #ISIS 115398 #SEQ ID 24.
 XX
 KW Antisense oligonucleotide; cytostatic; immunosuppressive;
 KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
 KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
 KW human.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate linkages, all cytosines are 5-
 FT methylcytosine"
 FT 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 XX
 PN WO2003031576-A2.
 XX
 PD 17-APR-2003.
 XX
 PF 03-OCT-2002; 2002WO-US031809.
 XX
 PR 06-OCT-2001; 2001US-00972607.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 XX Monia BP, Wyatt JR;
 PI
 XX WPI; 2003-457242/43.
 XX
 XX New compound having sequence targeted to nucleic acid encoding inhibitor-
 PT kappa B kinase-gamma, useful for preparing composition for treating e.g.,
 PT cancer, or inflammatory or autoimmune disorder.
 XX
 PS Claim 3; Page 76; 106pp; English.
 XX
 CC The invention relates to an antisense compound that is targeted to a
 CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
 CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
 CC and inhibiting its expression. Compounds of the invention are antisense
 CC

CC oligonucleotides comprising at least one modified internucleoside
 CC linkage, which is a phosphorothioate linkage, at least one modified sugar
 CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
 CC modified nucleobase, which is a 5-methylcytosine. Preferably, the
 CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of
 CC the invention is useful for preparing a composition for treating a
 CC hyperproliferative disorder e.g., cancer, or an autoimmune or
 CC inflammatory disorder. The methods are useful for inhibiting the
 CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
 CC treating an animal having a disease or condition associated with
 CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
 CC represent antisense oligonucleotides for the inhibition of human
 CC inhibitor-kappa B kinase-gamma mRNA levels.
 XX
 SQ Sequence 20 BP; 5 A; 3 C; 8 G; 4 T; 0 U; 0 Other;
 Query Match 2.6%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 385 TCTGCATTTCACAGCCAGCC 404
 Db 20 TCTGCATTTCACAGCCAGCC 1
 RESULT 15
 ADA44750/C
 ID ADA44750 standard; DNA; 20 BP.
 XX
 AC ADA44750;
 XX
 XX 20-NOV-2003 (first entry)
 DE Antisense oligonucleotide #ISIS 115422 #SEQ ID 48.
 XX
 KW Antisense oligonucleotide; cytostatic; immunosuppressive;
 KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
 KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
 KW human.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate linkages, all cytosines are 5-
 FT methylcytosine"
 FT 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 XX
 PN WO2003031576-A2.
 XX
 PD 17-APR-2003.
 XX
 PF 03-OCT-2002; 2002WO-US031809.
 XX
 PR 06-OCT-2001; 2001US-00972607.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 XX Monia BP, Wyatt JR;
 PI
 XX WPI; 2003-457242/43.
 XX
 XX New compound having sequence targeted to nucleic acid encoding inhibitor-
 PT kappa B kinase-gamma, useful for preparing composition for treating e.g.,
 PT cancer, or inflammatory or autoimmune disorder.
 XX

PT cancer, or inflammatory or autoimmune disorder.
 PS Claim 3; Page 77; 106pp; English.
 XX The invention relates to an antisense compound that is targeted to a
 CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
 CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
 CC and inhibiting its expression. Compounds of the invention are antisense
 CC oligonucleotides comprising at least one modified internucleoside
 CC linkage, which is a phosphorothioate linkage, at least one modified sugar
 CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
 CC modified nucleobase, which is a 5-methylcytosine. Preferably, the
 CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of
 CC the invention is useful for preparing a composition for treating a
 CC hyperproliferative disorder e.g., cancer, or an autoimmune or
 CC inflammatory disorder. The methods are useful for inhibiting the
 CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
 CC treating an animal having a disease or condition associated with
 CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
 CC represent antisense oligonucleotides for the inhibition of human
 CC inhibitor-kappa B kinase-gamma mRNA levels.
 XX Sequence 20 BP; 3 A; 10 C; 3 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 2.6%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 885 AGAGCAGCGTGGTGGCGACT 904
 DB 20 AGAGCAGCGTGGTGGCGACT 1
 RESULT 16
 ADA44719/C
 ID ADA44719 standard; DNA; 20 BP.
 AC ADA44719;
 XX 20-NOV-2003 (first entry)
 DT Antisense oligonucleotide #ISIS 115391 #SEQ ID 17.
 DE Antisense oligonucleotide; cytostatic; immunosuppressive;
 KW antinflammatory; gene therapy; hyperproliferative disorder; cancer;
 KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
 KW human.
 XX Homo sapiens.
 OS
 XX Key Location/Qualifiers
 FH modified_base 1..20
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate linkages, all cytosines are 5-
 FT methylcytosine"
 FT modified_base 1..5
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 XX WO2003031576-A2.
 PN
 XX 17-APR-2003.
 PD
 XX 03-OCT-2002; 2002WO-US031809.
 PF
 XX 06-OCT-2001; 2001US-00972607.
 PR
 XX

PA (ISIS-) ISIS PHARM INC.
 XX Monia BP, Wyatt JR;
 XX WPI; 2003-457242/43.
 DR
 XX New compound having sequence targeted to nucleic acid encoding inhibitor-
 PT kappa B kinase-gamma, useful for preparing composition for treating e.g.,
 PT cancer, or inflammatory or autoimmune disorder.
 XX Claim 3; Page 76; 106pp; English.
 PS The invention relates to an antisense compound that is targeted to a
 CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
 CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
 CC and inhibiting its expression. Compounds of the invention are antisense
 CC oligonucleotides comprising at least one modified internucleoside
 CC linkage, which is a phosphorothioate linkage, at least one modified sugar
 CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
 CC modified nucleobase, which is a 5-methylcytosine. Preferably, the
 CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of
 CC the invention is useful for preparing a composition for treating a
 CC hyperproliferative disorder e.g., cancer, or an autoimmune or
 CC inflammatory disorder. The methods are useful for inhibiting the
 CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
 CC treating an animal having a disease or condition associated with
 CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
 CC represent antisense oligonucleotides for the inhibition of human
 CC inhibitor-kappa B kinase-gamma mRNA levels.
 XX Sequence 20 BP; 2 A; 8 C; 7 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 2.6%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 195 CCAGTGGTGGCCCGCAGCA 214
 DB 20 CCAGTGGTGGCCCGCAGCA 1
 RESULT 17
 ADA44722/C
 ID ADA44722 standard; DNA; 20 BP.
 AC ADA44722;
 XX 20-NOV-2003 (first entry)
 DT Antisense oligonucleotide #ISIS 115394 #SEQ ID 20.
 DE Antisense oligonucleotide; cytostatic; immunosuppressive;
 KW antinflammatory; gene therapy; hyperproliferative disorder; cancer;
 KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
 KW human.
 XX Homo sapiens.
 OS
 XX Key Location/Qualifiers
 FH modified_base 1..20
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate linkages, all cytosines are 5-
 FT methylcytosine"
 FT modified_base 1..5
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 XX

```

PN W02003031576-A2.
XX
XX 17-APR-2003.
XX
XX 03-OCT-2002; 2002WO-US031809.
XX
XX 06-OCT-2001; 2001US-00972607.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Wyatt JR;
XX
XX WPI; 2003-457242/43.
XX
XX New compound having sequence targeted to nucleic acid encoding inhibitor-
XX kappa B kinase-gamma, useful for preparing composition for treating e.g.,
XX cancer, or inflammatory or autoimmune disorder.
XX
XX Example 15; Page 76; 106pp; English.
XX
XX The invention relates to an antisense compound that is targeted to a
XX nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
XX hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
XX and inhibiting its expression. Compounds of the invention are antisense
XX oligonucleotides comprising at least one modified internucleoside
XX linkage, which is a phosphorothioate linkage, at least one modified sugar
XX moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
XX modified nucleobase, which is a 5-methylcytosine. Preferably, the
XX antisense oligonucleotide is a chimeric oligonucleotide. The compound of
XX the invention is useful for preparing a composition for treating a
XX hyperproliferative disorder e.g., cancer, or an autoimmune or
XX inflammatory disorder. The methods are useful for inhibiting the
XX expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
XX treating an animal having a disease or condition associated with
XX inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
XX represent antisense oligonucleotides for the inhibition of human
XX inhibitor-kappa B kinase-gamma mRNA levels.
XX
XX Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 2.6%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 1.1e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
Qy 275 TCAGAACAGGCGCTCTCTGA 294
Db 20 TCAGAACAGGCGCTCTCTGA 1
XX
XX RESULT 18
XX ADA44732/c
XX ID ADA44732 standard; DNA; 20 BP.
XX
XX ADA44732;
XX
XX 20-NOV-2003 (first entry)
XX
XX Antisense oligonucleotide #ISIS 115404 #SEQ ID 30.
XX
XX Antisense oligonucleotide; cytostatic; immunosuppressive;
XX antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
XX human.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /tag= b
XX /mod_base= OTHER
XX /note= "Phosphorothioate linkages, all cytosines are 5-
XX methylcytosine"
XX modified_base 1..5

```

```

FT FT /*tag= a
FT FT /mod_base= OTHER
FT FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT FT 16..20
FT FT /*tag= c
FT FT /mod_base= OTHER
FT FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX W02003031576-A2.
XX
XX 17-APR-2003.
XX
XX 03-OCT-2002; 2002WO-US031809.
XX
XX 06-OCT-2001; 2001US-00972607.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Wyatt JR;
XX
XX WPI; 2003-457242/43.
XX
XX New compound having sequence targeted to nucleic acid encoding inhibitor-
XX kappa B kinase-gamma, useful for preparing composition for treating e.g.,
XX cancer, or inflammatory or autoimmune disorder.
XX
XX Claim 3; Page 77; 106pp; English.
XX
XX The invention relates to an antisense compound that is targeted to a
XX nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
XX hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
XX and inhibiting its expression. Compounds of the invention are antisense
XX oligonucleotides comprising at least one modified internucleoside
XX linkage, which is a phosphorothioate linkage, at least one modified sugar
XX moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
XX modified nucleobase, which is a 5-methylcytosine. Preferably, the
XX antisense oligonucleotide is a chimeric oligonucleotide. The compound of
XX the invention is useful for preparing a composition for treating a
XX hyperproliferative disorder e.g., cancer, or an autoimmune or
XX inflammatory disorder. The methods are useful for inhibiting the
XX expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
XX treating an animal having a disease or condition associated with
XX inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
XX represent antisense oligonucleotides for the inhibition of human
XX inhibitor-kappa B kinase-gamma mRNA levels.
XX
XX Sequence 20 BP; 1 A; 9 C; 2 G; 8 T; 0 U; 0 Other;
XX
XX Query Match 2.6%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 1.1e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
Qy 489 TGAAGAGGCGCAGAGGAGCAG 508
Db 20 TGAAGAGGCGCAGAGGAGCAG 1
XX
XX RESULT 19
XX ADA44739/c
XX ID ADA44739 standard; DNA; 20 BP.
XX
XX ADA44739;
XX
XX 20-NOV-2003 (first entry)
XX
XX Antisense oligonucleotide #ISIS 115411 #SEQ ID 37.
XX
XX Antisense oligonucleotide; cytostatic; immunosuppressive;
XX antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
XX human.
XX
XX Homo sapiens.
XX

```

```

XX FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages, all cytosines are 5-
FT methylcytosine"
FT modified_base 1..5
FT /tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
PN WO2003031576-A2.
XX 17-APR-2003.
XX 03-OCT-2002; 2002WO-US031809.
XX 06-OCT-2001; 2001US-00972607.
XX (ISIS-) ISIS PHARM INC.
XX Monia BP, Wyatt JR;
XX WPI; 2003-457242/43.
XX New compound having sequence targeted to nucleic acid encoding inhibitor-
XX kappa B kinase-gamma, useful for preparing composition for treating e.g.,
XX cancer, or inflammatory or autoimmune disorder.
XX Claim 3; Page 77; 106pp; English.
XX The invention relates to an antisense compound that is targeted to a
XX nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
XX hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
XX and inhibiting its expression. Compounds of the invention are antisense
XX oligonucleotides comprising at least one modified internucleoside
XX linkage, which is a phosphorothioate linkage, at least one modified sugar
XX moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
XX modified nucleobase, which is a 5-methylcytosine. Preferably, the
XX antisense oligonucleotide is a chimeric oligonucleotide. The compound of
XX the invention is useful for preparing a composition for treating a
XX hyperproliferative disorder e.g., cancer, or an autoimmune or
XX inflammatory disorder. The methods are useful for inhibiting the
XX expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
XX treating an animal having a disease or condition associated with
XX inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
XX represent antisense oligonucleotides for the inhibition of human
XX inhibitor-kappa B kinase-gamma mRNA levels.
XX Sequence 20 BP; 1 A; 8 C; 6 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 2.6%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 1.1e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 724 GCAGCAGCAGCGTCGAG 743
XX |||||
XX 20 GCAGCAGCAGCGTCGAG 1
XX
XX RESULT 20
XX ADA44742/c
XX ID ADA44742 standard; DNA; 20 BP.
XX AC ADA44742;
XX XX
XX 20-NOV-2003 (first entry)
XX DT
XX

```

```

DE Antisense oligonucleotide #ISIS 115414 #SEQ ID 40.
XX Antisense oligonucleotide; cytostatic; immunosuppressive;
XX antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
XX autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
XX human.
XX Homo sapiens.
XX Key Location/Qualifiers
XX modified_base 1..20
XX /tag= b
XX /mod_base= OTHER
XX /note= "phosphorothioate linkages, all cytosines are 5-
XX methylcytosine"
XX modified_base 1..5
XX /tag= a
XX /mod_base= OTHER
XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX modified_base 16..20
XX /tag= c
XX /mod_base= OTHER
XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX WO2003031576-A2.
XX 17-APR-2003.
XX 03-OCT-2002; 2002WO-US031809.
XX 06-OCT-2001; 2001US-00972607.
XX (ISIS-) ISIS PHARM INC.
XX Monia BP, Wyatt JR;
XX WPI; 2003-457242/43.
XX New compound having sequence targeted to nucleic acid encoding inhibitor-
XX kappa B kinase-gamma, useful for preparing composition for treating e.g.,
XX cancer, or inflammatory or autoimmune disorder.
XX Claim 3; Page 77; 106pp; English.
XX The invention relates to an antisense compound that is targeted to a
XX nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
XX hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
XX and inhibiting its expression. Compounds of the invention are antisense
XX oligonucleotides comprising at least one modified internucleoside
XX linkage, which is a phosphorothioate linkage, at least one modified sugar
XX moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
XX modified nucleobase, which is a 5-methylcytosine. Preferably, the
XX antisense oligonucleotide is a chimeric oligonucleotide. The compound of
XX the invention is useful for preparing a composition for treating a
XX hyperproliferative disorder e.g., cancer, or an autoimmune or
XX inflammatory disorder. The methods are useful for inhibiting the
XX expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
XX treating an animal having a disease or condition associated with
XX inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
XX represent antisense oligonucleotides for the inhibition of human
XX inhibitor-kappa B kinase-gamma mRNA levels.
XX Sequence 20 BP; 2 A; 8 C; 7 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 2.6%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 1.1e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 776 GAGGCGCGCTCCGATGGA 795
XX |||||
XX 20 GAGGCGCGCTCCGATGGA 1
XX
XX

```


CC treating an animal having a disease or condition associated with
CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
CC represent antisense oligonucleotides for the inhibition of human
CC inhibitor-kappa B kinase-gamma mRNA levels.
XX
SQ Sequence 20 BP; 1 A; 8 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. NO. 1.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 800 CAGGCCGCTCGAGGAGAA 819
Db 20 CAGGCCGCTCGAGGAGAA 1

RESULT 23
ADA44707/c
ID ADA44707 standard; DNA; 20 BP.
XX
AC ADA44707;
XX
DT 20-NOV-2003 (first entry)
XX
DE PCR primer for amplifying human inhibitor-kappa B kinase-gamma #SEQ ID 5.
XX
KW Antisense oligonucleotide; cytostatic; immunosuppressive;
KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; PCR;
KW primer; ss.
XX
OS Homo sapiens.
XX
PN WO2003031576-A2.
XX
PD 17-APR-2003.
XX
PF 03-OCT-2002; 2002WO-US031809.
XX
PR 06-OCT-2001; 2001US-00972607.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Wyatt JR;
XX
DR WPI; 2003-457242/43.
XX
PS New compound having sequence targeted to nucleic acid encoding inhibitor-kappa B kinase-gamma, useful for preparing composition for treating e.g., cancer, or inflammatory or autoimmune disorder.
XX
Example 13; Page 74; 106pp; English.
XX
The invention relates to an antisense compound that is targeted to a
CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
CC and inhibiting its expression. Compounds of the invention are antisense
CC oligonucleotides comprising at least one modified internucleoside
CC linkage, which is a phosphorothioate linkage, at least one modified sugar
CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
CC modified nucleobase, which is a 5-methylcytosine. Preferably, the
CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of
CC the invention is useful for preparing a composition for treating a
CC hyperproliferative disorder e.g., cancer, or an autoimmune or
CC inflammatory disorder. The methods are useful for inhibiting the
CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
CC treating an animal having a disease or condition associated with
CC inhibitor-kappa B kinase-gamma. The current sequence represents a reverse
CC PCR primer used in an example from the invention to amplify human
CC inhibitor-kappa B kinase-gamma DNA.
XX
SQ Sequence 20 BP; 3 A; 8 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. NO. 1.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 215 GATCAGGACGTACTCGGCGA 234
Db 20 GATCAGGACGTACTCGGCGA 1

RESULT 24
ADA44718/c
ID ADA44718 standard; DNA; 20 BP.
XX
AC ADA44718;
XX
DT 20-NOV-2003 (first entry)
XX
DE Antisense oligonucleotide #ISIS 115390 #SEQ ID 16.
XX
KW Antisense oligonucleotide; cytostatic; immunosuppressive;
KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
KW human.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages, all cytosines are 5-methylcytosine"
FT modified_base 1..5
FT /tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN WO2003031576-A2.
XX
PD 17-APR-2003.
XX
PF 03-OCT-2002; 2002WO-US031809.
XX
PR 06-OCT-2001; 2001US-00972607.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Wyatt JR;
XX
DR WPI; 2003-457242/43.
XX
PS New compound having sequence targeted to nucleic acid encoding inhibitor-kappa B kinase-gamma, useful for preparing composition for treating e.g., cancer, or inflammatory or autoimmune disorder.
XX
Claim 3; Page 76; 106pp; English.
XX
The invention relates to an antisense compound that is targeted to a
CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
CC and inhibiting its expression. Compounds of the invention are antisense
CC oligonucleotides comprising at least one modified internucleoside
CC linkage, which is a phosphorothioate linkage, at least one modified sugar
CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
CC modified nucleobase, which is a 5-methylcytosine. Preferably, the
CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of
CC the invention is useful for preparing a composition for treating a
CC hyperproliferative disorder e.g., cancer, or an autoimmune or
CC inflammatory disorder. The methods are useful for inhibiting the

CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
 CC treating an animal having a disease or condition associated with
 CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
 CC represent antisense oligonucleotides for the inhibition of human
 CC inhibitor-kappa B kinase-gamma mRNA levels.
 XX
 SQ Sequence 20 BP; 5 A; 6 C; 4 G; 5 T; 0 U; 0 Other;
 Query Match 2.6%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 162 TCTGGAAGAGCCCACTGTGT 181
 Db 20 TCTGGAAGAGCCCACTGTGT 1
 RESULT 25
 ADA44734/c
 ID ADA44734 standard; DNA; 20 BP.
 XX
 AC ADA44734;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Antisense oligonucleotide #ISIS 115406 #SEQ ID 32.
 XX
 KW Antisense oligonucleotide; cytostatic; immunosuppressive;
 KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
 KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
 KW human.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 XX
 PN WO2003031576-A2.
 XX
 PD 17-APR-2003.
 XX
 PF 03-OCT-2002; 2002WO-US031809.
 XX
 PR 06-OCT-2001; 2001US-00972607.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Monia BP, Wyatt JR;
 XX
 PD WPI; 2003-457242/43.
 XX
 DR New compound having sequence targeted to nucleic acid encoding inhibitor-kappa B kinase-gamma, useful for preparing composition for treating e.g., cancer, or inflammatory or autoimmune disorder.
 XX
 PS Claim 3; Page 77; 106pp; English.
 XX
 CC The invention relates to an antisense compound that is targeted to a
 CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
 CC hybridising to the nucleic acid encoding inhibitor-kappa B kinase-gamma
 CC and inhibiting its expression. Compounds of the invention are antisense

CC oligonucleotides comprising at least one modified internucleoside
 CC linkage, which is a phosphorothioate linkage, at least one modified sugar
 CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
 CC modified nucleobase, which is a 5-methylcytosine. Preferably, the
 CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of
 CC the invention is useful for preparing a composition for treating a
 CC hyperproliferative disorder e.g., cancer, or an autoimmune or
 CC inflammatory disorder. The methods are useful for inhibiting the
 CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
 CC treating an animal having a disease or condition associated with
 CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
 CC represent antisense oligonucleotides for the inhibition of human
 CC inhibitor-kappa B kinase-gamma mRNA levels.
 XX
 SQ Sequence 20 BP; 2 A; 7 C; 4 G; 7 T; 0 U; 0 Other;
 Query Match 2.6%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.1e+02; Indels 0; Gaps 0;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 534 AGAGATGCCAGCAGCAGATG 553
 Db 20 AGAGATGCCAGCAGCAGATG 1
 RESULT 26
 ADA44747/c
 ID ADA44747 standard; DNA; 20 BP.
 XX
 AC ADA44747;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Antisense oligonucleotide #ISIS 115419 #SEQ ID 45.
 XX
 KW Antisense oligonucleotide; cytostatic; immunosuppressive;
 KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
 KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
 KW human.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate linkages, all cytosines are 5-methylcytosine"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 XX
 PN WO2003031576-A2.
 XX
 PD 17-APR-2003.
 XX
 PF 03-OCT-2002; 2002WO-US031809.
 XX
 PR 06-OCT-2001; 2001US-00972607.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Monia BP, Wyatt JR;
 XX
 PD WPI; 2003-457242/43.
 XX
 DR New compound having sequence targeted to nucleic acid encoding inhibitor-kappa B kinase-gamma, useful for preparing composition for treating e.g., cancer, or inflammatory or autoimmune disorder.
 XX
 PS Claim 3; Page 77; 106pp; English.
 XX
 CC The invention relates to an antisense compound that is targeted to a
 CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
 CC hybridising to the nucleic acid encoding inhibitor-kappa B kinase-gamma
 CC and inhibiting its expression. Compounds of the invention are antisense

```
PT cancer, or inflammatory or autoimmune disorder.
PS Claim 3; Page 77; 106pp; English.
XX
CC The invention relates to an antisense compound that is targeted to a
CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
CC and inhibiting its expression. Compounds of the invention are antisense
CC oligonucleotides comprising at least one modified internucleoside
CC linkage, which is a 2'-O-methoxyethyl linkage, at least one modified sugar
CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
CC modified nucleobase, which is a 5-methylcytosine. Preferably, the
CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of
CC the invention is useful for preparing a composition for treating a
CC hyperproliferative disorder e.g., cancer, or an autoimmune or
CC inflammatory disorder. The methods are useful for inhibiting the
CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
CC treating an animal having a disease or condition associated with
CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
CC represent antisense oligonucleotides for the inhibition of human
CC inhibitor-kappa B kinase-gamma mRNA levels.
XX
SQ Sequence 20 BP; 4 A; 5 C; 7 G; 4 T; 0 U; 0 Other;

Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 840 AGGTGGCCTATCACCAGCTC 859
DB |||||
20 AGGTGGCCTATCACCAGCTC 1

RESULT 27
ADA44730/c
ID ADA44730 standard; DNA; 20 BP.
XX
AC ADA44730;
XX
XX 20-NOV-2003 (first entry)
XX
DE Antisense oligonucleotide #ISIS 115402 #SEQ ID 28.
XX
KW Antisense oligonucleotide; cytostatic; immunosuppressive;
KW antinflammatory; gene therapy; hyperproliferative disorder; cancer;
KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
KW human.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages, all cytosines are 5-
FT methylcytosine"
FT modified_base 1..5
FT /tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN WO2003031576-A2.
XX
XX 17-APR-2003.
XX
XX 03-OCT-2002; 2002WO-US031809.
XX
XX 06-OCT-2001; 2001US-00972607.
XX

(ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Wyatt JR;
XX
XX WPI; 2003-457242/43.
XX
XX New compound having sequence targeted to nucleic acid encoding inhibitor-
XX kappa B kinase-gamma, useful for preparing composition for treating e.g.,
XX cancer, or inflammatory or autoimmune disorder.
PS Claim 3; Page 77; 106pp; English.
XX
CC The invention relates to an antisense compound that is targeted to a
CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
CC and inhibiting its expression. Compounds of the invention are antisense
CC oligonucleotides comprising at least one modified internucleoside
CC linkage, which is a phosphorothioate linkage, at least one modified sugar
CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
CC modified nucleobase, which is a 5-methylcytosine. Preferably, the
CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of
CC the invention is useful for preparing a composition for treating a
CC hyperproliferative disorder e.g., cancer, or an autoimmune or
CC inflammatory disorder. The methods are useful for inhibiting the
CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
CC treating an animal having a disease or condition associated with
CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
CC represent antisense oligonucleotides for the inhibition of human
CC inhibitor-kappa B kinase-gamma mRNA levels.
XX
SQ Sequence 20 BP; 3 A; 7 C; 6 G; 4 T; 0 U; 0 Other;

Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 465 GACTGGCCTGGAGAAGCTC 484
DB |||||
20 GACTGGCCTGGAGAAGCTC 1

RESULT 28
ADA44733/c
ID ADA44733 standard; DNA; 20 BP.
XX
AC ADA44733;
XX
XX 20-NOV-2003 (first entry)
XX
DE Antisense oligonucleotide #ISIS 115405 #SEQ ID 31.
XX
KW Antisense oligonucleotide; cytostatic; immunosuppressive;
KW antinflammatory; gene therapy; hyperproliferative disorder; cancer;
KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
KW human.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages, all cytosines are 5-
FT methylcytosine"
FT modified_base 1..5
FT /tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
```

PN WO2003031576-A2.
XX 17-APR-2003.
XX 03-OCT-2002; 2002WO-US031809.
XX 06-OCT-2001; 2001US-00972607.
XX (ISIS-) ISIS PHARM INC.
XX Monia BP, Wyatt JR;
XX WPI; 2003-457242/43.
XX New compound having sequence targeted to nucleic acid encoding inhibitor-
PT kappa B kinase-gamma, useful for preparing composition for treating e.g.,
PT cancer, or inflammatory or autoimmune disorder.
XX Claim 3; Page 77; 106pp; English.
XX The invention relates to an antisense compound that is targeted to a
CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
CC and inhibiting its expression. Compounds of the invention are antisense
CC oligonucleotides comprising at least one modified internucleoside
CC linkage, which is a phosphorothioate linkage, at least one modified sugar
CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
CC modified nucleobase, which is a 5-methylcytosine. Preferably, the
CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of
CC the invention is useful for preparing a composition for treating a
CC hyperproliferative disorder e.g., cancer, or an autoimmune or
CC inflammatory disorder. The methods are useful for inhibiting the
CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
CC treating an animal having a disease or condition associated with
CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
CC represent antisense oligonucleotides for the inhibition of human
CC inhibitor-kappa B kinase-gamma mRNA levels.
XX SQ Sequence 20 BP; 3 A; 11 C; 3 G; 3 T; 0 U; 0 Other;
Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 507 AGGCTCTCGGGAGGTGGAG 526
DB 20 AGGCTCTCGGGAGGTGGAG 1
RESULT 29
ADA44741/c
ID ADA44741 standard; DNA; 20 BP.
XX ADA44741;
AC ADA44741;
XX 20-NOV-2003 (first entry)
DE Antisense oligonucleotide #ISIS 115413 #SEQ ID 39.
XX Antisense oligonucleotide; cytostatic; immunosuppressive;
KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; sb;
XX Homo sapiens.
OS Location/Qualifiers
FH Key 1..20
FT modified_base /tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages, all cytosines are 5-
FT methylcytosine"
FT modified_base 1..5

FT /tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 15..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX WO2003031576-A2.
XX 17-APR-2003.
PD 03-OCT-2002; 2002WO-US031809.
XX 06-OCT-2001; 2001US-00972607.
XX (ISIS-) ISIS PHARM INC.
XX Monia BP, Wyatt JR;
PI WPI; 2003-457242/43.
XX New compound having sequence targeted to nucleic acid encoding inhibitor-
PT kappa B kinase-gamma, useful for preparing composition for treating e.g.,
PT cancer, or inflammatory or autoimmune disorder.
XX Claim 3; Page 77; 106pp; English.
XX The invention relates to an antisense compound that is targeted to a
CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
CC and inhibiting its expression. Compounds of the invention are antisense
CC oligonucleotides comprising at least one modified internucleoside
CC linkage, which is a phosphorothioate linkage, at least one modified sugar
CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
CC modified nucleobase, which is a 5-methylcytosine. Preferably, the
CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of
CC the invention is useful for preparing a composition for treating a
CC hyperproliferative disorder e.g., cancer, or an autoimmune or
CC inflammatory disorder. The methods are useful for inhibiting the
CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
CC treating an animal having a disease or condition associated with
CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
CC represent antisense oligonucleotides for the inhibition of human
CC inhibitor-kappa B kinase-gamma mRNA levels.
XX SQ Sequence 20 BP; 2 A; 8 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 726 AGCAGCACGCGTGCAGGTG 745
DB 20 AGCAGCACGCGTGCAGGTG 1
RESULT 30
ADA44724/c
ID ADA44724 standard; DNA; 20 BP.
XX ADA44724;
AC ADA44724;
XX 20-NOV-2003 (first entry)
DE Antisense oligonucleotide #ISIS 115396 #SEQ ID 22.
XX Antisense oligonucleotide; cytostatic; immunosuppressive;
KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; sb;
XX Homo sapiens.
OS

XX FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate linkages, all cytosines are 5-methylcytosine"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 XX WO2003031576-A2.
 XX 17-APR-2003.
 XX 03-OCT-2002; 2002WO-US031809.
 XX 06-OCT-2001; 2001US-00972607.
 XX (ISIS-) ISIS PHARM INC.
 XX Monia BP, Wyatt JR;
 XX WPI; 2003-457242/43.
 XX New compound having sequence targeted to nucleic acid encoding inhibitor-kappa B kinase-gamma, useful for preparing composition for treating e.g., cancer, or inflammatory or autoimmune disorder.
 XX Claim 3; Page 76; 106pp; English.
 XX The invention relates to an antisense compound that is targeted to a nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma and inhibiting its expression. Compounds of the invention are antisense oligonucleotides comprising at least one modified internucleoside linkage, which is a phosphorothioate linkage, at least one modified sugar moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one modified nucleobase, which is a 5-methylcytosine. Preferably, the antisense oligonucleotide is a chimeric oligonucleotide. The compound of the invention is useful for preparing a composition for treating a hyperproliferative disorder e.g., cancer, or an autoimmune or inflammatory disorder. The methods are useful for inhibiting the expression of inhibitor-kappa B kinase-gamma in cells or tissues, and treating an animal having a disease or condition associated with inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790 represent antisense oligonucleotides for the inhibition of human inhibitor-kappa B kinase-gamma mRNA levels.
 XX Sequence 20 BP; 2 A; 7 C; 4 G; 7 T; 0 U; 0 Other;
 XX Query Match 2.6%; Score 20; DB 1; Length 20;
 XX Best Local Similarity 100.0%; Pred. No. 1.1e+02;
 XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 313 GGAGGAGATCAAGAGCTCC 332
 DB 20 GGAGGAGATCAAGAGCTCC 1
 RESULT 31
 ID ADA44727/c
 XX ADA44727 standard; DNA; 20 BP.
 XX AC ADA44727;
 XX 20-NOV-2003 (first entry)
 XX DT

DE, Antisense oligonucleotide #ISIS 115399 #SEQ ID 25.
 XX Antisense oligonucleotide; cytostatic; immunosuppressive;
 KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
 KW autoimmune, inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
 XX human.
 OS Homo sapiens.
 XX Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate linkages, all cytosines are 5-methylcytosine"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 XX WO2003031576-A2.
 XX 17-APR-2003.
 XX 03-OCT-2002; 2002WO-US031809.
 XX 06-OCT-2001; 2001US-00972607.
 XX (ISIS-) ISIS PHARM INC.
 XX Monia BP, Wyatt JR;
 XX WPI; 2003-457242/43.
 XX New compound having sequence targeted to nucleic acid encoding inhibitor-kappa B kinase-gamma, useful for preparing composition for treating e.g., cancer, or inflammatory or autoimmune disorder.
 XX Claim 3; Page 76; 106pp; English.
 XX The invention relates to an antisense compound that is targeted to a nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma and inhibiting its expression. Compounds of the invention are antisense oligonucleotides comprising at least one modified internucleoside linkage, which is a phosphorothioate linkage, at least one modified sugar moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one modified nucleobase, which is a 5-methylcytosine. Preferably, the antisense oligonucleotide is a chimeric oligonucleotide. The compound of the invention is useful for preparing a composition for treating a hyperproliferative disorder e.g., cancer, or an autoimmune or inflammatory disorder. The methods are useful for inhibiting the expression of inhibitor-kappa B kinase-gamma in cells or tissues, and treating an animal having a disease or condition associated with inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790 represent antisense oligonucleotides for the inhibition of human inhibitor-kappa B kinase-gamma mRNA levels.
 XX Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;
 XX Query Match 2.6%; Score 20; DB 1; Length 20;
 XX Best Local Similarity 100.0%; Pred. No. 1.1e+02;
 XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 391 TTTCACGACGACGAGGG 410
 DB 20 TTTCACGACGACGAGGG 1

```
Query Match
2.6%; Score 20; DB 1; Length 20;
```

CC treating an animal having a disease or condition associated with
 CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
 CC represent antisense oligonucleotides for the inhibition of human
 CC inhibitor-kappa B kinase-gamma mRNA levels.
 XX
 SQ Sequence 20 BP; 2 A; 7 C; 6 G; 5 T; 0 U; 0 Other;
 Query Match 2.6%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 725 CAGCAGCAGCGTGCAGGT 744
 |||||
 DB 20 CAGCAGCAGCGTGCAGGT 1
 RESULT 34
 ADA44725/c
 ID ADA44725 standard; DNA; 20 BP.
 XX
 AC ADA44725;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Antisense oligonucleotide #ISIS 115397 #SEQ ID 23.
 XX
 KW Antisense oligonucleotide; cytostatic; immunosuppressive;
 KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
 KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
 KW human.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate linkages, all cytosines are 5-
 FT methylcytosine"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 PN WO2003031576-A2.
 PD 17-APR-2003.
 XX
 PF 03-OCT-2002; 2002WO-US031809.
 XX
 PR 06-OCT-2001; 2001US-00972607.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Monia BP, Wyatt JR;
 XX
 DR WPI; 2003-457242/43.
 XX
 PT New compound having sequence targeted to nucleic acid encoding inhibitor-
 PT kappa B kinase-gamma, useful for preparing composition for treating e.g.,
 PT cancer, or inflammatory or autoimmune disorder.
 XX
 PS Claim 3; Page 76; 106pp; English.
 XX
 CC The invention relates to an antisense compound that is targeted to a
 CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
 CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
 CC and inhibiting its expression. Compounds of the invention are antisense
 CC oligonucleotides comprising at least one modified internucleoside

CC linkage, which is a phosphorothioate linkage, at least one modified sugar
 CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
 CC modified nucleobase, which is a 5-methylcytosine. Preferably, the
 CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of
 CC the invention is useful for preparing a composition for treating a
 CC hyperproliferative disorder e.g., cancer, or an autoimmune or
 CC inflammatory disorder. The methods are useful for inhibiting the
 CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
 CC treating an animal having a disease or condition associated with
 CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
 CC represent antisense oligonucleotides for the inhibition of human
 CC inhibitor-kappa B kinase-gamma mRNA levels.
 XX
 SQ Sequence 20 BP; 3 A; 5 C; 6 G; 6 T; 0 U; 0 Other;
 Query Match 2.6%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 344 CGGCAGACACACGATTCT 363
 |||||
 DB 20 CGGCAGACACACGATTCT 1
 RESULT 35
 ADA44731/c
 ID ADA44731 standard; DNA; 20 BP.
 XX
 AC ADA44731;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Antisense oligonucleotide #ISIS 115403 #SEQ ID 29.
 XX
 KW Antisense oligonucleotide; cytostatic; immunosuppressive;
 KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
 KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
 KW human.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate linkages, all cytosines are 5-
 FT methylcytosine"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 PN WO2003031576-A2.
 PD 17-APR-2003.
 XX
 PF 03-OCT-2002; 2002WO-US031809.
 XX
 PR 06-OCT-2001; 2001US-00972607.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Monia BP, Wyatt JR;
 XX
 DR WPI; 2003-457242/43.
 XX
 PT New compound having sequence targeted to nucleic acid encoding inhibitor-
 PT kappa B kinase-gamma, useful for preparing composition for treating e.g.,
 PT cancer, or inflammatory or autoimmune disorder.

XX PS Claim 3; Page 77; 106pp; English.

XX CC The invention relates to an antisense compound that is targeted to a

CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically

CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma

CC and inhibiting its expression. Compounds of the invention are antisense

CC oligonucleotides comprising at least one modified internucleoside

CC linkage, which is a phosphorothioate linkage, at least one modified sugar

CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one

CC modified nucleobase, which is a 5-methylcytosine. Preferably, the

CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of

CC the invention is useful for preparing a composition for treating a

CC hyperproliferative disorder e.g., cancer, or an autoimmune or

CC inflammatory disorder. The methods are useful for inhibiting the

CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and

CC treating an animal having a disease or condition associated with

CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790

CC represent antisense oligonucleotides for the inhibition of human

CC inhibitor-kappa B kinase-gamma mRNA levels.

XX SQ Sequence 20 BP; 3 A; 7 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 2.6%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.1e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 483 TCGATCTGAAGAGCGAGAG 502

DB 20 TCGATCTGAAGAGCGAGAG 1

RESULT 36

ADA44745/C

ID ADA44745 standard; DNA; 20 BP.

XX AC ADA44745;

XX DT 20-NOV-2003 (first entry)

XX DE Antisense oligonucleotide #ISIS 115417 #SEQ ID 43.

XX KW Antisense oligonucleotide; cytostatic; immunosuppressive;

KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;

KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;

XX OS Homo sapiens.

XX FH Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= b

FT /mod_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

FT modified_base 16..20

FT /*tag= c

FT /mod_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

XX PN WO2003031576-A2.

XX PD 17-APR-2003.

XX PF 03-OCT-2002; 2002WO-US031809.

XX PR 06-OCT-2001; 2001US-00972607.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Monia BP, Wyatt JR;

XX WPI; 2003-457242/43.

XX DR New compound having sequence targeted to nucleic acid encoding inhibitor-

PT kappa B kinase-gamma, useful for preparing composition for treating e.g.,

PT cancer, or inflammatory or autoimmune disorder.

XX PS Claim 3; Page 77; 106pp; English.

XX CC The invention relates to an antisense compound that is targeted to a

CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically

CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma

CC and inhibiting its expression. Compounds of the invention are antisense

CC oligonucleotides comprising at least one modified internucleoside

CC linkage, which is a phosphorothioate linkage, at least one modified sugar

CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one

CC modified nucleobase, which is a 5-methylcytosine. Preferably, the

CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of

CC the invention is useful for preparing a composition for treating a

CC hyperproliferative disorder e.g., cancer, or an autoimmune or

CC inflammatory disorder. The methods are useful for inhibiting the

CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and

CC treating an animal having a disease or condition associated with

CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790

CC represent antisense oligonucleotides for the inhibition of human

CC inhibitor-kappa B kinase-gamma mRNA levels.

XX SQ Sequence 20 BP; 1 A; 9 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.6%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.1e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 803 GCGGCTCGAGAGAGAG 822

DB 20 GCGGCTCGAGAGAGAG 1

RESULT 37

ADA44723/C

ID ADA44723 standard; DNA; 20 BP.

XX AC ADA44723;

XX DT 20-NOV-2003 (first entry)

XX DE Antisense oligonucleotide #ISIS 115395 #SEQ ID 21.

XX KW Antisense oligonucleotide; cytostatic; immunosuppressive;

KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;

KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;

XX OS Homo sapiens.

XX FH Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= b

FT /mod_base= OTHER

FT /note= "Phosphorothioate linkages, all cytosines are 5-

FT modified_base 1..5

FT /*tag= a

FT /mod_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

FT modified_base 16..20

FT /*tag= c

FT /mod_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

XX PN WO2003031576-A2.


```

XX PD 17-APR-2003.
XX PF 03-OCT-2002; 2002WO-US031809.
XX PR 06-OCT-2003; 2001US-00972607.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Monia BP, Wyatt JR;
XX PD WPI; 2003-457242/43.
XX DR New compound having sequence targeted to nucleic acid encoding inhibitor-
XX PT kappa B kinase-gamma, useful for preparing composition for treating e.g.,
XX PT cancer, or inflammatory or autoimmune disorder.
XX PS Claim 3; Page 76; 106pp; English.
XX CC The invention relates to an antisense compound that is targeted to a
XX CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
XX CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
XX CC and inhibiting its expression. Compounds of the invention are antisense
XX CC oligonucleotides comprising at least one modified internucleoside
XX CC linkage, which is a phosphorothioate linkage, at least one modified sugar
XX CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
XX CC modified nucleobase, which is a 5-methylcytosine. Preferably, the
XX CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of
XX CC the invention is useful for preparing a composition for treating a
XX CC hyperproliferative disorder e.g., cancer, or an autoimmune or
XX CC inflammatory disorder. The methods are useful for inhibiting the
XX CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
XX CC treating an animal having a disease or condition associated with
XX CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
XX CC represent antisense oligonucleotides for the inhibition of human
XX CC inhibitor-kappa B kinase-gamma mRNA levels.
XX SQ Sequence 20 BP; 2 A; 6 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 279 AACAGGGCGCTCTGAGACC 298
DB 20 AACAGGGCGCTCTGAGACC 1

RESULT 38
ADA44748/c
XX ID ADA44748 standard; DNA; 20 BP.
XX AC ADA44748;
XX DT 20-NOV-2003 (first entry)
XX DE Antisense oligonucleotide #ISIS 115420 #SEQ ID 46.
XX KW Antisense oligonucleotide; cytostatic; immunosuppressive;
XX KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
XX KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
XX KW human.
XX OS Homo sapiens.
XX PH Key Location/Qualifiers
XX FT modified_base 1..20
XX FT /*tag= b
XX FT /mod_base= OTHER
XX FT /note= "Phosphorothioate linkages, all cytosines are 5-
XX FT methylcytosine"
XX FT modified_base 1..5
XX FT /*tag= a

```

```

FT FT /mod_base= OTHER
FT FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT FT 16..20
FT FT /*tag= c
FT FT /mod_base= OTHER
FT FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX PN WO2003031576-A2.
XX PD 17-APR-2003.
XX PF 03-OCT-2002; 2002WO-US031809.
XX PR 06-OCT-2001; 2001US-00972607.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Monia BP, Wyatt JR;
XX PD WPI; 2003-457242/43.
XX DR New compound having sequence targeted to nucleic acid encoding inhibitor-
XX PT kappa B kinase-gamma, useful for preparing composition for treating e.g.,
XX PT cancer, or inflammatory or autoimmune disorder.
XX PS Claim 3; Page 77; 106pp; English.
XX CC The invention relates to an antisense compound that is targeted to a
XX CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
XX CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
XX CC and inhibiting its expression. Compounds of the invention are antisense
XX CC oligonucleotides comprising at least one modified internucleoside
XX CC linkage, which is a phosphorothioate linkage, at least one modified sugar
XX CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
XX CC modified nucleobase, which is a 5-methylcytosine. Preferably, the
XX CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of
XX CC the invention is useful for preparing a composition for treating a
XX CC hyperproliferative disorder e.g., cancer, or an autoimmune or
XX CC inflammatory disorder. The methods are useful for inhibiting the
XX CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
XX CC treating an animal having a disease or condition associated with
XX CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
XX CC represent antisense oligonucleotides for the inhibition of human
XX CC inhibitor-kappa B kinase-gamma mRNA levels.
XX SQ Sequence 20 BP; 6 A; 3 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 843 TGGCCTATCACCAGCTCTTC 862
DB 20 TGGCCTATCACCAGCTCTTC 1

RESULT 39
ADA44721/c
XX ID ADA44721 standard; DNA; 20 BP.
XX AC ADA44721;
XX DT 20-NOV-2003 (first entry)
XX DE Antisense oligonucleotide #ISIS 115393 #SEQ ID 19.
XX KW Antisense oligonucleotide; cytostatic; immunosuppressive;
XX KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
XX KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
XX KW human.
XX OS Homo sapiens.
XX PH Key Location/Qualifiers
XX FT modified_base 1..20
XX FT /*tag= b
XX FT /mod_base= OTHER
XX FT /note= "Phosphorothioate linkages, all cytosines are 5-
XX FT methylcytosine"
XX FT modified_base 1..5
XX FT /*tag= a

```

```

FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages, all cytosines are 5-
FT methylcytosine"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX WO2003031576-A2.
XX
XX 17-APR-2003.
XX
XX 03-OCT-2002; 2002WO-US031809.
XX
XX 06-OCT-2001; 2001US-00972607.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Wyatt JR;
XX
XX WPI; 2003-457242/43.
XX
CC The invention relates to an antisense compound that is targeted to a
CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
CC hybridising to the nucleic acid encoding inhibitor-kappa B kinase-gamma
CC and inhibiting its expression. Compounds of the invention are antisense
CC oligonucleotides comprising at least one modified internucleoside
CC linkage, which is a phosphorothioate linkage, at least one modified sugar
CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
CC modified nucleobase, which is a 5-methylcytosine. Preferably, the
CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of
CC the invention is useful for preparing a composition for treating a
CC hyperproliferative disorder e.g., cancer, or an autoimmune or
CC inflammatory disorder. The methods are useful for inhibiting the
CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
CC treating an animal having a disease or condition associated with
CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
CC represent antisense oligonucleotides for the inhibition of human
CC inhibitor-kappa B kinase-gamma mRNA levels.
XX
SQ Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 270 TGCCTTCAGACAGGGCGCT 289
DB 20 TGCCTTCAGACAGGGCGCT 1
RESULT 40
ADA44737/C
ID ADA44737 standard; DNA; 20 BP.
XX
XX ADA44737;
XX AC
XX CC
XX DT 20-NOV-2003 (first entry)
XX DE Antisense oligonucleotide #ISIS 115409 #SEQ ID 35.
XX
XX Antisense oligonucleotide; cytostatic; immunosuppressive;
XX antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
XX autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
XX human.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /*tag= b
XX /mod_base= OTHER
XX /note= "Phosphorothioate linkages, all cytosines are 5-
XX methylcytosine"
XX modified_base 1..5
XX /*tag= a
XX /mod_base= OTHER
XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX modified_base 16..20
XX /*tag= c
XX /mod_base= OTHER
XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX WO2003031576-A2.
XX
XX 17-APR-2003.
XX
XX 03-OCT-2002; 2002WO-US031809.
XX
XX 06-OCT-2001; 2001US-00972607.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Wyatt JR;
XX
XX WPI; 2003-457242/43.
XX
CC The invention relates to an antisense compound that is targeted to a
CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
CC hybridising to the nucleic acid encoding inhibitor-kappa B kinase-gamma
CC and inhibiting its expression. Compounds of the invention are antisense
CC oligonucleotides comprising at least one modified internucleoside
CC linkage, which is a phosphorothioate linkage, at least one modified sugar
CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
CC modified nucleobase, which is a 5-methylcytosine. Preferably, the
CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of
CC the invention is useful for preparing a composition for treating a
CC hyperproliferative disorder e.g., cancer, or an autoimmune or
CC inflammatory disorder. The methods are useful for inhibiting the
CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
CC treating an animal having a disease or condition associated with
CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
CC represent antisense oligonucleotides for the inhibition of human
CC inhibitor-kappa B kinase-gamma mRNA levels.
XX
SQ Sequence 20 BP; 1 A; 10 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 686 CAGCGCGCGCAGCTGGAGAG 705
DB 20 CAGCGCGCGCAGCTGGAGAG 1
RESULT 41
```

ADA44749/c
 ID ADA44749 standard; DNA; 20 BP.
 AC ADA44749;
 XX
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Antisense oligonucleotide #ISIS 115421 #SEQ ID 47.
 KW Antisense oligonucleotide; cytostatic; immunosuppressive;
 XX antinflammatory; gene therapy; hyperproliferative disorder; cancer;
 KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
 KW human.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate linkages, all cytosines are 5-
 methylcytosine"
 FT modified_base 1..5
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT
 PN WO2003031576-A2.
 XX
 XX 17-APR-2003.
 PD
 XX
 XX 03-OCT-2002; 2002WO-US031809.
 PF
 XX
 XX 06-OCT-2001; 2001US-00972607.
 PR
 XX
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX
 XX Monia BP, Wyatt JR;
 PI
 XX WPI; 2003-457242/43.
 DR
 XX
 XX New compound having sequence targeted to nucleic acid encoding inhibitor-
 PT kappa B kinase-gamma, useful for preparing composition for treating e.g.,
 PT cancer, or inflammatory or autoimmune disorder.
 PT
 XX
 PS Claim 3; Page 77; 106pp; English.
 XX
 CC The invention relates to an antisense compound that is targeted to a
 CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
 CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
 CC and inhibiting its expression. Compounds of the invention are antisense
 CC oligonucleotides comprising at least one modified internucleoside
 CC linkage, which is a phosphorothioate linkage, at least one modified sugar
 CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
 CC modified nucleobase, which is a 5-methylcytosine. Preferably, the
 CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of
 CC the invention is useful for preparing a composition for treating a
 CC hyperproliferative disorder e.g., cancer, or an autoimmune or
 CC inflammatory disorder. The methods are useful for inhibiting the
 CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
 CC treating an animal having a disease or condition associated with
 CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
 CC represent antisense oligonucleotides for the inhibition of human
 CC inhibitor-kappa B kinase-gamma mRNA levels.
 XX
 SQ Sequence 20 BP; 3 A; 9 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 2.6%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 882 TCACAGCAGCGTGTGGGC 901
 DB 20 TCAAGAGCAGCGTGTGGGC 1
 RESULT 42
 ADA44735/c
 ID ADA44735 standard; DNA; 20 BP.
 XX
 AC ADA44735;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Antisense oligonucleotide #ISIS 115407 #SEQ ID 33.
 KW Antisense oligonucleotide; cytostatic; immunosuppressive;
 KW antinflammatory; gene therapy; hyperproliferative disorder; cancer;
 KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
 KW human.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate linkages, all cytosines are 5-
 methylcytosine"
 FT modified_base 1..5
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT
 PN WO2003031576-A2.
 XX
 XX 17-APR-2003.
 PD
 XX
 XX 03-OCT-2002; 2002WO-US031809.
 PF
 XX
 XX 06-OCT-2001; 2001US-00972607.
 PR
 XX
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX
 XX Monia BP, Wyatt JR;
 PI
 XX WPI; 2003-457242/43.
 DR
 XX
 XX New compound having sequence targeted to nucleic acid encoding inhibitor-
 PT kappa B kinase-gamma, useful for preparing composition for treating e.g.,
 PT cancer, or inflammatory or autoimmune disorder.
 PT
 XX
 PS Claim 3; Page 77; 106pp; English.
 XX
 CC The invention relates to an antisense compound that is targeted to a
 CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
 CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
 CC and inhibiting its expression. Compounds of the invention are antisense
 CC oligonucleotides comprising at least one modified internucleoside
 CC linkage, which is a phosphorothioate linkage, at least one modified sugar
 CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
 CC modified nucleobase, which is a 5-methylcytosine. Preferably, the
 CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of
 CC the invention is useful for preparing a composition for treating a
 CC hyperproliferative disorder e.g., cancer, or an autoimmune or
 CC inflammatory disorder. The methods are useful for inhibiting the
 CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
 CC treating an animal having a disease or condition associated with
 CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
 CC represent antisense oligonucleotides for the inhibition of human
 CC inhibitor-kappa B kinase-gamma mRNA levels.
 XX
 SQ Sequence 20 BP; 3 A; 9 C; 4 G; 4 T; 0 U; 0 Other;

CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
CC represent antisense oligonucleotides for the inhibition of human
CC inhibitor-kappa B kinase-gamma mRNA levels.
XX
SQ Sequence 20 BP; 2 A; 8 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 604 GCTGCGGAGCCAGAGTC 623
DB 20 GCTGCGGAGCCAGAGTC 1
RESULT 43
ADA44743/C
ID ADA44743 standard; DNA; 20 BP.
XX
AC ADA44743;
XX
DT 20-NOV-2003 (first entry)
XX
DE Antisense oligonucleotide #ISIS 115415 #SEQ ID 41.
XX
KW Antisense oligonucleotide; cytostatic; immunosuppressive;
KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
KW human.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages, all cytosines are 5-
FT methylycytosine"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX WO2003031576-A2.
XX
PD 17-APR-2003.
XX
PF 03-OCT-2002; 2002WO-US031809.
XX
PR 06-OCT-2001; 2001US-00972607.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Wyatt JR;
XX
XX WPI; 2003-457242/43.
XX
DR New compound having sequence targeted to nucleic acid encoding inhibitor-
FT kappa B kinase-gamma, useful for preparing composition for treating e.g.,
PT cancer, or inflammatory or autoimmune disorder.
XX
PS Claim 3; Page 77; 106pp; English.
XX
XX The invention relates to an antisense compound that is targeted to a
CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
CC and inhibiting its expression. Compounds of the invention are antisense
CC oligonucleotides comprising at least one modified internucleoside
CC linkage, which is a phosphorothioate linkage, at least one modified sugar

CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
CC modified nucleobase, which is a 5-methylcytosine. Preferably, the
CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of
CC the invention is useful for preparing a composition for treating a
CC hyperproliferative disorder e.g., cancer, or an autoimmune or
CC inflammatory disorder. The methods are useful for inhibiting the
CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
CC treating an animal having a disease or condition associated with
CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
CC represent antisense oligonucleotides for the inhibition of human
CC inhibitor-kappa B kinase-gamma mRNA levels.
XX
SQ Sequence 20 BP; 2 A; 8 C; 8 G; 2 T; 0 U; 0 Other;
Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 792 TGGAGCGCCAGCGCGCTCG 811
DB 20 TGGAGCGCCAGCGCGCTCG 1
RESULT 44
ADA44729/C
ID ADA44729 standard; DNA; 20 BP.
XX
AC ADA44729;
XX
DT 20-NOV-2003 (first entry)
XX
DE Antisense oligonucleotide #ISIS 115401 #SEQ ID 27.
XX
KW Antisense oligonucleotide; cytostatic; immunosuppressive;
KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
KW human.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages, all cytosines are 5-
FT methylycytosine"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX WO2003031576-A2.
XX
PD 17-APR-2003.
XX
PF 03-OCT-2002; 2002WO-US031809.
XX
PR 06-OCT-2001; 2001US-00972607.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Wyatt JR;
XX
XX WPI; 2003-457242/43.
XX
DR New compound having sequence targeted to nucleic acid encoding inhibitor-
FT kappa B kinase-gamma, useful for preparing composition for treating e.g.,
PT cancer, or inflammatory or autoimmune disorder.
XX

PS Claim 3; Page 77; 106pp; English.

XX The invention relates to an antisense compound that is targeted to a

CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically

CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma

CC and inhibiting its expression. Compounds of the invention are antisense

CC oligonucleotides comprising at least one modified internucleoside

CC linkage, which is a phosphorothioate linkage, at least one modified sugar

CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one

CC modified nucleobase, which is a 5-methylcytosine. Preferably, the

CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of

CC the invention is useful for preparing a composition for treating a

CC hyperproliferative disorder e.g., cancer, or an autoimmune or

CC inflammatory disorder. The methods are useful for inhibiting the

CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and

CC treating an animal having a disease or condition associated with

CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790

CC represent antisense oligonucleotides for the inhibition of human

XX inhibitor-kappa B kinase-gamma mRNA levels.

SQ Sequence 20 BP; 3 A; 8 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 2.6%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.1e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 451 GAAACTGGTGGAGAGACTCG 470

DB 20 GAAACTGGTGGAGAGACTCG 1

|||||

RESULT 45

ADA44736/c

ID ADA44736 standard; DNA; 20 BP.

XX ADA44736;

XX 20-NOV-2003 (first entry)

XX Antisense oligonucleotide #ISIS 115408 #SEQ ID 34.

XX Antisense oligonucleotide; cytostatic; immunosuppressive;

KW antinflammatory; gene therapy; hyperproliferative disorder; cancer;

KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;

XX human.

XX Homo sapiens.

XX Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= b

FT /mod_base= OTHER

FT /note= "Phosphorothioate linkages, all cytosines are 5-methylcytosine"

FT modified_base 1..5

FT /*tag= a

FT /mod_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

FT modified_base 16..20

FT /*tag= c

FT /mod_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

FT WO200301576-A2.

PN 17-APR-2003.

XX 03-OCT-2002; 2002WO-US031809.

XX 06-OCT-2001; 2001US-00972607.

XX (ISIS-) ISIS PHARM INC.

XX

PI Monia BP, Wyatt JR;

XX WPI; 2003-457242/43.

XX New compound having sequence targeted to nucleic acid encoding inhibitor-kappa B kinase-gamma, useful for preparing composition for treating e.g., cancer, or inflammatory or autoimmune disorder.

PT Claim 3; Page 77; 106pp; English.

XX The invention relates to an antisense compound that is targeted to a

CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically

CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma

CC and inhibiting its expression. Compounds of the invention are antisense

CC oligonucleotides comprising at least one modified internucleoside

CC linkage, which is a phosphorothioate linkage, at least one modified sugar

CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one

CC modified nucleobase, which is a 5-methylcytosine. Preferably, the

CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of

CC the invention is useful for preparing a composition for treating a

CC hyperproliferative disorder e.g., cancer, or an autoimmune or

CC inflammatory disorder. The methods are useful for inhibiting the

CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and

CC treating an animal having a disease or condition associated with

CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790

CC represent antisense oligonucleotides for the inhibition of human

XX inhibitor-kappa B kinase-gamma mRNA levels.

SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 2.6%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.1e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 616 CCAGAGTCGCTGGAGGCTG 635

DB 20 CCAGAGTCGCTGGAGGCTG 1

|||||

RESULT 46

ACD23062/c

ID ACD23062 standard; DNA; 21 BP.

XX ACD23062;

XX 25-AUG-2003 (first entry)

XX Human NEMO gene RT-PCR primer R1.

XX Human; PCR; ss; NF-kappaB essential modulator; nuclear factor kappa B;

KW incontinentia pigmenti; X-linked disorder; chromosome Xq28; NEMO;

KW immunomodulatory; dermatological; osteopathic; neuropathic; primer;

KW apoptosis-related disease; immune-system related disease; RT-PCR;

KW blood vessel-related disease; skin defect; dental defect; osteopetrosis;

KW ophthalmologic defect; neurological defect; reverse transcriptase PCR.

XX Homo sapiens.

XX US2003032055-A1.

XX 13-FEB-2003.

XX 22-MAY-2001; 2001US-00863049.

XX 22-MAY-2000; 2000US-0206223P.

XX (KENN/) KENWICK S J.

PA (WOFF/) WOFFENDIN H.

PA (MUNN/) MUNNICH A.

PA (SMAH/) SMAHI A.

PA (ISRA/) ISRAEL A.

PA (POUS/) POUSTR A.

PA (HEIS/) HEISS N.

PA (DURS/) D'URSO M.
PA (LEWI/) LEWIS R. A.
PA (NELS/) NELSON D L.
PA (ARAD/) ARADHYA S.
PA (LEVY/) LEVY M.
XX
XX Kenrick SJ, Woffendin H, Munnich A, Smahi A, Israel A,
PI Poustka A, Heiss N, D'urso M, Lewis RA, Nelson DL, Aradhy S;
PI Levy M;
XX
XX WPI; 2003-492063/46.
XX
XX Detection of necrosis factor-kappa B related medical condition in
PT organism, by obtaining sample from the organism, and analyzing the sample
PT for alteration in specified amino acid sequences.
XX
XX Claim 40; Page 25; 44pp; English.
XX
XX The invention relates to a nuclear factor-kappa B (NF-kappa B) related
CC medical condition in an organism being detected by obtaining a sample
CC from the organism, and analyzing the sample for an alteration in a the
CC nuclear factor kappaB essential modifier (NEMO) gene or protein sequence
CC (neither shown in the specification). The alteration results in
CC inactivation of NF-kappa B. Also included are treating or preventing NF-
CC kappa B related medical condition in an organism by administering the
CC NEMO protein to the organism and screening a test organism for a compound
CC for the treatment of NF-kappa B related medical condition (by
CC administering the compound to the organism, and assaying for an
CC improvement in the NF-kappa B related medical condition). The method
CC useful is for detecting NF-kappa B related condition, e.g. incontinentia
CC pigmenti (IP), apoptosis-related disease, immune-system related disease,
CC blood vessel-related disease, skin defect, dental defect, osteopetrosis,
CC ophthalmologic defect, or neurological defect, in an organism, i.e. human
CC including affected individual, carrier individual, or noncarrier
CC individual. The NEMO gene is located on chromosome Xq28, incontinentia
CC pigmenti being an X-linked disorder. Experiments in this study show
CC variations in exon 2, 10, 9 and particularly intron 3 to be linked to
CC familial incontinentia pigmenti. The present sequence is a reverse
CC transcriptase (RT)-PCR primer used to amplify the human NEMO cDNA
XX
XX Sequence 21 BP; 4 A; 8 C; 5 G; 4 T; 0 U; 0 Other;
SQ
Query Match 2.6%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 645 AATCCAGGCTCTCGAGGCT 664
Db 20 AATCCAGGCTCTCGAGGCT 1
RESULT 47
ADAL3795/C
ID ADAL3795 standard; RNA; 21 BP.
XX
XX AC ADAL3795;
XX
XX 20-NOV-2003 (first entry)
XX
XX Short interfering nucleic acid (siNA) oligonucleotide SEQ ID NO:132.
XX
XX double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; expression; replication;
KW inhibition; RNA interference; virucide; anti-HIV; hepatotropic;
KW antiinflammatory; plant; antiviral; vasotropic; neuroprotective;
KW cytosolic; cardiovascular; immunosuppressive; respiratory; nephrotropic;
KW herpes simplex; cytomegalovirus; human papillomavirus;
KW respiratory syncytial virus; influenza virus; restenosis;
KW neurodegeneration; cancer; neurological; prion; inflammatory; autoimmune;
KW pulmonary; renal; liver; mitochondrial; reproductive disease;
KW chemical modification; ss.
XX
OS Synthetic.
XX WO2003070918-A2.
XX
XX 28-AUG-2003.
XX
XX 20-FEB-2003; 2003WO-US005346.
XX
XX 20-FEB-2002; 2002US-0358580P.
PR
XX 11-MAR-2002; 2002US-0363124P.
PR
XX 06-JUN-2002; 2002US-0386782P.
PR
XX 29-AUG-2002; 2002US-0406784P.
PR
XX 05-SEP-2002; 2002US-0408378P.
PR
XX 09-SEP-2002; 2002US-0409293P.
PR
XX 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX McSwiggen J, Beigelman L, Macejak D, Zinnen S, Pavco P;
PI Morrissey D, Fosnaugh K, Mokler V, Jamison S;
XX WPI; 2003-689785/65.
XX
XX New short interfering nucleic acid containing no ribonucleotides, useful
PT e.g. for treating viral infection, downregulates expression of target
PT gene or RNA.
XX
XX Example 4; Page 135; 204pp; English.
XX
XX The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of a target gene, where
CC the siNA molecule comprises no ribonucleotides and each strand of the
CC double-stranded siNA comprises about 21 nucleotides. Also described: (1)
CC a siNA molecule that inhibits expression of target RNA; (2) a siNA
CC molecule that inhibits replication of a virus and optionally does not
CC require presence of a ribonucleotide for inhibition; (3) a siNA molecule
CC that inhibits expression of a target gene and does not require presence
CC of a ribonucleotide for inhibition; (4) a siNA molecule that inhibits
CC expression of a target gene by mediating RNA interference; and (5) a
CC method for modulating expression of a gene in a cell using siNA
CC molecules. siNA's can have virucide, anti-HIV, hepatotropic,
CC antiinflammatory, plant antiviral, vasotropic, neuroprotective,
CC cytostatic, cardiovascular, immunosuppressive, respiratory, nephrotropic
CC and endocrine activities. The siNA's are useful for downregulating
CC expression of target genes, inhibiting expression of target RNA, and
CC inhibiting replication of a virus. siNA molecules can be used: (a) for
CC therapy of any disorder that responds to modulation of gene expression,
CC especially animal and plant viral infections, specifically hepatitis B or
CC C; HIV; herpes simplex; cytomegalovirus; human papilloma; respiratory
CC syncytial or influenza viruses, and also many other diseases such as
CC restenosis, neurodegeneration, cancers, and cardiovascular, neurological,
CC prion, inflammatory, autoimmune, pulmonary, renal, liver, mitochondrial,
CC endocrine or reproductive diseases; and (b) for diagnosis, target
CC validation, genomic discovery, genetic engineering, pharmacogenomics and
CC analysis of gene function. Chemical modification of siNA molecules
CC improves interfering activity; stability; cellular uptake; binding
CC affinity and/or mediates increased polymerase activity. siNA may be
CC designed to target many related genes containing a conserved sequence.
CC The present sequence represents a siNA oligonucleotide sequence, which is
CC used in the exemplification of the present invention.
XX
XX Sequence 21 BP; 2 A; 8 C; 3 G; 2 T; 6 U; 0 Other;
SQ
Query Match 2.6%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 546 AGCAGATGGCTGAGGCAAG 565
Db 20 AGCAGATGGCTGAGGCAAG 1
RESULT 48

ADG30046
ID ADG30046 standard; RNA; 23 BP.
AC ADG30046;
XX
XX
DT 26-FEB-2004 (first entry)
XX
DE IKKg-targeted siNA DNA-RNA hybrid - SEQ ID 612.
XX
KW double-stranded short interfering nucleic acid; siNA;
KW antiarteriosclerotic; neuroprotective; nontropic; antiparkinsonian;
KW anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW Alzheimer's; Parkinson's; epilepsy; dementia; Huntington's;
KW amyotrophic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid; IKKg.
XX
OS Unidentified.
OS Synthetic.
XX
XX WO2003074654-A2.
XX
XX 12-SEP-2003.
XX
XX 20-FEB-2003; 2003WO-US005028.
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX McSwiggen J, Beigelman L, Chowrira B, Pavco P, Fomenaugh K;
PI Jamison S, Uzman N, Thompson J;
XX
XX WPI; 2003-731676/69.
XX
XX New double-stranded short interfering nucleic acid molecule, useful for
PT down-regulating the expression of an endogenous mammalian target gene or
PT for treating diseases that respond to modulation of gene expression or
PT activity.
XX
XX Example 24; SEQ ID NO 612; 593pp; English.
XX
XX The invention relates to a double-stranded short interfering nucleic acid
CC (siNA) molecule that down-regulates expression of an endogenous mammalian
CC target gene comprising one or more chemical modifications and each strand
CC of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC the invention demonstrates antiarteriosclerotic, neuroprotective,
CC nontropic, antiparkinsonian and anticonvulsant activities and may be
CC useful for down-regulating the expression of an endogenous mammalian
CC target gene and therefore in the treatment of any disease or condition
CC that responds to modulation of gene expression or activity in a cell,
CC tissue or organism. The disease or condition may include pulmonary
CC diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC Parkinson's disease, epilepsy, dementia, Huntington's disease or
CC amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC gene therapy applications. The current sequence is that of the siNA DNA-
CC RNA hybrid of the invention.
XX
SQ Sequence 23 BP; 6 A; 2 C; 9 G; 2 T; 2 U; 2 Other;
Query Match 2.6%; Score 20; DB 1; Length 23;
Best Local Similarity 90.0%; Pred. No. 1.4e+02;
Matches 18; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 407 AGGAGGAGGAGGAGGTTCT 426
|||||
DB 2 AGGAGGAGGAGGAGGTTCT 21
|||||

RESULT 49
ACD23064/c
ID ACD23064 standard; DNA; 21 BP.
XX
XX ACD23064;
AC ACD23064;
XX
XX 25-AUG-2003 (first entry)
XX
DE Human NEMO gene RT-PCR primer R4.
XX
XX Human; PCR; ss; NF-kappaB essential modulator; nuclear factor kappa B;
KW incontinentia pigmenti; X-linked disorder; chromosome Xq28; NEMO;
KW immunomodulatory; dermatological; osteopathic; neuropathic; primer;
KW apoptosis-related disease; immune-system related disease; RT-PCR;
KW blood vessel-related disease; skin defect; dental defect; osteopetrosis;
KW ophthalmologic defect; neurological defect; reverse transcriptase PCR.
XX
OS Homo sapiens.
XX
XX US2003032055-A1.
XX
XX 13-FEB-2003.
XX
XX 22-MAY-2001; 2001US-00863049.
XX
XX 22-MAY-2000; 2000US-0206223P.
XX
XX (KENN/) KENNRICK S J.
PA (WOFF/) WOFFENDIN H.
PA (MUNN/) MUNNICH A.
PA (SMAH/) SMAHI A.
PA (ISRA/) ISRAEL A.
PA (POUS/) POUSTRKA A.
PA (HEIS/) HEISS N.
PA (DURS/) D'URSO M.
PA (LEWI/) LEWIS R A.
PA (NELS/) NELSON D L.
PA (ARAD/) ARADHYA S.
PA (LEVY/) LEVY M.
XX
XX Kenrick SJ, Woffendin H, Munnich A, Smahi A, Israel A;
PI Poustka A, Heiss N, D'urso M, Lewis RA, Nelson DL, Aradhyia S;
PI Levy M;
XX
XX WPI; 2003-492063/46.
XX
XX Detection of necrosis factor-kappa B related medical condition in
PT organism, by obtaining sample from the organism, and analyzing the sample
PT for alteration in specified amino acid sequences.
XX
XX Claim 40; Page 25; 44pp; English.
XX
XX The invention relates to a nuclear factor-kappa B (NF-kappa B) related
CC medical condition in an organism being detected by obtaining a sample
CC from the organism, and analysing the sample for an alteration in a the
CC nuclear factor kappaB essential modifier (NEMO) gene or protein sequence
CC (neither shown in the specification). The alteration results in
CC inactivation of NF-kappa B. Also included are treating or preventing NF-
CC kappa B related medical condition in an organism by administering the
CC NEMO protein to the organism and screening a test organism for a compound
CC for the treatment of NF-kappa B related medical condition (by
CC administering the compound to the organism, and assaying for an
CC improvement in the NF-kappa B related medical condition). The method
CC useful is for detecting NF-kappa B related condition, e.g. incontinentia
CC pigmenti (IP), apoptosis-related disease, immune-system related disease,
CC blood vessel-related disease, skin defect, dental defect, osteopetrosis,
CC ophthalmologic defect, or neurological defect, in an organism, i.e. human
CC including affected individual, carrier individual, or noncarrier
CC individual. The NEMO gene is located on chromosome Xq28, incontinentia
CC pigmenti being an X-linked disorder. Experiments in this study show
CC variations in exon 2, 10, 9 and particularly intron 3 to be linked to
CC familial incontinentia pigmenti the present sequence is a reverse
CC transcriptase (RT)-PCR primer used to amplify the human NEMO cDNA


```
XX SQ Sequence 21 BP; 4 A; 6 C; 5 G; 6 T; 0 U; 0 Other;
XX Query Match 2.6%; Score 19.4; DB 1; Length 21;
XX Best Local Similarity 95.2%; Pred. No. 1.5e+02;
XX Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 473 CTGGAGAGCTCGATCTGAAG 493
DB 21 CTCGAGAGCTCGATCTGAAG 1
RESULT 50
ADAL3790
ID ADAL3790 standard; RNA; 21 BP.
XX AC ADAL3790;
XX AC ADAL3790;
XX 20-NOV-2003 (first entry)
XX Short interfering nucleic acid (siNA) oligonucleotide SEQ ID NO:127.
XX double-stranded short interfering nucleic acid;
XX short interfering nucleic acid; siNA; expression; replication;
XX inhibition; RNA interference; virucide; anti-HIV; hepatotropic;
XX antiinflammatory; plant; antiviral; vasotropic; neuroprotective;
XX cytosolic; cardiovascular; immunosuppressive; respiratory; nephrotropic;
XX endocrine; viral infection; hepatitis B; hepatitis C; HIV;
XX herpes simplex; cytomegalovirus; human papillomavirus;
XX respiratory syncytial virus; influenza virus; restenosis;
XX neurodegeneration; cancer; neurological; prion; inflammatory; autoimmune;
XX pulmonary; renal; liver; mitochondrial; reproductive disease;
XX chemical modification; ss.
XX Synthetic.
XX OS
XX ADG30050/C
XX ID ADG30050 standard; RNA; 21 BP.
XX AC ADG30050;
XX AC ADG30050;
XX 26-FEB-2004 (first entry)
XX DE IKKg-targeted siNA DNA-RNA hybrid - SEQ ID 616.
XX double-stranded short interfering nucleic acid; siNA;
XX antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
XX anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
XX Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
XX amyotrophic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid; IKKg.
XX Unidentified.
XX OS
XX Synthetic.
XX WO2003074654-A2.
XX PN
XX 12-SEP-2003.
XX PD
XX 20-FEB-2003; 2003WO-US005028.
XX PF
XX 20-FEB-2002; 2002US-0358580P.
XX PR
XX 11-MAR-2002; 2002US-0363124P.
XX PR
XX 06-JUN-2002; 2002US-0386782P.
XX PR
XX 29-AUG-2002; 2002US-0406784P.
XX PR
XX 05-SEP-2002; 2002US-0408378P.
XX PR
XX 09-SEP-2002; 2002US-0409293P.
XX PR
XX 15-JAN-2003; 2003US-0440129P.
XX PA
XX (RIBO-) RIBOZYME PHARM INC.
XX PI
XX McSwiggen J, Beigelman L, Macejak D, Zinnen S, Pavco P;
XX Morrissey D, Fosnaugh K, Mokler V, Jamison S;
XX WPI; 2003-689785/65.
XX DR
XX New short interfering nucleic acid containing no ribonucleotides, useful
XX e.g. for treating viral infection, downregulates expression of target
XX gene or RNA.
XX FS
XX Example 4; Page 135; 204pp; English.
XX The present invention describes a double-stranded short interfering
XX nucleic acid (siNA) that downregulates expression of a target gene, where
XX the siNA molecule comprises no ribonucleotides and each strand of the
XX double-stranded siNA comprises about 21 nucleotides. Also described: (1)
XX a siNA molecule that inhibits expression of target RNA; (2) a siNA
XX molecule that inhibits replication of a virus and optionally does not
XX require presence of a ribonucleotide for inhibition; (3) a siNA molecule
XX that inhibits expression of a target gene and does not require presence
XX of a ribonucleotide for inhibition; (4) a siNA molecule that inhibits
XX expression of a target gene by mediating RNA interference; and (5) a
```

```
CC method for modulating expression of a gene in a cell using siNA
CC molecules. siNA's can have virucide, anti-HIV, hepatotropic,
CC antiinflammatory, plant antiviral, vasotropic, neuroprotective,
CC cytostatic, cardiovascular, immunosuppressive, respiratory, nephrotropic
CC and endocrine activities. The siNA's are useful for downregulating
CC expression of target genes, inhibiting expression of target RNA, and
CC inhibiting replication of a virus. siNA molecules can be used: (a) for
CC therapy of any disorder that responds to modulation of gene expression,
CC especially animal and plant viral infections, specifically hepatitis B or
CC C; HIV; herpes simplex; cytomegalovirus; human papilloma; respiratory
CC syncytial or influenza viruses, and also many other diseases such as
CC restenosis, neurodegeneration, cancers, and cardiovascular, neurological,
CC prion, inflammatory, autoimmune, pulmonary, renal, liver, mitochondrial,
CC endocrine or reproductive diseases; and (b) for diagnosis, target
CC validation, genomic discovery, genetic engineering, pharmacogenomics and
CC analysis of gene function. Chemical modification of siNA molecules
CC improves interfering activity; stability; cellular uptake; binding
CC affinity and/or mediates increased polymerase activity. siNA may be
CC designed to target many related genes containing a conserved sequence.
CC The present sequence represents a siNA oligonucleotide sequence, which is
CC used in the exemplification of the present invention.
XX SQ Sequence 21 BP; 5 A; 6 C; 5 G; 2 T; 3 U; 0 Other;
XX Query Match 2.6%; Score 19.4; DB 1; Length 21;
XX Best Local Similarity 81.0%; Pred. No. 1.5e+02;
XX Matches 17; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
OY 322 TCAAGAGCTCCGAGATGCCAT 342
DB 1 UCAAGAGCTCCGAGATGCCAT 21
RESULT 51
ADG30050/C
XX ID ADG30050 standard; RNA; 21 BP.
XX AC ADG30050;
XX AC ADG30050;
XX 26-FEB-2004 (first entry)
XX DE IKKg-targeted siNA DNA-RNA hybrid - SEQ ID 616.
XX double-stranded short interfering nucleic acid; siNA;
XX antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
XX anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
XX Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
XX amyotrophic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid; IKKg.
XX Unidentified.
XX OS
XX Synthetic.
XX WO2003074654-A2.
XX PN
XX 12-SEP-2003.
XX PD
XX 20-FEB-2003; 2003WO-US005028.
XX PF
XX 20-FEB-2002; 2002US-0358580P.
XX PR
XX 11-MAR-2002; 2002US-0363124P.
XX PR
XX 06-JUN-2002; 2002US-0386782P.
XX PR
XX 29-AUG-2002; 2002US-0406784P.
XX PR
XX 05-SEP-2002; 2002US-0408378P.
XX PR
XX 09-SEP-2002; 2002US-0409293P.
XX PR
XX 15-JAN-2003; 2003US-0440129P.
XX PA
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX PI
XX McSwiggen J, Beigelman L, Chowrira B, Pavco P, Fosnaugh K;
XX Jamison S, Usman N, Thompson J;
XX WPI; 2003-731676/69.
XX DR
```


CC target gene comprising one or more chemical modifications and each strand
CC of the double-stranded siRNA comprises about 21 nucleotides. The siRNA of
CC the invention demonstrates antiarteriosclerotic, neuroprotective,
CC neurotropic, antiparkinsonian and anticonvulsant activities and may be
CC useful for down-regulating the expression of an endogenous mammalian
CC target gene and therefore in the treatment of any disease or condition
CC that responds to modulation of gene expression or activity in a cell,
CC tissue or organism. The disease or condition may include pulmonary
CC diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC Parkinson's disease, epilepsy, dementia, Huntington's disease or
CC amyotrophic lateral sclerosis. Furthermore, the siRNA may be utilised for
CC gene therapy applications. The current sequence is that of the siRNA DNA-
CC RNA hybrid of the invention.

XX Sequence 23 BP; 6 A; 3 C; 7 G; 2 T; 3 U; 2 Other;
SQ Query Match 2.6%; Score 19.4; DB 1; Length 23;
Best Local Similarity 81.0%; Pred. No. 1.7e+02;
Matches 17; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 166 GAAGAGCCAACTGCTGCAGAT 186
Db 2 GAAGAGCCAACTGCTGCAGAT 22

RESULT 54
ACD23072
ID ACD23072 standard; DNA; 25 BP.
XX AC ACD23072;
XX AC ACD23072;
XX 25-AUG-2003 (first entry)
DE Human Nemo gene mutant exon 2 DNA sequence, family XL349.
XX Human; ds; NF-kappaB essential modulator; nuclear factor kappa B;
XX incontinentia pigmenti; X-linked disorder; chromosome Xq28; NEMO;
XX immunomodulatory; dermatological; osteopathic; neuropathic;
XX apoptosis-related disease; immune-system related disease;
XX blood vessel-related disease; skin defect; dental defect; osteopetrosis;
XX ophthalmologic defect; neurological defect.

XX Homo sapiens.
XX US2003032055-A1.
XX 13-FEB-2003.
XX 22-MAY-2001; 2001US-00863049.
XX 22-MAY-2000; 2000US-0206223P.
XX (KENW/) KENWICK S. J.
XX (WOFF/) WOFFENDIN H.
XX (MUNN/) MUNNICH A.
XX (SMAH/) SMAHI A.
XX (ISRA/) ISRAEL A.
XX (POUS/) POUSTKA A.
XX (HEIS/) HEISS N.
XX (DURS/) D'URSO M.
XX (LEWI/) LEWIS R. A.
XX (NELS/) NELSON D. L.
XX (ARAD/) ARADHYA S.
XX (LEVY/) LEVY M.

XX Kenrick SJ, Woffendin H, Munnich A, Smahi A, Israel A;
PI Poustka A, Heiss N, D'urso M, Lewis RA, Nelson DL, Aradhyha S;
PI Levy M;
XX WPI; 2003-492063/46.
XX P-PSDB; ABO17487.
XX Detection of necrosis factor-kappa B related medical condition in

PT organism, by obtaining sample from the organism, and analyzing the sample
PT for alteration in specified amino acid sequences.
XX Claim 41; Fig 5; 44pp; English.
XX The invention relates to a nuclear factor-kappa B (NF-kappa B) related
CC medical condition in an organism being detected by obtaining a sample
CC from the organism, and analysing the sample for an alteration in a the
CC nuclear factor kappaB essential modifier (NEMO) gene or protein sequence
CC (neither shown in the specification). The alteration results in
CC inactivation of NF-kappa B. Also included are treating or preventing NF-
CC kappa B related medical condition in an organism by administering the
CC NEMO protein to the organism and screening a test organism for a compound
CC for the treatment of NF-kappa B related medical condition (by
CC administering the compound to the organism, and assaying for an
CC improvement in the NF-kappa B related medical condition). The method
CC useful is for detecting NF-kappa B related condition, e.g. incontinentia
CC pigmenti (IP), apoptosis-related disease, immune-system related disease,
CC blood vessel-related disease, skin defect, dental defect, osteopetrosis,
CC ophthalmologic defect, or neurological defect, in an organism, i.e. human
CC including affected individual, carrier individual, or noncarrier
CC individual. The NEMO gene is located on chromosome Xq28, incontinentia
CC pigmenti being an X-linked disorder. Experiments in this study show
CC variations in exon 2, 10, 9 and particularly intron 3 to be linked to
CC familial incontinentia pigmenti. The present sequence is a mutant region
CC of the human NEMO gene found to be associated with familial incontinentia
CC pigmenti

XX Sequence 25 BP; 5 A; 10 C; 4 G; 6 T; 0 U; 0 Other;
SQ Query Match 2.6%; Score 19.4; DB 1; Length 25;
Best Local Similarity 95.2%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 263 CTGCACCTGCCTTCAGACAG 283
Db 5 CTTACCTGCCTTCAGACAG 25

RESULT 55
ADN75887
ID ADN75887 standard; RNA; 19 BP.
XX AC ADN75887;
XX 01-JUL-2004 (first entry)
XX IKK.2 associated siRNA #1.
XX small interfering RNA; siRNA; protein-tyrosine-phosphatase; PTP;
XX cytosolic; immunomodulator; antimicrobial; antiinflammatory;
XX antidiabetic; anorectic; cancer; autoimmune disease; infection;
XX inflammation; diabetes; obesity; RNA interference; gene silencing; ss.
XX Homo sapiens.
XX WO2004016735-A2.
XX 26-FEB-2004.
XX 23-MAY-2003; 2003WO-US016632.
XX 23-MAY-2002; 2002US-0383249P.
XX 14-APR-2003; 2003US-0462942P.
XX (CEPT-) CEPTVR INC.
XX (COLD-) COLD SPRING HARBOR LAB.
XX Klinghoffer R, Lewis SP, Tonks NK, Meng T;
XX WPI; 2004-203773/19.
XX New isolated small interfering RNA (siRNA) polynucleotide useful for

PT treating diseases with aberrant activity of the protein tyrosine
PT phosphatase, such as cancer, autoimmune disease, infection, inflammation,
PT diabetes and obesity.

PS Disclosure; SEQ ID NO 712; 392pp; English.

XX This invention describes novel small interfering RNA (siRNA)
CC polynucleotides capable of interfering with expression of a polypeptide
CC having protein-tyrosine-phosphatase (PTP) activity. The products of the
CC invention have cytosolic, immunomodulator, antimicrobial,
CC antiinflammatory, antidiabetic and anorectic activity. The methods and
CC compositions of the present invention are useful for treating diseases or
CC conditions associated with aberrant expression or activity of the protein
CC tyrosine phosphatase, such as cancer, autoimmune diseases, infection,
CC inflammation, diabetes and obesity. This sequence represents a siRNA
CC directed against dual specificity phosphatase (DSP) expression.

XX Sequence 19 BP; 4 A; 4 C; 6 G; 0 T; 5 U; 0 Other;

Query Match 2.5%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 1.4e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 418 GGAGTTCTCATGTGCAAG 436

DB 1 GGAGUUCUCAUGUGCAAG 19

RESULT 56

ADN75888/C

ID ADN75888 standard; RNA; 19 BP.

XX AC ADN75888;

DT 01-JUL-2004 (first entry)

XX IKK.2 associated siRNA #2.

XX small interfering RNA; siRNA; protein-tyrosine-phosphatase; PTP;
KW cytosolic; immunomodulator; antimicrobial; antiinflammatory;
KW antidiabetic; anorectic; cancer; autoimmune disease; infection;
KW inflammation; diabetes; obesity; RNA interference; gene silencing; ss.

XX Homo sapiens.

XX WO2004016735-A2.

XX 26-FEB-2004.

XX 23-MAY-2003; 2003WO-US016632.

XX 23-MAY-2002; 2002US-0383249P.

PR 14-APR-2003; 2003US-0462942P.

XX (CEPT-) CEPTYR INC.

PA (COLD-) COLD SPRING HARBOR LAB.

XX Klinghoffer R, Lewis SP, Tonks NK, Meng T;

XX WPI; 2004-203773/19.

XX New isolated small interfering RNA (siRNA) polynucleotide useful for
PT treating diseases with aberrant activity of the protein tyrosine
PT phosphatase, such as cancer, autoimmune disease, infection, inflammation,
PT diabetes and obesity.

XX Disclosure; SEQ ID NO 713; 392pp; English.

XX This invention describes novel small interfering RNA (siRNA)

CC polynucleotides capable of interfering with expression of a polypeptide
CC having protein-tyrosine-phosphatase (PTP) activity. The products of the
CC invention have cytosolic, immunomodulator, antimicrobial,
CC antiinflammatory, antidiabetic and anorectic activity. The methods and

CC compositions of the present invention are useful for treating diseases or
CC conditions associated with aberrant expression or activity of the protein
CC tyrosine phosphatase, such as cancer, autoimmune diseases, infection,
CC inflammation, diabetes and obesity. This sequence represents a siRNA
CC directed against dual specificity phosphatase (DSP) expression.

XX Sequence 19 BP; 5 A; 6 C; 4 G; 0 T; 4 U; 0 Other;

Query Match 2.5%; Score 19; DB 1; Length 19;

Best Local Similarity 100.0%; Pred. No. 1.4e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 418 GGAGTTCTCATGTGCAAG 436

DB 19 GGAGTTCTCATGTGCAAG 1

RESULT 57

ADN75892

ID ADN75892 standard; RNA; 19 BP.

XX AC ADN75892;

DT 01-JUL-2004 (first entry)

XX IKK.3 associated siRNA #1.

XX small interfering RNA; siRNA; protein-tyrosine-phosphatase; PTP;
KW cytosolic; immunomodulator; antimicrobial; antiinflammatory;
KW antidiabetic; anorectic; cancer; autoimmune disease; infection;
KW inflammation; diabetes; obesity; RNA interference; gene silencing; ss.

XX Homo sapiens.

XX WO2004016735-A2.

XX 26-FEB-2004.

XX 23-MAY-2003; 2003WO-US016632.

XX 23-MAY-2002; 2002US-0383249P.

PR 14-APR-2003; 2003US-0462942P.

XX (CEPT-) CEPTYR INC.

PA (COLD-) COLD SPRING HARBOR LAB.

XX Klinghoffer R, Lewis SP, Tonks NK, Meng T;

XX WPI; 2004-203773/19.

XX New isolated small interfering RNA (siRNA) polynucleotide useful for
PT treating diseases with aberrant activity of the protein tyrosine
PT phosphatase, such as cancer, autoimmune disease, infection, inflammation,
PT diabetes and obesity.

XX Disclosure; SEQ ID NO 717; 392pp; English.

XX This invention describes novel small interfering RNA (siRNA)
CC polynucleotides capable of interfering with expression of a polypeptide
CC having protein-tyrosine-phosphatase (PTP) activity. The products of the
CC invention have cytosolic, immunomodulator, antimicrobial,
CC antiinflammatory, antidiabetic and anorectic activity. The methods and
CC compositions of the present invention are useful for treating diseases or
CC conditions associated with aberrant expression or activity of the protein
CC tyrosine phosphatase, such as cancer, autoimmune diseases, infection,
CC inflammation, diabetes and obesity. This sequence represents a siRNA
CC directed against dual specificity phosphatase (DSP) expression.

XX Sequence 19 BP; 4 A; 6 C; 6 G; 0 T; 3 U; 0 Other;

Query Match 2.5%; Score 19; DB 1; Length 19;

Best Local Similarity 84.2%; Pred. No. 1.4e+02;

Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

XX 01-JUL-2004 (first entry)
XX
DE 1 IKK.3 associated siRNA #2.
XX
KW small interfering RNA; siRNA; protein-tyrosine-phosphatase; PTP;
KW cytosolic; immunomodulator; antimicrobial; antiinflammatory;
KW antidiabetic; anorectic; cancer; autoimmune disease; infection;
KW inflammation; diabetes; obesity; RNA interference; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004016735-A2.
XX
PD 26-FEB-2004.
XX
PF 23-MAY-2003; 2003WO-US016632.
XX
PR 23-MAY-2002; 2002US-0383249P.
PR 14-APR-2003; 2003US-0462942P.
XX
PA (CEPT-) CEPTVR INC.
PA (COLD-) COLD SPRING HARBOR LAB.
XX
PI Klinghoffer R, Lewis SP, Tonks NK, Meng T;
XX
DR WPI; 2004-203773/19.
XX
PT New isolated small interfering RNA (siRNA) polynucleotide useful for
PT treating diseases with aberrant activity of the protein tyrosine
PT phosphatase, such as cancer, autoimmune disease, infection, inflammation,
PT diabetes and obesity.
XX
PS Disclosure; SEQ ID NO 718; 392pp; English.
XX
CC This invention describes novel small interfering RNA (siRNA)
CC polynucleotides capable of interfering with expression of a polypeptide
CC having protein-tyrosine-phosphatase (PTP) activity. The products of the
CC invention have cytosolic, immunomodulator, antimicrobial,
CC antiinflammatory, antidiabetic and anorectic activity. The methods and
CC compositions of the present invention are useful for treating diseases or
CC conditions associated with aberrant expression or activity of the protein
CC tyrosine phosphatase, such as cancer, autoimmune diseases, infection,
CC inflammation, diabetes and obesity. This sequence represents a siRNA
CC directed against dual specificity phosphatase (DSP) expression.
XX
SQ Sequence 19 BP; 3 A; 6 C; 6 G; 0 T; 4 U; 0 Other;
Query Match 2.5%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 565 GGCTCTCTGTGAAGCCGAG 583
DB 19 GGCTCTCTGTGAAGCCGAG 1
RESULT 60
ADN75882
ID ADN75882 standard; RNA; 19 BP.
XX
AC ADN75882;
XX
XX 01-JUL-2004 (first entry)
XX
DE IKK.1 associated siRNA #1.
XX
KW small interfering RNA; siRNA; protein-tyrosine-phosphatase; PTP;
KW cytosolic; immunomodulator; antimicrobial; antiinflammatory;
KW antidiabetic; anorectic; cancer; autoimmune disease; infection;
KW inflammation; diabetes; obesity; RNA interference; gene silencing; ss.
OS Homo sapiens.

QY 565 GGCTCTCTGTGAAGCCGAG 583
DB 1 GGCTCTCTGTGAAGCCGAG 19
RESULT 58
ADN75883/C
ID ADN75883 standard; RNA; 19 BP.
XX
AC ADN75883;
XX
XX 01-JUL-2004 (first entry)
XX
DE IKK.1 associated siRNA #2.
XX
KW small interfering RNA; siRNA; protein-tyrosine-phosphatase; PTP;
KW cytosolic; immunomodulator; antimicrobial; antiinflammatory;
KW antidiabetic; anorectic; cancer; autoimmune disease; infection;
KW inflammation; diabetes; obesity; RNA interference; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004016735-A2.
XX
PD 26-FEB-2004.
XX
PF 23-MAY-2003; 2003WO-US016632.
XX
PR 23-MAY-2002; 2002US-0383249P.
PR 14-APR-2003; 2003US-0462942P.
XX
PA (CEPT-) CEPTVR INC.
PA (COLD-) COLD SPRING HARBOR LAB.
XX
PI Klinghoffer R, Lewis SP, Tonks NK, Meng T;
XX
DR WPI; 2004-203773/19.
XX
PT New isolated small interfering RNA (siRNA) polynucleotide useful for
PT treating diseases with aberrant activity of the protein tyrosine
PT phosphatase, such as cancer, autoimmune disease, infection, inflammation,
PT diabetes and obesity.
XX
PS Disclosure; SEQ ID NO 708; 392pp; English.
XX
CC This invention describes novel small interfering RNA (siRNA)
CC polynucleotides capable of interfering with expression of a polypeptide
CC having protein-tyrosine-phosphatase (PTP) activity. The products of the
CC invention have cytosolic, immunomodulator, antimicrobial,
CC antiinflammatory, antidiabetic and anorectic activity. The methods and
CC compositions of the present invention are useful for treating diseases or
CC conditions associated with aberrant expression or activity of the protein
CC tyrosine phosphatase, such as cancer, autoimmune diseases, infection,
CC inflammation, diabetes and obesity. This sequence represents a siRNA
CC directed against dual specificity phosphatase (DSP) expression.
XX
SQ Sequence 19 BP; 4 A; 7 C; 5 G; 0 T; 3 U; 0 Other;
Query Match 2.5%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 236 GAGTCTCTCTGGGGAAGC 254
DB 19 GAGTCTCTCTGGGGAAGC 1
RESULT 59
ADN75893/C
ID ADN75893 standard; RNA; 19 BP.
XX
AC ADN75893;

PS Disclosure; SEQ ID NO 722; 392pp; English.

XX This invention describes novel small interfering RNA (siRNA) polynucleotides capable of interfering with expression of a polypeptide having protein-tyrosine-phosphatase (PTP) activity. The products of the invention have cytostatic, immunomodulatory, antimicrobial, antiinflammatory, antidiabetic and anorectic activity. The methods and compositions of the present invention are useful for treating diseases or conditions associated with aberrant expression or activity of the protein tyrosine phosphatase, such as cancer, autoimmune diseases, infection, inflammation, diabetes and obesity. This sequence represents a siRNA directed against dual specificity phosphatase (DSP) expression.

XX Sequence 19 BP; 2 A; 5 C; 6 G; 0 T; 6 U; 0 Other;

SQ Query Match 2.5%; Score 19; DB 1; Length 19; Best Local Similarity 100.0%; Pred. No. 1.4e+02; Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 877 CCACATCAAGCAGCGTG 895

Db 19 CCACATCAAGCAGCGTG 1

RESULT 63

AD13794

ID AD13794 standard; RNA; 21 BP.

XX AD13794;

AC AD13794;

XX 20-NOV-2003 (first entry)

DT Short interfering nucleic acid (siNA) oligonucleotide SEQ ID NO:131.

DE double-stranded short interfering nucleic acid;

XX short interfering nucleic acid; siNA; expression; replication; inhibition; RNA interference; virucide; anti-HIV; hepatotropic; antiinflammatory; plant; antiviral; vasotropic; neuroprotective; cytosolic; cardiovascular; immunosuppressive; respiratory; nephrotropic; endocrine; viral infection; hepatitis B; hepatitis C; HIV; herpes simplex; cytomegalovirus; human papillomavirus; respiratory syncytial virus; influenza virus; restenosis; neurodegeneration; cancer; neurological; prion; inflammatory; autoimmune; pulmonary; renal; liver; mitochondrial; reproductive disease; chemical modification; ss.

XX Synthetic.

XX WO2003070918-A2.

XX 28-AUG-2003.

XX 20-FEB-2003; 2003WO-US005346.

XX 20-FEB-2002; 2002US-0358580P.

PR 11-MAR-2002; 2002US-0363124P.

PR 06-JUN-2002; 2002US-0386782P.

PR 29-AUG-2002; 2002US-0406784P.

PR 05-SEP-2002; 2002US-0408378P.

PR 09-SEP-2002; 2002US-0409293P.

PR 15-JAN-2003; 2003US-0440129P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Mcswiggen J, Beigelman L, Macejak D, Zinnen S, Pavco P; PI Morrissey D, Fornaugh K, Mokler V, Jamison S;

XX WPI; 2003-689785/65.

XX New short interfering nucleic acid containing no ribonucleotides, useful e.g. for treating viral infection, downregulates expression of target gene or RNA.

PS Example 4; Page 135; 204pp; English.

XX The present invention describes a double-stranded short interfering nucleic acid (siNA) that downregulates expression of a target gene, where the siNA molecule comprises no ribonucleotides and each strand of the double-stranded siNA comprises about 21 nucleotides. Also described: (1) a siNA molecule that inhibits expression of target RNA; (2) a siNA molecule that inhibits replication of a virus and optionally does not require presence of a ribonucleotide for inhibition; (3) a siNA molecule that inhibits expression of a target gene and does not require presence of a ribonucleotide for inhibition; (4) a siNA molecule that inhibits expression of a target gene by mediating RNA interference; and (5) a method for modulating expression of a gene in a cell using siNA molecules. siNA's can have virucide, anti-HIV, neuroprotective, antiinflammatory, plant antiviral, vasotropic, hepatotropic, cytosolic, cardiovascular, immunosuppressive, respiratory, nephrotropic and endocrine activities. The siNA's are useful for downregulating expression of target genes, inhibiting expression of target RNA, and inhibiting replication of a virus. siNA molecules can be used: (a) for therapy of any disorder that responds to modulation of gene expression, especially animal and plant viral infections, specifically hepatitis B or C; HIV; herpes simplex; cytomegalovirus; human papilloma; respiratory syncytial or influenza viruses, and also many other diseases such as restenosis, neurodegeneration, cancers, and cardiovascular, neurological, prion, inflammatory, autoimmune, pulmonary, renal, liver, mitochondrial, endocrine or reproductive diseases; and (b) for diagnosis, target validation, genomic discovery, genetic engineering, pharmacogenomics and analysis of gene function. Chemical modification of siNA molecules improves interfering activity; stability; cellular uptake; binding affinity and/or mediates increased polymerase activity. siNA may be designed to target many related genes containing a conserved sequence. The present sequence represents a siNA oligonucleotide sequence, which is used in the exemplification of the present invention.

XX Sequence 21 BP; 6 A; 3 C; 8 G; 2 T; 2 U; 0 Other;

SQ Query Match 2.5%; Score 19; DB 1; Length 21; Best Local Similarity 89.5%; Pred. No. 1.6e+02; Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 547 GCAGATGGCTGAGGACAAG 565

Db 1 GCAGATGGCTGAGGACAAG 19

RESULT 64

ADG30049/c

ID ADG30049 standard; RNA; 21 BP.

XX ADG30049;

XX 26-FEB-2004 (first entry)

DT IKKg-targeted siNA DNA-RNA hybrid - SEQ ID 615.

DE double-stranded short interfering nucleic acid; siNA; antiarteriosclerotic; neuroprotective; neurotropic; antiparkinsonian; anticonvulsant; pulmonary disease; restenosis; atherosclerosis; Alzheimer's; Parkinson's; epilepsy; dementia; Huntington's; amyotrophic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid; IKKg.

XX Unidentified.

OS Synthetic.

XX WO2003074654-A2.

XX 12-SEP-2003.

XX 20-FEB-2003; 2003WO-US005028.

XX 20-FEB-2002; 2002US-0358580P.

PR 11-MAR-2002; 2002US-0363124P.

PR 06-JUN-2002; 2002US-0386782P.

PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 XX
 XX (SIRN-) SIRNA THERAPEUTICS INC.
 PA Mcswiggen J, Beigelman L, Chowrira B, Pavco P, Fosnaugh K;
 PI Jamieson S, Ueman N, Thompson J;
 XX WPI; 2003-731676/69.
 XX
 XX New double-stranded short interfering nucleic acid molecule, useful for
 PT down-regulating the expression of an endogenous mammalian target gene or
 PT for treating diseases that respond to modulation of gene expression or
 PT activity.
 XX
 PS Example 24; SEQ ID NO 615; 593pp; English.
 XX
 CC The invention relates to a double-stranded short interfering nucleic acid
 CC (siRNA) molecule that down-regulates expression of an endogenous mammalian
 CC target gene comprising one or more chemical modifications and each strand
 CC of the double-stranded siRNA comprises about 21 nucleotides. The siRNA of
 CC the invention demonstrates antitumor, antidiabetic, neuroprotective,
 CC neurotropic, antiparkinsonian and anticonvulsant activities and may be
 CC useful for down-regulating the expression of an endogenous mammalian
 CC target gene and therefore in the treatment of any disease or condition
 CC that responds to modulation of gene expression or activity in a cell,
 CC tissue or organism. The disease or condition may include pulmonary
 CC diseases such as restenosis, atherosclerosis, Alzheimer's disease,
 CC Parkinson's disease, epilepsy, dementia, Huntington's disease or
 CC amyotrophic lateral sclerosis. Furthermore, the siRNA may be utilised for
 CC gene therapy applications. The current sequence is that of the siRNA DNA-
 CC RNA hybrid of the invention.
 XX
 XX Sequence 21 BP; 3 A; 7 C; 3 G; 2 T; 6 U; 0 Other;
 SQ
 Query Match 2.5%; Score 19; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 166 GAAGACCCCACTGTGTGAG 184
 DB |||||
 19 GAAGACCCCACTGTGTGAG 1
 RESULT 65
 ADN75900
 ID ADN75900 standard; RNA; 21 BP.
 XX
 AC ADN75900;
 XX
 DT 01-JUL-2004 (first entry)
 XX
 DE IKK.4 associated siRNA #4.
 XX
 KW small interfering RNA; siRNA; protein-tyrosine-phosphatase; PTP;
 KW cytosolic; immunomodulator; antimicrobial; antiinflammatory;
 KW antidiabetic; anorectic; cancer; autoimmune disease; infection;
 KW inflammation; diabetes; obesity; RNA interference; gene silencing; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004016735-A2.
 XX
 PD 26-FEB-2004.
 XX
 PF IKK.4 associated siRNA #4.
 XX
 KW small interfering RNA; siRNA; protein-tyrosine-phosphatase; PTP;
 KW cytosolic; immunomodulator; antimicrobial; antiinflammatory;
 KW antidiabetic; anorectic; cancer; autoimmune disease; infection;
 KW inflammation; diabetes; obesity; RNA interference; gene silencing; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004016735-A2.
 XX
 PD 26-FEB-2004.
 XX
 PF 23-MAY-2003; 2003WO-US016632.
 XX
 XX 23-MAY-2002; 2002US-0383249P.
 PR 14-APR-2003; 2003US-0462942P.
 XX
 XX (CEPT-) CEPTYR INC.
 PA
 (COLD-) COLD SPRING HARBOR LAB.
 PI Klinghoffer R, Lewis SP, Tonks NK, Meng T;
 XX WPI; 2004-203773/19.
 XX
 XX New isolated small interfering RNA (siRNA) polynucleotide useful for
 PT treating diseases with aberrant activity of the protein tyrosine
 PT phosphatase, such as cancer, autoimmune disease, infection, inflammation,
 PT diabetes and obesity.
 XX
 PS Disclosure; SEQ ID NO 725; 392pp; English.
 XX
 CC This invention describes novel small interfering RNA (siRNA)
 CC polynucleotides capable of interfering with expression of a polypeptide
 CC having protein-tyrosine-phosphatase (PTP) activity. The products of the
 CC invention have cytostatic, immunomodulator, antimicrobial,
 CC antiinflammatory, antidiabetic and anorectic activity. The methods and
 CC compositions of the present invention are useful for treating diseases or
 CC conditions associated with aberrant expression or activity of the protein
 CC tyrosine phosphatase, such as cancer, autoimmune diseases, infection,
 CC inflammation, diabetes and obesity. This sequence represents a siRNA
 CC directed against dual specificity phosphatase (DSP) expression.
 XX
 SQ Sequence 21 BP; 6 A; 6 C; 5 G; 0 T; 2 U; 2 Other;
 Query Match 2.5%; Score 19; DB 1; Length 21;
 Best Local Similarity 89.5%; Pred. No. 1.6e+02;
 Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 877 CCACATCAAGACGACGCGT 895
 DB |||||
 3 CCACAUCAAGACGACGCGUG 21
 RESULT 66
 ADN75884
 ID ADN75884 standard; RNA; 21 BP.
 XX
 AC ADN75884;
 XX
 DT 01-JUL-2004 (first entry)
 XX
 DE IKK.1 associated siRNA #3.
 XX
 KW small interfering RNA; siRNA; protein-tyrosine-phosphatase; PTP;
 KW cytosolic; immunomodulator; antimicrobial; antiinflammatory;
 KW antidiabetic; anorectic; cancer; autoimmune disease; infection;
 KW inflammation; diabetes; obesity; RNA interference; gene silencing; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004016735-A2.
 XX
 PD 26-FEB-2004.
 XX
 PF 23-MAY-2003; 2003WO-US016632.
 XX
 XX 23-MAY-2002; 2002US-0383249P.
 PR 14-APR-2003; 2003US-0462942P.
 XX
 XX (CEPT-) CEPTYR INC.
 PA
 (COLD-) COLD SPRING HARBOR LAB.
 PI Klinghoffer R, Lewis SP, Tonks NK, Meng T;
 XX WPI; 2004-203773/19.
 XX
 XX New isolated small interfering RNA (siRNA) polynucleotide useful for
 PT treating diseases with aberrant activity of the protein tyrosine
 PT phosphatase, such as cancer, autoimmune disease, infection, inflammation,
 PT diabetes and obesity.
 XX

PS	Disclosure; SEQ ID NO 709; 392pp; English.	CC	directed against dual specificity phosphatase (DSP) expression.
XX		XX	
CC	This invention describes novel small interfering RNA (siRNA)	SQ	Sequence 21 BP; 4 A; 6 C; 6 G; 0 T; 3 U; 2 Other;
CC	polynucleotides capable of interfering with expression of a polypeptide		
CC	having protein-tyrosine-phosphatase (PTP) activity. The products of the	Query Match	2.5%; Score 19; DB 1; Length 21;
CC	invention have cytosstatic, immunomodulator, antimicrobial,	Best Local Similarity	84.2%; Pred. No. 1.6e+02;
CC	antiinflammatory, antidiabetic and anorectic activity. The methods and	Matches 15; Conservative	4; Mismatches 0; Indels 0; Gaps 0;
CC	compositions of the present invention are useful for treating diseases or		
CC	conditions associated with aberrant expression or activity of the protein	QY	565 GGCTCTCTGTGAAGCCGAG 583
CC	tyrosine phosphatase, such as cancer, autoimmune diseases, infection,	DB	1 GGCCUCUGUGAAGCCGAG 19
CC	inflammation, diabetes and obesity. This sequence represents a siRNA		
CC	directed against dual specificity phosphatase (DSP) expression.		
XX			
SQ	Sequence 21 BP; 3 A; 5 C; 7 G; 0 T; 4 U; 2 Other;	RESULT 68	
		ADN75890/c	
	Query Match 2.5%; Score 19; DB 1; Length 21;	ID	ADN75890 standard; RNA; 21 BP.
	Best Local Similarity 78.9%; Pred. No. 1.6e+02;	XX	
	Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;	AC	ADN75890;
		XX	
QY	236 GAGTCTCTCTGGGAGC 254	DT	01-JUL-2004 (first entry)
DB	1 GAGUCUCUCUGGGGAGC 19	XX	
		DE	IKK.2 associated siRNA #4.
		XX	
RESULT 67		XX	small interfering RNA; siRNA; protein-tyrosine-phosphatase; PTP;
ADN75894		KW	cytosstatic; immunomodulator; antimicrobial; antiinflammatory;
ID	ADN75894 standard; RNA; 21 BP.	KW	antidiabetic; anorectic; cancer; autoimmune disease; infection;
XX		KW	inflammation; diabetes; obesity; RNA interference; gene silencing; ss.
AC	ADN75894;	XX	
XX		OS	Homo sapiens.
DT	01-JUL-2004 (first entry)	XX	
XX		XX	WO2004016735-A2.
DE	IKK.3 associated siRNA #3.	XX	26-FEB-2004.
XX		XX	
KW	small interfering RNA; siRNA; protein-tyrosine-phosphatase; PTP;	PF	23-MAY-2003; 2003WO-US016632.
KW	cytosstatic; immunomodulator; antimicrobial; antiinflammatory;	XX	
KW	antidiabetic; anorectic; cancer; autoimmune disease; infection;	PR	23-MAY-2002; 2002US-0383249P.
KW	inflammation; diabetes; obesity; RNA interference; gene silencing; ss.	PR	14-APR-2003; 2003US-0462942P.
XX		XX	
OS	Homo sapiens.	XX	(CEPT-) CEPTYR INC.
XX		PA	(COLD-) COLD SPRING HARBOR LAB.
XX		XX	
FN	WO2004016735-A2.	XX	
XX		PI	Klinghoffer R, Lewis SP, Tonks NK, Meng T;
PD	26-FEB-2004.	XX	
XX		DR	WPI; 2004-203773/19.
XX		XX	
PF	23-MAY-2003; 2003WO-US016632.	XX	
XX		XX	New isolated small interfering RNA (siRNA) polynucleotide useful for
PR	23-MAY-2002; 2002US-0383249P.	PT	treating diseases with aberrant activity of the protein tyrosine
PR	14-APR-2003; 2003US-0462942P.	PT	phosphatase, such as cancer, autoimmune disease, infection, inflammation,
XX		PT	diabetes and obesity.
XX		XX	
PA	(CEPT-) CEPTYR INC.	XX	Disclosure; SEQ ID NO 719; 392pp; English.
PA	(COLD-) COLD SPRING HARBOR LAB.	PS	
XX		XX	
PI	Klinghoffer R, Lewis SP, Tonks NK, Meng T;	XX	
XX		CC	This invention describes novel small interfering RNA (siRNA)
XX		CC	polynucleotides capable of interfering with expression of a polypeptide
XX		CC	having protein-tyrosine-phosphatase (PTP) activity. The products of the
XX		CC	invention have cytosstatic, immunomodulator, antimicrobial,
XX		CC	antiinflammatory, antidiabetic and anorectic activity. The methods and
XX		CC	compositions of the present invention are useful for treating diseases or
XX		CC	conditions associated with aberrant expression or activity of the protein
XX		CC	tyrosine phosphatase, such as cancer, autoimmune diseases, infection,
XX		CC	inflammation, diabetes and obesity. This sequence represents a siRNA


```

RESULT 69
ADN75881
ID ADN75881 standard; RNA; 21 BP.
XX
AC ADN75881;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human IKKgamma siRNA IKK.1.
XX
KW small interfering RNA; siRNA; protein-tyrosine-phosphatase; PTP;
KW cytosolic; immunomodulator; antimicrobial; antiinflammatory;
KW antidiabetic; anorectic; cancer; autoimmune disease; infection;
KW inflammation; diabetes; obesity; RNA interference; gene silencing; ss;
KW DNA-RNA hybrid.
XX
OS Homo sapiens.
XX
PN WO2004016735-A2.
XX
PD 26-FEB-2004.
XX
PF 23-MAY-2003; 2003WO-US016632.
XX
PR 23-MAY-2002; 2002US-0383249P.
XX
PR 14-APR-2003; 2003US-0462942P.
XX
PA (CEPT-) CEPTYR INC.
XX
PA (COLD-) COLD SPRING HARBOR LAB.
XX
PI Klinghoffer R, Lewis SP, Tonks NK, Meng T;
XX
WPI; 2004-203773/19.
XX
PT New isolated small interfering RNA (siRNA) polynucleotide useful for
PT treating diseases with aberrant activity of the protein tyrosine
PT phosphatase, such as cancer, autoimmune disease, infection, inflammation,
PT diabetes and obesity.
XX
PS Example 8; SEQ ID NO 706; 392pp; English.
XX
CC This invention describes novel small interfering RNA (siRNA)
CC polynucleotides capable of interfering with expression of a polypeptide
CC having protein-tyrosine-phosphatase (PTP) activity. The products of the
CC invention have cytostatic, immunomodulator, antimicrobial,
CC antiinflammatory, antidiabetic and anorectic activity. The methods and
CC compositions of the present invention are useful for treating diseases or
CC conditions associated with aberrant expression or activity of the protein
CC tyrosine phosphatase, such as cancer, autoimmune diseases, infection,
CC inflammation, diabetes and obesity. This sequence represents a siRNA
CC directed against dual specificity phosphatase (DSP) expression.
XX
SQ Sequence 21 BP; 3 A; 5 C; 7 G; 2 T; 4 U; 0 Other;
XX
Query Match 2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.6e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 236 GAGTCTCCTCTGGGAAGC 254
|||:|:|:|:|:|:|
Db 1 GAGUCUCCUGGGGAAGC 19

RESULT 70
ADN75899/c
ID ADN75899 standard; RNA; 21 BP.
XX
AC ADN75899;
XX
DT 01-JUL-2004 (first entry)
XX
XX

```

```

DE IKK.4 associated siRNA #3.
XX
KW small interfering RNA; siRNA; protein-tyrosine-phosphatase; PTP;
KW cytosolic; immunomodulator; antimicrobial; antiinflammatory;
KW antidiabetic; anorectic; cancer; autoimmune disease; infection;
KW inflammation; diabetes; obesity; RNA interference; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004016735-A2.
XX
PD 26-FEB-2004.
XX
PF 23-MAY-2003; 2003WO-US016632.
XX
PR 23-MAY-2002; 2002US-0383249P.
XX
PR 14-APR-2003; 2003US-0462942P.
XX
PA (CEPT-) CEPTYR INC.
XX
PA (COLD-) COLD SPRING HARBOR LAB.
XX
PI Klinghoffer R, Lewis SP, Tonks NK, Meng T;
XX
WPI; 2004-203773/19.
XX
PT New isolated small interfering RNA (siRNA) polynucleotide useful for
PT treating diseases with aberrant activity of the protein tyrosine
PT phosphatase, such as cancer, autoimmune disease, infection, inflammation,
PT diabetes and obesity.
XX
PS Disclosure; SEQ ID NO 724; 392pp; English.
XX
CC This invention describes novel small interfering RNA (siRNA)
CC polynucleotides capable of interfering with expression of a polypeptide
CC having protein-tyrosine-phosphatase (PTP) activity. The products of the
CC invention have cytostatic, immunomodulator, antimicrobial,
CC antiinflammatory, antidiabetic and anorectic activity. The methods and
CC compositions of the present invention are useful for treating diseases or
CC conditions associated with aberrant expression or activity of the protein
CC tyrosine phosphatase, such as cancer, autoimmune diseases, infection,
CC inflammation, diabetes and obesity. This sequence represents a siRNA
CC directed against dual specificity phosphatase (DSP) expression.
XX
SQ Sequence 21 BP; 2 A; 5 C; 6 G; 0 T; 6 U; 2 Other;
XX
Query Match 2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 877 CCACATCAAGAGCAGCGTG 895
|||:|:|:|:|:|:|
Db 19 CCACATCAAGAGCAGCGTG 1

RESULT 71
ADN75885/c
ID ADN75885 standard; RNA; 21 BP.
XX
AC ADN75885;
XX
DT 01-JUL-2004 (first entry)
XX
DE IKK.1 associated siRNA #4.
XX
KW small interfering RNA; siRNA; protein-tyrosine-phosphatase; PTP;
KW cytosolic; immunomodulator; antimicrobial; antiinflammatory;
KW antidiabetic; anorectic; cancer; autoimmune disease; infection;
KW inflammation; diabetes; obesity; RNA interference; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004016735-A2.
XX

```

PD 26-FEB-2004.
 XX 23-MAY-2003; 2003WO-US016632.
 XX 23-MAY-2002; 2002US-0383249P.
 PR 14-APR-2003; 2003US-0462942P.
 XX (CEPT-) CEPTYR INC.
 PA (COLD-) COLD SPRING HARBOR LAB.
 PI Klinghoffer R, Lewis SP, Tonks NK, Meng T;
 XX WPI; 2004-203773/19.
 XX New isolated small interfering RNA (siRNA) polynucleotide useful for
 PT treating diseases with aberrant activity of the protein tyrosine
 PT phosphatase, such as cancer, autoimmune disease, infection, inflammation,
 PT diabetes and obesity.
 XX Disclosure; SEQ ID NO 710; 392pp; English.
 XX This invention describes novel small interfering RNA (siRNA)
 CC polynucleotides capable of interfering with expression of a polypeptide
 CC having protein-tyrosine-phosphatase (PTP) activity. The products of the
 CC invention have cytostatic, immunomodulator, antimicrobial,
 CC antiinflammatory, antidiabetic and anorectic activity. The methods and
 CC compositions of the present invention are useful for treating diseases or
 CC conditions associated with aberrant expression or activity of the protein
 CC tyrosine phosphatase, such as cancer, autoimmune disease, infection,
 CC inflammation, diabetes and obesity. This sequence represents a siRNA
 CC directed against dual specificity phosphatase (DSP) expression.
 XX Sequence 21 BP; 4 A; 7 C; 5 G; 0 T; 3 U; 2 Other;
 SQ
 Query Match 2.5%; Score 19; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 236 GAGTCTCTCTGGGGAACG 254
 DB 21 GAGTCTCTCTGGGGAACG 3
 RESULT 72
 ADN75889
 ID ADN75889 standard; RNA; 21 BP.
 XX AC ADN75889;
 XX 01-JUL-2004 (first entry)
 XX IKK.2 associated siRNA #3.
 XX small interfering RNA; siRNA; protein-tyrosine-phosphatase; PTP;
 KW cytostatic; immunomodulator; antimicrobial; antiinflammatory;
 KW antidiabetic; anorectic; cancer; autoimmune disease; infection;
 KW inflammation; diabetes; obesity; RNA interference; gene silencing; ss.
 XX Homo sapiens.
 OS
 PA (CEPT-) CEPTYR INC.
 PA (COLD-) COLD SPRING HARBOR LAB.
 PI Klinghoffer R, Lewis SP, Tonks NK, Meng T;
 XX WPI; 2004-203773/19.
 XX New isolated small interfering RNA (siRNA) polynucleotide useful for
 PT treating diseases with aberrant activity of the protein tyrosine
 PT phosphatase, such as cancer, autoimmune disease, infection, inflammation,
 PT diabetes and obesity.
 XX Disclosure; SEQ ID NO 720; 392pp; English.
 XX This invention describes novel small interfering RNA (siRNA)

XX WPI; 2004-203773/19.
 XX New isolated small interfering RNA (siRNA) polynucleotide useful for
 PT treating diseases with aberrant activity of the protein tyrosine
 PT phosphatase, such as cancer, autoimmune disease, infection, inflammation,
 PT diabetes and obesity.
 XX Disclosure; SEQ ID NO 714; 392pp; English.
 XX This invention describes novel small interfering RNA (siRNA)
 CC polynucleotides capable of interfering with expression of a polypeptide
 CC having protein-tyrosine-phosphatase (PTP) activity. The products of the
 CC invention have cytostatic, immunomodulator, antimicrobial,
 CC antiinflammatory, antidiabetic and anorectic activity. The methods and
 CC compositions of the present invention are useful for treating diseases or
 CC conditions associated with aberrant expression or activity of the protein
 CC tyrosine phosphatase, such as cancer, autoimmune disease, infection,
 CC inflammation, diabetes and obesity. This sequence represents a siRNA
 CC directed against dual specificity phosphatase (DSP) expression.
 XX Sequence 21 BP; 4 A; 4 C; 6 G; 0 T; 5 U; 2 Other;
 SQ
 Query Match 2.5%; Score 19; DB 1; Length 21;
 Best Local Similarity 73.7%; Pred. No. 1.6e+02;
 Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
 OY 418 CGAGTTCTCTCATGTGCAAG 436
 DB 1 CGAGUUCUCAUGUGCAAG 19
 RESULT 73
 ADN75895/c
 ID ADN75895 standard; RNA; 21 BP.
 XX AC ADN75895;
 XX 01-JUL-2004 (first entry)
 XX IKK.3 associated siRNA #4.
 XX small interfering RNA; siRNA; protein-tyrosine-phosphatase; PTP;
 KW cytostatic; immunomodulator; antimicrobial; antiinflammatory;
 KW antidiabetic; anorectic; cancer; autoimmune disease; infection;
 KW inflammation; diabetes; obesity; RNA interference; gene silencing; ss.
 XX Homo sapiens.
 OS
 PA (CEPT-) CEPTYR INC.
 PA (COLD-) COLD SPRING HARBOR LAB.
 PI Klinghoffer R, Lewis SP, Tonks NK, Meng T;
 XX WPI; 2004-203773/19.
 XX New isolated small interfering RNA (siRNA) polynucleotide useful for
 PT treating diseases with aberrant activity of the protein tyrosine
 PT phosphatase, such as cancer, autoimmune disease, infection, inflammation,
 PT diabetes and obesity.
 XX Disclosure; SEQ ID NO 720; 392pp; English.
 XX This invention describes novel small interfering RNA (siRNA)

CC polynucleotides capable of interfering with expression of a polypeptide
 CC having protein-tyrosine-phosphatase (PTP) activity. The products of the
 CC invention have cytostatic, immunomodulator, antimicrobial,
 CC antiinflammatory, antidiabetic and anorectic activity. The methods and
 CC conditions of the present invention are useful for treating diseases or
 CC conditions associated with aberrant expression or activity of the protein
 CC tyrosine phosphatase, such as cancer, autoimmune diseases, infection,
 CC inflammation, diabetes and obesity. This sequence represents a siRNA
 CC directed against dual specificity phosphatase (DSP) expression.
 XX
 SQ Sequence 21 BP; 3 A; 6 C; 6 G; 0 T; 4 U; 2 Other;

Query Match 2.5%; Score 19; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 565 GGCTCTGTGAAGCCGAG 583
 DB 21 GGCTCTGTGAAGCCGAG 3

RESULT 74
 ADJ46760/C
 ID ADJ46760 standard; DNA; 20 BP.

XX ADJ46760;
 AC
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Human KIAA1531 antisense oligonucleotide ISIS #208184.
 XX
 KW human; KIAA1531; hyperproliferative disorder.; cancer;
 KW angiogenesis hyperactivation; chronic inflammation; ss; antisense.
 XX
 OS Homo sapiens.
 OS Synthetic.

XX
 XX US2004023378-A1.
 PN
 PD 05-FEB-2004.

XX 31-JUL-2002; 2002US-00210290.
 PF
 XX 31-JUL-2002; 2002US-00210290.
 PR
 XX (ISIS-) ISIS PHARM INC.

XX Chiang M, Marcusson EG, Dobie KW;
 PI WPI; 2004-142659/14.
 DR

XX New compound, particularly an antisense oligonucleotide targeted to a
 PT nucleic acid encoding KIAA1531, useful for treating cancer, chronic
 PT inflammation or conditions involving hyperactivation of angiogenesis.

XX Example 15; SEQ ID NO 37; 65pp; English.

XX The invention relates to a compound targeted to and which specifically
 CC hybridises with a nucleic acid molecule encoding KIAA1531 and inhibits
 CC the expression of KIAA1531. The compound, composition and methods are
 CC useful for treating a disease or condition associated with KIAA1531, such
 CC as a hyperproliferative disorder, e.g. cancer, a disease or condition
 CC involving hyperactivation of angiogenesis, or chronic inflammation. They
 CC are also useful in research and diagnostics for modulating the expression
 CC of KIAA1531. The present sequence represents a human KIAA1531 antisense
 CC oligonucleotide.

XX Sequence 20 BP; 2 A; 5 C; 6 G; 7 T; 0 U; 0 Other;

Query Match 2.4%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 1.8e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 877 CCACATCAAGACGCGTGG 896
 DB 20 CCACATCAAGACGCGTGG 1

RESULT 75
 AD031926/c
 ID ADO31926 standard; DNA; 20 BP.

XX ADO31926;
 AC
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Cyclin-dependent kinase 6, antisense oligonucleotide #23.
 XX
 KW antisense therapy; cyclin-dependent kinase 6;
 KW hyperproliferative disorder; cancer; bacterial infection;
 KW viral infection; apoptosis; ss; probe; human.

XX Homo sapiens.

XX US2004087523-A1.

XX 06-MAY-2004.

XX 31-JUL-2002; 2002US-00210802.

XX 31-JUL-2002; 2002US-00210802.

XX (ISIS-) ISIS PHARM INC.

XX Freier SM, Dobie KW;

XX WPI; 2004-356241/33.

XX New compounds, particularly antisense oligonucleotides targeted to a
 PT nucleic acid encoding cyclin-dependent kinase 6, useful for treating
 PT cancer, bacterial/viral infection or conditions involving aberrant
 PT apoptosis.

XX Disclosure; SEQ ID NO 37; 69pp; English.

XX The invention relates to antisense oligonucleotides targeted to cyclin-
 CC dependent kinase 6, and which inhibit the expression of cyclin-dependent
 CC kinase 6. The antisense oligonucleotides are useful for treating a
 CC disease or condition associated with cyclin-dependent kinase 6, such as a
 CC hyperproliferative disorder (e.g. cancer), or conditions arising from
 CC bacterial or viral infections, or involving aberrant apoptosis. They are
 CC also useful in research and diagnostics for modulating the expression of
 CC cyclin-dependent kinase 6. The present sequence represents a cyclin-
 CC dependent kinase 6 antisense oligonucleotide. Note: Seqid 15-134 are also
 CC used in Tables 1 and 2 (page 30-34) but these sequences do not match
 CC seqid 15-134 of the seq list.

XX Sequence 20 BP; 2 A; 5 C; 6 G; 7 T; 0 U; 0 Other;

Query Match 2.4%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 1.8e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 877 CCACATCAAGACGCGTGG 896
 DB 20 CCACATCAAGACGCGTGG 1

RESULT 76
 ADL47533
 ID ADL47533 standard; RNA; 17 BP.

XX ADL47533;

XX 20-MAY-2004 (first entry)
 DT

DE Human IKK-gamma substrate sequence #59.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS Unidentified.
 XX WO200281628-A2.
 PN 17-OCT-2002.
 PD 03-APR-2002; 2002WO-US010512.
 XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 PI Novel enzymatic nucleic acid that down-regulates expression of neurite
 XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT Claim 59; SEQ ID NO 1082; 317pp; English.
 PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 XX that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX Sequence 17 BP; 1 A; 4 C; 10 G; 0 T; 2 U; 0 Other;
 SQ Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 657 TGGAGGTCGGCCCGG 673
 Db 1 UGGAGGGGCGGCCCGG 17
 RESULT 79
 ADL47744
 ID ADL47744 standard; RNA; 17 BP.
 XX AC ADL47744;
 XX AC ADL47744;
 XX DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #254.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS Unidentified.
 XX WO200281628-A2.
 PN 17-OCT-2002.
 PD 03-APR-2002; 2002WO-US010512.
 XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 PI Novel enzymatic nucleic acid that down-regulates expression of neurite
 XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT Claim 59; SEQ ID NO 1277; 317pp; English.
 PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 XX that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX Sequence 17 BP; 4 A; 6 C; 6 G; 0 T; 1 U; 0 Other;
 SQ Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 203 GGCCCGGCGGAGATCA 219
 Db 1 GGCCCGGCGGAGATCA 17
 RESULT 80
 ADL47762
 ID ADL47762 standard; RNA; 17 BP.
 XX AC ADL47762;
 XX AC ADL47762;
 XX DT 20-MAY-2004 (first entry)
 XX

Human IKK-gamma substrate sequence #298.

antisense oligonucleotide; neurite growth inhibitor; NOGO; prostaglandin D2 receptor; PTGDR; ikappab kinase; IKK; protein kinase PKR; cerebrovascular accident; central nervous system injury; CNS injury; spinal cord injury; cancer; melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis; restenosis; asthma; Crohn's disease; diabetes; obesity; autoimmune disease; lupus; multiple sclerosis; transplant rejection; graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis; allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma substrate; ds.

Unidentified.

WO200281628-A2.

17-OCT-2002.

03-APR-2002; 2002WO-US010512.

05-APR-2001; 2001US-00827395.

28-MAY-2001; 2001US-0294412P.

28-AUG-2001; 2001US-0315315P.

(RIBO-) RIBOZYME PHARM INC.

Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

WPI; 2003-0598513/05.

Novel enzymatic nucleic acid that down-regulates expression of neurite growth inhibitor receptor, prostaglandin D2 receptor, ikappab kinase or protein kinase PKR genes, for treating cancer and inflammatory disease.

Claim S9; SEQ ID NO 1321; 317pp; English.

The invention comprises nucleic acids (e.g. antisense oligonucleotides) that down regulate the expression or inhibit the function of a receptor for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR), IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the invention are useful for treating: cerebrovascular accident, central nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma, lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis, restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune disease, lupus, multiple sclerosis, transplant/grraft rejection, ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The nucleic acids of the invention are also useful for down-regulating the expression of a target gene and as a diagnostic tool to examine genetic drifts and mutations within diseased cells or to detect the presence of a target RNA in a cell. The present RNA sequence represents a human IKK-gamma substrate sequence.

Sequence 17 BP; 2 A; 5 C; 4 G; 0 T; 6 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.2e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 379 GGAGCTTTCGATTCC 395
|||||:::||::||
Db 1 GGAGCUUCUGCAUUUCC 17

RESULT 82
ADL47794
ID ADL47794 standard; RNA; 17 BP.
XX AC
XX ADL47794;
XX DT
DT 20-MAY-2004 (first entry)
XX XX

DE Human IKK-gamma substrate sequence #304.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1327; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 that down regulate the expression or inhibit the function of a receptor
 for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 invention are useful for treating: cerebrovascular accident, central
 nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 disease, lupus, multiple sclerosis, transplant/graft rejection,
 ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 nucleic acids of the invention are also useful for down-regulating the
 expression of a target gene and as a diagnostic tool to examine genetic
 drifts and mutations within diseased cells or to detect the presence of a
 target RNA in a cell. The present RNA sequence represents a human IKK-
 gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 6 A; 4 C; 7 G; 0 T; 0 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 396 AAGCCAGCCAGGAGGAG 412
 DB 1 AAGCCAGCCAGGAGGAG 17
 RESULT 83
 ID ADL47821
 ADL47821 standard; RNA; 17 BP.
 XX
 AC ADL47821;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #331.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1354; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 that down regulate the expression or inhibit the function of a receptor
 for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 invention are useful for treating: cerebrovascular accident, central
 nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 disease, lupus, multiple sclerosis, transplant/graft rejection,
 ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 nucleic acids of the invention are also useful for down-regulating the
 expression of a target gene and as a diagnostic tool to examine genetic
 drifts and mutations within diseased cells or to detect the presence of a
 target RNA in a cell. The present RNA sequence represents a human IKK-
 gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 6 A; 3 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 548 CAGATGGCTGAGGACAA 564
 DB 1 CAGAUGGCTGAGGACAA 17
 RESULT 84
 ID ADL47839
 ADL47839 standard; RNA; 17 BP.
 XX
 AC ADL47839;
 XX
 DT 20-MAY-2004 (first entry)
 XX

Human IKK-gamma substrate sequence #351.

antisense oligonucleotide; neurite growth inhibitor; NOGO; prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK; protein kinase PKR; cerebrovascular accident; central nervous system injury; CNS injury; spinal cord injury; cancer; melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis; restenosis; asthma; Crohn's disease; diabetes; obesity; autoimmune disease; lupus; multiple sclerosis; transplant rejection; graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis; allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma substrate; ds.

Unidentified.

WO200281628-A2.

17-OCT-2002.

03-APR-2002; 2002WO-US010512.

05-APR-2001; 2001US-00827395.

29-MAY-2001; 2001US-0294412P.

28-AUG-2001; 2001US-0315315P.

(RIBO-) RIBOZYME PHARM INC.

Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K; WPI; 2003-058513/05.

Novel enzymatic nucleic acid that down-regulates expression of neurite growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or protein kinase PKR genes, for treating cancer and inflammatory disease.

Claim 59; SEQ ID NO 1374; 317pp; English.

The invention comprises nucleic acids (e.g. antisense oligonucleotides) that down regulate the expression or inhibit the function of a receptor for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR), IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the invention are useful for treating: cerebrovascular accident, central nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma, lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis, restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft rejection, ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The nucleic acids of the invention are also useful for down-regulating the expression of a target gene and as a diagnostic tool to examine genetic drifts and mutations within diseased cells or to detect the presence of a target RNA in a cell. The present RNA sequence represents a human IKK-gamma substrate sequence.

Sequence 17 BP; 4 A; 4 C; 6 G; 0 T; 3 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 642 AGGAATGCCAGGCTCTG 658
|||||:|||||:|
Db 1 AGGAATGCCAGGCUCUG 17

RESULT 86
ADL47859
ID ADL47859 standard; RNA; 17 BP.
XX AC ADL47859;
XX DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #369.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1392; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 5 C; 7 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 741 AGGTGACCACTGCGC 757
 Db 1 AGGUGGACCACTGCGC 17
 RESULT 87
 ADL48207
 ID ADL48207 standard; RNA; 17 BP.
 XX
 AC ADL48207;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #717.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1740; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 4 C; 7 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 180 GTGAGATGTCGAGCCC 196
 Db 1 GUGAGAGGTCGAGCCC 17
 RESULT 88
 ADL48222
 ID ADL48222 standard; RNA; 17 BP.
 XX
 AC ADL48222;
 XX
 DT 20-MAY-2004 (first entry)
 XX

Human IKK-gamma substrate sequence #732.

antisense oligonucleotide; neurite growth inhibitor; NOGO;
 prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 protein kinase PKR; cerebrovascular accident;
 central nervous system injury; CNS injury; spinal cord injury; cancer;
 melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 restenosis; asthma; Crohn's disease; diabetes; obesity;
 autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 substrate; ds.

Unidentified.

WO200281628-A2.

17-OCT-2002.

03-APR-2002; 2002WO-US010512.

05-APR-2001; 2001US-00827395.

29-MAY-2001; 2001US-0294412P.

28-AUG-2001; 2001US-0315315P.

(RIBO-) RIBOZYME PHARM INC.

Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 WPI; 2003-058513/05.

Novel enzymatic nucleic acid that down-regulates expression of neurite
 growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 protein kinase PKR genes, for treating cancer and inflammatory disease.

Claim 59; SEQ ID NO 1755; 317pp; English.

The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 that down regulate the expression or inhibit the function of a receptor
 for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 invention are useful for treating: cerebrovascular accident, central
 nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 disease, lupus, multiple sclerosis, transplant/graft rejection,
 ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 nucleic acids of the invention are also useful for down-regulating the
 expression of a target gene and as a diagnostic tool to examine genetic
 drifts and mutations within diseased cells or to detect the presence of a
 target RNA in a cell. The present RNA sequence represents a human IKK-
 gamma substrate sequence.

Sequence 17 BP; 3 A; 7 C; 3 G; 0 T; 4 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 2.2e+02;
 Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 263 CTGCACCTGCTTCAGA 279
 1 CUGACCCUCCUCCAGA 17

Db

RESULT 89
 ADL48232
 ID ADL48232 standard; RNA; 17 BP.
 AC ADL48232;
 XX
 DT 20-MAY-2004 (first entry)

Human IKK-gamma substrate sequence #742.

antisense oligonucleotide; neurite growth inhibitor; NOGO;
 prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 protein kinase PKR; cerebrovascular accident;
 central nervous system injury; CNS injury; spinal cord injury; cancer;
 melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 restenosis; asthma; Crohn's disease; diabetes; obesity;
 autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 substrate; ds.

Unidentified.

WO200281628-A2.

17-OCT-2002.

03-APR-2002; 2002WO-US010512.

05-APR-2001; 2001US-00827395.

29-MAY-2001; 2001US-0294412P.

28-AUG-2001; 2001US-0315315P.

(RIBO-) RIBOZYME PHARM INC.

Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 WPI; 2003-058513/05.

Novel enzymatic nucleic acid that down-regulates expression of neurite
 growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 protein kinase PKR genes, for treating cancer and inflammatory disease.

Claim 59; SEQ ID NO 1765; 317pp; English.

The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 that down regulate the expression or inhibit the function of a receptor
 for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 invention are useful for treating: cerebrovascular accident, central
 nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 disease, lupus, multiple sclerosis, transplant/graft rejection,
 ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 nucleic acids of the invention are also useful for down-regulating the
 expression of a target gene and as a diagnostic tool to examine genetic
 drifts and mutations within diseased cells or to detect the presence of a
 target RNA in a cell. The present RNA sequence represents a human IKK-
 gamma substrate sequence.

Sequence 17 BP; 3 A; 4 C; 7 G; 0 T; 3 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 356 CAGATTCTCGCGGAGCG 372
 1 CAGAUCUUCGCGGAGCG 17

Db

RESULT 90
 ADL48266
 ID ADL48266 standard; RNA; 17 BP.
 AC ADL48266;
 XX
 DT 20-MAY-2004 (first entry)

DE Human IKK-gamma substrate sequence #776.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1799; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 4 C; 7 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 607 GCAGGAGAGCCAGAGTC 623
 DB 1 GCAGGAGAGCCAGAGUC 17
 RESULT 91
 ADL48275
 ID ADL48275 standard; RNA; 17 BP.
 XX
 AC ADL48275;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #785.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1808; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 1 A; 7 C; 9 G; 0 T; 0 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 666 GGGCCCGGGCGGCCAGC 682
 DB 1 GGGCCCGGGCGGCCAGC 17
 RESULT 92
 ADL48280
 ID ADL48280 standard; RNA; 17 BP.
 XX
 AC ADL48280;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE	Human IKK-gamma substrate sequence #790.	DE	Human IKK-gamma substrate sequence #801.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX	substrate; ds.	XX	substrate; ds.
OS	Unidentified.	OS	Unidentified.
XX		XX	
PN	WO200281628-A2.	PN	WO200281628-A2.
XX		XX	
PD	17-OCT-2002.	PD	17-OCT-2002.
XX		XX	
PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.
XX		XX	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.
XX		XX	
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
XX		XX	
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
XX		XX	
PA	(RIBO-) RIBOZYME PHARM INC.	PA	(RIBO-) RIBOZYME PHARM INC.
XX		XX	
PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX		XX	
XX	WPI; 2003-058513/05.	XX	WPI; 2003-058513/05.
DR		DR	
XX		XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
PS	Claim 59; SEQ ID NO 1813; 317pp; English.	PS	Claim 59; SEQ ID NO 1824; 317pp; English.
XX		XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.	CC	gamma substrate sequence.
XX		XX	
SQ	Sequence 17 BP; 3 A; 5 C; 8 G; 0 T; 1 U; 0 Other;	SQ	Sequence 17 BP; 5 A; 6 C; 5 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;		Query Match 2.3%; Score 17; DB 1; Length 17;	
Best Local Similarity 94.1%; Pred. No. 2.2e+02;		Best Local Similarity 94.1%; Pred. No. 2.2e+02;	
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;		Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;	
QY	683 GAGCAGCGCGGCGCT 699	QY	722 CAGCAGCAGCAGCGCT 738
DB	1 GAGCAGCGCGGCGCT 17	DB	1 CAGCAGCAGCAGCGCT 17
RESULT 93		RESULT 94	
ADL48291		ADL48312	
ID ADL48291 standard; RNA; 17 BP.		ID ADL48312 standard; RNA; 17 BP.	
XX		XX	
AC ADL48291;		AC ADL48312;	
XX		XX	
DT 20-MAY-2004 (first entry)		DT 20-MAY-2004 (first entry)	
XX		XX	

DE Human IKK-gamma substrate sequence #822.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1845; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 that down regulate the expression or inhibit the function of a receptor
 for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 invention are useful for treating: cerebrovascular accident, central
 nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 disease, lupus, multiple sclerosis, transplant/graft rejection,
 ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 nucleic acids of the invention are also useful for down-regulating the
 expression of a target gene and as a diagnostic tool to examine genetic
 drifts and mutations within diseased cells or to detect the presence of a
 target RNA in a cell. The present RNA sequence represents a human IKK-
 gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 4 C; 7 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 822 GGAAGCTGCGCCAGTTG 838
 DB 1 GGAAGCTGCGCCAGTTG 17
 |||||:|||||:|
 RESULT 95
 ADL48482
 ID ADL48482 standard; RNA; 17 BP.
 XX
 AC ADL48482;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #992.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1015; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 that down regulate the expression or inhibit the function of a receptor
 for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 invention are useful for treating: cerebrovascular accident, central
 nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 disease, lupus, multiple sclerosis, transplant/graft rejection,
 ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 nucleic acids of the invention are also useful for down-regulating the
 expression of a target gene and as a diagnostic tool to examine genetic
 drifts and mutations within diseased cells or to detect the presence of a
 target RNA in a cell. The present RNA sequence represents a human IKK-
 gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 5 C; 5 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 351 GCAACGAGATTCTCGG 367
 DB 1 GCAACGAGATTCTCGG 17
 |||||:|||||:|
 RESULT 96
 ADL48559
 ID ADL48559 standard; RNA; 17 BP.
 XX
 AC ADL48559;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1088.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PS
 PS Claim 59; SEQ ID NO 2111; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 6 C; 5 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 276 CAGAACAGGCGCGTCTCT 292
 Db 1 CAGAACAGGCGCGCUCCU 17
 RESULT 99
 ADL48600
 ID ADL48600 standard; RNA; 17 BP.
 XX
 AC ADL48600;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1110.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PS
 PS Claim 59; SEQ ID NO 2133; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 7 A; 2 C; 8 G; 0 T; 0 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 401 AGCCAGAGGAGGAGAA 417
 Db 1 AGCCAGAGGAGGAGAA 17
 RESULT 100
 ADL48606
 ID ADL48606 standard; RNA; 17 BP.
 XX
 AC ADL48606;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE	Human IKK-gamma substrate sequence #1116.	DE	Human IKK-gamma substrate sequence #1127.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW	substrate; ds.	KW	substrate; ds.
XX	Unidentified.	XX	Unidentified.
OS		OS	
XX		XX	
PN	WO200281628-A2.	PN	WO200281628-A2.
XX		XX	
PD	17-OCT-2002.	PD	17-OCT-2002.
XX		XX	
XX		XX	
PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.
XX		XX	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.
XX		XX	
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
XX		XX	
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
XX	(RIBO-) RIBOZYME PHARM INC.	XX	(RIBO-) RIBOZYME PHARM INC.
PA		PA	
XX		XX	
PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX		XX	
XX	WPI; 2003-058513/05.	XX	WPI; 2003-058513/05.
DR		DR	
XX		XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
XX	Claim 59; SEQ ID NO 2139; 317pp; English.	XX	Claim 59; SEQ ID NO 2150; 317pp; English.
PS		PS	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.	CC	gamma substrate sequence.
XX		XX	
SQ	Sequence 17 BP; 5 A; 3 C; 6 G; 0 T; 3 U; 0 Other;	SQ	Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;
	Query Match 2.3%; Score 17; DB 1; Length 17;		Query Match 2.3%; Score 17; DB 1; Length 17;
	Best Local Similarity 82.4%; Pred. No. 2.2e+02;		Best Local Similarity 88.2%; Pred. No. 2.2e+02;
	Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;		Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY	411 AGGAGAAGGAGTTCCTC 427	QY	462 AGAGACTCGCGCTGGAG 478
	: :		: :
DB	1 AGGAGAAGGAGUUCUC 17	DB	1 AGAGACUCGCGCCUGGAG 17
RESULT 101		RESULT 102	
ADL48617		ADL48628	
ID	ADL48617 standard; RNA; 17 BP.	ID	ADL48628 standard; RNA; 17 BP.
XX		XX	
AC	ADL48617;	AC	ADL48628;
XX		XX	
DT	20-MAY-2004 (first entry)	DT	20-MAY-2004 (first entry)
XX		XX	


```

DE Human IKK-gamma substrate sequence #1138.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2161; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 500 AAGGAGCAGGCTCTGCG 516
DB 1 AAGGAGCAGGCTCTGCG 17
|||||
1 AAGGAGCAGGCTCTGCG 17

RESULT 103
ADL48630
ID ADL48630 standard; RNA; 17 BP.
XX
AC ADL48630;
XX
XX 20-MAY-2004 (first entry)
XX

```

```

DE Human IKK-gamma substrate sequence #1140.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2163; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 3 C; 9 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 509 GCTCTGCGGAGGTGGA 525
DB 1 GCUCUGCGGAGGUGGA 17
|||||
1 GCUCUGCGGAGGUGGA 17

RESULT 104
ADL48632
ID ADL48632 standard; RNA; 17 BP.
XX
AC ADL48632;
XX
XX 20-MAY-2004 (first entry)
XX

```

DE	Human IKK-gamma substrate sequence #1142.	DE	Human IKK-gamma substrate sequence #1163.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW	substrate; ds.	KW	substrate; ds.
OS	Unidentified.	OS	Unidentified.
XX		XX	
PN	WO200281628-A2.	PN	WO200281628-A2.
XX		XX	
PD	17-OCT-2002.	PD	17-OCT-2002.
XX		XX	
PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.
XX		XX	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.
XX		XX	
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
XX		XX	
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
PA	(RIBO-) RIBOZYME PHARM INC.	PA	(RIBO-) RIBOZYME PHARM INC.
XX		XX	
PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX		XX	
DR	WPI; 2003-058513/05.	DR	WPI; 2003-058513/05.
XX		XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
PS	Claim 59; SEQ ID NO 2165; 317pp; English.	PS	Claim 59; SEQ ID NO 2186; 317pp; English.
XX		XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.	CC	gamma substrate sequence.
XX		XX	
SQ	Sequence 17 BP; 3 A; 3 C; 9 G; 0 T; 2 U; 0 Other;	SQ	Sequence 17 BP; 5 A; 4 C; 7 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;		Query Match 2.3%; Score 17; DB 1; Length 17;	
Best Local Similarity 88.2%; Pred. No. 2.2e+02;		Best Local Similarity 94.1%; Pred. No. 2.2e+02;	
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;		Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;	
QY	512 CTGCGGAGGTGGAGCA 528	QY	605 CTGCAGGAGAGCCAGAG 621
: :		: :	
Db	1 CUGCGGAGGUGGAGCA 17	Db	1 CUGCAGGAGAGCCAGAG 17
RESULT 105		RESULT 106	
ADL48653		ADL48657	
ID	ADL48653 standard; RNA; 17 BP.	ID	ADL48657 standard; RNA; 17 BP.
XX		XX	
AC	ADL48653;	AC	ADL48657;
XX		XX	
DT	20-MAY-2004 (first entry)	DT	20-MAY-2004 (first entry)
XX		XX	

DE Human IKK-gamma substrate sequence #1167.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS
 XX
 XX WO200281628-A2.
 PN
 XX
 XX 17-OCT-2002.
 PD
 XX
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR
 XX 29-MAY-2001; 2001US-0294412P.
 PR
 XX 28-AUG-2001; 2001US-0315315P.
 PR
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX
 XX WPI; 2003-058513/05.
 DR
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX
 XX Claim 59; SEQ ID NO 2190; 317pp; English.
 PS
 XX
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 6 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 623 CGCTTGAGGCTGCCAC 639
 DB 1 CGCUGGAGGCGGCCAC 17
 |||:|||||:|||||
 RESULT 107
 ADL48700
 ID ADL48700 standard; RNA; 17 BP.
 XX
 AC ADL48700;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1210.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS
 XX
 XX WO200281628-A2.
 PN
 XX
 XX 17-OCT-2002.
 PD
 XX
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR
 XX 29-MAY-2001; 2001US-0294412P.
 PR
 XX 28-AUG-2001; 2001US-0315315P.
 PR
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX
 XX WPI; 2003-058513/05.
 DR
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX
 XX Claim 59; SEQ ID NO 2233; 317pp; English.
 PS
 XX
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 XX
 SQ Sequence 17 BP; 3 A; 4 C; 6 G; 0 T; 4 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 2.2e+02;
 Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 833 CAGTTCGAGGTGGCCTA 849
 DB 1 CAGUUGCAGGUGGCCUA 17
 |||:|||||:|||||
 RESULT 108
 ADL47525
 ID ADL47525 standard; RNA; 17 BP.
 XX
 AC ADL47525;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE	XX	Human IKK-gamma substrate sequence #44.
XX	XX	antitense oligonucleotide; neurite growth inhibitor; NOGO;
XX	XX	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX	XX	protein kinase PKR; cerebrovascular accident;
XX	XX	central nervous system injury; CNS injury; spinal cord injury; cancer;
XX	XX	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX	XX	restenosis; asthma; Crohn's disease; diabetes; obesity;
XX	XX	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX	XX	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX	XX	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX	XX	substrate; ds.
XX	OS	Unidentified.
XX	XX	WO200281628-A2.
XX	XX	17-OCT-2002.
XX	XX	03-APR-2002; 2002WO-US010512.
XX	XX	05-APR-2001; 2001US-00827395.
XX	XX	29-MAY-2001; 2001US-0294412P.
XX	XX	28-AUG-2001; 2001US-0315315P.
XX	XX	(RIBO-) RIBOZYME PHARM INC.
XX	XX	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Foesnaugh K;
XX	XX	WPI; 2003-058513/05.
XX	XX	Novel enzymatic nucleic acid that down-regulates expression of neurite
XX	XX	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX	XX	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX	XX	Claim 59; SEQ ID NO 1067; 317pp; English.
XX	XX	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX	XX	that down regulate the expression or inhibit the function of a receptor
XX	XX	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX	XX	IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
XX	XX	invention are useful for treating: cerebrovascular accident, central
XX	XX	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX	XX	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX	XX	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX	XX	disease, lupus, multiple sclerosis, transplant/graft rejection,
XX	XX	ischemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX	XX	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX	XX	nucleic acids of the invention are also useful for down-regulating the
XX	XX	expression of a target gene and as a diagnostic tool to examine genetic
XX	XX	drifts and mutations within diseased cells or to detect the presence of a
XX	XX	target RNA in a cell. The present RNA sequence represents a human IKK-
XX	XX	gamma substrate sequence.
XX	XX	Sequence 17 BP; 4 A; 4 C; 0 G; 0 T; 5 U; 0 Other;
XX	XX	Query Match 2.3%; Score 17; DB 1; Length 17;
XX	XX	Best Local Similarity 70.6%; Pred. No. 2.2e+02;
XX	XX	Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
XX	XX	QY 419 GAGTTCCTCATGTCGCA 435
XX	XX	: : : : :
XX	XX	Db 1 GAGUUCUUGUGGCA 17
XX	XX	RESULT 111
XX	XX	ADL47540
XX	XX	ID ADL47540 standard; RNA; 17 BP.
XX	XX	XX ADL47540;
XX	XX	AC ADL47540;
XX	XX	XX ADL47540;
XX	XX	DT 20-MAY-2004 (first entry)
XX	XX	XX

```

DE Human IKK-gamma substrate sequence #53.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX 17-OCT-2002.
XX PD
XX 03-APR-2002; 2002WO-US010512.
XX PF
XX 05-APR-2001; 2001US-00827395.
XX PR
XX 29-MAY-2001; 2001US-0294412P.
XX PR
XX 28-AUG-2001; 2001US-0315315P.
XX PR
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX PI
XX WPI; 2003-058513/05.
XX DR
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
PT
XX Claim 59; SEQ ID NO 1076; 317pp; English.
XX PS
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 1 A; 5 C; 7 G; 0 T; 4 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.2e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
Qy 586 GACGTCCTTGTCTCGGG 602
Db 1 GACGUCCTUUCGCGGG 17
|||||:|:|:|:|:|
1 GACGUCCTUUCGCGGG 17

RESULT 113
ADL47553
ID ADL47553 standard; RNA; 17 BP.
XX
XX AC ADL47553;
XX DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #63.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX 17-OCT-2002.
XX PD
XX 03-APR-2002; 2002WO-US010512.
XX PF
XX 05-APR-2001; 2001US-00827395.
XX PR
XX 29-MAY-2001; 2001US-0294412P.
XX PR
XX 28-AUG-2001; 2001US-0315315P.
XX PR
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX PI
XX WPI; 2003-058513/05.
XX DR
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
PT
XX Claim 59; SEQ ID NO 1086; 317pp; English.
XX PS
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 3 A; 6 C; 5 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
Qy 841 GGTCGCTATCACCAGC 857
Db 1 GGUGGCCUACUACCAGC 17
|||||:|:|:|:|:|
1 GGUGGCCUACUACCAGC 17

RESULT 114
ADL47737
ID ADL47737 standard; RNA; 17 BP.
XX
XX AC ADL47737;
XX DT 20-MAY-2004 (first entry)
XX

```

```

DE Human IKK-gamma substrate sequence #247.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1270; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 5 A; 3 C; 6 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 169 GAGCCAACTGTGTGAGA 185
Db 1 GAGCCAACTGTGTGAGA 17
|||||:|:|:|:|:|:|
1 GAGCCAACTGTGTGAGA 17

RESULT 115
ADL47758
ID ADL47758 standard; RNA; 17 BP.
XX
AC ADL47758;
XX
XX 20-MAY-2004 (first entry)
DT
XX

DE Human IKK-gamma substrate sequence #268.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1291; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 7 C; 3 G; 0 T; 5 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.2e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 261 TGCTGCACCTGCCTTCA 277
Db 1 UGUCGACCCUGCCUUA 17
|||||:|:|:|:|:|:|
1 UGUCGACCCUGCCUUA 17

RESULT 116
ADL47774
ID ADL47774 standard; RNA; 17 BP.
XX
AC ADL47774;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```


DE Human IKK-gamma substrate sequence #284.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS

XX WO200281628-A2.

PN

XX 17-OCT-2002.

PD

XX 03-APR-2002; 2002WO-US010512.

XX

XX 05-APR-2001; 2001US-00827395.

XX

XX 29-MAY-2001; 2001US-0294412P.

PR

XX 28-AUG-2001; 2001US-0315315P.

PR

XX (RIBO-) RIBOZYME PHARM INC.

PA

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

PI

XX WPI; 2003-058513/05.

DR

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

PT

XX Claim 59; SEQ ID NO 1307; 317pp; English.

PS

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

XX that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX

XX Sequence 17 BP; 3 A; 4 C; 8 G; 0 T; 2 U; 0 Other;

SQ

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.2e+02;

Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 304 GCGCTGCTGGAGGAGA 320

Db 1 GCGCTGCTGGAGGAGA 17

RESULT 117

ADL47777

ID ADL47777 standard; RNA; 17 BP.

XX

XX ADL47777;

AC

XX 20-MAY-2004 (first entry)

DT

XX

DE Human IKK-gamma substrate sequence #287.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS

XX WO200281628-A2.

PN

XX 17-OCT-2002.

PD

XX 03-APR-2002; 2002WO-US010512.

XX

XX 05-APR-2001; 2001US-00827395.

XX

XX 23-MAY-2001; 2001US-0294412P.

PR

XX 28-AUG-2001; 2001US-0315315P.

PR

XX (RIBO-) RIBOZYME PHARM INC.

PA

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

PI

XX WPI; 2003-058513/05.

DR

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

PT

XX Claim 59; SEQ ID NO 1310; 317pp; English.

PS

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

XX that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX

XX Sequence 17 BP; 5 A; 5 C; 5 G; 0 T; 2 U; 0 Other;

SQ

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.2e+02;

Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 324 AAGAGTCCGAGATGCC 340

Db 1 AAGAGTCCGAGATGCC 17

RESULT 118

ADL47783

ID ADL47783 standard; RNA; 17 BP.

XX

XX ADL47783;

AC

XX 20-MAY-2004 (first entry)

DT

XX


```

DE  Human IKK-gamma substrate sequence #293.
XX  antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW  prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW  protein kinase PKR; cerebrovascular accident;
KW  central nervous system injury; CNS injury; spinal cord injury; cancer;
KW  melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW  restenosis; asthma; Crohn's disease; diabetes; obesity;
KW  autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW  graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW  allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW  substrate; ds.
XX
OS  Unidentified.
XX
PN  WO200281628-A2.
XX
PD  17-OCT-2002.
XX
PF  03-APR-2002; 2002WO-US010512.
XX
PR  05-APR-2001; 2001US-00827395.
PR  29-MAY-2001; 2001US-0294412P.
PR  28-AUG-2001; 2001US-0315315P.
XX
PA  (RIBO-) RIBOZYME PHARM INC.
XX
PI  Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX  WPI; 2003-058513/05.
XX
PT  Novel enzymatic nucleic acid that down-regulates expression of neurite
PT  growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT  protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS  Claim 59; SEQ ID NO 1316; 317pp; English.
XX
CC  The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC  that down regulate the expression or inhibit the function of a receptor
CC  for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC  IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC  invention are useful for treating: cerebrovascular accident, central
CC  nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC  lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC  restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC  disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
CC  ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC  conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC  nucleic acids of the invention are also useful for down-regulating the
CC  expression of a target gene and as a diagnostic tool to examine genetic
CC  drifts and mutations within diseased cells or to detect the presence of a
CC  target RNA in a cell. The present RNA sequence represents a human IKK-
CC  gamma substrate sequence.
XX
SQ  Sequence 17 BP; 6 A; 4 C; 4 G; 0 T; 3 U; 0 Other;

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY  348 AGAGCAACCAACGATTCG 364
DB  1 AGAGCAACCAACGATTCG 17

RESULT 119
ADL47792
ID  ADL47792 standard; RNA; 17 BP.
XX
AC  ADL47792;
XX
XX  20-MAY-2004 (first entry)
DT
XX

```

```

DE  Human IKK-gamma substrate sequence #302.
XX  antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW  prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW  protein kinase PKR; cerebrovascular accident;
KW  central nervous system injury; CNS injury; spinal cord injury; cancer;
KW  melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW  restenosis; asthma; Crohn's disease; diabetes; obesity;
KW  autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW  graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW  allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW  substrate; ds.
XX
OS  Unidentified.
XX
PN  WO200281628-A2.
XX
PD  17-OCT-2002.
XX
PF  03-APR-2002; 2002WO-US010512.
XX
PR  05-APR-2001; 2001US-00827395.
PR  29-MAY-2001; 2001US-0294412P.
PR  28-AUG-2001; 2001US-0315315P.
XX
PA  (RIBO-) RIBOZYME PHARM INC.
XX
PI  Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX  WPI; 2003-058513/05.
XX
PT  Novel enzymatic nucleic acid that down-regulates expression of neurite
PT  growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT  protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS  Claim 59; SEQ ID NO 1325; 317pp; English.
XX
CC  The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC  that down regulate the expression or inhibit the function of a receptor
CC  for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC  IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC  invention are useful for treating: cerebrovascular accident, central
CC  nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC  lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC  restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC  disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
CC  ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC  conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC  nucleic acids of the invention are also useful for down-regulating the
CC  expression of a target gene and as a diagnostic tool to examine genetic
CC  drifts and mutations within diseased cells or to detect the presence of a
CC  target RNA in a cell. The present RNA sequence represents a human IKK-
CC  gamma substrate sequence.
XX
SQ  Sequence 17 BP; 5 A; 6 C; 4 G; 0 T; 2 U; 0 Other;

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY  392 TTCCAAGCCAGCCAGAG 408
DB  1 UUCAAGCCAGCCAGAG 17

RESULT 120
ADL47819
ID  ADL47819 standard; RNA; 17 BP.
XX
AC  ADL47819;
XX
XX  20-MAY-2004 (first entry)
DT
XX

```

Human IKK-gamma substrate sequence #329.

DE XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX substrate; ds.
XX OS Unidentified.
XX OS
XX PN W0200281628-A2.
XX PD 17-OCT-2002.
XX PD
XX PD
XX PF 03-APR-2002; 2002WO-US010512.
XX PF
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PR
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PA
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosenough K;
XX WPI; 2003-059513/05.
XX XX
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PS
XX PS Claim 59; SEQ ID NO 1352; 317pp; English.
XX XX
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX CC that down regulate the expression or inhibit the function of a receptor
XX CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX CC invention are useful for treating: cerebrovascular accident, central
XX CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX CC disease, lupus, multiple sclerosis, transplant/graft rejection,
XX CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX CC nucleic acids of the invention are also useful for down-regulating the
XX CC expression of a target gene and as a diagnostic tool to examine genetic
XX CC drifts and mutations within diseased cells or to detect the presence of a
XX CC target RNA in a cell. The present RNA sequence represents a human IKK-
XX CC gamma substrate sequence.
XX XX
XX SQ Sequence 17 BP; 5 A; 4 C; 6 G; 0 T; 2 U; 0 Other;
XX XX

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 538 ATGCCAGCAGCATGG 554
|:|||||:|:|:|
Db 1 AUGCCAGCAGCAUGG 17

RESULT 121
ADL47831
ID ADL47831 standard; RNA; 17 BP.
XX AC
XX AC ADL47831;
XX AC
XX AC 20-MAY-2004 (first entry)
XX DT
XX XX

DE	Human IKK-gamma substrate sequence #344.	DE	Human IKK-gamma substrate sequence #357.																																
XX		XX																																	
KW	antisense oligonucleotide; neurite growth inhibitor; NOGO;	KW	antisense oligonucleotide; neurite growth inhibitor; NOGO;																																
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;																																
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;																																
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;																																
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;																																
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;																																
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;																																
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;																																
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;																																
KW	substrate; ds.	KW	substrate; ds.																																
XX		XX																																	
OS	Unidentified.	OS	Unidentified.																																
XX		XX																																	
PN	WO200281628-A2.	PN	WO200281628-A2.																																
XX		XX																																	
PD	17-OCT-2002.	PD	17-OCT-2002.																																
XX		XX																																	
PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.																																
XX		XX																																	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.																																
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.																																
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.																																
XX		XX																																	
PA	(RIBO-) RIBOZYME PHARM INC.	PA	(RIBO-) RIBOZYME PHARM INC.																																
XX		XX																																	
PI	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;																																
XX		XX																																	
DR	WPI; 2003-058513/05.	DR	WPI; 2003-058513/05.																																
XX		XX																																	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite																																
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or																																
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.																																
XX		XX																																	
PS	Claim 59; SEQ ID NO 1367; 317pp; English.	PS	Claim 59; SEQ ID NO 1380; 317pp; English.																																
XX		XX																																	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)																																
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor																																
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),																																
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the																																
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central																																
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,																																
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,																																
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune																																
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,																																
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic																																
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The																																
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the																																
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic																																
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a																																
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-																																
CC	gamma substrate sequence.	CC	gamma substrate sequence.																																
XX		XX																																	
SQ	Sequence 17 BP; 5 A; 4 C; 7 G; 0 T; 1 U; 0 Other;	SQ	Sequence 17 BP; 3 A; 6 C; 8 G; 0 T; 0 U; 0 Other;																																
<table><tr><td>Query Match</td><td>2.3%;</td><td>Score 17;</td><td>DB 1;</td><td>Length 17;</td></tr><tr><td>Best Local Similarity</td><td>94.1%;</td><td>Pred. No. 2.2e+02;</td><td></td><td></td></tr><tr><td>Matches</td><td>16;</td><td>Conservative</td><td>1;</td><td>Mismatches 0; Indels 0; Gaps 0;</td></tr></table>				Query Match	2.3%;	Score 17;	DB 1;	Length 17;	Best Local Similarity	94.1%;	Pred. No. 2.2e+02;			Matches	16;	Conservative	1;	Mismatches 0; Indels 0; Gaps 0;																	
Query Match	2.3%;	Score 17;	DB 1;	Length 17;																															
Best Local Similarity	94.1%;	Pred. No. 2.2e+02;																																	
Matches	16;	Conservative	1;	Mismatches 0; Indels 0; Gaps 0;																															
QY	609 AGGAGAGCCAGAGTCGC 625	QY	671 CGGGCGGCAGCGAGCA 687																																
DB	1 AGGAGAGCCAGAGTCGC 17	DB	1 CGGGCGGCAGCGAGCA 17																																
<table><tr><td>RESULT 123</td><td></td><td>RESULT 124</td><td></td></tr><tr><td>ADL47847</td><td></td><td>ADL47857</td><td></td></tr><tr><td>ID ADL47847 standard; RNA; 17 BP.</td><td></td><td>ID ADL47857 standard; RNA; 17 BP.</td><td></td></tr><tr><td>XX</td><td></td><td>XX</td><td></td></tr><tr><td>AC ADL47847;</td><td></td><td>AC ADL47857;</td><td></td></tr><tr><td>XX</td><td></td><td>XX</td><td></td></tr><tr><td>DT 20-MAY-2004 (first entry)</td><td></td><td>DT 20-MAY-2004 (first entry)</td><td></td></tr><tr><td>XX</td><td></td><td>XX</td><td></td></tr></table>				RESULT 123		RESULT 124		ADL47847		ADL47857		ID ADL47847 standard; RNA; 17 BP.		ID ADL47857 standard; RNA; 17 BP.		XX		XX		AC ADL47847;		AC ADL47857;		XX		XX		DT 20-MAY-2004 (first entry)		DT 20-MAY-2004 (first entry)		XX		XX	
RESULT 123		RESULT 124																																	
ADL47847		ADL47857																																	
ID ADL47847 standard; RNA; 17 BP.		ID ADL47857 standard; RNA; 17 BP.																																	
XX		XX																																	
AC ADL47847;		AC ADL47857;																																	
XX		XX																																	
DT 20-MAY-2004 (first entry)		DT 20-MAY-2004 (first entry)																																	
XX		XX																																	

DE Human IKK-gamma substrate sequence #367.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX W0200281628-A2.
PN
XX 17-OCT-2002.
PD
XX 03-APR-2002; 2002WO-US010512.
PF
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
PR
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
DR
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1390; 317pp; English.
PS
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 5 A; 5 C; 6 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Oy 726 AGCAGCACAGCGTCAG 742
Db 1 AGCAGCACAGCGTCAG 17
RESULT 125
ADL47864
ID ADL47864 standard; RNA; 17 BP.
XX
XX AC ADL47864;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #374.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX W0200281628-A2.
PN
XX 17-OCT-2002.
PD
XX 03-APR-2002; 2002WO-US010512.
PF
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
PR
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
DR
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1397; 317pp; English.
PS
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 4 C; 8 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
Oy 759 TGCAGGGCCAGCGTG 775
Db 1 UGCAGGGCCAGCGUG 17
RESULT 126
ADL47876
ID ADL47876 standard; RNA; 17 BP.
XX
XX AC ADL47876;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #386.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1409; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection.
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 5 C; 5 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 824 AAGTGGCCCGAGTGGCA 840
 DB 1 AAGCGGCCCGAGTGGCA 17
 RESULT 127
 ADL47878
 ID ADL47878 standard; RNA; 17 BP.
 XX
 AC ADL47878;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #388.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1411; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection.
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 5 C; 7 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 826 GCTGCCCGAGTGGCAG 842
 DB 1 GCUGGCCCGAGTGGCAG 17
 RESULT 128
 ADL47886
 ID ADL47886 standard; RNA; 17 BP.
 XX
 AC ADL47886;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #396.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; ikappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 XX Claim 59; SEQ ID NO 1419; 317pp; English.
 PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC ikappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 XX Sequence 17 BP; 6 A; 6 C; 2 G; 0 T; 3 U; 0 Other;
 SQ
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 852 ACCAGCTCTTCCAAAGAA 868
 DB 1 ACCAGCUCUCCAAAGAA 17
 RESULT 129
 ADL48208
 ID ADL48208 standard; RNA; 17 BP.
 XX
 XX AC ADL48208;
 XX
 XX DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #718.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; ikappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 XX Claim 59; SEQ ID NO 1741; 317pp; English.
 PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC ikappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 XX Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;
 SQ
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 182 GAGATGGTGCAGCCGAG 198
 DB 1 GAGAGUGGUGCAGCCGAG 17
 RESULT 130
 ADL48210
 ID ADL48210 standard; RNA; 17 BP.
 XX
 XX AC ADL48210;
 XX
 XX DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #720.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1743; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 that down regulate the expression or inhibit the function of a receptor
 for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 invention are useful for treating: cerebrovascular accident, central
 nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 disease, lupus, multiple sclerosis, transplant/graft rejection,
 ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 nucleic acids of the invention are also useful for down-regulating the
 expression of a target gene and as a diagnostic tool to examine genetic
 drifts and mutations within diseased cells or to detect the presence of a
 target RNA in a cell. The present RNA sequence represents a human IKK-
 gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 7 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 190 GCAGCCAGTGGTGGCC 206
 DB 1 GCAGCCAGTGGTGGCC 17
 RESULT 131
 ID ADL48212
 ADL48212 standard; RNA; 17 BP.
 XX
 AC ADL48212;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #722.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1745; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 that down regulate the expression or inhibit the function of a receptor
 for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 invention are useful for treating: cerebrovascular accident, central
 nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 disease, lupus, multiple sclerosis, transplant/graft rejection,
 ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 nucleic acids of the invention are also useful for down-regulating the
 expression of a target gene and as a diagnostic tool to examine genetic
 drifts and mutations within diseased cells or to detect the presence of a
 target RNA in a cell. The present RNA sequence represents a human IKK-
 gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 5 C; 8 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 196 CAGTGGTGGCCGCGCAG 212
 DB 1 CAGTGGTGGCCGCGCAG 17
 RESULT 132
 ID ADL48213
 ADL48213 standard; RNA; 17 BP.
 XX
 AC ADL48213;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #723.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

OS Unidentified.

XX WO200281628-A2.

XX 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

XX 29-MAY-2001; 2001US-0294412P.

XX 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 1746; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX Sequence 17 BP; 3 A; 5 C; 7 G; 0 T; 2 U; 0 Other;

SQ Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.2e+02;

Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 201 GTGGCCCGGACAGAT 217

Db 1 GUGGCCCGGACAGAU 17

RESULT 133

ADL48241

ID ADL48241 standard; RNA; 17 BP.

XX AC ADL48241;

XX 20-MAY-2004 (first entry)

XX

DE Human IKK-gamma substrate sequence #751.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

OS Unidentified.

XX WO200281628-A2.

XX 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

XX 29-MAY-2001; 2001US-0294412P.

XX 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 1774; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX Sequence 17 BP; 3 A; 4 C; 3 G; 0 T; 7 U; 0 Other;

SQ Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 58.8%; Pred. No. 2.2e+02;

Matches 10; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 422 TTCTCATGTGCAAGTT 438

Db 1 UUCUCUAGUGCAGUU 17

RESULT 134

ADL48274

ID ADL48274 standard; RNA; 17 BP.

XX AC ADL48274;

XX 20-MAY-2004 (first entry)

XX


```

DE Human IKK-gamma substrate sequence #784.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prosta glandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1807; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 1 A; 5 C; 10 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 660 AGGGTCGGGCCCGGGCG 676
DB 1 AGGGTCGGGCCCGGGCG 17
|||||:|||||
1 AGGGTCGGGCCCGGGCG 17

RESULT 135
ADL48298
ID ADL48298 standard; RNA; 17 BP.
XX
AC ADL48298;
XX
XX 20-MAY-2004 (first entry)
DT
XX

DE Human IKK-gamma substrate sequence #808.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prosta glandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1831; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 6 C; 6 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 748 CCAGTCGGCGATGCAGG 764
DB 1 CCAGTCGGCGATGCAGG 17
|||||:|||||
1 CCAGTCGGCGATGCAGG 17

RESULT 136
ADL48301
ID ADL48301 standard; RNA; 17 BP.
XX
AC ADL48301;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```


DE Human IKK-gamma substrate sequence #990.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2013; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 7 C; 4 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 328 GCTCCGAGATGCCATCC 344
 Db 1 GCUCGAGAUCCCAUCC 17
 |||:|||||:|||||
 RESULT 139
 ID ADL48562
 ADL48562 standard; RNA; 17 BP.
 XX
 AC ADL48562;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1072.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2095; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 7 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 192 AGCCCGAGTGGTGGCCG 208
 Db 1 AGCCCGAGUGGUGGCCG 17
 |||:|||||:|||||
 RESULT 140
 ID ADL48580
 ADL48580 standard; RNA; 17 BP.
 XX
 AC ADL48580;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1108.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS Unidentified.
 XX WO200281628-A2.
 PN 17-OCT-2002.
 PD 03-APR-2002; 2002WO-US010512.
 XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX Claim 59; SEQ ID NO 2131; 317pp; English.
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX .Sequence 17 BP; 5 A; 4 C; 8 G; 0 T; 0 U; 0 Other;
 SQ Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 398 GCCAGCCAGGAGGAGGA 414
 Db |||||
 1 GCCAGCCAGGAGGAGGA 17
 RESULT 143
 ADL48656
 ID ADL48656 standard; RNA; 17 BP.
 XX AC ADL48656;
 XX 20-MAY-2004 (first entry)
 DT XX

DE Human IKK-gamma substrate sequence #1166.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS Unidentified.
 XX WO200281628-A2.
 PN 17-OCT-2002.
 PD 03-APR-2002; 2002WO-US010512.
 XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX Claim 59; SEQ ID NO 2189; 317pp; English.
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX .Sequence 17 BP; 1 A; 5 C; 7 G; 0 T; 4 U; 0 Other;
 SQ Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 2.2e+02;
 Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 621 GTCGTTGGAGCTGCC 637
 Db |||||
 1 GUCGCTUGGAGGCGGCC 17
 RESULT 144
 ADL48685
 ID ADL48685 standard; RNA; 17 BP.
 XX AC ADL48685;
 XX 20-MAY-2004 (first entry)
 DT XX

DE Human IKK-gamma substrate sequence #1195.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS
 XX WO200281628-A2.
 PN
 XX 17-OCT-2002.
 PD
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX 05-APR-2001; 2001US-00827395.
 PR
 XX 23-MAY-2001; 2001US-0294412P.
 PR
 XX 28-AUG-2001; 2001US-0315315P.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2218; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 5 C; 8 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 767 CAGAGCGTGGAGGCGC 783
 Db 1 CAGAGCGGAGGAGGCGC 17
 |||:|||||
 |||:|||||
 RESULT 145
 ADL47519
 ID ADL47519 standard; RNA; 17 BP.
 XX
 AC ADL47519;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #29.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS
 XX WO200281628-A2.
 PN
 XX 17-OCT-2002.
 PD
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX 05-APR-2001; 2001US-00827395.
 PR
 XX 23-MAY-2001; 2001US-0294412P.
 PR
 XX 28-AUG-2001; 2001US-0315315P.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1052; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 6 C; 4 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 268 CCTGCTTTCAGAACAGG 284
 Db 1 CCUGCCUUCAGAACAGG 17
 |||:|||||
 |||:|||||
 RESULT 146
 ADL47797
 ID ADL47797 standard; RNA; 17 BP.
 XX
 AC ADL47797;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE	Human IKK-gamma substrate sequence #307.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW	substrate; ds.
XX	Unidentified.
OS	
XX	
PN	WO200281628-A2.
XX	
PD	17-OCT-2002.
XX	
PF	03-APR-2002; 2002WO-US010512.
XX	
PR	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.
XX	
PA	(RIBO-) RIBOZYME PHARM INC.
XX	
PI	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
PI	WPI; 2003-058513/05.
DR	
XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
PS	Claim 59; SEQ ID NO 1330; 317pp; English.
XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.
XX	
SQ	Sequence 17 BP; 3 A; 4 C; 5 G; 0 T; 5 U; 0 Other;
	Query Match 2.3%; Score 17; DB 1; Length 17;
	Best Local Similarity 70.6%; Pred. No. 2.2e+02;
	Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
OY	418 GGAGTTCCTCATGTCCA 434 : : : : :
Db	1 GGAGUUCUCAUGCGCA 17
RESULT 147	
ADL47804	
ID	ADL47804 standard; RNA; 17 BP.
XX	
AC	ADL47804;
XX	
DT	20-MAY-2004 (first entry)
XX	

DE	Human IKK-gamma substrate sequence #314.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW	substrate; ds.
XX	Unidentified.
OS	
XX	
PN	WO200281628-A2.
XX	
PD	17-OCT-2002.
XX	
PF	03-APR-2002; 2002WO-US010512.
XX	
PR	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.
XX	
PA	(RIBO-) RIBOZYME PHARM INC.
XX	
PI	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
PI	WPI; 2003-058513/05.
DR	
XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
PS	Claim 59; SEQ ID NO 1337; 317pp; English.
XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.
XX	
SQ	Sequence 17 BP; 6 A; 2 C; 7 G; 0 T; 2 U; 0 Other;
	Query Match 2.3%; Score 17; DB 1; Length 17;
	Best Local Similarity 88.2%; Pred. No. 2.2e+02;
	Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
OY	448 CAGGAACCTGGTGAGA 464 :: : : : :
Db	1 CAGGAACCTGGTGAGA 17
RESULT 148	
ADL47806	
ID	ADL47806 standard; RNA; 17 BP.
XX	
AC	ADL47806;
XX	
DT	20-MAY-2004 (first entry)
XX	

DE Human IKK-gamma substrate sequence #316.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 XX WO200281628-A2.
 PN
 XX 17-OCT-2002.
 PD
 XX
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR
 XX 29-MAY-2001; 2001US-0294412P.
 PR
 XX 28-AUG-2001; 2001US-0315315P.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI WPI; 2003-058513/05.
 XX
 DR Novel enzymatic nucleic acid that down-regulates expression of neurite
 XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX
 XX Claim 59; SEQ ID NO 1339; 317pp; English.
 PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 XX
 SQ Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 465 GACTCGGCTCGAGAG 481
 DB 1 GACUCGGCCUGGAGAG 17
 |||:|||||:|||||:
 1 GACUCGGCCUGGAGAG 17
 RESULT 149
 ADL47816
 ID ADL47816 standard; RNA; 17 BP.
 XX
 XX AC ADL47816;
 XX
 XX DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #326.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 XX WO200281628-A2.
 PN
 XX 17-OCT-2002.
 PD
 XX
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR
 XX 29-MAY-2001; 2001US-0294412P.
 PR
 XX 28-AUG-2001; 2001US-0315315P.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI WPI; 2003-058513/05.
 XX
 DR Novel enzymatic nucleic acid that down-regulates expression of neurite
 XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX
 XX Claim 59; SEQ ID NO 1349; 317pp; English.
 PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 XX
 SQ Sequence 17 BP; 6 A; 3 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 523 GGAGCACCCTGAGAGAT 539
 DB 1 GGAGCACCCTGAGAGAU 17
 |||:|||||:|||||:
 1 GGAGCACCCTGAGAGAU 17
 RESULT 150
 ADL47837
 ID ADL47837 standard; RNA; 17 BP.
 XX
 XX AC ADL47837;
 XX
 XX DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #347.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS Unidentified.
 XX WO200281628-A2.
 PN 17-OCT-2002.
 PD 17-OCT-2002.
 XX 03-APR-2002; 2002WO-US010512.
 PF 05-APR-2001; 2001US-00827395.
 XX 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 PI Novel enzymatic nucleic acid that down-regulates expression of neurite
 XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT Claim 59; SEQ ID NO 1370; 317pp; English.
 PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 XX that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX SQ Sequence 17 BP; 4 A; 4 C; 5 G; 0 T; 4 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 2.2e+02;
 Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 626 TTGAGGCTGCACCTAA 642
 DB 1 UUGAGGCGGCCACUAA 17
 RESULT 151
 ADL47883
 ID ADL47883 standard; RNA; 17 BP.
 XX AC ADL47883;
 XX DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #393.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS Unidentified.
 XX WO200281628-A2.
 PN 17-OCT-2002.
 PD 17-OCT-2002.
 XX 03-APR-2002; 2002WO-US010512.
 PF 05-APR-2001; 2001US-00827395.
 XX 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 PI Novel enzymatic nucleic acid that down-regulates expression of neurite
 XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT Claim 59; SEQ ID NO 1416; 317pp; English.
 PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 XX that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX SQ Sequence 17 BP; 3 A; 8 C; 1 G; 0 T; 5 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 70.6%; Pred. No. 2.2e+02;
 Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
 QY 846 CCTATCACCAGCTTTC 862
 DB 1 CCUAUCACAGCUCUUC 17
 RESULT 152
 ADL48214
 ID ADL48214 standard; RNA; 17 BP.
 XX AC ADL48214;
 XX DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #724.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS WO200281628-A2.

XX 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

XX 29-MAY-2001; 2001US-0294412P.

XX 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

PI WPI; 2003-058513/05.

DR Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 1747; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX Sequence 17 BP; 4 A; 6 C; 6 G; 0 T; 1 U; 0 Other;

SQ

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 94.1%; Pred. No. 2.2e+02;

Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 204 GCCCGGCGAGCATCAG 220

DB 1 GCCCGGCGAGCATCAG 17

RESULT 153

ADL48225

ID ADL48225 standard; RNA; 17 BP.

XX AC

XX ADL48225;

XX 20-MAY-2004 (first entry)

DT

XX

DE Human IKK-gamma substrate sequence #735.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS WO200281628-A2.

XX 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

XX 29-MAY-2001; 2001US-0294412P.

XX 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

PI WPI; 2003-058513/05.

DR Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 1758; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX Sequence 17 BP; 2 A; 9 C; 3 G; 0 T; 3 U; 0 Other;

SQ

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 2.2e+02;

Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 296 ACCCTCCAGCGCTGCCT 312

DB 1 ACCCTCCAGCGCTGCCT 17

RESULT 154

ADL48245

ID ADL48245 standard; RNA; 17 BP.

XX AC

XX ADL48245;

XX 20-MAY-2004 (first entry)

DT

XX

DE Human IKK-gamma substrate sequence #755.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS Unidentified.
 XX WO200281628-A2.
 PN 17-OCT-2002.
 PD 03-APR-2002; 2002WO-US010512.
 XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 PI Novel enzymatic nucleic acid that down-regulates expression of neurite
 XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT Claim 59; SEQ ID NO 1778; 317pp; English.
 PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 XX that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX Query Match 2.3%; Score 17; DB 1; Length 17;
 XX Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 XX Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 450 GGAAACTGTGGAGAGA 466
 Db 1 GGAAACUGGGGAGAGA 17
 RESULT 155
 ADL48255
 ID ADL48255 standard; RNA; 17 BP.
 XX AC ADL48255;
 XX AC ADL48255;
 XX 20-MAY-2004 (first entry)
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #765.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS Unidentified.
 XX WO200281628-A2.
 PN 17-OCT-2002.
 PD 03-APR-2002; 2002WO-US010512.
 XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 PI Novel enzymatic nucleic acid that down-regulates expression of neurite
 XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT Claim 59; SEQ ID NO 1788; 317pp; English.
 PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 XX that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX Query Match 2.3%; Score 17; DB 1; Length 17;
 XX Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 XX Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 536 AGATCCGACGACGACAT 552
 Db 1 AGAUGCCGACGACGAGAU 17
 RESULT 156
 ADL48263
 ID ADL48263 standard; RNA; 17 BP.
 XX AC ADL48263;
 XX AC ADL48263;
 XX 20-MAY-2004 (first entry)
 DT 20-MAY-2004 (first entry)
 XX

```

DE Human IKK-gamma substrate sequence #773.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX PN WO200281628-A2.
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 28-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1796; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX Sequence 17 BP; 2 A; 5 C; 6 G; 0 T; 4 U; 0 Other;
XX
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.2e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
XX
QY 587 ACCTCCTTGTCTCGGGGA 603
Db 1 ACGUCCUUGCUGGGGA 17
|||||:|||||
1 ACGUCCUUGCUGGGGA 17

RESULT 157
ADL48282
ID ADL48282 standard; RNA; 17 BP.
XX
XX AC ADL48282;
XX
XX DT 20-MAY-2004 (first entry)
XX

```

```

DE Human IKK-gamma substrate sequence #792.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX PN WO200281628-A2.
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1815; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX Sequence 17 BP; 3 A; 4 C; 9 G; 0 T; 1 U; 0 Other;
XX
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
QY 689 GCGCGGCAGCTGGAGAG 705
Db 1 GCGCGGCAGCTGGAGAG 17
|||||:|||||
1 GCGCGGCAGCTGGAGAG 17

RESULT 158
ADL48299
ID ADL48299 standard; RNA; 17 BP.
XX
XX AC ADL48299;
XX
XX DT 20-MAY-2004 (first entry)
XX

```

DE Human IKK-gamma substrate sequence #809.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1832; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 6 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 752 CTGCGCATCGAGGCCA 768
 Db 1 CUGCGCAUGCAGGCCA 17
 RESULT 159
 ID ADL48302
 XX ADL48302 standard; RNA; 17 BP.
 AC ADL48302;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #812.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1835; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 5 C; 8 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 765 GCCAGAGCGTGAGGCC 781
 Db 1 GCCAGAGCGUGGAGGCC 17
 RESULT 160
 ID ADL48321
 XX ADL48321 standard; RNA; 17 BP.
 AC ADL48321;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #831.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS
 XX
 XX WO200281628-A2.
 PN
 XX
 XX 17-OCT-2002.
 PD
 XX
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR
 XX 29-MAY-2001; 2001US-0294412P.
 PR
 XX 28-AUG-2001; 2001US-0315315P.
 PR
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX
 XX WPI; 2003-058513/05.
 DR
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX
 XX Claim 59; SEQ ID NO 1854; 317pp; English.
 PS
 XX
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 XX Sequence 17 BP; 2 A; 3 C; 9 G; 0 T; 3 U; 0 Other;
 SQ
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 888 GCAGCGTGGTGGCAGT 904
 DB 1 GCAGCGTGGTGGCAGU 17
 RESULT 161
 ADL48479
 ID ADL48479 standard; RNA; 17 BP.
 XX
 AC ADL48479;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #989.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS
 XX
 XX WO200281628-A2.
 PN
 XX
 XX 17-OCT-2002.
 PD
 XX
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR
 XX 29-MAY-2001; 2001US-0294412P.
 PR
 XX 28-AUG-2001; 2001US-0315315P.
 PR
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX
 XX WPI; 2003-058513/05.
 DR
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX
 XX Claim 59; SEQ ID NO 1012; 317pp; English.
 PS
 XX
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 XX Sequence 17 BP; 7 A; 2 C; 7 G; 0 T; 1 U; 0 Other;
 SQ
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 313 GCAGGAGATCAAGAGC 329
 DB 1 GCAGGAGATCAAGAGC 17
 RESULT 162
 ADL48574
 ID ADL48574 standard; RNA; 17 BP.
 XX
 AC ADL48574;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

```

DE Human IKK-gamma substrate sequence #1084.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2107; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 5 C; 6 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 241 TCCTCTGGGAGGCCAG 257
DB 1 UCCUCUGGGAGGCCAG 17
:|||||
:|||||

RESULT 163
ADL48576
ID ADL48576 standard; RNA; 17 BP.
XX
AC ADL48576;
XX
DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #1086.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2109; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 5 C; 5 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 270 TGCCTTCAGACAGGCG 286
DB 1 UGCCUUCAGACAGGCG 17
:|||||
:|||||

RESULT 164
ADL48581
ID ADL48581 standard; RNA; 17 BP.
XX
AC ADL48581;
XX
DT 20-MAY-2004 (first entry)
XX

```



```

DE  Human IKK-gamma substrate sequence #1157.
XX  antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW  prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW  protein kinase PKR; cerebrovascular accident;
KW  central nervous system injury; CNS injury; spinal cord injury; cancer;
KW  melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW  restenosis; asthma; Crohn's disease; diabetes; obesity;
KW  autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW  graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW  allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW  substrate; ds.
XX
OS  Unidentified.
XX
PN  WO200281628-A2.
XX
PD  17-OCT-2002.
XX
XX  03-APR-2002; 2002WO-US010512.
XX
XX  05-APR-2001; 2001US-00827395.
PR
XX  29-MAY-2001; 2001US-0294412P.
PR
XX  28-AUG-2001; 2001US-0315315P.
XX
PA  (RIBO-) RIBOZYME PHARM INC.
XX
PI  Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX  WPI; 2003-058513/05.
DR
XX
PT  Novel enzymatic nucleic acid that down-regulates expression of neurite
PT  growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT  protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS  Claim 59; SEQ ID NO 2180; 317pp; English.
XX
CC  The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC  that down regulate the expression or inhibit the function of a receptor
CC  for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC  IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC  invention are useful for treating: cerebrovascular accident, central
CC  nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC  lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC  restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC  disease, lupus, multiple sclerosis, transplant/graft rejection,
CC  ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC  conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC  nucleic acids of the invention are also useful for down-regulating the
CC  expression of a target gene and as a diagnostic tool to examine genetic
CC  drifts and mutations within diseased cells or to detect the presence of a
CC  target RNA in a cell. The present RNA sequence represents a human IKK-
CC  gamma substrate sequence.
XX
SQ  Sequence 17 BP; 1 A; 5 C; 7 G; 0 T; 4 U; 0 Other;
    Query Match      2.3%; Score 17; DB 1; Length 17;
    Best Local Similarity 76.5%; Pred. No. 2.2e+02;
    Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY  591 CTTGCTCGGGAGCTG 607
DB  1 CCUUGCUCGGGAGCTG 17
    ::|||:|||||:|

RESULT 167
ADL48649
ID  ADL48649 standard; RNA; 17 BP.
XX
AC  ADL48649;
XX
XX  20-MAY-2004 (first entry)
DT
XX

```

```

DE  Human IKK-gamma substrate sequence #1159.
XX  antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW  prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW  protein kinase PKR; cerebrovascular accident;
KW  central nervous system injury; CNS injury; spinal cord injury; cancer;
KW  melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW  restenosis; asthma; Crohn's disease; diabetes; obesity;
KW  autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW  graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW  allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW  substrate; ds.
XX
OS  Unidentified.
XX
PN  WO200281628-A2.
XX
PD  17-OCT-2002.
XX
XX  03-APR-2002; 2002WO-US010512.
XX
XX  05-APR-2001; 2001US-00827395.
PR
XX  29-MAY-2001; 2001US-0294412P.
PR
XX  28-AUG-2001; 2001US-0315315P.
XX
PA  (RIBO-) RIBOZYME PHARM INC.
XX
PI  Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX  WPI; 2003-058513/05.
DR
XX
PT  Novel enzymatic nucleic acid that down-regulates expression of neurite
PT  growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT  protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS  Claim 59; SEQ ID NO 2182; 317pp; English.
XX
CC  The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC  that down regulate the expression or inhibit the function of a receptor
CC  for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC  IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC  invention are useful for treating: cerebrovascular accident, central
CC  nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC  lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC  restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC  disease, lupus, multiple sclerosis, transplant/graft rejection,
CC  ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC  conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC  nucleic acids of the invention are also useful for down-regulating the
CC  expression of a target gene and as a diagnostic tool to examine genetic
CC  drifts and mutations within diseased cells or to detect the presence of a
CC  target RNA in a cell. The present RNA sequence represents a human IKK-
CC  gamma substrate sequence.
XX
SQ  Sequence 17 BP; 2 A; 4 C; 7 G; 0 T; 4 U; 0 Other;
    Query Match      2.3%; Score 17; DB 1; Length 17;
    Best Local Similarity 76.5%; Pred. No. 2.2e+02;
    Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY  593 TTGCTCGGGAGCTCCA 609
DB  1 UUGCUCGGGAGCTGCA 17
    ::|||:|||||:|

RESULT 168
ADL48655
ID  ADL48655 standard; RNA; 17 BP.
XX
AC  ADL48655;
XX
XX  20-MAY-2004 (first entry)
DT
XX

```

DE	Human IKK-gamma substrate sequence #1165.	DE	Human IKK-gamma substrate sequence #39.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW	substrate; ds.	KW	substrate; ds.
OS	Unidentified.	OS	Unidentified.
XX		XX	
PN	WO200281628-A2.	PN	WO200281628-A2.
XX		XX	
PD	17-OCT-2002.	PD	17-OCT-2002.
XX		XX	
PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.
XX		XX	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
PA	(RIBO-) RIBOZYME PHARM INC.	PA	(RIBO-) RIBOZYME PHARM INC.
XX		XX	
PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX		XX	
DR	WPI; 2003-058513/05.	DR	WPI; 2003-058513/05.
XX		XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
PS	Claim 59; SEQ ID NO 2188; 317pp; English.	PS	Claim 59; SEQ ID NO 1062; 317pp; English.
XX		XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.	CC	gamma substrate sequence.
XX		XX	
SQ	Sequence 17 BP; 2 A; 4 C; 7 G; 0 T; 4 U; 0 Other;	SQ	Sequence 17 BP; 3 A; 6 C; 2 G; 0 T; 6 U; 0 Other;
	Query Match 2.3%; Score 17; DB 1; Length 17;		Query Match 2.3%; Score 17; DB 1; Length 17;
	Best Local Similarity 76.5%; Pred. No. 2.2e+02;		Best Local Similarity 64.7%; Pred. No. 2.2e+02;
	Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;		Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY	620 AGTCGCTGGAGGCTGC 636	QY	384 TTCTGCATTTCCAAGCC 400
	: :		::: : :
Db	1 AGUCGCTUGGAGGCTGC 17	Db	1 UUCUGCAUUUCCAGCC 17
RESULT 169		RESULT 170	
ADL47529		ADL47538	
ID ADL47529 standard; RNA; 17 BP.		ID ADL47538 standard; RNA; 17 BP.	
XX		XX	
AC ADL47529;		AC ADL47538;	
XX		XX	
DT 20-MAY-2004 (first entry)		DT 20-MAY-2004 (first entry)	
XX		XX	

```

DE      Human IKK-gamma substrate sequence #48.
XX      antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW      prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW      protein kinase PKR; cerebrovascular accident;
KW      central nervous system injury; CNS injury; spinal cord injury; cancer;
KW      melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW      restenosis; asthma; Crohn's disease; diabetes; obesity;
KW      autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW      graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW      allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW      substrate; ds.
XX
OS      Unidentified.
XX
PN      WO200281628-A2.
XX
PD      17-OCT-2002.
XX
PF      03-APR-2002; 2002WO-US010512.
XX
PR      05-APR-2001; 2001US-00827395.
PR      29-MAY-2001; 2001US-0294412P.
PR      28-AUG-2001; 2001US-0315315P.
XX
PA      (RIBO-) RIBOZYME PHARM INC.
XX
PI      Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX      WPI; 2003-058513/05.
DR
PT      Novel enzymatic nucleic acid that down-regulates expression of neurite
PT      growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT      protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS      Claim 59; SEQ ID NO 1071; 317pp; English.
XX
CC      The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC      that down regulate the expression or inhibit the function of a receptor
CC      for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC      IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC      invention are useful for treating: cerebrovascular accident, central
CC      nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC      lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC      restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC      disease, lupus, multiple sclerosis, transplant/graft rejection,
CC      ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC      conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC      nucleic acids of the invention are also useful for down-regulating the
CC      expression of a target gene and as a diagnostic tool to examine genetic
CC      drifts and mutations within diseased cells or to detect the presence of a
CC      target RNA in a cell. The present RNA sequence represents a human IKK-
CC      gamma substrate sequence.
XX
SQ      Sequence 17 BP; 6 A; 3 C; 5 G; 0 T; 3 U; 0 Other;
      Query Match      2.3%; Score 17; DB 1; Length 17;
      Best Local Similarity 82.4%; Pred.No. 2.2e+02;
      Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      476 GAGAGCTCGATCTGAA 492
DB      1 GAGAGCGUCGACUGAA 17
      |||||:||||:||||
      1 GAGAGCGUCGACUGAA 17

RESULT 171
ADL47745
ID      ADL47745 standard; RNA; 17 BP.
XX
AC      ADL47745;
XX
DT      20-MAY-2004 (first entry)
XX

DE      Human IKK-gamma substrate sequence #255.
XX      antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW      prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW      protein kinase PKR; cerebrovascular accident;
KW      central nervous system injury; CNS injury; spinal cord injury; cancer;
KW      melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW      restenosis; asthma; Crohn's disease; diabetes; obesity;
KW      autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW      graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW      allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW      substrate; ds.
XX
OS      Unidentified.
XX
PN      WO200281628-A2.
XX
PD      17-OCT-2002.
XX
PF      03-APR-2002; 2002WO-US010512.
XX
PR      05-APR-2001; 2001US-00827395.
PR      29-MAY-2001; 2001US-0294412P.
PR      28-AUG-2001; 2001US-0315315P.
XX
PA      (RIBO-) RIBOZYME PHARM INC.
XX
PI      Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX      WPI; 2003-058513/05.
DR
PT      Novel enzymatic nucleic acid that down-regulates expression of neurite
PT      growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT      protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS      Claim 59; SEQ ID NO 1278; 317pp; English.
XX
CC      The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC      that down regulate the expression or inhibit the function of a receptor
CC      for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC      IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC      invention are useful for treating: cerebrovascular accident, central
CC      nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC      lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC      restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC      disease, lupus, multiple sclerosis, transplant/graft rejection,
CC      ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC      conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC      nucleic acids of the invention are also useful for down-regulating the
CC      expression of a target gene and as a diagnostic tool to examine genetic
CC      drifts and mutations within diseased cells or to detect the presence of a
CC      target RNA in a cell. The present RNA sequence represents a human IKK-
CC      gamma substrate sequence.
XX
SQ      Sequence 17 BP; 5 A; 5 C; 6 G; 0 T; 1 U; 0 Other;
      Query Match      2.3%; Score 17; DB 1; Length 17;
      Best Local Similarity 94.1%; Pred.No. 2.2e+02;
      Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      206 CCGGCAGCAGATCAGGA 222
DB      1 CCGGCAGCAGCAUCAGGA 17
      |||||:||||:||||
      1 CCGGCAGCAGCAUCAGGA 17

RESULT 172
ADL47755
ID      ADL47755 standard; RNA; 17 BP.
XX
AC      ADL47755;
XX
DT      20-MAY-2004 (first entry)
XX

```

DE Human IKK-gamma substrate sequence #265.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX 05-APR-2001; 2001US-00827395.
 PR
 PR 29-MAY-2001; 2001US-0294412P.
 PR
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 XX Claim 59; SEQ ID NO 1288; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 7 C; 4 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 252 AGCCAGCCATGCTGCAC 268
 Db 1 AGCCAGCCCAUGCUGCAC 17
 RESULT 173
 ADL47769
 ID ADL47769 standard; RNA; 17 BP.
 XX
 AC ADL47769;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #279.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX 05-APR-2001; 2001US-00827395.
 PR
 PR 29-MAY-2001; 2001US-0294412P.
 PR
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 XX Claim 59; SEQ ID NO 1302; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 7 C; 4 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 292 TGAGACCTCCAGCGCT 308
 Db 1 UGAGACCCUCCAGCGCU 17
 RESULT 174
 ADL47828
 ID ADL47828 standard; RNA; 17 BP.
 XX
 AC ADL47828;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #338.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowwira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1361; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 4 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred.No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 574 GAAAGCCAGGTGACGT 590
 Db 1 GAAAGCCAGGTGACGT 17
 RESULT 175
 ADL47843
 ID ADL47843 standard; RNA; 17 BP.
 XX
 AC ADL47843;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #353.
 XX
 KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowwira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1376; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 4 C; 8 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred.No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 647 TGCCAGGCTCTGGAGGG 663
 Db 1 UGCCAGGCUCUGAGGG 17
 RESULT 176
 ADL47881
 ID ADL47881 standard; RNA; 17 BP.
 XX
 AC ADL47881;
 XX
 DT 20-MAY-2004 (first entry)
 XX

```

DE Human IKK-gamma substrate sequence #391.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX substrate; ds.
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX 17-OCT-2002.
XX PD
XX
XX 03-APR-2002; 2002WO-US010512.
XX PF
XX 05-APR-2001; 2001US-00827395.
XX PR
XX 29-MAY-2001; 2001US-0294412P.
XX PR
XX 28-AUG-2001; 2001US-0315315P.
XX PR
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX PI WPI; 2003-058513/05.
XX DR
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PT
XX Claim 59; SEQ ID NO 1414; 317pp; English.
XX PS
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX CC
XX Sequence 17 BP; 4 A; 5 C; 5 G; 0 T; 3 U; 0 Other;
SQ Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 840 AGGTGGCCTATCACCAG 856
DB |||:|||||:|||||
1 AGGUGGCCUACUACCAG 17

RESULT 177
ADL47889
ID ADL47889 standard; RNA; 17 BP.
XX
XX ADL47889;
XX AC
XX DT 20-MAY-2004 (first entry)
XX DT
XX

DE Human IKK-gamma substrate sequence #399.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX substrate; ds.
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX 17-OCT-2002.
XX PD
XX
XX 03-APR-2002; 2002WO-US010512.
XX PF
XX 05-APR-2001; 2001US-00827395.
XX PR
XX 29-MAY-2001; 2001US-0294412P.
XX PR
XX 28-AUG-2001; 2001US-0315315P.
XX PR
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX PI WPI; 2003-058513/05.
XX DR
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PT
XX Claim 59; SEQ ID NO 1422; 317pp; English.
XX PS
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX CC
XX Sequence 17 BP; 8 A; 6 C; 1 G; 0 T; 2 U; 0 Other;
SQ Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 867 AATACGACACCAATC 883
DB |||:|||||:|||||
1 AAUACGACCAACCAUC 17

RESULT 178
ADL47890
ID ADL47890 standard; RNA; 17 BP.
XX
XX ADL47890;
XX AC
XX DT 20-MAY-2004 (first entry)
XX DT
XX

```

DE Human IKK-gamma substrate sequence #400.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1423; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 8 A; 6 C; 2 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 870 AGCACAACCAATCAAG 886
 DB 1 AGCACAACCAUCAAG 17
 RESULT 179
 ADL48205
 ID ADL48205 standard; RNA; 17 BP.
 XX
 AC ADL48205;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #715.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1738; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 3 C; 5 G; 0 T; 4 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 2.2e+02;
 Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 170 AGCCAACTGTGTGAGAT 186
 DB 1 AGCCAACTGTGTGAGAU 17
 RESULT 180
 ADL48215
 ID ADL48215 standard; RNA; 17 BP.
 XX
 AC ADL48215;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE	XX	Human IKK-gamma substrate sequence #726.
XX	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	KW	protein kinase PKR; cerebrovascular accident;
KW	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW	KW	substrate; ds.
OS	XX	Unidentified.
OS	XX	WO200281628-A2.
PN	XX	17-OCT-2002.
PN	XX	03-APR-2002; 2002WO-US010512.
PP	XX	05-APR-2001; 2001US-00827395.
PR	XX	29-MAY-2001; 2001US-0294412P.
PR	XX	28-AUG-2001; 2001US-0315315P.
XX	XX	(RIBO-) RIBOZYME PHARM INC.
XX	XX	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI	XX	WPI; 2003-058513/05.
DR	XX	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX	XX	Claim 59; SEQ ID NO 1749; 317pp; English.
PS	XX	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX	XX	that down regulate the expression or inhibit the function of a receptor
CC	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	CC	invention are useful for treating: cerebrovascular accident, central
CC	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	CC	nucleic acids of the invention are also useful for down-regulating the
CC	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	CC	gamma substrate sequence.
XX	XX	Sequence 17 BP; 4 A; 3 C; 7 G; 0 T; 3 U; 0 Other;
XX	XX	Query Match 2.3%; Score 17; DB 1; Length 17;
XX	XX	Best Local Similarity 82.4%; Pred. No. 2.2e+02;
XX	XX	Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
Qy	223	CGTACTGGGCGAAGAGT 239
		:
		:
Db	1	CGUACUGGGCGAAGAGU 17
RESULT 182		
ADL48227		
ID	ADL48227	standard; RNA; 17 BP.
XX	AC	ADL48227;
XX	DT	20-MAY-2004 (first entry)
XX	XX	


```

DE Human IKK-gamma substrate sequence #737.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1760; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 6 C; 7 G; 0 T; 2 U; 0 Other;
  Query Match 2.3%; Score 17; DB 1; Length 17;
  Best Local Similarity 88.2%; Pred. No. 2.2e+02;
  Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 301 CCAGCGCTCCCTGGAGG 317
Db |||||:|||||
  1 CCAGCGCTCCCTGGAGG 17

RESULT 183
ADL48238
ID ADL48238 standard; RNA; 17 BP.
XX
AC ADL48238;
XX
DT 20-MAY-2004 (first entry)
XX

```

```

DE Human IKK-gamma substrate sequence #748.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1771; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 5 A; 6 C; 3 G; 0 T; 3 U; 0 Other;
  Query Match 2.3%; Score 17; DB 1; Length 17;
  Best Local Similarity 82.4%; Pred. No. 2.2e+02;
  Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 390 ATTTCCAGCCGAGCAG 406
Db |||||:|||||
  1 AUUUCAGCCGAGCCAG 17

RESULT 184
ADL48273
ID ADL48273 standard; RNA; 17 BP.
XX
AC ADL48273;
XX
DT 20-MAY-2004 (first entry)
XX

```



```

DE Human IKK-gamma substrate sequence #806.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1829; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 5 C; 6 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred.No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 743 GTGACCACTGGCGCAT 759
DB 1 GUGGACCAGCGCGCAU 17
|||||
1 GUGGACCAGCGCGCAU 17

RESULT 187
ADL48309
ID ADL48309 standard; RNA; 17 BP.
XX
AC ADL48309;
XX
XX 20-MAY-2004 (first entry)
DT
XX

DE Human IKK-gamma substrate sequence #819.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1842; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 8 C; 6 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred.No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 795 AGCGCCAGCGCGCTCG 811
DB 1 AGCGCCAGCGCGCTCG 17
|||||
1 AGCGCCAGCGCGCTCG 17

RESULT 188
ADL48313
ID ADL48313 standard; RNA; 17 BP.
XX
AC ADL48313;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

DE	Human IKK-gamma substrate sequence #823.	DE	Human IKK-gamma substrate sequence #997.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW	substrate; ds.	KW	substrate; ds.
OS	Unidentified.	OS	Unidentified.
XX		XX	
PN	WO200281628-A2.	PN	WO200281628-A2.
XX		XX	
PD	17-OCT-2002.	PD	17-OCT-2002.
XX		XX	
PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.
XX		XX	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.
XX		XX	
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
XX		XX	
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
PA	(RIBO-) RIBOZYME PHARM INC.	PA	(RIBO-) RIBOZYME PHARM INC.
XX		XX	
PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX		XX	
DR	WPI; 2003-058513/05.	DR	WPI; 2003-058513/05.
XX		XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
PS	Claim 59; SEQ ID NO 1846; 317pp; English.	PS	Claim 59; SEQ ID NO 2020; 317pp; English.
XX		XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.	CC	gamma substrate sequence.
XX		XX	
SQ	Sequence 17 BP; 2 A; 5 C; 6 G; 0 T; 4 U; 0 Other;	SQ	Sequence 17 BP; 5 A; 3 C; 7 G; 0 T; 2 U; 0 Other;
	Query Match 2.3%; Score 17; DB 1; Length 17;		Query Match 2.3%; Score 17; DB 1; Length 17;
	Best Local Similarity 76.5%; Pred. No. 2.2e+02;		Best Local Similarity 88.2%; Pred. No. 2.2e+02;
	Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;		Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
OY	827 CTGGCCCGAGTTCAGGT 843	OY	543 AGCAGCAGATGGCTGAG 559
	: :		: :
Db	1 CUGGCCAGUGCAGGU 17	Db	1 AGCAGCAGAGGCGUGAG 17
RESULT 189		RESULT 190	
ADL48487		ADL48595	
ID	ADL48487 standard; RNA; 17 BP.	ID	ADL48595 standard; RNA; 17 BP.
XX		XX	
AC	ADL48487;	AC	ADL48595;
XX		XX	
DT	20-MAY-2004 (first entry)	DT	20-MAY-2004 (first entry)
XX		XX	

DE Human IKK-gamma substrate sequence #1105.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PS Claim 59; SEQ ID NO 2128; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 4 C; 7 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 369 AGCGCTGCGAGGAGCTT 385
 DB 1 AGCGCTGCGAGGAGCTT 17
 |||||:|||||:
 RESULT 191
 ADL48605
 ID ADL48605 standard; RNA; 17 BP.
 XX
 AC ADL48605;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1115.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PS Claim 59; SEQ ID NO 2138; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 2 C; 7 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 410 GAGGAGAGGAGTCTCT 426
 DB 1 GAGGAGAGGAGTCTCT 17
 |||||:|||||:
 RESULT 192
 ADL48610
 ID ADL48610 standard; RNA; 17 BP.
 XX
 AC ADL48610;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1120.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS
 XX WO200281628-A2.
 PN
 XX 17-OCT-2002.
 PD
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX 05-APR-2001; 2001US-00827395.
 PR
 XX 29-MAY-2001; 2001US-0294412P.
 PR
 XX 28-AUG-2001; 2001US-0315315P.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 FI WPI; 2003-059513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2143; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 3 C; 8 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 442 GGAGCCAGGAACCTGG 458
 DB 1 GGAGCCAGGAACCTGG 17
 RESULT 193
 ADL48626
 ID ADL48626 standard; RNA; 17 BP.
 XX
 AC ADL48626;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1136.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS
 XX WO200281628-A2.
 PN
 XX 17-OCT-2002.
 PD
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX 05-APR-2001; 2001US-00827395.
 PR
 XX 29-MAY-2001; 2001US-0294412P.
 PR
 XX 28-AUG-2001; 2001US-0315315P.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 FI WPI; 2003-059513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2159; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 6 A; 3 C; 8 G; 0 T; 0 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 494 AGGCAGGAGGAGCAGGC 510
 DB 1 AGGCAGGAGGAGCAGGC 17
 RESULT 194
 ADL48678
 ID ADL48678 standard; RNA; 17 BP.
 XX
 AC ADL48678;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1188.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PF 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 XX
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2211; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 5 C; 8 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 707 GAGCGCGAGCGCTGCA 723
 Db 1 GAGCGCGAGCGCTGCA 17
 :|||||:|||||
 RESULT 195
 ADL48689
 ID ADL48689 standard; RNA; 17 BP.
 XX
 AC ADL48689;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1199.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PF 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 XX
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2222; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 6 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 786 TCCGCATGGAGCGCCAG 802
 Db 1 UCCGCAUGGAGCGCCAG 17
 :|||||:|||||
 RESULT 196
 ADL48702
 ID ADL48702 standard; RNA; 17 BP.
 XX
 AC ADL48702;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX


```

DE XX Human IKK-gamma substrate sequence #1212.
KW antisenase oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2235; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX Sequence 17 BP; 6 A; 5 C; 2 G; 0 T; 4 U; 0 Other;
XX
XX Query Match 2.3%; Score 17; DB 1; Length 17;
XX Best Local Similarity 76.5%; Pred. No. 2.2e+02;
XX Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 858 TCTTCCAGAAATACGAC 874
XX :||:|||||:|||||
XX Db 1 UCUUCCAGAAUACGAC 17
XX
XX RESULT 197
XX ADL47554
XX ID ADL47554 standard; RNA; 17 BP.
XX
XX AC ADL47554;
XX
XX 20-MAY-2004 (first entry)
XX
DE XX Human IKK-gamma substrate sequence #64.
KW antisenase oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1087; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX Sequence 17 BP; 3 A; 7 C; 3 G; 0 T; 4 U; 0 Other;
XX
XX Query Match 2.3%; Score 17; DB 1; Length 17;
XX Best Local Similarity 76.5%; Pred. No. 2.2e+02;
XX Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 843 TGGCCTATCACCAGCUC 859
XX :||||:|||||:|||||
XX Db 1 UGGCCUAUACCCAGCUC 17
XX
XX RESULT 198
XX ADL47558
XX ID ADL47558 standard; RNA; 17 BP.
XX
XX AC ADL47558;
XX
XX 20-MAY-2004 (first entry)
XX

```



```

DE Human IKK-gamma substrate sequence #68.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1091; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 8 A; 6 C; 2 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 862 CCAAGAATACGACAC 878
DB 1 CCAAGAAUACGACAC 17
|||||:|||||
1 CCAAGAAUACGACAC 17

RESULT 199
ADL47750
ID ADL47750 standard; RNA; 17 BP.
XX
AC ADL47750;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

```

DE Human IKK-gamma substrate sequence #260.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1283; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 4 C; 6 G; 0 T; 4 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.2e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 236 GAGTCTCTCTGGGAA 252
DB 1 GAGUCUCUCUGGGAA 17
|||||:|||||
1 GAGUCUCUCUGGGAA 17

RESULT 200
ADL47752
ID ADL47752 standard; RNA; 17 BP.
XX
AC ADL47752;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

```

DE Human IKK-gamma substrate sequence #262.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1285; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX Sequence 17 BP; 4 A; 5 C; 7 G; 0 T; 1 U; 0 Other;
XX
XX Query Match 2.3%; Score 17; DB 1; Length 17;
XX Best Local Similarity 94.1%; Pred. No. 2.2e+02;
XX Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 247 GGGGAAGCCAGCCATGC 263
XX Db 1 GGGGAAGCCAGCCATGC 17
XX
XX RESULT 201
XX ADL47756
XX ID ADL47756 standard; RNA; 17 BP.
XX
XX AC ADL47756;
XX
XX DT 20-MAY-2004 (first entry)
XX
DE Human IKK-gamma substrate sequence #266.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1289; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX Sequence 17 BP; 3 A; 7 C; 4 G; 0 T; 3 U; 0 Other;
XX
XX Query Match 2.3%; Score 17; DB 1; Length 17;
XX Best Local Similarity 82.4%; Pred. No. 2.2e+02;
XX Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 256 AGCCATGCTGCACCTGC 272
XX Db 1 AGCCATGCTGCACCTGC 17
XX
XX RESULT 202
XX ADL47773
XX ID ADL47773 standard; RNA; 17 BP.
XX
XX AC ADL47773;
XX
XX DT 20-MAY-2004 (first entry)
XX

```

DE Human IKK-gamma substrate sequence #283.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1306; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 4 C; 8 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 303 AGCGCTGCTGGAGGAG 319
 Db 1 AGCGCUGCCUGGAGGAG 17
 RESULT 203
 ADL47830
 ID ADL47830 standard; RNA; 17 BP.
 XX
 AC ADL47830;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #340.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1363; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 1 A; 5 C; 6 G; 0 T; 5 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 70.6%; Pred. No. 2.2e+02;
 Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
 QY 585 TGACGTCTCTGTCGGG 601
 Db 1 UGACGCGCCUGCGGG 17
 RESULT 204
 ADL47850
 ID ADL47850 standard; RNA; 17 BP.
 XX
 AC ADL47850;
 XX
 DT 20-MAY-2004 (first entry)
 XX

```
DE Human IKK-gamma substrate sequence #360.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1383; 317pp; English.
XX
SS The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 4 C; 9 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 688 GCGCGGCGAGCTGGAGA 704
DB 1 GCGCGGCGAGCTGGAGA 17
RESULT 205
ADL47895
ID ADL47895 standard; RNA; 17 BP.
XX
AC ADL47895;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human IKK-gamma substrate sequence #405.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1428; 317pp; English.
XX
SS The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 2 C; 10 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 894 TGGTGGCGAGCTGAGCGG 910
DB 1 UGGUGGCGAGUGAGCGG 17
RESULT 206
ADL48251
ID ADL48251 standard; RNA; 17 BP.
XX
AC ADL48251;
XX
DT 20-MAY-2004 (first entry)
XX
```

DE Human IKK-gamma substrate sequence #761.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1784; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 4 C; 8 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 506 CAGGCTCTCGGGAGGT 522
 DB 1 CAGGCUCUGCGGAGGU 17
 RESULT 207
 ADL48277
 ID ADL48277 standard; RNA; 17 BP.
 XX
 AC ADL48277;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #787.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1810; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 5 C; 9 G; 0 T; 0 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 673 GGCGCCGCGGAGGAGT 689
 DB 1 GGCGCCGCGGAGGAGG 17
 RESULT 208
 ADL48289
 ID ADL48289 standard; RNA; 17 BP.
 XX
 AC ADL48289;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #799.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 XX WO200281628-A2.
 XX
 XX 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 XX
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 XX Claim 59; SEQ ID NO 1822; 317pp; English.
 PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 XX Sequence 17 BP; 4 A; 6 C; 6 G; 0 T; 1 U; 0 Other;
 SQ
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 716 GCGCTGCAGCAGCAGCA 732
 Db 1 GCGCUGCAGCAGCAGCA 17
 |||||
 1 GCGCUGCAGCAGCAGCA 17

RESULT 209
 ADL48483
 ID ADL48483 standard; RNA; 17 BP.
 XX
 AC ADL48483;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #993.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 XX WO200281628-A2.
 XX
 XX 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 XX
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 XX Claim 59; SEQ ID NO 2016; 317pp; English.
 PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 XX Sequence 17 BP; 5 A; 3 C; 7 G; 0 T; 2 U; 0 Other;
 SQ
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 446 GCCAGGAAGTGTGTGGA 462
 Db 1 GCCAGGAAGTGTGTGGA 17
 |||||
 1 GCCAGGAAGTGTGTGGA 17

RESULT 210
 ADL48492
 ID ADL48492 standard; RNA; 17 BP.
 XX
 AC ADL48492;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1002.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2025; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 8 A; 4 C; 2 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 860 TTCCAAGAAATACGACAA 876
 Db 1 UUCCAAGAAUACGACAA 17
 :|||||:|||||
 :|||||:|||||
 RESULT 211
 ADL48561
 ID ADL48561 standard; RNA; 17 BP.
 XX
 AC ADL48561;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1071.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2094; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 3 C; 7 G; 0 T; 4 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 2.2e+02;
 Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 179 TGTGAGATGTCAGCC 195
 Db 1 UGUGAGAUUGGUGCAGCC 17
 :|||||:|||||
 :|||||:|||||
 RESULT 212
 ADL48571
 ID ADL48571 standard; RNA; 17 BP.
 XX
 AC ADL48571;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1143.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2166; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 4 C; 8 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 515 CGGGAGGTGGAGCACCT 531
 Db 1 CGGGAGGUGGAGCACCU 17
 |||||:|||||:
 RESULT 215
 ADL48666
 ID ADL48666 standard; RNA; 17 BP.
 XX
 AC ADL48666;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE: Human IKK-gamma substrate sequence #1176.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2199; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 1 A; 5 C; 10 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 659 GAGGTCGGCGCCCGGC 675
 Db 1 GAGGTCGGCGCCCGGC 17
 |||||:|||||:
 RESULT 216
 ADL48680
 ID ADL48680 standard; RNA; 17 BP.
 XX
 AC ADL48680;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1190.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS WO200281628-A2.

XX 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

PR 29-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 2213; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX Sequence 17 BP; 3 A; 4 C; 7 G; 0 T; 3 U; 0 Other;

SQ Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 2.2e+02;

Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 737 GTGCAGGTGGACGACT 753

Db 1 GUGCAGGUGGACGACGU 17

RESULT 217

ADL48683

ID ADL48683 standard; RNA; 17 BP.

XX AC ADL48683;

XX 20-MAY-2004 (first entry)

DT 20-MAY-2004 (first entry)

XX

DE Human IKK-gamma substrate sequence #1193.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS WO200281628-A2.

XX 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

PR 29-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 2216; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX Sequence 17 BP; 4 A; 5 C; 7 G; 0 T; 1 U; 0 Other;

SQ Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 94.1%; Pred. No. 2.2e+02;

Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 756 GCATGCAGGCGCCAGAGC 772

Db 1 GCAUGCAGGCGCCAGAGC 17

RESULT 218

ADL48687

ID ADL48687 standard; RNA; 17 BP.

XX AC ADL48687;

XX 20-MAY-2004 (first entry)

DT 20-MAY-2004 (first entry)

XX

DE Human IKK-gamma substrate sequence #1197.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2220; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 5 C; 8 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 770 AGCGTCGAGCGCGCT 786
 DB 1 AGCGUGGAGCGCGCU 17
 RESULT 219
 ADL48691
 ID ADL48691 standard; RNA; 17 BP.
 XX
 AC ADL48691;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1201.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2224; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 5 C; 7 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 803 GCCGCTCGAGAGAA 819
 DB 1 GCCGCTCGAGAGAA 17
 RESULT 220
 ADL48694
 ID ADL48694 standard; RNA; 17 BP.
 XX
 AC ADL48694;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1208.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2231; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 6 A; 2 C; 8 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 815 GAGAGAGGAGGCTGGC .831
 DB 1 GAGAGAGGAGGCTGGC 17
 |||||
 RESULT 223
 ADL48705
 ID ADL48705 standard; RNA; 17 BP.
 XX
 AC ADL48705;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1215.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2238; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 3 C; 9 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 887 AGCAGCGTGGTGGCGAG 903
 DB 1 AGCAGCGUGUGGGCAG 17
 |||||
 RESULT 224
 ADL47520
 ID ADL47520 standard; RNA; 17 BP.
 XX
 AC ADL47520;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #40.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1063; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 6 C; 2 G; 0 T; 5 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 70.6%; Pred. No. 2.2e+02;
 Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
 QY 385 TCTGCAATTCACGCCA 401
 DB :||||:|||||
 1 UCUGCAUUCACGCCA 17
 RESULT 227
 ID ADL47552
 ADL47552 standard; RNA; 17 BP.
 XX
 AC ADL47552;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #62.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1085; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 4 C; 8 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 829 GGCCCGATTCAGGTGG 845
 DB :||||:|||||
 1 GGCCCGATTCAGGTGG 17
 RESULT 228
 ID ADL47736
 ADL47736 standard; RNA; 17 BP.
 XX
 AC ADL47736;
 XX
 DT 20-MAY-2004 (first entry)
 XX


```

DE XX Human IKK-gamma substrate sequence #246.
KW XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW KW protein kinase PKR; cerebrovascular accident;
KW KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW KW substrate; ds.
XX OS Unidentified.
XX OS
XX PN W0200281628-A2.
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX XX (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR XX
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PS Claim 59; SEQ ID NO 1269; 317pp; English.
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX CC that down regulate the expression or inhibit the function of a receptor
XX CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX CC invention are useful for treating: cerebrovascular accident, central
XX CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX CC disease, lupus, multiple sclerosis, transplant/graft rejection,
XX CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX CC nucleic acids of the invention are also useful for down-regulating the
XX CC expression of a target gene and as a diagnostic tool to examine genetic
XX CC drifts and mutations within diseased cells or to detect the presence of a
XX CC target RNA in a cell. The present RNA sequence represents a human IKK-
XX CC gamma substrate sequence.
XX SQ Sequence 17 BP; 5 A; 3 C; 6 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 166 GAAGAGCCAACTGTGTG 182
Db 1 GAAGAGCCAACTGTGTG 17
|||||
1 GAAGAGCCAACTGTGTG 17

RESULT 229
ADL47751
ID ADL47751 standard; RNA; 17 BP.
XX AC
XX AC ADL47751;
XX DT 20-MAY-2004 (first entry)
XX DT

DE XX Human IKK-gamma substrate sequence #261.
KW XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW KW protein kinase PKR; cerebrovascular accident;
KW KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW KW substrate; ds.
XX OS Unidentified.
XX OS
XX PN W0200281628-A2.
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX XX (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR XX
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PS Claim 59; SEQ ID NO 1284; 317pp; English.
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX CC that down regulate the expression or inhibit the function of a receptor
XX CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX CC invention are useful for treating: cerebrovascular accident, central
XX CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX CC disease, lupus, multiple sclerosis, transplant/graft rejection,
XX CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX CC nucleic acids of the invention are also useful for down-regulating the
XX CC expression of a target gene and as a diagnostic tool to examine genetic
XX CC drifts and mutations within diseased cells or to detect the presence of a
XX CC target RNA in a cell. The present RNA sequence represents a human IKK-
XX CC gamma substrate sequence.
XX SQ Sequence 17 BP; 2 A; 5 C; 6 G; 0 T; 4 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.2e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 238 GTCTCTCTGTGGGAAGC 254
Db 1 GUCUCUCUGGGAAGC 17
|||||
1 GUCUCUCUGGGAAGC 17

RESULT 230
ADL47764
ID ADL47764 standard; RNA; 17 BP.
XX AC
XX AC ADL47764;
XX DT 20-MAY-2004 (first entry)
XX DT

```


DE Human IKK-gamma substrate sequence #274.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1297; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 6 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 281 CAGGGCGCTCTGAGAC 297
 DB 1 CAGGGCGCTCTGAGAC 17
 RESULT 231
 ADL47771
 ID ADL47771 standard; RNA; 17 BP.
 XX
 AC ADL47771;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #281.
 XX
 KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1304; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 9 C; 4 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 295 GACCCTCCAGCGCTGCC 311
 DB 1 GACCCTCCAGCGCTGCC 17
 RESULT 232
 ADL47776
 ID ADL47776 standard; RNA; 17 BP.
 XX
 AC ADL47776;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #313.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1336; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 6 A; 3 C; 7 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 441 AGGAGCCGAGGAACCTG 457
 DB 1 AGGAGCCGAGGAACUG 17
 RESULT 235
 ID ADL47809
 XX ADL47809 standard; RNA; 17 BP.
 AC ADL47809;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #319.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1342; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 4 C; 6 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 481 GCTCGATCTGAAGAGGC 497
 DB 1 GCUCGCAUCGAGAGGC 17
 RESULT 236
 ID ADL47810
 XX ADL47810 standard; RNA; 17 BP.
 AC ADL47810;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

```
DE Human IKK-gamma substrate sequence #320.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1343; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 7 A; 2 C; 8 G; 0 T; 0 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 490 GAAGAGGCGAGGAGGC 506
DB 1 GAAGAGGCGAGGAGGC 17
RESULT 237
ADL47840
ID ADL47840 standard; RNA; 17 BP.
XX
XX AC ADL47840;
XX
XX DT 20-MAY-2004 (first entry)
XX
DE Human IKK-gamma substrate sequence #350.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1373; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 5 A; 4 C; 5 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 632 GCTGCCCACTAAGGAATG 648
DB 1 GCUGCCACUAAAGGAUG 17
RESULT 238
ADL47851
ID ADL47851 standard; RNA; 17 BP.
XX
XX AC ADL47851;
XX
XX DT 20-MAY-2004 (first entry)
XX
```

DE	Human IKK-gamma substrate sequence #361.	DE	Human IKK-gamma substrate sequence #372.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX	substrate; ds.	XX	substrate; ds.
OS	Unidentified.	OS	Unidentified.
XX		XX	
PN	WO200281628-A2.	PN	WO200281628-A2.
PD	17-OCT-2002.	PD	17-OCT-2002.
XX		XX	
PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.
XX		XX	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
PA	(RIBO-) RIBOZYME PHARM INC.	PA	(RIBO-) RIBOZYME PHARM INC.
XX		XX	
PI	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX		XX	
DR	WPI; 2003-058513/05.	DR	WPI; 2003-058513/05.
XX		XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
PS	Claim 59; SEQ ID NO 1384; 317pp; English.	PS	Claim 59; SEQ ID NO 1395; 317pp; English.
XX		XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.	CC	gamma substrate sequence.
XX		XX	
SQ	Sequence 17 BP; 3 A; 3 C; 9 G; 0 T; 2 U; 0 Other;	SQ	Sequence 17 BP; 3 A; 5 C; 7 G; 0 T; 2 U; 0 Other;
	Query Match 2.3%; Score 17; DB 1; Length 17;		Query Match 2.3%; Score 17; DB 1; Length 17;
	Best Local Similarity 88.2%; Pred. No. 2.2e+02;		Best Local Similarity 88.2%; Pred. No. 2.2e+02;
	Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;		Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY	691 GCGGCGAGTGGAGAGTG 707	QY	750 AGCTGCGCATGCAGGCG 766
	:		:
Db	1 GCGGCGAGTGGAGAGUG 17	Db	1 AGCUGCGCAUGCAGGCG 17
RESULT 239		RESULT 240	
ADL47862		ADL47873	
ID ADL47862 standard; RNA; 17 BP.		ID ADL47873 standard; RNA; 17 BP.	
XX		XX	
AC ADL47862;		AC ADL47873;	
XX		XX	
DT 20-MAY-2004 (first entry)		DT 20-MAY-2004 (first entry)	
XX		XX	

DE Human IKK-gamma substrate sequence #727.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1750; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 5 C; 5 G; 0 T; 4 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred.No. 2.2e+02;
 Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 230 GGCGAAGAGTCTCTCTCT 246
 DB 1 GGCGAAGAGTCTCTCTCT 17
 RESULT 243
 ID ADL48249
 XX ADL48249 standard; RNA; 17 BP.
 XX
 AC ADL48249;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #759.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1782; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 4 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred.No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 497 CAGAAGGAGCAGGCTCT 513
 DB 1 CAGAAGGAGCAGGCTCT 17
 RESULT 244
 ID ADL48252
 XX ADL48252 standard; RNA; 17 BP.
 XX
 AC ADL48252;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX


```
DE Human IKK-gamma substrate sequence #762.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1785; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 3 A; 3 C; 9 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 513 TGGCGGAGGTGGAGCAC 529
Db 1 UGCGGAGGUGGAGCAC 17
:|||||:|||||
1 UGCGGAGGUGGAGCAC 17

RESULT 245
ADL48258
ID ADL48258 standard; RNA; 17 BP.
XX
XX AC ADL48258;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #768.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1791; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 4 A; 4 C; 6 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 558 AGGACAAGGCTCTGTG 574
Db 1 AGGACAAGGCTCTGTG 17
|||||:|||||:|
1 AGGACAAGGCTCTGTG 17

RESULT 246
ADL48265
ID ADL48265 standard; RNA; 17 BP.
XX
XX AC ADL48265;
XX
XX DT 20-MAY-2004 (first entry)
XX
```



```

DE XX Human IKK-gamma substrate sequence #775.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1798; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 2 C; 10 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 599 GGGGAGCTGCAGGAGAG 615
DB 1 GGGGAGCTGCAGGAGAG 17
|||||:|||||:|||||:
RESULT 247
ADL48269
ID ADL48269 standard; RNA; 17 BP.
XX
AC ADL48269;
XX
DT 20-MAY-2004 (first entry)
XX

DE XX Human IKK-gamma substrate sequence #779.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1802; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 5 C; 6 G; 0 T; 4 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.2e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 624 GCTTGGAGGCTGCCACT 640
DB 1 GCUUGAGGCGUCCACU 17
|||||:|||||:|||||:
RESULT 248
ADL48270
ID ADL48270 standard; RNA; 17 BP.
XX
AC ADL48270;
XX
DT 20-MAY-2004 (first entry)
XX

```

```
DE Human IKK-gamma substrate sequence #780.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
PR 29-MAY-2001; 2001US-0294412P.
PR
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1803; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 4 A; 4 C; 6 G; 0 T; 3 U; 0 Other;
SQ
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 627 TGAGGGTGCCTAAG 643
Db 1 UGGAGGCGGCACUAAG 17
:|||||:|||||
:|||||:|||||
RESULT 249
ADL48283
ID ADL48283 standard; RNA; 17 BP.
XX
XX ADL48283;
AC
XX
XX 20-MAY-2004 (first entry)
DT
XX
```

```
DE Human IKK-gamma substrate sequence #793.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
PR 29-MAY-2001; 2001US-0294412P.
PR
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1816; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 3 A; 3 C; 9 G; 0 T; 2 U; 0 Other;
SQ
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 697 GCTGGAGAGTGAGCGCG 713
Db 1 GCTGGAGAGTGAGCGCG 17
||:|||||:|||||
||:|||||:|||||
RESULT 250
ADL48295
ID ADL48295 standard; RNA; 17 BP.
XX
XX ADL48295;
AC
XX
XX 20-MAY-2004 (first entry)
DT
XX
```

DE Human IKK-gamma substrate sequence #805.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PS Claim 59; SEQ ID NO 1828; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 4 C; 8 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 735 GCCTGACGGTGACACG 751
 DB 1 GCUGCAGGUGGACACG 17
 RESULT 251
 ADL48320
 ID ADL48320 standard; RNA; 17 BP.
 XX
 AC ADL48320;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #830.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PS Claim 59; SEQ ID NO 1853; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 3 C; 9 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 885 AGAGCAGCGTGTGGGC 901
 DB 1 AGAGCAGCGTGTGGGC 17
 RESULT 252
 ADL48478
 ID ADL48478 standard; RNA; 17 BP.
 XX
 AC ADL48478;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #988.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

OS Unidentified.

XX WO200281628-A2.

PN 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

PR 29-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-059513/05.

DR Novel enzymatic nucleic acid that down-regulates expression of neurite

XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 1011; 317pp; English.

PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)

XX that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX Sequence 17 BP; 3 A; 3 C; 3 G; 0 T; 3 U; 0 Other;

SQ Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 2.2e+02;

Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 288 CTCCTGAGACCCCTCAG 304

DB 1 CUCCUGAGACCCUCCAG 17

RESULT 253

ADL48485

ID ADL48485 standard; RNA; 17 BP.

XX AC ADL48485;

XX AC ADL48485;

XX DT 20-MAY-2004 (first entry)

XX

DE Human IKK-gamma substrate sequence #995.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

OS Unidentified.

XX WO200281628-A2.

PN 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

PR 29-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-059513/05.

DR Novel enzymatic nucleic acid that down-regulates expression of neurite

XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 1018; 317pp; English.

PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)

XX that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX Sequence 17 BP; 6 A; 3 C; 5 G; 0 T; 3 U; 0 Other;

SQ Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 2.2e+02;

Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 478 GAAGCTCGATCTGAAGA 494

DB 1 GAAGCUCGACUUGAAGA 17

RESULT 254

ADL48583

ID ADL48583 standard; RNA; 17 BP.

XX AC ADL48583;

XX AC ADL48583;

XX DT 20-MAY-2004 (first entry)

XX

DE Human IKK-gamma substrate sequence #1093.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2116; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 3 C; 6 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 308 TGCCTGGAGGAGGAATCA 324
 :|||||:|||||:|||||:
 Db 1 UGCCUGGAGGAGGAUCA 17
 RESULT 255
 ADL48589
 ID ADL48589 standard; RNA; 17 BP.
 XX
 AC ADL48589;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1099.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2122; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 6 C; 5 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 337 TGCCATCCGGCAGAGCA 353
 :|||||:|||||:|||||:
 Db 1 UGCCAUCGCCGAGAGCA 17
 RESULT 256
 ADL48644
 ID ADL48644 standard; RNA; 17 BP.
 XX
 AC ADL48644;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

```
DE Human IKK-gamma substrate sequence #1154.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX
XX
XX
XX
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX
XX Claim 59; SEQ ID NO 2177; 317pp; English.
XX
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX
XX Sequence 17 BP; 4 A; 6 C; 4 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
Qy 566 GCCTCTGTGAAGCCCA 582
Db 1 GCCUCUGAAGCCCA 17
||||:|||||
1 GCCUCUGAAGCCCA 17
RESULT 257
ADL48654
ID ADL48654 standard; RNA; 17 BP.
XX
XX AC ADL48654;
XX
XX DT 20-MAY-2004 (first entry)
XX
```

```
DE Human IKK-gamma substrate sequence #1164.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX
XX
XX
XX
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX
XX Claim 59; SEQ ID NO 2187; 317pp; English.
XX
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX
XX Sequence 17 BP; 4 A; 4 C; 6 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
Qy 611 GAGAGCCAGAGTCGCTT 627
Db 1 GAGAGCCAGAGTCGCUU 17
||||:|||||
1 GAGAGCCAGAGTCGCUU 17
RESULT 258
ADL48686
ID ADL48686 standard; RNA; 17 BP.
XX
XX AC ADL48686;
XX
XX DT 20-MAY-2004 (first entry)
XX
```

DE	Human IKK-gamma substrate sequence #1196.	DE	Human IKK-gamma substrate sequence #1209.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX	substrate; ds.	XX	substrate; ds.
OS	Unidentified.	OS	Unidentified.
XX		XX	
PN	WO200281628-A2.	PN	WO200281628-A2.
XX		XX	
PD	17-OCT-2002.	PD	17-OCT-2002.
XX		XX	
PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.
XX		XX	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
PA	(RIBO-) RIBOZYME PHARM INC.	PA	(RIBO-) RIBOZYME PHARM INC.
XX		XX	
PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX		XX	
DR	WPI; 2003-058513/05.	DR	WPI; 2003-058513/05.
XX		XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
PS	Claim 59; SEQ ID NO 2219; 317pp; English.	PS	Claim 59; SEQ ID NO 2232; 317pp; English.
XX		XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.	CC	gamma substrate sequence.
XX		XX	
SQ	Sequence 17 BP; 3 A; 4 C; 9 G; 0 T; 1 U; 0 Other;	SQ	Sequence 17 BP; 4 A; 4 C; 6 G; 0 T; 3 U; 0 Other;
<p>Query Match 2.3%; Score 17; DB 1; Length 17; Best Local Similarity 94.1%; Pred. No. 2.2e+02; Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;</p>			
QY	768 AGAGCGTGAGGCGCG 784	QY	821 AGGAAGCTGGCCAGTT 837
DB	1 AGAGCGTGAGGCGCG 17	DB	1 AGGAAGCTGGCCAGTT 17
<p>RESULT 259 ADL48699 ID ADL48699 standard; RNA; 17 BP. XX AC ADL48699; XX DT 20-MAY-2004 (first entry) XX</p>			
<p>RESULT 260 ADL47559 ID ADL47559 standard; RNA; 17 BP. XX AC ADL47559; XX DT 20-MAY-2004 (first entry) XX</p>			


```

DE Human IKK-gamma substrate sequence #69.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
OS
XX WO200281628-A2.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
PF
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
PR
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1092; 317pp; English.
PS
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 8 A; 5 C; 3 G; 0 T; 1 U; 0 Other;
SQ
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 875 AACCAATCAGAGCAG 891
DB 1 AACCAATCAGAGCAG 17
|||||:|||||
|||||:|||||

RESULT 261
ADL47761
ID ADL47761 standard; RNA; 17 BP.
XX
XX ADL47761;
AC
XX 20-MAY-2004 (first entry)
DT
XX

DE Human IKK-gamma substrate sequence #271.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
OS
XX WO200281628-A2.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
PF
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
PR
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1294; 317pp; English.
PS
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 5 A; 7 C; 2 G; 0 T; 3 U; 0 Other;
SQ
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 266 CACCTGCCTTCAGAAC 282
DB 1 CACCTGCCTTCAGAAC 17
|||||:|||||
|||||:|||||

RESULT 262
ADL47781
ID ADL47781 standard; RNA; 17 BP.
XX
XX ADL47781;
AC
XX 20-MAY-2004 (first entry)
DT
XX

```


DE Human IKK-gamma substrate sequence #291.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1314; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 7 C; 4 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 340 CATCCGCGAGAGCAACC 356
 Db 1 CAUCCGCGAGAGCAACC 17
 RESULT 263
 ADL47782
 ID ADL47782 standard; RNA; 17 BP.
 XX
 AC ADL47782;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #292.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1315; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 6 A; 4 C; 5 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 345 GCGAGAGCAACCAAGATT 361
 Db 1 GCGAGAGCAACCAAGAUU 17
 RESULT 264
 ADL47785
 ID ADL47785 standard; RNA; 17 BP.
 XX
 AC ADL47785;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE	Human IKK-gamma substrate sequence #295.	DE	Human IKK-gamma substrate sequence #325.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	XX	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX	protein kinase PKR; cerebrovascular accident;	XX	protein kinase PKR; cerebrovascular accident;
XX	central nervous system injury; CNS injury; spinal cord injury; cancer;	XX	central nervous system injury; CNS injury; spinal cord injury; cancer;
XX	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	XX	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX	restenosis; asthma; Crohn's disease; diabetes; obesity;	XX	restenosis; asthma; Crohn's disease; diabetes; obesity;
XX	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	XX	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	XX	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	XX	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX	substrate; ds.	XX	substrate; ds.
XX	Unidentified.	XX	Unidentified.
XX	WO200281628-A2.	XX	WO200281628-A2.
XX	17-OCT-2002.	XX	17-OCT-2002.
XX	03-APR-2002; 2002WO-US010512.	XX	03-APR-2002; 2002WO-US010512.
XX	05-APR-2001; 2001US-00827395.	XX	05-APR-2001; 2001US-00827395.
XX	29-MAY-2001; 2001US-0294412P.	XX	29-MAY-2001; 2001US-0294412P.
XX	28-AUG-2001; 2001US-0315315P.	XX	28-AUG-2001; 2001US-0315315P.
XX	(RIBO-) RIBOZYME PHARM INC.	XX	(RIBO-) RIBOZYME PHARM INC.
XX	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;	XX	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX	WPI; 2003-058513/05.	XX	WPI; 2003-058513/05.
XX	Novel enzymatic nucleic acid that down-regulates expression of neurite	XX	Novel enzymatic nucleic acid that down-regulates expression of neurite
XX	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	XX	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX	protein kinase PKR genes, for treating cancer and inflammatory disease.	XX	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX	Claim 59; SEQ ID NO 1318; 317pp; English.	XX	Claim 59; SEQ ID NO 1348; 317pp; English.
XX	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	XX	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX	that down regulate the expression or inhibit the function of a receptor	XX	that down regulate the expression or inhibit the function of a receptor
XX	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	XX	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX	IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the	XX	IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
XX	invention are useful for treating: cerebrovascular accident, central	XX	invention are useful for treating: cerebrovascular accident, central
XX	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	XX	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	XX	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	XX	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX	disease, lupus, multiple sclerosis, transplant/graft rejection,	XX	disease, lupus, multiple sclerosis, transplant/graft rejection,
XX	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	XX	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	XX	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX	nucleic acids of the invention are also useful for down-regulating the	XX	nucleic acids of the invention are also useful for down-regulating the
XX	expression of a target gene and as a diagnostic tool to examine genetic	XX	expression of a target gene and as a diagnostic tool to examine genetic
XX	drifts and mutations within diseased cells or to detect the presence of a	XX	drifts and mutations within diseased cells or to detect the presence of a
XX	target RNA in a cell. The present RNA sequence represents a human IKK-	XX	target RNA in a cell. The present RNA sequence represents a human IKK-
XX	gamma substrate sequence.	XX	gamma substrate sequence.
XX	Sequence 17 BP; 3 A; 5 C; 6 G; 0 T; 3 U; 0 Other;	XX	Sequence 17 BP; 3 A; 5 C; 6 G; 0 T; 3 U; 0 Other;
QY	Query Match 2.3%; Score 17; DB 1; Length 17;	QY	Query Match 2.3%; Score 17; DB 1; Length 17;
DB	Best Local Similarity 82.4%; Pred. No. 2.2e+02;	DB	Best Local Similarity 88.2%; Pred. No. 2.2e+02;
	Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY	355 CCAGATTCTCGGGAGC 371	QY	522 TGAGCACCTGAAGAGA 538
DB	1 CCAGAUUUCGGGGAGC 17	DB	1 UGGAGCACCUAGAGA 17
RESULT 265		RESULT 266	
ADL47815		ADL47825	
ID	ADL47815 standard; RNA; 17 BP.	ID	ADL47825 standard; RNA; 17 BP.
XX	ADL47815;	XX	ADL47825;
XX	20-MAY-2004 (first entry)	XX	20-MAY-2004 (first entry)
DT		DT	
XX		XX	

```

DE Human IKK-gamma substrate sequence #335.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeblerli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1358; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 5 A; 4 C; 5 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 563 AAGGCCTCTGTGAAGC 579
DB 1 AAGGCCUCUGAAGC 17
|||||:|:|:|:|:|:|
1:|||||:|:|:|:|:|:|

RESULT 267
ADL47829
ID ADL47829 standard; RNA; 17 BP.
XX
AC ADL47829;
XX
XX 20-MAY-2004 (first entry)
DT
XX

DE Human IKK-gamma substrate sequence #339.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeblerli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1362; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 1 A; 5 C; 6 G; 0 T; 5 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.2e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 584 GTGACGTCCTTGCTCGG 600
DB 1 GUGACGUCUUGCUCGG 17
|||||:|:|:|:|:|:|
1:|||||:|:|:|:|:|:|

RESULT 268
ADL47838
ID ADL47838 standard; RNA; 17 BP.
XX
AC ADL47838;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

```
DE Human IKK-gamma substrate sequence #348.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX OS Unidentified.
XX
XX PN WO200281628-A2.
XX
XX PD 17-OCT-2002.
XX
XX PF 03-APR-2002; 2002WO-US010512.
XX
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX PS Claim 59; SEQ ID NO 1371; 317pp; English.
XX
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 5 A; 4 C; 6 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 629 GAGGCTGCCTACCTAAGGA 645
DB 1 GAGGCTGCCTACCTAAGGA 17
RESULT 269
ADL47848
ID ADL47848 standard; RNA; 17 BP.
XX
XX AC ADL47848;
XX
XX DT 20-MAY-2004 (first entry)
XX
DE Human IKK-gamma substrate sequence #358.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX OS Unidentified.
XX
XX PN WO200281628-A2.
XX
XX PD 17-OCT-2002.
XX
XX PF 03-APR-2002; 2002WO-US010512.
XX
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX PS Claim 59; SEQ ID NO 1381; 317pp; English.
XX
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 3 A; 5 C; 9 G; 0 T; 0 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 672 GGGCGGCCGACGAGCAG 688
DB 1 GGGCGGCCGACGAGCAG 17
RESULT 270
ADL47853
ID ADL47853 standard; RNA; 17 BP.
XX
XX AC ADL47853;
XX
XX DT 20-MAY-2004 (first entry)
XX
```

DE Human IKK-gamma substrate sequence #363.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite.
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1386; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 6 C; 7 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 715 GGCGTGCAGCAGCAGC 731
 DB 1 GGCGTGCAGCAGCAGC 17
 RESULT 271
 ADL47856
 ID ADL47856 standard; RNA; 17 BP.
 XX
 AC ADL47856;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #366.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite.
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1389; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 6 C; 6 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 724 GCAGCAGCAGCAGCAGC 740
 DB 1 GCAGCAGCAGCAGCAGC 17
 RESULT 272
 ADL47868
 ID ADL47868 standard; RNA; 17 BP.
 XX
 AC ADL47868;
 XX
 DT 20-MAY-2004 (first entry)
 XX

```

DE XX Human IKK-gamma substrate sequence #378.
KW antisenase oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX 29-MAY-2001; 2001US-0294412P.
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1401; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX Sequence 17 BP; 2 A; 7 C; 6 G; 0 T; 2 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 780 CCGCGCTCCGATGGAG 796
Db 1 CCGCGCTCCGATGGAG 17

RESULT 273
ADL47888
ID ADL47888 standard; RNA; 17 BP.
XX
XX AC ADL47888;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE XX Human IKK-gamma substrate sequence #398.
KW antisenase oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX 29-MAY-2001; 2001US-0294412P.
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1421; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX Sequence 17 BP; 5 A; 5 C; 3 G; 0 T; 4 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.2e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 856 GCTCTTCCAGATACG 872
Db 1 GCUCUCCAGAAUACG 17

RESULT 274
ADL48235
ID ADL48235 standard; RNA; 17 BP.
XX
XX AC ADL48235;
XX
XX DT 20-MAY-2004 (first entry)
XX

```

```

DE Human IKK-gamma substrate sequence #745.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1768; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 4 C; 9 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 367 GGAGCGCTGCGAGGAGC 383
Db 1 GGAGCGCGGAGGAGC 17
|||||:|||||
1 GGAGCGCGGAGGAGC 17

RESULT 275
ADL48237
ID ADL48237 standard; RNA; 17 BP.
XX
AC ADL48237;
XX
DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #747.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1770; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 5 C; 3 G; 0 T; 6 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.2e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 380 GAGCTTCGCAATTCCA 396
Db 1 GAGCUUCUGCAUUGCA 17
|||||:|||||
1 GAGCUUCUGCAUUGCA 17

RESULT 276
ADL48244
ID ADL48244 standard; RNA; 17 BP.
XX
AC ADL48244;
XX
DT 20-MAY-2004 (first entry)
XX

```



```
DE XX Human IKK-gamma substrate sequence #754.
KW antisenase oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX OS Unidentified.
XX PN WO200281628-A2.
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX Claim 59; SEQ ID NO 1777; 317pp; English.
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX SQ Sequence 17 BP; 6 A; 4 C; 6 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 438 TCCAGGAGGCCGAGAAA 454
Db 1 UCCAGGAGGCCGAGAAA 17
RESULT 277
ADL48259
ID ADL48259 standard; RNA; 17 BP.
XX AC ADL48259;
XX XX 20-MAY-2004 (first entry)
XX DT
XX
```

```
DE XX Human IKK-gamma substrate sequence #769.
KW antisenase oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX OS Unidentified.
XX PN WO200281628-A2.
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX Claim 59; SEQ ID NO 1792; 317pp; English.
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX SQ Sequence 17 BP; 4 A; 5 C; 5 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 564 AGGCCTCTGTGAAAGCC 580
Db 1 AGGCCUCUGUGAAGCC 17
RESULT 278
ADL48271
ID ADL48271 standard; RNA; 17 BP.
XX AC ADL48271;
XX XX 20-MAY-2004 (first entry)
XX DT
XX
```


DE	Human IKK-gamma substrate sequence #781.	DE	Human IKK-gamma substrate sequence #832.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW	substrate; ds.	KW	substrate; ds.
OS	Unidentified.	OS	Unidentified.
XX		XX	
PN	WO200281628-A2.	PN	WO200281628-A2.
XX		XX	
PD	17-OCT-2002.	PD	17-OCT-2002.
XX		XX	
PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.
XX		XX	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
PA	(RIBO-) RIBOZYME PHARM INC.	PA	(RIBO-) RIBOZYME PHARM INC.
XX		XX	
PI	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX		XX	
DR	WPI; 2003-058513/05.	DR	WPI; 2003-058513/05.
XX		XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
PS	Claim 59; SEQ ID NO 1804; 317pp; English.	PS	Claim 59; SEQ ID NO 1855; 317pp; English.
XX		XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.	CC	gamma substrate sequence.
XX		XX	
SQ	Sequence 17 BP; 5 A; 4 C; 5 G; 0 T; 3 U; 0 Other;	SQ	Sequence 17 BP; 2 A; 3 C; 9 G; 0 T; 3 U; 0 Other;
	Query Match 2.3%; Score 17; DB 1; Length 17;		Query Match 2.3%; Score 17; DB 1; Length 17;
	Best Local Similarity 82.4%; Pred. No. 2.2e+02;		Best Local Similarity 82.4%; Pred. No. 2.2e+02;
	Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;		Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY	640 TTAGGAATGCCAGGCTC 656	QY	892 COTGTGGCGAGTGAGC 908
	: :		: :
DB	1 UAAGGAATGCCAGGCTC 17	DB	1 CGUGGUGGCGAGGAGC 17
RESULT 279		RESULT 280	
ADL48322		ADL48474	
ID	ADL48322 standard; RNA; 17 BP.	ID	ADL48474 standard; RNA; 17 BP.
XX		XX	
AC	ADL48322;	AC	ADL48474;
XX		XX	
DT	20-MAY-2004 (first entry)	DT	20-MAY-2004 (first entry)
XX		XX	

DE	Human IKK-gamma substrate sequence #984.	XX
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX
XX	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	XX
XX	protein kinase PKR; cerebrovascular accident;	XX
XX	central nervous system injury; CNS injury; spinal cord injury; cancer;	XX
XX	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	XX
XX	restenosis; asthma; Crohn's disease; diabetes; obesity;	XX
XX	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	XX
XX	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	XX
XX	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	XX
XX	substrate; ds.	XX
XX	Unidentified.	XX
XX	WO200281628-A2.	XX
XX	17-OCT-2002.	XX
XX	03-APR-2002; 2002WO-US010512.	XX
XX	05-APR-2001; 2001US-00827395.	XX
XX	29-MAY-2001; 2001US-0294412P.	XX
XX	28-AUG-2001; 2001US-0315315P.	XX
XX	(RIBO-) RIBOZYME PHARM INC.	XX
XX	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;	XX
XX	WPI; 2003-058513/05.	XX
XX	Novel enzymatic nucleic acid that down-regulates expression of neurite	XX
XX	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	XX
XX	protein kinase PKR genes, for treating cancer and inflammatory disease.	XX
XX	Claim 59; SEQ ID NO 2007; 317pp; English.	XX
XX	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	XX
XX	that down regulate the expression or inhibit the function of a receptor	XX
XX	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	XX
XX	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	XX
XX	invention are useful for treating: cerebrovascular accident, central	XX
XX	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	XX
XX	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	XX
XX	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	XX
XX	disease, lupus, multiple sclerosis, transplant/graft rejection,	XX
XX	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	XX
XX	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	XX
XX	nucleic acids of the invention are also useful for down-regulating the	XX
XX	expression of a target gene and as a diagnostic tool to examine genetic	XX
XX	drifts and mutations within diseased cells or to detect the presence of a	XX
XX	target RNA in a cell. The present RNA sequence represents a human IKK-	XX
XX	gamma substrate sequence.	XX
XX	Sequence 17 BP; 3 A; 1 C; 8 G; 0 T; 5 U; 0 Other;	XX
XX	Query Match 2.3%; Score 17; DB 1; Length 17;	XX
XX	Best Local Similarity 70.6%; Pred. No. 2.2e+02;	XX
XX	Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;	XX
QY	177 TGTGTGAGTGTGGCAG 193	QY
DB	1 UGUGUGAGUGGUGGAG 17	DB
RESULT 281		RESULT 282
ADL48565		ADL48601
ID ADL48565 standard; RNA; 17 BP.		ID ADL48601 standard; RNA; 17 BP.
XX ADL48565;		XX ADL48601;
XX ADL48565;		XX ADL48601;
XX 20-MAY-2004 (first entry)		XX 20-MAY-2004 (first entry)
XX		XX

```

DE XX Human IKK-gamma substrate sequence #1111.
KW antisenase oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX 17-OCT-2002.
XX PD
XX
XX 03-APR-2002; 2002WO-US010512.
XX PF
XX 05-APR-2001; 2001US-00827395.
XX PR
XX 29-MAY-2001; 2001US-0294412P.
XX PR
XX 28-AUG-2001; 2001US-0315315P.
XX PR
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX
XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX PI
XX WPI; 2003-058513/05.
XX DR
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PT
XX Claim 59; SEQ ID NO 2134; 317pp; English.
XX PS
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX CC that down regulate the expression or inhibit the function of a receptor
XX CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
XX CC invention are useful for treating: cerebrovascular accident, central
XX CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX CC disease, lupus, multiple sclerosis, transplant/graft rejection,
XX CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX CC nucleic acids of the invention are also useful for down-regulating the
XX CC expression of a target gene and as a diagnostic tool to examine genetic
XX CC drifts and mutations within diseased cells or to detect the presence of a
XX CC target RNA in a cell. The present RNA sequence represents a human IKK-
XX CC gamma substrate sequence.
XX
XX Query Match 2.3%; Score 17; DB 1; Length 17;
XX Best Local Similarity 100.0%; Pred. No. 2.2e+02;
XX Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 402 GCCAGAGGAGGAGGAG 418
DB 1 GCCAGAGGAGGAGGAG 17
:::|||||
1 GCCAGAGGAGGAGGAG 17

RESULT 283
ADL48609
ID ADL48609 standard; RNA; 17 BP.
XX
XX AC ADL48609;
XX
XX 20-MAY-2004 (first entry)
XX DT
XX

```

```

DE XX Human IKK-gamma substrate sequence #1119.
XX antisenase oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX 17-OCT-2002.
XX PD
XX
XX 03-APR-2002; 2002WO-US010512.
XX PF
XX 05-APR-2001; 2001US-00827395.
XX PR
XX 29-MAY-2001; 2001US-0294412P.
XX PR
XX 28-AUG-2001; 2001US-0315315P.
XX PR
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX
XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX PI
XX WPI; 2003-058513/05.
XX DR
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PT
XX Claim 59; SEQ ID NO 2142; 317pp; English.
XX PS
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX CC that down regulate the expression or inhibit the function of a receptor
XX CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
XX CC invention are useful for treating: cerebrovascular accident, central
XX CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX CC disease, lupus, multiple sclerosis, transplant/graft rejection,
XX CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX CC nucleic acids of the invention are also useful for down-regulating the
XX CC expression of a target gene and as a diagnostic tool to examine genetic
XX CC drifts and mutations within diseased cells or to detect the presence of a
XX CC target RNA in a cell. The present RNA sequence represents a human IKK-
XX CC gamma substrate sequence.
XX
XX Query Match 2.3%; Score 17; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 2.2e+02;
XX Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 437 TTCCAGGAGGCCAGGAA 453
DB 1 UUCCAGGAGGCCAGGAA 17
:::|||||
1 UUCCAGGAGGCCAGGAA 17

RESULT 284
ADL48620
ID ADL48620 standard; RNA; 17 BP.
XX
XX AC ADL48620;
XX
XX 20-MAY-2004 (first entry)
XX DT
XX

```

DE Human IKK-gamma substrate sequence #1130.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS Unidentified.
 XX WO200281628-A2.
 PN 17-OCT-2002.
 XX 03-APR-2002; 2002WO-US010512.
 PF 05-APR-2001; 2001US-00827395.
 XX 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI WPI; 2003-058513/05.
 DR Novel enzymatic nucleic acid that down-regulates expression of neurite
 XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT Claim 59; SEQ ID NO 2153; 317pp; English.
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;
 SQ Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 470 GGCCCTGGAGAGCTCGA 486
 Db 1 GGCCUGGAGAGCUCGA 17
 RESULT 285
 ADL48623
 ID ADL48623 standard; RNA; 17 BP.
 XX AC ADL48623;
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1133.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS Unidentified.
 XX WO200281628-A2.
 PN 17-OCT-2002.
 XX 03-APR-2002; 2002WO-US010512.
 PF 05-APR-2001; 2001US-00827395.
 XX 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI WPI; 2003-058513/05.
 DR Novel enzymatic nucleic acid that down-regulates expression of neurite
 XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT Claim 59; SEQ ID NO 2156; 317pp; English.
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX Sequence 17 BP; 7 A; 2 C; 6 G; 0 T; 2 U; 0 Other;
 SQ Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 485 GATCTGAGAGGCGAGAA 501
 Db 1 GAUCUGAAGAGGCGAGAA 17
 RESULT 286
 ADL48639
 ID ADL48639 standard; RNA; 17 BP.
 XX AC ADL48639;
 XX 20-MAY-2004 (first entry)
 DT
 XX

```

DE XX Human IKK-gamma substrate sequence #1149.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2172; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 5 A; 3 C; 7 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 545 CAGCAGATCGCTGAGGA 561
DB 1 CAGCAGUGGUGAGGA 17
|||||:|||||
1 CAGCAGUGGUGAGGA 17

RESULT 287
ADL48640
ID ADL48640 standard; RNA; 17 BP.
XX
AC ADL48640;
XX
DT 20-MAY-2004 (first entry)
XX

DE XX Human IKK-gamma substrate sequence #1150.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2173; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 6 A; 2 C; 7 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 549 AGATCGCTGAGGACAAG 565
DB 1 AGAUGGUGGUGAGGA 17
|||||:|||||
1 AGAUGGUGGUGAGGA 17

RESULT 288
ADL48650
ID ADL48650 standard; RNA; 17 BP.
XX
AC ADL48650;
XX
DT 20-MAY-2004 (first entry)
XX

```

DE Human IKK-gamma substrate sequence #1160.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS

XX WO200281628-A2.

XX 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

XX 29-MAY-2001; 2001US-0294412P.

XX 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 2183; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX

SQ Sequence 17 BP; 2 A; 4 C; 8 G; 0 T; 3 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 2.2e+02;

Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 594 TGCTGGGGAGCTGCAG 610

Db 1 UGCUCCGGGAGCUGCAG 17

RESULT 289

ADL48672

ID ADL48672 standard; RNA; 17 BP.

XX AC ADL48672;

XX 20-MAY-2004 (first entry)

XX

DE Human IKK-gamma substrate sequence #1182.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS

XX WO200281628-A2.

XX 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

XX 29-MAY-2001; 2001US-0294412P.

XX 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 2205; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX

SQ Sequence 17 BP; 2 A; 5 C; 9 G; 0 T; 1 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 94.1%; Pred. No. 2.2e+02;

Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 685 GCAGGCGCGCAGCTCG 701

Db 1 GCAGGCGCGCAGCUG 17

RESULT 290

ADL48703

ID ADL48703 standard; RNA; 17 BP.

XX AC ADL48703;

XX 20-MAY-2004 (first entry)

XX

DE Human IKK-gamma substrate sequence #1213.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 PI Blatt L, Chowrira B, Haeberli P, McSwiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2236; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 9 A; 5 C; 2 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 864 AAGAATACGACCAACCAC 880
 DB 1 AAGAAUACGACCAACCAC 17
 |||||:|||||
 |||||:|||||
 RESULT 291
 ADL47513
 ID ADL47513 standard; RNA; 17 BP.
 XX
 AC ADL47513;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #23.
 XX
 KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 PI Blatt L, Chowrira B, Haeberli P, McSwiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1046; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 6 A; 4 C; 5 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 210 CAGCAGATCAGGACGTA 226
 DB 1 CAGCAGAUCCAGGACGUA 17
 |||||:|||||
 |||||:|||||
 RESULT 292
 ADL47517
 ID ADL47517 standard; RNA; 17 BP.
 XX
 AC ADL47517;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX


```
DE Human IKK-gamma substrate sequence #27.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1050; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 3 A; 4 C; 6 G; 0 T; 4 U; 0 Other;
SQ Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.2e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 237 AGTCTCTCTGGGGAAG 253
Db 1 AGUCUCCUCUGGGGAAG 17
RESULT 293
ADL47542
ID ADL47542 standard; RNA; 17 BP.
XX
XX AC ADL47542;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #52.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1075; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 1 A; 5 C; 6 G; 0 T; 5 U; 0 Other;
SQ Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.8%; Pred. No. 2.2e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY 583 GGTGACGTCCTGCTCG 599
Db 1 GGUGACGUCCUUCUG 17
RESULT 294
ADL47544
ID ADL47544 standard; RNA; 17 BP.
XX
XX AC ADL47544;
XX
XX DT 20-MAY-2004 (first entry)
XX
```



```

DE XX Human IKK-gamma substrate sequence #54.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1077; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 1 A; 5 C; 6 G; 0 T; 5 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.2e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 590 TCCTTCTCGGGAGCT 606
Db 1 UCCUUGCUGGGAGCU 17
:||||:|||||:|

RESULT 295
ADL47546
ID ADL47546 standard; RNA; 17 BP.
XX
XX AC ADL47546;
XX
XX DT 20-MAY-2004 (first entry)
XX

```

```

DE XX Human IKK-gamma substrate sequence #56.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1079; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 3 C; 8 G; 0 T; 4 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.2e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 619 GAGTCGCTGGAGCTG 635
Db 1 GAGUGCGUGGAGGCG 17
:||||:|||||:|

RESULT 296
ADL47550
ID ADL47550 standard; RNA; 17 BP.
XX
XX AC ADL47550;
XX
XX DT 20-MAY-2004 (first entry)
XX

```

```
DE Human IKK-gamma substrate sequence #60.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1083; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX Sequence 17 BP; 2 A; 7 C; 6 G; 0 T; 2 U; 0 Other;
XX
XX Query Match 2.3%; Score 17; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 2.2e+02;
XX Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 779 GCCGGCTCCGATCGGA 795
XX |||||:||||:||||
XX Db 1 GCCGGCTCCGCAUGGA 17
XX
XX RESULT 297
XX ADL47740
XX ID ADL47740 standard; RNA; 17 BP.
XX
XX AC ADL47740;
XX
XX XX
XX DT 20-MAY-2004 (first entry)
XX
XX
```

```
DE Human IKK-gamma substrate sequence #250.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1273; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX Sequence 17 BP; 2 A; 4 C; 8 G; 0 T; 3 U; 0 Other;
XX
XX Query Match 2.3%; Score 17; DB 1; Length 17;
XX Best Local Similarity 82.4%; Pred. No. 2.2e+02;
XX Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 188 GTCGAGCCGAGTGGTGG 204
XX |:|||||:||||:||||
XX Db 1 GUGCAGCCCGAGUGGUG 17
XX
XX RESULT 298
XX ADL47741
XX ID ADL47741 standard; RNA; 17 BP.
XX
XX AC ADL47741;
XX
XX XX
XX DT 20-MAY-2004 (first entry)
XX
```


DE Human IKK-gamma substrate sequence #282.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1305; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 6 C; 6 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
Qy 300 TCCAGCGCTGCTGGAG 316
:|||||:|||||:
Db 1 UCCAGCGCTGCTGGAG 17
RESULT 301
ADL47802
ID ADL47802 standard; RNA; 17 BP.
XX
AC ADL47802;
XX
DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #312.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1335; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 6 A; 4 C; 6 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Qy 440 CAGGAGCCAGGAACT 456
:|||||:|||||:
Db 1 CAGGAGCCAGGAACT 17
RESULT 302
ADL47824
ID ADL47824 standard; RNA; 17 BP.
XX
AC ADL47824;
XX
DT 20-MAY-2004 (first entry)
XX


```
DE Human IKK-gamma substrate sequence #362.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX OS Unidentified.
XX
XX PN WO200281628-A2.
XX
XX PD 17-OCT-2002.
XX
XX PF 03-APR-2002; 2002WO-US010512.
XX
XX PR 05-APR-2001; 2001US-00827395.
XX
XX PR 29-MAY-2001; 2001US-0294412P.
XX
XX PR 28-AUG-2001; 2001US-0315315P.
XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX DR WPI; 2003-058513/05.
XX
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX PS Claim 59; SEQ ID NO 1385; 317pp; English.
XX
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 3 A; 6 C; 7 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 712 CGAGGCGTGCAGCAGC 728
DB 1 CGAGGCGTGCAGCAGC 17
RESULT 305
ADL47861
ID ADL47861 standard; RNA; 17 BP.
XX
XX AC ADL47861;
XX
XX DT 20-MAY-2004 (first entry)
XX
DE Human IKK-gamma substrate sequence #371.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX OS Unidentified.
XX
XX PN WO200281628-A2.
XX
XX PD 17-OCT-2002.
XX
XX PF 03-APR-2002; 2002WO-US010512.
XX
XX PR 05-APR-2001; 2001US-00827395.
XX
XX PR 29-MAY-2001; 2001US-0294412P.
XX
XX PR 28-AUG-2001; 2001US-0315315P.
XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX DR WPI; 2003-058513/05.
XX
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX PS Claim 59; SEQ ID NO 1394; 317pp; English.
XX
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 3 A; 6 C; 6 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 745 GGACCAAGCTCGCATGC 761
DB 1 GGACCAAGCTCGCATGC 17
RESULT 306
ADL47863
ID ADL47863 standard; RNA; 17 BP.
XX
XX AC ADL47863;
XX
XX DT 20-MAY-2004 (first entry)
XX
```

```

DE XX Human IKK-gamma substrate sequence #373.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX PD 17-OCT-2002.
XX PF
XX PF 03-APR-2002; 2002WO-US010512.
XX PR
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX PS Claim 59; SEQ ID NO 1396; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX CC that down regulate the expression or inhibit the function of a receptor
XX CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
XX CC invention are useful for treating: cerebrovascular accident, central
XX CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX CC disease, lupus, multiple sclerosis, transplant/graft rejection,
XX CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX CC nucleic acids of the invention are also useful for down-regulating the
XX CC expression of a target gene and as a diagnostic tool to examine genetic
XX CC drifts and mutations within diseased cells or to detect the presence of a
XX CC target RNA in a cell. The present RNA sequence represents a human IKK-
XX CC gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 4 A; 5 C; 7 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 754 GCGCATGCGAGGCCGACA 770
DB 1 GCGCAUGCAGGCGCCAGA 17
|||||:|||||
1 GCGCAUGCAGGCGCCAGA 17

RESULT 307
ADL47874
ID ADL47874 standard; RNA; 17 BP.
XX
XX AC ADL47874;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE XX Human IKK-gamma substrate sequence #384.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX PD 17-OCT-2002.
XX PF
XX PF 03-APR-2002; 2002WO-US010512.
XX PR
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX PS Claim 59; SEQ ID NO 1407; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX CC that down regulate the expression or inhibit the function of a receptor
XX CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX CC invention are useful for treating: cerebrovascular accident, central
XX CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX CC disease, lupus, multiple sclerosis, transplant/graft rejection,
XX CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX CC nucleic acids of the invention are also useful for down-regulating the
XX CC expression of a target gene and as a diagnostic tool to examine genetic
XX CC drifts and mutations within diseased cells or to detect the presence of a
XX CC target RNA in a cell. The present RNA sequence represents a human IKK-
XX CC gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 3 A; 5 C; 8 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 801 AGGCGCGCTCGGAGGAG 817
DB 1 AGGCGCGCTCGGAGGAG 17
|||||:|||||
1 AGGCGCGCTCGGAGGAG 17

RESULT 308
ADL48209
ID ADL48209 standard; RNA; 17 BP.
XX
XX AC ADL48209;
XX
XX DT 20-MAY-2004 (first entry)
XX

```


DE Human IKK-gamma substrate sequence #719.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 XX WO200281628-A2.
 XX 17-OCT-2002.
 XX 03-APR-2002; 2002WO-US010512.
 XX 05-APR-2001; 2001US-00827395.
 XX 29-MAY-2001; 2001US-0294412P.
 XX 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX Claim 59; SEQ ID NO 1742; 317pp; English.
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX SQ Sequence 17 BP; 3 A; 4 C; 7 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 185 ATGTCAGCCAGTGG 201
 Db 1 AUGGUGCAGCCAGUGG 17
 RESULT 309
 ADL48228
 ID ADL48228 standard; RNA; 17 BP.
 XX AC ADL48228;
 XX 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #738.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 XX WO200281628-A2.
 XX 17-OCT-2002.
 XX 03-APR-2002; 2002WO-US010512.
 XX 05-APR-2001; 2001US-00827395.
 XX 29-MAY-2001; 2001US-0294412P.
 XX 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX Claim 59; SEQ ID NO 1761; 317pp; English.
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX SQ Sequence 17 BP; 7 A; 4 C; 4 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 320 AATCAAGAGCTCCGAGA 336
 Db 1 AAUCAAGAGCTCCGAGA 17
 RESULT 310
 ADL48247
 ID ADL48247 standard; RNA; 17 BP.
 XX AC ADL48247;
 XX 20-MAY-2004 (first entry)
 XX


```

DE Human IKK-gamma substrate sequence #757.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX PN WO200281628-A2.
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX PI Blatt L, Chowira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX PS Claim 59; SEQ ID NO 1780; 317pp; English.
XX
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 4 A; 4 C; 5 G; 0 T; 4 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred.No. 2.2e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 473 CTGAGAGAGCTCGATCT 489
DB 1 CUGGAGAGGCUCCAUUCU 17
|||||:|||||:|||||:
1 CUGGAGAGGCUCCAUUCU 17

RESULT 311
ADL48257
ID ADL48257 standard; RNA; 17 BP.
XX
XX AC ADL48257;
XX
XX DT 20-MAY-2004 (first entry)
XX

```

```

DE Human IKK-gamma substrate sequence #767.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX PN WO200281628-A2.
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX PI Blatt L, Chowira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX PS Claim 59; SEQ ID NO 1790; 317pp; English.
XX
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 5 A; 3 C; 7 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred.No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 546 AGCAGATGCGCTGAGGAC 562
DB 1 AGCAGAGUGGCGAGGAC 17
|||||:|||||:|||||:
1 AGCAGAGUGGCGAGGAC 17

RESULT 312
ADL48324
ID ADL48324 standard; RNA; 17 BP.
XX
XX AC ADL48324;
XX
XX DT 20-MAY-2004 (first entry)
XX

```

DE Human IKK-gamma substrate sequence #834.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS

XX WO200281628-A2.

PN

XX 17-OCT-2002.

PD

XX 03-APR-2002; 2002WO-US010512.

PF

XX 05-APR-2001; 2001US-00827395.

XX 29-MAY-2001; 2001US-0294412P.

PR

XX 28-AUG-2001; 2001US-0315315P.

PR

XX (RIBO-) RIBOZYME PHARM INC.

PA

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

PI

XX WPI; 2003-058513/05.

DR

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

PT

XX Claim 59; SEQ ID NO 1857; 317pp; English.

PS

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX

SQ Sequence 17 BP; 4 A; 3 C; 9 G; 0 T; 1 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 94.1%; Pred. No. 2.2e+02;

Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 899 GGCAGTGAGCGGAGCG 915

DB 1 GGCAGTGAGCGGAGCG 17

RESULT 313

ADL48563

ID ADL48563 standard; RNA; 17 BP.

XX

AC ADL48563;

XX

DT 20-MAY-2004 (first entry)

XX

DE Human IKK-gamma substrate sequence #1073.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS

XX WO200281628-A2.

PN

XX 17-OCT-2002.

PD

XX 03-APR-2002; 2002WO-US010512.

PF

XX 05-APR-2001; 2001US-00827395.

XX 29-MAY-2001; 2001US-0294412P.

PR

XX 28-AUG-2001; 2001US-0315315P.

PR

XX (RIBO-) RIBOZYME PHARM INC.

PA

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

PI

XX WPI; 2003-058513/05.

DR

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

PT

XX Claim 59; SEQ ID NO 2096; 317pp; English.

PS

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX

SQ Sequence 17 BP; 2 A; 6 C; 7 G; 0 T; 2 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.2e+02;

Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 195 CCAGTGGTGGCCCGGCA 211

DB 1 CCAGUGGUGGCCCGGCA 17

RESULT 314

ADL48579

ID ADL48579 standard; RNA; 17 BP.

XX

AC ADL48579;

XX

DT 20-MAY-2004 (first entry)

XX

DE Human IKK-gamma substrate sequence #1089.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 XX WO200281628-A2.
 PN
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR
 XX 23-MAY-2001; 2001US-0294412P.
 PR
 XX 28-AUG-2001; 2001US-0315315P.
 PR
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 XX Blatt L, Chowira B, Haerberli P, Meswiggen J, Fosnaugh K;
 PI
 XX
 DR WPI; 2003-058513/05.
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX
 PS Claim 59; SEQ ID NO 2112; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 8 C; 4 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred.No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 285 GCGCTCCTGAGACCCCTC 301
 Db 1 GCGCUCUGAGACCCUC 17
 RESULT 315
 ADL48585
 ID ADL48585 standard; RNA; 17 BP.
 XX
 AC ADL48585;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1095.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 XX WO200281628-A2.
 PN
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR
 XX 23-MAY-2001; 2001US-0294412P.
 PR
 XX 28-AUG-2001; 2001US-0315315P.
 PR
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 XX Blatt L, Chowira B, Haerberli P, Meswiggen J, Fosnaugh K;
 PI
 XX
 DR WPI; 2003-058513/05.
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX
 PS Claim 59; SEQ ID NO 2118; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 7 A; 2 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred.No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 311 CTGGAGGAGGAATCAAGA 327
 Db 1 CUGGAGGAGGAUCAAGA 17
 RESULT 316
 ADL48604
 ID ADL48604 standard; RNA; 17 BP.
 XX
 AC ADL48604;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

```
DE Human IKK-gamma substrate sequence #1114.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2137; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 6 A; 0 C; 9 G; 0 T; 2 U; 0 Other;
SQ Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 407 AGGAGGAGGAGGAGTT 423
Db 1 AGGAGGAGGAGGAGUU 17
|||||
1 AGGAGGAGGAGGAGUU 17

RESULT 317
ADL48607
ID ADL48607 standard; RNA; 17 BP.
XX
XX ADL48607;
XX
XX 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #1117.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2140; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 5 A; 4 C; 6 G; 0 T; 2 U; 0 Other;
SQ Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 434 AGTTCAGGAGGCCAG 450
Db 1 AAGUCCAGGAGGCCAG 17
|||||
1 AAGUCCAGGAGGCCAG 17

RESULT 318
ADL48613
ID ADL48613 standard; RNA; 17 BP.
XX
XX ADL48613;
XX
XX 20-MAY-2004 (first entry)
XX
```

DE Human IKK-gamma substrate sequence #1123.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 XX
 PD 17-OCT-2002.
 XX
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX
 PS Claim 59; SEQ ID NO 2146; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 6 A; 2 C; 6 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 OY 452 AAACUGGUGGAGAGACU 468
 DB 1 AAACUGGUGGAGAGACU 17
 |||:|||||:
 RESULT 319
 ID ADL48616
 XX ADL48616 standard; RNA; 17 BP.
 XX
 AC ADL48616;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1126.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 XX
 PD 17-OCT-2002.
 XX
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX
 PS Claim 59; SEQ ID NO 2149; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 4 C; 8 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 OY 457 GGTGGAGAGACTCGGCC 473
 DB 1 CGUGGAGAGACUCGCCC 17
 |||:|||||:
 RESULT 320
 ID ADL48621
 XX ADL48621 standard; RNA; 17 BP.
 XX
 AC ADL48621;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

```
DE Human IKK-gamma substrate sequence #1131.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX 17-OCT-2002.
XX PD
XX 03-APR-2002; 2002WO-US010512.
XX PF
XX 05-APR-2001; 2001US-00827395.
XX PR
XX 23-MAY-2001; 2001US-0294412P.
XX PR
XX 28-AUG-2001; 2001US-0315315P.
XX PR
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX PI
XX WPI; 2003-058513/05.
XX DR
XX
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PT
XX
XX PS Claim 59; SEQ ID NO 2154; 317pp; English.
XX PS
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX CC
XX SQ Sequence 17 BP; 6 A; 3 C; 5 G; 0 T; 3 U; 0 Other;
XX
XX Query Match 2.3%; Score 17; DB 1; Length 17;
XX Best Local Similarity 82.4%; Pred. No. 2.2e+02;
XX Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 477 AGAGCTCGATCTGAAG 493
XX Db 1 AAGAGCCGACUCGGAAG 17
XX
XX RESULT 321
XX ADL48622
XX ID ADL48622 standard; RNA; 17 BP.
XX AC
XX ADL48622;
XX XX
XX DT 20-MAY-2004 (first entry)
XX DT
XX
```

```
DE Human IKK-gamma substrate sequence #1132.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX 17-OCT-2002.
XX PD
XX 03-APR-2002; 2002WO-US010512.
XX PF
XX 05-APR-2001; 2001US-00827395.
XX PR
XX 23-MAY-2001; 2001US-0294412P.
XX PR
XX 28-AUG-2001; 2001US-0315315P.
XX PR
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX PI
XX WPI; 2003-058513/05.
XX DR
XX
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PT
XX
XX PS Claim 59; SEQ ID NO 2155; 317pp; English.
XX PS
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX CC
XX SQ Sequence 17 BP; 5 A; 4 C; 5 G; 0 T; 3 U; 0 Other;
XX
XX Query Match 2.3%; Score 17; DB 1; Length 17;
XX Best Local Similarity 82.4%; Pred. No. 2.2e+02;
XX Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 482 CTCGATCTGAAGAGGCA 498
XX Db 1 CUCGACUCGAGAGGCA 17
XX
XX RESULT 322
XX ADL48624
XX ID ADL48624 standard; RNA; 17 BP.
XX AC
XX ADL48624;
XX XX
XX DT 20-MAY-2004 (first entry)
XX DT
XX
```

```

DE Human IKK-gamma substrate sequence #1134.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
OS
XX WO200281628-A2.
PN
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
PF
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
PT
XX
XX Claim 59; SEQ ID NO 2157; 317pp; English.
PS
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 6 A; 2 C; 7 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 487 TCTGAGAGGAGGAGG 503
DB 1 UCUGAAGAGGAGGAGG 17
:|||||
:|||||

RESULT 323
ADL48627
ID ADL48627 standard; RNA; 17 BP.
XX
XX ADL48627;
AC
XX
XX 20-MAY-2004 (first entry)
DT
XX

DE Human IKK-gamma substrate sequence #1137.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
OS
XX WO200281628-A2.
PN
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
PF
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
PT
XX
XX Claim 59; SEQ ID NO 2160; 317pp; English.
PS
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 5 A; 3 C; 8 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 495 GGCAGAGGAGGAGGCT 511
DB 1 GGCAGAGGAGGAGGCT 17
:|||||
:|||||

RESULT 324
ADL48664
ID ADL48664 standard; RNA; 17 BP.
XX
XX ADL48664;
AC
XX
XX 20-MAY-2004 (first entry)
DT
XX

```


DE	Human IKK-gamma substrate sequence #1174.	
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	
XX	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	
KW	protein kinase PKR; cerebrovascular accident;	
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	
KW	substrate; ds.	
XX	Unidentified.	
OS	Unidentified.	
XX	WO200281628-A2.	
PN	17-OCT-2002.	
XX		
PD		
XX	03-APR-2002; 2002WO-US010512.	
PF		
XX	05-APR-2001; 2001US-00827395.	
PR	29-MAY-2001; 2001US-0294412P.	
PR	28-AUG-2001; 2001US-0315315P.	
XX		
XX	(RIBO-) RIBOZYME PHARM INC.	
PA		
XX	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;	
PI	WPI; 2003-058513/05.	
XX		
DR		
XX	Novel enzymatic nucleic acid that down-regulates expression of neurite	
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	
XX		
XX	Claim 59; SEQ ID NO 2197; 317pp; English.	
PS		
XX	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	
CC	that down regulate the expression or inhibit the function of a receptor	
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	
CC	IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the	
CC	invention are useful for treating: cerebrovascular accident, central	
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	
CC	nucleic acids of the invention are also useful for down-regulating the	
CC	expression of a target gene and as a diagnostic tool to examine genetic	
CC	drifts and mutations within diseased cells or to detect the presence of a	
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	
CC	gamma substrate sequence.	
XX		
XX	Sequence 17 BP; 1 A; 5 C; 8 G; 0 T; 3 U; 0 Other;	
SQ		
Query Match	2.3%; Score 17; DB 1; Length 17;	
Best Local Similarity	82.4%; Pred. No. 2.2e+02;	
Matches 14; Conservative	3; Mismatches 0; Indels 0; Gaps 0;	
QY	654 CTCCTGAGGGTGGGCC 670	
DB	1 CUCUGAGGGGCGGGCC 17	
RESULT 325		
ADL48668		
ID	ADL48668 standard; RNA; 17 BP.	
XX		
AC	ADL48668;	
XX		
XX	20-MAY-2004 (first entry)	
DT		
XX		

DE Human IKK-gamma substrate sequence #1179.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX 05-APR-2001; 2001US-00827395.
 PR
 PR 29-MAY-2001; 2001US-0294412P.
 PR
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2202; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 7 C; 8 G; 0 T; 0 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 668 GCCCGGGCGCGCAGCGA 684
 DB 1 GCCCGGGCGCGCAGCGA 17
 RESULT 327
 ADL48684
 ID ADL48684 standard; RNA; 17 BP.
 XX
 AC ADL48684;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1194.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX 05-APR-2001; 2001US-00827395.
 PR
 PR 29-MAY-2001; 2001US-0294412P.
 PR
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2217; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 4 C; 8 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 761 CAGGGCCAGCGTGA 777
 DB 1 CAGGGCCAGCGTGA 17
 RESULT 328
 ADL48697
 ID ADL48697 standard; RNA; 17 BP.
 XX
 AC ADL48697;
 XX
 DT 20-MAY-2004 (first entry)
 XX

```
DE Human IKK-gamma substrate sequence #1207.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
OS
XX
XX WO200281628-A2.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
PF
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX
XX 23-MAY-2001; 2001US-0294412P.
PR
XX
XX 28-AUG-2001; 2001US-0315315P.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
PT
XX
XX Claim 59; SEQ ID NO 2230; 317pp; English.
PS
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 6 A; 1 C; 9 G; 0 T; 1 U; 0 Other;
SQ Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 814 GGAGAGAGGAGCTGG 830
Db 1 GGAGAGAGGAGGCTGG 17
|||||:|||||:|

RESULT 329
ADL47523
ID ADL47523 standard; RNA; 17 BP.
XX
XX ADL47523;
AC
XX
XX 20-MAY-2004 (first entry)
DT
XX
```

```
DE Human IKK-gamma substrate sequence #33.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
OS
XX
XX WO200281628-A2.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
PF
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX
XX 23-MAY-2001; 2001US-0294412P.
PR
XX
XX 28-AUG-2001; 2001US-0315315P.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
PT
XX
XX Claim 59; SEQ ID NO 1056; 317pp; English.
PS
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 5 A; 5 C; 5 G; 0 T; 2 U; 0 Other;
SQ Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 323 CAAGAGCTCGAGATGC 339
Db 1 CAAGAGCTCGAGATGC 17
|||||:|||||:|

RESULT 330
ADL47739
ID ADL47739 standard; RNA; 17 BP.
XX
XX ADL47739;
AC
XX
XX 20-MAY-2004 (first entry)
DT
XX
```

DE Human IKK-gamma substrate sequence #249.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 growth inhibitor receptor, prostaglandin D2 receptor. IkappaB kinase or
 protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1272; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 4 C; 8 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 187 GTGCAGCCGAGTGGTG 203
 DB 1 GGUGACGCCAGUGGUG 17
 ||:|||||:|:|
 RESULT 331
 ADL47747
 ID ADL47747 standard; RNA; 17 BP.
 XX
 AC ADL47747;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #257.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 growth inhibitor receptor, prostaglandin D2 receptor. IkappaB kinase or
 protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1280; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 3 C; 8 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 220 GGACGCTACTGGCGAAG 236
 DB 1 GGACGACUGGCGGAAG 17
 |||||:|:|:|
 RESULT 332
 ADL47779
 ID ADL47779 standard; RNA; 17 BP.
 XX
 AC ADL47779;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #289.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 23-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1312; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 5 C; 6 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
OY 333 GAGATGCCATCCGCGAG 349
DB 1 GAGAUCCCAUCCGCGAG 17
|||||:|||||
1 GAGAUCCCAUCCGCGAG 17
RESULT 333
ADL47798
ID ADL47798 standard; RNA; 17 BP.
XX
XX AC ADL47798;
XX
XX 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #308.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 23-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1331; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 4 C; 4 G; 0 T; 5 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.2e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
OY 420 AGTTCTCTCATGTGCAAG 436
DB 1 AGUUCUCCAUUGUGCAAG 17
|||||:|||||
1 AGUUCUCCAUUGUGCAAG 17
RESULT 334
ADL47808
ID ADL47808 standard; RNA; 17 BP.
XX
XX AC ADL47808;
XX
XX 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #318.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1341; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 3 C; 6 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 475 GGAGAAGCTCGATCTGA 491
 Db 1 GGAGAAGCTCGAUCUGA 17
 RESULT 335
 ADL47827
 ID ADL47827 standard; RNA; 17 BP.
 XX
 AC ADL47827;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #337.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1360; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 4 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 573 TGAAGAGCCGAGTGACG 589
 Db 1 UGAAGAGCCGAGGUGACG 17
 RESULT 336
 ADL47844
 ID ADL47844 standard; RNA; 17 BP.
 XX
 AC ADL47844;
 XX
 DT 20-MAY-2004 (first entry)
 XX

```

DE XX Human IKK-gamma substrate sequence #354.
KW antisenase oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; ikappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1377; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX ikappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 2 A; 5 C; 7 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

OY 649 CCAGGCTCTCGAGGGTC 665
Db 1 CCAGGCUCUGAGGGUC 17
|||||:|||||:|
|:|||||:|:|

RESULT 337
ADL47884
ID ADL47884 standard; RNA; 17 BP.
XX
XX AC ADL47884;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE XX Human IKK-gamma substrate sequence #394.
KW antisenase oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; ikappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1417; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX ikappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 3 A; 8 C; 1 G; 0 T; 5 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.2e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

OY 847 CTATCACCCAGGCTTCC 863
Db 1 CUAUCACCCAGGCUUCC 17
|||||:|||||:|
|:|||||:|:|

RESULT 338
ADL47887
ID ADL47887 standard; RNA; 17 BP.
XX
XX AC ADL47887;
XX
XX DT 20-MAY-2004 (first entry)
XX

```

DE Human IKK-gamma substrate sequence #397.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1420; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 6 A; 5 C; 2 G; 0 T; 4 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred.No. 2.2e+02;
 Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 855 AGCTCTTCCAAGAAATAC 871
 DB 1 AGCTCTTCCAAGAAATAC 17
 RESULT 339
 ADL48221
 ID ADL48221 standard; RNA; 17 BP.
 XX
 AC ADL48221;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #731.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1754; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 8 C; 4 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred.No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 257 GCCATGCTGCACCTGCC 273
 DB 1 GCCAUGCUGCACCUGCC 17
 RESULT 340
 ADL48242
 ID ADL48242 standard; RNA; 17 BP.
 XX
 AC ADL48242;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #752.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 28-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1775; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 6 C; 3 G; 0 T; 5 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 70.6%; Pred. No. 2.2e+02;
 Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
 QY 424 CCTCATGTGCAAGTTCC 440
 Db 1 CCUCAUGGCAAGTUCC 17
 ||:||||:||||:
 RESULT 341
 ADL48243
 ID ADL48243 standard; RNA; 17 BP.
 XX
 AC ADL48243;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #753.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 28-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1776; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 3 C; 5 G; 0 T; 4 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 2.2e+02;
 Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 428 ATGTGCAAGTTCCAGGA 444
 Db 1 AUGUGCAAGUCCAGGA 17
 ||:||||:||||:
 RESULT 342
 ADL48246
 ID ADL48246 standard; RNA; 17 BP.
 XX
 AC ADL48246;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #756.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1779; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 463 GAGACTCGCGCTGGAGA 479
 Db 1 GAGACUCCGCCUGGAGA 17
 |||||:|||||:|||||
 1 GAGACUCCGCCUGGAGA 17
 RESULT 343
 ADL48267
 ID ADL48267 standard; RNA; 17 BP.
 XX
 AC ADL48267;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #777.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1800; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 4 C; 7 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 613 GAGCCAGAGTCGCTGG 629
 Db 1 GAGCCAGAGTCGCTGG 17
 |||||:|||||:|||||
 1 GAGCCAGAGTCGCTGG 17
 RESULT 344
 ADL48281
 ID ADL48281 standard; RNA; 17 BP.
 XX
 AC ADL48281;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #791.
 XX antisease oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 23-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1814; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 that down regulate the expression or inhibit the function of a receptor
 for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 invention are useful for treating: cerebrovascular accident, central
 nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 disease, lupus, multiple sclerosis, transplant/graft rejection,
 ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 nucleic acids of the invention are also useful for down-regulating the
 expression of a target gene and as a diagnostic tool to examine genetic
 drifts and mutations within diseased cells or to detect the presence of a
 target RNA in a cell. The present RNA sequence represents a human IKK-
 gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 5 C; 8 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 686 CAGGCGCGGAGCTGGA 702
 DB 1 CAGGCGCGGAGCTGGA 17
 RESULT 345
 ADL48284
 ID ADL48284 standard; RNA; 17 BP.
 XX
 AC ADL48284;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #794.
 XX antisease oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 23-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1817; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 that down regulate the expression or inhibit the function of a receptor
 for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 invention are useful for treating: cerebrovascular accident, central
 nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 disease, lupus, multiple sclerosis, transplant/graft rejection,
 ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 nucleic acids of the invention are also useful for down-regulating the
 expression of a target gene and as a diagnostic tool to examine genetic
 drifts and mutations within diseased cells or to detect the presence of a
 target RNA in a cell. The present RNA sequence represents a human IKK-
 gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 3 C; 9 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 701 GAGAGTGAGCGGAGGC 717
 DB 1 GAGAGTGAGCGGAGGC 17
 RESULT 346
 ADL48290
 ID ADL48290 standard; RNA; 17 BP.
 XX
 AC ADL48290;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #800.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1823; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 6 C; 5 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 719 CTGCAGCAGCAGCAGCAG 735
 DB 1 CUGCAGCAGCAGCAGCAG 17
 RESULT 347
 ID ADL48297
 XX ADL48297 standard; RNA; 17 BP.
 AC ADL48297;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #807.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1830; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 6 C; 5 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 746 GACCAGCTGCCATGCA 762
 DB 1 GACCAGCTGCCATGCA 17
 RESULT 348
 ID ADL48311
 XX ADL48311 standard; RNA; 17 BP.
 AC ADL48311;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #821.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS WO200281628-A2.

XX 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

PR 29-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

PA Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-059513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 1844; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX SQ Sequence 17 BP; 6 A; 4 C; 6 G; 0 T; 1 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 94.1%; Pred. No. 2.2e+02;

Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 818 AAGAGGAAGTGGGCCA 834

DB 1 AAGAGGAAGTGGGCCA 17

RESULT 349

ADL48488

ID ADL48488 standard; RNA; 17 BP.

XX AC ADL48488;

XX 20-MAY-2004 (first entry)

XX

DE Human IKK-gamma substrate sequence #998.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS WO200281628-A2.

XX 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

PR 29-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

PA Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 2021; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX SQ Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.2e+02;

Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 553 GGCTGAGGACAGGCCT 569

DB 1 GGCUGAGGACAGGCCU 17

RESULT 350

ADL48572

ID ADL48572 standard; RNA; 17 BP.

XX AC ADL48572;

XX 20-MAY-2004 (first entry)

XX

DE Human IKK-gamma substrate sequence #1118.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2141; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 435 AGTTCAGGAGCCAGG 451
 DB 1 AGUCCAGGAGCCAGG 17
 ||:|||||
 ||:|||||
 RESULT 355
 ADL48615
 ID ADL48615 standard; RNA; 17 BP.
 XX
 AC ADL48615;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1125.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2148; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 3 C; 8 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 455 CTGGTGGAGAGACTCGG 471
 DB 1 CUGGUGGAGAGACUGG 17
 ||:|||||
 ||:|||||
 RESULT 356
 ADL48634
 ID ADL48634 standard; RNA; 17 BP.
 XX
 AC ADL48634;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE	Human IKK-gamma substrate sequence #1158.	DE	Human IKK-gamma substrate sequence #1168.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX	substrate; ds.	XX	substrate; ds.
OS	Unidentified.	OS	Unidentified.
XX		XX	
PN	WO200281628-A2.	PN	WO200281628-A2.
XX		XX	
PD	17-OCT-2002.	PD	17-OCT-2002.
XX		XX	
PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.
XX		XX	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
PA	(RIBO-) RIBOZYME PHARM INC.	PA	(RIBO-) RIBOZYME PHARM INC.
XX		XX	
PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX		XX	
DR	WPI; 2003-058513/05.	DR	WPI; 2003-058513/05.
XX		XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
PS	Claim 59; SEQ ID NO 2181; 317pp; English.	PS	Claim 59; SEQ ID NO 2191; 317pp; English.
XX		XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.	CC	gamma substrate sequence.
XX		XX	
SQ	Sequence 17 BP; 1 A; 5 C; 7 G; 0 T; 4 U; 0 Other;	SQ	Sequence 17 BP; 6 A; 5 C; 4 G; 0 T; 2 U; 0 Other;
	Query Match 2.3%; Score 17; DB 1; Length 17;		Query Match 2.3%; Score 17; DB 1; Length 17;
	Best Local Similarity 76.5%; Pred. No. 2.2e+02;		Best Local Similarity 88.2%; Pred. No. 2.2e+02;
	Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;		Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY	592 CTTGCTCGGGAGCTGC 608	QY	635 GCCACTAAGGAATGCCA 651
DB	1 CUUGCUCGGGAGCUGC 17	DB	1 GCCACUAAGGAUGCCA 17
RESULT 359		RESULT 360	
ADL48658		ADL48667	
ID	ADL48658 standard; RNA; 17 BP.	ID	ADL48667 standard; RNA; 17 BP.
XX		XX	
AC	ADL48658;	AC	ADL48667;
XX		XX	
DT	20-MAY-2004 (first entry)	DT	20-MAY-2004 (first entry)
XX		XX	

```
DE Human IKK-gamma substrate sequence #1177.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX PN W0200281628-A2.
XX PD 17-OCT-2002.
XX PF
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2200; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX Sequence 17 BP; 1 A; 7 C; 8 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Qy 664 TCGGCGCCGCGCGGCCA 680
Db 1 UCGGCGCCGCGCGGCCA 17
:|||||
RESULT 361
ADL48677
ID ADL48677 standard; RNA; 17 BP.
XX
XX AC ADL48677;
XX
XX DT 20-MAY-2004 (first entry)
XX
```

```
DE Human IKK-gamma substrate sequence #1187.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX PN W0200281628-A2.
XX PD 17-OCT-2002.
XX PF
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2210; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX Sequence 17 BP; 2 A; 4 C; 9 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
Qy 705 GTGAGCGCGAGCGCTG 721
Db 1 GUGAGCGCGAGCGCTG 17
:|||||
RESULT 362
ADL48690
ID ADL48690 standard; RNA; 17 BP.
XX
XX AC ADL48690;
XX
XX DT 20-MAY-2004 (first entry)
XX
```

```

DE XX Human IKK-gamma substrate sequence #1200.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2223; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 8 C; 6 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 794 GAGCGCCAGCGCGCCTC 810
DB 1 GAGCGCCAGCGCGCCTC 17
|||||
1 GAGCGCCAGCGCGCCTC 17

RESULT 363
ADL47547
ID ADL47547 standard; RNA; 17 BP.
XX
XX AC ADL47547;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

```

DE XX Human IKK-gamma substrate sequence #57.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1080; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 5 A; 5 C; 4 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 633 CTGCCACTAAGGAATGC 649
DB 1 CUGCCACUAAGGAUGC 17
|||||
1 CUGCCACUAAGGAUGC 17

RESULT 364
ADL47556
ID ADL47556 standard; RNA; 17 BP.
XX
XX AC ADL47556;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

```

DE Human IKK-gamma substrate sequence #66.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX 29-MAY-2001; 2001US-0294412P.
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1089; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX Sequence 17 BP; 5 A; 6 C; 2 G; 0 T; 4 U; 0 Other;
XX
XX Query Match 2.3%; Score 17; DB 1; Length 17;
XX Best Local Similarity 76.5%; Pred. No. 2.2e+02;
XX Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 853 CCAGCTCTTCCAAAGAAAT 869
XX Db 1 CCAGCUCUCCAAAGAAU 17
XX
XX RESULT 365
XX ADL47557
XX ID ADL47557 standard; RNA; 17 BP.
XX
XX AC ADL47557;
XX
XX XX
XX DT 20-MAY-2004 (first entry)
XX

```

```

DE Human IKK-gamma substrate sequence #67.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX 29-MAY-2001; 2001US-0294412P.
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1090; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX Sequence 17 BP; 6 A; 5 C; 2 G; 0 T; 4 U; 0 Other;
XX
XX Query Match 2.3%; Score 17; DB 1; Length 17;
XX Best Local Similarity 76.5%; Pred. No. 2.2e+02;
XX Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 854 CAGCTCTTCCAAAGAAAT 870
XX Db 1 CAGCUCUCCAAAGAAU 17
XX
XX RESULT 366
XX ADL47743
XX ID ADL47743 standard; RNA; 17 BP.
XX
XX AC ADL47743;
XX
XX XX
XX DT 20-MAY-2004 (first entry)
XX

```

DE Human IKK-gamma substrate sequence #253.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1276; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 5 C; 8 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 199 TGGTGCCCGGCGAG 215
 Db 1 UGGUGGCGCGGCGAG 17
 RESULT 367
 ADL47754
 ID ADL47754 standard; RNA; 17 BP.
 XX
 AC ADL47754;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #264.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1287; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 6 C; 4 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 251 AAGCCAGCCATGCTGCA 267
 Db 1 AAGCCAGCCATGCTGCA 17
 RESULT 368
 ADL47775
 ID ADL47775 standard; RNA; 17 BP.
 XX
 AC ADL47775;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #236.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1319; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 3 C; 10 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 366 GGGAGCGCTCGAGGAG 382
 DB 1 GGGAGCGCTCGAGGAG 17
 RESULT 371
 ID ADL47799
 ADL47799 standard; RNA; 17 BP.
 XX
 AC ADL47799;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #309.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1332; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 4 G; 0 T; 5 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 70.6%; Pred. No. 2.2e+02;
 Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
 QY 426 TCATGTGCAAGTCCAG 442
 DB 1 UCAUGUGCAAGUCCAG 17
 RESULT 372
 ID ADL47814
 ADL47814 standard; RNA; 17 BP.
 XX
 AC ADL47814;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #379.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX Unidentified.
XX OS WO200281628-A2.
XX PN 17-OCT-2002.
XX PD 03-APR-2002; 2002WO-US010512.
XX PF 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX Claim 59; SEQ ID NO 1402; 317pp; English.
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX Sequence 17 BP; 2 A; 7 C; 6 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 783 CGCTCCGCGATGGAGCGC 799
DB 1 CGCUCGCGAGGAGCGC 17
RESULT 374
ADL47892
ID ADL47892 standard; RNA; 17 BP.
XX AC ADL47892;
XX AC 20-MAY-2004 (first entry)
XX DT 20-MAY-2004 (first entry)
XX XX

DE Human IKK-gamma substrate sequence #324.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX Unidentified.
XX OS WO200281628-A2.
XX PN 17-OCT-2002.
XX PD 03-APR-2002; 2002WO-US010512.
XX PF 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX Claim 59; SEQ ID NO 1347; 317pp; English.
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX Sequence 17 BP; 5 A; 3 C; 7 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 520 GGTGGAGCACCCTGAAGA 536
DB 1 GGUGGAGCACCCTGAAGA 17
RESULT 373
ADL47869
ID ADL47869 standard; RNA; 17 BP.
XX AC ADL47869;
XX AC 20-MAY-2004 (first entry)
XX DT 20-MAY-2004 (first entry)
XX XX

DE Human IKK-gamma substrate sequence #402.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1425; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 8 A; 6 C; 2 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 873 ACAACCAATCAAGAGC 889
 DB 1 ACAACCAATCAAGAGC 17
 RESULT 375
 ADL48223
 ID ADL48223 standard; RNA; 17 BP.
 XX
 AC ADL48223;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #733.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1756; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 5 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 277 AGAACAGGCGCTCTG 293
 DB 1 AGAACAGGCGCTCTG 17
 RESULT 376
 ADL48229
 ID ADL48229 standard; RNA; 17 BP.
 XX
 AC ADL48229;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #739.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS WO200281628-A2.

PN 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

PR 23-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

DR Novel enzymatic nucleic acid that down-regulates expression of neurite

XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 1762; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX Query Match 2.3%; Score 17; DB 1; Length 17;

XX Best Local Similarity 82.4%; Pred. No. 2.2e+02;

XX Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 330 TCCGAGATGCCATCCGG 346

DB :|||||:|||||:|||||

1 UCCGAGAUGCCAUCCGG 17

RESULT 377

ADL48230

ID ADL48230 standard; RNA; 17 BP.

XX ADL48230;

AC 20-MAY-2004 (first entry)

XX DT 20-MAY-2004 (first entry)

XX

DE Human IKK-gamma substrate sequence #740.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS WO200281628-A2.

PN 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

PR 29-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

DR Novel enzymatic nucleic acid that down-regulates expression of neurite

XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 1763; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX Query Match 2.3%; Score 17; DB 1; Length 17;

XX Best Local Similarity 94.1%; Pred. No. 2.2e+02;

XX Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 338 GCCATCCGCGCAGACAA 354

DB :|||||:|||||:|||||

1 GCCAUCGCGCAGACAA 17

RESULT 378

ADL48231

ID ADL48231 standard; RNA; 17 BP.

XX ADL48231;

AC 20-MAY-2004 (first entry)

XX DT 20-MAY-2004 (first entry)

XX

```

DE XX Human IKK-gamma substrate sequence #741.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
XX
PR 29-MAY-2001; 2001US-0294412P.
XX
PR 28-AUG-2001; 2001US-031531SP.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1764; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 6 A; 6 C; 5 G; 0 T; 0 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 343 CCGGCAGACGACACCGA 359
DB 1 CCGGCAGACGACACCGA 17

RESULT 379
ADL48262
ID ADL48262 standard; RNA; 17 BP.
XX
XX AC ADL48262;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE XX Human IKK-gamma substrate sequence #772.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
XX
PR 29-MAY-2001; 2001US-0294412P.
XX
PR 28-AUG-2001; 2001US-031531SP.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1795; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 5 C; 5 G; 0 T; 5 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.2e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 581 CAGGTGACGTCCTGCT 597
DB 1 CAGGTGACGTCCTGCT 17

RESULT 380
ADL48276
ID ADL48276 standard; RNA; 17 BP.
XX
XX AC ADL48276;
XX
XX DT 20-MAY-2004 (first entry)
XX

```

```

DE Human IKK-gamma substrate sequence #786.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1809; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 2 A; 7 C; 8 G; 0 T; 0 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 669 CCCGGCGCGCGCAGCGAG 685
Db 1 CCCGGCGCGCGCAGCGAG 17
RESULT 381
ADL48286
ID ADL48286 standard; RNA; 17 BP.
XX
XX AC ADL48286;
XX
XX DT 20-MAY-2004 (first entry)
XX
DE Human IKK-gamma substrate sequence #796.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1819; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 3 A; 5 C; 8 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Qy 708 AGCGCGAGCGCGCGAG 724
Db 1 AGCGCGAGCGCGCGAG 17
RESULT 382
ADL48292
ID ADL48292 standard; RNA; 17 BP.
XX
XX AC ADL48292;
XX
XX DT 20-MAY-2004 (first entry)
XX

```

```

DE XX Human IKK-gamma substrate sequence #802.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1825; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 5 C; 7 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 727 GCAGCACAGCGTGCAGG 743
DB 1 GCAGCACAGCGTGCAGG 17
|||||
1 GCAGCACAGCGTGCAGG 17

RESULT 383
ADL48305
ID ADL48305 standard; RNA; 17 BP.
XX
AC ADL48305;
XX
XX 20-MAY-2004 (first entry)
XX

```

```

DE XX Human IKK-gamma substrate sequence #815.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1838; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 7 C; 6 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 776 GAGCGCGCGCTCCGCAT 792
DB 1 GAGCGCGCGCTCCGCAT 17
|||||
1 GAGCGCGCGCTCCGCAT 17

RESULT 384
ADL48566
ID ADL48566 standard; RNA; 17 BP.
XX
AC ADL48566;
XX
XX 20-MAY-2004 (first entry)
XX

```

DE Human IKK-gamma substrate sequence #1076.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS Unidentified.
 XX WO200281628-A2.
 XX 17-OCT-2002.
 XX 03-APR-2002; 2002WO-US010512.
 XX 05-APR-2001; 2001US-00827395.
 XX 29-MAY-2001; 2001US-0294412P.
 XX 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX Claim 59; SEQ ID NO 2099; 317pp; English.
 PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX Sequence 17 BP; 5 A; 4 C; 5 G; 0 T; 3 U; 0 Other;
 SQ Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 212 GCAGATCAGGACGTACT 228
 DB 1 GCAGATCAGGACGTACT 17
 RESULT 385
 ADL48567
 ID ADL48567 standard; RNA; 17 BP.
 XX AC ADL48567;
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1077.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS Unidentified.
 XX WO200281628-A2.
 XX 17-OCT-2002.
 XX 03-APR-2002; 2002WO-US010512.
 XX 05-APR-2001; 2001US-00827395.
 XX 29-MAY-2001; 2001US-0294412P.
 XX 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX Claim 59; SEQ ID NO 2100; 317pp; English.
 PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX Sequence 17 BP; 5 A; 4 C; 5 G; 0 T; 3 U; 0 Other;
 SQ Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 213 CAGATCAGGACGTACTG 229
 DB 1 CAGATCAGGACGTACTG 17
 RESULT 386
 ADL48568
 ID ADL48568 standard; RNA; 17 BP.
 XX AC ADL48568;
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1078.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 XX Claim 59; SEQ ID NO 2101; 317pp; English.
 PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 3 C; 7 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 221 GACGTACTGGCGGAAGA 237
 DB 1 GACGUACUGGCGGAAGA 17
 RESULT 387
 ADL48577
 ID ADL48577 standard; RNA; 17 BP.
 XX
 AC ADL48577;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1087.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 XX Claim 59; SEQ ID NO 2110; 317pp; English.
 PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 6 C; 5 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 275 TCAGAACACAGGCGCTCC 291
 DB 1 UCAGAACACAGGCGCTCC 17
 RESULT 388
 ADL48586
 ID ADL48586 standard; RNA; 17 BP.
 XX
 AC ADL48586;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1096.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS

XX WO200281628-A2.

PN

XX 17-OCT-2002.

PD

XX 03-APR-2002; 2002WO-US010512.

PF

XX 05-APR-2001; 2001US-00827395.

PR

XX 29-MAY-2001; 2001US-0294412P.

PR

XX 28-AUG-2001; 2001US-0315315P.

PR

XX (RIBO-) RIBOZYME PHARM INC.

PA

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

PI

XX WPI; 2003-058513/05.

DR

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

PT

XX Claim 59; SEQ ID NO 2119; 317pp; English.

PS

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX

SQ Sequence 17 BP; 7 A; 4 C; 4 G; 0 T; 2 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.2e+02;

Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 318 AGAATCAAGAGCTCGA 334

||||:|||||

Db 1 AGAAUCRAGAGCUCGA 17

RESULT 389

ADL48603

ID ADL48603 standard; RNA; 17 BP.

XX

AC ADL48603;

XX

DT 20-MAY-2004 (first entry)

XX

DE Human IKK-gamma substrate sequence #1113.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS

XX WO200281628-A2.

PN

XX 17-OCT-2002.

PD

XX 03-APR-2002; 2002WO-US010512.

PF

XX 05-APR-2001; 2001US-00827395.

PR

XX 29-MAY-2001; 2001US-0294412P.

PR

XX 28-AUG-2001; 2001US-0315315P.

PR

XX (RIBO-) RIBOZYME PHARM INC.

PA

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

PI

XX WPI; 2003-058513/05.

DR

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

PT

XX Claim 59; SEQ ID NO 2136; 317pp; English.

PS

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX

SQ Sequence 17 BP; 7 A; 0 C; 10 G; 0 T; 0 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 2.2e+02;

Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 405 AGAGGGAGGAGAGGAG 421

|||||

Db 1 AGAGGGAGGAGAGGAG 17

RESULT 390

ADL48612

ID ADL48612 standard; RNA; 17 BP.

XX

AC ADL48612;

XX

DT 20-MAY-2004 (first entry)

XX


```

DE XX Human IKK-gamma substrate sequence #1122.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haeberli P, McSwiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2145; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 6 A; 1 C; 8 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 449 AGGAACACTGGTGGAGAG 465
Db 1 AGGAACUGGGAGGAG 17
|||||:|||||
1 AGGAACUGGGAGGAG 17

RESULT 391
ADL48629
ID ADL48629 standard; RNA; 17 BP.
XX
XX ADL48629;
XX
XX 20-MAY-2004 (first entry)
DT
XX

DE XX Human IKK-gamma substrate sequence #1139.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haeberli P, McSwiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2162; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 1 A; 3 C; 10 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 508 GGCTCTGCGGAGGTGG 524
Db 1 GGCUCUGCGGAGGUGG 17
|||||:|||||
1 GGCUCUGCGGAGGUGG 17

RESULT 392
ADL48631
ID ADL48631 standard; RNA; 17 BP.
XX
XX ADL48631;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

DE Human IKK-gamma substrate sequence #1141.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS Unidentified.
 XX WO200281628-A2.
 PN 17-OCT-2002.
 XX 03-APR-2002; 2002WO-US010512.
 XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 PI WPI; 2003-058513/05.
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX Claim 59; SEQ ID NO 2164; 317pp; English.
 PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX Sequence 17 BP; 2 A; 3 C; 9 G; 0 T; 3 U; 0 Other;
 SQ Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 OY 510 CTCTGCGGGAGGTGGAG 526
 Db 1 CUCUGCGGGAGGUGGAG 17
 RESULT 393
 ADL48661
 ID ADL48661 standard; RNA; 17 BP.
 XX AC ADL48661;
 XX 20-MAY-2004 (first entry)
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1171.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS Unidentified.
 XX WO200281628-A2.
 PN 17-OCT-2002.
 XX 03-APR-2002; 2002WO-US010512.
 XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 PI WPI; 2003-058513/05.
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX Claim 59; SEQ ID NO 2194; 317pp; English.
 PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX Sequence 17 BP; 2 A; 4 C; 8 G; 0 T; 3 U; 0 Other;
 SQ Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 OY 650 CAGGCTCTGGAGGTGCG 666
 Db 1 CAGGCTCTGGAGGTGCG 17
 RESULT 394
 ADL48674
 ID ADL48674 standard; RNA; 17 BP.
 XX AC ADL48674;
 XX 20-MAY-2004 (first entry)
 DT 20-MAY-2004 (first entry)
 XX

```

DE Human IKK-gamma substrate sequence #1184.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2207; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 2 C; 9 G; 0 T; 0 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 693 GGCAGCTGGAGAGTGAG 709
Db 1 GGCAGCTGGAGAGTGAG 17

RESULT 395
ADL48679
ID ADL48679 standard; RNA; 17 BP.
XX
AC ADL48679;
XX
DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #1189.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2212; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 734 AGCGTCAGGTGGACCA 750
Db 1 AGCGTCAGGTGGACCA 17

RESULT 396
ADL48693
ID ADL48693 standard; RNA; 17 BP.
XX
AC ADL48693;
XX
DT 20-MAY-2004 (first entry)
XX

```

DE Human IKK-gamma substrate sequence #1203.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2226; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 3 C; 8 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 Oy 806 GCCTCGGAGGAGAGAG 822
 |||:|||||||
 Db 1 GCCUCGGAGGAGAGAG 17
 RESULT 397
 ADL48707
 ID ADL48707 standard; RNA; 17 BP.
 XX
 AC ADL48707;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1217.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2240; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 2 C; 10 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 Oy 891 GCCTGGTGGCAGTGAG 907
 |||:|||||||
 Db 1 GCGUGGUGGCAGUGAG 17
 RESULT 398
 ADL47515
 ID ADL47515 standard; RNA; 17 BP.
 XX
 AC ADL47515;
 XX
 DT 20-MAY-2004 (first entry)
 XX

```

DE Human IKK-gamma substrate sequence #25.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX 17-OCT-2002.
XX PD
XX 03-APR-2002; 2002WO-US010512.
XX PF
XX 05-APR-2001; 2001US-00827395.
XX PR
XX 29-MAY-2001; 2001US-0294412P.
XX PR
XX 28-AUG-2001; 2001US-0315315P.
XX XX
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX PI
XX WPI; 2003-058513/05.
XX DR
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PT
XX Claim 59; SEQ ID NO 1048; 317pp; English.
XX PS
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX CC
XX SQ Sequence 17 BP; 3 A; 5 C; 5 G; 5 G; 0 T; 4 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.2e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

OY 232 CGAAGAGTCTCTCTGG 248
Db 1 CGAAGAGUCUCCUUG 17

RESULT 399
ADL47536
ID ADL47536 standard; RNA; 17 BP.
XX AC
XX ADL47536;
XX DT 20-MAY-2004 (first entry)
XX

```

```

DE Human IKK-gamma substrate sequence #46.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX 17-OCT-2002.
XX PD
XX 03-APR-2002; 2002WO-US010512.
XX PF
XX 05-APR-2001; 2001US-00827395.
XX PR
XX 29-MAY-2001; 2001US-0294412P.
XX PR
XX 28-AUG-2001; 2001US-0315315P.
XX XX
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX PI
XX WPI; 2003-058513/05.
XX DR
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PT
XX Claim 59; SEQ ID NO 1069; 317pp; English.
XX PS
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX CC
XX SQ Sequence 17 BP; 4 A; 4 C; 6 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

OY 431 TGCAGTTCAGGAGGC 447
Db 1 UGCAGUCCAGGAGGC 17

RESULT 400
ADL47753
ID ADL47753 standard; RNA; 17 BP.
XX AC
XX ADL47753;
XX DT 20-MAY-2004 (first entry)
XX

```

DE XX Human IKK-gamma substrate sequence #263.

KW antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX OS Unidentified.

XX XX WO200281628-A2.

XX PN 17-OCT-2002.

XX PD 03-APR-2002; 2002WO-US010512.

XX PF 05-APR-2001; 2001US-00827395.

XX PR 29-MAY-2001; 2001US-0294412P.

XX PR 28-AUG-2001; 2001US-0315315P.

XX PR (RIBO-) RIBOZYME PHARM INC.

XX PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX PI WPI; 2003-058513/05.

XX DR Novel enzymatic nucleic acid that down-regulates expression of neurite

XX PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or

XX PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX PS Claim 59; SEQ ID NO 1286; 317pp; English.

XX SS The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX SQ Sequence 17 BP; 4 A; 5 C; 6 G; 0 T; 2 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.2e+02;

Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 248 GGGGAGCCGAGCCATGCT 264

|||||

Db 1 GGGGAGCCGAGCCATGCT 17

RESULT 401

ADL47767

ID ADL47767 standard; RNA; 17 BP.

XX AC ADL47767;

XX DT 20-MAY-2004 (first entry)

XX XX

DE XX Human IKK-gamma substrate sequence #277.

KW antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX OS Unidentified.

XX XX WO200281628-A2.

XX PN 17-OCT-2002.

XX PD 03-APR-2002; 2002WO-US010512.

XX PF 05-APR-2001; 2001US-00827395.

XX PR 29-MAY-2001; 2001US-0294412P.

XX PR 28-AUG-2001; 2001US-0315315P.

XX PR (RIBO-) RIBOZYME PHARM INC.

XX PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX PI WPI; 2003-058513/05.

XX DR Novel enzymatic nucleic acid that down-regulates expression of neurite

XX PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or

XX PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX PS Claim 59; SEQ ID NO 1300; 317pp; English.

XX SS The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX SQ Sequence 17 BP; 3 A; 8 C; 4 G; 0 T; 2 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.2e+02;

Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 290 CCTGAGACCTCCAGCG 306

|||||

Db 1 CCUGAGACCTCCAGCG 17

RESULT 402

ADL47789

ID ADL47789 standard; RNA; 17 BP.

XX AC ADL47789;

XX DT 20-MAY-2004 (first entry)

XX XX

```

DE Human IKK-gamma substrate sequence #299.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1322; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 5 C; 3 G; 0 T; 6 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 64.7%; Pred.No. 2.2e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 382 GCTTCTGCAATTTCCAG 398
DB 1 GCUCUGCAUUCGAG 17

RESULT 403
ID ADL47807
XX ADL47807 standard; RNA; 17 BP.
XX
AC ADL47807;
XX
XX 20-MAY-2004 (first entry)
DT
XX

DE Human IKK-gamma substrate sequence #317.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1340; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 5 C; 6 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred.No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 466 ACTCGCGCTGGAGAGC 482
DB 1 ACUCGCGCCUGGAGAGC 17

RESULT 404
ID ADL47811
XX ADL47811 standard; RNA; 17 BP.
XX
AC ADL47811;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```



```
DE Human IKK-gamma substrate sequence #321.
XX
KW antiense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; ikappab kinase; IKK;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
FN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
XX
PF 03-APR-2002; 2002WO-US010512.
XX
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, ikappab kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1344; 317pp; English.
XX
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC ikappab kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 499 GAAGGAGCAGGCTCTGC 515
DB 1 GAAGGAGCAGGCTCTGC 17
|||||
RESULT 405
ADL47820
ID ADL47820 standard; RNA; 17 BP.
XX
AC ADL47820;
XX
XX 20-MAY-2004 (first entry)
XX
DE Human IKK-gamma substrate sequence #330.
XX
KW antiense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; ikappab kinase; IKK;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
FN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
XX
PF 03-APR-2002; 2002WO-US010512.
XX
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, ikappab kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1353; 317pp; English.
XX
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC ikappab kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 5 C; 6 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 541 CCAGCAGCAGATGGCTG 557
DB 1 CCAGCAGCAGATGGCTG 17
|||||
RESULT 406
ADL47823
ID ADL47823 standard; RNA; 17 BP.
XX
AC ADL47823;
XX
XX 20-MAY-2004 (first entry)
XX
```


DE Human IKK-gamma substrate sequence #333.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1356; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 4 C; 5 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 560 GACAAGGCTCTGTGTGAA 576
 DB 1 GACAAGGCTCTGTGTGAA 17
 RESULT 407
 ADL47836
 ID ADL47836 standard; RNA; 17 BP.
 XX
 AC ADL47836;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #346.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1369; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 3 C; 7 G; 0 T; 4 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 2.2e+02;
 Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 618 AGAGTCGCTTGAGGCT 634
 DB 1 AGAGTCGCTTGAGGCT 17
 RESULT 408
 ADL47845
 ID ADL47845 standard; RNA; 17 BP.
 XX
 AC ADL47845;
 XX
 DT 20-MAY-2004 (first entry)
 XX

```
DE Human IKK-gamma substrate sequence #355.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1378; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 0 A; 6 C; 10 G; 0 T; 1 U; 0 Other;
SQ
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 662 GGTCTGGGCCCCGGCGGC 678
DB 1 GGUCGGGCCCCGGCGGC 17
|||||
RESULT 409
ADL47849
ID ADL47849 standard; RNA; 17 BP.
XX
XX ADL47849;
XX
XX 20-MAY-2004 (first entry)
DT
XX

DE Human IKK-gamma substrate sequence #359.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1382; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 3 A; 6 C; 8 G; 0 T; 0 U; 0 Other;
SQ
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 679 CACCGAGCAGCGCGGC 695
DB 1 CACCGAGCAGCGCGGC 17
|||||
RESULT 410
ADL47860
ID ADL47860 standard; RNA; 17 BP.
XX
XX ADL47860;
XX
XX 20-MAY-2004 (first entry)
DT
XX
```

	Human IKK-gamma substrate sequence #370.	
DE	antisenase oligonucleotide; neurite growth inhibitor; NOGO;	
XX	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	
XX	protein kinase PKR; cerebrovascular accident;	
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	
KW	substrate; ds.	
XX	Unidentified.	
OS		
XX	WO200281628-A2.	
PX		
PD	17-OCT-2002.	
XX		
PF	03-APR-2002; 2002WO-US010512.	
XX		
PR	05-APR-2001; 2001US-00827395.	
PR	25-MAY-2001; 2001US-0294412P.	
PR	28-AUG-2001; 2001US-0315315P.	
XX		
PA	(RIBO-) RIBOZYME PHARM INC.	
XX		
PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;	
XX		
DR	WPI; 2003-058513/05.	
XX		
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	
XX		
PS	Claim 59; SEQ ID NO 1393; 317pp; English.	
XX		
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	
CC	that down regulate the expression or inhibit the function of a receptor	
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	
CC	IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the	
CC	invention are useful for treating: cerebrovascular accident, central	
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	
CC	nucleic acids of the invention are also useful for down-regulating the	
CC	expression of a target gene and as a diagnostic tool to examine genetic	
CC	drifts and mutations within diseased cells or to detect the presence of a	
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	
CC	gamma substrate sequence.	
XX		
SQ	Sequence 17 BP; 3 A; 5 C; 7 G; 0 T; 2 U; 0 Other;	
	Query Match 2.3%; Score 17; DB 1; Length 17;	
	Best Local Similarity 88.2%; Pred. No. 2.2e+02;	
	Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;	
QY	742 GGTGGACCGCTGCACA 758	
DB	: :	
	1 GGUGGACCAGCUGCACA 17	
RESULT 411		
ADL47882		
ID	ADL47882 standard; RNA; 17 BP.	
XX		
AC	ADL47882;	
XX		
DT	20-MAY-2004 (first entry)	
XX		

	Human IKK-gamma substrate sequence #392.	
DE	antisenase oligonucleotide; neurite growth inhibitor; NOGO;	
XX	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	
KW	protein kinase PKR; cerebrovascular accident;	
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	
KW	substrate; ds.	
XX	Unidentified.	
OS		
XX	WO200281628-A2.	
PX		
PD	17-OCT-2002.	
XX		
PF	03-APR-2002; 2002WO-US010512.	
XX		
PR	05-APR-2001; 2001US-00827395.	
PR	29-MAY-2001; 2001US-0294412P.	
PR	28-AUG-2001; 2001US-0315315P.	
XX		
PA	(RIBO-) RIBOZYME PHARM INC.	
XX		
PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;	
XX		
DR	WPI; 2003-058513/05.	
XX		
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	
XX		
PS	Claim 59; SEQ ID NO 1415; 317pp; English.	
XX		
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	
CC	that down regulate the expression or inhibit the function of a receptor	
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	
CC	IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the	
CC	invention are useful for treating: cerebrovascular accident, central	
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	
CC	nucleic acids of the invention are also useful for down-regulating the	
CC	expression of a target gene and as a diagnostic tool to examine genetic	
CC	drifts and mutations within diseased cells or to detect the presence of a	
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	
CC	gamma substrate sequence.	
XX		
SQ	Sequence 17 BP; 3 A; 7 C; 3 G; 0 T; 4 U; 0 Other;	
	Query Match 2.3%; Score 17; DB 1; Length 17;	
	Best Local Similarity 76.5%; Pred. No. 2.2e+02;	
	Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;	
QY	844 GGCCTATCACCACTCT 860	
DB	: :	
	1 GGCCUUAUCACCACTCT 17	
RESULT 412		
ADL48204		
ID	ADL48204 standard; RNA; 17 BP.	
XX		
AC	ADL48204;	

DE Human IKK-gamma substrate sequence #714.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 XX OS
 XX PN WO200281628-A2.
 XX PD 17-OCT-2002.
 XX PF 03-APR-2002; 2002WO-US010512.
 XX PR 05-APR-2001; 2001US-00827395.
 XX PR 23-MAY-2001; 2001US-0294412P.
 XX PR 28-AUG-2001; 2001US-0315315P.
 XX PA (RIBO-) RIBOZYME PHARM INC.
 XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 XX DR
 XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 XX PS Claim 59; SEQ ID NO 1737; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 XX SQ Sequence 17 BP; 5 A; 4 C; 5 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 163 CTGAGAGGCGCAACTGT 179
 Db 1 CUGAAGAGCGCAACUGU 17
 RESULT 413
 ADL48220
 ID ADL48220 standard; RNA; 17 BP.
 XX
 XX AC ADL48220;
 XX DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #730.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 XX OS
 XX PN WO200281628-A2.
 XX PD 17-OCT-2002.
 XX PF 03-APR-2002; 2002WO-US010512.
 XX PR 05-APR-2001; 2001US-00827395.
 XX PR 23-MAY-2001; 2001US-0294412P.
 XX PR 28-AUG-2001; 2001US-0315315P.
 XX PA (RIBO-) RIBOZYME PHARM INC.
 XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 XX DR
 XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 XX PS Claim 59; SEQ ID NO 1753; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 XX SQ Sequence 17 BP; 3 A; 8 C; 3 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 254 CCAGCCATCTGCACCT 270
 Db 1 CCAGCCATCTGCACCT 17
 RESULT 414
 ADL48253
 ID ADL48253 standard; RNA; 17 BP.
 XX
 XX AC ADL48253;
 XX DT 20-MAY-2004 (first entry)
 XX

```

DE Human IKK-gamma substrate sequence #763.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor. IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1786; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 5 A; 3 C; 7 G; 0 T; 2 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 518 GAGGTGGAGCAGCTGAA 534
DB 1 GAGGUGGAGCAGCCUGNA 17

RESULT 415
ADL48285
ID ADL48285 standard; RNA; 17 BP.
XX
AC ADL48285;
XX
DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #795.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor. IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1818; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 4 C; 9 G; 0 T; 1 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 703 GAGTGAGCGCGAGCGGC 719
DB 1 GAGUGAGCGCGAGCGGC 17

RESULT 416
ADL48304
ID ADL48304 standard; RNA; 17 BP.
XX
AC ADL48304;
XX
DT 20-MAY-2004 (first entry)
XX

```

DE Human IKK-gamma substrate sequence #814.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX Unidentified.
XX OS
XX PN WO200281628-A2.
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1837; 317pp; English.
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 1 A; 7 C; 7 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 774 TGGAGGCGCGCTCCGCG 790
Db 1 UGGAGGCGCGCTCCGCG 17
RESULT 417
ADL48308
ID ADL48308 standard; RNA; 17 BP.
XX
XX AC ADL48308;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #818.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX Unidentified.
XX OS
XX PN WO200281628-A2.
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1841; 317pp; English.
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 6 C; 7 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 790 CATGGAGCGCCAGCGCG 806
Db 1 CAUGGAGCGCCAGCGCG 17
RESULT 418
ADL48310
ID ADL48310 standard; RNA; 17 BP.
XX
XX AC ADL48310;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #820.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1843; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 7 C; 7 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 798 GCCAGCCGCCCTGGAG 814
 DB 1 GCCAGCCGCCCTGGAG 17
 RESULT 419
 ID ADL48475
 XX ADL48475 standard; RNA; 17 BP.
 AC ADL48475;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #985.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2008; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 4 C; 7 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 208 GCCAGCAGATCAGGACG 224
 DB 1 GCCAGCAGATCAGGACG 17
 RESULT 420
 ID ADL48481
 XX ADL48481 standard; RNA; 17 BP.
 AC ADL48481;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #991.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS Unidentified.
 XX WO200281628-A2.
 PN 17-OCT-2002.
 XX 03-APR-2002; 2002WO-US010512.
 PF 05-APR-2001; 2001US-00827395.
 XX 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI WPI; 2003-058513/05.
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX Claim 59; SEQ ID NO 2014; 317pp; English.
 PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX Sequence 17 BP; 6 A; 5 C; 4 G; 0 T; 2 U; 0 Other;
 SQ Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 OY 346 GCAGAGCAACCCAGATTC 362
 DB 1 GCAGAGCAACCCAGAUUC 17
 RESULT 421
 ADL48484
 ID ADL48484 standard; RNA; 17 BP.
 XX AC ADL48484;
 XX DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #994.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS Unidentified.
 XX WO200281628-A2.
 PN 17-OCT-2002.
 XX 03-APR-2002; 2002WO-US010512.
 PF 05-APR-2001; 2001US-00827395.
 XX 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI WPI; 2003-058513/05.
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX Claim 59; SEQ ID NO 2017; 317pp; English.
 PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX Sequence 17 BP; 3 A; 4 C; 7 G; 0 T; 3 U; 0 Other;
 SQ Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 OY 458 GTGAGAGACTCGGCT 474
 DB 1 GUGGAGAGACUCGGCCU 17
 RESULT 422
 ADL48486
 ID ADL48486 standard; RNA; 17 BP.
 XX AC ADL48486;
 XX DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #996.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX 05-APR-2001; 2001US-00827395.
 PR
 PR 29-MAY-2001; 2001US-0294412P.
 PR
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX
 PS Claim 59; SEQ ID NO 2019; 317pp; English.
 XX
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 PS Sequence 17 BP; 6 A; 4 C; 5 G; 0 T; 2 U; 0 Other;
 XX
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 530 CTGAAGAGATGCCAGCA 546
 DB 1 CUGAGAGAGGCCAGCA 17
 |:|||||:|||||:
 RESULT 423
 ADL48618
 ID ADL48618 standard; RNA; 17 BP.
 XX
 AC ADL48618;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1128.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX 05-APR-2001; 2001US-00827395.
 PR
 PR 29-MAY-2001; 2001US-0294412P.
 PR
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX
 PS Claim 59; SEQ ID NO 2151; 317pp; English.
 XX
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 PS Sequence 17 BP; 3 A; 5 C; 6 G; 0 T; 3 U; 0 Other;
 XX
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 467 CTCGGCCTGGAGAGCT 483
 DB 1 CUCGGCCUGGAGAGCTU 17
 |:|||||:|||||:
 RESULT 424
 ADL48641
 ID ADL48641 standard; RNA; 17 BP.
 XX
 AC ADL48641;
 XX
 DT 20-MAY-2004 (first entry)
 XX

```

DE Human IKK-gamma substrate sequence #1151.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
OS
XX
XX WO200281628-A2.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
PF
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX
XX 29-MAY-2001; 2001US-0294412P.
PR
XX
XX 28-AUG-2001; 2001US-0315315P.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
PT
XX
XX Claim 59; SEQ ID NO 2174; 317pp; English.
PS
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 5 A; 3 C; 7 G; 0 T; 2 U; 0 Other;
SQ

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 551 ATGGCTGAGGACCAAGGC 567
DB 1 AUGGCGAGGACCAAGGC 17

RESULT 425
ADL48645
ID ADL48645 standard; RNA; 17 BP.
XX
XX ADL48645;
XX
XX 20-MAY-2004 (first entry)
DT
XX

DE Human IKK-gamma substrate sequence #1155.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
OS
XX
XX WO200281628-A2.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
PF
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX
XX 29-MAY-2001; 2001US-0294412P.
PR
XX
XX 28-AUG-2001; 2001US-0315315P.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
PT
XX
XX Claim 59; SEQ ID NO 2178; 317pp; English.
PS
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 5 A; 5 C; 5 G; 0 T; 2 U; 0 Other;
SQ

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 575 AAAGCCAGGTGACGTC 591
DB 1 AAAGCCAGGTGACGTC 17

RESULT 426
ADL48646
ID ADL48646 standard; RNA; 17 BP.
XX
XX ADL48646;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

DE Human IKK-gamma substrate sequence #1156.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 XX
 PR 29-MAY-2001; 2001US-0294412P.
 XX
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2179; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 5 G; 0 T; 4 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 2.2e+02; Indels 0; Gaps 0;
 Matches 13; Conservative 4; Mismatches 0;
 QY 578 GCCCAGGTGACGTCCTT 594
 DB 1 GCCCAGGUGAGCCUUU 17
 RESULT 427
 ADL48670
 ID ADL48670 standard; RNA; 17 BP.
 XX
 AC ADL48670;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1180.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 XX
 PR 29-MAY-2001; 2001US-0294412P.
 XX
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2203; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 6 C; 8 G; 0 T; 0 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02; Indels 0; Gaps 0;
 Matches 17; Conservative 0; Mismatches 0;
 QY 675 CGGCCAGCGCAGCAGCG 691
 DB 1 CGGCCAGCGCAGCAGCG 17
 RESULT 428
 ADL48676
 ID ADL48676 standard; RNA; 17 BP.
 XX
 AC ADL48676;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1186.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS OS
 XX WO200281628-A2.
 PN
 XX 17-OCT-2002.
 PD
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX 05-APR-2001; 2001US-00827395.
 PR
 XX 23-MAY-2001; 2001US-0294412P.
 PR
 XX 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 XX Blatt L, Chowrira B, Haerberli P, Meswigen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX Claim 59; SEQ ID NO 2209; 317pp; English.
 PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 2 C; 9 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 699 TGGAGAGTGAGCGCGAG 715
 Db :||||:|||||
 1 UGGAGAGUGAGCGCGAG 17
 RESULT 429
 ADL48692
 ID ADL48692 standard; RNA; 17 BP.
 XX
 AC ADL48692;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1202.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS OS
 XX WO200281628-A2.
 PN
 XX 17-OCT-2002.
 PD
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX 05-APR-2001; 2001US-00827395.
 PR
 XX 23-MAY-2001; 2001US-0294412P.
 PR
 XX 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 XX Blatt L, Chowrira B, Haerberli P, Meswigen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX Claim 59; SEQ ID NO 2225; 317pp; English.
 PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 5 C; 7 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 804 CCGCTCGAGGAGAG 820
 Db :||||:|||||
 1 CCGCCUCCGAGGAGAG 17
 RESULT 430
 ADL48695
 ID ADL48695 standard; RNA; 17 BP.
 XX
 AC ADL48695;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

```

DE XX Human IKK-gamma substrate sequence #1205.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2228; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 7 A; 1 C; 8 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 809 TCGGAGGAGAGAGGAA 825
DB 1 UCGGAGGAGAGAGGAA 17
:|||||
RESULT 431
ADL47526
ID ADL47526 standard; RNA; 17 BP.
XX
AC ADL47526;
XX
DT 20-MAY-2004 (first entry)
XX

```

```

DE XX Human IKK-gamma substrate sequence #36.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1059; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 4 C; 6 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 354 ACCAGATTCTCGGAG 370
DB 1 ACCAGAUUCUGCGGAG 17
:|||||
RESULT 432
ADL47738
ID ADL47738 standard; RNA; 17 BP.
XX
AC ADL47738;
XX
DT 20-MAY-2004 (first entry)
XX

```

DE Human IKK-gamma substrate sequence #248.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS Unidentified.
 XX WO200281628-A2.
 PN 17-OCT-2002.
 XX 03-APR-2002; 2002WO-US010512.
 XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI WPI; 2003-058513/05.
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX Claim 59; SEQ ID NO 1271; 317pp; English.
 PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX Sequence 17 BP; 3 A; 4 C; 7 G; 0 T; 3 U; 0 Other;
 SQ Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 184 GATGGTCAGCCAGTG 200
 DB 1 GAUGGUCAGCCAGUG 17
 |||||:|||||:
 |||||:|||||:
 RESULT 433
 ADL47766
 ID ADL47766 standard; RNA; 17 BP.
 XX AC ADL47766;
 XX DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #276.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS Unidentified.
 XX WO200281628-A2.
 PN 17-OCT-2002.
 XX 03-APR-2002; 2002WO-US010512.
 XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI WPI; 2003-058513/05.
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX Claim 59; SEQ ID NO 1299; 317pp; English.
 PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX Sequence 17 BP; 2 A; 7 C; 5 G; 0 T; 3 U; 0 Other;
 SQ Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 284 GCGCTCCTGAGACCCCT 300
 DB 1 GGCGCUCUGAGACCCU 17
 |||||:|||||:
 |||||:|||||:
 RESULT 434
 ADL47768
 ID ADL47768 standard; RNA; 17 BP.
 XX AC ADL47768;
 XX DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #278.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1301; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 8 C; 4 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 291 CTGAGACCTCCAGCGC 307
 Db 1 CUGAGACCTCCAGCGC 17
 RESULT 435
 ADL47795
 ID ADL47795 standard; RNA; 17 BP.
 XX
 AC ADL47795;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #305.
 XX
 KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1328; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 4 C; 8 G; 0 T; 0 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 397 AGCCAGCCAGAGGAGG 413
 Db 1 AGCCAGCCAGAGGAGG 17
 RESULT 436
 ADL47817
 ID ADL47817 standard; RNA; 17 BP.
 XX
 AC ADL47817;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX


```

DE XX Human IKK-gamma substrate sequence #389.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1412; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 5 C; 6 G; 0 T; 4 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.2e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 832 CCAGTTGCGAGTGCGCT 848
DB 1 CCAGUUGCAGUGGCCU 17
|||||:|||||:|
1 CCAGUUGCAGUGGCCU 17

RESULT 439
ADL48206
ID ADL48206 standard; RNA; 17 BP.
XX
AC ADL48206;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

```

DE XX- Human IKK-gamma substrate sequence #716.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1739; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 3 C; 6 G; 0 T; 4 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.2e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 172 CCACTGTGTGAGATGG 188
DB 1 CCAACUGUGAGAGUGG 17
|||||:|||||:|
1 CCAACUGUGAGAGUGG 17

RESULT 440
ADL48233
ID ADL48233 standard; RNA; 17 BP.
XX
AC ADL48233;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

```
DE Human IKK-gamma substrate sequence #743.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX 17-OCT-2002.
XX PD
XX 03-APR-2002; 2002WO-US010512.
XX PF
XX 05-APR-2001; 2001US-00827395.
XX PR
XX 23-MAY-2001; 2001US-0294412P.
XX PR
XX 28-AUG-2001; 2001US-0315315P.
XX PR
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX PI
XX WPI; 2003-058513/05.
XX DR
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PT
XX Claim 59; SEQ ID NO 1766; 317pp; English.
XX PS
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX CC that down regulate the expression or inhibit the function of a receptor
XX CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX CC invention are useful for treating: cerebrovascular accident, central
XX CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX CC disease, lupus, multiple sclerosis, transplant/graft rejection,
XX CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX CC nucleic acids of the invention are also useful for down-regulating the
XX CC expression of a target gene and as a diagnostic tool to examine genetic
XX CC drifts and mutations within diseased cells or to detect the presence of a
XX CC target RNA in a cell. The present RNA sequence represents a human IKK-
XX CC gamma substrate sequence.
XX CC
XX SQ Sequence 17 BP; 2 A; 5 C; 8 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
Qy 362 CTCGGGAGCGCTCGCA 378
Db 1 CUGGGGAGCGCUGCGA 17
RESULT 441
ADL48250
ID ADL48250 standard; RNA; 17 BP.
XX AC
XX ADL48250;
XX AC
XX DT 20-MAY-2004 (first entry)
XX DT
XX
```

```
DE Human IKK-gamma substrate sequence #760.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX 17-OCT-2002.
XX PD
XX 03-APR-2002; 2002WO-US010512.
XX PF
XX 05-APR-2001; 2001US-00827395.
XX PR
XX 23-MAY-2001; 2001US-0294412P.
XX PR
XX 28-AUG-2001; 2001US-0315315P.
XX PR
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX PI
XX WPI; 2003-058513/05.
XX DR
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PT
XX Claim 59; SEQ ID NO 1783; 317pp; English.
XX PS
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX CC that down regulate the expression or inhibit the function of a receptor
XX CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX CC invention are useful for treating: cerebrovascular accident, central
XX CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX CC disease, lupus, multiple sclerosis, transplant/graft rejection,
XX CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX CC nucleic acids of the invention are also useful for down-regulating the
XX CC expression of a target gene and as a diagnostic tool to examine genetic
XX CC drifts and mutations within diseased cells or to detect the presence of a
XX CC target RNA in a cell. The present RNA sequence represents a human IKK-
XX CC gamma substrate sequence.
XX CC
XX SQ Sequence 17 BP; 3 A; 4 C; 8 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
Qy 501 AGGAGCAGGCTCTGCGG 517
Db 1 AGGAGCAGGCTCTGCGG 17
RESULT 442
ADL48261
ID ADL48261 standard; RNA; 17 BP.
XX AC
XX ADL48261;
XX AC
XX DT 20-MAY-2004 (first entry)
XX DT
XX
```

```

DE XX Human IKK-gamma substrate sequence #771.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1794; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 6 C; 5 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 576 AAGCCGAGTGACGTCC 592
DB 1 AAGCCGAGTGACGTCC 17
|||||
RESULT 443
ADL48287
ID ADL48287 standard; RNA; 17 BP.
XX
AC ADL48287;
XX
XX 20-MAY-2004 (first entry)
XX

DE XX Human IKK-gamma substrate sequence #797.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1820; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 6 C; 7 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 710 CGCGAGGCGCTGCAGCA 726
DB 1 CGCGAGGCGCTGCAGCA 17
|||||
RESULT 444
ADL48306
ID ADL48306 standard; RNA; 17 BP.
XX
AC ADL48306;
XX
XX 20-MAY-2004 (first entry)
XX

```

DE Human IKK-gamma substrate sequence #816.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
PN
XX 17-OCT-2002.
PD
XX 03-APR-2002; 2002WO-US010512.
PF
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
PR
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX Blatt L, Chowrira B, Haerberli P, McSwiggen J, Fosnaugh K;
PI WPI; 2003-059513/05.
XX
DR Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1839; 317pp; English.
PS
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 7 C; 6 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
Qy 781 CGCGCTCCGCGATGAGC 797
Db 1 CGCGCTCCGCGAUGGAGC 17
RESULT 445
ADL48584
ID ADL48584 standard; RNA; 17 BP.
XX
XX AC ADL48584;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #1094.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
PN
XX 17-OCT-2002.
PD
XX 03-APR-2002; 2002WO-US010512.
PF
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
PR
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX Blatt L, Chowrira B, Haerberli P, McSwiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
XX
DR Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2117; 317pp; English.
PS
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 6 A; 3 C; 6 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
Qy 309 GCCTGAGGAGGAATCAA 325
Db 1 GCCUGGAGGAGGAUCA 17
RESULT 446
ADL48587
ID ADL48587 standard; RNA; 17 BP.
XX
XX AC ADL48587;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #1097.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2120; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 5 C; 5 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 325 AGAGCTCCGAGATGCCA 341
 DB 1 AGAGCUCCGAGGAGCCCA 17
 |||||:|||||
 1 AGAGCUCCGAGGAGCCCA 17
 RESULT 447
 ADL48590
 ID ADL48590 standard; RNA; 17 BP.
 XX
 AC ADL48590;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1100.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2123; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 6 A; 6 C; 4 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 341 ATCCGCGAGAGCAACCA 357
 DB 1 AUCCGCGAGAGCAACCA 17
 |||||:|||||
 1 AUCCGCGAGAGCAACCA 17
 RESULT 448
 ADL48642
 ID ADL48642 standard; RNA; 17 BP.
 XX
 AC ADL48642;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1152.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS WO200281628-A2.

XX 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

PR 23-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 2175; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX Query Match 2.3%; Score 17; DB 1; Length 17;

XX Best Local Similarity 88.2%; Pred. No. 2.2e+02;

XX Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 552 TGCGTGGAGGACAGGCC 568

DB 1 UGCGUGAGGACAGGCC 17

RESULT 449

ADL48651

ID ADL48651 standard; RNA; 17 BP.

XX AC ADL48651;

XX DT 20-MAY-2004 (first entry)

XX

DE Human IKK-gamma substrate sequence #1161.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS WO200281628-A2.

XX 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

PR 29-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 2184; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX Query Match 2.3%; Score 17; DB 1; Length 17;

XX Best Local Similarity 94.1%; Pred. No. 2.2e+02;

XX Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 602 GAGCTGCAGGAGGCCA 618

DB 1 GAGCUGAGGAGGCCA 17

RESULT 450

ADL48701

ID ADL48701 standard; RNA; 17 BP.

XX AC ADL48701;

XX DT 20-MAY-2004 (first entry)

XX

```

DE  Human IKK-gamma substrate sequence #1211.
XX  antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW  prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW  protein kinase PKR; cerebrovascular accident;
KW  central nervous system injury; CNS injury; spinal cord injury; cancer;
KW  melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW  restenosis; asthma; Crohn's disease; diabetes; obesity;
KW  autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW  graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW  allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW  substrate; ds.
XX
XX  Unidentified.
XX  OS
XX  WO200281628-A2.
XX  PN
XX  PD 17-OCT-2002.
XX
XX  PF 03-APR-2002; 2002WO-US010512.
XX
XX  PR 05-APR-2001; 2001US-00827395.
XX  PR 29-MAY-2001; 2001US-0294412P.
XX  PR 28-AUG-2001; 2001US-0315315P.
XX
XX  PA (RIBO-) RIBOZYME PHARM INC.
XX
XX  PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX  WPI; 2003-058513/05.
XX  DR
XX  PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX  PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX  PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX  PS Claim 59; SEQ ID NO 2234; 317pp; English.
XX
XX  CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX  CC that down regulate the expression or inhibit the function of a receptor
XX  CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX  CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX  CC invention are useful for treating: cerebrovascular accident, central
XX  CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX  CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX  CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX  CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
XX  CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX  CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX  CC nucleic acids of the invention are also useful for down-regulating the
XX  CC expression of a target gene and as a diagnostic tool to examine genetic
XX  CC drifts and mutations within diseased cells or to detect the presence of a
XX  CC target RNA in a cell. The present RNA sequence represents a human IKK-
XX  CC gamma substrate sequence.
XX
SQ  Sequence 17 BP; 3 A; 4 C; 5 G; 0 T; 5 U; 0 Other;
    Query Match      2.3%; Score 17; DB 1; Length 17;
    Best Local Similarity 70.6%; Pred. No. 2.2e+02;
    Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY  836 TTGACGGTGGCCTATCA 852
DB  :|||||:|||||:
    1 UUGCAGGUGGCUAUCA 17

RESULT 451
ADL47521
ID  ADL47521 standard; RNA; 17 BP.
XX
XX  AC  ADL47521,
XX
XX  DT 20-MAY-2004 (first entry)
XX

DE  Human IKK-gamma substrate sequence #31.
XX  antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW  prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW  protein kinase PKR; cerebrovascular accident;
KW  central nervous system injury; CNS injury; spinal cord injury; cancer;
KW  melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW  restenosis; asthma; Crohn's disease; diabetes; obesity;
KW  autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW  graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW  allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW  substrate; ds.
XX
XX  Unidentified.
XX  OS
XX  WO200281628-A2.
XX  PN
XX  PD 17-OCT-2002.
XX
XX  PF 03-APR-2002; 2002WO-US010512.
XX
XX  PR 05-APR-2001; 2001US-00827395.
XX  PR 29-MAY-2001; 2001US-0294412P.
XX  PR 28-AUG-2001; 2001US-0315315P.
XX
XX  PA (RIBO-) RIBOZYME PHARM INC.
XX
XX  PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX  WPI; 2003-058513/05.
XX  DR
XX  PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX  PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX  PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX  PS Claim 59; SEQ ID NO 1054; 317pp; English.
XX
XX  CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX  CC that down regulate the expression or inhibit the function of a receptor
XX  CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX  CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX  CC invention are useful for treating: cerebrovascular accident, central
XX  CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX  CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX  CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX  CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
XX  CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX  CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX  CC nucleic acids of the invention are also useful for down-regulating the
XX  CC expression of a target gene and as a diagnostic tool to examine genetic
XX  CC drifts and mutations within diseased cells or to detect the presence of a
XX  CC target RNA in a cell. The present RNA sequence represents a human IKK-
XX  CC gamma substrate sequence.
XX
SQ  Sequence 17 BP; 3 A; 7 C; 5 G; 0 T; 2 U; 0 Other;
    Query Match      2.3%; Score 17; DB 1; Length 17;
    Best Local Similarity 88.2%; Pred. No. 2.2e+02;
    Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY  293 GAGACCCCTCCAGCGCTG 309
DB  :|||||:|||||:
    1 GAGACCCUCCAGCGCUG 17

RESULT 452
ADL47527
ID  ADL47527 standard; RNA; 17 BP.
XX
XX  AC  ADL47527,
XX
XX  DT 20-MAY-2004 (first entry)
XX

```


DE	Human IKK-gamma substrate sequence #41.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW	substrate; ds.
OS	Unidentified.
PN	WO200281628-A2.
XX	17-OCT-2002.
PD	03-APR-2002; 2002WO-USO10512.
XX	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.
XX	28-AUG-2001; 2001US-0315315P.
XX	(RIBO-) RIBOZYME PHARM INC.
XX	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI	WPI; 2003-058513/05.
DR	Novel enzymatic nucleic acid that down-regulates expression of neurite
XX	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
PT	Claim 59; SEQ ID NO 1064; 317pp; English.
PS	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drift and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.
XX	Sequence 17 BP; 4 A; 6 C; 3 G; 0 T; 4 U; 0 Other;
XX	Query Match 2.3%; Score 17; DB 1; Length 17;
XX	Best Local Similarity 76.5%; Pred. No. 2.2e+02;
XX	Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
Qy	386 CTCATTTCACGCCAG 402
Dd	: :: :: 1 CUGCAUUCUCCAAAGCCAG 17
RESULT 454	
ADL47539	
ID	ADL47539 standard; RNA; 17 BP.
XX	
AC	ADL47539;
XX	
DT	20-MAY-2004 (first entry)
XX	

DE Human IKK-gamma substrate sequence #49.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1072; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 3 C; 6 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 480 AGCTCGATCTGAAGAGG 496
 DB 1 AGCTCGAUCUGAAGAGG 17
 RESULT 455
 ADL47541
 ID ADL47541 standard; RNA; 17 BP.
 XX
 AC ADL47541;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #51.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1074; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 4 C; 5 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 562 CAAGGCCCTCTGTGAAG 578
 DB 1 CAAGGCCCTCTGTGAAG 17
 RESULT 456
 ADL47548
 ID ADL47548 standard; RNA; 17 BP.
 XX
 AC ADL47548;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX


```

DE Human IKK-gamma substrate sequence #267.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX 29-MAY-2001; 2001US-0294412P.
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Meswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1290; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 7 C; 3 G; 0 T; 5 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.8%; Pred. No. 2.2e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 259 CATGCTGCACCTGCTT 275
DB 1 CAUGCUGACCGCCUU 17
|||||
RESULT 459
ADL47801
ID ADL47801 standard; RNA; 17 BP.
XX
XX ADL47801;
AC
XX 20-MAY-2004 (first entry)
DT
XX

DE Human IKK-gamma substrate sequence #311.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX 29-MAY-2001; 2001US-0294412P.
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Meswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1334; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
SQ Sequence 17 BP; 5 A; 5 C; 5 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 433 CAAGTTCAGGAGGCCA 449
DB 1 CAAGUUCAGGAGGCCA 17
|||||
RESULT 460
ADL47813
ID ADL47813 standard; RNA; 17 BP.
XX
XX ADL47813;
AC
XX 20-MAY-2004 (first entry)
DT
XX

```

```
DE Human IKK-gamma substrate sequence #323.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1346; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 4 C; 9 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 505 GCAGGCTCTCGGGAGG 521
DB 1 GCAGGCTCTCGGGAGG 17
|||||:|||||
1 GCAGGCTCTCGGGAGG 17
RESULT 461
ADL47818
ID ADL47818 standard; RNA; 17 BP.
XX
AC ADL47818;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human IKK-gamma substrate sequence #328.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1351; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 6 A; 4 C; 6 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 535 GAGATGCCAGCAGCAGA 551
DB 1 GAGATGCCAGCAGCAGA 17
|||||:|||||
1 GAGATGCCAGCAGCAGA 17
RESULT 462
ADL47842
ID ADL47842 standard; RNA; 17 BP.
XX
AC ADL47842;
XX
DT 20-MAY-2004 (first entry)
XX
```

DE Human IKK-gamma substrate sequence #352.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX 05-APR-2001; 2001US-00827395.
 PR
 PR 29-MAY-2001; 2001US-0294412P.
 PR
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX
 PS Claim 59; SEQ ID NO 1375; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 4 C; 7 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 643 GGAATGCCAGGCTCTGG 659
 DB 1 GGAAUGCCAGGCTCUGG 17
 |||||:|||||:|||||
 RESULT 463
 ADL47858
 ID ADL47858 standard; RNA; 17 BP.
 XX
 AC ADL47858;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #368.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX 05-APR-2001; 2001US-00827395.
 PR
 PR 29-MAY-2001; 2001US-0294412P.
 PR
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX
 PS Claim 59; SEQ ID NO 1391; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 5 C; 7 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 733 CAGCGTGCAGGTGACC 749
 DB 1 CAGCGGCGCAGGUGGACC 17
 |||||:|||||:|||||
 RESULT 464
 ADL47865
 ID ADL47865 standard; RNA; 17 BP.
 XX
 AC ADL47865;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

```
DE Human IKK-gamma substrate sequence #375.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1398; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 3 A; 4 C; 9 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 760 GCAGGGCCAGAGCGTGG 776
DB 1 GCAGGGCCAGAGCGUGG 17
RESULT 465
ADL47870
ID ADL47870 standard; RNA; 17 BP.
XX
XX AC ADL47870;
XX
XX DT 20-MAY-2004 (first entry)
XX
```

```
DE Human IKK-gamma substrate sequence #380.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1403; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 2 A; 7 C; 7 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 792 TGGAGCGCCAGCGCGCC 808
DB 1 UGGAGCGCCAGCGCGCC 17
RESULT 466
ADL47875
ID ADL47875 standard; RNA; 17 BP.
XX
XX AC ADL47875;
XX
XX DT 20-MAY-2004 (first entry)
XX
```

DE Human IKK-gamma substrate sequence #385.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS OS
 XX WO200281628-A2.
 PN WO200281628-A2.
 XX 17-OCT-2002.
 PD 17-OCT-2002.
 XX 03-APR-2002; 2002WO-US010512.
 PF 03-APR-2002; 2002WO-US010512.
 XX 05-APR-2001; 2001US-00827395.
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Blatt L, Chowira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR WPI; 2003-058513/05.
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX Claim 59; SEQ ID NO 1408; 317pp; English.
 PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 XX that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX SQ Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 820 GAGGAAGCTGGCCAGT 836
 DB 1 GAGGAAGCTGGCCAGT 17
 RESULT 467
 ADL47893
 ID ADL47893 standard; RNA; 17 BP.
 XX AC ADL47893;
 XX 20-MAY-2004 (first entry)
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #403.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS OS
 XX WO200281628-A2.
 PN WO200281628-A2.
 XX 17-OCT-2002.
 PD 17-OCT-2002.
 XX 03-APR-2002; 2002WO-US010512.
 PF 03-APR-2002; 2002WO-US010512.
 XX 05-APR-2001; 2001US-00827395.
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Blatt L, Chowira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR WPI; 2003-058513/05.
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX Claim 59; SEQ ID NO 1426; 317pp; English.
 PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 XX that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX SQ Sequence 17 BP; 7 A; 6 C; 3 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 876 ACCACATCAAGAGCAGC 892
 DB 1 ACCACATCAAGAGCAGC 17
 RESULT 468
 ADL47894
 ID ADL47894 standard; RNA; 17 BP.
 XX AC ADL47894;
 XX 20-MAY-2004 (first entry)
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #734.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1757; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 that down regulate the expression or inhibit the function of a receptor
 for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 invention are useful for treating: cerebrovascular accident, central
 nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 disease, lupus, multiple sclerosis, transplant/graft rejection,
 ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 nucleic acids of the invention are also useful for down-regulating the
 expression of a target gene and as a diagnostic tool to examine genetic
 drifts and mutations within diseased cells or to detect the presence of a
 target RNA in a cell. The present RNA sequence represents a human IKK-
 gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 5 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 279 AACAGGGCGCTCTGTAG 295
 Db 1 AACAGGGCGCUCUGAG 17
 |||||
 RESULT 471
 ADL48254
 ID ADL48254 standard; RNA; 17 BP.
 XX
 AC ADL48254;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #764.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1787; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 that down regulate the expression or inhibit the function of a receptor
 for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 invention are useful for treating: cerebrovascular accident, central
 nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 disease, lupus, multiple sclerosis, transplant/graft rejection,
 ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 nucleic acids of the invention are also useful for down-regulating the
 expression of a target gene and as a diagnostic tool to examine genetic
 drifts and mutations within diseased cells or to detect the presence of a
 target RNA in a cell. The present RNA sequence represents a human IKK-
 gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 6 A; 4 C; 6 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 532 GAAGAGATGCCAGCAGC 548
 Db 1 GAAGAGATGCCAGCAGC 17
 |||||
 RESULT 472
 ADL48256
 ID ADL48256 standard; RNA; 17 BP.
 XX
 AC ADL48256;
 XX
 DT 20-MAY-2004 (first entry)
 XX

```
DE Human IKK-gamma substrate sequence #766.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
OS
XX
XX WO200281628-A2.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
PF
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
PT
XX
XX Claim 59; SEQ ID NO 1789; 317pp; English.
PS
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 4 A; 5 C; 6 G; 0 T; 2 U; 0 Other;
SQ
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 539 TGCCAGCAGCAGATGGC 555
DB 1 UGCCAGCAGCAGATGGC 17
:|||||:|||||:|||||
RESULT 473
ADL48268
ID ADL48268 standard; RNA; 17 BP.
XX
XX AC ADL48268;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #778.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
OS
XX
XX WO200281628-A2.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
PF
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
PT
XX
XX Claim 59; SEQ ID NO 1801; 317pp; English.
PS
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 3 A; 4 C; 7 G; 0 T; 3 U; 0 Other;
SQ
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 616 CCAGAGTCGCTTGAGG 632
DB 1 CCAGAGUCGUCUGGAGG 17
:|||||:|||||:|||||
RESULT 474
ADL48272
ID ADL48272 standard; RNA; 17 BP.
XX
XX AC ADL48272;
XX
XX DT 20-MAY-2004 (first entry)
XX
```

```

DE Human IKK-gamma substrate sequence #782.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Meswiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1805; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 4 C; 6 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

OY 645 AATGCAGGCTCTGGAG 661
DB 1 AAUGCCAGGCUCGGAG 17
|||||:|||||
1 AAUGCCAGGCUCGGAG 17

RESULT 475
ADL48293
ID ADL48293 standard; RNA; 17 BP.
XX
XX AC ADL48293;
XX
XX 20-MAY-2004 (first entry)
XX
XX

DE Human IKK-gamma substrate sequence #803.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Meswiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1826; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 729 AGCACAGCGTGCAGGTG 745
DB 1 AGCACAGCGTGCAGGTG 17
|||||:|||||
1 AGCACAGCGTGCAGGTG 17

RESULT 476
ADL48323
ID ADL48323 standard; RNA; 17 BP.
XX
XX AC ADL48323;
XX
XX 20-MAY-2004 (first entry)
XX
XX

```

DE Human IKK-gamma substrate sequence #833.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1856; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 2 C; 10 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
OY 895 GGTGGGGCAGTGAGCGGA 911
Db 1 GGUGGGCAGUGAGCGGA 17
|||:|||||:|||||
|||:|||||:|||||
RESULT 477
ADL48476
ID ADL48476 standard; RNA; 17 BP.
XX
AC ADL48476;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #986.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2009; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 5 A; 3 C; 6 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
OY 214 AGATCAGGACGACTCG 230
Db 1 AGAUCAGGACGACUGG 17
|||:|||||:|||||
|||:|||||:|||||
RESULT 478
ADL48569
ID ADL48569 standard; RNA; 17 BP.
XX
AC ADL48569;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #1079.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 XX substrate; ds.
 XX Unidentified.
 OS
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 XX Claim 59; SEQ ID NO 2102; 317pp; English.
 PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 3 C; 7 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 222 ACGTACTGCGCGAAGAG 238
 DB 1 ACGUACUGGCGAAGAG 17
 |||:|||||
 RESULT 479
 ADL48582
 ID ADL48582 standard; RNA; 17 BP.
 XX
 AC ADL48582;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1092.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 XX substrate; ds.
 XX Unidentified.
 OS
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 XX Claim 59; SEQ ID NO 2115; 317pp; English.
 PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 3 C; 7 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 306 GCTGCTGGGAGGAAT 322
 DB 1 GCUGCCUGGAGGAU 17
 |||:|||||
 RESULT 480
 ADL48596
 ID ADL48596 standard; RNA; 17 BP.
 XX
 AC ADL48596;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX


```

DE Human IKK-gamma substrate sequence #1146.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2169; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 6 A; 5 C; 4 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 527 CACCTGAAGAGATGCCA 543
Db 1 CACCUGAAGAGAUCCCA 17
||||:|||||:|||||
1 CACCUGAAGAGAUCCCA 17

RESULT 483
ADL48659
ID ADL48659 standard; RNA; 17 BP.
XX
AC ADL48659;
XX
XX 20-MAY-2004 (first entry)
DT
XX

DE Human IKK-gamma substrate sequence #1169.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2192; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 6 A; 5 C; 4 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 636 CCACCTAAGGAATGCCAG 652
Db 1 CCACUAGGAAUGCCAG 17
||||:|||||:|||||
1 CCACUAGGAAUGCCAG 17

RESULT 484
ADL48660
ID ADL48660 standard; RNA; 17 BP.
XX
AC ADL48660;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```


DE Human IKK-gamma substrate sequence #1170.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS

XX WO200281628-A2.

XX 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

XX 29-MAY-2001; 2001US-0294412P.

XX 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 2193; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident; central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX

SQ Sequence 17 BP; 4 A; 4 C; 6 G; 0 T; 3 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 2.2e+02;

Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 644 GAATGCCAGGCTGTGA 660

Db 1 GAAUGCCAGGCTUGGA 17

RESULT 485

ADL48663

ID ADL48663 standard; RNA; 17 BP.

XX

AC ADL48663;

XX

DT 20-MAY-2004 (first entry)

XX

DE Human IKK-gamma substrate sequence #1173.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS

XX WO200281628-A2.

XX 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

XX 29-MAY-2001; 2001US-0294412P.

XX 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 2196; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident; central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX

SQ Sequence 17 BP; 1 A; 4 C; 9 G; 0 T; 3 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 2.2e+02;

Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 653 GCTCTGGAGGTCGGGC 669

Db 1 GCUCUGAGGGGCGGGC 17

RESULT 486

ADL48673

ID ADL48673 standard; RNA; 17 BP.

XX

AC ADL48673;

XX

DT 20-MAY-2004 (first entry)

XX

DE Human IKK-gamma substrate sequence #1183.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2206; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 3 C; 8 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 692 CGGACGCTGGAGAGTGA 708
 DB 1 CGGACGCTGGAGAGTGA 17
 |||||:|||||:|||||:
 RESULT 487
 ADL48704
 ID ADL48704 standard; RNA; 17 BP.
 XX
 AC ADL48704;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1214.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2237; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 6 A; 5 C; 4 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 878 CACATCAAGAGCAGCGT 894
 DB 1 CACAUCAGAGCAGCGU 17
 |||||:|||||:|||||:
 RESULT 488
 ADL47524
 ID ADL47524 standard; RNA; 17 BP.
 XX
 AC ADL47524;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #34.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS
 XX
 XX WO200281628-A2.
 PN
 XX 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR
 XX 29-MAY-2001; 2001US-0294412P.
 PR
 XX 28-AUG-2001; 2001US-0315315P.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L., Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 XX Claim 59; SEQ ID NO 1057; 317pp; English.
 PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 XX Sequence 17 BP; 4 A; 5 C; 6 G; 0 T; 2 U; 0 Other;
 SQ
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 335 GATGCCATCCGGCAGAG 351
 Db 1 GAUGCCAUCGCGCAGAG 17
 ||:||||:|||||||
 ||:||||:|||||||
 RESULT 489
 ADL47535
 ID ADL47535 standard; RNA; 17 BP.
 XX
 XX AC ADL47535;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #45.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS
 XX
 XX WO200281628-A2.
 PN
 XX 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR
 XX 29-MAY-2001; 2001US-0294412P.
 PR
 XX 28-AUG-2001; 2001US-0315315P.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L., Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 XX Claim 59; SEQ ID NO 1068; 317pp; English.
 PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 XX Sequence 17 BP; 4 A; 3 C; 7 G; 0 T; 3 U; 0 Other;
 SQ
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 430 GTCGAAGTTCAGAGG 446
 Db 1 GUGCAAGUCCAGAGG 17
 ||:||||:|||||||
 ||:||||:|||||||
 RESULT 490
 ADL47545
 ID ADL47545 standard; RNA; 17 BP.
 XX
 XX AC ADL47545;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #55.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS
 XX
 XX WO200281628-A2.
 PN
 XX
 XX 17-OCT-2002.
 PD
 XX
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR
 XX 29-MAY-2001; 2001US-0294412P.
 PR
 XX 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX
 XX WPI; 2003-058513/05.
 DR
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX
 XX Claim 59; SEQ ID NO 1078; 317pp; English.
 PS
 XX
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 XX
 XX Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 615 GCCAGAGTCGCTTGAG 631
 DB 1 GCCAGAGCGCCTTGAG 17
 |||||:|||||:
 |||||:|||||:
 RESULT 491
 ADL47735
 ID ADL47735 standard; RNA; 17 BP.
 XX
 XX AC ADL47735;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #245.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS
 XX
 XX WO200281628-A2.
 PN
 XX
 XX 17-OCT-2002.
 PD
 XX
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR
 XX 29-MAY-2001; 2001US-0294412P.
 PR
 XX 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX
 XX WPI; 2003-058513/05.
 DR
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX
 XX Claim 59; SEQ ID NO 1268; 317pp; English.
 PS
 XX
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 XX
 XX Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 165 GGAAGAGCCAACTGTGT 181
 DB 1 GGAAGAGCCAACTGTGT 17
 |||||:|||||:
 |||||:|||||:
 RESULT 492
 ADL47746
 ID ADL47746 standard; RNA; 17 BP.
 XX
 XX AC ADL47746;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

Human IKK-gamma substrate sequence #256.

DE XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW XX protein kinase PKR; cerebrovascular accident;
 KW XX central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW XX restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW XX allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW XX substrate; ds.
 OS XX Unidentified.
 XX XX
 PN WO200281628-A2.
 XX XX
 PD 17-OCT-2002.
 XX XX
 XX 03-APR-2002; 2002WO-US010512.
 PF PF
 XX 05-APR-2001; 2001US-00827395.
 PR PR
 PR 29-MAY-2001; 2001US-0294412P.
 PR PR
 PR 28-AUG-2001; 2001US-0315315P.
 XX XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA PA
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI PI
 XX WPI; 2003-058513/05.
 DR DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX Claim 59; SEQ ID NO 1279; 317pp; English.
 PS PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX XX
 SQ Sequence 17 BP; 6 A; 4 C; 5 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 211 AGCAGTCAGGACGTAC 227
 |||||:|||||:|
 Db 1 AGCAGTCAGGACGTAC 17

RESULT 493
 ADL47748
 ID ADL47748 standard; RNA; 17 BP.
 XX XX
 AC ADL47748;
 XX XX
 DT 20-MAY-2004 (first entry)
 XX XX

Human IKK-gamma substrate sequence #258.

DE XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW XX protein kinase PKR; cerebrovascular accident;
 KW XX central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW XX restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW XX allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW XX substrate; ds.
 OS XX Unidentified.
 XX XX
 PN WO200281628-A2.
 XX XX
 PD 17-OCT-2002.
 XX XX
 XX 03-APR-2002; 2002WO-US010512.
 PF PF
 XX 05-APR-2001; 2001US-00827395.
 PR PR
 PR 29-MAY-2001; 2001US-0294412P.
 PR PR
 PR 28-AUG-2001; 2001US-0315315P.
 XX XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA PA
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI PI
 XX WPI; 2003-058513/05.
 DR DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX Claim 59; SEQ ID NO 1281; 317pp; English.
 PS PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX XX
 SQ Sequence 17 BP; 3 A; 4 C; 6 G; 0 T; 4 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 2.2e+02;
 Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 233 GAAGAGTCCTCTGGG 249
 |||||:|||||:|
 Db 1 GAAGAGTCCTCTGGG 17

RESULT 494
 ADL47760
 ID ADL47760 standard; RNA; 17 BP.
 XX XX
 AC ADL47760;
 XX XX
 DT 20-MAY-2004 (first entry)
 XX XX

DE Human IKK-gamma substrate sequence #270.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS WO200281628-A2.

PN 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

PR 29-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

PA Blatt L, Chowira B, Haerberli P, Meswiggen J, Fosnaugh K;

PI WPI; 2003-058513/05.

DR Novel enzymatic nucleic acid that down-regulates expression of neurite

XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 1293; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX SQ Sequence 17 BP; 4 A; 7 C; 3 G; 0 T; 3 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 2.2e+02;

Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 265 GCACCTGCCTTCAGAAC 281

Db 1 GCACCTGCCTTCAGAAC 17

RESULT 495

ADL47770

ID ADL47770 standard; RNA; 17 BP.

XX AC ADL47770;

XX 20-MAY-2004 (first entry)

DT

XX

DE Human IKK-gamma substrate sequence #280.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS WO200281628-A2.

PN 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

PR 29-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

PA Blatt L, Chowira B, Haerberli P, Meswiggen J, Fosnaugh K;

PI WPI; 2003-058513/05.

DR Novel enzymatic nucleic acid that down-regulates expression of neurite

XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 1303; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX SQ Sequence 17 BP; 3 A; 8 C; 4 G; 0 T; 2 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.2e+02;

Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 294 AGACCTTCAGCGCTGC 310

Db 1 AGACCTTCAGCGCTGC 17

RESULT 496

ADL47780

ID ADL47780 standard; RNA; 17 BP.

XX AC ADL47780;

XX 20-MAY-2004 (first entry)

DT

XX

```
DE Human IKK-gamma substrate sequence #290.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1313; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 6 C; 5 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 336 ATGCCATCCGCGAGC 352
Db 1 AUGCCAUCGCGAGC 17
RESULT 497
ADL47790
ID ADL47790 standard; RNA; 17 BP.
XX
XX AC ADL47790;
XX
XX DT 20-MAY-2004 (first entry)
XX
DE Human IKK-gamma substrate sequence #300.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1323; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 6 C; 3 G; 0 T; 4 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.2e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 387 TGCATTTCCAGCCAGC 403
Db 1 UGCAUUCCAAGCCAGC 17
RESULT 498
ADL47791
ID ADL47791 standard; RNA; 17 BP.
XX
XX AC ADL47791;
XX
XX DT 20-MAY-2004 (first entry)
XX
```

DE Human IKK-gamma substrate sequence #301.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1324; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 7 C; 3 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 388 GCATTTCACGAGCCAGCC 404
 DB 1 GCAUUUCCAAGCCAGCC 17
 :|||:|||||
 1 GCAUUUCCAAGCCAGCC 17
 RESULT 499
 ADL47793
 ID ADL47793 standard; RNA; 17 BP.
 XX
 AC ADL47793;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #303.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1326; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 6 C; 5 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 393 TCCAAGCCAGCCAGG 409
 DB 1 UCCAAGCCAGCCAGG 17
 :|||||
 1 UCCAAGCCAGCCAGG 17
 RESULT 500
 ADL47833
 ID ADL47833 standard; RNA; 17 BP.
 XX
 AC ADL47833;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE	Human IKK-gamma substrate sequence #343.	DE	Human IKK-gamma substrate sequence #345.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW	substrate; ds.	KW	substrate; ds.
OS	Unidentified.	OS	Unidentified.
XX		XX	
PN	WO200281628-A2.	PN	WO200281628-A2.
XX		XX	
PD	17-OCT-2002.	PD	17-OCT-2002.
XX		XX	
PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.
XX		XX	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
PA	(RIBO-) RIBOZYME PHARM INC.	PA	(RIBO-) RIBOZYME PHARM INC.
XX		XX	
PI	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX		XX	
DR	WPI; 2003-058513/05.	DR	WPI; 2003-058513/05.
XX		XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
PS	Claim 59; SEQ ID NO 1366; 317pp; English.	PS	Claim 59; SEQ ID NO 1368; 317pp; English.
XX		XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.	CC	gamma substrate sequence.
XX		XX	
SQ	Sequence 17 BP; 4 A; 4 C; 8 G; 0 T; 1 U; 0 Other;	SQ	Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;
	Query Match 2.3%; Score 17; DB 1; Length 17;		Query Match 2.3%; Score 17; DB 1; Length 17;
	Best Local Similarity 94.1%; Pred No. 2.2e+02;		Best Local Similarity 88.2%; Pred. No. 2.2e+02;
	Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;		Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
OY	601 GGAGCTGCAGGAGGCC 617	OY	610 GGAGGCCAGAGTCGCT 626
DB	1 GGAGCTGCAGGAGGCC 17	DB	1 GGAGGCCAGAGTCGCT 17
RESULT 501		RESULT 502	
ADL47835		ADL47855	
ID	ADL47835 standard; RNA; 17 BP.	ID	ADL47855 standard; RNA; 17 BP.
XX		XX	
AC	ADL47835;	AC	ADL47855;
XX		XX	
DT	20-MAY-2004 (first entry)	DT	20-MAY-2004 (first entry)
XX		XX	


```

DE Human IKK-gamma substrate sequence #365.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX 17-OCT-2002.
XX PD
XX PF 03-APR-2002; 2002WO-US010512.
XX PP
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX XX
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1388; 317pp; English.
XX PS
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 5 A; 6 C; 6 G; 0 T; 0 U; 0 Other;
SQ
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 721 GCAGCAGCAGCAGCAGCG 737
DB 1 GCAGCAGCAGCAGCAGCG 17
|||||
|||||

RESULT 503
ADL47866
ID ADL47866 standard; RNA; 17 BP.
XX
AC ADL47866;
XX
XX 20-MAY-2004 (first entry)
DT
XX

DE Human IKK-gamma substrate sequence #376.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX 17-OCT-2002.
XX PD
XX PF 03-APR-2002; 2002WO-US010512.
XX PP
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX XX
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1399; 317pp; English.
XX PS
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 1 A; 6 C; 8 G; 0 T; 2 U; 0 Other;
SQ
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 773 GTGAGAGCGCGCTCCG 789
DB 1 GUGGAGGCGCGCUCG 17
|||||
|||||

RESULT 504
ADL48219
ID ADL48219 standard; RNA; 17 BP.
XX
AC ADL48219;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```


DE Human IKK-gamma substrate sequence #770.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1793; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 4 C; 6 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 570 CTGTGAAGCCCGAGGTG 586
 Db 1 CUGUGAAGCCCGAGGTG 17
 RESULT 507
 ADL48294
 ID ADL48294 standard; RNA; 17 BP.
 XX
 AC ADL48294;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #804.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1827; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 731 CACAGCGTCAGGTGGA 747
 Db 1 CACAGCGTCAGGTGGA 17
 RESULT 508
 ADL48303
 ID ADL48303 standard; RNA; 17 BP.
 XX
 AC ADL48303;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE	Human IKK-gamma substrate sequence #813.	DE	Human IKK-gamma substrate sequence #817.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX	substrate; ds.	XX	substrate; ds.
OS	Unidentified.	OS	Unidentified.
XX		XX	
PN	WO200281628-A2.	PN	WO200281628-A2.
XX		XX	
PD	17-OCT-2002.	PD	17-OCT-2002.
XX		XX	
PP	03-APR-2002; 2002WO-US010512.	PP	03-APR-2002; 2002WO-US010512.
XX		XX	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
PA	(RIBO-) RIBOZYME PHARM INC.	PA	(RIBO-) RIBOZYME PHARM INC.
XX		XX	
PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX		XX	
DR	WPI; 2003-058513/05.	DR	WPI; 2003-058513/05.
XX		XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
PS	Claim 59; SEQ ID NO 1636; 317pp; English.	PS	Claim 59; SEQ ID NO 1840; 317pp; English.
XX		XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.	CC	gamma substrate sequence.
XX		XX	
SQ	Sequence 17 BP; 1 A; 6 C; 8 G; 0 T; 2 U; 0 Other;	SQ	Sequence 17 BP; 3 A; 6 C; 7 G; 0 T; 1 U; 0 Other;
	Query Match 2.3%; Score 17; DB 1; Length 17;		Query Match 2.3%; Score 17; DB 1; Length 17;
	Best Local Similarity 88.2%; Pred. No. 2.2e+02;		Best Local Similarity 94.1%; Pred. No. 2.2e+02;
	Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;		Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY	771 GCGTGGAGGCGCGCTC 787	QY	788 CGCATGGAGCGCCAGGC 804
	: :		: :
DB	1 GCGUGGAGGCGCGCUC 17	DB	1 CGCAUGGAGCGCCAGGC 17
RESULT 509		RESULT 510	
ADL48307		ADL48315	
ID	ADL48307 standard; RNA; 17 BP.	ID	ADL48315 standard; RNA; 17 BP.
XX		XX	
AC	ADL48307;	AC	ADL48315;
XX		XX	
DT	20-MAY-2004 (first entry)	DT	20-MAY-2004 (first entry)
XX		XX	

DE Human IKK-gamma substrate sequence #825.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1848; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 3 C; 6 G; 0 T; 5 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 70.6%; Pred. No. 2.2e+02;
 Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
 QY 834 AGTTCAGGTGGCCTAT 850
 DB 1 AGUUGCAGGUGGCUAU 17
 RESULT 511
 ADL48490
 ID ADL48490 standard; RNA; 17 BP.
 XX
 AC ADL48490;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1000.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2023; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 6 A; 4 C; 5 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 638 ACTAAGGAATGCCAGGC 654
 DB 1 ACUAAGGAUAGCCAGGC 17
 RESULT 512
 ADL48491
 ID ADL48491 standard; RNA; 17 BP.
 XX
 AC ADL48491;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1004.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2027; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 8 A; 6 C; 1 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 868 ATACGACAAACCAATCA 884
 Db 1 AUAAGCAACCAUCA 17
 RESULT 515
 ID ADL48597
 XX ADL48597 standard; RNA; 17 BP.
 AC ADL48597;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1107.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2130; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 4 C; 7 G; 0 T; 4 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 2.2e+02;
 Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 372 GCTCGAGGAGCTTCTG 388
 Db 1 GCUGCGAGGAGCUCUG 17
 RESULT 516
 ID ADL48611
 XX ADL48611 standard; RNA; 17 BP.
 AC ADL48611;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1121.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS WO200281628-A2.

XX 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

XX 29-MAY-2001; 2001US-0294412P.

XX 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 2144; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX Sequence 17 BP; 5 A; 3 C; 7 G; 0 T; 2 U; 0 Other;

SQ Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.2e+02;

Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 443 GAGGCCAGGAACCTGGT 459

Db 1 GAGGCCAGGAACCTGGU 17

RESULT 517

ADL48638

ID ADL48638 standard; RNA; 17 BP.

XX AC ADL48638;

XX DT 20-MAY-2004 (first entry)

XX

DE Human IKK-gamma substrate sequence #1148.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS WO200281628-A2.

XX 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

XX 29-MAY-2001; 2001US-0294412P.

XX 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 2171; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX Sequence 17 BP; 5 A; 4 C; 6 G; 0 T; 2 U; 0 Other;

SQ Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.2e+02;

Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 542 CAGCAGCAGATGGCTGA 558

Db 1 CAGCAGCAGATGGCTGA 17

RESULT 518

ADL48652

ID ADL48652 standard; RNA; 17 BP.

XX AC ADL48652;

XX DT 20-MAY-2004 (first entry)

XX


```

DE XX Human IKK-gamma substrate sequence #1162.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
PD 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2185; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 5 A; 4 C; 7 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 603 AGCTGAGGAGAGCCAG 619
DB 1 AGCTGAGGAGAGCCAG 17

RESULT 519
ADL48688
ID ADL48688 standard; RNA; 17 BP.
XX
AC ADL48688;
XX
XX 20-MAY-2004 (first entry)
DT
XX

DE XX Human IKK-gamma substrate sequence #1198.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
PD 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2221; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 7 C; 5 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 785 CTCGCGATGGAGGCCA 801
DB 1 CUCCGCAUGGAGGCCA 17

RESULT 520
ADL47514
ID ADL47514 standard; RNA; 17 BP.
XX
AC ADL47514;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

```

DE Human IKK-gamma substrate sequence #24.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX 17-OCT-2002.
XX PD
XX 03-APR-2002; 2002WO-US010512.
XX PF
XX 05-APR-2001; 2001US-00827395.
XX PR
XX 23-MAY-2001; 2001US-0294412P.
XX PR
XX 28-AUG-2001; 2001US-0315315P.
XX PR
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX PI
XX WPI; 2003-058513/05.
XX DR
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PT
XX Claim 59; SEQ ID NO 1047; 317pp; English.
XX PS
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX CC
XX Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;
SQ Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.3%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 218 CAGGACGTACTGGCGGA 234
Db |||||:|||||
1 CAGGACGACUACUGGCGGA 17

RESULT 521
ADL47518
ID ADL47518 standard; RNA; 17 BP.
XX
XX AC ADL47518;
XX AC
XX 20-MAY-2004 (first entry)
XX DT
XX

DE Human IKK-gamma substrate sequence #28.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX 17-OCT-2002.
XX PD
XX 03-APR-2002; 2002WO-US010512.
XX PF
XX 05-APR-2001; 2001US-00827395.
XX PR
XX 29-MAY-2001; 2001US-0294412P.
XX PR
XX 28-AUG-2001; 2001US-0315315P.
XX PR
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX PI
XX WPI; 2003-058513/05.
XX DR
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PT
XX Claim 59; SEQ ID NO 1051; 317pp; English.
XX PS
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX CC
XX Sequence 17 BP; 5 A; 6 C; 3 G; 0 T; 3 U; 0 Other;
SQ Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 267 ACCTGCTTCAGACAG 283
Db |||||:|||||
1 ACCUGCCUUCAGAACAG 17

RESULT 522
ADL47522
ID ADL47522 standard; RNA; 17 BP.
XX
XX AC ADL47522;
XX AC
XX 20-MAY-2004 (first entry)
XX DT
XX

```

DE Human IKK-gamma substrate sequence #32.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1055; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 7 A; 3 C; 5 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 315 AGGAGAAATCAAGAGCTC 331
 Db 1 AGGAGAAATCAAGAGCTC 17
 RESULT 523
 ADL47759
 ID ADL47759 standard; RNA; 17 BP.
 XX
 AC ADL47759;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #269.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1292; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 7 C; 4 G; 0 T; 4 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 2.2e+02;
 Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 262 GCTGCACCTGCCTTCAG 278
 Db 1 GCUGCACCUGCCUUCAG 17
 RESULT 524
 ADL47796
 ID ADL47796 standard; RNA; 17 BP.
 XX
 AC ADL47796;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE	Human IKK-gamma substrate sequence #306.	DE	Human IKK-gamma substrate sequence #322.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW	substrate; ds.	KW	substrate; ds.
OS	Unidentified.	OS	Unidentified.
XX		XX	
PN	WO200281628-A2.	PN	WO200281628-A2.
XX		XX	
PD	17-OCT-2002.	PD	17-OCT-2002.
XX		XX	
XX		XX	
PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.
XX		XX	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
PA	(RIBO-) RIBOZYME PHARM INC.	PA	(RIBO-) RIBOZYME PHARM INC.
XX		XX	
PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX		XX	
DR	WPI; 2003-058513/05.	DR	WPI; 2003-058513/05.
XX		XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
PS	Claim 59; SEQ ID NO 1329; 317pp; English.	PS	Claim 59; SEQ ID NO 1345; 317pp; English.
XX		XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.	CC	gamma substrate sequence.
XX		XX	
SQ	Sequence 17 BP; 3 A; 4 C; 5 G; 0 T; 5 U; 0 Other;	SQ	Sequence 17 BP; 3 A; 4 C; 8 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;		Query Match 2.3%; Score 17; DB 1; Length 17;	
Best Local Similarity 70.6%; Pred. No. 2.2e+02;		Best Local Similarity 88.2%; Pred. No. 2.2e+02;	
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;		Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;	
QY	417 AGGAGTTCCTCATGTGC 433	QY	503 GAGCAGGCTCTGGCGGA 519
DB	1 AGGAGUUCUCAUGUC 17	DB	1 GAGCAGGCTCTGGCGGA 17
RESULT 525		RESULT 526	
ADL47812		ADL47826	
ID ADL47812 standard; RNA; 17 BP.		ID ADL47826 standard; RNA; 17 BP.	
XX		XX	
AC ADL47812;		AC ADL47826;	
XX		XX	
DT 20-MAY-2004 (first entry)		DT 20-MAY-2004 (first entry)	
XX		XX	

```

DE Human IKK-gamma substrate sequence #336.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1359; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 5 A; 4 C; 6 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 572 GTGAAGCCAGGTGAC 588
DB 1 GUGAAAGCCAGGUGAC 17
|||||
|:|||||:|

RESULT 527
ADL47832
ID ADL47832 standard; RNA; 17 BP.
XX
AC ADL47832;
XX
XX 20-MAY-2004 (first entry)
DT
XX

DE Human IKK-gamma substrate sequence #342.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1365; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 3 C; 9 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 598 CGGGAGCTGCAGGAGA 614
DB 1 CGGGAGCTGCAGGAGA 17
|||||
|:|||||:|

RESULT 528
ADL47872
ID ADL47872 standard; RNA; 17 BP.
XX
AC ADL47872;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

DE Human IKK-gamma substrate sequence #382.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 XX OS
 XX WO200281628-A2.
 XX PN
 XX 17-OCT-2002.
 XX PD
 XX PF 03-APR-2002; 2002WO-US010512.
 XX PP
 XX 05-APR-2001; 2001US-00827395.
 XX PR 29-MAY-2001; 2001US-0294412P.
 XX PR 28-AUG-2001; 2001US-0315315P.
 XX PR
 XX (RIBO-) RIBOZYME PHARM INC.
 XX PA
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX PI
 XX WPI; 2003-058513/05.
 XX DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX Claim 59; SEQ ID NO 1405; 317pp; English.
 XX PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 8 C; 6 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 797 CGCCAGGCCGCGCTCGGA 813
 Db 1 CGCCAGGCCGCGCTCGGA 17
 |||||
 RESULT 529
 ADL47891
 ID ADL47891 standard; RNA; 17 BP.
 XX AC
 XX ADL47891;
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #401.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 XX OS
 XX WO200281628-A2.
 XX PN
 XX 17-OCT-2002.
 XX PD
 XX PF 03-APR-2002; 2002WO-US010512.
 XX PP
 XX 05-APR-2001; 2001US-00827395.
 XX PR 29-MAY-2001; 2001US-0294412P.
 XX PR 28-AUG-2001; 2001US-0315315P.
 XX PR
 XX (RIBO-) RIBOZYME PHARM INC.
 XX PA
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX PI
 XX WPI; 2003-058513/05.
 XX DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX Claim 59; SEQ ID NO 1424; 317pp; English.
 XX PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 8 A; 6 C; 2 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 871 CGACAACCCATCAAGA 887
 Db 1 CGACAACCCATCAAGA 17
 |||||
 RESULT 530
 ADL48211
 ID ADL48211 standard; RNA; 17 BP.
 XX AC
 XX ADL48211;
 XX 20-MAY-2004 (first entry)
 DT
 XX

```

DE Human IKK-gamma substrate sequence #721.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX PD 17-OCT-2002.
XX
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX
XX PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX PS Claim 59; SEQ ID NO 1744; 317pp; English.
XX
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 1 A; 6 C; 8 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 193 GCCCAGTGGTGGCCCGG 209
Db 1 GCCCAGUGGUGGCCCGG 17
|||||:|||||
|:|||||:|||||

RESULT 531
ADL48248
ID ADL48248 standard; RNA; 17 BP.
XX
XX AC ADL48248;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #758.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX PD 17-OCT-2002.
XX
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX
XX PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX PS Claim 59; SEQ ID NO 1781; 317pp; English.
XX
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 7 A; 2 C; 7 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 488 CTGAAGAGGCGAGGGA 504
Db 1 CUGAAGAGGCGAGGGA 17
|||||:|||||
|:|||||:|||||

RESULT 532
ADL48264
ID ADL48264 standard; RNA; 17 BP.
XX
XX AC ADL48264;
XX
XX DT 20-MAY-2004 (first entry)
XX

```


DE Human IKK-gamma substrate sequence #774.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS Unidentified.
 XX WO200281628-A2.
 PN 17-OCT-2002.
 XX 03-APR-2002; 2002WO-US010512.
 XX 05-APR-2001; 2001US-00827395.
 XX 29-MAY-2001; 2001US-0294412P.
 XX 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI WPI; 2003-058513/05.
 DR Novel enzymatic nucleic acid that down-regulates expression of neurite
 XX growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX Claim 59; SEQ ID NO 1797; 317pp; English.
 PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX Sequence 17 BP; 3 A; 4 C; 8 G; 0 T; 2 U; 0 Other;
 SQ Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 OY 596 CTCGGGGAGCTGCAGGA 612
 Db 1 CUCGGGGAGCTGCAGGA 17
 RESULT 533
 ADL48314
 ID ADL48314 standard; RNA; 17 BP.
 XX AC ADL48314;
 XX 20-MAY-2004 (first entry)
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #824.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS Unidentified.
 XX WO200281628-A2.
 PN 17-OCT-2002.
 XX 03-APR-2002; 2002WO-US010512.
 XX 05-APR-2001; 2001US-00827395.
 XX 29-MAY-2001; 2001US-0294412P.
 XX 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI WPI; 2003-058513/05.
 DR Novel enzymatic nucleic acid that down-regulates expression of neurite
 XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX Claim 59; SEQ ID NO 1847; 317pp; English.
 PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX Sequence 17 BP; 2 A; 5 C; 7 G; 0 T; 3 U; 0 Other;
 SQ Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 OY 830 GCCCAGTTCAGCTGGC 846
 Db 1 GCCCAGUUGCAGGUGGC 17
 RESULT 534
 ADL48316
 ID ADL48316 standard; RNA; 17 BP.
 XX AC ADL48316;
 XX 20-MAY-2004 (first entry)
 DT 20-MAY-2004 (first entry)
 XX

DE	Human IKK-gamma substrate sequence #826.	DE	Human IKK-gamma substrate sequence #999.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW	substrate; ds.	KW	substrate; ds.
OS	Unidentified.	OS	Unidentified.
XX		XX	
PN	WO200281628-A2.	PN	WO200281628-A2.
XX		XX	
PD	17-OCT-2002.	PD	17-OCT-2002.
XX		XX	
PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.
XX		XX	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
PA	(RIBO-) RIBOZYME PHARM INC.	PA	(RIBO-) RIBOZYME PHARM INC.
XX		XX	
PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX		XX	
DR	WPI; 2003-058513/05.	DR	WPI; 2003-058513/05.
XX		XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
PS	Claim S9; SEQ ID NO 1849; 317pp; English.	PS	Claim S9; SEQ ID NO 2022; 317pp; English.
XX		XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.	CC	gamma substrate sequence.
XX		XX	
SQ	Sequence 17 BP; 3 A; 5 C; 5 G; 0 T; 4 U; 0 Other;	SQ	Sequence 17 BP; 2 A; 6 C; 5 G; 0 T; 4 U; 0 Other;
	Query Match 2.3%; Score 17; DB 1; Length 17;		Query Match 2.3%; Score 17; DB 1; Length 17;
	Best Local Similarity 76.5%; Pred. No. 2.2e+02;		Best Local Similarity 76.5%; Pred. No. 2.2e+02;
	Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;		Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY	837 TGCAGGTGCCTATCAC 853	QY	579 CCCAGGTGACGTCCTTG 595
	: : : :		: : :
Db	1 UGCAGGUGGCCUAUCAC 17	Db	1 CCCAGGUGACGUUCUUG 17
RESULT 535		RESULT 536	
ADL48489		ADL48560	
ID	ADL48489 standard; RNA; 17 BP.	ID	ADL48560 standard; RNA; 17 BP.
XX		XX	
AC	ADL48489;	AC	ADL48560;
XX		XX	
DT	20-MAY-2004 (first entry)	DT	20-MAY-2004 (first entry)
XX		XX	


```

DE Human IKK-gamma substrate sequence #1124.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
PD 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
PR
PR 29-MAY-2001; 2001US-0294412P.
PR
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2147; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 5 A; 3 C; 6 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 453 AACTGGTGGAGAGACTC 469
Db 1 AACUGGUGGAGAGACUC 17
|||||:|||||:|

RESULT 539
ADL48625
ID ADL48625 standard; RNA; 17 BP.
XX
AC ADL48625;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

```

DE Human IKK-gamma substrate sequence #1135.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
PD 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
PR
PR 29-MAY-2001; 2001US-0294412P.
PR
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2158; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 8 A; 2 C; 7 G; 0 T; 0 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 491 AAGAGCGAGAGGACGA 507
Db 1 AAGAGCGAGAGGACGA 17
|||||:|||||:|

RESULT 540
ADL48671
ID ADL48671 standard; RNA; 17 BP.
XX
AC ADL48671;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

```
DE Human IKK-gamma substrate sequence #1181.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Posnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2204; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX Sequence 17 BP; 4 A; 5 C; 8 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 2.3%; Score 17; DB 1; Length 17;
XX Best Local Similarity 100.0%; Pred. No. 2.2e+02;
XX Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 680 AGCGAGCAGCGCGGCA 696
XX |||||
XX Db 1 AGCGAGCAGCGCGGCA 17
XX
XX RESULT 541
XX ADL48675
XX ID ADL48675 standard; RNA; 17 BP.
XX
XX AC ADL48675;
XX
XX XX 20-MAY-2004 (first entry)
XX
XX
```

```
DE Human IKK-gamma substrate sequence #1185.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Posnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2208; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX Sequence 17 BP; 4 A; 3 C; 8 G; 0 T; 2 U; 0 Other;
XX
XX Query Match 2.3%; Score 17; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 2.2e+02;
XX Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 695 CAGCTGGAGAGTGAGCG 711
XX |||||
XX Db 1 CAGCTGGAGAGTGAGCG 17
XX
XX RESULT 542
XX ADL48682
XX ID ADL48682 standard; RNA; 17 BP.
XX
XX AC ADL48682;
XX
XX XX 20-MAY-2004 (first entry)
XX
```

DE Human IKK-gamma substrate sequence #1192.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2215; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 5 C; 7 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 755 CGCATGCAGGCCAGAG 771
 DB 1 CGCAUGCAGGCCAGAG 17
 RESULT 543
 ADL47516
 ID ADL47516 standard; RNA; 17 BP.
 XX
 AC ADL47516;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #26.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1049; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 4 C; 6 G; 0 T; 4 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 2.2e+02;
 Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 234 AAGAGTCTCTCTGGG 250
 DB 1 AAGAGTCTCTCTGGG 17
 RESULT 544
 ADL47551
 ID ADL47551 standard; RNA; 17 BP.
 XX
 AC ADL47551;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE	Human IKK-gamma substrate sequence #61.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW	substrate; ds.
XX	Unidentified.
OS	WO200281628-A2.
PN	17-OCT-2002.
XX	
XX	03-APR-2002; 2002WO-US010512.
PF	
XX	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.
PR	
XX	(RIBO-) RIBOZYME PHARM INC.
PA	
XX	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI	WPI; 2003-058513/05.
XX	
XX	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
PT	
XX	Claim 59; SEQ ID NO 1084; 317bp; English.
PS	
XX	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.
CC	
XX	Sequence 17 BP; 3 A; 5 C; 8 G; 0 T; 1 U; 0 Other;
SQ	
Query Match 2.3%; Score 17; DB 1; Length 17;	
Best Local Similarity 94.1%; Pred. No. 2.2e+02;	
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;	
Qy	802 GGCGGCTCGGAGGAGA 818
Db	1 GGCGGCTCGGAGGAGA 17
:	
RESULT 545	
ADL47742	
ID	ADL47742 standard; RNA; 17 BP.
XX	
AC	ADL47742;
XX	
XX	20-MAY-2004 (first entry)
DT	
XX	


```

DE XX Human IKK-gamma substrate sequence #288.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX OS Unidentified.
XX
XX PN WO200281628-A2.
XX
XX PD 17-OCT-2002.
XX
XX PF 03-APR-2002; 2002WO-US010512.
XX
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX PS Claim 59; SEQ ID NO 1311; 317pp; English.
XX
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 4 A; 6 C; 5 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
Qy 332 CGAGATGCCATCCGGCA 348
Db 1 CGAGAGCCAUCCGGCA 17
|||||:|||||:|||||
1 CGAGAGCCAUCCGGCA 17

RESULT 549
ADL47787
ID ADL47787 standard; RNA; 17 BP.
XX
XX AC ADL47787;
XX
XX DT 20-MAY-2004 (first entry)
XX
XX

```

```

DE XX Human IKK-gamma substrate sequence #297.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX OS Unidentified.
XX
XX PN WO200281628-A2.
XX
XX PD 17-OCT-2002.
XX
XX PF 03-APR-2002; 2002WO-US010512.
XX
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX PS Claim 59; SEQ ID NO 1320; 317pp; English.
XX
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 3 A; 4 C; 5 G; 0 T; 5 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.2e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
Qy 376 CGAGGAGCTTCGCAAT 392
Db 1 CGAGGAGCTTCGCAAU 17
|||||:|||||:|||||
1 CGAGGAGCTTCGCAAU 17

RESULT 550
ADL47805
ID ADL47805 standard; RNA; 17 BP.
XX
XX AC ADL47805;
XX
XX DT 20-MAY-2004 (first entry)
XX
XX

```


DE	Human IKK-gamma substrate sequence #364.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX	substrate; ds.
OS	Unidentified.
XX	
PN	WO200281628-A2.
XX	
PD	17-OCT-2002.
XX	
PF	03-APR-2002; 2002WO-US010512.
XX	
PR	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.
XX	
PA	(RIBO-) RIBOZYME PHARM INC.
XX	
PI	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX	
DR	WPI; 2003-058513/05.
XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX	
PS	Claim 59; SEQ ID NO 1387; 317pp; English.
XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.
XX	
SQ	Sequence 17 BP; 5 A; 6 C; 5 G; 0 T; 1 U; 0 Other;
	Query Match 2.3%; Score 17; DB 1; Length 17;
	Best Local Similarity 94.1%; Fred. No. 2.2e+02;
	Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0
Oy	718 GCTGCAGCAGCGACCA 734
	:
Db	1 GCUCGACGACGACCA 17
RESULT 552	
ADL47867	
ID	ADL47867 standard; RNA; 17 BP.
XX	
AC	ADL47867;
XX	
DT	20-MAY-2004 (first entry)
XX	

DE Human IKK-gamma substrate sequence #377.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 23-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1400; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 1 A; 7 C; 7 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 778 GGCGCGCTCGCATGG 794
DB 1 GGCGCGCGCGCAUGG 17
RESULT 553
ADL47871
ID ADL47871 standard; RNA; 17 BP.
XX
AC ADL47871;
XX
DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #381.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 23-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1404; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 7 C; 7 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 793 GGAGCGCCAGCGCGCT 809
DB 1 GGAGCGCCAGCGCGCU 17
RESULT 554
ADL47877
ID ADL47877 standard; RNA; 17 BP.
XX
AC ADL47877;
XX
DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #387.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX 05-APR-2001; 2001US-00827395.
 PR
 XX 29-MAY-2001; 2001US-0294412P.
 PR
 XX 28-AUG-2001; 2001US-0315315P.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX Claim 59; SEQ ID NO 1410; 317pp; English.
 PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 5 C; 6 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 825 AGCTGCCCGCCAGTGGCAG 841
 Db 1 AGCUGGCCCGCCAGTGGCAG 17
 RESULT 555
 ADL47885
 ID ADL47885 standard; RNA; 17 BP.
 XX
 AC ADL47885;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #395.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX 05-APR-2001; 2001US-00827395.
 PR
 XX 29-MAY-2001; 2001US-0294412P.
 PR
 XX 28-AUG-2001; 2001US-0315315P.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX Claim 59; SEQ ID NO 1418; 317pp; English.
 PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 7 C; 2 G; 0 T; 4 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 2.2e+02;
 Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 850 TCACCAGCTCTTCCCAAG 866
 Db 1 UCACCAGCTCTTCCCAAG 17
 RESULT 556
 ADL48226
 ID ADL48226 standard; RNA; 17 BP.
 XX
 AC ADL48226;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

	Human IKK-gamma substrate sequence #744.	
DE	antisense oligonucleotide; neurite growth inhibitor; NOGO;	
XX	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	
KW	protein kinase PKR; cerebrovascular accident;	
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	
KW	substrate; ds.	
XX	Unidentified.	
OS	WO200281628-A2.	
PX	17-OCT-2002.	
XX	03-APR-2002; 2002WO-US010512.	
PF	05-APR-2001; 2001US-00827395.	
XX	PR 29-MAY-2001; 2001US-0294412P.	
PR	28-AUG-2001; 2001US-0315315P.	
XX	(RIBO-) RIBOZYME PHARM INC.	
PA	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;	
XX	WPI; 2003-058513/05.	
DR	Noel enzymatic nucleic acid that down-regulates expression of neurite	
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	
XX	Claim 59; SEQ ID NO 1767; 317pp; English.	
PS	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	
XX	that down regulate the expression or inhibit the function of a receptor	
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	
CC	IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the	
CC	invention are useful for treating: cerebrovascular accident, central	
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	
CC	ischemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	
CC	nucleic acids of the invention are also useful for down-regulating the	
CC	expression of a target gene and as a diagnostic tool to examine genetic	
CC	drifts and mutations within diseased cells or to detect the presence of a	
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	
CC	gamma substrate sequence.	
XX	Sequence 17 BP; 2 A; 4 C; 10 G; 0 T; 1 U; 0 Other;	
SQ	Query Match 2.3%; Score 17; DB 1; Length 17;	
	Best Local Similarity 94.1%; Pred. No. 2.2e+02;	
	Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;	
QY	364 GCGGGAGCGCTGCAGG 380	
	:	
Db	1 GCGGGAGCGCTGCAGG 17	
	RESULT 558	
ID	ADL48239 standard; RNA; 17 BP.	
XX	AC ADL48239;	
XX	DT 20-MAY-2004 (first entry)	
XX		

	Human IKK-gamma substrate sequence #736.	
DE	antisense oligonucleotide; neurite growth inhibitor; NOGO;	
XX	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	
KW	protein kinase PKR; cerebrovascular accident;	
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	
KW	substrate; ds.	
XX	Unidentified.	
OS	WO200281628-A2.	
PX	17-OCT-2002.	
XX	03-APR-2002; 2002WO-US010512.	
PF	05-APR-2001; 2001US-00827395.	
XX	PR 29-MAY-2001; 2001US-0294412P.	
PR	28-AUG-2001; 2001US-0315315P.	
XX	(RIBO-) RIBOZYME PHARM INC.	
PA	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;	
XX	WPI; 2003-058513/05.	
DR	Noel enzymatic nucleic acid that down-regulates expression of neurite	
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	
XX	Claim 59; SEQ ID NO 1759; 317pp; English.	
PS	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	
XX	that down regulate the expression or inhibit the function of a receptor	
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	
CC	IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the	
CC	invention are useful for treating: cerebrovascular accident, central	
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	
CC	ischemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	
CC	nucleic acids of the invention are also useful for down-regulating the	
CC	expression of a target gene and as a diagnostic tool to examine genetic	
CC	drifts and mutations within diseased cells or to detect the presence of a	
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	
CC	gamma substrate sequence.	
XX	Sequence 17 BP; 1 A; 8 C; 5 G; 0 T; 3 U; 0 Other;	
SQ	Query Match 2.3%; Score 17; DB 1; Length 17;	
	Best Local Similarity 82.4%; Pred. No. 2.2e+02;	
	Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;	
QY	298 CCTCCAGCGCTGCTGG 314	
	:	
Db	1 CCUCCAGCGCTGCCUGG 17	
	RESULT 557	
ID	ADL48234 standard; RNA; 17 BP.	
XX	AC ADL48234;	
XX	DT 20-MAY-2004 (first entry)	
XX		

DE	Human IKK-gamma substrate sequence #749.	DE	Human IKK-gamma substrate sequence #750.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX	substrate; ds.	XX	substrate; ds.
OS	Unidentified.	OS	Unidentified.
XX		XX	
PN	WO200281628-A2.	PN	WO200281628-A2.
XX		XX	
PD	17-OCT-2002.	PD	17-OCT-2002.
XX		XX	
PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.
XX		XX	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
PA	(RIBO-) RIBOZYME PHARM INC.	PA	(RIBO-) RIBOZYME PHARM INC.
XX		XX	
PI	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX		XX	
DR	WPI; 2003-058513/05.	DR	WPI; 2003-058513/05.
XX		XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
PS	Claim 59; SEQ ID NO 1772; 317pp; English.	PS	Claim 59; SEQ ID NO 1773; 317pp; English.
XX		XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
XX	gamma substrate sequence.	XX	gamma substrate sequence.
XX		XX	
SQ	Sequence 17 BP; 5 A; 6 C; 6 G; 0 T; 0 U; 0 Other;	SQ	Sequence 17 BP; 5 A; 3 C; 5 G; 0 T; 4 U; 0 Other;
	Query Match 2.3%; Score 17; DB 1; Length 17;		Query Match 2.3%; Score 17; DB 1; Length 17;
	Best Local Similarity 100.0%; Pred. No. 2.2e+02;		Best Local Similarity 76.5%; Pred. No. 2.2e+02;
	Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY	394 CCAAGCCAGCAGAGGG 410	QY	413 GAGAGGAGTTCCTCAT 429
DB	1 CCAAGCCAGCAGAGGG 17	DB	1 GAGAGGAGUUCUCAU 17
RESULT 559		RESULT 560	
ADL48240		ADL48278	
ID	ADL48240 standard; RNA; 17 BP.	ID	ADL48278 standard; RNA; 17 BP.
XX		XX	
AC	ADL48240;	AC	ADL48278;
XX		XX	
DT	20-MAY-2004 (first entry)	DT	20-MAY-2004 (first entry)
XX		XX	

DE Human IKK-gamma substrate sequence #788.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 23-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1811; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 6 C; 8 G; 0 T; 0 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 677 GCCAGCGAGCAGCGCG 693
 Db 1 GCCAGCGAGCAGCGCG 17
 RESULT 561
 ID ADL48288
 ADL48288 standard; RNA; 17 BP.
 AC ADL48288;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #798.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 23-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1821; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 5 C; 7 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 713 GAGGCGCTGCAGCAGCA 729
 Db 1 GAGGCGCTGCAGCAGCA 17
 RESULT 562
 ID ADL48300
 ADL48300 standard; RNA; 17 BP.
 AC ADL48300;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #810.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1833; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 5 C; 7 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 757 CATGCAGGCGCAGAGCG 773
 Db 1 CAUGCAGGCGCAGAGCG 17
 RESULT 563
 ADL48317
 ID ADL48317 standard; RNA; 17 BP.
 XX
 AC ADL48317;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #827.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1850; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 7 C; 1 G; 0 T; 5 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 70.6%; Pred. No. 2.2e+02;
 Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
 QY 848 TATCACCAGCTCTTCCA 864
 Db 1 UAUCACCGCUCUCCA 17
 RESULT 564
 ADL48318
 ID ADL48318 standard; RNA; 17 BP.
 XX
 AC ADL48318;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #987.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-031531SP.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2010; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 6 C; 5 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 272 CCTTCAGAACAGGGCGC 288
 Db 1 CCUUCAGAACAGGGCGC 17
 ||:|||||
 RESULT 567
 ADL48573
 ID ADL48573 standard; RNA; 17 BP.
 XX
 AC ADL48573;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1083.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-031531SP.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2106; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 6 C; 5 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 240 CTCCTCTGGGGAAGCCA 256
 Db 1 CUUCUCUGGGGAAGCCA 17
 ||:|||||
 RESULT 568
 ADL48592
 ID ADL48592 standard; RNA; 17 BP.
 XX
 AC ADL48592;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1102.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX Unidentified.
OS
XX
XX WO200281628-A2.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor; prostaglandin D2 receptor; IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
PT
XX
XX Claim 59; SEQ ID NO 2125; 317pp; English.
PS
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 4 C; 7 G; 0 T; 4 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.2e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 358 GATTCTGCGGAGCGCT 374
||:|||||
Db 1 GAUUCUGCGGAGCGCU 17
RESULT 569
ADL48593
ID ADL48593 standard; RNA; 17 BP.
XX
XX AC ADL48593;
XX
XX 20-MAY-2004 (first entry)
DT
XX

DE Human IKK-gamma substrate sequence #1103.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX Unidentified.
OS
XX
XX WO200281628-A2.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor; prostaglandin D2 receptor; IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
PT
XX
XX Claim 59; SEQ ID NO 2126; 317pp; English.
PS
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 4 C; 7 G; 0 T; 4 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.2e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 359 ATTCTGCGGAGCGCTG 375
||:|||||
Db 1 AUUCUGCGGAGCGCUG 17
RESULT 570
ADL48599
ID ADL48599 standard; RNA; 17 BP.
XX
XX AC ADL48599;
XX
XX 20-MAY-2004 (first entry)
DT
XX

DE Human IKK-gamma substrate sequence #1109.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2132; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 6 A; 3 C; 8 G; 0 T; 0 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 400 CAGCCAGAGGGAGGAGA 416
 Db 1 CAGCCAGAGGGAGGAGA 17
 RESULT 571
 ADL48635
 ID ADL48635 standard; RNA; 17 BP.
 XX
 AC ADL48635;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1145.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2168; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 6 A; 3 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 524 GAGCACCCTGAAGAGATG 540
 Db 1 GAGCACCCTGAAGAGATG 17
 RESULT 572
 ADL48662
 ID ADL48662 standard; RNA; 17 BP.
 XX
 AC ADL48662;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1172.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

XX substrate; ds.

XX Unidentified.

XX WO200281628-A2.

XX 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

XX 29-MAY-2001; 2001US-0294412P.

XX 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 2195; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX Sequence 17 BP; 2 A; 3 C; 9 G; 0 T; 3 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 2.2e+02;

Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 651 AGGCTCTGGAGGGTCGG 667

|||||:|||||:

Db 1 AGGCUCUGAGGGUCGG 17

RESULT 573

ADL48665

ID ADL48665 standard; RNA; 17 BP.

XX AC ADL48665;

XX 20-MAY-2004 (first entry)

XX DT

XX

DE Human IKK-gamma substrate sequence #1175.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

XX substrate; ds.

XX Unidentified.

XX WO200281628-A2.

XX 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

XX 29-MAY-2001; 2001US-0294412P.

XX 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 2198; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX Sequence 17 BP; 1 A; 4 C; 11 G; 0 T; 1 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 94.1%; Pred. No. 2.2e+02;

Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 658 GGAGGGTCGGGCCCGGG 674

|||||:|||||:

Db 1 GGAGGGTCGGGCCCGGG 17

RESULT 574

ADL48681

ID ADL48681 standard; RNA; 17 BP.

XX AC ADL48681;

XX 20-MAY-2004 (first entry)

XX DT

XX

DE Human IKK-gamma substrate sequence #1191.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2214; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 4 C; 7 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 738 TGCAGGTGGACCACTGTG 754
 Db :||||:||||:|
 1 UGCAGGUGGACCACTG 17
 RESULT 575
 ID ADL48706
 XX ADL48706 standard; RNA; 17 BP.
 AC ADL48706;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1216.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2239; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 2 C; 9 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 890 AGCGTGGTGGCAGTGA 906
 Db :||||:||||:|
 1 AGCGUGGUGGCGACUGA 17
 RESULT 576
 ID ADL48708
 XX ADL48708 standard; RNA; 17 BP.
 AC ADL48708;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

```
DE Human IKK-gamma substrate sequence #1218.
XX
XX antisenase oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
OS
XX
XX WO200281628-A2.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
PF
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
PR
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcawiggen J, Fosnaugh K;
PI
XX WPI; 2003-059513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
PT
XX
XX Claim 59; SEQ ID NO 2241; 317pp; English.
PS
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 4 A; 2 C; 9 G; 0 T; 2 U; 0 Other;
SQ Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 897 TGGGACGTGAGCGGAAG 913
:|||||:|||||
Db 1 UGGGACGTGAGCGGAAG 17
RESULT 577
ADI39139
ID ADI39139 standard; DNA; 18 BP.
XX
XX AC ADI39139;
XX
XX 22-APR-2004 (first entry)
DT
XX Human oligonucleotide sequence.
DE
DE Streptomyces coelicolor meth PCR primer #5.
XX fermentation; methionine; Coryneform bacterium; methionine synthase;
KW Meth; animal feed additive; sulphur; human nutrition; animal nutrition;
KW cosmetic; pharmaceutical; PCR; primer; ss.
XX
XX Streptomyces coelicolor.
OS
XX
XX WO2003087386-A2.
PN
XX
XX 23-OCT-2003.
PD
XX
XX 16-APR-2003; 2003WO-EP004010.
PF
XX
XX 17-APR-2002; 2002DE-01017058.
PR
XX
XX (BADI ) BASF AG.
PA
XX
XX Kroeger B, Zelder O, Klopprogge C, Schroeder H, Haefner S;
PI
XX WPI; 2003-877106/81.
DR
XX
XX Fermentative production of sulfur-containing compounds, particularly L-
PT methionine, useful as feed additives, by using Coryneform bacteria that
PT overexpress methionine synthase.
PT
XX
XX Example 7; SEQ ID NO 73; 304pp; German.
PS
XX
XX This invention describes a novel method for the fermentative production
CC of methionine by growing a sulphur-producing Coryneform bacteria that
CC expresses at least one heterologous nucleic acid encoding a protein with
CC methionine synthase (Meth) activity. Methionine accumulates in the medium
CC or the cells. The method can be used to produce an L-methionine-
CC containing animal feed additive by culturing an L-Met-producing
CC microorganism, removing water from the resulting broth, removing 0-100%
CC of the biomass formed and drying the product to produce the feed additive
CC in powdered or granular form. The nucleic acid encoding Meth has sequence
CC homology less than 100% with respect to the meth coding sequence of
CC Corynebacterium glutamicum ATCC 13032. Optionally at least one other gene
CC in the methionine biosynthesis pathway (e.g. aspartate kinase,
CC glyceraldehyde-3-phosphate dehydrogenase or 3-phosphoglycerate kinase) is
CC also amplified or mutated so that it is not affected by metabolites. Also
CC at least one metabolic pathway that reduces production of methionine is
CC at least partly switched off (e.g. homoserine kinase, threonine
CC dehydratase or threonine synthase). The method is especially used to
CC produce L-methionine, useful as an additive for animal feeds. More
CC generally sulphur-containing fine chemicals are useful in human and
CC animal nutrition, cosmetics and pharmaceuticals. This sequence represents
CC a PCR primer used to amplify the S. coelicolor meth gene for inclusion
CC into the construct pCPhsdh meth_Sc.
XX
XX Sequence 18 BP; 3 A; 6 C; 7 G; 2 T; 0 U; 0 Other;
SQ Query Match 2.3%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 469 CGGCCTGGAGAGCTCG 485
:|||||:|||||
Db 2 CGGCCTGGAGAGCTCG 18
RESULT 578
ABZ92117/C
ID ABZ92117 standard; DNA; 20 BP.
XX
XX AC ABZ92117;
XX
XX 17-OCT-2003 (first entry)
DT
XX Human oligonucleotide sequence.
DE
```

KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
OS Homo sapiens.
XX WO200285308-A2.
PN 31-OCT-2002.
XX 23-APR-2002; 2002WO-US013135.
PF 24-APR-2001; 2001US-0286137P.
PR (EPIG-) EPIGENESIS PHARM INC.
XX NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX Disclosure; SEQ ID NO 7359; 872pp; English.
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX Sequence 20 BP; 0 A; 9 C; 2 G; 9 T; 0 U; 0 Other;
SQ Query Match 2.2%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 2.9e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 402 GCCAGAGGGAGGAGGAGGAG 421
DB 20 GCCAGAGGAGGAGGAGGAGGAG 1
RESULT 579
ABD28347/C
ID ABD28347 standard; DNA; 20 BP.
XX ABD28347;
AC ABD28347;
DT 29-JUL-2004 (first entry)
XX AA463610-derived oligonucleotide SEQ ID 7359.
DE
XX

KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX Homo sapiens.
OS WO200285309-A2.
PN 31-OCT-2002.
XX 23-APR-2002; 2002WO-US013143.
PF 24-APR-2001; 2001US-0286036P.
PR (EPIG-) EPIGENESIS PHARM INC.
XX NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX Claim 15; SEQ ID NO 7359; 763pp; English.
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX Sequence 20 BP; 0 A; 9 C; 2 G; 9 T; 0 U; 0 Other;
SQ Query Match 2.2%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 2.9e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 402 GCCAGAGGGAGGAGGAGGAG 421
DB 20 GCCAGAGGAGGAGGAGGAGGAG 1


```
RESULT 580
ACC79548/c
ID ACC79548 standard; DNA; 21 BP.
XX
XX
AC ACC79548;
XX
XX
DT 05-AUG-2003 (first entry)
DE
DE Human TCH169 PCR primer SEQ ID NO:12.
XX
XX Human; TCH169; dicarboxylate transport; hepatotropic; cytostatic;
KW nephrotropic; vasotropic; antidiabetic; liver disease; hepatitis;
KW hepatic sclerosis; alcohol-related liver disease; prostate disease;
KW prostatitis; prostatic hypertrophy; spleen disease; spleen hyperactivity;
KW kidney disease; nephritis; kidney failure; nephritis; dropsy; diabetes;
KW diabetes-associated renal disease; metabolic disease; hyperlipaemia;
KW circulatory disease; arteriosclerosis; cancer; PCR primer; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2003025168-A1.
XX
XX 27-MAR-2003.
XX
XX 13-SEP-2002; 2002WO-JP009444.
XX
XX 17-SEP-2001; 2001JP-00281992.
XX
XX 02-OCT-2001; 2001JP-00306873.
XX
XX 16-APR-2002; 2002JP-00113279.
XX
XX (TAKE ) TAKEDA CHEM IND LTD.
XX
XX Nakanishi A, Uno Y, Sagiya Y;
XX WPI; 2003-313352/30.
XX
XX Protein TCH169 with dicarboxylate transport activity for treatment and
PT diagnosis of diseases including liver disease, cancer and circulatory
PT disorders.
XX
XX Example 1; Page 107; 132pp; Japanese.
XX
XX The present invention describes protein TCH169 and its salts having
CC dicarboxylate transport activity. TCH169 has hepatotropic, cytostatic,
CC nephrotropic, vasotropic and antidiabetic activities. The TCH169 protein
CC and polynucleotide can be used in the treatment, prevention and diagnosis
CC of liver disease (such as hepatitis, hepatic sclerosis and alcohol-
CC related liver disease); prostate disease (such as prostatitis and
CC prostatic hypertrophy); spleen disease (such as spleen hyperactivity);
CC kidney disease (such as nephritis, kidney failure, nephritis, dropsy and
CC diabetes-associated renal disease); metabolic disease (such as diabetes);
CC circulatory disease (such as hyperlipaemia and arteriosclerosis); and
CC cancer (such as non-small cell lung cancer, liver cancer, renal cancer,
CC ovarian cancer, prostate cancer, stomach cancer, pancreatic cancer,
CC breast cancer, colon cancer, bladder cancer and womb cancer). The present
CC sequence represents a PCR primer for human TCH169, which is used in an
CC example from the present invention
XX
SQ Sequence 21 BP; 7 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 2.2%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 3.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 423 TCCTCATGTGCAAGTTCAG 442
Db 20 TCCTCTTGTCAGGTTCCAG 1
RESULT 581
```

```
ACC79554
ID ACC79554 standard; DNA; 21 BP.
XX
XX
AC ACC79554;
XX
XX
DT 05-AUG-2003 (first entry)
DE
DE Human TCH169 PCR primer SEQ ID NO:18.
XX
XX Human; TCH169; dicarboxylate transport; hepatotropic; cytostatic;
KW nephrotropic; vasotropic; antidiabetic; liver disease; hepatitis;
KW hepatic sclerosis; alcohol-related liver disease; prostate disease;
KW prostatitis; prostatic hypertrophy; spleen disease; spleen hyperactivity;
KW kidney disease; nephritis; kidney failure; nephritis; dropsy; diabetes;
KW diabetes-associated renal disease; metabolic disease; hyperlipaemia;
KW circulatory disease; arteriosclerosis; cancer; PCR primer; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2003025168-A1.
XX
XX 27-MAR-2003.
XX
XX 13-SEP-2002; 2002WO-JP009444.
XX
XX 17-SEP-2001; 2001JP-00281992.
XX
XX 02-OCT-2001; 2001JP-00306873.
XX
XX 16-APR-2002; 2002JP-00113279.
XX
XX (TAKE ) TAKEDA CHEM IND LTD.
XX
XX Nakanishi A, Uno Y, Sagiya Y;
XX WPI; 2003-313352/30.
XX
XX Protein TCH169 with dicarboxylate transport activity for treatment and
PT diagnosis of diseases including liver disease, cancer and circulatory
PT disorders.
XX
XX Example 1; Page 109; 132pp; Japanese.
XX
XX The present invention describes protein TCH169 and its salts having
CC dicarboxylate transport activity. TCH169 has hepatotropic, cytostatic,
CC nephrotropic, vasotropic and antidiabetic activities. The TCH169 protein
CC and polynucleotide can be used in the treatment, prevention and diagnosis
CC of liver disease (such as hepatitis, hepatic sclerosis and alcohol-
CC related liver disease); prostate disease (such as prostatitis and
CC prostatic hypertrophy); spleen disease (such as spleen hyperactivity);
CC kidney disease (such as nephritis, kidney failure, nephritis, dropsy and
CC diabetes-associated renal disease); metabolic disease (such as diabetes);
CC circulatory disease (such as hyperlipaemia and arteriosclerosis); and
CC cancer (such as non-small cell lung cancer, liver cancer, renal cancer,
CC ovarian cancer, prostate cancer, stomach cancer, pancreatic cancer,
CC breast cancer, colon cancer, bladder cancer and womb cancer). The present
CC sequence represents a PCR primer for human TCH169, which is used in an
CC example from the present invention
XX
SQ Sequence 21 BP; 3 A; 6 C; 5 G; 7 T; 0 U; 0 Other;
Query Match 2.2%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 3.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 423 TCCTCATGTGCAAGTTCAG 442
Db 2 TCCTCTTGTCAGGTTCCAG 21
RESULT 582
AA36938
ID AAX36938 standard; DNA; 22 BP.
XX
```


AA36938;
 02-JUL-1999 (first entry)
 S. cereale microsatellite marker PCR primer 37.
 Microsatellite; marker; PCR primer; rye; plant; Triticeae; Poae;
 simple sequence repeat; SSR; sequence tag site; STS; genetic analysis;
 DNA fingerprinting; variety identification; self fertilization;
 detection; cross fertilization; cytological line; gene mapping;
 monogenic trait; polygenic trait; ss.
 Synthetic.
 Secale cereale.
 DE19835109-A1.
 15-APR-1999.
 04-AUG-1998; 98DE-01035109.
 02-OCT-1997; 97DE-01043671.
 (GVSE-) GVS GES ERWERB & VERWERTUNG LANDWIRTSCHA.
 Wricke G, Saal B;
 WPI; 1999-245522/21.
 Microsatellite markers derived from the genome of rye, useful for genetic
 mapping as markers of monogenic or polygenic traits.
 Claim 6; Page 19; 28pp; German.
 This invention describes Secale cereale microsatellite markers based on
 hypervariable genomic segments of Secale cereale and plants of the tribes
 Triticeae and Poae. The microsatellite markers comprise a simple
 sequence repeat (SSR) marker as sequence tag site (STS), defined by two
 specific S. cereale defined primers, of mean length 18-26 bases and
 flanking the microsatellite sequence (MSS). Such markers are useful for
 genetic analysis of rye, triticale and other species of the tribes
 Triticeae and Poae, e.g. for DNA fingerprinting; identification of
 varieties; detecting self or cross fertilization; studying similarity and
 relatedness; characterization of cytological lines, or generally any sort
 of gene mapping. Particularly, they are useful for genetic mapping and
 marking of mono- or poly-genic traits, selection and evaluation of
 varietal purity or checking culture stages (particularly in hybrid
 culture methods), purity of propagative materials, success of self-
 fertilization and required ratio of components in populations and
 hybrids. AAX36902-X36965 represent PCR primers used in the method of the
 invention
 Sequence 22 BP; 6 A; 4 C; 8 G; 4 T; 0 U; 0 Other;
 Query Match 2.2%; Score 16.8; DB 1; Length 22;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 543 AGCAGCAGATGGCTGAGGAC 562
 Db 3 AGCCGAGATGGTTGAGGAC 22
 RESULT 583
 AA23863
 ID AA23863 standard; DNA; 22 BP.
 AC AA23863;
 XX
 21-JAN-2000 (first entry)
 Rye microsatellite marker 19 PCR primer 1.
 XX

KW Microsatellite marker; rye; hypervariable genomic region; Poae;
 KW Triticeae; breeding program; DNA fingerprinting; variety; detection;
 KW self pollination; cross pollination; cytoplasmic line; genetic mapping;
 KW polymorphism; PCR primer; ss.
 XX
 OS Synthetic.
 OS Secale cereale.
 XX
 PN DE19811506-A1.
 XX
 PD 21-OCT-1999.
 XX
 PF 17-MAR-1998; 98DE-01011506.
 XX
 PR 17-MAR-1998; 98DE-01011506.
 XX
 PA (GVSE-) GVS GES ERWERB & VERW LANDWIRTSCHAFTLICH.
 XX
 DR WPI; 1999-591715/51.
 XX
 XX New microsatellite markers for rye and closely related grasses, used for
 PT genetic analysis and in breeding.
 XX
 PS Claim 6; Page 27; 28pp; German.
 XX
 CC This invention describes novel microsatellite markers (MSM), based on the
 CC hypervariable genomic regions of rye (Secale cereale) and of plants from
 CC the tribes Triticeae and Poae. MSM, which are new genetic markers for
 CC rye and closely related species, are used for genetic analysis and in
 CC breeding programs. Typical applications are in DNA fingerprinting;
 CC identification of varieties; detection of self and cross pollination;
 CC characterization of cytoplasmic lines, and genetic mapping (of mono- or
 CC poly-genic traits). MSM show a higher degree of polymorphism than known
 CC markers (both within and between different rye varieties and lines); can
 CC be detected by polymerase chain reaction, so that even very small samples
 CC may be analyzed, and generate many alleles per marker locus. AA23827-
 CC 223886 represent the microsatellite marker PCR primers described in the
 CC method of the invention
 XX
 SQ Sequence 22 BP; 6 A; 4 C; 8 G; 4 T; 0 U; 0 Other;
 Query Match 2.2%; Score 16.8; DB 1; Length 22;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 543 AGCAGCAGATGGCTGAGGAC 562
 Db 3 AGCCGAGATGGTTGAGGAC 22
 RESULT 584
 AA18609
 ID AA18609 standard; DNA; 20 BP.
 XX
 AC AA18609;
 XX
 DT 21-JUL-1998 (first entry)
 XX
 DE Synthetic human tumour necrosis factor related ligand PCR primer.
 KW
 KW TRELL; tumour necrosis factor related ligand; tnfr; treatment; cancer;
 KW autoimmune disease; immune system; stimulation; suppression;
 KW graft rejection; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 PN WO9805783-A1.
 XX
 PD 12-FEB-1998.
 XX
 XX 07-AUG-1997; 97WO-US013945.
 XX

PR 07-AUG-1996; 96US-0023541P.
 PR 18-OCT-1996; 96US-0028515P.
 PR 18-MAR-1997; 97US-0040820P.
 XX
 PA (BIOJ) BIOGEN INC.
 PA (UYGE-) UNIV GENEVA FACULTY MEDICINE.
 XX Chicheportiche Y, Browning JL;
 DR WPI; 1998-145619/13.
 XX Tumour necrosis factor related ligand - useful for, e.g. treating cancer,
 PT auto-immune disease and immune responses to tissue grafts.
 XX
 PS Example 2; Page 34; 69pp; English.
 XX The sequence is that of a PCR primer which was used in the cloning of
 CC cDNA coding for human tumour necrosis factor related ligand (TRELL). The
 CC sequence was derived from human EST R55379 (Genbank)
 XX
 SQ Sequence 20 BP; 3 A; 7 C; 7 G; 3 T; 0 U; 0 Other;
 Query Match 2.2%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 3.3e+02;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 301 CCAGCGCTGCTGGAGGA 318
 DB 2 CCTGGCTGCTGGAGGA 19
 RESULT 585
 AAV18602
 ID AAV18602 standard; DNA; 20 BP.
 XX
 AC AAV18602;
 XX
 DT 21-JUL-1998 (first entry)
 XX
 DE Synthetic human tumour necrosis factor related ligand PCR primer.
 XX
 KW TRELL; tumour necrosis factor related ligand; tnf; treatment; cancer;
 KW autoimmune disease; immune system; stimulation; suppression;
 KW graft rejection; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN W09805783-A1.
 XX
 PD 12-FEB-1998.
 XX
 PF 07-AUG-1997; 97WO-US013945.
 XX
 PR 07-AUG-1996; 96US-0023541P.
 PR 18-OCT-1996; 96US-0028515P.
 PR 18-MAR-1997; 97US-0040820P.
 XX
 PA (BIOJ) BIOGEN INC.
 PA (UYGE-) UNIV GENEVA FACULTY MEDICINE.
 XX Chicheportiche Y, Browning JL;
 DR WPI; 1998-145619/13.
 XX Tumour necrosis factor related ligand - useful for, e.g. treating cancer,
 PT auto-immune disease and immune responses to tissue grafts.
 XX
 PS Example 1; Page 29; 69pp; English.
 XX The sequence is that of PCR primer LTB-065 which was used in the
 CC isolation of cDNA coding for human tumour necrosis factor related ligand
 CC (TRELL). The sequence was derived from human EST AAR55379

XX
 SQ Sequence 20 BP; 3 A; 7 C; 7 G; 3 T; 0 U; 0 Other;
 Query Match 2.2%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 3.3e+02;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 301 CCAGCGCTGCTGGAGGA 318
 DB 2 CCTGGCTGCTGGAGGA 19
 RESULT 586
 ABZ87729
 ID ABZ87729 standard; DNA; 20 BP.
 XX
 AC ABZ87729;
 XX
 DT 17-OCT-2003 (first entry)
 XX
 DE Human oligonucleotide sequence.
 XX
 KW Human; antisense; lung dysfunction; nasal airway dysfunction;
 KW antiinflammatory steroid; ubinone; antiinflammatory; antiallergic;
 KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.
 XX
 OS Homo sapiens.
 XX
 PN W0200285308-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013135.
 XX
 PR 24-APR-2001; 2001US-0286137P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahbuddin S;
 XX
 DR WPI; 2003-229219/22.
 XX
 PT Pharmaceutical composition for treating ailments associated with impaired
 PT respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubinone.
 XX
 PS Disclosure; SEQ ID NO 2971; 872pp; English.
 XX
 CC The invention relates to a novel pharmaceutical composition, which has a
 CC first active agent comprising an oligonucleotide antisense to the
 CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
 CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
 CC junctions of genes encoding a polypeptide associated with lung and/or
 CC nasal airway dysfunction and a second active agent comprising an
 CC antiinflammatory steroid and ubinone. A composition of the invention
 CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
 CC immunosuppressive, and cytostatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an
 CC antiinflammatory steroid in a subject, for reducing or depleting levels
 CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
 CC receptor, producing bronchodilation, increasing levels of ubinone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: The sequence data for this patent is not represented in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences

XX
SQ Sequence 20 BP; 5 A; 3 C; 10 G; 2 T; 0 U; 0 Other;
Query Match 2.2%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 897 TGGGCAGTGCAGCGGAAGC 914
|||||
Db 2 TGGGCAGTGCAGCGGAAGC 19
RESULT 587
ID ABD23959 standard; DNA; 20 BP.
XX
AC ABD23959;
XX
DT 29-JUL-2004 (first entry)
XX Human calmodulin 2-derived oligonucleotide SEQ ID 2971.
DE
DE Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
XX Homo sapiens.
OS
XX
XX
PN WO200285309-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013143.
XX
XX 24-APR-2001; 2001US-0286036P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
PI Nyce JW, Li Y, Sandrasegura A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-093058/08.
XX
XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 2971; 763pp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The

CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 5 A; 3 C; 10 G; 2 T; 0 U; 0 Other;
Query Match 2.2%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 897 TGGGCAGTGCAGCGGAAGC 914
|||||
Db 2 TGGGCAGTGCAGCGGAAGC 19
RESULT 588
ID ADQ90611/c
XX ADQ90611 standard; DNA; 21 BP.
AC ADQ90611;
XX
XX 21-OCT-2004 (first entry)
XX
XX Sca-2 siRNA duplex sense oligonucleotide SEQ ID NO:8.
DE
XX lentiviral vector; small interference RNA; siRNA; cytostatic; virucide;
KW gene therapy; Sca-2; ss.
XX
XX Mus musculus.
OS Synthetic.
XX
XX WO2004065549-A2.
PN
XX
XX 05-AUG-2004.
XX
XX 15-JAN-2004; 2004WO-US001320.
PF
XX
XX 17-JAN-2003; 2003US-0440987P.
PR
XX (UYFL) UNIV FLORIDA.
PA
XX Chang L, He J;
PI
XX WPI; 2004-562155/54.
XX
XX New lentiviral vector comprising a nucleotide sequence encoding a small
PT interference RNA, useful for reducing expression of a target gene in a
PT cell.
XX
PS Example 1; SEQ ID NO 8; 51pp; English.
XX
XX The present invention describes a lentiviral vector comprising a
CC nucleotide sequence encoding a small interference RNA (siRNA). Also
CC described is a method of reducing expression of a target gene in a cell
CC comprising: (a) introducing into the cell a lentiviral vector encoding a
CC siRNA specific for the gene; and (b) placing the cell under conditions,
CC where the siRNA specific for the gene is expressed to cause a detectable
CC decrease in expression of the gene. The siRNA has cytostatic and virucide
CC activities, and can be used in gene therapy. The vector is useful for
CC reducing expression of a target gene in a cell. The present sequence
CC represents a Sca-2 siRNA duplex oligonucleotide, which is used in an
CC example from the present invention.
XX
XX Sequence 21 BP; 3 A; 7 C; 3 G; 8 T; 0 U; 0 Other;


```

Query Match      2.1%; Score 16; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3.e+02;
Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 901 CAGTGGCGGAGCGGA 916
DB 1 CAGUGAGCGGAGCGGA 16

RESULT 591
AAV29497/C
ID AAV29497 standard; DNA; 19 BP.
XX
AC AAV29497;
XX
DT 05-AUG-1998 (first entry)
XX
DE Serotonin 5HT7 receptor allelic variant amplifying ASA upper primer.
XX
KW Allelic variant; serotonin 5HT7 receptor; alcoholic offender; 5HT7leu;
KW neuropsychiatric drug; screening; allele specific amplification; ASA;
KW PCR primer; ss.
XX
OS Synthetic.
OS Homo sapiens.
PN US5763183-A.
XX
PD 09-JUN-1998.
XX
PF 08-NOV-1996; 96US-00745269.
XX
PR 09-NOV-1995; 95US-0006394P.
XX
PA (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI Virkkunen M, Goldman D, Pesonen U, Koulu M, Linnoila M;
XX
WPI; 1998-347310/30.
DR
XX
PT Allelic variant of serotonin 5HT7 receptor gene - is associated with
PT alcoholic offenders and is useful for screening neuropsychiatric drugs.
XX
PS Example 2; Col 7; 11pp; English.
XX
CC This PCR primer is used for allele specific amplification (ASA) of the
CC allelic variant of the serotonin 5HT7 receptor (5HT7leu). This is used
CC for screening large numbers of samples for 5HT7leu variant. The invention
CC provides a method for detecting DNA that codes for a 5HT7leu allelic
CC variant which comprises amplifying human DNA with primers capable of
CC amplifying a sequence encoding the third intracellular loop of the human
CC 5HT7 gene and determining if the amplified DNA comprises a sequence in
CC which a C-to-T alteration converts a Pro codon to a Leu codon. The
CC 5HT7leu variant and associated DNA and assays provide important
CC investigative tools for both behavioural research and the screening of
CC neuropsychiatric drug candidates
XX
SQ Sequence 19 BP; 3 A; 6 C; 3 G; 7 T; 0 U; 0 Other;

Query Match      2.1%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 3.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 441 AGGAGCCGAGAACTGGT 459
DB 19 AGGAGCCGAGAACTGGT 1

RESULT 592
ADL95276
ID ADL95276 standard; RNA; 19 BP.
XX

```

```

AC ADL95276;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human 23S rRNA molecular interaction site SeqID 290.
XX
KW molecular interaction site; 23S rRNA; combinatorial library;
KW antimicrobial; prokaryotic cell growth; ss; human.
XX
OS Homo sapiens.
XX
PN WO2003018750-A2.
XX
PD 06-MAR-2003.
XX
PF 21-AUG-2002; 2002WO-US026582.
XX
PR 22-AUG-2001; 2001US-0314251P.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Ecker DJ;
XX
WPI; 2003-457183/43.
XX
CC New polynucleotides comprising molecular interaction sites of 23S rRNA
CC that have secondary structures, useful for virtual or actual screening of
CC compounds that bind to it, and the modulation of the activity of the 23S
CC rRNA.
XX
CC Example 3; SEQ ID NO 290; 148pp; English.
XX
CC This invention relates to a novel polynucleotides that comprise molecular
CC interaction sites of 23S rRNA secondary structure. Specifically, it
CC refers to the virtual or actual screening of combinatorial libraries of
CC compounds that can bind to and modulate the activity of 23S rRNA, and as
CC such affect interactions with factors and proteins required for
CC translation and other cellular processes. The present invention describes
CC the identification of molecular interaction consensus sequences of 23S
CC rRNA (and their secondary structures) that can be used as antimicrobial
CC targets for compounds that modulate, inhibit or stimulate prokaryotic
CC cell growth, and thus are useful as novel drugs, agricultural chemicals
CC and industrial chemicals that operate through the modulation of 23S rRNA.
CC This oligonucleotide sequence is a 23S rRNA oligo, a targeted molecular
CC interaction site of the invention.
XX
SQ Sequence 19 BP; 1 A; 6 C; 10 G; 0 T; 2 U; 0 Other;

Query Match      2.1%; Score 15.8; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 3.6e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 652 GGCTCTGGAGGTCGGGCC 670
DB 1 GGCGCUGGAGCGUCGGGCC 19

RESULT 593
AAQ83789/C
ID AAQ83789 standard; DNA; 20 BP.
XX
AC AAQ83789;
XX
DT 25-MAR-2003 (revised)
DT 05-SEP-1995 (first entry)
XX
DE VEGF antisense oligonucleotide.
XX
KW Vascular endothelial growth factor; VEGF; antisense; phosphorothioate;
KW oligonucleotide; angiogenesis; diabetes; retinopathy; atherosclerosis;
KW wound healing; vulneryary; tumor; metastasis; ss.
XX
OS Synthetic.

```

```

XX Key Location/Qualifiers
FH m1sc_feature 1. .20
FT /*tag= a
FT /note= "phosphorothioate internucleotide linkages"
XX
XX WO9504142-A2.
XX
XX PD 09-FEB-1995.
XX
XX PF 26-JUL-1994; 94WO-US0008537.
XX
XX PR 27-JUL-1993; 93US-00098942.
XX
XX PA (HYBR-) HYBRIDON INC.
XX
XX PI Robinson GS;
XX
XX DR WPI; 1995-082226/11.
XX
XX New antisense oligo-nucleotide(s) inhibiting vascular endothelial growth
PT factor - for treating abnormal angiogenesis in cases of e.g. diabetic
PT retinopathy or tumour.
XX
XX Example 5; Page 35; 45pp; English.
XX
XX Inhibition of vascular endothelial growth factor (VEGF) expression, as a
CC means of controlling angiogenesis, is obtained using antisense
CC oligonucleotides (AODN) complementary to portions of VEGF RNA. The AODN
CC given in AAQ83789 is targeted against sequences in the 5'UTR of the human
CC VEGF molecule. It had no effect on VEGF protein production. (Updated on
CC 25-MAR-2003 to correct PN field.)
XX
XX Sequence 20 BP; 0 A; 11 C; 4 G; 5 T; 0 U; 0 Other;
SQ
Query Match 2.1%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 696 AGCTGGAGAGTGAGCGGA 714
XX ||| ||||| ||||| |||||
DB 19 AGCCGGAGAGGAGCGGA 1
XX
RESULT 594
AAQ90288
XX ID AAQ90288 standard; DNA; 20 BP.
XX
XX AC AAQ90288;
XX
XX DT 11-JAN-1996 (first entry)
XX
XX DE 16S rRNA gene PCR detection primer ER6.
XX
XX KW Primer; PCR; amplification; microorganism; bacterium; virus; fungus;
XX actinomycete; unicellular parasite; 16S; 23S; rRNA gene;
XX fluorescein isothiocyanate; gel electrophoresis; ss.
XX
XX OS Synthetic.
XX
XX PN WO9513396-A2.
XX
XX PD 18-MAY-1995.
XX
XX PF 11-NOV-1994; 94WO-NL000283.
XX
XX PR 11-NOV-1993; 93NL-00001957.
XX
XX PA (UGEN-) U GENE RES BV.
XX
XX PI Fluit AC, Widjoatmodjo MN;
XX
XX DR WPI; 1995-194113/25.

```

```

XX Identification of microorganisms by nucleic acid amplification - using
PT universal primers and comparison of electrophoretic sepn. patterns, esp.
PT for rapid species specific identification of bacteria.
XX
XX Claim 5; Page 31; 34pp; English.
XX
XX The primers AAQ90283-94 are used in a PCR amplification method for the
CC detection of microorganisms esp. bacteria, but also for viruses, fungi,
CC actinomycetes, unicellular parasites, etc. The primers are based on the
CC sequences of the 16S and 23S rRNA genes but can also include other 1041-
CC species and gene specific primers. This primer corresponds to bases 1041-
CC 60 of the 16S rRNA gene. The primers can be labelled for ease of
CC detection by e.g. fluorescein isothiocyanate (FITC). The amplification
CC products are converted to a single strand form and separated by gel
CC electrophoresis, based on sequence-dependent differences in mobility
CC (SDDM) of the single stranded DNA or RNA. The band pattern generated by
CC the electrophoresis can be used to identify the species or strain of
CC microorganism when compared to a set of electrophoresis patterns for
CC known microorganisms
XX
XX Sequence 20 BP; 4 A; 8 C; 4 G; 4 T; 0 U; 0 Other;
SQ
Query Match 2.1%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 256 AGCCATGCTGCACCTGCCT 274
XX ||||| ||||| ||||| |||||
DB 1 AGCCATGCTGCACCTGTCT 19
XX
RESULT 595
ABQ78472/c
XX ID ABQ78472 standard; DNA; 20 BP.
XX
XX AC ABQ78472;
XX
XX DT 05-NOV-2002 (first entry)
XX
XX DE Antisense oligonucleotide targeted to VEGF 3' untranslated region..
XX
XX KW Antisense oligonucleotide; vascular endothelial growth factor; VEGF;
XX vascular permeability factor; VPF; angiogenesis; phosphorothioate;
XX angiogenic disorder; diabetic retinopathy; tumour angiogenesis;
XX angiosclerotic plaque formation; wound healing; ss.
XX
XX OS Synthetic.
XX
XX OS Homo sapiens.
XX
XX FH Key Location/Qualifiers
FT modified_base 1. .20
FT /*tag= a
FT /note= "phosphorothioate internucleotide linkages"
XX
XX US6410322-B1.
XX
XX PD 25-JUN-2002.
XX
XX PF 27-JUL-1993; 93US-00098942.
XX
XX PR 27-JUL-1993; 93US-00098942.
XX
XX PA (ROBI/) ROBINSON G S.
XX
XX PI Robinson GS;
XX
XX DR WPI; 2002-588890/63.
XX
XX New antisense oligonucleotides that bind to Vascular Endothelial Growth
PT Factor (VEGF) RNA and inhibit production of the VEGF protein, useful for
PT treating angiogenic disorders, e.g. diabetic retinopathy and tumor
PT angiogenesis.

```

XX Example 5; Col 12; 16pp; English.

XX The present sequence represents an antisense oligonucleotides which is

XX targeted to vascular endothelial growth factor (VEGF) RNA. While the

XX present oligonucleotide did not inhibit VEGF protein production, other

XX antisense oligonucleotides (see ABQ78459-62 and ABQ78467-69) did. VEGF,

XX also known as vascular permeability factor (VPF), has been shown to play

XX an integral role in abnormal angiogenesis associated with a variety of

XX pathological states. These antisense oligonucleotides are useful in the

XX treatment of pathological states in which VEGF expression plays a role,

XX especially angiogenic disorders, e.g. diabetic retinopathy,

XX atherosclerotic plaque formation, wound healing and tumour angiogenesis.

XX Inhibition of VEGF expression by antisense oligonucleotide technology

XX will also be useful in determining the role of this cytokine in processes

XX where angiogenesis is involved. In vitro systems which mimic blood vessel

XX formation/permeability have been developed. The role of VEGF in these

XX systems can be determined using antisense oligonucleotides

XX

SQ Sequence 20 BP; 0 A; 11 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 2.1%; Score 15.8; DB 1; Length 20;

Best Local Similarity 89.5%; Pred. No. 3.9e+02;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 696 AGCTGGAGAGTGAGCGCGA 714

DB 19 AGCCGGAGGAGCGCGA 1

RESULT 596

ADP11986

ID ADP11986 standard; DNA; 20 BP.

XX ADP11986;

AC ADP11986;

DT 12-AUG-2004 (first entry)

XX Set 2 right PCR primer for marker probe #92.

DE transplant rejection; immune system; rheumatoid arthritis; lupus;

KW inflammatory bowel disease; multiple sclerosis; HIV; AIDS; ss; primer.

XX Homo sapiens.

OS WO2004042346-A2.

PN 21-MAY-2004.

PD 24-APR-2003; 2003WO-US012946.

PF 24-APR-2002; 2002US-00131831.

PR 20-DEC-2002; 2002US-00325899.

XX (EXPR-) EXPRESSION DIAGNOSTICS INC.

PA Wohlgemuth J, Fry K, Woodward R, Ly N, Prentice J, Morris M;

XX Rosenberg S;

PI WPI; 2004-400724/37.

DR Diagnosing or monitoring transplant rejection, e.g. heart, kidney, liver,

PT pancreas, pancreatic islet, lung, bone marrow or stem cell transplant

PT rejection, in an individual, comprises detecting the expression level of

PT the genes.

XX Claim 58; SEQ ID NO 1995; 1762pp; English.

XX The present invention relates to diagnosing or monitoring transplant

CC rejection, e.g. cardiac or kidney transplant rejection, in an individual

CC comprises detecting the expression level of one or more genes. The

CC methods, system and kits are useful in diagnosing or monitoring

CC transplant rejection, e.g. heart, kidney, liver, pancreas, pancreatic

CC islet, lung, bone marrow or stem cell transplant rejection,

CC xenotransplant rejection or mechanical organ replacement rejection, in an

CC individual. The method is also useful in assessing the immune status of

CC an individual. The methods are also useful in diagnosing and monitoring

CC diseases that involve the immune system, e.g. rheumatoid arthritis,

CC lupus, inflammatory bowel diseases, multiple sclerosis, HIV/AIDS or

CC viral, bacterial or fungal infection. The present sequence represents a

CC primer for a 50 mer oligonucleotide marker for diagnosis and monitoring

CC of allograft rejection and other disorders.

XX

SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 2.1%; Score 15.8; DB 1; Length 20;

Best Local Similarity 89.5%; Pred. No. 3.9e+02;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 510 CTCTCGGAGGAGTGAGCA 528

DB 2 CTCTCGGAGGAGTGAGCA 20

RESULT 597

ADOI5339/c

ID ADOI5339 standard; DNA; 20 BP.

XX ADOI5339;

AC ADOI5339;

DT 12-AUG-2004 (first entry)

XX DNA probe used for one-step real-time RT-PCR detection SeqID 15.

DE one step real-time RT-PCR; pharmaceutical; cosmetic; bacteria;

KW fungus-yeast; probe; ss.

XX Synthetic.

OS WO2004044247-A2.

PN 27-MAY-2004.

PD 03-NOV-2003; 2003WO-IB005312.

PF 12-NOV-2002; 2002US-0425327P.

PR (GENO-) GENOLIFE.

PA Chaubron F, Martin-Minvielle AC, Groulon S;

XX WPI; 2004-411742/38.

DR Determining presence of bacteria or fungus-yeast RNA in sample involves

PT carrying out reverse transcriptase-PCR reaction of fungus-yeast RNA and

PT treating amplified DNA with probes which hybridize to amplified DNA.

XX

PS Claim 1; SEQ ID NO 15; 31pp; English.

XX This invention relates to a novel method for one step real-time RT-PCR

CC kits useful for the detection of microorganisms occurring within

CC industrial products such as pharmaceuticals, cosmetic and non-clinical

CC samples. Specifically, it refers to determining the presence of bacteria

CC or fungus-yeast RNA in a sample suspected of containing such

CC contaminants. The present invention describes oligonucleotide primers and

CC probes that are natural nucleic acid or peptide nucleic acid (PNA)

CC molecules that can hybridize to the target nucleic acid (DNA and RNA).

CC Accordingly, the method enables rapid and simultaneous detection and

CC quantification of RNA from bacteria and fungus-yeast in either sterile or

CC non-sterile products in less than 24 hours. Furthermore, the one step

CC process reduces the risk of environmental contamination that could occur

CC when the reaction tubes are opened during the PCR procedure. This

CC oligonucleotide sequence is a PCR primer used in one-step real time RT-

CC PCR to amplify bacteria and fungus-yeast RNA, given in an exemplification

CC of the invention.

XX

SQ Sequence 20 BP; 3 A; 5 C; 7 G; 5 T; 0 U; 0 Other;
 Query Match 2.1%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 3.9e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 253 GCCAGCATGCTGCACCTG 271
 DB 20 GACAGCCATGACGACCTG 2

RESULT 598
 ABS60815/c
 ID ABS60815 standard; DNA; 21 BP.
 AC ABS60815;
 XX
 XX
 DT 05-NOV-2002 (first entry)
 XX
 XX Human polymorphism associated DNA sequence #452.
 XX
 XX Aminoacylase P; XPNEP2; bradykinin receptor B1; ds; BDKRB1;
 KW tachykinin receptor B1; TACR1; C1 esterase inhibitor; CLNH; kallikrein 1;
 KW KUK1; bradykinin receptor B2; BDKRB2; gene therapy;
 KW angiotensin converting enzyme 2; ACE2; protease inhibitor 4; PI4;
 KW polymorphism; haemangioma; tumour; sarcoma; Crohn's disease; trachoma;
 KW cardiovascular disease; angina pectoris; hypertension; heart failure;
 KW myocardial infarction; ventricular hypertrophy; vascular disease;
 KW aneurysm; embolism; thrombosis; coronary artery disease; angioedema;
 KW arteriosclerosis; atherosclerosis; hypersensitivity; sepsis;
 KW autoimmune disease; inflammatory arthritis; cancer; wound;
 KW viral infection; bacterial infection; fungal infection; COPD;
 KW Chronic obstructive pulmonary disease; enterocolitis.
 XX
 OS Homo sapiens.
 XX
 XX WO200261131-A2.
 XX
 XX 08-AUG-2002.
 XX
 XX 03-DEC-2001; 2001WO-US047235.
 XX
 XX 04-DEC-2000; 2000US-0251015P.
 XX 23-JAN-2001; 2001US-0263678P.
 XX 02-MAR-2001; 2001US-0273037P.
 XX
 XX (BRIM) BRISTOL-MYERS SQUIBB CO.
 XX (TSUC) TSUCHIHASHI Z.
 XX (HUI) HUI L.
 XX
 XX Tsuchihashi Z, Hui L, Zerba KE, Ma-Edmonds M, Perrone MH,
 XX Swanson BN, Powell JR;
 XX
 XX WPI; 2002-619265/66.
 XX
 XX New isolated nucleic acid with at least one polymorphic position, useful
 XX for detecting, diagnosing and treating disorders such as angioedema,
 XX cancer, viral, bacterial or fungal infection, cardiovascular and
 XX autoimmune diseases.
 XX
 XX Disclosure; Page 884; 977pp; English.
 XX
 XX The invention relates to an isolated nucleic acid from a human gene
 XX encoding aminopeptidase P (XPNEP2), bradykinin receptor B1 (BDKRB1),
 XX tachykinin receptor B1 (TACR1), C1 esterase inhibitor (CLNH), kallikrein
 XX 1 (KUK1), bradykinin receptor B2 (BDKRB2), angiotensin converting enzyme
 XX 2 (ACE2) or protease inhibitor 4 (PI4), comprising at least one
 XX polymorphic position. Also included are (1) a probe that hybridises to a
 XX polymorphic position as provided in the detailed summary of single
 XX nucleotide polymorphisms comprising additional 5' and 3' flanking genomic
 XX sequence; (2) analysing (M1) at least one nucleic acid sample comprising
 XX obtaining the sample from one or more individuals and determining the
 XX nucleic acid sequence at one or more polymorphic positions in a gene

CC encoding a protein selected from the group above; (3) constructing (M2)
 CC haplotypes using the genes comprising grouping at least two nucleic acids
 CC (4) identifying (M3) an individual at risk of developing a disorder
 CC upon administration of an ACE inhibitor and/or vasoconstrictor inhibitor
 CC using the polymorphic data; (5) a library of nucleic acids, each of which
 CC comprises one or more polymorphic positions within a gene encoding a
 CC human protein selected from the group above; and (6) genotyping (M4) an
 CC individual comprising obtaining a nucleic acid sample, determining the
 CC nucleotide present in at least one polymorphic position, and comparing at
 CC least one position with a known data set. The genes, (M1, M2, M3 and M4)
 CC and compositions are useful for detecting, diagnosing, treating,
 CC preventing various disorders such as angioedema and diseases which
 CC involve angiogenesis like haemangiomas, tumours, sarcomas, Crohn's
 CC disease, trachomas, and cardiovascular diseases like angina pectoris,
 CC hypertension, heart failure, myocardial infarction, ventricular
 CC hypertrophy, vascular diseases, aneurysm, embolism, thrombosis, coronary
 CC artery disease, arteriosclerosis and/or atherosclerosis, and
 CC hypersensitivity reactions, sepsis, autoimmune diseases, inflammatory
 CC arthritis, cancer, wounds, viral, bacterial or fungal infection, Chronic
 CC obstructive pulmonary disease (COPD) and enterocolitis (many other
 CC diseases and disorders are listed in the specification). The
 CC polynucleotides are also useful for chromosome identification. Antibodies
 CC against the proteins may be utilised for immunophenotyping of cell lines
 CC and biological samples. The present sequence is included in the sequence
 CC listing but is not referred to anywhere else in the specification
 XX
 XX Sequence 21 BP; 3 A; 4 C; 6 G; 8 T; 0 U; 0 Other;
 Query Match 2.1%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 89.5%; Pred. No. 4.1e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 390 ATTTCACGCCAGCAGAG 408
 DB 20 ATCTCCAGCCAGCAGAG 2

RESULT 599
 ABZ79515
 ID ABZ79515 standard; DNA; 21 BP.
 XX
 XX ABZ79515;
 XX
 XX 10-MAY-2003 (first entry)
 XX
 XX IL-10 forward primer # SEQ ID 20.
 XX
 XX AK155 receptor; cytokine receptor; inflammation; Crohn's disease;
 XX autoimmune disease; multiple sclerosis; rheumatoid arthritis; psoriasis;
 XX asthma; allergy; diabetes mellitus; Sjogren's syndrome;
 XX transplant rejection; angiogenesis; cancer; PCR; primer; ss.
 XX
 XX Unidentified.
 XX
 XX WO2003002717-A2.
 XX
 XX 09-JAN-2003.
 XX
 XX 27-JUN-2002; 2002WO-US020489.
 XX
 XX 28-JUN-2001; 2001US-0302176P.
 XX 03-JAN-2002; 2002US-0345690P.
 XX
 XX (SCHE) SCHERING CORP.
 XX (FINK) FINKENSCHER H.
 XX
 XX Finkenschcer H, De Waal Malefyt R, Nagalakshmi ML, Moore K;
 XX WPI; 2003-278256/27.
 XX
 XX New cells recombinantly altered to express an exogenous AK155 cytokine
 XX receptor, useful for identifying agents for treating AK155-mediated
 XX diseases, e.g. inflammation, angiogenesis or cancer.

XX Example 2; Page 51; 100pp; English.

XX The present invention relates to a cell recombinantly altered to express

CC an exogenous AK155 cytokine receptor comprising alpha and beta subunits.

CC The cytokine receptor, when expressed in Ba/F3 cells, binds to AK155 and

CC stimulates binding of STAT3 to interferon (IFN) gamma-activated

CC sequences. The cell is useful in expressing AK155 cytokine receptor which

CC may be used for identifying therapeutic agents useful for treating AK155-

CC mediated conditions or diseases, such as inflammation (e.g. Crohn's

CC disease), autoimmune diseases (e.g. multiple sclerosis, rheumatoid

CC arthritis, psoriasis, asthma, allergies, diabetes mellitus, Sjogren's

CC syndrome), transplant rejection, angiogenesis, and cancer. The current

XX sequence represents an IL-10 forward primer sequence

XX Sequence 21 BP; 5 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.1%; Score 15.8; DB 1; Length 21;

Best Local Similarity 89.5%; Pred. No. 4.1e+02;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 325 AGAGTCCGAGATGCCATC 343

DB 2 AGATCTCCGAGATGCCATC 20

|||||

RESULT 600

ACC79905/c

ID ACC79905 standard; DNA; 21 BP.

XX ACC79905;

AC ACC79905;

XX 08-SEP-2003 (first entry)

DT Mouse Rab38 probe SEQ ID NO:20.

DE

XX Malic enzyme; Men; F-box; ABC50; VhaPp1-1; vacuolar ATPase; Sec61 alpha;

KW glutathione S-transferase 2; GST2; Rab-Rp1 family; Csp; coronin;

KW cysteine string protein; actin-associated protein; antidiabetic;

KW hypotensive; gardant; anorectic; antiinflammatory; cytosstatic;

KW gene therapy; obesity; eating disorder; cachexia; diabetes mellitus;

KW hypertension; coronary heart disease; hypercholesterolaemia; cancer;

KW dyslipidaemia; osteoarthritis; gallstone; sleep apnea; PCR primer; ss.

XX Mus sp.

OS Synthetic.

XX WO2003040296-A2.

PN 15-MAY-2003.

XX 08-NOV-2002; 2002WO-EP012518.

PF

XX 08-NOV-2001; 2001EP-00126681.

PR 09-NOV-2001; 2001EP-00126804.

PR 13-NOV-2001; 2001EP-00126967.

PR 20-NOV-2001; 2001EP-00127669.

PR 23-NOV-2001; 2001EP-00127959.

PR 23-NOV-2001; 2001EP-00127960.

PR 28-NOV-2001; 2001EP-00128254.

PR 13-DEC-2001; 2001EP-00129727.

PR 19-DEC-2001; 2001EP-00130310.

PR 14-JAN-2002; 2002EP-00000819.

XX (DEVE-) DEVELOPEN ENTWICKLUNGSBIOLOGISCHE FORSCH.

PA (HAED/) HAEDER T.

XX Eulenber K, Steuernagel A, Broenner G;

PI WPI; 2003-441537/41.

XX New pharmaceutical composition comprising a nucleic acid molecule of the

PT malic enzyme, ABC50, VhaPp1-1, Sec61 alpha, glutathione S-transferase 2,

PT Rab-Rp1, F-box protein Lilina/FBL7, useful treating e.g., obesity.

XX Example 4; Page 73; 159pp; English.

XX The present invention describes a pharmaceutical composition comprising a

CC nucleic acid molecule of the malic enzyme (Men), F-box, ABC50, VhaPp1-1,

CC vacuolar ATPase, Sec61 alpha or glutathione S-transferase 2 (GST2) gene

CC family, Rab-Rp1 family of proteins, cysteine string protein (Csp) family

CC of proteins, F-box protein Lilina/FBL7, coronin family of actin-

CC associated proteins, or other polypeptides and a carrier. Also described:

CC (1) a non-human transgenic animal exhibiting a modified expression of the

CC polypeptide; (2) a recombinant host cell exhibiting the modified

CC expression of the homologous polypeptide; (3) a method of identifying a

CC polypeptide involved in regulation of the energy homeostasis and/or the

CC metabolism of triglycerides in a mammal; and (4) a method for screening

CC for an agent that modulates the activity of the homologous polypeptide or

CC interaction of the homologous polypeptide with a binding target/agent.

CC The pharmaceutical composition has anorectic, antidiabetic, hypotensive,

CC cardiant, antiinflammatory and cytosstatic activities, and can be used in

CC gene therapy. The pharmaceutical composition is useful for preparing a

CC composition for diagnosing or treating, evaluating treatment of obesity,

CC eating disorders, cachexia, diabetes mellitus, hypertension, coronary

CC heart disease, hypercholesterolaemia, dyslipidaemia, osteoarthritis,

CC gallstones, cancer or sleep apnea. The present sequence is used in the

CC exemplification of the present invention

XX Sequence 21 BP; 2 A; 5 C; 9 G; 5 T; 0 U; 0 Other;

Query Match 2.1%; Score 15.8; DB 1; Length 21;

Best Local Similarity 89.5%; Pred. No. 4.1e+02;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 839 CAGGTGGCTATCACCAGC 857

DB 20 CAGGTGGCTATCACCAGC 2

|||||

RESULT 601

AAD58225/c

ID AAD58225 standard; DNA; 21 BP.

XX AAD58225;

AC AAD58225;

XX 20-NOV-2003 (first entry)

DT Cytokine amplifying RT-PCR primer, IFN-alphaR.

DE Virus suppressing factor protein; VSP; immune cell; proteinase K;

XX immunoprecipitation; immunoneutralisation; viral infection; virucide;

KW RT-PCR; primer; ss.

XX Unidentified.

OS WO2003064461-A1.

PN 07-AUG-2003.

PD 30-JAN-2003; 2003WO-KR000231.

PR 01-FEB-2002; 2002KR-00005969.

XX (IMMU-) IMMUNEMED INC.

PA Kim Y, Kim Y, Choi Y, Ahn J, Woo S, Sin S, Cho M, Byun Y;

PI Kang J;

XX WPI; 2003-618354/58.

DR New virus suppressing factor protein having antiviral activity produced

PT in immune cell stimulated by encephalomyocarditis virus variant, useful

PT for suppressing proliferation or replication of virus e.g. herpes virus.

XX Example 4; Page 22; 95pp; English.

XX CC The invention relates to a virus suppressing factor (VSF) protein
 CC CC increasing produced in an immune cell stimulated by
 CC CC encephalomyocarditis virus variant. The protein has antiviral activity
 CC CC unchanged by immunoprecipitation and immunoneutralisation, is inactivated
 CC CC by proteinase K. Is not chosen from antiviral cytokines. The invention is
 CC CC useful for preventing or treating viral infections by administering the
 CC CC protein to a subject suffering from a viral infection. The invention has
 CC CC antiviral activity which is to suppress proliferation or replication of a
 CC CC virus belonging to Orthomyxoviridae, Picornaviridae, Retroviridae or
 CC CC Herpes. The present sequence is a RT-PCR primer used in the amplification
 CC CC of cytokines of the invention
 XX CC
 SQ Sequence 21 BP; 3 A; 10 C; 1 G; 7 T; 0 U; 0 Other;
 Query Match 2.1%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 89.5%; Pred. No. 4.1e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 404 CAGAGGAGGAGGAGT 422
 DB 21 CTGAGTGAGGAGGAGT 3
 RESULT 602
 ADQ90647/C
 ID ADQ90647 standard; mRNA; 21 BP.
 XX AC
 AC ADQ90647;
 XX DT 21-OCT-2004 (first entry)
 XX DE Mouse Sca-2 target oligonucleotide SEQ ID NO:44.
 XX KW lentiviral vector; small interference RNA; siRNA; cytostatic; virucide;
 KW KW gene therapy; Sca-2; ss.
 XX OS Mus musculus.
 OS OS Synthetic.
 XX PN WO2004065549-A2.
 FN 05-AUG-2004.
 PD 15-JAN-2004; 2004WO-US001320.
 PF 17-JAN-2003; 2003US-0440987P.
 XX PA (UYFL) UNIV FLORIDA.
 XX PI Chang L, He J;
 XX WPI; 2004-562155/54.
 XX New lentiviral vector comprising a nucleotide sequence encoding a small
 PT interference RNA, useful for reducing expression of a target gene in a
 PT cell.
 XX Example 1; SEQ ID NO 44; 51pp; English.
 XX The present invention describes a lentiviral vector comprising a
 CC nucleotide sequence encoding a small interference RNA (siRNA). Also
 CC described is a method of reducing expression of a target gene in a cell
 CC comprising: (a) introducing into the cell a lentiviral vector encoding a
 CC siRNA specific for the gene; and (b) placing the cell under conditions,
 CC where the siRNA specific for the gene is expressed to cause a detectable
 CC decrease in expression of the gene. The siRNA has cytostatic and virucide
 CC activities, and can be used in gene therapy. The vector is useful for
 CC reducing expression of a target gene in a cell. The present sequence
 CC represents a mouse Sca-2 target oligonucleotide, which is used in an
 CC example from the present invention.
 XX Sequence 21 BP; 5 A; 7 C; 3 G; 0 T; 6 U; 0 Other;
 Query Match 2.1%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 89.5%; Pred. No. 4.1e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 404 CAGAGGAGGAGGAGT 422
 DB 21 CTGAGTGAGGAGGAGT 3
 RESULT 602
 ADQ90647/C
 ID ADQ90647 standard; mRNA; 21 BP.
 XX AC
 AC ADQ90647;
 XX DT 21-OCT-2004 (first entry)
 XX DE Mouse Sca-2 target oligonucleotide SEQ ID NO:44.
 XX KW lentiviral vector; small interference RNA; siRNA; cytostatic; virucide;
 KW KW gene therapy; Sca-2; ss.
 XX OS Mus musculus.
 OS OS Synthetic.
 XX PN WO2004065549-A2.
 FN 05-AUG-2004.
 PD 15-JAN-2004; 2004WO-US001320.
 PF 17-JAN-2003; 2003US-0440987P.
 XX PA (UYFL) UNIV FLORIDA.
 XX PI Chang L, He J;
 XX WPI; 2004-562155/54.
 XX New lentiviral vector comprising a nucleotide sequence encoding a small
 PT interference RNA, useful for reducing expression of a target gene in a
 PT cell.
 XX Example 1; SEQ ID NO 44; 51pp; English.
 XX The present invention describes a lentiviral vector comprising a
 CC nucleotide sequence encoding a small interference RNA (siRNA). Also
 CC described is a method of reducing expression of a target gene in a cell
 CC comprising: (a) introducing into the cell a lentiviral vector encoding a
 CC siRNA specific for the gene; and (b) placing the cell under conditions,
 CC where the siRNA specific for the gene is expressed to cause a detectable
 CC decrease in expression of the gene. The siRNA has cytostatic and virucide
 CC activities, and can be used in gene therapy. The vector is useful for
 CC reducing expression of a target gene in a cell. The present sequence
 CC represents a mouse Sca-2 target oligonucleotide, which is used in an
 CC example from the present invention.
 XX Sequence 21 BP; 5 A; 7 C; 3 G; 0 T; 6 U; 0 Other;

Query Match 2.1%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 89.5%; Pred. No. 4.1e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 488 CTGAAGAGGAGGAGGAGC 506
 DB 21 CTGAAGTTGCAGAGGAGC 3
 RESULT 603
 ADQ90612
 ID ADQ90612 standard; DNA; 21 BP.
 XX AC ADQ90612;
 XX DT 21-OCT-2004 (first entry)
 XX DE Sca-2 siRNA duplex antisense oligonucleotide SEQ ID NO:9.
 XX KW lentiviral vector; small interference RNA; siRNA; cytostatic; virucide;
 KW KW gene therapy; Sca-2; ss.
 XX OS Mus musculus.
 OS OS Synthetic.
 XX PN WO2004065549-A2.
 FN 05-AUG-2004.
 PD 15-JAN-2004; 2004WO-US001320.
 PF 17-JAN-2003; 2003US-0440987P.
 XX PA (UYFL) UNIV FLORIDA.
 XX PI Chang L, He J;
 XX WPI; 2004-562155/54.
 XX New lentiviral vector comprising a nucleotide sequence encoding a small
 PT interference RNA, useful for reducing expression of a target gene in a
 PT cell.
 XX Example 1; SEQ ID NO 9; 51pp; English.
 XX The present invention describes a lentiviral vector comprising a
 CC nucleotide sequence encoding a small interference RNA (siRNA). Also
 CC described is a method of reducing expression of a target gene in a cell
 CC comprising: (a) introducing into the cell a lentiviral vector encoding a
 CC siRNA specific for the gene; and (b) placing the cell under conditions,
 CC where the siRNA specific for the gene is expressed to cause a detectable
 CC decrease in expression of the gene. The siRNA has cytostatic and virucide
 CC activities, and can be used in gene therapy. The vector is useful for
 CC reducing expression of a target gene in a cell. The present sequence
 CC represents a Sca-2 siRNA duplex oligonucleotide, which is used in an
 CC example from the present invention.
 XX Sequence 21 BP; 6 A; 3 C; 7 G; 5 T; 0 U; 0 Other;
 Query Match 2.1%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 89.5%; Pred. No. 4.1e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 488 CTGAAGAGGAGGAGGAGC 506
 DB 1 CTGAAGTTGCAGAGGAGC 19
 RESULT 604
 ABN07458
 ID ABN07458 standard; DNA; 17 BP.
 XX

CC and skeletal muscle disorders. hGDMPL-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPL-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence

XX Sequence 17 BP; 3 A; 2 C; 10 G; 2 T; 0 U; 0 Other;
 SQ

Query Match 2.0%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 3.5e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 697 GCTGGAGAGTGCAGCGG 713
 DB 1 GCTGGAGAGTGCAGCGG 17

RESULT 606
 ADJ34447/C
 ID ADJ34447 standard; DNA; 17 BP.
 AC ADJ34447;
 XX
 XX
 DT 06-MAY-2004 (first entry)
 DE Human secreted protein NOV17a/b RTQ PCR primer #2.
 DE Human; ss; PCR; NOVX; secreted protein; cancer; diabetes; obesity;
 KW endocrine disorder; CNS disorder; inflammatory disorder; gene therapy;
 KW primer; RTQ PCR; real time quantitative PCR.
 XX
 XX Homo sapiens.
 OS
 XX WO200400997-A2.
 XX
 XX 31-DEC-2003.
 XX
 XX 04-JUN-2003; 2003WO-US017512.
 XX
 PR 19-MAR-2002; 2002US-0365491P.
 PR 04-JUN-2002; 2002US-0385504P.
 PR 05-JUN-2002; 2002US-0386041P.
 PR 06-JUN-2002; 2002US-0386453P.
 PR 07-JUN-2002; 2002US-0386974P.
 PR 07-JUN-2002; 2002US-0386816P.
 PR 07-JUN-2002; 2002US-0387002P.
 PR 10-JUN-2002; 2002US-0387540P.
 PR 11-JUN-2002; 2002US-0387659P.
 PR 12-JUN-2002; 2002US-0387934P.
 PR 13-JUN-2002; 2002US-0389123P.
 PR 17-JUN-2002; 2002US-0389729P.
 PR 17-JUN-2002; 2002US-0389742P.
 PR 19-JUN-2002; 2002US-0390006P.
 PR 17-JUL-2002; 2002US-0396706P.
 PR 12-AUG-2002; 2002US-0402832P.
 PR 13-AUG-2002; 2002US-0403486P.
 PR 14-AUG-2002; 2002US-0403522P.
 PR 15-AUG-2002; 2002US-0403748P.
 PR 06-NOV-2002; 2002US-0387037P.
 PR 03-JUN-2003; 2003US-00454246.
 XX
 XX (CURA-) CURAGEN CORP.
 XX
 XX Anderson DM, Boldog FL, Burgess CE, Casman SJ, Edinger SR;
 PI Eisen A, Ellerman K, Gerlach VL, Gorman L, Guo X, Gusev VY, Ji W;
 PI Li L, Macdougall JR, Malyankar UM, Millet I, Ort T, Padigar M;
 PI Prayaga SK, Patturajan M, Pena CEA, Peyman JA, Rieger DK;
 PI Rothenberg ME, Sciore P, Shenoy SG, Smithson G, Zerkus BD, Zhong M;
 PI Taupier RJ, Tchernev VT, Vernet CAM, Voss EZ, Zerkus BD, Zhong M;
 XX WPI; 2004-082483/08.
 DR
 XX

PT New isolated NOVX polypeptides useful for treating, preventing and
 PT diagnosing pathological conditions with NOVX-associated disorders, such
 PT as cancer, obesity, diabetes and inflammatory or CNS diseases.
 XX
 XX Example D; SEQ ID NO 336; 418pp; English.
 XX
 CC The invention relates to a new isolated polypeptide (designated NOVX)
 CC comprising one of 141 fully defined sequences, their mature forms, a
 CC protein comprising one or more conservative substitutions or having at
 CC least 95% identity to one of the 141 proteins. Also included are a
 CC composition comprising NOVX (or a NOVX nucleic acid molecule (NA)), a kit
 CC comprising the composition of NOVX in one or more containers, an isolated
 CC nucleic acid molecule encoding a NOVX protein, producing NOVX (comprising
 CC culturing a cell under conditions that lead to expression of the
 CC polypeptide, where the cell comprises a vector comprising NOVX NA),
 CC identifying an agent that binds to NOVX, identifying a potential
 CC therapeutic agent for use in the treatment of a pathology that is related
 CC to aberrant expression or physiological interactions of NOVX, screening
 CC for a modulator of activity of or latency or predisposition to a
 CC pathology associated with NOVX, modulating the activity of NOVX, treating
 CC or preventing a pathology associated with NOVX, treating a pathological
 CC state in a mammal, a vector comprising the NOVX nucleic acid molecule, a
 CC cell comprising the vector, an antibody that immunospecifically binds to
 CC NOVX, determining the presence or amount of NOVX or the nucleic acid
 CC molecule in a sample, and determining the presence of or predisposition
 CC to a disease associated with altered levels of expression of NOVX or the
 CC nucleic acid molecule in a first mammalian subject. The methods and
 CC compositions of the present invention are useful for the diagnosis and
 CC treatment of disorders associated with aberrant expression or activity of
 CC the NOVX polypeptide, such as cancer, diabetes, obesity, and endocrine,
 CC CNS and inflammatory disorders. They can also be used in various
 CC detection and screening assays, chromosome mapping, tissue typing, gene
 CC therapy and predictive medicine. The present sequence is an RTQ (real
 CC time quantitative) PCR primer for an mRNA encoding a NOVX protein.
 XX
 XX Sequence 17 BP; 3 A; 6 C; 5 G; 3 T; 0 U; 0 Other;
 SQ

Query Match 2.0%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 3.5e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 556 TGAGGACAGGCGCTCTG 572
 DB 17 TGAGGACAGGCGCTCTG 1

RESULT 607
 ACN70344
 ID ACN70344 standard; DNA; 17 BP.
 XX
 XX ACN70344;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 XX Human GDMPL-1 probe SEQ ID NO:7246.
 DE
 DE Human; ss; probe; myosin-like protein-1; hGDMPL-1;
 KW hGDMPL-1 agonist hGDMPL antagonist; hGDMPL inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 XX Homo sapiens.
 OS
 XX US2004137589-A1.
 XX
 XX 15-JUL-2004.
 XX
 XX 26-NOV-2003; 2003US-00723361.
 XX
 XX 26-MAY-2000; 2000US-0207456P.
 XX 21-SEP-2000; 2000US-0234687P.
 XX 27-SEP-2000; 2000US-0236359P.
 XX 04-OCT-2000; 2000GB-00024263.
 XX 30-JAN-2001; 2001WO-US000661.
 XX

PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 PA (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 DR
 XX Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 XX
 PS Disclosure; SEQ ID NO 7246; Opp; English.
 XX
 CC The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX
 SQ Sequence 17 BP; 3 A; 2 C; 10 G; 2 T; 0 U; 0 Other;
 Query Match 2.0%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 3.5e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 697 GCTGGAGAGTGAGCGCG 713
 DB 1 GCTGGAGAGTGAGCGCG 17
 RESULT 608
 ACN70548
 ID ACN70548 standard; DNA; 17 BP.
 XX
 AC ACN70548;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Human GDMPLP-1 probe SEQ ID NO:7450.
 XX
 KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 OS Homo sapiens.
 XX
 PN US2004137589-A1.
 XX
 PD 15-JUL-2004.

XX 26-NOV-2003; 2003US-00723361.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 PA (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 DR
 XX Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 XX
 PS Disclosure; SEQ ID NO 7450; Opp; English.
 XX
 CC The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX
 SQ Sequence 17 BP; 5 A; 4 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 2.0%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 3.5e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 412 GGAGAGGAGGAGTCTCTCA 428
 DB 1 GGAGAGGAGGAGTCTCTCA 17
 RESULT 609
 AAX79593
 ID AAX79593 standard; DNA; 18 BP.
 XX
 AC AAX79593;
 XX
 DT 12-AUG-1999 (first entry)
 XX
 DE Probe SEQ ID No 32 for hybridisation assay.
 XX
 KW Hybridisation assay; nucleic acid analyte; detection; therapy; probe;

nonspecific hybridisation reduction; ss.

Synthetic.
WO9606950-A1.
07-MAR-1996.
30-AUG-1995; 95WO-US011115.
30-AUG-1994; 94US-00298073.
(CHIR) CHIRON CORP.
Collins ML, Horn T, Sheridan PE, Warner BD, Urdea MS;
WPI; 1996-160381/16.
Reducing non-specific hybridisation - by using non-natural nucleotide units in hybridisation assays, aptamers or anti-sense molecules.
Example 5; Page 43; 67pp; English.
This sequence represents a probe oligonucleotide used in a nucleic acid hybridisation assay. The invention relates to an improvement in a nucleic acid (NA) hybridisation assay for detecting a NA analyte in a sample using assay components each of which comprises at least 1 hybridising oligonucleotide (ON) segment, the improvement comprises incorporating into at least 1 hybridising ON segment a 1st nucleotidic unit which will not effectively base pair with adenosine (A), thymidine (T), cytidine (C), guanosine (G) or uridine (U) under conditions in which A-T and G-C base pairs are formed. Preferably the first nucleotidic unit can form a base pair with a second, complementary nucleotidic unit. Especially the non-natural base pair is formed between isocytosine and isoguanosine. The assay methods reduce nonspecific hybridisation to reduce background noise and increase sensitivity and specificity in the detection and quantitation of analytes. The aptamers and antisense molecules containing them prepared using the non-natural nucleotidic units can also have minimised nonspecific hybridisation when used, e.g. in therapy
SQ Sequence 18 BP; 8 A; 6 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 867 AATACGACACACATC 883
Db 2 AGTACGACACACATC 18

RESULT 610
AAT64410/C
ID AAT64410 standard; DNA; 18 BP.

AC AAT64410;
XX
XX 02-FEB-1998 (first entry)
XX
XX Protein kinase A subunit RI-alpha synthetic oligonucleotide #169.
XX
XX DNA/RNA hybrid; antisense; hybrid; inverted hybrid; mitogenicity;
KW inverted chimeric hybrid; protein kinase A subunit RI-alpha gene;
KW anti-thrombotic; cancer cell proliferation; tumour; ribonucleotide; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH misc_RNA 7. .11
FT /tag= a
FT /note= "ribonucleotide"
XX
XX WO9711171-A1.

XX 27-MAR-1997.
XX
XX 19-SEP-1996; 96WO-US015084.
XX
XX 22-SEP-1995; 95US-00532979.
XX
XX (HYBR-) HYBRIDON INC.
XX
XX Agrawal S;
XX
XX WPI; 1997-202880/18.
XX
XX Modified protein kinase A specific oligo:nucleotide(s) - are useful for the treatment of cancer.
XX
XX Example 10; Page 17; 66pp; English.

XX This sequence represents a synthetic, modified antisense oligonucleotide CC CC (#169) which was designed to be a mismatched inverted hybrid control. The CC CC modified oligonucleotide types used in this study were hybrid, inverted CC CC hybrid or inverted chimeric hybrid and have been found to down regulate CC CC protein kinase A subunit RI-alpha gene expression while producing fewer CC CC side effects than conventional oligonucleotides e.g. reduced CC CC mitogenicity, reduced activation of complement and reduced anti-thrombotic properties. By controlling the regulation of protein kinase A CC CC subunit RI-alpha inhibition of the proliferation of cancer cells and CC CC tumour growth is possible. This is a novel method for the treatment of CC CC disease and disorders caused by the overexpression or inappropriate CC CC expression of the gene
XX
SQ Sequence 18 BP; 0 A; 9 C; 6 G; 1 T; 2 U; 0 Other;

Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 677 GCCAGCGAGCGCGG 693
Db 18 GCCAGCGAGCGCGG 2

RESULT 611
AAT64405/C
ID AAT64405 standard; DNA; 18 BP.

XX AAT64405;
XX
XX 02-FEB-1998 (first entry)
XX
XX Protein kinase A subunit RI-alpha synthetic oligonucleotide #167.
XX
XX Antisense; hybrid; inverted hybrid; mitogenicity;
KW inverted chimeric hybrid; protein kinase A subunit RI-alpha gene;
KW anti-thrombotic; cancer cell proliferation; tumour; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 7. .12
FT /tag= a
FT /note= "Methylphosphonate nucleotides. Modification only applicable to mismatched inverted chimeric oligonucleotide."
XX
XX WO9711171-A1.

XX 27-MAR-1997.
XX
XX 19-SEP-1996; 96WO-US015084.
XX
XX 22-SEP-1995; 95US-00532979.
XX

XX New modified antisense oligonucleotides - which down-regulate the
PT expression of protein kinase A subunit R1a, used for inhibiting cancer
PT cell growth and treating cancers.
PS
XX Example 10; Page 17; 85pp; English.
XX
XX This sequence represents a example of a synthetic modified
CC oligonucleotide (ON) of the invention. The ONs are complementary to, and
CC capable of down-regulating the expression of nucleic acid encoding
CC protein kinase A (PKA) subunit R1a, the modified ON has from 15 to 30
CC nucleotides and is a hybrid, inverted hybrid, or inverted chimeric ON,
CC the hybrid ON comprising a region of at least 2 deoxyribonucleotides
CC flanked by 3' and 5' flanking ribonucleotide regions each having at least
CC 4 ribonucleotide regions flanked by 3' and 5' flanking ribonucleotide
CC regions of at least 2 deoxyribonucleotides, and the inverted chimeric ON
CC comprising an ON nonionic region of at least 4 nucleotides flanked by 2
CC ON phosphorothioate regions. The ONs down-regulate the expression of the
CC PKA R1a gene while producing fewer side effects than conventional ONs,
CC e.g. reduced mitogenicity, reduced activation of complement and reduced
CC antithrombotic properties, relative to conventional ONs. They can be used
CC for inhibiting the growth of cancer cells and for treating cancers or
CC uncontrolled cell proliferation in humans
XX
SQ Sequence 18 BP; 0 A; 9 C; 6 G; 1 T; 2 U; 0 Other;

Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGAGCGCGCG 693
DB 18 GCCAGCGAGCGCGCG 2

RESULT 614
AAV55620/C
ID AAV55620 standard; DNA; 18 BP.
XX
AC AAV55620;
XX
XX 15-MAR-1999 (first entry)
XX
XX Down-regulator oligo #167 for protein kinase A subunit R1a gene.
XX
XX Down-regulator; protein kinase A subunit R1a gene; reduced mitogenicity;
KW reduced activation of complement; reduced antithrombotic; cancer cell;
KW growth inhibitor; uncontrolled cell proliferation; therapy; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 7..12.
FT /tag= a
FT /note= "methylphosphonate nucleotides"
XX
XX WO9840479-A1.
XX
XX 17-SEP-1998.
XX
XX 12-FEB-1998; 98WO-US003003.
XX
XX 12-MAR-1997; 97US-0040740P.
XX
XX (HYBR-) HYBRIDON INC.
XX
XX Agrawal S;
XX
XX WPI; 1999-059623/05.
XX
XX New modified antisense oligonucleotides - which down-regulate the
PT expression of protein kinase A subunit R1a, used for inhibiting cancer

PT cell growth and treating cancers.
XX
XX Disclosure; Page 17; 85pp; English.
XX
XX This sequence represents a example of a synthetic modified
CC oligonucleotide (ON) of the invention. The ONs are complementary to, and
CC capable of down-regulating the expression of nucleic acid encoding
CC protein kinase A (PKA) subunit R1a, the modified ON has from 15 to 30
CC nucleotides and is a hybrid, inverted hybrid, or inverted chimeric ON,
CC the hybrid ON comprising a region of at least 2 deoxyribonucleotides
CC flanked by 3' and 5' flanking ribonucleotide regions each having at least
CC 4 ribonucleotide regions flanked by 3' and 5' flanking ribonucleotide
CC regions of at least 2 deoxyribonucleotides, and the inverted chimeric ON
CC comprising an ON nonionic region of at least 4 nucleotides flanked by 2
CC ON phosphorothioate regions. The ONs down-regulate the expression of the
CC PKA R1a gene while producing fewer side effects than conventional ONs,
CC e.g. reduced mitogenicity, reduced activation of complement and reduced
CC antithrombotic properties, relative to conventional ONs. They can be used
CC for inhibiting the growth of cancer cells and for treating cancers or
CC uncontrolled cell proliferation in humans
XX
SQ Sequence 18 BP; 0 A; 9 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGAGCGCGCG 693
DB 18 GCCAGCGAGCGCGCG 2

RESULT 615
ADD10679/C
ID ADD10679 standard; DNA; 18 BP.
XX
AC ADD10679;
XX
XX 01-JAN-2004 (first entry)
XX
XX Protein kinase A subunit R1alpa down-regulation related DNA seq id 7.
XX
XX cyostatic; gene therapy; antisense therapy;
KW protein kinase A subunit R1alpa-antagonist; cancer;
KW cancer cell proliferation; protein kinase A subunit R1alpa;
KW antisense technology; epidermal growth factor receptor; EGFR;
KW gene down-regulation;
KW protein kinase A subunit R1alpa expression reduction; ss;
KW DNA-RNA hybrid.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH misc_RNA 7..11
FT /tag= a
FT /note= "Ribonucleotide"
XX
XX US2003105035-A1.
XX
XX 05-JUN-2003.
XX
XX 05-OCT-1999; 99US-00412947.
XX
XX 05-OCT-1998; 98US-0103098P.
XX
XX (AGRA/) AGRAWAL S.
XX
XX Agrawal S;
XX
XX WPI; 2003-801243/75.
XX
XX Inhibiting proliferation of cancer cells comprises administering a

PT synthetic, modified oligonucleotide, and an antibody that binds to
 PT epidermal growth factor receptor or a cytotoxic agent.
 PS Example 10; SEQ ID NO 7; 46pp; English.
 XX
 CC The invention describes a method of inhibiting proliferation of cancer
 CC cells comprising administering a synthetic, modified oligonucleotide (I)
 CC to the cells, where the oligonucleotide is complementary to and capable
 CC of down-regulating the expression of nucleic acid encoding protein kinase
 CC A subunit Rialpha and then administering an antibody (II) that binds to
 CC epidermal growth factor receptor (EGFR) or a cytotoxic agent (III). The
 CC method is used to inhibit the proliferation of cancer cells. (I), (II)
 CC and (III) are used in a pharmaceutical composition for treating cancer in
 CC an afflicted individual. (I) demonstrate reduced mitogenicity, reduced
 CC activation of complement and reduced antithrombotic properties, relative to
 CC conventional oligonucleotides. This sequence represents an
 CC oligonucleotide associated with down-regulation of protein kinase A
 CC subunit Rialpha expression.
 XX
 SQ Sequence 18 BP; 0 A; 9 C; 6 G; 1 T; 2 U; 0 Other;
 Query Match 2.0%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 94.1%; Pred. No. 3.8e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 677 GCCAGCGAGGAGCGCG 693
 DB 18 GCCAGCGAGGAGCGCG 2
 RESULT 616
 ADD10682/c
 ID ADD10682 standard; DNA; 18 BP.
 AC ADD10682;
 XX
 DT 01-JAN-2004 (first entry)
 DE Protein kinase A subunit Rialpha down-regulation related DNA #2.
 KW cytostatic; gene therapy; antisense therapy;
 KW protein kinase A subunit Rialpha-antagonist; cancer;
 KW cancer cell proliferation; protein kinase A subunit Rialpha;
 KW antisense technology; epidermal growth factor receptor; EGFR;
 KW gene down-regulation;
 KW protein kinase A subunit Rialpha expression reduction; ss.
 XX
 OS Synthetic.
 XX
 PN US2003105035-A1.
 PD 05-JUN-2003.
 PF 05-OCT-1999; 99US-00412947.
 PP 05-OCT-1998; 98US-0103098P.
 PR (AGRA/) AGRAWAL S.
 PA Agrawal S;
 PI WPI; 2003-801243/75.
 DR Inhibiting proliferation of cancer cells comprises administering a
 PT synthetic, modified oligonucleotide, and an antibody that binds to
 PT epidermal growth factor receptor or a cytotoxic agent.
 PS Disclosure; Page 5; 46pp; English.
 XX
 CC The invention describes a method of inhibiting proliferation of cancer
 CC cells comprising administering a synthetic, modified oligonucleotide (I)
 CC to the cells, where the oligonucleotide is complementary to and capable
 CC of down-regulating the expression of nucleic acid encoding protein kinase

CC A subunit Rialpha and then administering an antibody (II) that binds to
 CC epidermal growth factor receptor (EGFR) or a cytotoxic agent (III). The
 CC method is used to inhibit the proliferation of cancer cells. (I), (II)
 CC and (III) are used in a pharmaceutical composition for treating cancer in
 CC an afflicted individual. (I) demonstrate reduced mitogenicity, reduced
 CC activation of complement and reduced antithrombotic properties, relative to
 CC conventional oligonucleotides. This sequence represents an
 CC oligonucleotide associated with down-regulation of protein kinase A
 CC subunit Rialpha expression. Note: This sequence differs from ADD10673
 CC shown in the sequence listing.
 XX
 SQ Sequence 18 BP; 0 A; 9 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 2.0%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 94.1%; Pred. No. 3.8e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 677 GCCAGCGAGGAGCGCG 693
 DB 18 GCCAGCGAGGAGCGCG 2
 RESULT 617
 ADD10677/c
 ID ADD10677 standard; DNA; 18 BP.
 AC ADD10677;
 XX
 DT 01-JAN-2004 (first entry)
 DE Protein kinase A subunit Rialpha down-regulation related DNA seq id 5.
 KW cytostatic; gene therapy; antisense therapy;
 KW protein kinase A subunit Rialpha-antagonist; cancer;
 KW cancer cell proliferation; protein kinase A subunit Rialpha;
 KW antisense technology; epidermal growth factor receptor; EGFR;
 KW gene down-regulation;
 KW protein kinase A subunit Rialpha expression reduction; ss;
 KW DNA-RNA hybrid.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT misc_RNA 7..11
 FT /*tag= a
 FT /*note= "Ribonucleotide"
 XX
 PN US2003105035-A1.
 PD 05-JUN-2003.
 PF 05-OCT-1999; 99US-00412947.
 PP 05-OCT-1998; 98US-0103098P.
 PR (AGRA/) AGRAWAL S.
 PA Agrawal S;
 PI WPI; 2003-801243/75.
 DR Inhibiting proliferation of cancer cells comprises administering a
 PT synthetic, modified oligonucleotide, and an antibody that binds to
 PT epidermal growth factor receptor or a cytotoxic agent.
 PS Example 10; SEQ ID NO 5; 46pp; English.
 XX
 CC The invention describes a method of inhibiting proliferation of cancer
 CC cells comprising administering a synthetic, modified oligonucleotide (I)
 CC to the cells, where the oligonucleotide is complementary to and capable
 CC of down-regulating the expression of nucleic acid encoding protein kinase
 CC A subunit Rialpha and then administering an antibody (II) that binds to
 CC epidermal growth factor receptor (EGFR) or a cytotoxic agent (III). The

CC method is used to inhibit the proliferation of cancer cells. (I), (II)
 CC And (III) are used in a pharmaceutical composition for treating cancer in
 CC an afflicted individual. (I) demonstrate reduced mitogenicity, reduced
 CC activation of complement and reduced antithrombic properties, relative to
 CC conventional oligonucleotides. This sequence represents an
 CC oligonucleotide associated with down-regulation of protein kinase A
 CC subunit R1alpha expression.
 XX
 SQ Sequence 18 BP; 0 A; 9 C; 6 G; 2 T; 1 U; 0 Other;

Query Match 2.0%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 94.1%; Pred. No. 3.8e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 677 GCCAGCGAGGAGCGCG 693
 DB 18 GCCAGCGAGGAGCGCG 2

RESULT 618
 ADD10674/c
 ID ADD10674 standard; DNA; 18 BP.
 XX
 AC ADD10674;
 XX
 DT 01-JAN-2004 (first entry)
 DT
 DE Protein kinase A subunit R1alpha down-regulation related DNA seq id 2.
 XX
 KW cytostatic; gene therapy; antisense therapy;
 KW protein kinase A subunit R1alpha-antagonist; cancer;
 KW cancer cell proliferation; protein kinase A subunit R1alpha;
 KW antisense technology; epidermal growth factor receptor; EGFR;
 KW gene down-regulation;
 KW protein kinase A subunit R1alpha expression reduction; ss.
 XX
 OS Synthetic.

US2003105035-A1.
 PD 05-JUN-2003.
 XX
 PF 05-OCT-1999; 99US-00412947.
 XX
 PR 05-OCT-1998; 98US-0103098P.
 XX
 PA (AGRA/) AGRAWAL S.
 XX
 PI Agrawal S;
 XX
 XX WPI; 2003-801243/75.
 XX
 PT Inhibiting proliferation of cancer cells comprises administering a
 PT synthetic, modified oligonucleotide, and an antibody that binds to
 PT epidermal growth factor receptor or a cytotoxic agent.
 XX
 PS Disclosure; SEQ ID NO 2; 46pp; English.

CC The invention describes a method of inhibiting proliferation of cancer
 CC cells comprising administering a synthetic, modified oligonucleotide (I)
 CC to the cells, where the oligonucleotide is complementary to and capable
 CC of down-regulating the expression of nucleic acid encoding protein kinase
 CC A subunit R1alpha and then administering an antibody (II) that binds to
 CC epidermal growth factor receptor (EGFR) or a cytotoxic agent (III). The
 CC method is used to inhibit the proliferation of cancer cells. (I), (II)
 CC and (III) are used in a pharmaceutical composition for treating cancer in
 CC an afflicted individual. (I) demonstrate reduced mitogenicity, reduced to
 CC activation of complement and reduced antithrombic properties, relative to
 CC conventional oligonucleotides. This sequence represents an
 CC oligonucleotide associated with down-regulation of protein kinase A
 CC subunit R1alpha expression.
 XX
 SQ Sequence 18 BP; 0 A; 9 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 2.0%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 94.1%; Pred. No. 3.8e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 677 GCCAGCGAGGAGCGCG 693
 DB 18 GCCAGCGAGGAGCGCG 2

RESULT 619
 ADF77884/c
 ID ADF77884 standard; DNA; 18 BP.
 XX
 AC ADF77884;
 XX
 DT 26-FEB-2004 (first entry)
 DT
 DE Human EST clone antisense oligonucleotide #12.
 XX
 KW reporter construct; reporter element; effective analysis;
 KW high-throughput; microtitre well format; light emission;
 KW primary cell screening; low level mRNA expression; ss; human; antisense;
 KW EST; expressed sequence tag.
 XX
 OS Synthetic.
 OS Homo sapiens.

US2003124523-A1.
 PD 03-JUL-2003.
 XX
 PF 18-JUN-2001; 2001US-00883573.
 PR 22-JUN-2000; 2000US-0213132P.
 PR 07-FEB-2001; 2001US-0266949P.
 XX
 PA (ASSE/) ASSELBERGS F A M.
 PA (HALL/) HALL J.
 PA (HUES/) HUESKEN D.
 PA (KINZ/) KINZEL B.
 PA (NATT/) NATT F.
 PA (WEILL/) WEILLER J.
 XX
 PI Asselbergs FAM, Hall J, Huesken D, Kinzel B, Natt F, Weiller J;
 XX
 XX WPI; 2004-009138/01.

PT Reporter construct, useful for identifying potential therapeutic oligo-
 PT or poly-nucleotides, comprises target nucleic acid inserted 3' to a
 PT reporter element.
 XX
 PS Example 4; Page 7; 22pp; English.
 XX
 CC The invention relates to a reporter construct (RC) comprises a reporter
 CC element (RE) and a target nucleic acid, inserted 3' to RE, in the
 CC untranslated region. RC are used to identify, particularly in screening
 CC assays, oligo- or poly-nucleotides that modulate expression of a target
 CC sequence, particularly antisense sequences and ribozymes, potentially
 CC useful as pharmaceuticals. RC provide (a) effective analysis of
 CC biological activity of many test sequences against specific targets; (b)
 CC monitoring of mRNA levels without the cost and extensive pipetting
 CC required in reverse transcription PCR; and (c) use of high-throughput,
 CC microtitre well formats for screening, with the reaction (light emission)
 CC read directly from the wells, with exactly the same conditions for each
 CC well (no need for a set of probes as in e.g. the Taqman assay). The
 CC method is especially useful for screening primary cells (or other cells
 CC that are difficult to obtain) or where target mRNA is expressed at very
 CC low levels. The present sequence is used in the exemplification of the
 CC present invention.
 XX
 SQ Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

```
Query Match      2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 302 CAGCGCTGCTGGAGGA 318
Db 17 CAGTGTCTGCTGGAGGA 1

RESULT 620
AAT74056
ID AAT74056 standard; DNA; 19 BP.
XX
AC AAT74056;
XX
DT 19-SEP-1997 (first entry)
XX
DE Oligonucleotide probe bla3, for conjugation to alkaline phosphatase.
XX
KW Hybridisation probe; alkaline phosphatase; label; conjugate; detection;
KW ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 19
FT /*tag= a
FT /mod_base= OTHER
FT /note= "N4-(6-aminocaproyl-2-aminoethyl)-5- methyl
FT -2'-deoxycytidine"
XX
PN WO9911813-A2.
XX
PD 11-MAR-1999.
XX
XX
PF 03-SEP-1998; 98WO-US018397.
XX
PR 04-SEP-1997; 97US-0057810P.
XX
PA (CHIR ) CHIRON DIAGNOSTICS CORP.
XX
PI Horn T, Schroeder HR, Warner BD, Fiss E, Sells T, Law S;
XX
DR WPI; 1999-243626/20.
XX
PT Oligonucleotide probes bearing quenchable fluorescent labels.
XX
PS Disclosure; Page 22; 68pp; English.
XX
CC This sequence represents a labelled probe. The invention relates to a
CC method for reducing background signals in nucleic acid hybridisation
CC assays using oligonucleotide probes bearing quenchable fluorescent
CC labels. The method can be used for the detection of oligonucleotides,
CC preferably wild-type genes. The method and probes are useful in assays
CC such as fluorescent in situ hybridisation assays, polymerase chain
CC reaction assays, ligase chain reaction assays, competitive hybridisation
CC assays and strand displacement assays. They are particularly useful in
CC sandwich hybridisation assays which involve binding the analyte to a
CC solid support, labelling the analyte and detecting the presence of label
CC on the support. Preferred methods involve the use of amplification
CC multimers which enable the binding of more label in the analyte-probe
CC complex, enhancing assay sensitivity and specificity. The use of
CC oligonucleotides bearing quenchable fluorescent labels reduced the
CC background signals encountered in nucleic acid hybridisation assays and
CC other assays involving hybridisation of a labelled oligomer to its
CC complement. The signal reduction occurs when the quenchable dye-labelled
CC oligomer forms a hybrid complex. The method is also used to enhance the
CC detectable signal emitted from an amplification multimer hybridised to an
CC oligomer probe to which a quenchable dye has been conjugated
XX
SQ Sequence 19 BP; 8 A; 6 C; 2 G; 2 T; 0 U; 0 Other;

Query Match      2.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 4.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 867 AATACGACCAACCATC 883
Db 2 AGTACGACCAACCATC 18

RESULT 622
AAS17227
ID AAS17227 standard; DNA; 19 BP.
```

XX AAS17227;
AC 12-MAR-2002 (first entry)
DT
DE
DE BLA3 probe, used to produce probes with multiple acridinium ester labels.
DE
XX Probe; multiple acridinium ester label; gene probe assay sensitivity; ss.
KW
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FH modified_base 19
FT /*tag= a
FT /*mod_base= OTHER
FT /note= "Primary amine group present at 3' end"
XX
XX EP1136569-A2.
PN
XX
XX 26-SEP-2001.
PD
XX
XX 13-MAR-2001; 2001EP-00105433.
XX
XX 24-MAR-2000; 2000US-0192026P.
XX
XX (FARB) BAYER CORP.
PA
XX Yang G, Ford DM, Law S, Monahan JE, Sells TB;
PI
XX WPI; 2002-063391/09.
DR
XX
XX New probes comprising a nucleic acid group and at least one tag group,
PT useful in hybridization reactions requiring highly labeled probes, for
PT detecting target sequences, or in reducing non-specific binding in
PT hybridization assays.
XX
XX Example 9; Page 10; 15pp; English.
PS
XX The present invention relates to new probes comprising a nucleic acid
CC group and at least one tag group. The probes are useful in hybridisation
CC reactions and assays where a highly labelled probe is desired, as a means
CC of detecting the presence of target sequences, in reducing non-specific
CC binding in hybridisation assays and in polymerase chain reaction assays.
CC The present nucleic acid sequence represents the BLA3 probe that was used
CC in the invention to produce probes with multiple acridinium ester labels
CC that allow greater gene probe assay sensitivity to be achieved
XX
XX Sequence 19 BP; 8 A; 6 C; 2 G; 3 T; 0 U; 0 Other;
SQ
Query Match 2.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 4.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 867 AATACGACACACATC 883
Db 2 AGTACGACACACATC 18
RESULT 623
ADE29788/c
ID ADE29788 standard; RNA; 19 BP.
XX
XX ADE29788;
AC
XX 29-JAN-2004 (first entry)
DT
XX Mitogen activated protein kinase siNA oligonucleotide SEQ ID NO:410.
DE
XX short interfering nucleic acid; siNA; downregulation; inhibition;
KW Mitogen-activated protein kinase; MAP kinase; MAPK; RNA interference;
KW cytosstatic; anorectic; antidiabetic; antiinflammatory; antiasthmatic;
KW immunosuppressive; antibacterial; antirheumatic; antiarthritic;
KW antipsoriatic; gastrointestinal; obesity; diabetes; tumour;

KW inflammatory disease; asthma; septic shock; rheumatoid arthritis;
KW psoriasis; inflammatory bowel disease; drug screening;
KW genetic engineering; pharmacogenomic; gene mapping; ss.
XX
OS Synthetic.
XX
PN WO2003072590-A1.
XX
PD 04-SEP-2003.
XX
XX 28-JAN-2003; 2003WO-US002510.
PF
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0408784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
PA
XX Mcswiggen J, Beigelman L, Usman N, Haerberli P, Chowrira B;
PI
XX WPI; 2003-689980/65.
XX
XX New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer, downregulates expression of mitogen-activated
PT protein kinase genes.
PT
XX Example 3; SEQ ID NO 410; 164pp; English.
PS
XX The present invention describes a short interfering nucleic acid (siNA)
CC that downregulates expression of a mitogen-activated protein kinase
CC (MAPK) genes by RNA interference. Also described: (1) a method for
CC modulating expression of MAPK genes in cells, tissue explants or
CC organisms by introduction of siNA; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; and (4)
CC vectors that express siNA and cells containing these vectors. MAPK siNAs
CC have cytostatic, anorectic, antidiabetic, antiinflammatory,
CC antiasthmatic, immunosuppressive, antibacterial, antirheumatic,
CC antiarthritic, antipsoriatic and gastrointestinal activities. The MAPK
CC siNAs can be used to modulate the expression of MAPK genes, in cells,
CC tissue explants or organisms, e.g. for treating obesity; diabetes types I
CC and II; a wide range of tumours, and inflammatory diseases (asthma,
CC septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel
CC disease). They can also be used for drug screening; diagnosis; target
CC identification and validation; genetic engineering; pharmacogenomics;
CC studying gene function and gene mapping (e.g. of single-nucleotide
CC polymorphisms). The present sequence represents a MAPK siNA which is used
CC in the exemplification of the present invention.
XX
XX Sequence 19 BP; 0 A; 9 C; 6 G; 0 T; 4 U; 0 Other;
SQ
Query Match 2.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 4.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 715 GCGGCTGCAGCAGCAGC 731
Db 19 GCGGCTGCAGCAGCAGC 3
RESULT 624
ADE29893
ID ADE29893 standard; RNA; 19 BP.
XX
XX ADE29893;
AC
XX 29-JAN-2004 (first entry)
DT
XX Mitogen activated protein kinase siNA oligonucleotide SEQ ID NO:515.
DE
XX


```

PN WO200259322-A2.
XX
PD 01-AUG-2002.
XX
XX 17-OCT-2001; 2001WO-US032354.
XX
XX 17-OCT-2000; 2000US-0240879P.
XX
XX 28-FEB-2001; 2001US-0272307P.
XX
XX 06-AUG-2001; 2001US-0310385P.
XX
XX (MIAO/) MIAO V P W.
XX (BRIA/) BRIAN P.
XX (BALZ/) BALZ R H.
XX (SILV/) SILVA C J.
XX
XX Miao VPW, Brian P, Baltz RH, Silva CJ;
XX
XX MPI; 2002-599794/64.
XX
XX Isolated nucleic acid molecule from a bacterial daptomycin biosynthetic
XX gene cluster encoding a thioesterase or thioesterase domain, useful for
XX generating novel linear and cyclic peptides, and products in a cell.
XX
XX Example 2; Page 91; 227pp; English.
XX
XX The invention relates to a novel isolated nucleic acid molecule
XX comprising a sequence that encodes a thioesterase or thioesterase domain,
XX derived from a bacterial daptomycin biosynthetic gene cluster. The
XX proteins of the invention have antibacterial, fungicide, virucide,
XX antiparasitic, immunomodulator, antilipemic, and cytostatic activity. The
XX polynucleotides may have a use in gene therapy. The compositions and
XX methods of the present invention are useful for generating novel linear
XX and cyclic peptides and improving yield of a product in a cell expressing
XX an daptomycin non-ribosomal peptide synthetase (NRPS) to be used as new
XX compounds or in producing new compounds, such as antibiotics,
XX antifungals, antivirals, antiparasitics, antimicrobials, antitumor agents,
XX immunomodulatory agents, anti-cholesterolemic agents, siderophores,
XX agrochemicals and cytostatics. The sequence represents a PCR primer used
XX in the invention to amplify the S. roseosporus daptomycin biosynthetic
XX gene cluster from a BAC library
XX
XX Sequence 20 BP; 3 A; 9 C; 3 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 2.0%; Score 15.4; DB 1; Length 20;
XX Best Local Similarity 94.1%; Pred. No. 4.3e+02;
XX Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 546 AGCAGATGGCTGAGGAC 562
XX || |||||
XX 18 AGGAGATGGCTGAGGAC 2
XX
XX RESULT 627
XX ACDD23022
XX ID ACD23022 standard; DNA; 20 BP.
XX
XX AC ACD23022;
XX
XX 25-AUG-2003 (first entry)
XX
XX Human NEMO gene intron 3 acceptor sequence.
XX
XX Human; ds; NF-kappaB essential modulator; nuclear factor kappa B;
XX incontinentia pigmenti; X-linked disorder; chromosome Xq28; NEMO;
XX immunomodulatory; dermatological; osteopathic; neuropathic;
XX apoptosis-related disease; immune-system related disease;
XX blood vessel-related disease; skin defect; dental defect; osteopetrosis;
XX ophthalmologic defect; neurological defect.
XX
XX Homo sapiens.
XX
XX US2003032055-A1.
XX

```

```

PD 13-FEB-2003.
XX
XX 22-MAY-2001; 2001US-00863049.
XX
XX 22-MAY-2000; 2000US-0206223P.
XX
XX (KENW/) KENWICK S J.
XX (WOPE/) WOFFENDIN H.
XX (MUNN/) MUNNICH A.
XX (SMAR/) SMARH A.
XX (ISRA/) ISRAEL A.
XX (POUS/) POUSTRKA A.
XX (HEIS/) HEISS N.
XX (DURS/) D'URSO M.
XX (LEWI/) LEWIS R A.
XX (NELS/) NELSON D L.
XX (ARAD/) ARADHYA S.
XX (LEVY/) LEVY M.
XX
XX Kenwick SJ, Woffendin H, Munnich A, Smah A, Israel A;
XX Poustka A, Heiss N, D'urso M, Lewis RA, Nelson DL, Aradhy S;
XX Levy M;
XX
XX MPI; 2003-492063/46.
XX
XX Detection of necrosis factor-kappa B related medical condition in
XX organism, by obtaining sample from the organism, and analyzing the sample
XX for alteration in specified amino acid sequences.
XX
XX Claim 40; Page 19; 44pp; English.
XX
XX The invention relates to a nuclear factor-kappa B (NF-kappa B) related
XX medical condition in an organism being detected by obtaining a sample
XX from the organism, and analysing the sample for an alteration in a the
XX nuclear factor kappaB essential modifier (NEMO) gene or protein sequence
XX (neither shown in the specification). The alteration results in
XX inactivation of NF-kappa B. Also included are treating or preventing NF-
XX kappa B related medical condition in an organism by administering the
XX NEMO protein to the organism and screening a test organism for a compound
XX for the treatment of NF-kappa B related medical condition (by
XX administering the compound to the organism, and assaying for an
XX improvement in the NF-kappa B related medical condition). The method
XX useful is for detecting NF-kappa B related condition, e.g. incontinentia
XX pigmenti (IP), apoptosis-related disease, immune-system related disease,
XX blood vessel-related disease, skin defect, dental defect, osteopetrosis,
XX ophthalmologic defect, or neurological defect, in an organism, i.e. human
XX including affected individual, carrier individual, or noncarrier
XX individual. The NEMO gene is located on chromosome Xq28, incontinentia
XX pigmenti being an X-linked disorder. Experiments in this study show
XX variations in exon 2, 10, 9 and particularly intron 3 to be linked to
XX familial incontinentia pigmenti. The present sequence is an intron donor
XX or acceptor site from the human NEMO gene
XX
XX Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 2.0%; Score 15.4; DB 1; Length 20;
XX Best Local Similarity 94.1%; Pred. No. 4.3e+02;
XX Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 541 CCAGCAGCAGATGGCTG 557
XX || |||||
XX 4 CCTGCAGCAGATGGCTG 20
XX
XX RESULT 628
XX ABZ85595/C
XX ID ABZ85595 standard; DNA; 20 BP.
XX
XX AC ABZ85595;
XX
XX 17-OCT-2003 (first entry)
XX
XX Human oligonucleotide sequence.
XX

```

```
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Claim 15; SEQ ID NO 837; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 0 A; 5 C; 7 G; 8 T; 0 U; 0 Other;
XX
Query Match 2.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 4.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 718 GCTGACGACGACGACCA 734
DB 18 GCAGCAGCAGCAGCAGCA 2
XX
RESULT 629
ADJ72244/c
ID ADJ72244 standard; DNA; 20 BP.
XX
AC ADJ72244;
XX
XX 06-MAY-2004 (first entry)
XX
DE Streptomyces roseosporus daptomycin biosynthesis gene cluster primer P92.
```

```
XX antibacterial; gene therapy; daptomycin biosynthesis gene cluster;
KW daptomycin non-ribosomal peptide synthetase; DptBC;
KW gram-positive bacterial infection; ss; primer.
XX
OS Streptomyces roseosporus.
XX
PN WO2003014297-A2.
XX
PD 20-FEB-2003.
XX
PF 31-JUL-2002; 2002WO-US024310.
XX
PR 06-AUG-2001; 2001US-0310385P.
PR 17-OCT-2001; 2001WO-US032354.
PR 10-MAY-2002; 2002US-0379866P.
XX
PA (CUBI-) CUBIST PHARM INC.
XX
PI Miao VPW, Brian P, Baltz RH, Coeffet-Legal MF;
XX
DR WPI; 2003-268192/26.
XX
XX New isolated nucleic acid molecule encoding a daptomycin non-ribosomal
PT peptide synthetase, useful for treatment of a gram-positive bacterial
PT infection of skeletal muscle, skin, bloodstream, kidneys, heart, lung and
PT bone.
XX
XX Example 2; SEQ ID NO 145; 292pp; English.
XX
CC The invention relates to new isolated nucleic acid (NA) molecules from
CC the streptomyces roseosporus daptomycin biosynthesis gene cluster,
CC especially a daptomycin non-ribosomal peptide synthetase (NRPS) or its
CC subunit, where the (NA) molecule encodes DptBC, and is not pRB159. The
CC methods and compositions of the present invention are useful for
CC treatment of a gram-positive bacterial infection of any organ or tissue
CC in the body, including skeletal muscle, skin, bloodstream, kidneys,
CC heart, lung and bone. This sequence represents a PCR primer used to
CC isolate and amplify the daptomycin biosynthesis gene cluster (ADJ72363).
XX
SQ Sequence 20 BP; 3 A; 9 C; 3 G; 5 T; 0 U; 0 Other;
XX
Query Match 2.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 4.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 546 AGCAGATGCTGACGAC 562
DB 18 AGGAGATGCTGACGAC 2
XX
RESULT 630
ABD21825/c
ID ABD21825 standard; DNA; 20 BP.
XX
AC ABD21825;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human stanniocalcin-derived oligo SEQ ID 837.
XX
XX Human; antisense; bronchoconstriction; allergy; hyoposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
```

XX 31-OCT-2002.
PD 23-APR-2002; 2002WO-US013143.
XX PR
XX 24-APR-2001; 2001US-0286036P.
XX (EPIG-) EPIGENESIS PHARM INC.
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX Claim 15; SEQ ID NO 837; 763pp; English.
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, cancer,
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
XX Sequence 20 BP; 0 A; 5 C; 7 G; 8 T; 0 U; 0 Other;
Query Match 2.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 4.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 718 GCTGCAGCAGCGACCA 734
DB 18 GCAGCAGCAGCGACCA 2
RESULT 631
AAT90087
XX AAT90087 standard; DNA; 20 BP.
XX AAT90087;
XX 20-APR-1998 (first entry)
XX Human oestrogen receptor protein PCR primer 10.
XX

KW Oestrogen receptor protein; steroid; alternative splicing; estradiol;
XX estone; estriol; screening; PCR primer; ss.
XX Synthetic.
OS Homo sapiens.
XX EP798378-A2.
PN 01-OCT-1997.
PD 25-MAR-1997; 97EP-00200903.
XX 26-MAR-1996; 96EP-00200820.
PR 22-NOV-1996; 96EP-00203284.
XX (ALKU) AKZO NOBEL NV.
PA Mosselman S, Dijkema R;
PI WPI; 1997-473188/44.
XX DNA encoding estrogen receptor - useful in screening assay to identify
PT novel ligands or hormonal analogues.
XX Example A; Page 8; 45pp; English.
XX AAT90087 and AAT90086 are PCR primers used to amplify a region of a novel
CC oestrogen receptor protein downstream of exon 7 using testis cDNA as a
CC template. AAT90087 is a gene specific primer and AAT90086 is designed
CC from the A1-2 region of the classical oestrogen receptor. This primer is
CC also used with AAT88405 and AAT90081 to detect splice variants of the
CC receptor. This receptor is able to bind and be activated by estradiol,
CC estone and estriol, can be used in a screening assay for the
CC identification of new drugs e.g. novel ligands or hormonal analogues
XX Sequence 20 BP; 3 A; 5 C; 7 G; 5 T; 0 U; 0 Other;
SQ Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 4.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 822 GGAAGCTGCCCGACTTGCAG 841
DB 1 GGAAGCTGCCCGACTTGCAG 20
RESULT 632
AAT96747
ID AAT96747 standard; DNA; 20 BP.
XX AAT96747;
XX 19-MAY-1998 (first entry)
XX Human G protein beta-3 subunit PCR primer 1.
XX G protein beta-3 subunit; variant; mutation; hypertension; diagnosis;
KW cardiovascular disease; metabolic disorder; immunological disorder; ss.
XX Synthetic.
OS Homo sapiens.
XX DE19619362-A1.
PN 20-NOV-1997.
PD 14-MAY-1996; 96DE-01019362.
PF 14-MAY-1996; 96DE-01019362.
PR (BADI) BASF AG.
XX Siffert W;
XX

XX WPI; 1998-000675/01.
 XX Assessing risk of disease, especially hypertension - by detecting
 PT mutation in human G-protein beta-3 sub:unit gene.
 XX
 XX Example 1; Page 3; 8pp; German.
 XX PCR primers AAT96747 and AAT96748 are used to amplify the gene encoding
 CC human G-protein beta-3 subunit. A variant of this gene can be used for
 CC diagnosis of diseases or assessing the risk of a disease associated with
 CC G-protein misregulation. G-protein misregulation is associated with
 CC hypertension, cardiovascular diseases e.g. coronary heart disease,
 CC atherosclerosis, restenosis, stroke and thrombosis, metabolic disorders
 CC such as diabetes, diabetic complications, disorders of lipid metabolism
 CC and central chemoreception dysfunction (e.g. sudden infant death
 CC syndrome), and immunological disorders such as impaired wound healing,
 CC tumours, AIDS, cirrhosis and transplant rejection
 XX
 XX Sequence 20 BP; 5 A; 2 C; 10 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 2.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 4.6e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 513 TGGGGGAGTGGGACCTG 532
 Db 1 TGGGGGAGTGGGACCTG 20
 RESULT 633
 AAZ57079/c
 ID AAZ57079 standard; DNA; 20 BP.
 XX
 AC AAZ57079;
 XX
 DT 19-MAY-2000 (first entry)
 XX
 DE Murine melanocortin receptor MC5-R amplifying primer.
 XX
 KW Medicament; agonist; melanocortin receptor type 3; ACTH; PMN; MC3-R;
 KW adrenocorticotrophic hormone; neutrophil chemoattractant; antigout;
 KW polymorphonuclear cell; septic shock; skin disorder; antiarthritic;
 KW melanocortin receptor; anti-inflammatory; antiasmatic; PCR primer; ss.
 XX
 OS Mus sp.
 XX
 PN WO200005263-A2.
 XX
 PD 03-FEB-2000.
 XX
 PF 22-JUL-1999; 99WO-GB002392.
 XX
 PR 24-JUL-1998; 98GB-00016234.
 XX
 PA (HARV-) HARVEY RES LTD WILLIAM.
 XX
 PI Perretti M, Getting S, Flower R;
 XX
 XX WPI; 2000-182651/16.
 DR
 XX Inhibition of neutrophil chemoattractant production, inhibition of
 PT polymorphonuclear cell accumulation or reduction/treatment of
 PT inflammation using compounds comprising the peptide sequence HFRW.
 PT
 XX Disclosure; Page 8; 20pp; English.
 XX
 CC The invention relates to the use of a compound comprising an amino acid
 CC sequence His-Phe-Arg-Tip (HFRW) in the manufacture of a medicament and/or
 CC an agonist of melanocortin receptor type 3 (MC3-R) where the compound is
 CC not adrenocorticotrophic hormone (ACTH)1-39. The compounds are used to
 CC inhibit neutrophil chemoattractant production, polymorphonuclear cell
 CC (PMN) accumulation or reduction/treatment of inflammation. Especially,

CC these compounds are agonists of the MC3-R. The inflammatory response/
 CC disease is selected from gout, gouty arthritis, rheumatoid arthritis,
 CC asthma, reperfusion injury or damage, stroke, myocardial infarction,
 CC septic shock, or a skin disorder. Sequences AAZ57073-80 represent PCR
 CC primers used for amplifying murine melanocortin receptors
 XX
 SQ Sequence 20 BP; 4 A; 10 C; 1 G; 5 T; 0 U; 0 Other;
 Query Match 2.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 4.6e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 407 AGGGAGGAGAGGAGCTTCT 426
 Db 20 AGGGTGGAGGAGGAGCTTCT 1
 RESULT 634
 AAZ43563
 ID AAZ43563 standard; DNA; 20 BP.
 XX
 AC AAZ43563;
 XX
 DT 21-FEB-2000 (first entry)
 XX
 DE Psychrotolerant Bacillus cereus detecting PCR primer Rps2.
 XX
 KW Psychrotolerance; mesophilia; detection; pastuerization; endospore;
 KW cold storage; lytic enzyme; toxin; food; spoilage; PCR primer; ss.
 XX
 OS Synthetic.
 OS Bacillus cereus.
 XX
 PN DE19824317-A1.
 XX
 PD 09-DEC-1999.
 XX
 PF 02-JUN-1998; 98DE-01024317.
 XX
 PR 02-JUN-1998; 98DE-01024317.
 XX
 PA (SCHE/) SCHERER S.
 XX
 PI Von Stetten F, Francis K, Lechner S, Scherer S, Mayr R;
 XX
 DR WPI; 2000-040061/04.
 XX
 PT Detecting psychrotolerance and mesophilia in Bacillus, from presence of
 PT signature sequences in ribosomal nucleic acid, for identifying food-
 PT spoilage strains.
 XX
 PS Example; Page 3; 6pp; German.
 XX
 CC This invention describes a novel method for determining psychrotolerance
 CC and mesophilia in Bacillus by using, as indicator, signature bases to
 CC present in ribosomal (deoxy)ribonucleic acids. The method is used to
 CC identify psychrotolerant strains, i.e. those that survive pastuerization
 CC as endospores and germinate and grow subsequently, even during cold
 CC storage, with production of lytic enzymes and toxins, resulting in
 CC spoilage of foods. This method allows rapid differentiation between
 CC psychrotolerant strains and mesophilic strains (which do not grow during
 CC cold storage), typically in 2 hr, compared with 14 days required for the
 CC conventional growth test. AAZ43561-243564 represent PCR primers used in
 CC the method of the invention
 XX
 SQ Sequence 20 BP; 6 A; 4 C; 5 G; 5 T; 0 U; 0 Other;
 Query Match 2.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 4.6e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 475 GGAGAGCTCGATCTGAGA 494
 |||||

Db 1 GGAGAGCTCTATCTCTAGA 20

RESULT 635
AAD11606
ID AAD11606 standard; DNA; 20 BP.
XX
AC AAD11606;
XX
XX
DT 24-SEP-2001 (first entry)
XX
XX Zinc finger primer NZlib5', to analyse Ap3-specific effector expression.
DE
XX Zinc finger protein; ZFP; gene expression; metabolic pathway regulator;
KW modulation; plant technology; agriculture; Ap3; APTAL3; PCR primer; ss.
XX
XX Unidentified.
OS
XX WO200152620-A2.
XX
XX 26-JUL-2001.
PD
XX 19-JAN-2001; 2001WO-US001817.
XX
XX 21-JAN-2000; 2000US-0177468P.
XX
XX 21-JUL-2000; 2000US-00620897.
PR
XX (SCRI) SCRIPPS RES INST.
PA (SYGN) SYNGENTA AGRIC DISCOVERY INC.
PA
XX Barbas CF, Stege JT, Guan X, Dalmia B;
XX WPI; 2001-465325/50.
XX
XX New zinc finger proteins, useful for modulating or regulating gene
PT expression and metabolic pathways in plants, e.g. for treating in the
PT plant cells a disorder that is associated with abnormal expression of the
PT target gene.
XX
XX Example 7C; Page 91; 156pp; English.
PS
XX The patent discloses methods and compositions to modulate the expression
CC of a target gene in plant cells. The method involves providing plant
CC cells with a zinc finger protein (ZFP) which is capable of specifically
CC binding to a target nucleotide sequence or its complementary strand
CC within a target gene and allowing the ZFP binding to the target
CC nucleotide sequence, where the expression of the target gene in the plant
CC cells is modulated. The ZFP and fusions of the ZFP proteins are useful
CC for modulating or regulating gene expression and metabolic pathways in
CC plants. The ZFP, fusion proteins and methods are useful in plant and
CC agricultural technology. The method is useful particularly for treating a
CC disorder in the plant cells, where the disorder is associated with
CC abnormal expression of the target gene. The present DNA sequence is Zinc
CC finger forward PCR primer NZlib5' which is used to analyse Ap3-specific
CC effector expression
XX
SQ Sequence 20 BP; 2 A; 9 C; 8 G; 1 T; 0 U; 0 Other;

Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 4.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 667 GGCCCGGGCGCCGAGCGAGC 686
||||| ||||| ||||| ||||| |||||
Db 1 GGCCCGGGCGCCGAGCGAGC 20
||||| ||||| ||||| ||||| |||||

RESULT 636
AAD09674/C
ID AAD09674 standard; DNA; 20 BP.
XX
AC AAD09674;
XX

DT 10-SEP-2001 (first entry)
XX
DE Human PKA C-alpha chimeric antisense oligonucleotide (ISIS# 102744).
XX
KW Human; protein kinase A; PKA catalytic subunit C-alpha inhibitor;
KW therapy; infection; inflammation; tumour; prophylaxis; antisense;
KW phosphorothioate backbone; chimeric; ss.
XX
OS Homo sapiens.
OS Synthetic.
OS Chimeric.
XX
XX Key Location/Qualifiers
FH modified_base 1. .20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone"
FT modified_base 1. .5
FT /tag= b
FT /mod_base= OTHER
FT /note= "Methoxyethyl residues"
FT modified_base 4
FT /tag= c
FT /mod_base= m5c
FT 6. .15
FT /tag= d
FT /note= "Central gap region"
FT modified_base 16. .20
FT /tag= e
FT /mod_base= OTHER
FT modified_base 17. .20
FT /tag= f
FT /mod_base= m5c
XX
XX US6248586-B1.
XX
XX 19-JUN-2001.
PD
XX 17-DEC-1999; 99US-00467082.
PF
XX 17-DEC-1999; 99US-00467082.
PR
XX (ISIS-) ISIS PHARM INC.
PA
XX Monia BP, Cowser LM;
PI
XX WPI; 2001-407321/43.
XX
XX Antisense oligonucleotides for inhibiting the expression of the human
PT protein kinase A catalytic subunit C-alpha, particularly useful for
PT preventing, delaying or treating infection, inflammation or tumor
PT formation.
XX
XX Claim 1; Col 45; 35pp; English.
PS
XX The invention is directed to antisense compounds, particularly
CC oligonucleotides which are targeted to a DNA encoding human protein
CC kinase A (PKA) catalytic subunit C-alpha to modulate (inhibit) its
CC expression. The antisense compounds are useful for diagnostics,
CC therapeutics, prophylaxis and as research reagents or kits. The antisense
CC oligonucleotides are useful for treating human, suspected of having or
CC being prone to a disease or condition associated with the expression of
CC PKA catalytic subunit C-alpha. In particular, the antisense
CC oligonucleotides are useful for preventing, delaying or treating
CC infection, inflammation and tumour formation. They are also useful in
CC antisense therapy. The present sequence is a chimeric antisense
CC oligonucleotide with a phosphorothioate backbone. This oligo is targeted
CC to the 3' untranslated region (UTR) of human PKA catalytic subunit C-
CC alpha to inhibit its expression
XX
SQ Sequence 20 BP; 1 A; 11 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 2.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 4.6e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 599 GGGGAGCTCGAGAGCCCA 618
 DB 20 GGGGAGCTCGAGAGCCCA 1

RESULT 637
 AAS0873/c
 ID AAS0873 standard; DNA; 20 BP.
 XX
 AC AAS0873;
 XX
 DT 26-SEP-2001 (first entry)
 XX
 DE Human PD-ABC form 2 DNA exon 32 3' splice site.
 XX
 KW PD-ATP-binding cassette; PD-ABC; chromosome 19p13.3; spleen; thymus; ds;
 KW peripheral blood leukocyte; bone marrow; lymph node; dyslipidaemia;
 KW cardiovascular disorder; inflammatory disorder; abnormal calcium flux;
 KW epilepsy; coronary artery disease; Tangier's disease; atherosclerosis;
 KW familial high-density lipoprotein deficiency; fatty liver disease;
 KW atherosclerosis; diabetes; insulin resistance; obesity; drug screening;
 KW alcoholism; retinal degeneration; hypertension; vascular disease.
 OS Homo sapiens.
 XX
 PN WO200153490-A1.
 XX
 PD 26-JUL-2001.
 XX
 PF 23-JAN-2001; 2001WO-US002191.
 XX
 PR 24-JAN-2000; 2000US-0177889P.
 XX
 PR 30-JUN-2000; 2000US-0215405P.
 XX
 PA (WARN) WARNER LAMBERT CO.
 XX
 PI Johns MA, Tafuri SR, Wang M;
 XX
 DR WPI; 2001-442259/47.
 XX
 PT New Human PD-ABC DNA molecules and proteins for diagnosis and treatment
 of dyslipidemia, epilepsy and diseases related to abnormal calcium flux.
 XX
 PS Disclosure; Page 40; 77pp; English.
 XX
 CC The sequence represents a splice site within a DNA molecule encoding
 human PD-ATP-binding cassette (PD-ABC) protein. PD-ABC maps to chromosome
 19p13.3 and is expressed in various tissues including spleen, thymus, DNA
 peripheral blood leukocytes, bone marrow and lymph nodes. The PD-ABC DNA
 molecules and proteins are used to diagnose and treat cardiovascular
 disorders, inflammatory disorders, dyslipidaemia, epilepsy, diseases
 related to abnormal calcium flux, coronary artery disease, Tangier's
 disease, familial high-density lipoprotein deficiency, atherosclerosis,
 diabetes, fatty liver disease, insulin resistance, obesity, alcoholism,
 retinal degeneration, hypertension and vascular disease. The sequences
 are also used in drug screening assays
 XX
 SQ Sequence 20 BP; 4 A; 5 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 2.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 4.6e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 292 TGAGACCTCCAGCGTGCC 311
 DB 20 TGAGACCTCCAGCGTGCC 1

RESULT 638
 AAI72138
 ID AAI72138 standard; DNA; 20 BP.
 XX
 AC AAI72138;
 XX
 DT 25-MAR-2002 (first entry)
 XX
 DE Primer #10 based on ER gene.
 XX
 KW DNA binding domain; DBD; ligand binding domain; LBD; chimeric receptor;

AAS08782/c
 ID AAS08782 standard; DNA; 20 BP.
 XX
 AC AAS08782;
 XX
 DT 26-SEP-2001 (first entry)
 XX
 DE Human PD-ABC form 1 DNA exon 32 3' splice site.
 XX
 KW PD-ATP-binding cassette; PD-ABC; chromosome 19p13.3; spleen; thymus; ds;
 KW peripheral blood leukocyte; bone marrow; lymph node; dyslipidaemia;
 KW cardiovascular disorder; inflammatory disorder; abnormal calcium flux;
 KW epilepsy; coronary artery disease; Tangier's disease; atherosclerosis;
 KW familial high-density lipoprotein deficiency; fatty liver disease;
 KW atherosclerosis; diabetes; insulin resistance; obesity; drug screening;
 KW alcoholism; retinal degeneration; hypertension; vascular disease.
 XX
 OS Homo sapiens.
 XX
 PN WO200153490-A1.
 XX
 PD 26-JUL-2001.
 XX
 PF 23-JAN-2001; 2001WO-US002191.
 XX
 PR 24-JAN-2000; 2000US-0177889P.
 XX
 PR 30-JUN-2000; 2000US-0215405P.
 XX
 PA (WARN) WARNER LAMBERT CO.
 XX
 PI Johns MA, Tafuri SR, Wang M;
 XX
 DR WPI; 2001-442259/47.
 XX
 PT New Human PD-ABC DNA molecules and proteins for diagnosis and treatment
 of dyslipidemia, epilepsy and diseases related to abnormal calcium flux.
 XX
 PS Disclosure; Page 38; 77pp; English.
 XX
 CC The sequence represents a splice site within a DNA molecule encoding
 human PD-ATP-binding cassette (PD-ABC) protein. PD-ABC maps to chromosome
 19p13.3 and is expressed in various tissues including spleen, thymus,
 peripheral blood leukocytes, bone marrow and lymph nodes. The PD-ABC DNA
 molecules and proteins are used to diagnose and treat cardiovascular
 disorders, inflammatory disorders, dyslipidaemia, epilepsy, diseases
 related to abnormal calcium flux, coronary artery disease, Tangier's
 disease, familial high-density lipoprotein deficiency, atherosclerosis,
 diabetes, fatty liver disease, insulin resistance, obesity, alcoholism,
 retinal degeneration, hypertension and vascular disease. The sequences
 are also used in drug screening assays
 XX
 SQ Sequence 20 BP; 4 A; 5 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 2.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 4.6e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 292 TGAGACCTCCAGCGTGCC 311
 DB 20 TGAGACCTCCAGCGTGCC 1

RESULT 639
 AAI72138
 ID AAI72138 standard; DNA; 20 BP.
 XX
 AC AAI72138;
 XX
 DT 25-MAR-2002 (first entry)
 XX
 DE Primer #10 based on ER gene.
 XX
 KW DNA binding domain; DBD; ligand binding domain; LBD; chimeric receptor;

KW estrogen receptor; ER; chromosome 14; ER-alpha; ER-beta; exon 8; PCR;
KW estradiol; nuclear receptor; progesterone receptor; amplify; primer;
KW polymerase chain reaction; ss.
XX Synthetic.
XX
PN EP1162264-A2.
XX
XX 12-DEC-2001.
XX
PF 25-MAR-1997; 2001EP-00202021.
XX
PR 26-MAR-1996; 96EP-00200820.
PR 22-NOV-1996; 96EP-00203284.
PR 25-MAR-1997; 97EP-00200903.
XX
PA (ALKU) AKZO NOBEL NV.
XX
PI Mosselman S, Dijkema R;
XX
DR WPI; 2002-084414/12.
XX
PT New isolated chimeric receptor comprising a DNA binding domain and/or
PT ligand binding domain of a new estrogen receptor, for identifying
PT functional ligands or hormonal analogs for the receptor.
XX
PS Example A; Page 8; 35pp; English.
XX
CC The sequences given in AAI72129-43 are primers which were used in the
CC amplification and cloning of a novel estrogen receptor (ER). The gene
CC encoding this new ER is located on chromosome 14 and has a different
CC tissue distribution from classical ER. This ER also has two orphan ER's,
CC ER-alpha and ER-beta. These orphan receptors have estrogen receptor
CC related structure but do not appear to be able to bind estradiol or other ER
CC ligands. The DNA binding domain (DBD) and ligand binding domain (LBD)
CC from this ER may be used in the chimeric receptor of the invention which
CC also has an N-terminal domain. The chimeric receptor, or DNA encoding it,
CC is useful in a screening assay for identification of new drugs. Similar
CC chimeric receptors comprising the LBD of the new ER, and also comprising
CC the DBD and an N-terminal domain derived from another nuclear receptor
CC e.g., progesterone receptor, are useful for the screening of compounds to
CC identify new ligands or hormone analogs which are able to activate the
CC new ER. Chimeric receptors comprising a DBD of the new ER, and LBD and an
CC N-terminal domain derived from another nuclear receptor, can be used to
CC identify new ligands or hormone analogs for the nuclear receptors
XX
SQ Sequence 20 BP; 3 A; 5 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 4.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 822 GGAAGCTGGCCAGTTCAG 841
Db 1 GGAAGCTGGCTCACTGCTG 20

RESULT 640
AAD34914/C
ID AAD34914 standard; DNA; 20 BP.
XX
AC AAD34914;
XX
DT 16-JUL-2002 (first entry)
XX
DE Human E2F transcription factor 2 antisense oligo, ISIS #114111.
XX
KW Human; E2F transcription factor 2; hyperproliferative disorder; cancer;
KW developmental disorder; antisense; therapy; phosphorothioate backbone;
KW cytosatic; ss.
XX
OS Homo sapiens.
OS Synthetic.

XX Key Location/Qualifiers
FH modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 2
FT /tag= c
FT /mod_base= m5c
FT modified_base 3
FT /tag= d
FT /mod_base= m5c
FT modified_base 8
FT /tag= e
FT /mod_base= m5c
FT modified_base 9
FT /tag= f
FT /mod_base= m5c
FT modified_base 11
FT /tag= g
FT /mod_base= m5c
FT modified_base 15
FT /tag= h
FT /mod_base= m5c
FT modified_base 16..20
FT /tag= i
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX WO200220551-A1.
XX 14-MAR-2002.
XX 07-SEP-2001; 2001WO-US028202.
XX 08-SEP-2000; 2000US-00658679.
XX (ISIS-) ISIS PHARM INC.
XX Popoff I, Wyatt JR;
XX WPI; 2002-329864/36.
XX
XX New antisense oligonucleotides targeted to a nucleic acid encoding E2F
XX transcription factor 2, useful for treating a disease or condition
XX associated with E2F transcription factor 2, e.g. hyperproliferative
XX disorders, such as cancer.
XX
XX Claim 3; Page 92; 120pp; English.
XX
XX The present invention relates to antisense oligonucleotides, compounds
XX and methods for modulating the expression of E2F transcription factor 2.
XX The antisense oligonucleotides specifically hybridise with and inhibit
XX the expression of E2F transcription factor 2. They are useful for
XX inhibiting the expression of E2F transcription factor 2 and for treating
XX diseases or conditions associated with E2F transcription factor 2, such
XX as hyperproliferative disorders, particularly cancer and developmental
XX disorders. They may also be used as research reagents and diagnostics, to
XX distinguish between functions of various members of a biological pathway
XX and in the treatment of a disease or disorder which can be treated by
XX modulating the expression of E2F transcription factor 2. The oligomeric
XX compounds, particularly the antisense oligonucleotides may be used to
XX modulate the function of nucleic acid molecules encoding E2F
XX transcription factor 2, ultimately modulating the amount of E2F
XX transcription factor produced. Sequences of the invention are also used
XX in antisense therapy. The present DNA sequence is human E2F transcription
XX factor 2 antisense oligonucleotide with a phosphorothioate backbone. This
XX sequence is targeted to the coding region of human E2F transcription
XX factor 2


```
XX
SQ Sequence 20 BP; 2 A; 6 C; 6 G; 6 T; 0 U; 0 Other;
    Query Match      2.0%; Score 15.2; DB 1; Length 20;
    Best Local Similarity 85.0%; Pred. No. 4.6e+02;
    Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 548 CAGATGGCTGAGGACAAAGGC 567
    |||||
Db 20 CACCTGACTGAGGACAAAGGC 1

RESULT 641
ABI96876/C
ID ABI96876 standard; DNA; 20 BP.
XX
AC ABI96876;
XX
DT 16-FEB-2002 (first entry)
XX
DE Capture oligonucleotide Zip ID#3963 oligo #9.
XX
KW Human; K-ras; PCR primer; probe; capture probe; mutation detection;
KW ligase detection reaction; LDR; p53; BRCA1; BRCA2; infectious disease;
KW infection; 21 hydroxylase deficiency; Turner Syndrome; obesity; cancer;
KW oncogene; tumour suppressor; human papillomavirus; forensic;
KW environmental monitoring; food industry; feed industry; ss.
XX
OS Synthetic.
XX
PN WO200179548-A2.
XX
PD 25-OCT-2001.
XX
PF 04-APR-2001; 2001WO-US010958.
XX
PR 14-APR-2000; 2000US-0197271P.
XX
PA (CORR ) CORNELL RES FOUND INC.
XX
PI Barany P, Zirvi M, Gerry NP, Favis R, Kliman R;
XX
WPI; 2002-034366/04.
XX
PT Designing capture oligonucleotide probes for use on a support to which
PT complementary oligonucleotides hybridize with little mismatch.
XX
PS Example 5; Fig 29; 300pp; English.
XX
CC The present invention describes a method (M1) for designing capture
CC oligonucleotide probes (I) for use on a support to which complementary
CC oligonucleotide probes (II) will hybridize with little mismatch, where
CC (I) have melting temperatures within a narrow range. The method is useful
CC for detecting infectious diseases caused by bacterial infectious agents
CC e.g. Salmonella, Listeria monocytogenes and Haemophilus influenza, fungal
CC infectious agents e.g. Cryptococcus neoformans, Candida albicans and
CC Aspergillus fumigatus, viruses e.g. T-cell lymphocytotropic virus,
CC Epstein-Barr virus and polio virus, and parasitic infectious agents
CC selected from Onchocerca volvulus, Entamoeba histolytica and Dracunculus
CC medinensis. The method is also useful for detecting genetic diseases such
CC as 21 hydroxylase deficiency, Turner Syndrome and obesity defects.
CC Detecting cancer involving oncogenes, tumour suppressor genes, or genes
CC involved in DNA amplification, replication, recombination or repair, the
CC cancer is specifically associated with a gene selected from BRCA1 gene,
CC p53 gene, human papillomavirus types 16 and 18 and liver cancers. The
CC method is also used for environmental monitoring, forensics and the food
CC and feed industry, detecting comprises scanning (using e.g. a scanning
CC electron microscope and infrared microscope) the support at the
CC particular sites and identifying if ligation of the oligonucleotide probe
CC sets occurred and correlating (using a computer) identified ligation to a
CC presence or absence of the target nucleotide sequences. ABI82074 to
CC ABI97546 represent oligonucleotide sequences used in the exemplification
CC of the present invention

XX
SQ Sequence 20 BP; 6 A; 6 C; 5 G; 3 T; 0 U; 0 Other;
    Query Match      2.0%; Score 15.2; DB 1; Length 20;
    Best Local Similarity 85.0%; Pred. No. 4.6e+02;
    Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 828 TGGCCCAAGTTGCAGGTGGCC 847
    |||||
Db 20 TTGCCCAAGTTGCAGGTGTCC 1

RESULT 642
ADB39025
ID ADB39025 standard; DNA; 20 BP.
XX
AC ADB39025;
XX
DT 04-DEC-2003 (first entry)
XX
DE PCR primer B-V3 AS related to microorganism identification.
XX
KW microorganism identification; electronic sequence analysis;
KW sequence library; PCR; primer; B-V3 AS; ss.
XX
OS Unidentified.
XX
PN WO2003066888-A2.
XX
PD 14-AUG-2003.
XX
PF 07-FEB-2003; 2003WO-GB000562.
XX
PR 07-FEB-2002; 2002GB-00002891.
XX
PA (PYRO-) PYROSEQUENCING AB.
XX
PI (SAMU/) SAMUELS A J.
XX
PI Jonasson J;
XX
WPI; 2003-636965/60.
XX
PT Identifying a microorganism by generating a sample sequence comprising
PT letters representing nucleic acid bases and identifying one or more
PT library sequences having the greatest degree of agreement with the sample
PT sequence.
XX
PS Disclosure; Page 11; 31pp; English.
XX
CC This invention relates to a novel method for the identification of a
CC microorganism through electronic sequence analysis. The method compares
CC an input sequence from the organism of interest to a library of sequences
CC from microorganisms of known identity. The method is useful for
CC identifying a microorganism. The present sequence is that of PCR primer B
CC -V3 AS related to the invention.
XX
SQ Sequence 20 BP; 6 A; 8 C; 4 G; 2 T; 0 U; 0 Other;
    Query Match      2.0%; Score 15.2; DB 1; Length 20;
    Best Local Similarity 85.0%; Pred. No. 4.6e+02;
    Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 251 AAGCCAGCCATGCTGCACCT 270
    |||||
Db 1 ACGACAGCCATGACGACCT 20

RESULT 643
ADD14252
ID ADD14252 standard; DNA; 20 BP.
XX
AC ADD14252;
XX
```

```

DT 01-JAN-2004 (first entry)
XX Human src biomarker forward PCR primer SEQ ID NO:441.
DE
XX
KW predictor set; protein tyrosine kinase activity modulator;
KW protein tyrosine kinase pathway; protein tyrosine kinase; cytostatic;
KW gene therapy; drug sensitivity; genetic profile; cancer; human;
KW PCR primer; ss.
XX
XX Synthetic.
OS Homo sapiens.
XX
XX WO2003062395-A2.
XX
XX 31-JUL-2003.
XX
XX 17-JAN-2003; 2003WO-US001981.
XX
XX 18-JAN-2002; 2002US-0350061P.
XX
XX (BRIM ) BRISTOL-MYERS SQUIBB CO.
XX
XX Huang F, Fairchild CR, Lee FY, Shaw P;
XX WPI; 2003-636735/60.
XX
XX New polynucleotides and polypeptides for predicting the activity of
XX compounds that interact with protein tyrosine kinases and/or protein
XX tyrosine kinase pathways.
XX
XX Example 2; SEQ ID NO 441; 139pp; English.
XX
XX The present invention describes a predictor set comprising a plurality of
XX polynucleotides or polypeptides whose expression pattern is predictive of
XX the response of cells to treatment with a compound that modulates protein
XX tyrosine kinase activity or members of the protein tyrosine kinase
XX pathway. Also described: (1) predicting whether a compound is capable of
XX modulating the activity of cells, comprising obtaining a sample of cells,
XX determining whether the cells express a plurality of markers, and
XX correlating the expression of the markers to the compound's ability to
XX modulate the activity of the cells; (2) a plurality of cell lines for
XX identifying polynucleotides and polypeptides whose expression levels
XX correlate with compound sensitivity or resistance of cells associated
XX with a disease state; and (3) identifying polynucleotides and
XX polypeptides that predict compound sensitivity or resistance of cells
XX associated with a disease state, comprising subjecting the plurality of
XX cell lines to one or more compounds, analysing the expression pattern of
XX a microarray of polynucleotides or polypeptides, and selecting
XX polynucleotides or polypeptides that predict the sensitivity or
XX resistance of cells associated with a disease state by using the
XX expression pattern of the microarray. The polynucleotides and
XX polypeptides have cytostatic activities, and can be used in gene therapy.
XX The polynucleotides and polypeptides are useful in predicting the
XX activity of compounds that interact with protein tyrosine kinases and/or
XX protein tyrosine kinase pathways. These may be used in determining drug
XX sensitivity in patients to allow the development of individualized
XX genetic profiles which aid in treating diseases and disorders (e.g.
XX cancer) based on patient response at a molecular level. The present
XX sequence is used in the exemplification of the present invention.
XX
XX Sequence 20 BP; 8 A; 3 C; 8 G; 1 T; 0 U; 0 Other;
Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 4.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 549 AGATGGCTGAGGACAAAGGCC 568
DB 1 AGAAGGCTGAGGACAAAGGCC 20
|||||
RESULT 644
ABZ93298

```

```

ID ABZ93298 standard; DNA; 20 BP.
XX
XX AC
XX ABZ93298;
XX
XX 17-OCT-2003 (first entry)
XX
XX Human oligonucleotide sequence.
DE
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
XX antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
XX antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
XX antisense gene therapy; respiratory; lung; adenosine sensitivity;
XX adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
XX lung inflammation; respiratory disease; ds.
XX
XX Homo sapiens.
OS
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasegura A, Katz E, Pabalan J, Aguilar D;
XX Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
XX respiration, has oligo(s) antisense to specific gene(s) or its
XX corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
XX ubiquinone.
XX
XX Disclosure; SEQ ID NO 8540; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
XX first active agent comprising an oligonucleotide antisense to the
XX initiation codon, coding region, 5' or 3' end genomic flanking regions,
XX 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
XX junctions of genes encoding a polypeptide associated with lung and/or
XX nasal airway dysfunction and a second active agent comprising an
XX antiinflammatory steroid and ubiquinone. A composition of the invention
XX has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
XX immunosuppressive, and cytostatic activity. The composition may have a
XX use in antisense gene therapy. The composition is useful for treating or
XX preventing a respiratory, lung or malignant disease or condition, also
XX for enhancing the prophylactic or therapeutic respiratory effect of an
XX antiinflammatory steroid in a subject, for reducing or depleting levels
XX of, or reducing sensitivity to adenosine, reducing levels of adenosine
XX receptor, producing bronchodilation, increasing levels of ubiquinone or
XX lung surfactant in a subject's tissue, or treating bronchoconstriction,
XX lung inflammation, lung allergies, or a respiratory disease or condition.
XX Note: The sequence data for this patent is not represented in the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 20 BP; 4 A; 3 C; 11 G; 2 T; 0 U; 0 Other;
Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 4.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 400 CAGCCAGAGGAGGAGGAGG 419
DB 1 CAGCCTGAGGAGGAGGAGG 20
|||||
RESULT 645
ABZ99074/c

```

ID	XX	ADM96498 standard; DNA; 20 BP.
XX	XX	ADM96498;
XX	AC	
XX	DT	17-JUN-2004 (first entry)
XX	XX	PCR primer of the invention B-V3.ASSEQ ID NO:7.
DE	XX	ss; microorganism; signature sequence; microorganism identification;
XX	XX	pathogenic; commonsal; saphorophyte; PCR; primer.
KW	XX	Synthetic.
OS	XX	
XX	XX	CA2363938-A1.
FN	XX	
XX	XX	28-MAY-2003.
PD	XX	
XX	XX	28-NOV-2001; 2001CA-02363938.
PF	XX	
XX	XX	28-NOV-2001; 2001CA-02363938.
XX	XX	(PYRO-) PYROSEQUENCING AB.
PR	XX	
XX	XX	Jonasson J;
PA	XX	
PI	XX	WPI; 2003-845757/79.
XX	XX	Identification of microorganism in biological sample, by determining
DR	XX	sequence of region of preset nucleotides in predetermined site in gene of
PT	XX	microorganism to obtain signature sequence and analyzing sequencing
PT	XX	information.
PT	XX	Disclosure; SEQ ID NO 7; 78pp; English.
PS	XX	
XX	XX	The invention relates to a novel method for identifying a microorganism
CC	XX	in a sample, comprising determining the sequence of a region of up to 50
CC	XX	nucleotides in a predetermined site (PS) in a gene of a microorganism, to
CC	XX	obtain a signature sequence (SS), and analysing sequencing information in
CC	XX	SS. The sequence is determined by detecting the nucleotides incorporated in
CC	XX	in a primer extension reaction performed using a primer binding at a PS
CC	XX	in a gene. The method is useful for identifying a microorganism such as
CC	XX	bacteria, fungi, algae or protozoa in a sample such as samples of
CC	XX	cellular or tissue material, body fluids like blood, saliva, urine or
CC	XX	semen and microbial isolates or cultures, water, food samples and soil.
CC	XX	The method allows pathogenic microorganisms to be distinguished from
CC	XX	commonsals or ephorophytes in the same sample, permits molecular
CC	XX	identification of microorganisms and therefore genotypic is achieved. The
CC	XX	method enables high capacity and convenient procedure for screening large
CC	XX	numbers of samples. The present sequence is used in the exemplification
CC	XX	of the invention.
XX	XX	
SQ	XX	Sequence 20 BP; 6 A; 8 C; 4 G; 2 T; 0 U; 0 Other;
Query Match 2.0%; Score 15.2; DB 1; Length 20;		
Best Local Similarity 85.0%; Pred. No. 4.6e+02;		
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;		
Qy	251	AAGCCAGCCATGTCGACCT 270
Db	1	ACGACAGCCATGACGACCT 20
RESULT 647		
ABD32105/C		
ID	XX	ABD32105 standard; DNA; 20 BP.
XX	XX	ABD32105;
XX	AC	
XX	DT	29-JUL-2004 (first entry)
XX	XX	Human PDB4C-derived oligonucleotide SEQ ID 14316.
DE	XX	Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW	XX	

KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytotatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX Homo sapiens.
XX WO200285309-A2.
XX 31-OCT-2002.
XX 23-APR-2002; 2002WO-US013143.
XX 24-APR-2001; 2001US-0286036P.
XX (EPIG-) EPIGENESIS PHARM INC.
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX Claim 15; SEQ ID NO 14316; 763pp; English.
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytotatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX Sequence 20 BP; 3 A; 9 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.04; Pred. No. 4.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 516 GGGAGGTGGAGCCTGAAG 535
DB 20 GGCAGGTGGATCCTGAGG 1
|||||
|||||

RESULT 648
ABD29528
ID ABD29528 standard; DNA; 20 BP.
XX ABD29528;
AC ABD29528;
XX 29-JUL-2004 (first entry)
XX AA664176-derived oligonucleotide SEQ ID 8540.
XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytotatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX Homo sapiens.
XX WO200285309-A2.
XX 31-OCT-2002.
XX 23-APR-2002; 2002WO-US013143.
XX 24-APR-2001; 2001US-0286036P.
XX (EPIG-) EPIGENESIS PHARM INC.
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX Claim 15; SEQ ID NO 8540; 763pp; English.
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytotatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to

```
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 4 A; 3 C; 11 G; 2 T; 0 U; 0 Other;

Query Match      2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 4.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 400 CAGCCAGAGGAGGAGGAGG 419
Db 1 CAGCCAGAGGAGGAGGAGG 20

RESULT 649
ID ADG86886/c
XX ADG86886 standard; DNA; 20 BP.
AC ADG86886;
XX
XX 11-MAR-2004 (first entry)
XX Mouse PPAR antisense oligonucleotide ISIS 221093.
DE
XX
XX Mouse; ss; PPAR delta; peroxisome proliferative activated receptor delta;
KW antisense gene therapy; cytostatic; osteopathic; antidiabetic; cancer;
KW osteoporosis; diabetes; endocrine disorder.
XX
XX Mus musculus.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages and all cytidines are 5
FT -methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl residue"
FT modified_base 15..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl residue"
XX
XX US2003224514-A1.
XX
XX 04-DEC-2003.
XX
XX 31-MAY-2002; 2002US-00160807.
XX
XX 31-MAY-2002; 2002US-00160807.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Gaarde W, Freier SM, Watt AT;
XX WPI; 2004-022078/02.
XX
XX New antisense oligonucleotides of 8-80 nucleobases, useful for treating
XX cancer, diabetes, osteoporosis or various endocrine disorders.
XX
XX Example 16; SEQ ID NO 122; 155pp; English.
XX
XX The invention relates to an antisense oligonucleotide comprising 8-80
XX nucleobases in length targeted to the coding region of a nucleic acid
XX molecule encoding PPAR-delta (peroxisome proliferative activated receptor
XX delta), where the antisense compound inhibits the expression of the PPAR-
XX delta and has any of the 66 sequences of 20 amino acids fully defined in
XX the specification. Also included are a compound of 8-80 nucleobases in
XX length that specifically hybridises with at least an 8-nucleobase portion
XX of a preferred target region on a nucleic acid molecule encoding PPAR-
XX delta and a composition comprising the antisense oligonucleotide and a
XX carrier. The antisense oligonucleotide comprises at least one modified
XX internucleoside linkage (preferably a phosphorothioate linkage), at least
XX one sugar moiety (preferably 2'-O-methoxyethyl moiety) and at least one
XX modified nucleobase (which is a 5-methyl cytosine). The antisense
XX compounds are useful for treating cancer, osteoporosis, diabetes or
XX various endocrine disorders. The Human PPAR delta gene is located on
XX chromosome 6p21. The present sequence is a mouse PPAR delta cDNA target
XX sequence for the antisense oligonucleotides of the invention.
XX
XX Sequence 20 BP; 4 A; 5 C; 8 G; 3 T; 0 U; 0 Other;

CC internucleoside linkage (preferably a phosphorothioate linkage), at least
CC one sugar moiety (preferably 2'-O-methoxyethyl moiety) and at least one
CC modified nucleobase (which is a 5-methyl cytosine). The antisense
CC compounds are useful for treating cancer, osteoporosis, diabetes or
CC various endocrine disorders. The Human PPAR delta gene is located on
CC chromosome 6p21. The present sequence is an antisense oligonucleotide of
CC the invention targeting mouse PPAR delta.
XX
SQ Sequence 20 BP; 3 A; 8 C; 5 G; 4 T; 0 U; 0 Other;

Query Match      2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 4.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 826 GCTGGCCAGGTTGCAGGTGG 845
Db 20 GCTGGACCAGCTGCAGATGG 1

RESULT 650
ADG87025
ID ADG87025 standard; cDNA; 20 BP.
XX
XX AC ADG87025;
XX
XX 11-MAR-2004 (first entry)
XX
XX Mouse PPAR antisense oligonucleotide target sequence #21.
DE
XX
XX Mouse; ss; PPAR delta; peroxisome proliferative activated receptor delta;
KW antisense gene therapy; cytostatic; osteopathic; antidiabetic; cancer;
KW osteoporosis; diabetes; endocrine disorder.
XX
XX Mus musculus.
XX
XX US2003224514-A1.
XX
XX 04-DEC-2003.
XX
XX 31-MAY-2002; 2002US-00160807.
XX
XX 31-MAY-2002; 2002US-00160807.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Gaarde W, Freier SM, Watt AT;
XX WPI; 2004-022078/02.
XX
XX New antisense oligonucleotides of 8-80 nucleobases, useful for treating
XX cancer, diabetes, osteoporosis or various endocrine disorders.
XX
XX Example 16; SEQ ID NO 261; 155pp; English.
XX
XX The invention relates to an antisense oligonucleotide comprising 8-80
XX nucleobases in length targeted to the coding region of a nucleic acid
XX molecule encoding PPAR-delta (peroxisome proliferative activated receptor
XX delta), where the antisense compound inhibits the expression of the PPAR-
XX delta and has any of the 66 sequences of 20 amino acids fully defined in
XX the specification. Also included are a compound of 8-80 nucleobases in
XX length that specifically hybridises with at least an 8-nucleobase portion
XX of a preferred target region on a nucleic acid molecule encoding PPAR-
XX delta and a composition comprising the antisense oligonucleotide and a
XX carrier. The antisense oligonucleotide comprises at least one modified
XX internucleoside linkage (preferably a phosphorothioate linkage), at least
XX one sugar moiety (preferably 2'-O-methoxyethyl moiety) and at least one
XX modified nucleobase (which is a 5-methyl cytosine). The antisense
XX compounds are useful for treating cancer, osteoporosis, diabetes or
XX various endocrine disorders. The Human PPAR delta gene is located on
XX chromosome 6p21. The present sequence is a mouse PPAR delta cDNA target
XX sequence for the antisense oligonucleotides of the invention.
XX
XX Sequence 20 BP; 4 A; 5 C; 8 G; 3 T; 0 U; 0 Other;
```

Query Match 2.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 4.6e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 826 GCTGGCCAGTTCAGGTGG 845
 ||||| ||||| ||||| ||||| |||||
 Db 1 GCTGGCCAGTTCAGGTGG 20

RESULT 651
 ADH44404
 ID ADH44404 standard; DNA; 20 BP.
 XX
 AC ADH44404;
 XX
 DT 25-MAR-2004 (first entry)
 XX
 DE Human Rb2/p130 DNA, antisense oligonucleotide #5.
 XX
 KW Antisense therapy; human; Rb2/p130; hyperproliferative disorder;
 KW breast cancer; ovarian cancer; hepatocellular cancer; prostate cancer;
 KW developmental disorder; aberrant apoptosis; cytostatic; antiinflammatory;
 KW antimicrobial; phosphorothioate; ss.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "This oligonucleotide has a phosphorothioate
 FT backbone and 2'-methoxyethyl (2'-MOE) wings at the 5'
 FT and 3' ends, which are 5 nucleotides in length at each
 FT end. All cytidine residues are 5-methylcytidines"
 FT
 XX US2003225015-A1.
 XX
 XX 04-DEC-2003.
 XX
 XX 31-MAY-2002; 2002US-00161983.
 XX
 XX 31-MAY-2002; 2002US-00161983.
 XX
 XX (ISIS-) ISIS PHARM INC.
 XX
 XX Ward DT, Freier SM;
 XX
 XX WPI; 2004-042170/04.
 XX
 XX New antisense oligonucleotides inhibiting the expression of Rb2/p130,
 XX useful for preventing or treating diseases associated with Rb2/p130, such
 XX as developmental or hyperproliferative disorders, infection or
 XX inflammation.
 XX
 XX Example 15; SEQ ID NO 15; 47pp; English.
 XX
 XX The present invention relates to antisense compounds targeted to a
 XX nucleic acid encoding Rb2/p130. The antisense compound comprises an
 XX antisense oligonucleotide that specifically hybridizes with the nucleic
 XX acid and inhibits the expression of Rb2/p130. The antisense
 XX oligonucleotide is a chimeric oligonucleotide. The antisense
 XX oligonucleotide comprises at least one modified internucleoside linkage,
 XX preferably a phosphorothioate linkage. It also comprises at least one
 XX modified sugar moiety, preferably a 2'-O-methoxyethyl (2'-MOE) sugar
 XX moiety. The antisense oligonucleotide further comprises at least one
 XX modified nucleobase, preferably a 5-methylcytosine. The antisense
 XX oligonucleotides are useful for the treatment of diseases such as
 XX hyperproliferative disorders, preferably cancer (particularly breast
 XX cancer, ovarian cancer, hepatocellular cancer or prostate cancer),
 XX developmental disorders, and disorders associated with aberrant
 XX apoptosis. The present sequence represents an antisense oligonucleotide
 XX used in the examples of the present invention.

XX
 SQ Sequence 20 BP; 3 A; 4 C; 6 G; 7 T; 0 U; 0 Other;
 Query Match 2.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 4.6e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 414 AGAAGGAGTTCCTCATGTGC 433
 ||||| ||||| ||||| ||||| |||||
 Db 1 AGTAGGAGTTTCTCTGTGC 20

RESULT 652
 ADH44441/C
 ID ADH44441 standard; DNA; 20 BP.
 XX
 AC ADH44441;
 XX
 DT 25-MAR-2004 (first entry)
 XX
 DE Human Rb2/p130 DNA target sequence #5.
 XX
 KW Antisense therapy; human; Rb2/p130; hyperproliferative disorder;
 KW breast cancer; ovarian cancer; hepatocellular cancer; prostate cancer;
 KW developmental disorder; aberrant apoptosis; cytostatic; antiinflammatory;
 KW antimicrobial; ds.
 XX
 OS Homo sapiens.
 XX
 XX US2003225015-A1.
 XX
 XX 04-DEC-2003.
 XX
 XX 31-MAY-2002; 2002US-00161983.
 XX
 XX 31-MAY-2002; 2002US-00161983.
 XX
 XX (ISIS-) ISIS PHARM INC.
 XX
 XX Ward DT, Freier SM;
 XX
 XX WPI; 2004-042170/04.
 XX
 XX New antisense oligonucleotides inhibiting the expression of Rb2/p130,
 XX useful for preventing or treating diseases associated with Rb2/p130, such
 XX as developmental or hyperproliferative disorders, infection or
 XX inflammation.
 XX
 XX Example 15; SEQ ID NO 52; 47pp; English.
 XX
 XX The present invention relates to antisense compounds targeted to a
 XX nucleic acid encoding Rb2/p130. The antisense compound comprises an
 XX antisense oligonucleotide that specifically hybridizes with the nucleic
 XX acid and inhibits the expression of Rb2/p130. The antisense
 XX oligonucleotide is a chimeric oligonucleotide. The antisense
 XX oligonucleotide comprises at least one modified internucleoside linkage,
 XX preferably a phosphorothioate linkage. It also comprises at least one
 XX modified sugar moiety, preferably a 2'-O-methoxyethyl (2'-MOE) sugar
 XX moiety. The antisense oligonucleotide further comprises at least one
 XX modified nucleobase, preferably a 5-methylcytosine. The antisense
 XX oligonucleotides are useful for the treatment of diseases such as
 XX hyperproliferative disorders, preferably cancer (particularly breast
 XX cancer, ovarian cancer, hepatocellular cancer or prostate cancer),
 XX developmental disorders, and disorders associated with aberrant
 XX apoptosis. The present sequence represents a human Rb2/p130 DNA target
 XX sequence for an antisense oligonucleotide.
 XX
 XX Sequence 20 BP; 7 A; 6 C; 4 G; 3 T; 0 U; 0 Other;
 Query Match 2.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 4.6e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 414 AGAAGGAGTTCCTCATGTCC 433
 Db 20 AGTAGGAGTTCTCCTGTCC 1

RESULT 653
 ADJ60959/c
 ID ADJ60959 standard; DNA; 20 BP.
 AC ADJ60959;
 XX
 XX
 DT 06-MAY-2004 (first entry)
 DE Oligonucleotide associated to PDE4C #25.
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 XX Homo sapiens.
 OS
 XX
 XX WO2004011613-A2.
 PN
 PD 05-FEB-2004.
 XX
 XX 25-JUL-2003; 2003WO-US023509.
 PF
 XX 29-JUL-2002; 2002US-0399076P.
 PR
 XX (EPIC-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Tang L, Sandrasaga A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-203534/19.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 XX Claim 2; SEQ ID NO 1815; 85pp; English.
 PS
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 XX Sequence 20 BP; 3 A; 9 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 2.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 4.6e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 516 GCGAGGTGGAGCCTTGAG 535
 Db 20 GCGAGGTGGATCCTGAGG 1

RESULT 654
 ADL34824/c
 ID ADL34824 standard; DNA; 20 BP.
 XX
 AC ADL34824;
 XX
 XX 17-JUN-2004 (first entry)
 DE Antisense oligonucleotide ISIS 221093.
 KW antisense; PPAR-delta; hybridisation; inhibitor;
 KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; cytostatic; gene therapy; ss;
 KW primer.
 XX
 XX Synthetic.
 OS
 XX US2004063129-A1.
 PN
 XX 01-APR-2004.
 PD
 XX 05-SEP-2003; 2003US-00655847.
 PF
 XX 31-MAY-2002; 2002US-00160807.
 PR
 XX (GAAR/) GAARDE W.
 PA (FREI/) FREIER S M.
 PA (WATT/) WATT A T.
 PI
 XX Gaarde W, Freier SM, Watt AT;
 PI WPI; 2004-282460/26.
 DR
 XX New antisense oligonucleotide, having a sequence targeted to a nucleic
 PT acid encoding PPAR-delta, useful for preparing a composition for treating
 PT hyperproliferative disorder, e.g., cancer.
 XX
 XX Example 16; SEQ ID NO 122; Opp; English.
 PS
 XX This invention describes novel antisense oligonucleotides targeted to a
 CC nucleic acid encoding PPAR-delta, which specifically hybridise to and
 CC inhibit expression of PPAR-delta. The oligonucleotide specifically
 CC hybridises with at least an 8-nucleobase portion of an active site on the
 CC nucleic acid molecule encoding the PPAR-delta and comprises at least one
 CC modified internucleoside linkage, which is a phosphorothioate linkage, at
 CC least one modified sugar moiety, which is a 2'-O-methoxyethyl sugar
 CC moiety or at least one modified nucleobase, which is a 5-methylcytosine.
 CC The antisense oligonucleotides are useful for preparing a composition for
 CC treating hyperproliferative disorders, e.g., cancer. The oligonucleotides
 CC of the invention have cytostatic activity and can be used for gene
 CC therapy.
 XX
 XX Sequence 20 BP; 3 A; 8 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 2.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 4.6e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 826 GCTGGCCAGTTCGAGGTGG 845
 Db 20 GCTGGACCAGCTGCAGATGG 1

RESULT 655
 ADL34963
 ID ADL34963 standard; DNA; 20 BP.
 XX
 AC ADL34963;
 XX
 XX 17-JUN-2004 (first entry)
 DT
 XX Murine PPAR-delta target site ID 137747.
 DE
 XX

KW antisense; PPAR-delta; hybridisation; inhibitor;
 KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; cytostatic; gene therapy; ds.
 XX
 OS Mus sp.
 XX
 PN US2004063129-A1.
 XX
 PD 01-APR-2004.
 XX
 XX 05-SEP-2003; 2003US-00655847.
 PF
 XX 31-MAY-2002; 2002US-00160807.
 PR
 XX (GAAR/) GAARDE W.
 PA (FREI/) FREIER S M.
 PA (WATT/) WATT A T.
 XX
 XX Gaarde W, Freier SM, Watt AT;
 PI WPI; 2004-282460/26.
 DR
 XX New antisense oligonucleotide, having a sequence targeted to a nucleic
 PT acid encoding PPAR-delta, useful for preparing a composition for treating
 PT hyperproliferative disorder, e.g., cancer.
 XX
 PS Example 16; SEQ ID NO 261; Opp; English.
 XX
 CC This invention describes novel antisense oligonucleotides targeted to a
 CC nucleic acid encoding PPAR-delta, which specifically hybridise to and
 CC inhibit expression of PPAR-delta. The oligonucleotide specifically
 CC hybridises with at least an 8-nucleobase portion of an active site on the
 CC nucleic acid molecule encoding the PPAR-delta and comprises at least one
 CC modified internucleoside linkage, which is a phosphorothioate linkage, at
 CC least one modified sugar moiety, which is a 2'-O-methoxyethyl sugar
 CC moiety or at least one modified nucleobase, which is a 5-methylcytosine.
 CC The antisense oligonucleotides are useful for preparing a composition for
 CC treating hyperproliferative disorders, e.g., cancer. The oligonucleotides
 CC of the invention have cytostatic activity and can be used for gene
 CC therapy.
 XX
 SQ Sequence 20 BP; 4 A; 5 C; 8 G; 3 T; 0 U; 0 Other;
 Query Match 2.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 4.6e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 826 GCTGGCCCGAGTTCAGGTGG 845
 DB 1 GCTGGACCGAGTTCAGATGG 20
 RESULT 656
 ADO46448/C
 ID ADO46448 standard; DNA; 20 BP.
 XX
 AC ADO46448;
 XX
 XX 15-JUL-2004 (first entry)
 DT
 XX Human oligonucleotide #1814.
 DE
 XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Foraxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.

XX US2004049022-A1.
 PN 11-MAR-2004.
 PD
 XX 25-JUL-2003; 2003US-00627930.
 PF
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHAUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-293804/27.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 CC Claim 2; SEQ ID NO 1815; 174pp; English.
 PS
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)-
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 3 A; 9 C; 4 G; 4 T; 0 U; 0 Other;
 Query Match 2.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 4.6e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 516 GCGAGGTGAGACCTGGAAG 535
 DB 20 GCGAGGTGATCCTGAGG 1
 RESULT 657
 ADP78915
 ID ADP78915 standard; DNA; 20 BP.
 XX
 AC ADP78915;
 XX

DT 12-AUG-2004 (first entry)
 XX Chimeric phosphorothioate oligonucleotide #2714.
 DE GFAT; Antidiabetic; Cardiant;
 XX Glutamine-fructose-6-phosphate amidotransferase; diabetes; ischemia;
 KW reperfusion; ss.
 XX Synthetic.
 OS
 XX
 PH Key Location/Qualifiers
 FT modified_base 1..4
 FT /*tag= a
 FT /mod_base= other
 FT /note= "2-methoxyethyl wing"
 FT modified_base 17..20
 FT /*tag= b
 FT /mod_base= other
 FT /note= "2-methoxyethyl wing"
 XX
 XX WO2004035763-A2.
 PN
 XX
 XX 29-APR-2004.
 PD
 XX
 XX 02-OCT-2003; 2003WO-US033332.
 PF
 XX
 XX 17-OCT-2002; 2002US-0419268P.
 PR
 XX
 XX (PHAA) PHARMACIA CORP.
 PA
 XX
 XX Broschat KO, Crosby SD;
 PI
 XX
 XX WPI; 2004-348453/32.
 DR
 XX
 XX New compounds, particularly antisense oligonucleotides targeted to a
 PT nucleic acid encoding glutamine-fructose-6-phosphate amidotransferase,
 PT (GFAT), for treating diabetes, a cardiovascular or neurologic disorder,
 PT ischemia/reperfusion injury.
 XX
 XX Claim 4; SEQ ID NO 2714; 175pp; English.
 PS
 XX The present invention relates to a compound which specifically hybridizes
 CC with a nucleic acid molecule encoding GFAT, and inhibits the expression
 CC of GFAT. Specifically claimed are antisense oligonucleotides capable of
 CC modulating the expression of GFAT, and which comprise any of the 3063
 CC sequences of 20 base pairs, given in the specification. The compound,
 CC composition and methods are useful for treating a disease or condition
 CC associated with GFAT, such as a disease or condition, e.g. diabetes, a
 CC cardiovascular or neurological disorder, ischemia/reperfusion injury.
 CC They are also useful in research and diagnostics for modulating the
 CC expression of GFAT. The present sequence represents a chimeric
 CC phosphorothioate oligonucleotide with 2'-MOE wings and a deoxy gap, these
 CC oligonucleotides inhibit human GFAT expression.
 XX
 SQ Sequence 20 BP; 5 A; 4 C; 5 G; 6 T; 0 U; 0 Other;
 Query Match 2.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 4.6e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 162 TCTGGAAGACCAACTGTGT 181
 Db 1 TATGGAAGTCCCACTGTGT 20
 RESULT 658
 ID AC23071
 XX AC23071 standard; DNA; 15 BP.
 AC
 XX AC23071;
 XX
 XX 25-AUG-2003 (first entry)
 DT
 XX

DE Human Nemo gene wild type exon 2 DNA sequence.
 XX
 XX Human; ds; NF-kappaB essential modulator; nuclear factor kappa B;
 KW incontinentia pigmenti; X-linked disorder; chromosome Xq28; NEMO;
 KW immunomodulatory; dermatological; osteopathic; neuropathic;
 KW apoptosis-related disease; immune-system related disease;
 KW blood vessel-related disease; skin defect; dental defect; osteopetrosis;
 KW ophthalmologic defect; neurological defect.
 XX
 XX Homo sapiens.
 OS
 XX
 XX US2003032055-A1.
 FN
 XX
 XX 13-FEB-2003.
 PD
 XX
 XX 22-MAY-2001; 2001US-00863049.
 PF
 XX
 XX 22-MAY-2000; 2000US-0206223P.
 PR
 XX
 XX (KENN/) KENNRICK S J.
 PA (WOPE/) WOFFENDIN H.
 PA (MUNN/) MUNNICH A.
 PA (SMAH/) SMAHI A.
 PA (ISRA/) ISRAEL A.
 PA (POUS/) POUSTKA A.
 PA (HEIS/) HEISS N.
 PA (DURS/) D'URSO M.
 PA (LEWI/) LEWIS R A.
 PA (NELS/) NELSON D L.
 PA (ARAD/) ARADHYA S.
 PA (LEVY/) LEVY M.
 XX
 XX Kenrick SJ, Woffendin H, Munnich A, Smahi A, Israel A;
 PI Poustka A, Heiss N, D'urso M, Lewis RA, Nelson DL, Aradhyia S;
 PI Levy M;
 XX
 XX WPI; 2003-492063/46.
 DR
 XX P-PSDB; ABO17486.
 PT
 PT Detection of necrosis factor-kappa B related medical condition in
 PT organism, by obtaining sample from the organism, and analyzing the sample
 PT for alteration in specified amino acid sequences.
 XX
 XX Claim 41; Fig 5; 44pp; English.
 CC
 CC The invention relates to a nuclear factor-kappa B (NF-kappa B) related
 CC medical condition in an organism being detected by obtaining a sample
 CC from the organism, and analysing the sample for an alteration in a the
 CC nuclear factor kappaB essential modifier (NEMO) gene or protein sequence
 CC (neither shown in the specification). The alteration results in
 CC inactivation of NF-kappa B. Also included are treating or preventing NF-
 CC kappa B related medical condition in an organism by administering the
 CC NEMO protein to the organism and screening a test organism for a compound
 CC for the treatment of NF-kappa B related medical condition (by
 CC administering the compound to the organism, and assaying for an
 CC improvement in the NF-kappa B related medical condition). The method
 CC useful is for detecting NF-kappa B related condition, e.g. incontinentia
 CC pigmenti (IP), apoptosis-related disease, immune-system related disease,
 CC blood vessel-related disease, skin defect, dental defect, osteopetrosis,
 CC ophthalmologic defect, or neurological defect, in an organism, i.e. human
 CC including affected individual, carrier individual, or noncarrier
 CC individual. The NEMO gene is located on chromosome Xq28, incontinentia
 CC pigmenti being an X-linked disorder. Experiments in this study show
 CC variations in exon 2, 10, 9 and particularly intron 3 to be linked to
 CC familial incontinentia pigmenti The present sequence is a wild-type
 CC region of the human NEMO gene found to be associated with familial
 CC incontinentia pigmenti
 XX
 SQ Sequence 15 BP; 4 A; 5 C; 3 G; 3 T; 0 U; 0 Other;
 Query Match 2.0%; Score 15; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 3.3e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 269 CTGCTTCAGAACAG 283
 Db 1 CTGCTTCAGAACAG 15

RESULT 659
 ADL50826
 ID ADL50826 standard; RNA; 15 BP.
 XX AC ADL50826;
 XX DT 20-MAY-2004 (first entry)
 XX DE Human PKR substrate sequence #1940.
 XX KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
 KW substrate; ds.
 XX OS Unidentified.
 XX PN WO200281628-A2.
 XX PD 17-OCT-2002.
 XX PF 03-APR-2002; 2002WO-US010512.
 XX PR 05-APR-2001; 2001US-00827395.
 XX PR 29-MAY-2001; 2001US-0294412P.
 XX PR 28-AUG-2001; 2001US-0315315P.
 XX PA (RIBO-) RIBOZYME PHARM INC.
 XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX PS Claim 59; SEQ ID NO 4359; 317pp; English.
 XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human PKR
 CC substrate sequence.
 XX SQ Sequence 15 BP; 5 A; 2 C; 6 G; 0 T; 2 U; 0 Other;

Query Match 2.0%; Score 15; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 3.3e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 549 AGATGCTCAGGACA 563
 Db 1 AGAUGGCUAGGACA 15

RESULT 660
 ADL50845
 ID ADL50845 standard; RNA; 15 BP.
 XX AC ADL50845;
 XX DT 20-MAY-2004 (first entry)
 XX DE Human PKR substrate sequence #1959.
 XX KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
 KW substrate; ds.
 XX OS Unidentified.
 XX PN WO200281628-A2.
 XX PD 17-OCT-2002.
 XX PF 03-APR-2002; 2002WO-US010512.
 XX PR 05-APR-2001; 2001US-00827395.
 XX PR 29-MAY-2001; 2001US-0294412P.
 XX PR 28-AUG-2001; 2001US-0315315P.
 XX PA (RIBO-) RIBOZYME PHARM INC.
 XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX PS Claim 59; SEQ ID NO 4378; 317pp; English.
 XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human PKR
 CC substrate sequence.
 XX SQ Sequence 15 BP; 1 A; 9 C; 3 G; 0 T; 2 U; 0 Other;

Query Match 2.0%; Score 15; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 3.3e+02;
 Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

```

QY 297 CCTCAGCGCTGCC 311
DB 1 CCUCAGCGCGGCC 15

RESULT 661
ADL50849
ID ADL50849 standard; RNA; 15 BP.
XX
AC ADL50849;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #1963.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 4382; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
SQ Sequence 15 BP; 5 A; 4 C; 4 G; 0 T; 2 U; 0 Other;

Query Match 2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 3.3e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 321 ATCAAGAGCTCCGAG 335
DB 1 AUCAGAGCUCCGAG 15

RESULT 662
ADL50864
ID ADL50864 standard; RNA; 15 BP.
XX
AC ADL50864;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #1978.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 4397; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
SQ Sequence 15 BP; 3 A; 3 C; 7 G; 0 T; 2 U; 0 Other;

Query Match 2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 3.3e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 734 AGGTGCGAGTGGAC 748
Db 1 AGCGUGCAGGUGGAC 15

RESULT 663
ADL50859
ID ADL50859 standard; RNA; 15 BP.
XX
AC ADL50859;
XX
XX 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #1973.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 4392; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
SQ Sequence 15 BP; 4 A; 3 C; 5 G; 0 T; 3 U; 0 Other;
Query Match 2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3.3e+02;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 431 TGCAGTTCAGGAG 445
Db 1 UGCAGUUCAGGAG 15

RESULT 664
ADL50876
ID ADL50876 standard; RNA; 15 BP.
XX
AC ADL50876;
XX
XX 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #1990.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 4409; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
SQ Sequence 15 BP; 7 A; 4 C; 2 G; 0 T; 2 U; 0 Other;
Query Match 2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 3.3e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

```

QY 861 TCCAGGAATACGACA 875
 :|||||:|||||
 Db 1 UCCAGAAUACGACA 15

RESULT 665
 ADL50879
 ID ADL50879 standard; RNA; 15 BP.
 XX
 AC ADL50879;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Human PKR substrate sequence #1993.
 XX
 KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; ikappab kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, ikappab kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 4412; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC ikappab kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human PKR
 CC substrate sequence.
 XX
 SQ Sequence 15 BP; 6 A; 1 C; 8 G; 0 T; 0 U; 0 Other;

Query Match 2.0%; Score 15; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 3.3e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 810 CGGAGGAGAGGAGA 824
 :|||||:|||||
 Db 1 CGGAGGAGAGGAGA 15

RESULT 666
 ADL50874
 ID ADL50874 standard; RNA; 15 BP.
 XX
 AC ADL50874;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Human PKR substrate sequence #1988.
 XX
 KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; ikappab kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, ikappab kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 4407; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC ikappab kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human PKR
 CC substrate sequence.
 XX
 SQ Sequence 15 BP; 5 A; 4 C; 5 G; 0 T; 1 U; 0 Other;

Query Match 2.0%; Score 15; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 3.3e+02;
 Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY	209	GCACGACATCAGGAC	223	QY	420	AGTTCCTCATGTCCA	434
Db	1	GCACGACATCAGGAC	15	Db	1	AGUUCUCAUGUGCA	15
<p>RESULT 667</p> <p>ADL50811</p> <p>ID ADL50811 standard; RNA; 15 BP.</p> <p>XX ADL50811;</p> <p>XX</p> <p>DT 20-MAY-2004 (first entry)</p> <p>XX</p> <p>DE Human PKR substrate sequence #1925.</p> <p>XX</p> <p>KW antisense oligonucleotide; neurite growth inhibitor; NOGO;</p> <p>KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;</p> <p>KW protein kinase PKR; cerebrovascular accident;</p> <p>KW central nervous system injury; CNS injury; spinal cord injury; cancer;</p> <p>KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;</p> <p>KW restenosis; asthma; Crohn's disease; diabetes; obesity;</p> <p>KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;</p> <p>KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;</p> <p>KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;</p> <p>KW substrate; ds.</p> <p>OS Unidentified.</p> <p>XX</p> <p>PN WO200281628-A2.</p> <p>XX</p> <p>PD 17-OCT-2002.</p> <p>XX</p> <p>PF 03-APR-2002; 2002WO-US010512.</p> <p>XX</p> <p>PR 05-APR-2001; 2001US-00827395.</p> <p>PR 29-MAY-2001; 2001US-0294412P.</p> <p>PR 28-AUG-2001; 2001US-0315315P.</p> <p>XX</p> <p>PA (RIBO-) RIBOZYME PHARM INC.</p> <p>XX</p> <p>PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;</p> <p>XX</p> <p>DR WPI; 2003-058513/05.</p> <p>XX</p> <p>PT Novel enzymatic nucleic acid that down-regulates expression of neurite</p> <p>PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or</p> <p>PT protein kinase PKR genes, for treating cancer and inflammatory disease.</p> <p>XX</p> <p>PS Claim 59; SEQ ID NO 4344; 317pp; English.</p> <p>XX</p> <p>CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)</p> <p>CC that down regulate the expression or inhibit the function of a receptor</p> <p>CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),</p> <p>CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the</p> <p>CC invention are useful for treating: cerebrovascular accident, central</p> <p>CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,</p> <p>CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,</p> <p>CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune</p> <p>CC disease, lupus, multiple sclerosis, transplant/graft rejection,</p> <p>CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic</p> <p>CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The</p> <p>CC nucleic acids of the invention are also useful for down-regulating the</p> <p>CC expression of a target gene and as a diagnostic tool to examine genetic</p> <p>CC drifts and mutations within diseased cells or to detect the presence of a</p> <p>CC target RNA in a cell. The present RNA sequence represents a human PKR</p> <p>CC substrate sequence.</p> <p>XX</p> <p>SQ Sequence 15 BP; 3 A; 4 C; 3 G; 0 T; 5 U; 0 Other;</p>							
Query Match				Query Match			
Best Local Similarity 66.7%;				Best Local Similarity 86.7%;			
Matches 10; Conservative 5; Mismatches 0; Indels 0; Gaps 0;				Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;			

QY 573 TGAAGCCCGAGGTGA 587
 :|||||:|||||:
 Db 1 UGAAGCCCGAGGUGA 15

RESULT 669

ADL50851
 ID ADL50851 standard; RNA; 15 BP.

XX
 AC ADL50851;

XX
 DT 20-MAY-2004 (first entry)

XX
 DE Human PKR substrate sequence #1965.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
 KW substrate; ds.

XX
 OS Unidentified.

XX
 PN WO200281628-A2.

XX
 PD 17-OCT-2002.

XX
 PF 03-APR-2002; 2002WO-US010512.

XX
 PR 05-APR-2001; 2001US-00827395.

PR
 29-MAY-2001; 2001US-0294412P.

PR
 28-AUG-2001; 2001US-0315315P.

XX
 PA (RIBO-) RIBOZYME PHARM INC.

XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;

XX
 DR WPI; 2003-058513/05.

XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX
 PS Claim 59; SEQ ID NO 4384; 317pp; English.

CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human PKR
 CC substrate sequence.

XX
 SQ Sequence 15 BP; 3 A; 4 C; 5 G; 0 T; 3 U; 0 Other;

Query Match

Best Local Similarity 2.0%; Score 15; DB 1; Length 15;

Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 565 GGCTCTGTGAAGC 579
 |||||:|:|||||:
 Db 1 GGCCUCUGUGAAGC 15

RESULT 670

ADL50827
 ID ADL50827 standard; RNA; 15 BP.

XX
 AC ADL50827;

XX
 DT 20-MAY-2004 (first entry)

XX
 DE Human PKR substrate sequence #1941.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
 KW substrate; ds.

XX
 OS Unidentified.

XX
 PN WO200281628-A2.

XX
 PD 17-OCT-2002.

XX
 PF 03-APR-2002; 2002WO-US010512.

XX
 PR 05-APR-2001; 2001US-00827395.

PR
 29-MAY-2001; 2001US-0294412P.

PR
 28-AUG-2001; 2001US-0315315P.

XX
 PA (RIBO-) RIBOZYME PHARM INC.

XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;

XX
 DR WPI; 2003-058513/05.

XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX
 PS Claim 59; SEQ ID NO 4360; 317pp; English.

CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human PKR
 CC substrate sequence.

XX
 SQ Sequence 15 BP; 4 A; 4 C; 4 G; 0 T; 3 U; 0 Other;

Query Match

Best Local Similarity 2.0%; Score 15; DB 1; Length 15;

Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 561 ACAAGGCTCTGTGGA 575
 Db 1 ACAAGGCCUCUGUGA 15

RESULT 671
 ADL50846
 ID ADL50846 standard; RNA; 15 BP.
 XX
 AC ADL50846;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Human PKR substrate sequence #1960.
 XX
 KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; ikappab kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, ikappab kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 4379; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC ikappab kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human PKR
 CC substrate sequence.
 XX
 SQ Sequence 15 BP; 1 A; 7 C; 4 G; 0 T; 3 U; 0 Other;

Query Match 2.0%; Score 15; DB 1; Length 15;
 Best Local Similarity 80.0%; Pred.No. 3.3e+02;
 Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 299 CTCACGGCTGCTG 313
 Db 1 CUCCAGCGCGCCUG 15

RESULT 672
 ADL50878
 ID ADL50878 standard; RNA; 15 BP.
 XX
 AC ADL50878;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Human PKR substrate sequence #1992.
 XX
 KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; ikappab kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, ikappab kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 4411; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC ikappab kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human PKR
 CC substrate sequence.
 XX
 SQ Sequence 15 BP; 5 A; 3 C; 6 G; 0 T; 1 U; 0 Other;

Query Match 2.0%; Score 15; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred.No. 3.3e+02;
 Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 208 GGCAGCAGATCAGGA 222
|||||:|||||
Db 1 GGCAGCAGATCAGGA 15

RESULT 673
ADL50824
ID ADL50824 standard; RNA; 15 BP.
XX
AC ADL50824;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #1938.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mowwigen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 4357; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
XX substrate sequence.
XX
SQ Sequence 15 BP; 6 A; 3 C; 4 G; 0 T; 2 U; 0 Other;

Query Match 2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 3.3e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 317 GAGAATCAAGAGCTC 331
|||||:|||||
Db 1 GAGAATCAAGAGCTC 15

RESULT 674
ADL50875
ID ADL50875 standard; RNA; 15 BP.
XX
AC ADL50875;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #1989.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mowwigen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 4408; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
XX substrate sequence.
XX
SQ Sequence 15 BP; 5 A; 3 C; 5 G; 0 T; 2 U; 0 Other;

Query Match 2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 3.3e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 531 TGAAGAGATGCCAGC 545
 Db :|||||:|||||
 1 UGAAGAGAUGCCAGC 15

RESULT 675
 ABN07253
 ID ABN07253 standard; DNA; 17 BP.
 AC ABN07253;
 XX
 XX
 XX 29-MAY-2002 (first entry)
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7245.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 XX 25-MAY-2001; 2001WO-US016981.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX
 DR WPI; 2002-179446/23.
 XX
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX
 XX Disclosure; SEQ ID NO 7245; 214pp; English.
 PS
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterize and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP-
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.

CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 3 A; 2 C; 9 G; 3 T; 0 U; 0 Other;
 Query Match 2.0%; Score 15; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 3.9e+02; Indels 0; Gaps 0;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 697 GCTGGAGAGTGAGCG 711
 Db 2 GCTGGAGAGTGAGCG 16
 RESULT 676
 ABN07252
 ID ABN07252 standard; DNA; 17 BP.
 XX
 AC ABN07252;
 XX
 XX 29-MAY-2002 (first entry)
 XX
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7244.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 XX 25-MAY-2001; 2001WO-US016981.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX
 DR WPI; 2002-179446/23.
 XX
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX
 XX Disclosure; SEQ ID NO 7244; 214pp; English.
 PS
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterize and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP-
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.

protein variants having desired phenotypic improvements, and for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be used as immunogens to raise antibodies that specifically recognise hGDMPLP-1 proteins, as standards in assays used to determine the concentration and/or amount specifically of hGDMPLP proteins, as specific biomolecule capture probes for surface-enhanced laser desorption/ionisation, as therapeutic supplement in patients having specific deficiency in hGDMPLP-1 production, and in vaccines or for replacement therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a disorder associated with the expression of hGDMPLP-1, in particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22. The present sequence represents an oligomer used in the screening of the hGDMPLP-1 sequence in the exemplification of the present invention. N.B. The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequence

SQ Sequence 17 BP; 3 A; 2 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 2.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 697 GCTGAGAGTGAGCG 711
|||||
DB 3 GCTGGAGAGTGAGCG 17

RESULT 677
ABT36384
ID ABT36384 standard; DNA; 17 BP.

AC ABT36384;

DT 12-JUN-2003 (first entry)

DE Tumour suppression related human fukutin oligo SEQ ID No 2021.

KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.

OS Homo sapiens.

PN WO2003025175-A2.

PD 27-WAR-2003.

PF 17-SEP-2002; 2002WO-IB004208.

PR 17-SEP-2001; 2001FR-00011978.

PA (MOLE-) MOLECULAR ENGINES LAB.

PI Telerman A, Amson R, Tuijnder M;

DR WPI; 2003-313353/30.

PT New isolated nucleic acid, useful for treating viral diseases associated with tumours and cell degeneration, also related polypeptides, antibodies and transfected cells.

PS Disclosure; Page 269; 720pp; French.

CC The invention relates to a novel isolated 17 mer nucleic acid sequence, given in the specification, a sequence containing at least 15 consecutive nucleotides from the 17 mer sequence, a sequence with, after optimal alignment, at least 80 % identity to the 17 mer sequence, a sequence that hybridizes to them under highly stringent conditions, or the complement of any of them, or the corresponding RNA. The novel isolated nucleic acids of the invention are useful as probes and primers for detecting, identifying, quantifying and/or amplifying a nucleic acid, e.g. as one

CC component of a gene chip, in vitro as (anti)sense reagents, and for production of recombinant polypeptides. Any of the nucleic acids, polypeptides, vectors containing the nucleic acids, cells containing the vector or antibodies directed against the polypeptides are useful for preparation of pharmaceuticals for prevention and/or treatment of viral diseases that are characterised by development of tumours or cell degeneration. Analysis of the expression of the 17 mer nucleic acids in schizophrenia. Analysis of the expression of the 17 mer nucleic acids in disease. The polypeptides can also be used to generate antibodies, and both the polypeptide and antibodies are useful as components of protein chips. The nucleic acid sequences of the invention can be used in gene therapy. This polynucleotide sequence represents a tumour suppression related human fukutin oligonucleotide of the invention

SQ Sequence 17 BP; 3 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 2.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 241 TCCTCTGGGAGGCC 255

DB 3 TCCTCTGGGAGGCC 17

RESULT 678

ADB45431

ID ADB45431 standard; DNA; 17 BP.

AC ADB45431;

DT 18-DEC-2003 (first entry)

DE Tumour suppression/reversion associated nucleotide #5754.

KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;

KW primer; probe; tumour suppression; tumour reversion; apoptosis;

KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia; diagnosis.

OS Homo sapiens.

PN WO2003040369-A2.

PD 15-MAY-2003.

PF 17-SEP-2002; 2002WO-IB004219.

PR 17-SEP-2001; 2001FR-00011981.

PA (MOLE-) MOLECULAR ENGINES LAB.

PI Telerman A, Amson R, Tuijnder M;

DR WPI; 2003-441574/41.

PT New nucleic acid encoding human prostate membrane-specific antigen, useful e.g. for treatment of tumours and viral infection, also related polypeptide and antibodies.

PS Disclosure; Page 704; 771pp; French.

CC The invention relates to the isolation of 6327 nucleotide sequences, fragments of at least 15 consecutive nucleotides of these nucleotides, a sequence having at least 80% identity, after optimal alignment, with the nucleotides, a sequence that hybridizes under stringent conditions with the nucleotides, or the complement, or corresponding RNA, of the nucleotides. The nucleotides are used as probes or primers for detecting, identifying, quantifying and/or amplifying nucleic acids, as in vitro sense and antisense sequences, of nucleotides involved in tumour suppression or reversion, apoptosis and or viral resistance, to produce recombinant polypeptides, and to prepare transgenic animals, as

CC experimental models. The nucleotides (also vectors containing them and
 CC cells containing the vectors), the encoded polypeptides and antibodies
 CC (Ab) against the polypeptide are useful for prevention and/or treatment
 CC of viral infections or diseases characterized by development of tumours
 CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
 CC Analysis of the expression of the nucleotides can be used for diagnosis
 CC and/or prognosis of these diseases. The nucleotides and polypeptides can
 CC also be used to screen for their specific interactive molecules,
 CC potentially useful for treating diseases associated with abnormal
 CC expression of the nucleotides.

XX Sequence 17 BP; 3 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 2.0%; Score 15; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 3.9e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 241 TCCTCTGGGGAGGCC 255
 |||||
 Db 3 TCCTCTGGGGAGGCC 17

RESULT 679
 ADI49287
 ID ADI49287 standard; DNA; 17 BP.

XX AC ADI49287;

XX DT 15-APR-2004 (first entry)

DE Human tumour suppression/reversion-related DNA sequence SeqID1790.

XX tumour suppression; tumour reversion; apoptosis; virus resistance;
 KW cytostatic; virucide; neuroprotective; nontropic; neuroleptic; probe;
 KW primer; PCR; gene chip; antisense; viral disease; tumour;
 KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.

XX OS Homo sapiens.

XX PN WO2003025177-A2.

XX PD 27-MAR-2003.

XX PF 17-SEP-2002; 2002WO-IB004523.

XX PR 17-SEP-2001; 2001FR-00011980.

XX PA (MOLE-) MOLECULAR ENGINES LAB.

XX PI Telerman A, Amson R, Tuijnder M;

XX WPI; 2003-313354/30.

PT New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.

PS Disclosure; SEQ ID NO 1790; 30pp; French.

XX This invention relates to novel isolated nucleic acid sequences involved
 CC in the phenomena of tumour suppression, tumour reversion, apoptosis
 CC and/or resistance to viruses. The invention may be useful for the
 CC development of compounds with a cytostatic, virucide, neuroprotective,
 CC nontropic or neuroleptic activity. The DNA sequences may be useful as
 CC probes and primers for detecting, identifying, quantifying and/or
 CC amplifying nucleic acid, for example as one component of a gene chip, in
 CC vitro as antisense reagents and for production of recombinant
 CC polypeptides. The invention may therefore be useful for preparation of
 CC pharmaceuticals for prevention and/or treatment of viral diseases that
 CC are characterised by development of tumours or cell degeneration,
 CC specifically cancer but also Alzheimer's disease and schizophrenia. The
 CC present sequence is that of a nucleic acid sequence of the invention.

CC Note: The sequence data for this patent did not form part of the printed

CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/publishedpct_sequences

XX Sequence 17 BP; 3 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 2.0%; Score 15; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 3.9e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 241 TCCTCTGGGGAGGCC 255
 |||||
 Db 3 TCCTCTGGGGAGGCC 17

RESULT 680
 ADL48710
 ID ADL48710 standard; RNA; 17 BP.

XX AC ADL48710;

XX DT 20-MAY-2004 (first entry)

DE Human IKK-gamma substrate sequence #1220.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW resenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.

XX Unidentified.

XX PN WO200281628-A2.

XX PD 17-OCT-2002.

XX PF 03-APR-2002; 2002WO-US010512.

XX PR 05-APR-2001; 2001US-00827395.

XX PR 29-MAY-2001; 2001US-0294412P.

XX PR 28-AUG-2001; 2001US-0315315P.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PI Blatt L, Chowrira B, Haerberli P, Meswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.

PS Claim 59; SEQ ID NO 2243; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC resenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 2 C; 9 G; 0 T; 1 U; 0 Other;
 Query Match 2.0%; Score 15; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 3.9e+02;
 Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 902 AGTGAGCGGAGCGA 916
 DB 1 AGUGAGCGGAGCGA 15
 RESULT 681
 ACN70343
 ID ACN70343 standard; DNA; 17 BP.
 XX
 AC ACN70343;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Human GDMPLP-1 probe SEQ ID NO:7245.
 XX
 KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 OS Homo sapiens.
 XX
 PN US2004137589-A1.
 XX
 PD 15-JUL-2004.
 XX
 PF 26-NOV-2003; 2003US-00723361.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 PA (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 DR
 XX Novel myosin-like protein-1, useful for treating or preventing disorder
 XX associated with decreased expression or activity of human genome-derived
 XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 XX function.
 XX
 PS Disclosure; SEQ ID NO 7245; Opp; English.
 XX
 CC The invention relates to a novel polypeptide (I) comprising a sequence

CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX
 SQ Sequence 17 BP; 3 A; 2 C; 9 G; 3 T; 0 U; 0 Other;
 Query Match 2.0%; Score 15; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 3.9e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 697 GCTGGAGAGTGAGCG 711
 DB 2 GCTGGAGAGTGAGCG 16
 RESULT 682
 ACN70342
 ID ACN70342 standard; DNA; 17 BP.
 XX
 AC ACN70342;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Human GDMPLP-1 probe SEQ ID NO:7244.
 XX
 KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 OS Homo sapiens.
 XX
 PN US2004137589-A1.
 XX
 PD 15-JUL-2004.
 XX
 PF 26-NOV-2003; 2003US-00723361.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 PA (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 DR
 XX

XX New single stranded oligonucleotides comprising a DNA domain having at
PT least one mismatch with respect to the genetic sequence of the
PT Huntington's disease gene to be altered, useful for treating or
PT preventing Huntington's disease.
XX
PS Example 7; Fig 20; 133pp; English.
XX
CC The present sequence is that of a portion of a mutated glutamine (CAG)
CC triplet repeat region of exon 1 of the human Huntington's disease (HD)
CC gene (see also AB281760). The triplet repeat region is mutated following
CC treatment with single-stranded phosphorothioate-containing HD gene-
CC targeted oligonucleotide HD3S/52 (see AB281756). The second glutamine
CC (CAG) repeat triplet is converted to CTG, creating a restriction fragment
CC length polymorphism site that enables cleavage by PvuII. HD3S/25 is an
CC example of oligonucleotides of the invention for targeted alteration of
CC the HD gene. Such oligonucleotides can be used for the treatment or
CC prevention of HD
XX
SQ Sequence 18 BP; 5 A; 6 C; 6 G; 1 T; 0 U; 0 Other;
XX
Query Match 2.0%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 4.2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 718 GCTGCAGCAGCAGCA 732
DB 3 GCTGCAGCAGCAGCA 17
XX
RESULT 685
AB281779
ID AB281779 standard; DNA; 18 BP.
XX
AC AB281779;
XX
DT 11-JUN-2003 (first entry)
XX
DE Huntington's disease gene mutated exon 1 region.
XX
DE Huntington's disease; nootropic; anticonvulsant; huntingtin; human;
XX
KW Huntington's disease; mutant; ds.
XX
KW Homo sapiens.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT mutation replace(5,A)
FT /*tag= a
XX
PN WO2003013437-A2.
XX
PD 20-FEB-2003.
XX
PF 07-AUG-2002; 2002WO-US025352.
XX
PR 07-AUG-2001; 2001US-0310757P.
XX
PR 08-AUG-2001; 2001US-0310770P.
XX
PR 08-AUG-2001; 2001US-0310889P.
XX
PR 04-DEC-2001; 2001US-0337219P.
XX
PA (UYDE) UNIV DELAWARE.
XX
PI Kmiec EB, Parekh-Olmedo H;
XX
XX WPI; 2003-256478/25.
XX
XX New single stranded oligonucleotides comprising a DNA domain having at
PT least one mismatch with respect to the genetic sequence of the
PT Huntington's disease gene to be altered, useful for treating or
PT preventing Huntington's disease.
XX
PS Example 7; Fig 20; 133pp; English.

XX The present sequence is that of a portion of a mutated glutamine (CAG)
CC triplet repeat region of exon 1 of the human Huntington's disease (HD)
CC gene (see also AB281760). The triplet repeat region is mutated following
CC treatment with single-stranded phosphorothioate-containing HD gene-
CC targeted oligonucleotide HD3S/25 (see AB281755). The second glutamine
CC (CAG) repeat triplet is converted to CTG, creating a restriction fragment
CC length polymorphism site that enables cleavage by PvuII. HD3S/25 is an
CC example of oligonucleotides of the invention for targeted alteration of
CC the HD gene. Such oligonucleotides can be used for the treatment or
CC prevention of HD
XX
SQ Sequence 18 BP; 5 A; 6 C; 6 G; 1 T; 0 U; 0 Other;
XX
Query Match 2.0%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 4.2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 718 GCTGCAGCAGCAGCA 732
DB 3 GCTGCAGCAGCAGCA 17
XX
RESULT 686
AAH48698
ID AAH48698 standard; DNA; 19 BP.
XX
AC AAH48698;
XX
DT 19-OCT-2001 (first entry)
XX
DE E. coli 16S rRNA primer RP.
XX
KW 16S rDNA; amplification; PCR primer; bacterial contamination;
KW food industry; bacterial quantification; pathogen detection;
KW water protection; ss.
XX
OS Escherichia coli.
XX
PN DE10004147-A1.
XX
PD 09-AUG-2001.
XX
PF 31-JAN-2000; 2000DE-01004147.
XX
PR 31-JAN-2000; 2000DE-01004147.
XX
PA (GSFU-) GSF FORSCHUNGSZENTRUM UMWELT & GESUNDHEI.
XX
PI Bach HJ, Schlöter M, Munch J, Tomanova J;
XX
XX WPI; 2001-489825/54.
XX
DR Claim 1; Page 12; 16pp; German.
XX
PT Oligonucleotides for the amplification and qualitative and quantitative
PT detection of bacterial 16S rRNA useful to determine bacterial
PT contamination of foodstuffs, waters, and in clinical microbiology.
XX
PS Claim 1; Page 12; 16pp; German.
XX
XX This invention describes a novel oligonucleotide for the amplification
CC and qualitative and quantitative detection of RNA sequences derived from
CC 16S rRNA genes or gene fragments. The oligonucleotide is used to quantify
CC bacterial contamination, particularly using TagMan (RTM) PCR. The
CC invention can be used in the foodstuffs industry, to quantify bacteria
CC particularly human pathogens, in water protection, to determine bacterial
CC titer in drinking water, natural waters and public swimming pools, in
CC clinical microbiology to determine non-specific infection in humans and
CC animals, and in laboratory diagnostics. Unlike prior art, this invention
CC is useful to detect not only known species but also unknown bacteria of
CC differing physiological groups, and does not require bacterial
CC cultivation. The invention also allows quantification of all 16S RNA
CC using a single DNA extraction. This sequence represents a PCR primer used
CC to illustrate the method of the invention

```

XX SQ Sequence 19 BP; 5 A; 7 C; 3 G; 2 T; 0 U; 2 Other;
Query Match      2.0%; Score 15; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 253 GCCAGCAGCTGCTGACCTG 271
Db 1 GACARCCATGCACACCTG 19

RESULT 687
ABK81885/c
ID ABK81885 standard; DNA; 20 BP.
XX
AC ABK81885;
XX
DT 13-AUG-2002 (first entry)
XX
DE Lung specific gene PCR primer #35.
XX
KW Lung specific gene; gene therapy; vaccine; lung cancer; cancer staging;
KW cancer monitoring; cancer diagnosis; imaging lung cancer; metastases;
KW PCR; primer; ss.
XX
OS Synthetic.
XX
FN WO200218576-A2.
XX
PD 07-MAR-2002.
XX
PF 27-AUG-2001; 2001WO-US026684.
XX
PR 28-AUG-2000; 2000US-0228378P.
XX
PA (DIAD-) DIADEXUS INC.
XX
PI Chen S, Macina RA, Sun Y, Recipon H;
XX
WPI; 2002-434904/46.
XX
New lung specific genes and their encoded proteins, useful in gene
therapy or as a vaccine for treating lung cancer, as well as for
measuring metastases of lung cancer, or staging, monitoring, diagnosing
or imaging lung cancer.
XX
Example 18; Page 153; 206pp; English.
XX
The invention describes a new lung specific gene and its variants. The
lung specific gene proteins and genes are useful in gene therapy or as a
vaccine for treating lung cancer. Lung specific genes are also useful for
staging, monitoring, diagnosing or imaging lung cancer, as well as for
measuring metastases of lung cancer. This sequence represents a PCR
primer used in microarray analysis to isolate a lung specific gene
thought to be involved in development of lung cancer
XX
SQ Sequence 20 BP; 5 A; 8 C; 2 G; 5 T; 0 U; 0 Other;
Query Match      2.0%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.8e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 890 AGCGTGTGGGCGAGT 904
Db 15 AGCGTGTGGGCGAGT 1

RESULT 688
ABZ98895/c
ID ABZ98895 standard; DNA; 20 BP.
XX
AC ABZ98895;

XX DT 17-OCT-2003 (first entry)
XX
DE Human PDE4A oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIC-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WPI; 2003-229219/22.
XX
Pharmaceutical composition for treating ailments associated with impaired
respiration, has oligo(s) antisense to specific gene(s) or its
corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
ubiquinone.
XX
Disclosure; SEQ ID NO 14137; 872pp; English.
XX
The invention relates to a novel pharmaceutical composition, which has a
first active agent comprising an oligonucleotide antisense to the
initiation codon, coding region, 5' or 3' end genomic flanking regions,
5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
junctions of genes encoding a polypeptide associated with lung and/or
nasal airway dysfunction and a second active agent comprising an
antiinflammatory steroid and ubiquinone. A composition of the invention
has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
immunosuppressive, and cytostatic activity. The composition may have a
use in antisense gene therapy. The composition is useful for treating or
preventing a respiratory, lung or malignant disease or condition, also
for enhancing the prophylactic or therapeutic respiratory effect of an
antiinflammatory steroid in a subject, for reducing or depleting levels
of, or reducing sensitivity to adenosine, reducing levels of adenosine
receptor, producing bronchodilation, increasing levels of ubiquinone or
lung surfactant in a subject's tissue, or treating bronchoconstriction,
lung inflammation, lung allergies, or a respiratory disease or condition.
Note: The sequence data for this patent is not represented in the printed
specification, but was obtained in electronic format directly from WIPO
at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 1 A; 6 C; 9 G; 4 T; 0 U; 0 Other;
Query Match      2.0%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.8e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 338 GCCATCGGCAGAGC 352
Db 18 GCCATCGGCAGAGC 4

RESULT 689
ABD31926/c
ID ABD31926 standard; DNA; 20 BP.
XX
AC ABD31926;

```

XX
DT 29-JUL-2004 (first entry)
DE Human PDE4A-derived oligonucleotide SEQ ID 14137.
DE
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-093058/08.
DR
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 14137; 763pp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 1 A; 6 C; 9 G; 4 T; 0 U; 0 Other;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 338 GCCATCCGCGAGC 352
DB 18 GCCATCCGCGAGC 4
RESULT 690
ADJ60778/c
ID ADJ60778 standard; DNA; 20 BP.
XX
AC ADJ60778;
XX
DT 06-MAY-2004 (first entry)
XX
DE Oligonucleotide associated to PDE4A #61.
XX
KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
OS Homo sapiens.
XX
PN WO2004011613-A2.
XX
PD 05-FEB-2004.
XX
PF 25-JUL-2003; 2003WO-US023509.
XX
PR 29-JUL-2002; 2002US-0399076P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
XX WPI; 2004-203534/19.
XX
PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCRI, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
PS Claim 2; SEQ ID NO 1634; 85pp; English.
XX
CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 1 A; 6 C; 9 G; 4 T; 0 U; 0 Other;
Query Match 2.0%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.8e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 338 GCCATCCGCGAGC 352
DB 18 GCCATCCGCGAGC 4

CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 1 A; 6 C; 9 G; 4 T; 0 U; 0 Other;
 Query Match 2.0%; Score 15; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 4.8e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 338 GCATCCGCGCAGC 352
 Db 18 GCATCCGCGCAGC 4
 RESULT 692
 AAV60911
 ID AAV60911 standard; DNA; 18 BP.
 XX AAV60911;
 AC AAV60911;
 XX
 XX 11-JAN-1999 (first entry)
 DT
 XX
 DE Angiogenin antisense oligonucleotide JF2S.
 XX
 KW Angiogenin; antisense; inhibitor; cancer; metastasis; angiogenesis;
 KW therapy; diagnosis; ss.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..18
 FT /*tag= a
 FT /note= "phosphorothioate linkages"
 XX
 PN WO9842722-A1.
 PD 01-OCT-1998.
 XX
 PF 20-MAR-1998; 98WO-US005651.
 XX
 PR 21-MAR-1997; 97US-0041182P.
 XX
 XX (HARD) HARVARD COLLEGE.
 PA
 XX
 PI Pett JW, Olson KA;
 XX
 DR WPI; 1998-531944/45.
 XX
 PT New oligo-nucleotide(s) that inhibit expression of angiogenin - for
 PT treatment of tumours and metastases, or other conditions involving
 PT abnormal angiogenesis.
 XX
 PS Claim 10; Page 38; 71pp; English.
 CC
 CC Antisense phosphorothioate oligonucleotide JF2S encompasses the AUG
 CC initiation codon of the human angiogenin gene (see AAV60918). JF2S, and
 CC other claimed antisense oligonucleotides (see AAV60912-17) with base
 CC sequences complementary to a target region of the angiogenin gene, are
 CC able to inhibit expression of angiogenin. They are used in claimed
 CC methods to decrease production of angiogenin, particularly to reduce the
 CC size of tumours associated with angiogenesis, to inhibit metastases,
 CC establishment of tumour cells or growth of tumours and, when labelled, to
 CC detect angiogenin for diagnosis of conditions associated with abnormal
 CC angiogenesis. They can also be used to treat a wide range of non-cancer
 CC conditions that involve angiogenesis, e.g. age-related macular
 CC degeneration, diabetic retinopathy, bacterial or fungal ulcers,
 CC rheumatoid arthritis, Paget's disease, Crohn's disease, haemangioma and
 CC many others listed
 XX
 SQ Sequence 18 BP; 3 A; 9 C; 1 G; 5 T; 0 U; 0 Other;

RESULT 691
 ADO46267/c
 ID ADO46267 standard; DNA; 20 BP.
 XX
 AC ADO46267;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1633.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR
 PR 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE// NYCE J W.
 PA (SAND// SANDRASAGRA A.
 PA (TANG// TANG L.
 PA (AGUI// AGUILAR D.
 PA (MILL// MILLER S.
 PA (SHAH// SHAHABUDDIN S.
 PA (LUHH// LU H.
 PA (CONG// CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 XX WPI; 2004-293804/27.
 DR
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 PS Claim 2; SEQ ID NO 1634; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)-
 CC 5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,


```

PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US017674.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 04-NOV-2002; 2002US-00287949.
PR 27-NOV-2002; 2002US-00306747.
PR 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX Mcswiggen J, Beigelman L, Pavco P;
XX WPI; 2003-679876/64.
XX
XX New double-stranded interfering nucleic acid, useful e.g. for treatment
XX and diagnosis of cancer, downregulates the vascular endothelial growth
XX factor receptor gene.
XX
XX Example 3; SEQ ID NO 1036; 207pp; English.
XX
XX The present invention describes a double-stranded short interfering
XX nucleic acid (siNA) that downregulates expression of the vascular
XX endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
XX siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
XX delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
XX that express siNA; and (5) single-stranded siNA with similar properties.
XX The siNAs have antiangiogenic, cytostatic, antidiabetic,
XX ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
XX gynaecological activities. The siNA are useful for modulating
XX (downregulating) the expression of VEGFR genes. The siNA are potentially
XX useful for treating a wide range of angiogenesis-associated conditions,
XX particularly cancers, diabetic retinopathy, macular degeneration,
XX neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
XX and polycystic kidney disease. The siNA may also be useful for diagnosis,
XX drug screening, target identification and validation, genetic
XX engineering, studying gene function, and also for gene mapping (e.g. of
XX single-nucleotide polymorphisms). The present sequence is used in the
XX exemplification of the present invention.
XX
XX Sequence 19 BP; 8 A; 2 C; 7 G; 0 T; 2 U; 0 Other;
XX
XX Query Match 2.0%; Score 14.8; DB 1; Length 19;
XX Best Local Similarity 83.3%; Pred. No. 4.8e+02;
XX Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
XX
Qy 811 GGAGGAGAGAGGAGCT 828
Db 1 GUAGAAGAGAGGAGCU 18
XX
RESULT 700
ADF37071/c
ID ADF37071 standard; RNA; 19 BP.
XX
XX ADF37071;
XX
XX 12-FEB-2004 (first entry)
XX
XX Human VEGFR2 short interfering nucleic acid (siNA) SEQ ID NO:1360.
XX
XX double-stranded short interfering nucleic acid;
XX short interfering nucleic acid; siNA; downregulation;
XX vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
XX cytosstatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
XX nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
XX diabetic retinopathy; macular degeneration; neovascular glaucoma;
XX arthritis; psoriasis; endometriosis; angiofibroma;
XX polycystic kidney disease; ss.

```

```

XX Synthetic.
XX Homo sapiens.
XX
XX WO2003070910-A2.
XX
XX 28-AUG-2003.
XX
XX 20-FEB-2003; 2003WO-US005022.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 29-MAY-2002; 2002WO-US017674.
XX 06-JUN-2002; 2002US-0386782P.
XX 03-JUL-2002; 2002US-0393796P.
XX 29-JUL-2002; 2002US-0399348P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 04-NOV-2002; 2002US-00287949.
XX 27-NOV-2002; 2002US-00306747.
XX 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX Mcswiggen J, Beigelman L, Pavco P;
XX WPI; 2003-679876/64.
XX
XX New double-stranded interfering nucleic acid, useful e.g. for treatment
XX and diagnosis of cancer, downregulates the vascular endothelial growth
XX factor receptor gene.
XX
XX Example 3; SEQ ID NO 1360; 207pp; English.
XX
XX The present invention describes a double-stranded short interfering
XX nucleic acid (siNA) that downregulates expression of the vascular
XX endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
XX siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
XX delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
XX that express siNA; and (5) single-stranded siNA with similar properties.
XX The siNAs have antiangiogenic, cytostatic, antidiabetic,
XX ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
XX gynaecological activities. The siNA are useful for modulating
XX (downregulating) the expression of VEGFR genes. The siNA are potentially
XX useful for treating a wide range of angiogenesis-associated conditions,
XX particularly cancers, diabetic retinopathy, macular degeneration,
XX neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
XX and polycystic kidney disease. The siNA may also be useful for diagnosis,
XX drug screening, target identification and validation, genetic
XX engineering, studying gene function, and also for gene mapping (e.g. of
XX single-nucleotide polymorphisms). The present sequence is used in the
XX exemplification of the present invention.
XX
XX Sequence 19 BP; 2 A; 7 C; 2 G; 0 T; 8 U; 0 Other;
XX
XX Query Match 2.0%; Score 14.8; DB 1; Length 19;
XX Best Local Similarity 88.9%; Pred. No. 4.8e+02;
XX Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
Qy 811 GGAGGAGAGAGGAGCT 828
Db 19 GTAGAAGAGAGGAGCT 2
XX
RESULT 701
ADN75388/c
ID ADN75388 standard; RNA; 19 BP.
XX
XX ADN75388;
XX
XX 01-JUL-2004 (first entry)
XX

```

DE Human CD45 CR region siRNA oligonucleotide SEQ ID 213.
 XX small interfering RNA; siRNA; protein-tyrosine-phosphatase; PTP;
 KW cytosolic; immunomodulator; antimicrobial; antiinflammatory;
 KW antidiabetic; anorectic; cancer; autoimmune disease; infection;
 KW inflammation; diabetes; obesity; RNA interference; gene silencing; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004016735-A2.
 XX
 PD 26-FEB-2004.
 XX
 XX 23-MAY-2003; 2003WO-US016632.
 PF 23-MAY-2003; 2003WO-US016632.
 PR 23-MAY-2003; 2003WO-US016632.
 PR 14-APR-2002; 2002US-0383249P.
 PR 24-APR-2002; 2002US-0462942P.
 XX (CEPT-) CEPTYR INC.
 PA (COLD-) COLD SPRING HARBOR LAB.
 XX
 PI Klinghoffer R, Lewis SP, Tonks NK, Meng T;
 XX WPI: 2004-203773/19.
 XX
 PT New isolated small interfering RNA (siRNA) polynucleotide useful for
 PT treating diseases with aberrant activity of the protein tyrosine
 PT phosphatase, such as cancer, autoimmune disease, infection, inflammation,
 PT diabetes and obesity.
 XX
 PS Example 2; SEQ ID NO 213; 392pp; English.
 XX
 CC This invention describes novel small interfering RNA (siRNA)
 CC polynucleotides capable of interfering with expression of a polypeptide
 CC having protein-tyrosine-phosphatase (PTP) activity. The products of the
 CC invention have cytostatic, immunomodulator, antimicrobial,
 CC antiinflammatory, antidiabetic and anorectic activity. The methods and
 CC compositions of the present invention are useful for treating diseases or
 CC conditions associated with aberrant expression or activity of the protein
 CC tyrosine phosphatase, such as cancer, autoimmune diseases, infection,
 CC inflammation, diabetes and obesity. This sequence represents a siRNA
 CC directed against dual specificity phosphatase (DSP) expression.
 XX
 SQ Sequence 19 BP; 4 A; 6 C; 4 G; 0 T; 5 U; 0 Other;
 Query Match 2.0%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 88.9%; Pred. No. 4.8e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 215 GATCAGGACGTACTGGGC 232
 DB 19 GATCAAGATGCTACTGGGC 2
 RESULT 702
 ID ADR75637/C
 XX ADR75637 standard; DNA; 19 BP.
 AC ADR75637;
 XX
 XX 16-DEC-2004 (first entry)
 DT
 XX Human apolipoprotein B (ApoB) oligonucleotide seqid 122.
 DE
 KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
 KW cytosolic; anticonvulsant; nootropic; muscular; anti-HIV;
 KW RNA interference; RNA; antisense technology; lipid metabolism;
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
 KW coronary artery disease; CAD; coronary heart disease; CHD;
 KW atherosclerosis; hepatic glucose production;
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
 KW colon cancer; lung cancer; neurological disease; Huntington disease;
 KW spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.

XX Homo sapiens.
 OS
 PN WO2004080406-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 08-MAR-2004; 2004WO-US007070.
 XX
 XX 07-MAR-2003; 2003US-0452682P.
 PR 12-MAR-2003; 2003US-0454265P.
 PR 13-MAR-2003; 2003US-0454962P.
 PR 13-MAR-2003; 2003US-0455050P.
 PR 14-APR-2003; 2003US-0462894P.
 PR 17-APR-2003; 2003US-0463772P.
 PR 25-APR-2003; 2003US-0465665P.
 PR 25-APR-2003; 2003US-0465802P.
 PR 09-MAY-2003; 2003US-0469612P.
 PR 08-AUG-2003; 2003US-0493986P.
 PR 11-AUG-2003; 2003US-0494597P.
 PR 26-SEP-2003; 2003US-0506341P.
 PR 09-OCT-2003; 2003US-0510246P.
 PR 10-OCT-2003; 2003US-0510318P.
 PR 07-NOV-2003; 2003US-0518453P.
 XX (ALNY-) ALNYLAM PHARM.
 PA Manoharan M, Bumcrot D;
 PI WPI: 2004-677362/66.
 XX
 PT Interference RNA agent useful for treating dyslipidemias, coronary artery
 PT disease, diabetes, cancer or neurological disease, comprises sense
 PT sequence and antisense sequence which has specific modifications.
 XX
 PS Example 5; SEQ ID NO 122; 378pp; English.
 XX
 CC The invention describes a RNA interference (iRNA) agent (I) comprising a
 CC sense sequence and an antisense sequence, where the sense sequences have
 CC one or more asymmetrical 2'-O alkyl modifications, the antisense
 CC sequences have one or more asymmetrical phosphorothioate modifications
 CC and the antisense sequence targets a human gene sequence. Also described
 CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
 CC levels or glucose-6-phosphatase levels in a subject; producing (I);
 CC stabilising (I), involves selecting a sequence with activity and
 CC introducing one or more asymmetrical modification in the sequence, where
 CC the modification decreases nuclease sensitivity while not decreasing its
 CC activity; a kit comprising (I) and instruction for its use; and a device
 CC that can be dispense or administer a composition comprising (I). (I) is
 CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
 CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
 CC The subject is suffering from a disorder characterised by elevated or
 CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
 CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
 CC disorder is chosen from the HDL/LDL cholesterol imbalance,
 CC dyslipidaemias, hypercholesterolaemia, statin-resistant
 CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
 CC inhibit hepatic glucose production or for treating glucose-metabolism-
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
 CC lung cancer), neurological disease (e.g., Huntington disease or
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
 CC represents a human apolipoprotein B (ApoB) antisense oligonucleotide that
 CC can be used to control ApoB gene expression.
 XX
 SQ Sequence 19 BP; 0 A; 7 C; 6 G; 6 T; 0 U; 0 Other;
 Query Match 2.0%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 88.9%; Pred. No. 4.8e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 718 GCTGCAGCAGCAGCAG 735

DB 18 GCAGCAGCAGCAGCGCAG 1

RESULT 703

ADNR78255/c

ID ADR78255 standard; DNA; 19 BP.

AC ADR78255;

XX

XX 16-DEC-2004 (first entry)

XX Human apolipoprotein B (ApoB) oligonucleotide seqid 2740.

XX antilipemic; cardiant; vasotropic; antiarteriosclerotic; anti-diabetic;

KW cytosolic; anticonvulsant; nootropic; musclic; anti-HIV;

KW RNA interference; iRNA; antisense technology; lipid metabolism;

KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;

KW coronary artery disease; CAD; coronary heart disease; CHD;

KW atherosclerosis; hepatic glucose production;

KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;

KW colon cancer; lung cancer; neurological disease; Huntington disease;

KW spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.

XX

OS Homo sapiens.

XX

XX WO2004080406-A2.

XX

XX 23-SEP-2004.

XX

XX 08-MAR-2004; 2004WO-US007070.

XX

XX 07-MAR-2003; 2003US-0452682P.

XX

XX 12-MAR-2003; 2003US-0454285P.

XX

XX 13-MAR-2003; 2003US-0454962P.

XX

XX 14-MAR-2003; 2003US-0455050P.

XX

XX 17-APR-2003; 2003US-0462894P.

XX

XX 25-APR-2003; 2003US-0463772P.

XX

XX 25-APR-2003; 2003US-0465665P.

XX

XX 25-APR-2003; 2003US-0465802P.

XX

XX 09-MAY-2003; 2003US-0469612P.

XX

XX 08-AUG-2003; 2003US-0493986P.

XX

XX 11-AUG-2003; 2003US-0494537P.

XX

XX 26-SEP-2003; 2003US-0506341P.

XX

XX 09-OCT-2003; 2003US-0510246P.

XX

XX 10-OCT-2003; 2003US-0510318P.

XX

XX 07-NOV-2003; 2003US-0518453P.

XX

XX (ALNY-) ALNYLAM PHARM.

XX

XX Manoharan M, Bumcrot D;

XX

XX WPI; 2004-677362/66.

XX

XX Interference RNA agent useful for treating dyslipidemias, coronary artery

PT disease, diabetes, cancer or neurological disease, comprises sense

PT sequence and antisense sequence which has specific modifications.

XX

XX Example 5; SEQ ID NO 2740; 378pp; English.

XX

XX The invention describes a RNA interference (iRNA) agent (I) comprising a

CC sense sequence and an antisense sequence, where the sense sequences have

CC one or more asymmetrical 2'-O alkyl modifications, the antisense

CC sequences have one or more asymmetrical phosphorothioate modifications

CC and the antisense sequence targets a human gene sequence. Also described

CC are: a pharmaceutical preparation comprising (I); reducing (MI) apoB-100

CC levels or glucose-6-phosphatase levels in a subject; producing (I);

CC stabilising (I), involves selecting a sequence with activity and

CC introducing one or more asymmetrical modification in the sequence, where

CC the modification decreases nuclease sensitivity while not decreasing its

CC activity; a kit comprising (I) and instruction for its use; and a device

CC that can be dispense or administer a composition comprising (I). (I) is

CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (MI)

CC

CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.

CC The subject is suffering from a disorder characterised by elevated or

CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted

CC levels of cholesterol, and/or dysregulation of lipid metabolism. The

CC disorder is chosen from the HDL/LDL cholesterol imbalance,

CC dyslipidaemias, hypercholesterolaemia, statin-resistant

CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart

CC disease (CHD) and atherosclerosis. (I) is administered to a subject to

CC inhibit hepatic glucose production or for treating glucose-metabolism-

CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for

CC treating the diseases as mentioned above, cancer (e.g. breast, colon or

CC lung cancer), neurological disease (e.g., Huntington disease or

CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence

CC represents a human apolipoprotein B (ApoB) antisense oligonucleotide that

CC can be used to control ApoB gene expression.

XX

SQ Sequence 19 BP; 0 A; 7 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 2.0%; Score 14.8; DB 1; Length 19;

Best Local Similarity 88.9%; Pred. No. 4.8e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 718 GCTGCAGCAGCAGCAGCAG 735

DB 18 GCAGCAGCAGCAGCGCAG 1

RESULT 704

ABN07457

ID ABN07457 standard; DNA; 17 BP.

XX

XX AC ABN07457;

XX

XX 29-MAY-2002 (first entry)

XX

XX Human GDMPL-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7449.

XX

KW Human; genome-derived myosin-like protein 1; GDMPL-1; hGDMPL-1; heart;

KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;

KW skeletal muscle disorder; amplicon; screening; ss.

XX

OS Homo sapiens.

XX

XX WO200192524-A2.

XX

XX 06-DEC-2001.

XX

XX 25-MAY-2001; 2001WO-US016981.

XX

XX 26-MAY-2000; 2000US-0207456P.

XX

XX 21-SEP-2000; 2000US-0234687P.

XX

XX 27-SEP-2000; 2000US-0236359P.

XX

XX 04-OCT-2000; 2000GB-00024263.

XX

XX 30-JAN-2001; 2001WO-US000661.

XX

XX 30-JAN-2001; 2001WO-US000662.

XX

XX 30-JAN-2001; 2001WO-US000663.

XX

XX 30-JAN-2001; 2001WO-US000664.

XX

XX 30-JAN-2001; 2001WO-US000665.

XX

XX 30-JAN-2001; 2001WO-US000666.

XX

XX 30-JAN-2001; 2001WO-US000667.

XX

XX 30-JAN-2001; 2001WO-US000668.

XX

XX 30-JAN-2001; 2001WO-US000669.

XX

XX 05-FEB-2001; 2001US-0266860P.

XX

XX (AEOM-) AEOMICA INC.

XX

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;

PI

XX WPI; 2002-179446/23.

XX

XX New polypeptide, for raising antibodies that recognize hGDMPL-1 proteins,

PT or as specific biomolecule capture probes for surface-enhanced laser

PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX (AEOM-) AEOMICA INC.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX Disclosure; SEQ ID NO 7247; 214pp; English.
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX Sequence 17 BP; 3 A; 3 C; 9 G; 2 T; 0 U; 0 Other;
 SQ Query Match 1.9%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 4.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 698 CTGAGAGTGCAGCGG 713
 Db 1 CTGAGAGTGCAGCGG 16
 RESULT 707
 ID ABN08979/c
 ID ABN08979 standard; DNA; 17 BP.
 XX AC ABN08979;
 XX 29-MAY-2002 (first entry)
 XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8971.
 XX Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;
 XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 XX skeletal muscle disorder; amplicon; screening; ss.

XX Homo sapiens.
 XX WO200192524-A2.
 XX 06-DEC-2001.
 XX 25-MAY-2001; 2001WO-US016981.
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX (AEOM-) AEOMICA INC.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX Disclosure; SEQ ID NO 8971; 214pp; English.
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX Sequence 17 BP; 4 A; 3 C; 7 G; 3 T; 0 U; 0 Other;
 SQ Query Match 1.9%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 4.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 851 CACCAGCTCTTCCAG 866
 Db 16 CACCAGCTCTTCCATG 1
 RESULT 708
 ABN08978/c

ID ABN08978 standard; DNA; 17 BP.
 AC ABN08978;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8970.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US016981.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon MB;
 XX
 XX WPI; 2002-179446/23.
 XX
 PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX
 PS Disclosure; SEQ ID NO 8970; 214pp; English.
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 XX Sequence 17 BP; 5 A; 2 C; 7 G; 3 T; 0 U; 0 Other;

*Query Match 1.9%; Score 14.4; DB 1; Length 17;
 . Best Local Similarity 93.8%; Pred. No. 4.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 851 CACGAGCTCTTCCAAG 866
 DB 17 CACGAGCTCTTCCATG 2
 RESULT 709
 ACDS9504/c
 ID ACDS9504 standard; RNA; 17 BP.
 XX
 AC ACDS9504;
 XX
 DT 24-SEP-2003 (first entry)
 XX
 DE HCV DNzyme substrate sequence #1362.
 XX
 KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
 KW RNA stability; RNA expression; RNA synthesis; antisense;
 KW enzymatic nucleic acid; hammerhead ribozyme; DNzyme; inozyme; zinzyme;
 KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
 KW HBV reverse transcriptase; Enhancer I region; viral replication;
 KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
 KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
 KW virucide; antiinflammatory; substrate; ss.
 XX
 OS Hepatitis C virus.
 XX
 PN WO200281494-A1.
 XX
 PD 17-OCT-2002.
 XX
 PF 26-MAR-2002; 2002WO-US009187.
 XX
 PR 26-MAR-2001; 2001US-00817879.
 PR 08-JUN-2001; 2001US-00877478.
 PR 08-JUN-2001; 2001US-0296876P.
 PR 24-OCT-2001; 2001US-0335059P.
 PR 05-DEC-2001; 2001US-0337055P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MACE/) MACEJAK D.
 PA (MCSW/) MCSWIGGEN J.
 PA (MORR/) MORRISSEY J.
 PA (PAVC/) PAVCO P.
 PA (LEEP/) LEE P.
 PA (DRAP/) DRAPER K.
 PA (ROBE/) ROBERTS E.
 XX
 PI Blatt L, Macejak D, Mcswiggen J, Morrissey J, Pavco P, Lee P;
 PI Draper K, Roberts E;
 XX
 WPI; 2003-229207/22.
 XX
 PT Novel compound useful for treating cirrhosis, liver failure,
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus
 PT infection.
 XX
 PS Claim 1; Page 258; 387pp; English.
 XX
 CC The present invention relates to nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
 CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV
 CC DNA. The nucleic acids may be used to modulate the expression of HBV
 CC genes and HBV viral replication. Also disclosed is a method for screening

CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HCV
CC DNase/minus strand DNase sequences disclosed in the present
CC invention
XX
SQ Sequence 17 BP; 3 A; 6 C; 6 G; 0 T; 2 U; 0 Other;

Query Match 1.9%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 4.7e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 594 TGCTCGGGAGCTGCA 609

DB 16 TGCTCGGGAGCTGCA 1

RESULT 710

ACN70345

ID ACN70345 standard; DNA; 17 BP.

XX AC ACN70345;

XX AC ACN70345;

DT 02-DEC-2004 (first entry)

XX Human GDMPL-1 probe SEQ ID NO:7247.

XX Human; ss; probe; myosin-like protein-1; hGDMPL-1;

KW hGDMPL-1 agonist hGDMPL antagonist; hGDMPL inhibitor; heart disorder;

KW skeletal muscle function.

XX Homo sapiens.

XX US2004137589-A1.

XX 15-JUL-2004.

XX 26-NOV-2003; 2003US-00723361.

XX 26-MAY-2000; 2000US-0207456P.

XX 21-SEP-2000; 2000US-0234687P.

XX 27-SEP-2000; 2000US-0236359P.

XX 04-OCT-2000; 2000GB-00024263.

XX 30-JAN-2001; 2001WO-US000661.

XX 30-JAN-2001; 2001WO-US000662.

XX 30-JAN-2001; 2001WO-US000663.

XX 30-JAN-2001; 2001WO-US000664.

XX 30-JAN-2001; 2001WO-US000665.

XX 30-JAN-2001; 2001WO-US000667.

XX 30-JAN-2001; 2001WO-US000668.

XX 30-JAN-2001; 2001WO-US000669.

XX 05-FEB-2001; 2001WO-US000670.

XX 25-MAY-2001; 2001US-0266860P.

XX 25-MAY-2001; 2001US-00866108.

XX (GUY/) GU Y.

XX (JIY/) JI Y.

XX (PENN/) PENN S G.

XX (HANZ/) HANZEL D K.

XX (RANK/) RANK D.

XX (CHEN/) CHEN W.

XX (SHAN/) SHANNON M E.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;

XX WPI; 2004-533378/51.

XX Novel myosin-like protein-1, useful for treating or preventing disorder

XX associated with decreased expression or activity of human genome-derived

PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle

PT function.

XX Disclosure; SEQ ID NO 7247; Opp; English.

CC The invention relates to a novel polypeptide (I) comprising a sequence
CC (SI) of myosin-like protein-1 (hGDMPL-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (SI), 95% deviation from (SI) which are conservative substitutions, and
CC 65% identity to (SI). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMPL-1, or as an inhibitor of hGDMPL-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMPL-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103

XX SQ Sequence 17 BP; 3 A; 3 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 1.9%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 4.7e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 698 CTGGAGAGTGAGCGG 713

DB 1 CTGGAGAGTGAGCGG 16

RESULT 711

ACN70547

ID ACN70547 standard; DNA; 17 BP.

XX AC ACN70547;

XX AC ACN70547;

DT 02-DEC-2004 (first entry)

XX Human GDMPL-1 probe SEQ ID NO:7449.

XX Human; ss; probe; myosin-like protein-1; hGDMPL-1;

KW hGDMPL-1 agonist hGDMPL antagonist; hGDMPL inhibitor; heart disorder;

KW skeletal muscle function.

XX Homo sapiens.

XX US2004137589-A1.

XX 15-JUL-2004.

XX 26-NOV-2003; 2003US-00723361.

XX 26-MAY-2000; 2000US-0207456P.

XX 21-SEP-2000; 2000US-0234687P.

XX 27-SEP-2000; 2000US-0236359P.

XX 04-OCT-2000; 2000GB-00024263.

XX 30-JAN-2001; 2001WO-US000661.

XX 30-JAN-2001; 2001WO-US000662.

XX 30-JAN-2001; 2001WO-US000663.

XX 30-JAN-2001; 2001WO-US000664.

XX 30-JAN-2001; 2001WO-US000665.

XX 30-JAN-2001; 2001WO-US000666.

XX 30-JAN-2001; 2001WO-US000667.

XX 30-JAN-2001; 2001WO-US000668.

XX 30-JAN-2001; 2001WO-US000669.

XX 05-FEB-2001; 2001WO-US000670.

XX 25-MAY-2001; 2001US-0266860P.

XX 25-MAY-2001; 2001US-00866108.

XX (GUY/) GU Y.

XX (JIY/) JI Y.

XX (PENN/) PENN S G.

XX (HANZ/) HANZEL D K.

XX (RANK/) RANK D.

XX (CHEN/) CHEN W.

PA (SHAN/) SHANNON M E.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 XX Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 XX Disclosure; SEQ ID NO 7449; Opp; English.
 XX The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX Sequence 17 BP; 4 A; 4 C; 5 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 1.9%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 4.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 412 GGAGAGAGGAGTTCCTC 427
 Db ||||| |||||
 2 GGAGAGAGGAGTTCCTC 17
 RESULT 712
 ACN72068/C
 ID ACN72068 standard; DNA; 17 BP.
 XX ACN72068;
 XX 02-DEC-2004 (first entry)
 DE Human GDMPLP-1 probe SEQ ID NO:8970.
 XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX Homo sapiens.
 OS US2004137589-A1.
 PN 15-JUL-2004.
 PD 26-NOV-2003; 2003US-00723361.
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001US-0266860P.

PR 25-MAY-2001; 2001US-00866108.
 XX (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 XX Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 XX Disclosure; SEQ ID NO 8970; Opp; English.
 XX The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX Sequence 17 BP; 5 A; 2 C; 7 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 1.9%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 4.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 851 CACCAGCTCTCCAG 866
 Db ||||| |||||
 17 CACCAGCTCTCCATG 2
 RESULT 713
 ACN70549
 ID ACN70549 standard; DNA; 17 BP.
 XX ACN70549;
 XX 02-DEC-2004 (first entry)
 DE Human GDMPLP-1 probe SEQ ID NO:7451.
 XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX Homo sapiens.
 OS US2004137589-A1.
 PN 15-JUL-2004.
 PD 26-NOV-2003; 2003US-00723361.
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001US-0266860P.

```

PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
PA (GUY/) GU Y.
PA (JIY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
PI WPI; 2004-533378/51.
XX
PT Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
PS Disclosure; SEQ ID NO 7451; Opp; English.
XX
CC The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
SQ Sequence 17 BP; 5 A; 4 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 4.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 413 GAGAGGAGGTTCTCTCA 428
DB 1 GAGAACGAGTTCTCTCA 16
RESULT 714
ACN72069/c
ID ACN72069 standard; DNA; 17 BP.
XX
AC ACN72069;
XX
DT 02-DEC-2004 (first entry)
XX
DE Human GDMLP-1 probe SEQ ID NO:8971.
XX
KW Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW skeletal muscle function.
XX
OS Homo sapiens.
XX
XX US2004137589-A1.
XX
PD 15-JUL-2004.
XX
PF 26-NOV-2003; 2003US-00723361.
XX
26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000SB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
PA (GUY/) GU Y.
PA (JIY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
PI WPI; 2004-533378/51.
XX
PT Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
PS Disclosure; SEQ ID NO 8971; Opp; English.
XX
CC The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
SQ Sequence 17 BP; 4 A; 3 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 4.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 851 CACCAGCTTCTCAAG 866
DB 16 CACCAGCTTCTCATG 1
RESULT 715
AAAX67194/c
ID AAAX67194 standard; RNA; 18 BP.
XX
AC AAAX67194;
XX
DT 20-JUL-1999 (first entry)
XX
DE Human CD40 hairpin ribozyme target SEQ ID NO:3826.
XX
KW Arthritic condition; graft tolerance; immune response; target; cleavage;
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;

```

KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
 KW diagnosis; ss.
 XX Homo sapiens.
 XX WO618736-A2.
 XX 20-JUN-1996.
 XX 22-NOV-1995; 95WO-US015516.
 XX 13-DEC-1994; 94US-00354920.
 XX 23-DEC-1994; 94US-00363253.
 XX 17-DEC-1994; 94US-00363254.
 XX 17-FEB-1995; 95US-00390850.
 XX 20-APR-1995; 95US-00426124.
 XX 02-MAY-1995; 95US-00432874.
 XX 04-MAY-1995; 95US-00434509.
 XX 07-JUL-1995; 95US-0000951P.
 XX 07-JUL-1995; 95US-0000974P.
 XX 07-AUG-1995; 95US-00512861.
 XX 05-OCT-1995; 95US-00541365.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;
 PI McSwiggan J, Gustofson J, Usman N, Wincott P, Matulic-Adamic J;
 PI Karpeisky A, Thompson JD, Modak A, Burgin A;
 XX WPI; 1996-300653/30.
 XX Enzymatic nucleic acid molecules having a hammer-head motif - used for
 PT the treatment of arthritis, induction of graft tolerance or treatment of
 PT auto-immune diseases.
 XX Claim 10; Page 218; 307pp; English.
 XX The present invention describes a novel enzymatic nucleic acid (ENA)
 CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
 CC; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
 CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
 CC can inhibit collagenase and stromelysin production in the synovial
 CC membrane of joints for the treatment or prevention of arthritis,
 CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
 CC be used to treat antigen presenting cells of a donor to induce tolerance
 CC in a recipient to an alloantigen of a donor. They can also be used for
 CC enhancing graft tolerance or for treating autoimmune disease, and for
 CC treating allergies and other inflammatory conditions. The ENA's can also
 CC be used in diagnosis. Ribozyme therapy impacts on the expression of
 CC stromelysin without introducing the non-specific effects upon gene
 CC expression which accompany treatment with retinoids and dexamethasone.
 CC The concentration of ribozyme required to affect a therapeutic treatment
 CC is lower than that required of antisense molecules, and is highly
 CC specific. The present sequence is used in the exemplification of the
 CC present invention
 XX Sequence 18 BP; 1 A; 4 C; 8 G; 0 T; 5 U; 0 Other;
 SQ Query Match 1.9%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 5e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 717 CGCTGCAGCAGCAGCA 732
 DB 16 CCCTGCAGCAGCAGCA 1
 RESULT 716
 AAZ76614/c
 ID AAZ76614 standard; DNA; 18 BP.
 XX AAZ76614;
 AC AAZ76614;
 XX

DT 10-SEP-2001 (first entry)
 XX Human biallelic marker downstream amplification primer SEQ ID NO:10970.
 XX Human genome; biallelic marker; high density disequilibrium map;
 KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
 KW haplotyping; hybridisation; identification; characterisation;
 KW amplification; single nucleotide polymorphism; SNP; PCR primer;
 KW diagnosis; ss.
 XX Homo sapiens.
 XX WO9954500-A2.
 XX 28-OCT-1999.
 XX 21-APR-1999; 99WO-IB000822.
 XX 21-APR-1999; 98US-0082614P.
 XX 23-NOV-1998; 98US-0109732P.
 XX (GEST) GENSET.
 XX Cohen D, Blumenfeld M, Chumakov I;
 PI WPI; 2000-013267/01.
 XX Novel biallelic markers used to construct a high density disequilibrium
 PT map of the human genome.
 XX Claim 9; Page 2569; 2745pp; English.
 XX AAZ65654 to AAZ69578 represent human biallelic markers from the present
 CC invention, which contain a polymorphic base at position 24 of their
 CC nucleotide sequences. AAZ69579 to AAZ7440 represent amplification
 CC primers for the biallelic markers. The biallelic markers of the invention
 CC have a variety of uses: they can be used for high density mapping of the
 CC human genome, and in complex association studies and haplotyping studies
 CC which are useful in determining the genetic basis for disease states.
 CC Compositions and methods of the invention can also be useful for the
 CC identification of the targets for the development of pharmaceutical
 CC agents and diagnostic methods, as well as the characterisation of the
 CC differential efficacious responses to and side effects from
 CC pharmaceutical agents acting on a disease as well as other treatment.
 CC N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
 CC 3367, are not actually given a sequence in the Sequence Listing from the
 CC present invention
 XX Sequence 18 BP; 1 A; 9 C; 0 G; 8 T; 0 U; 0 Other;
 SQ Query Match 1.9%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 5e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 811 GGAGGAGAGAGAGAG 826
 DB 17 GGAGGAGAGAGATGAAG 2
 RESULT 717
 AAH75205/c
 ID AAH75205 standard; DNA; 18 BP.
 XX AAH75205;
 AC AAH75205;
 XX 02-OCT-2001 (first entry)
 XX Human inducible NOS antisense oligonucleotide SEQ ID NO 49.
 XX Antisense oligonucleotide; inducible nitric oxide synthase; NOS;
 KW modulate expression; immunomodulator; antidiabetic; cardiovascular;
 KW cardiant; neuroprotective; vasotropic; ischaemia; reperfusion injury;
 KW 2'-O-methoxyethyl; phosphorothioate; human; ss.

XX OS Homo sapiens.

XX PH Key Location/Qualifiers

FT modified_base 1..18

FT /*tag= a

FT /mod_base= OTHER

FT /note= "phosphorothioate backbone, 5' and 3' four

FT nucleotide 2'-MOE (2'-O-methoxyethyl) wings (the cytidine

FT residues in the 2'-MOE wings are 5-methylcytidines) and a

FT deoxy gap"

XX PN W0200152902-A1.

XX PD 26-JUL-2001.

XX PD 15-JAN-2001; 2001WO-US001381.

XX PF 24-JAN-2000; 2000US-00490208.

XX PR (ISIS-) ISIS PHARM INC.

XX PA Bennett CF, Dean NM, Cowser LM;

XX PI WPI; 2001-465340/50.

XX DR New antisense oligonucleotides for modulating the expression of inducible

XX PT nitric oxide synthase in cells or tissues, particularly useful for

PT treating e.g. immunological, cardiovascular or neurological disorders, or

PT ischemia.

XX PS Claim 3; Page 84; 144pp; English.

XX CC The invention relates to antisense compounds, especially

CC oligonucleotides, which are targeted to a nucleic acid encoding inducible

CC nitric oxide synthase and which specifically hybridize to and modulate

CC expression of inducible nitric oxide synthase. The antisense compounds

CC have immunomodulator, antidiabetic, cardiovascular, cardiac,

CC neuroprotective, disorder and vasotropic activity. The antisense

CC oligonucleotides are useful for inhibiting the expression of inducible

CC nitric oxide synthase in cells or tissues. In particular, the antisense

CC oligonucleotides are useful for treating diseases or disorders associated

CC with inducible nitric oxide synthase, e.g. diabetes, immunological

CC disorder, cardiovascular disorder, neurological disorder or

CC ischemia/reperfusion injury. The antisense oligonucleotides are also

CC useful for research and diagnostics. The present sequence is that of an

CC antisense 2'-O-methoxyethyl gapmer oligonucleotide with a

CC phosphorothioate backbone, a central "gap" region of ten nucleotides

CC flanked by four nucleotide 2'-MOE (2'-methoxyethyl) wings (cytidine

CC residues in the 2'-MOE wings are 5-methylcytidines) and targeted to human

CC inducible nitric oxide synthase (NOS) mRNA (AAH47959)

XX SQ Sequence 18 BP; 2 A; 8 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 1.9%; Score 14.4; DB 1; Length 18;

Best Local Similarity 93.8%; Pred. No. 5e+02; Indels 0; Gaps 0;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 306 GCTGCTGGAGGAGAA 321

Db 17 GCTGCTGGAGGAGGA 2

RESULT 718

AAL55767/C

ID AAL55767 standard; DNA; 18 BP.

XX AC AAL55767;

XX DT 17-SEP-2003 (first entry)

XX DE Fluorogenic probe used to isolate human Her2 RNA.

XX

KW Biological array; frozen; breast cancer; Her2; ErbB2; VEGF; human;

KW microarray; ss; vascular endothelial growth factor; probe.

XX OS Homo sapiens.

XX OS Synthetic.

XX PH Key Location/Qualifiers

FT modified_base 1

FT /*tag= a

FT /mod_base= FAM tag

FT /note= "FAM = 6-carboxyfluorescein"

FT modified_base 18

FT /*tag= b

FT /mod_base= TAMRA tag

FT /note= "TAMRA = 6-carboxytetramethylrhodamine"

XX PN W02003044213-A2.

XX PD 30-MAY-2003.

XX PD 20-NOV-2002; 2002WO-US037054.

XX PF 20-NOV-2001; 2001US-0332293P.

XX PR 21-NOV-2001; 2001US-0332635P.

XX PR 07-FEB-2002; 2002US-0355205P.

XX PR 22-FEB-2002; 2002US-0359563P.

XX PR 17-JUN-2002; 2002US-0389610P.

XX PR 02-JUL-2002; 2002US-0393551P.

XX PA (GETH) GENENTECH INC.

XX PI Frantz G, Landon T, Peale FV, Pham TQ, Stephan JF, Dunlap DY;

PI Hillan KJ;

XX WPI; 2003-513598/48.

XX DR Biological array for analyzing biological molecules, has frozen matrix

XX PT formed from a temperature-sensitive material with several wells in it,

PT and biological samples and internal standard preparations contained in

PT the wells.

XX Example 4; Page 45; 111pp; English.

XX PS The invention relates to a novel biological array or microarray

XX CC comprising a frozen matrix formed of a temperature-sensitive material

CC which has a number of wells disposed in it. One or more biological

CC samples may be disposed within the wells and retained by the frozen

CC matrix surrounding the wells. Optionally, one or more internal standard

CC preparations may be contained within one or more of the wells. The

CC biological array of the invention may be useful for the detection of a

CC biological molecule i.e. a polynucleotide or a polypeptide, such as a

CC soluble receptor or extracellular domain (ECD) of a receptor. Such

CC molecules may be detected within a variety of biological samples

CC including normal, diseased or treated cells or tissues of blood, muscle

CC or breast. The biological array may be useful during detection of disease

CC within a biological sample, for example, breast cancer may be detected

CC via the identification of Her2 (ErbB2) or VEGF (vascular endothelial

CC growth factor) overexpression within a sample. Furthermore, the method of

CC array construction disclosed herein eliminates the need for a barrier

CC material between an array matrix and a biological sample and also the

CC need to chemically process a sample before use. This allows the integrity

CC of array samples to be maintained and makes the process of constructing a

CC biological array more cost effective and less time consuming. The current

CC sequence is that of the fluorogenic probe of the invention which was used

CC to isolate the human Her2 RNA

XX SQ Sequence 18 BP; 1 A; 7 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 1.9%; Score 14.4; DB 1; Length 18;

Best Local Similarity 93.8%; Pred. No. 5e+02; Indels 0; Gaps 0;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 207 CGGCAGCAGATCAGGA 222

```

Db      16 CGGAGCAGATCCGA 1
|||||
RESULT 719
ADD94303/C
ID      ADD94303 standard; DNA; 18 BP.
XX      AC
XX      ADD94303;
XX      DT
XX      29-JAN-2004 (first entry)
XX      DE
XX      Mouse HUI77/HUIV26 antibody related PCR primer SeqID188.
XX      KW
XX      grafted antibody; complementarity determining region; CDR; light CDR;
XX      heavy CDR; cryptic collagen epitope; solid tumour;
XX      new blood vessel growth; angiogenesis; tumour growth; cytostatic;
XX      collagen agonist; collagen antagonist; cancer metastasis;
XX      anti-cryptic collagen; HUI77; HUIV26; mouse; murine; PCR; primer; ss;
XX      heavy chain.
XX      OS
XX      Mus musculus.
XX      PN
XX      WO2003046204-A2.
XX      PD
XX      05-JUN-2003.
XX      PF
XX      26-NOV-2002; 2002WO-US038147.
XX      PR
XX      26-NOV-2001; 2001US-00995529.
XX      PR
XX      06-DEC-2001; 2001US-00011250.
XX      PA
XX      (CELL-) CELL MATRIX INC.
XX      PI
XX      Watking JD, Huse WD, Tang Y, Broek D, Brooks PC;
XX      WPI; 2003-513649/48.
XX      PT
XX      New cryptic collagen antibody with one or more complementarity
XX      determining regions, useful for diagnosing and treating disorders
XX      PT
XX      associated with angiogenesis, tumor growth and/or cancer metastasis.
XX      PS
XX      Example 1; SEQ ID NO 188; 232pp; English.
XX      CC
XX      This invention relates to a novel grafted antibody or its functional
XX      fragment comprising one or more complementarity determining regions
XX      (CDRs) of a defined light CDR and a heavy CDR with at least one amino
XX      acid (aa) substitution where the antibody has specific binding activity
XX      for a cryptic collagen epitope. The growth of all solid tumours requires
XX      new blood vessel growth, angiogenesis, inhibition of which is an approach
XX      CC
XX      to limiting tumour growth. The invention may allow development of
XX      therapeutics with a cytostatic activity as a collagen agonist or
XX      CC
XX      antagonist. The invention is useful for diagnosing and treating disorders
XX      CC
XX      associated with angiogenesis, tumour growth and/or cancer metastasis. The
XX      CC
XX      present sequence is that of a mutagenic PCR primer for amplification of
XX      CC
XX      the sequence encoding the light chain of mouse HUI77 or HUIV26 antibodies
XX      CC
XX      and used in the exemplification of the invention.
XX      SQ
XX      Sequence 18 BP; 2 A; 3 C; 6 G; 7 T; 0 U; 0 Other;
XX      Query Match 1.9%; Score 14.4; DB 1; Length 18;
XX      Best Local Similarity 93.8%; Pred. No. 5e+02;
XX      Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX      QY      347 CAGAGCAACAGATTC 362
XX      DB      17 CAGAGCAACAGATTC 2
XX      |||||
RESULT 720
AAT02688/C
ID      AAT02688 standard; RNA; 19 BP.
XX      XX
XX      AC
XX      AAT02688;
XX      DT
XX      06-JUN-1996 (first entry)
XX      DE
XX      Human papilloma virus (HPV)-11 E2 mRNA antisense oligo 2625-1.
XX      KW
XX      Antisense; human papilloma virus; HPV-11; treatment; diagnosis; E2 mRNA;
XX      translation initiation codon; ss.
XX      OS
XX      Synthetic.
XX      FH
XX      Key misc_feature 12..14
XX      Location/Qualifiers
XX      FT
XX      /*tag= a
XX      /note= "codon complementary to HPV E2 translation
XX      initiation codon"
XX      PN
XX      WO9528942-A1.
XX      PD
XX      02-NOV-1995.
XX      PF
XX      25-APR-1995; 95WO-US005179.
XX      PR
XX      26-APR-1994; 94US-00233778.
XX      PR
XX      04-MAY-1994; 94US-00238177.
XX      PR
XX      16-NOV-1994; 94WO-US013387.
XX      PR
XX      05-DEC-1994; 94US-00350431.
XX      PA
XX      (GENT-) GENTA INC.
XX      PI
XX      Giachetti C, Marich JE, Jaeger JA;
XX      WPI; 1995-382836/49.
XX      DR
XX      PT
XX      New anti-sense oligomers for inhibiting human papilloma:virus - having
XX      sequence complementary to target region of mRNA or pre-mRNA coding for
XX      E1, E2, E6 or E7.
XX      PS
XX      Example S; Page 93; 130pp; English.
XX      CC
XX      The present oligonucleotide is an antisense oligomer complementary to the
XX      area near the human papilloma virus (HPV)-11 E2 mRNA translation
XX      CC
XX      initiation codon (N2705-N2749), designed to interfere with, and/or
XX      prevent the expression of a HPV E2 mRNA. The CAR inhibition of this
XX      CC
XX      oligomer is 0%, and therefore it is not effective in the treatment and/or
XX      diagnosis of HPV infections
XX      SQ
XX      Sequence 19 BP; 1 A; 9 C; 2 G; 0 T; 7 U; 0 Other;
XX      Query Match 1.9%; Score 14.4; DB 1; Length 19;
XX      Best Local Similarity 93.8%; Pred. No. 5.3e+02;
XX      Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX      QY      494 AGGCAGAGGAGCAGG 509
XX      DB      16 AGGTAGAGGAGCAGG 1
XX      |||||
RESULT 721
AAT02696/C
ID      AAT02696 standard; DNA; 19 BP.
XX      XX
XX      AC
XX      AAT02696;
XX      DT
XX      06-JUN-1996 (first entry)
XX      DE
XX      Human papilloma virus (HPV)-11 E2 mRNA antisense oligo 2625-1.
XX      KW
XX      Antisense; human papilloma virus; HPV-11; treatment; diagnosis; E2 mRNA;
XX      translation initiation codon; ss.
XX      OS
XX      Synthetic.
XX      XX

```

```

FH Key          Location/Qualifiers
FT misc_feature 12..14
FT /*tag= a
FT /note= "Codon complementary to HPV E2 translation
FT initiation codon"
XX WO9528942-A1.
XX
XX PD 02-NOV-1995.
XX
XX PF 25-APR-1995; 95WO-US005179.
XX
XX PR 26-APR-1994; 94US-00233778.
XX PR 04-MAY-1994; 94US-00238177.
XX PR 16-NOV-1994; 94WO-US013387.
XX PR 03-DEC-1994; 94US-00350431.
XX
XX PA (GENT-) GENTA INC.
XX
XX PI Giachetti C, Marich JE, Jaeger JA;
XX
XX DR WPI; 1995-382836/49.
XX
XX PT New anti-sense oligomers for inhibiting human papilloma:virus - having
XX sequence complementary to target region of mRNA or pre-mRNA coding for
XX E1, E2, E6 or E7.
XX
XX PS Example S; Page 94; 130pp; English.
XX
XX CC The present oligonucleotide is an antisense oligomer complementary to the
XX area near the human papilloma virus (HPV)-11 E2 mRNA translation
XX CC initiation codon (N2705-N2749), designed to interfere with, and/or
XX CC prevent the expression of a HPV E2 mRNA. The CAT inhibition of this
XX CC oligomer is 0%, and therefore it is not effective in the treatment and/or
XX CC diagnosis of HPV infections
XX
XX SQ Sequence 19 BP; 1 A; 9 C; 2 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 1.9%; Score 14.4; DB 1; Length 19;
XX Best Local Similarity 93.8%; Pred. No. 5.3e+02;
XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 494 AGCGAGAAGGAGCAGG 509
DB 16 AGGTAGAAGGAGCAGG 1

RESULT 722
AAX01486
ID AAX01486 standard; DNA; 19 BP.
XX
XX AC AAX01486;
XX
XX DT 28-APR-1999 (first entry)
XX
XX DE Primer STS sY240 right primer used to isolate DAZ gene.
XX
XX KW DAZ gene; interval 6D; Y chromosome; reduced sperm count; oligospermia;
XX azoospermia; gene therapy; fertility disorder; spermatogenesis;
XX PCR primer; sequence tagged site; STS; ss.
XX
XX OS Synthetic.
XX OS Homo sapiens.
XX
XX PN US5871920-A.
XX
XX PD 16-FEB-1999.
XX
XX PF 31-JUL-1996; 96US-00690734.
XX
XX PR 22-SEP-1994; 94US-00310429.
XX
XX PA (WHED ) WHITEHEAD INST BIOMEDICAL RES.

```

```

XX ReiJo R, Page DC;
XX
XX DR WPI; 1999-166623/14.
XX
XX PT DAZ genes associated with reduced sperm counts - useful for diagnosing
XX and treating azoospermia or oligospermia.
XX
XX PS Example; Col 9-10; 25pp; English.
XX
XX CC This sequence is a PCR primer for a sequence tagged site (STS) present on
XX the Y chromosome. This primer was used to isolate the DAZ gene of the
XX invention, which is part of the DAZ family of genes, and was isolated
XX from interval 6D and/or 6E of the distal portion of the long arm of the Y
XX chromosome. Alteration of the DAZ gene (A) is known to be associated with
XX reduced sperm counts. Hence, the invention may be used to diagnostically
XX identify males with a condition that results in a reduced sperm count
XX such as oligospermia or azoospermia (i.e. where sperm count= 0 to 20
XX million semen per ml), in whom the gene (A) has been altered. It may also
XX be used therapeutically in gene therapy treatments to remedy fertility
XX disorders associated with the alteration or deletion of (A).
XX Additionally, (A) may be useful in designing or identifying agents which
XX may function as a male contraceptive by inducing reduced sperm count. It
XX also has an application as a research tool, as the DNA has been localised
XX to interval 6E of the distal portion of the long arm of the human Y
XX chromosome, it can, therefore, function as a marker for that interval.
XX Little is known about the causes of reduced spermatogenesis, especially
XX among the 10% of men who visit fertility clinics and are diagnosed as
XX having oligospermia (or azoospermia) of unknown origin. Although various
XX diagnostic tests and treatments are currently available, improved methods
XX are still needed. The invention provides new diagnostic methods and
XX treatments for oligospermia resulting from alteration or deletion of (A)
XX
XX SQ Sequence 19 BP; 4 A; 5 C; 6 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 1.9%; Score 14.4; DB 1; Length 19;
XX Best Local Similarity 93.8%; Pred. No. 5.3e+02;
XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 526 GCACCTGAAGAGTGTC 541
DB 1 GCACCTGAAGAGTGTC 16

RESULT 723
AAX292545
ID AAX292545 standard; DNA; 19 BP.
XX
XX AC AAX292545;
XX
XX DT 05-JUN-2000 (first entry)
XX
XX DE Human Y-specific STS PCR primer, SEQ ID NO:61.
XX
XX KW DAZ gene; chromosome Y; male infertility; sperm count; diagnosis;
XX sequence-tagged site; STS; treatment; gene therapy; PCR primer; ss.
XX
XX OS Homo sapiens.
XX
XX PN US6020476-A.
XX
XX PD 01-FEB-2000.
XX
XX PF 30-OCT-1996; 96US-00742185.
XX
XX PR 22-SEP-1994; 94US-00310429.
XX PR 31-JUL-1996; 96US-00690734.
XX
XX PA (WHED ) WHITEHEAD INST BIOMEDICAL RES.
XX
XX PI Hawkins T, Reeve MP, Saxena R, Page DC, ReiJo R;
XX
XX DR WPI; 2000-181393/16.

```


XX New nucleic acid, useful for diagnosis and treatment of reduced sperm
PT count, is derived from the human DAZ or DAZH genes.
XX
XX Claim 12; Col 17-18; 110pp; English.
XX
XX The invention relates to a family of human genes referred to as the DAZ
CC gene family, and to a functional DAZ homologue, DAZH. Members of the DAZ
CC gene family are clustered in the same region of the Y chromosome. In
CC particular, the invention relates to an isolated DAZ gene (AAZ92499),
CC present in interval 6D and/or 6E of the distal portion of Yq, mutations
CC in which are associated with reduced sperm count. The DAZH gene
CC (AAZ92580) is located on chromosome 3; however, the entire DAZ gene
CC family, including DAZH is expressed in germ cells. DAZ and DAZH
CC nucleotide sequences may be used as a source of primers and probes for
CC the diagnosis of cases of reduced sperm count associated with alteration
CC or deletion of the DAZ gene. They are also used as human chromosome Y
CC markers. Functional DAZ genes can be used in gene therapy for treating
CC reduced sperm counts. Sequences AAZ92502-292573 represent PCR primers
CC used in the exemplifications of the invention to test for Y-specific STSS
CC (sequence tagged sites)
XX
XX Sequence 19 BP; 4 A; 5 C; 6 G; 4 T; 0 U; 0 Other;
SQ
Query Match 1.9%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 5.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 526 GCACCTGAAGAGTGC 541
DB 1 GCACCTGAAGAGTGC 16
RESULT 724
AAT35047
ID AAT35047 standard; DNA; 15 BP.
XX
XX AAT35047;
XX
XX 18-FEB-1997 (first entry)
XX
XX HPV ORF-Ec target for triplex-forming oligo.
DE
XX HBV; oligodeoxyribonucleotide; homopurine-homopyrimidine target; block;
KW in vitro; DNA synthesis; DNA polymerase; Sequenase3; Taq; Vent; Pol I;
KW accessory replication protein; SSB protein; sequence-specific;
KW triplex-forming oligonucleotide; exon 3; inverted repeat; IR110;
KW hepatitis B virus; P gene; ss.
XX
XX Synthetic.
XX
XX WO9618732-A2.
XX
XX 20-JUN-1996.
XX
XX 14-DEC-1995; 95WO-US016368.
XX
XX 15-DEC-1994; 94US-00358089.
XX
XX (UNII) UNIV ILLINOIS FOUND.
XX
XX Mirkin SM, Samadashwily GM;
XX WPI; 1996-300649/30.
XX
XX Sequence specific inhibition of DNA synthesis - by triplex-forming
PT oligonucleotide(s), for detection of oncogene mutation(s) and treatment
PT of e.g. HSV, Hepatitis C and Papillomavirus infection.
XX
XX Example 4; Page 42; 78pp; English.
XX
XX Specifically designed oligodeoxyribonucleotides form triplexes in single-
CC or double-strand DNA at homopurine-homopyrimidine targets. These

CC triplexes block in vitro DNA synthesis by all DNA polymerases studied,
CC including Sequenase3, Taq, Vent, and Pol I. A similar phenomenon occurs
CC when DNA polymerases are supplemented with accessory replication
CC proteins, including SSB protein. Replication blockage is highly sequence-
CC specific and even one or two point substitutions within either the target
CC sequence or the oligonucleotide abolish the effect. Sequence-specific
CC blocking of DNA replication in vivo is facilitated by the methods and
CC compositions of the present invention. The present sequence is the ORF-Ec
CC human papilloma virus (HPV) target (position 436-452 in HPV57 and 438-452
CC in HPV2) for triplex-forming oligonucleotides AAT35030-31
XX
XX Sequence 15 BP; 5 A; 0 C; 10 G; 0 T; 0 U; 0 Other;
SQ
Query Match 1.9%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 408 GCGAGGAGGAGGAG 421
DB 1 GCGAGGAGGAGGAG 14
RESULT 725
ABN08981/c
ID ABN08981 standard; DNA; 17 BP.
XX
XX AC ABN08981;
XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8973.
XX
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 05-FEB-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon MB;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX Disclosure; SEQ ID NO 8973; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like

CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-1
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 XX Sequence 17 BP; 4 A; 2 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 1.9%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 5.2e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 851 CACCAGCTCTTCCA 864

DB 14 CACCAGCTCTTCCA 1

RESULT 726

ABN07251
 ID ABN07251 standard; DNA; 17 BP.
 XX
 AC ABN07251;

XX
 XX 29-MAY-2002 (first entry)
 DT
 XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7243.

DE Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 XX Homo sapiens.

OS
 XX WO200192524-A2.

XX
 XX 06-DEC-2001.

XX
 XX 25-MAY-2001; 2001WO-US016981.
 XX

XX 26-MAY-2000; 2000US-0207456P.
 PR

PR 21-SEP-2000; 2000US-0234687P.
 PR

PR 27-SEP-2000; 2000US-0236359P.
 PR

PR 04-OCT-2000; 2000GB-00024263.
 PR

PR 30-JAN-2001; 2001WO-US000661.
 PR

PR 30-JAN-2001; 2001WO-US000662.
 PR

PR 30-JAN-2001; 2001WO-US000663.
 PR

PR 30-JAN-2001; 2001WO-US000664.
 PR

PR 30-JAN-2001; 2001WO-US000665.
 PR

PR 30-JAN-2001; 2001WO-US000666.
 PR

PR 30-JAN-2001; 2001WO-US000667.
 PR

PR 30-JAN-2001; 2001WO-US000668.
 PR

PR 30-JAN-2001; 2001WO-US000669.
 PR

PR 05-FEB-2001; 2001US-0266860P.
 PR

XX (AEOM-) AEOMICA INC.

XX

PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption/ionization, comprises human myosin-like protein hGDMPLP-1.
 XX
 XX Disclosure; SEQ ID NO 7243; 214pp; English.

XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX

XX Sequence 17 BP; 3 A; 2 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 1.9%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 5.2e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 697 GCTGGAGAGTGAGC 710

DB 4 GCTGGAGAGTGAGC 17

RESULT 727

ABN08980/c
 ID ABN08980 standard; DNA; 17 BP.
 XX
 AC ABN08980;

XX
 XX 29-MAY-2002 (first entry)
 DT
 XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8972.

XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 XX Homo sapiens.

XX WO200192524-A2.
 PN

XX 06-DEC-2001.
 PD

XX 25-MAY-2001; 2001WO-US016981.
 PF

XX 26-MAY-2000; 2000US-0207456P.
 PR

PR 21-SEP-2000; 2000US-0234687P.
 PR

PR 27-SEP-2000; 2000US-0236359P.
 PR

PR 04-OCT-2000; 2000GB-00024263.
 PR

PR 30-JAN-2001; 2001WO-US000661.
 PR

PR 30-JAN-2001; 2001WO-US000662.
 PR

PR 30-JAN-2001; 2001WO-US000663.
 PR


```

PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
PA (GUY/) GU Y.
PA (JIY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
XX associated with decreased expression or activity of human genome-derived
XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle
XX function.
XX
XX Disclosure; SEQ ID NO 7243; Opp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
XX (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
XX defined in the specification, a fragment of at least 8 amino acids of
XX (S1), 95% deviation from (S1) which are conservative substitutions, and
XX 65% identity to (S1). A polypeptide of the invention acts as an agonist or
XX antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
XX pharmaceutical composition of the invention is useful for treating or
XX preventing a disorder associated with decreased expression or activity of
XX hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
XX The present sequence represents a 17-mer nucleotide, used in the
XX invention for scanning the sequence represented in ACN63103
XX
XX Sequence 17 BP; 3 A; 2 C; 9 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 1.9%; Score 14; DB 1; Length 17;
XX Best Local Similarity 100.0%; Pred. No. 5.2e+02;
XX Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 697 GCTGGAGAGTGAGC 710
XX DB 4 GCTGGAGAGTGAGC 17
XX
XX RESULT 730
XX ACN72070/C
XX ID ACN72070 standard; DNA; 17 BP.
XX AC ACN72070;
XX
XX 02-DEC-2004 (first entry)
XX
XX Human GDMPLP-1 probe SEQ ID NO:8972.
XX
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
XX hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
XX skeletal muscle function.
XX
XX Homo sapiens.
XX
XX US2004137589-A1.
XX
XX 15-JUL-2004.
XX
XX 26-NOV-2003; 2003US-00723361.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
XX (GUY/) GU Y.
XX (JIY/) JI Y.
XX (PENN/) PENN S G.
XX (HANZ/) HANZEL D K.
XX (RANK/) RANK D.
XX (CHEN/) CHEN W.
XX (SHAN/) SHANNON M E.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
XX associated with decreased expression or activity of human genome-derived
XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle
XX function.
XX
XX Disclosure; SEQ ID NO 8972; Opp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
XX (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
XX defined in the specification, a fragment of at least 8 amino acids of
XX (S1), 95% deviation from (S1) which are conservative substitutions, and
XX 65% identity to (S1). A polypeptide of the invention acts as an agonist or
XX antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
XX pharmaceutical composition of the invention is useful for treating or
XX preventing a disorder associated with decreased expression or activity of
XX hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
XX The present sequence represents a 17-mer nucleotide, used in the
XX invention for scanning the sequence represented in ACN63103
XX
XX Sequence 17 BP; 5 A; 2 C; 7 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 1.9%; Score 14; DB 1; Length 17;
XX Best Local Similarity 100.0%; Pred. No. 5.2e+02;
XX Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 851 CACCAGCTCTTCCA 864
XX DB 15 CACCAGCTCTTCCA 2
XX
XX RESULT 731
XX ACN72071/C
XX ID ACN72071 standard; DNA; 17 BP.
XX AC ACN72071;
XX
XX 02-DEC-2004 (first entry)
XX
XX Human GDMPLP-1 probe SEQ ID NO:8973.
XX
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
XX hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
XX skeletal muscle function.
XX
XX Homo sapiens.
XX
XX US2004137589-A1.
XX
XX 15-JUL-2004.
XX
XX

```

```

PF 26-NOV-2003; 2003US-00723361.
XX
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
PA (GUY/) GU Y.
PA (JIY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-53378/51.
DR
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
PS Disclosure; SEQ ID NO 8973; Opp; English.
XX
CC The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGMLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGMLP-1, or as an inhibitor of hGMLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
XX Sequence 17 BP; 4 A; 2 C; 8 G; 3 T; 0 U; 0 Other;
Query Match 1.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. NO. 5.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 851 CACCAGCTCTTCCA 864
DB 14 CACCAGCTCTTCCA 1
RESULT 732
AAA48792/c
ID AAA48792 standard; DNA; 18 BP.
XX
AC AAA48792;
XX
DT 08-SEP-2000 (first entry)
XX
DE Human G-alpha-16 antisense oligonucleotide ISIS# 20849.
XX
XX Human; G-alpha-16; G protein; cytostatic; hyperproliferative disorder;
KW cancer; inflammation; infection; antisense inhibition; ss.
KW

```

```

XX OS Homo sapiens.
XX WO2000032817-A1.
PN
XX 08-JUN-2000.
PD
XX
XX 25-AUG-1999; 99WO-US019613.
PF
XX 03-DEC-1998; 98US-00205143.
PR
XX (ISIS-) ISIS PHARM INC.
PA
XX Cowseert LM;
PI
XX WPI; 2000-412354/35.
DR
XX
XX A new antisense compound for inhibiting the expression of human G-alpha-
PT 16 and treating, preventing or delaying infections, inflammation or
PT hyperproliferative disorders such as cancer.
XX
XX Example 15; Page 73; 100pp; English.
XX
CC The present sequence is an antisense oligonucleotide used to modulate
CC expression of G-alpha-16. G-alpha-16 is a human G protein which interacts
CC differentially with several receptor types including members of the
CC opiod and chemokine receptor families. A series of antisense
CC oligonucleotides have been designed to target different regions of the
CC human G-alpha-16 RNA. They may be used to inhibit the expression of G-
CC alpha-16 in human cells and tissues and thus to treat diseases associated
CC with G-alpha-16, such as hyperproliferative disorders, especially cancer.
CC Infections, inflammation or tumour formation can be prevented or delayed.
CC The compounds can be used in research and diagnostics in sandwich and
CC other assays. Note: The sequence has a phosphorothioate backbone and may
CC be either an oligodeoxynucleotide or a chimeric oligonucleotide
CC containing 2'-methoxyethyl (2'-MOE) wings and a deoxy gap. The ISIS
CC number given above corresponds to the oligodeoxynucleotide sequence
XX
XX Sequence 18 BP; 2 A; 7 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 1.9%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 5.6e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 308 TGCCTGGAGGAGAA 321
DB 14 TGCCTGGAGGAGAA 1
RESULT 733
AAT81047/c
ID AAT81047 standard; RNA; 17 BP.
XX
AC AAT81047;
XX
DT 26-SEP-1997 (first entry)
XX
DE Human c-myc hammerhead ribozyme target sequence (nt. position 31).
XX
KW Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
KW smooth muscle cell; hyperproliferation; restenosis; cancer; c-myc;
KW coronary angioplasty; ss.
XX
OS Homo sapiens.
XX
PN WO9531541-A2.
XX
PD 23-NOV-1995.
XX
PF 18-MAY-1995; 95WO-US006368.
XX
XX 18-MAY-1994; 94US-00245466.
PR 13-JAN-1995; 95US-00373124.
PR

```

XX (RIBO-) RIBOZYME PHARM INC.
 XX Stinchcomb DT, Draper K, Mcswiggen J, Jarvis T;
 PI WPI; 1996-010927/01.
 XX New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myb,
 PT for treating restenosis or cancer.
 XX Claim 1; Page 64; 128pp; English.
 XX The present sequence represents the preferred target sequence for an
 CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
 CC the human c-myb sequence at the base position indicated in the descriptor
 CC line. The c-myb sequence was screened for optimal ribozyme target sites
 CC using a computer folding algorithm, and regions of the mRNA which did not
 CC form secondary folding structures and contained potential ribozyme
 CC cleavage sites were identified. Ribozymes were synthesised and their
 CC activities optimised by either varying the length of the binding arms or
 CC by modification to prevent degradation by nucleases. The ribozymes cleave
 CC the c-myb sequence and can be used to prevent smooth muscle cell
 CC hyperproliferation in restenosis, especially after coronary angioplasty,
 CC and in cancers
 XX
 SQ Sequence 17 BP; 0 A; 10 C; 0 G; 0 T; 7 U; 0 Other;
 Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 405 AGAGGGGAGGAGGAGGAG 421
 DB 17 AGGAGGGGAGGAGGAG 1
 RESULT 734
 AAX73242/c
 ID AAX73242 standard; RNA; 17 BP.
 XX
 AC AAX73242;
 XX
 DT 28-JUL-1999 (first entry)
 XX
 DE Mouse flk-1 VEGF receptor hammerhead ribozyme substrate #675.
 XX
 KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
 KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
 KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KW foetal liver kinase 1; ss.
 XX
 OS Mus sp.
 XX
 PN WO9715662-A2.
 XX
 PD 01-MAY-1997.
 XX
 PF 25-OCT-1996; 96WO-US017480.
 XX
 PR 26-OCT-1995; 95US-0005974P.
 PR 11-JAN-1996; 96US-00584040.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (CHIR) CHIRON CORP.
 XX
 PI Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
 XX WPI; 1997-259017/23.
 DR
 XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
 PT stability- useful for treating e.g. tumour angiogenesis, psoriasis,
 PT rheumatoid arthritis, etc., in a human patient.

XX Claim 4; Page 144; 218pp; English.
 XX
 CC The present invention describes nucleic acid molecules which modulate the
 CC synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient
 CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
 CC treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX67275 to AAX75752 represent specific examples
 CC of nucleic acid molecules from the present invention
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 5 G; 0 T; 4 U; 0 Other;
 Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 457 GGTGGAGAGACTCGGCC 473
 DB 17 GGTAGACAGACTCGGCC 1
 RESULT 735
 AAF01997
 ID AAF01997 standard; DNA; 17 BP.
 XX
 AC AAF01997;
 XX
 DT 16-FEB-2001 (first entry)
 XX
 DE Hammerhead ribozyme substrate #292.
 XX
 KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;
 KW interferon alpha; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200061729-A2.
 XX
 PD 19-OCT-2000.
 XX
 PF 11-APR-2000; 2000WO-US009721.
 XX
 PR 12-APR-1999; 99US-0129390P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Zwick M, Pavco P, Mcswiggen J;
 XX WPI; 2000-647423/62.
 DR
 XX Enzymatic and antisense nucleic acid inhibition of repressor genes,
 PT useful for producing e.g. granulocyte colony stimulating factor protein,
 PT interferon alpha and erythropoietin.
 XX
 PF Claim 37; Page 62; 164pp; English.
 XX
 CC The present invention relates to enzymatic and antisense nucleic acid
 CC molecules that act as inhibitors of the expression of repressor genes
 CC encoding the TR2 Orphan receptor, EAP3/COUP-TF-1, the GATA transcription
 CC factor gene, IRP-2 and/or the CAAT Displacement Protein (CDP).
 CC Inhibition of the repressors removes prevents inhibition (and
 CC consequently increases expression of) genes involved in the production of
 CC erythropoietin, granulocyte colony stimulating factor protein and
 CC interferon alpha
 XX
 SQ Sequence 17 BP; 3 A; 3 C; 8 G; 3 T; 0 U; 0 Other;
 Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.5e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 367 GGAGCGCTCGAGGAGC 383
 ||||| ||||| ||||| ||||| |||||

Db 1 GGAGTCTTCGAGGAGC 17

RESULT 736
 AAF01998
 ID AAF01998 standard; DNA; 17 BP.
 XX
 AC AAF01998;
 XX
 DT 16-FEB-2001 (first entry)
 XX
 DE Hammerhead ribozyme substrate #293.
 XX
 KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;
 KW interferon alpha; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200061729-A2.
 XX
 PD 19-OCT-2000.
 XX
 PF 11-APR-2000; 2000WO-US0009721.
 XX
 PR 12-APR-1999; 99US-0129390P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Zwick M, Pavco P, Mcswiggen J;
 XX
 DR WPI; 2000-647423/62.
 XX
 PT Enzymatic and antisense nucleic acid inhibition of repressor genes,
 PT useful for producing e.g. granulocyte colony stimulating factor protein,
 PT interferon alpha and erythropoietin.
 XX
 PS Claim 37; Page 62; 16app; English.
 XX
 CC The present invention relates to enzymatic and antisense nucleic acid
 CC molecules that act as inhibitors of the expression of repressor genes
 CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
 CC factor gene, IRF-2 and/or the C/EBP Displacement Protein (CDP).
 CC Inhibition of the repressors removes prevents inhibition (and
 CC consequently increases expression of) genes involved in the production of
 CC erythropoietin, granulocyte colony stimulating factor protein and
 CC interferon alpha
 XX
 SQ Sequence 17 BP; 3 A; 3 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 368 GAGCGCTCGAGGAGCT 384
 ||||| ||||| ||||| ||||| |||||

Db 1 GAGTCTTCGAGGAGCT 17

RESULT 737
 ABA80609
 ID ABA80609 standard; DNA; 17 BP.
 XX
 AC ABA80609;
 XX
 DT 24-JAN-2002 (first entry)
 XX
 DE APOE mutation correcting oligonucleotide SEQ ID NO: 3455.
 XX
 KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;

KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
 KW antilipemic; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200173002-A2.
 XX
 PD 04-OCT-2001.
 XX
 PF 27-MAR-2001; 2001WO-US009761.
 XX
 PR 27-MAR-2000; 2000US-0192176P.
 PR 27-MAR-2000; 2000US-0192179P.
 PR 01-JUN-2000; 2000US-0208538P.
 PR 30-OCT-2000; 2000US-0244989P.
 XX
 PA (UYDE) UNIV DELAWARE.
 XX
 PI Kmiec EB, Gamper HB, Rice MC;
 XX
 DR WPI; 2001-639230/73.
 XX
 PT Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.
 XX
 PS Claim 7; Page 233; 294pp; English.
 XX
 CC The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase; p53; beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 374 TCGAGGAGCTTCTGCA 390
 ||||| ||||| ||||| ||||| |||||

Db 1 TCGCAGCGCTTCTGCA 17

RESULT 738
 ABA80608/c
 ID ABA80608 standard; DNA; 17 BP.
 XX
 AC ABA80608;
 XX
 DT 24-JAN-2002 (first entry)
 XX
 DE APOE mutation correcting oligonucleotide SEQ ID NO: 3454.
 XX

RESULT 740
ABN07706/C
ID ABN07706 standard; DNA; 17 BP.
XX AC ABN07706;
XX AC ABN07706;
XX 29-MAY-2002 (first entry)
XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7698.
XX KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX OS Homo sapiens.
XX XX WO200192524-A2.
XX PN 06-DEC-2001.
XX PD 06-DEC-2001.
XX PF 25-MAY-2001; 2001WO-US016981.
XX XX 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PR 30-JAN-2001; 2001WO-US000661.
XX PR 30-JAN-2001; 2001WO-US000662.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000666.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 30-JAN-2001; 2001WO-US000670.
XX PR 05-FEB-2001; 2001US-0266860P.
XX XX (AEOM-) AEOMICA INC.
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX DR New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX PT or as specific biomolecule capture probes for surface-enhanced laser
XX PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX PS Disclosure; SEQ ID NO 7698; 214pp; English.
XX CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO

CC at ftp.wipo.int/pub/published_pct_sequence
XX XX
SQ Sequence 17 BP; 3 A; 7 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 827 CTGGCCCGAGTTCAGGT 843
DB 17 CTGGCCCGAGTTCAGGT 1
RESULT 741
ABN07821
ID ABN07821 standard; DNA; 17 BP.
XX AC ABN07821;
XX AC ABN07821;
XX DT 29-MAY-2002 (first entry)
XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7813.
XX KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX OS Homo sapiens.
XX XX WO200192524-A2.
XX PN 06-DEC-2001.
XX PD 06-DEC-2001.
XX PF 25-MAY-2001; 2001WO-US016981.
XX XX 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PR 30-JAN-2001; 2001WO-US000661.
XX PR 30-JAN-2001; 2001WO-US000662.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000666.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 30-JAN-2001; 2001WO-US000670.
XX PR 05-FEB-2001; 2001US-0266860P.
XX XX (AEOM-) AEOMICA INC.
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX DR New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX PT or as specific biomolecule capture probes for surface-enhanced laser
XX PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX PS Disclosure; SEQ ID NO 7813; 214pp; English.
XX CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration

CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX Sequence 17 BP; 8 A; 2 C; 7 G; 0 T; 0 U; 0 Other;
 SQ
 Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 493 GAGCGAGAGGAGCAGG 509
 Db 1 GAAGCAAAAGGAGCAGG 17
 RESULT 742
 ABN06831/C
 ID ABN06831 standard; DNA; 17 BP.
 XX AC ABN06831;
 XX 29-MAY-2002 (first entry)
 DT Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6823.
 DE Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX Homo sapiens.
 OS WO200192524-A2.
 XX 06-DEC-2001.
 XX 25-MAY-2001; 2001WO-US016981.
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001US-0266860P.
 XX (AEOM-) AEOMICA INC.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption/ionization, comprises human myosin-like protein hGDMPLP-1.
 XX Disclosure; SEQ ID NO 6823; 214pp; English.

XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP-
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX Sequence 17 BP; 3 A; 3 C; 5 G; 6 T; 0 U; 0 Other;
 SQ
 Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 266 CACCTGCCTTCAGACA 282
 Db 17 CACCTGCCTTCAGAAAA 1
 RESULT 743
 ABN08429
 ID ABN08429 standard; DNA; 17 BP.
 XX AC ABN08429;
 XX 29-MAY-2002 (first entry)
 DT Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8421.
 DE Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX Homo sapiens.
 OS WO200192524-A2.
 XX 06-DEC-2001.
 XX 25-MAY-2001; 2001WO-US016981.
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001US-0266860P.
 XX

(AEOM-) AEOMICA INC.
Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
WPI; 2002-179446/23.
New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
or as specific biomolecule capture probes for surface-enhanced laser
desorption ionization, comprises human myosin-like protein hGDMPLP-1.
Disclosure; SEQ ID NO 8421; 214pp; English.
The present invention describes a human genome-derived myosin-like
protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
1 can be used in gene therapy and vaccine production. The hGDMPLP-1
nucleic acids can be used as probes to detect, characterise and quantify
hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
provide initial substrates for the recombinant engineering of hGDMPLP-1
protein variants having desired phenotypic improvements, and for
expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
used as immunogens to raise antibodies that specifically recognise hGDMPLP
-1 proteins, as standards in assays used to determine the concentration
and/or amount specifically of hGDMPLP proteins, as specific biomolecule
capture probes for surface-enhanced laser desorption ionisation, as
therapeutic supplement in patients having specific deficiency in hGDMPLP-1
production, and in vaccines or for replacement therapy. The
polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
disorder associated with the expression of hGDMPLP-1, in particular heart
and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
The present sequence represents an oligomer used in the screening of the
hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
The sequence data for this patent did not form part of the printed
specification, but was obtained in electronic format directly from WIPO
at ftp.wipo.int/pub/published_pct_sequence
Sequence 17 BP; 6 A; 2 C; 7 G; 2 T; 0 U; 0 Other;
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 489 TGAAGAGCGAGAGAGAG 505
DB 1 TGAAGAGCGAGAGAGGTG 17
RESULT 744
ABV89590
ID ABV89590 standard; DNA; 17 BP.
AC ABV89590;
XX
XX 23-DEC-2002 (first entry)
XX Human POSHL1 scanning oligonucleotide SEQ ID NO 303.
XX Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
XX Rho GTPase; signal transduction; gene expression; cancer; vaccine;
XX Gene therapy; transgenic; ss.
XX Homo sapiens.
XX EP1239051-A2.
XX
XX 11-SEP-2002.
XX
XX 28-JAN-2002; 2002EP-00001165.
XX
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
30-JAN-2001; 2001WO-US000668.
30-JAN-2001; 2001WO-US000669.
30-JAN-2001; 2001WO-US000670.
23-MAY-2001; 2001US-00864761.
PR 10-OCT-2001; 2001US-0328205P.
XX
XX (AEOM-) AEOMICA INC.
XX Shannon M;
XX
XX WPI; 2002-684061/74.
XX
XX Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
-1, useful for treating disorders associated with decreased expression or
activity of human POSHL1.
XX
XX Example 2; SEQ ID NO 303; 60pp + Sequence Listing; English.
XX
XX The invention relates to an isolated SH3 domain (POSH)-like signalling
protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
acids (S1, AB883999), a sequence having 65% sequence identity to (S1),
CC (S1) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (II) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC caused by altered expression of human POSHL1 including diagnosing and
CC treating cancer, they useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention. Note: The present sequence did not form part of the
CC printed specification, but is based on sequence information supplied to
CC Derwent by the European Patent Office
XX
XX Sequence 17 BP; 4 A; 3 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 471 GCCTGAGAGAGCTCGAT 487
DB 1 GCCTGAGAGAGCTCGAT 17
RESULT 745
ABL31574
ID ABL31574 standard; DNA; 17 BP.
XX
XX ABL31574;
XX
XX 21-MAR-2002 (first entry)
XX
XX Human HLA genotyping oligonucleotide SEQ ID NO 1063.
DE Human; human leukocyte antigen; HLA; genotype; polymorphism;
XX immunogenetic; transplantation; genetic disease; ss.
XX Homo sapiens.
XX WO200192572-A1.
XX
XX 06-DEC-2001.
PD
XX 01-JUN-2001; 2001WO-JP004662.
XX
XX 01-JUN-2000; 2000JP-00164798.
XX
XX (N1SN) NISSHINBO IND INC.
PA

PA (SYST-) SYSTEM RES INC.
 XX Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
 XX WPI; 2002-122074/16.
 XX Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes of
 PT individuals e.g. by determining immunogenetic differences when
 PT transplanting between them.
 XX Claim 10; Page 294; 345pp; Japanese.
 XX The invention relates to a typing kit for judging human leukocyte antigen
 CC (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
 CC oligonucleotides (ABL30512-ABL31809) originating in the sequences of
 CC genes e.g. belonging to HLA class I antigens on human genome and
 CC containing gene polymorphisms as alloantigens have been immobilised as
 CC primers for amplification of cleaved nucleic acids relating to gene
 CC polymorphisms. The method is useful for judging HLA genotypes of
 CC individuals by determining immunogenetic differences before transplanting
 CC organ and tissue, providing genetic information to decide compatibility of
 CC pancreas, Langerhans islet in pancreas and cornea, susceptibility
 CC diagnosis of genetic diseases and identifying individuals
 XX
 SQ Sequence 17 BP; 1 A; 4 C; 10 G; 2 T; 0 U; 0 Other;
 Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 760 GCAGGCCGAGCGGTGG 776
 DB 1 GCAGGCCGCGTGGTGG 17
 RESULT 746
 ABK56107
 ID ABK56107 standard; RNA; 17 BP.
 XX
 AC ABK56107;
 XX
 DT 02-JUL-2002 (first entry)
 XX
 DE Human CLCA1 gene enzymatic nucleic acid #478.
 XX
 KW Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
 KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
 KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
 KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
 KW acetylcysteine.
 XX
 OS Homo sapiens.
 XX
 PN WO200211674-A2.
 XX
 PD 14-FEB-2002.
 XX
 PF 09-AUG-2001; 2001WO-US024970.
 XX
 PR 09-AUG-2000; 2000US-0224383P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (SYNT) SYNTEX USA LLC.
 PA (THOM/) THOMPSON J.
 XX
 PI Thompson J, Mcswiggen J, McKenzie T, Ayers D, Szymkowski DE;
 PI Grube A;
 XX
 DR WPI; 2002-217145/27.
 XX
 PT Enzymatic polynucleotide that down regulates expression of chloride
 channel calcium activated gene, useful for treating Chronic obstructive

PT pulmonary disease (COPD), chronic bronchitis and asthma.
 XX Claim 4; Page 61; 152pp; English.
 XX The invention relates to enzymatic nucleic acid molecules that down
 CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
 CC by cleaving RNA derived from the genes. The nucleic acid sequences are
 CC useful as pharmaceutical agents for treating conditions such as chronic
 CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
 CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
 CC that are related to or will respond to the levels of CLCA1 in a cell or
 CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,
 CC hence, are useful for treatment of a patient having a condition
 CC associated with the level of CLCA1, where the invention further comprises
 CC the use of one or more therapies under conditions suitable for the
 CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
 CC anticholinergics, vaccinations, acetylcysteine and mucokinetic agents. The
 CC nucleic acids of the invention are also used as diagnostic tools to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of CLCA1 RNA in a cell. This sequence represents an
 CC enzymatic nucleic acid molecule of the invention
 XX
 SQ Sequence 17 BP; 6 A; 2 C; 5 G; 0 T; 4 U; 0 Other;
 Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 70.6%; Pred. No. 5.5e+02;
 Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
 QY 476 GAGAGCTCGATCTGNA 492
 DB 1 GAUAGGCGUCGUGAA 17
 RESULT 747
 ACN08336/C
 ID ACN08336 standard; RNA; 17 BP.
 XX
 AC ACN08336;
 XX
 DT 22-APR-2004 (first entry)
 XX
 DE WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 8339.
 XX
 KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
 KW Amberzyme; Zinzyme; ss.
 XX
 OS West Nile Virus.
 XX
 PN WO200268637-A2.
 XX
 PD 06-SEP-2002.
 XX
 PF 19-OCT-2001; 2001WO-US048350.
 XX
 PR 20-OCT-2000; 2000US-0242411P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J A.
 XX
 PI Blatt L, Mcswiggen JA;
 XX
 DR WPI; 2002-706994/76.
 XX
 PT New nucleic acid molecule that modulates replication of West Nile Virus
 PT (WNV), useful for treating a condition related to WNV infection e.g.
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
 XX
 PS Claim 23; SEQ ID NO 8339; 495pp; English.
 XX

CC The invention relates to nucleic acid molecules that modulate replication
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 CC treating a condition related to WNV infection e.g. pancreatitis,
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 CC molecule is selected from the group of ribozymes consisting of
 CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
 CC nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
 CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention

XX Sequence 17 BP; 1 A; 7 C; 4 G; 0 T; 5 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 5.5e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 804 CCGCTCGAGGAGAG 820

DB 17 CCGCTCAGAGAGAG 1

RESULT 748

ACN10740/C

ID ACN10740 standard; RNA; 17 BP.

AC ACN10740;

DT 22-APR-2004 (first entry)

DE WNV minus strand Inozyme substrate SEQ ID NO 10743.

KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
 KW viricide; neuroprotective; antibacterial; replication; pancreatitis;
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
 KW Amberzyme; Zinzyme; ss.

OS West Nile Virus.

PN WO200268637-A2.

PD 06-SEP-2002.

PF 19-OCT-2001; 2001WO-US048350.

PR 20-OCT-2000; 2000US-0242411P.

PA (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.

PA (MCSW/) MCSWIGGEN J A.

PI Blatt L, Mcswiggen JA;

XX WPI; 2002-706994/76.

XX New nucleic acid molecule that modulates replication of West Nile Virus
 CC (WNV), useful for treating a condition related to WNV infection e.g.
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

PS Claim 23; SEQ ID NO 10743; 495pp; English.

XX The invention relates to nucleic acid molecules that modulate replication
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 CC treating a condition related to WNV infection e.g. pancreatitis,
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 CC molecule is selected from the group of ribozymes consisting of
 CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The

CC nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
 CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention

XX Sequence 17 BP; 1 A; 8 C; 2 G; 0 T; 6 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 5.5e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 806 GCGCTCGAGGAGAG 822

DB 17 GCGCTCAGAGAGAG 1

RESULT 749

ACN06511

ID ACN06511 standard; RNA; 17 BP.

XX ACN06511;

DT 22-APR-2004 (first entry)

DE WNV Amberzyme substrate SEQ ID NO 6514.

KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
 KW viricide; neuroprotective; antibacterial; replication; pancreatitis;
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
 KW Amberzyme; Zinzyme; ss.

OS West Nile Virus.

PN WO200268637-A2.

PD 06-SEP-2002.

PF 19-OCT-2001; 2001WO-US048350.

PR 20-OCT-2000; 2000US-0242411P.

PA (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.

PA (MCSW/) MCSWIGGEN J A.

PI Blatt L, Mcswiggen JA;

XX WPI; 2002-706994/76.

XX New nucleic acid molecule that modulates replication of West Nile Virus
 CC (WNV), useful for treating a condition related to WNV infection e.g.
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

PS Claim 23; SEQ ID NO 6514; 495pp; English.

XX The invention relates to nucleic acid molecules that modulate replication
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 CC treating a condition related to WNV infection e.g. pancreatitis,
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 CC molecule is selected from the group of ribozymes consisting of
 CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
 CC nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
 CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention


```

ID ACN10741 standard; RNA; 17 BP.
XX
AC ACN10741;
XX
DT 22-APR-2004 (first entry)
XX
DE WNV minus strand Inozyme substrate SEQ ID NO 10744.
XX
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyne; ss.
XX
OS West Nile Virus.
XX
DE WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyne; ss.
XX
OS West Nile Virus.
XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
DR WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 10744; 495pp; English.
XX
XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyne. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 1 A; 7 C; 3 G; 0 T; 6 U; 0 Other;
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 805 CGCCTCGGAGGAGAAGA 821
DB 17 CGGCTCAGAGGAGAAGA 1

RESULT 753
ACN02935/c
ID ACN02935 standard; RNA; 17 BP.
XX
AC ACN02935;
XX
DT 22-APR-2004 (first entry)
XX
DE WNV Inozyme substrate SEQ ID NO 2938.
XX
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyne; ss.
XX
OS West Nile Virus.
XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
DR WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 10744; 495pp; English.
XX
XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyne. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 1 A; 7 C; 3 G; 0 T; 6 U; 0 Other;
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 756 GCATCGAGGCGGAGAGC 772
DB 17 GCATGTAGGGGAGAGC 1

RESULT 754
ACA06363
ID ACA06363 standard; RNA; 17 BP.
XX
AC ACA06363;
XX
DT 03-JUN-2003 (first entry)
XX
DE NFKB sub-unit modulating inozyme substrate #182.
XX
XX Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyne;
KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;

```


[illegible]

AC	ACD65432;	Matches	12;	Conservative	3;	Mismatches	2;	Indels	0;	Gaps	0;
XX	30-SEP-2003 (first entry)	QY	180	GTGAGATGTCGAGCC 196							
XX	HCV minus strand DNazyme substrate sequence #2063.	DB	1	GUGACAUUGGACAGCCC 17							
DE		RESULT	759								
XX	Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;	ID	ADB40151	standard; DNA; 17 BP.							
KW	RNA stability; RNA expression; RNA synthesis; antisense;	XX	ADB40151;								
KW	enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;	AC	ADB40151;								
KW	amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;	AC									
KW	HBV reverse transcriptase; Enhancer I region; viral replication;	DT	18-DEC-2003 (revised)								
KW	degenerative; disease state; HBV infection; HCV infection; cirrhosis;	DT	04-DEC-2003 (first entry)								
KW	liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;	XX									
XX	virucide; antiinflammatory; substrate; ss.	DE	Tumour suppression/reversion associated nucleotide #474.								
XX	Hepatitis C virus.	XX									
XX	WO200281494-A1.	KW	cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;								
XX	17-OCT-2002.	KW	primer; probe; tumour suppression; tumour reversion; apoptosis;								
XX	26-MAR-2002; 2002WO-US009187.	KW	virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;								
XX	26-MAR-2001; 2001US-00817879.	XX	diagnosis.								
PR	08-JUN-2001; 2001US-00877478.	OS	Homo sapiens.								
PR	08-JUN-2001; 2001US-0296876P.	XX									
PR	24-OCT-2001; 2001US-0335059P.	PN	WO2003040369-A2.								
PR	05-DEC-2001; 2001US-0337055P.	XX	15-MAY-2003.								
XX	(RIBO-) RIBOZYME PHARM INC.	XX	17-SEP-2002; 2002WO-IB004219.								
PA	(BLAT/) BLATT L.	XX	17-SEP-2001; 2001FR-00011981.								
PA	(MACE/) MACEJAK D.	XX	(MOLE-) MOLECULAR ENGINES LAB.								
PA	(MCSW/) MCSWIGGEN J.	PA									
PA	(MORR/) MORRISSEY D.	XX	Teleman A, Amson R, Tuijnder M;								
PA	(PAVC/) PAVCO P.	XX	WPI; 2003-441574/41.								
PA	(LEEP/) LEE P.	XX									
PA	(DRAP/) DRAPER K.	XX									
PA	(ROBE/) ROBERTS E.	XX									
XX	Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;	PT	New nucleic acid encoding human prostate membrane-specific antigen,								
PI	Draper K, Roberts E;	PT	useful e.g. for treatment of tumors and viral infection, also related								
XX	WPI; 2003-229207/22.	PT	polypeptide and antibodies.								
XX	Novel compound useful for treating cirrhosis, liver failure,	PS	Disclosure; Page 87; 771pp; French.								
XX	hepatocellular carcinoma, or condition associated with hepatitis C virus	XX									
XX	infection.	XX									
XX	Claim 1; Page 311; 387pp; English.	XX									
XX	The present invention relates to nucleic acid molecules which modulate	XX									
CC	the synthesis, expression and/or stability of Hepatitis C virus (HCV) or	CC									
CC	Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense	CC									
CC	and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,	CC									
CC	inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed	CC									
CC	are nucleic acid decoy molecules and aptamers that bind to HBV reverse	CC									
CC	transcriptase and/or HBV reverse transcriptase primer sequences, as well	CC									
CC	as oligonucleotides that specifically bind the Enhancer I region of HBV	CC									
CC	DNA. The nucleic acids may be used to modulate the expression of HBV	CC									
CC	genes and HBV viral replication. Also disclosed is a method for screening	CC									
CC	compounds and/or potential therapies directed against HBV, and compounds	CC									
CC	that modulate the expression and/or replication of HCV. The compounds and	CC									
CC	methods of the invention are useful for the treatment of degenerative and	CC									
CC	disease states related to HBV and HCV infection, replication and gene	CC									
CC	expression such as cirrhosis, liver failure, and hepatocellular	CC									
CC	carcinoma. The present sequence represents a substrate for one of the HCV	CC									
CC	DNAzyme or minus strand DNazyme sequences disclosed in the present	CC									
CC	invention	XX									
XX	Sequence 17 BP; 4 A; 5 C; 5 G; 0 T; 3 U; 0 Other;	SQ	Sequence 17 BP; 3 A; 7 C; 4 G; 3 T; 0 U; 0 Other;								
XX	Query Match 1.8%; Score 13.8; DB 1; Length 17;		Query Match 1.8%; Score 13.8; DB 1; Length 17;								
XX	Best Local Similarity 70.6%; Pred. No. 5.5e+02;		Best Local Similarity 88.2%; Pred. No. 5.5e+02;								
XX	Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;		Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;								
XX	QY 250 GAGCCAGCCATGCTGC 266	QY	250 GAGCCAGCCATGCTGC 266								

CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
 CC during gene therapy and vaccine production procedures. The current
 CC sequence is that of the human PCCP1-related DNA fragment SEQ ID 4-
 CC directed probe of the invention. Note: The current sequence is not shown
 CC within the specification per se but was retrieved from the WipoWeb
 CC database.
 XX
 SQ Sequence 17 BP; 3 A; 4 C; 9 G; 1 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 672 GGGCGGCCGAGCGAGCAG 688
 DB 1 GGGCTGCGAGCGAGCAG 17

RESULT 765
 ADF64121
 ID ADF64121 standard; DNA; 17 BP.
 XX
 AC ADF64121;
 XX
 DT 12-FEB-2004 (first entry)
 XX
 DE Human PCCP1 DNA fragment SEQ ID 8-directed probe - SEQ ID 2025.
 XX
 KW chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
 KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
 KW human; ss; probe.
 XX
 OS Homo sapiens.
 XX
 PN WO2003050284-A1.
 XX
 PD 19-JUN-2003.
 XX
 PF 22-NOV-2002; 2002WO-US037506.
 XX
 PR 10-DEC-2001; 2001US-0339764P.
 XX
 PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.

PI Guo J;
 XX
 DR WPI; 2003-532916/50.
 XX
 PT New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
 PT composition for treating or preventing a disorder associated with
 PT decreased or increased expression or activity of PCCP1 e.g., tumor.
 XX
 PS Example 2; SEQ ID NO 2025; 164pp; English.
 XX

CC The invention relates to a novel isolated nucleic acid that encodes a
 CC protein with a chromatin organisation modifier (CHROMO) domain. The
 CC polynucleotide of the invention demonstrates cytostatic activity and may
 CC be useful for preparing a composition for treating or preventing a
 CC disorder associated with decreased or increased expression or activity of
 CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
 CC during gene therapy and vaccine production procedures. The current
 CC sequence is that of the human PCCP1-related DNA fragment SEQ ID 8-
 CC directed probe of the invention. Note: The current sequence is not shown
 CC within the specification per se but was retrieved from the WipoWeb
 CC database.
 XX
 SQ Sequence 17 BP; 4 A; 4 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 333 GAGATGCCATCCGCGCAG 349

Db 1 GAGATGGCATCCTGCAG 17

RESULT 766
 ADM09541/c
 ID ADM09541 standard; RNA; 17 BP.
 XX
 AC ADM09541;

DT 20-MAY-2004 (first entry)
 XX
 DE Human NOGO receptor amberyyme substrate sequence #96.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis;
 KW NOGO receptor amberyyme; substrate; ss.

OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.

XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 XX
 PR 28-AUG-2001; 2001US-0315315P.

XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.

XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 9; SEQ ID NO 936; 317pp; English.

CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human NOGO
 CC receptor amberyyme substrate sequence.

XX
 SQ Sequence 17 BP; 1 A; 7 C; 5 G; 0 T; 4 U; 0 Other;

QY 800 CAGGCCGCTCGGAGGA 816

Db 17 CAGGGCACCTCGGAGGA 1

RESULT 767
ADL48763
ID ADL48763 standard; RNA; 17 BP.
XX AC ADL48763;
XX DT 20-MAY-2004 (first entry)
XX DE Human IKK-gamma substrate sequence #1273.
XX KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX OS Unidentified.
XX PN WO200281628-A2.
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PS Claim 59; SEQ ID NO 2296; 317pp; English.
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX SQ Sequence 17 BP; 6 A; 3 C; 6 G; 0 T; 2 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 5.5e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 410 GAGGAGGAGGAGGTCCT 426

Db 1 GAGAGAGAGGAGGUCCU 17

RESULT 768
ADL49424/C
ID ADL49424 standard; RNA; 17 BP.
XX AC ADL49424;
XX DT 20-MAY-2004 (first entry)
XX DE Human PKR substrate sequence #538.
XX KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.
XX OS Unidentified.
XX PN WO200281628-A2.
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PS Claim 59; SEQ ID NO 2957; 317pp; English.
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX SQ Sequence 17 BP; 2 A; 7 C; 2 G; 0 T; 6 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 492 AGAGGAGGAGGAGCAG 508

Db 17 AGAGGCGAGGAGTTCAG 1

RESULT 769
ADL46635/C
ID ADL46635 standard; RNA; 17 BP.

XX ADL46635;

XX 20-MAY-2004 (first entry)

XX Human NOGO receptor inozyme substrate sequence #68.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis;
KW NOGO receptor inozyme; substrate; ds.

XX Unidentified.

XX WO200281628-A2.

XX 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

XX 29-MAY-2001; 2001US-0294412P.

XX 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX Claim 9; SEQ ID NO 168; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human NOGO
CC receptor inozyme substrate sequence.

XX SQ Sequence 17 BP; 1 A; 8 C; 4 G; 0 T; 4 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 685 GCAGGCGGCGAGTTCAG 701

Db 17 GCAGGCGGCGAGTTCG 1

RESULT 770
ADL51771/C
ID ADL51771 standard; RNA; 17 BP.

XX ADL51771;

XX 20-MAY-2004 (first entry)

XX Human PTGDR substrate sequence #890.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PTGDR;
KW substrate; ds.

XX Unidentified.

XX WO200281628-A2.

XX 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

XX 29-MAY-2001; 2001US-0294412P.

XX 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX Claim 161; SEQ ID NO 5304; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.

XX SQ Sequence 17 BP; 3 A; 8 C; 5 G; 0 T; 1 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 705 GTGAGCGGCGAGGCTG 721

KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
KW skeletal muscle function.
XX Homo sapiens.
XX US2004137589-A1.
XX 15-JUL-2004.
XX 26-NOV-2003; 2003US-00723361.
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 05-FEB-2001; 2001WO-US000670.
XX 25-MAY-2001; 2001US-00866108.
XX (GUY/) GU Y.
XX (JIY/) JI Y.
XX (PENN/) PENN S G.
XX (HANZ/) HANZEL D K.
XX (RANK/) RANK D.
XX (CHEN/) CHEN W.
XX (SHAN/) SHANNON M E.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX Novel myosin-like protein-1, useful for treating or preventing disorder
XX associated with decreased expression or activity of human genome-derived
XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle
XX function.
XX Disclosure; SEQ ID NO 6823; Opp; English.
XX The invention relates to a novel polypeptide (I) comprising a sequence
XX (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
XX defined in the specification, a fragment of at least 8 amino acids of
XX (S1), 95% deviation from (S1) which are conservative substitutions, and
XX 65% identity to (S1). A polypeptide of the invention acts as an agonist or
XX antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
XX pharmaceutical composition of the invention is useful for treating or
XX preventing a disorder associated with decreased expression or activity of
XX hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
XX The present sequence represents a 17-mer nucleotide, used in the
XX invention for scanning the sequence represented in ACN63103
XX Sequence 17 BP; 3 A; 3 C; 5 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 1.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 5.5e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 266 CACCTGCGCTTCAGAAC 282
Db |||||
17 CACCTGCGCTTCAGAAAA 1

RESULT 774
ACN70796/c

ID ACN70796 standard; DNA; 17 BP.
XX ACN70796;
XX 02-DEC-2004 (first entry)
XX Human GDMPLP-1 probe SEQ ID NO:7698.
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
KW skeletal muscle function.
XX Homo sapiens.
XX US2004137589-A1.
XX 15-JUL-2004.
XX 26-NOV-2003; 2003US-00723361.
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 05-FEB-2001; 2001WO-US000670.
XX 25-MAY-2001; 2001US-00866108.
XX (GUY/) GU Y.
XX (JIY/) JI Y.
XX (PENN/) PENN S G.
XX (HANZ/) HANZEL D K.
XX (RANK/) RANK D.
XX (CHEN/) CHEN W.
XX (SHAN/) SHANNON M E.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX Novel myosin-like protein-1, useful for treating or preventing disorder
XX associated with decreased expression or activity of human genome-derived
XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle
XX function.
XX Disclosure; SEQ ID NO 7698; Opp; English.
XX The invention relates to a novel polypeptide (I) comprising a sequence
XX (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
XX defined in the specification, a fragment of at least 8 amino acids of
XX (S1), 95% deviation from (S1) which are conservative substitutions, and
XX 65% identity to (S1). A polypeptide of the invention acts as an agonist or
XX antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
XX pharmaceutical composition of the invention is useful for treating or
XX preventing a disorder associated with decreased expression or activity of
XX hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
XX The present sequence represents a 17-mer nucleotide, used in the
XX invention for scanning the sequence represented in ACN63103
XX Sequence 17 BP; 3 A; 7 C; 5 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 1.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 5.5e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX

QY 827 CTGGCCAGTTCAGGT 843
Db 17 CTGGCCAGTTCAGGT 1
RESULT 775
ACN70911
ID ACN70911 standard; DNA; 17 BP.
XX AC ACN70911;
DT 02-DEC-2004 (first entry)
XX Human GDMPLP-1 probe SEQ ID NO:7813.
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
KW skeletal muscle function.
XX Homo sapiens.
XX US2004137589-A1.
XX 15-JUL-2004.
XX 26-NOV-2003; 2003US-00723361.
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX (GUIY/) GU Y.
PA (JIYI/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
PI WPI; 2004-533378/51.
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX Disclosure; SEQ ID NO 7813; Opp; English.
XX The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.

CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
SQ Sequence 17 BP; 8 A; 2 C; 7 G; 0 T; 0 U; 0 Other;
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. NO. 5.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 493 GAGGCAGAGGAGCAGG 509
Db 1 GAAGCAAAAGGAGCAGG 17
RESULT 776
ACN71520
ID ACN71520 standard; DNA; 17 BP.
XX AC ACN71520;
XX 02-DEC-2004 (first entry)
XX Human GDMPLP-1 probe SEQ ID NO:8422.
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
KW skeletal muscle function.
XX Homo sapiens.
XX US2004137589-A1.
XX 15-JUL-2004.
XX 26-NOV-2003; 2003US-00723361.
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX (GUIY/) GU Y.
PA (JIYI/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
PI WPI; 2004-533378/51.
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX Disclosure; SEQ ID NO 8422; Opp; English.
XX The invention relates to a novel polypeptide (I) comprising a sequence
CC

CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX
 SQ Sequence 17 BP; 6 A; 3 C; 7 G; 1 T; 0 U; 0 Other;
 Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 490 GAAGAGCGCAGAGGAGC 506
 DB 1 GAAGAGCGCAGAGGAGC 17
 RESULT 777
 ACN71519
 ID ACN71519 standard; DNA; 17 BP.
 XX
 AC ACN71519;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Human GDMPLP-1 probe SEQ ID NO:8421.
 XX
 KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 OS Homo sapiens.
 XX
 PN US2004137589-A1.
 XX
 PD 15-JUL-2004.
 XX
 PF 26-NOV-2003; 2003US-00723361.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 (GUYY/) GU Y.
 PA (JIVY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 XX

PT Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 XX
 PS Disclosure; SEQ ID NO 8421; Opp; English.
 XX
 CC The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX
 SQ Sequence 17 BP; 6 A; 2 C; 7 G; 2 T; 0 U; 0 Other;
 Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 489 TGAAGAGCGCAGAGGAG 505
 DB 1 TGAAGAGCGCAGAGGAG 17
 RESULT 778
 AAX75572/c
 ID AAX75572 standard; RNA; 18 BP.
 XX
 AC AAX75572;
 XX
 DT 28-JUL-1999 (first entry)
 XX
 DE Mouse flt-1 VEGF receptor hairpin ribozyme substrate #31.
 XX
 KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
 KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
 KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KW foetal liver kinase 1; ss.
 XX
 OS Mus sp.
 XX
 PN WO9715662-A2.
 XX
 PD 01-MAY-1997.
 XX
 PF 25-OCT-1996; 96WO-US017480.
 XX
 PR 26-OCT-1995; 95US-0005974P.
 PR 11-JAN-1996; 96US-00584040.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (CHIR) CHIRON CORP.
 XX
 PI Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
 XX WPI; 1997-259017/23.
 XX
 PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
 PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
 PT rheumatoid arthritis, etc., in a human patient.
 XX
 PS Claim 4; Page 185; 218pp; English.
 XX
 CC The present invention describes nucleic acid molecules which modulate the
 CC synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient

CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
 CC treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX67275 to AAX75752 represent specific examples
 CC of nucleic acid molecules from the present invention

XX SQ Sequence 18 BP; 3 A; 7 C; 5 G; 0 T; 3 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 5.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 688 GGCGCGCAGCTGAGA 704

DB 18 GGCGCGCAGCTGAGA 2

RESULT 779

AAT74250

ID AAT74250 standard; DNA; 18 BP.

XX AC AAT74250;

XX DT 10-FEB-1998 (first entry)

XX DE Estm9 primer R1.

XX Lyst1; mouse; lysosomal trafficking regulator; beige; bg gene;
 XX Chediak-Higashi syndrome; CH syndrome; Estm9; PCR; primer; ss.
 XX Synthetic.

XX WO9728262-A1.

XX 07-AUG-1997.

XX 31-JAN-1997; 97WO-US001748.

XX 01-FEB-1996; 96US-0011146P.

XX 20-DEC-1996; 96US-0033599P.

XX 23-DEC-1996; 96US-0034346P.

XX (UYFL) UNIV FLORIDA.

XX Kingsmore SF, Barbosa-Alleyne WDFS;

XX WPI; 1997-402616/37.

XX Mammalian lysosomal trafficking regulators LYST1, LYST1, LYST2 and LYST2
 XX - useful to diagnose Chediak-Higashi syndrome.

XX Example 2; Page 71; 237pp; English.

XX Estm9 primers R1 (AAT74250) and R2 (AAT74252) correspond to the 3' end of
 CC an Estm9 cDNA. Estm9 primers F1 (AAT74249) and F2 (AAT74251) correspond
 CC to the 3' end of an Estm9 cDNA. RT-PCR products were amplified from
 CC mouse bg, bgl, bgl2 and +/- RNA with Nid primers or Estm9 primers F1-R1
 CC or F2-R2. The RT-PCR analysis was used in the mapping of the bg (beige)
 CC locus to mouse chromosome 13 to provide a foundation for yeast artificial
 CC chromosome contig development and screening of candidate genes for bg.

CC Characterisation of the bg critical region in murine chromosome 13 and

CC positional cloning of bg were performed as an antecedent to

CC identification of the homologous human gene LYST1 (see AAT74201), which

CC is mutated in human Chediak-Higashi syndrome

XX SQ Sequence 18 BP; 4 A; 4 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 5.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 333 GAGATCCCATCCGCCAG 349

DB 1 GAGATCCCTTCAGGCAG 17

RESULT 780

AAV07833/C

ID AAV07833 standard; DNA; 18 BP.

XX AC AAV07833;

XX DT 25-MAR-2003 (revised)

XX DE 10-DEC-1998 (first entry)

XX Segment of branched nucleic acid polymer with two 5' ends.

XX Comb-type branched polynucleotide; amplification multimer; analyte;

XX hybridisation assay; hepatitis b virus; HBV; amplifier probe; ss.

XX Synthetic.

XX US5710264-A.

XX 20-JAN-1998.

XX 07-JUN-1995; 95US-00478085.

XX 27-JUL-1990; 90US-00558897.

XX 23-DEC-1991; 91US-00813586.

XX (CHIR) CHIRON CORP.

XX Chang C, Fultz TJ, Warner B, Urdea MS, Horn T;

XX WPI; 1998-109872/10.

XX New large comb-type branched polynucleotides - useful as amplification

XX multimers in nucleic acid hybridisation assays.

XX Example 6; Col 24; 33pp; English.

The invention relates to a large comb-type branched polynucleotide of
 formula: 3'-A-S-(S'-X')^m-S'-5', where X' is a branched site joined to -
 (R)n-S'-E-L; A is an oligonucleotide complementary to an analyte nucleic
 acid sequence; S is a first spacer segment of 1-50 linked monomers where
 each monomer is selected from nucleotides and a cleavable linker R; S' =
 a branching site spacer segment of 0-15 linked monomers where each of the
 monomers is selected from nucleotides and cleavable linker R; X' = a
 multifunctional nucleotide that provides a branch site; m = 1-100; S' =
 a second spacer segment of 0-10 linked monomers where each of the
 monomers is selected from nucleotides and cleavable linker R; R = a
 cleavable linker molecule; n = 0 or 1; S'' = a third spacer segment of 0
 -10 linked monomers where each of the monomers is selected from
 nucleotides and cleavable linker R; E = an oligonucleotide segment of 5-
 10 nucleotides; L = an oligonucleotide containing 2-10 iterations of a
 nucleotide sequence complementary to a labelled nucleic acid probe. The
 invention also relates to a branched nucleic acid polymer. The poly-
 nucleotides are useful as amplification multimers in nucleic acid
 hybridisation assays used for genetic research, biomedical research and
 clinical diagnostics. Since the polynucleotide multimers include a large
 number (at least 20) iterations of a sequence that are available for
 specific hybridisation, they permit a greater degree of amplification and
 decrease the threshold level of a detectable analyte. The present
 sequence is shown in the specification. (Updated on 25-MAR-2003 to
 correct PF field.)

XX SQ Sequence 18 BP; 2 A; 3 C; 6 G; 7 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 5.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 867 AATACGACACACATC 883


```

Db      17 AGTACGACCAACCGTC 1
      |||||||
RESULT 781
AAZ36676
ID AAX36676 standard; DNA; 18 BP.
XX.
AC AAX36676;
DT 13-JUL-1999 (first entry)
XX
DE PCR primer for marker D6S1713.
XX
KW PCR primer; detection; glaucoma allele; haplotype analysis; human; GLC1B;
KW chromosome 2; chromosome 6; GLC6p25; haplotype profile;
KW presymptomatic glaucoma; symptomatic glaucoma; ss.
XX
OS Synthetic.
OS Homo sapiens.
PN WO9916899-A2.
XX
DE PCR primer for marker D6S1713.
XX
KW PCR primer; detection; glaucoma allele; haplotype analysis; human; GLC1B;
KW chromosome 2; chromosome 6; GLC6p25; haplotype profile;
KW presymptomatic glaucoma; symptomatic glaucoma; ss.
XX
OS Synthetic.
OS Homo sapiens.
PN WO9916899-A2.
XX
DE 08-APR-1999.
XX
PF 29-SEP-1998; 98WO-CA000924.
XX
PR 30-SEP-1997; 97CA-02217097.
XX
PA (UYLA-) UNIV LAVAL.
XX
PI Raymond V, Morissette J, Falardeau P, Cote G, Anttil J;
XX WPI; 1999-263704/22.
XX
PT Haplotype analyses for indirect detection of glaucoma.
XX
PS Claim 18; Page 28; 41pp; English.
XX
CC This sequence represents a PCR primer used in the method of the
CC invention. The method is for detecting the presence of alleles for
CC glaucoma comprising haplotype analysis of human chromosome 2 and 6
CC respectively, where the haplotypes are associated with loci GLC1B and
CC GLC6p25 respectively. The primers are used to amplify gene sequences to
CC generate information necessary to compile haplotype profiles. The
CC haplotype profiles can be used to detect presymptomatic and symptomatic
CC glaucoma. They can also be used to localise, isolate and identify the
CC GLC1B and GLC6p25 loci so that detection of individuals with glaucoma is
CC enhanced. The haplotype analyses also provide means for identification
CC and following of mutant alleles in pedigrees or populations.
CC Identification of presymptomatic individuals using the methods allows
CC intervention in the disease process and obviates the impact of inheriting
CC a mutant allele causing disease, by medically disrupting the initiation
CC or progression of the disease
XX
SQ Sequence 18 BP; 4 A; 6 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 5.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 558 AGGACCAAGGCTCTGTG 574
Db 1 AGCCCAAGACCTCTGTG 17

RESULT 782
AAZ20075/c
ID AAZ20075 standard; DNA; 18 BP.
XX
AC AAZ20075;
XX
DT 21-DEC-1999 (first entry)

PCR primer for human ubiquitin conjugating enzyme 7 gene mapping.
Ubiquitin conjugating enzyme 7; hUBC7; USC7; human; protein degradation;
cystic fibrosis; therapy; PCR; primer; ss.
Synthetic.
Homo sapiens.
WO9950421-A1.
07-OCT-1999.
23-MAR-1999; 99WO-GB000919.
27-MAR-1998; 98GB-00006490.
09-APR-1998; 98GB-00007533.
(UYLE-) UNIV LEEDS.
Markham AF, Robinson PA;
WPI; 1999-591322/50.
Novel polypeptides used to treat clinical conditions resulting from
ubiquitin conjugating enzyme 7, UBC7, mediated protein degradation.
Disclosure; Page 15; 37pp; English.
This primer is one of a pair (see also AAZ20074) used to screen the NIGMS
human/rodent somatic cell hybrid panel, and the Genebridge 4 radiation
hybrid-mapping panel for the chromosomal localisation of the novel human
gene (see AAZ20069) coding for ubiquitin conjugating enzyme 7 (hUBC7, see
RAY31983). The gene mapped to chromosome 21 at 21q22. The invention
provides hUBC7 nucleic acids, protein, peptides and antibodies, a method
of screening for modulator compounds, a method of monitoring degradation
of cystic fibrosis transmembrane conductance regulator protein, and a
pharmaceutical composition comprising a UBC7 nucleic acid or protein used
to treat clinical conditions resulting from hUBC7 mediated protein
degradation, e.g. cystic fibrosis
Sequence 18 BP; 3 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 5.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 719 CTGCAGCAGCAGCAGCAG 735
Db 17 CTGTAGCTGCAGCAGCAG 1

RESULT 793
AAV83062/c
ID AAV83062 standard; DNA; 18 BP.
XX
AC AAV83062;
XX
DT 24-FEB-1999 (first entry)
XX
DE Oligonucleotide for synthesis of comb-type branched polynucleotide.
XX comb-type branched polynucleotide; multifunctional nucleotide;
KW pendant polynucleotide sidechain; hybridisation assay;
KW amplification multimer; sandwich assay; ss.
XX
OS Synthetic.
XX
PN US5849481-A.
XX
PD 15-DEC-1998.
XX
DT 05-JUN-1995; 95US-00470124.

```

```

XX
PR 27-JUL-1990; 90US-00558897.
PR 23-DEC-1991; 91US-00813588.
XX
XX (CHIR ) CHIRON CORP.
PA
XX
PI Warner B, Horn T, Fultz TJ, Urdea MS, Chang C;
XX
XX WPI; 1999-069715/06.
DR
XX
XX Improved nucleic acid hybridisation assays - using large comb-type
PT polypeptide(s).
XX
XX Example 6; Col 23; 31pp; English.
PS
XX
CC The present sequence is used in the synthesis of a comb-type branched
CC polynucleotide. The large comb-type branched polynucleotide of the
CC invention comprises a polynucleotide backbone having at least 15
CC multifunctional nucleotides each defining a sidechain site and pendant
CC polynucleotide sidechains extending from the multifunctional nucleotides,
CC each comprising iterations of an single stranded oligonucleotide unit
CC capable of binding specifically to a second single-stranded
CC polynucleotide sequence. The total number of iterations in all sidechains
CC is at least 20. The first single-stranded polynucleotide sequence is a
CC labelled polynucleotide, directly or indirectly linked to a nucleic acid
CC analyte. In the nucleic acid hybridisation assay of the invention, the
CC labelled nucleic acid probe is hybridised to the branched polymeric
CC nucleotide via the second single-stranded oligonucleotide unit. The comb-
CC type branched polynucleotides are used as amplification multimers in
CC nucleic acid hybridisation assays and other assays such as direct,
CC indirect and sandwich assays
XX
SQ Sequence 18 BP; 2 A; 3 C; 6 G; 7 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 5.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 867 AATACGACACACATC 883
DB 17 AGTACGACACACATC 1

RESULT 784
AAZ01227
ID AAZ01227 standard; DNA; 18 BP.
XX
AC AAZ01227;
XX
XX 27-SEP-1999 (first entry)
DT
XX
XX PCR primer for PGI biallelic markers 4-22-174 and 4-22-176.
DE
XX
XX PGI gene; biallelic marker; PCR primer; PGI-related biallelic marker;
KW cancer; prostate cancer; diagnosis; therapy; prostate specific antigen;
KW PSA; human; ss.
XX
XX Synthetic.
OS Homo sapiens.
XX
XX WO9932644-A2.
XX
XX 01-JUL-1999.
XX
XX 22-DEC-1998; 98WO-IB002133.
XX
XX 22-DEC-1997; 97US-00996306.
PR 09-SEP-1998; 98US-0099658P.
XX
XX (GEST ) GENSET.
PA
XX Cohen D, Blumenfeld M, Chumakov I, Bougueleret L;
PI
XX

```

```

DR WPI; 1999-405178/34.
XX
XX Use of a prostate cancer associated gene and biallelic markers derived
PT from it.
XX
XX Claim 4; Page 353; 385pp; English.
PS
XX
XX The invention relates to a mammalian PGI gene and protein, and a set of
CC PGI biallelic markers. The PGI polynucleotide and biallelic markers are
CC used in a hybridisation assay, a sequencing assay, or in an allele-
CC specific amplification assay for determining the identity of a nucleotide
CC at a PGI-related biallelic marker. The methods can be used to detect and
CC to assess the risk of developing cancer or prostate cancer. Early-stage
CC diagnosis of prostate cancer relies on prostate specific antigen (PSA)
CC dosage. However, the effectiveness of this is limited due to its
CC inability to discriminate between malignant and non-malignant affections
CC of the organ. A need exists for both a reliable diagnostic procedure
CC which would enable early-stage diagnosis, and for preventative and
CC curative treatments of the disease. The PGI gene can be used for
CC detection of prostate cancer, and the risk of developing it in the
CC future, and can also be used to determine therapies for the disease
XX
SQ Sequence 18 BP; 3 A; 2 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 5.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 372 GCTGCGAGGAGCTTCG 388
DB 2 GCTGAGAGGAGCTTTG 18

RESULT 785
AAZ48548/C
ID AAZ48548 standard; DNA; 18 BP.
XX
XX AAZ48548;
XX
XX 31-MAR-2000 (first entry)
DT
XX
XX Human TNFR1 mRNA inhibiting antisense oligo ISIS# 18941.
DE
XX
XX Tumour necrosis factor receptor type 1; TNFR1; antisense; infection;
KW inflammation; tumour formation; TNFR1; anticancer; ss.
XX
XX Synthetic.
OS Homo sapiens.
XX
XX US6007995-A.
XX
XX 28-DEC-1999.
XX
XX 26-JUN-1998; 98US-00106038.
XX
XX 26-JUN-1998; 98US-00106038.
XX
XX (ISIS-) ISIS PHARM INC.
PA
XX Baker BF, Cowseert LM;
PI
XX WPI; 2000-105333/09.
XX
XX Antisense inhibition of tumor necrosis factor type 1 expression for
PT diagnosis, treatment and prevention of disease, particularly tumors.
XX
XX Claim 1; Col 25; 34pp; English.
PS
XX
XX The invention provides antisense compounds targeted to human tumour
CC necrosis factor receptor type 1 (TNFR1) RNA. These antisense compounds
CC can be used in a method of inhibiting the expression of TNFR1 human cells
CC or tissues. The antisense compounds specifically hybridize with one or
CC more nucleic acids encoding TNFR1 modulating the function of nucleic acid

```

CC molecules encoding TNFR1, ultimately modulating the amount of TNFR1
 CC produced. The antisense compounds and method are useful as research
 CC reagents and diagnostics, and in the treatment and prophylaxis of
 CC infection, inflammation or tumour formation. Sequences AA248482-565
 CC represent antisense oligos used for inhibition of the human TNFR1 mRNA
 XX
 SQ Sequence 18 BP; 3 A; 9 C; 4 G; 2 T; 0 U; 0 Other;
 Query Match 1.8%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 5.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 302 CAGCGCTGCTGGAGGA 318
 Db 17 CTGGGCTGCTGGAGGA 1
 RESULT 786
 AAA74709/c
 ID AAA74709 standard; DNA; 18 BP.
 XX
 AC AAA74709;
 XX
 DT 12-JAN-2001 (first entry)
 XX
 DE Sequencing primer alpha.
 XX
 KW Mycobacterium bovis; Mycobacterium tuberculosis; SacB; levane saccharase;
 KW transposon mutagenesis; transposon IS1096; sequencing primer; ss.
 XX
 OS Mycobacterium sp.
 XX
 PN US6096549-A.
 XX
 PD 01-AUG-2000.
 XX
 PF 11-JUN-1997; 97US-00872917.
 XX
 PR 11-JUN-1996; . 96US-00661658.
 XX
 PA (INSP) INST PASTEUR.
 XX
 PI Gicquel B, Guillhot C, Jackson M, Pelicic V, Reytrat J;
 XX
 DR WPI; 2000-542306/49.
 XX
 PT Transforming Mycobacterium strains for positive selection of allelic
 PT exchange mutants, involves transfecting cells with vector comprising
 PT marker gene and transposon and selecting in medium containing sucrose.
 XX
 PS Disclosure; Col 16; 29pp; English.
 XX
 CC The present sequence is a sequencing primer based on transposon IS1096.
 CC It was used to sequence double-stranded plasmid DNA in a process for
 CC replacing a nucleotide sequence in the genome of a slow growing
 CC Mycobacterium strain. The process comprises transfecting Mycobacterium
 CC with a vector containing SacB gene coding for levane saccharase enzyme
 CC and selecting clones of transformed Mycobacteria by propagating the
 CC clones in a culture medium supplemented with sucrose. The method is
 CC useful for inserting a transposon in the genome of a Mycobacterium
 CC strain. Protective antigens, e.g. for use in BCG vaccine strains, may be
 CC cloned into the Mycobacterium genome. The process is also useful for
 CC random inactivation of genes coding for a protein involved in the
 CC virulence of a pathogenic mycobacterium strain. The method facilitates an
 CC increase of the proportion of allelic exchange mutants, making the
 CC screening of transformants easier
 XX
 SQ Sequence 18 BP; 0 A; 8 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 5.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 810 CGGAGGAGGAGGAGGAG 826
 Db 17 CGGAGGAGGAGGAGGAG 1
 RESULT 787
 AA293487
 ID AA293487 standard; DNA; 18 BP.
 XX
 AC AA293487;
 XX
 DT 24-JUL-2000 (first entry)
 XX
 DE TRADD antisense oligonucleotide.
 XX
 KW TRADD; TNF; tumour necrosis factor; NF-kappa-B; apoptosis;
 KW programmed cell death; antisense; inhibition; treatment; therapy;
 KW septic shock; inflammation; cancer; antiinflammatory; human; ss.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT misc_binding complement(1..18)
 FT /tag= a
 FT /note= "Complementary to bases 780-763 of the human TRADD
 FT sequence described in GENESEQ record AA293431"
 XX
 PN WO200012527-A1.
 XX
 PD 09-MAR-2000.
 XX
 PF 25-AUG-1999; 99WO-US019614.
 XX
 PR 28-AUG-1998; 98US-00143212.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Monia BP, Cowser LM;
 XX
 DR WPI; 2000-237846/20.
 XX
 PT New antisense compounds that limit the expression of human TRADD protein,
 PT useful in the treatment and diagnosis of cancer, inflammation and septic
 PT shock.
 XX
 PS Claim 3; Page 52; 85pp; English.
 XX
 CC The intracellular protein TRADD has been identified as a critical link
 CC between tumour necrosis factor (TNF) receptor binding and downstream
 CC activation of NF-kappa-B. Overexpression of native TRADD activates NF-
 CC kappa-B in the absence of TNF and dominant negative mutants of TRADD
 CC block TNF-induced NF-kappa-B activation. A second effect of TNF in many
 CC cell types is the induction of apoptosis (programmed cell death). TRADD
 CC overexpression has been shown to mimic TNF induction of apoptosis as
 CC well. Data indicates that TRADD and other downstream effector proteins
 CC are the rate limiting step of TNF action and would therefore serve as the
 CC most efficient targets for inhibition of TNF-induced events. Antisense
 CC oligonucleotides capable of inhibiting TRADD function may therefore be
 CC useful in a number of therapeutic, diagnostic and research applications.
 CC Inhibiting expression of TRADD by contacting human cells or tissues with
 CC the antisense compound may be used to treat a disease or condition
 CC associated with TRADD expression, for example, septic shock,
 CC inflammation, or cancer. TRADD antisense oligonucleotides of varying
 CC inhibitory capabilities are listed in GENESEQ records AA293438-293517.
 CC The antisense oligonucleotides exhibit enhanced inhibitory capabilities
 CC when they have 2'-MOE wings and a deoxy gap
 XX
 SQ Sequence 18 BP; 2 A; 9 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 5.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

QY 795 AGCGCCAGCGCGCTCG 811
Db 2 AGCGCCCGGAGCCTCG 18

RESULT 788
AAH56090/c
ID AAH56090 standard; DNA; 18 BP.
XX
AC AAH56090;
XX
XX 04-SEP-2001 (first entry)
XX
XX Human SCN3A PCR-SSCP PCR primer SEQ ID NO:334.
XX
XX Human; epilepsy; chromosome 2; SCN1A; SCN2A; SCN3A; identification;
XX diagnosis; mutation; chromosome 2q23-q31; neurological disorder;
XX anticonvulsant; neuroprotective; PCR primer; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX WO200138564-A2.
XX
XX 31-MAY-2001.
XX
XX 24-NOV-2000; 2000WO-CA001404.
XX
XX 26-NOV-1999; 99US-0167623P.
XX
XX (UVMC-) UNIV MCGILL.
XX
XX Rouleau GA, Lafreniere RG, Rochefort D, Cossette P, Ragsdale D;
XX WPI; 2001-355945/37.
XX
XX Determining a predisposition to epilepsy and/or development of epilepsy
XX comprises determining the genotype of SCN1A, SCN2A and/or SCN3A, or a DNA
XX variant, equivalent, or mutation which shows a linkage disequilibrium.
XX
XX Example 5; Fig 6; 268pp; English.
XX
XX The present invention describes a method (M1) of determining an
XX individual's predisposition to epilepsy and/or development of epilepsy,
XX as well as predicting the individual's response to medication. The method
XX comprises determining the genotype of at least one gene selected from
XX SCN1A, SCN2A or SCN3A, or a DNA variant, equivalent, or mutation which
XX shows a linkage disequilibrium. SCN1A, SCN2A and SCN3A are all sodium
XX channel genes located on chromosome 2. The idiopathic generalised
XX epilepsy (IGE) gene is more specifically localised on chromosome 2q23-
XX q31. Compounds identified as modulators of the biological activity of
XX SCN1A, SCN2A or SCN3A proteins or genes, are useful for treating epilepsy
XX or other neurological disorders. They have anticonvulsant and
XX neuroprotective activities. AAH5763 to AAH56164 and AAH99674 to AAH99679
XX represent SCN1A, SCN2A, and SCN3A cDNAs, gene fragments, PCR primers,
XX oligonucleotides and proteins given in the exemplification of the present
XX invention
XX
XX Sequence 18 BP; 3 A; 7 C; 5 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 1.8%; Score 13.8; DB 1; Length 18;
XX Best Local Similarity 88.2%; Pred. No. 5.9e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 617 CAGAGTCGCTGGAGGC 633
Db 18 CAGAATCGCTGGGGGC 2

RESULT 789
AAF89332
ID AAF89332 standard; DNA; 18 BP.
XX

```

```

AC AAF89332;
XX
XX 10-DEC-2001 (first entry)
XX
XX Sample member clustering method related human DNA PCR primer #69.
XX
XX Cluster; hierarchical clustering algorithm; population based study;
XX clinical trial; DNA fingerprint; genetic profile analysis; PCR primer;
XX SNP; single nucleotide polymorphism; ss.
XX
XX Homo sapiens.
XX
XX WO200129257-A2.
XX
XX 26-APR-2001.
XX
XX 20-OCT-2000; 2000WO-1B001632.
XX
XX 22-OCT-1999; 99US-0161231P.
XX
XX 07-JUL-2000; 2000US-0216897P.
XX
XX (GEST ) GENSET.
XX
XX Schork N, Skierczynski B;
XX WPI; 2001-316248/33.
XX
XX Genetic clustering by distributing members into optimal numbers of
XX clusters determined by a hierarchical clustering algorithm or by paired-
XX pair analysis of homozygous pairs in clusters got from non-hierarchical
XX clustering.
XX
XX Claim 61; Page 88; 100pp; English.
XX
XX The present invention describes methods of clustering members of a
XX sample, involving applying a hierarchical clustering algorithm to the
XX sample members, determining the optimal number of clusters based on this
XX and distributing the sample members into clusters using non-hierarchical
XX clustering. The methods are useful in population based studies such as
XX clinical trials, DNA fingerprinting and genetic profile analyses. The
XX present sequence was used to demonstrate the method of the invention
XX
XX Sequence 18 BP; 3 A; 2 C; 7 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 1.8%; Score 13.8; DB 1; Length 18;
XX Best Local Similarity 88.2%; Pred. No. 5.9e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 372 GCTGCGGAGGAGCTTCG 388
Db 2 GCTGAGAGGAGCTTTTG 18

RESULT 790
ABT13201
ID ABT13201 standard; DNA; 18 BP.
XX
XX AC ABT13201;
XX
XX 30-JAN-2003 (first entry)
XX
XX Fanconi anaemia FANCD2 related PCR primer SEQ ID NO 104.
XX
XX Cystostatic; dermatological; vasotropic; anti-anaemic; FA pathway defect;
XX Fanconi anaemia protein complex; FANCD2; DNA repair; Cockayne's syndrome;
XX cell cycle abnormality; Fanconi anaemia; ataxia telangiectasia; cancer;
XX Bloom's syndrome; Hereditary non-polyposis colon cancer; gene therapy;
XX Xeroderma pigmentosum; PCR; primer; ss.
XX
XX Unidentified.
XX
XX OS
XX PN WO200236761-A2.
XX

```

```
PD 10-MAY-2002.
XX
XX
PF 02-NOV-2001; 2001WO-US045561.
XX
XX
PR 03-NOV-2000; 2000US-0245756P.
XX
XX
XX (DAND ) DANA FARBER CANCER INST INC.
XX
XX
PI D'andrea AD, Taniguchi T, Timmers C, Grompe M;
XX
XX
DR WPI; 2002-519251/55.
XX
XX
PT Novel isolated Fanconi anemia protein complex polypeptide, termed FANCD2,
PT useful for treating Fanconi anemia pathway defect in cell target or for
PT treating patient with defective FANCD2 gene.
XX
XX
PS Claim 6; Page 43; 103pp; English.
XX
XX
CC The invention relates to an isolated Fanconi anemia protein complex
CC (FANCD2) polypeptide. The FANCD2 protein comprises a sequence of 1472
CC amino acids fully defined in the specification, its 90% identical
CC sequence, a sequence encoded by a polynucleotide that is at least 90%
CC identical to sequences given in specification such as a 5127 base pair
CC sequence, or a fragment which is at least 50 amino acids in length. The
CC FANCD2 protein is useful for treating an FA pathway defect in a cell
CC target or for treating a patient with a defective FANCD2 gene. The FANCD2
CC gene is useful for making a recombinant expression vector. The FANCD2
CC protein and its gene are useful as a novel target for therapeutic
CC development, and in diagnostic test and screening assays for diseases
CC associated with DNA repair and cell cycle abnormalities such as Fanconi
CC anemia, Bloom's syndrome, Cockayne's syndrome, Hereditary non-polyposis
CC colon cancer, ataxia telangiectasia and Xeroderma pigmentosum. The FANCD2
CC gene is useful in producing probes and primers for screening patients in
CC genetic based test, for diagnosing Fanconi anemia and cancer, for
CC preparing an experimental mouse model for use in screening new
CC therapeutics for treating conditions involving defective DNA repair, and
CC in gene therapy methods. A recombinant vector containing the FANCD2 gene
CC of the invention is useful in gene therapy. This polynucleotide sequence
CC represents a PCR primer of FANCD2 relating to the invention
XX
XX
SQ Sequence 18 BP; 2 A; 4 C; 8 G; 4 T; 0 U; 0 Other;
Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 5.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 647 TGCAGGCTCTGAGGG 663
DB 2 TGCAGACTCTGTGGG 18
RESULT 791
ABT05044/C
ID ABT05044 standard; DNA; 18 BP.
XX
XX
AC ABT05044;
XX
XX
DT 11-OCT-2002 (first entry)
XX
XX
DE TNFR1 expression modulation related antisense oligo SEQ ID No 74.
XX
XX
DE Antisense compound; tumour necrosis factor receptor 1; liver disease;
KW TNFR1; hepatitis; liver injury; hyperproliferative disorder; cancer;
KW human; GB.
XX
XX
OS Homo sapiens.
XX
XX
PN WO200248168-A1.
XX
XX
PD 20-JUN-2002.
XX
XX
PF 22-OCT-2001; 2001WO-US051224.
XX
XX
PT New truncated neublastin polypeptides lacking one or more amino-terminal
```

```
PR 24-OCT-2000; 2000US-00695451.
XX
XX
PA (ISIS-) ISIS PHARM INC.
XX
XX
PI Baker BF, Cowseert LM, Zhang H, Dean NM;
XX
XX
XX WPI; 2002-583481/62.
XX
XX
PT Novel antisense compound targeted to nucleic acid molecule encoding tumor
PT necrosis factor receptor 1 (TNFR1), useful for treating humans having
PT disease associated with TNFR1 e.g. hepatitis, liver injury, liver cancer.
XX
XX
PS Example 10; Page 45; 121pp; English.
XX
XX
CC The invention relates to an antisense compound 8 to 30 nucleotides in
CC length targeted to nucleic acid molecule encoding tumour necrosis factor
CC receptor 1 (TNFR1), where the antisense compound inhibits expression of
CC TNFR1. The antisense compound is useful for inhibiting the expression of
CC TNFR1 in cells or tissues. The antisense compound is also useful for
CC treating an animal (preferably human) having a disease or condition
CC associated with TNFR1, e.g. a liver disease (such as hepatitis, or liver
CC injury) or a hyperproliferative disorder such as cancer, by inhibiting
CC the expression of TNFR1. The antisense compound is useful for
CC diagnostics, therapeutics, prophylaxis and as research reagents and kits.
CC This polynucleotide sequence represents a human oligonucleotide relating
CC to the TNFR1 of the invention
XX
XX
SQ Sequence 18 BP; 3 A; 9 C; 4 G; 2 T; 0 U; 0 Other;
Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 5.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 302 CAGCGCTGCTGGAGGA 318
DB 17 CTGGGCTGCTGGAGGA 1
RESULT 792
ABT11916
ID ABT11916 standard; DNA; 18 BP.
XX
XX
AC ABT11916;
XX
XX
DT 19-DEC-2002 (first entry)
XX
XX
DE Neublastin DNA related PCR primer.
XX
XX
KW Nootropic; neuroprotective; antiparkinsonian; anticonvulsant; analgesic;
KW tranquiliser; antidiabetic; ophthalmological; neurodegenerative disorder;
KW neublastin; ischemic neuronal damage; traumatic brain injury; diabetes;
KW peripheral neuropathy; neuropathic pain; Alzheimer's disease; glaucoma;
KW Huntington's disease; Parkinson's disease; amyotrophic lateral sclerosis;
KW memory impairment; renal disease; PCR; primer; ss.
XX
XX
OS Unidentified.
XX
XX
PN WO200272826-A2.
XX
XX
PD 19-SEP-2002.
XX
XX
PF 12-MAR-2002; 2002WO-EP002691.
XX
XX
PR 12-MAR-2001; 2001US-00804615.
XX
XX
PA (BIOJ ) BIOGEN INC.
XX
XX
PA (NSGE-) NS GENE AS.
XX
XX
PI Sah DWY, Johansen TE, Rossomando A;
XX
XX
XX WPI; 2002-713515/77.
XX
XX
PT New truncated neublastin polypeptides lacking one or more amino-terminal
```

PT amino acids of a mature neublastin polypeptide useful for treating
PT neurodegenerative disorders, e.g. peripheral neuropathy, neuropathic
PT pain, brain injury.
XX
XX
PS Disclosure; Fig 8; 138pp; English.
XX
CC The invention relates to a truncated neublastin polypeptide comprising an
CC amino acid terminus that lacks one or more amino-terminal amino acids of
CC a mature neublastin polypeptide. The polypeptides and nucleic acids are
CC useful for treating neurodegenerative disorders such as ischemic neuronal
CC damage, traumatic brain injury, peripheral neuropathy, neuropathic pain,
CC Alzheimer's disease, Huntington's disease, Parkinson's disease,
CC amyotrophic lateral sclerosis, memory impairment, diabetes, renal
CC diseases, or glaucoma by moderating metabolism, growth, differentiation
CC or survival of a nerve or neuronal cell. This polynucleotide sequence is
CC a neublastin PCR primer of the invention
XX
SQ Sequence 18 BP; 1 A; 6 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 5.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 826 GCTGGCCCGCTGCAGG 842
DB 1 GCTGGCCCGCTGCAGG 17

RESULT 793
ADC42438
ID ADC42438 standard; DNA; 18 BP.
AC ADC42438;
XX
XX
DT 18-DEC-2003 (first entry)
XX
DE FANCD2 PCR primer MG476 SEQ ID NO:104.
XX
XX cancer; Fanconi Anemia; FA; BRCA; cytostatic; microarray;
XX chemosensitising; ss; PCR; primer.
XX
OS Synthetic.
XX
XX
XX WO2003039327-A2.
XX
XX 15-MAY-2003.
XX
XX 06-JUN-2002; 2002WO-US018153.
XX
XX
XX 02-NOV-2001; 2001US-00998027.
XX
XX 02-NOV-2001; 2001WO-US045561.
XX
XX (DAND) DANA FARBER CANCER INST.
XX
XX (UYOR-) UNIV OREGON HEALTH SCI.
XX
XX
XX D'andrea AD, Taniguchi T, Timmers C, Grompe M, Fox EA;
XX
XX WPI; 2003-441436/41.
XX
XX
XX Diagnosing or determining cancer or increased risk of cancer in a
XX patient, by testing Fanconi Anemia/BRCA pathway gene or protein for a
XX cancer-associated defect, that indicates cancer or increased risk of
XX cancer.
XX
XX Example 9; SEQ ID NO 104; 160pp; English.
XX
XX The invention relates to a novel method of diagnosing or determining if a
XX patient has cancer or is at increased risk of cancer, involving testing a
XX Fanconi Anaemia (FA)/BRCA pathway gene or protein for the presence of a
XX cancer-associated defect, where the presence of one or more cancer-
XX associated defects is indicative of cancer or an increased risk of cancer
XX in the patient. The method of the invention has cytostatic activity. The
XX method is useful for determining if a patient has cancer, or is at

CC increased risk of developing cancer, e.g. breast, ovarian or prostate
CC cancer. A microarray of the invention is useful for determining if a
CC patient has cancer, or is at increased risk of developing cancer, by
CC hybridising a nucleic acid sample to the nucleic acid sequences from the
CC array, and detecting the presence of mutations in FA/BRCA pathway genes
CC in the nucleic acid sample from the patient, where detecting the presence
CC of mutations is indicative of a patient who has cancer, or is at
CC increased risk of developing cancer. A method of the invention is useful
CC for screening a chemosensitising agent, and the agent obtained is useful
CC for treating a patient having a cancer. The present sequence is used in
CC the exemplification of the invention.
XX
SQ Sequence 18 BP; 2 A; 4 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 5.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 647 TGGCAGGCTCTGGAGGG 663
DB 2 TGGCAGGCTCTGGAGG 18

RESULT 794
ABX34421
ID ABX34421 standard; DNA; 18 BP.
XX
XX AC ABX34421;
XX
XX 11-FEB-2003 (first entry)
XX
DE PCR primer #2 for S. atroolivaceus leinamycin gene cluster ORF+4.
XX
XX Leinamycin biosynthesis gene cluster; Lmn; open reading frame; ORF;
XX anti-tumour antibiotic; broad spectrum antimicrobial activity;
XX Gram-positive; Gram-negative bacteria; chemical modification; metabolite;
XX apo-carrier protein; holo-carrier protein; tumour; polypeptide;
XX hybrid polypeptide/polypeptide metabolite; Lmn production; cytostatic;
XX PCR; primer; ss.
XX
XX Streptomyces atroolivaceus.
XX
XX WO200277179-A2.
XX
XX 03-OCT-2002.
XX
XX 22-MAR-2002; 2002WO-US008937.
XX
XX 26-MAR-2001; 2001US-0278935P.
XX
XX (REGC) UNIV CALIFORNIA.
XX (KYOW) KYOWA HAKKO KOGYO KK.
XX
XX Shen B, Cheng Y, Tang G;
XX
XX WPI; 2003-018907/01.
XX
XX Novel gene cluster responsible for synthesis of leinamycin in
XX Streptomyces atroolivaceus useful for making various peptide and/or
XX polypeptide, and/or hybrid polypeptide/polypeptide metabolites.
XX
XX Claim 1; Page 29; 185pp; English.
XX
XX The present invention relates to the isolation of the Streptomyces
XX atroolivaceus leinamycin (Lmn) biosynthesis gene cluster containing 71
XX open reading frames (ORFs) (ORFs -35 through -1, ORFs lnmA through lnmZ,
XX and ORFs +1 through +9). Leinamycin is a novel anti-tumour antibiotic
XX produced by several Streptomyces species. It exhibits broad spectrum
XX antimicrobial activity against Gram-positive and Gram-negative bacteria,
XX but not against fungi. The polypeptides encoded by the lnm biosynthesis
XX gene cluster ORFs are useful for chemically modifying a molecule in a
XX host cell. The host cell is a bacterium or eukaryotic cell, including a
XX mammalian, yeast, plant, fungal, or insect cell. The molecule is an


```
Query Match      1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 5.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 491 AAGAGGCAGGAGGCA 507
    ||||| |||||
Db 18 AAGAGGCAGCAGAAGCA 2

RESULT 797
ADP47488
ID ADP47488 standard; DNA; 18 BP.
XX
AC ADP47488;
XX
DT 09-SEP-2004 (first entry)
XX
DE Intelligent PCR primer for the identification of bacteria SeqID 143.
XX
KW PCR; ss; primer; pharmacogenetic analysis; medical diagnosis; cancer;
KW blood typing; virus stereotyping; pathogen; mass spectroscopy;
KW etiologic agent.
XX
OS Synthetic.
XX
PN WO2004052175-A2.
XX
PD 24-JUN-2004.
XX
PF 05-DEC-2003; 2003WO-US038830.
XX
PR 06-DEC-2002; 2002US-0431319P.
PR 18-DEC-2002; 2002US-00323233.
PR 18-DEC-2002; 2002US-00325526.
PR 18-DEC-2002; 2002US-00325527.
PR 18-DEC-2002; 2002US-00326051.
PR 29-JAN-2003; 2003US-0443443P.
PR 30-JAN-2003; 2003US-0443788P.
PR 14-FEB-2003; 2003US-0447529P.
PR 11-SEP-2003; 2003US-00660122.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Ecker DJ, Griffey RH, Hofstadler SA, Sampath R, Mcneil J;
PI Crooke ST;
XX
XX WPI; 2004-468672/44.
XX
PT Identifying a pathogen in a biological sample, useful in medical
PT diagnosis, comprises amplifying a nucleic acid from the sample with a
PT pair of intelligent primers, and determining the molecular mass of the
PT amplification product.
XX
PS Example 15; SEQ ID NO 143; 228pp; English.
XX
CC This invention relates to a novel method for the rapid identification of
CC pathogens occurring in environmental samples or biological samples
CC derived from humans and animals. Specifically, it refers to using
CC intelligent primers to obtain an amplification product in order that the
CC molecular mass of the amplicon can be determined by mass spectroscopy,
CC which in turn identifies the pathogen found in the sample. The present
CC invention describes the rapid detection and identification of an
CC etiologic agent that does not require nucleic acid sequencing, and
CC instead relies on the use of intelligent primers to target ribosomal RNA
CC or housekeeping genes. Accordingly, this method can be used to identify a
CC pathogen or infectious agent in a biological sample, which is useful in
CC pharmacogenetic analysis and medical diagnosis (including cancer
CC diagnosis based on mutations and polymorphisms), or for detecting single
CC nucleotide polymorphisms in blood typing or stereotyping of viruses. This
CC oligonucleotide sequence is an intelligent PCR primer used to identify
CC different bacterial strains, given in an exemplification of the
CC invention.
XX

SQ Sequence 18 BP; 3 A; 8 C; 3 G; 4 T; 0 U; 0 Other;
Query Match      1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 5.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 258 CCATGCTGCACCTGCT 274
    ||||| |||||
Db 1 CCATGCGACGACCTGTCT 17

RESULT 798
ADQ59846
ID ADQ59846 standard; DNA; 18 BP.
XX
AC ADQ59846;
XX
DT 07-OCT-2004 (first entry)
XX
DE Intelligent PCR primer 16S_EC_326_1058 reverse SEQ ID NO:143.
XX
KW ss; etiologic agent; disease; intelligent primer;
KW pathogen identification; PCR; primer.
XX
OS Synthetic.
XX
PN WO2004060278-A2.
XX
PD 22-JUL-2004.
XX
PF 05-DEC-2003; 2003WO-US038761.
XX
PR 06-DEC-2002; 2002US-0431319P.
PR 18-DEC-2002; 2002US-00323233.
PR 18-DEC-2002; 2002US-00325526.
PR 18-DEC-2002; 2002US-00325527.
PR 18-DEC-2002; 2002US-00326051.
PR 29-JAN-2003; 2003US-0443443P.
PR 30-JAN-2003; 2003US-0443788P.
PR 14-FEB-2003; 2003US-0447529P.
PR 11-SEP-2003; 2003US-0501926P.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Ecker DJ, Griffey RH, Sampath R, Hofstadler SA, Mcneil J;
PI Crooke ST, Blyn LB, Ranken R, Hall TA;
XX
XX WPI; 2004-534302/51.
XX
PT Identifying pathogens in humans or animals comprises amplifying a nucleic
PT acid molecule from the individual with intelligent primers to obtain
PT amplification products, and determining molecular masses of the
PT amplification products.
XX
PS Claim 40; SEQ ID NO 143; 184pp; English.
XX
CC The invention relates to a novel method for identifying etiologic agents
CC of disease in an individual comprising amplifying a nucleic acid from a
CC biological sample of the individual with intelligent primers to obtain
CC amplification products corresponding to the etiologic agents, and
CC determining the molecular masses of the amplification products. The
CC composition and methods of the invention are useful for identifying
CC pathogens in biological samples from humans and animals, resolving
CC etiologic agents present in samples obtained from humans and animals,
CC determining detailed genetic information about such pathogens or
CC etiologic agents, and for rapidly detecting and identifying bioagents
CC from environmental, clinical or other samples. The present sequence
CC represents an intelligent PCR primer of the invention.
XX
SQ Sequence 18 BP; 3 A; 8 C; 3 G; 4 T; 0 U; 0 Other;
Query Match      1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 5.9e+02;
```

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 258 CCATGCTGCACCTGCTT 274
 ||||| ||||| |||||
 Db 1 CCATGAGCAGCCTGCTT 17

RESULT 799
 ADR06076/c
 ID ADR06076 standard; DNA; 18 BP.
 XX
 AC ADR06076;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE Human TNFR1 antisense oligonucleotide seqid 74.
 XX
 KW cytostatic; gene therapy; apoptosis inhibitor;
 KW radiation-induced apoptosis; tumour necrosis factor receptor 1; TNFR1;
 KW human; antisense oligonucleotide; antisense technology; ss.
 OS Homo sapiens.
 XX

Key Location/Qualifiers
 modified_base 1..18
 /*tag= b
 /mod_base= OTHER
 /note= "OTHER= Phosphorothioate backbone"
 modified_base 1..14
 /*tag= a
 /mod_base= OTHER
 /note= "OTHER= Optionally 2'-O-Methoxyethyl (2'-MOE) nucleotides"
 modified_base 15..18
 /*tag= c
 /mod_base= OTHER
 /note= "OTHER= Optionally 2'-O-Methoxyethyl (2'-MOE) nucleotides"
 US2004147471-A1.
 XX
 PD 29-JUL-2004.
 XX
 PF 06-NOV-2003; 2003US-00702817.
 XX
 PR 26-JUN-1998; 98US-00106038.
 PR 17-JUN-1999; 99WO-US013763.
 PR 24-OCT-2000; 2000US-00695451.
 XX
 PA (ZHAN/) ZHANG H.
 XX
 PI Zhang H;
 XX
 DR WPI; 2004-561407/54.
 XX
 PT Inhibiting radiation-induced apoptosis in a cell or tissue comprises
 PT administering to the cell or tissue an antisense oligonucleotide targeted
 PT to a nucleic acid molecule encoding tumor necrosis factor receptor 1.
 XX
 PS Example 10; SEQ ID NO 74; 24pp; English.
 XX
 CC The invention describes a method of inhibiting radiation-induced
 CC apoptosis in a cell or tissue comprising administering to the cell or
 CC tissue an antisense oligonucleotide of 8-30 nucleotides in length
 CC targeted to a nucleic acid molecule encoding tumour necrosis factor
 CC receptor 1 (TNFR1). The method and antisense oligonucleotides are useful
 CC for inhibiting radiation-induced apoptosis in a cell or tissue, and for
 CC treating diseases associated with the expression of TNFR1. This sequence
 CC represents a human tumour necrosis factor receptor 1 (TNFR1) antisense
 CC oligonucleotide.
 XX
 SQ Sequence 18 BP; 3 A; 9 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 5.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 302 CAGCGCTGCTGGAGGA 318
 ||||| ||||| |||||
 Db 17 CTGGGCTGCTGGAGGA 1

RESULT 800
 ADT00917
 ID ADT00917 standard; DNA; 18 BP.
 XX
 AC ADT00917;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Novel mutant protein tyrosine kinase-related oligonucleotide SeqID905.
 XX
 KW tyrosine kinase; cancer; anti-cancer agent; signalling molecule;
 KW tumorigenesis; somatic alteration; colorectal cancer; NTRK3; FES;
 KW GUCY2F; MCKK; MLK4; kinase domain; cytostatic; tyrosine kinase inhibitor;
 KW guanylate cyclase stimulator; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004082458-A2.
 XX
 PD 30-SEP-2004.
 XX
 PF 18-FEB-2004; 2004WO-US004452.
 XX
 PR 21-FEB-2003; 2003US-0448537P.
 PR 29-MAY-2003; 2003US-0473895P.
 XX
 PA (UYJO) UNIV JOHNS HOPKINS.
 XX
 PI Bardelli A, Parsons W, Velculescu V, Kinzler KW, Vogelstein B;
 XX
 DR WPI; 2004-718702/70.
 XX
 PT Activated mutant protein tyrosine kinases (e.g. NTRK3, FES and MCKK) and
 PT associated methods for diagnosing cancer and screening for anti-cancer
 PT agents.
 XX
 PS Disclosure; SEQ ID NO 905; 363pp; English.
 XX
 CC This invention relates to a novel activated mutant protein tyrosine
 CC kinases and associated methods for diagnosing cancer and screening for
 CC anti-cancer agents. Protein kinases are signalling molecules involved in
 CC tumorigenesis. Mutational analysis of the human tyrosine kinase gene
 CC family identified somatic alteration sin 1 in 5 colorectal cancers, with
 CC the majority of mutations occurring in the NTRK3, FES, GUCY2F and
 CC MCKK/MLK4 genes. Most were identified in the kinase domain. The invention
 CC may be useful for the production of compounds with a cytostatic activity
 CC acting as protein tyrosine kinase inhibitors or guanylate cyclase
 CC stimulators. The invention may be useful for developing methods for
 CC detecting mutations involved in cancer or screening for anti-cancer
 CC agents. The present sequence is that of a human-derived oligonucleotide
 CC which is related to the invention.
 XX
 SQ Sequence 18 BP; 6 A; 2 C; 10 G; 0 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 5.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 402 GCCAGAGGGAGGAGAG 418
 ||||| ||||| |||||
 Db 2 GCCAGAGGGAGGAGAGG 18

RESULT 801

AD74661/c
 ID AD74661 standard; DNA; 18 BP.
 XX
 AC AD74661;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Allele specific primer A for human stenosis associated marker hCV1997488.
 XX
 DE Human; ss; PCR; primer; Allele specific primer; coronary stenosis;
 KW angina; ischaemic chest pain; myocardial infarction;
 KW sudden cardiac death; SNP; single nucleotide polymorphism.
 XX
 OS Homo sapiens.
 XX
 XX W02004081186-A2.
 PN
 XX 23-SEP-2004.
 PD
 XX 10-MAR-2004; 2004WO-US007140.
 PF
 XX 10-MAR-2003; 2003US-0453050P.
 PR
 XX 30-APR-2003; 2003US-0466437P.
 PR
 XX (APPL-) APPLERA CORP.
 PA
 XX Cargill M, Devlin JJ, Luke MW;
 PI
 XX WPI; 2004-668949/65.
 DR
 XX Identifying an individual who has altered risk for developing stenosis
 PT comprises detecting single nucleotide polymorphism (SNP), in the
 PT individual's nucleic acids.
 PT
 XX Claim 19; SEQ ID NO 67973; 146pp; English.
 PS
 XX The invention relates to identifying an individual who has altered risk
 CC for developing coronary stenosis comprising detecting a single nucleotide
 CC polymorphism (SNP) in any one of the 67073 nucleotide sequences (not
 CC given in the specification), in the individual's nucleic acids, where the
 CC presence of the SNP is correlated with an altered risk for stenosis in
 CC the individual. Also included are an isolated nucleic acid molecule
 CC comprising at least 8 contiguous nucleotides where one of the
 CC nucleotides is an SNP as cited above, or their complement), an isolated
 CC polypeptide comprising an amino acid sequence selected from any of the
 CC 696 amino acid sequences (not defined in the specification), an antibody
 CC that specifically binds to the polypeptide (or its antigen-binding
 CC fragment), an amplified polynucleotide containing the SNP as cited (where
 CC the amplified polynucleotide is between about 16 and about 1,000
 CC nucleotides in length), an isolated polynucleotide which specifically
 CC hybridises to a nucleic acid molecule containing the SNP, a kit for
 CC detecting a SNP in a nucleic acid, detecting a SNP in a nucleic acid
 CC molecule, detecting a variant polypeptide and identifying an agent useful
 CC in therapeutically or prophylactically treating stenosis. The detection
 CC step of the method is carried out by a process selected from allele-
 CC specific probe hybridisation, allele-specific primer extension, allele-
 CC specific amplification, sequencing, 5' nuclease digestion, molecular
 CC beacon assay, oligonucleotide ligation assay, size analysis, and single-
 CC stranded conformation polymorphism. The method is useful for identifying
 CC an individual who has altered risk for developing coronary stenosis,
 CC which can lead to angina (ischaemic chest pain), myocardial infarction
 CC and ultimately sudden cardiac death. The present sequence is an allele
 CC specific primer for amplifying a SNP-containing region of a human marker
 CC gene associated with stenosis. NOTE: SEQ ID 1-67771 are not shown in the
 CC specification but are provided on a CD-R named CL001510CDR which was not
 CC supplied with the specification.
 XX
 SQ Sequence 18 BP; 3 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 5.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 603 AGCTGCAGGAGAGCCAG 619
 Db 17 AGCTTCAGCAGAGCCAG 1
 RESULT 802
 AAV20512
 ID AAV20512 standard; DNA; 17 BP.
 XX
 AC AAV20512;
 XX
 DT 30-JUN-1998 (first entry)
 XX
 DE Probe for Conus geographus conantokin DNA.
 DE
 XX Conantokin; predatory cone snail; treatment; neurologic disorder;
 KW psychiatric disorder; anticonvulsant; neuroprotective; analgesic;
 KW HIV infection; ophthalmic indication; memory; learning defect;
 KW cognitive defect; probe; ss.
 XX
 OS Synthetic.
 OS Conus geographus.
 XX
 PN W09803541-A1.
 XX
 PD 29-JAN-1998.
 XX
 PF 21-JUL-1997; 97WO-US012618.
 XX
 PR 22-JUL-1996; 96US-00684742.
 PR
 XX (UTAH) UNIV UTAH RES FOUND.
 PA (COGN-) COGNETIX INC.
 XX
 PI Abogadie FC, Cruz LJ, Olivera BM, Walker C, Colledge C;
 PI Hillyard DR, Jimenez E, Laver RT, Zhou L, Shen GS, McCabe RT;
 PI Rivier JE;
 PI
 XX WPI; 1998-120694/11.
 DR
 XX New conantokin peptide(s) - useful for e.g. treating neurologic or
 PT psychiatric disorders, or the management of pain.
 PT
 XX Claim 20; Page 79; 122pp; English.
 PS
 XX The present sequence is a probe for the DNA encoding Conus geographus
 CC conantokin, peptide derivatives of which can be used to treat neurologic
 CC and psychiatric disorders, e.g. as an anticonvulsant, neuroprotective or
 CC analgesic agent. Neurologic and psychiatric disorders include epilepsy,
 CC convulsions, neurotoxic injury (associated with conditions of hypoxia,
 CC anoxia or ischaemia, which typically follow stroke, cerebrovascular
 CC accident, brain or spinal cord trauma, myocardial infarct, physical
 CC trauma, drowning, suffocation, perinatal asphyxia or hypoglycaemic
 CC events), neurodegeneration (associated with Alzheimer's disease, senile
 CC dementia, Amyotrophic lateral sclerosis, Multiple Sclerosis, Parkinson's
 CC disease, Huntington's disease, Down's Syndrome, Korsakoff's disease,
 CC schizophrenia, AIDS dementia, multi-infarct dementia, Binswanger dementia
 CC and neuronal damage associated with uncontrolled seizures), chemical
 CC toxicity (such as addiction, and morphine, opiate, opioid and barbiturate
 CC tolerance), pain (acute, chronic, migraine), anxiety, major depression,
 CC manic-depressive illness, obsessive-compulsive disorder, schizophrenia,
 CC and mood disorders (such as bipolar disorder, unipolar depression,
 CC dysthymia and seasonal affective disorder) and dystonia (movement
 CC disorder), sleep disorder, muscle relaxation and urinary incontinence.
 CC The peptide can also be used to treat HIV infection, ophthalmic
 CC indication and memory, learning or cognitive defects
 XX
 SQ Sequence 17 BP; 6 A; 2 C; 2 G; 1 T; 0 U; 6 Other;

Query Match 1.8%; Score 13.6; DB 1; Length 17;
 Best Local Similarity 62.5%; Pred. No. 5.8e+02;
 Matches 10; Conservative 6; Mismatches 0; Indels 0; Gaps 0;


```

QY 315 AGGAGAAATCAAGAGCT 330
   ||:||||:||||:|
Db 2 ARGARAAACAGARYT 17

RESULT 805
AAQ33752
ID AAQ33752 standard; DNA; 15 BP.
XX
AC AAQ33752;
XX
XX 25-MAR-2003 (revised)
DT 02-FEB-1993 (first entry)
XX
XX Microsatellite sequence from clone TGLA162.
XX
XX PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW genetic mapping; traits; amplification; ss.
XX
XX Bos taurus.
OS
XX
XX W09213102-A1.
PN
XX
XX 06-AUG-1992.
PD
XX
XX 15-JAN-1992; 92WO-US000340.
PF
XX
XX 15-JAN-1991; 91US-00642342.
PR
XX
XX (GENM-) GENMARK.
PA
XX
XX Georges M, Massey JM;
PI
XX
XX WPI; 1992-284684/34.
DR
XX
XX Polymorphic bovine DNA markers - used in genetic identification, gene
PT mapping, and selective breeding.
PS
XX Table 7; Page 231; 517pp; English.
XX
XX The sequence is that of a bovine microsatellite sequence obt'd. by
CC screening a library of bovine MboI DNA fragments of between 250 and 500
CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC clones cross-hybridised. Assuming independent distribution of
CC microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC in the bovine genome is estimated at >100, 000. The sequence information
CC for ca. 230 such bovine microsatellites is summarised in the
CC specification and indexed herein (see below). The sequences upstream and
CC downstream of the microsatellite sequence were used to generate the
CC required PCR primers for in vitro amplification of the corresp.
CC microsatellite (using the program OPTIPRIM). The microsatellites may be
CC used to identify individuals for parentage testing, and in the genetic
CC mapping of economic trait loci, or genes involved in the determination of
CC economically important traits esp. in cattle, to allow selective
CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC field.)
XX
XX Sequence 15 BP; 5 A; 5 C; 5 G; 0 T; 0 U; 0 Other;
QY Query Match 1.8%; Score 13.4; DB 1; Length 15;
   Best Local Similarity 93.3%; Pred. No. 5.3e+02;
   Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Db 718 GCTGACGACGACGA 732
   ||| ||||| ||||| |||||
   1 GCAGCAGCAGCAGCA 15

RESULT 806
AAT37567/c
ID AAT37567 standard; mRNA; 15 BP.
XX
AC AAT37567;

QY 11-NOV-1996 (first entry)
XX
XX Apo(a) mRNA (nt. pos. 11423) hammerhead ribozyme target sequence.
DE
XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
KW hammerhead ribozyme; target sequence; diagnosis; treatment;
KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
KW restenosis; heart disease; human; ss.
XX
XX Homo sapiens.
OS
XX
XX W09609392-A1.
PN
XX
XX 28-MAR-1996.
PD
XX
XX 21-SEP-1995; 95WO-US011995.
PF
XX
XX 23-SEP-1994; 94US-00311760.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Stinchcomb DT, Meswigen J, Newton RS, Ramharack R;
PI
XX
XX WPI; 1996-188454/19.
DR
XX
XX Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
PT treatment of conditions related to lip(a) levels, e.g. atherosclerosis,
PT myocardial infarction, and heart diseases.
XX
XX Claim 2; Page 18; 37pp; English.
XX
XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
CC complementary to the present sequence (nucleotide position 11423). The
CC ribozyme blocks to some extent apo(a) expression, and can therefore be
CC used to diagnose or treat conditions related to lipoprotein (a) levels,
CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
CC disease. PCR was used to generate a substrate for T7 RNA polymerase
CC transcription from human apo(a) cDNA clones. Labelled transcripts were
CC synthesised in vitro to form 2 templates. The oligonucleotides and
CC labelled transcripts were annealed, RNaseH added and the mixes.
CC incubated. After a designated time the reactions were stopped, and RNA
CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
CC cleaved was determined by autoradiographic quantification, and the most
CC accessible ribozyme target sites chosen
XX
XX Sequence 15 BP; 3 A; 7 C; 3 G; 0 T; 2 U; 0 Other;
QY Query Match 1.8%; Score 13.4; DB 1; Length 15;
   Best Local Similarity 93.3%; Pred. No. 5.3e+02;
   Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Db 456 TGCTGGAGAGACTCG 470
   ||||| ||||| |||||
   15 TGCTGGAGAGACTCG 1

RESULT 807
AAQ65327/c
ID AAQ65327 standard; RNA; 15 BP.
XX
XX
AC AAQ65327;
XX
XX 20-JUL-1999 (first entry)
DT
XX
XX Mouse B7-1 hammerhead ribozyme target SEQ ID NO:1959.
DE
XX
XX Arthritic condition; graft tolerance; immune response; target; cleavage;
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
KW diagnosis; ss.

```


XX PN WO200056930-A1.
XX PD 28-SEP-2000.
XX PF 20-MAR-2000; 2000WO-US007486.
XX PR 24-MAR-1999; 99US-00275850.
XX PA (NEXS-) NEXSTAR PHARM INC.
XX PI Pagratis N, Gold L, Shtatland T, Javornik B;
XX DR WPI; 2000-594583/56.
XX PT Identifying nucleic acid ligands of a target molecule comprises annealing
XX PT complementary oligonucleotides, partitioning the nucleic acids and
XX PT amplifying the nucleic acids exhibiting increased affinity.
XX PS Example 2; Page 76; 264pp; English.
XX CC The invention relates to a method of identifying nucleic acid ligands of
XX CC a target molecule from a candidate mixture composed of single stranded
XX CC nucleic acids, each having a region of randomised sequence and a region
XX CC of fixed sequence. The method uses modified versions of the SLEX
XX CC (systematic evolution of ligands by exponential enrichment) method in
XX CC which the participation of fixed sequences is minimised or eliminated.
XX CC This method comprises annealing complementary oligonucleotides to the
XX CC fixed sequences of the candidate molecule mixture, contacting the
XX CC candidate mixture with the target molecule, partitioning the nucleic
XX CC acids which have increased affinity relative to the candidate mixture,
XX CC and amplifying the nucleic acids exhibiting increased affinity to yield a
XX CC ligand enriched mixture of nucleic acids. In one embodiment of the
XX CC invention, one or more regions of fixed sequences is replaced with
XX CC different fixed sequences, and the binding, partitioning and
XX CC amplification steps are repeated. In another embodiment, the partitioned
XX CC nucleic acids are hybridised with a library of single stranded
XX CC complementary nucleic acids, are then amplified, and the fixed regions of
XX CC the increased affinity nucleic acids cleaved. In the exemplifications of
XX CC the invention, a consensus binding site for MS2 CP (bacteriophage MS2
XX CC replicase fragment was identified by SLEX. MS2 CP binding sites were
XX CC then identified in the Escherichia coli genomic library by SLEX or by
XX CC the RNAMOT program. The present sequence represents an E. coli MS2 CP
XX CC binding site identified by the RNAMOT program
XX SQ Sequence 15 BP; 4 A; 5 C; 5 G; 0 T; 1 U; 0 Other;

Query Match 1.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 5.3e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 720 TGCAGCAGCAGCACCA 734
Db :|||||||
1 UGCAGCAGCAGCGCA 15

RESULT 810
AAF45430
ID AAF45430 standard; DNA; 15 BP.
XX AC
XX AAF45430;
XX DT 30-MAR-2001 (first entry)
XX DE IGFBP2 oligonucleotide #269.
XX KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytosstatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
XX KW Homo sapiens.

KW neovascular condition of the retina; ss.
XX Homo sapiens.
XX PN WO200078341-A1.
XX PD 28-DEC-2000.
XX PF 21-JUN-2000; 2000WO-AU000693.
XX PR 21-JUN-1999; 99US-0140345P.
XX PA (MURD-) MURDOCH CHILDRENS RES INST.
XX PI Wraight CJ, Werther GA, Edmondson SR;
XX DR WPI; 2001-041421/05.
XX PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX PT inhibits or reduces growth factor mediated cell proliferation and/or
XX PT inflammation.
XX PS Example 6; Page 35; 201pp; English.
XX CC The present invention relates to a method for ameliorating the effects of
XX CC skin disorders. The method comprises contacting the skin with an
XX CC antisense oligonucleotide, [for Insulin-like Growth Factor [IGF]-1
XX CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3], which is capable of
XX CC inhibiting or reducing growth factor mediated cell proliferation,
XX CC inflammation and/or other disorders. The present sequence is an
XX CC oligonucleotide which can be used to design the antisense
XX CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
XX CC r45161). The method is useful for ameliorating the effects of psoriasis,
XX CC ichthyosis, ptyriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
XX CC neoplasia, scleroderma, warts, benign growths, cancers of the skin, a
XX CC hyperneovascular condition such as a neovascular condition of the retina,
XX CC brain or skin, growth factor-mediated malignancies, other sclerotic
XX CC disease, kidney disease, hyperproliferation of the inside of blood
XX CC vessels or any other hyperplasia
XX SQ Sequence 15 BP; 1 A; 7 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 5.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 795 AGCGCCAGCGCGCT 809
Db :|||||||
1 AGCGCTGCGCGCT 15

RESULT 811
AAF45429
ID AAF45429 standard; DNA; 15 BP.
XX AC
XX AAF45429;
XX DT 30-MAR-2001 (first entry)
XX DE IGFBP2 oligonucleotide #268.
XX KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytosstatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
XX KW Homo sapiens.

PN WO200078341-A1.
 XX 28-DEC-2000.
 XX 21-JUN-2000; 2000WO-AU000693.
 XX 21-JUN-1999; 99US-0140345P.
 XX (MURD-) MURDOCH CHILDRENS RES INST.
 XX Wright CJ, Werther GA, Edmondson SR;
 XX WPI; 2001-041421/05.
 XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisenescence nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX Example 6; Page 35; 201pp; English.
 XX The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisenescence oligonucleotide, (for insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisenescence
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloide, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX Sequence 15 BP; 1 A; 7 C; 6 G; 1 T; 0 U; 0 Other;
 SQ Query Match 1.8%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 5.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 794 GAGCGCCGCGCCGCC 808
 DB 1 GAGCGCCGCGCCGCC 15
 RESULT 812
 ID AAF47286/c
 XX AAF47286 standard; DNA; 15 BP.
 XX AAF47286;
 XX 30-MAR-2001 (first entry)
 XX IGFBP3 oligonucleotide #706.
 XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytoskeletal; dermatological; cardiant; virucide; ophthalmological; keloide;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX Homo sapiens.
 OS 2000078341-A1.
 PN 28-DEC-2000.
 XX

PF 21-JUN-2000; 2000WO-AU000693.
 XX 21-JUN-1999; 99US-0140345P.
 XX (MURD-) MURDOCH CHILDRENS RES INST.
 XX Wright CJ, Werther GA, Edmondson SR;
 XX WPI; 2001-041421/05.
 XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisenescence nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX Example 7; Page 48; 201pp; English.
 XX The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisenescence oligonucleotide, (for insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisenescence
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloide, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX Sequence 15 BP; 1 A; 7 C; 2 G; 5 T; 0 U; 0 Other;
 SQ Query Match 1.8%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 5.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 806 GCCTCGGAGGAGAG 820
 DB 15 GACTCGGAGGAGAG 1
 RESULT 813
 ID ABX01206/c
 XX ABX01206 standard; RNA; 15 BP.
 XX ABX01206;
 XX 23-DEC-2002 (first entry)
 XX Hepatitis C virus substrate #988 for HCV hammerhead ribozyme #988.
 DE Hepatitis C virus.
 XX Enzymatic nucleic acid; RNA cleavage; Hepatitis C virus infection;
 KW HCV ribozyme; HCV expression; HCV replication; cirrhosis; virucide;
 KW liver failure; hepatocellular carcinoma; HCV infection; drug therapy;
 KW type I interferon; interferon alpha; interferon beta; cytostatic;
 KW interferon gamma; consensus interferon; hepatotropic; antiinflammatory;
 KW substrate; hammerhead ribozyme; HH ribozyme; ss.
 XX Hepatitis C virus.
 OS US2002082225-A1.
 PN 27-JUN-2002.
 XX 23-MAR-1999; 99US-00274553.
 XX 23-MAR-1999; 99US-00274553.
 XX (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J A.

PN W05923225-A2.
 XX 31-AUG-1995.
 XX 23-FEB-1995; 95WO-1B000156.
 XX 23-FEB-1994; 94US-00201109.
 PR 29-MAR-1994; 94US-00218934.
 PR 04-APR-1994; 94US-00222795.
 PR 07-APR-1994; 94US-00224483.
 PR 15-APR-1994; 94US-00227958.
 PR 15-APR-1994; 94US-00228041.
 PR 18-MAY-1994; 94US-00245736.
 PR 06-JUL-1994; 94US-00271280.
 PR 16-AUG-1994; 94US-00291433.
 PR 17-AUG-1994; 94US-00292620.
 PR 19-AUG-1994; 94US-00293520.
 PR 02-SEP-1994; 94US-00300000.
 PR 08-SEP-1994; 94US-00303039.
 PR 23-SEP-1994; 94US-00311486.
 PR 23-SEP-1994; 94US-00311749.
 PR 28-SEP-1994; 94US-00314397.
 PR 03-OCT-1994; 94US-00316771.
 PR 07-OCT-1994; 94US-00319492.
 PR 11-OCT-1994; 94US-00321993.
 PR 04-NOV-1994; 94US-00334847.
 PR 10-NOV-1994; 94US-00337608.
 PR 28-NOV-1994; 94US-00345516.
 PR 16-DEC-1994; 94US-00357577.
 PR 23-DEC-1994; 94US-00363233.
 PR 30-JAN-1995; 95US-00380734.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX Stinchcomb DT, Chowrira B, Drenzo A, Draper KG, Dudycz LW;
 PI Grimm S, Karpeisky A, Kisich K, Matulic-Adamic J, Mcswiggen JA;
 PI Modak A, Pavco P, Beigleman L, Sullivan SM, Sweedler D, Thompson JD;
 PI Tracz D, Usman N, Wincott FE, Woolf T;
 XX WPI; 1995-351090/45.
 DR Ribozymes having modified bases and methods for producing them - for use
 XX in inhibiting disease related genes.
 PT Claim 2; Page 200; 407pp; English.
 PS The present sequence represents a preferred target sequence for an
 XX enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICAM-1 mRNA at the
 CC nucleotide base position indicated in the DE line. Regions of the mRNA
 CC that do not form secondary folding structures and that contain potential
 CC hammerhead and hairpin ribozyme cleavage sites were identified by
 CC computer analysis. Ribozymes directed against these mRNA sequences were
 CC designed and synthesised with modifications that improve their nuclease
 CC resistance. The ribozymes cleave the ICAM-1 target sequences and thereby
 CC inhibit ICAM-1 expression, making them useful for reducing transplant
 CC rejection and alleviating symptoms in patients with rheumatoid arthritis,
 CC asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to
 CC correct PI field.)
 XX SQ Sequence 16 BP; 2 A; 4 C; 7 G; 0 T; 3 U; 0 Other;
 Query Match 1.8%; Score 13.4; DB 1; Length 16;
 Best Local Similarity 80.0%; Pred. No. 5.7e+02;
 Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
 QY 304 GCGCTGCCTGGAGGA 318
 Db 1 GCGCGCCUGGUGGA 15
 RESULT 816
 ACF06258/c

ID ACF06258 standard; DNA; 16 BP.
 XX ACF06258;
 AC 06-OCT-2003 (first entry)
 DT Human NOV4 forward PCR primer SEQ ID NO:36.
 DE Human; NOVX; cytostatic; antidiabetic; neuroprotective; antiparkinsonian;
 XX anorectic; gene therapy; vaccine; cancer; neurodegenerative disorder;
 KW Parkinson's disease; metabolic disorder; diabetes; obesity;
 KW tissue typing; PCR primer; ss.
 XX Homo sapiens.
 OS Synthetic.
 OS WO2003052061-A2.
 PN 26-JUN-2003.
 XX 03-DEC-2002; 2002WO-US038821.
 PF 17-DEC-2001; 2001US-0341477P.
 PR 17-DEC-2001; 2001US-0341540P.
 PR 20-DEC-2001; 2001US-0342592P.
 PR 31-DEC-2001; 2001US-0344903P.
 PR 17-APR-2002; 2002US-0373288P.
 PR 15-MAY-2002; 2002US-0380981P.
 PR 17-MAY-2002; 2002US-0381495P.
 PR 28-MAY-2002; 2002US-0383744P.
 PR 29-MAY-2002; 2002US-0384024P.
 PR 07-AUG-2002; 2002US-0401788P.
 PR 26-AUG-2002; 2002US-0406353P.
 PR 31-OCT-2002; 2002US-0422756P.
 PR 02-DEC-2002; 2002US-00307928.
 XX (CURA-) CURAGEN CORP.
 PA Alsobrook JP, Anderson DW, Boldog FL, Burgess CE, Catterton E;
 PI Edinger SR, Gorman L, Guo X, Ji W, Kekuda R, Li L, Patturajan M;
 PI Rieger DK, Shenoy SG, Spytek KA, Vernet CM, Voss EZ, Zhong M;
 XX WPI; 2003-533005/50.
 DR New NOVX polypeptide, useful for preparing a composition for treating or
 XX preventing e.g. cancer, neurodegenerative disorders such as Parkinson's
 PT disease, or metabolic disorders such as diabetes or obesity, or for
 PT tissue typing.
 PS Example C; Page 159; 190pp; English.
 XX ACF06233 to ACF06242 encode the human NOVX proteins given in ABR83334 to
 CC ABR83343, designated NOV1a, NOV2a, NOV3a, NOV4a, NOV4b, NOV5a, NOV6a,
 CC NOV7a, NOV8a and NOV9a respectively. NOVX sequences can have cytostatic,
 CC antidiabetic, neuroprotective, antiparkinsonian and anorectic activities,
 CC and can be used in vaccines and gene therapy. The NOVX polypeptides can
 CC be used for preparing a composition for treating or preventing a
 CC pathology associated with the NOVX-polypeptides e.g. cancer, or
 CC neurodegenerative disorders such as Parkinson's disease, or metabolic
 CC disorders such as diabetes or obesity, or for tissue typing. The present
 CC sequence represents a PCR primer for human NOV4, which is used in an
 CC example from the present invention
 XX SQ Sequence 16 BP; 2 A; 6 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 1.8%; Score 13.4; DB 1; Length 16;
 Best Local Similarity 93.3%; Pred. No. 5.7e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 201 GTGGCCCGCAGCAG 215
 Db 15 GTGGCCCTGCAGCAG 1

RESULT 817
ADN01434/c
ID ADN01434 standard; DNA; 16 BP.
XX
AC ADN01434;
XX
01-JUL-2004 (first entry)
XX
DE Klebsiella oxytoca probe.
XX
XX detection; bacteria; hybridisation; probe; DNA chip; blood culture; ss.
XX
OS Klebsiella oxytoca.
XX
PN W02004029299-A2.
XX
PD 08-APR-2004.
XX
XX 23-SEP-2003; 2003MO-EP010584.
XX
XX 24-SEP-2002; 2002DE-01044456.
XX
XX (HAIN-) HAIN LIFESCENCE GMBH.
XX
XX Weizenegger M, Bollen M;
XX
XX WPI; 2004-340440/31.
XX
XX Detecting clinically important bacteria, useful for diagnosis,
PT particularly in blood cultures, comprises hybridization to sequence- or
PT species-specific probes.
XX
XX Claim 1; SEQ ID NO 27; 90pp; German.
XX
XX This invention describes a novel method for detecting clinically relevant
CC bacteria which comprises hybridisation in which a target nucleic acid,
CC representing part of the genome of the bacteria or its complement, is
CC hybridised under stringent conditions to a sequence- and/or species-
CC specific probe, then the nucleic acid, or its hybridisation to the probe,
CC is detected. Either the probes are immobilized (particularly to a solid
CC phase through a linker, e.g. on a DNA chip) and the nucleic acid is
CC labelled, or the probe is labelled. The method is useful for diagnostic
CC detection of bacteria, particularly in blood cultures, including
CC differentiation between species. A typical self-amplifying chip supported
CC 12 pairs of immobilized primers, each pair specific for a particular
CC species of bacterium, at different locations. It was used to perform a
CC solid-phase PCR (15 minutes at 95degC, then 40 cycles of 15 seconds at
CC 95degC and 45 seconds at 58degC, in presence of Cy5-labelled
CC deoxycytosine triphosphate), then washed and fluorescence at each
CC location measured using a confocal laser scanner. ADN01408-ADN01573
CC represent probes used in the method of the invention.
XX
SQ Sequence 16 BP; 5 A; 5 C; 4 G; 2 T; 0 U; 0 Other;
Query Match 1.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 5.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 592 CTTGCTCGGGAGCT 606
DB 15 CTTGCTCGGGAGCT 1
RESULT 818
AAT93742/c
ID AAT93742 standard; DNA; 17 BP.
XX
AC AAT93742;
XX
XX 25-MAR-2003 (revised)
DT 06-FEB-1998 (first entry)
XX

DE DNA probe 1 specific for type-T cytoplasmic male sterility in Zea mays.
XX
XX TURF 2H3; maize; cytoplasm male sterility; cms; type T; cms-T;
KW open reading frame 13; probe; restriction fragment; mitochondrial DNA;
KW sterility test; ss.
XX
OS Zea mays.
XX
PN US5660983-A.
XX
PD 26-AUG-1997.
XX
XX 23-NOV-1994; 94US-00345264.
PF
XX 04-DEC-1986; 86US-00937926.
PR
XX 17-JUN-1991; 91US-00716645.
PR
XX (MYCO) MYCOGEN PLANT SCI INC.
PA (UYNC-) UNIV NORTH CAROLINA STATE.
PA
XX Dewey R, Levings CS;
XX
XX WPI; 1997-434374/40.
DR
XX DNA probes specific for mitochondrial DNA associated with type-T
PT cytoplasmic male sterility - for detecting male sterility in maize
PT plants.
XX
XX Claim 4; Col 23; 16pp; English.
XX
XX This DNA fragment is part of the TURF 2H3 region of Zea Mays. TURF 2H3
CC (3547 nucleotides long) is found in mitochondrial DNA, and is uniquely
CC arranged in maize affected by cytoplasm male sterility type T (cms-T).
CC The present sequence corresponds to positions 1400-1416 of TURF 2H3, and
CC is located in the middle of open reading frame 13. A synthetic
CC oligonucleotide whose sequence is complementary to the present sequence
CC has also been claimed. Both oligonucleotides can be used as probes to
CC identify a restriction fragment whose size in cms-T mitochondrial DNA is
CC different from the corresponding fragment in normal mitochondrial DNA.
CC They are useful for rapidly and specifically testing maize plants for T-
CC type cytoplasmic male sterility. (Updated on 25-MAR-2003 to correct PF
CC field.)
XX
SQ Sequence 17 BP; 2 A; 6 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 754 GCGCATGCGAGGCCA 768
DB 17 GCTCATGCGAGGCCA 3
RESULT 819
AAX75272/c
ID AAX75272 standard; RNA; 17 BP.
XX
XX AAX75272;
AC
XX 28-JUL-1999 (first entry)
DT
XX
DE Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #800.
XX
XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage; ocular disease;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.
XX
XX Mus sp.
XX
XX W09715662-A2.
PN

XX 01-MAY-1997.
PD
XX
PD
XX
PF 25-OCT-1996; 96WO-US017480.
XX
XX 26-OCT-1995; 95US-0005974P.
PR 11-JAN-1996; 96US-00584040.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (CHIR) CHIRON CORP.
XX
XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
PI WPI; 1997-359017/23.
XX
XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.
XX
XX Claim 4; Page 179; 218pp; English.
XX
XX The present invention describes nucleic acid molecules which modulate the
CC synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention
XX
SQ Sequence 17 BP; 3 A; 8 C; 2 G; 0 T; 4 U; 0 Other;

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 696 AGCTGGAGAGTGAGC 710
DB 16 AGCTGGAGAGGGAGC 2

RESULT 820
ABN07456
ID ABN07456 standard; DNA; 17 BP.
XX
AC ABN07456;
XX
XX 29-MAY-2002 (first entry)
XX
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7448.
XX
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
XX
XX WO200192524-A2.
PN
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.

PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
PI WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX Disclosure; SEQ ID NO 7448; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterize and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 5 A; 3 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 412 GGAGAAGGAGTTCCT 426
DB 3 GGAGAAGGAGTTCCT 17

RESULT 821
ABN07256
ID ABN07256 standard; DNA; 17 BP.
XX
AC ABN07256;
XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7248.
XX
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
XX
XX WO200192524-A2.
PN
XX 06-DEC-2001.

XX PF 25-MAY-2001; 2001WO-US016981.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PR 30-JAN-2001; 2001WO-US000661.
XX PR 30-JAN-2001; 2001WO-US000662.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000666.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 05-FEB-2001; 2001US-0266860P.
XX PA (AEOM-) AEOMICA INC.
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX XX WPI; 2002-179446/23.
XX DR New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX PT or as specific biomolecule capture probes for surface-enhanced laser
XX PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX XX Disclosure; SEQ ID NO 7248; 214pp; English.
XX CC The present invention describes a human genome-derived myosin-like
XX CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
XX CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
XX CC nucleic acids can be used as probes to detect, characterise and quantify
XX CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
XX CC provide initial substrates for the recombinant engineering of hGDMPLP-1
XX CC protein variants having desired phenotypic improvements, and for
XX CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
XX CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
XX CC -1 proteins, as standards in assays used to determine the concentration
XX CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
XX CC capture probes for surface-enhanced laser desorption ionisation, as
XX CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
XX CC production, and in vaccines or for replacement therapy. The
XX CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
XX CC disorder associated with the expression of hGDMPLP-1, in particular heart
XX CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
XX CC The present sequence represents an oligomer used in the screening of the
XX CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
XX CC The sequence data for this patent did not form part of the printed
XX CC specification, but was obtained in electronic format directly from WIPO
XX CC at ftp.wipo.int/pub/published_pct_sequence
XX XX Sequence 17 BP; 4 A; 2 C; 9 G; 2 T; 0 U; 0 Other;
XX SQ Query Match 1.8%; Score 13.4; DB 1; Length 17;
XX Best Local Similarity 93.3%; Pred. No. 6.1e+02;
XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 699 TGGAGAGTGAGCGG 713
Db 1 TGGAGAGTGAGCGG 15
RESULT 822
ABN08977/c
XX ID ABN08977 standard; DNA; 17 BP.
XX AC ABN08977;
XX XX
XX DT 29-MAY-2002 (first entry)
XX XX

DE XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8969.
XX KW Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;
XX KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX XX skeletal muscle disorder; amplicon; screening; ss.
XX OS Homo sapiens.
XX XX WO200192524-A2.
XX PD 06-DEC-2001.
XX PF 25-MAY-2001; 2001WO-US016981.
XX XX 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PR 30-JAN-2001; 2001WO-US000661.
XX PR 30-JAN-2001; 2001WO-US000662.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000666.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 05-FEB-2001; 2001US-0266860P.
XX XX (AEOM-) AEOMICA INC.
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX XX WPI; 2002-179446/23.
XX DR New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX PT or as specific biomolecule capture probes for surface-enhanced laser
XX PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX XX Disclosure; SEQ ID NO 7248; 214pp; English.
XX CC The present invention describes a human genome-derived myosin-like
XX CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
XX CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
XX CC nucleic acids can be used as probes to detect, characterise and quantify
XX CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
XX CC provide initial substrates for the recombinant engineering of hGDMPLP-1
XX CC protein variants having desired phenotypic improvements, and for
XX CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
XX CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
XX CC -1 proteins, as standards in assays used to determine the concentration
XX CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
XX CC capture probes for surface-enhanced laser desorption ionisation, as
XX CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
XX CC production, and in vaccines or for replacement therapy. The
XX CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
XX CC disorder associated with the expression of hGDMPLP-1, in particular heart
XX CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
XX CC The present sequence represents an oligomer used in the screening of the
XX CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
XX CC The sequence data for this patent did not form part of the printed
XX CC specification, but was obtained in electronic format directly from WIPO
XX CC at ftp.wipo.int/pub/published_pct_sequence
XX XX Sequence 17 BP; 5 A; 2 C; 7 G; 3 T; 0 U; 0 Other;
XX SQ Query Match 1.8%; Score 13.4; DB 1; Length 17;
XX Best Local Similarity 93.3%; Pred. No. 6.1e+02;
XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 852 ACCAGCTCTTCCAG 866
|||||||

Db 17 ACCAGCTCTTCCATG 3

RESULT 823
ABN06832/C
ID ABN06832 standard; DNA; 17 BP.
XX AC ABN06832;
XX AC ABN06832;
XX 29-MAY-2002 (first entry)
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6824.
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX Homo sapiens.
XX WO200192524-A2.
XX 06-DEC-2001.
XX 25-MAY-2001; 2001WO-US016981.
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 05-FEB-2001; 2001US-0266860P.
XX (AEOM-) AEOMICA INC.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX Disclosure; SEQ ID NO 6824; 214pp; English.
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterize and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed

CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX Sequence 17 BP; 3 A; 3 C; 5 G; 6 T; 0 U; 0 Other;
SQ Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 266 CACCTGCCTTCAGAA 280
Db 16 CACCTGCCTTCAGAA 2

RESULT 824
ABN08427
ID ABN08427 standard; DNA; 17 BP.
XX AC ABN08427;
XX AC ABN08427;
XX 29-MAY-2002 (first entry)
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8419.
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX Homo sapiens.
XX WO200192524-A2.
XX 06-DEC-2001.
XX 25-MAY-2001; 2001WO-US016981.
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 05-FEB-2001; 2001US-0266860P.
XX (AEOM-) AEOMICA INC.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX Disclosure; SEQ ID NO 8419; 214pp; English.
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterize and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed

CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence

XX Sequence 17 BP; 6 A; 3 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 6.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 489 TGAAGAGCGCAGAGG 503
 ||||| |||||
 Db 3.TGAAGAGCGCAGAGG 17

RESULT 825

ABN08428
 ID ABN08428 standard; DNA; 17 BP.

XX AC ABN08428;
 XX 29-MAY-2002 (first entry)
 XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8420.
 XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX Homo sapiens.

XX WO200192524-A2.

XX 06-DEC-2001.

XX 25-MAY-2001; 2001WO-US016981.

XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000861.
 PR 30-JAN-2001; 2001WO-US000862.
 PR 30-JAN-2001; 2001WO-US000863.
 PR 30-JAN-2001; 2001WO-US000864.
 PR 30-JAN-2001; 2001WO-US000865.
 PR 30-JAN-2001; 2001WO-US000866.
 PR 30-JAN-2001; 2001WO-US000867.
 PR 30-JAN-2001; 2001WO-US000868.
 PR 30-JAN-2001; 2001WO-US000869.
 PR 05-FEB-2001; 2001US-0266860P.

XX (AEOM-) AEOMICA-INC.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;

XX WPI; 2002-179446/23.

XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
 FT or as specific biomolecule capture probes for surface-enhanced laser
 FT desorption/ionization, comprises human myosin-like protein hGDMLP-1.

XX

PS Disclosure; SEQ ID NO 8420; 214pp; English.
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence

SQ Sequence 17 BP; 6 A; 2 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 6.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 489 TGAAGAGCGCAGAGG 503
 ||||| |||||
 Db 2 TGAAGAGCGCAGAGG 16

RESULT 826

ABN06833/c
 ID ABN06833 standard; DNA; 17 BP.

XX AC ABN06833;

XX 29-MAY-2002 (first entry)

XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6825.

XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.

XX Homo sapiens.

XX WO200192524-A2.

XX 06-DEC-2001.

XX 25-MAY-2001; 2001WO-US016981.

XX 26-MAY-2000; 2000US-0207456P.

PR 21-SEP-2000; 2000US-0234687P.

PR 27-SEP-2000; 2000US-0236359P.

PR 04-OCT-2000; 2000GB-00024263.

PR 30-JAN-2001; 2001WO-US000661.

PR 30-JAN-2001; 2001WO-US000662.

PR 30-JAN-2001; 2001WO-US000663.

PR 30-JAN-2001; 2001WO-US000664.

PR 30-JAN-2001; 2001WO-US000665.

PR 30-JAN-2001; 2001WO-US000666.

PR 30-JAN-2001; 2001WO-US000667.

PR 30-JAN-2001; 2001WO-US000668.

PR 30-JAN-2001; 2001WO-US000669.

PR 05-FEB-2001; 2001WO-US000670.

PR 05-FEB-2001; 2001US-0266860P.

XX (AEOM-) AEOMICA INC.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon MB;
 XX WPI; 2002-179446/23.
 XX
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 XX or as specific biomolecule capture probes for surface-enhanced laser
 XX desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX
 XX Disclosure; SEQ ID NO 6825; 214pp; English.
 XX
 XX The present invention describes a human genome-derived myosin-like
 XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 XX nucleic acids can be used as probes to detect, characterize and quantify
 XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 XX provide initial substrates for the recombinant engineering of hGDMPLP-1
 XX protein variants having desired phenotypic improvements, and for
 XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 XX used as immunogens to raise antibodies that specifically recognise hGDMPLP
 XX -1 proteins, as standards in assays used to determine the concentration
 XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 XX capture probes for surface-enhanced laser desorption/ionisation, as
 XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 XX production, and in vaccines or for replacement therapy. The
 XX polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 XX disorder associated with the expression of hGDMPLP-1, in particular heart
 XX and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 XX The present sequence represents an oligomer used in the screening of the
 XX hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 XX The sequence data for this patent did not form part of the printed
 XX specification, but was obtained in electronic format directly from WIPO
 XX at ftp.wipo.int/pub/published_pct_sequence
 XX
 XX Sequence 17 BP; 3 A; 3 C; 6 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 1.8%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 6.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 266 CACCTGCTTCAGAA 280
 Db |||||
 15 CACCTGCTTCAGAA 1
 RESULT 827
 ABN07460
 ID ABN07460 standard; DNA; 17 BP.
 XX
 AC ABN07460;
 XX
 XX 29-MAY-2002 (first entry)
 XX
 XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7452.
 DE
 XX Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;
 XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 XX skeletal muscle disorder; amplicon; screening; 8s.
 OS Homo sapiens.
 XX
 XX WO200192524-A2.
 PN
 XX 06-DEC-2001.
 PD
 XX
 XX 25-MAY-2001; 2001WO-US016981.
 PF
 XX 26-MAY-2000; 2000US-0207456P.
 PR
 XX 21-SEP-2000; 2000US-0234687P.
 PR
 XX 27-SEP-2000; 2000US-0236359P.
 PR
 XX 04-OCT-2000; 2000GB-00024263.

PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-026860P.
 XX
 XX (AEOM-) AEOMICA INC.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon MB;
 XX WPI; 2002-179446/23.
 XX
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 XX or as specific biomolecule capture probes for surface-enhanced laser
 XX desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX
 XX Disclosure; SEQ ID NO 7452; 214pp; English.
 XX
 XX The present invention describes a human genome-derived myosin-like
 XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 XX nucleic acids can be used as probes to detect, characterize and quantify
 XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 XX provide initial substrates for the recombinant engineering of hGDMPLP-1
 XX protein variants having desired phenotypic improvements, and for
 XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 XX used as immunogens to raise antibodies that specifically recognise hGDMPLP
 XX -1 proteins, as standards in assays used to determine the concentration
 XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 XX capture probes for surface-enhanced laser desorption/ionisation, as
 XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 XX production, and in vaccines or for replacement therapy. The
 XX polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 XX disorder associated with the expression of hGDMPLP-1, in particular heart
 XX and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 XX The present sequence represents an oligomer used in the screening of the
 XX hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 XX The sequence data for this patent did not form part of the printed
 XX specification, but was obtained in electronic format directly from WIPO
 XX at ftp.wipo.int/pub/published_pct_sequence
 XX
 XX Sequence 17 BP; 6 A; 4 C; 4 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 1.8%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 6.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 414 AGAAGGAGTTCCTCA 428
 Db |||||
 1 AGAAGGAGTTCCTCA 15
 RESULT 828
 ABK25615
 ID ABK25615 standard; DNA; 17 BP.
 XX
 AC ABK25615;
 XX
 XX 09-APR-2002 (first entry)
 XX
 XX Stress tolerance conferring genome altering oligonucleotide #83.
 DE
 XX Chromosomal genomic alteration; genome altering oligonucleotide; PCR; 8s;
 XX o-methyl modification; LNA modification; phosphorothioate linkage;
 XX DNA repair; DNA alteration; environmental tolerance; hygromycin-B;
 XX abiotic stress tolerance; improved nutritional value; hygromycin; primer;
 XX amino acid over production; herbicide resistance; glyphosate resistance;

KW imidazolinone herbicide resistance; sulphonylurea herbicide resistance;
KW porphyrin herbicide resistance; triazine resistance; disease resistance;
KW modified oil production; modified starch production; waxy starch;
KW altered floral morphology; male-sterile plant; albino mutant;
KW modified fatty acid content; reduced palmitate production; albino plant;
KW increased stearate production; reduced linolenic acid production;
KW photosynthetic process.
XX Oryza sativa.
OS Synthetic.
XX W0200192512-A2.
XX 06-DEC-2001.
XX 01-JUN-2001; 2001WO-US017672.
XX 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
PR 27-MAR-2001; 2001US-00818875.
XX (UYDE) UNIV DELAWARE.
XX Kmiec EB, Gamper HB, Rice MC, Kim J;
XX WPI; 2002-106307/14.
XX New oligonucleotides with modified nuclease-resistant termini, useful for
PT creating plants with desired phenotypes, e.g. stress tolerance, improved
PT nutritional value, herbicide or disease resistance, or modified oil
PT production.
XX Claim 7; Page 101; 220pp; English.
XX The invention relates to an oligonucleotide for targeted alteration of a
CC genetic sequence, which comprises a single-stranded oligonucleotide
CC having a DNA domain. The DNA domain has at least one mismatch with
CC respect to the genetic sequence to be altered and further comprises
CC chemical modifications of the oligonucleotide. The chemical modifications
CC consist of o-methyl modification, an LNA modification, two or more
CC phosphorothioate linkages on a terminus, or a combination of any two or
CC more of these modifications. The oligonucleotides are useful for
CC directing repair or alteration of plant genetic information. The
CC oligonucleotides are particularly useful for creating plants with desired
CC phenotypes, e.g. environmental or abiotic stress tolerance, improved
CC nutritional value (e.g. altering amino acid content of plants or
CC conferring amino acid over production), herbicide resistance (e.g.
CC glyphosate resistance, imidazolinone and sulphonylurea herbicide
CC resistance, porphyrin herbicide resistance or triazine resistance),
CC disease resistance, modified oil production, modified starch production
CC (e.g. increased starch or production of waxy starch), altered floral
CC morphology (e.g. male-sterile plants) or modified fatty acid content
CC (e.g. reduced palmitate, increased stearate or reduced linolenic acid).
CC The oligonucleotides are also useful for producing albino mutants for the
CC analysis of photosynthetic processes. This sequence represents a genome
CC altering oligonucleotide of the invention
XX Sequence 17 BP; 4 A; 4 C; 8 G; 1 T; 0 U; 0 Other;
SQ Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 899 GGCACTGAGCGGAAG 913
DB 1 GGCAGTGGCCCAAG 15
RESULT 829
ID ABK25616/C
XX ABK25616 standard; DNA; 17 BP.
XX AC ABK25616;

XX 09-APR-2002 (first entry)
XX Stress tolerance conferring genome altering oligonucleotide #84.
XX Chromosomal genomic alteration; genome altering oligonucleotide; PCR; ss;
KW o-methyl modification; LNA modification; phosphorothioate linkage;
KW DNA repair; DNA alteration; environmental tolerance; hygromycin-B;
KW abiotic stress tolerance; improved nutritional value; hygromycin-B;
KW amino acid over production; herbicide resistance; glyphosate resistance;
KW imidazolinone herbicide resistance; sulphonylurea herbicide resistance;
KW porphyrin herbicide resistance; triazine resistance; disease resistance;
KW modified oil production; modified starch production; waxy starch;
KW altered floral morphology; male-sterile plant; albino mutant;
KW modified fatty acid content; reduced palmitate production; albino plant;
KW increased stearate production; reduced linolenic acid production;
KW photosynthetic process.
XX Oryza sativa.
OS Synthetic.
XX W0200192512-A2.
XX 06-DEC-2001.
XX 01-JUN-2001; 2001WO-US017672.
XX 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
PR 27-MAR-2001; 2001US-00818875.
XX (UYDE) UNIV DELAWARE.
XX Kmiec EB, Gamper HB, Rice MC, Kim J;
XX WPI; 2002-106307/14.
XX New oligonucleotides with modified nuclease-resistant termini, useful for
PT creating plants with desired phenotypes, e.g. stress tolerance, improved
PT nutritional value, herbicide or disease resistance, or modified oil
PT production.
XX Claim 7; Page 101; 220pp; English.
XX The invention relates to an oligonucleotide for targeted alteration of a
CC genetic sequence, which comprises a single-stranded oligonucleotide
CC having a DNA domain. The DNA domain has at least one mismatch with
CC respect to the genetic sequence to be altered and further comprises
CC chemical modifications of the oligonucleotide. The chemical modifications
CC consist of o-methyl modification, an LNA modification, two or more
CC phosphorothioate linkages on a terminus, or a combination of any two or
CC more of these modifications. The oligonucleotides are useful for
CC directing repair or alteration of plant genetic information. The
CC oligonucleotides are particularly useful for creating plants with desired
CC phenotypes, e.g. environmental or abiotic stress tolerance, improved
CC nutritional value (e.g. altering amino acid content of plants or
CC conferring amino acid over production), herbicide resistance (e.g.
CC glyphosate resistance, imidazolinone and sulphonylurea herbicide
CC resistance, porphyrin herbicide resistance or triazine resistance),
CC disease resistance, modified oil production, modified starch production
CC (e.g. increased starch or production of waxy starch), altered floral
CC morphology (e.g. male-sterile plants) or modified fatty acid content
CC (e.g. reduced palmitate, increased stearate or reduced linolenic acid).
CC The oligonucleotides are also useful for producing albino mutants for the
CC analysis of photosynthetic processes. This sequence represents a genome
CC altering oligonucleotide of the invention
XX Sequence 17 BP; 1 A; 8 C; 4 G; 4 T; 0 U; 0 Other;
SQ Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

QY 899 GGCAGTGAGCGGAAG 913
Db 17 GGCAGTGAGCGGAAG 3

RESULT 830
ACN06513
ID ACN06513 standard; RNA; 17 BP.
XX AC ACN06513;
XX ACN06513;
XX DT 22-APR-2004 (first entry)
XX WNV Amberzyme substrate SEQ ID NO 6516.
DE DE
DE WNV; West Nile Virus; antiinflammatory; cytotstatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyne; ss.
XX OS
XX West Nile Virus.
XX PN WO200268637-A2.
XX PD 06-SEP-2002.
XX PF 19-OCT-2001; 2001WO-US048350.
XX PR 20-OCT-2000; 2000US-0242411P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PA (BLAT/) BLATT L.
XX PA (MCSW/) MCSWIGGEN J A.
XX PI Blatt L, Mcswiggen JA;
XX WPI; 2002-706994/76.
XX PT New nucleic acid molecule that modulates replication of West Nile Virus
XX (WNV), useful for treating a condition related to WNV infection e.g.
XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX Claim 23; SEQ ID NO 6516; 495pp; English.
XX CC The invention relates to nucleic acid molecules that modulate replication
XX of the West Nile Virus (WNV). The nucleic acid molecules are useful for
XX treating a condition related to WNV infection e.g. pancreatitis,
XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX molecule is selected from the group of ribozymes consisting of
XX Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyne. The
XX nucleic acid molecules further comprise at least five ribose residues, at
XX least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX least three of the 5' terminal nucleotides and a 3' end modification of a
XX 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
XX are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
XX in the specification. The present sequence is that of a nucleic acid
XX molecule of the invention
XX SQ Sequence 17 BP; 7 A; 2 C; 7 G; 0 T; 1 U; 0 Other;

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 6.1e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 808 CTCGAGGAGAGAG 822
Db 2 CUCAGAGAGAGAG 16

RESULT 831
ACN08335
ID ACN08335 standard; RNA; 17 BP.
XX AC ACN08335;
XX ACN08335;
XX DT 22-APR-2004 (first entry)
XX WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 8338.
DE DE
DE WNV; West Nile Virus; antiinflammatory; cytotstatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyne; ss.
XX OS
XX West Nile Virus.
XX PN WO200268637-A2.
XX PD 06-SEP-2002.
XX PF 19-OCT-2001; 2001WO-US048350.
XX PR 20-OCT-2000; 2000US-0242411P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PA (BLAT/) BLATT L.
XX PA (MCSW/) MCSWIGGEN J A.
XX PI Blatt L, Mcswiggen JA;
XX WPI; 2002-706994/76.
XX PT New nucleic acid molecule that modulates replication of West Nile Virus
XX (WNV), useful for treating a condition related to WNV infection e.g.
XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX Claim 23; SEQ ID NO 8338; 495pp; English.
XX CC The invention relates to nucleic acid molecules that modulate replication
XX of the West Nile Virus (WNV). The nucleic acid molecules are useful for
XX treating a condition related to WNV infection e.g. pancreatitis,
XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX molecule is selected from the group of ribozymes consisting of
XX Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyne. The
XX nucleic acid molecules further comprise at least five ribose residues, at
XX least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX least three of the 5' terminal nucleotides and a 3' end modification of a
XX 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
XX are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
XX in the specification. The present sequence is that of a nucleic acid
XX molecule of the invention
XX SQ Sequence 17 BP; 1 A; 7 C; 2 G; 0 T; 7 U; 0 Other;

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 808 CTCGAGGAGAGAG 822
Db 16 CTCAGAGAGAGAG 2

RESULT 832
ACN10739
ID ACN10739 standard; RNA; 17 BP.
XX AC ACN10739;
XX ACN10739;
XX DT 22-APR-2004 (first entry)
XX WNV minus strand Inozyme substrate SEQ ID NO 10742.

```

XX MNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
XX WO200268637-A2.
XX
XX PD 06-SEP-2002.
XX
XX PF 19-OCT-2001; 2001WO-US048350.
XX
XX PR 20-OCT-2000; 2000US-0242411P.
XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX PA (MCSW/) MCSWIGGEN J A.
XX
XX PI Blatt L, Meswiggen JA;
XX
XX DR WPI; 2002-706994/76.
XX
XX PT New nucleic acid molecule that modulates replication of West Nile Virus
XX (MNV), useful for treating a condition related to MNV infection e.g.
XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX PS Claim 23; SEQ ID NO 10742; 495pp; English.
XX
XX CC The invention relates to nucleic acid molecules that modulate replication
XX of the West Nile Virus (MNV). The nucleic acid molecules are useful for
XX treating a condition related to MNV infection e.g. pancreatitis,
XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX molecule is selected from the group of ribozymes consisting of
XX Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
XX nucleic acid molecules further comprise at least five ribose residues, at
XX least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX least three of the 5' terminal nucleotides and a 3' end modification of a
XX 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
XX are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
XX in the specification. The present sequence is that of a nucleic acid
XX molecule of the invention
XX
SQ Sequence 17 BP; 1 A; 7 C; 2 G; 0 T; 7 U; 0 Other;

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 808 CTCGAGGAGAGAG 822
||| ||||| ||||| |||||
Db 17 CTCAGAGGAGAGAG 3

RESULT 833
ABT35244/c
ID ABT35244 standard; DNA; 17 BP.
XX
XX AC ABT35244;
XX
XX DT 12-JUN-2003 (first entry)
XX
XX DE Tumour suppression related human fukutin oligo SEQ ID No 881.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
XX OS Homo sapiens.

XX WO2003025175-A2.
XX
XX PD 27-MAR-2003.
XX
XX PF 17-SEP-2002; 2002WO-IB004208.
XX
XX PR 17-SEP-2001; 2001FR-00011978.
XX
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX
XX PI Telerman A, Amson R, Tuijnder M;
XX WPI; 2003-313353/30.
XX
XX DR New isolated nucleic acid, useful for treating viral diseases associated
XX with tumors and cell degeneration, also related polypeptides, antibodies
XX and transfected cells.
XX
XX PS Disclosure; Page 136; 720pp; French.
XX
XX CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
XX given in the specification, a sequence containing at least 15 consecutive
XX nucleotides from the 17 mer sequence, a sequence with, after optimal
XX alignment, at least 80 % identity to the 17 mer sequence, a sequence that
XX hybridizes to them under highly stringent conditions, or the complement
XX of any of them, or the corresponding RNA. The novel isolated nucleic
XX acids of the invention are useful as probes and primers for detecting,
XX identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
XX component of a gene chip, in vitro as (anti)sense reagents, and for
XX production of recombinant polypeptides. Any of the nucleic acids,
XX polypeptides, vectors containing the nucleic acids, cells containing the
XX vector or antibodies directed against the polypeptides are useful for
XX preparation of pharmaceuticals for prevention and/or treatment of viral
XX diseases that are characterised by development of tumours or cell
XX degeneration, specifically cancer but also Alzheimer's disease and
XX schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
XX patient samples is useful for diagnosis and/or prognosis of these
XX diseases. The polypeptides can also be used to generate antibodies, and
XX both the polypeptide and antibodies are useful as components of protein
XX chips. The nucleic acid sequences of the invention can be used in gene
XX therapy. This polynucleotide sequence represents a tumour suppression
XX related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 1 A; 8 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 493 GAGGCAGAGGAGCA 507
||||| ||||| ||||| |||||
Db 17 GAGGCAGAGGAGCA 3

RESULT 834
ACA07656
ID ACA07656 standard; RNA; 17 BP.
XX
XX AC ACA07656;
XX
XX DT 03-JUN-2003 (first entry)
XX
XX DE NFkB sub-unit modulating zinzyme substrate #55.
XX
KW Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme;
KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
KW cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;

KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection; ss.

XX Homo sapiens.

XX US2002177568-A1.

XX 28-NOV-2002.

XX 23-MAY-2001; 2001US-00864785.

XX 07-DEC-1992; 92US-00987132.

PR 18-MAY-1994; 94US-00245466.

PR 15-AUG-1994; 94US-00291932.

PR 23-DEC-1996; 96US-00777916.

XX (STIN/) STINCHCOMB D T.

PA (MCSW/) MCSWIGGEN J.

PA (DRAP/) DRAPER K G.

XX Stinchcomb DT, Mcswiggen J, Draper KG;

XX WPI; 2003-340953/32.

XX Novel enzymatic nucleic acid molecules which down regulates expression of
 PT a sequence encoding a subunit of nuclear factor kappa B useful for
 PT treating cancer, inflammatory disorders and autoimmune diseases.

XX Claim 3; Page 38; 72pp; English.

XX The invention describes an enzymatic nucleic acid molecule (I) which down
 CC regulates expression of a sequence encoding a subunit of nuclear factor
 CC kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat
 CC cancer and is useful for down-regulating REL-A activity in a cell, for
 CC treating a patient having a condition associated with the level of REL-A.
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 CC antisense nucleic acid molecules are useful for treating breast, lung,
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC infection. This sequence represents the substrate of a novel enzymatic
 CC nucleic acid molecule

XX Sequence 17 BP; 5 A; 2 C; 9 G; 0 T; 1 U; 0 Other;

XX Query Match 1.8%; Score 13.4; DB 1; Length 17;

XX Best Local Similarity 86.7%; Pred. No. 6.1e+02;

XX Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 884 AAGACGACGGTGGG 898

Db 2 AAGACGACGGTGGG 16

RESULT 835

ACA06305

ID ACA06305 standard; RNA; 17 BP.

XX

AC ACA06305;

XX 03-JUN-2003 (first entry)

XX NFkB sub-unit modulating inozyme substrate #124.

XX Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme;
 KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
 KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection; ss.

XX Homo sapiens.

XX US2002177568-A1.

XX 28-NOV-2002.

XX 23-MAY-2001; 2001US-00864785.

XX 07-DEC-1992; 92US-00987132.

PR 18-MAY-1994; 94US-00245466.

PR 15-AUG-1994; 94US-00291932.

PR 23-DEC-1996; 96US-00777916.

XX (STIN/) STINCHCOMB D T.

PA (MCSW/) MCSWIGGEN J.

PA (DRAP/) DRAPER K G.

XX Stinchcomb DT, Mcswiggen J, Draper KG;

XX WPI; 2003-340953/32.

XX Novel enzymatic nucleic acid molecules which down regulates expression of
 PT a sequence encoding a subunit of nuclear factor kappa B useful for
 PT treating cancer, inflammatory disorders and autoimmune diseases.

XX Claim 3; Page 29; 72pp; English.

XX The invention describes an enzymatic nucleic acid molecule (I) which down
 CC regulates expression of a sequence encoding a subunit of nuclear factor
 CC kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat
 CC cancer and is useful for down-regulating REL-A activity in a cell, for
 CC treating a patient having a condition associated with the level of REL-A.
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 CC antisense nucleic acid molecules are useful for treating breast, lung,
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC infection. This sequence represents the substrate of a novel enzymatic
 CC nucleic acid molecule

XX Sequence 17 BP; 5 A; 2 C; 9 G; 0 T; 1 U; 0 Other;

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 6.1e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 884 AAGAGCAGCGTGGTG 898
|||||||:|:|:|
Db 3 AAGAGCAGCGUGGG 17

RESULT 836
ABZ64849/C
ID ABZ64849 standard; RNA; 17 BP.
XX AC ABZ64849;
XX DT 21-MAR-2003 (first entry)
XX DE Human HER2 DNzyme substrate #306.
XX KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosstatic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.
XX OS Homo sapiens.
XX PN WO200297114-A2.
XX PD 05-DEC-2002.
XX PF 29-MAY-2002; 2002WO-US016940.
XX PR 29-MAY-2001; 2001US-0294140P.
XX PR 06-JUN-2001; 2001US-0296249P.
XX PR 10-SEP-2001; 2001US-0318471P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Mcswiggen J;
XX DR WPI; 2003-140484/13.

Novel short interfering RNA and enzymatic nucleic acid useful for
treating cancer, modulates the expression of a nucleic acid encoding
HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
Claim 4; Page 138; 185pp; English.

The invention relates to a novel short interfering RNA (siRNA) nucleic
acid molecule or an enzymatic nucleic acid molecule, that modulates
expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
human immunodeficiency virus (HIV) or a component of HIV. The nucleic
acid molecule of the invention has cytostatic, anti-HIV, and anti-
rheumatic activity. The nucleic acid molecules are useful for reducing
HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
also useful for treating breast, ovarian, colorectal, lung, prostate,
bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
ABZ66530 - ABZ66585 represent substrate/target sequences for the human
ribozymes of the invention

Sequence 17 BP; 2 A; 4 C; 6 G; 0 T; 5 U; 0 Other;
Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 642 AGGAATCCAGGCTC 656
|||||||:|:|:|
Db 16 AGAAATGCCAGGCTC 2

RESULT 837

ACD63165
ID ACD63165 standard; RNA; 17 BP.
XX AC ACD63165;
XX DT 24-SEP-2003 (first entry)
XX DE HCV minus strand DNzyme substrate sequence #916.
XX KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW RNA stability; RNA expression; RNA synthesis; antisense;
KW enzymatic nucleic acid; hammerhead ribozyme; DNzyme; inozyme; zinzyme;
KW amberyne; G-cleaver ribozyme; decoy molecule; aptamer;
KW HBV reverse transcriptase; Enhancer I region; viral replication;
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW virucide; antiinflammatory; substrate; ss.
XX OS Hepatitis C virus.
XX PN WO200281494-A1.
XX PD 17-OCT-2002.
XX PF 26-MAR-2002; 2002WO-US009187.
XX PR 26-MAR-2001; 2001US-00817879.
XX PR 08-JUN-2001; 2001US-00877478.
XX PR 08-JUN-2001; 2001US-0296876P.
XX PR 24-OCT-2001; 2001US-0335059P.
XX PR 05-DEC-2001; 2001US-0337055P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PA (BLAT/) BLATT L.
XX PA (MACE/) MACEJAK D.
XX PA (MCSW/) MCSWIGGEN J.
XX PA (MORR/) MORRISSEY D.
XX PA (PAVC/) PAVCO P.
XX PA (LEEP/) LEE P.
XX PA (DRAP/) DRAPER K.
XX PA (ROBE/) ROBERTS E.
XX PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX WPI; 2003-229207/22.
XX PT Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
infection.
XX PS Claim 1; Page 291; 387pp; English.
XX CC The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNzymes,
CC inozymes, zinzymes, amberyne, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HCV
CC DNzyme or minus strand DNzyme sequences disclosed in the present
XX invention
XX SQ Sequence 17 BP; 2 A; 6 C; 6 G; 0 T; 3 U; 0 Other;

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 6.1e+02;
Matches 11; Conservative 3; Mismatches 0; Gaps 0;

QY 594 TGCTCGGGGAGTGC 608
DB 3 UGCTCGCGGAGCUGC 17

RESULT 838
ADB45030
ID ADB45030 standard; DNA; 17 BP.
XX AC ADB45030;
XX DE Tumour suppression/reversion associated nucleotide #5353.
XX KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
XX KW primer; probe; tumour suppression; tumour reversion; apoptosis;
XX KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
XX KW diagnosis.
XX OS Homo sapiens.
XX PN WO2003040369-A2.
XX PD 15-MAY-2003.
XX PF 17-SEP-2002; 2002WO-IB004219.
XX PR 17-SEP-2001; 2001FR-00011981.
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX PI Telerman A, Amson R, Tuijnder M;
XX WPI; 2003-441574/41.

New nucleic acid encoding human prostate membrane-specific antigen, useful e.g. for treatment of tumors and viral infection, also related polypeptide and antibodies.
Disclosure; Page 657; 771pp; French.
The invention relates to the isolation of 6327 nucleotide sequences, fragments of at least 15 consecutive nucleotides of these nucleotides, a sequence having at least 80% identity, after optimal alignment, with the nucleotides, a sequence that hybridizes under stringent conditions with the nucleotides, or the complement, or corresponding RNA, of the nucleotides. The nucleotides are used as probes or primers for detecting, identifying, quantifying and/or amplifying nucleic acids, as in vitro sense and antisense sequences, of nucleotides involved in tumour suppression or reversion, apoptosis and or viral resistance, to produce recombinant polypeptides, and to prepare transgenic animals, as experimental models. The nucleotides (also vectors containing them and cells containing the vectors), the encoded polypeptides and antibodies (Ab) against the polypeptide are useful for prevention and/or treatment of viral infections or diseases characterized by development of tumours or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
Analysis of the expression of the nucleotides can be used for diagnosis and/or prognosis of these diseases. The nucleotides and polypeptides can also be used to screen for their specific interactive molecules, potentially useful for treating diseases associated with abnormal expression of the nucleotides.

Sequence 17 BP; 4 A; 6 C; 4 G; 3 T; 0 U; 0 Other;
Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 215 GATCAGGACCTACTG 229
DB 1 GATCAGGACCTACTG 15

RESULT 839
ADF62873
ID ADF62873 standard; DNA; 17 BP.
XX AC ADF62873;
XX DT 12-FEB-2004 (first entry)
XX DE Human PCCP1 DNA fragment SEQ ID 4-directed probe - SEQ ID 777.
XX KW chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
XX KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
XX KW human; ss; probe.
XX OS Homo sapiens.
XX PN WO2003050284-A1.
XX PD 19-JUN-2003.
XX PF 22-NOV-2002; 2002WO-US037506.
XX PR 10-DEC-2001; 2001US-0339764P.
XX PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.
XX PI Guo J;
XX WPI; 2003-532916/50.

New prostate cancer candidate protein 1 (PCCP1), useful for preparing a composition for treating or preventing a disorder associated with decreased or increased expression or activity of PCCP1 e.g., tumor.
Example 2; SEQ ID NO 777; 164pp; English.
The invention relates to a novel isolated nucleic acid that encodes a protein with a chromatin organisation modifier (CHROMO) domain. The polynucleotide of the invention demonstrates cytostatic activity and may be useful for preparing a composition for treating or preventing a disorder associated with decreased or increased expression or activity of PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as during gene therapy and vaccine production procedures. The current sequence is that of the human PCCP1-related DNA fragment SEQ ID 4-directed probe of the invention. Note: The current sequence is not shown within the specification per se but was retrieved from the WipoWeb database.
Sequence 17 BP; 6 A; 2 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 815 GAGAGAGGAGCTG 829
DB 3 GTGAGAGGAGCTG 17

RESULT 840
ADI51393
ID ADI51393 standard; DNA; 17 BP.
XX AC ADI51393;
XX DT 15-APR-2004 (first entry)
XX

DE Human tumour suppression/reversion-related DNA sequence SeqID3896.
XX
XX tumour suppression; tumour reversion; apoptosis; virus resistance;
KW cytoskeletal; virucide; neuroprotective; nontropic; neuroleptic; probe;
KW primer; PCR; gene chip; antisense; viral disease; tumour;
KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS Homo sapiens.
XX
XX WO2003025177-A2.
XX
XX 27-MAR-2003.
XX
XX 17-SEP-2002; 2002WO-IB004523.
XX
XX 17-SEP-2001; 2001FR-00011980.
XX
XX (MOLE-) MOLECULAR ENGINES LAB.
XX
XX Telerman A, Amson R, Tuijnder M;
XX
XX WPI; 2003-313354/30.
XX
XX New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
XX Disclosure; SEQ ID NO 3896; 30pp; French.
XX
XX This invention relates to novel isolated nucleic acid sequences involved
CC in the phenomena of tumour suppression, tumour reversion, apoptosis
CC and/or resistance to viruses. The invention may be useful for the
CC development of compounds with a cytostatic, virucide, neuroprotective,
CC nontropic or neuroleptic activity. The DNA sequences may be useful as
CC probes and primers for detecting, identifying, quantifying and/or
CC amplifying nucleic acid, for example as one component of a gene chip, in
CC vitro as antisense reagents and for production of recombinant
CC polypeptides. The invention may therefore be useful for preparation of
CC pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia. The
CC present sequence is that of a nucleic acid sequence of the invention.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/publishedpct_sequences
XX
XX Sequence 17 BP; 4 A; 6 C; 4 G; 3 T; 0 U; 0 Other;
SQ

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 215 GATCAGGACGTACTG 229
Db 1 GATCAGGACGTACTG 15
|:|||||
|:|||||

RESULT 841
ADL51696
ID ADL51696 standard; RNA; 17 BP.
XX
XX ADL51696;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human PTGDR substrate sequence #815.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PTGDR;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 28-MAY-2001; 2001US-0294412P.
XX
XX 23-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 161; SEQ ID NO 5229; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
XX Sequence 17 BP; 8 A; 3 C; 5 G; 0 T; 1 U; 0 Other;
SQ

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 6.1e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
Qy 488 CTGAAGAGGAGGAGAG 502
Db 1 CUGAGAGAGGAGAG 15
|:|||||
|:|||||

RESULT 842
ADL51925
ID ADL51925 standard; RNA; 17 BP.
XX
XX ADL51925;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human PTGDR substrate sequence #1044.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PTGDR;
KW substrate; ds.
XX Unidentified.
OS
PN WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowkira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 161; SEQ ID NO 5458; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
XX Sequence 17 BP; 7 A; 4 C; 4 G; 0 T; 2 U; 0 Other;
SQ
Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 6.1e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
QY 487 TCTGAGAGGCGAGAA 501
Db :|||||
3 UCUGAGAGAGCGAGAA 17
RESULT 843
ADU82133/C
ID ADL82133 standard; DNA; 17 BP.
XX
XX AC ADL82133;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human ER+ breast cancer differentially expressed sequence #103.
DE
XX gene therapy; ds; breast cancer; human; ER+ breast cancer.
XX
XX Homo sapiens.
OS
XX
XX US2003166026-A1.
XX

PD 04-SEP-2003.
XX
XX 08-JAN-2003; 2003US-00339782.
XX
XX 09-JAN-2002; 2002US-0348053P.
XX
XX (LYNX-) LYNX THERAPEUTICS INC.
XX
XX Goodman LJ, Bowen BA;
XX
XX WPI; 2004-069003/07.
XX
XX Vector containing nucleic acid associated with breast cancer, useful for
PT treating, diagnosing and characterizing breast cancer, also related
PT polypeptides and antibodies.
XX
XX Claim 1; SEQ ID NO 104; 61pp; English.
XX
XX The invention relates to a composition which contains at least one vector
CC containing a nucleic acid (I) associated with breast cancer. The
CC vector (B), also polypeptides (II) encoded by (I), are used for treatment
CC of breast cancer. Arrays based on (I), (II), or their fragments, and (II)
CC -specific antibodies (Ab) are used to predict characteristics (e.g.
CC invasiveness or stage) of breast cancer, and (I), or its fragments, are
CC used to modulate characteristics of such cells; to identify breast cancer
CC genes and to detect breast cancer (by detecting polymorphic nucleic acid
CC or its products). The present sequence represents a human ER+ breast
CC cancer differentially expressed sequence.
XX
XX Sequence 17 BP; 1 A; 6 C; 3 G; 7 T; 0 U; 0 Other;
SQ
Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 492 AGAGGCGAGAGGAGC 506
Db :|||||
15 AGAGGCGAGAGGAGTC 1
RESULT 844
ADU82156
ID ADL82156 standard; DNA; 17 BP.
XX
XX AC ADL82156;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human ER+ breast cancer differentially expressed sequence #126.
DE
XX gene therapy; ds; breast cancer; human; ER+ breast cancer.
XX
XX Homo sapiens.
OS
XX
XX US2003166026-A1.
XX
XX 04-SEP-2003.
XX
XX 08-JAN-2003; 2003US-00339782.
XX
XX 09-JAN-2002; 2002US-0348053P.
XX
XX (LYNX-) LYNX THERAPEUTICS INC.
XX
XX Goodman LJ, Bowen BA;
XX
XX WPI; 2004-069003/07.
XX
XX Vector containing nucleic acid associated with breast cancer, useful for
PT treating, diagnosing and characterizing breast cancer, also related
PT polypeptides and antibodies.
XX
XX Claim 1; SEQ ID NO 127; 61pp; English.
XX

XX The invention relates to a composition which contains at least one vector
CC (B) containing a nucleic acid (I) associated with breast cancer. The
CC vector (B), also polypeptides (II) encoded by (I), are used for treatment
CC of breast cancer. Arrays based on (I), (II), or their fragments, and (II)
CC -specific antibodies (Ab) are used to predict characteristics (e.g.
CC invasiveness or stage) of breast cancer, and (I), or its fragments, are
CC used to modulate characteristics of such cells; to identify breast cancer
CC genes and to detect breast cancer (by detecting polymorphic nucleic acid
CC or its products). The present sequence represents a human ER+ breast
CC cancer differentially expressed sequence.

XX Sequence 17 BP; 3 A; 4 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 241 TCCTCTGGGGAAGCC 255
Db 3 TCCTGTGGGGAAGCC 17

RESULT 845
ADI85947
ID ADI85947 standard; RNA; 17 BP.

AC ADI85947;

DT 03-JUN-2004 (first entry)

DE HCV DNazyme substrate sequence #3193.

XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KW HCV infection; type I interferon; DNazyme.

OS Hepatitis C virus.

XX US2003125270-A1.

XX 03-JUL-2003.

XX 18-DEC-2000; 2000US-00740332.

XX 18-DEC-2000; 2000US-00740332.

XX (BLAT/) BLATT L.

XX (MCSW/) MCSWIGGEN J.

XX (ROBE/) ROBERTS E.

XX (PAVC/) PAVCO P A.

XX (MACE/) MACEJACK D.

XX Blatt L, Meswiggen J, Roberts E, Pavco PA, Macejack D;

XX WPI; 2004-031273/03.

XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT especially in combination with type I interferon therapy.

XX Claim 1; SEQ ID NO 3193; 198pp; English.

XX The invention relates to an enzymatic nucleic acid molecule which
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC the binding arms of the enzymatic nucleic acid molecule comprises
CC sequences complementary to any of the defined substrate sequences given
CC in the specification. The nucleic acid molecule may be administered for
CC the treatment of HCV infections, especially in combination with type I
CC interferons. The present sequence represents a HCV DNazyme substrate
CC sequence.

XX Sequence 17 BP; 2 A; 6 C; 6 G; 0 T; 3 U; 0 Other;

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 6.1e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 594 TCCTCGGGGAGCTGC 608
Db 3 UGCUCGGCGAGCTGC 17

RESULT 846
ADN44307/C
ID ADN44307 standard; DNA; 17 BP.

AC ADN44307;

DT 15-JUL-2004 (first entry)

DE Mutant cell identification-related mutagenic oligonucleotide SeqID976.

XX cell identification; oligonucleotide-directed sequence alteration;
KW selectable phenotype; transgenic plant; herbicide resistance;
KW sterile plant; abiotic stress tolerance; albino plant;
KW amino acid production; ss.

OS Oryza sativa.

OS Synthetic.

XX WO2004033708-A2.

XX 22-APR-2004.

XX 07-OCT-2003; 2003WO-US031862.

XX 07-OCT-2002; 2002US-0416983P.

XX 07-MAR-2003; 2003US-0453360P.

XX (UYDE) UNIV DELAWARE.

XX (NAPR-) NAPRO BIO THERAPEUTICS INC.

XX Kmiec EB, Van Brabant A;

XX WPI; 2004-340941/31.

XX Identifying a cell with a desired oligonucleotide-directed sequence
PT alteration at a nucleic acid target site within the cell by identifying
PT the desired sequence alteration in cells selected for the presence of a
PT selectable phenotype.

XX Example 25; SEQ ID NO 976; 303pp; English.

XX This invention relates to a novel method of identifying a cell having a
CC desired oligonucleotide-directed sequence alteration at a first nucleic
CC acid target site within the cell. The method comprises identifying the
CC desired sequence alteration in cells that have been selected for the
CC presence of a selectable phenotype conferred by a concurrent
CC oligonucleotide-directed sequence alteration at a second nucleic acid
CC target site within the cells. The method is useful in identifying a cell
CC having a desired oligonucleotide-directed sequence alteration at a first
CC nucleic acid target site within the cell. The method may be useful for
CC the production of plants with herbicide resistance, male or female
CC sterile plants, abiotic stress tolerance, albino plants or plants with
CC altered amino acid production as well as for use in mammalian cell lines.
CC The present sequence is that of a mutagenic oligonucleotide which was
CC used in the exemplification of the invention.

XX Sequence 17 BP; 1 A; 8 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 899 GCGAGTGACGGAG 913
|||||

```
Db 17 GGCAGTGAGCGCAAG 3
RESULT 847
ADNA44306
AC ADN44306 standard; DNA; 17 BP.
XX
AC ADN44306;
XX
DT 15-JUL-2004 (first entry)
XX
DE Mutant cell identification-related mutagenic oligonucleotide SeqID975.
XX
KW cell identification; oligonucleotide-directed sequence alteration;
KW selectable phenotype; transgenic plant; herbicide resistance;
KW sterile plant; abiotic stress tolerance; albino plant;
KW amino acid production; ss.
XX
OS Oryza sativa.
OS Synthetic.
XX
PN WD2004033708-A2.
XX
PD 22-APR-2004.
XX
PF 07-OCT-2003; 2003WO-US031862.
XX
PR 07-OCT-2002; 2002US-0416983P.
PR 07-MAR-2003; 2003US-0453360P.
XX
XX (UYDE ) UNIV DELAWARE.
PA (NAPR-) NAPRO BIO THERAPEUTICS INC.
PA
PI Kmiec EB, Van Brabant A;
XX
XX WPI; 2004-340941/31.
XX
XX Identifying a cell with a desired oligonucleotide-directed sequence
PT alteration at a nucleic acid target site within the cell by identifying
PT the desired sequence alteration in cells selected for the presence of a
PT selectable phenotype.
XX
PS Example 25; SEQ ID NO 975; 303pp; English.
XX
XX This invention relates to a novel method of identifying a cell having a
CC desired oligonucleotide-directed sequence alteration at a first nucleic
CC acid target site within the cell. The method comprises identifying the
CC desired sequence alteration in cells that have been selected for the
CC presence of a selectable phenotype conferred by a concurrent
CC oligonucleotide-directed sequence alteration at a second nucleic acid
CC target site within the cells. The method is useful in identifying a cell
CC having a desired oligonucleotide-directed sequence alteration at a first
CC nucleic acid target site within the cell. The method may be useful for
CC the production of plants with herbicide resistance, male or female
CC sterile plants, abiotic stress tolerance, albino plants or plants with
CC altered amino acid production as well as for use in mammalian cell lines.
CC The present sequence is that of a mutagenic oligonucleotide which was
CC used in the exemplification of the invention.
XX
SQ Sequence 17 BP; 4 A; 4 C; 8 G; 1 T; 0 U; 0 Other;
Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 899 GGCAGTGAGCGCAAG 913
|||||
Db 1 GGCAGTGAGCGCAAG 15
RESULT 848
ACN69922/c
ID ACN69922 standard; DNA; 17 BP.
```

```
XX ACN69922;
XX
DT 02-DEC-2004 (first entry)
XX
DE Human GDMPLP-1 probe SEQ ID NO:6824.
XX
KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
KW skeletal muscle function.
XX
OS Homo sapiens.
XX
PN US2004137589-A1.
XX
PD 15-JUL-2004.
XX
PF 26-NOV-2003; 2003US-00723361.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
XX (GUY/) GU Y.
PA (JIY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
PS Disclosure; SEQ ID NO 6824; 0pp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1), which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as a agonist or
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
XX Sequence 17 BP; 3 A; 3 C; 5 G; 6 T; 0 U; 0 Other;
Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

QY 266 CACCTGCTTCAGAA 280
 Db 16 CACCTGCTTCAGAA 2

RESULT 849
 ACN70550
 ID ACN70550 standard; DNA; 17 BP.
 XX
 AC ACN70550;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Human GDMPLP-1 probe SEQ ID NO:7452.
 XX
 KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 OS Homo sapiens.
 XX
 PN US2004137589-A1.
 XX
 PD 15-JUL-2004.
 XX
 PF 26-NOV-2003; 2003US-00723361.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 PA (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 XX
 PT Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 XX
 PS Disclosure; SEQ ID NO 7452; Opp; English.
 XX
 CC The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the

CC invention for scanning the sequence represented in ACN63103
 XX
 SQ Sequence 17 BP; 6 A; 4 C; 4 G; 3 T; 0 U; 0 Other;
 Query Match 1.8%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 6.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 414 AGAAGAGTCTCTCA 428
 Db 1 AGAAGAGTCTCTCA 15

RESULT 850
 ACN71517
 ID ACN71517 standard; DNA; 17 BP.
 XX
 AC ACN71517;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Human GDMPLP-1 probe SEQ ID NO:8419.
 XX
 KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 OS Homo sapiens.
 XX
 PN US2004137589-A1.
 XX
 PD 15-JUL-2004.
 XX
 PF 26-NOV-2003; 2003US-00723361.
 XX
 PR 25-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 PA (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 XX
 PT Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 XX
 PS Disclosure; SEQ ID NO 8419; Opp; English.
 XX
 CC The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully

PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 DR
 XX Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 PT
 XX Disclosure; SEQ ID NO 8969; Opp; English.
 PS
 XX The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX
 SQ Sequence 17 BP; 5 A; 2 C; 7 G; 3 T; 0 U; 0 Other;
 Query Match 1.8%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 6.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 852 ACCAGCTCTTCCAG 866
 DB 17 ACCAGCTCTTCCATG 3
 RESULT 853
 ACN71518
 ID ACN71518 standard; DNA; 17 BP.
 AC ACN71518;
 XX
 XX 02-DEC-2004 (first entry)
 DT
 XX Human GDMPLP-1 probe SEQ ID NO:8420.
 DE
 XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 OS Homo sapiens.
 XX
 XX US2004137589-A1.
 PN
 XX 15-JUL-2004.
 PD
 XX 26-NOV-2003; 2003US-00723361.
 PF
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.

PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 PA (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 DR
 XX Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 PT
 XX Disclosure; SEQ ID NO 8420; Opp; English.
 PS
 XX The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX
 SQ Sequence 17 BP; 6 A; 2 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 1.8%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 6.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 489 TGAAGAGCGCAGAGG 503
 DB 2 TGAAGAGCGCAGAGG 16
 RESULT 854
 ACN70346
 ID ACN70346 standard; DNA; 17 BP.
 XX
 AC ACN70346;
 XX
 XX 02-DEC-2004 (first entry)
 DT
 XX Human GDMPLP-1 probe SEQ ID NO:7248.
 DE
 XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 OS Homo sapiens.
 XX
 XX US2004137589-A1.
 PN
 XX 15-JUL-2004.
 PD
 XX 26-NOV-2003; 2003US-00723361.
 PF
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.

```

PR 30-JAN-2001; 2001WO-US0000663.
PR 30-JAN-2001; 2001WO-US0000664.
PR 30-JAN-2001; 2001WO-US0000665.
PR 30-JAN-2001; 2001WO-US0000666.
PR 30-JAN-2001; 2001WO-US0000667.
PR 30-JAN-2001; 2001WO-US0000668.
PR 30-JAN-2001; 2001WO-US0000669.
PR 30-JAN-2001; 2001WO-US0000670.
PR 05-FEB-2001; 2001WO-US0000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
PA (GUYV/) GU Y.
PA (JIYV/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
PI WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
XX Disclosure; SEQ ID NO 7248; Opp; English.
XX
CC The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
XX Sequence 17 BP; 4 A; 2 C; 9 G; 2 T; 0 U; 0 Other;
SQ
Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 699 TGGAGAGTGAGCGCG 713
DB 1 TGGAGAGTGAGCGCG 15
XX
RESULT 855
ACN70546
ID ACN70546 standard; DNA; 17 BP.
XX
XX ACN70546;
XX
XX 02-DEC-2004 (first entry)
XX
XX Human GDMPLP-1 probe SEQ ID NO:7448.
XX
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
XX hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
XX skeletal muscle function.
XX
XX Homo sapiens.
XX
XX OS
XX US2004137589-A1.
XX
XX 15-JUL-2004.
XX

```

```

PF 26-NOV-2003; 2003US-00723361.
XX
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234587P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US0000661.
PR 30-JAN-2001; 2001WO-US0000662.
PR 30-JAN-2001; 2001WO-US0000663.
PR 30-JAN-2001; 2001WO-US0000664.
PR 30-JAN-2001; 2001WO-US0000665.
PR 30-JAN-2001; 2001WO-US0000666.
PR 30-JAN-2001; 2001WO-US0000667.
PR 30-JAN-2001; 2001WO-US0000668.
PR 30-JAN-2001; 2001WO-US0000669.
PR 30-JAN-2001; 2001WO-US0000670.
PR 05-FEB-2001; 2001WO-US0000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
XX (GUYV/) GU Y.
XX (JIYV/) JI Y.
XX (PENN/) PENN S G.
XX (HANZ/) HANZEL D K.
XX (RANK/) RANK D.
XX (CHEN/) CHEN W.
XX (SHAN/) SHANNON M E.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
PI WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
XX Disclosure; SEQ ID NO 7448; Opp; English.
XX
CC The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
XX Sequence 17 BP; 5 A; 3 C; 5 G; 4 T; 0 U; 0 Other;
SQ
Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 412 GGAGAAGGAGTTCCT 426
DB 3 GGAGAAGGAGTTCCT 17
XX
RESULT 856
ABF30519/C
ID ABF30519 standard; DNA; 13 BP.
XX
XX ABF30519;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 130516 for detecting SNP TSC0032599.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX

```

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 130516; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 0 A; 8 C; 0 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 1.7%; Score 13; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 4.9e+02;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 407 AGGGAGGAGAAGG 419
XX 13 AGGGAGGAGAAGG 1
XX
XX RESULT 857
XX ABF29699
XX ID ABF29699 standard; DNA; 13 BP.
XX AC ABF29699;
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 129696 for detecting SNP TSC0032456.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 129696; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 5 C; 0 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 1.7%; Score 13; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 4.9e+02;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 873 ACAACCAACATCAA 885
XX 1 ACAACCAACATCAA 13
XX
XX RESULT 858
XX ABF29698/c
XX ID ABF29698 standard; DNA; 13 BP.
XX AC ABF29698;
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 129695 for detecting SNP TSC0032456.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 129695; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX
 SQ Sequence 13 BP; 1 A; 0 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 4.9e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 873 ACAACCATCA 885
 DB 13 ACAACCATCA 1

RESULT 859
 ID ABF30518
 AC ABF30518;
 DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 130515 for detecting SNP TSC0032599.
 OS Homo sapiens.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 130515; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX
 SQ Sequence 13 BP; 5 A; 0 C; 8 G; 0 T; 0 U; 0 Other;

.Query Match 1.7%; Score 13; DB 1; Length 13;
 .Best Local Similarity 100.0%; Pred. No. 4.9e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 407 AGGGAGGAGG 419
 DB 1 AGGGAGGAGG 13

RESULT 860
 ID ADL50821 standard; RNA; 13 BP.
 XX
 AC ADL50821;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Human PKR substrate sequence #1935.
 XX
 KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrita B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 4354; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human PKR
 CC substrate sequence.
 XX
 SQ Sequence 13 BP; 2 A; 4 C; 5 G; 0 T; 2 U; 0 Other;

```
Query Match      1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 4.9e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 190 GCAGCCCACTGGT 202
Db 1 GCAGCCCACTGGT 13

RESULT 861
ADL50820
ID ADL50820 standard; RNA; 13 BP.
XX
AC ADL50820;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #1934.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
XX
PR 29-MAY-2001; 2001US-0294412P.
XX
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 4353; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
SQ Sequence 13 BP; 2 A; 4 C; 5 G; 0 T; 2 U; 0 Other;
```

```
Query Match      1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 4.9e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 189 TGCAGCCCACTGG 201
Db 1 UGCAGCCCACTGG 13

RESULT 862
ADL50850
ID ADL50850 standard; RNA; 13 BP.
XX
AC ADL50850;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #1964.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
XX
PR 29-MAY-2001; 2001US-0294412P.
XX
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 4383; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
SQ Sequence 13 BP; 3 A; 3 C; 4 G; 0 T; 3 U; 0 Other;
```

Query Match 1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 76.9%; Pred. No. 4.9e+02;
Matches 10; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 566 GCCTCTGTGAAAG 578
Db 1 GCCUCUGGAAAG 13
|||||:|||||
|:|:|:|:|

RESULT 863
ADL50830
ID ADL50830 standard; RNA; 13 BP.
XX
AC ADL50830;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #1944.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.

XX Unidentified.
OS
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.

XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.

XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Posnaugh K;
XX
DR WPI; 2003-058513/05.

XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX
PS Claim 59; SEQ ID NO 4363; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.

XX
SQ Sequence 13 BP; 2 A; 4 C; 5 G; 0 T; 2 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 4.9e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 743 GTGGACCACTGC 755
Db 1 GUGGACCACTGC 13
|:|:|:|:|:|:|
|:|:|:|:|:|:|

RESULT 864
ADL50823
ID ADL50823 standard; RNA; 13 BP.
XX
AC ADL50823;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #1937.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.

XX Unidentified.
OS
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.

XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.

XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Posnaugh K;
XX
DR WPI; 2003-058513/05.

XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX
PS Claim 59; SEQ ID NO 4356; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.

XX
SQ Sequence 13 BP; 6 A; 2 C; 3 G; 0 T; 2 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. NO. 4.9e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 318 AGAATCAAGAGCT 330
||||:|||||
Db 1 AGAAUCAAGAGCU 13

RESULT 865

ADL50848
ID ADL50848 standard; RNA; 13 BP.

XX
AC ADL50848;

XX
DT 20-MAY-2004 (first entry)

XX
DE Human PKR substrate sequence #1962.

XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.

XX
OS Unidentified.

XX
PN WO200281628-A2.

XX
PD 17-OCT-2002.

XX
PF 03-APR-2002; 2002WO-US010512.

XX
PR 05-APR-2001; 2001US-00827395.

XX
PR 29-MAY-2001; 2001US-0294412P.

XX
PR 28-AUG-2001; 2001US-0315315P.

XX
PA (RIBO-) RIBOZYME PHARM INC.

XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX
DR WPI; 2003-058513/05.

XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX
PS Claim 59; SEQ ID NO 4381; 317pp; English.

XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.

XX
SQ Sequence 13 BP; 4 A; 4 C; 3 G; 0 T; 2 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. NO. 4.9e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 322 TCAGAGCTCCGA 334
:|||||:|||||
Db 1 UCAAGAGCUCCGA 13

RESULT 866

ADL50822
ID ADL50822 standard; RNA; 13 BP.

XX
AC ADL50822;

XX
DT 20-MAY-2004 (first entry)

XX
DE Human PKR substrate sequence #1936.

XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.

XX
OS Unidentified.

XX
PN WO200281628-A2.

XX
PD 17-OCT-2002.

XX
PF 03-APR-2002; 2002WO-US010512.

XX
PR 05-APR-2001; 2001US-00827395.

XX
PR 29-MAY-2001; 2001US-0294412P.

XX
PR 28-AUG-2001; 2001US-0315315P.

XX
PA (RIBO-) RIBOZYME PHARM INC.

XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX
DR WPI; 2003-058513/05.

XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX
PS Claim 59; SEQ ID NO 4355; 317pp; English.

XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.

XX
SQ Sequence 13 BP; 1 A; 7 C; 3 G; 0 T; 2 U; 0 Other;

Query Match		1.7%;	Score 13;	DB 1;	Length 13;
Best Local Similarity		84.6%;	Pred. No. 4.9e+02;		
Matches 11;		Conservative 2;	Mismatches 0;	Indels 0;	Gaps 0;
QY	297	CCCTCCAGCGCTG	309		
DB	1	CCCCUCCAGCGCUG	13		
RESULT 867					
ADL50828					
ID	ADL50828 standard; RNA; 13 BP.				
XX					
AC	ADL50828;				
XX					
DT	20-MAY-2004 (first entry)				
XX					
DE	Human PKR substrate sequence #1942.				
XX					
KW	antisense oligonucleotide; neurite growth inhibitor; NOGO;				
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;				
KW	protein kinase PKR; cerebrovascular accident;				
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;				
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;				
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;				
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;				
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;				
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;				
KW	substrate; ds.				
XX					
OS	Unidentified.				
XX					
PN	WO200281628-A2.				
XX					
PD	17-OCT-2002.				
XX					
PF	03-APR-2002; 2002WO-US010512.				
XX					
PR	05-APR-2001; 2001US-00827395.				
PR	29-MAY-2001; 2001US-0294412P.				
PR	28-AUG-2001; 2001US-0315315P.				
XX					
PA	(RIBO-) RIBOZYME PHARM INC.				
XX					
PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;				
XX					
DR	WPI; 2003-058513/05.				
XX					
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite				
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or				
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.				
XX					
PS	Claim 59; SEQ ID NO 4361; 317pp; English.				
XX					
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)				
CC	that down regulate the expression or inhibit the function of a receptor				
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),				
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the				
CC	invention are useful for treating: cerebrovascular accident, central				
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,				
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,				
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune				
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,				
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic				
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The				
CC	nucleic acids of the invention are also useful for down-regulating the				
CC	expression of a target gene and as a diagnostic tool to examine genetic				
CC	drifts and mutations within diseased cells or to detect the presence of a				
CC	target RNA in a cell. The present RNA sequence represents a human PKR				
CC	substrate sequence.				
XX					
SQ	Sequence 13 BP; 3 A; 3 C; 4 G; 0 T; 3 U; 0 Other;				

Query Match		1.7%;	Score 13;	DB 1;	Length 13;
Best Local Similarity		76.9%;	Pred. No. 4.9e+02;		
Matches 10;		Conservative 3;	Mismatches 0;	Indels 0;	Gaps 0;
QY	565	GGCCTCTGTGAAA	577		
DB	1	GGCCUCUGGAAA	13		
RESULT 868					
ADL50852					
ID	ADL50852 standard; RNA; 13 BP.				
XX					
AC	ADL50852;				
XX					
DT	20-MAY-2004 (first entry)				
XX					
DE	Human PKR substrate sequence #1966.				
XX					
KW	antisense oligonucleotide; neurite growth inhibitor; NOGO;				
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;				
KW	protein kinase PKR; cerebrovascular accident;				
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;				
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;				
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;				
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;				
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;				
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;				
KW	substrate; ds.				
XX					
OS	Unidentified.				
XX					
PN	WO200281628-A2.				
XX					
PD	17-OCT-2002.				
XX					
PF	03-APR-2002; 2002WO-US010512.				
XX					
PR	05-APR-2001; 2001US-00827395.				
PR	29-MAY-2001; 2001US-0294412P.				
PR	28-AUG-2001; 2001US-0315315P.				
XX					
PA	(RIBO-) RIBOZYME PHARM INC.				
XX					
PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;				
XX					
DR	WPI; 2003-058513/05.				
XX					
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite				
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or				
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.				
XX					
PS	Claim 59; SEQ ID NO 4385; 317pp; English.				
XX					
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)				
CC	that down regulate the expression or inhibit the function of a receptor				
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),				
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the				
CC	invention are useful for treating: cerebrovascular accident, central				
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,				
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,				
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune				
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,				
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic				
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The				
CC	nucleic acids of the invention are also useful for down-regulating the				
CC	expression of a target gene and as a diagnostic tool to examine genetic				
CC	drifts and mutations within diseased cells or to detect the presence of a				
CC	target RNA in a cell. The present RNA sequence represents a human PKR				
CC	substrate sequence.				
XX					
SQ	Sequence 13 BP; 3 A; 1 C; 7 G; 0 T; 2 U; 0 Other;				

Query Match.	1.7%;	Score 13;	DB 1;	Length 13;
Best Local Similarity	76.9%;	Pred. No. 4.9e+02;		
Matches 10;	Conservative 3;	Mismatches 0;	Indels 0;	Gaps 0;
QY	565	GGCCTCTGTGAAA	577	
DB	1	GGCCUCUGUGAAA	13	
RESULT 868				
ADL50852	ADL50852 standard; RNA; 13 BP.			
XX				
AC	ADL50852;			
XX				
DT	20-MAY-2004 (first entry)			
XX				
DE	Human PKR substrate sequence #1966.			
XX				
KW	antisense oligonucleotide; neurite growth inhibitor; NOGO;			
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;			
KW	protein kinase PKR; cerebrovascular accident;			
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;			
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;			
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;			
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;			
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;			
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;			
KW	substrate; ds.			
XX				
OS	Unidentified.			
XX				
PN	WO200281628-A2.			
XX				
PD	17-OCT-2002.			
XX				
PF	03-APR-2002; 2002WO-US010512.			
XX				
PR	05-APR-2001; 2001US-00827395.			
PR	29-MAY-2001; 2001US-0294412P.			
PR	28-AUG-2001; 2001US-0315315P.			
XX				
PA	(RIBO-) RIBOZYME PHARM INC.			
XX				
PI	Blatt L, Chowrira B, Haerberli P, Meswigen J, Fosnaugh K;			
XX				
DR	WPI; 2003-058513/05.			
XX				
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite			
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or			
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.			
XX				
PS	Claim 59; SEQ ID NO 4385; 317pp; English.			
XX				
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)			
CC	that down regulate the expression or inhibit the function of a receptor			
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),			
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the			
CC	invention are useful for treating: cerebrovascular accident, central			
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,			
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,			
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune			
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,			
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic			
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The			
CC	nucleic acids of the invention are also useful for down-regulating the			
CC	expression of a target gene and as a diagnostic tool to examine genetic			
CC	drifts and mutations within diseased cells or to detect the presence of a			
CC	target RNA in a cell. The present RNA sequence represents a human PKR			
CC	substrate sequence.			
XX				
SQ	Sequence 13 BP; 3 A; 1 C; 7 G; 0 T; 2 U; 0 Other;			

Query Match 1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 4.9e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 699 TGGAGAGTGGAGCG 711
:|||||:|||||
Db 1 UGGAGAGUGAGCG 13

RESULT 869

ADL50825

ID ADL50825 standard; RNA; 13 BP.

XX

AC ADL50825;

XX

DT 20-MAY-2004 (first entry)

XX

DE Human PKR substrate sequence #1939.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;

KW substrate; ds.

XX

OS Unidentified.

XX

XX WO200281628-A2.

XX

XX PD 17-OCT-2002.

XX

XX PF 03-APR-2002; 2002WO-US010512.

XX

XX PR 05-APR-2001; 2001US-00827395.

XX

XX PR 29-MAY-2001; 2001US-0294412P.

XX

XX PR 28-AUG-2001; 2001US-0315315P.

XX

XX PA (RIBO-) RIBOZYME PHARM INC.

XX

XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX

XX WPI; 2003-058513/05.

XX

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX

XX PS Claim 59; SEQ ID NO 4358; 317pp; English.

XX

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human PKR

CC substrate sequence.

XX

XX SQ Sequence 13 BP; 3 A; 2 C; 6 G; 0 T; 2 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 4.9e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 550 GATGGCTGAGGAC 562
:|||||:|||||
Db 1 GAUGGCGUGAGGAC 13

RESULT 870

ADL50847

ID ADL50847 standard; RNA; 13 BP.

XX

AC ADL50847;

XX

DT 20-MAY-2004 (first entry)

XX

DE Human PKR substrate sequence #1961.

XX

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;

KW substrate; ds.

XX

OS Unidentified.

XX

XX PN WO200281628-A2.

XX

XX PD 17-OCT-2002.

XX

XX PF 03-APR-2002; 2002WO-US010512.

XX

XX PR 05-APR-2001; 2001US-00827395.

XX

XX PR 29-MAY-2001; 2001US-0294412P.

XX

XX PR 28-AUG-2001; 2001US-0315315P.

XX

XX PA (RIBO-) RIBOZYME PHARM INC.

XX

XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX

XX WPI; 2003-058513/05.

XX

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX

XX PS Claim 59; SEQ ID NO 4380; 317pp; English.

XX

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human PKR

CC substrate sequence.

XX

XX SQ Sequence 13 BP; 2 A; 4 C; 5 G; 0 T; 2 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 4.9e+02;
 Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 303 AGCGCTGCTGGA 315
 Db 1 AGCGCGCCUGGA 13
 |||||:|||||
 |||||:|||||

RESULT 871
 AAS02960
 ID AAS02960 standard; DNA; 15 BP.
 XX AAS02960;
 XX
 XX 29-AUG-2001 (first entry)
 XX
 XX Human CHMR1 allele specific oligonucleotide probe #20.
 DE
 XX Human; m1 acetylcholine receptor; CHRM1; immunogen; antibody;
 KW Alzheimer's disease; dementia with Lewy bodies; DLB;
 KW allele specific oligonucleotide probe; ss.
 XX
 OS Homo sapiens.
 PN WO200127312-A2.
 PD 19-APR-2001.
 XX
 XX 12-OCT-2000; 2000WO-US028211.
 PF
 PR 13-OCT-1999; 99US-0159269P.
 XX
 PA (GENA-) GENAISANCE PHARM INC.
 XX
 PI Choi JY, Denton RR, Nandabalan K, Stephens JC;
 XX WPI; 2001-282046/29.
 DR
 XX New variants of the m1 muscarinic acetylcholine receptor gene, useful to
 PT find treatment for Alzheimer's and dementia, have single nucleotide
 PT variations at one or more of five polymorphic sites.
 PS
 XX Claim 15; Page 19; 52pp; English.
 XX
 CC The sequence represents an allele specific oligonucleotide probe for
 CC genotyping individuals using the Human gene encoding the m1 muscarinic
 CC acetylcholine receptor, CHMR1. CHMR1 is one subtype of a family of 5
 CC genetically distinct muscarinic acetylcholine receptors, mAChR, that play
 CC important roles in higher brain function such as learning and memory. The
 CC protein is a possible drug target for treatments for Alzheimer's disease
 CC and dementia with Lewy bodies (DLB). The gene, polypeptide, haplotypes
 CC and antibodies raised against the protein are useful for diagnosing and
 CC developing treatments for diseases associated with the abnormal
 CC expression of the gene or activity of the protein, e.g. Alzheimer's
 CC disease and dementia with Lewy bodies
 XX
 SQ Sequence 15 BP; 2 A; 6 C; 7 G; 0 T; 0 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 5.9e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 203 GGCCCGGCGAGCAG 215
 Db 2 GGCCCGGCGAGCAG 14
 |||||:|||||
 |||||:|||||

RESULT 872
 AAF47284/C
 ID AAF47284 standard; DNA; 15 BP.
 XX
 XX AAF47284;
 AC

XX 30-MAR-2001 (first entry)
 DT IGFBP3 oligonucleotide #704.
 XX
 DE
 XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX
 XX Homo sapiens.
 OS
 PN WO200078341-A1.
 XX
 XX 28-DEC-2000.
 PD
 XX 21-JUN-2000; 2000WO-AU000693.
 PF
 XX 21-JUN-1999; 99US-0140345P.
 PR
 XX (MURD-) MURDOCH CHILDRENS RES INST.
 PA
 XX Wright CJ, Werther GA, Edmondson SR;
 PI WPI; 2001-041421/05.
 DR
 XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX
 PS Example 7; Page 48; 201pp; English.
 XX
 CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, ptyriasis, ruba, pilaris, serborrhea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX
 SQ Sequence 15 BP; 3 A; 6 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 5.9e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 808 CTCGGAGGAGAG 820
 Db 15 CTCGGAGGAGAG 3
 |||||:|||||
 |||||:|||||

RESULT 873
 AAF51567
 ID AAF51567 standard; DNA; 15 BP.
 XX
 XX AAF51567;
 AC
 XX 30-MAR-2001 (first entry)
 DT
 XX IGF-I oligonucleotide #2527.
 DE

XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX Homo sapiens.
 OS
 XX
 XX WO200078341-A1.
 PN
 XX
 XX 28-DEC-2000.
 PD
 XX
 XX 21-JUN-2000; 2000WO-AU000693.
 PF
 XX
 XX 21-JUN-1999; 99US-0140345P.
 PR
 XX
 XX (MURD-) MURDOCH CHILDRENS RES INST.
 PA
 XX
 XX Wright CJ, Werther GA, Edmondson SR;
 PI
 XX
 XX WPI; 2001-041421/05.
 DR
 XX
 XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 PT
 XX
 XX Example 8; Page 77; 201pp; English.
 PS
 XX
 XX The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation.
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX
 XX Sequence 15 BP; 6 A; 2 C; 6 G; 1 T; 0 U; 0 Other;
 SQ
 Query Match 1.7%; Score 13; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 5.9e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 496 GCAGAGGAGCAG 508
 Db 1 GCAGAGGAGCAG 13
 RESULT 874
 AAF51526/c
 ID AAF51526 standard; DNA; 15 BP.
 XX
 XX AAF51526;
 AC
 XX
 XX 30-MAR-2001 (first entry)
 DT
 XX
 XX IGF-I oligonucleotide #2486.
 DE
 XX
 XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.

KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX Homo sapiens.
 OS
 XX
 XX WO200078341-A1.
 PN
 XX
 XX 28-DEC-2000.
 PD
 XX
 XX 21-JUN-2000; 2000WO-AU000693.
 PF
 XX
 XX 21-JUN-1999; 99US-0140345P.
 PR
 XX
 XX (MURD-) MURDOCH CHILDRENS RES INST.
 PA
 XX
 XX Wright CJ, Werther GA, Edmondson SR;
 PI
 XX
 XX WPI; 2001-041421/05.
 DR
 XX
 XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 PT
 XX
 XX Example 8; Page 77; 201pp; English.
 PS
 XX
 XX The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation.
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX
 XX Sequence 15 BP; 2 A; 7 C; 4 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 1.7%; Score 13; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 5.9e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 713 GAGGCGCTGCAGC 725
 Db 13 GAGGCGCTGCAGC 1
 RESULT 875
 AAF51524/c
 ID AAF51524 standard; DNA; 15 BP.
 XX
 XX AAF51524;
 AC
 XX
 XX 30-MAR-2001 (first entry)
 DT
 XX
 XX IGF-I oligonucleotide #2484.
 DE
 XX
 XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;

```

KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU000693.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU000693.
XX
PR 21-JUN-1999; 99US-0140345P.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wright CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisenesc nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
PS Example 8; Page 77; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisenesc oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisenesc
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 1 A; 6 C; 6 G; 2 T; 0 U; 0 Other;
Query Match 1.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.9e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 713 GAGGCGCTGCAGC 725
DB 15 GAGGCGCTGCAGC 3

RESULT 876
AAF51566
ID AAF51566 standard; DNA; 15 BP.
XX
AC AAF51566;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGF-I oligonucleotide #2526.
XX
KW Antisenesc therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU000693.
XX
PR 21-JUN-1999; 99US-0140345P.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wright CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisenesc nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
PS Example 8; Page 77; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisenesc oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisenesc
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 6 A; 3 C; 6 G; 0 T; 0 U; 0 Other;
Query Match 1.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.9e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 496 GCAGAGGAGGAGCAG 508
DB 2 GCAGAGGAGGAGCAG 14

RESULT 877
AAF47285/c
ID AAF47285 standard; DNA; 15 BP.
XX
AC AAF47285;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGFBP3 oligonucleotide #705.
XX
KW Antisenesc therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX

```

```

PF 21-JUN-2000; 2000WO-AU000693.
XX
PR 21-JUN-1999; 99US-0140345P.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wright CJ, Werther GA, Edmondson SR;
XX
WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisenase nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
PS Example 7; Page 48; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisenase oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisenase
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 2 A; 6 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.9e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 808 CTCGGAGGAGAG 820
DB 14 CTCGGAGGAGAG 2

RESULT 878
AAF51525/c
ID AAF51525 standard; DNA; 15 BP.
XX
AC AAF51525;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGF-I oligonucleotide #2485.
XX
KW Antisenase therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO2000078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU000693.
XX
PR 21-JUN-1999; 99US-0140345P.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wright CJ, Werther GA, Edmondson SR;
XX
WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisenase nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
PS Example 8; Page 77; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisenase oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisenase
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 1 A; 7 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.9e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 713 GAGGCGCTGCAGC 725
DB 14 GAGGCGCTGCAGC 2

RESULT 879
AAF51565
ID AAF51565 standard; DNA; 15 BP.
XX
AC AAF51565;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGF-I oligonucleotide #2525.
XX
KW Antisenase therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO2000078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU000693.
XX
PR 21-JUN-1999; 99US-0140345P.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wright CJ, Werther GA, Edmondson SR;
XX
WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisenase nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
PS Example 8; Page 77; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisenase oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisenase
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 1 A; 7 C; 5 G; 2 T; 0 U; 0 Other;

```

DR WPI; 2001-041421/05.
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisenesc nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX Example 8; Page 77; 201pp; English.
XX The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisenesc oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisenesc
CC oligonucleotides of the present invention (see AAP45151 and AAP45153-
CC P45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, seborrheoa, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 5 A; 4 C; 6 G; 0 T; 0 U; 0 Other;
Query Match 1.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.9e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY . 496 GCAGAGGAGGAGCAG 508
DB . 3 GCAGAGGAGGAGCAG 15
RESULT 880
AAS95379
ID AAS95379 standard; DNA; 15 BP.
XX
AC AAS95379;
XX
XX 14-FEB-2002 (first entry)
XX Human ICAM2 gene allele-specific oligonucleotide sequencing primer #6.
DE Human; intercellular adhesion molecule 2; ICAM2; haplotyping; ss;
XX haplotype pair; single nucleotide polymorphism; genotyping; PCR primer;
KW gene therapy; drug screening; anti-HIV; antiinflammatory; probe;
KW human immunodeficiency virus; sequencing primer.
XX
XX Homo sapiens.
XX WO200185918-A1.
XX
XX 15-NOV-2001.
XX
XX 07-MAY-2001; 2001WO-US014714.
XX
XX 05-MAY-2000; 2000US-0201946P.
XX (GENA-) GENAISSANCE PHARM INC.
XX
XX Chew A, Choi JY, Denton RR, Klien SE, Lee HH, Nandabalan K;
XX WPI; 2002-055590/07.
XX
XX Novel polynucleotide containing polymorphisms in intercellular adhesion
PT molecule 2 gene, useful in developing drugs for treating human
PT immunodeficiency virus infection and inflammatory diseases.
XX
XX Claim 16; Page 13; 81pp; English.
XX

The invention relates to single nucleotide polymorphisms in the gene encoding human intercellular adhesion molecule 2 (ICAM2). A method for haplotyping the ICAM2 gene in an individual comprises identifying the nucleotide at one or more polymorphic sites and determining whether one of the copies of the gene is defined by one of the ICAM2 haplotypes given in the specification or whether both copies are defined by a haplotype pair. This method is useful in genotyping, whereby all possible haplotype pairs can be assigned to specific genotypes. An association between a trait and a haplotype or haplotype pair of the ICAM2 gene can be identified by comparing the frequency of the haplotype or haplotype pair in a population exhibiting the trait with the frequency of the haplotype or haplotype pair in a reference population, where a higher haplotype frequency in the trait population indicates the trait is associated with the haplotype or haplotype pair. ICAM2 and its corresponding DNA are used for studying the expression and function of ICAM2, for use in screening for candidate drugs to treat diseases related to ICAM2 activity, such as HIV infection and inflammatory diseases. The sequences are also useful for studying the effect of variation on the biological activity of ICAM2 as well as on the binding affinity of candidate drugs targeting ICAM2. Sequences AAS95362-AAS95417 and AAS95419-AAS95442 represent allele-specific oligonucleotide probes, sequencing primers, PCR primers and cDNA encoding human ICAM2
XX
SQ Sequence 15 BP; 4 A; 3 C; 6 G; 1 T; 0 U; 1 Other;
Query Match 1.7%; Score 13; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 5.9e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 210 CAGCAGATCAGGACG 224
DB 1 CAGCAGATCAGGGYG 15
RESULT 881
ABR98359/C
ID ABR98359 standard; DNA; 15 BP.
XX
AC ABR98359;
XX
XX 30-JUL-2002 (first entry)
XX SCN2B gene polymorphisms ASO primer #3.
DE Human; sodium channel voltage gated type 2 beta polypeptide; SCN2B; ds;
XX gene therapy; neuroprotective; demyelinating disease.
KW
XX Homo sapiens.
XX WO200179547-A1.
XX
XX 25-OCT-2001.
XX
XX 03-APR-2001; 2001WO-US010743.
XX
XX 13-APR-2000; 2000US-0196597P.
XX (GENA-) GENAISSANCE PHARM INC.
XX
XX Chew A, Choi JY, Koshy B;
XX WPI; 2002-075072/10.
XX
XX New polynucleotide containing polymorphisms in the human sodium channel
PT voltage gated type 2 beta polypeptide (SCN2B) gene, for developing drugs
PT for treating demyelinating diseases.
XX
XX Claim 15; Page 13; 63pp; English.
XX
XX This invention relates to an isolated polynucleotide which is a
CC polymorphic variant of a reference sequence for sodium channel voltage
CC gated type 2 beta polypeptide (SCN2B) gene. The methods have
CC applicability in developing diagnostic tests and therapeutic treatments
CC

CC for demyelinating diseases. The protein is useful for studying the
 CC expression and function of SCN2B and expressing SCN2B protein for use in
 CC screening for candidate drugs to treat diseases related to SCN2B
 CC activity. The polymorphism and haplotype data are useful for validating
 CC whether SCN2B is a suitable target for drugs to treat demyelinating
 CC diseases, screening for such drugs and reducing bias in clinical trials.
 CC The haplotyping method is useful to validate SCN2B as a candidate target
 CC for treating a specific condition or disease predicted to be associated
 CC with SCN2B activity. A recombinant non-human organism transformed or
 CC transfected with the polypeptide is useful for studying expression of the
 CC SCN2B isogenes in vivo, for in vivo screening and testing of drugs
 CC against SCN2B protein and for testing the efficacy of therapeutic agents
 CC and compounds for demyelinating diseases in a biological system. This
 CC sequence is used during the detection of polymorphisms of the SCN2B gene
 XX
 SQ Sequence 15 BP; 3 A; 2 C; 8 G; 1 T; 0 U; 1 Other;

Query Match 1.7%; Score 13; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 5.9e+02;
 Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 263 CTGCACCTGCTTCA 277
 Db 15 CTGCCCTGCTTCA 1

RESULT 882
 AAS18453
 ID AAS18453 standard; DNA; 15 BP.
 XX
 AC AAS18453;
 XX
 DT 12-MAR-2002 (first entry)
 DE ASO primer #5 to detect human beta2AR gene polymorphisms.
 XX
 KW Human; beta2-adrenergic receptor; beta2AR polymorphism; asthma;
 KW chromosome 5q31-32; migraine; congestive heart failure; hypertension;
 KW ischaemic heart disease; chronic obstructive pulmonary disease; COPD;
 KW obesity; diabetes mellitus; premature labour; vasotropic; cardiant;
 KW allele-specific oligonucleotide; ASO; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200179252-A1.
 XX
 PD 25-OCT-2001.
 XX
 PF 13-APR-2000; 2000WO-US010125.
 XX
 PR 13-APR-2000; 2000WO-US010125.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 PA (UYCI-) UNIV CINCINNATI.
 XX
 PI Stack CB, Drysdale CM, Stephens JC, Nandabalan K, Judson RS;
 PI Liggett SB;
 XX
 WIPI; 2002-061968/08.
 DR
 XX
 PT New isolated beta 2-adrenergic receptor polynucleotide, useful for
 PT studying expression and biological function of receptor and for
 PT developing drugs targeting receptor, comprises polymorphism of adenosine
 PT at P82 and thymine at P85.
 XX
 PS Disclosure; Page 19; 67pp; English.
 XX
 CC The present invention relates to polymorphisms and haplotypes of the
 CC human beta2-adrenergic receptor (beta2-AR) gene located on chromosome
 CC 5q31-32, and methods for haplotyping and/or genotyping the beta2AR gene
 CC in an individual. The methods of the invention make use of allele-
 CC specific oligonucleotides (ASOs) as probes and primers for detecting the
 CC beta2AR gene polymorphisms. The beta2AR gene polymorphisms are useful in

CC studying the expression and biological function of beta2AR, and for
 CC developing drugs targeting this receptor. They are also useful for
 CC therapeutic purposes such as treating disorders affected by expression or
 CC function of beta2AR such as congestive heart failure, arrhythmia,
 CC ischaemic heart disease, hypertension, migraine, asthma, chronic
 CC obstructive pulmonary disease (COPD), obesity, diabetes and premature
 CC labour. The method is useful for determining the frequency of a beta2AR
 CC genotype or haplotype in a population. AAS18449-AAS18456 represent ASO
 CC forward primers for detecting human beta2AR gene polymorphisms
 XX
 SQ Sequence 15 BP; 2 A; 4 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 5.9e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 196 CAGTGGTGGCCCG 208
 Db 3 CAGTGGTGGCCCG 15

RESULT 883
 AAS95907/C
 ID AAS95907 standard; DNA; 15 BP.
 XX
 AC AAS95907;
 XX
 DT 26-FEB-2002 (first entry)
 DE Human CALM1 gene allele-specific oligonucleotide #16.
 XX
 KW Calmodulin 1; CALM1; human; single nucleotide polymorphism; SNP;
 KW haplotyping; SCYA3; Alzheimer's disease; drug screening;
 KW calcium-dependent signal transduction; PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200179218-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 09-APR-2001; 2001WO-US011509.
 XX
 PR 12-APR-2000; 2000US-0196340P.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 XX
 PI Bentivegna SC, Chew A, Choi JY, Koshy B, Stephens JC;
 XX WPI; 2002-049190/06.
 DR
 XX
 PT New calmodulin-1 (CALM-1) isogene polymorphic variants, useful in
 PT expressing CALM1 protein for use in screening for candidate drugs to
 PT treat diseases related to CALM1 activity such as Alzheimer's disease.
 XX
 PS Claim 15; Page 13; 82pp; English.
 XX
 CC The invention relates to an isolated polynucleotide comprising a sequence
 CC selected from a polymorphic variant of calmodulin 1 (CALM1). The
 CC polymorphic variant comprises a CALM1 isogene defined by a haplotype
 CC selected from haplotypes 1-21 given in the specification. The
 CC polymorphisms are useful for studying the biological function of CALM1 as
 CC well as in identifying drugs targeting this protein for the treatment of
 CC a disorder related to its abnormal expression or function. The
 CC polymorphic variants may also be used in screening for compounds
 CC targeting CALM1 to treat a specific condition or disease predicted to be
 CC associated with CALM1 activity. Establishing CALM1 haplotype or haplotype
 CC pair of an individual is useful for improving the efficiency and
 CC reliability of several steps in the discovery and development of drugs
 CC for treating diseases associated with SCYA3 activity, e.g. Alzheimer's
 CC disease and diseases involving defects in calcium-dependent signal
 CC transduction. Haplotyping the CALM1 gene in an individual is also useful
 CC in the design of clinical trials of candidate drugs for treating a

CC specific condition or disease predicted to be associated with CALM1
 CC activity. AAS95892-AAS96018 represent human CALM1 allele- specific
 CC oligonucleotides and PCR primers of the invention
 XX
 SQ Sequence 15 BP; 1 A; 6 C; 6 G; 1 T; 0 U; 1 Other;
 Query Match 1.7%; Score 13; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 5.9e+02;
 Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 716 GCGCTGCAGCAGCAG 730
 Db 15 GCGCTGCAGCAGCCG 1
 RESULT 884
 AAS95951/C
 ID AAS95951 standard; DNA; 15 BP.
 XX
 AC AAS95951;
 DT 26-FEB-2002 (first entry)
 XX
 DE Human CALM1 gene allele-specific oligonucleotide #60.
 XX
 KW Calmodulin 1; CALM1; human; single nucleotide polymorphism; SNP;
 KW haplotyping; SCYA3; Alzheimer's disease; drug screening;
 KW calcium-dependent signal transduction; PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200179218-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 09-APR-2001; 2001WO-US011509.
 XX
 PR 12-APR-2000; 2000US-0196340P.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 XX
 PI Bentivegna SC, Chew A, Choi JY, Koshiy B, Stephens JC;
 XX
 DR WPI; 2002-049190/06.
 XX
 PT New calmodulin-1 (CALM-1) isogene polymorphic variants, useful in
 PT expressing CALM1 protein for use in screening for candidate drugs to
 PT treat diseases related to CALM1 activity such as Alzheimer's disease.
 XX
 PS Claim 15; Page 13; 82pp; English.
 CC The invention relates to an isolated polynucleotide comprising a sequence
 CC selected from a polymorphic variant of calmodulin 1 (CALM1). The
 CC polymorphic variant comprises an CALM1 isogene defined by a haplotype
 CC selected from haplotypes 1-21 given in the specification. The
 CC polymorphisms are useful for studying the biological function of CALM1 as
 CC well as in identifying drugs targeting this protein for the treatment of
 CC a disorder related to its abnormal expression or function. The
 CC polymorphic variants may also be used in screening for compounds
 CC targeting CALM1 to treat a specific condition or disease predicted to be
 CC associated with CALM1 activity. Establishing CALM1 haplotype or haplotype
 CC pair of an individual is useful for improving the efficiency and
 CC reliability of several steps in the discovery and development of drugs
 CC for treating diseases associated with SCYA3 activity, e.g. Alzheimer's
 CC disease and diseases involving defects in calcium-dependent signal
 CC transduction. Haplotyping the CALM1 gene in an individual is also useful
 CC in the design of clinical trials of candidate drugs for treating a
 CC specific condition or disease predicted to be associated with CALM1
 CC activity. AAS95892-AAS96018 represent human CALM1 allele- specific
 CC oligonucleotides and PCR primers of the invention
 XX
 SQ Sequence 15 BP; 1 A; 8 C; 4 G; 1 T; 0 U; 1 Other;

Query Match 1.7%; Score 13; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 5.9e+02;
 Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 713 GAGGCGCTGCAGCAG 727
 Db 15 GMGGCGCTGCGCAG 1
 RESULT 885
 AAT81046/C
 ID AAT81046 standard; RNA; 17 BP.
 XX
 AC AAT81046;
 DT 26-SEP-1997 (first entry)
 XX
 DE Human c-myb hammerhead ribozyme target sequence (nt. position 29).
 XX
 KW Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
 KW smooth muscle cell; hyperproliferation; restenosis; cancer; c-myb;
 KW coronary angioplasty; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO9531541-A2.
 XX
 PD 23-NOV-1995.
 XX
 PF 18-MAY-1995; 95WO-US006368.
 XX
 PR 18-MAY-1994; 94US-00245466.
 PR 13-JAN-1995; 95US-00373124.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Stinchcomb DT, Draper K, Mcswiggen J, Jarvis T;
 XX
 DR WPI; 1996-010927/01.
 XX
 PT New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myb,
 PT for treating restenosis or cancer.
 XX
 PS Claim 1; Page 64; 128pp; English.
 CC The present sequence represents the preferred target sequence for an
 CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
 CC the human c-myb sequence at the base position indicated in the descriptor
 CC line. The c-myb sequence was screened for optimal ribozyme target sites
 CC using a computer folding algorithm, and regions of the mRNA which did not
 CC form secondary folding structures and contained potential ribozyme
 CC cleavage sites were identified. Ribozymes were synthesised and their
 CC activities optimised by either varying the length of the binding arms or
 CC by modification to prevent degradation by nucleases. The ribozymes cleave
 CC the c-myb sequence and can be used to prevent smooth muscle cell
 CC hyperproliferation in restenosis, especially after coronary angioplasty,
 CC and in cancers
 XX
 SQ Sequence 17 BP; 0 A; 10 C; 0 G; 0 T; 7 U; 0 Other;
 Query Match 1.7%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 6.8e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 409 GGAGGAGAGAGGAG 421
 Db 15 GGAGGAGAGAGGAG 3
 RESULT 886
 AAT81045/C
 ID AAT81045 standard; RNA; 17 BP.
 XX

CC by the administration of a drug such as Wortmannin. The mice are used for
 CC screening drugs for the inhibition of phosphorylation of the tau-protein.
 CC Inhibitors of the phosphorylation may be used to treat Alzheimer's
 CC disease. Adapters AAC66345 - AAC66348 and PCR primers AAC66349 - AAC66354
 CC are used during the genetic modification of the mice and in the analysis
 CC of their DNA
 XX
 SQ Sequence 17 BP; 1 A; 7 C; 8 G; 1 T; 0 U; 0 Other;
 Query Match 1.7%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 6.8e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 667 GCGCCGGCGGCC 679
 DB 1 GCGCCGGCGGCC 13
 RESULT 889
 AAA24913/C
 ID AAA24913 standard; DNA; 17 BP.
 XX
 AC AAA24913;
 XX
 DT 19-JUL-2000 (first entry)
 XX
 DE Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:1411.
 XX
 KW Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;
 KW hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;
 KW gene expression modification; cancer; phosphorothioate; endonuclease;
 KW anticancer; breast cancer; endometrium cancer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO954459-A2.
 XX
 PD 28-OCT-1999.
 XX
 PF 19-APR-1999; 99WO-US008547.
 XX
 PR 20-APR-1998; 98US-0082404P.
 PR 23-JUN-1998; 98US-00103636.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Thompson JD, Beigelman L, Mcswiggen JA, Karpeisky A, Bellon L;
 PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haeblerl P;
 PI Matulic-Adamic J;
 XX
 DR WPI; 2000-013248/01.
 XX
 PT New nucleic acids that interact, and optionally cleave, target sequences,
 PT used to treat cancer.
 XX
 PS Claim 77; Page 62; 148pp; English.
 XX
 CC The present invention describes nucleic acids (A) that interact stably
 CC with a target sequence and contain at least one phosphorodithioate
 CC link, having endonuclease activity. (A), and more generally any catalytic
 CC nucleic acid (A') that modulates expression of the oestrogen receptor
 CC gene, are used to treat cancer (particularly of breast or endometrium),
 CC in vivo or by transforming cells ex vivo and implanting treated cells, or
 CC for other conditions associated with levels of oestrogen receptor.
 CC Because of the high selectivity for targeted RNA, (A) can also be used to
 CC correlate inhibition of gene expression with alterations in phenotype,
 CC particularly for identification of therapeutic targets, and as research
 CC reagents (for RNA, in the same way that restriction endonucleases are
 CC used with DNA). The combination of modifications in (A) improves
 CC resistance to nucleases, binding affinity and/or activity. AAA23503 to
 CC AAA24747 represent oestrogen receptor hammerhead ribozyme sequences, and
 CC AAA24748 to AAA25992 represent their corresponding target sequences.
 CC AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme

CC sequences, and AAA26107 to AAA26218 represent their corresponding target
 CC sequences. AAA26219 to AAA26271 represent other ribozyme sequences and
 CC antisense oligonucleotides used in the exemplification of the present
 CC invention
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 1.7%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 6.8e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 790 CATGGAGCGCCAG 802
 DB 13 CATGGAGCGCCAG 1
 RESULT 890
 ABN08982/C
 ID ABN08982 standard; DNA; 17 BP.
 XX
 AC ABN08982;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8974.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US016981.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-0004263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0268660P.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX
 DR WPI; 2002-179446/23.
 XX
 PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX
 PS Disclosure; SEQ ID NO 8974; 214pp; English.
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for

CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 4 A; 3 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 6.8e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 851 CACACGCTCTTCC 863
 Db 13 CACACGCTCTTCC 1

RESULT 891
 ABN07250
 ID ABN07250 standard; DNA; 17 BP.
 XX
 AC ABN07250;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7242.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US016981.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 PA (AEOM-) AEOMICA INC.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 PI WPI; 2002-179446/23.
 XX
 DR
 XX
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser

PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX Disclosure; SEQ ID NO 7242; 214pp; English.
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-1
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 4 A; 1 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 6.8e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 697 GCTGGAGAGTGAG 709
 Db 5 GCTGGAGAGTGAG 17

RESULT 892
 ACA07655
 ID ACA07655 standard; RNA; 17 BP.
 XX
 AC ACA07655;
 XX
 DT 03-JUN-2003 (first entry)
 XX
 DE NFKB sub-unit modulating zinnzyme substrate #54.

XX Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinnzyme;
 KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
 KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection; ss.

OS Homo sapiens.
 XX
 XX US2002177568-A1.
 XX
 PD 28-NOV-2002.
 XX
 PF 23-MAY-2001; 2001US-00864785.
 XX
 PR 07-DEC-1992; 92US-00987132.
 PR 18-MAY-1994; 94US-00245466.
 PR 15-AUG-1994; 94US-00291932.

```

PR 23-DEC-1996; 96US-00777916.
XX (STIN/) STINCHOMB D T.
PA (MCSW/) MCSWIGGEN J.
PA (DRAP/) DRAPER K G.
XX
PI Stinchcomb DT, Mcswiggen J, Draper KG;
XX
XX WPI; 2003-340953/32.
XX
XX Novel enzymatic nucleic acid molecules which down regulates expression of
PT a sequence encoding a subunit of nuclear factor kappa B useful for
PT treating cancer, inflammatory disorders and autoimmune diseases.
XX
XX Claim 3; Page 38; 72pp; English.
XX
XX The invention describes an enzymatic nucleic acid molecule (I) which down
XX regulates expression of a sequence encoding a subunit of nuclear factor
XX kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
XX configuration. The enzymatic nucleic acid molecule is adapted to treat
XX cancer and is useful for down-regulating REL-A activity in a cell, for
XX treating a patient having a condition associated with the level of REL-A.
XX (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
XX the presence of a divalent cation, especially Mg2+. The enzymatic and
XX antisense nucleic acid molecules are useful for treating breast, lung,
XX prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
XX cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
XX multidrug resistant cancer. The method involves use of other drug
XX therapies such as monoclonal antibodies, REL-A-specific inhibitors or
XX chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
XX cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
XX gemcitabine or radiation therapy. The enzymatic and antisense nucleic
XX acid molecules are also useful for treating inflammatory disease such as
XX rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
XX obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
XX rejection, gene therapy applications, ischaemia/reperfusion injury
XX (central nervous system (CNS) and myocardial), glomerulonephritis,
XX sepsis, allergic airway inflammation, inflammatory bowel disease or
XX infection. This sequence represents the substrate of a novel enzymatic
XX nucleic acid molecule
XX
XX Sequence 17 BP; 6 A; 2 C; 7 G; 0 T; 2 U; 0 Other;
XX
XX Query Match 1.7%; Score 13; DB 1; Length 17;
XX Best Local Similarity 92.3%; Pred. No. 6.8e+02;
XX Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
QY 884 AAGAGCAGCGTGG 896
DB 5 AAGAGCAGCGGUGG 17
|||||||
|
RESULT 893
ACD59950/c
ID ACD59950 standard; RNA; 17 BP.
XX
XX ACD59950;
XX
XX 24-SEP-2003 (first entry)
XX
XX HCV DNazyme substrate sequence #1584.
XX
XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
XX RNA stability; RNA expression; RNA synthesis; antisense;
XX enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;
XX amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
XX HBV reverse transcriptase; Enhancer I region; viral replication;
XX degenerative; disease state; HBV infection; HCV infection; cirrhosis;
XX liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
XX virucide; antiinflammatory; substrate; ss.
XX
XX Hepatitis C virus.
XX

```

```

PN WO200281494-A1.
XX
XX 17-OCT-2002.
XX
XX 26-MAR-2002; 2002WO-US009187.
XX
XX 26-MAR-2001; 2001US-00817879.
XX 08-JUN-2001; 2001US-00877478.
XX 08-JUN-2001; 2001US-0296876P.
XX 24-OCT-2001; 2001US-0335059P.
XX 05-DEC-2001; 2001US-0337055P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MACE/) MACEJAK D.
XX (MCSW/) MCSWIGGEN J.
XX (MORR/) MORRISSEY D.
XX (PAVC/) PAVCO P.
XX (LEEF/) LEE P.
XX (DRAP/) DRAPER K.
XX (ROBE/) ROBERTS E.
XX
XX Blatt L, Macsjak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
XX Draper K, Roberts E;
XX WPI; 2003-229207/22.
XX
XX Novel compound useful for treating cirrhosis, liver failure,
XX hepatocellular carcinoma, or condition associated with hepatitis C virus
XX infection.
XX
XX Claim 1; Page 262; 387pp; English.
XX
XX The present invention relates to nucleic acid molecules which modulate
XX the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
XX Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
XX and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
XX inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
XX are nucleic acid decoy molecules and aptamers that bind to HBV reverse
XX transcriptase and/or HBV reverse transcriptase primer sequences, as well
XX as oligonucleotides that specifically bind the Enhancer I region of HBV
XX DNA. The nucleic acids may be used to modulate the expression of HBV
XX genes and HBV viral replication. Also disclosed is a method for screening
XX compounds and/or potential therapies directed against HBV, and compounds
XX that modulate the expression and/or replication of HCV. The compounds and
XX methods of the invention are useful for the treatment of degenerative and
XX disease states related to HBV and HCV infection, replication and gene
XX expression such as cirrhosis, liver failure, and hepatocellular
XX carcinoma. The present sequence represents a substrate for one of the HCV
XX DNazyme or minus strand DNazyme sequences disclosed in the present
XX invention
XX
XX Sequence 17 BP; 2 A; 7 C; 6 G; 0 T; 2 U; 0 Other;
XX
XX Query Match 1.7%; Score 13; DB 1; Length 17;
XX Best Local Similarity 100.0%; Pred. No. 6.8e+02;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 782 GCGCTCCGCATGG 794
DB 17 GCGCTCCGCATGG 5
|||||||
|
RESULT 894
ACD62719
ID ACD62719 standard; RNA; 17 BP.
XX
XX ACD62719;
XX
XX 24-SEP-2003 (first entry)
XX
XX HCV minus strand DNazyme substrate sequence #694.
XX

```

KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
 KW RNA stability; RNA expression; RNA synthesis; antisense;
 KW enzymatic nucleic acid; hammerhead ribozyme; DNzyme; inozyme; zinzyme;
 KW anberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
 KW HBV reverse transcriptase; Enhancer I region; viral replication;
 KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
 KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
 KW virucide; antiinflammatory; substrate; ss.
 XX
 OS Hepatitis C virus.
 XX
 XX WO200281494-A1.
 XX
 XX 17-OCT-2002.
 XX
 XX 26-MAR-2002; 2002WO-US009187.
 XX
 XX 26-MAR-2001; 2001US-00817879.
 PR 08-JUN-2001; 2001US-00877478.
 PR 08-JUN-2001; 2001US-0296876P.
 PR 24-OCT-2001; 2001US-0335059P.
 PR 05-DEC-2001; 2001US-0337055P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MACE/) MACEJAK D.
 PA (MCSW/) MCSWIGGEN J.
 PA (MORR/) MORRISSEY D.
 PA (PAVC/) PAVCO P.
 PA (LEEP/) LEE P.
 PA (DRAP/) DRAPER K.
 PA (ROBE/) ROBERTS E.
 XX
 XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
 PI Draper K, Roberts E;
 PI WPI; 2003-229207/22.
 XX
 XX Novel compound useful for treating cirrhosis, liver failure,
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus
 PT infection.
 XX
 XX Claim 1; Page 287; 387pp; English.
 XX
 XX The present invention relates to nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNAsymes,
 CC inozymes, zinzymes, anberzymes, and G-cleaver ribozymes. Also disclosed
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV
 CC DNA. The nucleic acids may be used to modulate the expression of HBV
 CC genes and HBV viral replication. Also disclosed is a method for screening
 CC compounds and/or potential therapies directed against HBV, and compounds
 CC that modulate the expression and/or replication of HCV. The compounds and
 CC methods of the invention are useful for the treatment of degenerative and
 CC disease states related to HBV and HCV infection, replication and gene
 CC expression such as cirrhosis, liver failure, and hepatocellular
 CC carcinoma. The present sequence represents a substrate for one of the HCV
 CC DNzyme or minus strand DNzyme sequences disclosed in the present
 CC invention
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 6 G; 0 T; 3 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 17;
 Best Local Similarity 84.6%; Pred. No. 6.8e+02;
 Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 782 GCCTCCGATGG 794
 |||||:|||||:
 Db 2 GCCTCCGATGG 14

RESULT 895
 ADL48557
 ID ADL48557 standard; RNA; 17 BP.
 XX
 AC ADL48557;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Human IKK-gamma substrate sequence #1067.
 XX
 KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 XX WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 XX Blatt L, Chowira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI WPI; 2003-058513/05.
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 XX Claim 59; SEQ ID NO 2090; 317pp; English.
 XX
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 6 C; 4 G; 0 T; 2 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 17;
 Best Local Similarity 84.6%; Pred. No. 6.8e+02;
 Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 162 TCTGGAGAGCCA 174
 :|:|||||:
 Db 5 UCUGAAGAGCCA 17


```
RESULT 896
ADI85725
ID ADI85725 standard; RNA; 17 BP.
XX
XX
AC ADI85725;
DT 03-JUN-2004 (first entry)
XX
XX HCV DNzyme substrate sequence #2971.
DE
XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KW HCV infection; type I interferon; DNzyme.
XX
XX Hepatitis C virus.
OS
XX US2003125270-A1.
PN
XX 03-JUL-2003.
PD
XX
XX 18-DEC-2000; 2000US-00740332.
PF
XX
XX 18-DEC-2000; 2000US-00740332.
PR
XX
XX (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (ROBE/) ROBERTS E.
PA (PVC/) PAVCO P A.
PA (MACE/) MACEJACK D.
XX
XX Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
PI WPI; 2004-031273/03.
XX
XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT especially in combination with type I interferon therapy.
XX
XX Claim 1; SEQ ID NO 2971; 198pp; English.
XX
XX The invention relates to an enzymatic nucleic acid molecule which
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC the binding arms of the enzymatic nucleic acid molecule comprises
CC sequences complementary to any of the defined substrate sequences given
CC in the specification. The nucleic acid molecule may be administered for
CC the treatment of HCV infections, especially in combination with type I
CC interferons. The present sequence represents a HCV DNzyme substrate
CC sequence.
XX
XX Sequence 17 BP; 2 A; 6 C; 6 G; 0 T; 3 U; 0 Other;
SQ
Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 84.6%; Pred. No. 6.8e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 782 GGCCTCCGCATGG 794
Db |||||:|||||
2 GGCUCGCCAUGG 14

RESULT 897
ADI84338/c
ID ADI84338 standard; RNA; 17 BP.
XX
XX
AC ADI84338;
DT 03-JUN-2004 (first entry)
XX
XX HCV DNzyme substrate sequence #1584.
DE
XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KW HCV infection; type I interferon; DNzyme.
XX
XX
```

```
OS Hepatitis C virus.
XX
XX US2003125270-A1.
XX
XX 03-JUL-2003.
XX
XX 18-DEC-2000; 2000US-00740332.
XX
XX 18-DEC-2000; 2000US-00740332.
XX
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J.
XX (ROBE/) ROBERTS E.
XX (PVC/) PAVCO P A.
XX (MACE/) MACEJACK D.
XX
XX Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
PI WPI; 2004-031273/03.
XX
XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT especially in combination with type I interferon therapy.
XX
XX Claim 1; SEQ ID NO 1584; 198pp; English.
XX
XX The invention relates to an enzymatic nucleic acid molecule which
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC the binding arms of the enzymatic nucleic acid molecule comprises
CC sequences complementary to any of the defined substrate sequences given
CC in the specification. The nucleic acid molecule may be administered for
CC the treatment of HCV infections, especially in combination with type I
CC interferons. The present sequence represents a HCV DNzyme substrate
CC sequence.
XX
XX Sequence 17 BP; 2 A; 7 C; 6 G; 0 T; 2 U; 0 Other;
SQ
Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 782 GGCCTCCGCATGG 794
Db 17 GGCCTCCGCATGG 5

RESULT 898
ACN70340
ID ACN70340 standard; DNA; 17 BP.
XX
XX ACN70340;
AC
XX
XX 02-DEC-2004 (first entry)
DT
XX
XX Human GDMPL-1 probe SEQ ID NO:7242.
DE
XX
XX Human; ss; probe; myosin-like protein-1; hGDMPL-1;
KW hGDMPL-1 agonist hGDMPL antagonist; hGDMPL inhibitor; heart disorder;
KW skeletal muscle function.
XX
XX Homo sapiens.
OS
XX
XX US2004137589-A1.
PN
XX
XX 15-JUL-2004.
PD
XX
XX 26-NOV-2003; 2003US-00723361.
PF
XX
XX 26-MAY-2000; 2000US-0207456P.
PR
XX 21-SEP-2000; 2000US-0234687P.
PR
XX 27-SEP-2000; 2000US-0236359P.
PR
XX 04-OCT-2000; 2000GB-00024263.
PR
XX 30-JAN-2001; 2001WO-US000661.
PR
```

PR 30-JAN-2001; 2001WO-US0000662.
 PR 30-JAN-2001; 2001WO-US0000663.
 PR 30-JAN-2001; 2001WO-US0000664.
 PR 30-JAN-2001; 2001WO-US0000665.
 PR 30-JAN-2001; 2001WO-US0000666.
 PR 30-JAN-2001; 2001WO-US0000667.
 PR 30-JAN-2001; 2001WO-US0000668.
 PR 30-JAN-2001; 2001WO-US0000669.
 PR 30-JAN-2001; 2001WO-US0000670.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 PA (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 XX
 PT Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 XX
 PS Disclosure; SEQ ID NO 7242; Opp; English.
 XX
 CC The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX
 SQ Sequence 17 BP; 4 A; 1 C; 9 G; 3 T; 0 U; 0 Other;
 Query Match 1.7%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 6.8e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 697 GCTGGAGAGTGAG 709
 |||||
 Db 5 GCTGGAGAGTGAG 17
 RESULT 899
 ACN72072/c
 ID ACN72072 standard; DNA; 17 BP.
 XX
 AC ACN72072;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Human GDMPLP-1 probe SEQ ID NO:8974.
 XX
 KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 OS Homo sapiens.
 XX
 XX US2004137589-A1.
 XX
 PD 15-JUL-2004.

XX 26-NOV-2003; 2003US-00723361.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US0000661.
 PR 30-JAN-2001; 2001WO-US0000662.
 PR 30-JAN-2001; 2001WO-US0000663.
 PR 30-JAN-2001; 2001WO-US0000664.
 PR 30-JAN-2001; 2001WO-US0000665.
 PR 30-JAN-2001; 2001WO-US0000666.
 PR 30-JAN-2001; 2001WO-US0000667.
 PR 30-JAN-2001; 2001WO-US0000668.
 PR 30-JAN-2001; 2001WO-US0000669.
 PR 30-JAN-2001; 2001WO-US0000670.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 PA (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 XX
 PT Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 XX
 PS Disclosure; SEQ ID NO 8974; Opp; English.
 XX
 CC The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX
 SQ Sequence 17 BP; 4 A; 3 C; 8 G; 2 T; 0 U; 0 Other;
 Query Match 1.7%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 6.8e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 851 CACCAGCTCTTC 863
 |||||
 Db 13 CACCAGCTCTTC 1
 RESULT 900
 AAQ24927/c
 ID AAQ24927 standard; DNA; 16 BP.
 XX
 AC AAQ24927;
 XX
 DT 25-MAR-2003 (revised)
 DT 19-NOV-1992 (first entry)
 XX
 DE Homeo box consensus sequence primer (250).
 XX

KW Single primer amplification; SPAR; ss.
 OS Synthetic.
 XX
 PN WO9207948-A1.
 XX
 PD 14-MAY-1992.
 XX
 XX 05-NOV-1991; 91WO-US008233.
 PF
 XX 06-NOV-1990; 90US-00610973.
 PR
 PR 29-JUL-1991; 91US-00737919.
 XX
 XX (LUBR) LUBRIZOL CORP.
 PA
 XX Cardineau GA, Filner P;
 PI
 XX WPI; 1992-183683/22.
 DR
 XX Nucleic acid sequence single primer amplification - useful for genomic
 PT variation analysis and polymorphism detection for restriction fragment
 PT length data.
 PT
 XX
 PS Claim 16; Page 39; 65pp; English.
 XX
 CC The selected primer is used in practice of the single primer
 CC amplification reaction (SPAR). (Updated on 25-MAR-2003 to correct PN
 CC field.)
 XX
 XX Sequence 16 BP; 1 A; 8 C; 2 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 1.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 87.5%; Pred. No. 6.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 QY 694 GCAGCTGGAGAGTGAG 709
 DB 16 GCAGCTGGAGAGGAG 1
 XX
 RESULT 901
 AAV14335/C
 ID AAV14335 standard; DNA; 16 BP.
 XX
 AC AAV14335;
 XX
 DT 27-AUG-2003 (revised)
 DT 19-MAY-1998 (first entry)
 XX
 DE Probe HBPr242 for Hepatitis b virus.
 XX
 KW Probe; hepatitis b virus; HBV detection; RT pol region; genetic analysis;
 KW preCore region; HBsAg region; genotype specific target;
 KW mutation detection; ss.
 XX
 OS Synthetic.
 OS Hepatitis B virus.
 XX
 PN WO9740193-A2.
 XX
 PD 30-OCT-1997.
 XX
 PF 21-APR-1997; 97WO-EP002002.
 XX
 PR 19-APR-1996; 96EP-00870053.
 XX
 PA (INNO-) INNOGENETICS NV.
 XX
 XX Stuyver L, Rossau R, Maertens G;
 PI
 XX WPI; 1997-535867/49.
 DR
 XX Detection and/or genetic analysis of hepatitis B virus - specifically

PT genotype, preCore mutations, vaccine escape mutations and RT gene
 PT mutations selected by treatment with drugs.
 XX
 PS Disclosure; Page 32; 80pp; English.
 XX
 CC This sequence represents a probe for hepatitis b virus (HBV), used in the
 CC method of the invention for detection and/or genetic analysis of
 CC hepatitis B virus (HBV) in a sample. The method comprises: (a) optionally
 CC releasing, isolating or concentrating polynucleic acids (I) in the
 CC sample, and amplifying the relevant part of a suitable HBV gene in the
 CC sample with at least 1 suitable primer pair; (b) hybridising (I) with a
 CC combination of at least 2 nucleotide probes, which are applied to known
 CC locations on a solid support and hybridise specifically to mutant target
 CC sequences chosen from the HBV RT pol gene region, HBV preCore region,
 CC HBsAg region and/or HBV genotype specific target sequences, or their
 CC complements or U for T homologues; (c) detecting the hybrids formed in
 CC step (b), and inferring the HBV genotype and/or mutants present in the
 CC sample from the differential hybridisation signal(s). The composition can
 CC be used to diagnose and/or monitor HBV mutations and/or genotypes in a
 CC sample, specifically genotype, preCore mutations, vaccine escape
 CC mutations and RT gene mutations selected by treatment with drugs, e.g.
 CC lamivudine and penciclovir. (Updated on 27-AUG-2003 to correct OS field.)
 XX
 SQ Sequence 16 BP; 1 A; 6 C; 4 G; 5 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 87.5%; Pred. No. 6.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 QY 395 CAAGCCAGCCAGAGGG 410
 DB 16 CAAGCCAGCAGAGTGGG 1
 XX
 RESULT 902
 AA291311
 ID AA291311 standard; DNA; 16 BP.
 XX
 AC AA291311;
 XX
 DT 17-MAY-2000 (first entry)
 DT
 XX IL-6R and IL-6 fusion protein related oligonucleotide SEQ ID NO:10.
 DE
 XX Interleukin 6 receptor; IL-6R; interleukin 6; IL-6; fusion protein;
 KW antianaemic; haematopoietic stem cell; platelet; blood; primer; ss.
 KW
 XX Synthetic.
 OS
 PN WO200001731-A1.
 XX
 PD 13-JAN-2000.
 XX
 PF 01-JUL-1999; 99WO-JP003554.
 XX
 PR 06-JUL-1998; 98JP-00190597.
 PR 29-JAN-1999; 99JP-00021788.
 PR 30-APR-1999; 99JP-00123411.
 XX
 PA (TOXJ) TOSOH CORP.
 XX
 PI Ekida T, Yagame H, Iida H, Yasukawa K, Tauchiya S, Ide T;
 XX
 DR WPI; 2000-182106/16.
 XX
 XX Fusion protein containing IL-6 receptor directly bonded to IL-6 useful
 PT for stimulating hematopoietic stem cell and blood platelet augmentation.
 PT
 XX Example 2; Page 60; 83pp; Japanese.
 PS
 XX The present invention describes a fusion protein (I) comprising an
 CC interleukin-6 receptor (IL-6R) directly linked to interleukin 6 (IL-6),
 CC where an amino acid residue of the IL-6R is directly bonded to an amino

CC acid residue of the IL-6. (I) is useful for the augmentation of
 CC haematopoietic stem cells ex vivo, and augmentation of blood platelets
 CC either ex vivo or therapeutically. AA291302 to AA291360 and AA290115
 CC represent sequences used in the exemplification of the present invention
 XX
 SQ Sequence 16 BP; 2 A; 3 C; 10 G; 1 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 87.5%; Pred. No. 6.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 690 CGCGGAGCTGGAGAG 705
 || |||||
 Db 1 CGCGGAGCTGGAGGG 16

RESULT 903
 AAX82828/c
 ID AAX82828 standard; DNA; 16 BP.
 XX
 AC AAX82828;
 XX
 DT 30-JUN-2000 (first entry)
 XX
 DE Human ApoE gene probe #3.
 XX
 KW ApoE; detection; polymorphism; apolipoprotein; alpha-1 antichymotrypsin;
 KW diagnosis; Alzheimer's disease; PCR primer; probe; human; ss.
 XX
 OS Homo sapiens.
 XX
 PN JP2000050898-A.
 XX
 PD 22-FEB-2000.
 XX
 PF 06-AUG-1998; 98JP-00235033.
 XX
 PR 06-AUG-1998; 98JP-00235033.
 XX
 PA (NISS-) NISSHO KK.
 XX
 WP I; 2000-353229/31.
 XX

XX This invention describes a novel reagent for the detection of
 CC polymorphism in the apolipoprotein (Apo) E gene and alpha-1
 CC antichymotrypsin (ACT) gene. The method involves primers specific to ApoE
 CC gene, primers specific to the ACT gene, detection probes for detecting
 CC ApoE gene polymorphisms and detection probes for detecting ACT gene
 CC polymorphisms. The method of the invention can be used in the diagnosis
 CC of Alzheimer's disease in which the combination between the gene
 CC polymorphism of ApoE gene and the gene polymorphism of ACT gene detected
 CC by the described detection method is connected to the contraction of
 CC Alzheimer's disease. The method is used for the estimation of the level of
 CC Alzheimer's disease in the population. The reagent can amplify the two
 CC genes simultaneously and detect the gene polymorphism of the two genes in
 CC one step. AAX82822-X82831 represent PCR primers and probes used to
 CC illustrate the method of the invention
 XX

SQ Sequence 16 BP; 4 A; 5 C; 6 G; 1 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 87.5%; Pred. No. 6.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 373 CTGCGAGGAGCTTCTG 388

Db |||||
 16 CTGCCAGGCGCTTCTG 1

RESULT 904
 AAC83935/c
 ID AAC83935 standard; DNA; 16 BP.
 XX
 AC AAC83935;
 XX
 DT 02-MAR-2001 (first entry)
 XX
 DE ApoE gene polymorphism detection probe #3.

XX
 KW Osteoporosis; human; polymorphism; vitamin D receptor; VDR;
 KW oestrogen receptor; apolipoprotein E; ApoE; PCR primer; detection probe;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN EF1054066-A2.
 XX
 PD 22-NOV-2000.
 XX
 PF 18-MAY-2000; 2000EP-00110219.
 XX
 PR 18-MAY-1999; 99JP-00136653.
 PR 11-JUN-1999; 99JP-00165642.
 XX
 PA (NISS-) NISSHO CORP.
 XX
 PI Shiraki M, Ouchi Y, Hosoi T, Kusaba N, Baba T, Yoshida H;
 WP I; 2001-018132/03.

XX Diagnosing sensitivity to a medicine for osteoporosis involves analyzing
 CC genetic polymorphisms of vitamin D receptor gene, estrogen receptor gene
 CC and apolipoprotein E gene.
 XX
 PS Claim 22; Page 44; 5ipp; English.
 XX
 CC The present invention relates to a method for anticipating the
 CC sensitivity to a medicine for osteoporosis. The method involves analysing
 CC combinations of genetic polymorphisms of a vitamin D receptor gene (VDR),
 CC an oestrogen receptor (ER) gene, and an apolipoprotein E (ApoE) gene from
 CC a human genome DNA sample. PCR primers AAC83918-C83926 and AAC83937-
 CC C83942 were used in the method of the present invention to amplify the
 CC VDR, ER and ApoE genes, and detection probes AAC83927-C83936 were used
 CC for detecting VDR, ER and ApoE genetic polymorphism. By relating a
 CC combination of the genetic polymorphisms detected using the detection
 CC probes described in AAC83927-C83936, a remedy for a bone-associated
 CC disease can be selected
 XX
 SQ Sequence 16 BP; 4 A; 5 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 87.5%; Pred. No. 6.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 373 CTGCGAGGAGCTTCTG 388
 |||||
 Db 16 CTGCCAGGCGCTTCTG 1

RESULT 905
 AAD04745/c
 ID AAD04745 standard; DNA; 16 BP.
 XX
 AC AAD04745;
 XX
 DT 17-JUL-2001 (first entry)
 XX
 DE Sindbis virus erythropoietin DNA amplifying Epo-3' RT-PCR primer.

XX Alphaviral vector; vaccine; therapy; cancer; antiparasitic; antimalarial;
 KW anticancer; anti-HIV; antiviral; infectious disease;

KW Human immunodeficiency virus; HIV; influenza; passive immunisation;
 KW carcinoma; liver; skin; stomach; ovarian tumour; RT-PCR primer;
 KW erythropoietin; ss.
 XX
 XX Sindbis virus.
 XX WO200130989-A2.
 XX
 XX 03-MAY-2001.
 XX
 XX 26-OCT-2000; 2000WO-IB001557.
 PF
 XX 27-OCT-1999; 99US-0161796P.
 PR
 XX (CYTO-) CYTOS BIOTECHNOLOGY AG.
 PA (RENN/) RENNER W A.
 PA (NIEB/) NIEBA L.
 XX
 XX Renner WA, Nieba L;
 PI WPI; 2001-308631/32.
 DR
 XX Preparing alphaviral vectors with mutations in a selected gene, for use
 XX as vaccines, particularly against pathogens that mutate rapidly,
 PT comprises replicating in the presence of a nucleoside analog.
 PT
 XX Example 3; Page 59; 103pp; English.
 PS
 XX The present invention relates to a method for preparing viral vectors
 XX which comprises inserting a gene of interest into an alphaviral vector
 CC such as pCytts, pSInkps and replicating the vector in the presence of
 CC alphaviral replicase and nucleoside analogues (5'-azacytidine (AZT), FU-
 CC 5'-fluorouridine) to produce a modified gene of interest. The replication
 CC is repeated until the modified gene in 90 % of the vector population
 CC contain a mutation in the modified gene which is 90-99 % identical with
 CC the gene of interest. The vector populations are used in vaccines for
 CC treatment or prevention of a wide variety of infectious diseases (viral
 CC or parasitic, e.g. human immuno deficiency virus (HIV), influenza,
 CC Trypanosoma or Plasmodium) and cancers such as liver carcinoma, stomach
 CC carcinoma, skin carcinoma and ovarian tumours. Vaccines containing the
 CC mutant populations will therefore be effective against viral escape
 CC mutants. Mutagenesis in a eukaryotic cell ensures that expressed proteins
 CC are correctly glycosylated. Antisera raised against the vaccines can be
 CC used for passive immunisation. The present sequence is Epo-3' RT (reverse
 CC transcription) PCR primer used for amplifying erythropoietin DNA from
 CC Sindbis virus which is an alphavirus. Erythropoietin is the gene of
 CC interest
 CC
 XX Sequence 16 BP; 2 A; 6 C; 3 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 1.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 87.5%; Pred. No. 6.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 749 CAGCTGGCATGCAGG 764
 DB 16 CAGATGCATGCAGG 1
 RESULT 906
 ABA93196/C
 ID ABA93196 standard; DNA; 16 BP.
 XX
 XX ABA93196;
 AC
 XX 17-APR-2002 (first entry)
 DT
 XX Human apolipoprotein E gene probe SEQ ID NO:5.
 DE
 XX Human; vitamin D receptor; apolipoprotein E; oestrogen receptor; VDR;
 KW ApoE; bone-related disease; polymorphism; detection; probe; ss.
 KW
 XX Homo sapiens.
 OS

XX JP2001333798-A.
 XX 04-DEC-2001.
 XX 26-MAY-2000; 2000JP-00155871.
 PF
 XX 26-MAY-2000; 2000JP-00155871.
 PR
 XX (NISS-) NISSHO KK.
 XX
 XX WPI; 2002-135948/18.
 DR
 XX A reagent for detecting simultaneously a gene polymorphism of the vitamin
 PT D receptor gene, apolipoprotein E gene and estrogen receptor gene.
 PT
 XX Claim 1; Page 2; 13pp; Japanese.
 PS
 XX The present invention describes a reagent for detecting simultaneously
 CC the gene polymorphism of the vitamin D receptor (VDR) gene,
 CC apolipoprotein E (ApoE) gene and estrogen receptor (ER) gene. Also
 CC described is a method for detecting simultaneously the gene polymorphism
 CC of VDR gene, ApoE gene and ER gene in which the reagent is used to detect
 CC the gene polymorphism of VDR, ApoE and ER in a sample. The reagent can be
 CC used for selecting a treating agent for bone-related diseases. The
 CC present sequence represents a specifically claimed probe for the human
 CC ApoE gene, for use in a reagent of the present invention
 CC
 XX Sequence 16 BP; 4 A; 5 C; 6 G; 1 T; 0 U; 0 Other;
 SQ
 Query Match 1.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 87.5%; Pred. No. 6.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 373 CTGCGAGGAGCTTCG 388
 DB 16 CTGCCAGGCGCTTCG 1
 RESULT 907
 ABS98216/C
 ID ABS98216 standard; DNA; 16 BP.
 XX
 XX ABS98216;
 AC
 XX 23-DEC-2002 (first entry)
 DT
 XX Human lactoferrin (LTF) gene PCR primer #31.
 DE
 XX Human; ss; primer; cytochrome P450 A1; CYP4501A1; UGT2B4; MDR1; PCR;
 KW cytochrome P450 A2; CYP4501A2; cytochrome P450 02E; CYP45002B1; LTF;
 KW adrenergic receptor beta1; ADRB1; aryl hydrocarbon; AHR; MRP3; NR112;
 KW aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
 KW cyclooxygenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
 KW epoxide hydrolase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;
 KW glutathione-S-transferase 12; GST12; histamine-N-methyl transferase;
 KW HNMT; kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;
 KW NADPH quinone oxidoreductase 2; NQO2; sulfoltransferase thermolabile; STW;
 KW UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
 KW UGT2B7; UDP-glucuronosyl transferase; UGT2B15; uronidase receptor; UPA;
 KW multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
 KW multidrug resistance associated protein 3; cancer; prostate;
 KW acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR5;
 KW altered drug metabolism; cardiovascular function; colorectal tumour;
 KW central nervous system; pulmonary; immunological.
 XX
 XX Homo sapiens.
 OS
 XX WO200257410-A2.
 PN
 XX 25-JUL-2002.
 PD
 XX 28-NOV-2001; 2001WO-US044838.
 PF

XX 28-NOV-2000; 2000US-00724389.
XX (DNAS-) DNA SCI LAB INC.
XX Guida M, Hall J;
XX WPI; 2002-698522/75.
XX Isolated nucleic acid molecules having polymorphisms in known human genes
XX e.g. cytochrome p450 and cathepsin S useful as genetic linkage markers
XX for locating, identifying and characterizing the genes responsible for
XX disorder-related traits.
XX Example 23; Page 146; 714pp; English.
XX This invention relates to the sequence of an isolated nucleic acid
XX molecule comprising at least one base variation from that of a known
XX human cytochrome P450 A1 (CYP450A1), cytochrome P450 A2 (CYP450A2),
XX cytochrome P450 02B1 (CYP45002B1), adrenergic receptor beta1 (ADRB1),
XX aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator
XX (ARNT), cathepsin S (CTSS), cyclooxygenase 2 (COX2), diazepam binding
XX inhibitor (DBI), epoxide hydrolase 2 (EPHX2), 5-lipoxygenase activating
XX protein (FLAP), glutathione-S-transferase 12 (GST12), histamine-N-methyl
XX transferase (HNMT), kallikrein 2) KHK2, nicotinamide -N-methyl
XX transferase (NNMT), NADPH quinone oxidoreductase 2 (NQO2),
XX sulfoltransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4
XX (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl
XX transferase (UGT2B15), urokinase receptor (uPA), multidrug resistance 1
XX (MDR1), lactotransferrin (LTF), multidrug resistance associated protein 3
XX (MRP3), orphan nuclear receptor (NRI12), or acetylcholine muscarinic
XX receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence.
XX The polymorphisms in the human genes cited in the invention are useful as
XX genetic linkage markers for locating and characterising the genes that
XX are responsible for specific traits within the genome and eventually
XX identifying the genes responsible for a variety of disorder-related
XX traits as a result of their e.g., overexpression, constitutive
XX expression, mutation or underexpression, which may be used in diagnosing
XX and/or treating the disorders. The nucleic acid molecules comprising the
XX polymorphic sequences contained in CYP450A1, CYP450A2, CYP4502B1,
XX ARNT, EPHX2, GST12, NNMT, NQO2, NRI12, STM, UGT2B4, UGT2B7, UGT2B15, AHR,
XX MDR1 and/or MDR3 are useful for screening individuals for altered drug
XX metabolism. The polymorphic sequences contained in CYP450A1, CYP450A2,
XX AHR, MDR1 and/or MDR3 may also be used to screen individuals for
XX susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are
XX used to screen for altered cardiovascular function, in COX2 for altered
XX susceptibility to colorectal tumours, in DBI or CHMR1 for altered central
XX nervous system function, in FLAP and HNMT for altered pulmonary,
XX immunological or haematological function, in KHK2 for altered serine
XX protease activity in the prostate, in LTF for altered immunological or
XX haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and
XX peripheral nervous system function. The present sequence represents a PCR
XX primer used to amplify the sequences of the invention
XX
XX Sequence 16 BP; 1 A; 6 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 6.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 608 CAGGAGAGCCAGATC 623
Db 16 CAAGGAGCCAGATC 1
RESULT 908
ABA93184/C
ID ABA93184 standard; DNA; 16 BP.
XX ABA93184;
XX ABA93184;
XX 17-APR-2002 (first entry)
XX

DE Human apolipoprotein E gene PCR primer SEQ ID NO:18.
XX Human; vitamin D receptor; apolipoprotein E; oestrogen receptor; VDR;
KW ApoE; osteoporosis; polymorphism; allele; PCR primer; ss.
XX Homo sapiens.
OS
XX JF2001333799-A.
PN
XX 04-DEC-2001.
PD
XX 26-MAY-2000; 2000JP-00155993.
PF
XX 26-MAY-2000; 2000JP-00155993.
PR
XX (NISS-) NISSHO KK.
PA
XX WPI; 2002-135949/18.
DR
XX Estimate of sensitivity to drugs for osteoporosis and a reagent kit.
XX Example 1; Page 7; 13pp; Japanese.
XX The present invention describes a method for the estimation of
XX sensitivity to drugs for osteoporosis in which each gene polymorphism of
XX vitamin D receptor (VDR) gene, oestrogen receptor (ER) gene and
XX apolipoprotein E3 (ApoE3) allele (2/2, 2/3, 2/4, 3/3, 3/4 or 4/4) are
XX analysed from the genomic DNA contained in a sample collected from a
XX human and, based on these combinations of gene polymorphisms, it is
XX estimated that the sample is derived from an individual showing a
XX specific priority on the sensitivity against a plural of treating agents
XX for osteoporosis. Also described is a reagent kit for analysing gene
XX polymorphisms of VDR, ApoE and ER genes containing primers specific to
XX each of the genes and detecting probes for detecting each gene
XX polymorphisms. The reagent can be used for selecting an effective drug
XX for osteoporosis. The present sequence represents a PCR primer for human
XX ApoE which is used in the exemplification of the present invention
XX
XX Sequence 16 BP; 4 A; 5 C; 6 G; 1 T; 0 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 6.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 373 CTCGAGGAGCTTCTG 388
Db 16 CTCGAGGAGCTTCTG 1
RESULT 909
ADC98479
ID ADC98479 standard; DNA; 16 BP.
XX
XX ADC98479;
AC
XX 01-JAN-2004 (first entry)
DT
XX KJ1311 polymorphism marker PCR primer S primer seq.
DE
XX low bone mineral density; BMD; bone damage; polymorphism; osteoporosis;
KW single nucleotide polymorphism; SNP; PCR primer; ss; human.
XX Synthetic.
OS
XX Homo sapiens.
OS
XX WO2003054218-A2.
PN
XX 03-JUL-2003.
PD
XX 19-DEC-2002; 2002WO-US040948.
PF
XX 20-DEC-2001; 2001US-0342711P.
PR
XX 04-NOV-2002; 2002US-0423559P.
PR

XX PA (INCYTE-) INCYTE GENOMICS INC.

XX PI Jones KA, Valdes A, Townley DJ, Mangion J, Galwey N, Bennett S;

XX PI McKay I, Schafer A;

XX DR WPI; 2003-559156/52.

XX PT Determining whether an individual is predisposed to susceptibility to low

XX PT bone mineral density (BMD) and/or bone damage, involves identifying

XX PT polymorphisms in associated genes.

XX PS Example 8; Page 238; 246pp; English.

XX CC The present invention describes a method of determining whether an

XX CC individual is predisposed to susceptibility to low bone mineral density

XX CC (BMD) and/or bone damage comprising identifying whether the individual

XX CC has at least one polymorphism in a polynucleotide encoding a protein,

XX CC where the polynucleotide is one of 81 200-500 nucleotide sequences (S1,

XX CC see ADC98235 to ADC98315). An agent identified in an method from the

XX CC present invention which can be used for the prevention or treatment of a

XX CC disease resulting in susceptibility to low BMD and/or bone damage is

XX CC useful in the manufacture of a medicament for use in modulating the

XX CC susceptibility to low BMD and/or bone damage. The disease associated with

XX CC low BMD and/or bone damage is osteoporosis. The present PCR primer

XX CC sequence is used in the exemplification of the present invention.

XX SQ Sequence 16 BP; 7 A; 4 C; 4 G; 1 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 16;

Best Local Similarity 87.5%; Pred. No. 6.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 532 GAAGAGATGCCAGAG 547

DB 1 GAAAGATCCAGAG 16

RESULT 910

ID ADD20502/c

XX ID ADD20502 standard; DNA; 16 BP.

XX AC ADD20502;

XX DT 15-JAN-2004 (first entry)

XX DE Oreochromis niloticus microsatellite primer SEQ ID NO:1137.

XX KW single nucleotide polymorphism; SNP; fish; Salmo salar;

XX KW Oreochromis niloticus; Atlantic halibut; microsatellite; cod;

XX KW polymorphic site; seabass; salmonidae; Tilapia; rainbow trout; halibut;

XX KW detection; primer; ss.

XX OS Synthetic.

XX OS Oreochromis niloticus.

XX PN WO2003060160-A2.

XX PD 24-JUL-2003.

XX PF 17-JAN-2003; 2003WO-IB000112.

XX PR 18-JAN-2002; 2002US-0349950P.

XX PR 16-AUG-2002; 2002US-0404200P.

XX PA (GENO-) GENOMAR ASA.

XX PI Lie O, Slettan A, Hoyum M, Lingaas F;

XX DR WPI; 2003-627388/59.

XX PT Novel isolated nucleic acid molecule comprising single nucleotide

XX PT polymorphism associated with fish, useful for forming PCR primers which

are used for detecting single nucleotide polymorphisms in fish nucleic acids.

Claim 18; SEQ ID NO 1137; 233pp; English.

The present invention describes an isolated nucleic acid (I) comprising a single nucleotide polymorphism (SNP) chosen from: (i) a nucleic acid of Salmo salar SNPs, Oreochromis niloticus SNPs or Atlantic halibut SNPs; and (ii) a nucleic acid having nucleotide sequence that hybridises to (i), or its complement under highly stringent hybridisation conditions. Also described: (i) an isolated oligonucleotide (II) comprising at least 17 contiguous nucleotides of a nucleotide sequence of S. salar SNPs, O. niloticus SNPs, O. niloticus microsatellites, Atlantic halibut SNPs, cod polymorphic sites and seabass polymorphic sites, or their complement; (2) a primer pair (III) suitable for use in PCR, comprising two (II) capable of amplifying a nucleotide sequence chosen from S. salar SNPs and, O. niloticus SNPs, O. niloticus microsatellites, Atlantic halibut SNPs, cod polymorphic sites and seabass polymorphic sites; and determining (M1) the origin of fish sample comprising providing a parentage genotype database comprising a collection of candidate parent genotypes, where each of the candidate parent genotype represents a distinct origin, and comparing a sample genotype to the parentage genotype database, where a match between the sample genotype and one of the candidate parent genotype identifies to the origin of the sample. (M1) is useful for determining the origin of a fish sample such as family salmonidae, S. salar, Tilapia, O. niloticus, rainbow trout, halibut, seabass and Atlantic cod. (II) is useful for detecting nucleic acid molecule comprising SNP in a sample, which involves contacting the sample containing nucleic acids with one or more (II) derived from nucleotide sequence of S. salar SNPs and O. niloticus SNPs, and identifying nucleic acid that hybridises to (II). (II) is useful for detecting nucleic acid molecule comprising a polymorphic sequence in a sample, comprising contacting the sample containing nucleic acids with one or more (II) which is derived from O. niloticus microsatellite, O. niloticus SNPs, Atlantic halibut SNPs, cod polymorphic sites or seabass polymorphic sites, and identifying a nucleic acid that hybridises to (II). (III) is useful for detecting nucleic acid molecule comprising a microsatellite sequence in sample. The present sequence is used in the exemplification of the present invention.

Sequence 16 BP; 5 A; 5 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 16;

Best Local Similarity 87.5%; Pred. No. 6.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 622 TCGCTTGAGGTGCC 637

DB 16 TTGCTTGAGACTGCC 1

RESULT 911

ID ACC43260/c

XX ID ACC43260 standard; DNA; 16 BP.

XX AC ACC43260;

XX DT 11-AUG-2003 (first entry)

XX DE Nucleotide sequence of a fragment from an actin binding protein exon.

XX KW Sequence tag; trapped gene; gene-trap vector; actin binding protein; ss.

XX OS Mus musculus.

XX PN WO2003018765-A2.

XX PD 06-MAR-2003.

XX PF 26-AUG-2002; 2002WO-US027102.

XX PR 24-AUG-2001; 2001US-0314991P.

XX PA (HEAL-) HEALTH RES INC.

XX Pruitt SC, Mielnicki LM;
XX WPI; 2003-300726/29.
XX Identifying Sequence Tags from trapped genes, useful for diagnostic
PT applications, comprises using a gene-trap vector having a splice donor, a
PT type IIS restriction endonuclease cleavage site and a splice donor or
PT polyadenylation site.
XX Example 3; Page 25; 51pp; English.
XX The specification describes a method of identifying sequence tags from
XX trapped genes. The method comprises using a gene-trap vector that has a
CC splice donor, a type IIS restriction endonuclease cleavage site and a
CC splice donor or a polyadenylation site. mRNA is prepared from cells
CC stably transfected with the gene-trap vector; first and second cDNA
CC strands are synthesised from the mRNA; the cDNA strands are digested with
CC restriction endonucleases including the type IIS restriction
CC endonucleases to produce assay tags, where each assay tag comprises a
CC sequence Tag and a portion of the gene-trap vector; the assay tags are
CC concatenated, and the concatamers are amplified and sequenced to identify
CC the sequence of the assay tags and the sequence tags. The method is
CC useful for high throughput sequence tag identification based on
CC modifications of the serial analysis of gene expression technology, which
CC may be used in diagnosing or in finding cures for various pathological
CC conditions. The present sequence represents a sequence tag, identified
CC using the method of the invention
XX
SQ Sequence 16 BP; 3 A; 8 C; 0 G; 5 T; 0 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 6.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 407 AGGGAGGAGGAGGAGT 422
DB 16 AGGGAGGAGATGTAGT 1
RESULT 912
ADRO6457
ID ADR06457 standard; DNA; 16 BP.
XX ADR06457;
XX 21-OCT-2004 (first entry)
XX IMAGE:2631676 mRNA sequence tag.
XX Identification; gene expression; cell differentiation;
XX stem cell differentiation; murine; ss.
XX Mus musculus.
XX WO2004065553-A2.
XX 05-AUG-2004.
XX 16-JAN-2004; 2004WO-US001482.
XX 16-JAN-2003; 2003US-0440510P.
XX (HEAL-) HEALTH RES INC.
XX Pruitt SC, Maslov A;
XX WPI; 2004-571677/55.
XX Identifying genes expressed during differentiation of a cell, useful,
PT e.g. in research into mechanisms leading to differentiation of stem
PT cells, comprises integrating a cell lineage targeting vector into the
PT genome of a host cell.

XX Example 5; SEQ ID NO 8; 45pp; English.
XX The present invention relates to a method (M1) for identifying genes
XX expressed during cell differentiation. The method is useful in research
CC into the mechanisms that lead to differentiation of stem cells. Knowledge
CC of these mechanisms is important in understanding embryonic development
CC and homeostasis within somatic tissues, and is also relevant to the
CC therapeutic use of stem cells. The method comprises: integrating into a
CC site in a host cell genome, a cell lineage targeting vector comprising a
CC pair of recombinase recognition sites flanking one or more
CC polyadenylation sites, a first selectable marker placed downstream or
CC between the two recombinase recognition sites, a reporter gene placed
CC downstream of the recombinase recognition sites, and a cell lineage
CC specific gene promoter placed upstream of the recombinase recognition
CC sites or a cell specific lineage gene placed downstream of the
CC recombinase recognition sites; amplifying cells generated from the host
CC cell; integrating into the genome of a plurality of the amplified cells,
CC a gene-trap vector comprising a splice acceptor, a type IIS restriction
CC endonuclease cleavage site, one or more polyadenylation sites, a second
CC selectable marker and a splice donor; allowing the cells to differentiate
CC; isolating cells in which the reporter gene is expressed indicating
CC expression of the cell lineage specific gene; and identifying trapped
CC genes in the isolated cells. The present sequence was used to illustrate
XX the invention.
SQ Sequence 16 BP; 5 A; 0 C; 8 G; 3 T; 0 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 6.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 407 AGGGAGGAGGAGGAGT 422
DB 1 AGGGAGGAGATGTAGT 16
RESULT 913
ADRO6458/c
ID ADR06458 standard; DNA; 16 BP.
XX ADR06458;
XX 21-OCT-2004 (first entry)
XX Unigene cluster ENCL sequence tag.
XX Identification; gene expression; cell differentiation;
XX stem cell differentiation; murine; ss.
XX Mus musculus.
XX WO2004065553-A2.
XX 05-AUG-2004.
XX 16-JAN-2004; 2004WO-US001482.
XX 16-JAN-2003; 2003US-0440510P.
XX (HEAL-) HEALTH RES INC.
XX Pruitt SC, Maslov A;
XX WPI; 2004-571677/55.
XX Identifying genes expressed during differentiation of a cell, useful,
PT e.g. in research into mechanisms leading to differentiation of stem
PT cells, comprises integrating a cell lineage targeting vector into the
PT genome of a host cell.
XX Example 5; SEQ ID NO 9; 45pp; English.
XX

CC The present invention relates to a method (M1) for identifying genes
 CC expressed during cell differentiation. The method is useful in research
 CC into the mechanisms that lead to differentiation of stem cells. Knowledge
 CC of these mechanisms is important in understanding embryonic development
 CC and homeostasis within somatic tissues, and is also relevant to the
 CC therapeutic use of stem cells. The method comprises: integrating into a
 CC site in a host cell genome, a cell lineage targeting vector comprising a
 CC pair of recombinase recognition sites flanking one or more
 CC polyadenylation sites, a first selectable marker placed downstream or
 CC between the two recombinase recognition sites, a reporter gene placed
 CC downstream of the recombinase recognition sites, and a cell lineage
 CC specific gene promoter placed upstream of the recombinase recognition
 CC sites or a cell specific lineage gene placed downstream of the
 CC recombinase recognition sites; amplifying cells generated from the host
 CC cell; integrating into the genome of a plurality of the amplified cells,
 CC a gene-trap vector comprising a splice acceptor, a type IIS restriction
 CC endonuclease cleavage site, one or more polyadenylation sites, a second
 CC selectable marker and a splice donor; allowing the cells to differentiate
 CC; isolating cells in which the reporter gene is expressed indicating
 CC expression of the cell lineage specific gene; and identifying trapped
 CC genes in the isolated cells. The present sequence was used to illustrate
 CC the invention.

SQ Sequence 16 BP; 3 A; 8 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 87.5%; Pred. No. 6.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 407 AGCGAGAGAGAGAGT 422

DB 16 AGCGAGAGAGATGTAGT 1

RESULT 914

AAQ52083
 ID AAQ52083 standard; RNA; 17 BP.

XX
 AC AAQ52083;

DT 25-MAR-2003 (revised)

DT 26-MAY-1994 (first entry)

DE Breast cancer specific mRNA ribozyme cleavable nucleotide (1699).

XX Multiple drug resistance; mdr-1; ribozyme; membrane protein; liver;
 KW resistance; chemotherapeutic agent; colchicine; doxorubicin; colon;
 KW actinomycin D; vinblastine; small intestine; kidney; adrenal gland;
 KW adenocarcinoma; bowel; transformed phenotype; promyelocytic leukemia;
 KW human; chronic myelogenous leukemia; CML; follicular lymphoma;
 KW B-cell acute lymphocytic leukemia; breast cancer; colon carcinoma;
 KW neuroblastoma; lung cancer; genetic drift; mutation; hammerhead motif;
 KW hairpin; hepatitis delta virus; group I intron; RNaseP; ss.

XX Homo sapiens.

OS
 XX WO9323057-A1.

XX
 PD 25-NOV-1993.

XX
 PF 13-MAY-1993; 93WO-US0004573.

XX
 PR 14-MAY-1992; 92US-00882822.

PR
 PR 14-MAY-1992; 92US-00882885.

PR
 PR 26-AUG-1992; 92US-00936110.

PR
 PR 26-AUG-1992; 92US-00936421.

PR
 PR 26-AUG-1992; 92US-00936422.

PR
 PR 26-AUG-1992; 92US-00936531.

PR
 PR 26-AUG-1992; 92US-00936532.

PR
 PR 07-DEC-1992; 92US-00987131.

PR
 PR 19-JAN-1993; 93US-00006122.

PR
 PR 19-JAN-1993; 93US-00008910.

PA (RIBO-) RIBOZYME PHARM INC.

XX
 PI Thompson JD, Draper KG;

XX
 DR WPI; 1993-386203/48.

XX New enzymatic RNA molecules (ribozymes) - which cleave mRNA associated
 PT with tumours or mRNA expressed from gene encoding multiple drug
 PT resistance.

PS Claim 3; Fig 8; 69pp; English.

XX The sequences given in AAQ51825-2266 represent areas of mRNAs which are
 CC associated with development or maintenance of chronic myelogenous
 CC leukemia (CML), promyelocytic leukemia, Burkitt's lymphoma, or acute
 CC lymphocytic leukemia, follicular lymphoma, B-cell acute lymphocytic
 CC leukemia, breast cancer, colon carcinoma, neuroblastoma and lung cancer.
 CC The full length mRNAs containing these target sequences, encode aberrant
 CC cellular proteins which are able to control cellular proliferation and
 CC are directly linked to a leukemic phenotype. These target sequences are
 CC identified by the ribozyme of the invention. The ribozymes is formed in a
 CC hammerhead motif, but may also be formed in the motif of a hairpin,
 CC hepatitis delta virus, group I intron or RNaseP-like RNA. These ribozymes
 CC may be used to inhibit the development or expression of a transformed
 CC phenotype in man and other animals by modulating expression of the
 CC corresponding gene. Cleavage of target mRNAs expressed in pre-neoplastic
 CC and transformed cells elicits inhibition of the transformed state.
 CC Multiple drug resistance (mdr-1) mRNA specific ribozymes remove the
 CC mechanism of drug resistance used by transformed cells and thus enhances
 CC drug therapies for tumours. The ribozymes may also be used to study
 CC genetic drift and mutations within cells. (Updated on 25-MAR-2003 to
 CC correct PN field.)

SQ Sequence 17 BP; 2 A; 8 C; 4 G; 0 T; 3 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 68.8%; Pred. No. 7.2e+02;
 Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 843 TGGCCTATCACCAGCT 858

DB 2 UGGCCUGCCACCAGCU 17

RESULT 915

AAQ53562

ID AAT53562 standard; RNA; 17 BP.

XX
 AC AAT53562;

XX
 DT 25-MAR-2003 (revised)

DT 27-MAR-1997 (first entry)

XX Rat ICAM hammerhead ribozyme target sequence (nt. position 1678).

XX Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
 KW gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
 KW intercellular adhesion molecule; rel A; tumour necrosis factor;
 KW TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
 KW translocation; chronic myelogenous leukaemia; CML; cancer;
 KW Philadelphia chromosome; inflammation; autoimmune disease;
 KW atherosclerosis; myocardial infarction; stroke; restenosis;
 KW transplant rejection; rheumatoid arthritis; psoriasis;
 KW myocardial ischaemia; Kawasaki disease; septic shock; HIV;
 KW human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
 KW ss.

XX Rattus rattus.

XX
 OS WO9523225-A2.

XX
 PN 31-AUG-1995.

XX

CC resistance. The ribozymes cleave the ICAM-1 target sequences and thereby
 CC inhibit ICAM-1 expression, making them useful for reducing transplant
 CC rejection and alleviating symptoms in patients with rheumatoid arthritis,
 CC asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to
 CC correct PI field.)

XX Sequence 17 BP; 3 A; 5 C; 7 G; 0 T; 2 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 75.0%; Pred. No. 7.2e+02;

Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 461 GAGAGACTCGGCTGG 476

DB 1 GAGAACCCGCGCCUGG 16

RESULT 917

AAT53620

ID AAT53620 standard; RNA; 17 BP.

XX AC

XX AAT53620;

XX 25-MAR-2003 (revised)

DT 27-MAR-1997 (first entry)

XX DE

XX Rat ICAM hammerhead ribozyme target sequence (nt. position 2220).

XX Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
 KW gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
 KW intercellular adhesion molecule; rel A; tumour necrosis factor;
 KW TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
 KW Philadelphia chromosome; chronic myelogenous leukaemia; CML; cancer;
 KW Philadelphia chromosome; inflammation; autoimmune disease;
 KW atherosclerosis; myocardial infarction; stroke; restenosis;
 KW transplant rejection; rheumatoid arthritis; psoriasis;
 KW myocardial ischaemia; Kawasaki disease; septic shock; HIV;
 KW human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
 KW ss.

XX OS Rattus rattus.

XX XX

XX WO9523225-A2.

XX 31-AUG-1995.

XX 23-FEB-1995;

XX 94US-00201109.

XX 94US-00218934.

XX 94US-00222795.

XX 94US-00224483.

XX 94US-00227958.

XX 94US-00228041.

XX 94US-00245736.

XX 94US-00271280.

XX 94US-00291932.

XX 94US-00291433.

XX 94US-00292620.

XX 94US-00293520.

XX 94US-00300000.

XX 94US-00303039.

XX 94US-00311486.

XX 94US-00311749.

XX 94US-00314397.

XX 94US-00316771.

XX 94US-00319492.

XX 94US-00321993.

XX 94US-00334847.

XX 94US-00337608.

XX 94US-00345516.

XX 94US-00357577.

XX 94US-00363233.

PR 30-JAN-1995; 95US-00380734.

XX (RIBO-) RIBOZYME PHARM INC.

PA Stinchcomb DT, Chowrira B, Direnzo A, Draper KG, Dudycz LW;

XX Grimm S, Karpeisky A, Kisich K, Matulic-Adamic J, Mcawiggen JA;

PI Modak A, Pavco P, Beigleman L, Sullivan SM, Sweedler D, Thompson JD;

PI Tracz D, Usman N, Wincott FE, Woolf T;

XX WPI; 1995-351090/45.

XX Ribozymes having modified bases and methods for producing them - for use

XX in inhibiting disease related genes.

PT Claim 2; Page 203; 407pp; English.

XX The present sequence represents a preferred target sequence for an

XX enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICAM-1 mRNA at the

CC nucleotide base position indicated in the DE line. Regions of the mRNA

CC that do not form secondary folding structures and that contain potential

CC hammerhead and hairpin ribozyme cleavage sites were identified by

CC computer analysis. Ribozymes directed against these mRNA sequences were

CC designed and synthesised with modifications that improve their nuclease

CC resistance. The ribozymes cleave the ICAM-1 target sequences and thereby

CC inhibit ICAM-1 expression, making them useful for reducing transplant

CC rejection and alleviating symptoms in patients with rheumatoid arthritis,

CC asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to

CC correct PI field.)

XX Sequence 17 BP; 3 A; 5 C; 7 G; 0 T; 2 U; 0 Other;

SQ Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 75.0%; Pred. No. 7.2e+02;

Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 461 GAGAGACTCGGCTGG 476

DB 1 GAGAACCCGCGCCUGG 16

RESULT 918

AAT53439

ID AAT53439 standard; RNA; 17 BP.

XX AC

XX AAT53439;

XX 25-MAR-2003 (revised)

DT 27-MAR-1997 (first entry)

XX DE

XX Rat ICAM hammerhead ribozyme target sequence (nt. position 48).

XX Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
 KW gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
 KW intercellular adhesion molecule; rel A; tumour necrosis factor;
 KW TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
 KW Philadelphia chromosome; chronic myelogenous leukaemia; CML; cancer;
 KW Philadelphia chromosome; inflammation; autoimmune disease;
 KW atherosclerosis; myocardial infarction; stroke; restenosis;
 KW transplant rejection; rheumatoid arthritis; psoriasis;
 KW myocardial ischaemia; Kawasaki disease; septic shock; HIV;
 KW human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
 KW ss.

XX OS Rattus rattus.

XX XX

XX WO9523225-A2.

XX 31-AUG-1995.

XX 23-FEB-1995;

XX 94US-00201109.

XX 94US-00218934.

XX 94US-00218934.

```
PR 04-APR-1994; 94US-00222795.
PR 07-APR-1994; 94US-00224483.
PR 15-APR-1994; 94US-00227958.
PR 15-APR-1994; 94US-00228041.
PR 18-MAY-1994; 94US-00245736.
PR 06-JUL-1994; 94US-00271280.
PR 15-AUG-1994; 94US-00291932.
PR 16-AUG-1994; 94US-00291433.
PR 17-AUG-1994; 94US-00292620.
PR 19-AUG-1994; 94US-00293520.
PR 02-SEP-1994; 94US-00300000.
PR 08-SEP-1994; 94US-00303039.
PR 23-SEP-1994; 94US-00311486.
PR 28-SEP-1994; 94US-00314397.
PR 03-OCT-1994; 94US-00316771.
PR 07-OCT-1994; 94US-00319492.
PR 11-OCT-1994; 94US-00321993.
PR 04-NOV-1994; 94US-00334847.
PR 10-NOV-1994; 94US-00337608.
PR 28-NOV-1994; 94US-00345516.
PR 16-DEC-1994; 94US-00357577.
PR 23-DEC-1994; 94US-00363233.
PR 30-JAN-1995; 95US-00380734.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Stinchcomb DT, Chowrira B, Drenzo A, Draper KG, Dudycz LW;
PI Grimm S, Karpeisky A, Kisich K, Matulic-Adamic J, Mcswiggen JA;
PI Modak A, Pavco P, Beigleman L, Sullivan SM, Sweedler D, Thompson JD;
PI Tracz D, Ueman N, Wincott FE, Woolf T;
XX
XX WPI; 1995-351090/45.
XX
XX Ribozyms having modified bases and methods for producing them - for use
XX in inhibiting disease related genes.
XX
XX Claim 2; Page 201; 407pp; English.
XX
XX The present sequence represents a preferred target sequence for an
XX enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICAM-1 mRNA at the
XX nucleotide base position indicated in the DE line. Regions of the mRNA
XX that do not form secondary folding structures and that contain potential
XX hammerhead and hairpin ribozyme cleavage sites were identified by
XX computer analysis. Ribozymes directed against these mRNA sequences were
XX designed and synthesised with modifications that improve their nuclease
XX resistance. The ribozymes cleave the ICAM-1 target sequences and thereby
XX inhibit ICAM-1 expression, making them useful for reducing transplant
XX rejection and alleviating symptoms in patients with rheumatoid arthritis,
XX asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to
XX correct PI field.)
XX
XX Sequence 17 BP; 3 A; 5 C; 7 G; 0 T; 2 U; 0 Other;
XX
XX Query Match 1.7%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 75.0%; Pred. No. 7.2e+02;
XX Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
XX
Qy 461 GAGAGACTCGGCTGG 476
Db 1 GAGAACCCGCGCCUGG 16
XX
RESULT 919
AAT53627
ID AAT53627 standard; RNA; 17 BP.
XX
XX AAT53627;
AC AAT53627;
XX
XX 25-MAR-2003 (revised)
DT 27-MAR-1997 (first entry)
XX
XX Rat ICAM hammerhead ribozyme target sequence (nt. position 1983).
DE
```

Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition; gene expression; downregulation; interleukin-5; IL-5; ICAM-1; intercellular adhesion molecule; rel A; tumour necrosis factor; TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene; translocation; chronic myelogenous leukaemia; CML; cancer; Philadelphia chromosome; inflammation; autoimmune disease; atherosclerosis; myocardial infarction; stroke; restenosis; transplant rejection; rheumatoid arthritis; psoriasis; myocardial ischaemia; Kawasaki disease; septic shock; HIV; human immunodeficiency virus; acquired immune deficiency syndrome; AIDS; ss.

Rattus rattus.

WO9523225-A2.

31-AUG-1995.

23-FEB-1995; 95WO-IB000156.

23-FEB-1994; 94US-00201109.

29-MAR-1994; 94US-00218934.

04-APR-1994; 94US-00222795.

07-APR-1994; 94US-00224483.

15-APR-1994; 94US-00227958.

15-APR-1994; 94US-00228041.

18-MAY-1994; 94US-00245736.

08-JUL-1994; 94US-00271280.

15-AUG-1994; 94US-00291932.

16-AUG-1994; 94US-00291433.

17-AUG-1994; 94US-00292620.

19-AUG-1994; 94US-00293520.

02-SEP-1994; 94US-00300000.

08-SEP-1994; 94US-00303039.

23-SEP-1994; 94US-00311486.

28-SEP-1994; 94US-00314397.

03-OCT-1994; 94US-00316771.

07-OCT-1994; 94US-00319492.

11-OCT-1994; 94US-00321993.

04-NOV-1994; 94US-00334847.

10-NOV-1994; 94US-00337608.

28-NOV-1994; 94US-00345516.

16-DEC-1994; 94US-00357577.

23-DEC-1994; 94US-00363233.

30-JAN-1995; 95US-00380734.

(RIBO-) RIBOZYME PHARM INC.

Stinchcomb DT, Chowrira B, Drenzo A, Draper KG, Dudycz LW; Grimm S, Karpeisky A, Kisich K, Matulic-Adamic J, Mcswiggen JA; Modak A, Pavco P, Beigleman L, Sullivan SM, Sweedler D, Thompson JD; Tracz D, Ueman N, Wincott FE, Woolf T;

WPI; 1995-351090/45.

Ribozyms having modified bases and methods for producing them - for use in inhibiting disease related genes.

Claim 2; Page 201; 407pp; English.

The present sequence represents a preferred target sequence for an enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICAM-1 mRNA at the nucleotide base position indicated in the DE line. Regions of the mRNA that do not form secondary folding structures and that contain potential hammerhead and hairpin ribozyme cleavage sites were identified by computer analysis. Ribozymes directed against these mRNA sequences were designed and synthesised with modifications that improve their nuclease resistance. The ribozymes cleave the ICAM-1 target sequences and thereby inhibit ICAM-1 expression, making them useful for reducing transplant rejection and alleviating symptoms in patients with rheumatoid arthritis, asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to correct PI field.)

Sequence 17 BP; 3 A; 5 C; 7 G; 0 T; 2 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17; Best Local Similarity 75.0%; Pred. No. 7.2e+02; Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

461 GAGAGACTCGGCTGG 476
1 GAGAACCCGCGCCUGG 16

RESULT 919
AAT53627
ID AAT53627 standard; RNA; 17 BP.
AAT53627;
AAT53627;
25-MAR-2003 (revised)
DT 27-MAR-1997 (first entry)
Rat ICAM hammerhead ribozyme target sequence (nt. position 1983).

```

CC correct PI field.)
SQ Sequence 17 BP; 3 A; 5 C; 7 G; 0 T; 2 U; 0 Other;

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.2e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 461 GAGAGACTCGGCTGG 476
   ||||| :|||:|
Db 1 GAGAACCCGCGCCUGG 16

RESULT 920
AAT04961/c
ID AAT04961 standard; cDNA; 17 BP.
XX AC AAT04961;
XX DT 30-JAN-1996 (first entry)
XX DE Antimicrobial protein Ib-AMPI PCR primer IbAMP1-B.
XX KW Antimicrobial protein 1; Ib-AMPI; antifungal; fungicide; antibacterial;
KW phytocidine; disease-resistance; antibiotic; preservative;
KW Impatiens balsamina; PCR; primer; polymerase chain reaction; ss.
XX OS Synthetic.
XX FH Key Location/Qualifiers
FT modified_base 6 /*tag= a
FT /*mod_base= i
FT modified_base 9 /*tag= b
FT /*mod_base= i
XX PN WO9524486-A1.
XX PD 14-SEP-1995.
XX PF 09-MAR-1995; 95WO-GB000509.
XX PR 11-MAR-1994; 94GB-00004807.
XX PA (ZENE ) ZENECA LTD.
XX PI Attenborough S, Broekaert WF, Osborn RW, Ray JA, Rees SB;
PI Tailor RH;
XX DR WPI; 1995-328277/42.
XX PT New antimicrobial proteins from Aralia and Impatiens seeds - useful as
PT fungicides or antibiotics in agricultural or pharmaceutical applications.
XX PS Example 8; Page 27; 64pp; English.
XX CC An Impatiens balsamina (Ib) seed cDNA library in lambda ZAP11 was
CC screened with a DNA probe generated using 2 degenerate PCR primers
CC (AAT04960-61) based on the available peptide sequence for antimicrobial
CC protein Ib-AMPI (AAR82938). cDNA clone Ib22 was obtd. that encoded Ib-AMP
CC (AAR82942)
XX SQ Sequence 17 BP; 5 A; 6 C; 0 G; 1 T; 0 U; 5 Other;

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 7.2e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 175 ACTGTGTGAGATGGT 190
   ||||| :|||:|
Db 16 AYTGYGTNMGNTGGT 1

```

```

RESULT 921
AAT81043/c
ID AAT81043 standard; RNA; 17 BP.
XX AC AAT81043;
XX DT 26-SEP-1997 (first entry)
XX DE Human c-myb hammerhead ribozyme target sequence (nt. position 22).
XX KW Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
KW smooth muscle cell; hyperproliferation; restenosis; cancer; c-myb;
KW coronary angioplasty; ss.
XX OS Homo sapiens.
XX PN WO9531541-A2.
XX PD 23-NOV-1995.
XX PF 18-MAY-1995; 95WO-US006368.
XX PR 18-MAY-1994; 94US-00245466.
XX PR 13-JAN-1995; 95US-00373124.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Stinchcomb DT, Draper K, Mcswiggen J, Jarvis T;
XX DR WPI; 1996-010927/01.
XX PT New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myb,
PT for treating restenosis or cancer.
XX PS Claim 1; Page 64; 128pp; English.
XX CC The present sequence represents the preferred target sequence for an
CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
CC the human c-myb sequence at the base position indicated in the descriptor
CC line. The c-myb sequence was screened for optimal ribozyme target sites
CC using a computer folding algorithm, and regions of the mRNA which did not
CC form secondary folding structures and contained potential ribozyme
CC cleavage sites were identified. Ribozymes were synthesised and their
CC activities optimised by either varying the length of the binding arms or
CC by modification to prevent degradation by nucleases. The ribozymes cleave
CC the c-myb sequence and can be used to prevent smooth muscle cell
CC hyperproliferation in restenosis, especially after coronary angioplasty,
CC and in cancers
XX SQ Sequence 17 BP; 0 A; 9 C; 0 G; 0 T; 8 U; 0 Other;

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 405 AGAGGGAGGAGGAGGA 420
   ||||| :|||:|
Db 17 AGAAGGAGGAGGAGGA 2

RESULT 922
AAX69184
ID AAX69184 standard; RNA; 17 BP.
XX AC AAX69184;
XX DT 28-JUL-1999 (first entry)
XX DE Human flt1 VEGF receptor hammerhead ribozyme substrate #479.
XX KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;

```


PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.
XX
PS Claim 4; Page 167; 218pp; English.
XX
CC The present invention describes nucleic acid molecules which modulate the
CC synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention
XX
SQ Sequence 17 BP; 8 A; 5 C; 2 G; 0 T; 2 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.2e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 875 AACCACTCAGAGCA 890
|||||:|||||
Db 1 AACUACCUCAGAGCA 16

RESULT 925
AAV17893/C
ID AAV17893 standard; DNA; 17 BP.
XX
AC AAV17893;
XX
DT 15-JUL-1998 (first entry)
XX
DE Primer used to construct a hybrid endoglucanase.
XX
KW Endo-beta-1,4-glucanase; degradation; plant; cellulose; PCR primer; ss.
XX
OS Synthetic.
XX
PN WO9808940-A1.
XX
PD 05-MAR-1998.
XX
PF 26-AUG-1997; 97WO-DK000348.
XX
PR 26-AUG-1996; 96DK-00000893.
PR 17-SEP-1996; 96DK-00001015.
XX
PA (NOVO) NOVO-NORDISK AS.
XX
PI Bjornvad ME, Nielsen P;
XX
DR WPI; 1998-179431/16.
XX
PT New endo-glucanase from Cellvibrio species and related DNA, vectors and
PT transformed cells - used to degrade plant material, treat fabrics or
PT paper pulp, and to clarify colours on laundry.
XX
PS Example 8; Page 77; 117pp; English.
XX
CC PCR primers AAV17899-96 were used to construct a hybrid endoglucanase,
CC which comprises the Humicola insolens family 45 endonuclease signal
CC peptide and the Pseudomonas fluorescens family 45 endoglucanase catalytic
CC domain and the linker cellulose binding domain of H. insolens
CC endoglucanase. The endoglucanase is used for degrading and modifying
CC plant materials such as cell walls, e.g. for production of wine or fruit
CC or vegetable juices to increase yield, to hydrolyse waste products, for
CC isolation of beta-glucans, to improve feed efficiency or ensilaging and
CC to decrease water binding capacity. It can also be used in the treatment
CC of fabrics and textiles, for biopolishing, for "stone washing"

CC cellulose, and for treating paper pulp
XX
SQ Sequence 17 BP; 2 A; 8 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 707 GAGCGGAGCGCTGC 722
|||||:|||||
Db 16 GAGCGGATGAGCTGC 1

RESULT 926
AAV96651
ID AAV96651 standard; RNA; 17 BP.
XX
AC AAV96651;
XX
DT 01-MAR-1999 (first entry)
XX
DE Potato citrate synthase target sequence position 1373.
XX
KW Solanidine; Glucosyltransferase; potato; citrate synthase; target;
KW hammerhead ribozyme; hairpin ribozyme; alkaloid biosynthesis;
KW flower formation; cleavage; solanaceous plant; ss.
XX
OS Solanum tuberosum.
XX
PN WO9832843-A2.
XX
PD 30-JUL-1998.
XX
PF 14-JAN-1998; 98WO-US000738.
XX
PR 28-JAN-1997; 97US-0036545P.
PR 28-JAN-1997; 97US-0036599P.
PR 24-NOV-1997; 97US-00979416.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Zwick MG, Mcewiggen JA;
XX
DR WPI; 1998-427939/36.
XX
PT New enzymatic nucleic acid(s) - useful for, e.g. reducing alkaloid
PT biosynthesis or regulating flowering.
XX
PS Claim 53; Page 56; 79pp; English.
XX
CC The present invention describes enzymatic nucleic acid molecules with RNA
CC -cleaving activity (e.g. ribozymes) which are capable of modulating the
CC expression of plant genes: (i) involved in biosynthesis of alkaloids; or
CC (ii) involved in flower formation. AAV95982 to AAV96334, and AAV96335 to
CC AAV96354 represent potato solanidine glucosyltransferase hammerhead and
CC hairpin ribozymes, respectively. AAV95629 to AAV95981, and AAV96355 to
CC AAV96734 represent potato solanidine glucosyltransferase target
CC sequences. AAV96773 to AAV97170, and AAV97171 to AAV97195 represent
CC potato citrate synthase hammerhead and hairpin ribozymes, respectively.
CC AAV96735 to AAV96772, and AAV97196 to AAV97220 represent potato citrate
CC synthase target sequences. Ribozymes of the present invention can be used
CC to inhibit the synthesis of toxic alkaloids in solanaceous plants,
CC particularly potato but also tomato, pepper, aubergine and ditura or to
CC inhibit flowering in potato, lettuce, spinach, cabbage, brussel sprouts,
CC arugula, kale, collards, chard, beet, turnip, sweet potato and turf
CC grass. Also the ribozymes can be used for RNA manipulation in the same
CC way that restriction endonucleases are for DNA, as well as to examine
CC genetic drift and mutations in plants and to detect specific RNA. The
CC ribozymes can be targeted to specific genes or to consensus sequences
CC within a family of related genes, and being catalytic need to be present
CC at only very low concentrations
XX
SQ Sequence 17 BP; 4 A; 4 C; 5 G; 0 T; 4 U; 0 Other;

CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
CC integrin subunit alpha-6, or integrin subunit beta-3
XX
SQ Sequence 17 BP; 1 A; 7 C; 5 G; 0 T; 4 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.2e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 316 GGAGATCAAGAGCTC 331
|||:|||||:
Db 2 GGCGUAACAAGAGC 17

RESULT 927
AAA20387/C
ID AAA20387 standard; RNA; 17 BP.
XX
AC AAA20387;
XX
DT 19-JUN-2000 (first entry)
XX
DE Integrin alpha 6 subunit substrate sequence SEQ ID NO:3613.
XX
XX Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
KW hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;
KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
KW age related macular degeneration; cancer; diabetic retinopathy; arthritis;
KW myopic degeneration; psoriasis; verruca vulgaris; neovascular glaucoma;
KW tubercous sclerosis; pot-wine stain; Sturge Weber syndrome;
KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX
OS Homo sapiens.
XX
XX WO9950403-A2.
XX
XX 07-OCT-1999.
XX
XX 24-MAR-1999; 99WO-US006507.
XX
XX 27-MAR-1998; 98US-0079678P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;
XX WPI; 1999-591315/50.
XX
XX Novel ribozymes for modulating the synthesis, expression and/or stability
XX of an mRNA encoding an angiogenic factors.
XX
XX Claim 55; Page 142; 305pp; English.

The present invention describes enzymatic cleavage of RNA molecules with RNA
cleaving activity, which specifically cleave RNA encoded by an aryl
hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
and AAA19155 to AAA19222 represent their corresponding target sequences;
AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
AAA21596 to AAA21688 represent their corresponding target sequences;
AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme
sequences for integrin subunit beta-3, and AAA22476 to AAA23262, AAA23343 to
AAA23422 represent their corresponding target sequences. The ribozymes of
the invention are used for modulating the synthesis, expression and/or
stability of an mRNA encoding angiogenic factor, especially ARNT,
integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
especially used to treat cancer, diabetic retinopathy, age related
macular degeneration (ARMD), inflammation, and arthritis, as well as
neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber

CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
CC integrin subunit alpha-6, or integrin subunit beta-3
XX
SQ Sequence 17 BP; 1 A; 7 C; 5 G; 0 T; 4 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 676 GGCCGCGAGGAGCG 691
|||||||:
Db 16 GGCCGCGAGGAGCG 1

RESULT 928
AAA17439/C
ID AAA17439 standard; RNA; 17 BP.
XX
AC AAA17439;
XX
DT 19-JUN-2000 (first entry)
XX
DE Aryl hydrocarbon nuclear transport substrate sequence SEQ ID NO:665.
XX
XX Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
KW hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;
KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
KW age related macular degeneration; cancer; diabetic retinopathy; arthritis;
KW myopic degeneration; psoriasis; verruca vulgaris; neovascular glaucoma;
KW tubercous sclerosis; pot-wine stain; Sturge Weber syndrome;
KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX
OS Homo sapiens.
XX
XX WO9950403-A2.
XX
XX 07-OCT-1999.
XX
XX 24-MAR-1999; 99WO-US006507.
XX
XX 27-MAR-1998; 98US-0079678P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;
XX WPI; 1999-591315/50.
XX
XX Novel ribozymes for modulating the synthesis, expression and/or stability
XX of an mRNA encoding an angiogenic factors.
XX
XX Claim 53; Page 80; 305pp; English.

The present invention describes enzymatic cleavage of RNA molecules with RNA
cleaving activity, which specifically cleave RNA encoded by an aryl
hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
and AAA19155 to AAA19222 represent their corresponding target sequences;
AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
AAA21596 to AAA21688 represent their corresponding target sequences;
AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme
sequences for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
AAA23422 represent their corresponding target sequences. The ribozymes of
the invention are used for modulating the synthesis, expression and/or
stability of an mRNA encoding angiogenic factor, especially ARNT,

CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 CC especially used to treat cancer, diabetic retinopathy, age related
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
 CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
 CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
 CC integrin subunit alpha-6, or integrin subunit beta-3
 XX
 SQ Sequence 17 BP; 3 A; 7 C; 3 G; 0 T; 4 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 542 CAGCAGCAGTGGCTG 557
 DB 17 CAGAGCTGATGGCTG 2
 AC AAA22723;
 RESULT 929
 AAA22723/c
 ID AAA22723 standard; RNA; 17 BP.
 XX
 AC AAA22723;
 DT 19-JUN-2000 (first entry)
 XX
 DE Integrin subunit beta 3 substrate sequence SEQ ID NO:5949.
 XX
 KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
 KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
 KW hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
 KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
 KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
 KW age related macular degeneration; inflammation; neovascular glaucoma;
 KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
 KW tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;
 KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO9950403-A2.
 XX
 XX 07-OCT-1999.
 XX
 PF 24-MAR-1999; 99WO-US006507.
 XX
 PR 27-MAR-1998; 98US-0079678P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;
 XX
 DR WPI; 1999-591315/50.
 XX
 PT Novel ribozymes for modulating the synthesis, expression and/or stability
 PT of an mRNA encoding an angiogenic factors.
 XX
 PS Claim 54; Page 238; 305pp; English.
 XX
 CC The present invention describes enzymatic cleavage of RNA
 CC cleaving activity, which specifically cleave RNA encoded by an aryl
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
 CC and AAA1768 to AAA17623 represent ribozyme sequences for ARNT,
 CC and AAA1768 to AAA17560 and AAA17623 to AAA17684 represent their
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
 CC and AAA19155 to AAA19222 represent their corresponding target sequences;
 CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
 CC AAA21596 to AAA21688 represent their corresponding target sequences;

CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
 CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
 CC AAA23422 represent their corresponding target sequences. The ribozymes of
 CC the invention are used for modulating the synthesis, expression and/or
 CC stability of an mRNA encoding angiogenic factor, especially ARNT.
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 CC especially used to treat cancer, diabetic retinopathy, age related
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
 CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
 CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
 CC integrin subunit alpha-6, or integrin subunit beta-3
 XX
 SQ Sequence 17 BP; 2 A; 8 C; 2 G; 0 T; 5 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 493 GAGGCAGAGGAGGAGCAG 508
 DB 16 GAGGCAGAGGAGGAGCAG 1
 AC AAX78357;
 RESULT 930
 AAX78357
 ID AAX78357 standard; DNA; 17 BP.
 XX
 AC AAX78357;
 DT 25-AUG-1999 (first entry)
 XX
 DE Human BRCA2 C2192G mutation allele specific probe 1.
 XX
 KW BRCA2; breast cancer; PCR primer; mutation; detection; human; cancer;
 KW susceptibility; predisposition; ovarian cancer; assay; allele specific;
 KW sequence variation; probe; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 XX WO9928506-A2.
 XX
 XX 10-JUN-1999.
 XX
 PF 02-DEC-1998; 98WO-US025511.
 XX
 PR 02-DEC-1997; 97US-00984034.
 XX
 PA (GENE-) GENE LOGIC.
 XX
 PI Lescallett JL, Lawrence T, Allen AP, Olson SJ, Thurber DB;
 PI White MB;
 XX
 DR WPI; 1999-371141/31.
 XX
 PT Detecting mutations in the BRCA2 gene.
 XX
 PS Claim 3; Page 58; 76pp; English.
 XX
 CC This invention describes novel primers and probes (AAX78355-X78378) which
 CC are used to detect novel mutations in the human BRCA2 gene at nucleotide
 CC positions 2192, 3772, 5193, 5374, 6495 or 6909. The products of the
 CC invention are used for detecting in an individual a predisposition or
 CC higher susceptibility to cancers such as breast or ovarian cancer. The
 CC invention describes a process for the accurate identification of sequence
 CC variation in a BRCA2 polynucleotide and the identification process
 CC includes allele-specific sequence based assays of known sequence
 CC variations
 XX
 SQ Sequence 17 BP; 6 A; 3 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 166 GAAGAGCCACTCTGT 181
 ||||| ||||| |||||
 Db 2 GAAGAACCACACTTGT 17
 ||||| ||||| |||||

RESULT 931
 AAX01065
 ID AAX01065 standard; DNA; 17 BP.
 XX
 AC AAX01065;
 XX
 DT 06-APR-1999 (first entry)
 XX
 DE IPF1 gene exon 1 amplifying primer S17b.
 XX
 KW Mature onset diabetes of the young; MODY; insulin promoter factor 1;
 KW IPF1; mutation; MODY4; pancreatic disorder; PCR primer; ss.
 KW
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9859078-A1.
 XX
 PD 30-DEC-1998.
 XX
 PF 24-JUN-1998; 98WO-US013467.
 XX
 PR 24-JUN-1997; 97US-00881450.
 XX
 PA (GEO) GEN HOSPITAL CORP.
 XX
 PI Habener JF, Stoffers DA;
 XX
 DR WPI; 1999-105636/09.
 XX
 PT Detecting heterozygosity for insulin promoter factor 1 - useful to detect
 PT the presence of, or predisposition for, mature onset diabetes of the
 PT young.
 XX
 PS Example 1; Page 9; 46pp; English.
 XX
 CC The invention relates to a new method to screen for mature onset diabetes
 CC of the young (MODY). The method comprises detecting a mutation in the
 CC gene encoding insulin promoter factor 1 (IPF1), wherein heterozygosity
 CC for the mutation is indicative of MODY. The method may be used to
 CC determine if a patient with MODY symptoms has MODY4, to assess patients
 CC risk of developing MODY4, to assess the risk of a couple's progeny of
 CC inheriting MODY, and to assist in determining the genetic basis for other
 CC pancreatic disorders that might result from IPF1 deficiency. Sequences
 CC AAX01063-66 represent primers used for amplifying the exon 1 of the IPF1
 CC gene using a nested PCR priming scheme
 XX
 SQ Sequence 17 BP; 4 A; 3 C; 10 G; 0 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 680 AGCGAGCAGCGGCGGC 695
 ||||| ||||| |||||
 Db 1 AGCGAGCAGCGGAGGC 16
 ||||| ||||| |||||

RESULT 932
 AAA36589
 ID AAA36589 standard; DNA; 17 BP.
 XX
 AC AAA36589;
 XX

DT 26-JUL-2000 (first entry)
 XX
 DE Human genomic SNP allele specific oligonucleotide SEQ ID NO:654.
 XX
 KW Human; single nucleotide polymorphism; SNP; genotyping; DNA analysis;
 KW allele specific oligonucleotide; ASO; reduced complexity genome; RCG;
 KW genomic classification; identification; DNA fingerprinting;
 KW tumour characterisation; hybridisation; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200018960-A2.
 XX
 PD 06-APR-2000.
 XX
 PF 24-SEP-1999; 99WO-US022283.
 XX
 PR 25-SEP-1998; 98US-0101757P.
 XX
 PA (NASI) MASSACHUSETTS INST TECHNOLOGY.
 XX
 PI Landers JE, Jordan B, Housman DE, Charest A;
 XX
 DR WPI; 2000-293181/25.
 XX
 PT Detection of single nucleotide polymorphisms in genomes by preparation
 PT and analysis of reduced complexity genomes, useful for genotyping,
 PT fingerprinting and determining allele frequency of SNPs.
 XX
 PS Disclosure; Page 72; 111pp; English.
 XX
 CC A method has been developed for detecting the presence or absence of a
 CC single nucleotide polymorphism (SNP) allele in a genomic sample. The
 CC method comprises preparing a reduced complexity genome (RCG) from the
 CC genomic sample and analysing the RCG for the presence or absence of a SNP
 CC allele. The method can be used to characterise a tumour, to generate a
 CC genomic pattern for an individual genome or to generate a genomic
 CC classification code for a genome. The method can be used to assess
 CC whether a subject is at risk for developing a disease or to identify a
 CC set of SNP alleles associated with a disease. The method can also be used
 CC to perform linkage analysis. AAA35944 to AAA35947 represent sequences
 CC used in the exemplification of the present invention. AAA35948 to
 CC AAA36632 represent nucleotide sequences containing SNPs
 XX
 SQ Sequence 17 BP; 6 A; 2 C; 8 G; 1 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 397 AGCGAGCAGCGGAG 412
 ||||| ||||| |||||
 Db 1 AGCGAGCAGCGGAG 16
 ||||| ||||| |||||

RESULT 933
 AAF01886/C
 ID AAF01886 standard; DNA; 17 BP.
 XX
 AC AAF01886;
 XX
 DT 16-FEB-2001 (first entry)
 XX
 DE Hammerhead ribozyme substrate #181.
 XX
 KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;
 KW interferon alpha; ss.
 XX
 OS Homo sapiens.
 OS
 PN WO200061729-A2.
 XX
 PD 19-OCT-2000.


```
RESULT 936
AAF02618/c
ID AAF02618 standard; DNA; 17 BP.
XX
AC AAF02618;
XX
DT 16-FEB-2001 (first entry)
XX
DE Hammerhead ribozyme substrate #913.
XX
KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW interferon alpha; ss.
XX
OS Homo sapiens.
XX
PN WO200061729-A2.
XX
PD 19-OCT-2000.
XX
PF 11-APR-2000; 2000WO-US009721.
XX
PR 12-APR-1999; 99US-0129390P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX
DR WPI; 2000-647423/62.
XX
PT Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT useful for producing e.g. granulocyte colony stimulating factor protein,
PT interferon alpha and erythropoietin.
XX
PS Claim 37; Page 76; 164pp; English.
XX
CC The present invention relates to enzymatic and antisense nucleic acid
CC molecules that act as inhibitors of the expression of repressor genes
CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC factor gene, IRF-2 and/or the CAATT Displacement protein (CDP).
CC Inhibition of the repressors removes prevents inhibition (and
CC consequently increases expression of) genes involved in the production of
CC erythropoietin, granulocyte colony stimulating factor protein and
CC interferon alpha
XX
SQ Sequence 17 BP; 1 A; 9 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 510 CTCGCGGAGGTCGA 525
Db 17 CTCGCGGAGGCGGA 2
RESULT 937
AAA70589
ID AAA70589 standard; DNA; 17 BP.
XX
AC AAA70589;
XX
DT 15-SEP-2003 (revised)
DT 06-DEC-2000 (first entry)
XX
DE Sindbis-like virus strain YN87448 complete genome primer R5810-5826.
XX
KW Genome; Sindbis-like virus strain YN87448; primer; RT-PCR; vaccine;
KW epidemic; Sindbis encephalitis; evolution; epidemiology; ss.
XX
OS Sindbis-like virus; strain YN87448.
XX
PN CN1252445-A.
```

```
XX
PD 10-MAY-2000.
XX
PF 27-OCT-1998; 98CN-00120694.
XX
PR 27-OCT-1998; 98CN-00120694.
XX
PA (VIRO-) INST VIROLOGY CHINESE ACAD PREVENTIVE ME.
XX
PI Liang G, Zhou G, Li L;
XX
DR WPI; 2000-443226/39.
XX
PT Whole genome sequence of YN87448 virus strain and its cloning method.
XX
PS Claim 3; Page 10; 24pp; Chinese.
XX
CC Primers AAA70578-A70603 were used to RT-PCR amplify the complete genome
CC of the Sindbis-like virus strain YN87448 (AAA70577). The genome was
CC cloned as 15 fragments using these PCR primers for inclusion into the
CC plasmid pGEM-T. The invention relates to the isolation and method of
CC cloning the complete genome for the Sindbis-like virus strain YN87448 by
CC a RT-PCR process. The YN87448 strain virus appears to be the optimal
CC candidate for a vaccine to prevent epidemics of Sindbis encephalitis. The
CC sequence of this strain's genome shows the difference between this viral
CC strain and other epidemic Sindbis virus strains at the molecular level
CC and is useful for understanding the source, evolution and molecular
CC epidemiology of Sindbis viruses. (Updated on 15-SEP-2003 to standardise
CC OS field)
XX
SQ Sequence 17 BP; 4 A; 7 C; 3 G; 3 T; 0 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 276 CAGACAGCGCGCTCC 291
Db 2 CAGACATTCGCGCTCC 17
RESULT 938
AAH94701/c
ID AAH94701 standard; RNA; 17 BP.
XX
AC AAH94701;
XX
DT 09-OCT-2001 (first entry)
XX
DE Human Chk1 ribozyme substrate SEQ ID NO: 126.
XX
KW Human; checkpoint kinase-1; Chk1; antisense; ribozyme; gene therapy;
KW RNA cleavage; cancer; ss.
XX
OS Homo sapiens.
XX
PN WO200157206-A2.
XX
PD 09-AUG-2001.
XX
PF 02-FEB-2001; 2001WO-US003504.
XX
PR 03-FEB-2000; 2000US-0179983P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (FATT/) FATTAEY A R.
XX
PI Fattaey AR, Jarvis T, Mcswiggen J, Booher RN, Holman PS;
XX
DR WPI; 2001-496922/54.
XX
PT Novel nucleic acid molecule e.g., ribozymes or antisense nucleic acid
PT molecules, which downregulates expression of a checkpoint kinase-1 gene,
```

PT useful for treating colorectal, lung, breast or prostate cancers.
 PS Claim 4; Page 54; 115pp; English.
 XX
 CC The present invention provides nucleic acid molecules capable of
 CC downregulating the expression of the human checkpoint kinase-1 (Chk1)
 CC gene. These may be antisense or ribozyme sequences, and are useful in the
 CC treatment of diseases associated with conditions affected by Chk1 levels,
 CC including cancer. The present sequence is an oligonucleotide described in
 CC the exemplification of the invention
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 3 G; 0 T; 6 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 606 TGCAGGAGCCAGAG 621
 DB 16 TGCAGGAGCCAGAG 1
 RESULT 939
 AAH95054/C
 ID AAH95054 standard; RNA; 17 BP.
 XX
 AC AAH95054;
 XX
 DT 09-OCT-2001 (first entry)
 XX
 DE Human Chk1 ribozyme substrate SEQ ID NO: 479.
 XX
 KW Human; checkpoint kinase-1; Chk1; antisense; ribozyme; gene therapy;
 KW RNA cleavage; cancer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200157206-A2.
 XX
 PD 09-AUG-2001.
 XX
 PF 02-FEB-2001; 2001WO-US003504.
 XX
 PR 03-FEB-2000; 2000US-0179983P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (PATT/) PATTAY A R.
 XX
 PI Fattaey AR, Jarvis T, Mcswiggen J, Booher RN, Holman PS;
 XX WPI; 2001-496922/54.
 DR
 XX Novel nucleic acid molecule e.g., ribozymes or antisense nucleic acid
 PT molecules, which downregulate expression of a checkpoint kinase-1 gene,
 PT useful for treating colorectal, lung, breast or prostate cancers.
 XX
 PS Claim 4; Page 62; 115pp; English.
 XX
 CC The present invention provides nucleic acid molecules capable of
 CC downregulating the expression of the human checkpoint kinase-1 (Chk1)
 CC gene. These may be antisense or ribozyme sequences, and are useful in the
 CC treatment of diseases associated with conditions affected by Chk1 levels,
 CC including cancer. The present sequence is an oligonucleotide described in
 CC the exemplification of the invention
 XX
 SQ Sequence 17 BP; 2 A; 7 C; 3 G; 0 T; 5 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 606 TGCAGGAGCCAGAG 621
 DB 16 TGCAGGAGCCAGAG 1

Db 17 TGCAGGAGCCAGAG 2
 RESULT 940
 ABK00015
 ID ABK00015 standard; RNA; 17 BP.
 XX
 AC ABK00015;
 XX
 DT 12-MAR-2002 (first entry)
 XX
 DE Human NOGO Hammerhead Ribozyme #15.
 XX
 KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
 KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KW DNzyme; inozyme; G-cleaver; amberyzyme; zinzyme; lymphoma; leukaemia;
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
 KW inflammatory arthropathy; central nervous system injury;
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KW Parkinson's disease; ataxia; Huntington's disease;
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200159103-A2.
 XX
 PD 16-AUG-2001.
 XX
 PF 09-FEB-2001; 2001WO-US004273.
 XX
 PR 11-FEB-2000; 2000US-0181797P.
 PR 28-FEB-2000; 2000US-0185516P.
 PR 06-MAR-2000; 2000US-0187128P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J.
 PA (CHOW/) CHOWRIRA B M.
 XX
 PI Blatt L, Mcswiggen J, Chowrira BM;
 DR WPI; 2001-607195/69.
 XX
 PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
 PT central nervous system injury.
 XX
 PS Claim 88; Page 66; 200pp; English.
 XX
 CC The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOGO). The
 CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
 CC DNzyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or
 CC an amberyzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
 CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
 CC the cell and treat a patient having a condition associated with the level
 CC of CD20. The treatment may further comprise the use of one or more
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to
 CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
 CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
 CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-

CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the
 CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
 CC cell and treat a patient having a condition associated with the level of
 CC NOGO. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NOGO-targetting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The present
 CC sequence is a hammerhead ribozyme of the invention
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 5 G; 0 T; 4 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 62.5%; Pred. No. 7.2e+02;
 Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
 QY 233 GAAGAGTCCTCTCTGG 248
 Db 2 GACCAGUCUCCUGG 17
 |||:::|::|::|
 RESULT 941
 ABK00785
 ID ABK00785 standard; RNA; 17 BP.
 XX
 AC ABK00785;
 DT 12-MAR-2002 (first entry)
 DE Human NOGO Inozyme #55.
 XX
 KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
 KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KW DNazyme; inozyme; G-cleaver; amberszyme; zinzyme; lymphoma; leukaemia;
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
 KW inflammatory arthropathy; central nervous system injury;
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KW Parkinson's disease; ataxia; Huntington's disease;
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200159103-A2.
 PD 16-AUG-2001.
 XX
 PF 09-FEB-2001; 2001WO-US004273.
 XX
 PR 11-FEB-2000; 2000US-0181797P.
 PR 28-FEB-2000; 2000US-0185516P.
 PR 06-MAR-2000; 2000US-0187128P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J.
 PA (CHOW/) CHOWIRA B M.
 XX
 FI Blatt L, Mcswiggen J, Chowira BM;
 XX WPI; 2001-607195/69.
 DR
 XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and

PT central nervous system injury.
 XX Claim 88; Page 78; 200pp; English.
 XX
 CC The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOGO). The
 CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
 CC DNazyme) an Inozyme (an endolytic nucleic acid cleaving an RNA molecule
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or
 CC an amberszyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
 CC with a VGY motif). The CD20-targetting nucleic acid is used to cleave RNA
 CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
 CC the cell and treat a patient having a condition associated with the level
 CC of CD20. The treatment may further comprise the use of one or more
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to
 CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
 CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
 CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
 CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the
 CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
 CC cell and treat a patient having a condition associated with the level of
 CC NOGO. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NOGO-targetting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The present
 CC sequence is an inozyme of the invention
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 4 G; 0 T; 5 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 62.5%; Pred. No. 7.2e+02;
 Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
 QY 233 GAAGAGTCCTCTCTGG 248
 Db 1 GACCAGUCUCCUGG 16
 |||:::|::|::|
 RESULT 942
 ABK01938
 ID ABK01938 standard; RNA; 17 BP.
 XX
 AC ABK01938;
 DT 12-MAR-2002 (first entry)
 DE Human NOGO Zinzyme #260.
 XX
 KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
 KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KW DNazyme; inozyme; G-cleaver; amberszyme; zinzyme; lymphoma; leukaemia;
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
 KW inflammatory arthropathy; central nervous system injury;
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KW Parkinson's disease; ataxia; Huntington's disease;
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX

PN	WO200159103-A2.	AC	ABK02540;
XX	16-AUG-2001.	XX	12-MAR-2002 (first entry)
XX	09-FEB-2001; 2001WO-US004273.	XX	Human NOGO Amberyze #212.
XX	11-FEB-2000; 2000US-0181797P.	KW	Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic; cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
PR	28-FEB-2000; 2000US-0185516P.	KW	Muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
XX	06-MAR-2000; 2000US-0187128P.	KW	DNAzyme; inozyme; G-cleaver; amberyze; zinzyme; lymphoma; leukaemia;
XX	(RIBO-) RIBOZYME PHARM INC.	KW	B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
PA	(BLAT/) BLATT L.	KW	human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
PA	(MCSW/) MCSWIGGEN J.	KW	MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
PA	(CHOW/) CHOWRIRA B M.	KW	inflammatory arthropathy; central nervous system injury;
XX	Blatt L, Mcswiggen J, Chowrira BM;	KW	cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
XX	WPI; 2001-607195/69.	KW	Parkinson's disease; ataxia; Huntington's disease;
DR	Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense constructs, which down regulate expression of a CD20 gene or neurite growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and central nervous system injury.	KW	Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX	Claim 88; Page 100; 200pp; English.	OS	Homo sapiens.
CC	The invention relates to a nucleic acid molecule which down regulates expression of a CD20 gene and a nucleic acid molecule which down regulates expression of a neurite growth inhibitor gene (NOGO). The nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a DNAzyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or an amberyze (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA of CD20 in the presence of a divalent cation that is preferably Mg ²⁺ . Furthermore, it may be contacted with a cell to reduce CD20 activity of the cell and treat a patient having a condition associated with the level of CD20. The treatment may further comprise the use of one or more therapies. In particular, the CD20 targeting nucleic acid may be used to treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma, immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-targeting nucleic acid is used to cleave RNA of the NOGO gene in the presence of a divalent cation that is preferably Mg ²⁺ . Furthermore, the nucleic acid may be contacted with a cell to reduce NOGO activity of the cell and treat a patient having a condition associated with the level of NOGO. The treatment may further comprise the use of one or more therapies. In particular, the NOGO-targeting nucleic acid may be used to treat central nervous system (CNS) injury and cerebrovascular accident (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS), chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS), Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob disease, muscular dystrophy, and/or other neurodegenerative disease states which respond to the modulation of NOGO expression. The present sequence is a zinzyme molecule of the invention	OS	Synthetic.
XX	Sequence 17 BP; 6 A; 2 C; 5 G; 0 T; 4 U; 0 Other;	PN	WO200159103-A2.
XX	Query Match	XX	16-AUG-2001.
XX	Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;	XX	09-FEB-2001; 2001WO-US004273.
XX	Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;	XX	11-FEB-2000; 2000US-0181797P.
QY	487 TCTGAGAGGCGAGAG 502	XX	28-FEB-2000; 2000US-0185516P.
DB	1 UUUUAGAGUCAGAG 16	XX	06-MAR-2000; 2000US-0187128P.
RESULT 943		XX	(RIBO-) RIBOZYME PHARM INC.
ABK02540		XX	(BLAT/) BLATT L.
ID	ABK02540 standard; RNA; 17 BP.	XX	(MCSW/) MCSWIGGEN J.
XX		XX	(CHOW/) CHOWRIRA B M.

CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The present
 CC sequence is an amberzyme molecule of the invention
 XX
 SQ Sequence 17 BP; 7 A; 2 C; 4 G; 0 T; 4 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 75.0%; Pred. No. 7.2e+02;
 Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
 QY 486 ATCTGAAGAGCGAGAA 501
 Bb : : ||||| |||||
 2 AUUUGAAGAGUCAGAA 17
 RESULT 944
 ABA80257/C
 ID ABA80257 standard; DNA; 17 BP.
 XX AC ABA80257;
 XX DT 24-JAN-2002 (first entry)
 XX DE MLH1 mutation correcting oligonucleotide SEQ ID NO: 3103.
 XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalasassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antitickling; antianaemic; haemostatic;
 KW antilipemic; ss.
 XX Homo sapiens.
 OS
 XX WO200173002-A2.
 PN
 XX 04-OCT-2001.
 PD
 XX 27-MAR-2001; 2001WO-US009761.
 PF
 XX 27-MAR-2000; 2000US-0192176P.
 PR
 XX 27-MAR-2000; 2000US-0192176P.
 PR
 XX 01-JUN-2000; 2000US-0208538P.
 PR
 XX 30-OCT-2000; 2000US-0244989P.
 PR
 XX (UYDE) UNIV DELAWARE.
 PA
 XX Kmiec EB, Gamper HB, Rice MC;
 PI
 XX WPI; 2001-639230/73.
 DR
 XX Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.
 XX
 PS Claim 7; Page 215; 294pp; English.
 XX The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase

CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalasassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention
 XX
 SQ Sequence 17 BP; 1 A; 5 C; 5 G; 6 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 724 GCAGCAGCAGCAGCGTG 739
 Bb : : ||||| |||||
 17 GCAGCAGCAGCATCGAG 2
 RESULT 945
 ABA80568
 ID ABA80568 standard; DNA; 17 BP.
 XX AC ABA80568;
 XX DT 24-JAN-2002 (first entry)
 XX DE APOE mutation correcting oligonucleotide SEQ ID NO: 3414.
 XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalasassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antitickling; antianaemic; haemostatic;
 KW antilipemic; ss.
 XX Homo sapiens.
 OS
 XX WO200173002-A2.
 PN
 XX 04-OCT-2001.
 PD
 XX 27-MAR-2001; 2001WO-US009761.
 PF
 XX 27-MAR-2000; 2000US-0192176P.
 PR
 XX 27-MAR-2000; 2000US-0192176P.
 PR
 XX 01-JUN-2000; 2000US-0208538P.
 PR
 XX 30-OCT-2000; 2000US-0244989P.
 PR
 XX (UYDE) UNIV DELAWARE.
 PA
 XX Kmiec EB, Gamper HB, Rice MC;
 PI
 XX WPI; 2001-639230/73.
 DR
 XX Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.
 XX
 PS Claim 7; Page 232; 294pp; English.
 XX The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,

CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX
SQ Sequence 17 BP; 4 A; 6 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 757 CATGCGAGCCAGAGC 772
||||| |||||
Db 1 CATGCTGGCCAGAGC 16

RESULT 946
ABA77505
ID ABA77505 standard; DNA; 17 BP.
XX
AC ABA77505;
XX
DT 24-JAN-2002 (first entry)
XX
DE p53 mutation correcting oligonucleotide SEQ ID NO: 351.
XX
KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytostatic; antitickling; antianaemic; haemostatic;
KW antileptic; ss.
XX
OS Homo sapiens.
XX
PN WO200173002-A2.
XX
PD 04-OCT-2001.
XX
PF 27-MAR-2001; 2001WO-US009761.
XX
PR 27-MAR-2000; 2000US-0192176P.
PR 27-MAR-2000; 2000US-0192179P.
PR 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
XX
PA (UYDE) UNIV DELAWARE.
XX
XX Kmiec EB, Gamper HB, Rice MC;
XX WPI; 2001-639230/73.
XX
PT Oligonucleotide for targeted alterations of genetic sequences and for
PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification.
XX
PS Claim 7; Page 63; 294pp; English.
XX
CC The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus

CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX
SQ Sequence 17 BP; 2 A; 4 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 364 GCGGAGCGCTGCGAG 379
||||| |||||
Db 2 GCGTGAGCGCTTCGAG 17

RESULT 947
ABA78530
ID ABA78530 standard; DNA; 17 BP.
XX
AC ABA78530;
XX
DT 24-JAN-2002 (first entry)
XX
DE CDKN2A mutation correcting oligonucleotide SEQ ID NO: 1376.
XX
KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytostatic; antitickling; antianaemic; haemostatic;
KW antileptic; ss.
XX
OS Homo sapiens.
XX
PN WO200173002-A2.
XX
PD 04-OCT-2001.
XX
PF 27-MAR-2001; 2001WO-US009761.
XX
PR 27-MAR-2000; 2000US-0192176P.
PR 27-MAR-2000; 2000US-0192179P.
PR 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
XX
PA (UYDE) UNIV DELAWARE.
XX
XX Kmiec EB, Gamper HB, Rice MC;
XX WPI; 2001-639230/73.
XX
PT Oligonucleotide for targeted alterations of genetic sequences and for
PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification.
XX
PS Claim 7; Page 128; 294pp; English.
XX
CC The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A

CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention
 XX
 SQ Sequence 17 BP; 3 A; 8 C; 5 G; 1 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 7.2e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 721 GCAGCAGCAGCAGC 736

DB 1 GCAGCAGCAGCTCCG 16

RESULT 948

ABA77506/c

ID ABA77506 standard; DNA; 17 BP.

XX AC ABA77506;

XX DT 24-JAN-2002 (first entry)

XX DE p53 mutation correcting oligonucleotide SEQ ID NO: 352.

XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
 KW antilipemic; ss.

XX OS Homo sapiens.

XX PN WO200173002-A2.

XX PD 04-OCT-2001.

XX PF 27-MAR-2001; 2001WO-US009761.

XX PR 27-MAR-2000; 2000US-0192176P.

XX PR 27-MAR-2000; 2000US-0192179P.

XX PR 01-JUN-2000; 2000US-0208538P.

XX PR 30-OCT-2000; 2000US-0244989P.

XX PA (UYDE) UNIV DELAWARE.

XX PI Kmiec EB, Gamper HB, Rice MC;

XX DR WPI; 2001-639230/73.

XX Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.
 XX
 XX Claim 7; Page 63; 294pp; English.

XX The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,

CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention
 XX

SQ Sequence 17 BP; 3 A; 8 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 7.2e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 364 GCGGAGCGCTGCGAG 379

DB 16 GCGTGAGCGCTTCGAG 1

RESULT 949

ABA78529/c

ID ABA78529 standard; DNA; 17 BP.

XX AC ABA78529;

XX DT 24-JAN-2002 (first entry)

XX DE CDKN2A mutation correcting oligonucleotide SEQ ID NO: 1375.

XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
 KW antilipemic; ss.

XX OS Homo sapiens.

XX PN WO200173002-A2.

XX PD 04-OCT-2001.

XX PF 27-MAR-2001; 2001WO-US009761.

XX PR 27-MAR-2000; 2000US-0192176P.

XX PR 27-MAR-2000; 2000US-0192179P.

XX PR 01-JUN-2000; 2000US-0208538P.

XX PR 30-OCT-2000; 2000US-0244989P.

XX PA (UYDE) UNIV DELAWARE.

XX PI Kmiec EB, Gamper HB, Rice MC;

XX DR WPI; 2001-639230/73.

XX Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.
 XX
 XX Claim 7; Page 128; 294pp; English.

XX The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at

CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention
 XX
 XX
 SQ Sequence 17 BP; 1 A; 5 C; 8 G; 3 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 721 GCAGCAGCAGCAGCAGC 736
 Db 17 GCAGCAGCAGCTCCG 2
 RESULT 950
 ABA80256
 ID ABA80256 standard; DNA; 17 BP.
 AC ABA80256;
 DT 24-JAN-2002 (first entry)
 DE MLH1 mutation correcting oligonucleotide SEQ ID NO: 3102.
 XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisen-
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
 KW antilipemic; ss.
 XX Homo sapiens.
 OS
 XX
 XX WO200173002-A2.
 PN
 XX
 PD 04-OCT-2001.
 XX
 XX 27-MAR-2001; 2001WO-US009761.
 PF
 XX 27-MAR-2000; 2000US-0192176P.
 PR 27-MAR-2000; 2000US-0192179P.
 PR 01-JUN-2000; 2000US-0208538P.
 PR 30-OCT-2000; 2000US-0244989P.
 XX
 XX (UYDE) UNIV DELAWARE.
 PA
 XX
 XX Kniec EB, Gamper HB, Rice MC;
 PI
 XX WPI; 2001-639230/73.
 DR
 XX Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.
 XX
 XX Claim 7; Page 215; 294pp; English.
 PS
 XX The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic

CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention
 XX
 XX
 SQ Sequence 17 BP; 6 A; 5 C; 5 G; 1 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 724 GCAGCAGCAGCAGCGTG 739
 Db 1 GCAGCAGCAGCATCGAG 16
 RESULT 951
 ABA80569/C
 ID ABA80569 standard; DNA; 17 BP.
 XX ABA80569;
 AC ABA80569;
 DT 24-JAN-2002 (first entry)
 DE APOE mutation correcting oligonucleotide SEQ ID NO: 3415.
 XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisen-
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
 KW antilipemic; ss.
 XX Homo sapiens.
 OS
 XX
 XX WO200173002-A2.
 PN
 XX
 PD 04-OCT-2001.
 XX
 XX 27-MAR-2001; 2001WO-US009761.
 PF
 XX 27-MAR-2000; 2000US-0192176P.
 PR 27-MAR-2000; 2000US-0192179P.
 PR 01-JUN-2000; 2000US-0208538P.
 PR 30-OCT-2000; 2000US-0244989P.
 XX
 XX (UYDE) UNIV DELAWARE.
 PA
 XX
 XX Kniec EB, Gamper HB, Rice MC;
 PI
 XX WPI; 2001-639230/73.
 DR
 XX Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.
 XX
 XX Claim 7; Page 232; 294pp; English.
 PS
 XX The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the

CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CTRF, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention

SQ Sequence 17 BP; 2 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 757 CATGCGGCCGAGGC 772

Db 17 CATGCTCGGCAGAGC 2

RESULT 952

ABL58272/c

ID ABL58272 standard; DNA; 17 BP.

XX AC ABL58272;

XX DT 15-JUL-2002 (first entry)

XX DE Rice OsEP3A gene fragment amplifying primer P1.

XX KW Rice; cysteine proteinase; CysP; OsEP3A; plant; transgenic; promoter;
 KW aleurone; germination; nitrogen; senescence; PCR; primer; ss.
 XX OS Oryza sativa.

XX PN USG388067-B1.

XX PD 14-MAY-2002.

XX PF 10-JAN-2000; 2000US-00480017.

XX PR 12-FEB-2000; 2000CA-02296052.

XX PA (SINI-) ACAD SINICA.

XX PI Yu S, Tong W;

XX DR WPI; 2001-597345/68.

XX PT New rice cysteine proteinase gene promoter, useful in stress-induced
 PT regulation of heterologous proteins in plants or plant cells, or as
 PT probes for isolating promoters or genes whose expression stress-induced
 PT or during senescence.

XX PS Disclosure; Col 6; 10pp; English.

XX CC The invention relates to a new promoter derived from rice cysteine
 CC proteinase (CysP) gene (OsEP3A). The promoter directs the expression of a
 CC heterologous protein in the aleurone layer of transgenic rice seeds
 CC during germination and in cultured rice suspension cells under nitrogen
 CC starvation. The nucleic acids can be used as probes to isolate other
 CC promoters and/or genes whose expression is induced under stress or during
 CC senescence, and in stress-induced regulation of heterologous proteins in
 CC plants (including embryos, organs and seeds) or plant cells. The present
 CC sequence represents a PCR primer for amplifying a OsEP3A DNA fragment

XX SQ Sequence 17 BP; 3 A; 10 C; 1 G; 3 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 699 TGGAGAGTGAGCGCGA 714

Db 17 TGGAGGTGAGGGCGA 2

RESULT 953

ABN87370/c

ID ABN87370 standard; DNA; 17 BP.

XX AC ABN87370;

XX DT 01-AUG-2002 (first entry)

XX DE Rice cysteine proteinase OsEP3A PCR primer SEQ ID NO:8.

XX KW Rice; cysteine proteinase; OsEP3A; CysP; enzyme; promoter; plant;
 KW aleurone layer; transgenic rice; seed; germination; nitrogen starvation;
 KW stress; senescence; stress-induced regulation; PCR primer; ss.
 XX OS Oryza sativa.

XX PN CA2296052-A1.

XX PD 12-AUG-2001.

XX PF 12-FEB-2000; 2000CA-02296052.

XX PR 12-FEB-2000; 2000CA-02296052.

XX PA (SINI-) ACAD SINICA.

XX PI Tong W, Yu S;

XX DR WPI; 2001-597345/68.

XX PT New rice cysteine proteinase gene promoter, useful in stress-induced
 PT regulation of heterologous proteins in plants or plant cells, or as
 PT probes for isolating promoters or genes whose expression stress-induced
 PT or during senescence.

XX PS Example; Page 9; 27pp; English.

XX CC The present invention describes a rice cysteine proteinase (OsEP3A, also
 CC known as CysP) gene promoter. The promoter directs the expression of a
 CC heterologous protein in the aleurone layer of transgenic rice seeds
 CC during germination and in cultured rice suspension cells under nitrogen
 CC starvation. The promoter nucleic acid sequence can be used as a probe to
 CC isolate other promoters and/or genes whose expression is induced under
 CC stress or during senescence, and in stress-induced regulation of
 CC heterologous proteins in plants (including embryos, organs and seeds) or
 CC plant cells. The present sequence represents a PCR primer for rice
 CC OsEP3A, which is used in an example from the present invention

XX SQ Sequence 17 BP; 3 A; 10 C; 1 G; 3 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 699 TGGAGAGTGAGCGCGA 714

Db 17 TGGAGGTGAGGGCGA 2

RESULT 954

ABL46638

ID ABL46638 standard; RNA; 17 BP.

XX

AC ABL46638;
XX
DT 27-JUN-2003 (first entry)
XX
DE Human GR1D NCH ribozyme substrate oligonucleotide #92.
XX
KW Human; Grb2-related with Insert Domain; GR1D; T-cell;
KW co-stimulatory adaptor protein; tissue rejection; graft rejection;
KW leukaemia; cytostatic; ss.
XX
OS Homo sapiens.
XX
PN WO200162911-A2.
XX
PD 30-AUG-2001.
XX
PF 23-FEB-2001; 2001WO-US005957.
XX
PR 24-FEB-2000; 2000US-0184594P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (GLAX) GLAXO GROUP LTD.
XX
PI Jarvis T, Von Carlowitz I, Mcswiggen JA, Hamblin PA, Ellis JH;
XX WPI; 2001-550088/61.
XX
XX New nucleic acid(s) for regulating the Grb2-related with Insert Domain
XX (GR1D) gene comprises using antisense and enzymatic nucleic acid
XX molecules such as hammerhead ribozymes.
XX
XX Claim 4; Page 64; 108pp; English.
XX
XX The present invention relates to oligonucleotides that downregulate the
XX expression of human Grb2-related with Insert Domain (GR1D) gene. GR1D is
XX a T-cell co-stimulatory adaptor protein. The oligonucleotides are useful
XX for modulating the expression of GR1D, to treat conditions such as
XX tissue/graft rejection and leukaemia. The oligonucleotides can also be
XX administered in conjunction with other therapies such as radiation,
XX chemotherapy and cyclosporin treatment. The present oligonucleotide was
XX used to illustrate the invention
XX
XX Sequence 17 BP; 4 A; 6 C; 6 G; 0 T; 1 U; 0 Other;
XX
XX New nucleic acid(s) for regulating the Grb2-related with Insert Domain
XX (GR1D) gene comprises using antisense and enzymatic nucleic acid
XX molecules such as hammerhead ribozymes.
XX
XX Claim 4; Page 64; 108pp; English.
XX
XX The present invention relates to oligonucleotides that downregulate the
XX expression of human Grb2-related with Insert Domain (GR1D) gene. GR1D is
XX a T-cell co-stimulatory adaptor protein. The oligonucleotides are useful
XX for modulating the expression of GR1D, to treat conditions such as
XX tissue/graft rejection and leukaemia. The oligonucleotides can also be
XX administered in conjunction with other therapies such as radiation,
XX chemotherapy and cyclosporin treatment. The present oligonucleotide was
XX used to illustrate the invention
XX
XX Sequence 17 BP; 4 A; 6 C; 6 G; 0 T; 1 U; 0 Other;
XX
XX Query Match 1.7%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 81.2%; Pred. NO. 7.2e+02;
XX Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
XX
QY 393 TCCAGCCGAGCCAGAG 408
DB :||| ||||| |||||
2 UCGGGCCGAGCCAGAG 17
XX
RESULT 955
ABL46974
ID ABL46974 standard; RNA; 17 BP.
XX
AC ABL46974;
XX
DT 27-JUN-2003 (first entry)
XX
DE Human GR1D zinzyme substrate oligonucleotide #58.
XX
KW Human; Grb2-related with Insert Domain; GR1D; T-cell;
KW co-stimulatory adaptor protein; tissue rejection; graft rejection;
KW leukaemia; cytostatic; ss.
XX
OS Homo sapiens.
XX
PN WO200162911-A2.
XX
PD 30-AUG-2001.
XX

PF 23-FEB-2001; 2001WO-US005957.
XX
PR 24-FEB-2000; 2000US-0184594P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (GLAX) GLAXO GROUP LTD.
XX
PI Jarvis T, Von Carlowitz I, Mcswiggen JA, Hamblin PA, Ellis JH;
XX WPI; 2001-550088/61.
XX
XX New nucleic acid(s) for regulating the Grb2-related with Insert Domain
XX (GR1D) gene comprises using antisense and enzymatic nucleic acid
XX molecules such as hammerhead ribozymes.
XX
XX Claim 4; Page 72; 108pp; English.
XX
XX The present invention relates to oligonucleotides that downregulate the
XX expression of human Grb2-related with Insert Domain (GR1D) gene. GR1D is
XX a T-cell co-stimulatory adaptor protein. The oligonucleotides are useful
XX for modulating the expression of GR1D, to treat conditions such as
XX tissue/graft rejection and leukaemia. The oligonucleotides can also be
XX administered in conjunction with other therapies such as radiation,
XX chemotherapy and cyclosporin treatment. The present oligonucleotide was
XX used to illustrate the invention
XX
XX Sequence 17 BP; 4 A; 9 C; 3 G; 0 T; 1 U; 0 Other;
XX
XX Query Match 1.7%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 81.2%; Pred. NO. 7.2e+02;
XX Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
XX
QY 717 CGCTGCAGCAGCAGCA 732
DB :||| ||||| |||||
2 CCUGCAGCAGCAGCA 17
XX
RESULT 956
ABL47241
ID ABL47241 standard; RNA; 17 BP.
XX
AC ABL47241;
XX
DT 27-JUN-2003 (first entry)
XX
DE Human GR1D Amberzyme substrate oligonucleotide #141.
XX
KW Human; Grb2-related with Insert Domain; GR1D; T-cell;
KW co-stimulatory adaptor protein; tissue rejection; graft rejection;
KW leukaemia; cytostatic; ss.
XX
OS Homo sapiens.
XX
PN WO200162911-A2.
XX
PD 30-AUG-2001.
XX
PF 23-FEB-2001; 2001WO-US005957.
XX
PR 24-FEB-2000; 2000US-0184594P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (GLAX) GLAXO GROUP LTD.
XX
PI Jarvis T, Von Carlowitz I, Mcswiggen JA, Hamblin PA, Ellis JH;
XX WPI; 2001-550088/61.
XX
XX New nucleic acid(s) for regulating the Grb2-related with Insert Domain
XX (GR1D) gene comprises using antisense and enzymatic nucleic acid
XX molecules such as hammerhead ribozymes.
XX
XX Claim 4; Page 88; 108pp; English.
XX

XX The present invention relates to oligonucleotides that downregulate the
CC expression of human Grb2-related with Insert Domain (GRID) gene. GRID is
CC a T-cell co-stimulatory adaptor protein. The oligonucleotides are useful
CC for modulating the expression of GRID, to treat conditions such as
CC tissue/graft rejection and leukaemia. The oligonucleotides can also be
CC administered in conjunction with other therapies such as radiation,
CC chemotherapy and cyclosporin treatment. The present oligonucleotide was
CC used to illustrate the invention
SQ Sequence 17 BP; 3 A; 3 C; 9 G; 0 T; 2 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.2e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 731 CACAGCGTGAGGTGG 746
Db ||||| :||
1 CACAGCGGGAGGTGG 16

RESULT 957
ABL46728
ID ABL46728 standard; RNA; 17 BP.
XX
AC ABL46728;
XX
DT 27-JUN-2003 (first entry)
XX
DE Human GRID NCH ribozyme substrate oligonucleotide #182.
XX
KW Human; Grb2-related with Insert Domain; GRID; T-cell;
KW co-stimulatory adaptor protein; tissue rejection; graft rejection;
KW leukaemia; cytostatic; ss.
XX
OS Homo sapiens.
XX
PN WO200162911-A2.
XX
PD 30-AUG-2001.
XX
PF 23-FEB-2001; 2001WO-US005957.
XX
PR 24-FEB-2000; 2000US-0184594P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (GLAX) GLAXO GROUP LTD.
XX
PI Jarvis T, Von Carlowitz I, Mcswiggen JA, Hamblin PA, Ellis JH;
XX WPI; 2001-550088/61.
XX
DR New nucleic acid(s) for regulating the Grb2-related with Insert Domain
XX (GRID) gene comprises using antisense and enzymatic nucleic acid
XX molecules such as hammerhead ribozymes.
XX
PS Claim 4; Page 66; 108pp; English.
XX
CC The present invention relates to oligonucleotides that downregulate the
CC expression of human Grb2-related with Insert Domain (GRID) gene. GRID is
CC a T-cell co-stimulatory adaptor protein. The oligonucleotides are useful
CC for modulating the expression of GRID, to treat conditions such as
CC tissue/graft rejection and leukaemia. The oligonucleotides can also be
CC administered in conjunction with other therapies such as radiation,
CC chemotherapy and cyclosporin treatment. The present oligonucleotide was
CC used to illustrate the invention
SQ Sequence 17 BP; 5 A; 8 C; 4 G; 0 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 718 GGTGACGACGACGAC 733
Db ||||| :||
1 GCAGCAGCAGCAGCAGC 16

RESULT 958
ABL46639
ID ABL46639 standard; RNA; 17 BP.
XX
AC ABL46639;
XX
DT 27-JUN-2003 (first entry)
XX
DE Human GRID NCH ribozyme substrate oligonucleotide #93.
XX
KW Human; Grb2-related with Insert Domain; GRID; T-cell;
KW co-stimulatory adaptor protein; tissue rejection; graft rejection;
KW leukaemia; cytostatic; ss.
XX
OS Homo sapiens.
XX
PN WO200162911-A2.
XX
PD 30-AUG-2001.
XX
PF 23-FEB-2001; 2001WO-US005957.
XX
PR 24-FEB-2000; 2000US-0184594P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (GLAX) GLAXO GROUP LTD.
XX
PI Jarvis T, Von Carlowitz I, Mcswiggen JA, Hamblin PA, Ellis JH;
XX WPI; 2001-550088/61.
XX
DR New nucleic acid(s) for regulating the Grb2-related with Insert Domain
XX (GRID) gene comprises using antisense and enzymatic nucleic acid
XX molecules such as hammerhead ribozymes.
XX
PS Claim 4; Page 64; 108pp; English.
XX
CC The present invention relates to oligonucleotides that downregulate the
CC expression of human Grb2-related with Insert Domain (GRID) gene. GRID is
CC a T-cell co-stimulatory adaptor protein. The oligonucleotides are useful
CC for modulating the expression of GRID, to treat conditions such as
CC tissue/graft rejection and leukaemia. The oligonucleotides can also be
CC administered in conjunction with other therapies such as radiation,
CC chemotherapy and cyclosporin treatment. The present oligonucleotide was
CC used to illustrate the invention
SQ Sequence 17 BP; 3 A; 7 C; 6 G; 0 T; 1 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.2e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 393 TCCAAGCCAGCCAGAG 408
Db :|| :||
1 UCCGGCCAGCCAGAG 16

RESULT 959
ABL47240
ID ABL47240 standard; RNA; 17 BP.
XX
AC ABL47240;
XX
DT 27-JUN-2003 (first entry)
XX
DE Human GRID Amberzyme substrate oligonucleotide #140.
XX
KW Human; Grb2-related with Insert Domain; GRID; T-cell;

PN WO200192524-A2.
XX 06-DEC-2001.
XX 25-MAY-2001; 2001WO-US016981.
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 05-FEB-2001; 2001US-0266860P.
XX (AEOM-) AEOMICA INC.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX Disclosure; SEQ ID NO 673; 214pp; English.
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterize and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX Sequence 17 BP; 6 A; 6 C; 3 G; 2 T; 0 U; 0 Other;
SQ Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 233 GAAGAGTCTCTCTGG 248
DB 16 GATGAGTCTCTCTGG 1
RESULT 962
ABN07707/c
ID ABN07707 standard; DNA; 17 BP.
XX
AC ABN07707;

XX 29-MAY-2002 (first entry)
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7699.
DE
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX Homo sapiens.
XX WO200192524-A2.
XX 06-DEC-2001.
XX 25-MAY-2001; 2001WO-US016981.
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 05-FEB-2001; 2001US-0266860P.
XX (AEOM-) AEOMICA INC.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX Disclosure; SEQ ID NO 7699; 214pp; English.
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterize and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX Sequence 17 BP; 2 A; 7 C; 6 G; 2 T; 0 U; 0 Other;
SQ Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 827 CTGCGCCAGTTGAGG 842
 Db 16 CTGCGCCAGCTGCAGG 1

RESULT 963

ABN08041
 ID ABN08041 standard; DNA; 17 BP.

AC ABN08041;

DT 29-MAY-2002 (first entry)

DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8033.

XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.

XX Homo sapiens.

XX WO200192524-A2.

XX 06-DEC-2001.

XX 25-MAY-2001; 2001WO-US016981.

XX 26-MAY-2000; 2000US-0207456P.

XX 21-SEP-2000; 2000US-0234687P.

XX 27-SEP-2000; 2000US-0236359P.

XX 04-OCT-2000; 2000GB-00024263.

XX 30-JAN-2001; 2001WO-US000661.

XX 30-JAN-2001; 2001WO-US000662.

XX 30-JAN-2001; 2001WO-US000663.

XX 30-JAN-2001; 2001WO-US000664.

XX 30-JAN-2001; 2001WO-US000665.

XX 30-JAN-2001; 2001WO-US000666.

XX 30-JAN-2001; 2001WO-US000667.

XX 30-JAN-2001; 2001WO-US000668.

XX 30-JAN-2001; 2001WO-US000669.

XX 05-FEB-2001; 2001WO-US000670.

XX (AEOM-) AEOMICA INC.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;

XX WPI; 2002-179446/23.

XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX Disclosure; SEQ ID NO 8033; 214pp; English.

XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.

CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence

XX Sequence 17 BP; 4 A; 3 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 7.2e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 696 AGCTGGAGAGTGAGCG 711

Db 2 AGCTGGAGATCGAGCG 17

RESULT 964

ABN06898/c

ID ABN06898 standard; DNA; 17 BP.

XX ABN06898;

XX 29-MAY-2002 (first entry)

XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6890.

XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.

XX Homo sapiens.

XX WO200192524-A2.

XX 06-DEC-2001.

XX 25-MAY-2001; 2001WO-US016981.

XX 26-MAY-2000; 2000US-0207456P.

XX 21-SEP-2000; 2000US-0234687P.

XX 27-SEP-2000; 2000US-0236359P.

XX 04-OCT-2000; 2000GB-00024263.

XX 30-JAN-2001; 2001WO-US000661.

XX 30-JAN-2001; 2001WO-US000662.

XX 30-JAN-2001; 2001WO-US000663.

XX 30-JAN-2001; 2001WO-US000664.

XX 30-JAN-2001; 2001WO-US000665.

XX 30-JAN-2001; 2001WO-US000666.

XX 30-JAN-2001; 2001WO-US000667.

XX 30-JAN-2001; 2001WO-US000668.

XX 30-JAN-2001; 2001WO-US000669.

XX 05-FEB-2001; 2001WO-US000670.

XX (AEOM-) AEOMICA INC.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;

XX WPI; 2002-179446/23.

XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX Disclosure; SEQ ID NO 6890; 214pp; English.

XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1

CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 1 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Qy 306 GCTCCTGGAGGAGAA 321
 Db 17 GCCGCTGGAAGAGAA 2
 RESULT 965
 ABN07685
 ID ABN07685 standard; DNA; 17 BP.
 XX
 AC ABN07685;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7677.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US016981.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX
 DR WPI; 2002-179446/23.
 XX
 PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,

PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption/ionization, comprises human myosin-like protein hGDMPLP-1.
 XX
 PS Disclosure; SEQ ID NO 7677; 214pp; English.
 CC
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 10 A; 1 C; 6 G; 0 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Qy 490 GAAGAGCGCAGAGGAG 505
 Db 2 GAAGAGCAGAGAGAG 17
 RESULT 966
 ABN08431
 ID ABN08431 standard; DNA; 17 BP.
 XX
 AC ABN08431;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8423.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US016981.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.

30-JAN-2001; 2001WO-US000669.
 30-JAN-2001; 2001WO-US000670.
 05-FEB-2001; 2001US-0266860P.
 (AEOM-) AEOMICA INC.
 Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 WPI; 2002-179446/23.
 New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 or as specific biomolecule capture probes for surface-enhanced laser
 desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 Disclosure; SEQ ID NO 8423; 214pp; English.
 The present invention describes a human genome-derived myosin-like
 protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 nucleic acids can be used as probes to detect, characterise and quantify
 hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 provide initial substrates for the recombinant engineering of hGDMPLP-1
 protein variants having desired phenotypic improvements, and for
 expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 used as immunogens to raise antibodies that specifically recognise hGDMPLP
 -1 proteins, as standards in assays used to determine the concentration
 and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 capture probes for surface-enhanced laser desorption ionisation, as
 therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 production, and in vaccines or for replacement therapy. The
 polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 disorder associated with the expression of hGDMPLP-1, in particular heart
 and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 The present sequence represents an oligomer used in the screening of the
 hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 The sequence data for this patent did not form part of the printed
 specification, but was obtained in electronic format directly from WIPO
 at ftp.wipo.int/pub/published_pct_sequence
 Sequence 17 BP; 6 A; 3 C; 6 G; 2 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 491 AAGAGGCGAGGAGGAGC 506
 DB 1 AAGAGCGAGGAGGAGTC 16
 RESULT 967
 ABN00680/c
 ID ABN00680 standard; DNA; 17 BP.
 XX AC ABN00680;
 XX 29-MAY-2002 (first entry)
 XX Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:672.
 XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 XX skeletal muscle disorder; amplicon; screening; ss.
 XX Homo sapiens.
 XX WO200192524-A2.
 XX 06-DEC-2001.
 XX 25-MAY-2001; 2001WO-US016981.
 XX 26-MAY-2000; 2000US-0207456P.

21-SEP-2000; 2000US-0234687P.
 27-SEP-2000; 2000US-0236359P.
 04-OCT-2000; 2000GB-00024263.
 30-JAN-2001; 2001WO-US000661.
 30-JAN-2001; 2001WO-US000662.
 30-JAN-2001; 2001WO-US000663.
 30-JAN-2001; 2001WO-US000664.
 30-JAN-2001; 2001WO-US000665.
 30-JAN-2001; 2001WO-US000666.
 30-JAN-2001; 2001WO-US000667.
 30-JAN-2001; 2001WO-US000668.
 30-JAN-2001; 2001WO-US000669.
 30-JAN-2001; 2001WO-US000670.
 05-FEB-2001; 2001US-0266860P.
 (AEOM-) AEOMICA INC.
 Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 WPI; 2002-179446/23.
 New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 or as specific biomolecule capture probes for surface-enhanced laser
 desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 Disclosure; SEQ ID NO 672; 214pp; English.
 The present invention describes a human genome-derived myosin-like
 protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 nucleic acids can be used as probes to detect, characterise and quantify
 hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 provide initial substrates for the recombinant engineering of hGDMPLP-1
 protein variants having desired phenotypic improvements, and for
 expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 used as immunogens to raise antibodies that specifically recognise hGDMPLP
 -1 proteins, as standards in assays used to determine the concentration
 and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 capture probes for surface-enhanced laser desorption ionisation, as
 therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 production, and in vaccines or for replacement therapy. The
 polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 disorder associated with the expression of hGDMPLP-1, in particular heart
 and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 The present sequence represents an oligomer used in the screening of the
 hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 The sequence data for this patent did not form part of the printed
 specification, but was obtained in electronic format directly from WIPO
 at ftp.wipo.int/pub/published_pct_sequence
 Sequence 17 BP; 6 A; 5 C; 4 G; 2 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 233 GAAGAGTCTCTCTCTGG 248
 DB 17 GATGAGTCTCTCTCTGG 2
 RESULT 968
 ABN02004/c
 ID ABN02004 standard; DNA; 17 BP.
 XX AC ABN02004;
 XX 29-MAY-2002 (first entry)
 XX Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1996.
 XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;

KW skeletal muscle disorder; amplicon; screening; ss.
 XX Homo sapiens.
 XX WO200192524-A2.
 XX 06-DEC-2001.
 XX 25-MAY-2001; 2001WO-US016981.
 XX 26-MAY-2000; 2000US-0207456P.
 XX 21-SEP-2000; 2000US-0234687P.
 XX 27-SEP-2000; 2000US-0236359P.
 XX 04-OCT-2000; 2000GB-00024263.
 XX 30-JAN-2001; 2001WO-US000661.
 XX 30-JAN-2001; 2001WO-US000662.
 XX 30-JAN-2001; 2001WO-US000663.
 XX 30-JAN-2001; 2001WO-US000664.
 XX 30-JAN-2001; 2001WO-US000665.
 XX 30-JAN-2001; 2001WO-US000666.
 XX 30-JAN-2001; 2001WO-US000667.
 XX 30-JAN-2001; 2001WO-US000668.
 XX 30-JAN-2001; 2001WO-US000669.
 XX 05-FEB-2001; 2001US-0266860P.
 XX (AEOM-) AEOMICA INC.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 XX or as specific biomolecule capture probes for surface-enhanced laser
 XX desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX Disclosure; SEQ ID NO 1996; 214pp; English.
 XX The present invention describes a human genome-derived myosin-like
 XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 XX nucleic acids can be used as probes to detect, characterise and quantify
 XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 XX provide initial substrates for the recombinant engineering of hGDMPLP-1
 XX protein variants having desired phenotypic improvements, and for
 XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 XX used as immunogens to raise antibodies that specifically recognise hGDMPLP
 XX -1 proteins, as standards in assays used to determine the concentration
 XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 XX capture probes for surface-enhanced laser desorption ionisation, as
 XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 XX production, and in vaccines or for replacement therapy. The
 XX polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 XX disorder associated with the expression of hGDMPLP-1, in particular heart
 XX and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 XX The present sequence represents an oligomer used in the screening of the
 XX hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 XX The sequence data for this patent did not form part of the printed
 XX specification, but was obtained in electronic format directly from WIPO
 XX at ftp.wipo.int/pub/published_pct_sequence
 XX Sequence 17 BP; 2 A; 7 C; 3 G; 5 T; 0 U; 0 Other;
 XX Query Match 1.7%; Score 12.8; DB 1; Length 17;
 XX Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Qy 309 GCCTGGAGGAGCAATCA 324
 Db 17 GGCTGGAGGAGCAATCA 2
 RESULT 969

ABNO1729/c
 ID ABNO1729 standard; DNA; 17 BP.
 XX AC ABNO1729;
 XX 29-MAY-2002 (first entry)
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1721.
 XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX Homo sapiens.
 XX WO200192524-A2.
 XX 06-DEC-2001.
 XX 25-MAY-2001; 2001WO-US016981.
 XX 26-MAY-2000; 2000US-0207456P.
 XX 21-SEP-2000; 2000US-0234687P.
 XX 27-SEP-2000; 2000US-0236359P.
 XX 04-OCT-2000; 2000GB-00024263.
 XX 30-JAN-2001; 2001WO-US000661.
 XX 30-JAN-2001; 2001WO-US000662.
 XX 30-JAN-2001; 2001WO-US000663.
 XX 30-JAN-2001; 2001WO-US000664.
 XX 30-JAN-2001; 2001WO-US000665.
 XX 30-JAN-2001; 2001WO-US000666.
 XX 30-JAN-2001; 2001WO-US000667.
 XX 30-JAN-2001; 2001WO-US000668.
 XX 30-JAN-2001; 2001WO-US000669.
 XX 05-FEB-2001; 2001US-0266860P.
 XX (AEOM-) AEOMICA INC.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 XX or as specific biomolecule capture probes for surface-enhanced laser
 XX desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX Disclosure; SEQ ID NO 1721; 214pp; English.
 XX The present invention describes a human genome-derived myosin-like
 XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 XX nucleic acids can be used as probes to detect, characterise and quantify
 XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 XX provide initial substrates for the recombinant engineering of hGDMPLP-1
 XX protein variants having desired phenotypic improvements, and for
 XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 XX used as immunogens to raise antibodies that specifically recognise hGDMPLP
 XX -1 proteins, as standards in assays used to determine the concentration
 XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 XX capture probes for surface-enhanced laser desorption ionisation, as
 XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 XX production, and in vaccines or for replacement therapy. The
 XX polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 XX disorder associated with the expression of hGDMPLP-1, in particular heart
 XX and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 XX The present sequence represents an oligomer used in the screening of the
 XX hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 XX The sequence data for this patent did not form part of the printed
 XX specification, but was obtained in electronic format directly from WIPO
 XX at ftp.wipo.int/pub/published_pct_sequence
 XX Sequence 17 BP; 3 A; 4 C; 6 G; 4 T; 0 U; 0 Other;

```
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 392 TTCCAGCCAGCCAGCA 407
Db 16 TTCTGAGCCAGCCAGA 1

RESULT 970
ABN07686
ID ABN07686 standard; DNA; 17 BP.
XX
AC ABN07686;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7678.
XX
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 05-FEB-2001; 2001WO-US000670.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
PS Disclosure; SEQ ID NO 7678; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterize and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
```

```
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 9 A; 1 C; 6 G; 1 T; 0 U; 0 Other;

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 490 GAAGAGGCCAGAGGAG 505
Db 1 GAAGAGGCCAGAGGAG 16

RESULT 971
ABN08042
ID ABN08042 standard; DNA; 17 BP.
XX
AC ABN08042;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8034.
XX
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 05-FEB-2001; 2001WO-US000670.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
PS Disclosure; SEQ ID NO 8034; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
```

CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 4 A; 3 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 696 AGCTGGAGATCGAGCG 711

Db 1 AGCTGGAGATCGAGCG 16

RESULT 972

ABN07705/C

ID ABN07705 standard; DNA; 17 BP.

XX AC ABN07705;

XX 29-MAY-2002 (first entry)

DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7697.

XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.

XX Homo sapiens.

XX W0200192524-A2.

XX 06-DEC-2001.

XX 25-MAY-2001; 2001WO-US016981.

XX 26-MAY-2000; 2000US-0207456P.

XX 21-SEP-2000; 2000US-0234687P.

XX 27-SEP-2000; 2000US-0236359P.

XX 04-OCT-2000; 2000GB-00024263.

XX 30-JAN-2001; 2001WO-US000661.

XX 30-JAN-2001; 2001WO-US000662.

XX 30-JAN-2001; 2001WO-US000663.

XX 30-JAN-2001; 2001WO-US000664.

XX 30-JAN-2001; 2001WO-US000665.

XX 30-JAN-2001; 2001WO-US000666.

XX 30-JAN-2001; 2001WO-US000667.

XX 30-JAN-2001; 2001WO-US000668.

XX 30-JAN-2001; 2001WO-US000669.

XX 05-FEB-2001; 2001US-0266860P.

XX (AEOM-) AEOMICA INC.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;

XX

XX

DR WPI; 2002-179446/23.

XX

PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption/ionization, comprises human myosin-like protein hGDMPLP-1.

XX

PS Disclosure; SEQ ID NO 7697; 214pp; English.

XX

CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX

SQ Sequence 17 BP; 3 A; 7 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 7.2e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 828 TGGCCCGAGTTGCAGGT 843

Db 17 TGGCCCGAGTTGCAGGT 2

RESULT 973

ABN01531/C

ID ABN01531 standard; DNA; 17 BP.

XX AC ABN01531;

XX 29-MAY-2002 (first entry)

DE Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1523.

XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.

XX Homo sapiens.

XX W0200192524-A2.

XX 06-DEC-2001.

XX 25-MAY-2001; 2001WO-US016981.

XX 26-MAY-2000; 2000US-0207456P.

XX 21-SEP-2000; 2000US-0234687P.

XX 27-SEP-2000; 2000US-0236359P.

XX 04-OCT-2000; 2000GB-00024263.

XX 30-JAN-2001; 2001WO-US000661.

XX 30-JAN-2001; 2001WO-US000662.

XX 30-JAN-2001; 2001WO-US000663.

XX 30-JAN-2001; 2001WO-US000664.

XX

DE Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1720.
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX Homo sapiens.
XX WO200192524-A2.
XX 06-DEC-2001.
XX 25-MAY-2001; 2001WO-US016981.
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 05-FEB-2001; 2001US-0268680P.
XX (AEOM-) AEOMICA INC.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX Disclosure; SEQ ID NO 1720; 214pp; English.
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
XX nucleic acids can be used as probes to detect, characterise and quantify
XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMPLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMPLP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption/ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMPLP-1, in particular heart
XX and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence
XX Sequence 17 BP; 3 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
XX Query Match 1.7%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 7.2e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX 392 TTCTGAGCCAGCCAGA 407
XXX |||||

Db 17 TTCTGAGCCAGCCAGA 2
RESULT 976
ABNO2005/C
ID ABNO2005 standard; DNA; 17 BP.
XX AC ABNO2005;
XX 29-MAY-2002 (first entry)
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1997.
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX Homo sapiens.
XX WO200192524-A2.
XX 06-DEC-2001.
XX 25-MAY-2001; 2001WO-US016981.
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 05-FEB-2001; 2001US-0268680P.
XX (AEOM-) AEOMICA INC.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX Disclosure; SEQ ID NO 1997; 214pp; English.
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
XX nucleic acids can be used as probes to detect, characterise and quantify
XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMPLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMPLP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption/ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMPLP-1, in particular heart
XX and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence
XX Sequence 17 BP; 3 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
XX Query Match 1.7%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 7.2e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX 392 TTCTGAGCCAGCCAGA 407
XXX |||||

CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 2 A; 7 C; 3 G; 5 T; 0 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 309 GCGTGGAGGAGATCA 324
DB 16 GCGTGGAGGAGATCA 1
RESULT 977
ID ABN07820 standard; DNA; 17 BP.
XX
AC ABN07820;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7812.
XX
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
OS Homo sapiens.
XX
XX WO200192524-A2.
PN
PD 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX Disclosure; SEQ ID NO 7812; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP

CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 8 A; 2 C; 6 G; 1 T; 0 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 493 GAGGCAGAGGAGCAG 508
DB 2 GAAGCAAAAGGAGCAG 17
RESULT 978
ID ABN00362/C
XX
AC ABN00362;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:354.
XX
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
OS Homo sapiens.
XX
XX WO200192524-A2.
PN
PD 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX Disclosure; SEQ ID NO 7812; 214pp; English.

PS Disclosure; SEQ ID NO 354; 214pp; English.

XX The present invention describes a human genome-derived myosin-like

CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-

CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1

CC nucleic acids can be used as probes to detect, characterise and quantify

CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to

CC provide initial substrates for the recombinant engineering of hGDMPLP-1

CC protein variants having desired phenotypic improvements, and for

CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be

CC used as immunogens to raise antibodies that specifically recognise hGDMPLP

CC -1 proteins, as standards in assays used to determine the concentration

CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule

CC capture probes for surface-enhanced laser desorption/ionisation, as

CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1

CC production, and in vaccines or for replacement therapy. The

CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a

CC disorder associated with the expression of hGDMPLP-1, in particular heart

CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.

CC The present sequence represents an oligomer used in the screening of the

CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.

CC The sequence data for this patent did not form part of the printed

CC specification, but was obtained in electronic format directly from WIPO

CC at ftp.wipo.int/pub/published_pct_sequence

XX SQ Sequence 17 BP; 4 A; 7 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 7.2e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 482 CTCGATCTCGAGAGGC 497

Db 17 CTCGTTCTCGAGAGGC 2

RESULT 979

ABN06899/c

ID ABN06899 standard; DNA; 17 BP.

XX AC ABN06899;

XX DT 29-MAY-2002 (first entry)

XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6891.

XX KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;

XX KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;

XX KW skeletal muscle disorder; amplicon; screening; ss.

XX OS Homo sapiens.

XX PN WO200192524-A2.

XX PD 06-DEC-2001.

XX PF 25-MAY-2001; 2001WO-US016981.

XX PR 26-MAY-2000; 2000US-0207456P.

XX PR 27-SEP-2000; 2000US-0234687P.

XX PR 27-SEP-2000; 2000US-0236359P.

XX PR 04-OCT-2000; 2000GB-00024263.

XX PR 30-JAN-2001; 2001WO-US000661.

XX PR 30-JAN-2001; 2001WO-US000662.

XX PR 30-JAN-2001; 2001WO-US000663.

XX PR 30-JAN-2001; 2001WO-US000664.

XX PR 30-JAN-2001; 2001WO-US000665.

XX PR 30-JAN-2001; 2001WO-US000666.

XX PR 30-JAN-2001; 2001WO-US000667.

XX PR 30-JAN-2001; 2001WO-US000668.

XX PR 30-JAN-2001; 2001WO-US000669.

XX PR 05-FEB-2001; 2001US-0266860P.

XX PA (AEOM-) AEOMICA INC.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon MB;

XX WPI; 2002-179446/23.

XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,

XX or as specific biomolecule capture probes for surface-enhanced laser

XX desorption/ionization, comprises human myosin-like protein hGDMPLP-1.

XX Disclosure; SEQ ID NO 6891; 214pp; English.

XX The present invention describes a human genome-derived myosin-like

XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-

XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1

XX nucleic acids can be used as probes to detect, characterise and quantify

XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to

XX provide initial substrates for the recombinant engineering of hGDMPLP-1

XX protein variants having desired phenotypic improvements, and for

XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be

XX used as immunogens to raise antibodies that specifically recognise hGDMPLP

XX -1 proteins, as standards in assays used to determine the concentration

XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule

XX capture probes for surface-enhanced laser desorption/ionisation, as

XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1

XX production, and in vaccines or for replacement therapy. The

XX polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a

XX disorder associated with the expression of hGDMPLP-1, in particular heart

XX and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.

XX The present sequence represents an oligomer used in the screening of the

XX hGDMPLP-1 sequence in the exemplification of the present invention. N.B.

XX The sequence data for this patent did not form part of the printed

XX specification, but was obtained in electronic format directly from WIPO

XX at ftp.wipo.int/pub/published_pct_sequence

XX SQ Sequence 17 BP; 1 A; 6 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 7.2e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 306 GCTGCTCTGGAGAGAA 321

Db 16 GCCGCTCTGGAAGAA 1

RESULT 980

ABN07822

ID ABN07822 standard; DNA; 17 BP.

XX AC ABN07822;

XX DT 29-MAY-2002 (first entry)

XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7814.

XX KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;

XX KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;

XX KW skeletal muscle disorder; amplicon; screening; ss.

XX OS Homo sapiens.

XX PN WO200192524-A2.

XX PD 06-DEC-2001.

XX PF 25-MAY-2001; 2001WO-US016981.

XX PR 26-MAY-2000; 2000US-0207456P.

XX PR 21-SEP-2000; 2000US-0234687P.

XX PR 27-SEP-2000; 2000US-0236359P.

XX PR 04-OCT-2000; 2000GB-00024263.

PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX (AEOM-) AEOMICA INC.
 PA
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 PI
 XX WPI; 2002-179446/23.
 DR
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 PS Disclosure; SEQ ID NO 7814; 214pp; English.
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 9 A; 2 C; 6 G; 0 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 494 AGCAGAGAGGAGGAGG 509
 Db 1 AAGCAAAAGGAGGAGG 16
 RESULT 981
 ID ABO06830/c
 XX ABO06830 standard; DNA; 17 BP.
 AC ABO06830;
 XX
 DT 29-MAY-2002 (first entry)
 XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6822.
 DE
 XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX Homo sapiens.
 OS

XX WO200192524-A2.
 PN
 XX 06-DEC-2001.
 PD
 XX 25-MAY-2001; 2001WO-US016981.
 PF
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX (AEOM-) AEOMICA INC.
 PA
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 PI
 XX WPI; 2002-179446/23.
 DR
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 PS Disclosure; SEQ ID NO 6822; 214pp; English.
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 3 A; 3 C; 4 G; 7 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 267 ACCTGCTTCAGAACCA 282
 Db 17 ACCTGCTTCAGAAAA 2
 RESULT 982
 ABO63785/c
 XX ABO63785 standard; DNA; 17 BP.
 OS

AC	ABQ63785;	XX
XX		AC
DT	20-AUG-2002 (first entry)	XX
XX		DT
DE	Human KTOM1a portion (ABQ63232) probe # 498.	XX
XX		DE
KW	Human, KTOM1a; KTOM1; kidney tumor overexpressed membrane; cytostatic;	XX
KW	gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;	KW
KW	kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.	KW
XX		XX
OS	Homo sapiens.	OS
XX		XX
PN	WO200224750-A2.	PN
XX		XX
PD	28-MAR-2002.	PD
XX		XX
PF	21-SEP-2001; 2001WO-US029656.	XX
XX		XX
PR	21-SEP-2000; 2000US-0234687P.	PR
PR	27-SEP-2000; 2000US-0236359P.	PR
PR	04-OCT-2000; 2000GB-00024263.	PR
PR	30-JAN-2001; 2001WO-US000661.	PR
PR	30-JAN-2001; 2001WO-US000662.	PR
PR	30-JAN-2001; 2001WO-US000663.	PR
PR	30-JAN-2001; 2001WO-US000664.	PR
PR	30-JAN-2001; 2001WO-US000665.	PR
PR	30-JAN-2001; 2001WO-US000666.	PR
PR	30-JAN-2001; 2001WO-US000667.	PR
PR	30-JAN-2001; 2001WO-US000668.	PR
PR	30-JAN-2001; 2001WO-US000669.	PR
PR	30-JAN-2001; 2001WO-US000670.	PR
PR	23-MAY-2001; 2001US-00864761.	PR
PR	28-AUG-2001; 2001US-0315676P.	PR
XX		XX
PA	(AEOM-) AEOMICA INC.	PA
XX		XX
PI	Zhang J;	XX
XX		PI
XX	WPI; 2002-479509/51.	XX
DR		XX
XX	New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic	XX
PT	acids encoding the protein, useful for treating subjects having defects	PT
PT	in KTOM1 which can manifest as cancer of the kidney, or as a disorder of	PT
PT	e.g., liver or bone.	PT
XX		XX
XX	Example 2; Page 223; 418pp; English.	XX
PS		PS
CC	The invention relates to a novel isolated nucleic acid encoding human	CC
CC	KTOM1 (kidney tumor overexpressed membrane) protein. The protein of the	CC
CC	invention has cytostatic activity. The nucleotide may have a use in gene	CC
CC	therapy. The KTOM1 nucleic acids may be used to diagnose, treat or	CC
CC	monitor a disease caused by altered expression of human KTOM1.	CC
CC	Compositions comprising the nucleic acids, proteins or antibodies may be	CC
CC	used to treat subjects having defects in KTOM1 which can manifest as	CC
CC	cancer of the kidney, as well as a disorder of liver, bone marrow, brain,	CC
CC	heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta	CC
CC	function. The sequence represents a probe used in the invention to scan	CC
CC	the nt 1-1001 portion of human KTOM1a (ABQ63232)	CC
XX		XX
SQ	Sequence 17 BP; 3 A; 6 C; 5 G; 3 T; 0 U; 0 Other;	SQ
	Query Match 1.7%; Score 12.8; DB 1; Length 17;	
	Best Local Similarity 87.5%; Pred. No. 7.2e+02;	
	Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Oy	372 GCTCGAGGAGCTCTCT 387	Oy
Db	17 GCTGAGAGGAGCTCTCT 2	Db
RESULT 983		
ABQ63786/c		
ID	ABQ63786-standard; DNA; 17 BP.	

XX	ABQ63786;	XX
AC		AC
DT	20-AUG-2002 (first entry)	XX
XX		DT
DE	Human KTOM1a portion (ABQ63232) probe # 499.	XX
XX		DE
KW	Human, KTOM1a; KTOM1; kidney tumor overexpressed membrane; cytostatic;	XX
KW	gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;	KW
KW	kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.	KW
XX		XX
OS	Homo sapiens.	OS
XX		XX
PN	WO200224750-A2.	PN
XX		XX
PD	28-MAR-2002.	PD
XX		XX
PF	21-SEP-2001; 2001WO-US029656.	XX
XX		XX
PR	21-SEP-2000; 2000US-0234687P.	PR
PR	27-SEP-2000; 2000US-0236359P.	PR
PR	04-OCT-2000; 2000GB-00024263.	PR
PR	30-JAN-2001; 2001WO-US000661.	PR
PR	30-JAN-2001; 2001WO-US000662.	PR
PR	30-JAN-2001; 2001WO-US000663.	PR
PR	30-JAN-2001; 2001WO-US000664.	PR
PR	30-JAN-2001; 2001WO-US000665.	PR
PR	30-JAN-2001; 2001WO-US000666.	PR
PR	30-JAN-2001; 2001WO-US000667.	PR
PR	30-JAN-2001; 2001WO-US000668.	PR
PR	30-JAN-2001; 2001WO-US000669.	PR
PR	30-JAN-2001; 2001WO-US000670.	PR
PR	23-MAY-2001; 2001US-00864761.	PR
PR	28-AUG-2001; 2001US-0315676P.	PR
XX		XX
PA	(AEOM-) AEOMICA INC.	PA
XX		XX
PI	Zhang J;	XX
XX		PI
XX	WPI; 2002-479509/51.	XX
DR		XX
XX	New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic	XX
PT	acids encoding the protein, useful for treating subjects having defects	PT
PT	in KTOM1 which can manifest as cancer of the kidney, or as a disorder of	PT
PT	e.g., liver or bone.	PT
XX		XX
XX	Example 2; Page 223; 418pp; English.	XX
PS		PS
CC	The invention relates to a novel isolated nucleic acid encoding human	CC
CC	KTOM1 (kidney tumor overexpressed membrane) protein. The protein of the	CC
CC	invention has cytostatic activity. The nucleotide may have a use in gene	CC
CC	therapy. The KTOM1 nucleic acids may be used to diagnose, treat or	CC
CC	monitor a disease caused by altered expression of human KTOM1.	CC
CC	Compositions comprising the nucleic acids, proteins or antibodies may be	CC
CC	used to treat subjects having defects in KTOM1 which can manifest as	CC
CC	cancer of the kidney, as well as a disorder of liver, bone marrow, brain,	CC
CC	heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta	CC
CC	function. The sequence represents a probe used in the invention to scan	CC
CC	the nt 1-1001 portion of human KTOM1a (ABQ63232)	CC
XX		XX
SQ	Sequence 17 BP; 3 A; 7 C; 4 G; 3 T; 0 U; 0 Other;	SQ
	Query Match 1.7%; Score 12.8; DB 1; Length 17;	
	Best Local Similarity 87.5%; Pred. No. 7.2e+02;	
	Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Oy	372 GCTCGAGGAGCTCTCT 387	Oy
Db	16 GCTGAGAGGAGCTCTCT 1	Db
RESULT 984		
ABQ63786/c		
ID	ABK26264/c	

ID ABK26264 standard; DNA; 17 BP.
AC ABK26264;
XX
XX
XX 09-APR-2002 (first entry)
XX
XX Increased starch production genome altering oligonucleotide #116.
XX
XX Chromosomal genomic alteration; genome altering oligonucleotide; PCR; ss;
KW o-methyl modification; LNA modification; phosphorothioate linkage;
KW DNA repair; DNA alteration; environmental tolerance; hygromycin-B;
KW abiotic stress tolerance; improved nutritional value; hygromycin-B;
KW amino acid over production; herbicide resistance; glyphosate resistance;
KW imidazolinone herbicide resistance; sulphonylurea herbicide resistance;
KW porphyrin herbicide resistance; triazine resistance; disease resistance;
KW modified oil production; modified starch production; waxy starch;
KW altered floral morphology; male-sterile plant; albino mutant;
KW modified fatty acid content; reduced palmitate production; albino plant;
KW increased stearate production; reduced linolenic acid production;
KW photosynthetic process.
XX
XX Oryza sativa.
OS Synthetic.
XX
XX WO200192512-A2.
XX
XX 06-DEC-2001.
XX
XX 01-JUN-2001; 2001WO-US017672.
XX
XX 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
PR 27-MAR-2001; 2001US-00818875.
XX
XX (UYDE) UNIV DELAWARE.
XX
XX Kmiec EB, Gamper HB, Rice MC, Kim J;
PI WPI; 2002-106307/14.
DR
XX
XX New oligonucleotides with modified nuclease-resistant termini, useful for
PT creating plants with desired phenotypes, e.g. stress tolerance, improved
PT nutritional value, herbicide or disease resistance, or modified oil
PT production.
XX
XX Claim 7; Page 141; 220pp; English.
XX
XX The invention relates to an oligonucleotide for targeted alteration of a
CC genetic sequence, which comprises a single-stranded oligonucleotide
CC having a DNA domain. The DNA domain has at least one mismatch with
CC respect to the genetic sequence to be altered and further comprises
CC chemical modifications of the oligonucleotide. The chemical modifications
CC consist of o-methyl modification, an LNA modification, two or more
CC phosphorothioate linkages on a terminus, or a combination of any two or
CC more of these modifications. The oligonucleotides are useful for
CC directing repair or alteration of plant genetic information. The
CC oligonucleotides are particularly useful for creating plants with desired
CC phenotypes, e.g. environmental or abiotic stress tolerance, improved
CC nutritional value (e.g. altering amino acid content of plants or
CC conferring amino acid over production), herbicide resistance (e.g.
CC glyphosate resistance, imidazolinone and sulphonylurea herbicide
CC resistance, porphyrin herbicide resistance or triazine resistance),
CC disease resistance, modified oil production, modified starch production
CC (e.g. increased starch or production of waxy starch), altered floral
CC morphology (e.g. male-sterile plants) or modified fatty acid content
CC (e.g. reduced palmitate, increased stearate or reduced linolenic acid).
CC The oligonucleotides are also useful for producing albino mutants for the
CC analysis of photosynthetic processes. This sequence represents a genome
CC altering oligonucleotide of the invention
XX
SQ Sequence 17 BP; 3 A; 7 C; 2 G; 5 T; 0 U; 0 Other;

Query Match

1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 409 GGAGGAGAGGAGTTC 424
||||| |||||||
DB 16 GGAGGAGAGGAGTTC 1

RESULT 985
ABK26263
ID ABK26263 standard; DNA; 17 BP.
XX
XX AC ABK26263;
XX
XX 09-APR-2002 (first entry)
DT
DE Increased starch production genome altering oligonucleotide #115.
XX
XX Chromosomal genomic alteration; genome altering oligonucleotide; PCR; ss;
KW o-methyl modification; LNA modification; phosphorothioate linkage;
KW DNA repair; DNA alteration; environmental tolerance; hygromycin-B;
KW abiotic stress tolerance; improved nutritional value; hygromycin-B;
KW amino acid over production; herbicide resistance; glyphosate resistance;
KW imidazolinone herbicide resistance; sulphonylurea herbicide resistance;
KW porphyrin herbicide resistance; triazine resistance; disease resistance;
KW modified oil production; modified starch production; waxy starch;
KW altered floral morphology; male-sterile plant; albino mutant;
KW modified fatty acid content; reduced palmitate production; albino plant;
KW increased stearate production; reduced linolenic acid production;
KW photosynthetic process.
XX
XX Oryza sativa.
OS Synthetic.
XX
XX WO200192512-A2.
XX
XX 06-DEC-2001.
XX
XX 01-JUN-2001; 2001WO-US017672.
XX
XX 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
PR 27-MAR-2001; 2001US-00818875.
XX
XX (UYDE) UNIV DELAWARE.
XX
XX Kmiec EB, Gamper HB, Rice MC, Kim J;
PI WPI; 2002-106307/14.
DR
XX
XX New oligonucleotides with modified nuclease-resistant termini, useful for
PT creating plants with desired phenotypes, e.g. stress tolerance, improved
PT nutritional value, herbicide or disease resistance, or modified oil
PT production.
XX
XX Claim 7; Page 141; 220pp; English.
XX
XX The invention relates to an oligonucleotide for targeted alteration of a
CC genetic sequence, which comprises a single-stranded oligonucleotide
CC having a DNA domain. The DNA domain has at least one mismatch with
CC respect to the genetic sequence to be altered and further comprises
CC chemical modifications of the oligonucleotide. The chemical modifications
CC consist of o-methyl modification, an LNA modification, two or more
CC phosphorothioate linkages on a terminus, or a combination of any two or
CC more of these modifications. The oligonucleotides are useful for
CC directing repair or alteration of plant genetic information. The
CC oligonucleotides are particularly useful for creating plants with desired
CC phenotypes, e.g. environmental or abiotic stress tolerance, improved
CC nutritional value (e.g. altering amino acid content of plants or
CC conferring amino acid over production), herbicide resistance (e.g.
CC glyphosate resistance, imidazolinone and sulphonylurea herbicide
CC resistance, porphyrin herbicide resistance or triazine resistance),
CC disease resistance, modified oil production, modified starch production

CC (e.g. increased starch or production of waxy starch), altered floral
 CC morphology (e.g. male-sterile plants) or modified fatty acid content
 CC (e.g. reduced palmitate, increased stearate or reduced linolenic acid).
 CC The oligonucleotides are also useful for producing albino mutants for the
 CC analysis of photosynthetic processes. This sequence represents a genome
 CC altering oligonucleotide of the invention

XX Sequence 17 BP; 5 A; 2 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 7.2e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 409 GGAGGAGAGGAGTTC 424

DB 2 GGAGGCAAGGAGTTC 17

RESULT 986

ABK19193

ID ABK19193 standard; RNA; 17 BP.

XX AC ABK19193;

XX 09-APR-2002 (first entry)

DE Human ERG Amberzyme target sequence Seq ID No 1840.

XX Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
 KW Ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
 KW vulnarary; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
 KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
 KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
 KW angiofibroma of tuberous sclerosis; port-wine stain; wound healing;
 KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
 KW Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNazyme; inozyme;

XX Homo sapiens.

PN WO200188124-A2.

XX 22-NOV-2001.

XX 16-MAY-2001; 2001WO-US015866.

XX 16-MAY-2000; 2000US-00572021.

XX (RIBO-) RIBOZYME PHARM INC.

XX (GLAX) GLAXO GROUP LTD.

XX Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM;

XX WPI; 2002-082995/11.

XX Novel polynucleotide which down regulates expression of Ets-related gene,
 PT useful for treating cancer, diabetic retinopathy, macular degeneration,
 PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.

XX Claim 4; Page 122; 149pp; English.

XX The invention relates to a nucleic acid molecule (I) which down regulates
 CC expression of an Ets-related gene (ERG). (I) is useful for treating
 CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
 CC tumour angiogenesis, diabetic retinopathy, macular degeneration,
 CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
 CC vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge
 CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
 CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
 CC treating a patient having a condition associated with the level of ERG,
 CC by contacting cells of the patient with (I) under conditions suitable for
 CC the treatment. The method comprises the use of one or more therapies
 CC under conditions suitable for the treatment. Leukaemia or tumour

CC angiogenesis is treated by administering (I) to the patient in
 CC conjunction with one or more of other therapies such as radiation or
 CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
 CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
 CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
 CC cation such as Mg2+. (I) is useful for diagnosis of conditions and
 CC diseases related to the expression of ERG, and as diagnostic tool to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of ERG RNA in a cell. (I) is useful for specifically
 CC targeting genes that share homology with ERG gene or ERG fusion genes.
 CC ASK17354-ABK22719 represent nucleic acids, including antisense and
 CC enzymatic nucleic acid molecules which regulate expression of ERG, and
 CC related PCR primers of the invention

XX SQ Sequence 17 BP; 6 A; 2 C; 7 G; 0 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 75.0%; Pred. No. 7.2e+02;

Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 306 GCTGCTGGAGGAGAA 321

DB 1 GCUCAUGGAGGAGAA 16

RESULT 987

ABK18809/c

ID ABK18809 standard; RNA; 17 BP.

XX AC ABK18809;

XX 09-APR-2002 (first entry)

DE Human ERG DNazyme target sequence Seq ID No 1456.

XX Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
 KW Ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
 KW vulnarary; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
 KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
 KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
 KW angiofibroma of tuberous sclerosis; port-wine stain; wound healing;
 KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
 KW Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNazyme; inozyme;

XX Homo sapiens.

PN WO200188124-A2.

XX 22-NOV-2001.

XX 16-MAY-2001; 2001WO-US015866.

XX 16-MAY-2000; 2000US-00572021.

XX (RIBO-) RIBOZYME PHARM INC.

XX (GLAX) GLAXO GROUP LTD.

XX Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM;

XX WPI; 2002-082995/11.

XX Novel polynucleotide which down regulates expression of Ets-related gene,
 PT useful for treating cancer, diabetic retinopathy, macular degeneration,
 PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.

XX Claim 4; Page 92; 149pp; English.

XX The invention relates to a nucleic acid molecule (I) which down regulates
 CC expression of an Ets-related gene (ERG). (I) is useful for treating
 CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
 CC tumour angiogenesis, diabetic retinopathy, macular degeneration,
 CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca

CC vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge
 CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Oslar-Weber-rendu
 CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
 CC treating a patient having a condition associated with the level of ERG,
 CC by contacting cells of the patient with (I) under conditions suitable for
 CC the treatment. The method comprises the use of one or more therapies
 CC under conditions suitable for the treatment. Leukaemia or tumour
 CC angiogenesis is treated by administering (I) to the patient in
 CC conjunction with one or more of other therapies such as radiation or
 CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
 CC cell, by contacting the cell with RNA. (I) is useful for cleaving RNA of
 CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
 CC cation such as Mg²⁺. (I) is useful for diagnosis of conditions and
 CC diseases related to the expression of ERG, and as diagnostic tool to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of ERG RNA in a cell. (I) is useful for specifically
 CC targeting genes that share homology with ERG gene or ERG fusion genes.
 CC ABK17354-ABK22719 represent nucleic acids, including antisense and
 CC enzymatic nucleic acid molecules which regulate expression of ERG, and
 CC related PCR primers of the invention
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 8 G; 0 T; 1 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 796 GCGCCAGGCGCCTCG 811
 DB 17 GCGCCGCGCACCTCG 2
 RESULT 988
 ABK19192
 ID ABK19192 standard; RNA; 17 BP.
 XX
 AC ABK19192;
 DT
 DT 09-APR-2002 (first entry)
 DE Human ERG Amberzyme target sequence Seq ID No 1839.
 XX Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
 KW ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
 KW vulnary; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
 KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
 KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
 KW angiofibroma of tuberous sclerosis; port-wine stain; wound healing;
 KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
 KW Oslar-Weber-rendu syndrome, leukaemia; osteoporosis; DNAzyme; inozyme;
 KW amberzyme.
 XX Homo sapiens.
 XX WO200188124-A2.
 XX 22-NOV-2001.
 XX 16-MAY-2001; 2001WO-US015866.
 XX 16-MAY-2000; 2000US-00572021.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX (GLAX) GLAXO GROUP LTD.
 XX
 PI Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM;
 XX WPI; 2002-082995/11.
 XX Novel polynucleotide which down regulates expression of Ets-related gene,
 PT useful for treating cancer, diabetic retinopathy, macular degeneration,
 PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.
 XX

PS Claim 4; Page 122; 149pp; English.
 XX The invention relates to a nucleic acid molecule (I) which down regulates
 CC expression of an Ets-related gene (ERG). (I) is useful for treating
 CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
 CC tumour angiogenesis, diabetic retinopathy, macular degeneration, verruca
 CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, Sturge
 CC vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge
 CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Oslar-Weber-rendu
 CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
 CC treating a patient having a condition associated with the level of ERG,
 CC by contacting cells of the patient with (I) under conditions suitable for
 CC the treatment. The method comprises the use of one or more therapies
 CC under conditions suitable for the treatment. Leukaemia or tumour
 CC angiogenesis is treated by administering (I) to the patient in
 CC conjunction with one or more of other therapies such as radiation or
 CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
 CC cell, by contacting the cell with RNA. (I) is useful for cleaving RNA of
 CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
 CC cation such as Mg²⁺. (I) is useful for diagnosis of conditions and
 CC diseases related to the expression of ERG, and as diagnostic tool to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of ERG RNA in a cell. (I) is useful for specifically
 CC targeting genes that share homology with ERG gene or ERG fusion genes.
 CC ABK17354-ABK22719 represent nucleic acids, including antisense and
 CC enzymatic nucleic acid molecules which regulate expression of ERG, and
 CC related PCR primers of the invention
 XX
 SQ Sequence 17 BP; 7 A; 2 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 75.0%; Pred. No. 7.2e+02;
 Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
 OY 306 GCTGCTCGAGGAGAA 321
 DB 2 GCUACAGGAGGAGAA 17
 RESULT 989
 ABK18232
 ID ABK18232 standard; RNA; 17 BP.
 XX
 AC ABK18232;
 XX
 DT 09-APR-2002 (first entry)
 XX Human ERG hammerhead ribozyme target sequence, Seq ID No 879.
 DE Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
 KW ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
 KW vulnary; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
 KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
 KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
 KW angiofibroma of tuberous sclerosis; port-wine stain; wound healing;
 KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
 KW Oslar-Weber-rendu syndrome, leukaemia; osteoporosis; DNAzyme; inozyme;
 KW amberzyme.
 XX Homo sapiens.
 OS
 XX WO200188124-A2.
 XX 22-NOV-2001.
 XX 16-MAY-2001; 2001WO-US015866.
 XX 16-MAY-2000; 2000US-00572021.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX (GLAX) GLAXO GROUP LTD.
 XX
 PI Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM;

```

XX DR WPI; 2002-082995/11.
XX PR
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PA (GLAX ) GLAXO GROUP LTD.
XX PI Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM;
XX PI WPI; 2002-082995/11.
XX DR
XX PT Novel polynucleotide which down regulates expression of Ets-related gene,
XX PT useful for treating cancer, diabetic retinopathy, macular degeneration,
XX PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.
XX PS Claim 4; Page 74; 149pp; English.
XX CC The invention relates to a nucleic acid molecule (I) which down regulates
XX CC expression of an Ets-related gene (ERG). (I) is useful for treating
XX CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
XX CC tumour angiogenesis, diabetic retinopathy, macular degeneration,
XX CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
XX CC vulgaris, angiofibroma of tuberosus sclerosis, port-wine stains, Sturge
XX CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
XX CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
XX CC treating a patient having a condition associated with the level of ERG,
XX CC by contacting cells of the patient with (I) under conditions suitable for
XX CC the treatment. The method comprises the use of one or more therapies
XX CC under conditions suitable for the treatment. Leukaemia or tumour
XX CC angiogenesis is treated by administering (I) to the patient in
XX CC conjunction with one or more of other therapies such as radiation or
XX CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
XX CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
XX CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
XX CC cation such as Mg2+. (I) is useful for diagnosis of conditions and
XX CC diseases related to the expression of ERG, and as diagnostic tool to
XX CC examine genetic drift and mutations within diseased cells or to detect
XX CC the presence of ERG RNA in a cell. (I) is useful for specifically
XX CC targeting genes that share homology with ERG gene or ERG fusion genes.
XX CC ABK17354-ABK22719 represent nucleic acids, including antisense and
XX CC enzymatic nucleic acid molecules which regulate expression of ERG, and
XX CC related PCR primers of the invention
XX SQ Sequence 17 BP; 2 A; 12 C; 1 G; 0 T; 2 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.2e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
Oy 296 ACCCTCCAGCGCTGCC 311
Db 2 ACCCTCCAGCGCTGCC 17
||||:|||||:|
|:|:|:|:|:|:|:|

RESULT 990
ABK18227/c
ID ABK18227 standard; RNA; 17 BP.
XX AC ABK18227;
XX DT 09-APR-2002 (first entry)
XX DE Human ERG hammerhead ribozyme target sequence, Seq ID No 874.
XX KW Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
XX KW ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
XX KW vulnery; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
XX KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
XX KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
XX KW angiofibroma of tuberosus sclerosis; port-wine stain; wound healing;
XX KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
XX KW Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNzyme; inozyme;
XX KW amberzyme.
XX OS Homo sapiens.
XX PN WO200188124-A2.
XX PD 22-NOV-2001.
XX PF 16-MAY-2001; 2001WO-US015866.

```

```

XX PR 16-MAY-2000; 2000US-00572021.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PA (GLAX ) GLAXO GROUP LTD.
XX PI Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM;
XX PI WPI; 2002-082995/11.
XX DR
XX PT Novel polynucleotide which down regulates expression of Ets-related gene,
XX PT useful for treating cancer, diabetic retinopathy, macular degeneration,
XX PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.
XX PS Claim 4; Page 74; 149pp; English.
XX CC The invention relates to a nucleic acid molecule (I) which down regulates
XX CC expression of an Ets-related gene (ERG). (I) is useful for treating
XX CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
XX CC tumour angiogenesis, diabetic retinopathy, macular degeneration,
XX CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, Sturge
XX CC vulgaris, angiofibroma of tuberosus sclerosis, port-wine stains, Sturge
XX CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
XX CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
XX CC treating a patient having a condition associated with the level of ERG,
XX CC by contacting cells of the patient with (I) under conditions suitable for
XX CC the treatment. The method comprises the use of one or more therapies
XX CC under conditions suitable for the treatment. Leukaemia or tumour
XX CC angiogenesis is treated by administering (I) to the patient in
XX CC conjunction with one or more of other therapies such as radiation or
XX CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
XX CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
XX CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
XX CC cation such as Mg2+. (I) is useful for diagnosis of conditions and
XX CC diseases related to the expression of ERG, and as diagnostic tool to
XX CC examine genetic drift and mutations within diseased cells or to detect
XX CC the presence of ERG RNA in a cell. (I) is useful for specifically
XX CC targeting genes that share homology with ERG gene or ERG fusion genes.
XX CC ABK17354-ABK22719 represent nucleic acids, including antisense and
XX CC enzymatic nucleic acid molecules which regulate expression of ERG, and
XX CC related PCR primers of the invention
XX SQ Sequence 17 BP; 2 A; 10 C; 4 G; 0 T; 1 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 656 CTGGAGGGTGGGGCC 671
Db 17 CTGGAGGGTGGGGCGC 2
||||:|||||:|
|:|:|:|:|:|:|:|

RESULT 991
ABK18149/c
ID ABK18149 standard; RNA; 17 BP.
XX AC ABK18149;
XX DT 09-APR-2002 (first entry)
XX DE Human ERG hammerhead ribozyme target sequence, Seq ID No 796.
XX KW Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
XX KW ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
XX KW vulnery; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
XX KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
XX KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
XX KW angiofibroma of tuberosus sclerosis; port-wine stain; wound healing;
XX KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
XX KW Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNzyme; inozyme;
XX KW amberzyme.

```

OS Homo sapiens.
 PN WO200188124-A2.
 XX
 XX
 PD 22-NOV-2001.
 XX
 PF 16-MAY-2001; 2001WO-US015866.
 XX
 PR 16-MAY-2000; 2000US-00572021.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (GLAX) GLAXO GROUP LTD.
 XX
 XX Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM;
 XX WPI; 2002-082995/11.
 DR
 XX Novel polynucleotide which down regulates expression of Ets-related gene,
 PT useful for treating cancer, diabetic retinopathy, macular degeneration,
 PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.
 XX
 PS Claim 4; Page 73; 149pp; English.
 XX
 CC The invention relates to a nucleic acid molecule (I) which down regulates
 CC expression of an Ets-related gene (ERG). (I) is useful for treating
 CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
 CC tumour angiogenesis, diabetic retinopathy, macular degeneration,
 CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
 CC vulgaris, angiobroma of tuberosus sclerosis, port-wine stains, Sturge
 CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
 CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
 CC treating a patient having a condition associated with the level of ERG,
 CC by contacting cells of the patient with (I) under conditions suitable for
 CC the treatment. The method comprises the use of one or more therapies
 CC under conditions suitable for the treatment. Leukaemia or tumour
 CC angiogenesis is treated by administering (I) to the patient in
 CC conjunction with one or more of other therapies such as radiation or
 CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
 CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
 CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
 CC cation such as Mg2+. (I) is useful for diagnosis of conditions and
 CC diseases related to the expression of ERG, and as diagnostic tool to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of ERG RNA in a cell. (I) is useful for specifically
 CC targeting genes that share homology with ERG gene or ERG fusion genes.
 CC ABK17354-ABK22719 represent nucleic acids, including antisense and
 CC enzymatic nucleic acid molecules which regulate expression of ERG, and
 CC related PCR primers of the invention
 XX
 SQ Sequence 17 BP; 1 A; 5 C; 9 G; 0 T; 2 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02; Indels 0; Gaps 0;
 Matches 14; Conservative 0; Mismatches 2; Mismatches 2; Indels 0; Gaps 0;
 QY 795 AGCGCCAGCGCGCTC 810
 DB 16 AGCGCCGGCCACCTC 1
 RESULT 992
 ID ABK18826
 XX ABK18826 standard; RNA; 17 BP.
 AC ABK18826;
 XX
 XX 09-APR-2002 (first entry)
 DT Human ERG DNAzyme target sequence Seq ID No 1473.
 DE
 XX Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
 KW ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
 KW vulnarary; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;

KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
 KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
 KW angiobroma of tuberosus sclerosis; port-wine stain; wound healing;
 KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
 KW Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNAzyme; inozyme;
 KW amberzyme.
 XX
 OS Homo sapiens.
 XX
 PN WO200188124-A2.
 XX
 XX 22-NOV-2001.
 PD
 PF 16-MAY-2001; 2001WO-US015866.
 XX
 PR 16-MAY-2000; 2000US-00572021.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (GLAX) GLAXO GROUP LTD.
 XX
 XX Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM;
 XX WPI; 2002-082995/11.
 DR
 XX Novel polynucleotide which down regulates expression of Ets-related gene,
 PT useful for treating cancer, diabetic retinopathy, macular degeneration,
 PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.
 XX
 PS Claim 4; Page 92; 149pp; English.
 XX
 CC The invention relates to a nucleic acid molecule (I) which down regulates
 CC expression of an Ets-related gene (ERG). (I) is useful for treating
 CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
 CC tumour angiogenesis, diabetic retinopathy, macular degeneration,
 CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
 CC vulgaris, angiobroma of tuberosus sclerosis, port-wine stains, Sturge
 CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
 CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
 CC treating a patient having a condition associated with the level of ERG,
 CC by contacting cells of the patient with (I) under conditions suitable for
 CC the treatment. The method comprises the use of one or more therapies
 CC under conditions suitable for the treatment. Leukaemia or tumour
 CC angiogenesis is treated by administering (I) to the patient in
 CC conjunction with one or more of other therapies such as radiation or
 CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
 CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
 CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
 CC cation such as Mg2+. (I) is useful for diagnosis of conditions and
 CC diseases related to the expression of ERG, and as diagnostic tool to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of ERG RNA in a cell. (I) is useful for specifically
 CC targeting genes that share homology with ERG gene or ERG fusion genes.
 CC ABK17354-ABK22719 represent nucleic acids, including antisense and
 CC enzymatic nucleic acid molecules which regulate expression of ERG, and
 CC related PCR primers of the invention
 XX
 SQ Sequence 17 BP; 2 A; 12 C; 1 G; 0 T; 2 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 75.0%; Pred. No. 7.2e+02; Indels 0; Gaps 0;
 Matches 12; Conservative 2; Mismatches 2; Mismatches 2; Indels 0; Gaps 0;
 QY 296 ACCCTCCAGCGCTGCC 311
 DB 1 ACCCUCCAGCCUCC 16
 RESULT 993
 ID ABV90334
 XX ABV90334 standard; DNA; 17 BP.
 AC ABV90334;
 XX


```

DT 23-DEC-2002 (first entry)
XX Human POSHL1 scanning oligonucleotide SEQ ID NO 1047.
DE
XX
XX Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
OS Homo sapiens.
XX
PN EPI239051-A2.
XX
XX 11-SEP-2002.
XX
XX 28-JAN-2002; 2002EP-00001165.
XX
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 10-OCT-2001; 2001US-0328205P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Shannon M;
XX
XX WPI; 2002-684061/74.
XX
XX Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
PT -1, useful for treating disorders associated with decreased expression or
PT activity of human POSHL1.
XX
PS Example 2; SEQ ID NO 1047; 60pp + Sequence Listing; English.
XX
XX The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC acids (SI, AB83999), a sequence having 65% sequence identity to (SI),
CC (SI) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC caused by altered expression of human POSHL1 including diagnosing and
CC treating cancer, they useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention. Note: The present sequence did not form part of the
CC printed specification, but is based on sequence information supplied to
CC Derwent by the European Patent Office
XX
XX Sequence 17 BP; 4 A; 7 C; 3 G; 3 T; 0 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. NO. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 253 GCCAGCCATGCTGCAC 268
DB 1 GCCAGTCATCTGCAC 16
RESULT 994
ABV89595
ID ABV89595 standard; DNA; 17 BP.

```

```

XX AC ABV89595;
XX
XX 23-DEC-2002 (first entry)
XX
XX Human POSHL1 scanning oligonucleotide SEQ ID NO 308.
DE
XX
XX Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
OS Homo sapiens.
XX
PN EPI239051-A2.
XX
XX 11-SEP-2002.
XX
XX 28-JAN-2002; 2002EP-00001165.
XX
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 23-MAY-2001; 2001US-00864761.
XX 10-OCT-2001; 2001US-0328205P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Shannon M;
XX
XX WPI; 2002-684061/74.
XX
XX Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
PT -1, useful for treating disorders associated with decreased expression or
PT activity of human POSHL1.
XX
PS Example 2; SEQ ID NO 308; 60pp + Sequence Listing; English.
XX
XX The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC acids (SI, AB83999), a sequence having 65% sequence identity to (SI),
CC (SI) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC caused by altered expression of human POSHL1 including diagnosing and
CC treating cancer, they useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention. Note: The present sequence did not form part of the
CC printed specification, but is based on sequence information supplied to
CC Derwent by the European Patent Office
XX
XX Sequence 17 BP; 5 A; 4 C; 5 G; 3 T; 0 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. NO. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 476 GAGAGCTCGATCTGA 491
DB 1 GAGAGCTCGATGTCA 16

```

```

RESULT 995
ABV89594
ID ABV89594 standard; DNA; 17 BP.
AC ABV89594;
XX
XX
XX 23-DEC-2002 (first entry)
XX Human POSHL1 scanning oligonucleotide SEQ ID NO 307.
XX
XX Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
XX Homo sapiens.
XX EP1239051-A2.
XX
XX 11-SEP-2002.
XX
XX 28-JAN-2002; 2002EP-00001165.
XX
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 23-MAY-2001; 2001US-00864761.
XX 10-OCT-2001; 2001US-0328205P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Shannon M;
XX WPI; 2002-684061/74.
XX
XX Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
PT -1, useful for treating disorders associated with decreased expression or
PT activity of human POSHL1.
XX
XX Example 2; SEQ ID NO 307; 60pp + Sequence Listing; English.
XX
XX The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC acids (S1, AB83999), a sequence having 65% sequence identity to (S1),
CC (S1) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoded by altered expression of human POSHL1 including diagnosing and
CC treating cancer, they useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention. Note: The present sequence did not form part of the
CC printed specification, but is based on sequence information supplied to
CC Derwent by the European Patent Office
XX
XX Sequence 17 BP; 5 A; 3 C; 5 G; 4 T; 0 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

RESULT 996
ABV89339
ID ABV89339 standard; DNA; 17 BP.
AC ABV89339;
XX
XX 23-DEC-2002 (first entry)
XX Human POSHL1 scanning oligonucleotide SEQ ID NO 52.
XX
XX Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
XX Homo sapiens.
XX EP1239051-A2.
XX
XX 11-SEP-2002.
XX
XX 28-JAN-2002; 2002EP-00001165.
XX
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 23-MAY-2001; 2001US-00864761.
XX 10-OCT-2001; 2001US-0328205P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Shannon M;
XX WPI; 2002-684061/74.
XX
XX Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
PT -1, useful for treating disorders associated with decreased expression or
PT activity of human POSHL1.
XX
XX Example 2; SEQ ID NO 52; 60pp + Sequence Listing; English.
XX
XX The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC acids (S1, AB83999), a sequence having 65% sequence identity to (S1),
CC (S1) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoded by altered expression of human POSHL1 including diagnosing and
CC treating cancer, they useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention. Note: The present sequence did not form part of the
CC printed specification, but is based on sequence information supplied to
CC Derwent by the European Patent Office
XX
XX Sequence 17 BP; 3 A; 4 C; 8 G; 2 T; 0 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

QY 617 CAGAGTCGCTGGAGG 632
 DB 1 CAGCGCGCTGGAGG 16
 RESULT 997
 ID ABV90333 standard; DNA, 17 BP.
 AC ABV90333;
 XX 23-DEC-2002 (first entry)
 DT Human POSHL1 scanning oligonucleotide SEQ ID NO 1046.
 DE Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
 KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
 KW gene therapy; transgenic; ss.
 XX Homo sapiens.
 OS
 XX EPI239051-A2.
 PN 11-SEP-2002.
 PD 28-JAN-2002; 2002EP-00001165.
 XX 30-JAN-2001; 2001WO-US0000663.
 PR 30-JAN-2001; 2001WO-US0000664.
 PR 30-JAN-2001; 2001WO-US0000665.
 PR 30-JAN-2001; 2001WO-US0000666.
 PR 30-JAN-2001; 2001WO-US0000667.
 PR 30-JAN-2001; 2001WO-US0000668.
 PR 30-JAN-2001; 2001WO-US0000669.
 PR 30-JAN-2001; 2001WO-US0000670.
 PR 23-MAY-2001; 2001US-00864761.
 PR 10-OCT-2001; 2001US-0328205P.
 XX (AEOM-) AEOMICA INC.
 XX Shannon M;
 PI WPI; 2002-684061/74.
 XX Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide, POSHL
 PT -1, useful for treating disorders associated with decreased expression or
 PT activity of human POSHL1.
 PS Example 2; SEQ ID NO 1046; 60pp + Sequence Listing; English.
 XX The invention relates to an isolated SH3 domain (POSH)-like signalling
 CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
 CC acids (SI, ABB83999), a sequence having 65% sequence identity to (SI),
 CC (SI) having 95% deviations, especially conservative substitutions or a
 CC fragment of the sequences comprising at least 8 contiguous amino acids.
 CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
 CC adaptor protein that interacts with Rho family small GTPases as well as
 CC downstream components of the signal transduction pathway. (I) is useful
 CC for identifying a specific binding partner. (I) and nucleic acids (II)
 CC encoding (I) are useful for diagnosing, monitoring disease and treating
 CC caused by altered expression of human POSHL1 including diagnosing and
 CC treating cancer, they useful in the development of vaccines and (II) is
 CC useful in gene therapy. (II) is useful for constructing microarrays which
 CC are useful for measuring and for surveying gene expression and creating
 CC transgenic non-human animals capable of producing the proteins. The
 CC present sequence is that of a scanning oligonucleotide useful in examples
 CC of the invention. Note: The present sequence did not form part of the
 CC printed specification, but is based on sequence information supplied to
 CC Derwent by the European Patent Office
 XX Sequence 17 BP; 3 A; 8 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. NO. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 253 GCCAGCCTGCTGCAC 268
 DB 2 GCCAGTCATCTGCAC 17
 RESULT 998
 ABV89591
 ID ABV89591 standard; DNA, 17 BP.
 XX ABV89591;
 AC 23-DEC-2002 (first entry)
 DT Human POSHL1 scanning oligonucleotide SEQ ID NO 304.
 DE Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
 KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
 KW gene therapy; transgenic; ss.
 XX Homo sapiens.
 OS
 XX EPI239051-A2.
 PN 11-SEP-2002.
 PD 28-JAN-2002; 2002EP-00001165.
 XX 30-JAN-2001; 2001WO-US0000663.
 PR 30-JAN-2001; 2001WO-US0000664.
 PR 30-JAN-2001; 2001WO-US0000665.
 PR 30-JAN-2001; 2001WO-US0000666.
 PR 30-JAN-2001; 2001WO-US0000667.
 PR 30-JAN-2001; 2001WO-US0000668.
 PR 30-JAN-2001; 2001WO-US0000669.
 PR 30-JAN-2001; 2001WO-US0000670.
 PR 23-MAY-2001; 2001US-00864761.
 PR 10-OCT-2001; 2001US-0328205P.
 XX (AEOM-) AEOMICA INC.
 XX Shannon M;
 PI WPI; 2002-684061/74.
 XX Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide, POSHL
 PT -1, useful for treating disorders associated with decreased expression or
 PT activity of human POSHL1.
 PS Example 2; SEQ ID NO 304; 60pp + Sequence Listing; English.
 XX The invention relates to an isolated SH3 domain (POSH)-like signalling
 CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
 CC acids (SI, ABB83999), a sequence having 65% sequence identity to (SI),
 CC (SI) having 95% deviations, especially conservative substitutions or a
 CC fragment of the sequences comprising at least 8 contiguous amino acids.
 CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
 CC adaptor protein that interacts with Rho family small GTPases as well as
 CC downstream components of the signal transduction pathway. (I) is useful
 CC for identifying a specific binding partner. (I) and nucleic acids (II)
 CC encoding (I) are useful for diagnosing, monitoring disease and treating
 CC caused by altered expression of human POSHL1 including diagnosing and
 CC treating cancer, they useful in the development of vaccines and (II) is
 CC useful in gene therapy. (II) is useful for constructing microarrays which
 CC are useful for measuring and for surveying gene expression and creating
 CC transgenic non-human animals capable of producing the proteins. The
 CC present sequence is that of a scanning oligonucleotide useful in examples
 CC of the invention. Note: The present sequence did not form part of the
 CC printed specification, but is based on sequence information supplied to
 CC Derwent by the European Patent Office

CC are useful for measuring and for surveying gene expression and creating
 CC transgenic non-human animals capable of producing the proteins. The
 CC present sequence is that of a scanning oligonucleotide useful in examples
 CC of the invention. Note: The present sequence did not form part of the
 CC printed specification, but is based on sequence information supplied to
 CC Derwent by the European Patent Office
 CC
 XX Sequence 17 BP; 4 A; 3 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 471 GCCTGGAGAGCTCGA 486
 ||| ||||| |||||
 Db 2 GCTTTGAGAGCTCGA 17

RESULT 1001
 ABV89593
 ID ABV89593 standard; DNA; 17 BP.
 XX
 AC ABV89593;
 XX
 DT 23-DEC-2002 (first entry)
 XX
 DE Human POSHL1 scanning oligonucleotide SEQ ID NO 306.
 XX
 KW Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
 KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
 KW gene therapy; transgenic; ss.
 XX
 OS Homo sapiens.
 XX
 PN EP1239051-A2.
 XX
 PD 11-SEP-2002.
 XX
 PF 28-JAN-2002; 2002EP-00001165.
 XX
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 23-MAY-2001; 2001US-00864761.
 PR 10-OCT-2001; 2001US-0328205P.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Shannon M;
 XX
 WPI; 2002-684061/74.
 XX
 PT Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
 PT -1, useful for treating disorders associated with decreased expression or
 PT activity of human POSHL1.
 XX
 PS Example 2; SEQ ID NO 306; 60pp + Sequence Listing; English.
 XX

CC The invention relates to an isolated SH3 domain (POSH)-like signalling
 CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
 CC acids (SI, AB883999), a sequence having 65% sequence identity to (SI),
 CC (SI) having 95% deviations, especially conservative substitutions or a
 CC fragment of the sequences comprising at least 8 contiguous amino acids.
 CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
 CC adaptor protein that interacts with Rho family small GTPases as well as
 CC downstream components of the signal transduction pathway. (I) is useful
 CC for identifying a specific binding partner. (I) and nucleic acids (II)
 CC encoding (I) are useful for diagnosing, monitoring disease and treating

CC caused by altered expression of human POSHL1 including diagnosing and
 CC treating cancer, they useful in the development of vaccines and (II) is
 CC useful in gene therapy. (II) is useful for constructing microarrays which
 CC are useful for measuring and for surveying gene expression and creating
 CC transgenic non-human animals capable of producing the proteins. The
 CC present sequence is that of a scanning oligonucleotide useful in examples
 CC of the invention. Note: The present sequence did not form part of the
 CC printed specification, but is based on sequence information supplied to
 CC Derwent by the European Patent Office
 CC
 XX Sequence 17 BP; 4 A; 3 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 474 TCGAGAGCTCGATCT 489
 ||| ||||| |||||
 Db 1 TTGAGAGCTCGATGT 16

RESULT 1002
 ABV89338
 ID ABV89338 standard; DNA; 17 BP.
 XX
 AC ABV89338;
 XX
 DT 23-DEC-2002 (first entry)
 XX
 DE Human POSHL1 scanning oligonucleotide SEQ ID NO 51.
 XX
 KW Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
 KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
 KW gene therapy; transgenic; ss.
 XX
 OS Homo sapiens.
 XX
 PN EP1239051-A2.
 XX
 PD 11-SEP-2002.
 XX
 PF 28-JAN-2002; 2002EP-00001165.
 XX
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 23-MAY-2001; 2001US-00864761.
 PR 10-OCT-2001; 2001US-0328205P.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Shannon M;
 XX
 WPI; 2002-684061/74.
 XX
 PT Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
 PT -1, useful for treating disorders associated with decreased expression or
 PT activity of human POSHL1.
 XX
 PS Example 2; SEQ ID NO 51; 60pp + Sequence Listing; English.
 XX

CC The invention relates to an isolated SH3 domain (POSH)-like signalling
 CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
 CC acids (SI, AB883999), a sequence having 65% sequence identity to (SI),
 CC (SI) having 95% deviations, especially conservative substitutions or a
 CC fragment of the sequences comprising at least 8 contiguous amino acids.
 CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
 CC adaptor protein that interacts with Rho family small GTPases as well as

CC downstream components of the signal transduction pathway. (I) is useful
 CC for identifying a specific binding partner. (I) and nucleic acids (II)
 CC encoding (I) are useful for diagnosing, monitoring disease and treating
 CC caused by altered expression of human POSHL1 including diagnosing and
 CC treating cancer, they are useful in the development of vaccines and (II) is
 CC useful in gene therapy. (II) is useful for constructing microarrays which
 CC are useful for measuring and for surveying gene expression and creating
 CC transgenic non-human animals capable of producing the proteins. The
 CC present sequence is that of a scanning oligonucleotide useful in examples
 CC of the invention. Note: The present sequence did not form part of the
 CC printed specification, but is based on sequence information supplied to
 CC Derwent by the European Patent Office

XX Sequence 17 BP; 2 A; 4 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 617 CAGAGTCGCTTGAGG 632
 ||| |||||
 Db 2 CAGCGGCGCTTGAGG 17

RESULT 1003
 ABK56982
 ID ABK56982 standard; RNA; 17 BP.

XX AC ABK56982;

XX DT 02-JUL-2002 (first entry)

XX DE Human CLCA1 gene enzymatic nucleic acid #1353.

XX KW Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
 KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
 KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
 KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
 KW acetylcysteine.

XX OS Homo sapiens.

XX PN WO200211674-A2.

XX PD 14-FEB-2002.

XX PF 09-AUG-2001; 2001WO-US024970.

XX PR 09-AUG-2000; 2000US-0224383P.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PA (SYNT) SYNTEX USA LLC.

XX PA (THOM) THOMPSON J.

XX PI Thompson J, Mcswiggen J, McKenzie T, Ayers D, Szymkowski DE;
 PI Grupe A;

XX DR WPI; 2002-217145/27.

XX PT Enzymatic polynucleotide that down regulates expression of chloride
 PT channel calcium activated gene, useful for treating Chronic obstructive
 PT pulmonary disease (COPD), chronic bronchitis and asthma.

XX PS Claim 4; Page 88; 152pp; English.

XX CC The invention relates to enzymatic nucleic acid molecules that down
 CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
 CC by cleaving RNA derived from the genes. The nucleic acid sequences are
 CC useful as pharmaceutical agents for treating conditions such as chronic
 CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
 CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
 CC that are related to or will respond to the levels of CLCA1 in a cell or
 CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,

CC hence, are useful for treatment of a patient having a condition
 CC associated with the level of CLCA1, where the invention further comprises
 CC the use of one or more therapies under conditions suitable for the
 CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
 CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
 CC nucleic acids of the invention are also used as diagnostic tools to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of CLCA1 RNA in a cell. This sequence represents an
 CC enzymatic nucleic acid molecule of the invention

XX Sequence 17 BP; 7 A; 2 C; 4 G; 0 T; 4 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 68.8%; Pred. No. 7.2e+02;
 Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

OY 477 AGAAGTCGATCTGAA 492
 ||| |||||
 Db 1 AUAAGUCGCAUCGAA 16

RESULT 1004

ACN06154

ID ACN06154 standard; RNA; 17 BP.

XX AC ACN06154;

XX DT 22-APR-2004 (first entry)

XX DE WNV Amberzyme substrate SEQ ID NO 6157.

XX KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
 KW viricide; neuroprotective; antibacterial; replication; pancreatitis;
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
 KW Amberzyme; Zinzyme; ss.

XX OS West Nile Virus.

XX PN WO200268637-A2.

XX PD 06-SEP-2002.

XX PF 19-OCT-2001; 2001WO-US048350.

XX PR 20-OCT-2000; 2000US-0242411P.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PA (BLAT/) BLATT L.

XX PA (MCSW/) MCSWIGGEN J A.

XX PI Blatt L, Mcswiggen JA;

XX DR WPI; 2002-706994/76.

XX PT New nucleic acid molecule that modulates replication of West Nile Virus
 PT (WNV), useful for treating a condition related to WNV infection e.g.
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

XX PS Claim 23; SEQ ID NO 6157; 495pp; English.

XX CC The invention relates to nucleic acid molecules that modulate replication
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 CC treating a condition related to WNV infection e.g. pancreatitis,
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 CC molecule is selected from the group of ribozymes consisting of
 CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
 CC nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given

CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention
 XX Sequence 17 BP; 6 A; 3 C; 5 G; 0 T; 3 U; 0 Other;
 SQ Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 75.0%; Pred. No. 7.2e+02;
 Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 530 CTGAAGAGATGCCAGC 545
 Db 2 CUGAAGUGAUGACAGC 17

RESULT 1005
 ACN10742/c
 ID ACN10742 standard; RNA; 17 BP.
 XX ACN10742;
 AC ACN10742;
 XX 22-APR-2004 (first entry)
 DT 22-APR-2004 (first entry)
 XX WNV minus strand Inozyme substrate SEQ ID NO 10745.
 DE WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
 XX virucide; neuroprotective; antibacterial; replication; pancreatitis;
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
 KW Amberzyme; Zinzyme; ss.
 XX West Nile Virus.
 OS WO200268637-A2.
 XX 06-SEP-2002.
 PD 19-OCT-2001; 2001WO-US048350.
 PF 20-OCT-2000; 2000US-0242411P.
 PR (RIBO-) RIBOZYME PHARM INC.
 XX (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J A.
 XX Blatt L, Mcswiggen JA;
 PI WPI; 2002-706994/76.
 DR New nucleic acid molecule that modulates replication of West Nile Virus
 XX (WNV), useful for treating a condition related to WNV infection e.g.
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
 PS Claim 23; SEQ ID NO 10745; 495pp; English.
 XX The invention relates to nucleic acid molecules that modulate replication
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 CC treating a condition related to WNV infection e.g. pancreatitis,
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 CC molecule is selected from the group of ribozymes consisting of
 CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
 CC nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
 CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention
 XX Sequence 17 BP; 1 A; 6 C; 4 G; 0 T; 6 U; 0 Other;
 SQ Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 804 CGCCTCGGAGGAGAA 819
 Db 16 CCGCTCAGAGAGAA 1

RESULT 1006
 ACN12591
 ID ACN12591 standard; RNA; 17 BP.
 XX ACN12591;
 AC ACN12591;
 XX 22-APR-2004 (first entry)
 DT 22-APR-2004 (first entry)
 XX WNV minus strand Zinzyme substrate SEQ ID NO 12594.
 DE WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
 XX virucide; neuroprotective; antibacterial; replication; pancreatitis;
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
 KW Amberzyme; Zinzyme; ss.
 XX West Nile Virus.
 OS WO200268637-A2.
 XX 06-SEP-2002.
 PD 19-OCT-2001; 2001WO-US048350.
 PF 20-OCT-2000; 2000US-0242411P.
 PR (RIBO-) RIBOZYME PHARM INC.
 XX (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J A.
 XX Blatt L, Mcswiggen JA;
 PI WPI; 2002-706994/76.
 DR New nucleic acid molecule that modulates replication of West Nile Virus
 XX (WNV), useful for treating a condition related to WNV infection e.g.
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
 PS Claim 23; SEQ ID NO 12594; 495pp; English.
 XX The invention relates to nucleic acid molecules that modulate replication
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 CC treating a condition related to WNV infection e.g. pancreatitis,
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 CC molecule is selected from the group of ribozymes consisting of
 CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
 CC nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
 CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention
 XX Sequence 17 BP; 3 A; 5 C; 4 G; 0 T; 5 U; 0 Other;
 SQ Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 62.5%; Pred. No. 7.2e+02;
 Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 474 TGGAGAGCTCGATCT 489
 Db 2 UGGAGAGCUCCAUCU 17


```
RESULT 1007
ACN05002
ID ACN05002 standard; RNA; 17 BP.
XX
AC ACN05002;
XX
XX 22-APR-2004 (first entry)
XX
XX WNV DNzyme substrate SEQ ID NO 5005.
XX
XX WNV; West Nile Virus; antiinflammatory; cytotatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNzyme;
KW Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
XX
XX WO200268637-A2.
XX
XX 06-SEP-2002.
XX
XX 19-OCT-2001; 2001WO-US048350.
XX
XX 20-OCT-2000; 2000US-0242411P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J A.
XX
XX Blatt L, Mcswiggen JA;
XX
XX WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 5005; 495pp; English.
XX
XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNzyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
XX Sequence 17 BP; 5 A; 3 C; 5 G; 0 T; 4 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.2e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
QY 530 CTGAAGAGATGCCAGC 545
Db 1 CUGAAGUGAUGACAGC 16
XX
RESULT 1008
ACN06034
ID ACN06034 standard; RNA; 17 BP.
XX
AC ACN06034;
XX
XX 22-APR-2004 (first entry)
XX
XX WNV DNzyme substrate SEQ ID NO 4479.
XX
XX WNV; West Nile Virus; antiinflammatory; cytotatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNzyme;
KW
XX
```

```
XX
XX WNV Amberzyme substrate SEQ ID NO 6037.
XX
XX WNV; West Nile Virus; antiinflammatory; cytotatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNzyme;
KW Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
XX
XX WO200268637-A2.
XX
XX 06-SEP-2002.
XX
XX 19-OCT-2001; 2001WO-US048350.
XX
XX 20-OCT-2000; 2000US-0242411P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J A.
XX
XX Blatt L, Mcswiggen JA;
XX
XX WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 6037; 495pp; English.
XX
XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNzyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
XX Sequence 17 BP; 3 A; 5 C; 6 G; 0 T; 3 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.2e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 718 GCTGCAGCAGCAGCAGC 733
Db 2 GCUGCAGCAGCAGCAGC 17
XX
RESULT 1009
ACN04476
ID ACN04476 standard; RNA; 17 BP.
XX
AC ACN04476;
XX
XX 22-APR-2004 (first entry)
XX
XX WNV Zinzyme substrate SEQ ID NO 4479.
XX
XX WNV; West Nile Virus; antiinflammatory; cytotatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNzyme;
KW
```

KW	Amberzyme; Zinzyne; ss.	XX	19-OCT-2001; 2001WO-US048350.	XX
XX	West Nile Virus.	XX	20-OCT-2000; 2000US-0242411P.	XX
XX	WO200268637-A2.	XX	(RIBO-) RIBOZYME PHARM INC.	XX
XX	06-SEP-2002.	XX	(BLAT/) BLATT L.	XX
XX		XX	(MCSW/) MCSWIGGEN J A.	XX
XX		XX	Blatt L, Mcswiggen JA;	XX
XX		XX	WPI; 2002-706994/76.	XX
XX		XX	New nucleic acid molecule that modulates replication of West Nile Virus (WNV), useful for treating a condition related to WNV infection e.g. pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.	XX
XX		XX	Claim 23; SEQ ID NO 4479; 495pp; English.	XX
XX		XX	The invention relates to nucleic acid molecules that modulate replication of the West Nile Virus (WNV). The nucleic acid molecules are useful for treating a condition related to WNV infection e.g. pancreatitis, encephalitis, myocarditis, meningitis, neurologic infection, hepatitis, liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid molecule is selected from the group of ribozymes consisting of Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyne. The nucleic acid molecules further comprise at least five ribose residues, at least ten 2'-O-methyl modifications, phosphorothioate linkages on at least three of the 5' terminal nucleotides and a 3' end modification of a 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080 are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given in the specification. The present sequence is that of a nucleic acid molecule of the invention	XX
XX		XX	Sequence 17 BP; 5 A; 3 C; 8 G; 0 T; 1 U; 0 Other;	XX
XX		XX	Query Match 1.7%; Score 12.8; DB 1; Length 17;	XX
XX		XX	Best Local Similarity 81.2%; Pred. No. 7.2e+02;	XX
XX		XX	Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;	XX
QY	606 TGCAGGAGCGCCAGAG 621	QY	756 GCATGCGAGCGCCAGAG 771	QY
DB	2 UGGAGGAGCGCCAGAG 17	DB	16 GCATGAGGGCGAG 1	DB
RESULT 1010		RESULT 1011		RESULT 1011
ACN02936/c		ACN07596		ACN07596
ID ACN02936 standard; RNA; 17 BP.		ID ACN07596 standard; RNA; 17 BP.		ID ACN07596
AC ACN02936;		AC ACN07596;		AC ACN07596;
XX 22-APR-2004 (first entry)		XX 22-APR-2004 (first entry)		XX 22-APR-2004 (first entry)
DE WNV Inozyme substrate SEQ ID NO 2939.		DE WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 7599.		DE WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 7599.
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;		XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;		XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
XX virucide; neuroprotective; antibacterial; replication; pancreatitis;		XX virucide; neuroprotective; antibacterial; replication; pancreatitis;		XX virucide; neuroprotective; antibacterial; replication; pancreatitis;
XX encephalitis; myocarditis; meningitis; infection; hepatitis;		XX encephalitis; myocarditis; meningitis; infection; hepatitis;		XX encephalitis; myocarditis; meningitis; infection; hepatitis;
XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;		XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;		XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
XX Amberzyme; Zinzyne; ss.		XX Amberzyme; Zinzyne; ss.		XX Amberzyme; Zinzyne; ss.
XX West Nile Virus.		XX West Nile Virus.		XX West Nile Virus.
XX WO200268637-A2.		XX WO200268637-A2.		XX WO200268637-A2.
XX 06-SEP-2002.		XX 06-SEP-2002.		XX 06-SEP-2002.

PA (MCSW/) MCSWIGGEN J A.
 PI Blatt L, Mcswiggen JA;
 XX WPI; 2002-706994/76.
 DR
 XX New nucleic acid molecule that modulates replication of West Nile Virus
 XX (WNV), useful for treating a condition related to WNV infection e.g.
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
 PT
 XX Claim 23; SEQ ID NO 7599; 495pp; English.
 PS
 XX The invention relates to nucleic acid molecules that modulate replication
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 CC treating a condition related to WNV infection e.g. pancreatitis,
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 CC molecule is selected from the group of ribozymes consisting of
 CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
 CC nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
 CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention
 XX
 SQ Sequence 17 BP; 2 A; 3 C; 6 G; 0 T; 6 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 62.5%; Pred. No. 7.2e+02;
 Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
 QY 238 GTCTCTCTCGGGAAG 253
 Db 2 GUCUCUCUGUGGAAG 17
 RESULT 1012
 ACN14468
 ID ACN14468 standard; RNA; 17 BP.
 XX
 AC ACN14468;
 XX
 DT 22-APR-2004 (first entry)
 XX
 DE WNV minus strand Amberzyme substrate SEQ ID NO 14471.
 XX
 KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
 KW Amberzyme; Zinzyme; ss.
 XX
 OS West Nile Virus.
 XX
 PN WO200268637-A2.
 XX
 PD 06-SEP-2002.
 XX
 PF 19-OCT-2001; 2001WO-US048350.
 XX
 PR 20-OCT-2000; 2000US-0242411P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J A.
 XX
 PI Blatt L, Mcswiggen JA;
 XX WPI; 2002-706994/76.
 DR
 XX New nucleic acid molecule that modulates replication of West Nile Virus
 XX (WNV), useful for treating a condition related to WNV infection e.g.
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
 PT
 XX Claim 23; SEQ ID NO 2565; 495pp; English.
 PS
 XX The invention relates to nucleic acid molecules that modulate replication
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 CC treating a condition related to WNV infection e.g. pancreatitis,
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 CC molecule is selected from the group of ribozymes consisting of
 CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
 CC nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
 CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention
 XX
 SQ Sequence 17 BP; 5 A; 3 C; 7 G; 0 T; 2 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 81.2%; Pred. No. 7.2e+02;
 Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 757 CATGCAGGGCCGAGC 772
 Db 1 CAUGUAGGGCCGAGC 16
 RESULT 1013
 ACN02562
 ID ACN02562 standard; RNA; 17 BP.
 XX
 AC ACN02562;
 XX
 DT 22-APR-2004 (first entry)
 XX
 DE WNV Inozyme substrate SEQ ID NO 2565.
 XX
 KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
 KW Amberzyme; Zinzyme; ss.
 XX
 OS West Nile Virus.
 XX
 PN WO200268637-A2.
 XX
 PD 06-SEP-2002.
 XX
 PF 19-OCT-2001; 2001WO-US048350.
 XX
 PR 20-OCT-2000; 2000US-0242411P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J A.
 XX
 PI Blatt L, Mcswiggen JA;
 XX WPI; 2002-706994/76.
 DR
 XX New nucleic acid molecule that modulates replication of West Nile Virus
 XX (WNV), useful for treating a condition related to WNV infection e.g.
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
 PT
 XX Claim 23; SEQ ID NO 2565; 495pp; English.
 PS
 XX The invention relates to nucleic acid molecules that modulate replication
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for

CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, inozyme, G-cleaver, DNzyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention

XX SQ Sequence 17 BP; 6 A; 4 C; 6 G; 0 T; 1 U; 0 Other;
XX

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.2e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 804 CCGCTCGAGGAGAA 819
||| |. | |||||
Db 2 CCGCTCAGAGGAGAA 17

RESULT 1014
ACN08730/C
ID ACN08730 standard; RNA; 17 BP.
XX AC ACN08730;
XX

DT 22-APR-2004 (first entry)
XX WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 8733.
XX

DE WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNzyme;
KW Amberzyme; Zinzyme; ss.
XX

OS West Nile Virus.
XX

XX WO200268637-A2.
XX

XX 06-SEP-2002.
XX

XX 19-OCT-2001; 2001WO-US048350.
XX

XX 20-OCT-2000; 2000US-0242411P.
XX

XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J A.
XX

PI Blatt L, Mcswiggen JA;
XX WPI; 2002-706994/76.
XX

XX New nucleic acid molecule that modulates replication of West Nile Virus
XX (WNV), useful for treating a condition related to WNV infection e.g.
XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX

XX Claim 23; SEQ ID NO 8733; 495pp; English.
XX

XX The invention relates to nucleic acid molecules that modulate replication
XX of the West Nile Virus (WNV). The nucleic acid molecules are useful for
XX treating a condition related to WNV infection e.g. pancreatitis,
XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX molecule is selected from the group of ribozymes consisting of
XX Hammerhead, inozyme, G-cleaver, DNzyme, Amberzyme and Zinzyme. The
XX nucleic acid molecules further comprise at least five ribose residues, at
XX least ten 2'-O-methyl modifications, phosphorothioate linkages on at

CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention

XX SQ Sequence 17 BP; 3 A; 5 C; 3 G; 0 T; 6 U; 0 Other;
XX

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 530 CTGAAGAGATGCCAGC 545
||||| |||||
Db 16 CTGAGTGATGACAGC 1

RESULT 1015
ACN11414/C
ID ACN11414 standard; RNA; 17 BP.
XX AC ACN11414;
XX

DT 22-APR-2004 (first entry)
XX WNV minus strand Inozyme substrate SEQ ID NO 11417.
XX

DE WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNzyme;
KW Amberzyme; Zinzyme; ss.
XX

OS West Nile Virus.
XX

XX WO200268637-A2.
XX

XX 06-SEP-2002.
XX

XX 19-OCT-2001; 2001WO-US048350.
XX

XX 20-OCT-2000; 2000US-0242411P.
XX

XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J A.
XX

PI Blatt L, Mcswiggen JA;
XX WPI; 2002-706994/76.
XX

XX New nucleic acid molecule that modulates replication of West Nile Virus
XX (WNV), useful for treating a condition related to WNV infection e.g.
XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX

XX Claim 23; SEQ ID NO 11417; 495pp; English.
XX

XX The invention relates to nucleic acid molecules that modulate replication
XX of the West Nile Virus (WNV). The nucleic acid molecules are useful for
XX treating a condition related to WNV infection e.g. pancreatitis,
XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX molecule is selected from the group of ribozymes consisting of
XX Hammerhead, inozyme, G-cleaver, DNzyme, Amberzyme and Zinzyme. The
XX nucleic acid molecules further comprise at least five ribose residues, at
XX least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX least three of the 5' terminal nucleotides and a 3' end modification of a
XX 3'-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
XX are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
XX in the specification. The present sequence is that of a nucleic acid
XX molecule of the invention

XX SQ Sequence 17 BP; 2 A; 6 C; 6 G; 0 T; 3 U; 0 Other;
XX

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 718 GCTGCAGGAGCGAC 733
 DB 17 GCTGCAGGAGCGAC 2

RESULT 1016
 ACN12508/c
 ID ACN12508 standard; RNA; 17 BP.

XX ACN12508;
 XX 22-APR-2004 (first entry)
 XX WNV minus strand zinzyme substrate SEQ ID NO 12511.
 XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
 KW Amberzyme; Zinzyme; ss.
 XX West Nile Virus.
 XX W0200268637-A2.
 XX 06-SEP-2002.
 XX 19-OCT-2001; 2001WO-US048350.
 XX 20-OCT-2000; 2000US-0242411P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J A.
 XX Blatt L, Mcswiggen JA;
 XX WPI; 2002-706994/76.

XX New nucleic acid molecule that modulates replication of West Nile Virus
 PT (WNV), useful for treating a condition related to WNV infection e.g.
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
 XX Claim 23; SEQ ID NO 12511; 495pp; English.

XX The invention relates to nucleic acid molecules that modulate replication
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 CC treating a condition related to WNV infection e.g. pancreatitis,
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 CC molecule is selected from the group of ribozymes consisting of
 CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
 CC nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
 CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention

XX Sequence 17 BP; 1 A; 8 C; 3 G; 0 T; 5 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 606 TGCAGGAGCGAC 621
 DB 17 GCTGCAGGAGCGAC 2

RESULT 1018
 ACN14466
 ID ACN14466 standard; RNA; 17 BP.

XX

Db 17 TGCAGGAGCGACGAG 2

RESULT 1017
 ACN08869/c
 ID ACN08869 standard; RNA; 17 BP.

XX ACN08869;
 XX 22-APR-2004 (first entry)
 XX WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 8872.
 XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
 KW Amberzyme; Zinzyme; ss.
 XX West Nile Virus.
 XX W0200268637-A2.
 XX 06-SEP-2002.
 XX 19-OCT-2001; 2001WO-US048350.
 XX 20-OCT-2000; 2000US-0242411P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J A.
 XX Blatt L, Mcswiggen JA;
 XX WPI; 2002-706994/76.

XX New nucleic acid molecule that modulates replication of West Nile Virus
 PT (WNV), useful for treating a condition related to WNV infection e.g.
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
 XX Claim 23; SEQ ID NO 8872; 495pp; English.

XX The invention relates to nucleic acid molecules that modulate replication
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 CC treating a condition related to WNV infection e.g. pancreatitis,
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 CC molecule is selected from the group of ribozymes consisting of
 CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
 CC nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
 CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention

XX Sequence 17 BP; 3 A; 6 C; 5 G; 0 T; 3 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 718 GCTGCAGGAGCGAC 733
 DB 16 GCTGCAGGAGCGAC 1

RESULT 1018
 ACN14466
 ID ACN14466 standard; RNA; 17 BP.

XX

AC ACN14466;
XX 22-APR-2004 (first entry)
XX WNV minus strand Amberzyme substrate SEQ ID NO 14469.
XX
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
XX
XX WO200268637-A2.
XX
XX 06-SEP-2002.
XX
XX 19-OCT-2001; 2001WO-US048350.
XX
XX 20-OCT-2000; 2000US-0242411P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
XX Blatt L, Mcswiggen JA;
XX
XX WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 14469; 495pp; English.
XX
XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
XX Sequence 17 BP; 4 A; 2 C; 9 G; 0 T; 2 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.2e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 756 GCATGCGAGGCGCAGAG 771
DB 2 GCAUGAGGGGCGAG 17
RESULT 1019
ACN04405/c
ID ACN04405 standard; RNA; 17 BP.
XX
XX ACN04405;
XX
XX 22-APR-2004 (first entry)
XX
XX WNV Zinzyme substrate SEQ ID NO 4408.
XX
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;

KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
XX
XX WO200268637-A2.
XX
XX 06-SEP-2002.
XX
XX 19-OCT-2001; 2001WO-US048350.
XX
XX 20-OCT-2000; 2000US-0242411P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
XX Blatt L, Mcswiggen JA;
XX
XX WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 4408; 495pp; English.
XX
XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
XX Sequence 17 BP; 5 A; 4 C; 5 G; 0 T; 3 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 474 TGGAGAGCTCGATCT 489
DB 17 TGGAGCAGCTCCATCT 2
RESULT 1020
ACN02934/c
ID ACN02934 standard; RNA; 17 BP.
XX
XX ACN02934;
XX
XX 22-APR-2004 (first entry)
XX
XX WNV Inozyme substrate SEQ ID NO 2937.
XX
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
XX

PN WO200268637-A2.
 XX
 PD 06-SEP-2002.
 XX
 XX 19-OCT-2001; 2001WO-US048350.
 XX
 PR 20-OCT-2000; 2000US-0242411P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J A.
 XX
 PI Blatt L, Mcswiggen JA;
 XX
 DR WPI; 2002-706994/76.
 XX
 PT New nucleic acid molecule that modulates replication of West Nile Virus
 XX (WNV), useful for treating a condition related to WNV infection e.g.
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
 XX
 PS Claim 23; SEQ ID NO 2937; 495pp; English.
 XX
 CC The invention relates to nucleic acid molecules that modulate replication
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 CC treating a condition related to WNV infection e.g. pancreatitis,
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 CC molecule is selected from the group of ribozymes consisting of
 CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
 CC nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
 CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention
 XX
 SQ Sequence 17 BP; 2 A; 7 C; 3 G; 0 T; 5 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 757 CATGCAGGGCCAGAGC 772
 Db ||||| ||||| |||||
 17 CATGTAGGGCCAGAGC 2
 RESULT 1021
 ACN09764
 ID ACN09764 standard; RNA; 17 BP.
 XX
 AC ACN09764;
 XX
 XX 22-APR-2004 (first entry)
 XX
 XX WNV minus strand Inozyme substrate SEQ ID NO 9767.
 DE
 XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
 KW Amberzyme; Zinzyme; ss.
 XX
 OS West Nile Virus.
 XX
 XX WO200268637-A2.
 PN
 XX 06-SEP-2002.
 XX
 XX 19-OCT-2001; 2001WO-US048350.
 PF
 XX 20-OCT-2000; 2000US-0242411P.

XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J A.
 XX
 PI Blatt L, Mcswiggen JA;
 XX
 DR WPI; 2002-706994/76.
 XX
 PT New nucleic acid molecule that modulates replication of West Nile Virus
 XX (WNV), useful for treating a condition related to WNV infection e.g.
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
 XX
 PS Claim 23; SEQ ID NO 9767; 495pp; English.
 XX
 CC The invention relates to nucleic acid molecules that modulate replication
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 CC treating a condition related to WNV infection e.g. pancreatitis,
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 CC molecule is selected from the group of ribozymes consisting of
 CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
 CC nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
 CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention
 XX
 SQ Sequence 17 BP; 2 A; 3 C; 5 G; 0 T; 7 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 62.5%; Pred. No. 7.2e+02;
 Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
 OY 238 GTCTCTCTGGGGAAG 253
 Db ||:|:|:|:|:|:|
 1 GUCUCUUCUGUGGAAG 16
 RESULT 1022
 ACN03270/C
 ID ACN03270 standard; RNA; 17 BP.
 XX
 AC ACN03270;
 XX
 XX 22-APR-2004 (first entry)
 XX
 XX WNV Inozyme substrate SEQ ID NO 3273.
 DE
 XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
 KW Amberzyme; Zinzyme; ss.
 XX
 OS West Nile Virus.
 XX
 XX WO200268637-A2.
 PN
 XX 06-SEP-2002.
 XX
 XX 19-OCT-2001; 2001WO-US048350.
 PF
 XX 20-OCT-2000; 2000US-0242411P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J A.
 XX
 PI Blatt L, Mcswiggen JA;
 XX

DR WPI; 2002-706994/76.

XX New nucleic acid molecule that modulates replication of West Nile Virus

PT (WNV), useful for treating a condition related to WNV infection e.g.

PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

XX

PS Claim 23; SEQ ID NO 3273; 495pp; English.

XX

CC The invention relates to nucleic acid molecules that modulate replication

CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for

CC treating a condition related to WNV infection e.g. pancreatitis,

CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,

CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid

CC molecule is selected from the group of ribozymes consisting of

CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The

CC nucleic acid molecules further comprise at least five ribose residues, at

CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at

CC least three of the 5' terminal nucleotides and a 3' end modification of a

CC 3'-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080

CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given

CC in the specification. The present sequence is that of a nucleic acid

CC molecule of the invention

XX

SQ Sequence 17 BP; 7 A; 5 C; 3 G; 0 T; 2 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 7.2e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 238 GTCTCTCTCTGGGAAG 253

DB 17 GTCTCTCTCTGGGAAG 2

|||||

RESULT 1023

ACN07198/C

ID ACN07198 standard; RNA; 17 BP.

XX

AC ACN07198;

XX

DT 22-APR-2004 (first entry)

XX

DE WNV Amberzyme substrate SEQ ID NO 7201.

XX

DE WNV, West Nile Virus; antiinflammatory; cytostatic; hepatotropic;

KW virucide; neuroprotective; antibacterial; replication; pancreatitis;

KW encephalitis; myocarditis; meningitis; infection; hepatitis;

KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;

KW Amberzyme; Zinzyme; ss.

XX

OS West Nile Virus.

XX

XX WO200268637-A2.

PN

XX

PD 06-SEP-2002.

XX

XX 19-OCT-2001; 2001WO-US048350.

XX

XX 20-OCT-2000; 2000US-0242411P.

PR

XX

PA (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.

PA (MCSW/) MCSWIGGEN J A.

XX

XX Blatt L, Mcswiggen JA;

PI

XX

XX WPI; 2002-706994/76.

DR

XX

PT New nucleic acid molecule that modulates replication of West Nile Virus

PT (WNV), useful for treating a condition related to WNV infection e.g.

PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

PT

PS Claim 23; SEQ ID NO 7201; 495pp; English.

XX

CC The invention relates to nucleic acid molecules that modulate replication

CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for

CC treating a condition related to WNV infection e.g. pancreatitis,

CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,

CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid

CC molecule is selected from the group of ribozymes consisting of

CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The

CC nucleic acid molecules further comprise at least five ribose residues, at

CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at

CC least three of the 5' terminal nucleotides and a 3' end modification of a

CC 3'-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080

CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given

CC in the specification. The present sequence is that of a nucleic acid

CC molecule of the invention

XX

SQ Sequence 17 BP; 6 A; 6 C; 3 G; 0 T; 2 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 7.2e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 238 GTCTCTCTCTGGGAAG 253

DB 16 GTCTCTCTCTGGGAAG 1

|||||

RESULT 1024

ABT35838/C

ID ABT35838 standard; DNA; 17 BP.

XX

AC ABT35838;

XX

DT 12-JUN-2003 (first entry)

XX

DE Tumour suppression related human fukutin oligo SEQ ID NO 1475.

XX

DE Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;

KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;

KW schizophrenia; protein chip; gene therapy; tumour suppression;

KW human fukutin; ds.

XX

OS Homo sapiens.

XX

XX WO2003025175-A2.

PN

XX

PD 27-MAR-2003.

XX

XX 17-SEP-2002; 2002WO-IB004208.

PF

XX

PR 17-SEP-2001; 2001FR-00011978.

XX

XX (MOLE-) MOLECULAR ENGINES LAB.

PA

XX

XX Telerman A, Amson R, Tuijnder M;

PI

XX

XX WPI; 2003-313353/30.

DR

XX

PT New isolated nucleic acid, useful for treating viral diseases associated

PT with tumors and cell degeneration, also related polypeptides, antibodies

PT and transfected cells.

PT

PS Disclosure; Page 205; 720pp; French.

XX

XX

CC The invention relates to a novel isolated 17 mer nucleic acid sequence,

CC given in the specification, a sequence containing at least 15 consecutive

CC nucleotides from the 17 mer sequence, a sequence with, after optimal

CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that

CC hybridizes to them under highly stringent conditions, or the complement

CC of any of them, or the corresponding RNA. The novel isolated nucleic

CC acids of the invention are useful as probes and primers for detecting,

CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one

CC component of a gene chip, in vitro as (anti)sense reagents, and for

CC production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterized by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention
 XX
 SQ Sequence 17 BP; 3 A; 6 C; 3 G; 5 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 601 GGAGCTGCAGCAGC 616
 |||||
 DB 16 GGAGCTGCAGTAGTC 1
 RESULT 1025
 ABT36928
 ID ABT36928 standard; DNA; 17 BP.
 XX
 AC ABT36928;
 XX
 DT 12-JUN-2003 (first entry)
 XX
 DE Tumour suppression related human fukutin oligo SEQ ID No 2565.
 XX
 KW Cytostatic; virucide; neuroprotective; nontropic; neuroleptic; gene chip;
 KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; protein chip; gene therapy; tumour suppression;
 KW human fukutin; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO2003025175-A2.
 XX
 PD 27-MAR-2003.
 XX
 PF 17-SEP-2002; 2002WO-IB004208.
 XX
 PR 17-SEP-2001; 2001FR-00011978.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Telerman A, Amson R, Tuijnder M;
 XX
 DR WPI; 2003-313353/30.
 XX
 PT New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.
 XX
 PS Disclosure; Page 332; 720pp; French.
 XX
 SS The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15 consecutive
 CC nucleotides from the 17 mer sequence, a sequence with, after optimal
 CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
 CC hybridizes to them under highly stringent conditions, or the complement
 CC of any of them, or the corresponding RNA. The novel isolated nucleic
 CC acids of the invention are useful as probes and primers for detecting,
 CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
 CC component of a gene chip, in vitro as (anti)sense reagents, and for
 CC production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, cells containing the

CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterized by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention
 XX
 SQ Sequence 17 BP; 5 A; 3 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 881 ATCAAGAGCAGCGTGG 896
 |||||
 DB 2 ATCTAGAGCAGCATGG 17
 RESULT 1026
 ABT37923/C
 ID ABT37923 standard; DNA; 17 BP.
 XX
 AC ABT37923;
 XX
 DT 12-JUN-2003 (first entry)
 XX
 DE Tumour suppression related human fukutin oligo SEQ ID No 3560.
 XX
 KW Cytostatic; virucide; neuroprotective; nontropic; neuroleptic; gene chip;
 KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; protein chip; gene therapy; tumour suppression;
 KW human fukutin; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO2003025175-A2.
 XX
 PD 27-MAR-2003.
 XX
 PF 17-SEP-2002; 2002WO-IB004208.
 XX
 PR 17-SEP-2001; 2001FR-00011978.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Telerman A, Amson R, Tuijnder M;
 XX
 DR WPI; 2003-313353/30.
 XX
 PT New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.
 XX
 PS Disclosure; Page 450; 720pp; French.
 XX
 SS The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15 consecutive
 CC nucleotides from the 17 mer sequence, a sequence with, after optimal
 CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
 CC hybridizes to them under highly stringent conditions, or the complement
 CC of any of them, or the corresponding RNA. The novel isolated nucleic
 CC acids of the invention are useful as probes and primers for detecting,
 CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
 CC component of a gene chip, in vitro as (anti)sense reagents, and for
 CC production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral

CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 2 A; 7 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 203 GGCCCGGCGACGATC 218
Db 16 GGGCTGGCAGCAGATC 1
RESULT 1027
ACA07771
ID ACA07771 standard; RNA; 17 BP.
AC ACA07771;
DT 03-JUN-2003 (first entry)
XX NFKB sub-unit modulating zinzyme substrate #170.
DE
XX Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
KW chemotherap; paclitaxel; docetaxel; cisplatin; methotrexate;
KW gencitabine; radiation therapy; inflammatory disease; asthma; diabetes;
KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; diabetes;
KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
KW allergic airway inflammation; inflammatory bowel disease; infection; ss.
XX Homo sapiens.
OS
XX US2002177568-A1.
FN (MCSW/) MCSWIGGEN J.
PA (DRAP/) DRAPER K G.
XX Stinchcomb DT, Mcswiggen J, Draper KG;
PI WPT; 2003-340953/32.
XX Novel enzymatic nucleic acid molecules which down regulates expression of
DR a sequence encoding a subunit of nuclear factor kappa B useful for
PT treating cancer, inflammatory disorders and autoimmune diseases.
PT
XX Claim 3; Page 40; 72pp; English.
PS
XX The invention describes an enzymatic nucleic acid molecule (I) which down

CC regulates expression of a sequence encoding a subunit of nuclear factor
CC kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
CC configuration. The enzymatic nucleic acid molecule is adapted to treat
CC cancer and is useful for down-regulating REL-A activity in a cell, for
CC treating a patient having a condition associated with the level of REL-A.
CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
CC antisense nucleic acid molecules are useful for treating breast, lung,
CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
CC multidrug resistant cancer. The method involves use of other drug
CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
CC cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate,
CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
CC acid molecules are also useful for treating inflammatory disease such as
CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
CC rejection, gene therapy applications, ischaemia/reperfusion injury
CC (central nervous system (CNS) and myocardial), glomerulonephritis,
CC sepsis, allergic airway inflammation, inflammatory bowel disease or
CC infection. This sequence represents the substrate of a novel enzymatic
CC nucleic acid molecule
XX
SQ Sequence 17 BP; 2 A; 7 C; 5 G; 0 T; 3 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 7.2e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
QY 257 GCATGCTGCACCTGC 272
Db 1 GCCCGCGCAGCAGCUGC 16
RESULT 1028
ACA07885/c
ID ACA07885 standard; RNA; 17 BP.
XX ACA07885;
AC
XX 03-JUN-2003 (first entry)
DT
XX NFKB sub-unit modulating zinzyme substrate #284.
DE
XX Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
KW chemotherap; paclitaxel; docetaxel; cisplatin; methotrexate;
KW cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;
KW gencitabine; radiation therapy; inflammatory disease; asthma; diabetes;
KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; diabetes;
KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
KW allergic airway inflammation; inflammatory bowel disease; infection; ss.
XX Homo sapiens.
OS
XX US2002177568-A1.
FN
XX 28-NOV-2002.
PD
XX 23-MAY-2001; 2001US-00864785.
PF
XX 07-DEC-1992; 92US-00987132.
PR
XX 18-MAY-1994; 94US-00245466.
PR
XX 15-AUG-1994; 94US-00291932.
PR
XX 23-DEC-1996; 96US-00777916.
PR
XX (STIN/) STINCHOMB D T.
PA (MCSW/) MCSWIGGEN J.
XX (DRAP/) DRAPER K G.
XX Stinchcomb DT, Mcswiggen J, Draper KG;
PI WPT; 2003-340953/32.
XX Novel enzymatic nucleic acid molecules which down regulates expression of
DR a sequence encoding a subunit of nuclear factor kappa B useful for
PT treating cancer, inflammatory disorders and autoimmune diseases.
PT
XX Claim 3; Page 40; 72pp; English.
PS
XX The invention describes an enzymatic nucleic acid molecule (I) which down

PA (MCSW/) MCSWIGGEN J.
PA (DRAP/) DRAPER K G.
XX
XX Stinchcomb DT, Mcswiggen J, Draper KG;
XX WPI; 2003-340953/32.
XX
XX Novel enzymatic nucleic acid molecules which down regulates expression of
PT a sequence encoding a subunit of nuclear factor kappa B useful for
PT treating cancer, inflammatory disorders and autoimmune diseases.
XX
XX Claim 3; Page 41; 72pp; English.
XX
XX The invention describes an enzymatic nucleic acid molecule (I) which down
CC regulates expression of a sequence encoding a subunit of nuclear factor
CC kappa B (NFkB), where (I) is an inozyme, zinyzyme, G-cleaver or amberzyme
CC configuration. The enzymatic nucleic acid molecule is adapted to treat
CC cancer and is useful for down-regulating REL-A activity in a cell, for
CC treating a patient having a condition associated with the level of REL-A.
CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
CC antisenase nucleic acid molecules are useful for treating breast, lung,
CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
CC multidrug resistant cancer. The method involves use of other drug
CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
CC gemcitabine or radiation therapy. The enzymatic and antisenase nucleic
CC acid molecules are also useful for treating inflammatory disease such as
CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
CC rejection, gene therapy applications, ischaemia/reperfusion injury
CC (central nervous system (CNS) and myocardial), glomerulonephritis,
CC sepsis, allergic airway inflammation, inflammatory bowel disease or
CC infection. This sequence represents the substrate of a novel enzymatic
CC nucleic acid molecule
XX
XX Sequence 17 BP; 2 A; 6 C; 6 G; 0 T; 3 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 530 CTGAGAGATGCCAGC 545
Db 17 CTGAGAGATGCCAGC 2
RESULT 1029
ACA08935
ID ACA08935 standard; RNA; 17 BP.
XX
XX ACA08935;
XX
XX 03-JUN-2003 (first entry)
XX
XX NFkB sub-unit modulating amberzyme substrate #98.
XX
XX Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinyzyme;
KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
KW allergic airway inflammation; inflammatory bowel disease; infection; ss.
XX

OS Homo sapiens.
XX US2002177568-A1.
XX
XX 28-NOV-2002.
XX
XX 23-MAY-2001; 2001US-00864785.
XX
XX 07-DEC-1992; 92US-00987132.
XX
XX 18-MAY-1994; 94US-00245466.
XX
XX 15-AUG-1994; 94US-00291932.
XX
XX 23-DEC-1996; 96US-00777916.
XX
XX (STIN/) STINCHCOMB D T.
XX (MCSW/) MCSWIGGEN J.
XX (DRAP/) DRAPER K G.
XX
XX Stinchcomb DT, Mcswiggen J, Draper KG;
XX WPI; 2003-340953/32.
XX
XX Novel enzymatic nucleic acid molecules which down regulates expression of
PT a sequence encoding a subunit of nuclear factor kappa B useful for
PT treating cancer, inflammatory disorders and autoimmune diseases.
XX
XX Claim 3; Page 51; 72pp; English.
XX
XX The invention describes an enzymatic nucleic acid molecule (I) which down
CC regulates expression of a sequence encoding a subunit of nuclear factor
CC kappa B (NFkB), where (I) is an inozyme, zinyzyme, G-cleaver or amberzyme
CC configuration. The enzymatic nucleic acid molecule is adapted to treat
CC cancer and is useful for down-regulating REL-A activity in a cell, for
CC treating a patient having a condition associated with the level of REL-A.
CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
CC antisenase nucleic acid molecules are useful for treating breast, lung,
CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
CC multidrug resistant cancer. The method involves use of other drug
CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
CC gemcitabine or radiation therapy. The enzymatic and antisenase nucleic
CC acid molecules are also useful for treating inflammatory disease such as
CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
CC rejection, gene therapy applications, ischaemia/reperfusion injury
CC (central nervous system (CNS) and myocardial), glomerulonephritis,
CC sepsis, allergic airway inflammation, inflammatory bowel disease or
CC infection. This sequence represents the substrate of a novel enzymatic
CC nucleic acid molecule
XX
XX Sequence 17 BP; 4 A; 2 C; 6 G; 0 T; 5 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 7.2e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
QY 175 ACTGTGTGAGATGGTG 190
Db 2 ACUGUGGACAAAGGUG 17
RESULT 1030
ACA07770
ID ACA07770 standard; RNA; 17 BP.
XX
XX ACA07770;
XX
XX 03-JUN-2003 (first entry)
XX
XX NFkB sub-unit modulating zinyzyme substrate #169.
XX

KW Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinyzme; zinyzme;
 KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
 KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection; ss.
 XX
 OS Homo sapiens.
 XX
 PA US2002177568-A1.
 PA (DRAP//) DRAPER K G.
 XX
 PI Stinchcomb DT, Mcswiggen J, Draper KG;
 XX
 XX WPI; 2003-340953/32.
 XX
 DR Novel enzymatic nucleic acid molecules which down regulates expression of
 XX a sequence encoding a subunit of nuclear factor kappa B useful for
 XX treating cancer, inflammatory disorders and autoimmune diseases.
 XX
 PS Claim 3; Page 40; 72pp; English.
 XX
 CC The invention describes an enzymatic nucleic acid molecule (I) which down
 CC regulates expression of a sequence encoding a subunit of nuclear factor
 CC kappa B (NFkB), where (I) is an inozyme, zinyzme, G-cleaver or amberzyme
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat
 CC cancer and is useful for down-regulating REL-A activity in a cell, for
 CC treating a patient having a condition associated with the level of REL-A.
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 CC antisense nucleic acid molecules are useful for treating breast, lung,
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC infection. This sequence represents the substrate of a novel enzymatic
 CC nucleic acid molecule
 XX

Sequence 17 BP; 2 A; 6 C; 6 G; 0 T; 3 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 81.2%; Pred. No. 7.2e+02;
 Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 713 GAGGCCGCTCAGCAGC 728

Db 1 GAGGCCGCTCAGCAGC 16
 RESULT 1031
 ACA06585
 ID ACA06585 standard; RNA; 17 BP.
 XX
 AC ACA06585;
 XX
 DT 03-JUN-2003 (first entry)
 XX
 DE NFkB sub-unit modulating inozyme substrate #404.
 XX
 KW Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinyzme;
 KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
 KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection; ss.
 XX
 OS Homo sapiens.
 XX
 PA US2002177568-A1.
 PA (DRAP//) DRAPER K G.
 XX
 PI Stinchcomb DT, Mcswiggen J, Draper KG;
 XX
 XX WPI; 2003-340953/32.
 XX
 DR Novel enzymatic nucleic acid molecules which down regulates expression of
 XX a sequence encoding a subunit of nuclear factor kappa B useful for
 XX treating cancer, inflammatory disorders and autoimmune diseases.
 XX
 PS Claim 3; Page 33; 72pp; English.
 XX
 CC The invention describes an enzymatic nucleic acid molecule (I) which down
 CC regulates expression of a sequence encoding a subunit of nuclear factor
 CC kappa B (NFkB), where (I) is an inozyme, zinyzme, G-cleaver or amberzyme
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat
 CC cancer and is useful for down-regulating REL-A activity in a cell, for
 CC treating a patient having a condition associated with the level of REL-A.
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 CC antisense nucleic acid molecules are useful for treating breast, lung,
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,

CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC infection. This sequence represents the substrate of a novel enzymatic
 CC nucleic acid molecule
 XX
 SQ Sequence 17 BP; 3 A; 6 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 81.2%; Pred. No. 7.2e+02;
 Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 713 GAGGCGCTGACGAGC 728
 ||||| :|||
 Db 2 GAGGCGCTGACGAGC 17
 RESULT 1032
 ACA06586
 ID ACA06586 standard; RNA; 17 BP.
 XX
 AC ACA06586;
 XX
 DT 03-JUN-2003 (first entry)
 XX
 DE NFKB sub-unit modulating inozyme substrate #405.
 XX
 KW Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
 KW G-cleaver; ambrzyme; cancer; REL-A activity; breast cancer; human;
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
 KW cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection; ss.
 XX
 OS Homo sapiens.
 XX
 US2002177568-A1.
 XX
 PN 28-NOV-2002.
 PD
 XX
 PF 23-MAY-2001; 2001US-00864785.
 XX
 PR 07-DEC-1992; 92US-00987132.
 PR 18-MAY-1994; 94US-00245466.
 PR 15-AUG-1994; 94US-00291932.
 PR 23-DEC-1996; 96US-00777916.
 XX
 (STIN/) STINCHOMB D T.
 PA (MCSW/) MCSWIGGEN J.
 PA (DRAP/) DRAPER K G.
 XX
 PI Stinchcomb DT, Mcswiggen J, Draper KG;
 XX
 WPI; 2003-340953/32.
 XX
 PT Novel enzymatic nucleic acid molecules which down regulates expression of
 PT a sequence encoding a subunit of nuclear factor kappa B useful for
 PT treating cancer, inflammatory disorders and autoimmune diseases.
 XX
 PS Claim 3; Page 33; 72pp; English.
 XX
 CC The invention describes an enzymatic nucleic acid molecule (I) which down
 CC regulates expression of a sequence encoding a subunit of nuclear factor
 CC kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or ambrzyme
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat

CC cancer and is useful for down-regulating REL-A activity in a cell, for
 CC treating a patient having a condition associated with the level of REL-A.
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 CC antisenese nucleic acid molecules are useful for treating breast, lung,
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate,
 CC gemcitabine or radiation therapy. The enzymatic and antisenese nucleic
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC infection. This sequence represents the substrate of a novel enzymatic
 CC nucleic acid molecule
 XX
 SQ Sequence 17 BP; 1 A; 7 C; 6 G; 0 T; 3 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 68.8%; Pred. No. 7.2e+02;
 Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
 QY 257 GCCATGCTGCACCTGC 272
 ||||| :|||
 Db 2 GCCCTGCTGCACCTGC 17
 RESULT 1033
 ADA99742/c
 ID ADA99742 standard; DNA; 17 BP.
 XX
 AC ADA99742;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human MDZ3 scanning oligonucleotide SEQ ID 731.
 XX
 KW Cytostatic; immunostimulant; gene therapy; vaccine; human;
 KW zinc finger protein; MDZ3; MDZ4; MDZ7; MDZ12; chromosome 7q22.1;
 KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
 KW developmental disorder; ss.
 XX
 OS Homo sapiens.
 XX
 PN EP1281758-A2.
 XX
 PD 05-FEB-2003.
 XX
 PF 30-JUL-2002; 2002EP-00016874.
 XX
 PR 02-AUG-2001; 2001US-00922181.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Shannon M, Gu Y, Nguyen C;
 XX
 WPI; 2003-423107/40.
 XX
 PT New zinc finger-containing proteins and nucleic acids, useful in
 PT manufacturing a medicament for treating or preventing a disorder
 PT associated with decreased or increased expression or activity of MDZ3,
 PT MDZ4, MDZ7 or MDZ12, e.g. cancer.
 XX
 PS Example 8; SEQ ID NO 731; 103pp; English.
 XX
 CC The present invention relates to novel human zinc finger-containing
 CC proteins and their coding sequences; MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is
 CC encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2,


```

QY      263 CTGCACCTGCCTTCAG 278
Db      1 CUCUCCUGCCUUCAG 16

RESULT 1036
ID      ABZ61885 standard; RNA; 17 BP.
XX
AC      ABZ61885;
XX
DT      21-MAR-2003 (first entry)
XX
DE      Human H-Ras DNzyme target #676.
XX
KW      Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW      enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosstatic; anti-HIV;
KW      anti-rheumatic; cancer; AIDS; ss.
XX
OS      Homo sapiens.
XX
PN      WO200297114-A2.
XX
PD      05-DEC-2002.
XX
PF      29-MAY-2002; 2002WO-US016840.
XX
PR      29-MAY-2001; 2001US-0294140P.
PR      06-JUN-2001; 2001US-0296249P.
PR      10-SEP-2001; 2001US-0318471P.
XX
PA      (RIBO-) RIBOZYME PHARM INC.
XX
PI      Mcswiggen J;
XX
DR      WPI; 2003-140484/13.
XX
PT      Novel short interfering RNA and enzymatic nucleic acid useful for
PT      treating cancer, modulates the expression of a nucleic acid encoding
PT      HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS      Claim 58; Page 124; 185pp; English.
XX
CC      The invention relates to a novel short interfering RNA (siRNA) nucleic
CC      acid molecule or an enzymatic nucleic acid molecule, that modulates
CC      expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC      human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC      acid molecule of the invention has cytosstatic, anti-HIV, and anti-
CC      rheumatic activity. The nucleic acid molecules are useful for reducing
CC      HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC      also useful for treating breast, ovarian, colorectal, lung, prostate,
CC      bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC      shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC      ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC      ribozymes of the invention
XX
SQ      Sequence 17 BP; 2 A; 8 C; 3 G; 0 T; 4 U; 0 Other;

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      571 TGTGAAGCCCGAGTG 586
Db      17 TGTGAAGCCCGAGG 2

RESULT 1037
ID      ABZ61923/c
XX
AC      ABZ61923 standard; RNA; 17 BP.
XX
XX      ABZ61923;

QY      263 CTGCACCTGCCTTCAG 278
Db      1 CUCUCCUGCCUUCAG 16

RESULT 1036
ID      ABZ61885 standard; RNA; 17 BP.
XX
AC      ABZ61885;
XX
DT      21-MAR-2003 (first entry)
XX
DE      Human H-Ras DNzyme target #676.
XX
KW      Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW      enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosstatic; anti-HIV;
KW      anti-rheumatic; cancer; AIDS; ss.
XX
OS      Homo sapiens.
XX
PN      WO200297114-A2.
XX
PD      05-DEC-2002.
XX
PF      29-MAY-2002; 2002WO-US016840.
XX
PR      29-MAY-2001; 2001US-0294140P.
PR      06-JUN-2001; 2001US-0296249P.
PR      10-SEP-2001; 2001US-0318471P.
XX
PA      (RIBO-) RIBOZYME PHARM INC.
XX
PI      Mcswiggen J;
XX
DR      WPI; 2003-140484/13.
XX
PT      Novel short interfering RNA and enzymatic nucleic acid useful for
PT      treating cancer, modulates the expression of a nucleic acid encoding
PT      HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS      Claim 58; Page 124; 185pp; English.
XX
CC      The invention relates to a novel short interfering RNA (siRNA) nucleic
CC      acid molecule or an enzymatic nucleic acid molecule, that modulates
CC      expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC      human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC      acid molecule of the invention has cytosstatic, anti-HIV, and anti-
CC      rheumatic activity. The nucleic acid molecules are useful for reducing
CC      HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC      also useful for treating breast, ovarian, colorectal, lung, prostate,
CC      bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC      shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC      ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC      ribozymes of the invention
XX
SQ      Sequence 17 BP; 2 A; 8 C; 3 G; 0 T; 4 U; 0 Other;

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      571 TGTGAAGCCCGAGTG 586
Db      17 TGTGAAGCCCGAGG 2

RESULT 1037
ID      ABZ61923/c
XX
AC      ABZ61923 standard; RNA; 17 BP.
XX
XX      ABZ61923;

QY      263 CTGCACCTGCCTTCAG 278
Db      1 CUCUCCUGCCUUCAG 16

RESULT 1036
ID      ABZ61885 standard; RNA; 17 BP.
XX
AC      ABZ61885;
XX
DT      21-MAR-2003 (first entry)
XX
DE      Human H-Ras DNzyme target #676.
XX
KW      Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW      enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosstatic; anti-HIV;
KW      anti-rheumatic; cancer; AIDS; ss.
XX
OS      Homo sapiens.
XX
PN      WO200297114-A2.
XX
PD      05-DEC-2002.
XX
PF      29-MAY-2002; 2002WO-US016840.
XX
PR      29-MAY-2001; 2001US-0294140P.
PR      06-JUN-2001; 2001US-0296249P.
PR      10-SEP-2001; 2001US-0318471P.
XX
PA      (RIBO-) RIBOZYME PHARM INC.
XX
PI      Mcswiggen J;
XX
DR      WPI; 2003-140484/13.
XX
PT      Novel short interfering RNA and enzymatic nucleic acid useful for
PT      treating cancer, modulates the expression of a nucleic acid encoding
PT      HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS      Claim 58; Page 124; 185pp; English.
XX
CC      The invention relates to a novel short interfering RNA (siRNA) nucleic
CC      acid molecule or an enzymatic nucleic acid molecule, that modulates
CC      expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC      human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC      acid molecule of the invention has cytosstatic, anti-HIV, and anti-
CC      rheumatic activity. The nucleic acid molecules are useful for reducing
CC      HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC      also useful for treating breast, ovarian, colorectal, lung, prostate,
CC      bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC      shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC      ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC      ribozymes of the invention
XX
SQ      Sequence 17 BP; 1 A; 5 C; 7 G; 0 T; 4 U; 0 Other;

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      740 CAGTGGACGACGCTGC 755
Db      17 CAGACGACGACGCTGC 2

RESULT 1038
ABZ64678
ID      ABZ64678 standard; RNA; 17 BP.
XX
AC      ABZ64678;
XX
DT      21-MAR-2003 (first entry)
XX
DE      Human HER2 DNzyme substrate #135.
XX
KW      Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW      enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosstatic; anti-HIV;
KW      anti-rheumatic; cancer; AIDS; ss.
XX
OS      Homo sapiens.
XX
PN      WO200297114-A2.

```

```

XX 05-DEC-2002.
PD 29-MAY-2002; 2002WO-US016840.
XX
XX 29-MAY-2001; 2001US-0294140P.
XX 06-JUN-2001; 2001US-0296249P.
PR 10-SEP-2001; 2001US-0318471P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Mcswiggen J;
XX
XX WPI; 2003-140484/13.
XX
XX Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
XX Claim 4; Page 135; 185pp; English.
XX
XX The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in ABZ59899 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
XX Sequence 17 BP; 2 A; 5 C; 7 G; 0 T; 3 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.2e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
QY 512 CTGCGGGAGGTGGAGC 527
DB 1 CUGCGGGAGCGCAGC 16
RESULT 1039
ACDS1596/C
ID ACDS1596 standard; RNA; 17 BP.
XX
XX ACDS1596;
XX
XX 24-SEP-2003 (first entry)
XX
XX HBV hammerhead ribozyme substrate sequence #654.
XX
XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
XX RNA stability; RNA expression; RNA synthesis; antisense;
XX enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
XX amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
XX HBV reverse transcriptase; Enhancer I region; viral replication;
XX degenerative; disease state; HBV infection; HCV infection; cirrhosis;
XX liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
XX virucide; antiinflammatory; substrate; ss.
XX
XX Hepatitis B virus.
XX
XX WO200201494-A1.
XX
XX 17-OCT-2002.
XX
XX 26-MAR-2002; 2002WO-US009187.
XX
XX 26-MAR-2001; 2001US-00817879.
XX

```

```

PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MACE/) MACEJAK D.
XX (MCSW/) MCSWIGGEN J.
XX (MORR/) MORRISSEY D.
XX (PAVC/) PAVCO P.
XX (LEER/) LEE P.
XX (DRAP/) DRAPER K.
XX (ROBE/) ROBERTS E.
XX
XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX
XX WPI; 2003-229207/22.
XX
XX Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
XX Example 1; Page 148; 387pp; English.
XX
XX The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HBV
CC ribozyme, inozyme, G-cleaver, zinzyme, DNAzyme or amberzyme sequences
CC disclosed in the present invention
XX
XX Sequence 17 BP; 0 A; 11 C; 1 G; 0 T; 5 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 406 GAGGAGGAGGAGGAG 421
DB 16 GAGGAGGAGGAGGAG 1
RESULT 1040
ACD64419/C
ID ACD64419 standard; RNA; 17 BP.
XX
XX ACD64419;
XX
XX 30-SEP-2003 (first entry)
XX
XX HCV minus strand DNAzyme substrate sequence #1554.
XX
XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
XX RNA stability; RNA expression; RNA synthesis; antisense;
XX enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
XX amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
XX HBV reverse transcriptase; Enhancer I region; viral replication;
XX degenerative; disease state; HBV infection; HCV infection; cirrhosis;
XX liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
XX

```

KW virucide; antiinflammatory; substrate; ss.
 XX Hepatitis C virus.
 OS WO200281494-A1.
 XX 17-OCT-2002.
 XX 26-MAR-2002; 2002WO-US009187.
 XX 26-MAR-2001; 2001US-00817879.
 PR 08-JUN-2001; 2001US-00877478.
 PR 08-JUN-2001; 2001US-0296876P.
 PR 24-OCT-2001; 2001US-0335059P.
 PR 05-DEC-2001; 2001US-0337055P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MACE/) MACEJAK D.
 PA (MCSW/) MCSWIGGEN J.
 PA (MORR/) MORRISSEY D.
 PA (PAVC/) PAVCO P.
 PA (LEEP/) LEE P.
 PA (DRAP/) DRAPER K.
 PA (ROBE/) ROBERTS E.
 XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
 PI Draper K, Roberts E;
 PI WPI; 2003-229207/22.
 DR Novel compound useful for treating cirrhosis, liver failure,
 XX hepatocellular carcinoma, or condition associated with hepatitis C virus
 PT infection.
 PT Claim 1; Page 302; 387pp; English.
 XX The present invention relates to nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
 CC inozymes, zinzymes, ambezymes, and G-cleaver ribozymes. Also disclosed
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV
 CC DNA. The nucleic acids may be used to modulate the expression of HBV
 CC genes and HBV viral replication. Also disclosed is a method for screening
 CC compounds and/or potential therapies directed against HBV, and compounds
 CC that modulate the expression and/or replication of HCV. The compounds and
 CC methods of the invention are useful for the treatment of degenerative and
 CC disease states related to HBV and HCV infection, replication and gene
 CC expression such as cirrhosis, liver failure, and hepatocellular
 CC carcinoma. The present sequence represents a substrate for one of the HCV
 CC DNazyme or minus strand DNazyme sequences disclosed in the present
 CC invention
 XX Sequence 17 BP; 3 A; 7 C; 3 G; 0 T; 4 U; 0 Other;
 SQ Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 829 GGCCAGTTCAGGTG 844
 DB 16 GGCCAGTTCAGGTG 1
 RESULT 1041
 ACD63931
 ID ACD63931 standard; RNA; 17 BP.
 XX
 AC ACD63931;
 XX

DT 30-SEP-2003 (first entry)
 XX HCV minus strand DNazyme substrate sequence #1290.
 KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
 XX RNA stability; RNA expression; RNA synthesis; antisense;
 KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;
 KW amberyne; G-cleaver ribozyme; decoy molecule; aptamer;
 KW HBV reverse transcriptase; Enhancer I region; HCV infection; cirrhosis;
 KW degenerative; disease state; HBV infection; liver failure; hepatocellular
 KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
 KW virucide; antiinflammatory; substrate; ss.
 XX Hepatitis C virus.
 OS WO200281494-A1.
 XX 17-OCT-2002.
 XX 26-MAR-2002; 2002WO-US009187.
 XX 26-MAR-2001; 2001US-00817879.
 PR 08-JUN-2001; 2001US-00877478.
 PR 08-JUN-2001; 2001US-0296876P.
 PR 24-OCT-2001; 2001US-0335059P.
 PR 05-DEC-2001; 2001US-0337055P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MACE/) MACEJAK D.
 PA (MCSW/) MCSWIGGEN J.
 PA (MORR/) MORRISSEY D.
 PA (PAVC/) PAVCO P.
 PA (LEEP/) LEE P.
 PA (DRAP/) DRAPER K.
 PA (ROBE/) ROBERTS E.
 XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
 PI Draper K, Roberts E;
 PI WPI; 2003-229207/22.
 DR Novel compound useful for treating cirrhosis, liver failure,
 XX hepatocellular carcinoma, or condition associated with hepatitis C virus
 PT infection.
 PT Claim 1; Page 298; 387pp; English.
 XX The present invention relates to nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
 CC inozymes, zinzymes, ambezymes, and G-cleaver ribozymes. Also disclosed
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV
 CC DNA. The nucleic acids may be used to modulate the expression of HBV
 CC genes and HBV viral replication. Also disclosed is a method for screening
 CC compounds and/or potential therapies directed against HBV, and compounds
 CC that modulate the expression and/or replication of HCV. The compounds and
 CC methods of the invention are useful for the treatment of degenerative and
 CC disease states related to HBV and HCV infection, replication and gene
 CC expression such as cirrhosis, liver failure, and hepatocellular
 CC carcinoma. The present sequence represents a substrate for one of the HCV
 CC DNazyme or minus strand DNazyme sequences disclosed in the present
 CC invention
 XX Sequence 17 BP; 2 A; 4 C; 8 G; 0 T; 3 U; 0 Other;
 SQ Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 75.0%; Pred. No. 7.2e+02;
 Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
 QY 829 GGCCAGTTCAGGTG 844
 DB 16 GGCCAGTTCAGGTG 1
 RESULT 1041
 ACD63931
 ID ACD63931 standard; RNA; 17 BP.
 XX
 AC ACD63931;
 XX

Qy 735 GCGTGCAGGTGGACCA 750
 Db 1 GCGUGUAGGUGGGCCA 16

RESULT 1042
 ACDS3095/C
 ID ACDS3095 standard; RNA; 17 BP.
 XX AC ACDS3095;
 XX 24-SEP-2003 (first entry)
 DT
 DE HBV inozyme substrate sequence #715.

Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
 RNA stability; RNA expression; RNA synthesis; antisense;
 enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;
 amberyne; G-cleaver ribozyme; decoy molecule; aptamer;
 HBV reverse transcriptase; Enhancer I region; viral replication;
 degenerative; disease state; HBV infection; HCV infection; cirrhosis;
 liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
 virucide; antiinflammatory; substrate; ss.

OS Hepatitis B virus.
 XX
 XX WO200281494-A1.
 XX
 XX 17-OCT-2002.
 XX
 XX 26-MAR-2002; 2002WO-US009187.
 XX
 XX 26-MAR-2001; 2001US-00817879.
 PR 08-JUN-2001; 2001US-00877478.
 PR 08-JUN-2001; 2001US-0296876P.
 PR 24-OCT-2001; 2001US-0335059P.
 PR 05-DEC-2001; 2001US-0337055P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MACE/) MACEJAK D.
 PA (MCSW/) MCSWIGGEN J.
 PA (MORR/) MORRISSEY D.
 PA (PVC/) PAVCO P.
 PA (LEPP/) LEE P.
 PA (DRAP/) DRAPER K.
 PA (ROBE/) ROBERTS E.
 XX
 XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
 PI Draper K, Roberts E;
 XX WPI; 2003-229207/22.

Novel compound useful for treating cirrhosis, liver failure,
 hepatocellular carcinoma, or condition associated with hepatitis C virus
 infection.

Example 1; Page 164; 387pp; English.

The present invention relates to nucleic acid molecules which modulate
 the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
 Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
 and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
 inozymes, zinzymes, amberyne, and G-cleaver ribozymes. Also disclosed
 are nucleic acid decoy molecules and aptamers that bind to HBV reverse
 transcriptase and/or HBV reverse transcriptase primer sequences, as well
 as oligonucleotides that specifically bind the Enhancer I region of HBV
 DNA. The nucleic acids may be used to modulate the expression of HBV
 genes and HBV viral replication. Also disclosed is a method for screening
 compounds and/or potential therapies directed against HBV, and compounds
 that modulate the expression and/or replication of HCV. The compounds and
 methods of the invention are useful for the treatment of degenerative and
 disease states related to HBV and HCV infection, replication and gene

CC expression such as cirrhosis, liver failure, and hepatocellular
 CC carcinoma. The present sequence represents a substrate for one of the HBV
 CC ribozyme, inozyme, G-cleaver, zinzyme, DNazyme or amberyne sequences
 CC disclosed in the present invention

XX
 SQ Sequence 17 BP; 0 A; 10 C; 2 G; 0 T; 5 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 406 GAGGAGGAGGAGGAG 421
 Db 17 GAGGAGGAGGAGGAG 2

RESULT 1043
 ACDS5033
 ID ACDS5033 standard; RNA; 17 BP.
 XX AC ACDS5033;
 XX 24-SEP-2003 (first entry)
 DT
 DE HCV DNazyme substrate sequence #1115.

Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
 RNA stability; RNA expression; RNA synthesis; antisense;
 enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;
 amberyne; G-cleaver ribozyme; decoy molecule; aptamer;
 HBV reverse transcriptase; Enhancer I region; viral replication;
 degenerative; disease state; HBV infection; HCV infection; cirrhosis;
 liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
 virucide; antiinflammatory; substrate; ss.

OS Hepatitis C virus.
 XX
 XX WO200281494-A1.
 XX
 XX 17-OCT-2002.
 XX
 XX 26-MAR-2002; 2002WO-US009187.
 XX
 XX 26-MAR-2001; 2001US-00817879.
 PR 08-JUN-2001; 2001US-00877478.
 PR 08-JUN-2001; 2001US-0296876P.
 PR 24-OCT-2001; 2001US-0335059P.
 PR 05-DEC-2001; 2001US-0337055P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MACE/) MACEJAK D.
 PA (MCSW/) MCSWIGGEN J.
 PA (MORR/) MORRISSEY D.
 PA (PVC/) PAVCO P.
 PA (LEPP/) LEE P.
 PA (DRAP/) DRAPER K.
 PA (ROBE/) ROBERTS E.
 XX
 XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
 PI Draper K, Roberts E;
 XX WPI; 2003-229207/22.

Novel compound useful for treating cirrhosis, liver failure,
 hepatocellular carcinoma, or condition associated with hepatitis C virus
 infection.

Example 1; Page 254; 387pp; English.

The present invention relates to nucleic acid molecules which modulate
 the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
 Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
 and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
 inozymes, zinzymes, amberyne, and G-cleaver ribozymes. Also disclosed
 are nucleic acid decoy molecules and aptamers that bind to HBV reverse
 transcriptase and/or HBV reverse transcriptase primer sequences, as well
 as oligonucleotides that specifically bind the Enhancer I region of HBV
 DNA. The nucleic acids may be used to modulate the expression of HBV
 genes and HBV viral replication. Also disclosed is a method for screening
 compounds and/or potential therapies directed against HBV, and compounds
 that modulate the expression and/or replication of HCV. The compounds and
 methods of the invention are useful for the treatment of degenerative and
 disease states related to HBV and HCV infection, replication and gene

CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
 CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV
 CC DNA. The nucleic acids may be used to modulate the expression of HBV
 CC genes and HBV viral replication. Also disclosed is a method for screening
 CC compounds and/or potential therapies directed against HBV, and compounds
 CC that modulate the expression and/or replication of HCV. The compounds and
 CC methods of the invention are useful for the treatment of degenerative and
 CC disease states related to HBV and HCV infection, replication and gene
 CC expression such as cirrhosis, liver failure, and hepatocellular
 CC carcinoma. The present sequence represents a substrate for one of the HCV
 CC DNazyme or minus strand DNazyme sequences disclosed in the present
 CC invention
 XX
 SQ Sequence 17 BP; 4 A; 6 C; 2 G; 0 T; 5 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 56.2%; Pred. No. 7.2e+02;
 Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
 QY 383 CTTCTGCATTCCAAG 398
 Db 1 CUUCUGCCAUCUCCAAG 16
 RESULT 1044
 ACDS7181/C
 ID ACDS7181 standard; RNA; 17 BP.
 AC ACDS7181;
 XX
 DT 23-SEP-2003 (first entry)
 XX
 DE HCV DNazyme substrate sequence #215.
 XX
 KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
 KW RNA stability; RNA expression; RNA synthesis; antisense;
 KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; zinzyme; zinzyme;
 KW amberyne; G-cleaver ribozyme; decoy molecule; aptamer;
 KW HBV reverse transcriptase; Enhancer I region; viral replication;
 KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
 KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
 KW virucide; antiinflammatory; substrate; ss.
 XX
 OS Hepatitis C virus.
 XX
 PN WO200281494-A1.
 XX
 PD 17-OCT-2002.
 XX
 XX 26-MAR-2002; 2002WO-US009187.
 XX
 PR 26-MAR-2001; 2001US-00817879.
 PR 08-JUN-2001; 2001US-00877478.
 PR 08-JUN-2001; 2001US-0296876P.
 PR 24-OCT-2001; 2001US-0335059P.
 PR 05-DEC-2001; 2001US-0337055P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MACE/) MACEJAK D.
 PA (MCSW/) MCSWIGGEN J.
 PA (MORR/) MORRISSEY D.
 PA (PAVC/) PAVCO P.
 PA (LEEP/) LEE P.
 PA (DRAP/) DRAPER K.
 PA (ROBE/) ROBERTS E.
 XX
 PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
 PI Draper K, Roberts E;
 XX

DR WPI; 2003-229207/22.
 XX
 PT Novel compound useful for treating cirrhosis, liver failure,
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus
 PT infection.
 XX
 XX Claim 1; Page 237; 387pp; English.
 PS
 CC The present invention relates to nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
 CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV
 CC DNA. The nucleic acids may be used to modulate the expression of HBV
 CC genes and HBV viral replication. Also disclosed is a method for screening
 CC compounds and/or potential therapies directed against HBV, and compounds
 CC that modulate the expression and/or replication of HCV. The compounds and
 CC methods of the invention are useful for the treatment of degenerative and
 CC disease states related to HBV and HCV infection, replication and gene
 CC expression such as cirrhosis, liver failure, and hepatocellular
 CC carcinoma. The present sequence represents a substrate for one of the HCV
 CC DNazyme or minus strand DNazyme sequences disclosed in the present
 CC invention
 XX
 SQ Sequence 17 BP; 3 A; 5 C; 5 G; 0 T; 4 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 181 TGAGATGGTGCGAGCCC 196
 Db 17 TGACATGGTACAGCCC 2
 RESULT 1045
 ACC66800/C
 ID ACC66800 standard; DNA; 17 BP.
 XX
 AC ACC66800;
 XX
 DT 01-JUL-2003 (first entry)
 XX
 DE Murine oligonucleotide associated with tumour suppression, SEQ ID 4047.
 XX
 KW Cytostatic; virucide; neuroprotective; neurotropic; neuroleptic; murine;
 KW tumour suppression; tumour reversion; apoptosis; virus resistance;
 KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizoprenia; ss.
 XX
 OS Mus musculus.
 XX
 PN WO2003025176-A2.
 XX
 PD 27-MAR-2003.
 XX
 PF 17-SEP-2002; 2002WO-IB004210.
 XX
 PR 17-SEP-2001; 2001FR-00011979.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Telerman A, Anson R, Tuijnder M;
 XXr
 DR WPI; 2003-333167/31.
 XX
 PT New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.
 XX

PS Disclosure; Page 504; 738pp; French.

XX The present invention relates to murine oligonucleotides (ACC62754-ACC68806), which are associated with tumour suppression, tumour

CC reversal, apoptosis and virus resistance. The oligonucleotides are

CC useful as (1) as probes and primers for detecting, identifying,

CC quantifying and/or amplifying nucleic acid, e.g. as one component of a

CC gene chip; in vitro as (anti)sense reagents; and (2) for production of a

CC recombinant polypeptides. The oligonucleotides are useful for preparation

CC of pharmaceuticals for prevention and/or treatment of viral diseases that

CC are characterised by development of tumours or cell degeneration,

CC specifically cancer but also Alzheimer's disease and schizophrenia

XX

SQ Sequence 17 BP; 3 A; 4 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 7.2e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 570 CTGTGAAGCCAGGT 585

Db 17 CTGTGACAGCCAGAT 2

RESULT 1046

ACC66750

ID ACC66750 standard; DNA; 17 BP.

XX

AC ACC66750;

XX

DT 01-JUL-2003 (first entry)

XX

DE Murine oligonucleotide associated with tumour suppression, SEQ ID 3997.

XX

KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;

KW tumour suppression; tumour reversion; apoptosis; virus resistance;

KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;

KW schizophrenia; ss.

XX

XX Mus musculus.

XX

XX WO2003025176-A2.

XX

XX 27-MAR-2003.

XX

XX 17-SEP-2002; 2002WO-IB004210.

XX

XX 17-SEP-2001; 2001FR-00011979.

XX

XX (MOLE-) MOLECULAR ENGINES LAB.

XX

XX Telerman A, Amson R, Tuijnder M;

XX

XX WPI; 2003-333167/31.

XX

XX New isolated nucleic acid, useful for treating viral diseases associated

XX with tumours and cell degeneration, also related polypeptides, antibodies

XX and transfected cells.

XX

PS Disclosure; Page 498; 738pp; French.

XX

XX The present invention relates to murine oligonucleotides (ACC62754-ACC68806), which are associated with tumour suppression, tumour

CC reversal, apoptosis and virus resistance. The oligonucleotides are

CC useful as (1) as probes and primers for detecting, identifying,

CC quantifying and/or amplifying nucleic acid, e.g. as one component of a

CC gene chip; in vitro as (anti)sense reagents; and (2) for production of

CC recombinant polypeptides. The oligonucleotides are useful for preparation

CC of pharmaceuticals for prevention and/or treatment of viral diseases that

CC are characterised by development of tumours or cell degeneration,

CC specifically cancer but also Alzheimer's disease and schizophrenia

XX

SQ Sequence 17 BP; 5 A; 3 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 7.2e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 485 GATCTGAAGGCGAGA 500

Db 1 GATCTGAAGTGGCACA 16

RESULT 1047

ADB43036/c

ID ADB43036 standard; DNA; 17 BP.

XX

AC ADB43036;

XX

DT 18-DEC-2003 (revised)

DT 04-DEC-2003 (first entry)

XX

DE Tumour suppression/reversion associated nucleotide #3359.

XX

KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;

KW primer; probe; tumour suppression; tumour reversion; apoptosis;

KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;

KW diagnosis.

XX

XX Homo sapiens.

XX

XX WO2003040369-A2.

XX

XX 15-MAY-2003.

XX

XX 17-SEP-2002; 2002WO-IB004219.

XX

XX 17-SEP-2001; 2001FR-00011981.

XX

XX (MOLE-) MOLECULAR ENGINES LAB.

XX

XX Telerman A, Amson R, Tuijnder M;

XX

XX WPI; 2003-441574/41.

XX

XX New nucleic acid encoding human prostate membrane-specific antigen,

XX useful e.g. for treatment of tumors and viral infection, also related

XX polypeptide and antibodies.

XX

PS Disclosure; Page 424; 771pp; French.

XX

XX The invention relates to the isolation of 6327 nucleotide sequences,

XX fragments of at least 15 consecutive nucleotides of these nucleotides, a

XX sequence having at least 80% identity, after optimal alignment, with the

XX nucleotides, a sequence that hybridizes under stringent conditions with

XX the nucleotides, or the complement, or corresponding RNA, of the

XX nucleotides. The nucleotides are used as probes or primers for detecting,

XX identifying, quantifying and/or amplifying nucleic acids, as in vitro

XX sense and antisense sequences, of nucleotides involved in tumour

XX suppression or reversion, apoptosis and or viral resistance, to produce

XX recombinant polypeptides, and to prepare transgenic animals, as

XX experimental models. The nucleotides (also vectors containing them and

XX cells containing the vectors), the encoded polypeptides and antibodies

XX (Ab) against the polypeptide are useful for prevention and/or treatment

XX of viral infections or diseases characterized by development of tumours

XX or cell degeneration (e.g. Alzheimer's disease or schizophrenia).

XX Analysis of the expression of the nucleotides can be used for diagnosis

XX and/or prognosis of these diseases. The nucleotides and polypeptides can

XX also be used to screen for their specific interactive molecules,

XX potentially useful for treating diseases associated with abnormal

XX expression of the nucleotides.

XX

SQ Sequence 17 BP; 3 A; 1 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 7.2e+02;

Matches	14;	Conservative	0;	Mismatches	2;	Indels	0;	Gaps	0;
QY	874	CAACCATCATCAGAGC	889						
Db	16	CACCCACATCAGATC	1						
RESULT 1048									
ADB43479/C									
ID	ADB43479	standard; DNA; 17 BP.							
XX	AC	ADB43479;							
XX	AC								
XX	DT	18-DEC-2003 (revised)							
DT	04-DEC-2003	(first entry)							
XX	XX	Tumour suppression/reversion associated nucleotide #3802.							
DE	DE								
XX	XX	cytostatic; antiviral; neuroprotective; nontropic; neuroleptic; ss;							
KW	KW	primer; probe; tumour suppression; tumour reversion; apoptosis;							
KW	KW	virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;							
KW	KW	diagnosis.							
XX	XX	Homo sapiens.							
OS	OS								
XX	XX	WO2003040369-A2.							
PN	PN								
XX	XX	15-MAY-2003.							
PD	PD								
XX	XX	17-SEP-2002; 2002WO-IB004219.							
PF	PF								
XX	XX	17-SEP-2001; 2001FR-00011981.							
PR	PR								
XX	XX	(MOL-) MOLECULAR ENGINES LAB.							
PA	PA								
XX	XX	Telerman A, Amson R, Tuijnder M;							
PI	PI								
XX	XX	WPI; 2003-441574/41.							
DR	DR								
XX	XX	New nucleic acid encoding human prostate membrane-specific antigen,							
PT	PT	useful e.g. for treatment of tumors and viral infection, also related							
PT	PT	polypeptide and antibodies.							
XX	XX	Disclosure; Page 476; 771pp; French.							
PS	PS								
XX	XX	The invention relates to the isolation of 6327 nucleotide sequences,							
CC	CC	fragments of at least 15 consecutive nucleotides of these nucleotides, a							
CC	CC	sequence having at least 80% identity, after optimal alignment, with the							
CC	CC	nucleotides, a sequence that hybridizes under stringent conditions with							
CC	CC	the nucleotides, or the complement, or corresponding RNA, of the							
CC	CC	nucleotides. The nucleotides are used as probes or primers for detecting,							
CC	CC	identifying, quantifying and/or amplifying nucleic acids, as in vitro							
CC	CC	sense and antisense sequences, of nucleotides involved in tumour							
CC	CC	suppression or reversion, apoptosis and or viral resistance, to produce							
CC	CC	recombinant polypeptides, and to prepare transgenic animals, as							
CC	CC	experimental models. The nucleotides (also vectors containing them and							
CC	CC	cells containing the vectors), the encoded polypeptides and antibodies							
CC	CC	(Ab) against the polypeptide are useful for prevention and/or treatment							
CC	CC	of viral infections or diseases characterized by development of tumours							
CC	CC	or cell degeneration (e.g. Alzheimer's disease or schizophrenia).							
CC	CC	Analysis of the expression of the nucleotides can be used for diagnosis							
CC	CC	and/or prognosis of these diseases. The nucleotides and polypeptides can							
CC	CC	also be used to screen for their specific interactive molecules,							
CC	CC	potentially useful for treating diseases associated with abnormal							
CC	CC	expression of the nucleotides.							
XX	XX	Sequence 17 BP; 2 A; 7 C; 5 G; 3 T; 0 U; 0 Other;							
SQ	SQ								
Query Match		1.7%; Score 12.8; DB 1; Length 17;							
Best Local Similarity		87.5%; Pred. No. 7.2e+02;							
Matches	14;	Conservative	0;	Mismatches	2;	Indels	0;	Gaps	0;
QY	203	GGCCCGGCGAGATC	218						

Db	16	GGCTGGCAGATC	1						
RESULT 1049									
ADB42794/C									
ID	ADB42794	standard; DNA; 17 BP.							
XX	AC	ADB42794;							
XX	AC								
XX	DT	18-DEC-2003 (revised)							
DT	04-DEC-2003	(first entry)							
XX	XX	Tumour suppression/reversion associated nucleotide #3117.							
DE	DE								
XX	XX	cytostatic; antiviral; neuroprotective; nontropic; neuroleptic; ss;							
KW	KW	primer; probe; tumour suppression; tumour reversion; apoptosis;							
KW	KW	virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;							
KW	KW	diagnosis.							
XX	XX	Homo sapiens.							
OS	OS								
XX	XX	WO2003040369-A2.							
PN	PN								
XX	XX	15-MAY-2003.							
PD	PD								
XX	XX	17-SEP-2002; 2002WO-IB004219.							
PF	PF								
XX	XX	17-SEP-2001; 2001FR-00011981.							
PR	PR								
XX	XX	(MOLE-) MOLECULAR ENGINES LAB.							
PA	PA								
XX	XX	Telerman A, Amson R, Tuijnder M;							
PI	PI								
XX	XX	WPI; 2003-441574/41.							
DR	DR								
XX	XX	New nucleic acid encoding human prostate membrane-specific antigen,							
PT	PT	useful e.g. for treatment of tumors and viral infection, also related							
PT	PT	polypeptide and antibodies.							
XX	XX	Disclosure; Page 396; 771pp; French.							
PS	PS								
XX	XX	The invention relates to the isolation of 6327 nucleotide sequences,							
CC	CC	fragments of at least 15 consecutive nucleotides of these nucleotides, a							
CC	CC	sequence having at least 80% identity, after optimal alignment, with the							
CC	CC	nucleotides, a sequence that hybridizes under stringent conditions with							
CC	CC	the nucleotides, or the complement, or corresponding RNA, of the							
CC	CC	nucleotides. The nucleotides are used as probes or primers for detecting,							
CC	CC	identifying, quantifying and/or amplifying nucleic acids, as in vitro							
CC	CC	sense and antisense sequences, of nucleotides involved in tumour							
CC	CC	suppression or reversion, apoptosis and or viral resistance, to produce							
CC	CC	recombinant polypeptides, and to prepare transgenic animals, as							
CC	CC	experimental models. The nucleotides (also vectors containing them and							
CC	CC	cells containing the vectors), the encoded polypeptides and antibodies							
CC	CC	(Ab) against the polypeptide are useful for prevention and/or treatment							
CC	CC	of viral infections or diseases characterized by development of tumours							
CC	CC	or cell degeneration (e.g. Alzheimer's disease or schizophrenia).							
CC	CC	Analysis of the expression of the nucleotides can be used for diagnosis							
CC	CC	and/or prognosis of these diseases. The nucleotides and polypeptides can							
CC	CC	also be used to screen for their specific interactive molecules,							
CC	CC	potentially useful for treating diseases associated with abnormal							
CC	CC	expression of the nucleotides.							
XX	XX	Sequence 17 BP; 1 A; 6 C; 3 G; 7 T; 0 U; 0 Other;							
SQ	SQ								
Query Match		1.7%; Score 12.8; DB 1; Length 17;							
Best Local Similarity		87.5%; Pred. No. 7.2e+02;							
Matches	14;	Conservative	0;	Mismatches	2;	Indels	0;	Gaps	0;
QY	345	GGCAGGCGACCATCAT	360						
Db	17	GGAGAGCAAGCAGAT	2						


```
RESULT 1050
ADC03749
ID   ADC03749 standard; DNA; 17 BP.
XX
XX   AC   ADC03749;
XX
XX   DT   18-DEC-2003 (first entry)
XX
XX   DE   Human Na/H exchanger-like protein 1 gene oligonucleotide #196.
XX
XX   ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein;
XX   NHELP1; passive replacement therapy; vaccine; diagnosis.
XX
XX   KW   Homo sapiens.
XX
XX   OS   EPI273660-A2.
XX
XX   FN   08-JAN-2003.
XX
XX   PD   25-JAN-2002; 2002EP-00001160.
XX
XX   PF   30-JAN-2001; 2001WO-US000666.
XX
XX   PR   23-MAY-2001; 2001US-00864761.
XX
XX   PR   21-DEC-2001; 2001US-0343331P.
XX
XX   PA   (AEOM-) AEOMICA INC.
XX
XX   PI   Gu Y;
XX
XX   PI   WPI; 2003-302724/30.
XX
XX   DR   New human sodium-hydrogen exchanger like protein 1 (NHELP1), useful as a
XX   PT   passive replacement therapy or as a vaccine for treating or preventing
XX   PT   disorders associated with aberrant expression or activity of human
XX   PT   NHELP1.
XX
XX   PS   Example 2; SEQ ID NO 236; 468pp; English.
XX
XX   CC   The invention relates to a nucleic acid molecule which encodes a Na+/H+
XX   CC   exchanger like protein (NHELP1). The NHELP1 nucleic acid molecule, NHELP1
XX   CC   polypeptide, an antibody against the protein or its antigen-binding
XX   CC   fragment is useful in therapy. The NHELP1 nucleic acid molecule, NHELP1
XX   CC   polypeptide and an agonist are particularly useful for manufacturing a
XX   CC   medicament for treating or preventing a disorder associated with
XX   CC   decreased expression or activity of human NHELP1. The antibody or its
XX   CC   antigen-binding fragment, and an antagonist, are useful for manufacturing
XX   CC   a medicament for treating or preventing a disorder associated with
XX   CC   increased expression or activity of human NHELP1. The NHELP1 nucleic acid
XX   CC   or protein is useful as passive replacement therapy, as a vaccine, or in
XX   CC   diagnostic methods. This sequence corresponds to a 17-mer oligonucleotide
XX   CC   spanning the sequence of the human NHELP1 gene (ADC03514).
XX
XX   SQ   Sequence 17 BP; 6 A; 2 C; 7 G; 2 T; 0 U; 0 Other;
XX
XX   Query Match      1.7%; Score 12.8; DB 1; Length 17;
XX   Best Local Similarity 87.5%; Pred. No. 7.2e+02;
XX   Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX   Qy   448 CAGGAACCTGGTGAG 463
XX   Db   2 CATGAACCTGGAGGAG 17
XX
XX   RESULT 1051
XX   ADC04990/c
XX   ID   ADC04990 standard; DNA; 17 BP.
XX
XX   AC   ADC04990;
XX
XX   DT   18-DEC-2003 (first entry)
XX
XX   DE   Human Na/H exchanger-like protein 1 gene oligonucleotide #1437.
XX
```

```
XX
XX   ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein;
XX   NHELP1; passive replacement therapy; vaccine; diagnosis.
XX
XX   KW   Homo sapiens.
XX
XX   OS   EPI273660-A2.
XX
XX   FN   08-JAN-2003.
XX
XX   PD   25-JAN-2002; 2002EP-00001160.
XX
XX   PF   30-JAN-2001; 2001WO-US000666.
XX
XX   PR   23-MAY-2001; 2001US-00864761.
XX
XX   PR   21-DEC-2001; 2001US-0343331P.
XX
XX   PA   (AEOM-) AEOMICA INC.
XX
XX   PI   Gu Y;
XX
XX   PI   WPI; 2003-302724/30.
XX
XX   DR   New human sodium-hydrogen exchanger like protein 1 (NHELP1), useful as a
XX   PT   passive replacement therapy or as a vaccine for treating or preventing
XX   PT   disorders associated with aberrant expression or activity of human
XX   PT   NHELP1.
XX
XX   PS   Example 2; SEQ ID NO 1477; 468pp; English.
XX
XX   CC   The invention relates to a nucleic acid molecule which encodes a Na+/H+
XX   CC   exchanger like protein (NHELP1). The NHELP1 nucleic acid molecule, NHELP1
XX   CC   polypeptide, an antibody against the protein or its antigen-binding
XX   CC   fragment is useful in therapy. The NHELP1 nucleic acid molecule, NHELP1
XX   CC   polypeptide and an agonist are particularly useful for manufacturing a
XX   CC   medicament for treating or preventing a disorder associated with
XX   CC   decreased expression or activity of human NHELP1. The antibody or its
XX   CC   antigen-binding fragment, and an antagonist, are useful for manufacturing
XX   CC   a medicament for treating or preventing a disorder associated with
XX   CC   increased expression or activity of human NHELP1. The NHELP1 nucleic acid
XX   CC   or protein is useful as passive replacement therapy, as a vaccine, or in
XX   CC   diagnostic methods. This sequence corresponds to a 17-mer oligonucleotide
XX   CC   spanning the sequence of the human NHELP1 gene (ADC03514).
XX
XX   SQ   Sequence 17 BP; 2 A; 9 C; 2 G; 4 T; 0 U; 0 Other;
XX
XX   Query Match      1.7%; Score 12.8; DB 1; Length 17;
XX   Best Local Similarity 87.5%; Pred. No. 7.2e+02;
XX   Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX   Qy   884 AAGAGCAGCGTGTGG 899
XX   Db   16 AGGAGCAGCGTAGTGG 1
XX
XX   RESULT 1052
XX   ADC04989/c
XX   ID   ADC04989 standard; DNA; 17 BP.
XX
XX   AC   ADC04989;
XX
XX   DT   18-DEC-2003 (first entry)
XX
XX   DE   Human Na/H exchanger-like protein 1 gene oligonucleotide #1436.
XX
XX   ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein;
XX   NHELP1; passive replacement therapy; vaccine; diagnosis.
XX
XX   KW   Homo sapiens.
XX
XX   OS   EPI273660-A2.
XX
XX   FN   08-JAN-2003.
XX
```

```

PF 25-JAN-2002; 2002EP-00001160.
XX
PR 30-JAN-2001; 2001WO-US000666.
PR 23-MAY-2001; 2001US-00864761.
PR 21-DEC-2001; 2001US-0343331P.
XX
PA (AEOM-) AEOMICA INC.
XX
XX Gu Y;
XX
XX WPI; 2003-302724/30.
XX
XX New human sodium-hydrogen exchanger like protein 1 (NHEP1), useful as a
PT passive replacement therapy or as a vaccine for treating or preventing
PT disorders associated with aberrant expression or activity of human
PT NHEP1.
XX
XX Example 2; SEQ ID NO 1476; 468pp; English.
XX
XX The invention relates to a nucleic acid molecule which encodes a Na+/H+
CC exchanger like protein (NHEP1). The NHEP1 nucleic acid molecule, NHEP1
CC polypeptide, an antibody against the protein or its antigen-binding
CC fragment is useful in therapy. The NHEP1 nucleic acid molecule, NHEP1
CC polypeptide and an agonist are particularly useful for manufacturing a
CC medicament for treating or preventing a disorder associated with
CC decreased expression or activity of human NHEP1. The antibody or its
CC antigen-binding fragment, and an antagonist, are useful for manufacturing
CC a medicament for treating or preventing a disorder associated with
CC increased expression or activity of human NHEP1. The NHEP1 nucleic acid
CC or protein is useful as passive replacement therapy, as a vaccine, or in
CC diagnostic methods. This sequence corresponds to a 17-mer oligonucleotide
CC spanning the sequence of the human NHEP1 gene (ADC03514).
XX
XX Sequence 17 BP; 3 A; 8 C; 2 G; 4 T; 0 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 884 AAGAGCAGCGTGTGG 899
DB 17 AGGAGCAGCGTAGTGG 2
RESULT 1053
ADC03750
ID ADC03750 standard; DNA; 17 BP.
XX
AC ADC03750;
XX
XX 18-DEC-2003 (first entry)
XX
XX Human Na/H exchanger-like protein 1 gene oligonucleotide #197.
DE
XX
XX ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein;
KW NHEP1; passive replacement therapy; vaccine; diagnosis.
XX
XX Homo sapiens.
OS
XX
XX EP1273660-A2.
PN
XX
XX 08-JAN-2003.
PD
XX
XX 25-JAN-2002; 2002EP-00001160.
PF
XX
PR 30-JAN-2001; 2001WO-US000666.
PR 23-MAY-2001; 2001US-00864761.
PR 21-DEC-2001; 2001US-0343331P.
XX
XX (AEOM-) AEOMICA INC.
PA
XX
XX Gu Y;
XX
XX
XX

```

```

DR WPI; 2003-302724/30.
XX
XX New human sodium-hydrogen exchanger like protein 1 (NHEP1), useful as a
PT passive replacement therapy or as a vaccine for treating or preventing
PT disorders associated with aberrant expression or activity of human
PT NHEP1.
XX
XX Example 2; SEQ ID NO 237; 468pp; English.
XX
XX The invention relates to a nucleic acid molecule which encodes a Na+/H+
CC exchanger like protein (NHEP1). The NHEP1 nucleic acid molecule, NHEP1
CC polypeptide, an antibody against the protein or its antigen-binding
CC fragment is useful in therapy. The NHEP1 nucleic acid molecule, NHEP1
CC polypeptide and an agonist are particularly useful for manufacturing a
CC medicament for treating or preventing a disorder associated with
CC decreased expression or activity of human NHEP1. The antibody or its
CC antigen-binding fragment, and an antagonist, are useful for manufacturing
CC a medicament for treating or preventing a disorder associated with
CC increased expression or activity of human NHEP1. The NHEP1 nucleic acid
CC or protein is useful as passive replacement therapy, as a vaccine, or in
CC diagnostic methods. This sequence corresponds to a 17-mer oligonucleotide
CC spanning the sequence of the human NHEP1 gene (ADC03514).
XX
XX Sequence 17 BP; 6 A; 3 C; 6 G; 2 T; 0 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 448 CAGGAACCTGGTGGAG 463
DB 1 CATGAACTGGAGGAG 16
RESULT 1054
ADB44625/C
ID ADB44625 standard; DNA; 17 BP.
XX
AC ADB44625;
XX
XX 18-DEC-2003 (first entry)
XX
XX Tumour suppression/reversion associated nucleotide #4948.
DE
XX
XX cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.
XX
XX Homo sapiens.
OS
XX
XX WO2003040369-A2.
PN
XX
XX 15-MAY-2003.
PD
XX
XX 17-SEP-2002; 2002WO-IB004219.
PF
XX
XX 17-SEP-2001; 2001FR-00011981.
PR
XX
XX (MOLE-) MOLECULAR ENGINES LAB.
PA
XX
XX Telerman A, Amson R, Tuijnder M;
PI
XX
XX WPI; 2003-441574/41.
DR
XX
XX New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT polypeptide and antibodies.
XX
XX Disclosure; Page 610; 771pp; French.
PS
XX
XX The invention relates to the isolation of 6327 nucleotide sequences,
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC

```

CC sequence having at least 80% identity, after optimal alignment, with the
CC nucleotides, a sequence that hybridizes under stringent conditions with
CC the nucleotides, or the complement, or corresponding RNA, of the
CC nucleotides. The nucleotides are used as probes or primers for detecting,
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC sense and antisense sequences, of nucleotides involved in tumour
CC suppression or reversion, apoptosis and or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as
CC experimental models. The nucleotides (also vectors containing them and
CC cells containing the vectors), the encoded polypeptides and antibodies
CC (Ab) against the polypeptide are useful for prevention and/or treatment
CC of viral infections or diseases characterized by development of tumours
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC Analysis of the expression of the nucleotides can be used for diagnosis
CC and/or prognosis of these diseases. The nucleotides and polypeptides can
CC also be used to screen for their specific interactive molecules,
CC potentially useful for treating diseases associated with abnormal
CC expression of the nucleotides.
XX
SQ Sequence 17 BP; 2 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 537 GATGCCAGCAGCAGAT 552
Db 17 GCTGCCAGCAGCAGAT 2

RESULT 1055
ADC35279/c
ID ADC35279 standard; DNA; 17 BP.
XX
AC ADC35279;
XX
DT 18-DEC-2003 (first entry)
XX
DE MaSpII silk protein PCR primer SEQ ID 40.
XX

XX Silk; biofilament; spider; lepidopteran insect; ADF-3; ss; MaSpII; PCR;
KW primer.
XX

XX Unidentified.
OS

XX WO2003057727-A1.
PN

XX 17-JUL-2003.
PD

XX 13-JAN-2003; 2003WO-IB000346.
XX

XX 11-JAN-2002; 2002US-0347509P.
XX

XX (NEXI-) NEXIA BIOTECHNOLOGIES INC.
XX

XX Karatzas CN, Turcotte C;
XX

XX WPI; 2003-721511/68.
XX

XX New silk polypeptide for producing biofilaments having useful properties
PT similar to those of natural spider or lepidopteran insect silks, e.g.
PT strength, comprises repetitive units and a non-repetitive hydrophilic
PT amino acid domain.
XX

XX Example 1; Page 38; 77pp; English.
PS

XX The present invention relates to novel silk polypeptides (ADC35240-
CC ADC35242). The polypeptides are useful in producing biofilaments having
CC useful properties similar or superior to those of natural spider and
CC lepidopteran insect silks, such as strength and elasticity. The present
CC sequence is a PCR primer, which was used in an example from the
CC invention.
XX

SQ Sequence 17 BP; 0 A; 6 C; 8 G; 3 T; 0 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 718 GCTGCGCAGCAGCAC 733
Db 16 GCCGCGCAGCAGCCCC 1

RESULT 1056
ADF62166
ID ADF62166 standard; DNA; 17 BP.

XX
AC ADF62166;
XX

XX 12-FEB-2004 (first entry)
DT

XX Human PCCP1 DNA fragment SEQ ID 4-directed probe - SEQ ID 70.
DE

XX chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
KW human; ss; probe.
XX

XX Homo sapiens.
OS

XX WO2003050284-A1.
PN

XX 19-JUN-2003.
PD

XX 22-NOV-2002; 2002WO-US037506.
XX

XX 10-DEC-2001; 2001US-0339764P.
XX

XX (AMSH) AMERSHAM BIOSCIENCES SV CORP.
XX

XX Guo J;
XX

XX WPI; 2003-532916/50.
XX

XX New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
PT composition for treating or preventing a disorder associated with
PT decreased or increased expression or activity of PCCP1 e.g., tumor.
XX

XX Example 2; SEQ ID NO 70; 164pp; English.
PS

XX The invention relates to a novel isolated nucleic acid that encodes a
CC protein with a chromatin organisation modifier (CHROMO) domain. The
CC polynucleotide of the invention demonstrates cytostatic activity and may
CC be useful for preparing a composition for treating or preventing a
CC disorder associated with decreased or increased expression or activity of
CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
CC during gene therapy and vaccine production procedures. The current
CC sequence is that of the human PCCP1-related DNA fragment SEQ ID 4-
CC directed probe of the invention. Note: The current sequence is not shown
CC within the specification per se but was retrieved from the Wipoweb
CC database.
XX

SQ Sequence 17 BP; 4 A; 5 C; 7 G; 1 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 677 GCCGCGCAGCAGCGCG 692
Db 2 GCCGCGCAGCAGCGCG 17

RESULT 1057
ADF64207
ID ADF64207 standard; DNA; 17 BP.

```
XX ADF64207;
XX
XX 12-FEB-2004 (first entry)
XX
XX Human PCCP1 DNA fragment SEQ ID 8-directed probe - SEQ ID 2111.
XX
XX chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
XX prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
XX human; ss; probe.
XX
XX Homo sapiens.
XX
XX WO2003050284-A1.
XX
XX 19-JUN-2003.
XX
XX 22-NOV-2002; 2002WO-US037506.
XX
XX 10-DEC-2001; 2001US-0339764P.
XX (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
XX Guo J;
XX
XX WPI; 2003-532916/50.
XX
XX New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
XX composition for treating or preventing a disorder associated with
XX decreased or increased expression or activity of PCCP1 e.g., tumor.
XX
XX Example 2; SEQ ID NO 2111; 164pp; English.
XX
XX The invention relates to a novel isolated nucleic acid that encodes a
XX protein with a chromatin organisation modifier (CHROMO) domain. The
XX polynucleotide of the invention demonstrates cytostatic activity and may
XX be useful for preparing a composition for treating or preventing a
XX disorder associated with decreased or increased expression or activity of
XX PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
XX during gene therapy and vaccine production procedures. The current
XX sequence is that of the human PCCP1-related DNA fragment SEQ ID 8-
XX directed probe of the invention. Note: The current sequence is not shown
XX within the specification per se but was retrieved from the WipoWeb
XX database.
XX
XX Sequence 17 BP; 6 A; 4 C; 5 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 1.7%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 7.2e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 413 GAGAGGAGTTCCTCA 428
XX |||||
XX 2 GAGAGGAGTTCCTCA 17
XX
XX RESULT 1058
XX ADF62161
XX ID ADF62161 standard; DNA; 17 BP.
XX
XX AC ADF62161;
XX
XX 12-FEB-2004 (first entry)
XX
XX Human PCCP1 DNA fragment SEQ ID 4-directed probe - SEQ ID 65.
XX
XX chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
XX prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
XX human; ss; probe.
XX
XX Homo sapiens.
XX
XX WO2003050284-A1.
XX
XX 19-JUN-2003.
XX
XX 22-NOV-2002; 2002WO-US037506.
XX
XX 10-DEC-2001; 2001US-0339764P.
XX (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
XX Guo J;
XX
XX WPI; 2003-532916/50.
XX
XX New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
XX composition for treating or preventing a disorder associated with
XX decreased or increased expression or activity of PCCP1 e.g., tumor.
XX
XX Example 2; SEQ ID NO 2111; 164pp; English.
XX
XX The invention relates to a novel isolated nucleic acid that encodes a
XX protein with a chromatin organisation modifier (CHROMO) domain. The
XX polynucleotide of the invention demonstrates cytostatic activity and may
XX be useful for preparing a composition for treating or preventing a
XX disorder associated with decreased or increased expression or activity of
XX PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
XX during gene therapy and vaccine production procedures. The current
XX sequence is that of the human PCCP1-related DNA fragment SEQ ID 8-
XX directed probe of the invention. Note: The current sequence is not shown
XX within the specification per se but was retrieved from the WipoWeb
XX database.
XX
XX Sequence 17 BP; 6 A; 4 C; 5 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 1.7%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 7.2e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 413 GAGAGGAGTTCCTCA 428
XX |||||
XX 2 GAGAGGAGTTCCTCA 17
XX
XX RESULT 1058
XX ADF62161
XX ID ADF62161 standard; DNA; 17 BP.
XX
XX AC ADF62161;
XX
XX 12-FEB-2004 (first entry)
XX
XX Human PCCP1 DNA fragment SEQ ID 4-directed probe - SEQ ID 65.
XX
XX chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
XX prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
XX human; ss; probe.
XX
XX Homo sapiens.
XX
XX WO2003050284-A1.
XX
XX 19-JUN-2003.
XX
XX 22-NOV-2002; 2002WO-US037506.
XX
XX 10-DEC-2001; 2001US-0339764P.
XX (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
XX Guo J;
XX
XX WPI; 2003-532916/50.
XX
XX New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
```

```
XX 19-JUN-2003.
XX
XX 22-NOV-2002; 2002WO-US037506.
XX
XX 10-DEC-2001; 2001US-0339764P.
XX (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
XX Guo J;
XX
XX WPI; 2003-532916/50.
XX
XX New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
XX composition for treating or preventing a disorder associated with
XX decreased or increased expression or activity of PCCP1 e.g., tumor.
XX
XX Example 2; SEQ ID NO 65; 164pp; English.
XX
XX The invention relates to a novel isolated nucleic acid that encodes a
XX protein with a chromatin organisation modifier (CHROMO) domain. The
XX polynucleotide of the invention demonstrates cytostatic activity and may
XX be useful for preparing a composition for treating or preventing a
XX disorder associated with decreased or increased expression or activity of
XX PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
XX during gene therapy and vaccine production procedures. The current
XX sequence is that of the human PCCP1-related DNA fragment SEQ ID 4-
XX directed probe of the invention. Note: The current sequence is not shown
XX within the specification per se but was retrieved from the WipoWeb
XX database.
XX
XX Sequence 17 BP; 4 A; 4 C; 8 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 1.7%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 7.2e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 672 GGGCGCGCCAGCGAGCA 687
XX |||||
XX 2 GGGCTGCGAGCGAGCA 17
XX
XX RESULT 1059
XX ADF62163
XX ID ADF62163 standard; DNA; 17 BP.
XX
XX AC ADF62163;
XX
XX 12-FEB-2004 (first entry)
XX
XX Human PCCP1 DNA fragment SEQ ID 4-directed probe - SEQ ID 67.
XX
XX chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
XX prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
XX human; ss; probe.
XX
XX Homo sapiens.
XX
XX WO2003050284-A1.
XX
XX 19-JUN-2003.
XX
XX 22-NOV-2002; 2002WO-US037506.
XX
XX 10-DEC-2001; 2001US-0339764P.
XX (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
XX Guo J;
XX
XX WPI; 2003-532916/50.
XX
XX New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
```

PT composition for treating or preventing a disorder associated with
PT decreased or increased expression or activity of PCCP1 e.g., tumor.
PS
PS Example 2; SEQ ID NO 67; 164pp; English.
XX
XX The invention relates to a novel isolated nucleic acid that encodes a
CC protein with a chromatin organisation modifier (CHROMO) domain. The
CC polynucleotide of the invention demonstrates cytostatic activity and may
CC be useful for preparing a composition for treating or preventing a
CC disorder associated with decreased or increased expression or activity of
CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
CC during gene therapy and vaccine production procedures. The current
CC sequence is that of the human PCCP1-related DNA fragment SEQ ID 4-
CC directed probe of the invention. Note: The current sequence is not shown
CC within the specification per se but was retrieved from the Wipoweb
CC database.
XX
SQ Sequence 17 BP; 4 A; 4 C; 8 G; 1 T; 0 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 673 GCGGCGCAGCGAGCAG 688
Db 1 GGCTGCGAGCGAGCAG 16
RESULT 1060
ADF64120
ID ADF64120 standard; DNA; 17 BP.
XX
AC ADF64120;
XX
DT 12-FEB-2004 (first entry)
DE Human PCCP1 DNA fragment SEQ ID 8-directed probe - SEQ ID 2024.
XX
XX chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
KW human; ss; probe.
XX
XX Homo sapiens.
XX
XX WO2003050284-A1.
XX
XX 19-JUN-2003.
XX
XX 22-NOV-2002; 2002WO-US037506.
XX
XX 10-DEC-2001; 2001US-0339764P.
XX
XX (AMSH) AMERSHAM BIOSCIENCES SV CORP.
XX
XX Guo J;
XX
XX WPI; 2003-532916/50.
XX
XX New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
PT composition for treating or preventing a disorder associated with
PT decreased or increased expression or activity of PCCP1 e.g., tumor.
XX
XX Example 2; SEQ ID NO 2024; 164pp; English.
XX
XX The invention relates to a novel isolated nucleic acid that encodes a
CC protein with a chromatin organisation modifier (CHROMO) domain. The
CC polynucleotide of the invention demonstrates cytostatic activity and may
CC be useful for preparing a composition for treating or preventing a
CC disorder associated with decreased or increased expression or activity of
CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
CC during gene therapy and vaccine production procedures. The current
CC sequence is that of the human PCCP1-related DNA fragment SEQ ID 8-
CC directed probe of the invention. Note: The current sequence is not shown

CC within the specification per se but was retrieved from the Wipoweb
CC database.
XX
SQ Sequence 17 BP; 4 A; 4 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 333 GAGATGCCATCCGCGCA 348
Db 2 GAGATGCCATCCGCGCA 17
RESULT 1061
ADF64122
ID ADF64122 standard; DNA; 17 BP.
XX
AC ADF64122;
XX
DT 12-FEB-2004 (first entry)
DE Human PCCP1 DNA fragment SEQ ID 8-directed probe - SEQ ID 2026.
XX
XX chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
KW human; ss; probe.
XX
XX Homo sapiens.
XX
XX WO2003050284-A1.
XX
XX 19-JUN-2003.
XX
XX 22-NOV-2002; 2002WO-US037506.
XX
XX 10-DEC-2001; 2001US-0339764P.
XX
XX (AMSH) AMERSHAM BIOSCIENCES SV CORP.
XX
XX Guo J;
XX
XX WPI; 2003-532916/50.
XX
XX New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
PT composition for treating or preventing a disorder associated with
PT decreased or increased expression or activity of PCCP1 e.g., tumor.
XX
XX Example 2; SEQ ID NO 2026; 164pp; English.
XX
XX The invention relates to a novel isolated nucleic acid that encodes a
CC protein with a chromatin organisation modifier (CHROMO) domain. The
CC polynucleotide of the invention demonstrates cytostatic activity and may
CC be useful for preparing a composition for treating or preventing a
CC disorder associated with decreased or increased expression or activity of
CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
CC during gene therapy and vaccine production procedures. The current
CC sequence is that of the human PCCP1-related DNA fragment SEQ ID 8-
CC directed probe of the invention. Note: The current sequence is not shown
CC within the specification per se but was retrieved from the Wipoweb
CC database.
XX
SQ Sequence 17 BP; 4 A; 4 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 334 AGATGCCATCCGCGCAG 349
Db 1 AGATGCCATCCGCGCAG 16

```
RESULT 1062
ADF62168
ID ADF62168 standard; DNA; 17 BP.
XX
AC ADF62168;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human PCCP1 DNA fragment SEQ ID 4-directed probe - SEQ ID 72.
XX
XX chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
KW human; ss; probe.
XX
OS Homo sapiens.
XX
XX WO2003050284-A1.
XX
XX 19-JUN-2003.
XX
XX 22-NOV-2002; 2002WO-US037506.
XX
XX 10-DEC-2001; 2001US-0339764P.
XX
XX (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
XX Guo J;
XX
XX WPI; 2003-532916/50.
XX
XX New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
composition for treating or preventing a disorder associated with
decreased or increased expression or activity of PCCP1 e.g., tumor.
XX
XX Example 2; SEQ ID NO 2114; 164pp; English.
XX
XX The invention relates to a novel isolated nucleic acid that encodes a
protein with a chromatin organisation modifier (CHROMO) domain. The
polynucleotide of the invention demonstrates cytostatic activity and may
be useful for preparing a composition for treating or preventing a
disorder associated with decreased or increased expression or activity of
PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
during gene therapy and vaccine production procedures. The current
sequence is that of the human PCCP1-related DNA fragment SEQ ID 4-
directed probe of the invention. Note: The current sequence is not shown
within the specification per se but was retrieved from the WipoWeb
database.
XX
XX Sequence 17 BP; 4 A; 6 C; 7 G; 0 T; 0 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 678 CCAGCGAGCAGCGCG 693
DB 1 CGAGCGAGCAGCGCG 16
RESULT 1063
ADF64210
ID ADF64210 standard; DNA; 17 BP.
XX
AC ADF64210;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human PCCP1 DNA fragment SEQ ID 8-directed probe - SEQ ID 2114.
XX
XX chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
KW human; ss; probe.
XX
OS Homo sapiens.
XX
XX WO2003050284-A1.
XX
XX 19-JUN-2003.
XX
XX 22-NOV-2002; 2002WO-US037506.
XX
XX 10-DEC-2001; 2001US-0339764P.
XX
XX (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
XX Guo J;
XX
XX WPI; 2003-532916/50.
XX
XX New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
composition for treating or preventing a disorder associated with
decreased or increased expression or activity of PCCP1 e.g., tumor.
XX
XX Example 2; SEQ ID NO 72; 164pp; English.
XX
XX The invention relates to a novel isolated nucleic acid that encodes a
protein with a chromatin organisation modifier (CHROMO) domain. The
polynucleotide of the invention demonstrates cytostatic activity and may
be useful for preparing a composition for treating or preventing a
disorder associated with decreased or increased expression or activity of
PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
during gene therapy and vaccine production procedures. The current
sequence is that of the human PCCP1-related DNA fragment SEQ ID 4-
directed probe of the invention. Note: The current sequence is not shown
within the specification per se but was retrieved from the WipoWeb
database.
XX
XX Sequence 17 BP; 5 A; 4 C; 5 G; 3 T; 0 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 415 GAAGGAGTTCCTCATG 430
DB 1 GAAGGAATGCTCATG 16
RESULT 1064
ADF87667
ID ADF87667 standard; DNA; 17 BP.
XX
AC ADF87667;
XX
DT 26-FEB-2004 (first entry)
XX
DE Single nucleotide polymorphism detection primer, SEQ ID No 1250.
XX
XX human; single nucleotide polymorphism; microarray; side effect; ss;
KW primer; PCR.
XX
XX Synthetic.
OS Homo sapiens.
XX
XX JP2003235571-A.
XX
XX 26-AUG-2003.
XX
XX 12-FEB-2002; 2002JP-00034717.
XX
XX 12-FEB-2002; 2002JP-00034717.
XX
XX (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
XX
XX WPI; 2003-820454/77.
XX
```

PT Novel polynucleotide useful for detecting single nucleotide polymorphisms
in human gene.
PS Claim 2; SEQ ID NO 1250; 704pp; Japanese.
XX
CC The invention relates to a novel polynucleotide isolated and purified
from a human gene having any one of 935 fully defined sequences as given
in specification, or a sequence having a base substitution. The invention
further relates to: an oligonucleotide containing single nucleotide
polymorphisms; a PCR primer set chosen from the combination of two DNA
fragments from any one of 1220 fully defined sequences as given in
specification; a labelling probe containing the SNP containing oligo; and
a microarray equipped with the SNP containing oligo. The isolated human
gene of the invention is useful for detecting the single nucleotide
polymorphisms in human gene. The isolated human gene is also useful for
diagnosis of disease and determination of side effect to a medical agent.
CC The isolated human gene is also effective in detecting single nucleotide
polymorphisms in a human gene. This polynucleotide sequence represents
one of the PCR primers used in the single nucleotide polymorphism
detection method of the invention.
XX
SQ Sequence 17 BP; 3 A; 4 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 517 GGAGTGGAGCCTG 532
|||||
Db 2 GGAGCTGGAGGACCTG 17

RESULT 1065
ADI49767/C
ID ADI49767 standard; DNA; 17 BP.
XX AC ADI49767;
XX
DT 15-APR-2004 (first entry)
XX
DE Human tumour suppression/reversion-related DNA sequence SeqID2270.
XX
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW cytostatic; virucide; neuroprotective; nontropic; neuroleptic; probe;
KW primer; PCR; gene chip; antisense; viral disease; tumour;
KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS Homo sapiens.
XX
PN WO2003025177-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004523.
XX
PR 17-SEP-2001; 2001FR-00011980.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313354/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
with tumors and cell degeneration, also related polypeptides, antibodies
and transfected cells.
XX
PS Disclosure; SEQ ID NO 2270; 30pp; French.
XX
CC This invention relates to novel isolated nucleic acid sequences involved
in the phenomena of tumour suppression, tumour reversion, apoptosis
and/or resistance to viruses. The invention may be useful for the
development of compounds with a cytostatic, virucide, neuroprotective,
nontropic or neuroleptic activity. The DNA sequences may be useful as
probes and primers for detecting, identifying, quantifying and/or
amplifying nucleic acid, for example as one component of a gene chip, in
vitro as antisense reagents and for production of recombinant
polypeptides. The invention may therefore be useful for preparation of
pharmaceuticals for prevention and/or treatment of viral diseases that
are characterised by development of tumours or cell degeneration, but also Alzheimer's disease and schizophrenia. The

CC nontropic or neuroleptic activity. The DNA sequences may be useful as
probes and primers for detecting, identifying, quantifying and/or
amplifying nucleic acid, for example as one component of a gene chip, in
vitro as antisense reagents and for production of recombinant
polypeptides. The invention may therefore be useful for preparation of
pharmaceuticals for prevention and/or treatment of viral diseases that
are characterised by development of tumours or cell degeneration, but also Alzheimer's disease and schizophrenia. The
present sequence is that of a nucleic acid sequence of the invention.
CC Note: The sequence data for this patent did not form part of the printed
specification, but was obtained in electronic format directly from WIPO
at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ Sequence 17 BP; 4 A; 4 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 473 CTGGAGAGCTCGATC 488
|||||
Db 16 CTGGAGAGCTAGATC 1

RESULT 1066
ADI51254
ID ADI51254 standard; DNA; 17 BP.
XX AC ADI51254;
XX
DT 15-APR-2004 (first entry)
XX
DE Human tumour suppression/reversion-related DNA sequence SeqID3757.
XX
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW cytostatic; virucide; neuroprotective; nontropic; neuroleptic; probe;
KW primer; PCR; gene chip; antisense; viral disease; tumour;
KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS Homo sapiens.
XX
PN WO2003025177-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004523.
XX
PR 17-SEP-2001; 2001FR-00011980.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313354/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
with tumors and cell degeneration, also related polypeptides, antibodies
and transfected cells.
XX
PS Disclosure; SEQ ID NO 3757; 30pp; French.
XX
CC This invention relates to novel isolated nucleic acid sequences involved
in the phenomena of tumour suppression, tumour reversion, apoptosis
and/or resistance to viruses. The invention may be useful for the
development of compounds with a cytostatic, virucide, neuroprotective,
nontropic or neuroleptic activity. The DNA sequences may be useful as
probes and primers for detecting, identifying, quantifying and/or
amplifying nucleic acid, for example as one component of a gene chip, in
vitro as antisense reagents and for production of recombinant
polypeptides. The invention may therefore be useful for preparation of
pharmaceuticals for prevention and/or treatment of viral diseases that
are characterised by development of tumours or cell degeneration, but also Alzheimer's disease and schizophrenia. The

CC present sequence is that of a nucleic acid sequence of the invention.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/publishedpct_sequences
SQ Sequence 17 BP; 4 A; 6 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 341 ATCGCGCAGACCAACC 356
||| ||||| ||
DB 2 ATCTCGACAGCATCC 17

RESULT 1067
AD149316
ID AD149316 standard; DNA; 17 BP.
XX AC AD149316;
XX AC AD149316;
DT 15-APR-2004 (first entry)
XX Human tumour suppression/reversion-related DNA sequence SeqID1819.
DE Human tumour suppression/reversion-related DNA sequence SeqID1819.
XX tumour suppression; tumour reversion; apoptosis; virus resistance;
XX cytosstatic; virucide; neuroprotective; nontropic; neuroleptic; probe;
KW primer; PCR; gene chip; antisense; viral disease; tumour;
KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX Homo sapiens.

OS Homo sapiens.
XX WO2003025177-A2.
XX 27-MAR-2003.
XX 17-SEP-2002; 2002WO-IB004523.
XX 17-SEP-2001; 2001FR-00011980.
XX (MOLE-) MOLECULAR ENGINES LAB.
XX Telerman A, Amson R, Tuijnder M;
XX WPI; 2003-313354/30.

XX New isolated nucleic acid, useful for treating viral diseases associated
XX with tumors and cell degeneration, also related polypeptides, antibodies
XX and transfected cells.
XX Disclosure; SEQ ID NO 1819; 30pp; French.

XX This invention relates to novel isolated nucleic acid sequences involved
XX in the phenomena of tumour suppression, tumour reversion, apoptosis
XX and/or resistance to viruses. The invention may be useful for the
XX development of compounds with a cytostatic, virucide, neuroprotective,
XX nontropic or neuroleptic activity. The DNA sequences may be useful as
XX probes and primers for detecting, identifying, quantifying and/or
XX amplifying nucleic acid, for example as one component of a gene chip, in
XX vitro as antisense reagents and for production of recombinant
XX pharmaceuticals for prevention and/or treatment of viral diseases that
XX are characterised by development of tumours or cell degeneration.
XX specifically cancer but also Alzheimer's disease and schizophrenia. The
XX present sequence is that of a nucleic acid sequence of the invention.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/publishedpct_sequences

XX Sequence 17 BP; 4 A; 2 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 215 GATCAGGAGCTACTGG 230
||||| ||||| |||||
DB 1 GATCAGGAAGTTCTGG 16

RESULT 1068
ACC54048/c
ID ACC54048 standard; DNA; 17 BP.
XX AC ACC54048;
XX 27-JUN-2003 (first entry)
XX Human tumour suppressor sequence #2815.

XX ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
KW tumour regression; apoptosis; virus resistance; diagnosis;
KW cellular degeneration.

OS Homo sapiens.

XX FR2826373-A1.

XX 27-DEC-2002.

XX 20-JUN-2001; 2001FR-00008139.

XX 20-JUN-2001; 2001FR-00008139.

XX (MOLE-) MOLECULAR ENGINES LAB SA.

XX Tuijnder M, Telerman A, Amson R;

XX WPI; 2003-250498/25.

XX New nucleic acid sequences associated with tumor suppression, regression,
XX apoptosis or virus resistance are useful to diagnose and treat viral
XX disease, development of tumor cells and cell degeneration.

XX Claim 1; Page 690; 798pp; French.

XX This sequence represents an isolated nucleic acid sequence associated
XX with tumour suppression or regression, apoptosis or virus resistance. The
XX invention relates to these sequences or sequences having at least 80%
XX identity to them, and polypeptides encoded by the sequences or
XX polypeptides having 80% identity to the polypeptide sequences. The
XX invention is used to diagnose or treat viral disease or disease
XX characterized by development of tumour cells or cellular degeneration

XX Sequence 17 BP; 2 A; 7 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 203 GGCCTGGCAGCAGATC 218
||| ||||| |||||
DB 16 GGCCTGGCAGCAGATC 1

RESULT 1069
ACC54057/c
ID ACC54057 standard; DNA; 17 BP.

XX AC ACC54057;

XX 27-JUN-2003 (first entry)

XX Human tumour suppressor sequence #2824.

KW ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
 KW tumour regression; apoptosis; virus resistance; diagnosis;
 KW cellular degeneration.
 XX Homo sapiens.
 OS
 XX FR2826373-A1.
 PN
 XX 27-DEC-2002.
 PD
 XX 20-JUN-2001; 2001FR-00008139.
 PF
 XX 20-JUN-2001; 2001FR-00008139.
 PR
 XX (MOLE-) MOLECULAR ENGINES LAB SA.
 PA
 XX
 PI Tuijnder M, Telerman A, Amson R;
 XX WPI; 2003-250498/25.
 DR
 XX New nucleic acid sequences associated with tumor suppression, regression,
 PT apoptosis or virus resistance are useful to diagnose and treat viral
 PT disease, development of tumor cells and cell degeneration.
 PS Claim 1; Page 692; 798pp; French.
 XX This sequence represents an isolated nucleic acid sequence associated
 CC with tumour suppression or regression, apoptosis or virus resistance. The
 CC invention relates to these sequences or sequences having at least 80%
 CC identity to them, and polypeptides encoded by the sequences or
 CC polypeptides having 80% identity to the polypeptide sequences. The
 CC invention is used to diagnose or treat viral disease or disease
 CC characterized by development of tumour cells or cellular degeneration
 XX
 SQ Sequence 17 BP; 2 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 537 GATGCCAGCAGCAGAT 552
 | | | | | | | | | | | | | | | | | | | | | |
 Db 17 GCTGCCAGAGCAGAT 2

RESULT 1070
 ADL46532/C
 ID ADL46532 standard; RNA; 17 BP.

XX ADL46532;
 AC
 XX 20-MAY-2004 (first entry)
 DT
 XX Human NOGO receptor hammerhead ribozyme substrate sequence #65.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis;
 KW NOGO receptor hammerhead ribozyme; substrate; ds.

XX Unidentified.
 OS
 XX WO200281628-A2.
 PN
 XX 17-OCT-2002.
 PD
 XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.
 PR 23-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 9; SEQ ID NO 65; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human NOGO
 CC receptor hammerhead ribozyme substrate sequence.

SQ Sequence 17 BP; 1 A; 8 C; 4 G; 0 T; 4 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 805 CGCCTGGAGGAGAAG 820
 | | | | | | | | | | | | | | | | | | | | | |
 Db 16 CACCTGGAGGAGGAG 1

RESULT 1071
 ADL49918/C
 ID ADL49918 standard; RNA; 17 BP.

XX ADL49918;
 AC
 XX 20-MAY-2004 (first entry)
 DT
 XX Human PKR substrate sequence #1032.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
 KW substrate; ds.

XX Unidentified.
 OS
 XX WO200281628-A2.
 PN
 XX 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

```
XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 3451; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC ikappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
XX Sequence 17 BP; 3 A; 7 C; 2 G; 0 T; 5 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 493 GAGGCGAGAGGAGCAG 508
DB ||||| ||||| |||||
17 GAGGCGAGAGGAGGAGCAG 2
RESULT 1072
ADL51337/c
ID ADL51337 standard; RNA; 17 BP.
XX
XX ADL51337;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human PTGDR substrate sequence #456.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; ikappaB kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis; human PTGDR;
XX substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
```

```
XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 161; SEQ ID NO 4870; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC ikappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
XX Sequence 17 BP; 0 A; 8 C; 4 G; 0 T; 5 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 677 GCACGCGACGAGCGC 692
DB ||||| ||||| |||||
16 GCACGCGAGAGGCGC 1
RESULT 1073
ADL47063/c
ID ADL47063 standard; RNA; 17 BP.
XX
XX ADL47063;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human NOGO receptor zinzyme substrate sequence #50.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; ikappaB kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis;
XX NOGO receptor zinzyme; substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
```

```
XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 9; SEQ ID NO 596; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human NOGO
CC receptor zynzyme substrate sequence.
XX
XX Sequence 17 BP; 1 A; 8 C; 4 G; 0 T; 4 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 685 GCAGCGCGGCGAGCTG 700
Db 16 GCAGGCACGGAAGCTG 1
RESULT 1074
ADL48356
ID ADL48356 standard; RNA; 17 BP.
XX
XX ADL48356;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human IKK-gamma substrate sequence #866.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
```

```
XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1889; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 4 A; 5 C; 6 G; 0 T; 2 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.2e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
Qy 740 CAGGTGGACCCAGCTGC 755
Db 1 CAGCUGGAGCAGCUGC 16
RESULT 1075
ADL49919/C
ID ADL49919 standard; RNA; 17 BP.
XX
XX ADL49919;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human PKR substrate sequence #1033.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
XX substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
```

```

XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 3452; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC ikappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
XX Sequence 17 BP; 2 A; 6 C; 3 G; 0 T; 6 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 491 AGAGGCGAGGAGC 506
DB 16 AGAGGCGAGGAGTTC 1

RESULT 1076
ADL51141/c
ID ADL51141 standard; RNA; 17 BP.
XX
XX ADL51141;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human PTGDR substrate sequence #260.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; ikappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PTGDR;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.

```

```

XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 161; SEQ ID NO 4674; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC ikappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
XX Sequence 17 BP; 3 A; 8 C; 5 G; 0 T; 1 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 706 TGAGCGCGAGCGCTG 721
DB 17 TGAGCGCGCTGCGCTG 2

RESULT 1077
ADL51504/c
ID ADL51504 standard; RNA; 17 BP.
XX
XX ADL51504;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human PTGDR substrate sequence #623.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; ikappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PTGDR;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.

```

```

XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 161; SEQ ID NO 5037; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
XX Sequence 17 BP; 3 A; 8 C; 5 G; 0 T; 1 U; 0 Other;
SQ

```

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

QY 705 GTGAGCGCGGCGCT 720
DB 16 GTGAGCGCTGGCGCT 1

```

RESULT 1078
ADL46486/c
ID ADL46486 standard; RNA; 17 BP.
XX
XX ADL46486;
XX
XX 20-MAY-2004 (first entry)
XX Human NOGO receptor hammerhead ribozyme substrate sequence #19.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis;
XX NOGO receptor hammerhead ribozyme; substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.

```

XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 9; SEQ ID NO 19; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human NOGO
CC receptor hammerhead ribozyme substrate sequence.
XX
XX Sequence 17 BP; 2 A; 7 C; 5 G; 0 T; 3 U; 0 Other;
SQ

```

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

QY 604 GCTGCAGGAGGCCAG 619
DB 16 GCTCCAGGAGGCCAG 1

```

RESULT 1079
ADL46844/c
ID ADL46844 standard; RNA; 17 BP.
XX
XX ADL46844;
XX
XX 20-MAY-2004 (first entry)
XX Human NOGO receptor inozyme substrate sequence #277.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis;
XX NOGO receptor inozyme; substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.

```

XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PS Claim 9; SEQ ID NO 377; 317pp; English.
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX CC that down regulate the expression or inhibit the function of a receptor
XX CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX CC invention are useful for treating: cerebrovascular accident, central
XX CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX CC disease, lupus, multiple sclerosis, transplant/graft rejection,
XX CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX CC nucleic acids of the invention are also useful for down-regulating the
XX CC expression of a target gene and as a diagnostic tool to examine genetic
XX CC drifts and mutations within diseased cells or to detect the presence of a
XX CC target RNA in a cell. The present RNA sequence represents a human NOGO
XX CC receptor inozyme substrate sequence.
XX SQ Sequence 17 BP; 2 A; 9 C; 4 G; 0 T; 2 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 506 CAGGCTCTCGGGAGG 521
DB ||||| ||||| |||||
16 CAGGCTTGGGGAGG 1

RESULT 1080
ADL48057/C
ID ADL48057 standard; RNA; 17 BP.
XX AC ADL48057;
XX AC
XX DT 20-MAY-2004 (first entry)
XX DE Human IKK-gamma substrate sequence #567.
XX KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX KW protein kinase PKR; cerebrovascular accident;
XX KW central nervous system injury; CNS injury; spinal cord injury; cancer;
XX KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX KW restenosis; asthma; Crohn's disease; diabetes; obesity;
XX KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX KW substrate; ds.
XX OS Unidentified.
XX OS
XX PN WO200281628-A2.
XX XX
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 190 GCAGCCCACTGGTGGC 205
DB ||||| ||||| |||||
16 GCATCCCACTGGTGGC 1

RESULT 1081
ADL48768
ID ADL48768 standard; RNA; 17 BP.
XX AC ADL48768;
XX AC
XX DT 20-MAY-2004 (first entry)
XX DE Human IKK-gamma substrate sequence #1278.
XX KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX KW protein kinase PKR; cerebrovascular accident;
XX KW central nervous system injury; CNS injury; spinal cord injury; cancer;
XX KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX KW restenosis; asthma; Crohn's disease; diabetes; obesity;
XX KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX KW substrate; ds.
XX OS Unidentified.
XX OS
XX PN WO200281628-A2.
XX XX
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.

```



```

XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2301; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.2e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
QY 739 GCAGGTGGACGAGCTG 754
DB 2 GCAGCUGGAGCAGCUG 17
|||||:|||||:|
|

RESULT 1082
ADL48354/c
ID ADL48354 standard; RNA; 17 BP.
XX
XX ADL48354;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human IKK-gamma substrate sequence #864.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX substrate; db.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.

```

```

XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1887; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 748 CCAGCTGCGCATGCAG 763
DB 16 CCAGCTGCTCTCTGCAG 1
|||||:|||||:|
|

RESULT 1083
ADL48766/c
ID ADL48766 standard; RNA; 17 BP.
XX
XX ADL48766;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human IKK-gamma substrate sequence #1276.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX substrate; db.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.

```

```
XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2299; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC ikappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 5 C; 6 G; 0 T; 3 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 749 CAGCTGGCATGCAGG 764
DB 17 CAGCTGCTCTGCAGG 2

RESULT 1084
ADL47943
ID ADL47943 standard; RNA; 17 BP.
XX
XX ADL47943;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human IKK-gamma substrate sequence #453.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; ikappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
```

```
XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1476; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC ikappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 3 C; 8 G; 0 T; 2 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.2e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 694 GCAGCTGGAGAGTGAG 709
DB 1 GCAGCTGCAGAGGAG 16

RESULT 1085
ADL48357
ID ADL48357 standard; RNA; 17 BP.
XX
XX ADL48357;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human IKK-gamma substrate sequence #867.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; ikappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
```

```
XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1890; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.2e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
QY 522 TGGAGCACCTGAGAG 537
Db :||||| |:|||||
2 UGGAGCAGCUGCAGAG 17
RESULT 1086
ADL46662/C
ID ADL46662 standard; RNA, 17 BP.
XX
XX ADL46662;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human NOGO receptor inozyme substrate sequence #95.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis;
XX NOGO receptor inozyme; substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
```

```
XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 9; SEQ ID NO 195; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human NOGO
CC receptor inozyme substrate sequence.
XX
XX Sequence 17 BP; 1 A; 8 C; 5 G; 0 T; 3 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 604 GCTGCAGGAGGCCAG 619
Db :||||| |:|||||
17 GCTCCAGAGGGCCAG 2
RESULT 1087
ADL48764
ID ADL48764 standard; RNA, 17 BP.
XX
XX ADL48764;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human IKK-gamma substrate sequence #1274.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
```

```

XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2297; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 6 A; 3 C; 6 G; 0 T; 2 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.2e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
OY 411 AGGAGAGGAGGTTCTCT 426
DB 1 AGAAGAAGGAGGCCUCCU 16
|||||
|AGGAGAGGAGGAGGAGG 16

RESULT 1088
ADL47162/C
ID ADL47162 standard; RNA; 17 BP.
XX
XX ADL47162;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human NOGO receptor zinzyme substrate sequence #149.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis;
XX NOGO receptor zinzyme; substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.

```

```

XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 9; SEQ ID NO 695; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human NOGO
CC receptor zinzyme substrate sequence.
XX
XX Sequence 17 BP; 1 A; 8 C; 5 G; 0 T; 3 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 800 CAGGCGCCTCGGAGG 815
DB 16 CAGGCGCCTCGGAGG 1
|||||
|CAGGCGCCTCGGAGG 16

RESULT 1089
ADL48783
ID ADL48783 standard; RNA; 17 BP.
XX
XX ADL48783;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human IKK-gamma substrate sequence #1293.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.

```


XX	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.
XX	
XX	(RIBO-) RIBOZYME PHARM INC.
PA	
XX	
PI	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX	WPI; 2003-058513/05.
DR	
XX	
XX	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX	
XX	Claim 161; SEQ ID NO 4521; 317pp; English.
PS	
PS	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human PKR
CC	substrate sequence.
XX	
XX	Sequence 17 BP; 1 A; 8 C; 4 G; 0 T; 4 U; 0 Other;
SQ	
Query Match	1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity	87.5%; Pred. No. 7.2e+02;
Matches	14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY	577 GCCACGCGAGCGGC 692
Db	
	17 GCCACGGGAGAGCGGC 2
RESULT 1094	
ID	ADL51681
ID	ADL51681 standard; RNA; 17 BP.
XX	
XX	ADL51681;
AC	
XX	
DT	20-MAY-2004 (first entry)
XX	
DE	Human PTGDR substrate sequence #800.
XX	
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; human PTGDR;
XX	substrate; db.
XX	
XX	Unidentified.
OS	
XX	
PN	WO200281628-A2.
XX	
XX	17-OCT-2002.
PD	
XX	
XX	03-APR-2002; 2002WO-US010512.
PF	

XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI WPI; 2003-058513/05.
 XX
 DR Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 9; SEQ ID NO 935; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC ikappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human NOGO
 CC receptor amberzyme substrate sequence.
 XX
 SQ Sequence 17 BP; 1 A; 9 C; 4 G; 0 T; 3 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 802 GGCGGCTCGGAGGAG 817
 DB 17 GGGCACCTCGGAGGAG 2
 RESULT 1056
 ADL46479/C
 ID ADL46479 standard; RNA; 17 BP.
 XX
 AC ADL46479;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Human NOGO receptor hammerhead ribozyme substrate sequence #12.
 XX
 KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; ikappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis;
 KW NOGO receptor hammerhead ribozyme; substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI WPI; 2003-058513/05.
 XX
 DR Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 9; SEQ ID NO 12; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC ikappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human NOGO
 CC receptor hammerhead ribozyme substrate sequence.
 XX
 SQ Sequence 17 BP; 1 A; 7 C; 5 G; 0 T; 4 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 686 CAGGCGCGCAGCTGG 701
 DB 17 CAGGCGCGGAGCTGG 2
 RESULT 1097
 ADL48516/C
 ID ADL48516 standard; RNA; 17 BP.
 XX
 AC ADL48516;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Human IKK-gamma substrate sequence #1026.
 XX
 KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; ikappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI WPI; 2003-058513/05.
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX Claim 59; SEQ ID NO 2049; 317pp; English.
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/perfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma subunit sequence.
 XX SQ Sequence 17 BP; 4 A; 4 C; 6 G; 0 T; 3 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Qy 191 CAGCCAGTGTGGCC 206
 || ||||| |||||
 Db 17 CATCCAGTTGTGGCC 2
 RESULT 1098
 ADM53997
 ID ADM53997 standard; mRNA; 17 BP.
 XX AC ADM53997;
 XX DT 03-JUN-2004 (first entry)
 XX DE Human GRID mRNA substrate sequence #272.
 XX Human; ss; GRID; Grb2-related with insert domain; hammerhead ribozyme;
 KW NCH ribozyme; G-cleaver ribozyme; Zinzyne; DNazyme; amberzyme; Inozyme;
 KW hairpin ribozyme; tissue rejection; graft rejection; leukaemia.
 XX OS Homo sapiens.
 XX US2003134806-A1.
 XX PD 17-JUL-2003.
 XX PF 23-FEB-2001; 2001US-00792818.
 XX PR 10-FEB-2000; 2000US-0181594P.
 XX (JARV/) JARVIS T.
 PA (CARL/) CARLOWITZ I V.
 PA (MCSW/) MCSWIGGEN J.
 PA (HAMB/) HAMBLIN P A.
 XX (ELLI/) ELLIS J H.

PA (ELLI/) ELLIS J H.
 XX Jarvis T, Carlowitz IV, Mcswiggen J, Hamblin PA, Ellis JH;
 XX WPI; 2003-829646/77.
 XX New nucleic acid molecule that down-regulates expression of Grb2-related
 PT with insert domain (GRID) gene, useful for treating a condition
 PT associated with the level of GRID, e.g. tissue/graft rejection and
 PT leukemia.
 XX Claim 4; SEQ ID NO 272; 74pp; English.
 XX The invention relates to a nucleic acid molecule that down-regulates
 CC expression of Grb2-related with insert domain (GRID) gene, e.g. a
 CC hammerhead ribozyme, NCH ribozyme, G-cleaver ribozyme, Zinzyne, DNazyme,
 CC amberzyme, Inozyme or hairpin ribozyme. Also include are a mammalian cell
 CC including the novel nucleic acid molecule, reducing GRID activity in a
 CC cell by contacting the cell with the novel nucleic acid molecule,
 CC treating a patient having a condition associated with the level of GRID
 CC (e.g. tissue/graft rejection or leukaemia) by contacting the cell with
 CC the novel nucleic acid molecule, cleaving RNA of a GRID gene by
 CC contacting the cell with the novel nucleic acid molecule, an expression
 CC vector comprising a nucleic acid sequences (encoding at least the novel
 CC nucleic acid molecule in a manner that allows its expression), a
 CC mammalian cell including the expression vector and an enzymatic nucleic
 CC acid molecule that cleaves RNA derived from a GRID gene. The nucleic acid
 CC molecule is useful for treating a condition associated with the level of
 CC GRID, e.g. tissue/graft rejection and leukaemia. The present sequence is
 CC a target region for the enzymatic nucleic acids of the invention.
 XX SQ Sequence 17 BP; 3 A; 7 C; 6 G; 0 T; 1 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 81.2%; Pred. No. 7.2e+02;
 Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 Qy 393 TCCAAGCCAGCCAGAG 408
 :|| ||||| |||||
 Db 1 UCCGGGCCAGCCAGAG 16
 RESULT 1099
 ADM53996
 ID ADM53996 standard; mRNA; 17 BP.
 XX AC ADM53996;
 XX DT 03-JUN-2004 (first entry)
 XX DE Human GRID mRNA substrate sequence #271.
 XX Human; ss; GRID; Grb2-related with insert domain; hammerhead ribozyme;
 KW NCH ribozyme; G-cleaver ribozyme; Zinzyne; DNazyme; amberzyme; Inozyme;
 KW hairpin ribozyme; tissue rejection; graft rejection; leukaemia.
 XX OS Homo sapiens.
 XX US2003134806-A1.
 XX PD 17-JUL-2003.
 XX PF 23-FEB-2001; 2001US-00792818.
 XX PR 10-FEB-2000; 2000US-0181594P.
 XX (JARV/) JARVIS T.
 PA (CARL/) CARLOWITZ I V.
 PA (MCSW/) MCSWIGGEN J.
 PA (HAMB/) HAMBLIN P A.
 PA (ELLI/) ELLIS J H.
 XX Jarvis T, Carlowitz IV, Mcswiggen J, Hamblin PA, Ellis JH;
 PI WPI; 2003-829646/77.

XX WPI; 2003-829646/77.

XX

XX New nucleic acid molecule that down-regulates expression of Grb2-related

PT with insert domain (GRID) gene, useful for treating a condition

PT associated with the level of GRID, e.g. tissue/graft rejection and

PT leukemia.

XX

XX Claim 4; SEQ ID NO 271; 74pp; English.

XX

XX The invention relates to a nucleic acid molecule that down-regulates

CC expression of Grb2-related with insert domain (GRID) gene, e.g. a

CC hammerhead ribozyme, NCH ribozyme, G-cleaver ribozyme, Zinzyme, DNzyme,

CC amberzyme, inozyme or hairpin ribozyme. Also include are a mammalian cell

CC including the novel nucleic acid molecule, reducing GRID activity in a

CC cell by contacting the cell with the novel nucleic acid molecule,

CC treating a patient having a condition associated with the level of GRID

CC (e.g. tissue/graft rejection or leukaemia) by contacting the cell with

CC the novel nucleic acid molecule, cleaving RNA of a GRID gene by

CC contacting the cell with the novel nucleic acid molecule, an expression

CC vector comprising a nucleic acid sequences (encoding at least the novel

CC nucleic acid molecule in a manner that allows its expression), a

CC mammalian cell including the expression vector and an enzymatic nucleic

CC acid molecule that cleaves RNA derived from a GRID gene. The nucleic acid

CC molecule is useful for treating a condition associated with the level of

CC GRID, e.g. tissue/graft rejection and leukaemia. The present sequence is

CC a target region for the enzymatic nucleic acids of the invention.

XX

XX Sequence 17 BP; 4 A; 6 C; 6 G; 0 T; 1 U; 0 Other;

SQ

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 81.2%; Pred. No. 7.2e+02;

Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 393 TCCAAGCCAGCCAGAG 408

DB :|| ||||| |||||

2 UCCGGGCCAGCCAGAG 17

RESULT 1100

ADM54086

ID ADM54086 standard; mRNA; 17 BP.

AC ADM54086;

XX

XX 03-JUN-2004 (first entry)

XX

XX Human GRID mRNA substrate sequence #361.

XX

XX Human; ss; GRID; Grb2-related with insert domain; hammerhead ribozyme;

KW NCH ribozyme; G-cleaver ribozyme; Zinzyme; DNzyme; amberzyme; inozyme;

KW hairpin ribozyme; tissue rejection; graft rejection; leukaemia.

XX

XX Homo sapiens.

XX

XX US2003134806-A1.

XX

XX 17-JUL-2003.

XX

XX 23-FEB-2001; 2001US-00792818.

XX

XX 10-FEB-2000; 2000US-0181594P.

XX

XX (JARV/) JARVIS T.

PA (CARL/) CARLOWITZ I V.

PA (MCSW/) MCSWIGGEN J.

PA (HAMB/) HAMBLIN P A.

PA (ELLI/) ELLIS J H.

XX

XX Jarvis T, Carlowitz IV, Mcswiggen J, Hamblin PA, Ellis JH;

PI WPI; 2003-829646/77.

XX

XX

New nucleic acid molecule that down-regulates expression of Grb2-related with insert domain (GRID) gene, useful for treating a condition associated with the level of GRID, e.g. tissue/graft rejection and leukemia.

Claim 4; SEQ ID NO 361; 74pp; English.

The invention relates to a nucleic acid molecule that down-regulates expression of Grb2-related with insert domain (GRID) gene, e.g. a hammerhead ribozyme, NCH ribozyme, G-cleaver ribozyme, Zinzyme, DNazyme, amberyse, Inozyne or hairpin ribozyme. Also include are a mammalian cell including the novel nucleic acid molecule, reducing GRID activity in a cell by contacting the cell with the novel nucleic acid molecule, treating a patient having a condition associated with the level of GRID (e.g. tissue/graft rejection or leukaemia) by contacting the cell with the novel nucleic acid molecule, cleaving RNA of a GRID gene by contacting the cell with the novel nucleic acid molecule, an expression vector comprising a nucleic acid sequences (encoding at least the novel nucleic acid molecule in a manner that allows its expression), a mammalian cell including the expression vector and an enzymatic nucleic acid molecule that cleaves RNA derived from a GRID gene. The nucleic acid molecule is useful for treating a condition associated with the level of GRID, e.g. tissue/graft rejection and leukaemia. The present sequence is a target region for the enzymatic nucleic acids of the invention.

Sequence 17 BP; 5 A; 8 C; 4 G; 0 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0

Qy 718 GCTGCAGCAGCAGCAC 733
Dy 1 GCAGCAGCACCAGCAC 16

RESULT 1101
ADM54561
ID ADM54561 standard; mRNA; 17 BP.
XX AC ADM54561;
XX 03-JUN-2004 (first entry)
XX Human GRID mRNA substrate sequence #871.
XX Human; ss; GRID; Grb2-related with insert domain; hammerhead ribozyme;
KW NCH ribozyme; G-cleaver ribozyme; Zinzyme; DNazyme; amberyse; Inozyne;
KW hairpin ribozyme; tissue rejection; graft rejection; leukaemia.
XX Homo sapiens.
XX OS
XX US2003134806-A1.
XX 17-JUL-2003.
XX 23-FEB-2001; 2001US-00792818.
XX 10-FEB-2000; 2000US-0181594P.
XX (JARV/) JARVIS T.
PA (CARL/) CARLOWITZ I V.
PA (MCSW/) MCSWIGGEN J.
PA (HAMB/) HAMELIN P A.
XX (ELLI/) ELLIS J H.
XX Jarvis T, Carlowitz IV, Mcswiggen J, Hamblin PA, Ellis JH;
PI WPI; 2003-829646/77.
DR
XX New nucleic acid molecule that down-regulates expression of Grb2-related with insert domain (GRID) gene, useful for treating a condition associated with the level of GRID, e.g. tissue/graft rejection and

PT leukemia.

XX Claim 4; SEQ ID NO 874; 74pp; English.

PS The invention relates to a nucleic acid molecule that down-regulates

XX expression of Grb2-related with insert domain (GRID) gene, e.g. a

CC hammerhead ribozyme, NCH ribozyme, G-cleaver ribozyme, Zinzyme, DNasezyme,

CC amberyzyme, inozyme or hairpin ribozyme. Also include are a mammalian cell

CC including the novel nucleic acid molecule, reducing GRID activity in a

CC cell by contacting the cell with the novel nucleic acid molecule,

CC treating a patient having a condition associated with the level of GRID

CC (e.g. tissue/graft rejection or leukaemia) by contacting the cell with

CC the novel nucleic acid molecule, cleaving RNA of a GRID gene by

CC contacting the cell with the novel nucleic acid molecule, an expression

CC vector comprising a nucleic acid sequence (encoding at least the novel

CC nucleic acid molecule) in a manner that allows its expression), a

CC mammalian cell including the expression vector and an enzymatic nucleic

CC acid molecule that cleaves RNA derived from a GRID gene. The nucleic acid

CC molecule is useful for treating a condition associated with the level of

CC GRID, e.g. tissue/graft rejection and leukaemia. The present sequence is

CC a target region for the enzymatic nucleic acids of the invention.

XX

SQ Sequence 17 BP; 3 A; 3 C; 9 G; 0 T; 2 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 81.2%; Pred. No. 7.2e+02;

Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 731 CACAGCGTGCAGGTGG 746

DB 1 CACAGCGGGAGGUGG 16

RESULT 1102

ADM54297

ID ADM54297 standard; mRNA; 17 BP.

AC ADM54297;

XX 03-JUN-2004 (first entry)

DT Human GRID mRNA substrate sequence #607.

DE Human; ss; GRID; Grb2-related with insert domain; hammerhead ribozyme;

XX NCH ribozyme; G-cleaver ribozyme; Zinzyme; DNasezyme; inozyme;

XX hairpin ribozyme; tissue rejection; graft rejection; leukaemia.

OS Homo sapiens.

XX US2003134806-A1.

PN 17-JUL-2003.

PD 23-FEB-2001; 2001US-00792818.

XX 10-FEB-2000; 2000US-0181594P.

XX (JARVIS) JARVIS T.

XX (CARL) CARLOWITZ I V.

XX (MCSW) MCSWIGGEN J.

XX (HAMB) HAMLIN P A.

XX (ELLI) ELLIS J H.

XX Jarvis T, Carlowitz IV, Mcswiggen J, Hamblin PA, Ellis JH;

XX WPI; 2003-829646/77.

XX New nucleic acid molecule that down-regulates expression of Grb2-related

XX with insert domain (GRID) gene, useful for treating a condition

XX associated with the level of GRID, e.g. tissue/graft rejection and

XX leukemia.

XX Claim 4; SEQ ID NO 607; 74pp; English.

XX The invention relates to a nucleic acid molecule that down-regulates

CC expression of Grb2-related with insert domain (GRID) gene, e.g. a

CC hammerhead ribozyme, NCH ribozyme, G-cleaver ribozyme, Zinzyme, DNasezyme,

CC amberyzyme, inozyme or hairpin ribozyme. Also include are a mammalian cell

CC including the novel nucleic acid molecule, reducing GRID activity in a

CC cell by contacting the cell with the novel nucleic acid molecule,

CC treating a patient having a condition associated with the level of GRID

CC (e.g. tissue/graft rejection or leukaemia) by contacting the cell with

CC the novel nucleic acid molecule, cleaving RNA of a GRID gene by

CC contacting the cell with the novel nucleic acid molecule, an expression

CC vector comprising a nucleic acid sequence (encoding at least the novel

CC nucleic acid molecule) in a manner that allows its expression), a

CC mammalian cell including the expression vector and an enzymatic nucleic

CC acid molecule that cleaves RNA derived from a GRID gene. The nucleic acid

CC molecule is useful for treating a condition associated with the level of

CC GRID, e.g. tissue/graft rejection and leukaemia. The present sequence is

CC a target region for the enzymatic nucleic acids of the invention.

XX

SQ Sequence 17 BP; 4 A; 9 C; 3 G; 0 T; 1 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 81.2%; Pred. No. 7.2e+02;

Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 717 CGCTGAGCAGCAGCA 732

DB 2 CCCGCGCAGCAGCACCA 17

RESULT 1103

ADF92040

ID ADF92040 standard; DNA; 17 BP.

XX ADF92040;

XX 26-FEB-2004 (first entry)

DT Human cytokeratin 18-derived R1c DNA - SEQ ID 128.

XX human; cytokeratin; CK; LAMP; loop mediated isothermal amplification;

XX tumour metastasis; prostate cancer; lymphoma; human; CK18; ss; primer;

XX PCR; R1c; probe.

XX Homo sapiens.

XX WO2003097878-A1.

XX 27-NOV-2003.

XX 20-MAY-2003; 2003WO-JP006256.

XX 21-MAY-2002; 2002JP-00145689.

XX 17-JUN-2002; 2002JP-00175271.

XX 09-JUL-2002; 2002JP-00199759.

XX (SYSM-) SYSMEX CORP.

XX Tada S, Akai Y, Imura Y, Abe S, Minekawa H;

XX WPI; 2004-012543/01.

XX LAMP nucleic acid amplification primers for detection of cytokeratin

XX expression as indicator in diagnosis of tumour metastasis.

XX Claim 3; SEQ ID NO 128; 266pp; Japanese.

XX The invention relates to novel nucleic acid amplification primers for the

XX detection of human cytokeratin (CK) 18, 19 or 20 expression by the LAMP

XX (loop mediated isothermal amplification) method. The primers of the

XX invention may be useful for the detecting cytokeratin 18-20 expression as

XX an indicator for the diagnosis of tumour metastasis, particularly

XX prostate cancer and lymphoma. The amplification using the primers is

CC highly efficient and allows very sensitive detection of tumour
CC metastasis. The current sequence is that of the human CK18-derived DNA of
CC the invention.

SX Sequence 17 BP; 4 A; 3 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 400 CAGCCAGAGGAGGAG 415
Db 2 CAGCCTGAGGAGGTG 17

RESULT 1104
ADF92290/c
ID ADF92290 standard; DNA; 17 BP.

XX ADF92290;

XX 26-FEB-2004 (first entry)

XX Human cytokeratin 19-related R3 PCR primer - SEQ ID 378.

XX human; cytokeratin; CK; LAMP; loop mediated isothermal amplification;
KW tumour metastasis; prostate cancer; lymphoma; human; CK19; ss; primer;
KW PCR; R3.

XX Homo sapiens.

XX WO2003097878-A1.

XX 27-NOV-2003.

XX 20-MAY-2003; 2003WO-JP006256.

XX 21-MAY-2002; 2002JP-00145689.

PR 17-JUN-2002; 2002JP-00175271.

PR 09-JUL-2002; 2002JP-00199759.

XX (SYSM-) SYSMEX CORP.

XX Tada S, Akai Y, Imura Y, Abe S, Minekawa H;

XX WPI; 2004-012543/01.

XX LAMP nucleic acid amplification primers for detection of cytokeratin
PT expression as indicator in diagnosis of tumour metastasis.

XX Claim 19; SEQ ID NO 378; 266pp; Japanese.

XX The invention relates to novel nucleic acid amplification primers for the
CC detection of human cytokeratin (CK) 18, 19 or 20 expression by the LAMP
CC (loop mediated isothermal amplification) method. The primers of the
CC invention may be useful for the detecting cytokeratin 18-20 expression as
CC an indicator for the diagnosis of tumour metastasis, particularly
CC prostate cancer and lymphoma. The amplification using the primers is
CC highly efficient and allows very sensitive detection of tumour
CC metastasis. The current sequence is that of the human CK19-related PCR
CC primer of the invention.

SX Sequence 17 BP; 2 A; 6 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 498 AGAAGGAGCAGGCTCT 513
Db 16 AGACGGAACAGGCTCT 1

RESULT 1105
ADK95913

ID ADK95913 standard; DNA; 17 BP.

XX ADK95913;

XX 06-MAY-2004 (first entry)

XX Primer of the invention #1633.

XX human; single nucleotide polymorphism; SNP; ss; primer.

XX Synthetic.

XX JP2003259875-A.

XX 16-SEP-2003.

XX 08-MAR-2002; 2002JP-00064373.

XX 08-MAR-2002; 2002JP-00064373.

XX (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.

XX WPI; 2004-093977/10.

XX Novel polynucleotide useful for PCR amplification along with two DNA
PT fragment from another set of sequences, or for detecting single
PT nucleotide polymorphism in human gene.

XX Claim 2; SEQ ID NO 4942; 2627pp; Japanese.

XX The present invention relates to a polynucleotide isolated from a human
CC gene and is useful for detecting a single nucleotide polymorphism in a
CC human gene or for diagnosing of disease. The invention enables the
CC detection of a single nucleotide polymorphism in a human gene. The
CC present sequence represents a primer of the invention.

SX Sequence 17 BP; 2 A; 5 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 648 GCCAGGCTCTGGAGG 663

Db 1 GCCTGGCTCTGGAGG 16

RESULT 1106
ADM59282/c

ID ADM59282 standard; RNA; 17 BP.

XX ADM59282;

XX 03-JUN-2004 (first entry)

XX Hepatitis B virus (HBV) RNA target sequence #1416.

XX Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
KW hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
KW cirrhosis; liver failure; lamivudine; interferon; genetic drift;
KW virucide; hepatotropic; antiinflammatory; cytostatic.

XX Hepatitis B virus.

XX US2004054156-A1.

XX 18-MAR-2004.

XX 15-JAN-2003; 2003US-00342902.

XX 14-MAY-1992; 92US-00882712.

```

PR 07-FEB-1994; 94US-00193627.
PR 08-NOV-1999; 99US-00436430.
PR 20-MAR-2000; 2000US-00531025.
PR 20-AUG-2000; 2000US-00636385.
PR 09-AUG-2000; 2000US-00636385.
PR 24-OCT-2000; 2000US-00696347.
PR 24-OCT-2000; 2000US-00696347.
PR 08-JUN-2001; 2001US-00877478.
XX
XX (DRAP/) DRAPER K.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
PA (MORR/) MORRISSEY D.
XX
XX Draper K, Blatt L, Mcswiggen JA, Morrissey D;
PI WPI; 2004-247781/23.
XX
XX Novel enzymatic nucleic acid molecule such as DNazymes and inozymes
XX specifically cleaving RNA derived from hepatitis B virus and comprising
XX one or more binding arms, useful for treating hepatitis and cirrhosis.
XX
XX Disclosure; SEQ ID NO 1416; 122pp; English.
XX
XX The invention relates to an enzymatic nucleic acid molecule that
XX specifically cleaves RNA derived from hepatitis B virus (HBV) and
XX comprising one or more binding arms, without requiring the presence of a
XX 2'-OH group within the molecule for activity. The nucleic acids are
XX useful for treating hepatitis B virus infection, hepatitis,
XX hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
XX combination with other therapies such as lamivudine and interferons. The
XX nucleic acids are useful as diagnostic tools to examine genetic drift and
XX mutations within diseased cells, for detecting the presence of HBV RNA in
XX a cell, for the study of RNA and for down-regulating gene expression of
XX target genes in bacterial, fungal, viral, plant or mammalian cells. This
XX sequence represents an HBV RNA target sequence, used in the scope of the
XX invention. Note: The sequence data for this patent is also available in
XX electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 17 BP; 0 A; 10 C; 2 G; 0 T; 5 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 406 GAGGAGGAGGAGGAG 421
Db 17 GAGGAGGAGGAGGAG 2
RESULT 1107
ADM58553/c
ID ADM58553 standard; RNA; 17 BP.
XX
XX ADM58553;
AC
XX
XX 03-JUN-2004 (first entry)
DT
XX
XX Hepatitis B virus (HBV) RNA target sequence #687.
DE
XX
XX Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
KW hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
KW cirrhosis; liver failure; lamivudine; interferon; genetic drift;
KW virucide; hepatotropic; antiinflammatory; cytostatic.
XX
XX Hepatitis B virus.
OS
XX
XX US2004054156-A1.
PN
XX
XX 18-MAR-2004.
PD
XX
XX 15-JAN-2003; 2003US-00342902.
PF
XX
XX 14-MAY-1992; 92US-0082712.
XX
XX 07-FEB-1994; 94US-00193627.
PR

```

```

PR 08-NOV-1999; 99US-00436430.
PR 20-MAR-2000; 2000US-00531025.
PR 09-AUG-2000; 2000US-00636385.
PR 24-OCT-2000; 2000US-00696347.
PR 24-OCT-2000; 2000US-00696347.
PR 08-JUN-2001; 2001US-00877478.
XX
XX (DRAP/) DRAPER K.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
PA (MORR/) MORRISSEY D.
XX
XX Draper K, Blatt L, Mcswiggen JA, Morrissey D;
PI WPI; 2004-247781/23.
XX
XX Novel enzymatic nucleic acid molecule such as DNazymes and inozymes
XX specifically cleaving RNA derived from hepatitis B virus and comprising
XX one or more binding arms, useful for treating hepatitis and cirrhosis.
XX
XX Disclosure; SEQ ID NO 687; 122pp; English.
XX
XX The invention relates to an enzymatic nucleic acid molecule that
XX specifically cleaves RNA derived from hepatitis B virus (HBV) and
XX comprising one or more binding arms, without requiring the presence of a
XX 2'-OH group within the molecule for activity. The nucleic acids are
XX useful for treating hepatitis B virus infection, hepatitis,
XX hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
XX combination with other therapies such as lamivudine and interferons. The
XX nucleic acids are useful as diagnostic tools to examine genetic drift and
XX mutations within diseased cells, for detecting the presence of HBV RNA in
XX a cell, for the study of RNA and for down-regulating gene expression of
XX target genes in bacterial, fungal, viral, plant or mammalian cells. This
XX sequence represents an HBV RNA target sequence, used in the scope of the
XX invention. Note: The sequence data for this patent is also available in
XX electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 17 BP; 0 A; 11 C; 1 G; 0 T; 5 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 406 GAGGAGGAGGAGGAG 421
Db 16 GAGGAGGAGGAGGAG 1
RESULT 1108
ADI86585/c
ID ADI86585 standard; RNA; 17 BP.
XX
XX ADI86585;
AC
XX
XX 03-JUN-2004 (first entry)
DT
XX
XX HCV DNzyme substrate sequence #3831.
DE
XX
XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KW HCV infection; type I interferon; DNzyme.
XX
XX Hepatitis C virus.
OS
XX
XX US2003125270-A1.
PN
XX
XX 03-JUL-2003.
PD
XX
XX 18-DEC-2000; 2000US-00740332.
PF
XX
XX 18-DEC-2000; 2000US-00740332.
PR
XX
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J.
XX (ROBE/) ROBERTS E.
PR

```



```

QY 735 GCGTGCAGGTGGACCA 750
Db 1 GCGUGUAGGUGGACCA 16

RESULT 1111
ADI83869
ID ADI83869 standard; RNA; 17 BP.
XX
XX ADI83869;
AC
XX
XX 03-JUN-2004 (first entry)
DE HCV DNzyme substrate sequence #1115.
XX
XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KW HCV infection; type I interferon; DNzyme.
XX
XX Hepatitis C virus.
XX
XX US2003125270-A1.
XX
XX 03-JUL-2003.
XX
XX 18-DEC-2000; 2000US-00740332.
XX
XX 18-DEC-2000; 2000US-00740332.
XX
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J.
XX (ROBE/) ROBERTS E.
XX (PAVC/) PAVCO P A.
XX (MACE/) MACEJACK D.
XX
XX Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
PI WPI; 2004-031273/03.
XX
XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT especially in combination with type I interferon therapy.
XX
XX Claim 1; SEQ ID NO 1115; 198pp; English.
XX
XX The invention relates to an enzymatic nucleic acid molecule which
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC the binding arms of the enzymatic nucleic acid molecule comprises
CC sequences complementary to any of the defined substrate sequences given
CC in the specification. The nucleic acid molecule may be administered for
CC the treatment of HCV infections, especially in combination with type I
CC interferons. The present sequence represents a HCV DNzyme substrate
CC sequence.
XX
XX Sequence 17 BP; 4 A; 6 C; 2 G; 0 T; 5 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 7.2e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 383 CTTCTGCAATTCACAG 398
Db 1 CUUCUGCCAUCACAG 16

RESULT 1112
ADI84116/C
ID ADI84116 standard; RNA; 17 BP.
XX
XX ADI84116;
AC
XX
XX 03-JUN-2004 (first entry)
DE HCV DNzyme substrate sequence #1362.

XX
XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KW HCV infection; type I interferon; DNzyme.
XX
XX Hepatitis C virus.
XX
XX US2003125270-A1.
XX
XX 03-JUL-2003.
XX
XX 18-DEC-2000; 2000US-00740332.
XX
XX 18-DEC-2000; 2000US-00740332.
XX
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J.
XX (ROBE/) ROBERTS E.
XX (PAVC/) PAVCO P A.
XX (MACE/) MACEJACK D.
XX
XX Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
PI WPI; 2004-031273/03.
XX
XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT especially in combination with type I interferon therapy.
XX
XX Claim 1; SEQ ID NO 1115; 198pp; English.
XX
XX The invention relates to an enzymatic nucleic acid molecule which
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC the binding arms of the enzymatic nucleic acid molecule comprises
CC sequences complementary to any of the defined substrate sequences given
CC in the specification. The nucleic acid molecule may be administered for
CC the treatment of HCV infections, especially in combination with type I
CC interferons. The present sequence represents a HCV DNzyme substrate
CC sequence.
XX
XX Sequence 17 BP; 4 A; 6 C; 2 G; 0 T; 5 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 7.2e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 594 TGCTCGGGGAGCTGCA 609
Db 16 TGCTCGGGGAGGTGGA 1

RESULT 1113
ADO30697
ID ADO30697 standard; DNA; 17 BP.
XX
XX ADO30697;
AC
XX
XX 15-JUL-2004 (first entry)
DE
DE Quadruplex modulator detection method test quadruplex molecule #9.
XX
XX ss; cytotstatic; quadruplex DNA; stabilization;
KW cell proliferative disorder; colorectal cancer; leukemia;
KW Hodgkin's disease.
XX
XX Synthetic.
XX
XX WO2004019283-A2.
XX
XX 04-MAR-2004.
XX
XX 20-AUG-2003; 2003WO-US026267.
XX
XX 20-AUG-2002; 2002US-0404965P.
XX

```

XX (CYTE-) CYTERNEX INC.
XX Ebbinghaus SW, Hurley LH, Siddiqui-Jain A, Memmott R;
XX WPI; 2004-239051/22.
XX
XX Identifying molecule that modulates biological activity of native
PT quadruplex DNA, by contacting test quadruplex DNA with candidate
PT molecule, determining presence or absence of interaction between the
PT molecule and test quadruplex DNA.
XX
XX Claim 2; Page 36; 43pp; English.
XX
XX The invention relates to a method of identifying (M1) a molecule that
CC modulates biological activity of native quadruplex DNA, by contacting
CC test quadruplex DNA with candidate molecule, and determining presence or
CC absence of interaction between candidate molecule and test quadruplex
CC DNA, where candidate molecule that interacts with test quadruplex DNA is
CC identified as molecule that modulates biological activity of native
CC quadruplex DNA. (M1) is useful for identifying molecule that modulates
CC biological activity of native quadruplex DNA (claimed). (M1) is useful
CC for identifying molecule that modulates biological activity of native
CC quadruplex DNA, where the identified molecule stabilizes quadruplex
CC structure which can exert a therapeutic effect for certain cell
CC proliferative disorders e.g., colorectal cancer, leukemia's, Hodgkin's
CC disease, etc. This sequence corresponds to a test quadruplex molecule
CC used in the method of the invention.
XX
SQ Sequence 17 BP; 7 A; 0 C; 10 G; 0 T; 0 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 490 GAAGAGCGAAGAGGAG 505
Db . 2 GAAGAGGGGAGGAGG 17
RESULT 1114
ADN44954
ID ADN44954 standard; DNA; 17 BP.
XX
XX AC ADN44954;
XX
XX 15-JUL-2004 (first entry)
XX
XX Mutant cell identification-related mutagenic oligonucleotide SeqID1623.
XX
XX cell identification; oligonucleotide-directed sequence alteration;
KW selectable phenotype; transgenic plant; herbicide resistance;
KW sterile plant; abiotic stress tolerance; albino plant;
KW amino acid production; ss.
XX
XX Oryza sativa.
XX
XX Synthetic.
XX
XX WO2004033708-A2.
XX
XX 22-APR-2004.
XX
XX 07-OCT-2003; 2003WO-US031862.
XX
XX 07-OCT-2002; 2002US-0416983P.
XX
XX 07-MAR-2003; 2003US-0453360P.
XX
XX (UYDE) UNIV DELAWARE.
XX (NAPR-) NAPRO BIO THERAPEUTICS INC.
XX
XX Kmiec EB, Van Brabant A;
XX
XX WPI; 2004-340941/31.

XX Identifying a cell with a desired oligonucleotide-directed sequence
PT alteration at a nucleic acid target site within the cell by identifying
PT the desired sequence alteration in cells selected for the presence of a
PT selectable phenotype.
XX
XX Example 28; SEQ ID NO 1623; 303pp; English.
XX
XX This invention relates to a novel method of identifying a cell having a
CC desired oligonucleotide-directed sequence alteration at a first nucleic
CC acid target site within the cell. The method comprises identifying the
CC desired sequence alteration in cells that have been selected for the
CC presence of a selectable phenotype conferred by a concurrent
CC oligonucleotide-directed sequence alteration at a second nucleic acid
CC target site within the cells. The method is useful in identifying a cell
CC having a desired oligonucleotide-directed sequence alteration at a first
CC nucleic acid target site within the cell. The method may be useful for
CC the production of plants with herbicide resistance, male or female
CC sterile plants, abiotic stress tolerance, albino plants or plants with
CC altered amino acid production as well as for use in mammalian cell lines.
CC The present sequence is that of a mutagenic oligonucleotide which was
CC used in the exemplification of the invention.
XX
SQ Sequence 17 BP; 5 A; 2 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 409 GGAGGAGAGGAGGATTC 424
Db 2 GGAGGCAAGAGGATTC 17
RESULT 1115
ADN44955/C
ID ADN44955 standard; DNA; 17 BP.
XX
XX AC ADN44955;
XX
XX 15-JUL-2004 (first entry)
XX
XX Mutant cell identification-related mutagenic oligonucleotide SeqID1624.
XX
XX cell identification; oligonucleotide-directed sequence alteration;
KW selectable phenotype; transgenic plant; herbicide resistance;
KW sterile plant; abiotic stress tolerance; albino plant;
KW amino acid production; ss.
XX
XX Oryza sativa.
XX
XX Synthetic.
XX
XX WO2004033708-A2.
XX
XX 22-APR-2004.
XX
XX 07-OCT-2003; 2003WO-US031862.
XX
XX 07-OCT-2002; 2002US-0416983P.
XX
XX 07-MAR-2003; 2003US-0453360P.
XX
XX (UYDE) UNIV DELAWARE.
XX (NAPR-) NAPRO BIO THERAPEUTICS INC.
XX
XX Kmiec EB, Van Brabant A;
XX
XX WPI; 2004-340941/31.
XX
XX Identifying a cell with a desired oligonucleotide-directed sequence
PT alteration at a nucleic acid target site within the cell by identifying
PT the desired sequence alteration in cells selected for the presence of a
PT selectable phenotype.
XX

```
PS Example 28; SEQ ID NO 1624; 303pp; English.
XX
CC This invention relates to a novel method of identifying a cell having a
CC desired oligonucleotide-directed sequence alteration at a first nucleic
CC acid target site within the cell. The method comprises identifying the
CC desired sequence alteration in cells that have been selected for the
CC presence of a selectable phenotype conferred by a concurrent
CC oligonucleotide-directed sequence alteration at a second nucleic acid
CC target site within the cells. The method is useful in identifying a cell
CC having a desired oligonucleotide-directed sequence alteration at a first
CC nucleic acid target site within the cell. The method may be useful for
CC the production of plants with herbicide resistance, male or female
CC sterile plants, abiotic stress tolerance, albino plants or plants with
CC altered amino acid production as well as for use in mammalian cell lines.
CC The present sequence is that of a mutagenic oligonucleotide which was
CC used in the exemplification of the invention.
XX
SQ Sequence 17 BP; 3 A; 7 C; 2 G; 5 T; 0 U; 0 Other;
    Query Match      1.7%; Score 12.8; DB 1; Length 17;
    Best Local Similarity 87.5%; Pred. No. 7.2e+02;
    Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 409 GGAGGAGGAGGAGTTC 424
DB 16 GGAGGCAAGGAGTTC 1
    RESULT 1116
    ACN64621/c
    ID ACN64621 standard; DNA; 17 BP.
    XX
    AC ACN64621;
    XX
    DT 02-DEC-2004 (first entry)
    XX
    DE Human GDMPLP-1 probe SEQ ID NO:1523.
    XX
    KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
    KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
    KW skeletal muscle function.
    XX
    OS Homo sapiens.
    XX
    PN US2004137589-A1.
    XX
    PD 15-JUL-2004.
    XX
    PF 26-NOV-2003; 2003US-00723361.
    XX
    PR 26-MAY-2000; 2000US-0207456P.
    PR 21-SEP-2000; 2000US-0234687P.
    PR 27-SEP-2000; 2000US-0236359P.
    PR 04-OCT-2000; 2000GB-00024263.
    PR 30-JAN-2001; 2001WO-US000661.
    PR 30-JAN-2001; 2001WO-US000662.
    PR 30-JAN-2001; 2001WO-US000663.
    PR 30-JAN-2001; 2001WO-US000664.
    PR 30-JAN-2001; 2001WO-US000665.
    PR 30-JAN-2001; 2001WO-US000666.
    PR 30-JAN-2001; 2001WO-US000667.
    PR 30-JAN-2001; 2001WO-US000668.
    PR 30-JAN-2001; 2001WO-US000669.
    PR 05-FEB-2001; 2001WO-US000670.
    PR 25-MAY-2001; 2001US-00866108.
    XX
    PA (GUY/) GU Y.
    PA (JIY/) JI Y.
    PA (PENN/) PENN S G.
    PA (HANZ/) HANZEL D K.
    PA (RANK/) RANK D.
    PA (CHEN/) CHEN W.
```

```
PA (SHAN/) SHANNON M E.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
DR
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
PS Disclosure; SEQ ID NO 1523; 0pp; English.
XX
CC The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63102
XX
SQ Sequence 17 BP; 5 A; 2 C; 8 G; 2 T; 0 U; 0 Other;
    Query Match      1.7%; Score 12.8; DB 1; Length 17;
    Best Local Similarity 87.5%; Pred. No. 7.2e+02;
    Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 846 CCTATCACCAGCTCTT 861
DB 17 CCTATCACCAGCTCTT 2
    RESULT 1117
    ACN65094/c
    ID ACN65094 standard; DNA; 17 BP.
    XX
    AC ACN65094;
    XX
    DT 02-DEC-2004 (first entry)
    XX
    DE Human GDMPLP-1 probe SEQ ID NO:1996.
    XX
    KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
    KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
    KW skeletal muscle function.
    XX
    OS Homo sapiens.
    XX
    PN US2004137589-A1.
    XX
    PD 15-JUL-2004.
    XX
    PF 26-NOV-2003; 2003US-00723361.
    XX
    PR 26-MAY-2000; 2000US-0207456P.
    PR 21-SEP-2000; 2000US-0234687P.
    PR 27-SEP-2000; 2000US-0236359P.
    PR 04-OCT-2000; 2000GB-00024263.
    PR 30-JAN-2001; 2001WO-US000661.
    PR 30-JAN-2001; 2001WO-US000662.
    PR 30-JAN-2001; 2001WO-US000663.
    PR 30-JAN-2001; 2001WO-US000664.
    PR 30-JAN-2001; 2001WO-US000665.
    PR 30-JAN-2001; 2001WO-US000666.
    PR 30-JAN-2001; 2001WO-US000667.
    PR 30-JAN-2001; 2001WO-US000668.
    PR 30-JAN-2001; 2001WO-US000669.
    PR 05-FEB-2001; 2001WO-US000670.
    PR 25-MAY-2001; 2001US-0086680P.
```

PR 25-MAY-2001; 2001US-00866108.
XX (GUY/) GU Y.
PA (JIY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
DR
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
PS Disclosure; SEQ ID NO 1996; Opp; English.
XX
CC The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63102
XX
SQ Sequence 17 BP; 2 A; 7 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.3%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 309 GCCTGGAGGAGATCA 324
DB 17 GGCTGGAGGACATCA 2

RESULT 1118
ACN70797/c
ID ACN70797 standard; DNA; 17 BP.
XX
AC ACN70797;
XX
DT 02-DEC-2004 (first entry)
XX
DE Human GDMPLP-1 probe SEQ ID NO:7699.
XX
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
KW skeletal muscle function.
XX
OS Homo sapiens.
XX
XX US2004137589-A1.
XX
PD 15-JUL-2004.
XX
XX 26-NOV-2003; 2003US-00723361.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.

PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
XX (GUY/) GU Y.
PA (JIY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
DR
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
PS Disclosure; SEQ ID NO 7699; Opp; English.
XX
CC The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
SQ Sequence 17 BP; 2 A; 7 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 827 CTGGCCCGAGTTCAGG 842
DB 16 CTGGCCCGAGTTCAGG 1

RESULT 1119
ACN64622/c
ID ACN64622 standard; DNA; 17 BP.
XX
XX ACN64622;
AC
DT 02-DEC-2004 (first entry)
XX
DE Human GDMPLP-1 probe SEQ ID NO:1524.
XX
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
KW skeletal muscle function.
XX
XX Homo sapiens.
XX
XX US2004137589-A1.
XX
XX 15-JUL-2004.
XX
XX 26-NOV-2003; 2003US-00723361.

```

XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PR 30-JAN-2001; 2001WO-US000661.
XX PR 30-JAN-2001; 2001WO-US000662.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000666.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 05-FEB-2001; 2001WO-US000670.
XX PR 25-MAY-2001; 2001US-0266860P.
XX PR 25-MAY-2001; 2001US-00866108.
XX PA (GUYV/) GU Y.
XX PA (JIYV/) JI Y.
XX PA (PENNV/) PENN S G.
XX PA (HANZ/) HANZEL D K.
XX PA (RANK/) RANK D.
XX PA (CHEN/) CHEN W.
XX PA (SHAN/) SHANNON M E.
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX Novel myosin-like protein-1, useful for treating or preventing disorder
XX associated with decreased expression or activity of human genome-derived
XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle
XX function.
XX Disclosure; SEQ ID NO 1524; Opp; English.
XX The invention relates to a novel polypeptide (I) comprising a sequence
XX (SI) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
XX defined in the specification, a fragment of at least 8 amino acids of
XX (SI), 95% deviation from (SI) which are conservative substitutions, and
XX 65% identity to (SI). A polypeptide of the invention acts as an agonist or
XX antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
XX pharmaceutical composition of the invention is useful for treating or
XX preventing a disorder associated with decreased expression or activity of
XX hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
XX The present sequence represents a 17-mer nucleotide, used in the
XX invention for scanning the sequence represented in ACN63102
XX SQ Sequence 17 BP; 5 A; 1 C; 9 G; 2 T; 0 U; 0 Other;
XX Query Match 1.7%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 7.2e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX QY 846 CCTATCACCAGCTCTT 861
XX |||||
XX Db 16 CCCATCAGCTGCTT 1
XX RESULT 1120
XX ACN64818/c
XX ID ACN64818 standard; DNA; 17 BP.
XX AC ACN64818;
XX XX 02-DEC-2004 (first entry)
XX XX Human GDMLP-1 probe SEQ ID NO:1720.
XX KW Human; ss; probe; myosin-like protein-1; hGDMLP-1;
XX KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
XX KW skeletal muscle function.

```

```

XX OS Homo sapiens.
XX PN US2004137589-A1.
XX XX 15-JUL-2004.
XX PF 26-NOV-2003; 2003US-00723361.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PR 30-JAN-2001; 2001WO-US000661.
XX PR 30-JAN-2001; 2001WO-US000662.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000666.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 05-FEB-2001; 2001WO-US000670.
XX PR 25-MAY-2001; 2001US-0266860P.
XX PR 25-MAY-2001; 2001US-00866108.
XX PA (GUYV/) GU Y.
XX PA (JIYV/) JI Y.
XX PA (PENNV/) PENN S G.
XX PA (HANZ/) HANZEL D K.
XX PA (RANK/) RANK D.
XX PA (CHEN/) CHEN W.
XX PA (SHAN/) SHANNON M E.
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX Novel myosin-like protein-1, useful for treating or preventing disorder
XX associated with decreased expression or activity of human genome-derived
XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle
XX function.
XX Disclosure; SEQ ID NO 1720; Opp; English.
XX The invention relates to a novel polypeptide (I) comprising a sequence
XX (SI) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
XX defined in the specification, a fragment of at least 8 amino acids of
XX (SI), 95% deviation from (SI) which are conservative substitutions, and
XX 65% identity to (SI). A polypeptide of the invention acts as an agonist or
XX antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
XX pharmaceutical composition of the invention is useful for treating or
XX preventing a disorder associated with decreased expression or activity of
XX hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
XX The present sequence represents a 17-mer nucleotide, used in the
XX invention for scanning the sequence represented in ACN63102
XX SQ Sequence 17 BP; 3 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
XX Query Match 1.7%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 7.2e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX QY 392 TTCCAAGCCAGCCAGA 407
XX |||||
XX Db 17 TTCTGAGCCAGCCAGA 2
XX RESULT 1121
XX ACN70912
XX ID ACN70912 standard; DNA; 17 BP.
XX AC ACN70912;

```

XX 02-DEC-2004 (first entry)
XX Human GDMPLP-1 probe SEQ ID NO:7814.
XX
DE Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
KW skeletal muscle function.
XX
XX Homo sapiens.
XX US2004137589-A1.
XX
XX 15-JUL-2004.
XX 26-NOV-2003; 2003US-00723361.
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 05-FEB-2001; 2001US-0266860P.
XX 25-MAY-2001; 2001US-00866108.
XX
XX (GUY/) GU Y.
XX (JIY/) JI Y.
XX (PENN/) PENN S G.
XX (HANK/) HANZEL D K.
XX (RANK/) RANK D.
XX (CHEN/) CHEN W.
XX (SHAN/) SHANNON M E.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
PI WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
XX Disclosure; SEQ ID NO 7814; Opp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
SQ Sequence 17 BP; 9 A; 2 C; 6 G; 0 T; 0 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
||| |||||

QY 494 AGCAGAGGAGCAGG 509

Db 1 AAGCAAAAGGAGCAGG 16
RESULT 1122
ACN63452/C
ID ACN63452 standard; DNA; 17 BP.
XX ACN63452;
XX
XX 02-DEC-2004 (first entry)
XX Human GDMPLP-1 probe SEQ ID NO:354.
XX
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
KW skeletal muscle function.
XX
XX Homo sapiens.
XX US2004137589-A1.
XX
XX 15-JUL-2004.
XX 26-NOV-2003; 2003US-00723361.
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 05-FEB-2001; 2001US-0266860P.
XX 25-MAY-2001; 2001US-00866108.
XX
XX (GUY/) GU Y.
XX (JIY/) JI Y.
XX (PENN/) PENN S G.
XX (HANK/) HANZEL D K.
XX (RANK/) RANK D.
XX (CHEN/) CHEN W.
XX (SHAN/) SHANNON M E.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
PI WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
XX Disclosure; SEQ ID NO 354; Opp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63102
XX
XX

```
SQ Sequence 17 BP; 4 A; 7 C; 4 G; 2 T; 0 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 482 CTCGATCTGAAGAGGC 497
Db 17 CTCGTTCTGGAGAGGC 2

RESULT 1123
ACN69989/c
ID ACN69989 standard; DNA; 17 BP.
XX AC ACN69989;
XX AC ACN69989;
XX 02-DEC-2004 (first entry)
XX Human GDMPLP-1 probe SEQ ID NO:6891.
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
XX hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
XX skeletal muscle function.
XX Homo sapiens.
XX US2004137589-A1.
XX 15-JUL-2004.
XX 26-NOV-2003; 2003US-00723361.
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 05-FEB-2001; 2001US-0266860P.
XX 25-MAY-2001; 2001US-00866108.
XX (GUY/) GU Y.
XX (JIY/) JI Y.
XX (PENN/) PENN S G.
XX (HANZ/) HANZEL D K.
XX (RANK/) RANK D.
XX (CHEN/) CHEN W.
XX (SHAN/) SHANNON M E.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX Novel myosin-like protein-1, useful for treating or preventing disorder
XX associated with decreased expression or activity of human genome-derived
XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle
XX function.
XX Disclosure; SEQ ID NO 6891; Opp; English.
XX The invention relates to a novel polypeptide (I) comprising a sequence
XX (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
XX defined in the specification, a fragment of at least 8 amino acids of
XX (S1), 95% deviation from (S1) which are conservative substitutions, and
```


PT function.
 PS Disclosure; SEQ ID NO 1721; Opp; English.
 XX
 CC The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63102
 XX
 SQ Sequence 17 BP; 3 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 392 TTCCAGCCAGCCAGA 407
 Db 16 TTCTGAGCCAGCCAGA 1
 RESULT 1125
 ACN71521
 ID ACN71521 standard; DNA; 17 BP.
 XX AC ACN71521;
 DT 02-DEC-2004 (first entry)
 XX Human GDMPLP-1 probe SEQ ID NO:8423.
 DE Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX Homo sapiens.
 XX US2004137589-A1.
 XX 15-JUL-2004.
 XX 26-NOV-2003; 2003US-00723361.
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001WO-US000670.
 PR 25-MAY-2001; 2001US-0266860P.
 XX (GUY)/ GU Y.
 PA (JIY)/ JI Y.
 PA (PENN)/ PENN S G.
 PA (HANZ)/ HANZEL D K.
 PA (RANK)/ RANK D.
 PA (CHEN)/ CHEN W.
 PA (SHAN)/ SHANNON M E.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 XX Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 XX Disclosure; SEQ ID NO 8423; Opp; English.
 XX The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX
 SQ Sequence 17 BP; 6 A; 3 C; 6 G; 2 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 491 AAGAGCGCAGAGGAGC 506
 Db 1 AAGAGCGCAGAGGAGTGC 16
 RESULT 1126
 ACN63771/C
 ID ACN63771 standard; DNA; 17 BP.
 XX AC ACN63771;
 XX 02-DEC-2004 (first entry)
 XX Human GDMPLP-1 probe SEQ ID NO:673.
 DE Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX Homo sapiens.
 XX US2004137589-A1.
 XX 15-JUL-2004.
 XX 26-NOV-2003; 2003US-00723361.
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001WO-US000670.
 PR 25-MAY-2001; 2001US-0266860P.
 XX (GUY)/ GU Y.
 PA (JIY)/ JI Y.
 PA (PENN)/ PENN S G.
 PA (HANZ)/ HANZEL D K.
 PA (RANK)/ RANK D.
 PA (CHEN)/ CHEN W.
 PA (SHAN)/ SHANNON M E.

XX (GUY/) GU Y.
PA (JIY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
XX Disclosure; SEQ ID NO 673; Opp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
CC (SI) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (SI), 95% deviation from (SI) which are conservative substitutions, and
CC 65% identity to (SI). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63102
XX
XX Sequence 17 BP; 6 A; 6 C; 3 G; 2 T; 0 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 233 GAAGAGTCTCCTCGG 248
DB 16 GATGAGCTTCTCTCGG 1
RESULT 1127
ACN69920/C
ID ACN69920 standard; DNA; 17 BP.
XX ACN69920;
XX
XX 02-DEC-2004 (first entry)
XX Human GDMLP-1 probe SEQ ID NO:6822.
XX
XX Human; ss; probe; myosin-like protein-1; hGDMLP-1;
XX hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
XX skeletal muscle function.
XX Homo sapiens.
XX
XX US2004137589-A1.
XX
XX 15-JUL-2004.
XX
XX 26-NOV-2003; 2003US-00723361.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.

PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-026860P.
PR 25-MAY-2001; 2001US-00866108.
XX
XX (GUY/) GU Y.
PA (JIY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
XX Disclosure; SEQ ID NO 6822; Opp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
CC (SI) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (SI), 95% deviation from (SI) which are conservative substitutions, and
CC 65% identity to (SI). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
XX Sequence 17 BP; 3 A; 3 C; 4 G; 7 T; 0 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 267 ACCTGCCTTCAGACA 282
DB 17 ACCTGCCTTCAGAAAA 2
RESULT 1128
ACN70795/C
ID ACN70795 standard; DNA; 17 BP.
XX ACN70795;
XX
XX 02-DEC-2004 (first entry)
XX Human GDMLP-1 probe SEQ ID NO:7697.
XX
XX Human; ss; probe; myosin-like protein-1; hGDMLP-1;
XX hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
XX skeletal muscle function.
XX Homo sapiens.
XX
XX US2004137589-A1.
XX
XX 15-JUL-2004.
XX
XX 26-NOV-2003; 2003US-00723361.
XX

DT 02-DEC-2004 (first entry)
 XX Human GDMPLP-1 probe SEQ ID NO:1997.
 XX
 XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 XX Homo sapiens.
 XX
 XX US2004137589-A1.
 XX
 XX 15-JUL-2004.
 XX
 XX 26-NOV-2003; 2003US-00723361.
 XX
 XX 26-MAY-2000; 2000US-0207456P.
 XX
 XX 21-SEP-2000; 2000US-0234687P.
 XX
 XX 27-SEP-2000; 2000US-0236359P.
 XX
 XX 04-OCT-2000; 2000GB-00024263.
 XX
 XX 30-JAN-2001; 2001WO-US000661.
 XX
 XX 30-JAN-2001; 2001WO-US000662.
 XX
 XX 30-JAN-2001; 2001WO-US000663.
 XX
 XX 30-JAN-2001; 2001WO-US000664.
 XX
 XX 30-JAN-2001; 2001WO-US000665.
 XX
 XX 30-JAN-2001; 2001WO-US000666.
 XX
 XX 30-JAN-2001; 2001WO-US000667.
 XX
 XX 30-JAN-2001; 2001WO-US000668.
 XX
 XX 30-JAN-2001; 2001WO-US000669.
 XX
 XX 05-FEB-2001; 2001WO-US000670.
 XX
 XX 25-MAY-2001; 2001US-0266860P.
 XX
 XX (GUY/) GU Y.
 XX (JIY/) JI Y.
 XX (PEN/) PENN S G.
 XX (HAN/) HANZEL D K.
 XX (RANK/) RANK D.
 XX (CHEN/) CHEN W.
 XX (SHAN/) SHANNON M E.
 XX
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 XX
 XX Novel myosin-like protein-1, useful for treating or preventing disorder
 XX associated with decreased expression or activity of human genome-derived
 XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 XX function.
 XX
 XX Disclosure; SEQ ID NO 1997; Opp; English.
 XX
 XX The invention relates to a novel polypeptide (I) comprising a sequence
 XX (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 XX defined in the specification, a fragment of at least 8 amino acids of
 XX (S1), 95% deviation from (S1) which are conservative substitutions, and
 XX 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 XX antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 XX pharmaceutical composition of the invention is useful for treating or
 XX preventing a disorder associated with decreased expression or activity of
 XX hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 XX The present sequence represents a 17-mer nucleotide, used in the
 XX invention for scanning the sequence represented in ACN63102
 XX
 XX Sequence 17 BP; 2 A; 7 C; 3 G; 5 T; 0 U; 0 Other;
 XX
 XX Query Match 1.7%; Score 12.8; DB 1; Length 17;
 XX Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 XX 309 GCTGTGGAGGAGATCA 324
 XX 16 GGCTGGAGGACATCA 1

RESULT 1131
 ACN71131
 ID ACN71131 standard; DNA; 17 BP.
 XX
 XX ACN71131;
 XX
 XX 02-DEC-2004 (first entry)
 XX
 XX Human GDMPLP-1 probe SEQ ID NO:8033.
 XX
 XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 XX Homo sapiens.
 XX
 XX US2004137589-A1.
 XX
 XX 15-JUL-2004.
 XX
 XX 26-NOV-2003; 2003US-00723361.
 XX
 XX 26-MAY-2000; 2000US-0207456P.
 XX
 XX 21-SEP-2000; 2000US-0234687P.
 XX
 XX 27-SEP-2000; 2000US-0236359P.
 XX
 XX 04-OCT-2000; 2000GB-00024263.
 XX
 XX 30-JAN-2001; 2001WO-US000661.
 XX
 XX 30-JAN-2001; 2001WO-US000662.
 XX
 XX 30-JAN-2001; 2001WO-US000663.
 XX
 XX 30-JAN-2001; 2001WO-US000664.
 XX
 XX 30-JAN-2001; 2001WO-US000665.
 XX
 XX 30-JAN-2001; 2001WO-US000666.
 XX
 XX 30-JAN-2001; 2001WO-US000667.
 XX
 XX 30-JAN-2001; 2001WO-US000668.
 XX
 XX 30-JAN-2001; 2001WO-US000669.
 XX
 XX 05-FEB-2001; 2001WO-US000670.
 XX
 XX 25-MAY-2001; 2001US-00866108.
 XX
 XX (GUY/) GU Y.
 XX (JIY/) JI Y.
 XX (PEN/) PENN S G.
 XX (HAN/) HANZEL D K.
 XX (RANK/) RANK D.
 XX (CHEN/) CHEN W.
 XX (SHAN/) SHANNON M E.
 XX
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 XX
 XX Novel myosin-like protein-1, useful for treating or preventing disorder
 XX associated with decreased expression or activity of human genome-derived
 XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 XX function.
 XX
 XX Disclosure; SEQ ID NO 8033; Opp; English.
 XX
 XX The invention relates to a novel polypeptide (I) comprising a sequence
 XX (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 XX defined in the specification, a fragment of at least 8 amino acids of
 XX (S1), 95% deviation from (S1) which are conservative substitutions, and
 XX 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 XX antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 XX pharmaceutical composition of the invention is useful for treating or
 XX preventing a disorder associated with decreased expression or activity of
 XX hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 XX The present sequence represents a 17-mer nucleotide, used in the
 XX invention for scanning the sequence represented in ACN63103
 XX
 XX Sequence 17 BP; 4 A; 3 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 696 AGCTGAGAGTGGCG 711
DB 2 AGCTGAGAGTGGCG 17

RESULT 1132
ACN63770/C
ID ACN63770 standard; DNA; 17 BP.
AC ACN63770;
XX
XX
XX
DT 02-DEC-2004 (first entry)
XX
DE Human GDMPLP-1 probe SEQ ID NO:672.
XX
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
KW skeletal muscle function.
XX
XX Homo sapiens.
XX
XX US2004137589-A1.
XX
XX 15-JUL-2004.
XX
XX 26-NOV-2003; 2003US-00723361.
XX
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 05-FEB-2001; 2001WO-US000670.
PR 25-MAY-2001; 2001US-0266860P.
XX
XX (GUY/) GU Y.
PA (JIY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
PI WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
PT
XX Disclosure; SEQ ID NO 672; Opp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or

CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63102
XX
SQ Sequence 17 BP; 6 A; 5 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 233 GAAGAGTCTCTCTGG 248
DB 17 GATGAGTCTCTCTGG 2

RESULT 1133
ACN70776
ID ACN70776 standard; DNA; 17 BP.
XX
XX ACN70776;
XX
XX 02-DEC-2004 (first entry)
XX
XX Human GDMPLP-1 probe SEQ ID NO:7678.
XX
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
KW skeletal muscle function.
XX
XX Homo sapiens.
XX
XX US2004137589-A1.
XX
XX 15-JUL-2004.
XX
XX 26-NOV-2003; 2003US-00723361.
XX
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 05-FEB-2001; 2001WO-US000670.
PR 25-MAY-2001; 2001US-0266860P.
XX
XX (GUY/) GU Y.
PA (JIY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
PI WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.

XX Disclosure; SEQ ID NO 7678; Opp; English.

XX The invention relates to a novel polypeptide (I) comprising a sequence

CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully

CC defined in the specification, a fragment of at least 8 amino acids of

CC (S1), 95% deviation from (S1) which are conservative substitutions, and

CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or

CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A

CC pharmaceutical composition of the invention is useful for treating or

CC preventing a disorder associated with decreased expression or activity of

CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.

CC The present sequence represents a 17-mer nucleotide, used in the

CC invention for scanning the sequence represented in ACN63103

XX

SQ Sequence 17 BP; 9 A; 1 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 7.2e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 490 GAAGAGGCGAGGAGGAG 505

Db 1 GAAGAGGCGAGGAGGAG 16

RESULT 1134

ACN70910

ID ACN70910 standard; DNA; 17 BP.

XX

AC ACN70910;

XX

DT 02-DEC-2004 (first entry)

XX

DE Human GDMLP-1 probe SEQ ID NO:7812.

XX

XX Human; ss; probe; myosin-like protein-1; hGDMLP-1;

KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;

KW skeletal muscle function.

XX

OS Homo sapiens.

XX

PN US2004137589-A1.

XX

PD 15-JUL-2004.

XX

PF 26-NOV-2003; 2003US-00723361.

XX

PR 26-MAY-2000; 2000US-0207456P.

PR 21-SEP-2000; 2000US-0234687P.

PR 27-SEP-2000; 2000US-0236359P.

PR 04-OCT-2000; 2000GB-00024263.

PR 30-JAN-2001; 2001WO-US000661.

PR 30-JAN-2001; 2001WO-US000662.

PR 30-JAN-2001; 2001WO-US000663.

PR 30-JAN-2001; 2001WO-US000664.

PR 30-JAN-2001; 2001WO-US000665.

PR 30-JAN-2001; 2001WO-US000666.

PR 30-JAN-2001; 2001WO-US000667.

PR 30-JAN-2001; 2001WO-US000668.

PR 30-JAN-2001; 2001WO-US000669.

PR 05-FEB-2001; 2001US-0266860P.

PR 25-MAY-2001; 2001US-00866108.

XX

PA (GUY)/ GU Y.

PA (JIY)/ JI Y.

PA (PEN)/ PEN S G.

PA (HANZ)/ HANZEL D K.

PA (RANK)/ RANK D.

PA (CHEN)/ CHEN W.

PA (SHAN)/ SHANNON M E.

XX

PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;

XX WPI; 2004-533378/51.

XX Novel myosin-like protein-1, useful for treating or preventing disorder

PT associated with decreased expression or activity of human genome-derived

PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle

PT function.

XX

PS Disclosure; SEQ ID NO 7812; Opp; English.

XX

CC The invention relates to a novel polypeptide (I) comprising a sequence

CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully

CC defined in the specification, a fragment of at least 8 amino acids of

CC (S1), 95% deviation from (S1) which are conservative substitutions, and

CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or

CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A

CC pharmaceutical composition of the invention is useful for treating or

CC preventing a disorder associated with decreased expression or activity of

CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.

CC The present sequence represents a 17-mer nucleotide, used in the

CC invention for scanning the sequence represented in ACN63103

XX

SQ Sequence 17 BP; 8 A; 2 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 7.2e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 493 GAGCGAGAGGAGGAGGAG 508

Db 2 GAAGCAAAAGGAGGAG 17

RESULT 1135

ACN63453/C

ID ACN63453 standard; DNA; 17 BP.

XX

AC ACN63453;

XX

DT 02-DEC-2004 (first entry)

XX

DE Human GDMLP-1 probe SEQ ID NO:355.

XX

XX Human; ss; probe; myosin-like protein-1; hGDMLP-1;

KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;

KW skeletal muscle function.

XX

OS Homo sapiens.

XX

PN US2004137589-A1.

XX

PD 15-JUL-2004.

XX

PF 26-NOV-2003; 2003US-00723361.

XX

PR 26-MAY-2000; 2000US-0207456P.

PR 21-SEP-2000; 2000US-0234687P.

PR 27-SEP-2000; 2000US-0236359P.

PR 04-OCT-2000; 2000GB-00024263.

PR 30-JAN-2001; 2001WO-US000661.

PR 30-JAN-2001; 2001WO-US000662.

PR 30-JAN-2001; 2001WO-US000663.

PR 30-JAN-2001; 2001WO-US000664.

PR 30-JAN-2001; 2001WO-US000665.

PR 30-JAN-2001; 2001WO-US000666.

PR 30-JAN-2001; 2001WO-US000667.

PR 30-JAN-2001; 2001WO-US000668.

PR 30-JAN-2001; 2001WO-US000669.

PR 05-FEB-2001; 2001US-0266860P.

PR 25-MAY-2001; 2001US-00866108.

XX

PA (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 PI WPI; 2004-533378/51.
 DR
 XX Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 PT
 XX Disclosure; SEQ ID NO 355; Opp; English.
 PS
 XX The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as a agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63102
 XX
 XX Sequence 17 BP; 5 A; 6 C; 4 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 482 CTCGATCTGAAGGCG 497
 DB 16 CTCGTTCTGGAGAGC 1
 RESULT 1136
 ACN70775
 ID ACN70775 standard; DNA; 17 BP.
 XX
 AC ACN70775;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Human GDMPLP-1 probe SEQ ID NO:7677.
 XX
 XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 OS Homo sapiens.
 XX
 PN US20041137589-A1.
 XX
 XX 15-JUL-2004.
 PD
 XX 26-NOV-2003; 2003US-00723361.
 PF
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.

PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 XX (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 PI WPI; 2004-533378/51.
 DR
 XX Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 PT
 XX Disclosure; SEQ ID NO 7677; Opp; English.
 PS
 XX The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as a agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX
 XX Sequence 17 BP; 10 A; 1 C; 6 G; 0 T; 0 U; 0 Other;
 SQ
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 490 GAAGAGGCAGAGAGG 505
 DB 2 GAAGAGGCAGAGAGG 17
 RESULT 1137
 ACN69988/C
 ID ACN69988 standard; DNA; 17 BP.
 XX
 AC ACN69988;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Human GDMPLP-1 probe SEQ ID NO:6890.
 XX
 XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 OS Homo sapiens.
 XX
 PN US20041137589-A1.
 XX
 XX 15-JUL-2004.
 PD
 XX 26-NOV-2003; 2003US-00723361.
 PF
 XX 26-MAY-2000; 2000US-0207456P.

PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.

XX (GUYU/) GU Y.

PA (JIYU/) JI Y.

PA (PENN/) PENN S G.

PA (HANZ/) HANZEL D K.

PA (RANK/) RANK D.

PA (CHEN/) CHEN W.

PA (SHAN/) SHANNON M E.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 PI WPI; 2004-533378/51.

XX Novel myosin-like protein-1, useful for treating or preventing disorder

PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.

XX Disclosure; SEQ ID NO 6890; Opp; English.

XX The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103

XX Sequence 17 BP; 1 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 7.2e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 306 GCTGCTGAGGAGAA 321

Db 17 GCCGCTGGAAGAA 2

RESULT 1138

ADR74662/C

ID ADR74662 standard; DNA; 17 BP.

XX ADR74662;

XX 16-DEC-2004 (first entry)

XX Allele specific primer B for human stenosis associated marker hCV1997488.

XX Human; ss; PCR; primer; Allele specific primer; coronary stenosis;
 KW angina; ischaemic chest pain; myocardial infarction;
 KW sudden cardiac death; SNP; single nucleotide polymorphism.

XX Homo sapiens.

XX WO2004081186-A2.

XX 23-SEP-2004.

XX 10-MAR-2004; 2004WO-US007140.

XX 10-MAR-2003; 2003US-0453050P.

XX 30-APR-2003; 2003US-0466437P.

XX (APPL-) APPLERA CORP.

XX Cargill M, Devlin JJ, Luke MM;

XX WPI; 2004-668949/65.

XX Identifying an individual who has altered risk for developing stenosis
 PT comprises detecting single nucleotide polymorphism (SNP), in the
 PT individual's nucleic acids.

XX Claim 19; SEQ ID NO 67974; 146pp; English.

XX The invention relates to identifying an individual who has altered risk
 CC for developing coronary stenosis comprising detecting a single nucleotide
 CC polymorphism (SNP) in any one of the 67073 nucleotide sequences (not
 CC given in the specification), in the individual's nucleic acids, where the
 CC presence of the SNP is correlated with an altered risk for stenosis in
 CC the individual. Also included are an isolated nucleic acid molecule
 CC comprising at least 8 contiguous nucleotides where one of the
 CC nucleotides is an SNP as cited above, or their complement, an isolated
 CC polypeptide comprising an amino acid sequence selected from any of the
 CC 696 amino acid sequences (not defined in the specification), an antibody
 CC that specifically binds to the polypeptide (or its antigen-binding
 CC fragment), an amplified polynucleotide containing the SNP as cited (where
 CC the amplified polynucleotide is between about 16 and about 1,000
 CC nucleotides in length), an isolated polynucleotide which specifically
 CC hybridises to a nucleic acid molecule containing the SNP, a kit for
 CC detecting a SNP in a nucleic acid, detecting a SNP in a nucleic acid
 CC molecule, detecting a variant polypeptide and identifying an agent useful
 CC in therapeutically or prophylactically treating stenosis. The detection
 CC step of the method is carried out by a process selected from allele-
 CC specific probe hybridisation, allele-specific primer extension, allele-
 CC specific amplification, sequencing, 5' nuclease digestion, molecular
 CC beacon assay, oligonucleotide ligation assay, size analysis, and single-
 CC stranded conformation polymorphism. The method is useful for identifying
 CC an individual who has altered risk for developing coronary stenosis,
 CC which can lead to angina (ischaemic chest pain), myocardial infarction
 CC and ultimately sudden cardiac death. The present sequence is an allele
 CC specific primer for amplifying a SNP-containing region of a human marker
 CC gene associated with stenosis. NOTE: SEQ ID 1-67771 are not shown in the
 CC specification but are provided on a CD-R named CL001510CDR which was not
 CC supplied with the specification.

XX Sequence 17 BP; 2 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 7.2e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 603 AGCTGAGGAGGAGCA 618

Db 16 AGCTTCAGCAGAGCA 1

Search completed: April 8, 2005, 08:45:30

Job time : 15 secs

GenCore version 5.1.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 8, 2005, 08:39:07 ; Search time 3 Seconds
(without alignments)
3.120 Million cell updates/sec

Title: US-10-628-841-3

Perfect score: 755

Sequence: 1 tctggaagagcaactgtgt.....tgggcagtgagcgaagcga 755

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 0.5

Searched: 361 seqs, 6198 residues

Total number of hits satisfying chosen parameters: 722

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 361 summaries

Database : fetch3rge.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	17	2.3	18	1	ACCESSION:AX910601
2	15.8	2.1	19	1	ACCESSION:A68936
3	15.8	2.1	19	1	ACCESSION:AR102011
4	15.8	2.1	19	1	ACCESSION:AR139162
5	15.8	2.1	19	1	ACCESSION:AR342346
6	15.8	2.1	19	1	ACCESSION:BD006049
7	15.8	2.1	20	1	ACCESSION:A32036
8	15.8	2.1	20	1	ACCESSION:A44459
9	15.8	2.1	20	1	ACCESSION:Q818178
10	15.8	2.1	20	1	ACCESSION:AR215451
11	15.8	2.1	21	1	ACCESSION:AX764372
12	15.4	2.0	17	1	ACCESSION:Q622506
13	15.4	2.0	17	1	ACCESSION:Q622710
14	15.4	2.0	17	1	ACCESSION:AR463569
15	15.4	2.0	17	1	ACCESSION:AR463773
16	15.4	2.0	18	1	ACCESSION:AR018170
17	15.4	2.0	18	1	ACCESSION:AR080884
18	15.4	2.0	18	1	ACCESSION:AR080887
19	15.4	2.0	18	1	ACCESSION:AR080889
20	15.4	2.0	18	1	ACCESSION:AR152352
21	15.4	2.0	18	1	ACCESSION:I71081
22	15.4	2.0	18	1	ACCESSION:AR236347
23	15.4	2.0	18	1	ACCESSION:BD107650
24	15.4	2.0	18	1	BD107653
25	15.4	2.0	18	1	BD107655
26	15.4	2.0	19	1	AR017595
27	15.4	2.0	19	1	AR068241
28	15.4	2.0	19	1	BD014243
29	15.4	2.0	20	1	I03563
30	15.4	2.0	20	1	ACCESSION:AR208100
31	15.2	2.0	20	1	A65119
32	15.2	2.0	20	1	AR156208
33	15.2	2.0	20	1	BD228536

c	34	15.2	2.0	20	1	AR225911
	35	15.2	2.0	20	1	AR359761
	36	15.2	2.0	20	1	AR454156
	37	15.2	2.0	20	1	AR490587
	38	15.2	2.0	20	1	AX202443
c	39	15.2	2.0	20	1	AX296834
	40	15.2	2.0	20	1	AX323070
	41	15.2	2.0	20	1	AX816171
	42	15	2.0	17	1	CQ622504
	43	15	2.0	17	1	CQ622505
	44	15	2.0	17	1	AR463567
	45	15	2.0	17	1	AR463568
	46	15	2.0	17	1	AX730387
	47	15	2.0	17	1	AX736200
	48	15	2.0	17	1	AX762433
c	49	15	2.0	18	1	AR134262
	50	15	2.0	19	1	AX287102
c	51	15	2.0	20	1	AX473022
	52	14.8	2.0	18	1	AR296947
c	53	14.8	2.0	19	1	BD205460
	54	14.8	2.0	19	1	AX481359
	55	14.8	2.0	19	1	BD104776
	56	14.4	1.9	17	1	CQ622507
	57	14.4	1.9	17	1	CQ622709
	58	14.4	1.9	17	1	CQ622711
c	59	14.4	1.9	17	1	CQ624230
c	60	14.4	1.9	17	1	CQ624231
	61	14.4	1.9	17	1	AR463570
	62	14.4	1.9	17	1	AR463772
	63	14.4	1.9	17	1	AR463774
c	64	14.4	1.9	17	1	AR465293
c	65	14.4	1.9	17	1	AR465294
	66	14.4	1.9	18	1	AR134263
c	67	14.4	1.9	18	1	AR299235
	68	14.4	1.9	19	1	AR035629
	69	14	1.9	17	1	CQ622503
c	70	14	1.9	17	1	CQ624232
c	71	14	1.9	17	1	CQ624233
	72	14	1.9	17	1	AR463566
c	73	14	1.9	17	1	AR465295
	74	14	1.9	17	1	AR465296
c	75	14	1.9	17	1	AX673623
c	76	14	1.9	18	1	AR106794
c	77	13.8	1.8	17	1	AR045391
	78	13.8	1.8	17	1	BD254195
	79	13.8	1.8	17	1	BD254196
c	80	13.8	1.8	17	1	CQ622083
c	81	13.8	1.8	17	1	CQ622958
	82	13.8	1.8	17	1	CQ623073
	83	13.8	1.8	17	1	CQ623681
c	85	13.8	1.8	17	1	I52443
c	86	13.8	1.8	17	1	AR190504
c	87	13.8	1.8	17	1	AR325427
	88	13.8	1.8	17	1	AR327369
c	89	13.8	1.8	17	1	AR329402
c	90	13.8	1.8	17	1	AR463146
c	91	13.8	1.8	17	1	AR464021
	92	13.8	1.8	17	1	AR464136
	93	13.8	1.8	17	1	AR464744
	94	13.8	1.8	17	1	AR464745
c	95	13.8	1.8	17	1	AX266063
	96	13.8	1.8	17	1	AX266064
	97	13.8	1.8	17	1	AX530794
	98	13.8	1.8	17	1	AX578640
c	99	13.8	1.8	17	1	AX687997
c	100	13.8	1.8	17	1	AX687998
	101	13.8	1.8	17	1	AX757153
	102	13.8	1.8	17	1	AX757735
	103	13.8	1.8	17	1	AX781735
	104	13.8	1.8	17	1	AX781740
	105	13.8	1.8	17	1	AX783694
	106	13.8	1.8	17	1	AX783781

ACCESSION:AR225911
ACCESSION:AR359761
ACCESSION:AR454156
ACCESSION:AR490587
ACCESSION:AX202443
ACCESSION:AX296834
ACCESSION:AX323070
ACCESSION:AX816171
ACCESSION:CQ622504
ACCESSION:CQ622505
ACCESSION:AR463567
ACCESSION:AR463568
ACCESSION:AX730387
ACCESSION:AX736200
ACCESSION:AX762433
ACCESSION:AR134262
ACCESSION:AX287102
ACCESSION:AX473022
ACCESSION:AR296947
ACCESSION:BD205460
ACCESSION:AX481359
ACCESSION:BD104776
ACCESSION:CQ622507
ACCESSION:CQ622709
ACCESSION:CQ622711
ACCESSION:CQ624230
ACCESSION:CQ624231
ACCESSION:AR463570
ACCESSION:AR463772
ACCESSION:AR463774
ACCESSION:AR465293
ACCESSION:AR465294
ACCESSION:AR134263
ACCESSION:AR299235
ACCESSION:AR035629
ACCESSION:CQ622503
ACCESSION:CQ624232
ACCESSION:CQ624233
ACCESSION:AR463566
ACCESSION:AR465295
ACCESSION:AR465296
ACCESSION:AX673623
ACCESSION:AR106794
ACCESSION:AR045391
ACCESSION:BD254195
ACCESSION:BD254196
ACCESSION:CQ622083
ACCESSION:CQ622958
ACCESSION:CQ623073
ACCESSION:CQ623681
ACCESSION:CQ623682
ACCESSION:I52443
ACCESSION:AR190504
ACCESSION:AR325427
ACCESSION:AR327369
ACCESSION:AR329402
ACCESSION:AR463146
ACCESSION:AR464021
ACCESSION:AR464136
ACCESSION:AR464744
ACCESSION:AR464745
ACCESSION:AX266063
ACCESSION:AX266064
ACCESSION:AX530794
ACCESSION:AX578640
ACCESSION:AX687997
ACCESSION:AX687998
ACCESSION:AX757153
ACCESSION:AX757735
ACCESSION:AX781735
ACCESSION:AX781740
ACCESSION:AX783694
ACCESSION:AX783781

JOURNAL	PATENT	US 6207165-A	10-27-MAR-2001	
FEATURES	Location/Qualifiers			
source	1..19	/organism="unknown"	/mol_type="unassigned DNA"	
Query Match	2.1%; Score 15.8; DB 1; Length 19;			
Best Local Similarity	89.5%; Pred. No. 64;			
Matches 17; Conservative	0; Mismatches 2; Indels 0; Gaps 0;			
QY	372 GCTGCGAGGAGCTTCTGCA 390			
DB	1 GCTGCGAGGAGCATCTGCA 19			
RESULT 5				
AR342346	AR342346	19 bp	DNA	linear PAT 17-AUG-2003
LOCUS	Sequence 8 from patent US 6576243.			
DEFINITION	AR342346			
ACCESSION	AR342346.1	GI:33737313		
VERSION				
KEYWORDS	Unknown.			
SOURCE	Unknown.			
ORGANISM	Unclassified.			
REFERENCE	1 (bases 1 to 19)			
AUTHORS	Audonnet,J.-C., Bouchardon,A., Baudu,P. and Riviere,M.			
TITLE	Polynucleotide vaccine formula against porcine reproductive and respiratory pathologies			
JOURNAL	Patent: US 6576243-A 8 10-JUN-2003;			
FEATURES	Location/Qualifiers			
source	1..19			
	/organism="unknown"			
	/mol_type="genomic DNA"			
Query Match	2.1%; Score 15.8; DB 1; Length 19;			
Best Local Similarity	89.5%; Pred. No. 64;			
Matches 17; Conservative	0; Mismatches 2; Indels 0; Gaps 0;			
QY	372 GCTGCGAGGAGCTTCTGCA 390			
DB	1 GCTGCGAGGAGCATCTGCA 19			
RESULT 6				
BD006049	BD006049	19 bp	DNA	linear PAT 31-JAN-2002
LOCUS	Polynucleotide vaccine formula for treating porcine respiratory and reproductive diseases.			
DEFINITION	BD006049.1	GI:18634420		
ACCESSION	BD006049			
VERSION	JP 2001500111-A/8.			
KEYWORDS	unidentified			
SOURCE	unidentified			
ORGANISM	unclassified.			
REFERENCE	1 (bases 1 to 19)			
AUTHORS	Audonnet,J.-C., Bouchardon,A., Baudu,P. and Riviere,M.			
TITLE	Polynucleotide vaccine formula for treating porcine respiratory and reproductive diseases			
JOURNAL	Patent: JP 2001500111-A 8 09-JAN-2001;			
COMMENT	MERIAL			
	OS PRVGD			
	PN JP 2001500111-A/8			
	PD 09-JAN-2001			
	PR 15-JUL-1997 JP 1998506628			
	PF 19-JUL-1996 FR 96/09338			
	PI JEAN CHRISTOPHE AUDONNET,ANNABELLE BOUCHARDON,PHILIPPE BAUDU,			
	P1 MICHEL RIVIERE			
	PC C12N15/38,C12N15/44,C12N15/40,C12N15/35,C12N15/31,A61K39/295			
	CC			
	FH Key			
	FT source			
	FT 1..19			
	FT /organism='PRVGD'.			

```

FEATURES
  source
    Location/Qualifiers
      1..19
        /organism="unidentified"
        /mol_type="genomic DNA"
        /db_xref="taxon:32644"

Query Match
  Best Local Similarity 2.1%; Score 15.8; DB 1; Length 19;
  Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 372 GCTGCAGGAGCTCTGCA 390
Db 1 GCTGCAGGAGCTCTGCA 19

RESULT 7
A32036
LOCUS A32036 20 bp DNA linear PAT 08-DEC-1995
DEFINITION Primer DNA U2 from patent EP0395292.
ACCESSION A32036
VERSION A32036.1 GI:1249491
KEYWORDS
SOURCE
  ORGANISM
    synthetic construct
    other sequences; artificial sequences.
REFERENCE
  1 (bases 1 to 20)
  Barry, T.G., Gannon, B.X. and Powell, R.
  Generation of specific probes for target nucleotide sequences
  Patent: EP 0395292-A 6 31-OCT-1990;
  Barry, Thomas Gerard; Gannon, Bernard Francis Xavier; BIORESEARCH
  IRELAND; Powell, Richard; UNIVERSITY COLLEGE GALWAY; Barry, Thomas
  Gerard; Gannon, Bernard Francis Xavier; BIORESEARCH IRELAND;
  Powell, Richard; UNIVERSITY COLLEGE GALWAY; Barry, Thomas Gerard;
  Gannon, Bernard Francis Xavier; EOLAS (trading as BioResearch
  Ireland) - The Irish Science and Technology Agency; Powell,
  Richard; UNIVERSITY COLLEGE GALWAY
  Location/Qualifiers
    1..20
      /organism="synthetic construct"
      /mol_type="unassigned DNA"
      /db_xref="taxon:32630"

FEATURES
  source
    Location/Qualifiers
      1..20
        /organism="synthetic construct"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32630"

Query Match
  Best Local Similarity 2.1%; Score 15.8; DB 1; Length 20;
  Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 253 GCCAGCCATGTCGACCTG 271
Db 1 GACAGCCATGTCGACCTG 19

RESULT 8
A44459
LOCUS A44459 20 bp DNA linear PAT 07-MAR-1997
DEFINITION Sequence 6 from Patent WO9513396.
ACCESSION A44459
VERSION A44459.1 GI:2299285
KEYWORDS
SOURCE
  ORGANISM
    unidentified
    unclassified.
REFERENCE
  1 (bases 1 to 20)
  Fluit, A.C. and Widojoatmodjo, M.N.
  A METHOD FOR IDENTIFYING MICROORGANISMS, AND AIDS USEFUL THEREOF
  Patent: WO 9513396-A 6 18-MAY-1995;
  U GENE RESEARCH BV (NL)
  Other publication NL 9301957 950601.
  Location/Qualifiers
    1..20
      /organism="unidentified"
      /mol_type="unassigned DNA"
      /db_xref="taxon:32644"

FEATURES
  source
    Location/Qualifiers
      1..20
        /organism="unassigned DNA"
        /mol_type="genomic DNA"

Query Match
  Best Local Similarity 2.1%; Score 15.8; DB 1; Length 20;
  Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 256 AGCCATGTCGACCTGCTT 274
Db 1 AGCCATGTCGACCTGCTT 19

RESULT 9
CQ818178/c
LOCUS CQ818178 20 bp DNA linear PAT 07-JUN-2004
DEFINITION Sequence 15 from Patent WO200404247.
ACCESSION CQ818178
VERSION CQ818178.1 GI:48426970
KEYWORDS
SOURCE
  ORGANISM
    synthetic construct
    other sequences; artificial sequences.
REFERENCE
  1
  Chaubron, F., Martin-Minvielle, A.C. and Groulon, S.
  One step real-time rt pcr kits for the universal detection of
  organisms in industrial products
  Patent: WO 200404247-A 15 27-MAY-2004;
  Genolife (FR)
  Location/Qualifiers
    1..20
      /organism="synthetic construct"
      /mol_type="unassigned DNA"
      /db_xref="taxon:32630"
      /note="#Description of artificial sequence:
      oligonucleotide primer#"

Query Match
  Best Local Similarity 2.1%; Score 15.8; DB 1; Length 20;
  Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 253 GCCAGCCATGTCGACCTG 271
Db 20 GACAGCCATGTCGACCTG 2

RESULT 10
AR215451/c
LOCUS AR215451 20 bp DNA linear PAT 25-SEP-2002
DEFINITION Sequence 16 from patent US 6410322.
ACCESSION AR215451
VERSION AR215451.1 GI:23313707
KEYWORDS
SOURCE
  ORGANISM
    Unknown.
    Unclassified.
REFERENCE
  1 (bases 1 to 20)
  Robinson, G.S.
  Antisense oligonucleotide inhibition of vascular endothelial growth
  factor expression
  Patent: US 6410322-A 16 25-JUN-2002;
  Location/Qualifiers
    1..20
      /organism="unknown"
      /mol_type="genomic DNA"

Query Match
  Best Local Similarity 2.1%; Score 15.8; DB 1; Length 20;
  Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 696 AGCTGGAGAGTGGCGCA 714
Db 19 AGCCGGAGAGGAGCGCGA 1

RESULT 11
AX764372/c

```

```

LOCUS       AX764372               21 bp    DNA             linear     PAT 25-JUN-2003
DEFINITION   Sequence 20 from Patent WO03040296.
ACCESSION    AX764372
VERSION      AX764372.1  GI:32258677
KEYWORDS     synthetic construct
SOURCE       synthetic construct
            other sequences; artificial sequences.
REFERENCE    1
AUTHORS      Eulenbergh,K., Steuermagel,A. and Broenner,G.
TITLE        Men protein, gst2, rab-rpl, csp, f-box protein lilina/fbl7, abc50,
            coronin, sec6l1 alpha, or vhhapal-1, or homologous proteins involved
            in the regulation of energy homeostasis
JOURNAL      Patent: WO 03040296-A 20 15-MAY-2003;
            DeveloGen Aktiengesellschaft fuer entwicklungsbiologische Forschung
            (DE)
FEATURES     source
            1..21
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="Mouse Rab38 tagman probe"
            misc_feature
            1
            /note="5/6-FAM"
            misc_feature
            21
            /note="5/6-TAMRA"

Query Match      2.1%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 58;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      839  CAGGTGGCGCTATCACCAGC 857
          ||||| ||||| ||||| |||||
DB      20  CAGGTGGCGGATCACCAGC 2

RESULT 12
LOCUS     CQ622506               17 bp    DNA             linear     PAT 02-FEB-2004
DEFINITION   Sequence 7246 from Patent WO0192524.
ACCESSION    CQ622506
VERSION      CQ622506.1  GI:41672724
KEYWORDS     Homo sapiens (human)
SOURCE       Homo sapiens
ORGANISM     Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS      Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE        Myosin-like gene expressed in human heart and muscle
JOURNAL      Patent: WO 0192524-A 7246 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES     source
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      2.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 83;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      697  GCTGGAGAGTGAGCGCG 713
          ||||| ||||| ||||| |||||
DB      1    GCTGGAGAGTGAGCGCG 17

RESULT 13
LOCUS     CQ622710               17 bp    DNA             linear     PAT 02-FEB-2004
DEFINITION   Sequence 7450 from Patent WO0192524.
ACCESSION    CQ622710

```

```

VERSION      CQ622710.1  GI:41672928
KEYWORDS     Homo sapiens (human)
SOURCE       Homo sapiens
ORGANISM     Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS      Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE        Myosin-like gene expressed in human heart and muscle
JOURNAL      Patent: WO 0192524-A 7450 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES     Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      2.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 83;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      412  GGAGAAGGAGTTCCTCA 428
          ||||| ||||| ||||| |||||
DB      1    GGAGAAGGAGTTCCTCA 17

RESULT 14
LOCUS     AR463569               17 bp    DNA             linear     PAT 20-FEB-2004
DEFINITION   Sequence 7246 from patent US 6686188.
ACCESSION    AR463569
VERSION      AR463569.1  GI:42698626
KEYWORDS     Unknown.
SOURCE       Unknown.
ORGANISM     Unknown.
            Unclassified.
REFERENCE    1 (bases 1 to 17)
AUTHORS      Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE        Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
JOURNAL      Patent: US 6686188-A 7246 03-FEB-2004;
            Aeomica, Inc. (US)
FEATURES     Location/Qualifiers
            source
            1..17
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match      2.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 83;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      697  GCTGGAGAGTGAGCGCG 713
          ||||| ||||| ||||| |||||
DB      1    GCTGGAGAGTGAGCGCG 17

RESULT 15
LOCUS     AR463773               17 bp    DNA             linear     PAT 20-FEB-2004
DEFINITION   Sequence 7450 from patent US 6686188.
ACCESSION    AR463773
VERSION      AR463773.1  GI:42698830
KEYWORDS     Unknown.
SOURCE       Unknown.
ORGANISM     Unknown.
            Unclassified.
REFERENCE    1 (bases 1 to 17)
AUTHORS      Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE        Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
JOURNAL      Patent: US 6686188-A 7450 03-FEB-2004;

```



```
FEATURES
  source      Location/Qualifiers
            1..17      18 bp      DNA      linear      PAT 31-AUG-2000
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match      2.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 83;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 412 GGAGAGGAGTTCTCTCA 428
Db 1 GGAGAGGAGTTCTCTCA 17

RESULT 16
LOCUS AR018170      18 bp      DNA      linear      PAT 05-DEC-1998
DEFINITION Sequence 32 from patent US 5780610.
ACCESSION AR018170
VERSION AR018170.1 GI:3973773
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Collins,M.L., Horn,T., Sheridan,P.J., Warner,B.D. and Urdea,M.S.
TITLE Reduction of nonspecific hybridization by using novel base-pairing
JOURNAL Patent: US 5780610-A 32 14-JUL-1998;
FEATURES
  source      Location/Qualifiers
            1..18      /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 78;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 867 AATACGACCAACCATC 883
Db 2 AGTACGACCAACCATC 18

RESULT 17
LOCUS AR080884/c      18 bp      DNA      linear      PAT 31-AUG-2000
DEFINITION Sequence 2 from patent US 5969117.
ACCESSION AR080884
VERSION AR080884.1 GI:10007613
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Agrawal,S.
TITLE Modified protein kinase a-specific oligonucleotide
JOURNAL Patent: US 5969117-A 2 19-OCT-1999;
FEATURES
  source      Location/Qualifiers
            1..18      /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 78;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGAGCGCG 693
Db 18 GCCAGCGAGCGCG 2

RESULT 18
LOCUS AR018170      18 bp      DNA      linear      PAT 05-DEC-1998
DEFINITION Sequence 32 from patent US 5780610.
ACCESSION AR018170
VERSION AR018170.1 GI:3973773
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Collins,M.L., Horn,T., Sheridan,P.J., Warner,B.D. and Urdea,M.S.
TITLE Reduction of nonspecific hybridization by using novel base-pairing
JOURNAL Patent: US 5780610-A 32 14-JUL-1998;
FEATURES
  source      Location/Qualifiers
            1..18      /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 78;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGAGCGCG 693
Db 18 GCCAGCGAGCGCG 2

RESULT 19
LOCUS AR080889/c      18 bp      DNA      linear      PAT 31-AUG-2000
DEFINITION Sequence 7 from patent US 5969117.
ACCESSION AR080889
VERSION AR080889.1 GI:10007618
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Agrawal,S.
TITLE Modified protein kinase a-specific oligonucleotide
JOURNAL Patent: US 5969117-A 7 19-OCT-1999;
FEATURES
  source      Location/Qualifiers
            1..18      /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 78;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGAGCGCG 693
Db 18 GCCAGCGAGCGCG 2

RESULT 20
LOCUS AR152352      18 bp      DNA      linear      PAT 08-AUG-2001
DEFINITION Sequence 32 from patent US 6232462.
ACCESSION AR152352
VERSION AR152352.1 GI:15118402
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Collins,M.L., Horn,T., Sheridan,P.J., Warner,B.D. and Urdea,M.S.
TITLE Reduction of nonspecific hybridization by using novel base-pairing
JOURNAL Patent: US 6232462-A 32 15-MAY-2001;
FEATURES
  source      Location/Qualifiers
            1..18      /organism="unknown"
            /mol_type="unassigned DNA"
```

Query Match 2.0%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 94.1%; Pred. No. 78;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 867 AATACGACACCATC 883
 Db 2 AGTAGCACACCATC 18

RESULT 21
 LOCUS I71081 18 bp DNA linear PAT 03-APR-1998
 DEFINITION Sequence 32 from patent US 5681702.
 ACCESSION I71081
 VERSION I71081.1 GI:3007216
 KEYWORDS
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 18)
 AUTHORS Collins, M.L., Horn, T., Sheridan, P.J., Warner, B.D. and Urdea, M.S.
 TITLE Reduction of nonspecific hybridization by using novel base-pairing schemes
 JOURNAL Patent: US 5681702-A 32 28-OCT-1997;
 FEATURES Location/Qualifiers
 source 1..18
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 2.0%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 94.1%; Pred. No. 78;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 867 AATACGACACCATC 883
 Db 2 AGTAGCACACCATC 18

RESULT 22
 LOCUS AR236347 18 bp DNA linear PAT 20-DEC-2002
 DEFINITION Sequence 3 from patent US 6465175.
 ACCESSION AR236347
 VERSION AR236347.1 GI:27280275
 KEYWORDS
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 18)
 AUTHORS Horn, T., Schroeder, H.R., Warner, B.D., Fiss, E., Sells, T. and Law, S.-J.
 TITLE Oligonucleotide probes bearing quenchable fluorescent labels, and methods of use thereof
 JOURNAL Patent: US 6465175-A 3 15-OCT-2002;
 FEATURES Location/Qualifiers
 source 1..18
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 2.0%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 94.1%; Pred. No. 78;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 867 AATACGACACCATC 883
 Db 2 AGTAGCACACCATC 18

RESULT 23
 LOCUS BD107650/c 18 bp DNA linear PAT 18-SEP-2002
 DEFINITION Modified protein kinase A-specific oligonucleotides and methods of

their use.
 ACCESSION BD107650
 VERSION BD107650.1 GI:23202468
 KEYWORDS JP 2002501370-A/2.
 SOURCE unidentified
 ORGANISM unidentified
 REFERENCE 1 (bases 1 to 18)
 AUTHORS Agrawal, S.
 TITLE Modified protein kinase A-specific oligonucleotides and methods of their use
 JOURNAL Patent: JP 2002501370-A 2 15-JAN-2002;
 COMMENT HYBRIDON INC
 OS Unidentified
 PN JP 2002501370-A/2
 PD 15-JAN-2002
 PF 12-FEB-1998 JP 1998539567
 PR 12-MAR-1997 US 60/040740
 PI SUDHIR AGRAWAL
 PC C12N15/11,A61K31/70,C07H21/04
 CC Strandedness: Single;
 CC Topology: Linear;
 CC Modified protein kinase A-specific oligonucleotides and methods of their use
 CC use
 FH Key Location/Qualifiers
 FT source 1..18
 /organism="unidentified"
 /mol_type="genomic DNA"
 /db_xref="taxon:32644"

Query Match 2.0%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 94.1%; Pred. No. 78;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 677 GCCAGCGAGGCGCG 693
 Db 18 GCCAGCGAGGCGCG 2

RESULT 24
 LOCUS BD107653/c 18 bp DNA linear PAT 18-SEP-2002
 DEFINITION Modified protein kinase A-specific oligonucleotides and methods of their use.
 ACCESSION BD107653
 VERSION BD107653.1 GI:23202471
 KEYWORDS JP 2002501370-A/5.
 SOURCE unidentified
 ORGANISM unidentified
 REFERENCE 1 (bases 1 to 18)
 AUTHORS Agrawal, S.
 TITLE Modified protein kinase A-specific oligonucleotides and methods of their use
 JOURNAL Patent: JP 2002501370-A 5 15-JAN-2002;
 COMMENT HYBRIDON INC
 OS Unidentified
 PN JP 2002501370-A/5
 PD 15-JAN-2002
 PF 12-FEB-1998 JP 1998539567
 PR 12-MAR-1997 US 60/040740
 PI SUDHIR AGRAWAL
 PC C12N15/11,A61K31/70,C07H21/04
 CC Strandedness: Single;
 CC Topology: Linear;
 CC Modified protein kinase A-specific oligonucleotides and methods of their use
 CC use
 FH Key Location/Qualifiers

```
FT source 1. .18 /organism='Unidentified'.
FEATURES
  source
    1. .18
      Location/Qualifiers
        /organism='unidentified'
        /mol_type='genomic DNA'
        /db_xref='taxon:32644'

Query Match
  Best Local Similarity 2.0%; Score 15.4; DB 1; Length 18;
  Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGAGGCGCG 693
Db 18 GCCAGCGAGGCGCG 2

RESULT 25
BD107655/c
LOCUS
  DEFINITION Modified protein kinase A-specific oligonucleotides and methods of
  their use.
  ACCESSION BD107655
  VERSION JP 2002501370-A/7.
  KEYWORDS unidentifed
  SOURCE unidentifed
  ORGANISM unclassified.
  REFERENCE 1 (bases 1 to 18)
  AUTHORS Agrawal,S.
  TITLE Modified protein kinase A-specific oligonucleotides and methods of
  their use
  JOURNAL Patent: JP 2002501370-A 7 15-JAN-2002;
  COMMENT HYBRIDON INC
  OS Unidentified
  PN JP 2002501370-A/7
  PD 15-JAN-2002
  PF 12-FEB-1998 JP 1998539567
  PR 12-MAR-1997 US 60/040740
  PI SUPHIR AGRAWAL
  PC C12N15/11,A61K31/70,C07H21/04
  CC Strandedness: Single;
  CC Topology: Linear;
  CC Modified protein kinase A-specific oligonucleotides and CC
  methods of their
  CC use
  FH Key Location/Qualifiers
  FT source 1. .18 /organism='Unidentified'.
  FT Location/Qualifiers
    1. .18
      /organism='unidentified'
      /mol_type='genomic DNA'
      /db_xref='taxon:32644'

FEATURES
  source
    1. .18
      Location/Qualifiers
        /organism='unidentified'
        /mol_type='genomic DNA'
        /db_xref='taxon:32644'

Query Match
  Best Local Similarity 2.0%; Score 15.4; DB 1; Length 18;
  Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGAGGCGCG 693
Db 18 GCCAGCGAGGCGCG 2

RESULT 26
AR017595
LOCUS
  DEFINITION Sequence 1 from patent US 5780227.
  ACCESSION AR017595
  VERSION AR017595.1 GI:3973198
  KEYWORDS Unknown.
  SOURCE Unknown.
  ORGANISM Unknown.

FT source 1. .18 /organism='Unidentified'.
FEATURES
  source
    1. .18
      Location/Qualifiers
        /organism='unidentified'
        /mol_type='genomic DNA'
        /db_xref='taxon:32644'

Query Match
  Best Local Similarity 2.0%; Score 15.4; DB 1; Length 18;
  Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGAGGCGCG 693
Db 18 GCCAGCGAGGCGCG 2

RESULT 27
AR068241
LOCUS
  DEFINITION Sequence 1 from patent US 5853974.
  ACCESSION AR068241
  VERSION AR068241.1 GI:6000448
  KEYWORDS Unknown.
  SOURCE Unknown.
  ORGANISM Unclassified.
  REFERENCE 1 (bases 1 to 19)
  AUTHORS Sheridan,P.J.
  TITLE Enhancement of alkaline phosphatase with SDS in chemiluminescent
  substrates
  JOURNAL Patent: US 5853974-A 1 29-DEC-1998;
  FEATURES
    source
      1. .19
        /organism='unassigned DNA'
        /mol_type='unassigned DNA'

Query Match
  Best Local Similarity 2.0%; Score 15.4; DB 1; Length 19;
  Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 867 AATACGACCAACCATC 883
Db 2 AGTACGACCAACCATC 18

RESULT 28
BD014243
LOCUS
  DEFINITION Probe for nucleic acid hybridization.
  ACCESSION BD014243
  VERSION BD014243.1 GI:22554572
  KEYWORDS JP 2001095590-A/109.
  SOURCE synthetic construct
  ORGANISM other sequences; artificial sequences.
  REFERENCE 1 (bases 1 to 19)
  AUTHORS Adair,M.S.
  TITLE Probe for nucleic acid hybridization
  JOURNAL Patent: JP 2001095590-A 109 10-APR-2001;
  COMMENT BAYER CORP
  OS Artificial Sequence
  PN JP 2001095590-A/109
  PD 10-APR-2001
  PF 08-AUG-2000 JP 2000240494
  PR 10-JAN-1990 US 463022
  PI MICHAEL S ADAIR
  PC C12N15/09,C12Q1/68,G01N33/569,G01N33/576,C12N15/00 CC
  Description of Artificial Sequence: Probe
  FH Key Location/Qualifiers
```

```

FT      source      1. .19
FT      /organism='Artificial Sequence'.
FEATURES
  source
    1. .19
    Location/Qualifiers
      /organism="synthetic construct"
      /mol_type="genomic DNA"
      /db_xref="taxon:32630"
Query Match      2.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 74;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      867 AATACGACCAACCATC 883
Db      3 AGTACGACCAACCATC 19

RESULT 29
LOCUS      I03563      20 bp ss-DNA      linear      PAT 21-MAY-1993
DEFINITION      Sequence 9 from Patent US 4654419.
ACCESSION      I03563
VERSION      I03563.1 GI:313892
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 20)
AUTHORS      Vaughan,J.H.; Carson,D.A.; Rhodes,G. and Houghten,R.
TITLE      Synthetic polypeptides and antibodies related to epstein-barr virus
JOURNAL
COMMENT      Patent: US 4654419-A 9 31-MAR-1987;
      Scripps Clinic and Research Foundation; La Jolla, CA
      On Jul 30, 1993 this sequence version replaced gi:268684.
FEATURES
  source
    1. .20
    /organism="unknown"
    /mol_type="unassigned DNA"
Query Match      2.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 70;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      405 AGAGGGAGGAGGAGGAG 421
Db      1 AGAGGGAGGAGGAGGAG 17

RESULT 30
LOCUS      AR208100      20 bp      DNA      linear      PAT 20-JUN-2002
DEFINITION      Sequence 18 from patent US 6379960.
ACCESSION      AR208100
VERSION      AR208100.1 GI:21508028
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 20)
AUTHORS      Popoff,I. and Wyatt,J.
TITLE      Antisense modulation of damage-specific DNA binding protein 2, p48
JOURNAL      expression
COMMENT      Patent: US 6379960-A 18 30-APR-2002;
      Location/Qualifiers
FEATURES
  source
    1. .20
    /organism="unknown"
    /mol_type="unassigned DNA"
Query Match      2.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 70;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      815 GAGAGGAGGAGGAGGAG 831
```

```

Db      3 GAGTAGAGGAGGAGGAG 19

RESULT 31
LOCUS      A65119      20 bp      DNA      linear      PAT 29-MAR-1999
DEFINITION      Sequence 16 from Patent EP0798378.
ACCESSION      A65119
VERSION      A65119.1 GI:4530984
KEYWORDS
SOURCE      unidentified
      unidentified
      unclassified.
REFERENCE      1
AUTHORS      Mosselman,S. and Dijkema,R.
TITLE      Estrogen receptor
JOURNAL      Patent: EP 0798378-A 16 01-OCT-1997;
      AKZO NOBEL NV (NL)
COMMENT      Other publication CA 2200423 19970926
      Other publication AU 1652197 19971002.
      Location/Qualifiers
FEATURES
  source
    1. .20
    /organism="unidentified"
    /mol_type="unassigned DNA"
    /db_xref="taxon:32644"
Query Match      2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 76;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      822 GGNAGCTGGCCAGTTCGAG 841
Db      1 GGAAGCTGGCTCAGTTCGTG 20

RESULT 32
LOCUS      AR156208      20 bp      DNA      linear      PAT 08-AUG-2001
DEFINITION      Sequence 3 from patent US 6242181.
ACCESSION      AR156208
VERSION      AR156208.1 GI:15124912
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 20)
AUTHORS      Siffert,W.
TITLE      Methods for diagnosing hypertension by detecting a mutation in the
      human G protein .beta.3 subunit gene
JOURNAL      Patent: US 6242181-A 3 05-JUN-2001;
      Location/Qualifiers
FEATURES
  source
    1. .20
    /organism="unknown"
    /mol_type="unassigned DNA"
Query Match      2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 76;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      513 TGGGGGAGGTGGAGCACTG 532
Db      1 TGGGGGAGATGGAGCAACTG 20

RESULT 33
LOCUS      BD228536      20 bp      DNA      linear      PAT 17-JUL-2003
DEFINITION      IL-17 homologous polypeptide and its application to remedy.
ACCESSION      BD228536
VERSION      BD228536.1 GI:33038306
KEYWORDS      JP 2002515246-A/131.
SOURCE      unidentified
```

ORGANISM unidentified
unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Chen,J., Filvaroff,E., Goddard,A., Gurney,A.L., Li,H. and Wood,W.I.
TITLE IL-17 homologous polypeptide and its application to remedy
JOURNAL Patent: JP 2002515246-A 131 28-MAY-2002;
GENENTECH INC
COMMENT OS Unidentified
FN JP 2002515246-A/131
PD 28-MAY-2002
PF 14-MAY-1999 JP 2000549734
PR 15-MAY-1998 US 60/085579,23-DEC-1998 US 60/113621 PI
JIAN CHEN,ELLEN FILVAROFF,AUDLEY GODDARD,AUSTIN L GURNEY, PI
HANZHONG LI,
PI WILLIAM I WOOD
PC C12N15/09,A61K38/21,A61K45/00,A61P19/00,C07K14/52,C07K16/24,
C07K19/00,
PC C12N1/19,C12N1/21,C12N5/10,C12P21/02,C12P21/08,C12Q1/00 PC
C12Q1/68,C12N15/00,
PC A61K37/66,C12N5/00
CC Strandedness: Single;
CC Topology: Linear;
CC IL-17 homologous polypeptide and its application to remedy FH
Key source 1..20
Location/Qualifiers
FT source
FT /organism='Unidentified'.
FEATURES
source 1..20
/organism='unidentified'
/mol_type='genomic DNA'
/db_xrefs='taxon:32644'
Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 76;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 471 GCCTGGAGAGCTCGATCTG 490
|||||
Db 1 GCCTGGAGAGCTCGATCTG 20
RESULT 34
AR225911/c
LOCUS 20 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 61 from patent US 644464.
ACCESSION AR225911
VERSION AR225911.1 GI:27264055
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Wyatt,J
TITLE Antisense modulation of E2F transcription factor 2 expression
JOURNAL Patent: US 644464-A 61 03-SEP-2002;
FEATURES Location/Qualifiers
source 1..20
/organism='unknown'
/mol_type='genomic DNA'
Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 76;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 548 CAGATGGCTGAGGACAGGC 567
|||||
Db 20 CACCTGACTGAGGACAGGC 1
RESULT 35
AR359761
LOCUS 20 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 131 from patent US 6593456.

ACCESSION AR359761
VERSION AR359761.1 GI:33766505
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Gatanaga,T. and Granger,G.A.
TITLE Tumor necrosis factor receptor releasing enzyme
JOURNAL Patent: US 6593456-A 131 15-JUL-2003;
FEATURES Location/Qualifiers
source 1..20
/organism='unknown'
/mol_type='genomic DNA'
Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 76;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 471 GCCTGGAGAGCTCGATCTG 490
|||||
Db 1 GCCTGGAGAGCTCGATCTG 20
RESULT 36
AR454156
LOCUS 20 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 16 from patent US 6680368.
ACCESSION AR454156
VERSION AR454156.1 GI:42687192
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Mosselman,S. and Dijkema,R.
TITLE Estrogen receptor beta
JOURNAL Patent: US 6680368-A 16 20-JAN-2004;
FEATURES Location/Qualifiers
source 1..20
/organism='unknown'
/mol_type='genomic DNA'
Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 76;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 822 GGAGCTGGCCCGCTGCTG 841
|||||
Db 1 GGAGCTGGCTCACTTCTG 20
RESULT 37
AR490587
LOCUS 20 bp DNA linear PAT 15-MAY-2004
DEFINITION Sequence 16 from patent US 6713270.
ACCESSION AR490587
VERSION AR490587.1 GI:47257976
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Mosselman,S. and Dijkema,R.
TITLE Method for identifying ligand of estrogen receptor beta
JOURNAL Patent: US 6713270-A 16 30-MAR-2004;
FEATURES Location/Qualifiers
source 1..20
/organism='unknown'
/mol_type='genomic DNA'
Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 76;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 822 GGAAGCTGGCCAGTTCGAG 841
|||||
Db 1 GGAAGCTGGCTCACTTGCTG 20

RESULT 38
AX202443
LOCUS AX202443 20 bp DNA linear PAT 30-AUG-2001
DEFINITION Sequence 31 from Patent WO0152620.
ACCESSION AX202443
VERSION AX202443.1 GI:15392192
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Barbas, C.F., Stege, J.T., Guan, X. and Dalmia, B.
TITLE Methods and compositions to modulate expression in plants
JOURNAL Patent: WO 0152620-A 31 26-JUL-2001;
The Scripps Research Institute (US); SYNGENTA AGRICULTURAL
DISCOVERY, INC. (CA)

FEATURES
source
1. .20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer NZlib5"

Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 76;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 667 GGCCCGGGCGCCAGCGAGC 686
|||||
Db 1 GGCCAGCGCCCTCGAGC 20

RESULT 39
AX296834/c
LOCUS AX296834 20 bp DNA linear PAT 21-NOV-2001
DEFINITION Sequence 8596 from Patent WO0179548.
ACCESSION AX296834
VERSION AX296834.1 GI:17058523
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Barany, F., Zirvi, M., Gerry, N.P., Favis, R. and Kliman, R.
TITLE Method of designing addressable array for detection of nucleic acid
JOURNAL sequence differences using ligase detection reaction
Patent: WO 0179548-A 8596 25-OCT-2001;
CORNELL RESEARCH FOUNDATION, INC. (US)

FEATURES
source
1. .20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Hypothetical Probe Sequence"

Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 76;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 828 TGGCCAGTTCAGGTGCC 847
|||||
Db 20 TTGCCAAGTTGAGGTGCC 1

RESULT 40
AX23070

LOCUS AX323070 20 bp DNA linear PAT 07-JAN-2002
DEFINITION Sequence 16 from Patent EP1162264.
ACCESSION AX323070
VERSION AX323070.1 GI:18093953
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Mosselman, S. and Dijkema, R.
TITLE Chimeric hormone receptor
JOURNAL Patent: EP 1162264-A 16 12-DEC-2001;
Akzo Nobel N.V. (NL)

FEATURES
source
1. .20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer/Probe"

Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 76;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 822 GGAAGCTGGCCAGTTCGAG 841
|||||
Db 1 GGAAGCTGGCTCACTTGCTG 20

RESULT 41
AX816171
LOCUS AX816171 20 bp DNA linear PAT 09-DEC-2003
DEFINITION Sequence 4 from Patent WO03066888.
ACCESSION AX816171
VERSION AX816171.1 GI:39646730
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Jonasson, J.
TITLE Method and apparatus for microorganism identification
JOURNAL Patent: WO 03066888-A 4 14-AUG-2003;
Pyrosequencing AB (SE)

FEATURES
source
1. .20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 76;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 251 AAGCCAGCCATGCTGCACCT 270
|||||
Db 1 ACGACGCCATGCGACCT 20

RESULT 42
CO622504
LOCUS CO622504 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 7244 from Patent WO0192524.
ACCESSION CO622504
VERSION CO622504.1 GI:41672722
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.

```

TITLE      Myosin-like gene expressed in human heart and muscle
JOURNAL    Patent: WO 0192524-A 7244 06-DEC-2001;
           Aeomica, Inc. (US)
FEATURES   source
           1. .17
           /organism="Homo sapiens"
           /mol_type="unassigned DNA"
           /db_xref="taxon:9606"

Query Match      2.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      697 GCTGGAGAGTGAGCG 711
Db      3 GCTGGAGAGTGAGCG 17

RESULT 43
LOCUS   CQ622505
DEFINITION Sequence 7245 from Patent WO0192524.
ACCESSION CQ622505
VERSION   CQ622505.1 GI:41672723
KEYWORDS
SOURCE   Homo sapiens (human)
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS  Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
           Shannon,M.E.
TITLE    Myosin-like gene expressed in human heart and muscle
JOURNAL  Patent: WO 0192524-A 7244 06-DEC-2001;
           Aeomica, Inc. (US)
FEATURES   source
           1. .17
           /organism="Homo sapiens"
           /mol_type="unassigned DNA"
           /db_xref="taxon:9606"

Query Match      2.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      697 GCTGGAGAGTGAGCG 711
Db      3 GCTGGAGAGTGAGCG 17

RESULT 44
LOCUS   AR463567
DEFINITION Sequence 7244 from patent US 6686188.
ACCESSION AR463567
VERSION   AR463567.1 GI:42698624
KEYWORDS
SOURCE   Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS  Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
           Shannon,M.E.
TITLE    Polynucleotide encoding a human myosin-like polypeptide expressed
           predominantly in heart and muscle
JOURNAL  Patent: US 6686188-A 7244 03-FEB-2004;
           Aeomica, Inc. (US)
FEATURES   source
           1. .17
           /organism="unknown"
           /mol_type="genomic DNA"

Query Match      2.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      697 GCTGGAGAGTGAGCG 711
Db      2 GCTGGAGAGTGAGCG 16

RESULT 45
LOCUS   AR463568
DEFINITION Sequence 7245 from patent US 6686188.
ACCESSION AR463568
VERSION   AR463568.1 GI:42698625
KEYWORDS
SOURCE   Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS  Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
           Shannon,M.E.
TITLE    Polynucleotide encoding a human myosin-like polypeptide expressed
           predominantly in heart and muscle
JOURNAL  Patent: US 6686188-A 7245 03-FEB-2004;
           Aeomica, Inc. (US)
FEATURES   source
           1. .17
           /organism="unknown"
           /mol_type="genomic DNA"

Query Match      2.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      697 GCTGGAGAGTGAGCG 711
Db      2 GCTGGAGAGTGAGCG 16

RESULT 46
LOCUS   AX730387
DEFINITION Sequence 2021 from Patent WO03025175.
ACCESSION AX730387
VERSION   AX730387.1 GI:30509730
KEYWORDS
SOURCE   Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS  Telerman,A., Amson,R. and Tuijnder,M.
TITLE    Sequences involved in phenomena of tumour suppression, tumour
           reversion, apoptosis and/or virus resistance and their use as
           medicines
JOURNAL  Patent: WO 03025175-A 2021 27-MAR-2003;
           Molecular Engines Laboratories (FR)
FEATURES   source
           1. .17
           /organism="Homo sapiens"
           /mol_type="unassigned DNA"
           /db_xref="taxon:9606"

Query Match      2.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      241 TCCTCTGGGGAGGCC 255
Db      3 TCCTCTGGGGAGGCC 17

RESULT 47
LOCUS   AX736200

```


METATAGS

```

Best Local Similarity 100.0%; Pred. No. 81;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 890 AGCGTGGTGGCAGT 904
Db 15 AGCGTGGTGGCAGT 1

RESULT 52
AR296947
LOCUS AR296947 18 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 8682 from patent US 6537751.
ACCESSION AR296947
VERSION AR296947.1 GI:31684231
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 18)
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.
TITLE Biallelic markers for use in constructing a high density
disequilibrium map of the human genome
JOURNAL Patent: US 6537751-A 8682 25-MAR-2003;
FEATURES
Location/Qualifiers
1..18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 2.0%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 97;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 492 AGAGGAGGAGGAGGAGG 509
Db 1 AGAGGAGGAGGAGGAGG 18

RESULT 53
BD205460/c
LOCUS BD205460 19 bp DNA linear PAT 17-JUL-2003
DEFINITION Recombinant protein of Treponemapallidum and utilization thereof
for syphilis vaccine.
ACCESSION BD205460
VERSION BD205460.1 GI:33015230
KEYWORDS JP 2002511275-A/43.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences: artificial sequences.
REFERENCE
1 (bases 1 to 19)
AUTHORS Voothis,W.C.V., Lukehart,S.A., Lara,G.A.C. and Cameron,C.E.S.
TITLE Recombinant protein of Treponemapallidum and utilization thereof
for syphilis vaccine
JOURNAL Patent: JP 2002511275-A 43 16-APR-2002;
UNIVERSITY OF WASHINGTON
COMMENT OS Artificial Sequence
PN JP 2002511275-A/43
PD 16-APR-2002
PF 09-APR-1999 JP 2000543645
PR 10-APR-1998 US 09/058968
PI WESLEY C VAN VOORHIS, SHEILA A LUKEHART, GLABER A CENTURION
LARA, CAROLINE E STEBECK CAMERON
PC C12N15/09,A61K39/02,A61P37/04,C07K14/20,C12Q1/68,G01N33/571,
PC C12N15/00
CC Description of Artificial Sequence: T7, PCR3.1 CC
Oligonucleotide used for DNA sequencing.
FH Key Location/Qualifiers
FT misc_feature (1)..(19).
1..19
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 2.0%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 92;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 810 CGGAGGAGGAGGAGGAGC 827
Db 19 CGAGGAGGAGGAGGAGC 2

RESULT 54
AX481359
LOCUS AX481359 19 bp DNA linear PAT 16-AUG-2002
DEFINITION Sequence 6 from Patent EP1225232.
ACCESSION AX481359
VERSION AX481359.1 GI:22316280
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
1
AUTHORS Rubin,B.Y. and Anderson,S.L.
TITLE Detection of mutations in a gene encoding Ikappab
kinase-complex-associated protein to diagnose familial dysautonomia
JOURNAL Patent: EP 1225232-A 6 24-JUL-2002;
Rubin, Berish Y. (US); Anderson, Silvia L. (US)
FEATURES
Location/Qualifiers
1..19
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 2.0%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 92;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 348 AGAGCAACGAGATTCTGC 365
Db 2 AGAACACACGAGATTCTGC 19

RESULT 55
BD104776
LOCUS BD104776 19 bp DNA linear PAT 27-AUG-2002
DEFINITION Kit and method for determining HLA type.
ACCESSION BD104776
VERSION BD104776.1 GI:22650350
KEYWORDS WO 0192572-A/880.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE
1 (bases 1 to 19)
AUTHORS Inoko,H., Kagiya,T., Ichihara,T., Matsumura,Y., Moriya,S. and
Nishida,M.
TITLE Kit and method for determining HLA type
JOURNAL Patent: WO 0192572-A 880 06-DEC-2001;
NISHINBO INDUSTRIES INC,SYSTEM RESEARCH INC,HIDETOSHI INOKO, TAEKO
KAGIYA, TATSUO ICHIHARA,YOSHIYUKI MATSUMURA,SHOGO MORIYA,MICHIO
NISHIDA
COMMENT OS Artificial Sequence
PN WO 0192572-A/880
PD 06-DEC-2001
PF 01-JUN-2001 WO 2001JP004562
PR 01-JUN-2000 JP 00P 164798
PI HIDETOSHI INOKO,TAEKO KAGIYA,TATSUO ICHIHARA,YOSHIYUKI PI
MATSUMURA,
PI SHOGO MORIYA,MICHIO NISHIDA
PC C12Q1/68,C12M1/00,C12N15/09,G01N33/53
CC Description of Artificial Sequence:capture
FH Key Location/Qualifiers
FT source 1..19
/organism='Artificial Sequence'

```

```

FEATURES
  source
    Location/Qualifiers
      1..19
      /organism="synthetic construct"
      /mol_type="genomic DNA"
      /db_xref="taxon:32630"

Query Match
  Best Local Similarity 88.9%; Score 14.8; DB 1; Length 19;
  Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 310 CTTGAGGAGCAATCAAGA 327
Db 1 CTTGAGGAGCAATCGGA 18

RESULT 56
LOCUS CQ622507 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 7247 from Patent WO0192524.
ACCESSION CQ622507
VERSION CQ622507.1 GI:41672725
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE
  AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
  TITLE Myosin-like gene expressed in human heart and muscle
  JOURNAL Patent: WO 0192524-A 7247 06-DEC-2001;
  Aeomica, Inc. (US)
FEATURES
  source
    Location/Qualifiers
      1..17
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match
  Best Local Similarity 93.8%; Score 14.4; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 412 CGAGAGGAGTTCTCTC 427
Db 2 CGAGAACGAGTTCTCTC 17

RESULT 57
LOCUS CQ622709 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 7449 from Patent WO0192524.
ACCESSION CQ622709
VERSION CQ622709.1 GI:41672927
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE
  AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
  TITLE Myosin-like gene expressed in human heart and muscle
  JOURNAL Patent: WO 0192524-A 7449 06-DEC-2001;
  Aeomica, Inc. (US)
FEATURES
  source
    Location/Qualifiers
      1..17
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match
  Best Local Similarity 93.8%; Score 14.4; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 698 CTGGAGAGTGAGCGCG 713
Db 1 CTGGAGAGTGAGCGGG 16

RESULT 58
LOCUS CQ622711 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 7451 from Patent WO0192524.
ACCESSION CQ622711
VERSION CQ622711.1 GI:41672929
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE
  AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
  TITLE Myosin-like gene expressed in human heart and muscle
  JOURNAL Patent: WO 0192524-A 7451 06-DEC-2001;
  Aeomica, Inc. (US)
FEATURES
  source
    Location/Qualifiers
      1..17
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match
  Best Local Similarity 93.8%; Score 14.4; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 413 GAGAGGAGTTCTCTCA 428
Db 1 GAGAGGAGTTCTCTCA 16

RESULT 59
LOCUS CQ624230 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8970 from Patent WO0192524.
ACCESSION CQ624230
VERSION CQ624230.1 GI:41674448
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE
  AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
  TITLE Myosin-like gene expressed in human heart and muscle
  JOURNAL Patent: WO 0192524-A 8970 06-DEC-2001;
  Aeomica, Inc. (US)
FEATURES
  source
    Location/Qualifiers
      1..17
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match
  Best Local Similarity 93.8%; Score 14.4; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 851 CACCAGCTCTCCAG 866
Db 17 CACCAGCTCTCCATG 2

RESULT 60
LOCUS CQ624231 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8970 from Patent WO0192524.
ACCESSION CQ624231
VERSION CQ624231.1 GI:41674448
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE
  AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
  TITLE Myosin-like gene expressed in human heart and muscle
  JOURNAL Patent: WO 0192524-A 8970 06-DEC-2001;
  Aeomica, Inc. (US)
FEATURES
  source
    Location/Qualifiers
      1..17
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match
  Best Local Similarity 93.8%; Score 14.4; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 851 CACCAGCTCTCCAG 866
Db 17 CACCAGCTCTCCATG 2

RESULT 60
LOCUS CQ624231 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8970 from Patent WO0192524.
ACCESSION CQ624231
VERSION CQ624231.1 GI:41674448
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE
  AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
  TITLE Myosin-like gene expressed in human heart and muscle
  JOURNAL Patent: WO 0192524-A 8970 06-DEC-2001;
  Aeomica, Inc. (US)
FEATURES
  source
    Location/Qualifiers
      1..17
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match
  Best Local Similarity 93.8%; Score 14.4; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 851 CACCAGCTCTCCAG 866
Db 17 CACCAGCTCTCCATG 2

```

<p>Sequence 8971 from Patent WO0192524.</p> <p>DEFINITION CQ624231 ACCESSION VERSION CQ624231.1 GI:41674449</p> <p>KEYWORDS SOURCE ORGANISM Homo sapiens (human)</p> <p>REFERENCE 1 AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.</p> <p>TITLE Myosin-like gene expressed in human heart and muscle</p> <p>JOURNAL Patent: WO 0192524-A 8971 06-DEC-2001;</p> <p>FEATURES Location/Qualifiers 1..17 /organism="Homo sapiens" /mol_type="unassigned DNA" /db_xref="taxon:9606"</p> <p>Query Match Best Local Similarity 1.9%; Score 14.4; DB 1; Length 17; Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;</p> <p>QY 851 CACCAGCTTCCAG 866 Db 16 CACCAGCTTCCATG 1</p> <p>RESULT 61 AR463570 LOCUS DEFINITION Sequence 7247 from patent US 6686188. AR463570 ACCESSION VERSION AR463570.1 GI:42698627</p> <p>KEYWORDS SOURCE ORGANISM Unknown. Unclassified.</p> <p>REFERENCE 1 (bases 1 to 17) AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.</p> <p>TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle</p> <p>JOURNAL Patent: US 6686188-A 7247 03-FEB-2004;</p> <p>FEATURES Location/Qualifiers 1..17 /organism="unknown" /mol_type="genomic DNA"</p> <p>Query Match Best Local Similarity 1.9%; Score 14.4; DB 1; Length 17; Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;</p> <p>QY 698 CTGAGAGTGAGCGG 713 Db 1 CTGAGAGTGAGCGG 16</p> <p>RESULT 62 AR463772 LOCUS DEFINITION Sequence 7449 from patent US 6686188. AR463772 ACCESSION VERSION AR463772.1 GI:42698829</p> <p>KEYWORDS SOURCE ORGANISM Unknown. Unclassified.</p> <p>REFERENCE 1 (bases 1 to 17) AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.</p> <p>TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle</p> <p>JOURNAL Patent: US 6686188-A 7449 03-FEB-2004;</p> <p>FEATURES Location/Qualifiers 1..17 /organism="unknown" /mol_type="genomic DNA"</p> <p>Query Match Best Local Similarity 1.9%; Score 14.4; DB 1; Length 17; Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;</p> <p>QY 412 GGAGAGGAGTTCTC 427 Db 2 GGAGAGGAGTTCTC 17</p> <p>RESULT 63 AR463774 LOCUS DEFINITION Sequence 7451 from patent US 6686188. AR463774 ACCESSION VERSION AR463774.1 GI:42698831</p> <p>KEYWORDS SOURCE ORGANISM Unknown. Unclassified.</p> <p>REFERENCE 1 (bases 1 to 17) AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.</p> <p>TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle</p> <p>JOURNAL Patent: US 6686188-A 7451 03-FEB-2004;</p> <p>FEATURES Location/Qualifiers 1..17 /organism="unknown" /mol_type="genomic DNA"</p> <p>Query Match Best Local Similarity 1.9%; Score 14.4; DB 1; Length 17; Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;</p> <p>QY 413 GAGAGGAGTTCTCA 428 Db 1 GAGAGGAGTTCTCA 16</p> <p>RESULT 64 AR465293/c LOCUS DEFINITION Sequence 8970 from patent US 6686188. AR465293 ACCESSION VERSION AR465293.1 GI:42700350</p> <p>KEYWORDS SOURCE ORGANISM Unknown. Unclassified.</p> <p>REFERENCE 1 (bases 1 to 17) AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.</p> <p>TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle</p> <p>JOURNAL Patent: US 6686188-A 8970 03-FEB-2004;</p> <p>FEATURES Location/Qualifiers 1..17 /organism="unknown" /mol_type="genomic DNA"</p> <p>Query Match Best Local Similarity 1.9%; Score 14.4; DB 1; Length 17; Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;</p> <p>QY 851 CACCAGCTTCCAG 866 Db 1 CACCAGCTTCCAG 866</p>	<p>predominantly in heart and muscle</p> <p>JOURNAL Patent: US 6686188-A 7449 03-FEB-2004;</p> <p>FEATURES Location/Qualifiers 1..17 /organism="unknown" /mol_type="genomic DNA"</p> <p>Query Match Best Local Similarity 1.9%; Score 14.4; DB 1; Length 17; Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;</p> <p>QY 412 GGAGAGGAGTTCTC 427 Db 2 GGAGAGGAGTTCTC 17</p> <p>RESULT 63 AR463774 LOCUS DEFINITION Sequence 7451 from patent US 6686188. AR463774 ACCESSION VERSION AR463774.1 GI:42698831</p> <p>KEYWORDS SOURCE ORGANISM Unknown. Unclassified.</p> <p>REFERENCE 1 (bases 1 to 17) AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.</p> <p>TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle</p> <p>JOURNAL Patent: US 6686188-A 7451 03-FEB-2004;</p> <p>FEATURES Location/Qualifiers 1..17 /organism="unknown" /mol_type="genomic DNA"</p> <p>Query Match Best Local Similarity 1.9%; Score 14.4; DB 1; Length 17; Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;</p> <p>QY 413 GAGAGGAGTTCTCA 428 Db 1 GAGAGGAGTTCTCA 16</p> <p>RESULT 64 AR465293/c LOCUS DEFINITION Sequence 8970 from patent US 6686188. AR465293 ACCESSION VERSION AR465293.1 GI:42700350</p> <p>KEYWORDS SOURCE ORGANISM Unknown. Unclassified.</p> <p>REFERENCE 1 (bases 1 to 17) AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.</p> <p>TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle</p> <p>JOURNAL Patent: US 6686188-A 8970 03-FEB-2004;</p> <p>FEATURES Location/Qualifiers 1..17 /organism="unknown" /mol_type="genomic DNA"</p> <p>Query Match Best Local Similarity 1.9%; Score 14.4; DB 1; Length 17; Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;</p> <p>QY 851 CACCAGCTTCCAG 866 </p>
--	--

Db 17 CACGAGCTCTTCATG 2

RESULT 65
AR465294/c
LOCUS AR465294 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 8971 from patent US 6686188.
ACCESSION AR465294
VERSION AR465294.1 GI:42700351
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8971 03-FEB-2004;
FEATURES
source 1. .17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 851 CACGAGCTCTTCATG 866
Db 16 CACGAGCTCTTCATG 1

RESULT 66
AR134263/c
LOCUS AR134263 18 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 2688 from patent US 6194150.
ACCESSION AR134263
VERSION AR134263.1 GI:14123168
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Stinchcomb, D.T., Jarvis, T. and McSwiggen, J.
TITLE Nucleic acid based inhibition of CD40
JOURNAL Patent: US 6194150-A 2688 27-FEB-2001;
FEATURES
source 1. .18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 717 CGCTGCAGCAGCAGCA 732
Db 16 CCCTGCAGCAGCAGCA 1

RESULT 67
AR299235/c
LOCUS AR299235 18 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 10970 from patent US 6537751.
ACCESSION AR299235
VERSION AR299235.1 GI:31686519
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Cohen, D., Chumakov, I. and Blumenfeld, M.

TITLE Biallelic markers for use in constructing a high density disequilibrium map of the human genome
JOURNAL Patent: US 6537751-A 10970 25-MAR-2003;
FEATURES
source 1. .18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 811 GGAGGAGAGAGAG 826
Db 17 GGAGGAGAGATCAAG 2

RESULT 68
AR035629
LOCUS AR035629 19 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 61 from patent US 5871920.
ACCESSION AR035629
VERSION AR035629.1 GI:5952297
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Page, D.C. and Reijo, R.
TITLE Daz: a gene associated with azoospermia
JOURNAL Patent: US 5871920-A 61 16-FEB-1999;
FEATURES
source 1. .19
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.9%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 526 GCACCTGAAGAGCTGC 541
Db 1 GCACCTGAAGAGCTGC 16

RESULT 69
CQ622503
LOCUS CQ622503 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 7243 from Patent WO0192524.
ACCESSION CQ622503
VERSION CQ622503.1 GI:41672721
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 7243 06-DEC-2001;
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 697 GCTGGAGAGTGAGC 710

Db 4 GCTGGAGAGTGAGC 17
|||||
CQ624232 17 bp DNA linear PAT 02-FEB-2004
Sequence 8972 from Patent WO0192524.
ACCESSION CQ624232
VERSION CQ624232.1 GI:41674450
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8972 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 851 CACCAGCTCTTCCA 864
|||||
Db 15 CACCAGCTCTTCCA 2
Query Match 1.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 851 CACCAGCTCTTCCA 864
|||||
Db 14 CACCAGCTCTTCCA 1
RESULT 70
CQ624232/c
LOCUS CQ624232 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8972 from Patent WO0192524.
ACCESSION CQ624232
VERSION CQ624232.1 GI:41674450
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8972 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 851 CACCAGCTCTTCCA 864
|||||
Db 15 CACCAGCTCTTCCA 2
RESULT 71
CQ624233/c
LOCUS CQ624233 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8973 from Patent WO0192524.
ACCESSION CQ624233
VERSION CQ624233.1 GI:41674451
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8973 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 851 CACCAGCTCTTCCA 864
|||||
Db 14 CACCAGCTCTTCCA 1
RESULT 72
AR463566
LOCUS AR463566 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 7243 from patent US 6686188.
ACCESSION AR463566

VERSION AR463566.1 GI:42698623
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 7243 03-FEB-2004;
FEATURES Location/Qualifiers
source
1..17
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 697 GCTGGAGAGTGAGC 710
|||||
Db 4 GCTGGAGAGTGAGC 17
RESULT 73
AR465295/c
LOCUS AR465295 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 8972 from patent US 6686188.
ACCESSION AR465295
VERSION AR465295.1 GI:42700352
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8972 03-FEB-2004;
FEATURES Location/Qualifiers
source
1..17
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 851 CACCAGCTCTTCCA 864
|||||
Db 15 CACCAGCTCTTCCA 2
RESULT 74
AR465296/c
LOCUS AR465296 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 8973 from patent US 6686188.
ACCESSION AR465296
VERSION AR465296.1 GI:42700353
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8973 03-FEB-2004;
FEATURES Location/Qualifiers
source
1..17
/organism="unknown"
/mol_type="genomic DNA"

```

/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 1.9%; Score 14; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 851 CACCAGCTCTTCCA 864
Db 14 CACCAGCTCTTCCA 1

RESULT 75
AX673623/c
LOCUS AX673623 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 2068 from Patent WO03004526.
ACCESSION AX673623
VERSION AX673623.1 GI:29331971
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 2068 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 1.9%; Score 14; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 475 GGAGAAGCTCGATC 488
Db 14 GGAGAAGCTCGATC 1

RESULT 76
AR106794/c
LOCUS AR106794 18 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 42 from patent US 6107091.
ACCESSION AR106794
VERSION AR106794.1 GI:12821324
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Cowsert,L.M.
TITLE Antisense inhibition of G-alpha-16 expression
JOURNAL Patent: US 6107091-A 42 22-AUG-2000;
FEATURES
source
1. .18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.9%; Score 14; DB 1; Length 18;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 308 TGCTGGAGGAGAA 321
Db 14 TGCTGGAGGAGAA 1

/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 1.9%; Score 14; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 851 CACCAGCTCTTCCA 864
Db 14 CACCAGCTCTTCCA 1

RESULT 77
AR045391/c
LOCUS AR045391 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 184 from patent US 5817796.
ACCESSION AR045391
VERSION AR045391.1 GI:5966856
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myd ribozymes having 2'-5'-linked adenylylate residues
JOURNAL Patent: US 5817796-A 184 06-OCT-1998;
FEATURES
source
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 405 AGAGGAGGAGGAGGAG 421
Db 17 AGAGGAGGAGGAGGAG 1

RESULT 78
BD254195
LOCUS BD254195 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD254195
VERSION BD254195.1 GI:33063965
KEYWORDS JP 2002541795-A/1988.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 1988 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT
OS Eukaryote
PN JP 2002541795-A/1988
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT,MICHAEL,ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
C12P21/02,
PC
C12P21/02,C12P21/02//A61K31/711.(C12N5/10,C12R1:91),(C12P21/02, PC
C12R1:91),
PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
PC A61K37/02,
PC (C12N5/00,C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1. .17
/organism='Eukaryote'.
FEATURES
source
1. .17
Location/Qualifiers
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 1.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 367 GGAGCGCTCGAGGAGC 383
Db 17 GGAGCGCTCGAGGAGC 1
```



```

Db      1 GGAGTGTCTTCGAGGAGC 17

RESULT 79
BD254196
LOCUS      17 bp      DNA      linear      PAT 17-JUL-2003
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION  BD254196
VERSION     BD254196.1 GI:33063966
KEYWORDS    JP 2002541795-A/1989.
SOURCE      unidentified
ORGANISM    unclassified.
REFERENCE   1 (bases 1 to 17)
AUTHORS     Blatt, L., Zwick, M., Pavco, P. and Mcswiggen, J.
TITLE       Regulation of repressor genes using nucleic acid molecules
JOURNAL     Patent: JP 2002541795-A 1989 10-DEC-2002;
RIBOZYME    PHARMACEUTICALS INC
OS          Eukaryote
PN          JP 2002541795-A/1989
PF          10-DEC-2002
PR          11-APR-2000 JP 2000611654
PI          12-APR-1999 US 60/129390
PT          LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAYCO, JAMES MCSWIGGEN PC
PC          C12N15/09, A61K38/00, A61K48/00, A61P43/00, A61P43/00, C12N5/10, PC
C12P21/02,
PC          C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
C12R1:91),
PC          (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N5/00, C12N5/00,
PC          A61K37/02, C12R1:91)
PC          (C12N5/00, C12R1:91)
CC          Regulation of repressor genes using nucleic acid molecules FH
KEY          Location/Qualifiers
FT          source
FT          1..17
FT          Location/Qualifiers
FT          1..17
FT          /organism="Eukaryote".
FT          /organism="unidentified"
FT          /mol_type="genomic DNA"
FT          /db_xref="taxon:32644"

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      368 GAGCGCTCGAGGAGCT 384
Db      1 GAGTGTCTTCGAGGAGCT 17

RESULT 80
CO622083/c
LOCUS      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 6823 from Patent WO0192524.
ACCESSION  CO622083
VERSION     CO622083.1 GI:41672301
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 6823 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES    Location/Qualifiers
source      1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      827 CTGGCCAGTTGCAGGT 843
Db      17 CTGGCCAGTTGCAGGT 1

RESULT 81
CO622958/c
LOCUS      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 7698 from Patent WO0192524.
ACCESSION  CO622958
VERSION     CO622958.1 GI:41673176
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 7698 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES    Location/Qualifiers
source      1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      827 CTGGCCAGTTGCAGGT 843
Db      17 CTGGCCAGTTGCAGGT 1

RESULT 82
CO623073
LOCUS      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 7813 from Patent WO0192524.
ACCESSION  CO623073
VERSION     CO623073.1 GI:41673291
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 7813 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES    Location/Qualifiers
source      1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      493 GAGCAGAGGAGGAGGAGG 509
Db      1 GAAGCAAAAGGAGGAGG 17

```

```
RESULT 83
CQ623681
LOCUS      CQ623681      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 8421 from Patent WO0192524.
ACCESSION CQ623681
VERSION    CQ623681.1 GI:41673899
KEYWORDS   .
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE      Myosin-like gene expressed in human heart and muscle
JOURNAL    Patent: WO 0192524-A 8421 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES   Location/Qualifiers
            source          1..17
                        /organism="Homo sapiens"
                        /mol_type="unassigned DNA"
                        /db_xref="taxon:9606"
Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      489 TGAAGAGCGCAGAGGAG 505
Db      1 TGAAGAGCGCAGAGGTG 17

RESULT 84
CQ623682
LOCUS      CQ623682      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 8422 from Patent WO0192524.
ACCESSION CQ623682
VERSION    CQ623682.1 GI:41673900
KEYWORDS   .
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE      Myosin-like gene expressed in human heart and muscle
JOURNAL    Patent: WO 0192524-A 8422 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES   Location/Qualifiers
            source          1..17
                        /organism="Homo sapiens"
                        /mol_type="unassigned DNA"
                        /db_xref="taxon:9606"
Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      490 GAAGAGCGCAGAGGAGC 506
Db      1 GAAGAGCGCAGAGGTGC 17

RESULT 85
I52443
LOCUS      I52443      17 bp      DNA      linear      PAT 07-OCT-1997
DEFINITION Sequence 184 from patent US 5646042.
ACCESSION I52443
VERSION    I52443.1 GI:2473644
KEYWORDS   .
SOURCE     Unknown.

ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 17)
AUTHORS    Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE      C-myb targeted ribozymes
JOURNAL    Patent: US 5646042-A 184 08-JUL-1997;
FEATURES   Location/Qualifiers
            source          1..17
                        /organism="unknown"
                        /mol_type="unassigned DNA"
Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      405 AGAGGGAGGAGAGGAG 421
Db      17 AGAGGGAGGAGAGGAG 1

RESULT 86
AR190504/c
LOCUS      AR190504      17 bp      DNA      linear      PAT 20-APR-2002
DEFINITION Sequence.5992 from patent US 6346398.
ACCESSION AR190504
VERSION    AR190504.1 GI:20236469
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 17)
AUTHORS    Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE      Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
JOURNAL    Patent: US 6346398-A 5992 12-FEB-2002;
FEATURES   Location/Qualifiers
            source          1..17
                        /organism="unknown"
                        /mol_type="unassigned DNA"
Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      457 GGTGAGAGACTCGGCC 473
Db      17 GGTAGACAGACTCGGCC 1

RESULT 87
AR325427/c
LOCUS      AR325427      17 bp      RNA      linear      PAT 17-AUG-2003
DEFINITION Sequence 2829 from patent US 6566127.
ACCESSION AR325427
VERSION    AR325427.1 GI:33711235
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 17)
AUTHORS    Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE      Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
JOURNAL    Patent: US 6566127-A 2829 20-MAY-2003;
FEATURES   Location/Qualifiers
            source          1..17
                        /organism="unknown"
                        /mol_type="unassigned RNA"
Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

Qy	457	GGTGGAGACTCGGCC	473
Db	17	GGTAGACAGACTCGGCC	1
RESULT 88			
LOCUS	AR327369	17 bp RNA linear PAT 17-AUG-2003	
DEFINITION	Sequence 4771 from patent US 6566127.		
ACCESSION	AR327369		
VERSION	AR327369.1 GI:33713177		
KEYWORDS	Unknown.		
SOURCE	Unknown.		
ORGANISM	Unknown.		
REFERENCE	1 (bases 1 to 17)		
AUTHORS	Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.		
TITLE	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor		
JOURNAL	Patent: US 6566127-A 4771 20-MAY-2003;		
FEATURES	Location/Qualifiers		
source	1..17		
	/organism="unknown"		
	/mol_type="unassigned RNA"		
Query Match	1.8%; Score 13.8; DB 1; Length 17;		
Best Local Similarity	88.2%; Pred. No. 1.5e+02;		
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;		
Qy	874	CAACCACATCAAGACGA	890
Db	1	CAACTACTCTAAGACGA	17
RESULT 89			
LOCUS	AR329402/c	17 bp RNA linear PAT 17-AUG-2003	
DEFINITION	Sequence 6804 from patent US 6566127.		
ACCESSION	AR329402		
VERSION	AR329402.1 GI:33715210		
KEYWORDS	Unknown.		
SOURCE	Unknown.		
ORGANISM	Unknown.		
REFERENCE	1 (bases 1 to 17)		
AUTHORS	Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.		
TITLE	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor		
JOURNAL	Patent: US 6566127-A 6804 20-MAY-2003;		
FEATURES	Location/Qualifiers		
source	1..17		
	/organism="unknown"		
	/mol_type="unassigned RNA"		
Query Match	1.8%; Score 13.8; DB 1; Length 17;		
Best Local Similarity	88.2%; Pred. No. 1.5e+02;		
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;		
Qy	337	TGCCATCCGGCAGACGA	353
Db	17	TGCCATCTCTGTGACGA	1
RESULT 90			
LOCUS	AR463146/c	17 bp DNA linear PAT 20-FEB-2004	
DEFINITION	Sequence 6823 from patent US 6686188.		
ACCESSION	AR463146		
VERSION	AR463146.1 GI:42698203		
KEYWORDS	Unknown.		
SOURCE	Unknown.		
ORGANISM	Unknown.		
REFERENCE	1 (bases 1 to 17)		
AUTHORS	Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.		
TITLE	Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle		
JOURNAL	Patent: US 6686188-A 7813 03-FEB-2004;		
FEATURES	Location/Qualifiers		
source	1..17		
	/organism="unknown"		
	/mol_type="genomic DNA"		
Query Match	1.8%; Score 13.8; DB 1; Length 17;		
Best Local Similarity	88.2%; Pred. No. 1.5e+02;		
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;		
Qy	827	CTGGCCCAGTTGCAGGT	843
Db	17	CTGGCCAGCTGCAGGT	1
RESULT 92			
LOCUS	AR464136	17 bp DNA linear PAT 20-FEB-2004	
DEFINITION	Sequence 7813 from patent US 6686188.		
ACCESSION	AR464136		
VERSION	AR464136.1 GI:42699193		
KEYWORDS	Unknown.		
SOURCE	Unknown.		
ORGANISM	Unknown.		
REFERENCE	1 (bases 1 to 17)		
AUTHORS	Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.		
TITLE	Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle		
JOURNAL	Patent: US 6686188-A 7813 03-FEB-2004;		
FEATURES	Location/Qualifiers		
source	1..17		
	/organism="unknown"		
	/mol_type="genomic DNA"		
Query Match	1.8%; Score 13.8; DB 1; Length 17;		
Best Local Similarity	88.2%; Pred. No. 1.5e+02;		
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;		
Qy	827	CTGGCCCAGTTGCAGGT	843
Db	17	CTGGCCAGCTGCAGGT	1
RESULT 92			
LOCUS	AR464136	17 bp DNA linear PAT 20-FEB-2004	
DEFINITION	Sequence 7813 from patent US 6686188.		
ACCESSION	AR464136		
VERSION	AR464136.1 GI:42699193		
KEYWORDS	Unknown.		
SOURCE	Unknown.		
ORGANISM	Unknown.		
REFERENCE	1 (bases 1 to 17)		
AUTHORS	Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.		
TITLE	Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle		
JOURNAL	Patent: US 6686188-A 7813 03-FEB-2004;		
FEATURES	Location/Qualifiers		
source	1..17		
	/organism="unknown"		
	/mol_type="genomic DNA"		
Query Match	1.8%; Score 13.8; DB 1; Length 17;		
Best Local Similarity	88.2%; Pred. No. 1.5e+02;		
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;		
Qy	827	CTGGCCCAGTTGCAGGT	843
Db	17	CTGGCCAGCTGCAGGT	1
RESULT 92			
LOCUS	AR464136	17 bp DNA linear PAT	

Matches	15;	Conservative	0;	Mismatches	2;	Indels	0;	Gaps	0;
QY	493	GAGCGAAGAGGAGGAGG	509						
DB	1	GAAGCAAAAGGAGGAGG	17						
RESULT 93									
LOCUS	AR464744			17 bp	DNA			linear - PAT 20-FEB-2004	
DEFINITION	Sequence 8421 from patent US 6686188.								
ACCESSION	AR464744								
VERSION	AR464744.1	GI:42699801							
KEYWORDS	Unknown.								
SOURCE	Unknown.								
ORGANISM	Unclassified.								
REFERENCE	1 (bases 1 to 17)								
AUTHORS	Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.								
TITLE	Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle								
JOURNAL	Patent: US 6686188-A	8421 03-FEB-2004;							
FEATURES	Location/Qualifiers								
source	1..17								
	/organism="unknown"								
	/mol_type="genomic DNA"								
Query Match		1.8%;	Score 13.8;	DB 1;	Length 17;				
Best Local Similarity		88.2%;	Pred. No. 1.5e+02;						
Matches	15;	Conservative	0;	Mismatches	2;	Indels	0;	Gaps	0;
QY	489	TGAAGAGCGCAGAGGAGG	505						
DB	1	TGAAGAGCGCAGAGGTC	17						
RESULT 94									
LOCUS	AR464745			17 bp	DNA			linear	PAT 20-FEB-2004
DEFINITION	Sequence 8422 from patent US 6686188.								
ACCESSION	AR464745								
VERSION	AR464745.1	GI:42699802							
KEYWORDS	Unknown.								
SOURCE	Unknown.								
ORGANISM	Unclassified.								
REFERENCE	1 (bases 1 to 17)								
AUTHORS	Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.								
TITLE	Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle								
JOURNAL	Patent: US 6686188-A	8422 03-FEB-2004;							
FEATURES	Location/Qualifiers								
source	1..17								
	/organism="unknown"								
	/mol_type="genomic DNA"								
Query Match		1.8%;	Score 13.8;	DB 1;	Length 17;				
Best Local Similarity		88.2%;	Pred. No. 1.5e+02;						
Matches	15;	Conservative	0;	Mismatches	2;	Indels	0;	Gaps	0;
QY	490	GAAGAGGCGCAGAGGAGC	506						
DB	1	GAAGAGGCGCAGAGGTC	17						
RESULT 95									
LOCUS	AX266063/c			17 bp	DNA			linear	PAT 26-OCT-2001
DEFINITION	Sequence 3454 from Patent WO0173002.								
ACCESSION	AX266063								
VERSION	AX266063.1	GI:16514862							

KEYWORDS Homo sapiens (human)
SOURCE ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE 1
AUTHORS Kmiec, E.B., Ganper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 3454 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)

FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 374 TGCAGGAGCTTCTGCA 390
|||||
Db 17 TGCAGGCGCTTCTGCA 1

RESULT 96
AX266064 17 bp DNA linear PAT 26-OCT-2001
LOCUS AX266064
DEFINITION Sequence 3455 from Patent WO0173002.
ACCESSION AX266064
VERSION AX266064.1 GI:16514863
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE 1
AUTHORS Kmiec, E.B., Ganper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 3455 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)

FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 374 TGCAGGAGCTTCTGCA 390
|||||
Db 1 TGCAGGCGCTTCTGCA 17

RESULT 97
AX530794 17 bp DNA linear PAT 22-NOV-2002
LOCUS AX530794
DEFINITION Sequence 303 from Patent EP1239051.
ACCESSION AX530794
VERSION AX530794.1 GI:25253383
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE 1
AUTHORS Shannon, M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 303 11-SEP-2002;

```
FEATURES
  source
    Aeomica, Inc. (US)
    1..17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

Query Match
  Best Local Similarity 1.8%; Score 13.8; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 471 GCTGAGAGCTCGAT 487
Db 1 GCTTTGAGAGCTCGAT 17

RESULT 98
AX578640
LOCUS AX578640 17 bp RNA linear PAT 10-JAN-2003
DEFINITION Sequence 478 from Patent WO0211674.
ACCESSION AX578640
VERSION AX578640.1 GI:27647842
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1 Thompson, J., McSwiggen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
  and Grupe, A.
  Method and reagent for the inhibition of calcium activated chloride
  channel-1 (clca-1)
  Patent: WO 0211674-A 478 14-FEB-2002;
  RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
  Thompson, James (US)
FEATURES
  source
    1..17
    /organism="Homo sapiens"
    /mol_type="unassigned RNA"
    /db_xref="taxon:9606"

Query Match
  Best Local Similarity 1.8%; Score 13.8; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 476 GAGAGCTCGATCTGAA 492
Db 1 GATAAGGTCGATCTGAA 17

RESULT 99
AX587997/c
LOCUS AX587997 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 729 from Patent EP1281758.
ACCESSION AX587997
VERSION AX587997.1 GI:29410695
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1 Shannon, M., Gu, Y. and Nguyen, C.T.
  Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
  mdz12
  Patent: EP 1281758-A 729 05-FEB-2003;
  Aeomica, Inc. (US)
FEATURES
  source
    1..17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

FEATURES
  source
    Aeomica, Inc. (US)
    1..17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

Query Match
  Best Local Similarity 1.8%; Score 13.8; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 268 CCTGCCTTCAGAACAGG 284
Db 17 CCCGCCCTGCAGAACAGG 1

RESULT 100
AX587998/c
LOCUS AX587998 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 730 from Patent EP1281758.
ACCESSION AX587998
VERSION AX587998.1 GI:29410696
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1 Shannon, M., Gu, Y. and Nguyen, C.T.
  Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
  mdz12
  Patent: EP 1281758-A 730 05-FEB-2003;
  Aeomica, Inc. (US)
FEATURES
  source
    1..17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

Query Match
  Best Local Similarity 1.8%; Score 13.8; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 267 ACCTGCCTTCAGAACAG 283
Db 17 ACCCGCCTGCAGAACAG 1

RESULT 101
AX757153
LOCUS AX757153 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 474 from Patent WO03040369.
ACCESSION AX757153
VERSION AX757153.1 GI:32251769
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1 Telerman, A., Amson, R. and Tuijinder, M.
  Sequences involved in tumoral suppression, tumoral reversion,
  apoptosis and/or viral resistance phenomena and their use as
  medicines
  Patent: WO 03040369-A 474 15-MAY-2003;
  Molecular Engines Laboratories (FR)
FEATURES
  source
    1..17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

Query Match
  Best Local Similarity 1.8%; Score 13.8; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 250 GAAGCCAGCCATGCTGC 266
Db 1 GATCCAGCCATGCTGC 17
```

```
RESULT 102
AX757735
LOCUS AX757735 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 1056 from Patent WO03040369.
ACCESSION AX757735
VERSION AX757735.1 GI:32252351
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Guo,J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 71 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 677 GCGAGCGAGCGGCGG 693
Db 1 GCGAGCGAGCGAGCGG 17

RESULT 105
AX783694
LOCUS AX783694 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 2025 from Patent WO03050284.
ACCESSION AX783694
VERSION AX783694.1 GI:32951543
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
REFERENCE
AUTHORS Guo,J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 2025 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 333 GAGATGCCATCCGCGAG 349
Db 1 GAGATGCCATCCCTGCAG 17

RESULT 106
AX783781
LOCUS AX783781 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 2112 from Patent WO03050284.
ACCESSION AX783781
VERSION AX783781.1 GI:32951630
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
REFERENCE
AUTHORS Guo,J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 2112 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"

RESULT 103
AX781735
LOCUS AX781735 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 66 from Patent WO03050284.
ACCESSION AX781735
VERSION AX781735.1 GI:32949569
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
REFERENCE
AUTHORS Guo,J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 66 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 485 GATCTGAAGAGCAGGA 501
Db 1 GATCTGAAGAGACAGTA 17

RESULT 104
AX781740
LOCUS AX781740 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 71 from Patent WO03050284.
ACCESSION AX781740
VERSION AX781740.1 GI:32949574
KEYWORDS Homo sapiens (human)
SOURCE
```

```
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 1.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 413 GAGAGGAGTCTCAT 429
DB 1 GAGAAGGAATGCTCAT 17

RESULT 107
AX783782
LOCUS AX783782 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 2113 from Patent WO03050284.
ACCESSION AX783782
VERSION AX783782.1 GI:32951631
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Guo,J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 2113 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 1.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 414 AGAAGGAGTCTCATG 430
DB 1 AGAAGGAATGCCTCATG 17

RESULT 108
BD104959
LOCUS BD104959 17 bp DNA linear PAT 27-AUG-2002
DEFINITION Kit and method for determining HLA type.
ACCESSION BD104959
VERSION BD104959.1 GI:22650533
KEYWORDS WO 0192572-A/1063.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 17)
AUTHORS Inoko,H., Kagiya,T., Ichiwara,T., Matsumura,Y., Moriya,S. and
Nishida,M.
TITLE Kit and method for determining HLA type
JOURNAL Patent: WO 0192572-A 1063 06-DEC-2001;
NISHINOBO INDUSTRIES INC. SYSTEM RESEARCH INC. HIDEOTOSHI INOKO, TAEKO
KAGIYA, TATSUO ICHIHARA, YOSHIYUKI MATSUMURA, SHOGO MORIYA, MICHIO
NISHIDA
COMMENT OS Artificial Sequence
PN WO 0192572-A/1063
PD 06-DEC-2001
PP 01-JUN-2001 WO 2001JP004662
PR 01-JUN-2000 JP 00P 164798
PI HIDEOTOSHI INOKO,TAEKO KAGIYA,TATSUO ICHIHARA,YOSHIYUKI PI
MATSUMURA,
PI SHOGO MORIYA,MICHIO NISHIDA
PC C12M1/68,C12M1/00,C12N15/09,G01N33/53
CC Description of Artificial Sequence:capture
FH Key Location/Qualifiers
FT source
1..17

/organism='Artificial Sequence'.
Location/Qualifiers
1..17
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match
Best Local Similarity 1.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 760 GCAGGGCCAGAGCGTGG 776
DB 1 GCAGGGCCGTCGTGG 17

RESULT 109
AR064931/c
LOCUS AR064931 18 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 56 from patent US 5849481.
ACCESSION AR064931
VERSION AR064931.1 GI:5995147
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Urdea,M.S.; Horn,T.; Chang,C.-A.; Warner,B. and Fultz,T.J.
TITLE Nucleic acid hybridization assays employing large comb-type
branched polynucleotides
JOURNAL Patent: US 5849481-A 56 15-DEC-1998;
FEATURES
source
1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.8%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 867 AATACGACACACATC 883
DB 17 AGTACGACACACGTC 1

RESULT 110
AR096403/c
LOCUS AR096403 18 bp DNA linear PAT 08-SEP-2000
DEFINITION Sequence 74 from patent US 6007995.
ACCESSION AR096403
VERSION AR096403.1 GI:10025178
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Baker,B.F. and Cowseert,L.M.
TITLE Antisense inhibition of TNFR1 expression
JOURNAL Patent: US 6007995-A 74 28-DEC-1999;
FEATURES
source
1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.8%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 302 CAGCGCTGCTGGAGGA 318
DB 17 CTGGGCTGCTGGAGGA 1
```



```
RESULT 111
AR098802
LOCUS AR098802 18 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 57 from patent US 6077672.
ACCESSION AR098802
VERSION AR098802.1 GI:12808568
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Monia,B.P. and Cowsert,L.M.
TITLE Antisense modulation of TRADD expression
JOURNAL Patent: US 6077672-A 57 20-JUN-2000;
FEATURES
source
1..18
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred.No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 795 AGCGCCAGCGCGCTCG 811
|||||
Db 2 AGCGCCAGCGCGCTCG 18
|||||

RESULT 112
AR105438/c
LOCUS AR105438 18 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 1 from patent US 6096549.
ACCESSION AR105438
VERSION AR105438.1 GI:12819035
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Pelicic,V., Revrat,J.-M., Gicquel,B., Guilhot,C. and Jackson,M.
TITLE Method of selection of allelic exchange mutants
JOURNAL Patent: US 6096549-A 1 01-AUG-2000;
FEATURES
source
1..18
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred.No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 810 CGGAGGAGAGGAGGAG 826
|||||
Db 17 CGGAGGAGAGGAGGAG 1
|||||

RESULT 113
BD196769
LOCUS BD196769 18 bp DNA linear PAT 17-JUL-2003
DEFINITION Prostatic cancer gene.
ACCESSION BD196769
VERSION BD196769.1 GI:33006539
KEYWORDS JP 2002516657-A/358.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 18)
AUTHORS Cohen,D., Blumenfeld,M., Chumakov,I. and Bougueleret,L.
TITLE Prostatic cancer gene
JOURNAL Patent: JP 2002516657-A 358 11-JUN-2002;
COMMENT OS Homo sapiens (human)

PN JP 2002516657-A/358
PD 11-JUN-2002
PF 22-DEC-1998 JP 2000525562
PR 22-DEC-1997 US 08/996306,09-SEP-1998 US 60/099658 PI
DANIEL COHEN,MARTA BLUMENFELD,ILYA CHUMAKOV,LYDIE BOUGUELERET,PC
C12N15/09,C12N15/09,A01K67/027,C07K14/47,C07K16/18,C12N1/15,PC
C12N1/19,
PC C12N1/21,C12N5/10,C12N5/10,C12P21/08,C12Q1/68,G01N33/50 PC
,C12N15/00,C12N5/00,
PC C12N5/00,C12N15/00
CC downstream amplification primer for SEQ
190, SEQ 267, SEQ 191,
CC
FH Key Location/Qualifiers
FT primer bind 1..18.
Location/Qualifiers
1..18
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred.No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 372 GCTGCGAGGAGCTTCTG 388
|||||
Db 2 GCTGAGAGGAGCTTTTG 18
|||||

RESULT 114
BD217451/c
LOCUS BD217451 18 bp DNA linear PAT 17-JUL-2003
DEFINITION Antisense modulation of TNFR1 expression.
ACCESSION BD217451
VERSION BD217451.1 GI:33027221
KEYWORDS JP 2002519015-A/74.
SOURCE unidentified
ORGANISM unidentified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Baker,B.F. and Cowsert,L.M.
TITLE Antisense modulation of TNFR1 expression
JOURNAL Patent: JP 2002519015-A 74 02-JUL-2002;
COMMENT ISIS PHARMACEUTICALS INC
OS Unidentified
PN JP 2002519015-A/74
PD 02-JUL-2002
PF 17-JUN-1999 JP 2000557265
PR 26-JUN-1998 US 09/106038
PI BRENDA F BAKER,LEX M COWSERT
PC
C12N15/09,A61K31/7105,A61K48/00,A61P29/00,A61P43/00,PC
C12Q1/68,
PC C12N15/00
CC Strandedness: Single;
CC Topology: Linear;
CC Antisense modulation of TNFR1 expression
FH Key Location/Qualifiers
FT source 1..18
/organism="Unidentified".
Location/Qualifiers
1..18
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred.No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 302 CAGCGCTGCTGAGGA 318
|||||
```

Db 17 CTGGCGCTGCTGAGGA 1 linear PAT 20-APR-2002

RESULT 115
ARI92834/c 18 bp DNA
LOCUS Sequence 8322 from patent US 6346398.
DEFINITION ARI92834
ACCESSION ARI92834.1 GI:20238799
VERSION
KEYWORDS
SOURCE
ORGANISM
Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 8322 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 688 GGCGCGGAGCTGGAGA 704
Db 18 GGCGCGGAGCTGTAGA 2

RESULT 116
AR326578/c 18 bp RNA
LOCUS Sequence 3980 from patent US 6566127.
DEFINITION AR326578
ACCESSION AR326578
VERSION AR326578.1 GI:33712386
KEYWORDS
SOURCE
ORGANISM
Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 3980 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 688 GGCGCGGAGCTGGAGA 704
Db 18 GGCGCGGAGCTGTAGA 2

RESULT 117
AR359325 18 bp DNA
LOCUS Sequence 38 from patent US 6593133.
DEFINITION AR359325
ACCESSION AR359325
VERSION AR359325.1 GI:33765538
KEYWORDS
SOURCE
ORGANISM
Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Johansen,T.E., Blom,N. and Hansen,C.

TITLE Neurotrophic factors
JOURNAL Patent: US 6593133-A 38 15-JUL-2003;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 826 GCTGGCCCGCTGCAGG 842
Db 1 GCTGGCCCGCTGCAGG 17

RESULT 118
AR534884 18 bp DNA
LOCUS Sequence 38 from patent US 6734284.
DEFINITION AR534884
ACCESSION AR534884
VERSION AR534884.1 GI:53925596
KEYWORDS
SOURCE
ORGANISM
Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Johansen,T.E., Blom,N. and Hansen,C.
TITLE Neublastin neurotrophic factors
JOURNAL Patent: US 6734284-A 38 11-MAY-2004;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 826 GCTGGCCCGCTGCAGG 842
Db 1 GCTGGCCCGCTGCAGG 17

RESULT 119
AX004444 18 bp DNA
LOCUS Sequence 26 from Patent WO9916899.
DEFINITION AX004444
ACCESSION AX004444
VERSION AX004444.1 GI:9927903
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Anttil,J.L. and Cote,G.
TITLE Molecular diagnostic of glaucomas associated with chromosomes 2 and 6
JOURNAL Patent: WO 9916899-A 26 08-APR-1999;
FEATURES ANCTIL JEAN LOUIS (CA); COTE GILLES (CA)
Location/Qualifiers
source 1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="OLIGONUCLEOTIDE"

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 558 AGGACAAGGCCTCTGTG 574
||||| ||||| ||||| |||||

```

Db      1 AGGCCAAGACCTCTGTG 17

RESULT 120
LOCUS   AX015708/c
DEFINITION Sequence 10 from Patent WO950421.
ACCESSION AX015708
VERSION   AX015708.1 GI:10041536
KEYWORDS Homo sapiens (human)
SOURCE    Homo sapiens
ORGANISM  Homo sapiens

REFERENCE
AUTHORS   Markham,A.F. and Robinson,P.A.
TITLE     Ubiquitin conjugating enzyme
JOURNAL   Patent: WO 950421-A 10 07-OCT-1999;
          UNIV LEEDS (GB); MARKHAM ALEXANDER FRED (GB); ROBINSON PHILIP ALAN (GB)

FEATURES
source    Location/Qualifiers
          1..18
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      719 CTGCAGCAGCAGCACAG 735
Db      17 CTGTAGCTGCAGCACAG 1

RESULT 121
LOCUS   AX114463
DEFINITION Sequence 132 from Patent WO0129257.
ACCESSION AX114463
VERSION   AX114463.1 GI:14031427
KEYWORDS Homo sapiens (human)
SOURCE    Homo sapiens
ORGANISM  Homo sapiens

REFERENCE
AUTHORS   Schork,N. and Skierczynski,B.
TITLE     Methods of genetic cluster analysis and use thereof
JOURNAL   Patent: WO 0129257-A 132 26-APR-2001;
          GENSET (FR)

FEATURES
source    Location/Qualifiers
          1..18
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

primer_bind 1..18
            /notes="downstream amplification primer 4-22 for SEQ 6, in complement"

Query Match      1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      372 GCTGCGAGGAGCTTCTG 388
Db      2 GCTGAGAGGAGCTTTTG 18

RESULT 122
LOCUS   AX164504/c
DEFINITION Sequence 334 from Patent WO0138564.

```

```

ACCESSION AX164504
VERSION   AX164504.1 GI:14545438
KEYWORDS synthetic construct
SOURCE    synthetic construct
ORGANISM  other sequences; artificial sequences.

REFERENCE
AUTHORS   Rouleau,G.A., Lafreniere,R.G., Rochefort,D., Cossette,P. and Ragsdale,D.
TITLE     Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy
JOURNAL   Patent: WO 0138564-A 334 31-MAY-2001;
          McGill University (CA)
FEATURES
source    Location/Qualifiers
          1..18
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="synthetic oligonucleotide"

Query Match      1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      617 CAGAGTCGCTTGGAGGC 633
Db      18 CAGATCGCTTGGGGGC 2

RESULT 123
LOCUS   AX587328
DEFINITION Sequence 104 from Patent WO0236761.
ACCESSION AX587328
VERSION   AX587328.1 GI:27656193
KEYWORDS synthetic construct
SOURCE    synthetic construct
ORGANISM  other sequences; artificial sequences.

REFERENCE
AUTHORS   D'Andrea,A.D., Taniguchi,T., Timmers,C. and Grompe,M.
TITLE     Methods and compositions for the diagnosis of cancer susceptibility and defective dna repair mechanisms and treatment thereof
JOURNAL   Patent: WO 0236761-A 104 10-MAY-2002;
          DANA FARBEN CANCER INSTITUTE (US)
FEATURES
source    Location/Qualifiers
          1..18
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="MG476"

Query Match      1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      647 TGCAGGCTCTGGAGGG 663
Db      2 TGCAGACTCTGGTGG 18

RESULT 124
LOCUS   AR124643
DEFINITION Sequence 44 from patent US 6172041.
ACCESSION AR124643
VERSION   AR124643.1 GI:14110004
KEYWORDS Unknown.
SOURCE    Unknown.
ORGANISM  Unclassified.
REFERENCE 1 (bases 1 to 17)

```



```

AUTHORS      Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE        Nucleic acid based inhibition of CD40
JOURNAL      Patent: US 6194150-A 821 27-FEB-2001;
FEATURES     Location/Qualifiers
source       1..15
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      1.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 579 CCCAGGTGACGTCT 593
Db 15 CCCAGGTGAAGTCT 1

RESULT 129
BD208731/c
LOCUS          15 bp      RNA      linear      PAT 17-JUL-2003
DEFINITION     Enzymatic nucleic acid treatment of diseases or conditions related
                to hepatitis C virus infection.
ACCESSION      BD208731
VERSION        BD208731.1 GI:33018501
KEYWORDS       JP 2002512791-A/2321.
SOURCE         unidentified
ORGANISM       unclassified.
REFERENCE      1 (bases 1 to 15)
AUTHORS        Blatt,L., McSwiggen,J.A., Roberts,E., Pavco,P.A. and Macejak,D.
TITLE          Enzymatic nucleic acid treatment of diseases or conditions related
                to hepatitis C virus infection
JOURNAL        Patent: JP 2002512791-A 2321 08-MAY-2002;
                RIBOZYME PHARMACEUTICALS INC
COMMENT        OS Hepatitis virus (hepatitis C virus)
                PN JP 2002512791-A/2321
                PD 08-MAY-2002
                PP 26-APR-1999 JP 2000545991
                PR 27-APR-1998 US 60/083217,18-SEP-1998 US 60/100842 PR
                25-FEB-1999 US 09/257608,23-MAR-1999 US 09/274553 PI
                LAWRENCE BLATT,JAMES A MCSWIGGEN,ELISABETH ROBERTS,PAMELA A PI
                PAVCO, DENNIS MACEJAK
                PI C12N9/00,A61K31/7105,A61K38/21,A61K48/00,A61P31/12,C12N15/09,
                PC A61K37/66,
                PC C12N15/00
                CC Enzymatic nucleic acid treatment of diseases or conditions CC
                related to
                CC hepatitis C virus infection.
                FH Key
                FT source
                FT virus'.
FEATURES       Location/Qualifiers
source         1..15
             /organism="unidentified"
             /mol_type="genomic RNA"
             /db_xref="taxon:32644"

Query Match      1.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 595 GCTCGGGAGCTGCA 609
Db 15 GCTCGGGAGCTGCA 1

RESULT 130
AR057415
LOCUS          16 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION     Sequence 1619 from patent US 5837542.
ACCESSION      AR057415

```

```

VERSION       AR057415.1 GI:5982992
KEYWORDS      Unknown.
SOURCE        Unknown.
ORGANISM      Unclassified.
REFERENCE     1 (bases 1 to 16)
AUTHORS       Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
              Draper,K.G.
TITLE         Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL       Patent: US 5837542-A 1619 17-NOV-1998;
FEATURES      Location/Qualifiers
source        1..16
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      1.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 304 GCGCTGCCTGGAGGA 318
Db 1 GCGCTGCCTGGTGA 15

RESULT 131
AR115173
LOCUS          16 bp      DNA      linear      PAT 16-MAY-2001
DEFINITION     Sequence 1619 from patent US 6132967.
ACCESSION      AR115173
VERSION        AR115173.1 GI:14095495
KEYWORDS       Unknown.
SOURCE         Unknown.
ORGANISM       Unclassified.
REFERENCE      1 (bases 1 to 16)
AUTHORS        Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
              Draper,K.G.
TITLE          Ribozyme treatment of diseases or conditions related to levels of
                intercellular adhesion molecule-1 (ICAM-1)
JOURNAL        Patent: US 6132967-A 1619 17-OCT-2000;
FEATURES       Location/Qualifiers
source         1..16
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      1.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 304 GCGCTGCCTGGAGGA 318
Db 1 GCGCTGCCTGGTGA 15

RESULT 132
CO797647/c
LOCUS          16 bp      DNA      linear      PAT 20-APR-2004
DEFINITION     Sequence 27 from Patent WO2004029299.
ACCESSION      CO797647
VERSION        CO797647.1 GI:46425927
KEYWORDS       Klebsiella oxytoca
SOURCE         Klebsiella oxytoca
ORGANISM       Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
                Enterobacteriaceae; Klebsiella.
REFERENCE      1
AUTHORS        Weizenegger,M. and Bollen,M.
TITLE          Methods for detecting and differentiating bacteria
JOURNAL        Patent: WO 2004029299-A 27 08-APR-2004;
                Hain Lifescience GmbH (DE)
FEATURES       Location/Qualifiers
source         1..16
             /organism="Klebsiella oxytoca"

```

```

/mol_type="unassigned DNA"
/db_xref="taxon:571"

Query Match
Best Local Similarity 93.3%; Score 13.4; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 592 CTTGCTCGGGAGCT 606
Db 15 CTTGCTCGGGAGCT 1

RESULT 133
LOCUS AX634461
DEFINITION Sequence 1600 from Patent EP1260586.
ACCESSION AX634461
VERSION AX634461.1 GI:28470075
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Wolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
Genes
JOURNAL Patent: EP 1260586-A 1600 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source
1. .16
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 1.8%; Score 13.4; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 304 GCGCTCGCTGGAGGA 318
Db 1 GCGCTCGCTGGTGA 15

RESULT 134
LOCUS A08221/c
DEFINITION synthetic oligonucleotide primer III.
ACCESSION A08221
VERSION A08221.1 GI:413426
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 17)
AUTHORS Seemann,G., Besslet,K. and Sedlacek,H.H.
TITLE Antigens composed of major histocompatibility complex class I
antigens and specific carrier molecules, their production and use
JOURNAL Patent: EP 0352761-A 3 31-JAN-1990;
BEHRINGERWERKE Aktiengesellschaft
FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match
Best Local Similarity 1.8%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 293 GAGACCTCCAGCGC 307
Db 17 GAGACGCTCCAGCGC 3

RESULT 135
LOCUS CQ622084/c
DEFINITION Sequence 6824 from Patent WO0192524.
ACCESSION CQ622084
VERSION CQ622084.1 GI:41672302
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 6824 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 1.8%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 266 CACCTGCCTTCAGAA 280
Db 16 CACCTGCCTTGAGAA 2

RESULT 136
LOCUS CQ622085/c
DEFINITION Sequence 6825 from Patent WO0192524.
ACCESSION CQ622085
VERSION CQ622085.1 GI:41672303
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 6825 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 1.8%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 266 CACCTGCCTTCAGAA 280
Db 15 CACCTGCCTTGAGAA 1

RESULT 137
LOCUS CQ622508
DEFINITION Sequence 7248 from Patent WO0192524.

```

```
ACCESSION      CQ622508
VERSION        CQ622508.1  GI:41672726
KEYWORDS
SOURCE         Homo sapiens (human)
ORGANISM       Homo sapiens
               Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      1
AUTHORS       Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
               Shannon, M.E.
TITLE         Myosin-like gene expressed in human heart and muscle
JOURNAL       Patent: WO 0192524-A 7448 06-DEC-2001;
               Aeomica, Inc. (US)
FEATURES      1. .17
               Location/Qualifiers
               source
               1. .17
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match   1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 699 TGGAGAGTGAGCGCG 713
      |||||
Db 1 TGGAGAGTGAGCGCG 15

RESULT 138
CQ622708
LOCUS         CQ622708 17 bp DNA linear PAT 02-FEB-2004
DEFINITION   Sequence 7448 from Patent WO0192524.
ACCESSION    CQ622708
VERSION      CQ622708.1  GI:41672926
KEYWORDS
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
               Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS     Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
               Shannon, M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 7448 06-DEC-2001;
               Aeomica, Inc. (US)
FEATURES    1. .17
               Location/Qualifiers
               source
               1. .17
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match   1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 412 GGAGAGGAGTTCT 426
      |||||
Db 3 GGAGAGGAGTTCT 17

RESULT 139
CQ622712
LOCUS         CQ622712 17 bp DNA linear PAT 02-FEB-2004
DEFINITION   Sequence 7452 from Patent WO0192524.
ACCESSION    CQ622712
VERSION      CQ622712.1  GI:41672930
KEYWORDS
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
               Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS     Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
               Shannon, M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 7448 06-DEC-2001;
               Aeomica, Inc. (US)
FEATURES    1. .17
               Location/Qualifiers
               source
               1. .17
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match   1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 412 GGAGAGGAGTTCT 426
      |||||
Db 3 GGAGAGGAGTTCT 17

RESULT 140
CQ623679
LOCUS         CQ623679 17 bp DNA linear PAT 02-FEB-2004
DEFINITION   Sequence 8419 from Patent WO0192524.
ACCESSION    CQ623679
VERSION      CQ623679.1  GI:41673897
KEYWORDS
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
               Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS     Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
               Shannon, M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 8419 06-DEC-2001;
               Aeomica, Inc. (US)
FEATURES    1. .17
               Location/Qualifiers
               source
               1. .17
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match   1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 414 AGAAGGAGTTCTCA 428
      |||||
Db 1 AGAAGGAGTTCTCA 15

RESULT 141
CQ623680
LOCUS         CQ623680 17 bp DNA linear PAT 02-FEB-2004
DEFINITION   Sequence 8420 from Patent WO0192524.
ACCESSION    CQ623680
VERSION      CQ623680.1  GI:41673898
KEYWORDS
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
               Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS     Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
               Shannon, M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 8420 06-DEC-2001;
               Aeomica, Inc. (US)
FEATURES    1. .17
               Location/Qualifiers
               source
               1. .17
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"
```

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 489 TGAAGAGCGCAGG 503
DB 2 TGAAGAGCGCAGG 16

RESULT 142
LOCUS CO624229/c
DEFINITION Sequence 8969 from Patent WO0192524.
ACCESSION CO624229
VERSION CO624229.1 GI:41674447
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
AUTHORS Gu, Y., Ji, Y., Penn, S. G., Hanzel, D. K., Rank, D. R., Chen, W. and
Shannon, M. E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8969 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1. .17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 852 ACCAGCTCTTCCAAG 866
DB 17 ACCAGCTCTTCCATG 3

RESULT 143
LOCUS I62755/c
DEFINITION Sequence 1 from patent US 5660983.
ACCESSION I62755
VERSION I62755.1 GI:2480463
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Levings, C. S. III and Dewey, R.
TITLE Maize cytoplasmic male sterility type T (cms-T) mitochondria DNA
JOURNAL Patent: US 5660983-A 1 26-AUG-1997;
FEATURES
source
1. .17
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 754 GCGCATGCGAGGCCA 768
DB 17 GCTCATGCGAGGCCA 3

RESULT 144
LOCUS AR192534/c
DEFINITION Sequence 8022 from patent US 6346398.
ACCESSION AR192534
VERSION AR192534.1 GI:20238499
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 8022 12-FEB-2003;
FEATURES
source
1. .17
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 696 AGCTGGAGAGTGAGC 710
DB 16 AGCTGGAGAGGAGC 2

RESULT 145
LOCUS AR286285/c
DEFINITION Sequence 657 from patent US 6528640.
ACCESSION AR286285
VERSION AR286285.1 GI:29723881
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Beigelman, L., Burgin, A., Beaudry, A., Karpelsky, A.,
Matulic-Adamic, J., Sweedler, D. and Zinnen, S.
TITLE Synthetic ribonucleic acids with RNase activity
JOURNAL Patent: US 6528640-A 657 04-MAR-2003;
FEATURES
source
1. .17
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 642 AGGAATGCCAGGCTC 656
DB 16 AGAATGCCAGGCTC 2

RESULT 146
LOCUS AR326403/c
DEFINITION Sequence 3805 from patent US 6566127.
ACCESSION AR326403
VERSION AR326403.1 GI:33712211
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J. A., Stinchcomb, D. T. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 3805 20-MAY-2003;
FEATURES
source
1. .17
Location/Qualifiers
/organism="unknown"

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 696 AGCTGGAGAGTGAGC 710
Db 16 AGCTGGAGAGGAGC 2

RESULT 147
AR398275/c
LOCUS AR398275 17 bp RNA linear PAT 18-DEC-2003
DEFINITION Sequence 656 from patent US 6617438.
ACCESSION AR398275
VERSION AR398275.1 GI:40135951
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Beigelman,L., Burgin,A.B., Beaudry,A., Karpeisky,A.,
Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE Oligoribonucleotides with enzymatic activity
JOURNAL Patent: US 6617438-A 656 09-SEP-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 642 AGGAATGCCAGGCTC 656
Db 16 AGAAATGCCAGGCTC 2

RESULT 148
AR463147/c
LOCUS AR463147 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 6824 from patent US 6686188.
ACCESSION AR463147
VERSION AR463147.1 GI:42698204
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
JOURNAL predominantly in heart and muscle
FEATURES Patent: US 6686188-A 6824 03-FEB-2004;
Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 266 CACCTGCCTTCAGAA 280
Db 16 CACCTGCCTTCAGAA 2

RESULT 149
AR463148/c
LOCUS AR463148 17 bp DNA linear PAT 20-FEB-2004

DEFINITION Sequence 6825 from patent US 6686188.
ACCESSION AR463148
VERSION AR463148.1 GI:42698205
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
JOURNAL predominantly in heart and muscle
FEATURES Patent: US 6686188-A 6825 03-FEB-2004;
Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 266 CACCTGCCTTCAGAA 280
Db 15 CACCTGCCTTCAGAA 1

RESULT 150
AR463571
LOCUS AR463571 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 7248 from patent US 6686188.
ACCESSION AR463571
VERSION AR463571.1 GI:42698628
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
JOURNAL predominantly in heart and muscle
FEATURES Patent: US 6686188-A 7248 03-FEB-2004;
Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 699 TGGAGAGTGAGCGCG 713
Db 1 TGGAGAGTGAGCGGG 15

RESULT 151
AR463771
LOCUS AR463771 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 7448 from patent US 6686188.
ACCESSION AR463771
VERSION AR463771.1 GI:42698828
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
JOURNAL predominantly in heart and muscle
FEATURES Patent: US 6686188-A 7448 03-FEB-2004;

```
FEATURES
  source
    Location/Qualifiers
      1..17
        /organism="unknown"
        /mol_type="genomic DNA"

Query Match
  Best Local Similarity 1.8%; Score 13.4; DB 1; Length 17;
  Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 412 GCAGAGGAGTTCCT 426
Db 3 GCAGAGGAGTTCCT 17

RESULT 152
LOCUS AR463775
DEFINITION Sequence 7452 from patent US 6686188.
ACCESSION AR463775
VERSION AR463775.1 GI:42698832
KEYWORDS
SOURCE
ORGANISM
  Unknown.
REFERENCE
  1 (bases 1 to 17)
  Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
  Shannon, M.E.
  Polynucleotide encoding a human myosin-like polypeptide expressed
  predominantly in heart and muscle
  Patent: US 6686188-A 7452 03-FEB-2004;
  Location/Qualifiers
    1..17
      /organism="unknown"
      /mol_type="genomic DNA"

Query Match
  Best Local Similarity 1.8%; Score 13.4; DB 1; Length 17;
  Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 414 AGAAGGAGTTCCTCA 428
Db 1 AGAAGGAGTTCCTCA 15

RESULT 153
LOCUS AR464742
DEFINITION Sequence 8419 from patent US 6686188.
ACCESSION AR464742
VERSION AR464742.1 GI:42699799
KEYWORDS
SOURCE
ORGANISM
  Unknown.
REFERENCE
  1 (bases 1 to 17)
  Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
  Shannon, M.E.
  Polynucleotide encoding a human myosin-like polypeptide expressed
  predominantly in heart and muscle
  Patent: US 6686188-A 8419 03-FEB-2004;
  Location/Qualifiers
    1..17
      /organism="unknown"
      /mol_type="genomic DNA"

Query Match
  Best Local Similarity 1.8%; Score 13.4; DB 1; Length 17;
  Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 489 TGAAGAGCGAGAAGG 503
Db 3 TGAAGAGCGAGAAGG 17

RESULT 154
LOCUS AR464743
DEFINITION Sequence 8420 from patent US 6686188.
ACCESSION AR464743
VERSION AR464743.1 GI:42699800
KEYWORDS
SOURCE
ORGANISM
  Unknown.
REFERENCE
  1 (bases 1 to 17)
  Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
  Shannon, M.E.
  Polynucleotide encoding a human myosin-like polypeptide expressed
  predominantly in heart and muscle
  Patent: US 6686188-A 8420 03-FEB-2004;
  Location/Qualifiers
    1..17
      /organism="unknown"
      /mol_type="genomic DNA"

Query Match
  Best Local Similarity 1.8%; Score 13.4; DB 1; Length 17;
  Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 489 TGAAGAGCGAGAAGG 503
Db 2 TGAAGAGCGAGAAGG 16

RESULT 155
LOCUS AR465292
DEFINITION Sequence 8969 from patent US 6686188.
ACCESSION AR465292
VERSION AR465292.1 GI:42700349
KEYWORDS
SOURCE
ORGANISM
  Unknown.
REFERENCE
  1 (bases 1 to 17)
  Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
  Shannon, M.E.
  Polynucleotide encoding a human myosin-like polypeptide expressed
  predominantly in heart and muscle
  Patent: US 6686188-A 8969 03-FEB-2004;
  Location/Qualifiers
    1..17
      /organism="unknown"
      /mol_type="genomic DNA"

Query Match
  Best Local Similarity 1.8%; Score 13.4; DB 1; Length 17;
  Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 852 ACCAGCTCTTCCAAG 866
Db 17 ACCAGCTCTTCCATG 3

RESULT 156
LOCUS AX324837
DEFINITION Sequence 975 from Patent WO0192512.
ACCESSION AX324837
VERSION AX324837.1 GI:18095590
KEYWORDS
SOURCE
ORGANISM
  Oryza sativa
  Oryza sativa
  Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
  Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
  Ehrhartoideae; Oryzaceae; Oryza.
```

```
REFERENCE 1
AUTHORS Kniec,E.B., Gamper,H.B., Rice,M.C. and Kim,J.
TITLE Targeted chromosomal genomic alterations in plants using modified
JOURNAL single stranded oligonucleotides
PATENT Patent: WO 0192512-A 975 06-DEC-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES Location/Qualifiers
source 1..17
/organism="Oryza sativa"
/mol_type="unassigned DNA"
/db_xref="taxon:4530"

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 899 GGCAGTGAGCGGAAG 913
Db 1 GGCAGTGAGCGGAAG 15

RESULT 157
LOCUS AX324838 17 bp DNA linear PAT 02-SEP-2002
DEFINITION Sequence 976 from Patent WO0192512.
ACCESSION AX324838
VERSION AX324838.1 GI:18095591
KEYWORDS Oryza sativa
SOURCE Oryza sativa
ORGANISM Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzeae; Oryza.

REFERENCE 1
AUTHORS Kniec,E.B., Gamper,H.B., Rice,M.C. and Kim,J.
TITLE Targeted chromosomal genomic alterations in plants using modified
JOURNAL single stranded oligonucleotides
PATENT Patent: WO 0192512-A 976 06-DEC-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES Location/Qualifiers
source 1..17
/organism="Oryza sativa"
/mol_type="unassigned DNA"
/db_xref="taxon:4530"

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 899 GGCAGTGAGCGGAAG 913
Db 17 GGCAGTGAGCGGAAG 3

RESULT 158
AX729247/c
LOCUS AX729247 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 881 from Patent WO03025175.
ACCESSION AX729247
VERSION AX729247.1 GI:30508590
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
JOURNAL medicines
PATENT Patent: WO 03025175-A 881 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or viral resistance phenomena and their use as
JOURNAL medicines
PATENT Patent: WO 03040369-A 5353 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
JOURNAL thereof as medicaments
PATENT Patent: WO 03025177-A 3896 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 215 GATCAGGACGTACTG 229
Db 1 GATCAGGACGTACTG 15

RESULT 160
AX762032
LOCUS AX762032 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 5353 from Patent WO03040369.
ACCESSION AX762032
VERSION AX762032.1 GI:32256648
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijinder,M.
TITLE Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
JOURNAL medicines
PATENT Patent: WO 03040369-A 5353 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 215 GATCAGGACGTACTG 229
Db 1 GATCAGGACGTACTG 15

RESULT 160
AX762032
LOCUS AX762032 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 5353 from Patent WO03040369.
ACCESSION AX762032
VERSION AX762032.1 GI:32256648
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijinder,M.
TITLE Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
JOURNAL medicines
PATENT Patent: WO 03040369-A 5353 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 215 GATCAGGACGTACTG 229
Db 1 GATCAGGACGTACTG 15
```

Matches	14; Conservative	0; Mismatches	1; Indels	0; Gaps	0;
QY	215	GATCAGGAGTACTG	229		
Db	1	GATCAGGAGTACTG	15		
RESULT 161					
LOCUS	AX782446	17 bp	DNA		
DEFINITION	Sequence 777 from Patent WO03050284.				
ACCESSION	AX782446				
VERSION	AX782446.1	GI:32950295			
KEYWORDS					
SOURCE	Homo sapiens (human)				
ORGANISM	Homo sapiens				
REFERENCE	1				
AUTHORS	Guo,J.				
TITLE	Human prostate cancer candidate protein 1				
JOURNAL	Patent: WO 03050284-A 777 19-JUN-2003;				
FEATURES	Amersham Biosciences (SV) Corp. (US)				
source	Location/Qualifiers				
	1..17				
Query Match	1.8%;	Score 13.4;	DB 1;	Length 17;	
Best Local Similarity	93.3%;	Pred. No. 1.7e+02;			
Matches	14; Conservative	0; Mismatches	1; Indels	0; Gaps	0;
QY	815	GAGAGGAGGAGCTG	829		
Db	3	GTAAGAGGAGGAGCTG	17		
RESULT 162					
LOCUS	AR349716	15 bp	DNA		
DEFINITION	Sequence 11 from patent US 6586183.				
ACCESSION	AR349716				
VERSION	AR349716.1	GI:33750527			
KEYWORDS					
SOURCE	Unknown.				
ORGANISM	Unclassified.				
REFERENCE	1				
AUTHORS	Drysdale,C.M., Judson,R.S., Liggett,S.B., Mandabalan,K., Stack,C.B.				
TITLE	Association of .beta.2-adrenergic receptor haplotypes with drug				
JOURNAL	response				
FEATURES	Patent: US 6586183-A 11 01-JUL-2003;				
source	Location/Qualifiers				
	1..15				
Query Match	1.7%;	Score 13;	DB 1;	Length 15;	
Best Local Similarity	100.0%;	Pred. No. 2.2e+02;			
Matches	13; Conservative	0; Mismatches	0; Indels	0; Gaps	0;
QY	196	CAGTGGTGGCCG	208		
Db	3	CAGTGGTGGCCG	15		
RESULT 163					
LOCUS	AR045387/c	17 bp	DNA		
DEFINITION	Sequence 180 from patent US 5817796.				
ACCESSION	AR045387				
VERSION	AR045387				
KEYWORDS					
SOURCE	Unknown.				
ORGANISM	Unclassified.				
REFERENCE	1				
AUTHORS	Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.				
TITLE	C-myb ribozymes having 2'-5'-linked adenylyate residues				
JOURNAL	Patent: US 5817796-A 182 06-OCT-1998;				
FEATURES	Location/Qualifiers				
source	1..17				
Query Match	1.7%;	Score 13;	DB 1;	Length 17;	
Best Local Similarity	100.0%;	Pred. No. 1.9e+02;			
Matches	13; Conservative	0; Mismatches	0; Indels	0; Gaps	0;
QY	409	GGAGGAGGAGGAG	421		
Db	16	GGAGGAGGAGGAG	4		
RESULT 164					
LOCUS	AR045389	17 bp	DNA		
DEFINITION	Sequence 182 from patent US 5817796.				
ACCESSION	AR045389				
VERSION	AR045389.1	GI:5966854			
KEYWORDS					
SOURCE	Unknown.				
ORGANISM	Unclassified.				
REFERENCE	1				
AUTHORS	Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.				
TITLE	C-myb ribozymes having 2'-5'-linked adenylyate residues				
JOURNAL	Patent: US 5817796-A 182 06-OCT-1998;				
FEATURES	Location/Qualifiers				
source	1..17				
Query Match	1.7%;	Score 13;	DB 1;	Length 17;	
Best Local Similarity	100.0%;	Pred. No. 1.9e+02;			
Matches	13; Conservative	0; Mismatches	0; Indels	0; Gaps	0;
QY	409	GGAGGAGGAGGAG	421		
Db	16	GGAGGAGGAGGAG	4		
RESULT 165					
LOCUS	CQ622502	17 bp	DNA		
DEFINITION	Sequence 7242 from Patent WO0192524.				
ACCESSION	CQ622502				
VERSION	CQ622502.1	GI:41672720			
KEYWORDS					
SOURCE	Homo sapiens (human)				
ORGANISM	Homo sapiens				
REFERENCE	1				
AUTHORS	Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and				
TITLE					

```

Query Match      1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 697 GCTGGAGAGTGAG 709
Db 5 GCTGGAGAGTGAG 17

RESULT 166
LOCUS CO624234/C
DEFINITION Sequence 8974 from Patent WO0192524.
ACCESSION CO624234
VERSION CO624234.1 GI:41674452
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8974 06-DEC-2001;
FEATURES
source 1.17
/organism="Homo sapiens"
/db_xref="taxon:9606"

Query Match      1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 851 CACCAGCTCTTCC 863
Db 13 CACCAGCTCTTCC 1

RESULT 167
LOCUS I52439/C
DEFINITION Sequence 180 from patent US 5646042.
ACCESSION I52439
VERSION I52439.1 GI:2473640
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 180 08-JUL-1997;
FEATURES
source 1.17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match      1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 409 GGAGGAGAGGAG 421
Db 16 GGAGGAGAGGAG 4

RESULT 168
LOCUS I52441/C
DEFINITION Sequence 8974 from Patent WO0192524.
ACCESSION I52441
VERSION I52441.1 GI:2473642
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 182 08-JUL-1997;
FEATURES
source 1.17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match      1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 409 GGAGGAGAGGAG 421
Db 15 GGAGGAGAGGAG 3

RESULT 169
LOCUS AR463565
DEFINITION Sequence 7242 from patent US 6686188.
ACCESSION AR463565
VERSION AR463565.1 GI:42698622
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 7242 03-FEB-2004;
FEATURES
source 1.17
/organism="unknown"
/mol_type="genomic DNA"

Query Match      1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 697 GCTGGAGAGTGAG 709
Db 5 GCTGGAGAGTGAG 17

RESULT 170
LOCUS AR465297/C
DEFINITION Sequence 8974 from patent US 6686188.
ACCESSION AR465297
VERSION AR465297.1 GI:42700354
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8974 03-FEB-2004;
FEATURES
source 1.17

```

```
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 1.7%; Score 13; DB 1; Length 17;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 851 CACCAGCTCTTCC 863
DB 13 CACCAGCTCTTCC 1

RESULT 171
AX046409/c
LOCUS AX046409 17 bp DNA linear PAT 24-NOV-2000
DEFINITION Sequence 76 from Patent WO011168.
ACCESSION AX046409
VERSION AX046409.1 GI:11344379
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Lemischka, I. and Moore, K.
TITLE Genes that regulate hematopoietic blood forming stem cells and uses thereof
JOURNAL Patent: WO 0011168-A 76 02-MAR-2000;
Princeton University (US)
FEATURES
source
1..17
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer"

Query Match
Best Local Similarity 1.7%; Score 13; DB 1; Length 17;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 667 GGCCCGGGGGCC 679
DB 17 GGCCCGGGGGCC 5

RESULT 172
A67075/c
LOCUS A67075 16 bp DNA linear PAT 29-MAR-1999
DEFINITION Sequence 242 from Patent WO9740193.
ACCESSION A67075
VERSION A67075.1 GI:4538446
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Stuyver, L., Rossau, R. and Maertens, G.
TITLE METHOD FOR TYPING AND DETECTING HBV
JOURNAL Patent: WO 9740193-A 242 30-OCT-1997;
INNOGENETICS NV (BE)
FEATURES
source
1..16
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 395 CAAGCCAGCAGGG 410
DB 16 CAAGCCAGCAGTGGG 1

/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Annealed Sequence"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 690 CGCGCAGCTGGAGAG 705
DB 1 CGGCGCAGCTGGAGGG 16

RESULT 174
E33195/c
LOCUS E33195 16 bp DNA linear PAT 18-JUN-2001
DEFINITION Reagent for detecting gene polymorphism of apolipoprotein E gene and alpha-1antichymotrypsin gene and detection method.
ACCESSION E33195
VERSION E33195.1 GI:13022358
KEYWORDS JP 2000050898-A/7.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 16)
AUTHORS Norinobu, K. and Toshiaki, B.
TITLE Reagent for detecting gene polymorphism of apolipoprotein E gene and alpha-1antichymotrypsin gene and detection method
JOURNAL Patent: JP 2000050898-A 7 22-FEB-2000;
NISHIO CORP
COMMENT OS Unidentified
PN JP 2000050898-A/7
PD 22-FEB-2000
PP 06-AUG-1998 JP 1998235033
PR
PI NORINOBU KUSABA, TOSHIAKI BABA
PC C12Q1/68, A61B5/00, C12N15/09, G01N33/566, C12N15/00 CC
Strandedness: Single;
CC Topology: Linear;
FH Key Location/Qualifiers
FT source 1..16 /organism='Unidentified'.
FEATURES
source
1..16
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 373 CTGCGAGGAGCTTCTG 388
DB 373 CTGCGAGGAGCTTCTG 388
```

Db 16 CTCCGAGCGCTTCTG 1

RESULT 175
E52013
LOCUS IL-6 receptor/IL-6 directly fused protein. 16 bp DNA linear PAT 31-JAN-2002
DEFINITION E52013
ACCESSION E52013
VERSION E52013.1 GI:18629574
KEYWORDS JP 2001008690-A/10.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 16)
AUTHORS Ekita,T., Iegame,H., Ida,H., Yasukawa,K., Tsuchiya,S. and Ide,T.
TITLE IL-6 receptor/IL-6 directly fused protein
JOURNAL Patent: JP 2001008690-A 10 16-JAN-2001;
TOSOH CORP
COMMENT OS Artificial Sequence
PN JP 2001008690-A/10
PD 16-JAN-2001
PF 02-JUL-1999 JP 1999188650
PR TEIJI EKITA,HARUO IEGAME,HIROSHI IDA,KIYOSHI YASUKAWA, PI
SHIGEO TSUCHIYA,
PI TERUHIKO IDE
PC C12N15/09,A61K31/00,A61K38/00,C07K14/715,
C07K19/00,
PC C12N1/19,C12P21/02//((C12N1/19,C12R1:84),(C12P21/02,C12R1:84),
C12N15/00,
PC A61K37/02
CC
FH Key Location/Qualifiers
FT source 1..16
FT /organism='Artificial Sequence'.
FEATURES
source 1..16
Location/Qualifiers
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 690 CGCGGCGAGCTGGAGG 705
Db 1 CGGGCGAGCTGGAGG 16
RESULT 176
AR322209/c
LOCUS AR322209 16 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 18 from patent US 6566064.
ACCESSION AR322209
VERSION AR322209.1 GI:33707773
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Shiraki,M., Ouchi,Y., Hosoi,T., Kusaba,N., Baba,T. and Yoshida,H.
TITLE Method for anticipating sensitivity to medicine for osteoporosis
JOURNAL Patent: US 6566064-A 18 20-MAY-2003;
FEATURES
source 1..16
Location/Qualifiers
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 749 CAGCTCGCATGCAGG 764
Db 16 CAGATGAGCATGCAGG 1
RESULT 179
AX804969/c
LOCUS AX804969 16 bp DNA linear PAT 25-NOV-2003
DEFINITION Sequence 1137 from Patent WO03060160.
ACCESSION AX804969
VERSION AX804969.1 GI:38522110
KEYWORDS

QY 373 CTCCGAGGAGCTTCTG 388
Db 16 CTGCCAGGCGCTTCTG 1

RESULT 177
AR488577/c
LOCUS AR488577 16 bp DNA linear PAT 15-MAY-2004
DEFINITION Sequence 242 from patent US 6709812.
ACCESSION AR488577
VERSION AR488577.1 GI:47254629
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Stuyver,L., Rossau,R. and Maertens,G.
TITLE Method for typing and detecting HBV
JOURNAL Patent: US 6709812-A 242 23-MAR-2004;
FEATURES
source 1..16
Location/Qualifiers
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 395 CAAGCCAGCCAGAGGG 410
Db 16 CAAGCCAGACAGTGGG 1

RESULT 178
AX128605/c
LOCUS AX128605 16 bp DNA linear PAT 15-MAY-2001
DEFINITION Sequence 5 from Patent WO0130989.
ACCESSION AX128605
VERSION AX128605.1 GI:14135067
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Renner,W.A. and Nieba,L.
TITLE Method for creating divergent populations of nucleic acid molecules
JOURNAL Patent: WO 0130989-A 5 03-MAY-2001;
Cytos Biotechnology AG (CH) ; Renner, Wolfgang Andreas (CH) ;
Nieba, Lars (CH)
FEATURES
source 1..16
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="primer"
Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 749 CAGCTCGCATGCAGG 764
Db 16 CAGATGAGCATGCAGG 1

RESULT 179
AX804969/c
LOCUS AX804969 16 bp DNA linear PAT 25-NOV-2003
DEFINITION Sequence 1137 from Patent WO03060160.
ACCESSION AX804969
VERSION AX804969.1 GI:38522110
KEYWORDS

```

SOURCE      Oreochromis niloticus (Nile tilapia)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
            Acanthopterygii; Acanthopterygii; Perciformes; Perciformes;
            Labroidae; Cichlidae; Oreochromis.

REFERENCE   Lie,Y., Slettan,A., Hoeyum,M. and Lingaas,F.
AUTHORS    Verification of food origin based on nucleic acid pattern
TITLE      recognition
JOURNAL    Patent: WO 03060160-A 1137 24-JUL-2003;
            Genomar ASA (NO)

FEATURES   Location/Qualifiers
            source
            1..16
            /organism="Oreochromis niloticus"
            /mol_type="unassigned DNA"
            /db_xref="taxon:8128"

Query Match      1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      622 TCGCTTGGAGGCTGCC 637
Db      16 TTGCTGGAGACTGCC 1

RESULT 180
BD083852/c
LOCUS     16 bp      DNA      linear      PAT 27-AUG-2002
DEFINITION Method for predicting sensitivity to osteoporosis drug and reagent
            kit therefor.
ACCESSION BD083852
VERSION   BD083852.1 GI:22629462
KEYWORDS  JP 2001333799-A/18.
SOURCE    Homo sapiens (human)
ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
            1 (bases 1 to 16)
AUTHORS   Shiraki,M., Ouchi,Y. and Hosoi,T.
TITLE     Method for predicting sensitivity to osteoporosis drug and reagent
            kit therefor
JOURNAL   Patent: JP 2001333799-A 18 04-DEC-2001;
            NISSHO CORP

COMMENT   OS Homo sapiens (human)
            PN JP 2001333799-A/18
            PD 04-DEC-2001
            PF 26-MAY-2000 JP 2000155993
            PI MASATAKA SHIRAKI,YASUYOSHI OUCHI,TAKAYUKI HOSOI PC
            C12Q1/68,C12N15/09,G01N33/53,G01N33/566,C12N15/00 CC A part of
            the base sequence of apolipoprotein E gene FH Key
            Location/Qualifiers
            FT source      1..16
            /organism="Homo sapiens (human)"

FEATURES   Location/Qualifiers
            source
            1..16
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"

Query Match      1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      373 CTGCGAGGAGCTTCTG 388
Db      16 CTGCCAGGCGTCTCTG 1

RESULT 181
BD083870/c
LOCUS     16 bp      DNA      linear      PAT 27-AUG-2002
DEFINITION Method for predicting sensitivity to osteoporosis drug and reagent
            kit therefor.
ACCESSION BD083870
VERSION   BD083870.1 GI:22629480
KEYWORDS  JP 2001333798-A/5.
SOURCE    Homo sapiens (human)
ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
            1 (bases 1 to 16)
AUTHORS   Kusaba,N., Baba,T. and Yoshida,H.
TITLE     Reagent and method for the simultaneous detection of gene
            polymorphisms in vitamin D receptor gene, apolipoprotein E gene and
            estrogen receptor gene
JOURNAL   Patent: JP 2001333798-A 5 04-DEC-2001;
            NISSHO CORP

COMMENT   OS Homo sapiens (human)
            PN JP 2001333798-A/5
            PD 04-DEC-2001
            PF 26-MAY-2000 JP 2000155871
            PI NORINOBU KUSABA,TOSHITAKI BABA,HIROSHI YOSHIDA PC
            C12Q1/68,A61K45/00,A61P19/08,C12N15/09,G01N33/15,G01N33/50, PC
            G01N33/53.
            PC G01N33/566,C12N15/00
            CC Part of base sequence of apolipoprotein E gene FH Key
            Location/Qualifiers
            FT source      1..16
            /organism="Homo sapiens (human)"

FEATURES   Location/Qualifiers
            source
            1..16
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      373 CTGCGAGGAGCTTCTG 388
Db      16 CTGCCAGGCGTCTCTG 1

RESULT 182
BD083870/c
LOCUS     17 bp      DNA      linear      PAT 10-DEC-1993
DEFINITION EBI 782.
ACCESSION AL2195
VERSION   AL2195.1 GI:491298
KEYWORDS  JP 2001333798-A/5.
SOURCE    Homo sapiens (human)
ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
            1 (bases 1 to 17)
AUTHORS   Heckl,K., Spevak,W., Ostermann,E., Zoepfel,A., Krystek,E.,
            Maurer-Fogy,I., Wiche-Castanon,M.J., Stratowa,C. and Hauptmann,R.
            Human manganese superoxide dismutase (hMn-SOD)
            Patent: EP 0282899-A 18 21-SEP-1988;
            BOEHRINGER INGELHEIM INTERNATIONAL GmbH
            Location/Qualifiers
            FT source      1..17
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      373 CTGCGAGGAGCTTCTG 388
Db      16 CTGCCAGGCGTCTCTG 1

```


RESULT 183
A34251
LOCUS A34251 17 bp DNA linear PAT 03-JUL-2002
DEFINITION Synthetic sequencing primer.
ACCESSION A34251
VERSION A34251.1 GI:21694203
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Odink,K.G., Tarcsey,L., Brueggen,J., Wiesendanger,W., Cerletti,N.,
Sorg,C., DeWolf-Peters,C. and Delabie,J.
TITLE Novel cytokines
JOURNAL Patent: EP 0412050-A 11 06-FEB-1991;
CIBA-GEIGY AG
FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 438 TCCAGGAGGCCAGGAA 453
Db 1 TCCAGGAGGCCCTGAA 16
RESULT 184
AR045383/c
LOCUS AR045383 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 176 from patent US 5817796.
ACCESSION AR045383
VERSION AR045383.1 GI:5966848
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb ribozymes having 2'-5'-linked adenylate residues
JOURNAL Patent: US 5817796-A 176 06-OCT-1998;
FEATURES
source
1. .17
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 405 AGAGGGAGGAGAGGA 420
Db 17 AGAAGGAGGAGGAGGA 2
RESULT 185
AR057435
LOCUS AR057435 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1639 from patent US 5837542.
ACCESSION AR057435
VERSION AR057435.1 GI:5983012
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and

Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 1639 17-NOV-1998;
FEATURES
source
1. .17
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 461 GAGAGACTCGGCTGG 476
Db 1 GAGAACCTCGGCTGG 16
RESULT 186
AR057586
LOCUS AR057586 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1790 from patent US 5837542.
ACCESSION AR057586
VERSION AR057586.1 GI:5983163
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 1790 17-NOV-1998;
FEATURES
source
1. .17
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 461 GAGAGACTCGGCTGG 476
Db 1 GAGAACCTCGGCTGG 16
RESULT 187
AR057597
LOCUS AR057597 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1801 from patent US 5837542.
ACCESSION AR057597
VERSION AR057597.1 GI:5983174
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 1801 17-NOV-1998;
FEATURES
source
1. .17
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 461 GAGAGACTCGGCTGG 476
Db 1 GAGAACCTCGGCTGG 16
RESULT 188
AR057597
LOCUS AR057597 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1801 from patent US 5837542.
ACCESSION AR057597
VERSION AR057597.1 GI:5983174
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 1801 17-NOV-1998;
FEATURES
source
1. .17
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 461 GAGAGACTCGGCTGG 476
Db 1 GAGAACCTCGGCTGG 16

```
RESULT 188
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
    AR057619
    Sequence 1823 from patent US 5837542.
    AR057619
    AR057619.1 GI:5983196
    Unknown.
    SOURCE
    ORGANISM
    Unclassified.
    1 (bases 1 to 17)
    Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
    Draper,K.G.
    Intercellular adhesion molecule-1 (ICAM-1) ribozymes
    Patent: US 5837542-A 1823 17-NOV-1998;
    Location/Qualifiers
    1..17
    /organism="unknown"
    /mol_type="unassigned DNA"
    Query Match
    Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
    Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 461 GAGAGACTCGGCTGG 476
Db 1 GAGAACCTCGGCTGG 16

RESULT 189
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
    AR057664
    Sequence 1868 from patent US 5837542.
    AR057664
    AR057664.1 GI:5983241
    Unknown.
    SOURCE
    ORGANISM
    Unclassified.
    1 (bases 1 to 17)
    Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
    Draper,K.G.
    Intercellular adhesion molecule-1 (ICAM-1) ribozymes
    Patent: US 5837542-A 1868 17-NOV-1998;
    Location/Qualifiers
    1..17
    /organism="unknown"
    /mol_type="unassigned DNA"
    Query Match
    Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
    Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 461 GAGAGACTCGGCTGG 476
Db 1 GAGAACCTCGGCTGG 16

RESULT 190
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
    AR115193
    Sequence 1639 from patent US 6132967.
    AR115193
    AR115193.1 GI:14095515
    Unknown.
    SOURCE
    ORGANISM
    Unclassified.
    1 (bases 1 to 17)
    Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
    Draper,K.G.
    Intercellular adhesion molecule-1 (ICAM-1) ribozymes
    Patent: US 6132967-A 1639 17-OCT-2000;
    Location/Qualifiers
    1..17
    /organism="unknown"
    /mol_type="unassigned DNA"
    Query Match
    Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
    Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 461 GAGAGACTCGGCTGG 476
Db 1 GAGAACCTCGGCTGG 16

RESULT 191
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
    AR115344
    Sequence 1790 from patent US 6132967.
    AR115344
    AR115344.1 GI:14095666
    Unknown.
    SOURCE
    ORGANISM
    Unclassified.
    1 (bases 1 to 17)
    Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
    Draper,K.G.
    Ribozyme treatment of diseases or conditions related to levels of
    intercellular adhesion molecule-1 (ICAM-1)
    Patent: US 6132967-A 1790 17-OCT-2000;
    Location/Qualifiers
    1..17
    /organism="unknown"
    /mol_type="unassigned DNA"
    Query Match
    Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
    Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 461 GAGAGACTCGGCTGG 476
Db 1 GAGAACCTCGGCTGG 16

RESULT 192
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
    AR115355
    Sequence 1801 from patent US 6132967.
    AR115355
    AR115355.1 GI:14095677
    Unknown.
    SOURCE
    ORGANISM
    Unclassified.
    1 (bases 1 to 17)
    Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
    Draper,K.G.
    Ribozyme treatment of diseases or conditions related to levels of
    intercellular adhesion molecule-1 (ICAM-1)
    Patent: US 6132967-A 1801 17-OCT-2000;
    Location/Qualifiers
    1..17
    /organism="unknown"
    /mol_type="unassigned DNA"
    Query Match
    Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
    Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 461 GAGAGACTCGGCTGG 476
Db 1 GAGAACCTCGGCTGG 16

RESULT 193
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
    AR115355
    Sequence 1801 from patent US 6132967.
    AR115355
    AR115355.1 GI:14095677
    Unknown.
    SOURCE
    ORGANISM
    Unclassified.
    1 (bases 1 to 17)
    Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
    Draper,K.G.
    Ribozyme treatment of diseases or conditions related to levels of
    intercellular adhesion molecule-1 (ICAM-1)
    Patent: US 6132967-A 1801 17-OCT-2000;
    Location/Qualifiers
    1..17
    /organism="unknown"
    /mol_type="unassigned DNA"
    Query Match
    Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
    Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 461 GAGAGACTCGGCTGG 476
Db 1 GAGAACCTCGGCTGG 16
```

```

Db          1  GAGAACTCGGCGCTGG 16
||||| ||||| ||||| ||||| |||||
RESULT 193
AR115377  AR115377  17 bp  DNA  linear  PAT 16-MAY-2001
LOCUS      Sequence 1823 from patent US 6132967.
DEFINITION AR115377
ACCESSION  AR115377
VERSION    AR115377.1 GI:14095699
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 17)
AUTHORS    Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
           Draper,K.G.
TITLE      Ribozyme treatment of diseases or conditions related to levels of
           intercellular adhesion molecule-1 (ICAM-1)
JOURNAL    Patent: US 6132967-A 1823 17-OCT-2000;
FEATURES   Location/Qualifiers
            source          1..17
                        /organism="unknown"
                        /mol_type="unassigned DNA"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 461 GAGAACTCGGCGCTGG 476
||||| ||||| ||||| ||||| |||||
Db          1  GAGAACTCGGCGCTGG 16

RESULT 194
AR115422  AR115422  17 bp  DNA  linear  PAT 16-MAY-2001
LOCUS      Sequence 1868 from patent US 6132967.
DEFINITION AR115422
ACCESSION  AR115422
VERSION    AR115422.1 GI:14095744
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 17)
AUTHORS    Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
           Draper,K.G.
TITLE      Ribozyme treatment of diseases or conditions related to levels of
           intercellular adhesion molecule-1 (ICAM-1)
JOURNAL    Patent: US 6132967-A 1868 17-OCT-2000;
FEATURES   Location/Qualifiers
            source          1..17
                        /organism="unknown"
                        /mol_type="unassigned DNA"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 461 GAGAACTCGGCGCTGG 476
||||| ||||| ||||| ||||| |||||
Db          1  GAGAACTCGGCGCTGG 16

RESULT 195
AR164573  AR164573  17 bp  DNA  linear  PAT 17-OCT-2001
LOCUS      Sequence 6 from patent US 6274310.
DEFINITION AR164573
ACCESSION  AR164573
VERSION    AR164573.1 GI:16237643
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 17)
AUTHORS    Habener,J.F. and Stoffers,D.A.
TITLE      Compositions and methods for detecting pancreatic disease
JOURNAL    Patent: US 6274310-A 6 14-AUG-2001;
FEATURES   Location/Qualifiers
            source          1..17
                        /organism="unknown"
                        /mol_type="unassigned DNA"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 680 AGCGAGCAGCGCGGC 695
||||| ||||| ||||| ||||| |||||
Db          1  AGCGAGCAGCGGAGGC 16

RESULT 196
BD197639/c
LOCUS      BD197639
DEFINITION Method and reagent for treating diseases or conditions concerning
           molecule participating in vasculogenic response.
ACCESSION  BD197639
VERSION    BD197639.1 GI:33007409
KEYWORDS   JP 2002509721-A/665.
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
           1 (bases 1 to 17)

REFERENCE  1 (bases 1 to 17)
AUTHORS    Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
TITLE      Method and reagent for treating diseases or conditions concerning
           molecule participating in vasculogenic response
JOURNAL    Patent: JP 2002509721-A 665 02-APR-2002;
           RIBOZYME PHARMACEUTICALS INC
COMMENT    OS Homo sapiens (human)
           PN JP 2002509721-A/665
           PD 02-APR-2002
           PF 24-MAR-1999 JP 2000541291
           PR 27-MAR-1998 US 60/079678
           PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
           FI JAMES A MCSWIGGEN
           PC C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
           A61P29/00,
           PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
           C12N5/00
           CC Method and reagent for treating diseases or conditions CC
           concerning molecule
           CC participating in vasculogenic response
           PH Key Location/Qualifiers
           FT source          1..17
                        /organism="Homo sapiens (human)".
           FT Location/Qualifiers
            source          1..17
                        /organism="Homo sapiens"
                        /mol_type="genomic RNA"
                        /db_xref="taxon:9606"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 542 CAGCAGCAGATGGCTG 557
||||| ||||| ||||| ||||| |||||
Db          17  CAGACGCTGATGGCTG 2

RESULT 197
BD200587/c
LOCUS      BD200587
DEFINITION 17 bp RNA linear PAT 17-JUL-2003

```

```

DEFINITION      Method and reagent for treating diseases or conditions concerning
ACCESSION       BD200587
VERSION         BD200587.1  GI:33010357
KEYWORDS        JP 2002509721-A/3613.
SOURCE          Homo sapiens (human)
ORGANISM        Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE       1 (bases 1 to 17)
AUTHORS        Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
TITLE          Method and reagent for treating diseases or conditions concerning
                molecule participating in vasculogenic response
JOURNAL        Patent: JP 2002509721-A 3613 02-APR-2002;
COMMENT        RIBOZYME PHARMACEUTICALS INC
                OS Homo sapiens (human)
                PN JP 2002509721-A/3613
                PD 02-APR-2002
                PF 24-MAR-1999 JP 2000541291
                PR 27-MAR-1998 US 60/079678
                PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
                PJ JAMES A MCSWIGGEN
                PC
C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
concerning molecule
CC participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1..17
FT /organism='Homo sapiens (human)'.
FEATURES
source
Query Match 1..7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 676 GCCCAGCGGAGCGGC 691
DB 16 GCCCAGCGGAGAGCGC 1
RESULT 198
BD202923/c
LOCUS
DEFINITION      Method and reagent for treating diseases or conditions concerning
ACCESSION       BD202923
VERSION         BD202923.1  GI:33012693
KEYWORDS        JP 2002509721-A/5949.
SOURCE          Homo sapiens (human)
ORGANISM        Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE       1 (bases 1 to 17)
AUTHORS        Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
TITLE          Method and reagent for treating diseases or conditions concerning
                molecule participating in vasculogenic response
JOURNAL        Patent: JP 2002509721-A 5949 02-APR-2002;
COMMENT        RIBOZYME PHARMACEUTICALS INC
                OS Homo sapiens (human)
                PN JP 2002509721-A/5949
                PD 02-APR-2002
                PF 24-MAR-1999 JP 2000541291
                PR 27-MAR-1998 US 60/079678
                PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
                PJ JAMES A MCSWIGGEN

```

```

PC C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
concerning molecule
CC participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1..17
FT /organism='Homo sapiens (human)'.
FEATURES
source
Query Match 1..7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 493 GAGCGCAGGAGGAGCAG 508
DB 16 GAGCGCAGAGTTGCAG 1
RESULT 199
BD241701
LOCUS
DEFINITION      Methods and products related to genotyping and DNA analysis.
ACCESSION       BD241701
VERSION         BD241701.1  GI:33051471
KEYWORDS        JP 2002525127-A/648.
SOURCE          Homo sapiens (human)
ORGANISM        Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE       1 (bases 1 to 17)
AUTHORS        Landers,J.E., Jordan,B., Housman,D.E. and Charest,A.
TITLE          Methods and products related to genotyping and DNA analysis
JOURNAL        Patent: JP 2002525127-A 648 13-AUG-2002;
                MASSACHUSETTS INSTITUTE OF TECHNOLOGY
COMMENT        OS Homo sapiens (human)
                PN JP 2002525127-A/648
                PD 13-AUG-2002
                PF 24-SEP-1999 JP 2000572407
                PR 25-SEP-1998 US 60/101757
                PI JOHN E LANDERS,BARBARA JORDAN,DAVID E HOUSMAN,ALAIN CHAREST PC
                C12N15/09,C12Q1/68,G01N33/53,G01N33/566,G01N33/58,G01N37/00, PC
                G01N37/00,
                PC C12N15/00
                CC Methods and products related to genotyping and DNA analysis FH
                FT source 1..17
                FT /organism='Homo sapiens (human)'.
FEATURES
source
Query Match 1..7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 397 ACCCAGCGCAGGAGGAG 412
DB 1 AGGCAGCTAGAGGAGGAG 16
RESULT 200
BD254084/c
LOCUS

```

DEFINITION Regulation of repressor genes using nucleic acid molecules.
 ACCESSION BD254084
 VERSION BD254084.1 GI:33063854
 KEYWORDS JP 2002541795-A/1877.
 SOURCE unidentified
 ORGANISM unclassified

REFERENCE 1 (bases 1 to 17)
 AUTHORS Blatt, L., Zwick, M., Pavco, P. and Mcswiggen, J.
 TITLE Regulation of repressor genes using nucleic acid molecules
 JOURNAL Patent: JP 2002541795-A 1877 10-DEC-2002;
 RIBOZYME PHARMACEUTICALS INC

COMMENT OS Eukaryote
 PN JP 2002541795-A/1877
 PD 10-DEC-2002
 PF 11-APR-2000 JP 2000611654
 PR 12-APR-1999 US 60/129390
 PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
 C12N15/09, A61K38/00, A61K48/00, A61P43/00, A61P43/00, C12N5/10, PC
 C12P21/02.

PC C12P21/02, C12P21/02//A61K31/71.1, (C12N5/10, C12R1:91), (C12P21/02, PC
 C12R1:91)
 PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,
 PC A61K37/02,
 PC (C12N5/00, C12R1:91)
 CC Regulation of repressor genes using nucleic acid molecules FH
 KEY Location/Qualifiers
 FT source 1..17
 FT /organism='Eukaryote'.
 FEATURES source
 1..17
 /organism='unidentified'
 /mol_type='genomic DNA'
 /db_xref='taxon:32644'

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 458 GTGGAGAGACTCGGCC 473
 Db 16 GGGAGGGAGCTCGGCC 1

RESULT 201
 BD254283/c
 LOCUS
 DEFINITION Regulation of repressor genes using nucleic acid molecules.
 ACCESSION BD254283
 VERSION BD254283.1 GI:33064053
 KEYWORDS JP 2002541795-A/2076.
 SOURCE unidentified
 ORGANISM unclassified

REFERENCE 1 (bases 1 to 17)
 AUTHORS Blatt, L., Zwick, M., Pavco, P. and Mcswiggen, J.
 TITLE Regulation of repressor genes using nucleic acid molecules
 JOURNAL Patent: JP 2002541795-A 2076 10-DEC-2002;
 RIBOZYME PHARMACEUTICALS INC

COMMENT OS Eukaryote
 PN JP 2002541795-A/2076
 PD 10-DEC-2002
 PF 11-APR-2000 JP 2000611654
 PR 12-APR-1999 US 60/129390
 PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
 C12N15/09, A61K38/00, A61K48/00, A61P43/00, A61P43/00, C12N5/10, PC
 C12P21/02,
 PC C12P21/02, C12P21/02//A61K31/71.1, (C12N5/10, C12R1:91), (C12P21/02, PC
 C12R1:91)
 PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,
 PC A61K37/02,

PC (C12N5/00, C12R1:91)
 CC Regulation of repressor genes using nucleic acid molecules FH
 KEY Location/Qualifiers
 FT source 1..17
 FT /organism='Eukaryote'.
 FEATURES source
 1..17
 /organism='unidentified'
 /mol_type='genomic DNA'
 /db_xref='taxon:32644'

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 812 GAGGAGAGAGGAGC 827
 Db 17 GAGGAGAGAGGGTGC 2

RESULT 202
 BD254816/c
 LOCUS
 DEFINITION Regulation of repressor genes using nucleic acid molecules.
 ACCESSION BD254816
 VERSION BD254816.1 GI:33064586
 KEYWORDS JP 2002541795-A/2609.
 SOURCE unidentified
 ORGANISM unclassified

REFERENCE 1 (bases 1 to 17)
 AUTHORS Blatt, L., Zwick, M., Pavco, P. and Mcswiggen, J.
 TITLE Regulation of repressor genes using nucleic acid molecules
 JOURNAL Patent: JP 2002541795-A 2609 10-DEC-2002;
 RIBOZYME PHARMACEUTICALS INC

COMMENT OS Eukaryote
 PN JP 2002541795-A/2609
 PD 10-DEC-2002
 PF 11-APR-2000 JP 2000611654
 PR 12-APR-1999 US 60/129390
 PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
 C12N15/09, A61K38/00, A61K48/00, A61P43/00, A61P43/00, C12N5/10, PC
 C12P21/02,
 PC C12P21/02, C12P21/02//A61K31/71.1, (C12N5/10, C12R1:91), (C12P21/02, PC
 C12R1:91)
 PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,
 PC A61K37/02,
 PC (C12N5/00, C12R1:91)
 CC Regulation of repressor genes using nucleic acid molecules FH
 KEY Location/Qualifiers
 FT source 1..17
 FT /organism='Eukaryote'.
 FEATURES source
 1..17
 /organism='unidentified'
 /mol_type='genomic DNA'
 /db_xref='taxon:32644'

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 510 CTCGCGGGAGGTGGA 525
 Db 17 CTCGCGGGAGGGCGGA 2

RESULT 203
 BD257476/c
 LOCUS
 DEFINITION Regulation of repressor genes using nucleic acid molecules.
 ACCESSION BD257476

```

VERSION      BD257476.1 GI:33067246
KEYWORDS     JP 2002541795-A/5269.
SOURCE       unidentifed
ORGANISM     unidentifed
REFERENCE    1 (bases 1 to 17)
AUTHORS     Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE       Regulation of repressor genes using nucleic acid molecules
JOURNAL     Patent: JP 2002541795-A 5269 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS Eukaryote
            PN JP 2002541795-A/5269
            PD 10-DEC-2002
            PF 11-APR-2000 JP 2000611654
            PR 12-APR-1999 US 60/129390
            PI LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
            C12R1:91),
            PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC A61K37/02,
            PC (C12N5/00,C12R1:91)
            CC Regulation of repressor genes using nucleic acid molecules FH
            Key
            FT source 1..17
            FT Location/Qualifiers
            /organism='Eukaryote'.
            /organism="unidentified"
            /mol_type="genomic DNA"
            /db_xref="taxon:32644"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 811 GGAGGAGAGAGGAG 826
Db 16 GGAGGGGAGAGGGGAG 1

RESULT 204
LOCUS      BD272834
DEFINITION Cancer-susceptible mutation in BRCA2.
ACCESSION  BD272834
VERSION     JP 2002533054-A/3.
KEYWORDS   Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 17)
AUTHORS     Lescalliet,J.L., Lawrence,T., Allen,A.P., Olson,S.J., Thurber,D.B.
            and White,M.B.
TITLE       Cancer-susceptible mutation in BRCA2
JOURNAL     Patent: JP 2002533054-A 3 08-OCT-2002;
            GENE LOGIC INC
COMMENT     OS Homo sapiens (human)
            PN JP 2002533054-A/3
            PD 08-OCT-2002
            PF 02-DEC-1998 JP 2000523381
            PR 02-DEC-1997 US 08/984034
            PI JENNIFER L LESCALLETT,TAMMY LAWRENCE,ANTONETTE P ALLEN,SHERI J
            OLSON,
            PI DENISE B THURBER,MARGA B WHITE
            PC C12N15/09,C12N15/09,C12M1/00,C12Q1/68,C12Q1/68,G01N33/53, PC
            G01N37/00,
            PC C12N15/00,C12N15/00
            CC Cancer-susceptible mutation in BRCA2

FEATURES             source
            source
            FH Key Location/Qualifiers
            FT source 1..17
            /organism='Homo sapiens (human)'.
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"

FEATURES             source
            source
            QY 166 GAAGAGCCCAACTGTGT 181
            Db 2 GAAGAACCACACTTTGT 17

RESULT 205
LOCUS      CQ615614/c
DEFINITION Sequence 354 from Patent WO0192524.
ACCESSION  CQ615614
VERSION     CQ615614.1 GI:41665832
KEYWORDS   Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS     Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 354 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES     source
            source 1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 482 CTCGATCTCGAGAGGC 497
Db 17 CTCGTTCTGGAGAGGC 2

RESULT 206
LOCUS      CQ615615/c
DEFINITION Sequence 355 from Patent WO0192524.
ACCESSION  CQ615615
VERSION     CQ615615.1 GI:41665833
KEYWORDS   Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS     Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 355 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES     source
            source 1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

```

```

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 482 CTCGATCTGAGAGGC 497
Db 16 CTCGTTCTGGAGAGC 1

RESULT 207
CO615932/c
LOCUS          17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION     Sequence 672 from Patent WO0192524.
ACCESSION      CO615932
VERSION        CO615932.1 GI:41666150
KEYWORDS       Homo sapiens (human)
ORGANISM       Homo sapiens
REFERENCE      1
AUTHORS       Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
              Shannon, M.E.
TITLE         Myosin-like gene expressed in human heart and muscle
JOURNAL       Patent: WO 0192524-A 672 06-DEC-2001;
              Aeomica, Inc. (US)
FEATURES       Location/Qualifiers
               source
               1..17
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 233 GAAGAGTCTCTCTGG 248
Db 17 GATGAGTCTTCTCTGG 2

RESULT 208
CO615933/c
LOCUS          17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION     Sequence 673 from Patent WO0192524.
ACCESSION      CO615933
VERSION        CO615933.1 GI:41666151
KEYWORDS       Homo sapiens (human)
ORGANISM       Homo sapiens
REFERENCE      1
AUTHORS       Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
              Shannon, M.E.
TITLE         Myosin-like gene expressed in human heart and muscle
JOURNAL       Patent: WO 0192524-A 673 06-DEC-2001;
              Aeomica, Inc. (US)
FEATURES       Location/Qualifiers
               source
               1..17
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 233 GAAGAGTCTCTCTGG 248
Db 16 GATGAGTCTTCTCTGG 1

RESULT 209
CO616783/c
LOCUS          17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION     Sequence 1523 from Patent WO0192524.
ACCESSION      CO616783
VERSION        CO616783.1 GI:41667001
KEYWORDS       Homo sapiens (human)
ORGANISM       Homo sapiens
REFERENCE      1
AUTHORS       Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
              Shannon, M.E.
TITLE         Myosin-like gene expressed in human heart and muscle
JOURNAL       Patent: WO 0192524-A 1523 06-DEC-2001;
              Aeomica, Inc. (US)
FEATURES       Location/Qualifiers
               source
               1..17
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 846 CCTATCACCAGCTCTT 861
Db 17 CCATCACCCTGCTCTT 2

RESULT 210
CO616784/c
LOCUS          17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION     Sequence 1524 from Patent WO0192524.
ACCESSION      CO616784
VERSION        CO616784.1 GI:41667002
KEYWORDS       Homo sapiens (human)
ORGANISM       Homo sapiens
REFERENCE      1
AUTHORS       Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
              Shannon, M.E.
TITLE         Myosin-like gene expressed in human heart and muscle
JOURNAL       Patent: WO 0192524-A 1524 06-DEC-2001;
              Aeomica, Inc. (US)
FEATURES       Location/Qualifiers
               source
               1..17
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 846 CCTATCACCAGCTCTT 861
Db 16 CCATCACCCTGCTCTT 1

RESULT 211
CO616980/c
LOCUS          17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION     Sequence 1720 from Patent WO0192524.
ACCESSION      CO616980
VERSION        CO616980.1 GI:41667198
KEYWORDS       Homo sapiens (human)
ORGANISM       Homo sapiens

```

```

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS    Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
            Shannon, M.E.
TITLE      Myosin-like gene expressed in human heart and muscle
JOURNAL    Patent: WO 0192524-A 1720 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES   Location/Qualifiers
            source
              1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 392 TTCCAGCCGCGCAGA 407
Db 17 TTCTGAGCGCGCAGA 2

RESULT 212
CQ616981/c
LOCUS      CQ616981
DEFINITION Sequence 1721 from Patent WO0192524.
ACCESSION CQ616981
VERSION   CQ616981.1 GI:41667199
KEYWORDS  Homo sapiens (human)
SOURCE    Homo sapiens
ORGANISM  Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS    Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
            Shannon, M.E.
TITLE      Myosin-like gene expressed in human heart and muscle
JOURNAL    Patent: WO 0192524-A 1721 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES   Location/Qualifiers
            source
              1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 392 TTCCAGCCGCGCAGA 407
Db 16 TTCTGAGCGCGCAGA 1

RESULT 213
CQ617256/c
LOCUS      CQ617256
DEFINITION Sequence 1996 from Patent WO0192524.
ACCESSION CQ617256
VERSION   CQ617256.1 GI:41667474
KEYWORDS  Homo sapiens (human)
SOURCE    Homo sapiens
ORGANISM  Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS    Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
            Shannon, M.E.
TITLE      Myosin-like gene expressed in human heart and muscle
JOURNAL    Patent: WO 0192524-A 1996 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES   Location/Qualifiers

```

```

source
  1..17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 309 GCCTGGAGGAGCAATCA 324
Db 17 GCCTGGAGGAGCAATCA 2

RESULT 214
CQ617257/c
LOCUS      CQ617257
DEFINITION Sequence 1997 from Patent WO0192524.
ACCESSION CQ617257
VERSION   CQ617257.1 GI:41667475
KEYWORDS  Homo sapiens (human)
SOURCE    Homo sapiens
ORGANISM  Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS    Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
            Shannon, M.E.
TITLE      Myosin-like gene expressed in human heart and muscle
JOURNAL    Patent: WO 0192524-A 1997 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES   Location/Qualifiers
            source
              1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 309 GCCTGGAGGAGCAATCA 324
Db 16 GCCTGGAGGAGCAATCA 1

RESULT 215
CQ622082/c
LOCUS      CQ622082
DEFINITION Sequence 6822 from Patent WO0192524.
ACCESSION CQ622082
VERSION   CQ622082.1 GI:41672300
KEYWORDS  Homo sapiens (human)
SOURCE    Homo sapiens
ORGANISM  Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS    Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
            Shannon, M.E.
TITLE      Myosin-like gene expressed in human heart and muscle
JOURNAL    Patent: WO 0192524-A 6822 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES   Location/Qualifiers
            source
              1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```



```
Shannon,M.E.
Myosin-like gene expressed in human heart and muscle
Patent: WO 0192524-A 7697 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
    source
        1..17
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 828 TGGCCAGTTCGAGGT 843
Db 17 TGGCCAGTTCGAGGT 2

RESULT 221
LOCUS CQ622959/c 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 7699 from Patent WO0192524.
ACCESSION CQ622959
VERSION CQ622959.1 GI:41673177
KEYWORDS Homo sapiens (human)
SOURCE Aeomica, Inc. (US)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 7699 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
    source
        1..17
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 827 CTGGCCAGTTCGAGG 842
Db 16 CTGGCCAGTTCGAGG 1

RESULT 222
LOCUS CQ623072 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 7812 from Patent WO0192524.
ACCESSION CQ623072
VERSION CQ623072.1 GI:41673290
KEYWORDS Homo sapiens (human)
SOURCE Aeomica, Inc. (US)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 7812 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
    source
        1..17
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Shannon,M.E.
Myosin-like gene expressed in human heart and muscle
Patent: WO 0192524-A 7697 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
    source
        1..17
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 493 GAGCAGAGGAGCAGCAG 508
Db 2 GAGCAGAGGAGCAGCAG 17

RESULT 223
LOCUS CQ623074 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 7814 from Patent WO0192524.
ACCESSION CQ623074
VERSION CQ623074.1 GI:41673292
KEYWORDS Homo sapiens (human)
SOURCE Aeomica, Inc. (US)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 7814 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
    source
        1..17
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 494 AGGCAGAGGAGCAGCAG 509
Db 1 AAGCAGAGGAGCAGCAG 16

RESULT 224
LOCUS CQ623293 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8033 from Patent WO0192524.
ACCESSION CQ623293
VERSION CQ623293.1 GI:41673511
KEYWORDS Homo sapiens (human)
SOURCE Aeomica, Inc. (US)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8033 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
    source
        1..17
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 696 AGCTGAGAGTGCAGCG 711
Db 2 AGCTGAGAGTGCAGCG 17
```

RESULT 225
C0623294
LOCUS 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8034 from Patent WO0192524.
ACCESSION C0623294
VERSION C0623294.1 GI:41673512
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8034 06-DEC-2001;
Aecomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 696 AGCTGGAGATGAGCG 711
|||||
Db 1 AGCTGGAGATGAGCG 16
RESULT 226
C0623683
LOCUS 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8423 from Patent WO0192524.
ACCESSION C0623683
VERSION C0623683.1 GI:41673901
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8423 06-DEC-2001;
Aecomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 491 AAGAGGCGAGAGGAGCG 506
|||||
Db 1 AAGAGGCGAGAGGAGCG 16
RESULT 227
I34958
LOCUS 17 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 44 from patent US 5599704.
ACCESSION I34958
VERSION I34958.1 GI:2087926
KEYWORDS
SOURCE Unknown.

ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Thompson,J.D. and Draper,K.G.
TITLE ErbB2/neu targeted ribozymes
JOURNAL Patent: US 5599704-A 44 04-FEB-1997;
FEATURES
source
1..17
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 843 TGGCCTATCACCAGCT 858
|||||
Db 2 TGGCCTGCCACCAGCT 17
RESULT 228
I52435/c
LOCUS 17 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 176 from patent US 5646042.
ACCESSION I52435
VERSION I52435.1 GI:2473636
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 176 08-JUL-1997;
FEATURES
source
1..17
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 405 AGAGGAGGAGGAGGA 420
|||||
Db 17 AGAAGGAGGAGGAGGA 2
RESULT 229
AR186446
LOCUS 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 1934 from patent US 6346398.
ACCESSION AR186446
VERSION AR186446.1 GI:20232411
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 1934 12-FEB-2002;
FEATURES
source
1..17
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 875 AACCACATCAGAGCA 890

```
|||||
1 AACTACCTCAAGAGCA 16

RESULT 230
AR192127
LOCUS AR192127 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 7615 from patent US 6346398.
ACCESSION AR192127
VERSION AR192127.1 GI:20238092
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 7615 12-FEB-2002;
FEATURES
source
1. .17
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 875 AACCATCAAGAGCA 890
|||||
1 AACTACCTCAAGAGCA 16

RESULT 231
AR192284/c
LOCUS AR192284 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 7772 from patent US 6346398.
ACCESSION AR192284
VERSION AR192284.1 GI:20238249
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 7772 12-FEB-2002;
FEATURES
source
1. .17
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 815 GAGAAGGAGGAGCTGG 830
|||||
17 GAGAAGGAGGAGCTGG 2

RESULT 232
AR286106
LOCUS AR286106 17 bp RNA linear PAT 10-APR-2003
DEFINITION Sequence 478 from patent US 6528640.
ACCESSION AR286106
VERSION AR286106.1 GI:29723702
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 17)

QY 875 AACCATCAAGAGCA 890
|||||
1 AACTACCTCAAGAGCA 16

AUTHORS Beigelman,L., Burgin,A., Beaudry,A., Karpeisky,A.,
Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE Synthetic ribonucleic acids with RNase activity
JOURNAL Patent: US 6528640-A 478 04-MAR-2003;
FEATURES
source
1. .17
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned RNA"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 263 CTGCACCTGCGCTTCAG 278
|||||
1 CTCTCTCTGCGCTTCAG 16

RESULT 233
AR286233
LOCUS AR286233 17 bp RNA linear PAT 10-APR-2003
DEFINITION Sequence 605 from patent US 6528640.
ACCESSION AR286233
VERSION AR286233.1 GI:29723829
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 17)
AUTHORS Beigelman,L., Burgin,A., Beaudry,A., Karpeisky,A.,
Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE Synthetic ribonucleic acids with RNase activity
JOURNAL Patent: US 6528640-A 605 04-MAR-2003;
FEATURES
source
1. .17
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned RNA"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 512 CTGCGGAGGTGGAGC 527
|||||
1 CTGCGGAGGTGGAGC 16

RESULT 234
AR323077
LOCUS AR323077 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 479 from patent US 6566127.
ACCESSION AR323077
VERSION AR323077.1 GI:33708885
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 479 20-MAY-2003;
FEATURES
source
1. .17
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned RNA"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 875 AACCATCAAGAGCA 890
|||||
1 AACTACCTCAAGAGCA 16
```

Db 1 AACTACCTCAAGACCA 16

RESULT 235
AR326154/c

LOCUS AR326154 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 3556 from patent US 6566127.
ACCESSION AR326154
VERSION AR326154.1 GI:33711962
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 3556 20-MAY-2003;
FEATURES
source Location/Qualifiers
1. .17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 815 GAGAGAGGAGGCTGG 830
||||| |||||
Db 17 GAGAGCAGAGCTGG 2

RESULT 236
AR327368

LOCUS AR327368 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 4770 from patent US 6566127.
ACCESSION AR327368
VERSION AR327368.1 GI:33713176
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 4770 20-MAY-2003;
FEATURES
source Location/Qualifiers
1. .17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 874 CAACCATCAAGAGC 889
||||| |||||
Db 2 CAATACCTCAAGAGC 17

RESULT 237
AR363927

LOCUS AR363927 17 bp DNA linear PAT 03-SEP-2003
DEFINITION Sequence 22 from patent US 5240847.
ACCESSION AR363927
VERSION AR363927.1 GI:34426034
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Heckl,K., Spevak,W., Ostermann,E., Zophel,A., Krystek,E.,

TITLE Maurer-Fogy,I., Wiche-Castanon,M.J., Stratowa,C. and Hauptmann,R.
JOURNAL Human manganese superoxide dismutase (hMn-SOD)
FEATURES Patent: US 5240847-A 22 31-AUG-1993;
source Location/Qualifiers
1. .17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 182 GAGATGTCAGCCCA 197
||||| |||||
Db 2 GAGATGTTACAGCCCA 17

RESULT 238
AR398096

LOCUS AR398096 17 bp RNA linear PAT 18-DEC-2003
DEFINITION Sequence 477 from patent US 6617438.
ACCESSION AR398096
VERSION AR398096.1 GI:40135629
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Beigelman,L., Burgin,A.B., Beaudry,A., Karpeisky,A., Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE Oligoribonucleotides with enzymatic activity
JOURNAL Patent: US 6617438-A 477 09-SEP-2003;
FEATURES
source Location/Qualifiers
1. .17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 263 CTCACCTGCCTTCAG 278
||||| |||||
Db 1 CTCCTCTGCCTTCAG 16

RESULT 239
AR398223

LOCUS AR398223 17 bp RNA linear PAT 18-DEC-2003
DEFINITION Sequence 604 from patent US 6617438.
ACCESSION AR398223
VERSION AR398223.1 GI:40135860
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Beigelman,L., Burgin,A.B., Beaudry,A., Karpeisky,A., Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE Oligoribonucleotides with enzymatic activity
JOURNAL Patent: US 6617438-A 604 09-SEP-2003;
FEATURES
source Location/Qualifiers
1. .17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 512 CTGCGGGAGGTGGAGC 527
||||| |||||
Db 1 CTGCGGGAGCTGCAGC 16

RESULT 240
LOCUS AR456677/c 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 354 from patent US 6686188.
ACCESSION AR456677
VERSION AR456677.1 GI:42691734
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 354 03-FEB-2004;
FEATURES Location/Qualifiers
 1..17
 /mol_type="genomic DNA"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 482 CTCGATCTGAAGAGGC 497
Db 17 CTCGTTCTGGAGAGC 2
RESULT 241
LOCUS AR456678/c 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 355 from patent US 6686188.
ACCESSION AR456678
VERSION AR456678.1 GI:42691735
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 355 03-FEB-2004;
FEATURES Location/Qualifiers
 1..17
 /mol_type="genomic DNA"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 482 CTCGATCTGAAGAGGC 497
Db 17 CTCGTTCTGGAGAGC 2
RESULT 242
LOCUS AR456695/c 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 672 from patent US 6686188.
ACCESSION AR456695
VERSION AR456695.1 GI:42692052
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1523 03-FEB-2004;
FEATURES Location/Qualifiers
 1..17
 /mol_type="genomic DNA"

AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 672 03-FEB-2004;
FEATURES Location/Qualifiers
 1..17
 /mol_type="genomic DNA"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 233 GAAGAGTCTCTCTCGG 248
Db 17 GATGAGTCTCTCTCGG 2
RESULT 243
LOCUS AR456996/c 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 673 from patent US 6686188.
ACCESSION AR456996
VERSION AR456996.1 GI:42692053
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 673 03-FEB-2004;
FEATURES Location/Qualifiers
 1..17
 /mol_type="genomic DNA"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 233 GAAGAGTCTCTCTCGG 248
Db 16 GATGAGTCTCTCTCGG 1
RESULT 244
LOCUS AR457846/c 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 1523 from patent US 6686188.
ACCESSION AR457846
VERSION AR457846.1 GI:42692903
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1523 03-FEB-2004;
FEATURES Location/Qualifiers
 1..17
 /mol_type="genomic DNA"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 846 CCTATCACCGCTCTT 861
Db 17 CCCATCACCTGCTCTT 2

RESULT 245
AR457847/c
LOCUS AR457847 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 1524 from patent US 6686188.
ACCESSION AR457847
VERSION AR457847.1 GI:42692904
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1524 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 846 CCTATCACCGCTCTT 861
Db 16 CCCATCACCTGCTCTT 1

RESULT 246
AR458043/c
LOCUS AR458043 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 1720 from patent US 6686188.
ACCESSION AR458043
VERSION AR458043.1 GI:42693100
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1720 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 846 CCTATCACCGCTCTT 861
Db 16 CCCATCACCTGCTCTT 1

RESULT 247
AR458044/c
LOCUS AR458044 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 1721 from patent US 6686188.
ACCESSION AR458044
VERSION AR458044.1 GI:42693101
KEYWORDS

SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1721 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 392 TTCCAGCCGCGCAGA 407
Db 16 TTCTGAGCCGCGCAGA 1

RESULT 248
AR458319/c
LOCUS AR458319 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 1996 from patent US 6686188.
ACCESSION AR458319
VERSION AR458319.1 GI:42693376
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1996 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 309 GCGTCGAGGAGCAATCA 324
Db 17 GCGTCGAGGAGCAATCA 2

RESULT 249
AR458320/c
LOCUS AR458320 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 1997 from patent US 6686188.
ACCESSION AR458320
VERSION AR458320.1 GI:42693377
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1997 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 309 GCTGGAGGAGATCA 324
Db 16 GCGTGGAGGACATCA 1

RESULT 250
AR463145/C
LOCUS AR463145 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 6822 from patent US 6686188.
ACCESSION AR463145
VERSION AR463145.1 GI:42698202
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 6822 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 267 ACCTGCTTCAGAAC 282
Db 17 ACCTGCTTCAGAAAA 2

RESULT 251
AR463213/C
LOCUS AR463213 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 6890 from patent US 6686188.
ACCESSION AR463213
VERSION AR463213.1 GI:42698270
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 6890 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 306 GCTGCTCGAGGAGAA 321
Db 17 GCCGCTCGAAGAGAA 2

RESULT 252
AR463214/C
LOCUS AR463214 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 6891 from patent US 6686188.
ACCESSION AR463214.1 GI:42698271
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 6891 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 306 GCTGCTCGAGGAGAA 321
Db 16 GCCGCTCGAAGAGAA 1

RESULT 253
AR464000
LOCUS AR464000 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 7677 from patent US 6686188.
ACCESSION AR464000
VERSION AR464000.1 GI:42699057
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 7677 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 490 GAAGAGCGAGAGAGAG 505
Db 2 GAAGAAGCAGAGAGAAG 17

RESULT 254
AR464001
LOCUS AR464001 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 7678 from patent US 6686188.
ACCESSION AR464001
VERSION AR464001.1 GI:42699058
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 7678 03-FEB-2004;

DEFINITION Sequence 6891 from patent US 6686188.
ACCESSION AR463214
VERSION AR463214.1 GI:42698271
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 6891 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 306 GCTGCTCGAGGAGAA 321
Db 16 GCCGCTCGAAGAGAA 1

RESULT 253
AR464000
LOCUS AR464000 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 7677 from patent US 6686188.
ACCESSION AR464000
VERSION AR464000.1 GI:42699057
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 7677 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 490 GAAGAGCGAGAGAGAG 505
Db 2 GAAGAAGCAGAGAGAAG 17

RESULT 254
AR464001
LOCUS AR464001 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 7678 from patent US 6686188.
ACCESSION AR464001
VERSION AR464001.1 GI:42699058
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 7678 03-FEB-2004;


```
FEATURES
  source
    Location/Qualifiers
      1..17
      /organism="unknown"
      /mol_type="genomic DNA"

Query Match
  Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 490 GAAGAGGCAGAGGAG 505
    ||||| ||||| ||||| |||||
Db 1 GAAGAGCAGAGAGAG 16

RESULT 255
LOCUS AR464020/c 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 7697 from patent US 6686188.
ACCESSION AR464020
VERSION AR464020.1 GI:42699077
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 7697 03-FEB-2004;
FEATURES
  source
    Location/Qualifiers
      1..17
      /organism="unknown"
      /mol_type="genomic DNA"

Query Match
  Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 828 TGGCCAGTTCAGGT 843
    ||||| ||||| ||||| |||||
Db 17 TGGCCAGCTGCAGGT 2

RESULT 256
LOCUS AR464022/c 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 7699 from patent US 6686188.
ACCESSION AR464022
VERSION AR464022.1 GI:42699079
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 7699 03-FEB-2004;
FEATURES
  source
    Location/Qualifiers
      1..17
      /organism="unknown"
      /mol_type="genomic DNA"

Query Match
  Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 827 CTGGCCAGTTCAGG 842
    ||||| ||||| ||||| |||||
Db 16 CTGGCCAGCTGCAGG 1
```

```
RESULT 257
LOCUS AR464135 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 7812 from patent US 6686188.
ACCESSION AR464135
VERSION AR464135.1 GI:42699192
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 7812 03-FEB-2004;
FEATURES
  source
    Location/Qualifiers
      1..17
      /organism="unknown"
      /mol_type="genomic DNA"

Query Match
  Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 493 GAGGCAGAGGAGCAG 508
    ||||| ||||| ||||| |||||
Db 2 GAAGCAAGAGGAGCAG 17

RESULT 258
LOCUS AR464137 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 7814 from patent US 6686188.
ACCESSION AR464137
VERSION AR464137.1 GI:42699194
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 7814 03-FEB-2004;
FEATURES
  source
    Location/Qualifiers
      1..17
      /organism="unknown"
      /mol_type="genomic DNA"

Query Match
  Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

RESULT 259
LOCUS AR464356 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 8033 from patent US 6686188.
ACCESSION AR464356
VERSION AR464356.1 GI:42699413
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
```

Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8033 03-FEB-2004;
FEATURES Location/Qualifiers
source
1. .17
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 696 AGCTGGAGAGTGAGCG 711
Db 2 AGCTGGAGATCGAGCG 17

RESULT 260
AR464357
LOCUS Sequence 8034 from patent US 6686188.
DEFINITION AR464357
ACCESSION AR464357
VERSION AR464357.1 GI:42699414
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8034 03-FEB-2004;
FEATURES Location/Qualifiers
source
1. .17
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 696 AGCTGGAGAGTGAGCG 711
Db 1 AGCTGGAGATCGAGCG 16

RESULT 261
AR464746
LOCUS Sequence 8423 from patent US 6686188.
DEFINITION AR464746
ACCESSION AR464746
VERSION AR464746.1 GI:42699803
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8423 03-FEB-2004;
FEATURES Location/Qualifiers
source
1. .17
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8033 03-FEB-2004;
FEATURES Location/Qualifiers
source
1. .17
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 696 AGCTGGAGAGTGAGCG 711
Db 2 AGCTGGAGATCGAGCG 17

RESULT 260
AR464357
LOCUS Sequence 8034 from patent US 6686188.
DEFINITION AR464357
ACCESSION AR464357
VERSION AR464357.1 GI:42699414
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8034 03-FEB-2004;
FEATURES Location/Qualifiers
source
1. .17
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 696 AGCTGGAGAGTGAGCG 711
Db 1 AGCTGGAGATCGAGCG 16

RESULT 261
AR464746
LOCUS Sequence 8423 from patent US 6686188.
DEFINITION AR464746
ACCESSION AR464746
VERSION AR464746.1 GI:42699803
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8423 03-FEB-2004;
FEATURES Location/Qualifiers
source
1. .17
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 491 AAGAGCGCAGAGGAGC 506
Db 1 AAGAGCGCAGAGGAGTGC 16

RESULT 262
AR483202
LOCUS Sequence 648 from patent US 6703228.
DEFINITION AR483202
ACCESSION AR483202
VERSION AR483202.1 GI:47245725
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Landers,J., Jordan,B., Housman,D.E. and Charest,A.
TITLE Methods and products related to genotyping and DNA analysis
JOURNAL Patent: US 6703228-A 648 09-MAR-2004;
FEATURES Location/Qualifiers
source
1. .17
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 397 AGCCAGCCAGAGGGAG 412
Db 1 AGGCAGCTAGAGGGAG 16

RESULT 263
AX214573
LOCUS Sequence 15 from Patent WO0159103.
DEFINITION AX214573
ACCESSION AX214573
VERSION AX214573.1 GI:15524616
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Blatt,L., Mcswiggen,J. and Chowrira,B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
JOURNAL Patent: WO 0159103-A 15 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; Mcswiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES Location/Qualifiers
source
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 233 GAAGAGTCTCTCTCTGG 248
Db 2 GACCAGTCTCTCTCTGG 17

RESULT 264
AX215343
LOCUS Sequence 785 from Patent WO0159103.
DEFINITION AX215343
ACCESSION AX215343
VERSION AX215343.1 GI:15525386
KEYWORDS

SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
JOURNAL Patent: WO 0159103-A 785 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 233 GAAGAGTCTCTCTGG 248
Db 1 GACCAGTCTCTCTGG 16
RESULT 265
AX216496
LOCUS AX216496 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 1938 from Patent WO0159103.
ACCESSION AX216496
VERSION AX216496.1 GI:15526557
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
JOURNAL Patent: WO 0159103-A 1938 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 487 TCTGAAGGCGAGGAG 502
Db 1 TTTGAGAGTCAGGAG 16
RESULT 266
AX217098
LOCUS AX217098 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 2540 from Patent WO0159103.
ACCESSION AX217098
VERSION AX217098.1 GI:15527159
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression

JOURNAL Patent: WO 0159103-A 2540 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 486 ATCTGAAGGCGAGGAG 501
Db 2 ATTTGAGAGTCAGAA 17
RESULT 267
AX226754/c
LOCUS AX226754 17 bp RNA linear PAT 10-SEP-2001
DEFINITION Sequence 126 from Patent WO0157206.
ACCESSION AX226754
VERSION AX226754.1 GI:15555895
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Fattaey, A.R., Jarvis, T., Mcswiggen, J., Boher, R.N. and Holman, P.S.
TITLE Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme
JOURNAL Patent: WO 0157206-A 126 09-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Fattaey, Ali R. (US)
FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 606 TGCAGGAGGCGGAGAG 621
Db 16 TGCAGGAGGAGCTAGAG 1
RESULT 268
AX227107/c
LOCUS AX227107 17 bp RNA linear PAT 10-SEP-2001
DEFINITION Sequence 479 from Patent WO0157206.
ACCESSION AX227107
VERSION AX227107.1 GI:15556248
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Fattaey, A.R., Jarvis, T., Mcswiggen, J., Boher, R.N. and Holman, P.S.
TITLE Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme
JOURNAL Patent: WO 0157206-A 479 09-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Fattaey, Ali R. (US)
FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

Best Local Similarity 87.5%; Pred. No. 2.1e+02; Mismatches 2; Indels 0; Gaps 0;
Matches 14; Conservative 0;

QY 606 TGCAGGAGCCGAG 621
Db 17 TGCAGCAGAGCTAG 2

RESULT 269
AX262960
LOCUS AX262960 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 351 from Patent WO0173002.
ACCESSION AX262960
VERSION AX262960.1 GI:16511759
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 351 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 364 GCGGAGCGCTGCGAG 379
Db 2 GCGTGAGCGCTTCGAG 17

RESULT 270
AX262961/c
LOCUS AX262961 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 352 from Patent WO0173002.
ACCESSION AX262961
VERSION AX262961.1 GI:16511760
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 352 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 364 GCGGAGCGCTGCGAG 379
Db 16 GCGTGAGCGCTTCGAG 1

RESULT 271
AX262961/c
LOCUS AX262961 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 352 from Patent WO0173002.
ACCESSION AX262961
VERSION AX262961.1 GI:16511760
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 352 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 364 GCGGAGCGCTGCGAG 379
Db 16 GCGTGAGCGCTTCGAG 1

RESULT 272
AX263985
LOCUS AX263985 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 1376 from Patent WO0173002.
ACCESSION AX263985
VERSION AX263985.1 GI:16512784
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 1376 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 721 GCAGCAGCAGCAGC 736
Db 17 GCAGCAGCAGCTCCGC 2

RESULT 273
AX263984/c
LOCUS AX263984 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 1375 from Patent WO0173002.
ACCESSION AX263984
VERSION AX263984.1 GI:16512783
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 1375 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 721 GCAGCAGCAGCAGC 736
Db 1 GCAGCAGCAGCTCCGC 16

RESULT 273
AX265711
LOCUS AX265711 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 3102 from Patent WO0173002.
ACCESSION AX265711
VERSION AX265711.1 GI:16514510
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

```

```
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
Kniec,E.B., Gamber,H.B. and Rice,M.C.
Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
Patent: WO 0173002-A 3102 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 724 GCAGCAGCAGCGTG 739
Db 1 GCAGCAGCAGCATCGAG 16

RESULT 274
AX265712/c
LOCUS AX265712 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 3103 from Patent WO0173002.
ACCESSION AX265712
VERSION AX265712.1 GI:16514511
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
Kniec,E.B., Gamber,H.B. and Rice,M.C.
Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
Patent: WO 0173002-A 3103 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 724 GCAGCAGCAGCGTG 739
Db 17 GCAGCAGCAGCATCGAG 2

RESULT 275
AX266023
LOCUS AX266023 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 3414 from Patent WO0173002.
ACCESSION AX266023
VERSION AX266023.1 GI:16514822
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
Kniec,E.B., Gamber,H.B. and Rice,M.C.
Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
Patent: WO 0173002-A 3414 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
Location/Qualifiers
1. .17
```

```
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 757 CATGCAGGCCAGAGC 772
Db 1 CATGCTCGGCCAGAGC 16

RESULT 276
AX266024/c
LOCUS AX266024 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 3415 from Patent WO0173002.
ACCESSION AX266024
VERSION AX266024.1 GI:16514823
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
Kniec,E.B., Gamber,H.B. and Rice,M.C.
Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
Patent: WO 0173002-A 3415 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 757 CATGCAGGCCAGAGC 772
Db 17 CATGCTCGGCCAGAGC 2

RESULT 277
AX272702
LOCUS AX272702 17 bp RNA linear PAT 29-OCT-2001
DEFINITION Sequence 271 from Patent WO0162911.
ACCESSION AX272702
VERSION AX272702.1 GI:16545439
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., Hamblin,P.A. and
Ellis,J.H.
Method and reagent for the inhibition of grid
Patent: WO 0162911-A 271 30-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 393 TCCAGCCAGCCAGAG 408
```

```
Db          2 TCCGGCCAGCCAGAG 17
|||||
RESULT 278
AX272703    AX272703    17 bp    RNA    linear    PAT 29-OCT-2001
DEFINITION  Sequence 272 from Patent WO0162911.
ACCESSION  AX272703
VERSION    AX272703.1 GI:16545440
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS    Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., Hamblin,P.A. and
           Ellis,J.H.
TITLE      Method and reagent for the inhibition of grid
JOURNAL    Patent: WO 0162911-A 272 30-AUG-2001;
RIBOZYME   PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES   Location/Qualifiers
           source
           1..17
           /organism="Homo sapiens"
           /mol_type="unassigned RNA"
           /db_xref="taxon:9606"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 393 TCCAGCCAGCCAGAG 408
|||||
Db 1 TCCGGCCAGCCAGAG 16

RESULT 279
AX272792    AX272792    17 bp    RNA    linear    PAT 29-OCT-2001
DEFINITION  Sequence 361 from Patent WO0162911.
ACCESSION  AX272792
VERSION    AX272792.1 GI:16545529
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS    Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., Hamblin,P.A. and
           Ellis,J.H.
TITLE      Method and reagent for the inhibition of grid
JOURNAL    Patent: WO 0162911-A 361 30-AUG-2001;
RIBOZYME   PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES   Location/Qualifiers
           source
           1..17
           /organism="Homo sapiens"
           /mol_type="unassigned RNA"
           /db_xref="taxon:9606"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 718 GCTGACGAGCAGCAC 733
|||||
Db 1 GCAGCAGCAGCAGCAC 16

RESULT 280
AX273038    AX273038    17 bp    RNA    linear    PAT 29-OCT-2001
DEFINITION  Sequence 607 from Patent WO0162911.
ACCESSION  AX273038
```

```
VERSION     AX273038.1 GI:16545775
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
REFERENCE  1
AUTHORS     Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., Hamblin,P.A. and
           Ellis,J.H.
TITLE       Method and reagent for the inhibition of grid
JOURNAL     Patent: WO 0162911-A 607 30-AUG-2001;
RIBOZYME    PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES    Location/Qualifiers
           source
           1..17
           /organism="Homo sapiens"
           /mol_type="unassigned RNA"
           /db_xref="taxon:9606"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 717 CGCTGCAGCAGCAGCA 732
|||||
Db 2 CCCTGCAGCAGCAGCA 17

RESULT 281
AX273304    AX273304    17 bp    RNA    linear    PAT 29-OCT-2001
DEFINITION  Sequence 873 from Patent WO0162911.
ACCESSION  AX273304
VERSION    AX273304.1 GI:16546041
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS    Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., Hamblin,P.A. and
           Ellis,J.H.
TITLE      Method and reagent for the inhibition of grid
JOURNAL    Patent: WO 0162911-A 873 30-AUG-2001;
RIBOZYME    PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES    Location/Qualifiers
           source
           1..17
           /organism="Homo sapiens"
           /mol_type="unassigned RNA"
           /db_xref="taxon:9606"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 731 CACAGCGTGCGGTGG 746
|||||
Db 2 CACAGCGGGGAGGTGG 17

RESULT 282
AX273305    AX273305    17 bp    RNA    linear    PAT 29-OCT-2001
DEFINITION  Sequence 874 from Patent WO0162911.
ACCESSION  AX273305
VERSION    AX273305.1 GI:16546042
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS    Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., Hamblin,P.A. and
           Ellis,J.H.
```

```

TITLE      Method and reagent for the inhibition of grid
JOURNAL    Patent: WO 0162911-A 874 30-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES   Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned RNA"
            /db_xref="taxon:9606"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      731 CACAGCGTGCAGGTGG 746
      1 CACAGCGGGGAGGTGG 16
      ||||| ||||| |||||
      ||||| ||||| |||||

RESULT 283
AX325485
LOCUS      AX325485              17 bp  DNA      linear      PAT 02-SEP-2002
DEFINITION Sequence 1623 from Patent WO0192512.
ACCESSION  AX325485
VERSION     AX325485.1  GI:18096242
KEYWORDS
SOURCE      Oryza sativa
ORGANISM    Oryza sativa
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1
AUTHORS    Kniec,E.B., Gamper,H.B., Rice,M.C. and Kim,J.
TITLE      Targeted chromosomal genomic alterations in plants using modified
            single stranded oligonucleotides
JOURNAL    Patent: WO 0192512-A 1623 06-DEC-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES   Location/Qualifiers
            source
            1..17
            /organism="Oryza sativa"
            /mol_type="unassigned DNA"
            /db_xref="taxon:4530"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      409 GGAGGAGAGGAGTTC 424
      2 GGAGGCCAAGGAGTTC 17
      ||||| ||||| |||||
      ||||| ||||| |||||

RESULT 284
AX325486/c
LOCUS      AX325486/c          17 bp  DNA      linear      PAT 02-SEP-2002
DEFINITION Sequence 1624 from Patent WO0192512.
ACCESSION  AX325486
VERSION     AX325486.1  GI:18096243
KEYWORDS
SOURCE      Oryza sativa
ORGANISM    Oryza sativa
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1
AUTHORS    Kniec,E.B., Gamper,H.B., Rice,M.C. and Kim,J.
TITLE      Targeted chromosomal genomic alterations in plants using modified
            single stranded oligonucleotides
JOURNAL    Patent: WO 0192512-A 1624 06-DEC-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES   Location/Qualifiers
            source
            1..17
            /organism="Oryza sativa"
            /mol_type="unassigned DNA"

TITLE      Method and reagent for the inhibition of grid
JOURNAL    Patent: WO 0162911-A 874 30-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES   Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned RNA"
            /db_xref="taxon:9606"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      409 GGAGGAGAGGAGTTC 424
      16 GGAGGCCAAGGAGTTC 1
      ||||| ||||| |||||
      ||||| ||||| |||||

RESULT 285
AX422460/c
LOCUS      AX422460              17 bp  RNA      linear      PAT 18-JUN-2002
DEFINITION Sequence 796 from Patent WO0188124.
ACCESSION  AX422460
VERSION     AX422460.1  GI:21525842
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS    Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
            Randi,A.M.
TITLE      Method and reagent for the inhibition of erg
JOURNAL    Patent: WO 0188124-A 796 22-NOV-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES   Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned RNA"
            /db_xref="taxon:9606"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      795 AGCGCCAGCGCGCTC 810
      16 AGCGCGGGCCACCTC 1
      ||||| ||||| |||||
      ||||| ||||| |||||

RESULT 286
AX422538/c
LOCUS      AX422538              17 bp  RNA      linear      PAT 18-JUN-2002
DEFINITION Sequence 874 from Patent WO0188124.
ACCESSION  AX422538
VERSION     AX422538.1  GI:21525920
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS    Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
            Randi,A.M.
TITLE      Method and reagent for the inhibition of erg
JOURNAL    Patent: WO 0188124-A 874 22-NOV-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES   Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned RNA"
            /db_xref="taxon:9606"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      656 CTGGAGGTCGGGGCC 671
      17 CTGGAGGGTGGGGCGC 2
      ||||| ||||| |||||
      ||||| ||||| |||||
```

```
RESULT 287
AX422543
LOCUS      17 bp      RNA      linear      PAT 18-JUN-2002
DEFINITION Sequence 879 from Patent WO0188124.
ACCESSION AX422543
VERSION    AX422543.1 GI:21525925
KEYWORDS
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
REFERENCE
AUTHORS    Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
            Randi,A.M.
TITLE      Method and reagent for the inhibition of erg
JOURNAL    Patent: WO 0188124-A 879 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source     1. .17
            /organism="Homo sapiens"
            /mol_type="unassigned RNA"
            /db_xref="taxon:9606"
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      296 ACCCTCCAGCGCTGCC 311
Db      2 ACCCTCCAGCGCTGCC 17

RESULT 288
AX423120/C
LOCUS      17 bp      RNA      linear      PAT 18-JUN-2002
DEFINITION Sequence 1456 from Patent WO0188124.
ACCESSION AX423120
VERSION    AX423120.1 GI:21526502
KEYWORDS
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
REFERENCE
AUTHORS    Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
            Randi,A.M.
TITLE      Method and reagent for the inhibition of erg
JOURNAL    Patent: WO 0188124-A 1456 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source     1. .17
            /organism="Homo sapiens"
            /mol_type="unassigned RNA"
            /db_xref="taxon:9606"
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      796 GCGCCAGCGCGCTCG 811
Db      17 GCGCCAGCGCGCTCG 2

RESULT 289
AX423137
LOCUS      17 bp      RNA      linear      PAT 18-JUN-2002
DEFINITION Sequence 1473 from Patent WO0188124.
ACCESSION AX423137
VERSION    AX423137.1 GI:21526519
KEYWORDS
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
REFERENCE
AUTHORS    Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
            Randi,A.M.
TITLE      Method and reagent for the inhibition of erg
JOURNAL    Patent: WO 0188124-A 1473 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source     1. .17
            /organism="Homo sapiens"
            /mol_type="unassigned RNA"
            /db_xref="taxon:9606"
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      306 GCTGCTGGAGGAGAA 321
Db      2 GCTGCTGGAGGAGAA 17

RESULT 291
AX423504
LOCUS      17 bp      RNA      linear      PAT 18-JUN-2002
DEFINITION Sequence 1840 from Patent WO0188124.
ACCESSION AX423504
VERSION    AX423504.1 GI:21526886
KEYWORDS
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
REFERENCE
AUTHORS    Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
            Randi,A.M.
TITLE      Method and reagent for the inhibition of erg
JOURNAL    Patent: WO 0188124-A 1839 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source     1. .17
            /organism="Homo sapiens"
            /mol_type="unassigned RNA"
            /db_xref="taxon:9606"
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      306 GCTGCTGGAGGAGAA 321
Db      2 GCTGCTGGAGGAGAA 17

RESULT 292
AX423504
LOCUS      17 bp      RNA      linear      PAT 18-JUN-2002
DEFINITION Sequence 1839 from Patent WO0188124.
ACCESSION AX423503
VERSION    AX423503.1 GI:21526885
KEYWORDS
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
REFERENCE
AUTHORS    Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
            Randi,A.M.
TITLE      Method and reagent for the inhibition of erg
JOURNAL    Patent: WO 0188124-A 1839 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source     1. .17
            /organism="Homo sapiens"
            /mol_type="unassigned RNA"
            /db_xref="taxon:9606"
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      296 ACCCTCCAGCGCTGCC 311
Db      1 ACCCTCCAGCGCTGCC 16

RESULT 293
AX423503
LOCUS      17 bp      RNA      linear      PAT 18-JUN-2002
DEFINITION Sequence 1839 from Patent WO0188124.
ACCESSION AX423503
VERSION    AX423503.1 GI:21526885
KEYWORDS
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
REFERENCE
AUTHORS    Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
            Randi,A.M.
TITLE      Method and reagent for the inhibition of erg
JOURNAL    Patent: WO 0188124-A 1839 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source     1. .17
            /organism="Homo sapiens"
            /mol_type="unassigned RNA"
            /db_xref="taxon:9606"
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      296 ACCCTCCAGCGCTGCC 311
Db      1 ACCCTCCAGCGCTGCC 16
```



```

FEATURES
  source
    RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
    1. .17
    /location/Qualifiers
    /organism="Homo sapiens"
    /mol_type="unassigned RNA"
    /db_xref="taxon:9606"

  Query Match
    1.7%; Score 12.8; DB 1; Length 17;
  Best Local Similarity 87.5%; Pred. No. 2.1e+02;
  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 306 GCTGCGGAGGAGCTTCT 387
Db 1 GCTACATGGAGGAGAA 16

RESULT 292
AX475340/c
LOCUS
DEFINITION
  Sequence 561 from Patent WO0224750.
ACCESSION
  AX475340
VERSION
  AX475340.1 GI:22214625
KEYWORDS
  Homo sapiens (human)
ORGANISM
  Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1
  Zhang, J.
  Human kidney tumor overexpressed membrane protein 1
  JOURNAL
  Patent: WO 0224750-A 561 28-MAR-2002;
  Acomica, Inc. (US)
FEATURES
  source
    1. .17
    /location/Qualifiers
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

  Query Match
    1.7%; Score 12.8; DB 1; Length 17;
  Best Local Similarity 87.5%; Pred. No. 2.1e+02;
  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 372 GCTGCGGAGGAGCTTCT 387
Db 17 GCTGAGAGGAGCTCT 2

RESULT 293
AX475341/c
LOCUS
DEFINITION
  Sequence 562 from Patent WO0224750.
ACCESSION
  AX475341
VERSION
  AX475341.1 GI:22214626
KEYWORDS
  Homo sapiens (human)
ORGANISM
  Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1
  Zhang, J.
  Human kidney tumor overexpressed membrane protein 1
  JOURNAL
  Patent: WO 0224750-A 562 28-MAR-2002;
  Acomica, Inc. (US)
FEATURES
  source
    1. .17
    /location/Qualifiers
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

  Query Match
    1.7%; Score 12.8; DB 1; Length 17;
  Best Local Similarity 87.5%; Pred. No. 2.1e+02;
  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 306 GCTGCGGAGGAGCTTCT 387
Db 16 GCTGAGAGGAGCTCT 1

RESULT 294
AX530542
LOCUS
DEFINITION
  Sequence 51 from Patent EP1239051.
ACCESSION
  AX530542
VERSION
  AX530542.1 GI:25252461
KEYWORDS
  Homo sapiens (human)
ORGANISM
  Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1
  Shannon, M.
  Human posh-like protein 1
  JOURNAL
  Patent: EP 1239051-A 51 11-SEP-2002;
  Acomica, Inc. (US)
FEATURES
  source
    1. .17
    /location/Qualifiers
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

  Query Match
    1.7%; Score 12.8; DB 1; Length 17;
  Best Local Similarity 87.5%; Pred. No. 2.1e+02;
  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 617 CAGAGTCGCTTGAGG 632
Db 2 CAGCGGCGCTTGAGG 17

RESULT 295
AX530543
LOCUS
DEFINITION
  Sequence 52 from Patent EP1239051.
ACCESSION
  AX530543
VERSION
  AX530543.1 GI:25252463
KEYWORDS
  Homo sapiens (human)
ORGANISM
  Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1
  Shannon, M.
  Human posh-like protein 1
  JOURNAL
  Patent: EP 1239051-A 52 11-SEP-2002;
  Acomica, Inc. (US)
FEATURES
  source
    1. .17
    /location/Qualifiers
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

  Query Match
    1.7%; Score 12.8; DB 1; Length 17;
  Best Local Similarity 87.5%; Pred. No. 2.1e+02;
  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 617 CAGAGTCGCTTGAGG 632
Db 1 CAGCGGCGCTTGAGG 16

RESULT 296
AX530793
LOCUS
DEFINITION
  Sequence 302 from Patent EP1239051.
ACCESSION
  AX530793
VERSION
  AX530793.1 GI:25253381
```

```
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Shannon,M.
TITLE       Human posh-like protein 1
JOURNAL     Patent: EP 1239051-A 302 11-SEP-2002;
            Aeomica, Inc. (US)
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 471 GCTTGAGAGCTCGA 486
Db 2 GCTTGAGAGCTCGA 17
RESULT 297
AX530795
LOCUS      AX530795 17 bp DNA linear PAT 22-NOV-2002
DEFINITION Sequence 304 from Patent EP1239051.
ACCESSION  AX530795
VERSION     AX530795.1 GI:25253385
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Shannon,M.
TITLE       Human posh-like protein 1
JOURNAL     Patent: EP 1239051-A 304 11-SEP-2002;
            Aeomica, Inc. (US)
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 472 CCTGAGAGCTCGAT 487
Db 1 CTTGAGAGCTCGAT 16
RESULT 298
AX530796
LOCUS      AX530796 17 bp DNA linear PAT 22-NOV-2002
DEFINITION Sequence 305 from Patent EP1239051.
ACCESSION  AX530796
VERSION     AX530796.1 GI:25253387
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Shannon,M.
TITLE       Human posh-like protein 1
JOURNAL     Patent: EP 1239051-A 305 11-SEP-2002;
            Aeomica, Inc. (US)
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 473 CCTGAGAGCTCGAT 487
Db 1 CTTGAGAGCTCGAT 16
RESULT 299
AX530797
LOCUS      AX530797 17 bp DNA linear PAT 22-NOV-2002
DEFINITION Sequence 306 from Patent EP1239051.
ACCESSION  AX530797
VERSION     AX530797.1 GI:25253389
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Shannon,M.
TITLE       Human posh-like protein 1
JOURNAL     Patent: EP 1239051-A 306 11-SEP-2002;
            Aeomica, Inc. (US)
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 474 TGGAGAGCTCGATCT 489
Db 2 TTGAGAGCTCGATGT 17
RESULT 300
AX530798
LOCUS      AX530798 17 bp DNA linear PAT 22-NOV-2002
DEFINITION Sequence 307 from Patent EP1239051.
ACCESSION  AX530798
VERSION     AX530798.1 GI:25253391
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Shannon,M.
TITLE       Human posh-like protein 1
JOURNAL     Patent: EP 1239051-A 307 11-SEP-2002;
            Aeomica, Inc. (US)
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 475 TGGAGAGCTCGATCT 489
Db 1 TTGAGAGCTCGATGT 16
RESULT 301
AX530799
LOCUS      AX530799 17 bp DNA linear PAT 22-NOV-2002
DEFINITION Sequence 308 from Patent EP1239051.
ACCESSION  AX530799
VERSION     AX530799.1 GI:25253393
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Shannon,M.
TITLE       Human posh-like protein 1
JOURNAL     Patent: EP 1239051-A 308 11-SEP-2002;
            Aeomica, Inc. (US)
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 476 GAGAGAGCTCGATCTGA 491
Db 1 TTGAGAGCTCGATGT 16
```

Db 2 GAGAGCTCGATGCA 17

RESULT 301
AX530799
LOCUS AX530799 17 bp DNA linear PAT 22-NOV-2002
DEFINITION Sequence 308 from Patent EP1239051.
ACCESSION AX530799
VERSION AX530799.1 GI:25253393
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Shannon,M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 308 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 476 GAGAGCTCGATGCA 491
|||||
Db 1 GAGAGCTCGATGCA 16

RESULT 302
AX531537
LOCUS AX531537 17 bp DNA linear PAT 22-NOV-2002
DEFINITION Sequence 1046 from Patent EP1239051.
ACCESSION AX531537
VERSION AX531537.1 GI:25254845
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Shannon,M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 1046 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 476 GAGAGCTCGATGCA 491
|||||
Db 1 GAGAGCTCGATGCA 16

RESULT 303
AX531538
LOCUS AX531538 17 bp DNA linear PAT 22-NOV-2002
DEFINITION Sequence 1047 from Patent EP1239051.
ACCESSION AX531538
VERSION AX531538.1 GI:25254847
KEYWORDS
SOURCE Homo sapiens (human)

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Shannon,M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 1047 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 253 GCCAGCCATGCTGCAC 268
|||||
Db 2 GCCAGTCATCTGCAC 17

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Shannon,M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 1047 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 253 GCCAGCCATGCTGCAC 268
|||||
Db 1 GCCAGTCATCTGCAC 16

RESULT 304
AX579515
LOCUS AX579515 17 bp RNA linear PAT 10-JAN-2003
DEFINITION Sequence 1353 from Patent WO0211674.
ACCESSION AX579515
VERSION AX579515.1 GI:27648717
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
and Grupe,A.
TITLE Method and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
JOURNAL Patent: WO 0211674-A 1353 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES
source Location/Qualifiers
1.17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 477 AGAAGCTCGATCTGAA 492
|||||
Db 1 ATAAGTCGATCTGAA 16

RESULT 305
AX615504
LOCUS AX615504 17 bp DNA linear PAT 20-FEB-2003
DEFINITION Sequence 311 from Patent EP1262488.
ACCESSION AX615504
VERSION AX615504.1 GI:28446550
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Gu,Y. and Nguyen,C.T.
TITLE Human lcll-domain containing protein
JOURNAL Patent: EP 1262488-A 311 04-DEC-2002;
Aeomica, Inc. (US)

```

FEATURES
  source      Location/Qualifiers
    1..17
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match
  Best Local Similarity 87.5%; Score 12.8; DB 1; Length 17;
  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 500 AAGGAGCAGGCTCTGC 515
    ||| ||||| |||
Db 2 AAGAGCAGGCTATGC 17

RESULT 306
AX615505
LOCUS AX615505 17 bp DNA linear PAT 20-FEB-2003
DEFINITION Sequence 312 from Patent EP1262488.
ACCESSION AX615505
VERSION AX615505.1 GI:28446551
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Gu, Y. and Nguyen, C.T.
TITLE Human lcc1-domain containing protein
JOURNAL Patent: EP 1262488-A 312 04-DEC-2002;
Aeomica, Inc. (US)
FEATURES
  source      Location/Qualifiers
    1..17
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match
  Best Local Similarity 87.5%; Score 12.8; DB 1; Length 17;
  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 500 AAGGAGCAGGCTCTGC 515
    ||| ||||| |||
Db 1 AAGAGCAGGCTATGC 16

RESULT 307
AX634500
LOCUS AX634500 17 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 1639 from Patent EP1260586.
ACCESSION AX634500
VERSION AX634500.1 GI:28470114
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb, D.T., Dudycz, L.W., Chowirza, B., Grimm, S., Direnzo, A.,
Karpeisky, A., Draper, K.G., Kisich, K., Matulic-Adamic, J.,
McSwiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M.,
Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, F.E. and
Woolf, T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 1639 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
  source      Location/Qualifiers
    1..17
      /organism="unidentified"
      /mol_type="unassigned RNA"
      /db_xref="taxon:32644"

Query Match
  Best Local Similarity 87.5%; Score 12.8; DB 1; Length 17;
  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 500 AAGGAGCAGGCTCTGC 515
    ||| ||||| |||
Db 1 AAGAGCAGGCTATGC 16

RESULT 308
AX634623
LOCUS AX634623 17 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 1762 from Patent EP1260586.
ACCESSION AX634623
VERSION AX634623.1 GI:28470237
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb, D.T., Dudycz, L.W., Chowirza, B., Grimm, S., Direnzo, A.,
Karpeisky, A., Draper, K.G., Kisich, K., Matulic-Adamic, J.,
McSwiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M.,
Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, F.E. and
Woolf, T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 1762 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
  source      Location/Qualifiers
    1..17
      /organism="unidentified"
      /mol_type="unassigned RNA"
      /db_xref="taxon:32644"

Query Match
  Best Local Similarity 87.5%; Score 12.8; DB 1; Length 17;
  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 461 GAGAGACTCGGCTGG 476
    ||| ||||| |||
Db 1 GAGAACCTCGGCTGG 16

RESULT 309
AX634645
LOCUS AX634645 17 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 1784 from Patent EP1260586.
ACCESSION AX634645
VERSION AX634645.1 GI:28470259
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb, D.T., Dudycz, L.W., Chowirza, B., Grimm, S., Direnzo, A.,
Karpeisky, A., Draper, K.G., Kisich, K., Matulic-Adamic, J.,
McSwiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M.,
Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, F.E. and
Woolf, T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 1784 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
  source      Location/Qualifiers
    1..17
      /organism="unidentified"
      /mol_type="unassigned RNA"
      /db_xref="taxon:32644"

Query Match
  Best Local Similarity 87.5%; Score 12.8; DB 1; Length 17;
  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 461 GAGAGACTCGGCTGG 476
    ||| ||||| |||
Db 1 GAGAACCTCGGCTGG 16

```

Qy 461 GAGAGACTCGGCTGG 476
|||||
Db 1 GAGAACCTCGGCTGG 16

RESULT 310
AX634681
LOCUS AX634681 17 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 1820 from Patent EP1260586.
ACCESSION AX634681
VERSION AX634681.1 GI:28470295
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A., Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J., Meswigen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.B. and Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related genes
JOURNAL Patent: EP 1260586-A 1820 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source 1. .17
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 461 GAGAGACTCGGCTGG 476
|||||
Db 1 GAGAACCTCGGCTGG 16

RESULT 311
AX634688
LOCUS AX634688 17 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 1827 from Patent EP1260586.
ACCESSION AX634688
VERSION AX634688.1 GI:28470302
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A., Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J., Meswigen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.B. and Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related genes
JOURNAL Patent: EP 1260586-A 1827 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source 1. .17
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 461 GAGAGACTCGGCTGG 476
|||||
Db 1 GAGAACCTCGGCTGG 16

RESULT 312
AX648396
LOCUS AX648396 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 236 from Patent EP1273660.
ACCESSION AX648396
VERSION AX648396.1 GI:29151214
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Gu,Y.
TITLE Human sodium-hydrogen exchanger like protein 1
JOURNAL Patent: EP 1273660-A 236 08-JAN-2003;
Aeomica, Inc. (US)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 448 CAGGAACTCGTGGAG 463
|||||
Db 2 CATGAACTCGGAG 17

RESULT 313
AX648397
LOCUS AX648397 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 237 from Patent EP1273660.
ACCESSION AX648397
VERSION AX648397.1 GI:29151215
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Gu,Y.
TITLE Human sodium-hydrogen exchanger like protein 1
JOURNAL Patent: EP 1273660-A 237 08-JAN-2003;
Aeomica, Inc. (US)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 448 CAGGAACTCGTGGAG 463
|||||
Db 1 CATGAACTCGGAG 16

RESULT 314
AX649636/c
LOCUS AX649636/c 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 1476 from Patent EP1273660.
ACCESSION AX649636
VERSION AX649636.1 GI:29152454
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE

1 Gu, Y.
TITLE Human sodium-hydrogen exchanger like protein 1
JOURNAL Patent: EP 1273660-A 1476 08-JAN-2003;
Aeomica, Inc. (US)

FEATURES

source
1. .17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 884 AGAGCAGCGTGTGG 899

Db 17 AGGAGCAGCGTAGTGG 2

RESULT 315

AX649637/c
LOCUS AX649637 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 1477 from Patent EP1273660.
ACCESSION AX649637
VERSION AX649637.1 GI:29152455

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
Gu, Y.

REFERENCE

1
AUTHORS Human sodium-hydrogen exchanger like protein 1
TITLE Patent: EP 1273660-A 1477 08-JAN-2003;
JOURNAL Aeomica, Inc. (US)

FEATURES

source
1. .17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 884 AGAGCAGCGTGTGG 899

Db 16 AGGAGCAGCGTAGTGG 1

RESULT 316

AX674370/c
LOCUS AX674370 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 2815 from Patent WO03004526.
ACCESSION AX674370
VERSION AX674370.1 GI:29332718

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
Telerman, A., Anson, R. and Tuijinder, M.

REFERENCE

1
AUTHORS Sequences involved in phenomena of tumour suppression, tumour
TITLE reversion, apoptosis and/or resistance to viruses and their use as
JOURNAL medicines
Patent: WO 03004526-A 2815 16-JAN-2003;
Molecular Engines Laboratories (FR)

FEATURES

source
1. .17
Location/Qualifiers

/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 203 GGCCCGCAGCAGATC 218

Db 16 GGCTGGCAGCAGATC 1

RESULT 317

AX674379/c
LOCUS AX674379 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 2824 from Patent WO03004526.
ACCESSION AX674379
VERSION AX674379.1 GI:29332727

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
Telerman, A., Anson, R. and Tuijinder, M.

REFERENCE

1
AUTHORS Sequences involved in phenomena of tumour suppression, tumour
TITLE reversion, apoptosis and/or resistance to viruses and their use as
JOURNAL medicines
Patent: WO 03004526-A 2824 16-JAN-2003;
Molecular Engines Laboratories (FR)

FEATURES

source
1. .17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 537 GATGCCAGCAGCAGAT 552

Db 17 GCTGCCAGAGCAGAT 2

RESULT 318

AX687996/c
LOCUS AX687996 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 728 from Patent EP1281758.
ACCESSION AX687996
VERSION AX687996.1 GI:29410694

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
Shannon, M., Gu, Y. and Nguyen, C.T.

REFERENCE

1
AUTHORS Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
TITLE mdz12
JOURNAL Patent: EP 1281758-A 728 05-FEB-2003;
Aeomica, Inc. (US)

FEATURES

source
1. .17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 269 CTGCGCTTCAGAACAGG 284
Db 17 CCGCGCTGCAGAACAGG 2

RESULT 319
AX726310/c
LOCUS AX726310 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 731 from Patent EP1281758.
ACCESSION AX687999
VERSION AX687999.1 GI:29410697
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 731 05-FEB-2003;
Acomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 267 ACCGCTTCAGAAC 282
Db 16 ACCGCTGCAGAAC 1

RESULT 320
AX726310/c
LOCUS AX726310 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 3997 from Patent WO03025175.
ACCESSION AX726310
VERSION AX726310.1 GI:30505653
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025176-A 3997 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 485 GATCTGAAGGCGACA 500
Db 1 GATCTGAAGTGCACA 16

RESULT 321
AX726360/c
LOCUS AX726360 17 bp DNA linear PAT 08-MAY-2003

DEFINITION Sequence 4047 from Patent WO03025176.
ACCESSION AX726360
VERSION AX726360.1 GI:30505703
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025176-A 4047 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 570 CTGTGAAGCCAGGT 585
Db 17 CTGTGACAGCCAGAT 2

RESULT 322
AX729841/c
LOCUS AX729841 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 1475 from Patent WO03025175.
ACCESSION AX729841
VERSION AX729841.1 GI:30509184
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025175-A 1475 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 601 GGAGCTGCAGGAGC 616
Db 16 GGAGCTGCAGTAGATC 1

RESULT 323
AX730931/c
LOCUS AX730931 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2565 from Patent WO03025175.
ACCESSION AX730931
VERSION AX730931.1 GI:30510274
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

```

REFERENCE 1 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS 1 Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
        reversion, apoptosis and/or virus resistance and their use as
        medicines
JOURNAL Patent: WO 03025175-A 2565 27-MAR-2003;
        Molecular Engines Laboratories (FR)
FEATURES 1. .17
        source Location/Qualifiers
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 881 ATCAAGCAGCAGCTGG 896
Db 2 ATCTAGCAGCAGCTGG 17

RESULT 324
AX731926/c AX731926 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 3560 from Patent WO03025175.
DEFINITION AX731926
ACCESSION AX731926
VERSION AX731926.1 GI:30511269
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
        reversion, apoptosis and/or virus resistance and their use as
        medicines
JOURNAL Patent: WO 03025175-A 3560 27-MAR-2003;
        Molecular Engines Laboratories (FR)
FEATURES 1. .17
        source Location/Qualifiers
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 203 GGCCCGCAGCAGATC 218
Db 16 GGCTGGCAGCAGATC 1

RESULT 325
AX736229 AX736229 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 1819 from Patent WO03025177.
DEFINITION AX736229
ACCESSION AX736229
VERSION AX736229.1 GI:30515506
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
        reversion, apoptosis and/or resistance to viruses and the use
        thereof as medicaments
JOURNAL Patent: WO 03025177-A 1819 27-MAR-2003;
        Molecular Engines Laboratories (FR)

```

```

FEATURES 1. .17
        source Location/Qualifiers
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 215 GATCAGCAGCTACTGG 230
Db 1 GATCAGGAAGTTCTGG 16 {

RESULT 326
AX736680/c AX736680 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 2270 from Patent WO03025177.
DEFINITION AX736680
ACCESSION AX736680
VERSION AX736680.1 GI:30515968
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
        reversion, apoptosis and/or resistance to viruses and the use
        thereof as medicaments
JOURNAL Patent: WO 03025177-A 2270 27-MAR-2003;
        Molecular Engines Laboratories (FR)
FEATURES 1. .17
        source Location/Qualifiers
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 473 CTGGAGAGCTCGATC 488
Db 16 CTGGAGACCTAGATC 1

RESULT 327
AX738167 AX738167 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 3757 from Patent WO03025177.
DEFINITION AX738167
ACCESSION AX738167
VERSION AX738167.1 GI:30517455
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
        reversion, apoptosis and/or resistance to viruses and the use
        thereof as medicaments
JOURNAL Patent: WO 03025177-A 3757 27-MAR-2003;
        Molecular Engines Laboratories (FR)
FEATURES 1. .17
        source Location/Qualifiers
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

```



```
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 341 ATCCGGCAGAGCAACC 356
Db 2 ATCTGCGAGAGCATCC 17

RESULT 328
AX759796/c
LOCUS AX759796 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 3117 from Patent WO03040369.
ACCESSION AX759796
VERSION AX759796.1 GI:32254412
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 3117 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 345 GGCAGAGCAACACGAT 360
Db 17 GGAAGAGCAACGACAT 2

RESULT 329
AX760038/c
LOCUS AX760038 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 3359 from Patent WO03040369.
ACCESSION AX760038
VERSION AX760038.1 GI:32254654
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 3359 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 874 CAACCAATCAAGAGC 889
Db 16 CACCACATCAAGATC 1
```

```
RESULT 330
AX760481/c
LOCUS AX760481 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 3802 from Patent WO03040369.
ACCESSION AX760481
VERSION AX760481.1 GI:32255097
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 3802 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 203 GGCCCGCAGCAGATC 218
Db 16 GGGCTGCGCAGCATC 1

RESULT 331
AX761627/c
LOCUS AX761627 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 4948 from Patent WO03040369.
ACCESSION AX761627
VERSION AX761627.1 GI:32256243
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 4948 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 537 GATCCCGCAGCAGATC 552
Db 17 GCTGCCAGAGCAGAT 2

RESULT 332
AX781734
LOCUS AX781734 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 65 from Patent WO03050284.
ACCESSION AX781734
```

[illegible]

```
Db 2 GAGATGGCATCCTGCA 17
||||| ||||| |||
RESULT 337
AX783695
LOCUS AX783695 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 2026 from Patent WO03050284.
ACCESSION AX783695
VERSION AX783695.1 GI:32951544
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Guo,J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 2026 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 334 AGATGCCATCGGCAG 349
||||| ||||| |||||
Db 1 AGATGGCATCTGCAG 16
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 334 AGATGCCATCGGCAG 349
||||| ||||| |||||
Db 1 AGATGGCATCTGCAG 16
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
RESULT 338
AX783780
LOCUS AX783780 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 2111 from Patent WO03050284.
ACCESSION AX783780
VERSION AX783780.1 GI:32951629
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Guo,J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 2111 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 334 AGATGCCATCGGCAG 349
||||| ||||| |||||
Db 1 AGATGGCATCTGCAG 16
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
RESULT 339
AX783783
LOCUS AX783783 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 2114 from Patent WO03050284.
ACCESSION AX783783
VERSION AX783783.1 GI:32951632
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Guo,J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 2114 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 413 GAGAGGAGTTCCTCA 428
||||| ||||| |||||
Db 2 GAGAAGGAATGCCTCA 17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
RESULT 340
AX802176/c
LOCUS AX802176 17 bp DNA linear PAT 24-NOV-2003
DEFINITION Sequence 39 from Patent WO03057727.
ACCESSION AX802176
VERSION AX802176.1 GI:38501075
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Karatzas,C.N. and Turcotte,C.
TITLE Methods of producing silk polypeptides and products thereof
JOURNAL Patent: WO 03057727-A 39 17-JUL-2003;
Nexia Biotechnologies, Inc. (CA)
FEATURES
source
1..17
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Linker sequence"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 718 GCTGCAGCAGCAGCAC 733
||||| ||||| |||||
Db 16 GCCGCAGCAGCAGCCCC 1
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Linker sequence"
RESULT 341
AX802177/c
LOCUS AX802177 17 bp DNA linear PAT 24-NOV-2003
DEFINITION Sequence 40 from Patent WO03057727.
ACCESSION AX802177
VERSION AX802177.1 GI:38501076
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Karatzas,C.N. and Turcotte,C.
TITLE Methods of producing silk polypeptides and products thereof
JOURNAL Patent: WO 03057727-A 40 17-JUL-2003;
Nexia Biotechnologies, Inc. (CA)
FEATURES
source
1..17
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Linker sequence"
```

LOCUS	DEFINITION	SEQUENCE	LENGTH	DB	DATE	STATUS
ARI32395	Sequence 820 from patent US 6194150.	15 bp	15	US	6194150	linear
DEFINITION	Sequence 820 from patent US 6194150.					
ACCESSION	ARI32395					
VERSION	ARI32395.1	GI:14121300				
KEYWORDS	Unknown.					
SOURCE	Unknown.					
ORGANISM	Unknown.					
REFERENCE	1 (bases 1 to 15)					
AUTHORS	Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.					
TITLE	Nucleic acid based inhibition of CD40					
JOURNAL	Patent: US 6194150-A 820 27-FEB-2001;					
FEATURES	Location/Qualifiers					
source	1..15					
ORGANISM="unknown"						
/mol_type="unassigned DNA"						
Query Match	1.6%; Score 12.4; DB 1; Length 15;					
Best Local Similarity	92.9%; Pred. No. 2.7e+02;					
Matches	13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;					
QY	580 CCAGGTGACGTCCT 593					
Db	15 CCAGGTGACGTCCT 2					
RESULT 345						
ARI32460/c						
LOCUS	Sequence 885 from patent US 6194150.	15 bp	15	US	6194150	linear
DEFINITION	Sequence 885 from patent US 6194150.					
ACCESSION	ARI32460					
VERSION	ARI32460.1	GI:14121365				
KEYWORDS	Unknown.					
SOURCE	Unknown.					
ORGANISM	Unknown.					
REFERENCE	1 (bases 1 to 15)					
AUTHORS	Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.					
TITLE	Nucleic acid based inhibition of CD40					
JOURNAL	Patent: US 6194150-A 885 27-FEB-2001;					
FEATURES	Location/Qualifiers					
source	1..15					
ORGANISM="unknown"						
/mol_type="unassigned DNA"						
Query Match	1.6%; Score 12.4; DB 1; Length 15;					
Best Local Similarity	92.9%; Pred. No. 2.7e+02;					
Matches	13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;					
QY	273 CTTCAACAGGCG 286					
Db	15 CTTCAACAGGCG 2					
RESULT 346						
ARI32461/c						
LOCUS	Sequence 886 from patent US 6194150.	15 bp	15	US	6194150	linear
DEFINITION	Sequence 886 from patent US 6194150.					
ACCESSION	ARI32461					
VERSION	ARI32461.1	GI:14121366				
KEYWORDS	Unknown.					
SOURCE	Unknown.					
ORGANISM	Unknown.					
REFERENCE	1 (bases 1 to 15)					
AUTHORS	Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.					
TITLE	Nucleic acid based inhibition of CD40					
JOURNAL	Patent: US 6194150-A 886 27-FEB-2001;					
FEATURES	Location/Qualifiers					
source	1..15					
ORGANISM="unknown"						
/mol_type="unassigned DNA"						
Query Match	1.6%; Score 12.4; DB 1; Length 14;					
Best Local Similarity	92.9%; Pred. No. 2.9e+02;					
Matches	13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;					
QY	380 GAGCTTCTGCATT 393					
Db	14 GAGCTTCTGCATT 1					
RESULT 343						
I93842/c						
LOCUS	Sequence 5 from patent US 5731295.	14 bp	14	US	5731295	linear
DEFINITION	Sequence 5 from patent US 5731295.					
ACCESSION	I93842					
VERSION	I93842.1	GI:3938312				
KEYWORDS						

<hr/>					
Query Match 1.6%; Score 12.4; DB 1; Length 15;					
Best Local Similarity 92.9%; Pred. No. 2.7e+02;					
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;					
<hr/>					
QY	273	CITTCAGAACGAGGC	286		
DB	14	CITTCAGAAAGGGC	1		
<hr/>					
RESULT 347					
BD238450					
LOCUS 15 bp DNA linear PAT 17-JUL-2003					
DEFINITION Nucleic acids provided for modulating cellular activation.					
ACCESSION BD238450					
VERSION BD238450.1 GI:33048220					
KEYWORDS JP 2002517181-A/6.					
SOURCE synthetic construct					
ORGANISM other sequences; artificial sequences.					
REFERENCE 1 (bases 1 to 15)					
AUTHORS Abken,H.					
TITLE Nucleic acids provided for modulating cellular activation					
JOURNAL Patent: JP 2002517181-A 6 18-JUN-2002;					
COMMENT CURACYTE AG					
OS Artificial Sequence					
PN JP 2002517181-A/6					
PD 18-JUN-2002					
PF 05-FEB-1999 JP 2000530601					
PR 06-FEB-1998 DE 198 38 967.1.22-DEC-1998 DE 198 59 056.3 PI					
HINRICH ABKEN					
PC C12N15/09,A61K31/7105,A61P35/00,A61P37/02,A61P43/00, PC					
C12N15/00					
CC Description of Artificial Sequence:synthetic DNA FH Key					
LOCATION/Qualifiers					
FT source 1..15					
FT Location/Qualifiers					
FEATURES					
source					
Query Match 1.6%; Score 12.4; DB 1; Length 15;					
Best Local Similarity 92.9%; Pred. No. 2.7e+02;					
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;					
<hr/>					
QY	369	AGCGCTGCGAGGAG	382		
DB	2	AGCGCGCGAGGAG	15		
<hr/>					
RESULT 348					
BD266203/c					
LOCUS 15 bp DNA linear PAT 17-JUL-2003					
DEFINITION Universal arrays.					
ACCESSION BD266203					
VERSION BD266203.1 GI:33075971					
KEYWORDS JP 2002539849-A/203.					
SOURCE synthetic construct					
ORGANISM other sequences; artificial sequences.					
REFERENCE 1 (bases 1 to 15)					
AUTHORS Fan,J.B., Hirschhorn,J.N., Huang,X., Kaplan,P., Lander,E.S.,					
LOCKHART,D.J., RYDER,T. and SKLAR.P.					
TITLE Universal arrays					
JOURNAL Patent: JP 2002539849-A 203 26-NOV-2002;					
COMMENT WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH, AFFYMETRIX INC					
OS Artificial Sequence					
PN JP 2002539849-A/203					
PD 26-NOV-2002					
PF 27-MAR-2000 JP 2000608794					
PR 26-MAR-1999 US 60/126473,23-JUN-1999 US 60/140359 PI					
<hr/>					
Query Match 1.6%; Score 12.4; DB 1; Length 15;					
Best Local Similarity 92.9%; Pred. No. 2.7e+02;					
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;					
<hr/>					
QY	273	CITTCAGAACGAGGC	286		
DB	14	CITTCAGAAAGGGC	1		
<hr/>					
RESULT 347					
BD238450					
LOCUS 15 bp DNA linear PAT 17-JUL-2003					
DEFINITION Nucleic acids provided for modulating cellular activation.					
ACCESSION BD238450					
VERSION BD238450.1 GI:33048220					
KEYWORDS JP 2002517181-A/6.					
SOURCE synthetic construct					
ORGANISM other sequences; artificial sequences.					
REFERENCE 1 (bases 1 to 15)					
AUTHORS Abken,H.					
TITLE Nucleic acids provided for modulating cellular activation					
JOURNAL Patent: JP 2002517181-A 6 18-JUN-2002;					
COMMENT CURACYTE AG					
OS Artificial Sequence					
PN JP 2002517181-A/6					
PD 18-JUN-2002					
PF 05-FEB-1999 JP 2000530601					
PR 06-FEB-1998 DE 198 38 967.1.22-DEC-1998 DE 198 59 056.3 PI					
HINRICH ABKEN					
PC C12N15/09,A61K31/7105,A61P35/00,A61P37/02,A61P43/00, PC					
C12N15/00					
CC Description of Artificial Sequence:synthetic DNA FH Key					
LOCATION/Qualifiers					
FT source 1..15					
FT Location/Qualifiers					
FEATURES					
source					
Query Match 1.6%; Score 12.4; DB 1; Length 15;					
Best Local Similarity 92.9%; Pred. No. 2.7e+02;					
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;					
<hr/>					
QY	369	AGCGCTGCGAGGAG	382		
DB	2	AGCGCGCGAGGAG	15		
<hr/>					
RESULT 348					
BD266203/c					
LOCUS 15 bp DNA linear PAT 17-JUL-2003					
DEFINITION Universal arrays.					
ACCESSION BD266203					
VERSION BD266203.1 GI:33075971					
KEYWORDS JP 2002539849-A/203.					
SOURCE synthetic construct					
ORGANISM other sequences; artificial sequences.					
REFERENCE 1 (bases 1 to 15)					
AUTHORS Fan,J.B., Hirschhorn,J.N., Huang,X., Kaplan,P., Lander,E.S.,					
LOCKHART,D.J., RYDER,T. and SKLAR.P.					
TITLE Universal arrays					
JOURNAL Patent: JP 2002539849-A 203 26-NOV-2002;					
COMMENT WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH, AFFYMETRIX INC					
OS Artificial Sequence					
PN JP 2002539849-A/203					
PD 26-NOV-2002					
PF 27-MAR-2000 JP 2000608794					
PR 26-MAR-1999 US 60/126473,23-JUN-1999 US 60/140359 PI					
<hr/>					
Query Match 1.6%; Score 12.4; DB 1; Length 15;					
Best Local Similarity 92.9%; Pred. No. 2.7e+02;					
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;					
<hr/>					
QY	308	TGCTGTGGAGGAGAA	321		
DB	14	TGCTGTGGAGAAAA	1		
<hr/>					
RESULT 350					
I64669/c					
LOCUS 15 bp DNA linear PAT 07-OCT-1999					
DEFINITION Sequence 18 from patent US 5665580.					
ACCESSION I64669					
VERSION I64669.1 GI:2481563					
KEYWORDS .					
SOURCE Unknown.					
ORGANISM Unknown.					
REFERENCE 1 (bases 1 to 15)					
AUTHORS Crooke,S.T., Mirabelli,C.K., Ecker,D.J. and Cowsett,L.M.					
TITLE Antisense oligonucleotide inhibition of papillomavirus transformed					
JOURNAL cells					
PATENT: US 5665580-A 18 09-SEP-1997;					

```

Query Match      1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 404 CAGAGGAGGAGGAA 417
    ||||| ||||| |||||
Db 14 CAGAGGAGGAGGAA 1

RESULT 351
AR242016 AR242016 15 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 304 from patent US 6472154.
ACCESSION AR242016
VERSION AR242016.1 GI:27287828
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Garner,H.R., Wren,J.D., Minna,J.D. and Fondon,J.W. III.
TITLE Polymorphic repeats in human genes
JOURNAL Patent: US 6472154-A 304 29-OCT-2002;
FEATURES Location/Qualifiers
    source
        1..15
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match      1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 719 CTCGAGCAGCAGCA 732
    ||||| ||||| |||||
Db 1 CAGCAGCAGCAGCA 14

RESULT 352
AX019392 AX019392 15 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 8 from Patent WO9940187.
ACCESSION AX019392
VERSION AX019392.1 GI:10043362
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Abken,H.
TITLE Nucleic acids provided for modulating cellular activation
JOURNAL Patent: WO 9940187-A 8 12-AUG-1999;
ABKEN HINRICH (DE)
FEATURES Location/Qualifiers
    source
        1..15
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="synthetische"

Query Match      1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 369 AGCGCTGGAGGAG 382
    ||||| ||||| |||||
Db 2 AGCGCGGAGGAG 15

RESULT 353
AX635410 AX635410 15 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 2549 from Patent EP1260586.

```

```

ACCESSION AX635410
VERSION AX635410.1 GI:28471024
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
Genes
JOURNAL Patent: EP 1260586-A 2549 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES Location/Qualifiers
    source
        1..15
            /organism="unidentified"
            /mol_type="unassigned RNA"
            /db_xref="taxon:32644"

Query Match      1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 308 TGCCTGGAGGAGAA 321
    ||||| ||||| |||||
Db 14 TGCCTGGAGGAGAA 1

RESULT 354
BD266350 BD266350 16 bp DNA linear PAT 17-JUL-2003
LOCUS Universal arrays.
DEFINITION
ACCESSION BD266350
VERSION BD266350.1 GI:33076118
KEYWORDS JP 2002539849-A/350.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 16)
AUTHORS Fan,J.B., Hirschhorn,J.N., Huang,X., Kaplan,P., Lander,E.S.,
Lockhart,D.J., Ryder,T. and Sklar,P.
TITLE Universal arrays
JOURNAL Patent: JP 2002539849-A 350 26-NOV-2002;
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH,AFFYMETRIX INC
COMMENT OS Artificial Sequence
    PN JP 2002539849-A/350
    PD 26-NOV-2002
    PR 27-MAR-2000 JP 2000608794
    PI 60/126473,23-JUN-1999 US 60/140359 PI
    JIAN BING FAN,JOEL N HIRSCHHORN,XIAOHUA
    HUANG,PAUL KAPLAN,ERIC
    PI S LANDER,
    PC C12Q1/68,C12M1/00,C12N15/09,C12N15/00,G01N33/53, PC
    GOIN33/566,
    PC GOIN37/00,C12N15/00,C12N15/00,C12N15/00
    CC Primer
    FH Key
    FT source
    FT source
    FT Location/Qualifiers
        1..16
            /organism="synthetic construct"
            /mol_type="genomic DNA"
            /db_xref="taxon:32630"

FEATURES
    source
        1..16
            /organism="synthetic construct"
            /mol_type="genomic DNA"
            /db_xref="taxon:32630"

Query Match      1.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.8%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

Qy 496 GCAGAGGAGGAGG 509
Db 16 GCAGAGGAGGAGG 3

RESULT 355
LOCUS AR211619 16 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 38 from patent US 6399340.
ACCESSION AR211619
VERSION AR211619.1 GI:21514989
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
AUTHORS Saito,Y., Noguchi,Y., Yoshikawa,K. and Soeda,S.
TITLE Vector derivatives of gluconobacter plasmid pF4
JOURNAL Patent: US 6399340-A 38 04-JUN-2002;
FEATURES Location/Qualifiers
source 1..16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 741 AGGTGGACCACTG 754
Db 1 AGGTGGACCACTG 14

RESULT 356
LOCUS AR305487/c 16 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 445 from patent US 6545137.
ACCESSION AR305487
VERSION AR305487.1 GI:31694797
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
AUTHORS Todd,J.A., Hess,J.W., Caskey,C.T., Cox,R.D., Gerhold,D.,
Hammond,H., Hey,P., Kawaguchi,Y., Merriman,T.R., Metzker,M.L.,
Nakagawa,Y., Phillips,M.S. and Twells,R.C.J.
TITLE Receptor
JOURNAL Patent: US 6545137-A 445 08-APR-2003;
FEATURES Location/Qualifiers
source 1..16
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 508 GGCTCTGGGGAGG 521
Db 14 GGCTCTGGGGAGG 1

RESULT 357
LOCUS AR309591/c 16 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 445 from patent US 6555654.
ACCESSION AR309591
VERSION AR309591.1 GI:31701596
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
AUTHORS Remacle,J., Hamels,S., Zammatteo,N., Lockman,L., Dufour,S.,
Alexandre,I. and de Longueville,F.
TITLE Identification of biological (micro) organisms by detection of the
JOURNAL ir homologous nucleotide sequences on arrays
Patent: WO 0177372-A 150 18-OCT-2001;
Facultes Universitaires Notre-Dame de la Paix (BE)
FEATURES Location/Qualifiers
source 1..16
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db xref="taxon:32630"
/note="Antisense consensus Primer subtypes 5A, 5B"

REFERENCE 1 (bases 1 to 16)
AUTHORS Todd,J.A., Hess,J.W., Caskey,C.T., Cox,R.D., Gerhold,D.,
Hammond,H., Hey,P., Kawaguchi,Y., Merriman,T.R., Metzker,M.L.,
Nakagawa,Y., Phillips,M.S. and Twells,R.C.J.
TITLE LDL-receptor
JOURNAL Patent: US 6555654-A 445 29-APR-2003;
FEATURES Location/Qualifiers
source 1..16
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 508 GGCTCTGGGGAGG 521
Db 14 GGCTCTGGGGAGG 1

RESULT 358
LOCUS AR328254/c 16 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 5656 from patent US 6566127.
ACCESSION AR328254
VERSION AR328254.1 GI:33714062
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 5656 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..16
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 1.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 705 GTGAGCGCGAGCGG 718
Db 16 GTGAGCGCGAGCGG 3

RESULT 359
LOCUS AX278613 16 bp DNA linear PAT 02-NOV-2001
DEFINITION Sequence 150 from Patent WO0177372.
ACCESSION AX278613
VERSION AX278613.1 GI:16606067
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE
AUTHORS Remacle,J., Hamels,S., Zammatteo,N., Lockman,L., Dufour,S.,
Alexandre,I. and de Longueville,F.
TITLE Identification of biological (micro) organisms by detection of the
JOURNAL ir homologous nucleotide sequences on arrays
Patent: WO 0177372-A 150 18-OCT-2001;
Facultes Universitaires Notre-Dame de la Paix (BE)
FEATURES Location/Qualifiers
source 1..16
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db xref="taxon:32630"
/note="Antisense consensus Primer subtypes 5A, 5B"

```

Query Match      1.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 406 GAGGGAGGAGGAGG 419
Db 14 GAGGGAGGAGGAGG 1

RESULT 360
AX659627
LOCUS AX659627 16 bp DNA linear PAT 03-APR-2003
DEFINITION Sequence 21 from Patent WO02103014.
ACCESSION AX659627
VERSION AX659627.1 GI:29161809
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE
1
AUTHORS Al-Mahmood,S.
TITLE Antisense oligonucleotides which can inhibit the formation of
capillary tubes by endothelial cells
JOURNAL Patent: WO 02103014-A 21 27-DEC-2002;
Al-Mahmood, Salman (PR)
FEATURES
source
1..16
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonucleotide anti-sens."

Query Match      1.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 253 GCACGCCATGCTGC 266
Db 2 GCCTGCCATGCTGC 15

RESULT 361
BD106398/c
LOCUS BD106398 16 bp DNA linear PAT 18-SEP-2002
DEFINITION Novel LDL-receptor.
ACCESSION BD106398
VERSION BD106398.1 GI:23201216
KEYWORDS JP 2002501376-A/413.
SOURCE Chlamydia sp.
ORGANISM Chlamydia sp.
REFERENCE
1 (bases 1 to 16)
AUTHORS Todd,J.A., Hess,J.W., Caskey,C.T., Cox,R.D., Gerhold,D., Hammond,H.
and Hey,P.
TITLE Novel LDL-receptor
JOURNAL Patent: JP 2002501376-A 413 15-JAN-2002;
THE WELLCOME TRUST LTD AS TRUSTEE TO THE WELLCOME TRUST, MERCK & CO
INC
COMMENT
PN JP 2002501376-A/413
PD 15-JAN-2002
PF 15-APR-1998 JP 1998543635
PR 15-APR-1997 US 60/043553,05-JUN-1997 US 60/048740 PI
JOHN ANDREW TODD,JOHN WILFRED HESS,CHARLES
THOMAS CASKEY,ROGER
PI DAVID COX
PI DAVID GERHOLD,HOLLY HAMMOND,PATRICIA HEY
PC C12N15/12,C12N15/11,C12Q1/68,C07K14/705,C07K16/28,A61K38/17,
A61K39/395,
PC A61K48/00
CC Strandedness: Double;
CC Topology: Linear;
CC Key Location/Qualifiers.
FH Key Location/Qualifiers

```

```

source 1..16
/organism="Chlamydia sp."
/mol_type="genomic DNA"
/db_xref="taxon:35827"

Query Match      1.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 508 GGCTCTGGCGGAGG 521
Db 14 GGCTCTGGCGGAGG 1

Search completed: April 8, 2005, 08:39:11
Job time : 4 secs

```


THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 8, 2005, 08:53:42 ; Search time 1 Seconds
(without alignments)
0.630 Million cell updates/sec

Title: US-10-628-841-3
Perfect score: 755
Sequence: 1 tctggaagagccaactgtgt.....tgggcagtgcggaagcga 755

Scoring table: IDENTITY NUC
Gapop 10_0 , Gapext 0.5

Searched: 31 seqs, 417 residues

Total number of hits satisfying chosen parameters: 62

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 32 summaries

Database : fetch3rst.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
C 1	16.8	2.2	22	1	BG926061	ACCESSION:BG926061
2	12.8	1.7	17	1	CF305567	ACCESSION:CF305567
3	12	1.6	12	1	AJ593912	ACCESSION:AJ593912
4	12	1.6	12	1	AJ594491	ACCESSION:AJ594491
5	12	1.6	13	1	AJ590284	ACCESSION:AJ590284
6	12	1.6	13	1	AJ592721	ACCESSION:AJ592721
7	12	1.6	13	1	AJ593693	ACCESSION:AJ593693
8	12	1.6	13	1	AJ593750	ACCESSION:AJ593750
9	12	1.6	13	1	AJ594409	ACCESSION:AJ594409
10	12	1.6	14	1	AJ587585	ACCESSION:AJ587585
11	12	1.6	14	1	AJ592722	ACCESSION:AJ592722
12	12	1.6	14	1	AJ592942	ACCESSION:AJ592942
13	12	1.6	15	1	AJ593961	ACCESSION:AJ593961
14	12	1.6	16	1	AJ588998	ACCESSION:AJ588998
15	11.4	1.5	15	1	AJ595331	ACCESSION:AJ595331
16	11	1.5	13	1	AJ591455	ACCESSION:AJ591455
C 17	10.6	1.4	17	1	CF305567	ACCESSION:CF305567
18	10.4	1.4	12	1	AJ587934	ACCESSION:AJ587934
19	10.4	1.4	12	1	AJ593993	ACCESSION:AJ593993
20	10.4	1.4	13	1	AJ593342	ACCESSION:AJ593342
21	10.4	1.4	13	1	AJ594410	ACCESSION:AJ594410
22	10.4	1.4	13	1	AJ598779	ACCESSION:AJ598779
23	10.4	1.4	13	1	AJ598718	ACCESSION:AJ598718
24	10.4	1.4	13	1	AJ599128	ACCESSION:AJ599128
25	10.4	1.4	13	1	AJ599161	ACCESSION:AJ599161
26	10	1.3	10	1	AJ592517	ACCESSION:AJ592517
27	10	1.3	11	1	BM395068	ACCESSION:BM395068
C 28	9.8	1.3	13	1	AJ650760	ACCESSION:AJ650760
C 29	9.8	1.3	13	1	AJ687457	ACCESSION:AJ687457
C 30	9.8	1.3	13	1	BG926067	ACCESSION:BG926067
31	9.8	1.3	13	1	CF921303	ACCESSION:CF921303
C 32	9.8	1.3	13	1	AJ588600	ACCESSION:AJ588600

ALIGNMENTS

```
RESULT 1
BG926061/c
LOCUS      HNC23-1-E2.R HNC (Human Normal Cartilage) Homo sapiens cDNA, mRNA
DEFINITION
sequence.
ACCESSION  BG926061
VERSION    BG926061.1
KEYWORDS   GI:14320584
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
REFERENCE  1 (bases 1 to 22)
AUTHORS   Kumar,S., Connor,J.R., Dodds,R.A., Halsey,W., Van Horn,M., Mao,J.,
          Satche,G., Mui,P., Agarwal,P., Badger,A.M., Lee,J.C., Gowen,M. and
          Lark,M.W.
TITLE      Identification and initial characterization of 5000 expressed
          sequenced tags (ESTs) each from adult human normal and
          osteoarthritic cartilage cDNA libraries
JOURNAL    Osteoarthritis. Cartil. 9 (7), 641-653 (2001)
MEDLINE    21482651
PUBMED     11597177
COMMENT    Contact: Sanjay Kumar
          UW2109
          GlaxoSmithKline
          709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406, USA
          Tel: 610-270-7245
          Fax: 610-270-5598
          Email: sanjay.kumar-1@gsk.com
          Seq primer: 17.
FEATURES   Location/Qualifiers
            source          1..22
                        /organism="Homo sapiens"
                        /mol_type="mRNA"
                        /db_xref="taxon:9606"
                        /tissue_type="cartilage"
                        /lab_host="E.coli DH10 B"
                        /clone_lib="HNC (Human Normal Cartilage)"
                        /note="Vector: pSPORT 1; Site_1: SalI; Site_2: NotI;
                        Directional"
            Query Match    2.2%; Score 16.8; DB 1; Length 22;
            Best Local Similarity 90.0%; Pred. No. 1.2;
            Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
            Qy 402 GCCAGAGGGAGGAGGAGGAG 421
            Db 21 GCGCGAGGGAGGAGGAGGAG 2
            RESULT 2
CF305567
LOCUS      HDAL1--01-B07.g1 OshDAC1-overexpressing transgenic rice lambda phage
DEFINITION
cDNA library 1 (HDAL1) Oryza sativa (japonica cultivar-group) cDNA
clone HDAL1--01-B07, mRNA sequence.
ACCESSION  CF305567
VERSION    CF305567.1
KEYWORDS   GI:33677328
SOURCE     Oryza sativa (japonica cultivar-group)
ORGANISM   Oryza sativa (japonica cultivar-group)
REFERENCE  1 (bases 1 to 17)
AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
          Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
          Large-scale Sequencing Analysis of Rice ESTs
          Unpublished (2003)
          JOURNAL
```

```

COMMENT
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@gbio.com, bhnahm@bio.myongji.ac.kr.

FEATURES
source
1. .17
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39347"
/clone="HDAL-01-B07"
/tissue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 2 weeks"
/lab_host="E.coli SOLR"
/clone_lib="OSHDAC1-overexpressing transgenic rice lambda
phage cDNA library I (HDAL)"
/notes="Vector: pBluescript SK(+); Site 1: EcoRI; Site 2:
XhoI; Callus was treated with ABA(20um) for 1 hour. cDNA
was inserted into lambda Uni-ZAP XR vector at 5' end with
EcoRI and 3' end with XhoI site. mRNA was derived from
rice Histone Deacetylase overexpression line."

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 709 GCGGAGCGCTGCAG 724
| | | | | | | | | | | | | | | |
Db 2 GCACGAGCGCTGCCG 17

RESULT 3
AJ593912
LOCUS
DEFINITION
Arabidopsis thaliana T-DNA flanking sequence, left border, clone
389E12, genomic survey sequence.
ACCESSION
AJ593912
VERSION
AJ593912.1 Gi:37943536
KEYWORDS
GSS; left border; T-DNA flanking sequence.
SOURCE
Arabidopsis thaliana
ORGANISM
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
1
REFERENCE
AUTHORS
Brunaud,V., Balzerque,S., Dubreucq,B., Aubourg,S., Samson,F.,
Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pelletier,G.,
Lepiniec,L., Caboche,M. and Lecharny,A.
T-DNA integration into the Arabidopsis genome depends on sequences
of pre-insertion sites
EMBO Rep. 3 (12), 1152-1157 (2002)
2363535
12446565
2 (bases 1 to 12)
Balzerque,S.
Direct Submission
Submitted (23-OCT-2003) Balzerque S., UMRGV, INRA/CNRS, 2 rue
Gaston Cremieux, 91057 Evry cedex, FRANCE
PCR was performed on DNA from transformants of Arabidopsis thaliana
plants from INRA (Versailles). The DNA fragment(s) resulting from
the PCR were directly sequenced from the left or the right border
to determine the genomic sequence flanking the insertion. T-DNA
derived sequences were removed. Information to order the
corresponding mutant line and a link to a database providing a
graphical display of the insertion site are available at
http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
been generated in the framework of the French plant genomics
program 'Genoplante' (http://www.genoplante.com and
http://genoplante-info.infobiogen.fr).
Location/Qualifiers

FEATURES
source
1. .12
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassiljewskija"
/db_xref="taxon:3702"
/clone="389E12"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
/notes="T-DNA flanking sequence
left border"

Query Match 1.6%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 6.3;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 669 CCCGCGCGGCCA 680
| | | | | | | | | | | | | | | |
Db 1 CCCGCGCGGCCA 12

RESULT 4
AJ594491
LOCUS
DEFINITION
Arabidopsis thaliana T-DNA flanking sequence, left border, clone
399F03, genomic survey sequence.
ACCESSION
AJ594491
VERSION
AJ594491.1 Gi:37944115
KEYWORDS
GSS; left border; T-DNA flanking sequence.
SOURCE
Arabidopsis thaliana (thale cress)
ORGANISM
Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
1
REFERENCE
AUTHORS
Brunaud,V., Balzerque,S., Dubreucq,B., Aubourg,S., Samson,F.,
Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pelletier,G.,
Lepiniec,L., Caboche,M. and Lecharny,A.
T-DNA integration into the Arabidopsis genome depends on sequences
of pre-insertion sites
EMBO Rep. 3 (12), 1152-1157 (2002)
22363535
12446565
2 (bases 1 to 12)
Balzerque,S.
Direct Submission
Submitted (23-OCT-2003) Balzerque S., UMRGV, INRA/CNRS, 2 rue
Gaston Cremieux, 91057 Evry cedex, FRANCE
PCR was performed on DNA from transformants of Arabidopsis thaliana
plants from INRA (Versailles). The DNA fragment(s) resulting from
the PCR were directly sequenced from the left or the right border
to determine the genomic sequence flanking the insertion. T-DNA
derived sequences were removed. Information to order the
corresponding mutant line and a link to a database providing a
graphical display of the insertion site are available at
http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
been generated in the framework of the French plant genomics
program 'Genoplante' (http://www.genoplante.com and
http://genoplante-info.infobiogen.fr).
Location/Qualifiers

FEATURES
source
1. .12
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassiljewskija"
/db_xref="taxon:3702"
/clone="399F03"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
/notes="T-DNA flanking sequence
left border"

Query Match 1.6%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 6.3;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      669  CCCGGCGGCCA 680
Db      1  CCCGGCGGCCA 12

RESULT 5
AJ590284
LOCUS   Arabidopsis thaliana T-DNA flanking sequence, left border, clone
DEFINITION
ACCESSION AJ590284.1 GI:37939908
VERSION   13 bp DNA linear GSS 15-JAN-2004
KEYWORDS GSS; left border; T-DNA flanking sequence.
SOURCE   Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana
          Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
          Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
          rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE
AUTHORS  Brunaud, V., Balzergue, S., Dubreucq, B., Aubourg, S., Samson, F.,
          Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,
          Lepiniec, L., Caboche, M. and Lecharny, A.
          T-DNA integration into the Arabidopsis genome depends on sequences
          of pre-insertion sites
          EMBO Rep. 3 (12), 1152-1157 (2002)
JOURNAL  22363535
MEDLINE  12446565
PUBMED   12446565
REFERENCE 2 (bases 1 to 13)
AUTHORS  Balzergue, S.
TITLE    Direct Submission
JOURNAL  Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue
          Gaston Cremieux, 91057 Evry cedex, FRANCE
COMMENT  PCR was performed on DNA from transformants of Arabidopsis thaliana
          plants from INRA (Versailles). The DNA fragment(s) resulting from
          the PCR were directly sequenced from the left or the right border
          to determine the genomic sequence flanking the insertion. T-DNA
          derived sequences were removed. Information to order the
          corresponding mutant line and a link to a database providing a
          graphical display of the insertion site are available at
          http://dbgap.versailles.inra.fr/publiclines/. This sequence has
          been generated in the framework of the French plant genomics
          program 'Genoplatane' (http://www.genoplatane.com and
          http://genoplatane-info.infobiogen.fr).

FEATURES
source
1..13
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassillewskija"
/db_xref="taxon:3702"
/clone="631A03"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
misc_feature
1..13
/notes="T-DNA flanking sequence
right border"

Query Match 1.6%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 7.2;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      669  CCCGGCGGCCA 680
Db      2  CCCGGCGGCCA 13

RESULT 7
AJ593693
LOCUS   Arabidopsis thaliana T-DNA flanking sequence, left border, clone
DEFINITION
ACCESSION AJ593693
VERSION   13 bp DNA linear GSS 15-JAN-2004
KEYWORDS GSS; left border; T-DNA flanking sequence.
SOURCE   Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana
          Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
          Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
          rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE
AUTHORS  Brunaud, V., Balzergue, S., Dubreucq, B., Aubourg, S., Samson, F.,
          Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,
          Lepiniec, L., Caboche, M. and Lecharny, A.
          T-DNA integration into the Arabidopsis genome depends on sequences
          of pre-insertion sites
          EMBO Rep. 3 (12), 1152-1157 (2002)
JOURNAL  22363535
MEDLINE  12446565
PUBMED   12446565

```

```

REFERENCE
AUTHORS      2 (bases 1 to 13)
TITLE        Balzerque,S.
JOURNAL      Direct Submission
COMMENT      Submitted (23-OCT-2003) Balzerque S., UMRGV, INRA/CNRS, 2 rue
             Gaston Cremieux, 91057 Evry cedex, FRANCE
             PCR was performed on DNA from transformants of Arabidopsis thaliana
             plants from INRA (Versailles). The DNA fragment(s) resulting from
             the PCR were directly sequenced from the left or the right border
             to determine the genomic sequence flanking the insertion. T-DNA
             derived sequences were removed. Information to order the
             corresponding mutant line and a link to a database providing a
             graphical display of the insertion site are available at
             http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
             been generated in the framework of the French plant genomics
             program 'Genoplante' (http://www.genoplante.com and
             http://genoplante-info.infobiogen.fr).

FEATURES             source
             1..13
             /organism="Arabidopsis thaliana"
             /mol_type="genomic DNA"
             /cultivar="Wassilewskija"
             /db_xref="taxon:3702"
             /clone="385F05"
             /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
             misc_feature
             1..13
             /note="T-DNA flanking sequence
             left border"

             Query Match      1.6%; Score 12; DB 1; Length 13;
             Best Local Similarity 100.0%; Pred. No. 7.2;
             Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

             QY      669 CCGGGCGGCCA 680
             Db      2 CCGGGCGGCCA 13
             |||||
             RESULT 9
             AJ594409
             LOCUS
             DEFINITION Arabidopsis thaliana T-DNA flanking sequence
             ACCESSION AJ594409
             VERSION AJ594409.1 GI:37943374
             KEYWORDS GSS; left border; T-DNA flanking sequence.
             SOURCE Arabidopsis thaliana (thale cress)
             ORGANISM Arabidopsis thaliana
                     Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
                     Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
                     rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
             REFERENCE
             AUTHORS      1
                     Brunaud,V., Balzerque,S., Dubreucq,B., Aubourg,S., Samson,F.,
                     Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pelletier,G.,
                     Lepiniec,L., Caboche,M. and Lecharny,A.
                     T-DNA integration into the Arabidopsis genome depends on sequences
                     of pre-insertion sites
                     EMBO Rep. 3 (12), 1152-1157 (2002)
                     22363535
                     PUBLISHED 12446565
                     REFERENCE 2 (bases 1 to 13)
                     Balzerque,S.
                     Direct Submission
                     Submitted (23-OCT-2003) Balzerque S., UMRGV, INRA/CNRS, 2 rue
                     Gaston Cremieux, 91057 Evry cedex, FRANCE
                     PCR was performed on DNA from transformants of Arabidopsis thaliana
                     plants from INRA (Versailles). The DNA fragment(s) resulting from
                     the PCR were directly sequenced from the left or the right border
                     to determine the genomic sequence flanking the insertion. T-DNA
                     derived sequences were removed. Information to order the
                     corresponding mutant line and a link to a database providing a
                     graphical display of the insertion site are available at
                     http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
                     been generated in the framework of the French plant genomics
                     program 'Genoplante' (http://www.genoplante.com and
                     http://genoplante-info.infobiogen.fr).

FEATURES             source
             1..13
             /organism="Arabidopsis thaliana"
             /mol_type="genomic DNA"
             /cultivar="Wassilewskija"
             /db_xref="taxon:3702"
             /clone="385F05"
             /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
             misc_feature
             1..13
             /note="T-DNA flanking sequence
             left border"

             Query Match      1.6%; Score 12; DB 1; Length 13;
             Best Local Similarity 100.0%; Pred. No. 7.2;
             Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

             QY      669 CCGGGCGGCCA 680
             Db      2 CCGGGCGGCCA 13
             |||||
             RESULT 8
             AJ593750
             LOCUS
             DEFINITION Arabidopsis thaliana T-DNA flanking sequence, left border, clone
             385F02, genomic survey sequence.
             ACCESSION AJ593750
             VERSION AJ593750.1 GI:37943374
             KEYWORDS GSS; left border; T-DNA flanking sequence.
             SOURCE Arabidopsis thaliana (thale cress)
             ORGANISM Arabidopsis thaliana
                     Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
                     Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
                     rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
             REFERENCE
             AUTHORS      1
                     Brunaud,V., Balzerque,S., Dubreucq,B., Aubourg,S., Samson,F.,
                     Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pelletier,G.,
                     Lepiniec,L., Caboche,M., and Lecharny,A.
                     T-DNA integration into the Arabidopsis genome depends on sequences
                     of pre-insertion sites
                     EMBO Rep. 3 (12), 1152-1157 (2002)
                     22363535
                     PUBLISHED 12446565
                     REFERENCE 2 (bases 1 to 13)
                     Balzerque,S.
                     Direct Submission
                     Submitted (23-OCT-2003) Balzerque S., UMRGV, INRA/CNRS, 2 rue
                     Gaston Cremieux, 91057 Evry cedex, FRANCE
                     PCR was performed on DNA from transformants of Arabidopsis thaliana
                     plants from INRA (Versailles). The DNA fragment(s) resulting from
                     the PCR were directly sequenced from the left or the right border
                     to determine the genomic sequence flanking the insertion. T-DNA
                     derived sequences were removed. Information to order the
                     corresponding mutant line and a link to a database providing a
                     graphical display of the insertion site are available at
                     http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
                     been generated in the framework of the French plant genomics

```

```

Query Match      1.6%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 7.2;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 669 CCGGGCGGCCA 680
Db 2 CCGGGCGGCCA 13

RESULT 10
AJ587585
LOCUS
DEFINITION
  Arabidopsis thaliana T-DNA flanking sequence, left border, clone
  296A05, genomic survey sequence.
ACCESSION
  AJ587585
VERSION
  1 GI:37937209
KEYWORDS
  GSS; left border; T-DNA flanking sequence.
SOURCE
  Arabidopsis thaliana (thale cress)
ORGANISM
  Arabidopsis thaliana
  Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
  Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
  rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE
1
AUTHORS
  Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, F.,
  Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,
  Lepiniec, L., Caboche, M. and Lecharny, A.
  T-DNA integration into the Arabidopsis genome depends on sequences
  of pre-insertion sites
JOURNAL
  EMBO Rep. 3 (12), 1152-1157 (2002)
MEDLINE
  22363535
PUBMED
  12446565
REFERENCE
2 (bases 1 to 14)
AUTHORS
  Balzerque, S.
TITLE
  Direct Submission
  Submitted (23-OCT-2003) Balzerque S., UMRGV, INRA/CNRS, 2 rue
  Gaston Cremieux, 91057 Evry cedex, FRANCE
COMMENT
  PCR was performed on DNA from transformants of Arabidopsis thaliana
  plants from INRA (Versailles). The DNA fragment(s) resulting from
  the PCR were directly sequenced from the left or the right border
  to determine the genomic sequence flanking the insertion. T-DNA
  derived sequences were removed. Information to order the
  corresponding mutant line and a link to a database providing a
  graphical display of the insertion site are available at
  http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
  been generated in the framework of the French plant genomics
  program 'Genoplatte' (http://www.genoplatte.com and
  http://genoplatte-info.infobiogen.fr).

FEATURES
    source
        1..14
            /organism="Arabidopsis thaliana"
            /mol_type="genomic DNA"
            /cultivar="Wassiljewskija"
            /db_xref="taxon:3702"
            /clone="296A05"
            /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
    misc_feature
        1..14
            /note="T-DNA flanking sequence
            left border"

Query Match      1.6%; Score 12; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 8.1;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 669 CCGGGCGGCCA 680
Db 1 CCGGGCGGCCA 12

RESULT 12
AJ592942
LOCUS
DEFINITION
  Arabidopsis thaliana T-DNA flanking sequence, left border, clone
  372B12, genomic survey sequence.
ACCESSION
  AJ592942
VERSION
  1 GI:37942566
KEYWORDS
  GSS; left border; T-DNA flanking sequence.
SOURCE
  Arabidopsis thaliana (thale cress)
ORGANISM
  Arabidopsis thaliana
  Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
  Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
  rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE
1
AUTHORS
  Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, F.,
  Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,
  Lepiniec, L., Caboche, M. and Lecharny, A.
  T-DNA integration into the Arabidopsis genome depends on sequences
  of pre-insertion sites

QY 669 CCGGGCGGCCA 680
Db 2 CCGGGCGGCCA 13

RESULT 11
AJ592722
LOCUS
DEFINITION
  Arabidopsis thaliana T-DNA flanking sequence, left border, clone
  369E05, genomic survey sequence.

```

JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS
JOURNAL

EMBO Rep. 3 (12), 1152-1157 (2002)
22363535
12446565
2 (bases 1 to 14)
Balzergue, S.
Direct Submission
Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue
Gaston Cremieux, 91057 Evry cedex, FRANCE
PCR was performed on DNA from transformants of *Arabidopsis thaliana*
plants from INRA (Versailles). The DNA fragment(s) resulting from
the PCR were directly sequenced from the left or the right border
to determine the genomic sequence flanking the insertion. T-DNA
derived sequences were removed. Information to order the
corresponding mutant line and a link to a database providing a
graphical display of the insertion site are available at
<http://dbsgap.versailles.inra.fr/publiclines/>. This sequence has
been generated in the framework of the French plant genomics
program 'Genoplante' (<http://www.genoplante.com> and
<http://genoplante-info.infobiogen.fr>).

FEATURES
source
Location/Qualifiers
1..14
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassiljewskija"
/db_xref="taxon:3702"
/clone="372B12"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
misc_feature
1..14
/notes="T-DNA flanking sequence
left border"

Query Match 1.6%; Score 12; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 8.1;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 669 CCGGGCGGCCA 680
|||||
Db 1 CCGGGCGGCCA 12

RESULT 13
AJ593961
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

AJ593961 15 bp DNA linear GSS 15-JAN-2004
Arabidopsis thaliana T-DNA flanking sequence, left border, clone
390C05, genomic survey sequence.
AJ593961.1 GI:37943585
GSS; left border; T-DNA flanking sequence.
Arabidopsis thaliana (thale cress)
Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE
AUTHORS
TITLE
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS
JOURNAL

Brunaud, V., Balzergue, S., Dubreucq, B., Aubourg, S., Samson, F.,
Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,
Lepiniec, L., Caboche, M. and Lecharny, A.
T-DNA integration into the *Arabidopsis* genome depends on sequences
of pre-insertion sites
EMBO Rep. 3 (12), 1152-1157 (2002)
22363535
12446565
2 (bases 1 to 15)
Balzergue, S.
Direct Submission
Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue
Gaston Cremieux, 91057 Evry cedex, FRANCE
PCR was performed on DNA from transformants of *Arabidopsis thaliana*
plants from INRA (Versailles). The DNA fragment(s) resulting from
the PCR were directly sequenced from the left or the right border
to determine the genomic sequence flanking the insertion. T-DNA
derived sequences were removed. Information to order the
corresponding mutant line and a link to a database providing a

graphical display of the insertion site are available at
<http://dbsgap.versailles.inra.fr/publiclines/>. This sequence has
been generated in the framework of the French plant genomics
program 'Genoplante' (<http://www.genoplante.com> and
<http://genoplante-info.infobiogen.fr>).

FEATURES
source
Location/Qualifiers
1..15
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassiljewskija"
/db_xref="taxon:3702"
/clone="390C05"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
misc_feature
1..15
/notes="T-DNA flanking sequence
left border"

Query Match 1.6%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 9;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 669 CCGGGCGGCCA 680
|||||
Db 1 CCGGGCGGCCA 12

RESULT 14
AJ588998
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

AJ588998 16 bp DNA linear GSS 15-JAN-2004
Arabidopsis thaliana T-DNA flanking sequence, right border, clone
542F02, genomic survey sequence.
AJ588998.1 GI:37938622
GSS; right border; T-DNA flanking sequence.
Arabidopsis thaliana (thale cress)
Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE
AUTHORS
TITLE
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS
JOURNAL

Brunaud, V., Balzergue, S., Dubreucq, B., Aubourg, S., Samson, F.,
Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,
Lepiniec, L., Caboche, M. and Lecharny, A.
T-DNA integration into the *Arabidopsis* genome depends on sequences
of pre-insertion sites
EMBO Rep. 3 (12), 1152-1157 (2002)
22363535
12446565
2 (bases 1 to 16)
Balzergue, S.
Direct Submission
Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue
Gaston Cremieux, 91057 Evry cedex, FRANCE
PCR was performed on DNA from transformants of *Arabidopsis thaliana*
plants from INRA (Versailles). The DNA fragment(s) resulting from
the PCR were directly sequenced from the left or the right border
to determine the genomic sequence flanking the insertion. T-DNA
derived sequences were removed. Information to order the
corresponding mutant line and a link to a database providing a
graphical display of the insertion site are available at
<http://dbsgap.versailles.inra.fr/publiclines/>. This sequence has
been generated in the framework of the French plant genomics
program 'Genoplante' (<http://www.genoplante.com> and
<http://genoplante-info.infobiogen.fr>).

FEATURES
source
Location/Qualifiers
1..16
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassiljewskija"
/db_xref="taxon:3702"
/clone="542F02"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
misc_feature
1..16

```

/note="T-DNA flanking sequence
right border"

Query Match      1.6%; Score 12; DB 1; Length 16;
Best Local Similarity 92.3%; Pred. No. 10;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 668 GCCCGGGCGGCCA 680
    ||||| |||||
Db 4 GCCCGGCGGCCA 16

RESULT 15
AJ595331
LOCUS      Arabidopsis thaliana T-DNA flanking sequence, left border, clone
DEFINITION
VERSION    AJ595331.1 GI:37944955
KEYWORDS   GSS; left border; T-DNA flanking sequence.
SOURCE     Arabidopsis thaliana (thale cress)
ORGANISM   Arabidopsis thaliana
REFERENCE  1
AUTHORS    Brunaud,V., Balzergue,S., Dubreucq,B., Aubourg,S., Samson,F.,
            Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pelletier,G.,
            Lepiniec,L., Caboche,M. and Lecharny,A.
            T-DNA integration into the Arabidopsis genome depends on sequences
            of pre-insertion sites
            EMBO Rep. 3 (12), 1152-1157 (2002)
            22363535
            PUBMED 12446565
            REFERENCE 2 (bases 1 to 15)
            Balzergue,S.
            Direct Submission
            Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue
            Gaston Cremieux, 91057 Evry cedex, FRANCE
            PCR was performed on DNA from transformants of Arabidopsis thaliana
            plants from INRA (Versailles). The DNA fragment(s) resulting from
            the PCR were directly sequenced from the left or the right border
            to determine the genomic sequence flanking the insertion. T-DNA
            derived sequences were removed. Information to order the
            corresponding mutant line and a link to a database providing a
            graphical display of the insertion site are available at
            http://dbgap.versailles.inra.fr/publiclines/. This sequence has
            been generated in the framework of the French plant genomics
            program 'Genoplante' (http://www.genoplante.com and
            http://genoplante-info.inbio.gen.fr).
            Location/Qualifiers
            source          1..15
                           /organism="Arabidopsis thaliana"
                           /mol_type="genomic DNA"
                           /cultivar="Wassillewskija"
                           /db_xref="taxon:3702"
                           /clone="415C10"
                           /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
            misc_feature    1..15
                           /note="T-DNA flanking sequence
                           left border"

Query Match      1.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 12;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 669 CCCGGCGGCCAGCG 683
    ||||| |||||
Db 1 CCCGGCGGCCCTNNG 15

RESULT 16
AJ591455
LOCUS      Arabidopsis thaliana T-DNA flanking sequence, left border, clone
DEFINITION
VERSION    AJ591455
KEYWORDS   GSS; left border; T-DNA flanking sequence.
SOURCE     Arabidopsis thaliana (thale cress)
ORGANISM   Arabidopsis thaliana
REFERENCE  1
AUTHORS    Brunaud,V., Balzergue,S., Dubreucq,B., Aubourg,S., Samson,F.,
            Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pelletier,G.,
            Lepiniec,L., Caboche,M. and Lecharny,A.
            T-DNA integration into the Arabidopsis genome depends on sequences
            of pre-insertion sites
            EMBO Rep. 3 (12), 1152-1157 (2002)
            22363535
            PUBMED 12446565
            REFERENCE 2 (bases 1 to 13)
            Balzergue,S.
            Direct Submission
            Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue
            Gaston Cremieux, 91057 Evry cedex, FRANCE
            PCR was performed on DNA from transformants of Arabidopsis thaliana
            plants from INRA (Versailles). The DNA fragment(s) resulting from
            the PCR were directly sequenced from the left or the right border
            to determine the genomic sequence flanking the insertion. T-DNA
            derived sequences were removed. Information to order the
            corresponding mutant line and a link to a database providing a
            graphical display of the insertion site are available at
            http://dbgap.versailles.inra.fr/publiclines/. This sequence has
            been generated in the framework of the French plant genomics
            program 'Genoplante' (http://www.genoplante.com and
            http://genoplante-info.inbio.gen.fr).
            Location/Qualifiers
            source          1..13
                           /organism="Arabidopsis thaliana"
                           /mol_type="genomic DNA"
                           /cultivar="Wassillewskija"
                           /db_xref="taxon:3702"
                           /clone="585E11"
                           /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
            misc_feature    1..13
                           /note="T-DNA flanking sequence
                           left border"

Query Match      1.5%; Score 11; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 12;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 669 CCCGGCGGCCA 680
    ||||| |||||
Db 2 CCCGGCGGCCA 13

RESULT 17
CF305567/c
LOCUS      HDAL-01-B07.g1 OsHDA1-overexpressing transgenic rice lambda phage
DEFINITION
VERSION    CF305567.1 GI:33677328
KEYWORDS   EST.
SOURCE     Oryza sativa (japonica cultivar-group)
ORGANISM   Oryza sativa (japonica cultivar-group)
REFERENCE  1 (bases 1 to 17)
AUTHORS    Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            HDAL-01-B07.g1 OsHDA1-overexpressing transgenic rice lambda phage
            cDNA library I (HDAL) Oryza sativa (japonica cultivar-group) cDNA
            clone HDAL-01-B07, mRNA sequence.
            CF305567
            EST.
            CF305567.1 GI:33677328
            Oryza sativa (japonica cultivar-group)
            Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzae; Oryza.
            1 (bases 1 to 17)
            Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,

```


Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)

TITLE JOURNAL COMMENT

Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@bio.com, bhnahm@bio.myongji.ac.kr.

FEATURES

source
1. .17
Location/Qualifiers
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="rRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="HDA1-01-B07"
/issue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 2 weeks"
/lab_host="E.coli SOLR"
/clone_lib="OSHDA1-overexpressing transgenic rice lambda
phage cDNA library I (HDA1)"
/notes="vector: pBluescript SK(+); Site 1: EcoRI; Site 2:
XhoI; Callus was treated with ABA(20um) for 1hour. cDNA
was inserted into lambda Uni-ZAP XR vector at 5' end with
EcoRI and 3' end with XhoI site. mRNA was derived from
rice Histone Deacetylase overexpression line."

Query Match 1.4%; Score 10.6; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 21;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 725 CAGCAGCAGCGTGA 741
DB 17 CGCAGCGCTCGTGA 1

RESULT 18

AJ587934
LOCUS Arabidopsis thaliana T-DNA flanking sequence, left border, clone,
DEFINITION 342D03, genomic survey sequence.
ACCESSION AJ587934.1 GI:37937558
VERSION AJ587934
KEYWORDS GSS; left border; T-DNA flanking sequence.
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE

AUTHORS Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, P.,
Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,
Lepiniec, L., Caboche, M. and Lecharny, A.
TITLE T-DNA integration into the Arabidopsis genome depends on sequences
of pre-insertion sites

JOURNAL

MEDLINE EMBO Rep. 3 (12), 1152-1157 (2002)
PUBMED 22363535
REFERENCE 2 (bases 1 to 12)
AUTHORS Balzerque, S.

TITLE

JOURNAL Submitted (23-OCT-2003) Balzerque S., UMRGV, INRA/CNRS, 2 rue
Gaston Cremieux, 91057 Evry cedex, FRANCE
COMMENT PCR was performed on DNA from transformants of Arabidopsis thaliana
plants from INRA (Versailles). The DNA fragment(s) resulting from
the PCR were directly sequenced from the left or the right border
to determine the genomic sequence flanking the insertion. T-DNA
derived sequences were removed. Information to order the
corresponding mutant line and a link to a database providing a
graphical display of the insertion site are available at
http://dbgap.versailles.inra.fr/publiclines/. This sequence has
been generated in the framework of the French plant genomics

program 'Genoplante' (<http://www.genoplante.com> and
<http://genoplante-info.infobiogen.fr>).

FEATURES

source
1. .12
Location/Qualifiers
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassiliewskija"
/db_xref="taxon:3702"
/clone="342D03"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
misc_feature 1. .12
/note="T-DNA flanking sequence
left border"

Query Match 1.4%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 15;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 511 TCTGCGGAGGT 522

DB 1 TCGCGGGAGGT 12

RESULT 19

AJ593983
LOCUS Arabidopsis thaliana T-DNA flanking sequence, left border, clone
DEFINITION 390F01, genomic survey sequence.
ACCESSION AJ593983
VERSION AJ593983.1 GI:37943607
KEYWORDS GSS; left border; T-DNA flanking sequence.
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE

AUTHORS Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, P.,
Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,
Lepiniec, L., Caboche, M. and Lecharny, A.
TITLE T-DNA integration into the Arabidopsis genome depends on sequences
of pre-insertion sites

JOURNAL

MEDLINE EMBO Rep. 3 (12), 1152-1157 (2002)
PUBMED 22363535
REFERENCE 2 (bases 1 to 12)
AUTHORS Balzerque, S.

TITLE

JOURNAL Submitted (23-OCT-2003) Balzerque S., UMRGV, INRA/CNRS, 2 rue
Gaston Cremieux, 91057 Evry cedex, FRANCE
COMMENT PCR was performed on DNA from transformants of Arabidopsis thaliana
plants from INRA (Versailles). The DNA fragment(s) resulting from
the PCR were directly sequenced from the left or the right border
to determine the genomic sequence flanking the insertion. T-DNA
derived sequences were removed. Information to order the
corresponding mutant line and a link to a database providing a
graphical display of the insertion site are available at
<http://dbgap.versailles.inra.fr/publiclines/>. This sequence has
been generated in the framework of the French plant genomics
program 'Genoplante' (<http://www.genoplante.com> and
<http://genoplante-info.infobiogen.fr>).

FEATURES

source
1. .12
Location/Qualifiers
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassiliewskija"
/db_xref="taxon:3702"
/clone="390F01"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
misc_feature 1. .12
/note="T-DNA flanking sequence
left border"

Query Match	1.4%; Score 10.4; DB 1; Length 12;	
Best Local Similarity	91.7%; Pred. No. 15;	
Matches	11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	669 CCGGGCGGCCA 680 	
Db	1 CCGGGCGGCCA 12 	
RESULT 20		
AJ593342		
LOCUS	AJ593342 13 bp DNA linear GSS 15-JAN-2004	
DEFINITION	Arabidopsis thaliana T-DNA flanking sequence, left border, clone 378G03, genomic survey sequence.	
ACCESSION	AJ593342	
VERSION	AJ593342.1 GI:37942966	
KEYWORDS	GSS; left border; T-DNA flanking sequence.	
SOURCE	Arabidopsis thaliana (thale cress)	
ORGANISM	Arabidopsis thaliana	
REFERENCE		
AUTHORS	Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.	
COMMENT	Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, F., Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G., Lepiniec, L., Caboche, M., and Lecharny, A. T-DNA integration into the Arabidopsis genome depends on sequences of pre-insertion sites	
JOURNAL	EMBO Rep. 3 (12), 1152-1157 (2002)	
MEDLINE	22363535	
PUBMED	12446565	
REFERENCE	2 (bases 1 to 13)	
AUTHORS	Balzerque, S.	
TITLE	Direct Submission	
JOURNAL	Submitted (23-OCT-2003) Balzerque S., UMRGV, INRA/CNRS, 2 rue Gaston Cremieux, 91057 Evry cedex, FRANCE	
COMMENT	PCR was performed on DNA from transformants of Arabidopsis thaliana plants from INRA (Versailles). The DNA fragment(s) resulting from the PCR were directly sequenced from the left or the right border to determine the genomic sequence flanking the insertion. T-DNA derived sequences were removed. Information to order the corresponding mutant line and a link to a database providing a graphical display of the insertion site are available at http://dbseqg.versailles.inra.fr/publiclines/ . This sequence has been generated in the framework of the French plant genomics program 'Genoplante' (http://www.genoplante.com and http://genoplante-info.infobiogen.fr).	
FEATURES		
source	1..13 Location/Qualifiers /organism="Arabidopsis thaliana" /mol_type="genomic DNA" /cultivar="Wassiljewskija" /db_xref="taxon:3702" /clone="398B09" /clone_lib="Arabidopsis thaliana T-DNA insertion lines"	
misc_feature	1..13 /note="T-DNA flanking sequence left border"	
Query Match	1.4%; Score 10.4; DB 1; Length 13;	
Best Local Similarity	91.7%; Pred. No. 17;	
Matches	11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	669 CCGGGCGGCCA 680 	
Db	2 CCGGGCGGCCA 13 	
RESULT 22		
AJ597879		
LOCUS	AJ597879 13 bp DNA linear GSS 15-JAN-2004	
DEFINITION	Arabidopsis thaliana T-DNA flanking sequence, left border, clone 458C03, genomic survey sequence.	
ACCESSION	AJ597879	
VERSION	AJ597879.1 GI:37947507	
KEYWORDS	GSS; left border; T-DNA flanking sequence.	
SOURCE	Arabidopsis thaliana (thale cress)	
ORGANISM	Arabidopsis thaliana	
REFERENCE		
AUTHORS	Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.	
COMMENT	Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, F., Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G., Lepiniec, L., Caboche, M., and Lecharny, A. T-DNA integration into the Arabidopsis genome depends on sequences of pre-insertion sites	
JOURNAL	EMBO Rep. 3 (12), 1152-1157 (2002)	
MEDLINE	22363535	
PUBMED	12446565	
REFERENCE	2 (bases 1 to 13)	
AUTHORS	Balzerque, S.	
TITLE	Direct Submission	
JOURNAL	Submitted (23-OCT-2003) Balzerque S., UMRGV, INRA/CNRS, 2 rue Gaston Cremieux, 91057 Evry cedex, FRANCE	
COMMENT	PCR was performed on DNA from transformants of Arabidopsis thaliana plants from INRA (Versailles). The DNA fragment(s) resulting from the PCR were directly sequenced from the left or the right border to determine the genomic sequence flanking the insertion. T-DNA derived sequences were removed. Information to order the corresponding mutant line and a link to a database providing a graphical display of the insertion site are available at http://dbseqg.versailles.inra.fr/publiclines/ . This sequence has been generated in the framework of the French plant genomics program 'Genoplante' (http://www.genoplante.com and http://genoplante-info.infobiogen.fr).	
FEATURES		
source	1..13 Location/Qualifiers /organism="Arabidopsis thaliana" /mol_type="genomic DNA" /cultivar="Wassiljewskija" /db_xref="taxon:3702" /clones="378G03" /clone_lib="Arabidopsis thaliana T-DNA insertion lines"	
misc_feature	1..13 /note="T-DNA flanking sequence left border"	
Query Match	1.4%; Score 10.4; DB 1; Length 13;	
Best Local Similarity	91.7%; Pred. No. 17;	
Matches	11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	669 CCGGGCGGCCA 680 	
Db	2 CCGGGCGGCCA 13 	
RESULT 21		
AJ594410		
LOCUS	AJ594410 13 bp DNA linear GSS 15-JAN-2004	
DEFINITION	Arabidopsis thaliana T-DNA flanking sequence, left border, clone 398B09, genomic survey sequence.	

JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS
JOURNAL

EMBO Rep. 3 (12), 1152-1157 (2002)
22363535
12446565
2 (bases 1 to 13)
Balzerque, S.
Direct Submission
Submitted (23-OCT-2003) Balzerque S., UMRGV, INRA/CNRS, 2 rue
Gaston Cremieux, 91057 Evry cedex, FRANCE
PCR was performed on DNA from transformants of Arabidopsis thaliana
plants from INRA (Versailles). The DNA fragment(s) resulting from
the PCR were directly sequenced from the left or the right border
to determine the genomic sequence flanking the insertion. T-DNA
derived sequences were removed. Information to order the
corresponding mutant line and a link to a database providing a
graphical display of the insertion site are available at
http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
been generated in the framework of the French plant genomics
program 'Genoplante' (http://www.genoplante.com and
http://genoplante-info.infobiogen.fr).

FEATURES
source
1..13
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassillewskija"
/db_xref="taxon:3702"
/clone="458C03"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
misc_feature
1..13
/note="T-DNA flanking sequence
left border"

Query Match 1.4%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 17;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 669 CCGGGCGGCCA 680
|||||
Db 2 CCGGGCGGCCA 13

RESULT 24
AJ598718
LOCUS
DEFINITION
Arabidopsis thaliana T-DNA flanking sequence, left border, clone
473E08, genomic survey sequence.

ACCESSION
AJ598718.1 GI:37948346
VERSION
GSS; left border; T-DNA flanking sequence.
KEYWORDS
Arabidopsis thaliana
SOURCE
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE
AUTHORS
Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, F.,
Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,
Lepiniec, L., Caboche, M. and Lecharny, A.
T-DNA integration into the Arabidopsis genome depends on sequences
of pre-insertion sites

TITLE
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS
JOURNAL

EMBO Rep. 3 (12), 1152-1157 (2002)
22363535
12446565
2 (bases 1 to 13)
Balzerque, S.
Direct Submission
Submitted (23-OCT-2003) Balzerque S., UMRGV, INRA/CNRS, 2 rue
Gaston Cremieux, 91057 Evry cedex, FRANCE
PCR was performed on DNA from transformants of Arabidopsis thaliana
plants from INRA (Versailles). The DNA fragment(s) resulting from
the PCR were directly sequenced from the left or the right border
to determine the genomic sequence flanking the insertion. T-DNA
derived sequences were removed. Information to order the
corresponding mutant line and a link to a database providing a

graphical display of the insertion site are available at
http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
been generated in the framework of the French plant genomics
program 'Genoplante' (http://www.genoplante.com and
http://genoplante-info.infobiogen.fr).

FEATURES
source
1..13
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassillewskija"
/db_xref="taxon:3702"
/clone="473E08"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
misc_feature
1..13
/note="T-DNA flanking sequence
left border"

Query Match 1.4%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 17;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 669 CCGGGCGGCCA 680
|||||
Db 2 CCGGGCGGCCA 13

RESULT 24
AJ599128
LOCUS
DEFINITION
Arabidopsis thaliana T-DNA flanking sequence, left border, clone
481B05, genomic survey sequence.

ACCESSION
AJ599128
VERSION
GSS; left border; T-DNA flanking sequence.
KEYWORDS
Arabidopsis thaliana
SOURCE
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE
AUTHORS
Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, F.,
Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,
Lepiniec, L., Caboche, M. and Lecharny, A.
T-DNA integration into the Arabidopsis genome depends on sequences
of pre-insertion sites

TITLE
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS
JOURNAL

EMBO Rep. 3 (12), 1152-1157 (2002)
22363535
12446565
2 (bases 1 to 13)
Balzerque, S.
Direct Submission
Submitted (23-OCT-2003) Balzerque S., UMRGV, INRA/CNRS, 2 rue
Gaston Cremieux, 91057 Evry cedex, FRANCE
PCR was performed on DNA from transformants of Arabidopsis thaliana
plants from INRA (Versailles). The DNA fragment(s) resulting from
the PCR were directly sequenced from the left or the right border
to determine the genomic sequence flanking the insertion. T-DNA
derived sequences were removed. Information to order the
corresponding mutant line and a link to a database providing a
graphical display of the insertion site are available at
http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
been generated in the framework of the French plant genomics
program 'Genoplante' (http://www.genoplante.com and
http://genoplante-info.infobiogen.fr).

FEATURES
source
1..13
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassillewskija"
/db_xref="taxon:3702"
/clone="481B05"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
misc_feature
1..13

```

/note="T-DNA flanking sequence
left border"

Query Match      1.4%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 17;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 669 CCGGGCGGCCA 680
      ||||| |||||
DB 2 CCGGGCGGCCA 13

RESULT 25
AJ599161
LOCUS
DEFINITION
Arabidopsis thaliana T-DNA flanking sequence, left border, clone
481F10, genomic survey sequence.
ACCESSION
AJ599161
VERSION
AJ599161.1 GI:37948789
KEYWORDS
GSS; left border; T-DNA flanking sequence.
SOURCE
Arabidopsis thaliana (thale cress)
ORGANISM
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
Rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE
1
AUTHORS
Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, F.,
Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,
Lepiniec, L., Caboche, M. and Lecharny, A.
T-DNA integration into the Arabidopsis genome depends on sequences
of pre-insertion sites
EMBO Rep. 3 (12), 1152-1157 (2002)
JOURNAL
22363535
MEDLINE
12446565
PUBMED
12446565
REFERENCE
2 (bases 1 to 13)
AUTHORS
Balzerque, S.
TITLE
Direct Submission
JOURNAL
Submitted (23-OCT-2003) Balzerque S., UMRGV, INRA/CNRS, 2 rue
Gaston Crenieux, 91057 Evry cedex, FRANCE
COMMENT
PCR was performed on DNA from transformants of Arabidopsis thaliana
plants from INRA (Versailles). The DNA fragment(s) resulting from
the PCR were directly sequenced from the left or the right border
to determine the genomic sequence flanking the insertion. T-DNA
derived sequences were removed. Information to order the
corresponding mutant line and a link to a database providing a
graphical display of the insertion site are available at
http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
been generated in the framework of the French plant genomics
program 'Genoplatte' (http://www.genoplatte.com and
http://genoplatte-info.infobiogen.fr).
FEATURES
Location/Qualifiers
1..13
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassillewskija"
/db_xref="taxon:3702"
/clone="481F10"
/misc_feature 1..13
/note="T-DNA flanking sequence
left border"

Query Match      1.4%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 17;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 669 CCGGGCGGCCA 680
      ||||| |||||
DB 2 CCGGGCGGCCA 13

RESULT 26
AJ592517
LOCUS
DEFINITION
Arabidopsis thaliana T-DNA flanking sequence, right border, clone
621G09, genomic survey sequence.
ACCESSION
AJ592517
VERSION
AJ592517.1 GI:37942141
KEYWORDS
GSS; right border; T-DNA flanking sequence.
SOURCE
Arabidopsis thaliana (thale cress)
ORGANISM
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
Rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE
1
AUTHORS
Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, F.,
Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,
Lepiniec, L., Caboche, M. and Lecharny, A.
T-DNA integration into the Arabidopsis genome depends on sequences
of pre-insertion sites
EMBO Rep. 3 (12), 1152-1157 (2002)
JOURNAL
22363535
MEDLINE
12446565
PUBMED
12446565
REFERENCE
2 (bases 1 to 10)
AUTHORS
Balzerque, S.
TITLE
Direct Submission
JOURNAL
Submitted (23-OCT-2003) Balzerque S., UMRGV, INRA/CNRS, 2 rue
Gaston Crenieux, 91057 Evry cedex, FRANCE
COMMENT
PCR was performed on DNA from transformants of Arabidopsis thaliana
plants from INRA (Versailles). The DNA fragment(s) resulting from
the PCR were directly sequenced from the left or the right border
to determine the genomic sequence flanking the insertion. T-DNA
derived sequences were removed. Information to order the
corresponding mutant line and a link to a database providing a
graphical display of the insertion site are available at
http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
been generated in the framework of the French plant genomics
program 'Genoplatte' (http://www.genoplatte.com and
http://genoplatte-info.infobiogen.fr).
FEATURES
Location/Qualifiers
1..10
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassillewskija"
/db_xref="taxon:3702"
/clone="621G09"
/misc_feature 1..10
/note="T-DNA flanking sequence
right border"

Query Match      1.3%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 14;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 672 GGGCGGCCAG 681
      ||||| |||||
DB 1 GGGCGGCCAG 10

RESULT 27
BM395068
LOCUS
DEFINITION
50072-2-7-D04.r.1 Chilcoat/Turkewitz cDNA (large fraction)
Tetrahymena thermophila cDNA, mRNA sequence.
ACCESSION
BM395068
VERSION
BM395068.1 GI:18195121
KEYWORDS
EST.
SOURCE
Tetrahymena thermophila
ORGANISM
Eukaryota; Alveolata; Ciliophora; Oligohymenophorea;
Hymenostomatida; Tetrahymenina; Tetrahymenidae; Tetrahymena.
REFERENCE
1 (bases 1 to 11)
AUTHORS
Turkewitz, A.P., Karrer, K.M., Jahn, C., Orlas, E., Kirk, K.E.,
Frankel, J. and Klobutcher, L.
EST from Tetrahymena thermophila, strain CU428.1, growing cells

```

```

JOURNAL Unpublished (2002)
COMMENT Contact: Turkewitz AP
Molecular Genetics and Cell Biology
University of Chicago
920 E. 58th Street, Chicago, IL 60637, USA
Tel: 773 702 4374
Fax: 773 702 3172
Email: apturkew@midway.uchicago.edu
Seq primer: T3.

FEATURES
source
1..11
/organism="Tetrahymena thermophila"
/mol_type="mRNA"
/strain="CU428.1"
/db_xref="taxon:5911"
/clone_lib="Chilcoat/Turkewitz cDNA (large fraction)"
/notes="Vector: Bluescript2 SK+; Details on library
preparation can be found in Chilcoat and Turkewitz (2001)
Proc. Natl. Acad. Sci USA, 98: 8709-8713."

Query Match 1.3%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 16;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 662 GGTGGGCCCC 671
Db 2 GGTGGGCCCC 11

RESULT 28
AJ650760/c
LOCUS
DEFINITION AJ650760 CSEQRAN19 Sus scrofa cDNA clone C0003276_E04, mRNA
sequence.
ACCESSION AJ650760
VERSION AJ650760.1 GI:49327605
KEYWORDS EST.
SOURCE Sus scrofa (pig)
ORGANISM Sus scrofa
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
REFERENCE 1 (bases 1 to 13)
AUTHORS Anderson,S.I., Finlayson,H.A. and Archibald,A.L.
TITLE Development of cDNA and EST resources for studying reproduction and
embryo development in pigs and cattle
JOURNAL Unpublished (2004)
COMMENT Contact: Anderson SI
Genomics and Bioinformatics
Roslin Institute
Roslin, Midlothian, EH25 9PS, UNITED KINGDOM
Single pass sequencing. Bases called and trimmed with phred
v0.020425.c. Vector identified by cross match with the -minscore 20
and -mismatch 12 options. Vector: pBluescriptII (KS+) R. Site1: EcoRI
R. Site2: NotI 5' Seq Primer M13F Normalised library constructed
from pooled ovaries. Clones available from UK Centre for Functional
Genomics in Farm Animals, Roslin Institute, Roslin, Midlothian, UK,
EH25 9PS, www.ark-genomics.org.

FEATURES
source
1..13
/organism="Sus scrofa"
/mol_type="mRNA"
/db_xref="taxon:9823"
/clone="C0003276_E04"
/tissue_type="ovary"
/clone_lib="CSEQRAN19"
/notes="Vector: pBluescriptII (KS+); Site 1: EcoRI; Site 2:
NotI; Single pass sequencing; Normalised library
constructed from pooled ovaries"

Query Match 1.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 22;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

JOURNAL Unpublished (2002)
COMMENT Contact: Turkewitz AP
Molecular Genetics and Cell Biology
University of Chicago
920 E. 58th Street, Chicago, IL 60637, USA
Tel: 773 702 4374
Fax: 773 702 3172
Email: apturkew@midway.uchicago.edu
Seq primer: T3.

FEATURES
source
1..11
/organism="Tetrahymena thermophila"
/mol_type="mRNA"
/strain="CU428.1"
/db_xref="taxon:5911"
/clone_lib="Chilcoat/Turkewitz cDNA (large fraction)"
/notes="Vector: Bluescript2 SK+; Details on library
preparation can be found in Chilcoat and Turkewitz (2001)
Proc. Natl. Acad. Sci USA, 98: 8709-8713."

Query Match 1.3%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 16;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 662 GGTGGGCCCC 671
Db 2 GGTGGGCCCC 11

RESULT 28
AJ650760/c
LOCUS
DEFINITION AJ650760 CSEQRAN19 Sus scrofa cDNA clone C0003276_E04, mRNA
sequence.
ACCESSION AJ650760
VERSION AJ650760.1 GI:49327605
KEYWORDS EST.
SOURCE Sus scrofa (pig)
ORGANISM Sus scrofa
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
REFERENCE 1 (bases 1 to 13)
AUTHORS Anderson,S.I., Finlayson,H.A. and Archibald,A.L.
TITLE Development of cDNA and EST resources for studying reproduction and
embryo development in pigs and cattle
JOURNAL Unpublished (2004)
COMMENT Contact: Anderson SI
Genomics and Bioinformatics
Roslin Institute
Roslin, Midlothian, EH25 9PS, UNITED KINGDOM
Single pass sequencing. Bases called and trimmed with phred
v0.020425.c. Vector identified by cross match with the -minscore 20
and -mismatch 12 options. Vector: pBluescriptII (KS+) R. Site1: EcoRI
R. Site2: NotI 5' Seq Primer M13F Normalised library constructed
from pooled ovaries. Clones available from UK Centre for Functional
Genomics in Farm Animals, Roslin Institute, Roslin, Midlothian, UK,
EH25 9PS, www.ark-genomics.org.

FEATURES
source
1..13
/organism="Sus scrofa"
/mol_type="mRNA"
/db_xref="taxon:9823"
/clone="C0003276_E04"
/tissue_type="ovary"
/clone_lib="CSEQRAN19"
/notes="Vector: pBluescriptII (KS+); Site 1: EcoRI; Site 2:
NotI; Single pass sequencing; Normalised library
constructed from pooled ovaries"

Query Match 1.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 22;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

JOURNAL Unpublished (2002)
COMMENT Contact: Turkewitz AP
Molecular Genetics and Cell Biology
University of Chicago
920 E. 58th Street, Chicago, IL 60637, USA
Tel: 773 702 4374
Fax: 773 702 3172
Email: apturkew@midway.uchicago.edu
Seq primer: T3.

FEATURES
source
1..11
/organism="Tetrahymena thermophila"
/mol_type="mRNA"
/strain="CU428.1"
/db_xref="taxon:5911"
/clone_lib="Chilcoat/Turkewitz cDNA (large fraction)"
/notes="Vector: Bluescript2 SK+; Details on library
preparation can be found in Chilcoat and Turkewitz (2001)
Proc. Natl. Acad. Sci USA, 98: 8709-8713."

Query Match 1.3%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 16;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 662 GGTGGGCCCC 671
Db 2 GGTGGGCCCC 11

RESULT 28
AJ650760/c
LOCUS
DEFINITION AJ650760 CSEQRAN19 Sus scrofa cDNA clone C0003276_E04, mRNA
sequence.
ACCESSION AJ650760
VERSION AJ650760.1 GI:49327605
KEYWORDS EST.
SOURCE Sus scrofa (pig)
ORGANISM Sus scrofa
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
REFERENCE 1 (bases 1 to 13)
AUTHORS Anderson,S.I., Finlayson,H.A. and Archibald,A.L.
TITLE Development of cDNA and EST resources for studying reproduction and
embryo development in pigs and cattle
JOURNAL Unpublished (2004)
COMMENT Contact: Anderson SI
Genomics and Bioinformatics
Roslin Institute
Roslin, Midlothian, EH25 9PS, UNITED KINGDOM
Single pass sequencing. Bases called and trimmed with phred
v0.020425.c. Vector identified by cross match with the -minscore 20
and -mismatch 12 options. Vector: pBluescriptII (KS+) R. Site1: EcoRI
R. Site2: NotI 5' Seq Primer M13F Normalised library constructed
from pig uterus. Clones available from UK Centre for Functional
Genomics in Farm Animals, Roslin Institute, Roslin, Midlothian, UK,
EH25 9PS, www.arkgenomics.org.

FEATURES
source
1..13
/organism="Sus scrofa"
/mol_type="mRNA"
/db_xref="taxon:9823"
/clone="C0001814_M18"
/tissue_type="uterus"
/clone_lib="CSEQRAN04"
/notes="Vector: pBluescriptII (KS+); Site 1: EcoRI; Site 2:
NotI; Single pass sequencing. Normalised library
constructed from pig uterus."

Query Match 1.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 22;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 489 TGAAGAGGCAGAA 501
Db 13 TGAAGAGGCAGAA 1

RESULT 30
BG926067/c
LOCUS
DEFINITION BG926067 HNC23-1-E8.R HNC (Human Normal Cartilage) Homo sapiens cDNA, mRNA
sequence.
ACCESSION BG926067
VERSION BG926067.1 GI:14320590
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE 1 (bases 1 to 13)
AUTHORS Kumar,S., Connor,J.R., Dodds,R.A., Halsey,W., Van Horn,M., Mao,J.,
Sathe,G., Mui,P., Agarwal,P., Badger,A.M., Lee,J.C., Gowen,M. and
Lark,M.W.
TITLE Identification and initial characterization of 5000 expressed
sequenced tags (ESTs) each from adult human normal and
osteoarthritic cartilage cDNA libraries

```

Query Match 1.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 22;

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 8, 2005, 08:52:33 ; Search time 7 Seconds
(without alignments)
4.110 Million cell updates/sec

Title: US-10-628-841-3

Perfect score: 755

Sequence: 1 tctggaagagccaaactgtgt.....tgggcagtgagcggaagcga 755

Scoring table: IDENTITY NUC

Gapop 10_0 , Gapext 0.5

Searched: 1089 seqs, 19055 residues

Total number of hits satisfying chosen parameters: 2178

Minimum DB seq length: 8

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 1090 summaries

Database : fetchrnpb.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	29	3.8	29	1	US-09-972-607-6
2	29	3.8	29	1	US-10-628-841-6
3	27	3.6	27	1	US-10-972-607-24
4	22	3.9	22	1	US-09-863-049A-61
5	21	2.8	21	1	US-10-444-795B-711
6	21	2.8	21	1	US-10-444-795B-721
7	20	2.6	20	1	US-09-972-607-5
8	20	2.6	20	1	US-09-972-607-16
9	20	2.6	20	1	US-09-972-607-17
10	20	2.6	20	1	US-09-972-607-18
11	20	2.6	20	1	US-09-972-607-19
12	20	2.6	20	1	US-09-972-607-20
13	20	2.6	20	1	US-09-972-607-21
14	20	2.6	20	1	US-09-972-607-22
15	20	2.6	20	1	US-09-972-607-23
16	20	2.6	20	1	US-09-972-607-24
17	20	2.6	20	1	US-09-972-607-25
18	20	2.6	20	1	US-09-972-607-26
19	20	2.6	20	1	US-09-972-607-27
20	20	2.6	20	1	US-09-972-607-28
21	20	2.6	20	1	US-09-972-607-29
22	20	2.6	20	1	US-09-972-607-30
23	20	2.6	20	1	US-09-972-607-31
24	20	2.6	20	1	US-09-972-607-32
25	20	2.6	20	1	US-09-972-607-33
26	20	2.6	20	1	US-09-972-607-34
27	20	2.6	20	1	US-09-972-607-35
28	20	2.6	20	1	US-09-972-607-36
29	20	2.6	20	1	US-09-972-607-37
30	20	2.6	20	1	US-09-972-607-38
31	20	2.6	20	1	US-09-972-607-39
32	20	2.6	20	1	US-09-972-607-40
33	20	2.6	20	1	US-09-972-607-41

Sequence 42, Appl
Sequence 43, Appl
Sequence 44, Appl
Sequence 45, Appl
Sequence 46, Appl
Sequence 47, Appl
Sequence 48, Appl
Sequence 49, Appl
Sequence 5, Appl
Sequence 16, Appl
Sequence 17, Appl
Sequence 18, Appl
Sequence 19, Appl
Sequence 20, Appl
Sequence 21, Appl
Sequence 22, Appl
Sequence 23, Appl
Sequence 24, Appl
Sequence 25, Appl
Sequence 26, Appl
Sequence 27, Appl
Sequence 28, Appl
Sequence 29, Appl
Sequence 30, Appl
Sequence 31, Appl
Sequence 32, Appl
Sequence 33, Appl
Sequence 34, Appl
Sequence 35, Appl
Sequence 36, Appl
Sequence 37, Appl
Sequence 38, Appl
Sequence 39, Appl
Sequence 40, Appl
Sequence 41, Appl
Sequence 42, Appl
Sequence 43, Appl
Sequence 44, Appl
Sequence 45, Appl
Sequence 46, Appl
Sequence 47, Appl
Sequence 48, Appl
Sequence 49, Appl
Sequence 53, Appl
Sequence 13872, A
Sequence 55, Appl
Sequence 716, Appl
Sequence 63, Appl
Sequence 590469,
Sequence 707, App
Sequence 708, App
Sequence 712, App
Sequence 713, App
Sequence 717, App
Sequence 718, App
Sequence 722, App
Sequence 723, App
Sequence 706, App
Sequence 709, App
Sequence 710, App
Sequence 714, App
Sequence 715, App
Sequence 719, App
Sequence 720, App
Sequence 724, App
Sequence 725, App
Sequence 123, App
Sequence 124, App
Sequence 127, App
Sequence 128, App
Sequence 131, App
Sequence 132, App
Sequence 133, App

19	19	1	US-10-757-803-124	Sequence 124, App	180	17	2.3	17	1	US-10-156-306-4810	Sequence 4810, App
107	19	2.5	US-10-757-803-127	Sequence 127, App	181	17	2.3	17	1	US-10-156-306-4811	Sequence 4811, App
108	19	2.5	US-10-757-803-128	Sequence 128, App	182	17	2.3	17	1	US-10-156-306-4812	Sequence 4812, App
109	19	2.5	US-10-757-803-131	Sequence 131, App	183	17	2.3	17	1	US-10-156-306-4813	Sequence 4813, App
110	19	2.5	US-10-757-803-132	Sequence 132, App	184	17	2.3	17	1	US-10-156-306-4814	Sequence 4814, App
111	19	2.5	US-10-826-966-123	Sequence 123, App	185	17	2.3	17	1	US-10-156-306-4815	Sequence 4815, App
112	19	2.5	US-10-826-966-124	Sequence 124, App	186	17	2.3	17	1	US-10-156-306-4816	Sequence 4816, App
113	19	2.5	US-10-826-966-127	Sequence 127, App	187	17	2.3	17	1	US-10-156-306-4817	Sequence 4817, App
114	19	2.5	US-10-826-966-128	Sequence 128, App	188	17	2.3	17	1	US-10-156-306-4818	Sequence 4818, App
115	19	2.5	US-10-826-966-131	Sequence 131, App	189	17	2.3	17	1	US-10-156-306-4819	Sequence 4819, App
116	19	2.5	US-10-826-966-132	Sequence 132, App	190	17	2.3	17	1	US-10-156-306-4820	Sequence 4820, App
117	19	2.5	US-10-826-966-137	Sequence 37, Appl	191	17	2.3	17	1	US-10-156-306-4821	Sequence 4821, App
118	18.4	2.4	US-10-210-290-37	Sequence 37, Appl	192	17	2.3	17	1	US-10-156-306-4822	Sequence 4822, App
119	18.4	2.4	US-10-210-802-37	Sequence 9484, App	193	17	2.3	17	1	US-10-156-306-4823	Sequence 4823, App
120	17.4	2.3	US-10-751-736-9485	Sequence 9485, App	194	17	2.3	17	1	US-10-156-306-4824	Sequence 4824, App
121	17.4	2.3	US-10-751-736-9488	Sequence 9488, App	195	17	2.3	17	1	US-10-156-306-4825	Sequence 4825, App
122	17	2.3	US-10-156-306-4384	Sequence 4384, App	196	17	2.3	17	1	US-10-156-306-4826	Sequence 4826, App
123	17	2.3	US-10-156-306-4385	Sequence 4385, App	197	17	2.3	17	1	US-10-156-306-4827	Sequence 4827, App
124	17	2.3	US-10-156-306-4386	Sequence 4386, App	198	17	2.3	17	1	US-10-156-306-4828	Sequence 4828, App
125	17	2.3	US-10-156-306-4387	Sequence 4387, App	199	17	2.3	17	1	US-10-156-306-4829	Sequence 4829, App
126	17	2.3	US-10-156-306-4388	Sequence 4388, App	200	17	2.3	17	1	US-10-156-306-4830	Sequence 4830, App
127	17	2.3	US-10-156-306-4389	Sequence 4389, App	201	17	2.3	17	1	US-10-156-306-4831	Sequence 4831, App
128	17	2.3	US-10-156-306-4390	Sequence 4390, App	202	17	2.3	17	1	US-10-156-306-4832	Sequence 4832, App
129	17	2.3	US-10-156-306-4391	Sequence 4391, App	203	17	2.3	17	1	US-10-156-306-4833	Sequence 4833, App
130	17	2.3	US-10-156-306-4392	Sequence 4392, App	204	17	2.3	17	1	US-10-156-306-4834	Sequence 4834, App
131	17	2.3	US-10-156-306-4393	Sequence 4393, App	205	17	2.3	17	1	US-10-156-306-4835	Sequence 4835, App
132	17	2.3	US-10-156-306-4394	Sequence 4394, App	206	17	2.3	17	1	US-10-156-306-4836	Sequence 4836, App
133	17	2.3	US-10-156-306-4395	Sequence 4395, App	207	17	2.3	17	1	US-10-156-306-4837	Sequence 4837, App
134	17	2.3	US-10-156-306-4396	Sequence 4396, App	208	17	2.3	17	1	US-10-156-306-4838	Sequence 4838, App
135	17	2.3	US-10-156-306-4397	Sequence 4397, App	209	17	2.3	17	1	US-10-156-306-4839	Sequence 4839, App
136	17	2.3	US-10-156-306-4398	Sequence 4398, App	210	17	2.3	17	1	US-10-156-306-4840	Sequence 4840, App

399	17	2.3	1	US-10-156-306-5841	Sequence 5841, Ap	472	17	2.3	1	US-10-156-306-6339	Sequence 6339, Ap
400	17	2.3	1	US-10-156-306-5842	Sequence 5842, Ap	473	17	2.3	1	US-10-156-306-6814	Sequence 6814, Ap
401	17	2.3	1	US-10-156-306-5843	Sequence 5843, Ap	474	17	2.3	1	US-10-156-306-6815	Sequence 6815, Ap
402	17	2.3	1	US-10-156-306-5844	Sequence 5844, Ap	475	17	2.3	1	US-10-156-306-6816	Sequence 6816, Ap
403	17	2.3	1	US-10-156-306-5845	Sequence 5845, Ap	476	17	2.3	1	US-10-156-306-6817	Sequence 6817, Ap
404	17	2.3	1	US-10-156-306-5846	Sequence 5846, Ap	477	17	2.3	1	US-10-156-306-6818	Sequence 6818, Ap
405	17	2.3	1	US-10-156-306-5847	Sequence 5847, Ap	478	17	2.3	1	US-10-156-306-6819	Sequence 6819, Ap
406	17	2.3	1	US-10-156-306-5848	Sequence 5848, Ap	479	17	2.3	1	US-10-156-306-6820	Sequence 6820, Ap
407	17	2.3	1	US-10-156-306-5849	Sequence 5849, Ap	480	17	2.3	1	US-10-156-306-6821	Sequence 6821, Ap
408	17	2.3	1	US-10-156-306-5850	Sequence 5850, Ap	481	17	2.3	1	US-10-156-306-6822	Sequence 6822, Ap
409	17	2.3	1	US-10-156-306-5851	Sequence 5851, Ap	482	17	2.3	1	US-10-156-306-6823	Sequence 6823, Ap
410	17	2.3	1	US-10-156-306-5852	Sequence 5852, Ap	483	17	2.3	1	US-10-156-306-6824	Sequence 6824, Ap
411	17	2.3	1	US-10-156-306-5853	Sequence 5853, Ap	484	17	2.3	1	US-10-156-306-6825	Sequence 6825, Ap
412	17	2.3	1	US-10-156-306-5854	Sequence 5854, Ap	485	17	2.3	1	US-10-156-306-6826	Sequence 6826, Ap
413	17	2.3	1	US-10-156-306-5855	Sequence 5855, Ap	486	17	2.3	1	US-10-156-306-6827	Sequence 6827, Ap
414	17	2.3	1	US-10-156-306-5856	Sequence 5856, Ap	487	17	2.3	1	US-10-156-306-6828	Sequence 6828, Ap
415	17	2.3	1	US-10-156-306-5857	Sequence 5857, Ap	488	17	2.3	1	US-10-156-306-6829	Sequence 6829, Ap
416	17	2.3	1	US-10-156-306-5858	Sequence 5858, Ap	489	17	2.3	1	US-10-156-306-6830	Sequence 6830, Ap
417	17	2.3	1	US-10-156-306-5859	Sequence 5859, Ap	490	17	2.3	1	US-10-156-306-6831	Sequence 6831, Ap
418	17	2.3	1	US-10-156-306-5860	Sequence 5860, Ap	491	17	2.3	1	US-10-156-306-6832	Sequence 6832, Ap
419	17	2.3	1	US-10-156-306-5861	Sequence 5861, Ap	492	17	2.3	1	US-10-156-306-6833	Sequence 6833, Ap
420	17	2.3	1	US-10-156-306-5862	Sequence 5862, Ap	493	17	2.3	1	US-10-156-306-6834	Sequence 6834, Ap
421	17	2.3	1	US-10-156-306-5863	Sequence 5863, Ap	494	17	2.3	1	US-10-156-306-6835	Sequence 6835, Ap
422	17	2.3	1	US-10-156-306-5864	Sequence 5864, Ap	495	17	2.3	1	US-10-156-306-6836	Sequence 6836, Ap
423	17	2.3	1	US-10-156-306-5865	Sequence 5865, Ap	496	17	2.3	1	US-10-156-306-6837	Sequence 6837, Ap
424	17	2.3	1	US-10-156-306-5866	Sequence 5866, Ap	497	17	2.3	1	US-10-156-306-6838	Sequence 6838, Ap
425	17	2.3	1	US-10-156-306-5867	Sequence 5867, Ap	498	17	2.3	1	US-10-156-306-6839	Sequence 6839, Ap
426	17	2.3	1	US-10-156-306-5868	Sequence 5868, Ap	499	17	2.3	1	US-10-156-306-6840	Sequence 6840, Ap
427	17	2.3	1	US-10-156-306-5869	Sequence 5869, Ap	500	17	2.3	1	US-10-156-306-6841	Sequence 6841, Ap
428	17	2.3	1	US-10-156-306-5870	Sequence 5870, Ap	501	17	2.3	1	US-10-156-306-6842	Sequence 6842, Ap
429	17	2.3	1	US-10-156-306-5871	Sequence 5871, Ap	502	17	2.3	1	US-10-156-306-6843	Sequence 6843, Ap
430	17	2.3	1	US-10-156-306-5872	Sequence 5872, Ap	503	17	2.3	1	US-10-156-306-6844	Sequence 6844, Ap
431	17	2.3	1	US-10-156-306-5873	Sequence 5873, Ap	504	17	2.3	1	US-10-156-306-6845	Sequence 6845, Ap
432	17	2.3	1	US-10-156-306-5874	Sequence 5874, Ap	505	17	2.3	1	US-10-156-306-6846	Sequence 6846, Ap
433	17	2.3	1	US-10-156-306-5875	Sequence 5875, Ap	506	17	2.3	1	US-10-156-306-6847	Sequence 6847, Ap
434	17	2.3	1	US-10-156-306-5876	Sequence 5876, Ap	507	17	2.3	1	US-10-156-306-6848	Sequence 6848, Ap
435	17	2.3	1	US-10-156-306-5877	Sequence 5877, Ap	508	17	2.3	1	US-10-156-306-6849	Sequence 6849, Ap
436	17	2.3	1	US-10-156-306-5878	Sequence 5878, Ap	509	17	2.3	1	US-10-156-306-6850	Sequence 6850, Ap
437	17	2.3	1	US-10-156-306-5879	Sequence 5879, Ap	510	17	2.3	1	US-10-156-306-6851	Sequence 6851, Ap
438	17	2.3	1	US-10-156-306-5880	Sequence 5880, Ap	511	17	2.3	1	US-10-156-306-6852	Sequence 6852, Ap
439	17	2.3	1	US-10-156-306-5881	Sequence 5881, Ap	512	17	2.3	1	US-10-156-306-6853	Sequence 6853, Ap
440	17	2.3	1	US-10-156-306-5882	Sequence 5882, Ap	513	17	2.3	1	US-10-156-306-6854	Sequence 6854, Ap
441	17	2.3	1	US-10-156-306-5883	Sequence 5883, Ap	514	17	2.3	1	US-10-156-306-6855	Sequence 6855, Ap
442	17	2.3	1	US-10-156-306-5884	Sequence 5884, Ap	515	17	2.3	1	US-10-156-306-6856	Sequence 6856, Ap
443	17	2.3	1	US-10-156-306-5885	Sequence 5885, Ap	516	17	2.3	1	US-10-156-306-6857	Sequence 6857, Ap
444	17	2.3	1	US-10-156-306-5886	Sequence 5886, Ap	517	17	2.3	1	US-10-156-306-6858	Sequence 6858, Ap
445	17	2.3	1	US-10-156-306-5887	Sequence 5887, Ap	518	17	2.3	1	US-10-156-306-6859	Sequence 6859, Ap
446	17	2.3	1	US-10-156-306-5888	Sequence 5888, Ap	519	17	2.3	1	US-10-156-306-6860	Sequence 6860, Ap
447	17	2.3	1	US-10-156-306-5889	Sequence 5889, Ap	520	17	2.3	1	US-10-156-306-6861	Sequence 6861, Ap
448	17	2.3	1	US-10-156-306-5890	Sequence 5890, Ap	521	17	2.3	1	US-10-156-306-6862	Sequence 6862, Ap
449	17	2.3	1	US-10-156-306-5891	Sequence 5891, Ap	522	17	2.3	1	US-10-156-306-6863	Sequence 6863, Ap
450	17	2.3	1	US-10-156-306-5892	Sequence 5892, Ap	523	17	2.3	1	US-10-156-306-6864	Sequence 6864, Ap
451	17	2.3	1	US-10-156-306-5893	Sequence 5893, Ap	524	17	2.3	1	US-10-156-306-6865	Sequence 6865, Ap
452	17	2.3	1	US-10-156-306-5894	Sequence 5894, Ap	525	17	2.3	1	US-10-156-306-6866	Sequence 6866, Ap
453	17	2.3	1	US-10-156-306-5895	Sequence 5895, Ap	526	17	2.3	1	US-10-156-306-6867	Sequence 6867, Ap
454	17	2.3	1	US-10-156-306-5896	Sequence 5896, Ap	527	17	2.3	1	US-10-156-306-6868	Sequence 6868, Ap
455	17	2.3	1	US-10-156-306-5897	Sequence 5897, Ap	528	17	2.3	1	US-10-156-306-6869	Sequence 6869, Ap
456	17	2.3	1	US-10-156-306-5898	Sequence 5898, Ap	529	17	2.3	1	US-10-156-306-6870	Sequence 6870, Ap
457	17	2.3	1	US-10-156-306-5899	Sequence 5899, Ap	530	17	2.3	1	US-10-156-306-6871	Sequence 6871, Ap
458	17	2.3	1	US-10-156-306-5900	Sequence 5900, Ap	531	17	2.3	1	US-10-156-306-6872	Sequence 6872, Ap
459	17	2.3	1	US-10-156-306-5901	Sequence 5901, Ap	532	17	2.3	1	US-10-156-306-6873	Sequence 6873, Ap
460	17	2.3	1	US-10-156-306-5902	Sequence 5902, Ap	533	17	2.3	1	US-10-156-306-6874	Sequence 6874, Ap
461	17	2.3	1	US-10-156-306-5903	Sequence 5903, Ap	534	17	2.3	1	US-10-156-306-6875	Sequence 6875, Ap
462	17	2.3	1	US-10-156-306-5904	Sequence 5904, Ap	535	17	2.3	1	US-10-156-306-6876	Sequence 6876, Ap
463	17	2.3	1	US-10-156-306-5905	Sequence 5905, Ap	536	17	2.3	1	US-10-156-306-6877	Sequence 6877, Ap
464	17	2.3	1	US-10-156-306-5906	Sequence 5906, Ap	537	17	2.3	1	US-10-156-306-6878	Sequence 6878, Ap
465	17	2.3	1	US-10-156-306-5907	Sequence 5907, Ap	538	17	2.3	1	US-10-156-306-6879	Sequence 6879, Ap
466	17	2.3	1	US-10-156-306-5908	Sequence 5908, Ap	539	17	2.3	1	US-10-156-306-6880	Sequence 6880, Ap
467	17	2.3	1	US-10-156-306-5909	Sequence 5909, Ap	540	17	2.3	1	US-10-156-306-6881	Sequence 6881, Ap
468	17	2.3	1	US-10-156-306-5910	Sequence 5910, Ap	541	17	2.3	1	US-10-156-306-6882	Sequence 6882, Ap
469	17	2.3	1	US-10-156-306-5911	Sequence 5911, Ap	542	17	2.3	1	US-10-156-306-6883	Sequence 6883, Ap
470	17	2.3	1	US-10-156-306-5912	Sequence 5912, Ap	543	17	2.3	1	US-10-156-306-6884	Sequence 6884, Ap
471	17	2.3	1	US-10-156-306-5913	Sequence 5913, Ap	544	17	2.3	1	US-10-156-306-6885	Sequence 6885, Ap

545	17	2.3	17	1	US-10-156-306-6886	Sequence 6886, Ap	618	17	2.3	17	1	US-10-156-306-6959	Sequence 6959, Ap
546	17	2.3	17	1	US-10-156-306-6887	Sequence 6887, Ap	619	17	2.3	17	1	US-10-156-306-6960	Sequence 6960, Ap
547	17	2.3	17	1	US-10-156-306-6888	Sequence 6888, Ap	620	17	2.3	17	1	US-10-156-306-6961	Sequence 6961, Ap
548	17	2.3	17	1	US-10-156-306-6889	Sequence 6889, Ap	621	17	2.3	17	1	US-10-156-306-6962	Sequence 6962, Ap
549	17	2.3	17	1	US-10-156-306-6890	Sequence 6890, Ap	622	17	2.3	17	1	US-10-156-306-6963	Sequence 6963, Ap
550	17	2.3	17	1	US-10-156-306-6891	Sequence 6891, Ap	623	16.8	2.2	21	1	US-10-786-720-11195	Sequence 11195, A
551	17	2.3	17	1	US-10-156-306-6892	Sequence 6892, Ap	624	16.8	2.2	21	1	US-10-490-080-12	Sequence 12, Appl
552	17	2.3	17	1	US-10-156-306-6893	Sequence 6893, Ap	625	16.8	2.2	21	1	US-10-490-080-18	Sequence 18, Appl
553	17	2.3	17	1	US-10-156-306-6894	Sequence 6894, Ap	626	16.8	2.2	21	1	US-10-751-736-18624	Sequence 18624, A
554	17	2.3	17	1	US-10-156-306-6895	Sequence 6895, Ap	627	16.8	2.2	21	1	US-10-751-736-49885	Sequence 49885, A
555	17	2.3	17	1	US-10-156-306-6896	Sequence 6896, Ap	628	16.4	2.2	21	1	US-10-751-736-9649	Sequence 9649, Ap
556	17	2.3	17	1	US-10-156-306-6897	Sequence 6897, Ap	629	16.4	2.2	21	1	US-10-751-736-9650	Sequence 9650, Ap
557	17	2.3	17	1	US-10-156-306-6898	Sequence 6898, Ap	630	16.2	2.1	21	1	US-10-786-720-11196	Sequence 11196, A
558	17	2.3	17	1	US-10-156-306-6899	Sequence 6899, Ap	631	16.2	2.1	21	1	US-10-751-736-39475	Sequence 39475, A
559	17	2.3	17	1	US-10-156-306-6900	Sequence 6900, Ap	632	16.2	2.1	21	1	US-10-751-736-39478	Sequence 39478, A
560	17	2.3	17	1	US-10-156-306-6901	Sequence 6901, Ap	633	16	2.1	17	1	US-10-156-306-6813	Sequence 6813, Ap
561	17	2.3	17	1	US-10-156-306-6902	Sequence 6902, Ap	634	16	2.1	17	1	US-10-156-306-6964	Sequence 6964, Ap
562	17	2.3	17	1	US-10-156-306-6903	Sequence 6903, Ap	635	15.8	2.1	19	1	US-10-224-836-290	Sequence 290, App
563	17	2.3	17	1	US-10-156-306-6904	Sequence 6904, Ap	636	15.8	2.1	19	1	US-10-670-011-56	Sequence 56, Appl
564	17	2.3	17	1	US-10-156-306-6905	Sequence 6905, Ap	637	15.8	2.1	19	1	US-10-670-011-152	Sequence 152, App
565	17	2.3	17	1	US-10-156-306-6906	Sequence 6906, Ap	638	15.8	2.1	19	1	US-10-764-957-56	Sequence 56, Appl
566	17	2.3	17	1	US-10-156-306-6907	Sequence 6907, Ap	639	15.8	2.1	19	1	US-10-764-957-152	Sequence 152, App
567	17	2.3	17	1	US-10-156-306-6908	Sequence 6908, Ap	640	15.8	2.1	21	1	US-10-083-720A-10	Sequence 10, Appl
568	17	2.3	17	1	US-10-156-306-6909	Sequence 6909, Ap	641	15.8	2.1	21	1	US-10-186-180-20	Sequence 20, Appl
569	17	2.3	17	1	US-10-156-306-6910	Sequence 6910, Ap	642	15.8	2.1	21	1	US-10-005-956-1033	Sequence 1033, Ap
570	17	2.3	17	1	US-10-156-306-6911	Sequence 6911, Ap	643	15.8	2.1	21	1	US-10-786-720-11194	Sequence 11194, A
571	17	2.3	17	1	US-10-156-306-6912	Sequence 6912, Ap	644	15.8	2.1	21	1	US-10-683-990-202	Sequence 202, App
572	17	2.3	17	1	US-10-156-306-6913	Sequence 6913, Ap	645	15.8	2.1	21	1	US-10-683-990-206	Sequence 206, App
573	17	2.3	17	1	US-10-156-306-6914	Sequence 6914, Ap	646	15.8	2.1	21	1	US-10-683-990-210	Sequence 210, App
574	17	2.3	17	1	US-10-156-306-6915	Sequence 6915, Ap	647	15.8	2.1	21	1	US-10-683-990-214	Sequence 214, App
575	17	2.3	17	1	US-10-156-306-6916	Sequence 6916, Ap	648	15.8	2.1	21	1	US-10-683-990-218	Sequence 218, App
576	17	2.3	17	1	US-10-156-306-6917	Sequence 6917, Ap	649	15.8	2.1	21	1	US-10-683-990-222	Sequence 222, App
577	17	2.3	17	1	US-10-156-306-6918	Sequence 6918, Ap	650	15.8	2.1	21	1	US-10-683-990-226	Sequence 226, App
578	17	2.3	17	1	US-10-156-306-6919	Sequence 6919, Ap	651	15.8	2.1	21	1	US-10-683-990-230	Sequence 230, App
579	17	2.3	17	1	US-10-156-306-6920	Sequence 6920, Ap	652	15.8	2.1	21	1	US-10-683-990-234	Sequence 234, App
580	17	2.3	17	1	US-10-156-306-6921	Sequence 6921, Ap	653	15.8	2.1	21	1	US-10-683-990-238	Sequence 238, App
581	17	2.3	17	1	US-10-156-306-6922	Sequence 6922, Ap	654	15.8	2.1	21	1	US-10-751-736-16993	Sequence 16993, A
582	17	2.3	17	1	US-10-156-306-6923	Sequence 6923, Ap	655	15.8	2.1	21	1	US-10-751-736-18963	Sequence 18963, A
583	17	2.3	17	1	US-10-156-306-6924	Sequence 6924, Ap	656	15.8	2.1	21	1	US-10-751-736-49882	Sequence 49882, A
584	17	2.3	17	1	US-10-156-306-6925	Sequence 6925, Ap	657	15.8	2.1	21	1	US-10-751-736-49883	Sequence 49883, A
585	17	2.3	17	1	US-10-156-306-6926	Sequence 6926, Ap	658	15.8	2.1	21	1	US-10-916-256-10	Sequence 10, Appl
586	17	2.3	17	1	US-10-156-306-6927	Sequence 6927, Ap	659	15.8	2.1	21	1	US-10-494-921-20	Sequence 20, Appl
587	17	2.3	17	1	US-10-156-306-6928	Sequence 6928, Ap	660	15.4	2.0	17	1	US-09-866-108-7246	Sequence 7246, Ap
588	17	2.3	17	1	US-10-156-306-6929	Sequence 6929, Ap	661	15.4	2.0	17	1	US-09-866-108-7450	Sequence 7450, Ap
589	17	2.3	17	1	US-10-156-306-6930	Sequence 6930, Ap	662	15.4	2.0	17	1	US-10-723-361-7246	Sequence 7246, Ap
590	17	2.3	17	1	US-10-156-306-6931	Sequence 6931, Ap	663	15.4	2.0	17	1	US-10-723-361-7450	Sequence 7450, Ap
591	17	2.3	17	1	US-10-156-306-6932	Sequence 6932, Ap	664	15.4	2.0	17	1	US-10-454-246-336	Sequence 336, App
592	17	2.3	17	1	US-10-156-306-6933	Sequence 6933, Ap	665	15.4	2.0	18	1	US-09-146-157-3	Sequence 3, Appli
593	17	2.3	17	1	US-10-156-306-6934	Sequence 6934, Ap	666	15.4	2.0	18	1	US-09-412-947-2	Sequence 2, Appli
594	17	2.3	17	1	US-10-156-306-6935	Sequence 6935, Ap	667	15.4	2.0	18	1	US-09-412-947-5	Sequence 5, Appli
595	17	2.3	17	1	US-10-156-306-6936	Sequence 6936, Ap	668	15.4	2.0	18	1	US-09-412-947-7	Sequence 7, Appli
596	17	2.3	17	1	US-10-156-306-6937	Sequence 6937, Ap	669	15.4	2.0	18	1	US-10-641-521-2	Sequence 2, Appli
597	17	2.3	17	1	US-10-156-306-6938	Sequence 6938, Ap	670	15.4	2.0	18	1	US-10-641-521-5	Sequence 5, Appli
598	17	2.3	17	1	US-10-156-306-6939	Sequence 6939, Ap	671	15.4	2.0	18	1	US-10-641-521-7	Sequence 7, Appli
599	17	2.3	17	1	US-10-156-306-6940	Sequence 6940, Ap	672	15.4	2.0	18	1	US-10-854-989-2	Sequence 2, Appli
600	17	2.3	17	1	US-10-156-306-6941	Sequence 6941, Ap	673	15.4	2.0	18	1	US-10-854-989-5	Sequence 5, Appli
601	17	2.3	17	1	US-10-156-306-6942	Sequence 6942, Ap	674	15.4	2.0	18	1	US-10-854-989-7	Sequence 7, Appli
602	17	2.3	17	1	US-10-156-306-6943	Sequence 6943, Ap	675	15.4	2.0	20	1	US-09-863-049A-13	Sequence 13, Appl
603	17	2.3	17	1	US-10-156-306-6944	Sequence 6944, Ap	676	15.4	2.0	20	1	US-10-211-028-145	Sequence 145, App
604	17	2.3	17	1	US-10-156-306-6945	Sequence 6945, Ap	677	15.2	2.0	20	1	US-09-752-639-131	Sequence 131, App
605	17	2.3	17	1	US-10-156-306-6946	Sequence 6946, Ap	678	15.2	2.0	20	1	US-09-984-198-131	Sequence 131, App
606	17	2.3	17	1	US-10-156-306-6947	Sequence 6947, Ap	679	15.2	2.0	20	1	US-09-836-697-3	Sequence 3, Appli
607	17	2.3	17	1	US-10-156-306-6948	Sequence 6948, Ap	680	15.2	2.0	20	1	US-09-765-555-31	Sequence 31, Appl
608	17	2.3	17	1	US-10-156-306-6949	Sequence 6949, Ap	681	15.2	2.0	20	1	US-10-160-807-122	Sequence 122, App
609	17	2.3	17	1	US-10-156-306-6950	Sequence 6950, Ap	682	15.2	2.0	20	1	US-10-160-807-261	Sequence 261, App
610	17	2.3	17	1	US-10-156-306-6951	Sequence 6951, Ap	683	15.2	2.0	20	1	US-10-161-983-15	Sequence 15, Appl
611	17	2.3	17	1	US-10-156-306-6952	Sequence 6952, Ap	684	15.2	2.0	20	1	US-10-161-983-52	Sequence 52, Appl
612	17	2.3	17	1	US-10-156-306-6953	Sequence 6953, Ap	685	15.2	2.0	20	1	US-10-303-199A-7	Sequence 7, Appli
613	17	2.3	17	1	US-10-156-306-6954	Sequence 6954, Ap	686	15.2	2.0	20	1	US-10-380-125-61	Sequence 61, Appl
614	17	2.3	17	1	US-10-156-306-6955	Sequence 6955, Ap	687	15.2	2.0	20	1	US-10-655-847-122	Sequence 122, App
615	17	2.3	17	1	US-10-156-306-6956	Sequence 6956, Ap	688	15.2	2.0	20	1	US-10-655-847-261	Sequence 261, App
616	17	2.3	17	1	US-10-156-306-6957	Sequence 6957, Ap	689	15.2	2.0	20	1	US-10-688-706-2714	Sequence 2714, Ap
617	17	2.3	17	1	US-10-156-306-6958	Sequence 6958, Ap	690	15	2.0	15	1	US-09-863-049A-62	Sequence 62, Appl

691 15 2.0 15 1 US-10-156-306-7813 Sequence 7813, Ap
692 15 2.0 15 1 US-10-156-306-7826 Sequence 7826, Ap
693 15 2.0 15 1 US-10-156-306-7828 Sequence 7828, Ap
694 15 2.0 15 1 US-10-156-306-7829 Sequence 7829, Ap
695 15 2.0 15 1 US-10-156-306-7831 Sequence 7831, Ap
696 15 2.0 15 1 US-10-156-306-7837 Sequence 7837, Ap
697 15 2.0 15 1 US-10-156-306-7847 Sequence 7847, Ap
698 15 2.0 15 1 US-10-156-306-7851 Sequence 7851, Ap
699 15 2.0 15 1 US-10-156-306-7853 Sequence 7853, Ap
700 15 2.0 15 1 US-10-156-306-7861 Sequence 7861, Ap
701 15 2.0 15 1 US-10-156-306-7866 Sequence 7866, Ap
702 15 2.0 15 1 US-10-156-306-7876 Sequence 7876, Ap
703 15 2.0 15 1 US-10-156-306-7877 Sequence 7877, Ap
704 15 2.0 15 1 US-10-156-306-7878 Sequence 7878, Ap
705 15 2.0 15 1 US-10-156-306-7880 Sequence 7880, Ap
706 15 2.0 15 1 US-10-156-306-7881 Sequence 7881, Ap
707 15 2.0 17 1 US-09-866-108-7244 Sequence 7244, Ap
708 15 2.0 17 1 US-09-866-108-7245 Sequence 7245, Ap
709 15 2.0 17 1 US-10-156-306-6965 Sequence 6965, Ap
710 15 2.0 17 1 US-10-723-361-7244 Sequence 7244, Ap
711 15 2.0 17 1 US-10-723-361-7245 Sequence 7245, Ap
712 15 2.0 18 1 US-10-440-850-1112 Sequence 1112, Ap
713 15 2.0 20 1 US-09-940-227-71 Sequence 71, Appl
714 15 2.0 20 1 US-09-933-058-71 Sequence 3, Appl
715 14.8 2.0 18 1 US-09-863-777-3 Sequence 4, Appl
716 14.8 2.0 18 1 US-09-863-777-4 Sequence 6882, Ap
717 14.8 2.0 18 1 US-10-349-143-8682 Sequence 880, App
718 14.8 2.0 19 1 US-10-297-068-880 Sequence 213, App
719 14.8 2.0 19 1 US-10-444-795B-213 Sequence 1036, Ap
720 14.8 2.0 19 1 US-10-665-951-1036 Sequence 1360, Ap
721 14.8 2.0 19 1 US-10-665-951-1360 Sequence 7247, Ap
722 14.4 1.9 17 1 US-09-866-108-7247 Sequence 7449, Ap
723 14.4 1.9 17 1 US-09-866-108-7449 Sequence 7451, Ap
724 14.4 1.9 17 1 US-09-866-108-7451 Sequence 8870, Ap
725 14.4 1.9 17 1 US-09-866-108-8970 Sequence 8971, Ap
726 14.4 1.9 17 1 US-09-866-108-8971 Sequence 1362, Ap
727 14.4 1.9 17 1 US-09-740-332-1362 Sequence 1362, Ap
728 14.4 1.9 17 1 US-09-817-879-1362 Sequence 3955, Ap
729 14.4 1.9 17 1 US-10-669-841-3955 Sequence 7247, Ap
730 14.4 1.9 17 1 US-10-723-361-7247 Sequence 7449, Ap
731 14.4 1.9 17 1 US-10-723-361-7449 Sequence 7451, Ap
732 14.4 1.9 17 1 US-10-723-361-7451 Sequence 8870, Ap
733 14.4 1.9 17 1 US-10-723-361-8970 Sequence 8971, Ap
734 14.4 1.9 17 1 US-10-723-361-8971 Sequence 8971, Ap
735 14.4 1.9 18 1 US-09-995-529-188 Sequence 188, App
736 14.4 1.9 18 1 US-09-995-529-188 Sequence 188, App
737 14.4 1.9 18 1 US-10-440-850-1113 Sequence 1113, Ap
738 14.4 1.9 18 1 US-10-440-850-1113 Sequence 10970, A
739 14.4 1.9 18 1 US-10-349-143-10970 Sequence 70, Appl
740 14.4 1.9 19 1 US-10-226-992-70 Sequence 153, App
741 14.4 1.9 19 1 US-10-226-992-153 Sequence 8, Appl
742 14 1.9 19 1 US-10-830-287A-8 Sequence 7243, Ap
743 14 1.9 17 1 US-09-866-108-7243 Sequence 7243, Ap
744 14 1.9 17 1 US-09-866-108-8972 Sequence 8972, Ap
745 14 1.9 17 1 US-09-866-108-8973 Sequence 8973, Ap
746 14 1.9 17 1 US-09-866-108-8973 Sequence 3739, Ap
747 14 1.9 17 1 US-10-084-839-3739 Sequence 7243, Ap
748 14 1.9 17 1 US-10-723-361-7243 Sequence 8972, Ap
749 13.8 1.8 17 1 US-10-723-361-8972 Sequence 8973, Ap
750 13.8 1.8 17 1 US-10-723-361-8973 Sequence 6823, Ap
751 13.8 1.8 17 1 US-09-866-108-6823 Sequence 7698, Ap
752 13.8 1.8 17 1 US-09-866-108-7698 Sequence 7813, Ap
753 13.8 1.8 17 1 US-09-866-108-7813 Sequence 8421, Ap
754 13.8 1.8 17 1 US-09-866-108-8421 Sequence 8422, Ap
755 13.8 1.8 17 1 US-09-866-108-8422 Sequence 8422, Ap
756 13.8 1.8 17 1 US-09-864-785-182 Sequence 182, App
757 13.8 1.8 17 1 US-09-864-785-2053 Sequence 2053, App
758 13.8 1.8 17 1 US-09-864-785-3454 Sequence 3454, Ap
759 13.8 1.8 17 1 US-09-818-875-3455 Sequence 478, App
760 13.8 1.8 17 1 US-09-818-875-478 Sequence 168, App
761 13.8 1.8 17 1 US-09-827-395A-168 Sequence 936, App
762 13.8 1.8 17 1 US-09-827-395A-936 Sequence 4340, Ap
763 13.8 1.8 17 1 US-09-740-332-4340 Sequence 4340, Ap
764 13.8 1.8 17 1 US-09-817-879-4340 Sequence 538, App

c 764 13.8 1.8 17 1 US-10-156-306-539 Sequence 539, App
c 765 13.8 1.8 17 1 US-10-156-306-7018 Sequence 7018, Ap
c 766 13.8 1.8 17 1 US-10-061-201-303 Sequence 303, App
c 767 13.8 1.8 17 1 US-10-230-006-2067 Sequence 2067, Ap
c 768 13.8 1.8 17 1 US-10-430-882-168 Sequence 168, App
c 769 13.8 1.8 17 1 US-10-430-882-936 Sequence 936, App
c 770 13.8 1.8 17 1 US-10-209-787-3454 Sequence 3454, Ap
c 771 13.8 1.8 17 1 US-10-209-787-3455 Sequence 3455, Ap
c 772 13.8 1.8 17 1 US-10-261-185-3454 Sequence 1063, Ap
c 773 13.8 1.8 17 1 US-10-261-185-3454 Sequence 3455, Ap
c 774 13.8 1.8 17 1 US-10-261-185-3455 Sequence 3455, Ap
c 775 13.8 1.8 17 1 US-10-138-674-4771 Sequence 4771, Ap
c 776 13.8 1.8 17 1 US-10-138-674-4771 Sequence 6804, Ap
c 777 13.8 1.8 17 1 US-10-138-674-4771 Sequence 2829, Ap
c 778 13.8 1.8 17 1 US-10-287-949A-2829 Sequence 2829, Ap
c 779 13.8 1.8 17 1 US-10-287-949A-4771 Sequence 4771, Ap
c 780 13.8 1.8 17 1 US-10-287-949A-6804 Sequence 6804, Ap
c 781 13.8 1.8 17 1 US-10-712-672-60 Sequence 60, Appl
c 782 13.8 1.8 17 1 US-10-712-672-508 Sequence 508, App
c 783 13.8 1.8 17 1 US-10-669-841-6933 Sequence 6933, Ap
c 784 13.8 1.8 17 1 US-10-723-361-6823 Sequence 6823, Ap
c 785 13.8 1.8 17 1 US-10-723-361-7698 Sequence 7698, Ap
c 786 13.8 1.8 17 1 US-10-723-361-7813 Sequence 7813, Ap
c 787 13.8 1.8 17 1 US-10-723-361-8421 Sequence 8421, Ap
c 788 13.8 1.8 17 1 US-10-723-361-8422 Sequence 8422, Ap
c 789 13.8 1.8 17 1 US-10-681-074-3454 Sequence 3454, Ap
c 790 13.8 1.8 17 1 US-10-681-074-3455 Sequence 3455, Ap
c 791 13.8 1.8 17 1 US-10-498-462-71 Sequence 66, Appl
c 792 13.8 1.8 17 1 US-10-498-462-71 Sequence 71, Appl
c 793 13.8 1.8 17 1 US-10-498-462-2025 Sequence 2025, Ap
c 794 13.8 1.8 17 1 US-10-498-462-2112 Sequence 2112, Ap
c 795 13.8 1.8 17 1 US-10-498-462-2113 Sequence 2113, Ap
c 796 13.8 1.8 17 1 US-10-498-462-2113 Sequence 73509, A
c 797 13.8 1.8 18 1 US-10-741-600-73509 Sequence 384, App
c 798 13.8 1.8 18 1 US-09-901-484A-384 Sequence 384, App
c 799 13.8 1.8 18 1 US-09-853-526-384 Sequence 384, App
c 800 13.8 1.8 18 1 US-09-881-012-194 Sequence 194, App
c 801 13.8 1.8 18 1 US-09-881-012-194 Sequence 194, App
c 802 13.8 1.8 18 1 US-09-998-027-104 Sequence 104, App
c 803 13.8 1.8 18 1 US-10-314-657-204 Sequence 204, App
c 804 13.8 1.8 18 1 US-10-165-099-104 Sequence 104, App
c 805 13.8 1.8 18 1 US-10-138-674-3980 Sequence 3980, Ap
c 806 13.8 1.8 18 1 US-10-664-422-334 Sequence 334, App
c 807 13.8 1.8 18 1 US-10-664-422-334 Sequence 334, App
c 808 13.8 1.8 18 1 US-10-287-949A-3980 Sequence 3980, Ap
c 809 13.8 1.8 18 1 US-10-765-500-57 Sequence 57, Appl
c 810 13.8 1.8 18 1 US-10-664-603-334 Sequence 334, App
c 811 13.8 1.8 18 1 US-10-660-122-143 Sequence 38, Appl
c 812 13.8 1.8 18 1 US-10-806-793-38 Sequence 38, Appl
c 813 13.6 1.8 25 1 US-10-357-467-44 Sequence 13872, A
c 814 13.4 1.8 15 1 US-09-504-231A-988 Sequence 44, Appl
c 815 13.4 1.8 15 1 US-09-274-553D-988 Sequence 988, App
c 816 13.4 1.8 15 1 US-09-907-111-18 Sequence 988, App
c 817 13.4 1.8 15 1 US-09-907-111-18 Sequence 18, Appl
c 818 13.4 1.8 15 1 US-10-440-850-387 Sequence 387, App
c 819 13.4 1.8 16 1 US-10-407-818-7 Sequence 7, Appl
c 820 13.4 1.8 16 1 US-10-307-928A-36 Sequence 36, Appl
c 821 13.4 1.8 17 1 US-09-866-108-6824 Sequence 6824, Ap
c 822 13.4 1.8 17 1 US-09-866-108-6825 Sequence 6825, Ap
c 823 13.4 1.8 17 1 US-09-866-108-7248 Sequence 7248, Ap
c 824 13.4 1.8 17 1 US-09-866-108-7248 Sequence 7448, Ap
c 825 13.4 1.8 17 1 US-09-866-108-7448 Sequence 7452, Ap
c 826 13.4 1.8 17 1 US-09-866-108-7452 Sequence 8419, Ap
c 827 13.4 1.8 17 1 US-09-866-108-8419 Sequence 8420, Ap
c 828 13.4 1.8 17 1 US-09-866-108-8420 Sequence 8969, Ap
c 829 13.4 1.8 17 1 US-09-866-108-8969 Sequence 8969, Ap
c 830 13.4 1.8 17 1 US-09-864-785-1475 Sequence 1475, Ap
c 831 13.4 1.8 17 1 US-09-864-785-1475 Sequence 1475, Ap
c 832 13.4 1.8 17 1 US-09-825-805-656 Sequence 656, App
c 833 13.4 1.8 17 1 US-09-817-879-3193 Sequence 3193, Ap
c 834 13.4 1.8 17 1 US-09-817-879-3193 Sequence 3193, Ap
c 835 13.4 1.8 17 1 US-10-163-552-306 Sequence 306, App
c 836 13.4 1.8 17 1 US-10-339-782-104 Sequence 104, App
c 837 13.4 1.8 17 1 US-10-339-782-127 Sequence 127, App
c 838 13.4 1.8 17 1 US-10-230-006-1418 Sequence 1418, Ap


```
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; PRIOR FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 6
; LENGTH: 29
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Probe
US-10-628-841-6

Query Match          3.8%; Score 29; DB 1; Length 29;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 162 TCTGGAAGAGCCCACTGTGTGAGATGGTG 190
Db 1 TCTGGAAGAGCCCACTGTGTGAGATGGTG 29

RESULT 3
US-10-792-063-24/c
; Sequence 24, Application US/10792063
; Publication No. US20040175797A1
; GENERAL INFORMATION:
; APPLICANT: Johnson, Jason
; APPLICANT: Garrett-Engle, Phillip
; APPLICANT: Kan, Zhengyan
; TITLE OF INVENTION: IKK $\beta$ 
; FILE REFERENCE: R03-011-208PV
; CURRENT APPLICATION NUMBER: US/10/792,063
; CURRENT FILING DATE: 2004-03-03
; PRIOR APPLICATION NUMBER: US 06/452,293
; PRIOR FILING DATE: 2003-03-04
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 24
; LENGTH: 27
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-792-063-24

Query Match          3.6%; Score 27; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 35;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 880 CATCAAGACGAGCGTGGTGGGCAGTGA 906
Db 27 CATCAAGACGAGCGTGGTGGGCAGTGA 1

RESULT 4
US-09-863-049A-61
; Sequence 61, Application US/09863049A
; Publication No. US20030032055A1
; GENERAL INFORMATION:
; APPLICANT: Kenwick, Sue J.
; APPLICANT: Nelson, David L.
; APPLICANT: Aradhyia, Swaroop
; APPLICANT: D'Urso, Michele
; APPLICANT: Woffendin, Hayley
; APPLICANT: Munnich, Arnold
; APPLICANT: Smahi, Aamae
; APPLICANT: Israel, Alain
; APPLICANT: Foustka, Annemarie
; APPLICANT: Lewis, Richard A
```

```
; APPLICANT: Levy, Moise
; APPLICANT: Heiss, Nina
; TITLE OF INVENTION: Diagnosis and Treatment of Medical Conditions Associated with Def
; TITLE OF INVENTION: NFKAPPA B (NF- $\kappa$ B) Activation
; FILE REFERENCE: HO-P01961U51
; CURRENT APPLICATION NUMBER: US/09/863,049A
; CURRENT FILING DATE: 2001-05-22
; PRIOR APPLICATION NUMBER: US 60/206,223
; PRIOR FILING DATE: 2000-05-22
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 61
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(22)
; OTHER INFORMATION: Primer
US-09-863-049A-61

Query Match          2.9%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 99;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 344 CGGCAGACCAACGAGATTCTGC 365
Db 1 CGGCAGACCAACGAGATTCTGC 22

RESULT 5
US-10-444-795B-711
; Sequence 711, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; APPLICANT: Lewis, Stephen Patrick
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; TITLE OF INVENTION: TRANSDUCTION BY RNA INTERFERENCE
; FILE REFERENCE: 200125.449
; CURRENT APPLICATION NUMBER: US/10/444,795B
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 711
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA - IKK.2
US-10-444-795B-711

Query Match          2.8%; Score 21; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 418 GGAGTTCTCTCATGTGCAAGTT 438
Db 1 GGAGUUCUCCUAGUGCAAGTT 21

RESULT 6
US-10-444-795B-721/c
; Sequence 721, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; APPLICANT: Lewis, Stephen Patrick
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; TITLE OF INVENTION: TRANSDUCTION BY RNA INTERFERENCE
; FILE REFERENCE: 200125.449
```


; CURRENT APPLICATION NUMBER: US/10/444,795B
 ; CURRENT FILING DATE: 2003-05-23
 ; NUMBER OF SEQ ID NOS: 842
 ; SOFTWARE: FastSeq for Windows Version 4.0
 ; SEQ ID NO 721
 ; LENGTH: 21
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Small interfering RNA - IKK.4
 US-10-444-795B-721

Query Match 2.8%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 875 AACCATCAAGACGACGGTG 895
 Db 21 AACCATCAAGACGACGGTG 1

RESULT 7
 US-09-972-607-5/c
 ; Sequence 5, Application US/09972607
 ; Publication No. US20030105037A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Brett P. Monia
 ; APPLICANT: Jacqueline Wyatt
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
 ; FILE REFERENCE: RTS-0191
 ; CURRENT APPLICATION NUMBER: US/09/972,607
 ; CURRENT FILING DATE: 2001-10-06
 ; NUMBER OF SEQ ID NOS: 88
 ; SEQ ID NO 5
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: PCR Primer
 US-09-972-607-5

Query Match 2.6%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 215 GATCAGGACGTACTGGCGA 234
 Db 20 GATCAGGACGTACTGGCGA 1

RESULT 8
 US-09-972-607-16/c
 ; Sequence 16, Application US/09972607
 ; Publication No. US20030105037A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Brett P. Monia
 ; APPLICANT: Jacqueline Wyatt
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
 ; FILE REFERENCE: RTS-0191
 ; CURRENT APPLICATION NUMBER: US/09/972,607
 ; CURRENT FILING DATE: 2001-10-06
 ; NUMBER OF SEQ ID NOS: 88
 ; SEQ ID NO 16
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Antisense Oligonucleotide
 US-09-972-607-16

Query Match 2.6%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 162 TCTGGAAGGCCAACTGTGT 181
 Db 20 TCTGGAAGGCCAACTGTGT 1

RESULT 9
 US-09-972-607-17/c
 ; Sequence 17, Application US/09972607
 ; Publication No. US20030105037A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Brett P. Monia
 ; APPLICANT: Jacqueline Wyatt
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
 ; FILE REFERENCE: RTS-0191
 ; CURRENT APPLICATION NUMBER: US/09/972,607
 ; CURRENT FILING DATE: 2001-10-06
 ; NUMBER OF SEQ ID NOS: 88
 ; SEQ ID NO 17
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Antisense Oligonucleotide
 US-09-972-607-17

Query Match 2.6%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 195 CCAGTGTGCGCCGCGCAGCA 214
 Db 20 CCAGTGTGCGCCGCGCAGCA 1

RESULT 10
 US-09-972-607-18/c
 ; Sequence 18, Application US/09972607
 ; Publication No. US20030105037A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Brett P. Monia
 ; APPLICANT: Jacqueline Wyatt
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
 ; FILE REFERENCE: RTS-0191
 ; CURRENT APPLICATION NUMBER: US/09/972,607
 ; CURRENT FILING DATE: 2001-10-06
 ; NUMBER OF SEQ ID NOS: 88
 ; SEQ ID NO 18
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Antisense Oligonucleotide
 US-09-972-607-18

Query Match 2.6%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 231 GCGAAGAGTCTCTCTGGGG 250
 Db 20 GCGAAGAGTCTCTCTGGGG 1

RESULT 11
 US-09-972-607-19/c
 ; Sequence 19, Application US/09972607
 ; Publication No. US20030105037A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Brett P. Monia
 ; APPLICANT: Jacqueline Wyatt
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
 ; FILE REFERENCE: RTS-0191

; CURRENT APPLICATION NUMBER: US/09/972,607
 ; CURRENT FILING DATE: 2001-10-06
 ; NUMBER OF SEQ ID NOS: 88
 ; SEQ ID NO 19
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Antisense Oligonucleotide
 US-09-972-607-19

Query Match 2.6%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 270 TGCCTTCAGAACAGGGCGCT 289
 |||||
 Db 20 TGCCTTCAGAACAGGGCGCT 1

RESULT 12
 US-09-972-607-20/c
 ; Sequence 20, Application US/09972607
 ; Publication No. US20030105037A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Brett P. Monia
 ; APPLICANT: Jacqueline Wyatt
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
 ; FILE REFERENCE: RTS-0191
 ; CURRENT APPLICATION NUMBER: US/09/972,607
 ; CURRENT FILING DATE: 2001-10-06
 ; NUMBER OF SEQ ID NOS: 88
 ; SEQ ID NO 20
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Antisense Oligonucleotide
 US-09-972-607-20

Query Match 2.6%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 275 TCAGAACAGGGCGCTCTCTGA 294
 |||||
 Db 20 TCAGAACAGGGCGCTCTCTGA 1

RESULT 13
 US-09-972-607-21/c
 ; Sequence 21, Application US/09972607
 ; Publication No. US20030105037A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Brett P. Monia
 ; APPLICANT: Jacqueline Wyatt
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
 ; FILE REFERENCE: RTS-0191
 ; CURRENT APPLICATION NUMBER: US/09/972,607
 ; CURRENT FILING DATE: 2001-10-06
 ; NUMBER OF SEQ ID NOS: 88
 ; SEQ ID NO 21
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Antisense Oligonucleotide
 US-09-972-607-21

Query Match 2.6%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 279 AACAGGGCGCTCTCTGAGACC 298
 |||||
 Db 20 AACAGGGCGCTCTCTGAGACC 1

RESULT 14
 US-09-972-607-22/c
 ; Sequence 22, Application US/09972607
 ; Publication No. US20030105037A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Brett P. Monia
 ; APPLICANT: Jacqueline Wyatt
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
 ; FILE REFERENCE: RTS-0191
 ; CURRENT APPLICATION NUMBER: US/09/972,607
 ; CURRENT FILING DATE: 2001-10-06
 ; NUMBER OF SEQ ID NOS: 88
 ; SEQ ID NO 22
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Antisense Oligonucleotide
 US-09-972-607-22

Query Match 2.6%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 313 GGAGGAGAAATCAAGAGCTCC 332
 |||||
 Db 20 GGAGGAGAAATCAAGAGCTCC 1

RESULT 15
 US-09-972-607-23/c
 ; Sequence 23, Application US/09972607
 ; Publication No. US20030105037A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Brett P. Monia
 ; APPLICANT: Jacqueline Wyatt
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
 ; FILE REFERENCE: RTS-0191
 ; CURRENT APPLICATION NUMBER: US/09/972,607
 ; CURRENT FILING DATE: 2001-10-06
 ; NUMBER OF SEQ ID NOS: 88
 ; SEQ ID NO 23
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Antisense Oligonucleotide
 US-09-972-607-23

Query Match 2.6%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 344 CGGACAGCAACCAAGATTCT 363
 |||||
 Db 20 CGGACAGCAACCAAGATTCT 1

RESULT 16
 US-09-972-607-24/c
 ; Sequence 24, Application US/09972607
 ; Publication No. US20030105037A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Brett P. Monia
 ; APPLICANT: Jacqueline Wyatt
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
 ; FILE REFERENCE: RTS-0191
 ; CURRENT APPLICATION NUMBER: US/09/972,607

Query Match 2.6%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 24
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-24

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 385 TCTGCAATTCACGCCAGCC 404
Db 20 TCTGCAATTCACGCCAGCC 1

RESULT 17
US-09-972-607-25/c
; Sequence 25, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-25

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 391 TTTCACAGCCAGCCAGGG 410
Db 20 TTTCACAGCCAGCCAGGG 1

RESULT 18
US-09-972-607-26/c
; Sequence 26, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-26

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 419 GAGTTCCTCATGTGCAAGTT 438

```

```

Db 20 GAGTTCCTCATGTGCAAGTT 1

RESULT 19
US-09-972-607-27/c
; Sequence 27, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 27
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-27

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 451 GAAACTGCTGGAGAGACTCG 470
Db 20 GAAACTGCTGGAGAGACTCG 1

RESULT 20
US-09-972-607-28/c
; Sequence 28, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 28
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-28

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 465 GACTCGGCCTGGAGAGCTC 484
Db 20 GACTCGGCCTGGAGAGCTC 1

RESULT 21
US-09-972-607-29/c
; Sequence 29, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06

```

```
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 29
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-29

Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 483 TCGATCTGAAGAGCGCAGAAG 502
      |||||
Db 20 TCGATCTGAAGAGCGCAGAAG 1

RESULT 22
US-09-972-607-30/c
; Sequence 30, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 30
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-30

Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 489 TGAAGAGCGCAGAGGAGCGAG 508
      |||||
Db 20 TGAAGAGCGCAGAGGAGCGAG 1

RESULT 23
US-09-972-607-31/c
; Sequence 31, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 31
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-31

Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 507 AGGCTCTGCGGAGGTGGAG 526
      |||||
```

```
Db 20 AGGCTCTGCGGAGGTGGAG 1

RESULT 24
US-09-972-607-32/c
; Sequence 32, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 32
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-32

Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 534 AGAGATGCCAGCAGCAGATG 553
      |||||
Db 20 AGAGATGCCAGCAGCAGATG 1

RESULT 25
US-09-972-607-33/c
; Sequence 33, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-33

Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 604 GCTGCAGGAGAGCCAGATC 623
      |||||
Db 20 GCTGCAGGAGAGCCAGATC 1

RESULT 26
US-09-972-607-34/c
; Sequence 34, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
```

```

; SEQ ID NO 34
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-09-972-607-34

Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      616 CCAGAGTCGCTTGAGGCTG 635
Db      20 CCAGAGTCGCTTGAGGCTG 1

RESULT 27
US-09-972-607-35/c
; Sequence 35, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 35
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-09-972-607-35

Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      686 CAGCGCGCGCAGCTGCAGAG 705
Db      20 CAGCGCGCGCAGCTGCAGAG 1

RESULT 28
US-09-972-607-36/c
; Sequence 36, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-09-972-607-36

Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      715 GCGGCTGCAGCAGCAGCACA 734
Db      20 GCGGCTGCAGCAGCAGCACA 1
```

```

RESULT 29
US-09-972-607-37/c
; Sequence 37, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 37
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-09-972-607-37

Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      724 GCAGCAGCACAGCGTGCAGG 743
Db      20 GCAGCAGCACAGCGTGCAGG 1

RESULT 30
US-09-972-607-38/c
; Sequence 38, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 38
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-09-972-607-38

Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      725 CAGCAGCACAGCGTGCAGGT 744
Db      20 CAGCAGCACAGCGTGCAGGT 1

RESULT 31
US-09-972-607-39/c
; Sequence 39, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 39
```

; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-39

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 726 AGCAGCACACGCTGCAGGTG 745
|||||
Db 20 AGCAGCACACGCTGCAGGTG 1

RESULT 32

US-09-972-607-40/c
; Sequence 40, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-40

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 776 GAGGCCGCGCTCCGCATGGA 795
|||||
Db 20 GAGGCCGCGCTCCGCATGGA 1

RESULT 33

US-09-972-607-41/c
; Sequence 41, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 41
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-41

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 792 TGGAGCGCCAGGCCGCTCG 811
|||||
Db 20 TGGAGCGCCAGGCCGCTCG 1

RESULT 34

US-09-972-607-42/c
; Sequence 42, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-42

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 800 CAGGCCGCGCTCCGAGGAGAA 819
|||||
Db 20 CAGGCCGCGCTCCGAGGAGAA 1

RESULT 35

US-09-972-607-43/c
; Sequence 43, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 43
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-43

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 803 GCGCCCTCGAGGAGAGAG 822
|||||
Db 20 GCGCCCTCGAGGAGAGAG 1

RESULT 36

US-09-972-607-44/c
; Sequence 44, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 44
; LENGTH: 20

TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-44

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 830 GCCAGTTCAGGTGGCCTA 849
| | | | | | | | | | | | | | | | | | | | | |
Db 20 GCCAGTTCAGGTGGCCTA 1

RESULT 37
US-09-972-607-45/c
Sequence 45, Application US/09972607
Publication No. US20030105037A1
GENERAL INFORMATION:
APPLICANT: Brett P. Monia
TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
FILE REFERENCE: RTS-0191
CURRENT APPLICATION NUMBER: US/09/972,607
CURRENT FILING DATE: 2001-10-06
NUMBER OF SEQ ID NOS: 88
SEQ ID NO 45
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-45

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 840 AGGTGGCTATCACCAGCTC 859
| | | | | | | | | | | | | | | | | | | | | |
Db 20 AGGTGGCTATCACCAGCTC 1

RESULT 38
US-09-972-607-46/c
Sequence 46, Application US/09972607
Publication No. US20030105037A1
GENERAL INFORMATION:
APPLICANT: Brett P. Monia
TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
FILE REFERENCE: RTS-0191
CURRENT APPLICATION NUMBER: US/09/972,607
CURRENT FILING DATE: 2001-10-06
NUMBER OF SEQ ID NOS: 88
SEQ ID NO 46
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-46

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 843 TGGCCTATCACCAGCTCTTC 862
| | | | | | | | | | | | | | | | | | | | | |
Db 20 TGGCCTATCACCAGCTCTTC 1

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 39
US-09-972-607-47/c
Sequence 47, Application US/09972607
Publication No. US20030105037A1
GENERAL INFORMATION:
APPLICANT: Brett P. Monia
TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
FILE REFERENCE: RTS-0191
CURRENT APPLICATION NUMBER: US/09/972,607
CURRENT FILING DATE: 2001-10-06
NUMBER OF SEQ ID NOS: 88
SEQ ID NO 47
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-47

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 882 TCAAGAGCAGCGTGGTGGC 901
| | | | | | | | | | | | | | | | | | | | | |
Db 20 TCAAGAGCAGCGTGGTGGC 1

RESULT 40
US-09-972-607-48/c
Sequence 48, Application US/09972607
Publication No. US20030105037A1
GENERAL INFORMATION:
APPLICANT: Brett P. Monia
TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
FILE REFERENCE: RTS-0191
CURRENT APPLICATION NUMBER: US/09/972,607
CURRENT FILING DATE: 2001-10-06
NUMBER OF SEQ ID NOS: 88
SEQ ID NO 48
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-48

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 885 AGACGACGCGTGGGCGAGT 904
| | | | | | | | | | | | | | | | | | | | | |
Db 20 AGACGACGCGTGGGCGAGT 1

RESULT 41
US-09-972-607-49/c
Sequence 49, Application US/09972607
Publication No. US20030105037A1
GENERAL INFORMATION:
APPLICANT: Brett P. Monia
TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
FILE REFERENCE: RTS-0191
CURRENT APPLICATION NUMBER: US/09/972,607
CURRENT FILING DATE: 2001-10-06
NUMBER OF SEQ ID NOS: 88
SEQ ID NO 49
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-49

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 885 AGACGACGCGTGGGCGAGT 904
| | | | | | | | | | | | | | | | | | | | | |
Db 20 AGACGACGCGTGGGCGAGT 1

RESULT 41
US-09-972-607-49/c
Sequence 49, Application US/09972607
Publication No. US20030105037A1
GENERAL INFORMATION:
APPLICANT: Brett P. Monia
TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
FILE REFERENCE: RTS-0191
CURRENT APPLICATION NUMBER: US/09/972,607
CURRENT FILING DATE: 2001-10-06
NUMBER OF SEQ ID NOS: 88
SEQ ID NO 49
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-49

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 885 AGACGACGCGTGGGCGAGT 904
| | | | | | | | | | | | | | | | | | | | | |
Db 20 AGACGACGCGTGGGCGAGT 1

RESULT 41
US-09-972-607-49/c
Sequence 49, Application US/09972607
Publication No. US20030105037A1
GENERAL INFORMATION:
APPLICANT: Brett P. Monia
TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
FILE REFERENCE: RTS-0191
CURRENT APPLICATION NUMBER: US/09/972,607
CURRENT FILING DATE: 2001-10-06
NUMBER OF SEQ ID NOS: 88
SEQ ID NO 49
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-49

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 885 AGACGACGCGTGGGCGAGT 904
| | | | | | | | | | | | | | | | | | | | | |
Db 20 AGACGACGCGTGGGCGAGT 1

RESULT 41
US-09-972-607-49/c
Sequence 49, Application US/09972607
Publication No. US20030105037A1
GENERAL INFORMATION:
APPLICANT: Brett P. Monia
TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
FILE REFERENCE: RTS-0191
CURRENT APPLICATION NUMBER: US/09/972,607
CURRENT FILING DATE: 2001-10-06
NUMBER OF SEQ ID NOS: 88
SEQ ID NO 49
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-49

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-49

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 897 TGGCAGTGGCGGAGCGCA 916
Db 20 TGGCAGTGGCGGAGCGCA 1
|||||

RESULT 42

US-10-628-841-5/c
; Sequence 5, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:

; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 5
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-10-628-841-5

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 215 GATCAGGAGTCTACTGGCGCA 234
Db 20 GATCAGGAGTCTACTGGCGCA 1
|||||

RESULT 43

US-10-628-841-16/c
; Sequence 16, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:

; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-16

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 162 TCTGGAAGAGCCCACTGTGT 181
|||||

Db 20 TCTGGAAGAGCCCACTGTGT 1

RESULT 44

US-10-628-841-17/c
; Sequence 17, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:

; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-17

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 195 CCAGTGGTGGCCCGGCGCA 214
Db 20 CCAGTGGTGGCCCGGCGCA 1
|||||

RESULT 45

US-10-628-841-18/c
; Sequence 18, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:

; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 18
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-18

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 231 GCGAAGAGTCTCTCTGGGG 250
Db 20 GCGAAGAGTCTCTCTGGGG 1
|||||

RESULT 46

US-10-628-841-19/c
; Sequence 19, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:

; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION


```

; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-19

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 270 TGCCTTCAGAACAGGGCGCT 289
Db 20 TGCCTTCAGAACAGGGCGCT 1

RESULT 47
US-10-628-841-20/c
; Sequence 20, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 20
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-20

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 275 TCAGAACAGGGCGCTCCTGA 294
Db 20 TCAGAACAGGGCGCTCCTGA 1

RESULT 48
US-10-628-841-21/c
; Sequence 21, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:

```

```

; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-21

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 279 AACAGGGCGCTCCTGAGACC 298
Db 20 AACAGGGCGCTCCTGAGACC 1

RESULT 49
US-10-628-841-22/c
; Sequence 22, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-22

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 313 GGAGGAGAAATCAAGAGCTCC 332
Db 20 GGAGGAGAAATCAAGAGCTCC 1

RESULT 50
US-10-628-841-23/c
; Sequence 23, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-23

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 344 CGGAGAGCAACACAGATTCT 363
Db 20 CGGAGAGCAACACAGATTCT 1

```

```
RESULT 51
US-10-628-841-24/c
; Sequence 24, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; PRIOR FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 24
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-24

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 385 TCTGCATTTCCAGCCAGCC 404
Db 20 TCTGCATTTCCAGCCAGCC 1

RESULT 52
US-10-628-841-25/c
; Sequence 25, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; PRIOR FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-25

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 391 TTTCCAGCCAGCCAGGG 410
Db 20 TTTCCAGCCAGCCAGGG 1

RESULT 53
US-10-628-841-26/c
; Sequence 26, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
```

```
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-26

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 419 GAGTTCCTCATGTGCAAGTT 438
Db 20 GAGTTCCTCATGTGCAAGTT 1

RESULT 54
US-10-628-841-27/c
; Sequence 27, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 27
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-27

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 451 GAAACTGTTGGAGAGACTCG 470
Db 20 GAAACTGTTGGAGAGACTCG 1

RESULT 55
US-10-628-841-28/c
; Sequence 28, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 28
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-28
```

```
Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 465 GACTCGGCTGGAGAGCTC 484
Db 20 GACTCGGCTGGAGAGCTC 1

RESULT 56
US-10-628-841-29/c
; Sequence 29, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 29
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-29

Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 483 TCGATCTGAAGAGGCGAGAAG 502
Db 20 TCGATCTGAAGAGGCGAGAAG 1

RESULT 57
US-10-628-841-30/c
; Sequence 30, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 30
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-30

Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 489 TGAAGAGGCGAGAAGGAGCAG 508
Db 20 TGAAGAGGCGAGAAGGAGCAG 1

RESULT 58
```

```
US-10-628-841-31/c
; Sequence 31, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 31
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-31

Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 507 AGGCTCTGGGGAGGTGGAG 526
Db 20 AGGCTCTGGGGAGGTGGAG 1

RESULT 59
US-10-628-841-32/c
; Sequence 32, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 32
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-32

Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 534 AGAGATCCAGCAGCAGATG 553
Db 20 AGAGATCCAGCAGCAGATG 1

RESULT 60
US-10-628-841-33/c
; Sequence 33, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
```

```
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-33

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 604 GCTGCAGGAGAGCCAGAGTC 623
Db 20 GCTGCAGGAGAGCCAGAGTC 1

RESULT 61
US-10-628-841-34/c
; Sequence 34, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 34
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-34

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 616 CCAGAGTCGCTGGAGGCTG 635
Db 20 CCAGAGTCGCTGGAGGCTG 1

RESULT 62
US-10-628-841-35/c
; Sequence 35, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 35
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-35

Query Match          2.6%; Score 20; DB 1; Length 20;
```

```
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 686 CAGGCGCGCAGCTGGAGAG 705
Db 20 CAGGCGCGCAGCTGGAGAG 1

RESULT 63
US-10-628-841-36/c
; Sequence 36, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-36

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 715 GCGCTGCAGCAGCAGCACA 734
Db 20 GCGCTGCAGCAGCAGCACA 1

RESULT 64
US-10-628-841-37/c
; Sequence 37, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 37
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-37

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 724 GCAGCAGCAGCAGCTGCAGG 743
Db 20 GCAGCAGCAGCAGCTGCAGG 1

RESULT 65
US-10-628-841-38/c
; Sequence 38, Application US/10628841
```

```
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; PRIOR FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 38
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-38

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 725 CAGCAGCACGCGTGCAGGT 744
    |||||
Db 20 CAGCAGCACGCGTGCAGGT 1

RESULT 66
US-10-628-841-39/c
; Sequence 39, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 39
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-39

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 726 AGCAGCACGCGTGCAGGTG 745
    |||||
Db 20 AGCAGCACGCGTGCAGGTG 1

RESULT 67
US-10-628-841-40/c
; Sequence 40, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
```

```
; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-40

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 776 GAGCGCGCGCTCCGCATGGA 795
    |||||
Db 20 GAGCGCGCGCTCCGCATGGA 1

RESULT 68
US-10-628-841-41/c
; Sequence 41, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 41
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-41

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 792 TGGAGCGCCAGCGCGCTCG 811
    |||||
Db 20 TGGAGCGCCAGCGCGCTCG 1

RESULT 69
US-10-628-841-42/c
; Sequence 42, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-42

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      800 CAGGCCGCTCGAGGAGAA 819
      |||||
Db      20 CAGGCCGCTCGAGGAGAA 1

RESULT 70
US-10-628-841-43/c
; Sequence 43, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 43
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-43

Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      803 GCCGCTCGAGGAGAAG 822
      |||||
Db      20 GCCGCTCGAGGAGAAG 1

RESULT 71
US-10-628-841-44/c
; Sequence 44, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 44
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-44

Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      830 GCCAGTTGAGGTGGCCTA 849
      |||||
Db      20 GCCAGTTGAGGTGGCCTA 1

RESULT 72
US-10-628-841-45/c
; Sequence 45, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 45
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-45

Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      840 AGGTGGCTATCACCAGCTC 859
      |||||
Db      20 AGGTGGCTATCACCAGCTC 1

RESULT 73
US-10-628-841-46/c
; Sequence 46, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 46
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-46

Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      843 TGGCCTATCACCAGCTCTTC 862
      |||||
Db      20 TGGCCTATCACCAGCTCTTC 1

RESULT 74
US-10-628-841-47/c
; Sequence 47, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 47
; LENGTH: 20
```

```

; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-47

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 882 TCAAGACGCGGTGGGCG 901
Db 20 TCAAGACGCGGTGGGCG 1

RESULT 75
US-10-628-841-48/c
; Sequence 48, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 48
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-48

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 885 AGAGCAGCGTGGTGGCGAGT 904
Db 20 AGAGCAGCGTGGTGGCGAGT 1

RESULT 76
US-10-628-841-49/c
; Sequence 49, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 49
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-49

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 897 TGGGCACTGAGCGGACCGA 916

```

```

Db 20 TGGGCAGTGAGCGGAAGCGA 1

RESULT 77
US-09-863-049A-53/c
; Sequence 53, Application US/09863049A
; Publication No. US20030032055A1
; GENERAL INFORMATION:
; APPLICANT: Kenwick, Sue J.
; APPLICANT: Nelson, David L.
; APPLICANT: Arachya, Swaroop
; APPLICANT: D'Urso, Michele
; APPLICANT: Woffendin, Hayley
; APPLICANT: Munnich, Arnold
; APPLICANT: Smahi, Asmae
; APPLICANT: Israel, Alain
; APPLICANT: Poustka, Annemarie
; APPLICANT: Lewis, Richard A
; APPLICANT: Levy, Moise
; APPLICANT: Heiss, Nina
; TITLE OF INVENTION: Diagnosis and Treatment of Medical Conditions Associated with Defi
; TITLE OF INVENTION: NFKAPPA B (NF-KB) Activation
; FILE REFERENCE: HO-P01961US1
; CURRENT APPLICATION NUMBER: US/09/863,049A
; CURRENT FILING DATE: 2001-05-22
; PRIOR APPLICATION NUMBER: US 60/206,223
; PRIOR FILING DATE: 2000-05-22
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 53
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Human
US-09-863-049A-53

Query Match          2.6%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 645 AATGCCAGGCTCTGGAGGGT 664
Db 20 AATGCCAGGCTCTGGAGGGT 1

RESULT 78
US-10-809-189-13872
; Sequence 13872, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 13872
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-809-189-13872

Query Match          2.6%; Score 19.8; DB 1; Length 25;
Best Local Similarity 91.3%; Pred. No. 2.1e+02;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```



```

; FILE REFERENCE: 200125.449
; CURRENT APPLICATION NUMBER: US/10/444,795B
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 712
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA - IKK.2
US-10-444-795B-712

Query Match      2.5%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 1.8e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 418 GGAGTTCTCTCATGTGCAAG 436
      ||||:||||:||||:||||:
Db 1 GGAGUUCUCCAUUGGCAAG 19

RESULT 86
US-10-444-795B-713/c
; Sequence 713, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; APPLICANT: Lewis, Stephen Patrick
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; TITLE OF INVENTION: TRANSDUCTION BY RNA INTERFERENCE
; FILE REFERENCE: 200125.449
; CURRENT APPLICATION NUMBER: US/10/444,795B
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 713
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA - IKK.2
US-10-444-795B-713

Query Match      2.5%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 418 GGAGTTCTCTCATGTGCAAG 436
      |||||:|||||:|||||:|||||
Db 19 GGAGTTCTCTCATGTGCAAG 1

RESULT 87
US-10-444-795B-717
; Sequence 717, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; APPLICANT: Lewis, Stephen Patrick
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; TITLE OF INVENTION: TRANSDUCTION BY RNA INTERFERENCE
; FILE REFERENCE: 200125.449
; CURRENT APPLICATION NUMBER: US/10/444,795B
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 717
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA - IKK.3
```

```

; FILE REFERENCE: 200125.449
; CURRENT APPLICATION NUMBER: US/10/444,795B
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 707
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA - IKK.1
US-10-444-795B-707

Query Match      2.5%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.8e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 236 GAGTCTCTCTCTGGGGAAGC 254
      ||||:||||:||||:||||:
Db 1 GAGUUCUCCUGGGGAAGC 19

RESULT 84
US-10-444-795B-708/c
; Sequence 708, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; APPLICANT: Lewis, Stephen Patrick
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; TITLE OF INVENTION: TRANSDUCTION BY RNA INTERFERENCE
; FILE REFERENCE: 200125.449
; CURRENT APPLICATION NUMBER: US/10/444,795B
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 708
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA - IKK.1
US-10-444-795B-708

Query Match      2.5%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 236 GAGTCTCTCTCTGGGGAAGC 254
      |||||:|||||:|||||:|||||
Db 19 GAGTCTCTCTCTGGGGAAGC 1

RESULT 85
US-10-444-795B-712
; Sequence 712, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; APPLICANT: Lewis, Stephen Patrick
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; TITLE OF INVENTION: TRANSDUCTION BY RNA INTERFERENCE
```

US-10-444-795B-717

Query Match 2.5%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 1.8e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 565 GGCCTCTGTGAAGCCCGAG 583
||||:|:|||||
Db 1 GGCCUCUGAGAAAGCCCGAG 19

RESULT 88

US-10-444-795B-718/c
; Sequence 718, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; APPLICANT: Lewis, Stephen Patrick
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; FILE REFERENCE: 200125.449
; CURRENT APPLICATION NUMBER: US/10/444,795B
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 718
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA - IKK.3
US-10-444-795B-718

Query Match 2.5%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 565 GGCCTCTGTGAAGCCCGAG 583
||||:|:|||||
Db 19 GGCCCTCTGTGAAGCCCGAG 1

RESULT 89

US-10-444-795B-722/c
; Sequence 722, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; APPLICANT: Lewis, Stephen Patrick
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; FILE REFERENCE: 200125.449
; CURRENT APPLICATION NUMBER: US/10/444,795B
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 722
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA - IKK.4
US-10-444-795B-722

Query Match 2.5%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 877 CCACATCAAGAGCGCGTG 895
||||:|:|||||
Db 19 CCACATCAAGAGCGCGTG 1

RESULT 90

US-10-444-795B-723
; Sequence 723, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; APPLICANT: Lewis, Stephen Patrick
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; FILE REFERENCE: 200125.449
; CURRENT APPLICATION NUMBER: US/10/444,795B
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 723
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA - IKK.4
US-10-444-795B-723

Query Match 2.5%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.8e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 877 CCACATCAAGAGCGCGTG 895
||||:|:|||||
Db 1 CCACATCAAGAGCGCGUG 19

RESULT 91

US-10-444-795B-706
; Sequence 706, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; APPLICANT: Lewis, Stephen Patrick
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; FILE REFERENCE: 200125.449
; CURRENT APPLICATION NUMBER: US/10/444,795B
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 706
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA - IKK.1
US-10-444-795B-706

Query Match 2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 2.1e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 236 GAGTCCTCTCTGGGGAAGC 254
||||:|:|||||
Db 1 GAGUCUCCUCUGGGGAAGC 19

RESULT 92

US-10-444-795B-709
; Sequence 709, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; APPLICANT: Lewis, Stephen Patrick
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; FILE REFERENCE: 200125.449
; CURRENT APPLICATION NUMBER: US/10/444,795B

```
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 709
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA - IKK.1
; NAME/KEY: misc_feature
; LOCATION: 20..21
; OTHER INFORMATION: n = A,T,C,G or U
US-10-444-795B-709

Query Match      2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 2.1e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 236 GAGTCTCTCTGGGGAAGC 254
Db 1 GAGUCUCCUCUGGGGAAGC 19

RESULT 93
US-10-444-795B-710/c
; Sequence 710, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; APPLICANT: Lewis, Stephen Patrick
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; TITLE OF INVENTION: TRANSDUCTION BY RNA INTERFERENCE
; FILE REFERENCE: 200125.449
; CURRENT APPLICATION NUMBER: US/10/444,795B
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 710
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA - IKK.1
; NAME/KEY: misc_feature
; LOCATION: 1, 2
; OTHER INFORMATION: n = A,T,C,G or U
US-10-444-795B-710

Query Match      2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 236 GAGTCTCTCTGGGGAAGC 254
Db 21 GAGTCTCTCTGGGGAAGC 3

RESULT 94
US-10-444-795B-714
; Sequence 714, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; APPLICANT: Lewis, Stephen Patrick
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; TITLE OF INVENTION: TRANSDUCTION BY RNA INTERFERENCE
; FILE REFERENCE: 200125.449
; CURRENT APPLICATION NUMBER: US/10/444,795B
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 714
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA - IKK.2
; NAME/KEY: misc_feature
; LOCATION: 1, 2
; OTHER INFORMATION: n = A,T,C,G or U
US-10-444-795B-715

Query Match      2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 418 GGAGTTCTCTCATGTGCAAG 436
Db 21 GGAGTTCTCTCATGTGCAAG 3

RESULT 95
US-10-444-795B-715/c
; Sequence 715, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; APPLICANT: Lewis, Stephen Patrick
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; TITLE OF INVENTION: TRANSDUCTION BY RNA INTERFERENCE
; FILE REFERENCE: 200125.449
; CURRENT APPLICATION NUMBER: US/10/444,795B
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 715
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA - IKK.2
; NAME/KEY: misc_feature
; LOCATION: 1, 2
; OTHER INFORMATION: n = A,T,C,G or U
US-10-444-795B-715

Query Match      2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 2.1e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 418 GGAGTTCTCTCATGTGCAAG 436
Db 1 GGAGUUCUCCAUUGUGCAAG 19

RESULT 96
US-10-444-795B-719
; Sequence 719, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; APPLICANT: Lewis, Stephen Patrick
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; TITLE OF INVENTION: TRANSDUCTION BY RNA INTERFERENCE
; FILE REFERENCE: 200125.449
; CURRENT APPLICATION NUMBER: US/10/444,795B
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 719
; LENGTH: 21
; TYPE: DNA
```

```

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA - IKK.3
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 20..21
; OTHER INFORMATION: n = A,T,C,G or U
US-10-444-795B-719

Query Match          2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 2.1e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 565 GGCCTCTGTGAAAGCCAC 583
DB 1 GGCCUCUGUGAAAGCCAC 19

RESULT 97
US-10-444-795B-720/c
; Sequence 720, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; TITLE OF INVENTION: TRANSDUCTION BY RNA INTERFERENCE
; FILE REFERENCE: 200125.449
; CURRENT APPLICATION NUMBER: US/10/444,795B
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 720
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA - IKK.3
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1, 2
; OTHER INFORMATION: n = A,T,C,G or U
US-10-444-795B-720

Query Match          2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 565 GGCCTCTGTGAAAGCCAC 583
DB 21 GGCTCTGTGAAAGCCAC 3

RESULT 98
US-10-444-795B-724/c
; Sequence 724, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; APPLICANT: Lewis, Stephen Patrick
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; TITLE OF INVENTION: TRANSDUCTION BY RNA INTERFERENCE
; FILE REFERENCE: 200125.449
; CURRENT APPLICATION NUMBER: US/10/444,795B
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 724
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA - IKK.4

```

```

; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 20..21
; OTHER INFORMATION: n = A,T,C,G or U
US-10-444-795B-724

Query Match          2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 877 CCACATCAAGACGCGTG 895
DB 19 CCACATCAAGACGCGTG 1

RESULT 99
US-10-444-795B-725
; Sequence 725, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; APPLICANT: Lewis, Stephen Patrick
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; TITLE OF INVENTION: TRANSDUCTION BY RNA INTERFERENCE
; FILE REFERENCE: 200125.449
; CURRENT APPLICATION NUMBER: US/10/444,795B
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 725
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA - IKK.4
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1, 2
; OTHER INFORMATION: n = A,T,C,G or U
US-10-444-795B-725

Query Match          2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 877 CCACATCAAGACGCGTG 895
DB 3 CCACATCAAGACGCGUG 21

RESULT 100
US-10-444-853A-123
; Sequence 123, Application US/10444853A
; Publication No. US20040192626A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Haeblerli, Peter
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Macejak, Dennis
; APPLICANT: Zinnen, Shawn
; APPLICANT: Pavco, Pamela
; APPLICANT: Morrissey, David
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: Mokier, Victor
; APPLICANT: Jamison, Sharon
; APPLICANT: Vaish, Narendra
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/114 (MBH03-465)
; CURRENT APPLICATION NUMBER: US/10/444,853A
; CURRENT FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/417,012

```

PRIOR FILING DATE: 2003-04-16
 PRIOR APPLICATION NUMBER: PCT/US03/05346
 PRIOR FILING DATE: 2003-02-20
 PRIOR APPLICATION NUMBER: PCT/US03/05028
 PRIOR FILING DATE: 2003-02-20
 PRIOR APPLICATION NUMBER: US 60/358,580
 PRIOR FILING DATE: 2002-02-20
 PRIOR APPLICATION NUMBER: US 60/363,124
 PRIOR FILING DATE: 2002-03-11
 PRIOR APPLICATION NUMBER: US 60/386,782
 PRIOR FILING DATE: 2002-06-06
 PRIOR APPLICATION NUMBER: US 60/406,784
 PRIOR FILING DATE: 2002-08-29
 PRIOR APPLICATION NUMBER: US 60/408,378
 PRIOR FILING DATE: 2002-09-05
 PRIOR APPLICATION NUMBER: US 60/409,293
 PRIOR FILING DATE: 2002-09-09
 PRIOR APPLICATION NUMBER: US 60/440,129
 PRIOR FILING DATE: 2003-01-15
 Remaining Prior Application data removed - See File Wrapper or PALM.
 NUMBER OF SEQ ID NOS: 626
 SOFTWARE: PatentIn version 3.2
 SEQ ID NO 123
 LENGTH: 21
 TYPE: RNA
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
 FEATURE:
 NAME/KEY: misc feature
 LOCATION: (20)-(21)
 OTHER INFORMATION: n stands for thymidine
 US-10-444-853A-123

Query Match 2.5%; Score 19; DB 1; Length 21;
 Best Local Similarity 73.7%; Pred.No. 2.1e+02;
 Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 418 GGAGTTCCTCATGTGCAAG 436
 |||::||::||::|||
 DB 1 GGAGUUCUCCUAUGUGCAAG 19

RESULT 101
 US-10-444-853A-124/c
 ; Sequence 124, Application US/10444853A
 ; Publication No. US20040192626A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Sirna Therapeutics, Inc.
 ; APPLICANT: Haerberli, Peter
 ; APPLICANT: McSwiggen, James
 ; APPLICANT: Beigelman, Leonid
 ; APPLICANT: Macejak, Dennis
 ; APPLICANT: Zimen, Shawn
 ; APPLICANT: Pavco, Pamela
 ; APPLICANT: Morrissey, David
 ; APPLICANT: Fosnaugh, Kathy
 ; APPLICANT: Mokler, Victor
 ; APPLICANT: Jamison, Sharon
 ; APPLICANT: Vaish, Narendra
 ; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
 ; FILE REFERENCE: 400/114 (MBHH03-465)
 ; CURRENT APPLICATION NUMBER: US/10/444,853A
 ; CURRENT FILING DATE: 2003-05-23
 ; PRIOR APPLICATION NUMBER: US 10/417,012
 ; PRIOR FILING DATE: 2003-04-16
 ; PRIOR APPLICATION NUMBER: PCT/US03/05346
 ; PRIOR FILING DATE: 2003-02-20
 ; PRIOR APPLICATION NUMBER: PCT/US03/05028
 ; PRIOR FILING DATE: 2003-02-20
 ; PRIOR APPLICATION NUMBER: US 60/358,580
 ; PRIOR FILING DATE: 2002-02-20

```

; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US 60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 626
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 127
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-444-853A-127

Query Match          2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 2.1e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 322 TCAAGAGCTCCGAGATGCC 340
DB 1 UCAAGAGCTCCGAGATGCC 19

RESULT 103
US-10-444-853A-128/c
; Sequence 128, Application US/10444853A
; Publication No. US20040192626A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Haerberli, Peter
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Macejak, Dennis
; APPLICANT: Zinnen, Shawn
; APPLICANT: Pavco, Pamela
; APPLICANT: Morrissey, David
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: Mokler, Victor
; APPLICANT: Jamison, Sharon
; APPLICANT: Vaish, Narendra
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/114 (MBHB03-465)
; CURRENT APPLICATION NUMBER: US/10/444,853A
; CURRENT FILING DATE: 2003-05-23
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US 60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 626

```

```

; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 128
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-444-853A-128

Query Match          2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 322 TCAAGAGCTCCGAGATGCC 340
DB 19 TCAAGAGCTCCGAGATGCC 1

RESULT 104
US-10-444-853A-131
; Sequence 131, Application US/10444853A
; Publication No. US20040192626A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Haerberli, Peter
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Macejak, Dennis
; APPLICANT: Zinnen, Shawn
; APPLICANT: Pavco, Pamela
; APPLICANT: Morrissey, David
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: Mokler, Victor
; APPLICANT: Jamison, Sharon
; APPLICANT: Vaish, Narendra
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/114 (MBHB03-465)
; CURRENT APPLICATION NUMBER: US/10/444,853A
; CURRENT FILING DATE: 2003-05-23
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US 60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 626
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 131
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region

```

```

;
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-444-853A-131

Query Match      2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.le+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 547 GCAGATGGCTGAGGACAAG 565
Db 1 GCAGATGGCTGAGGACAAG 19

RESULT 105
US-10-444-853A-132/c
; Sequence 132, Application US/10444853A
; Publication No. US20040192628A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Haerberli, Peter
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Macejak, Dennis
; APPLICANT: Zinnen, Shawn
; APPLICANT: Pavco, Pamela
; APPLICANT: Morrissey, David
; APPLICANT: Fossnaugh, Kathy
; APPLICANT: Mokler, Victor
; APPLICANT: Jamison, Sharon
; APPLICANT: Vaish, Narendra
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/114 (MEH803-465)
; CURRENT APPLICATION NUMBER: US/10/444,853A
; CURRENT FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US 60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 626
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 132
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-444-853A-132

Query Match      2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.le+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

```

```

Best Local Similarity 100.0%; Pred. No. 2.le+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 547 GCAGATGGCTGAGGACAAG 565
Db 19 GCAGATGGCTGAGGACAAG 1

RESULT 106
US-10-757-803-123
; Sequence 123, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Haerberli, Peter
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Macejak, Dennis
; APPLICANT: Zinnen, Shawn
; APPLICANT: Pavco, Pamela
; APPLICANT: Morrissey, David
; APPLICANT: Fossnaugh, Kathy
; APPLICANT: Jamison, Sharon
; APPLICANT: Vaish, Narendra
; APPLICANT: Chowrira, Bharat
; APPLICANT: Usman, Nassim
; APPLICANT: James, Thompson
; APPLICANT: Vargeese, Chandra
; APPLICANT: Wang, Weimen
; APPLICANT: Tongqian, Chen
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/142 (03-465-C)
; CURRENT APPLICATION NUMBER: US/10/757,803
; CURRENT FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/652,791
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/422,704
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 669
; SOFTWARE: Patent in version 3.3
; SEQ ID NO 123
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-757-803-123

Query Match      2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 2.le+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

```

QY 418 GGAGTTCTCATGTGCAAG 436
 Db 1 GGAGUUCUUGUGCAAG 19

RESULT 107
 US-10-757-803-124/c
 ; Sequence 124, Application US/10757803
 ; Publication No. US20050020525A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Sirna Therapeutics, Inc.
 ; APPLICANT: Haerberli, Peter
 ; APPLICANT: McSwiggen, James
 ; APPLICANT: Beigelman, Leonid
 ; APPLICANT: Macejak, Dennis
 ; APPLICANT: Zinnen, Shawn
 ; APPLICANT: Pavco, Pamela
 ; APPLICANT: Morrissey, David
 ; APPLICANT: Fosnaugh, Kathy
 ; APPLICANT: Jamison, Sharon
 ; APPLICANT: Vaish, Nerendra
 ; APPLICANT: Chowrira, Bharat
 ; APPLICANT: Usman, Nassim
 ; APPLICANT: James, Thompson
 ; APPLICANT: Vargeese, Chandra
 ; APPLICANT: Wang, Weimen
 ; APPLICANT: Tonggian, Chen
 ; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
 ; FILE REFERENCE: 400/142 (03-465-C)
 ; CURRENT APPLICATION NUMBER: US/10/757,803
 ; CURRENT FILING DATE: 2004-01-14
 ; PRIOR APPLICATION NUMBER: US 10/720,448
 ; PRIOR FILING DATE: 2003-11-24
 ; PRIOR APPLICATION NUMBER: US 10/693,059
 ; PRIOR FILING DATE: 2003-10-23
 ; PRIOR APPLICATION NUMBER: US 10/444,853
 ; PRIOR FILING DATE: 2003-05-23
 ; PRIOR APPLICATION NUMBER: US 10/652,791
 ; PRIOR FILING DATE: 2003-08-29
 ; PRIOR APPLICATION NUMBER: US 10/422,704
 ; PRIOR FILING DATE: 2003-04-24
 ; PRIOR APPLICATION NUMBER: US 10/417,012
 ; PRIOR FILING DATE: 2003-04-16
 ; PRIOR APPLICATION NUMBER: US 10/427,160
 ; PRIOR FILING DATE: 2003-04-30
 ; PRIOR APPLICATION NUMBER: PCT/US03/05346
 ; PRIOR FILING DATE: 2003-02-20
 ; PRIOR APPLICATION NUMBER: PCT/US03/05028
 ; PRIOR FILING DATE: 2003-02-20
 ; PRIOR APPLICATION NUMBER: US 60/358,580
 ; PRIOR FILING DATE: 2002-02-20
 ; Remaining Prior Application data removed - See File Wrapper or PALM.
 ; NUMBER OF SEQ ID NOS: 669
 ; SOFTWARE: Patentin version 3.3
 ; SEQ ID NO 124
 ; LENGTH: 21
 ; TYPE: RNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
 ; FEATURE:
 ; NAME/KEY: misc feature
 ; LOCATION: (20)..(21)
 ; OTHER INFORMATION: n stands for thymidine
 US-10-757-803-124

Query Match 2.5%; Score 19; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 2.1e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 418 GGAGTTCTCATGTGCAAG 436

Db 19 GGAGTTCTCATGTGCAAG 1

RESULT 108
 US-10-757-803-127
 ; Sequence 127, Application US/10757803
 ; Publication No. US20050020525A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Sirna Therapeutics, Inc.
 ; APPLICANT: Haerberli, Peter
 ; APPLICANT: McSwiggen, James
 ; APPLICANT: Beigelman, Leonid
 ; APPLICANT: Macejak, Dennis
 ; APPLICANT: Zinnen, Shawn
 ; APPLICANT: Pavco, Pamela
 ; APPLICANT: Morrissey, David
 ; APPLICANT: Fosnaugh, Kathy
 ; APPLICANT: Jamison, Sharon
 ; APPLICANT: Vaish, Nerendra
 ; APPLICANT: Chowrira, Bharat
 ; APPLICANT: Usman, Nassim
 ; APPLICANT: James, Thompson
 ; APPLICANT: Vargeese, Chandra
 ; APPLICANT: Wang, Weimen
 ; APPLICANT: Tonggian, Chen
 ; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
 ; FILE REFERENCE: 400/142 (03-465-C)
 ; CURRENT APPLICATION NUMBER: US/10/757,803
 ; CURRENT FILING DATE: 2004-01-14
 ; PRIOR APPLICATION NUMBER: US 10/720,448
 ; PRIOR FILING DATE: 2003-11-24
 ; PRIOR APPLICATION NUMBER: US 10/693,059
 ; PRIOR FILING DATE: 2003-10-23
 ; PRIOR APPLICATION NUMBER: US 10/444,853
 ; PRIOR FILING DATE: 2003-05-23
 ; PRIOR APPLICATION NUMBER: US 10/652,791
 ; PRIOR FILING DATE: 2003-08-29
 ; PRIOR APPLICATION NUMBER: US 10/422,704
 ; PRIOR FILING DATE: 2003-04-24
 ; PRIOR APPLICATION NUMBER: US 10/417,012
 ; PRIOR FILING DATE: 2003-04-16
 ; PRIOR APPLICATION NUMBER: US 10/427,160
 ; PRIOR FILING DATE: 2003-04-30
 ; PRIOR APPLICATION NUMBER: PCT/US03/05346
 ; PRIOR FILING DATE: 2003-02-20
 ; PRIOR APPLICATION NUMBER: PCT/US03/05028
 ; PRIOR FILING DATE: 2003-02-20
 ; PRIOR APPLICATION NUMBER: US 60/358,580
 ; PRIOR FILING DATE: 2002-02-20
 ; Remaining Prior Application data removed - See File Wrapper or PALM.
 ; NUMBER OF SEQ ID NOS: 669
 ; SOFTWARE: Patentin version 3.3
 ; SEQ ID NO 127
 ; LENGTH: 21
 ; TYPE: RNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
 ; FEATURE:
 ; NAME/KEY: misc feature
 ; LOCATION: (20)..(21)
 ; OTHER INFORMATION: n stands for thymidine
 US-10-757-803-127

Query Match 2.5%; Score 19; DB 1; Length 21;
 Best Local Similarity 84.2%; Pred. No. 2.1e+02;
 Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 322 TCAAGAGTCCGAGATGCC 340

Db 1 UCAAGAGTCCGAGATGCC 19

RESULT 109

US-10-757-803-128/c

Sequence 128, Application US/10757803

Publication No. US20050020525A1

GENERAL INFORMATION:

APPLICANT: Sirna Therapeutics, Inc.

APPLICANT: Haerberli, Peter

APPLICANT: McSwiggen, James

APPLICANT: Beigelman, Leonid

APPLICANT: Macejak, Dennis

APPLICANT: Zinnen, Shawn

APPLICANT: Pavco, Pamela

APPLICANT: Morrissey, David

APPLICANT: Fosnaugh, Kathy

APPLICANT: Jamison, Sharon

APPLICANT: Vaish, Narendra

APPLICANT: Chowrira, Bharat

APPLICANT: Usman, Nassim

APPLICANT: James, Thompson

APPLICANT: Vargeese, Chandra

APPLICANT: Wang, Weimen

APPLICANT: Tongqian, Chen

TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using

TITLE OF INVENTION: Chemically Modified Short Interfering Nucleic Acid (siNA)

FILE REFERENCE: 400/142 (03-465-C)

CURRENT FILING DATE: 2004-01-14

PRIOR APPLICATION NUMBER: US 10/720,448

PRIOR FILING DATE: 2003-11-24

PRIOR APPLICATION NUMBER: US 10/693,059

PRIOR FILING DATE: 2003-10-23

PRIOR APPLICATION NUMBER: US 10/444,853

PRIOR FILING DATE: 2003-05-23

PRIOR APPLICATION NUMBER: US 10/652,791

PRIOR FILING DATE: 2003-08-29

PRIOR APPLICATION NUMBER: US 10/422,704

PRIOR FILING DATE: 2003-04-24

PRIOR APPLICATION NUMBER: US 10/417,012

PRIOR FILING DATE: 2003-04-16

PRIOR APPLICATION NUMBER: US 10/427,160

PRIOR FILING DATE: 2003-04-30

PRIOR APPLICATION NUMBER: PCT/US03/05346

PRIOR FILING DATE: 2003-02-20

PRIOR APPLICATION NUMBER: PCT/US03/05028

PRIOR FILING DATE: 2003-02-20

PRIOR APPLICATION NUMBER: US 60/358,580

PRIOR FILING DATE: 2002-02-20

Remaining Prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 669

SOFTWARE: Patentin version 3.3

SEQ ID NO 128

LENGTH: 21

TYPE: RNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region

FEATURE:

NAME/KEY: misc_feature

LOCATION: (20)..(21)

OTHER INFORMATION: n stands for thymidine

US-10-757-803-128

Query Match 2.5%; Score 19; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 2.1e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 322 TCAAGAGCTCCGAGATGCC 340

Db 19 TCAAGAGCTCCGAGATGCC 1

RESULT 110

US-10-757-803-131

Sequence 131, Application US/10757803

Publication No. US20050020525A1

GENERAL INFORMATION:

APPLICANT: Sirna Therapeutics, Inc.

APPLICANT: Haerberli, Peter

APPLICANT: McSwiggen, James

APPLICANT: Beigelman, Leonid

APPLICANT: Macejak, Dennis

APPLICANT: Zinnen, Shawn

APPLICANT: Pavco, Pamela

APPLICANT: Morrissey, David

APPLICANT: Fosnaugh, Kathy

APPLICANT: Jamison, Sharon

APPLICANT: Vaish, Narendra

APPLICANT: Chowrira, Bharat

APPLICANT: Usman, Nassim

APPLICANT: James, Thompson

APPLICANT: Vargeese, Chandra

APPLICANT: Wang, Weimen

APPLICANT: Tongqian, Chen

TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using

TITLE OF INVENTION: Chemically Modified Short Interfering Nucleic Acid (siNA)

FILE REFERENCE: 400/142 (03-465-C)

CURRENT FILING DATE: 2004-01-14

PRIOR APPLICATION NUMBER: US 10/720,448

PRIOR FILING DATE: 2003-11-24

PRIOR APPLICATION NUMBER: US 10/693,059

PRIOR FILING DATE: 2003-10-23

PRIOR APPLICATION NUMBER: US 10/444,853

PRIOR FILING DATE: 2003-05-23

PRIOR APPLICATION NUMBER: US 10/652,791

PRIOR FILING DATE: 2003-08-29

PRIOR APPLICATION NUMBER: US 10/422,704

PRIOR FILING DATE: 2003-04-24

PRIOR APPLICATION NUMBER: US 10/417,012

PRIOR FILING DATE: 2003-04-16

PRIOR APPLICATION NUMBER: US 10/427,160

PRIOR FILING DATE: 2003-04-30

PRIOR APPLICATION NUMBER: PCT/US03/05346

PRIOR FILING DATE: 2003-02-20

PRIOR APPLICATION NUMBER: PCT/US03/05028

PRIOR FILING DATE: 2003-02-20

PRIOR APPLICATION NUMBER: US 60/358,580

PRIOR FILING DATE: 2002-02-20

Remaining Prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 669

SOFTWARE: Patentin version 3.3

SEQ ID NO 131

LENGTH: 21

TYPE: RNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: siNA sense region

FEATURE:

NAME/KEY: misc_feature

LOCATION: (20)..(21)

OTHER INFORMATION: n stands for thymidine

US-10-757-803-131

Query Match 2.5%; Score 19; DB 1; Length 21;

Best Local Similarity 89.5%; Pred. No. 2.1e+02;

Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 547 GCAGATGGCTCGAGACAAG 565

Db 1 GCAGAGGCGUGAGACAAG 19

```

; Sequence 132, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Haerberli, Peter
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Macejak, Dennis
; APPLICANT: Zinnen, Shawn
; APPLICANT: Pavco, Pamela
; APPLICANT: Morrissey, David
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: Jamison, Sharon
; APPLICANT: Vaish, Narendra
; APPLICANT: Chowrira, Bharat
; APPLICANT: Usman, Nassim
; APPLICANT: James, Thompson
; APPLICANT: Vargeese, Chandra
; APPLICANT: Wang, Weimen
; APPLICANT: Tongqian, Chen
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/142 (03-465-C)
; CURRENT FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US/10/757,803
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/652,791
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/422,704
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 669
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 132
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sirna antisense region
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-757-803-132

Query Match 2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 547 GCAGTGGCTGAGGACAAAG 565
Db 19 GCAGTGGCTGAGGACAAAG 1

RESULT 112
US-10-826-966-123
; Sequence 123, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Macejak, Dennis
; APPLICANT: Morrissey, David
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/151 (03-465-D)
; CURRENT FILING DATE: 2004-04-16
; CURRENT APPLICATION NUMBER: US/10/826,966
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059

```

```

; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Macejak, Dennis
; APPLICANT: Morrissey, David
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/151 (03-465-D)
; CURRENT FILING DATE: 2004-04-16
; CURRENT APPLICATION NUMBER: US/10/826,966
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/652,791
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/422,704
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 669
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 123
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sirna sense region
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-826-966-123

Query Match 2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 2.1e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 418 GGAGTTCTCATGTGCAAG 436
Db 1 GGAGUUCUCAUGGCAAG 19

RESULT 113
US-10-826-966-124/c
; Sequence 124, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Macejak, Dennis
; APPLICANT: Morrissey, David
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/151 (03-465-D)
; CURRENT FILING DATE: 2004-04-16
; CURRENT APPLICATION NUMBER: US/10/826,966
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059

```

```

; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/652,791
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/422,704
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 669
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 124
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-826-966-124

Query Match          2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 418 GGAGTTCCTCATGTGCGAAG 436
      |||||||
DB 19 GGAGTTCCTCATGTGCGAAG 1

RESULT 114
US-10-826-966-127
; Sequence 127, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Macejak, Dennis
; APPLICANT: Morrissey, David
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/151 (03-465-D)
; CURRENT APPLICATION NUMBER: US/10/826,966
; CURRENT FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/422,704
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 669
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 128
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-826-966-128

```

```

; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 669
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 127
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-826-966-127

Query Match          2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 2.1e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 322 TCAAGAGCTCCGAGATGCC 340
      |||||||
DB 1 UCAAGAGCUCCGAGAUGCC 19

RESULT 115
US-10-826-966-128/c
; Sequence 128, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Macejak, Dennis
; APPLICANT: Morrissey, David
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/151 (03-465-D)
; CURRENT APPLICATION NUMBER: US/10/826,966
; CURRENT FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/652,791
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/422,704
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 669
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 128
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-826-966-128

```

```

Query Match          2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 322 TCAAGAGCTCCGAGTACC 340
Db 19 TCAAGAGCTCCGAGTACC 1

RESULT 116
US-10-826-966-131
; Sequence 131, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Macejak, Dennis
; APPLICANT: Morrissey, David
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/151 (03-465-D)
; CURRENT APPLICATION NUMBER: US/10/826,966
; CURRENT FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/422,704
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 669
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 131
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-826-966-131

Query Match          2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 547 GCAGATGGCTGAGGACAAG 565
Db 1 GCAGATGGCTGAGGACAAG 19

RESULT 117
US-10-826-966-132/c
; Sequence 132, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.

```

```

; APPLICANT: McSwiggen, James
; APPLICANT: Macejak, Dennis
; APPLICANT: Morrissey, David
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/151 (03-465-D)
; CURRENT APPLICATION NUMBER: US/10/826,966
; CURRENT FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/652,791
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/422,704
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 669
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 132
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-826-966-132

Query Match          2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 547 GCAGATGGCTGAGGACAAG 565
Db 19 GCAGATGGCTGAGGACAAG 1

RESULT 118
US-10-210-290-37/c
; Sequence 37, Application US/10210290
; Publication No. US20040023378A1
; GENERAL INFORMATION:
; APPLICANT: Ming-Yi Chiang
; APPLICANT: Eric G. Marcussen
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: ANTISENSE MODULATION OF KIAA1531 PROTEIN EXPRESSION
; FILE REFERENCE: RTS-0367
; CURRENT APPLICATION NUMBER: US/10/210,290
; CURRENT FILING DATE: 2002-07-31
; NUMBER OF SEQ ID NOS: 134
; SEQ ID NO 37
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-210-290-37

```

```

Query Match          2.4%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 2.3e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 877 CCACATCAAGAGCAGCGTGG 896
Db 20 CCACATCAAGAGCAGCGTGG 1

RESULT 119
US-10-210-802-37/c
; Sequence 37, Application US/10210802
; Publication No. US20040087523A1
; GENERAL INFORMATION:
; APPLICANT: Ming-Yi Chiang
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF KIA1531 PROTEIN EXPRESSION
; FILE REFERENCE: RTS-0367
; CURRENT APPLICATION NUMBER: US/10/210,802
; CURRENT FILING DATE: 2002-07-31
; NUMBER OF SEQ ID NOS: 134
; SEQ ID NO 37
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide.
US-10-210-802-37

Query Match          2.4%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 2.3e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 877 CCACATCAAGAGCAGCGTGG 896
Db 20 CCACATCAAGAGCAGCGTGG 1

RESULT 120
US-10-751-736-9484/c
; Sequence 9484, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9484
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-9484

Query Match          2.3%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 3.1e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 376 CGAGGAGCTTCTGCATTTC 394
Db 21 CGAGGAACCTCTGCATTTC 3

RESULT 121
US-10-751-736-9485/c
; Sequence 9485, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9485
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-9485

Query Match          2.3%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 3.1e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 376 CGAGGAGCTTCTGCATTTC 394
Db 19 CGAGGAACCTCTGCATTTC 1

RESULT 122
US-10-156-306-4383
; Sequence 4383, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4383
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4383

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 210 CAGCAGATCAGGACGTA 226
Db 1 CAGCAGAUCAAGGACGUA 17

RESULT 123
US-10-156-306-4384
; Sequence 4384, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
```

; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4384
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4384

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 218 CAGGACGTACTGGCGCA 234
|||||:|:|:|:|
Db 1 CAGGACGUACUGGGCGA 17

RESULT 124

US-10-156-306-4385
; Sequence 4385, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4385
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4385

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 232 CGAAGAGTCTCTCTGG 248
|||||:|:|:|:|
Db 1 CGAAGAGUCUCCUCUGG 17

RESULT 125

US-10-156-306-4386
; Sequence 4386, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4386
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4386

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 234 AAGAGTCTCTCTGGGG 250
|||||:|:|:|:|
Db 1 AAGAGUCUCCUCUGGG 17

RESULT 126

US-10-156-306-4387
; Sequence 4387, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4387
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4387

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 237 AGTCTCTCTCTGGGAAG 253
|||||:|:|:|:|
Db 1 AGUCUCCUCUGGGGAAG 17

RESULT 127

US-10-156-306-4388
; Sequence 4388, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4388
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4388

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 267 ACCTGCTTCAGAACAG 283
|||||:|:|:|:|
Db 1 ACCUGCCUUCAGAACAG 17

RESULT 128

US-10-156-306-4389
; Sequence 4389, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0

```

; SEQ ID NO 4389
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4389

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 268 CCTGCCTTCAGACAGG 284
|||:||||:|||||
Db 1 CCUGCCUUCAGACAGG 17

RESULT 129
US-10-156-306-4390
; Sequence 4390, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4390
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4390

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 282 AGGGCGCTCTGAGACC 298
|||||:|||||
Db 1 AGGGCGCUCCUGAGACC 17

RESULT 130
US-10-156-306-4391
; Sequence 4391, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4391
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4391

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 293 GAGACCTTCAGCGCTG 309
|||||:|||||
Db 1 GAGACCUCCUGAGCGUG 17
```

```

RESULT 131
US-10-156-306-4392
; Sequence 4392, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4392
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4392

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 315 AGGAGAATCAAGAGCTC 331
|||||:|||||
Db 1 AGGAGAAUCAAGAGCUC 17

RESULT 132
US-10-156-306-4393
; Sequence 4393, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4393
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4393

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 323 CAAGAGCTCCGAGATGC 339
|||||:|||||
Db 1 CAAGAGCUCCGAGAUGC 17

RESULT 133
US-10-156-306-4394
; Sequence 4394, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4394
```

```
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4394

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 335 GATCCATCGGCAGAG 351
    ||::||::||::||::||
Db 1 GAUGCAUCCGCAGAG 17

RESULT 134
US-10-156-306-4395
; Sequence 4395, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4395
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4395

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 353 AACCAAGATTCTGCGGGA 369
    ||::||::||::||::||
Db 1 AACCAGAUUUCUGCGGA 17

RESULT 135
US-10-156-306-4396
; Sequence 4396, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4396
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4396

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 354 ACCAGATTCTGCGGAG 370
    ||::||::||::||::||
Db 1 ACCAGAUUUCUGCGGAG 17

RESULT 136
```

```
US-10-156-306-4397
; Sequence 4397, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4397
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4397

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.6e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 377 GAGGAGCTTCTGCATT 393
    ||::||::||::||::||
Db 1 GAGGAGCUUCUGCAUUC 17

RESULT 137
US-10-156-306-4398
; Sequence 4398, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4398
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4398

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.6e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 378 AGGAGCTTCTGCATTTC 394
    ||::||::||::||::||
Db 1 AGGAGCUUCUGCAUUC 17

RESULT 138
US-10-156-306-4399
; Sequence 4399, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4399
; LENGTH: 17
```



```

; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4399

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.6e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 384 TTTCGATTTCCTCAAGCC 400
Db 1 UUCGCAUUUCCCAAGCC 17
      :|||:|||||
      :|||:|||||

RESULT 139
US-10-156-306-4400
; Sequence 4400, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4400
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4400

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 385 TCTGCATTTCCTCAAGCCA 401
Db 1 UCUGCAUUUCCCAAGCCA 17
      :|||:|||||
      :|||:|||||

RESULT 140
US-10-156-306-4401
; Sequence 4401, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4401
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4401

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 386 CTGCAATTTCCTCAAGCCAG 402
Db 1 CUGCAUUUCCCAAGCCAG 17
      :|||:|||||
      :|||:|||||

RESULT 141
US-10-156-306-4402

```

```

; Sequence 4402, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4402
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4402

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 415 GAAGGAGTTCTCTCATGT 431
Db 1 GAAGGAGUUCUCAUGU 17
      |||||:|||||
      |||||:|||||

RESULT 142
US-10-156-306-4403
; Sequence 4403, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4403
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4403

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 416 AAGGAGTTCTCTCATGTG 432
Db 1 AAGGAGUUCUCAUGUG 17
      |||||:|||||
      |||||:|||||

RESULT 143
US-10-156-306-4404
; Sequence 4404, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4404
; LENGTH: 17
; TYPE: RNA

```

```
; ORGANISM: Homo sapiens
US-10-156-306-4404

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 419 GAGTTCTCATGTGCAA 435
      |||:||||:|||||
Db 1 GAGUUCUCAUGGCAA 17

RESULT 144
US-10-156-306-4405
; Sequence 4405, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4405
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4405

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 430 GTCAAGTTCAGGAGG 446
      |:||||:|||||
Db 1 GUGCAAGUCCAGGAGG 17

RESULT 145
US-10-156-306-4406
; Sequence 4406, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4406
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4406

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 431 TGCAAGTTCAGGAGGC 447
      :||||:|||||
Db 1 UGCAAGUCCAGGAGGC 17

RESULT 146
US-10-156-306-4407
; Sequence 4407, Application US/10156306
```

```
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4407
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4407

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 461 GAGAGACTCGGCTGGA 477
      |||||:||||:|
Db 1 GAGAGACUGGCCUGGA 17

RESULT 147
US-10-156-306-4408
; Sequence 4408, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4408
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4408

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 476 GAGAAGCTCGATCTGAA 492
      |||||:||||:|
Db 1 GAGAAGCUCGACUGAA 17

RESULT 148
US-10-156-306-4409
; Sequence 4409, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4409
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
```

US-10-156-306-4409

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 480 AGCTGCTGCTGAGAGG 496
|||||:|:|:|:|:|:|
Db 1 AGCUGAUGAGAGG 17

RESULT 149

US-10-156-306-4410
; Sequence 4410, Application US/10156306
; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 4410

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-4410

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 504 AGCAGGCTCTCGGGAG 520
|||||:|:|:|:|:|:|
Db 1 AGCAGGCTCTCGGGAG 17

RESULT 150

US-10-156-306-4411
; Sequence 4411, Application US/10156306
; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 4411

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-4411

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 562 CAAGGCCCTCTGGAAG 578
|||||:|:|:|:|:|:|
Db 1 CAAGGCCCTCTGGAAG 17

RESULT 151

US-10-156-306-4412
; Sequence 4412, Application US/10156306
; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 4412

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-4412

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 583 GGTGAGCTCTGCTCG 599
|||||:|:|:|:|:|:|
Db 1 GGTGAGCTCTGCTCG 17

RESULT 152

US-10-156-306-4413

; Sequence 4413, Application US/10156306

; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 4413

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-4413

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 586 GAGTCTCTGCTCGGG 602
|||||:|:|:|:|:|:|
Db 1 GAGTCTCTGCTCGGG 17

RESULT 153

US-10-156-306-4414

; Sequence 4414, Application US/10156306

; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 4414

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-4414

```
Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 590 TCCTTGCTGGGAGCT 606
      :||:||||:||||:
Db 1 UCCUUGCUGGGAGCU 17

RESULT 154
US-10-156-306-4415
; Sequence 4415, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4415
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4415

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 615 GCCAGAGTCGCTGGAG 631
      |||||:||||:||||
Db 1 GCCAGAGUCGCUUGAG 17

RESULT 155
US-10-156-306-4416
; Sequence 4416, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4416
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4416

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 619 GAGTCGCTGGAGGCTG 635
      ||||:||||:||||:|
Db 1 GAGUUCGUGGAGGCG 17

RESULT 156
US-10-156-306-4417
; Sequence 4417, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4417
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4417

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 633 CTGCCACTAAGGAATGC 649
      |:||||:||||:|
Db 1 CUGCCACUAAGGAUGC 17

RESULT 157
US-10-156-306-4418
; Sequence 4418, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4418
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4418

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 648 GCCAGGCTCTGGAGGT 664
      |||||:||||:|
Db 1 GCCAGGCUCUGGAGGCU 17

RESULT 158
US-10-156-306-4419
; Sequence 4419, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4419
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4419
```

```
Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 657 TGGAGGCTCGGCCCG 673
Db 1 UGGAGGGUCCGGCCCG 17

RESULT 159
US-10-156-306-4420
; Sequence 4420, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4420
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4420

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 779 GCCGCGCTCCGATGGA 795
Db 1 GCCGCGCTCCGCAUGGA 17

RESULT 160
US-10-156-306-4421
; Sequence 4421, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4421
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4421

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 802 GGCGCGCTCGGAGGAGA 818
Db 1 GGCGCGCTCGGAGGAGA 17

RESULT 161
US-10-156-306-4422
; Sequence 4422, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
```

```
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4422
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4422

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 829 GGCCCAAGTTGCAGGTGG 845
Db 1 GGCCCAAGUUGCAGGUGG 17

RESULT 162
US-10-156-306-4423
; Sequence 4423, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4423
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4423

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 841 GGTGGCTATCACCAGC 857
Db 1 GGUGGCCUACACCAGC 17

RESULT 163
US-10-156-306-4424
; Sequence 4424, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4424
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4424

Query Match      2.3%; Score 17; DB 1; Length 17;
```

```
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 843 TGGCCTATCACCAGCTC 859
Db 1 UGCCUAUCCAGGUC 17

RESULT 164
US-10-156-306-4425
; Sequence 4425, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4425
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4425

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 851 CACGCTCTTCCAAGA 867
Db 1 CACGCUUCCAGAA 17

RESULT 165
US-10-156-306-4426
; Sequence 4426, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4426
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4426

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 853 CCAGCTCTTCCAAGAT 869
Db 1 CCAGCUUCCAGAAU 17

RESULT 166
US-10-156-306-4427
; Sequence 4427, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
```

```
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4427
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4427

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 854 CAGCTCTTCCAAGATA 870
Db 1 CAGCUUCCAGAAUA 17

RESULT 167
US-10-156-306-4428
; Sequence 4428, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4428
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4428

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 862 CCAAGATACGACACC 878
Db 1 CCAAGAAUACGACACC 17

RESULT 168
US-10-156-306-4429
; Sequence 4429, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4429
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4429

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
```

Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;	
QY	875 AACACATCAAGAGCAG 891 :
Db	1 AACCAACAAGAGCAG 17 :
RESULT 169	
US-10-156-306-4799	
; Sequence 4799, Application US/10156306	
; Publication No. US20030119017A1	
; GENERAL INFORMATION:	
; APPLICANT: Ribozyme Pharmaceuticals, Inc.	
; APPLICANT: McSwiggen, James	
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related	
; FILE REFERENCE: MBH01-664-A (400/050)	
; CURRENT APPLICATION NUMBER: US/10/156,306	
; CURRENT FILING DATE: 2002-05-28	
; NUMBER OF SEQ ID NOS: 8013	
; SOFTWARE: PatentIn version 3.0	
; SEQ ID NO 4799	
; LENGTH: 17	
; TYPE: RNA	
; ORGANISM: Homo sapiens	
US-10-156-306-4799	
Query Match 2.3%; Score 17; DB 1; Length 17;	
Best Local Similarity 82.4%; Pred. No. 2.6e+02;	
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;	
QY	165 GGAAGAGCCACTGTGT 181 :
Db	1 GGAAGAGCCACUGUGU 17 :
RESULT 170	
US-10-156-306-4800	
; Sequence 4800, Application US/10156306	
; Publication No. US20030119017A1	
; GENERAL INFORMATION:	
; APPLICANT: Ribozyme Pharmaceuticals, Inc.	
; APPLICANT: McSwiggen, James	
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related	
; FILE REFERENCE: MBH01-664-A (400/050)	
; CURRENT APPLICATION NUMBER: US/10/156,306	
; CURRENT FILING DATE: 2002-05-28	
; NUMBER OF SEQ ID NOS: 8013	
; SOFTWARE: PatentIn version 3.0	
; SEQ ID NO 4800	
; LENGTH: 17	
; TYPE: RNA	
; ORGANISM: Homo sapiens	
US-10-156-306-4800	
Query Match 2.3%; Score 17; DB 1; Length 17;	
Best Local Similarity 82.4%; Pred. No. 2.6e+02;	
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;	
QY	166 GAAGAGCCAACTGTGT 182 :
Db	1 GAAGAGCCACUGUGU 17 :
RESULT 171	
US-10-156-306-4801	
; Sequence 4801, Application US/10156306	
; Publication No. US20030119017A1	
; GENERAL INFORMATION:	
; APPLICANT: Ribozyme Pharmaceuticals, Inc.	
; APPLICANT: McSwiggen, James	
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related	

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR	
; FILE REFERENCE: MBH01-664-A (400/050)	
; CURRENT APPLICATION NUMBER: US/10/156,306	
; CURRENT FILING DATE: 2002-05-28	
; NUMBER OF SEQ ID NOS: 8013	
; SOFTWARE: PatentIn version 3.0	
; SEQ ID NO 4801	
; LENGTH: 17	
; TYPE: RNA	
; ORGANISM: Homo sapiens	
US-10-156-306-4801	
Query Match 2.3%; Score 17; DB 1; Length 17;	
Best Local Similarity 82.4%; Pred. No. 2.6e+02;	
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;	
QY	169 GAGCCAACTGTGTGAGA 185 :
Db	1 GAGCCAACTUGUGUGAGA 17 :
RESULT 172	
US-10-156-306-4802	
; Sequence 4802, Application US/10156306	
; Publication No. US20030119017A1	
; GENERAL INFORMATION:	
; APPLICANT: Ribozyme Pharmaceuticals, Inc.	
; APPLICANT: McSwiggen, James	
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related	
; FILE REFERENCE: MBH01-664-A (400/050)	
; CURRENT APPLICATION NUMBER: US/10/156,306	
; CURRENT FILING DATE: 2002-05-28	
; NUMBER OF SEQ ID NOS: 8013	
; SOFTWARE: PatentIn version 3.0	
; SEQ ID NO 4802	
; LENGTH: 17	
; TYPE: RNA	
; ORGANISM: Homo sapiens	
US-10-156-306-4802	
Query Match 2.3%; Score 17; DB 1; Length 17;	
Best Local Similarity 82.4%; Pred. No. 2.6e+02;	
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;	
QY	184 GATGTCGACCCAGTG 200 :
Db	1 GAUGGUGACGCCAGUG 17 :
RESULT 173	
US-10-156-306-4803	
; Sequence 4803, Application US/10156306	
; Publication No. US20030119017A1	
; GENERAL INFORMATION:	
; APPLICANT: Ribozyme Pharmaceuticals, Inc.	
; APPLICANT: McSwiggen, James	
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related	
; FILE REFERENCE: MBH01-664-A (400/050)	
; CURRENT APPLICATION NUMBER: US/10/156,306	
; CURRENT FILING DATE: 2002-05-28	
; NUMBER OF SEQ ID NOS: 8013	
; SOFTWARE: PatentIn version 3.0	
; SEQ ID NO 4803	
; LENGTH: 17	
; TYPE: RNA	
; ORGANISM: Homo sapiens	
US-10-156-306-4803	
Query Match 2.3%; Score 17; DB 1; Length 17;	
Best Local Similarity 82.4%; Pred. No. 2.6e+02;	
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;	

```

QY 187 GTGCGAGCCAGTGGTG 203
||:|||||:|:|
Db 1 GGUGGAGCCAGUGGUG 17

RESULT 174
US-10-156-306-4804
; Sequence 4804, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4804
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4804

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 188 GTGCGAGCCAGTGGTG 204
||:|||||:|:|
Db 1 GUGGAGCCAGUGGUG 17

RESULT 175
US-10-156-306-4805
; Sequence 4805, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4805
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4805

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 189 TGCAGCCAGTGGTG 205
||:|||||:|:|
Db 1 UGCAGCCAGUGGUG 17

RESULT 176
US-10-156-306-4806
; Sequence 4806, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

```

```

; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4806
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4806

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 198 GTGCGGCCCGGAGCA 214
||:|||||:|:|
Db 1 GUGGUGGCCCGGAGCA 17

RESULT 177
US-10-156-306-4807
; Sequence 4807, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4807
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4807

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 199 TGGTGGCCCGGAGCAG 215
||:|||||:|:|
Db 1 UGUGGCCCGGAGCAG 17

RESULT 178
US-10-156-306-4808
; Sequence 4808, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4808
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4808

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```



```
Qy 203 GGCCCGGCGACGATCA 219
      |||||
Db 1 GGCCCGGCGACGACGA 17

RESULT 179
US-10-156-306-4809
; Sequence 4809, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4809
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4809

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 206 CCGGCGACGACGATCAGGA 222
      |||||
Db 1 CCGGCGACGACGACGA 17

RESULT 180
US-10-156-306-4810
; Sequence 4810, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4810
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4810

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 211 AGCAGATCAGGACGTAC 227
      |||||
Db 1 AGCAGACGACGACGUA 17

RESULT 181
US-10-156-306-4811
; Sequence 4811, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
```

```
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4811
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4811

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 220 GGACGTACTGGCGGAAG 236
      |||||
Db 1 GGACGUACUGGCGGAAG 17

RESULT 182
US-10-156-306-4812
; Sequence 4812, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4812
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4812

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 233 GAAGAGTCCTCTGGG 249
      |||||
Db 1 GAAGAGUCUCUCUGGG 17

RESULT 183
US-10-156-306-4813
; Sequence 4813, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4813
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4813

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 235 AGAGTCCTCTGGGA 251
```

```

Db      1 AGAGUCUCUCUGGGGA 17
||||:|:|:|:|:|:|
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4816
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4814
RESULT 184
US-10-156-306-4814
; Sequence 4814, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4814
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4814
Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY      236 GAGTCCTCCTCGGGGA 252
||||:|:|:|:|:|:|
Db      1 GAGUCUCUCUGGGGA 17
RESULT 185
US-10-156-306-4815
; Sequence 4815, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4815
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4815
Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY      238 GTCTCCTCTGGGAAGC 254
|:|:|:|:|:|:|:|
Db      1 GUCUCUCUCUGGGGAAGC 17
RESULT 186
US-10-156-306-4816
; Sequence 4816, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306

```

```

; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4816
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4816
Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY      247 GGGGAAGCCAGCCATGC 263
||||:|:|:|:|:|:|
Db      1 GGGGAAGCCAGCCCAUGC 17
RESULT 187
US-10-156-306-4817
; Sequence 4817, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4817
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4817
Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY      248 GGGGAAGCCAGCCATGCT 264
||||:|:|:|:|:|:|
Db      1 GGGGAAGCCAGCCCAUGC 17
RESULT 188
US-10-156-306-4818
; Sequence 4818, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4818
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4818
Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY      251 AAGCCAGCCATGCTGCA 267
||||:|:|:|:|:|:|

```

Db 1 AAGCCAGCCAUGCUGCA 17

RESULT 189

US-10-156-306-4819
; Sequence 4819, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4819
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4819

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 252 AGCCAGCCATGCTGCAC 268

Db 1 AGCCAGCCATGCTGCAC 17

RESULT 190

US-10-156-306-4820
; Sequence 4820, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4820
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4820

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 256 AGCCATGCTGCACCTGC 272

Db 1 AGCCATGCTGCACCTGC 17

RESULT 191

US-10-156-306-4821
; Sequence 4821, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4821
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4821

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 259 CATGTCACCTGCCTT 275

Db 1 CAUGCUGCACCUGCCU 17

RESULT 192

US-10-156-306-4822
; Sequence 4822, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4822
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4822

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 261 TGCTGCACCTGCCTTCA 277

Db 1 UGCUGCACCUGCCU 17

RESULT 193

US-10-156-306-4823
; Sequence 4823, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4823
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4823

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 262 GCTGCACCTGCCTTCA 278

Db 1 GCUGCACCUGCCU 17

```
RESULT 194
US-10-156-306-4824
; Sequence 4824, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4824
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4824

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 265 GCACCTGCCTTCAGAAC 281
Db 1 GCACCGCCUUCAGAAC 17

RESULT 195
US-10-156-306-4825
; Sequence 4825, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4825
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4825

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 266 CACCTGCCTTCAGAAC 282
Db 1 CACCGCCUUCAGAAC 17

RESULT 196
US-10-156-306-4826
; Sequence 4826, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
```

```
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4826
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4826

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 269 CTGCCTTCAGAACAGG 285
Db 1 CUGCCUUCAGAACAGG 17

RESULT 197
US-10-156-306-4827
; Sequence 4827, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4827
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4827

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 274 TTCAGAACAGGCGGCTC 290
Db 1 UUCAGAACAGGCGGCGCUC 17

RESULT 198
US-10-156-306-4828
; Sequence 4828, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4828
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4828

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 281 CAGGGCGCTCCTGAGAC 297
Db 1 CAGGGCGCCUUCUGAGAC 17
```

```
RESULT 199
US-10-156-306-4829
; Sequence 4829, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4829
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4829

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 283 GGGCGCTCCTGAGACCC 299
Db 1 GGGCGCUCCUGAGACCC 17

RESULT 200
US-10-156-306-4830
; Sequence 4830, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4830
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4830

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 283 GGGCGCTCCTGAGACCC 299
Db 1 GGGCGCUCCUGAGACCC 17

RESULT 201
US-10-156-306-4831
; Sequence 4831, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4831
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4831

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 284 GGGCGCTCCTGAGACCC 300
Db 1 GGGCGCUCCUGAGACCC 17

RESULT 202
US-10-156-306-4832
; Sequence 4832, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4832
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4832

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 290 CCTGAGACCCCTCAGCG 306
Db 1 CCTGAGACCCCTCAGCG 17

RESULT 203
US-10-156-306-4833
; Sequence 4833, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4833
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4833

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 284 GGGCGCTCCTGAGACCC 300
Db 1 GGGCGCUCCUGAGACCC 17
```

```
; SEQ ID NO 4831
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4831
```

```
Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 290 CCTGAGACCCCTCAGCG 306
Db 1 CCTGAGACCCCTCAGCG 17
```

```
RESULT 202
US-10-156-306-4832
; Sequence 4832, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4832
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4832
```

```
Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 291 CTGAGACCCCTCAGCGC 307
Db 1 CUGAGACCCUCCAGCGC 17
```

```
RESULT 203
US-10-156-306-4833
; Sequence 4833, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4833
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4833
```

```
Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 292 TGAGACCCCTCAGCGCT 308
Db 1 UGAGACCCUCCAGCGCU 17
```

```
RESULT 204
US-10-156-306-4834
; Sequence 4834, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4834
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4834

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 294 AGACCTCCAGCGCTGCC 310
      |||||:|||||:|||||
Db 1 AGACCCUCCAGCGCUGCC 17

RESULT 205
US-10-156-306-4835
; Sequence 4835, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4835
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4835

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 295 GACCTCCAGCGCTGCC 311
      |||||:|||||:|||||
Db 1 GACCCUCCAGCGCUGCC 17

RESULT 206
US-10-156-306-4836
; Sequence 4836, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4836
```

```
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4836

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 300 TCCAGCGCTCCCTGGAG 316
      :|||||:|||||:|||||
Db 1 UCCAGCGCUGCCUGGAG 17

RESULT 207
US-10-156-306-4837
; Sequence 4837, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4837
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4837

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 303 AGCGCTGCCTGGAGGAG 319
      |||||:|||||:|||||
Db 1 AGCGCUGCCUGGAGGAG 17

RESULT 208
US-10-156-306-4838
; Sequence 4838, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4838
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4838

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 304 GCGCTGCCTGGAGGAGA 320
      :|||||:|||||:|||||
Db 1 GCGCUGCCUGGAGGAGA 17

RESULT 209
```

US-10-156-306-4839
; Sequence 4839, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4839
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4839

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 316 GGAGATCAAGAGTCC 332
|||||:|||||:
Db 1 GGAGAUCCAGAGCUCC 17

RESULT 210
US-10-156-306-4840
; Sequence 4840, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4840
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4840

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 322 TCAAGAGCTCCGAGATG 338
:|||||:|||||:
Db 1 UCAAGAGCUCCGAGAUG 17

RESULT 211
US-10-156-306-4841
; Sequence 4841, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4841
; LENGTH: 17

; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4841

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 324 AAGAGCTCCGAGATGCC 340
|||||:|||||:
Db 1 AAGAGCUCCGAGAUGCC 17

RESULT 212
US-10-156-306-4842
; Sequence 4842, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4842
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4842

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 332 CGAGATGCCATCCGGCA 348
|||||:|||||:
Db 1 CGAGAUCCCAUCCGGCA 17

RESULT 213
US-10-156-306-4843
; Sequence 4843, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4843
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4843

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 333 GAGATGCCATCCGGCAG 349
|||||:|||||:
Db 1 GAGAUCCCAUCCGGCAG 17

RESULT 214
US-10-156-306-4844

```
; Sequence 4844, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4844
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4844

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 336 ATCCATCCGGCAGAC 352
Db 1 AUGCCAUCGGCAGAC 17

RESULT 215
US-10-156-306-4845
; Sequence 4845, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4845
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4845

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 340 CATCCGGCAGACCAAC 356
Db 1 CAUCCGGCAGACCAAC 17

RESULT 216
US-10-156-306-4846
; Sequence 4846, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4846
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4846

; Sequence 4844, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4844
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4844

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 336 ATCCATCCGGCAGAC 352
Db 1 AUGCCAUCGGCAGAC 17

RESULT 215
US-10-156-306-4845
; Sequence 4845, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4845
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4845

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 340 CATCCGGCAGACCAAC 356
Db 1 CAUCCGGCAGACCAAC 17

RESULT 216
US-10-156-306-4846
; Sequence 4846, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4846
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4846
```

```
; ORGANISM: Homo sapiens
US-10-156-306-4846

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 345 GCGAGAGCAACGAGTT 361
Db 1 GCGAGAGCAACGAGAUU 17

RESULT 217
US-10-156-306-4847
; Sequence 4847, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4847
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4847

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 348 AGAGCAACGAGATTCGTG 364
Db 1 AGAGCAACGAGAUUCUG 17

RESULT 218
US-10-156-306-4848
; Sequence 4848, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4848
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4848

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 349 GAGCAACGAGATTCGTC 365
Db 1 GAGCAACGAGAUUCUGC 17

RESULT 219
US-10-156-306-4849
; Sequence 4849, Application US/10156306
```



```
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4849
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4849

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 92.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 355 CCAGATTCTCGGGAGC 371
      |||||:|:|||||
Db 1 CCAGAUUCUGGGAGC 17

RESULT 220
US-10-156-306-4850
; Sequence 4850, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4850
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4850

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 366 GGGAGCGCTCGGAGGAG 382
      |||||:|:|||||
Db 1 GGGAGCGUGCGGAGGAG 17

RESULT 221
US-10-156-306-4851
; Sequence 4851, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4851
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
```

US-10-156-306-4851

```
Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 376 CGAGGAGCTTCGCAATT 392
      |||||:|:|||||
Db 1 CGAGGAGCUUCUGCAU 17
```

RESULT 222

```
US-10-156-306-4852
; Sequence 4852, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4852
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4852
```

```
Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.6e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 379 GGAGCTTCTGCAATTC 395
      |||||:|:|||||
Db 1 GGAGCUUCUGCAUUC 17
```

RESULT 223

```
US-10-156-306-4853
; Sequence 4853, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4853
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4853
```

```
Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.6e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 382 GCTTCTGCAATTCGAG 398
      |||||:|:|||||
Db 1 GCUUCUGCAUUCGAG 17
```

RESULT 224

```
US-10-156-306-4854
; Sequence 4854, Application US/10156306
; Publication No. US20030119017A1
```

```
; GENERAL INFORMATION:
; APPLICANT: McSwiggen Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4854
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4854

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 387 TGCATTTCGAAGCCAGC 403
Db 1 UGCAUUCGAGCCAGC 17

RESULT 225
US-10-156-306-4855
; Sequence 4855, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4855
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4855

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 388 GCATTTCGAAGCCAGCC 404
Db 1 GCAUUCGAGCCAGCC 17

RESULT 226
US-10-156-306-4856
; Sequence 4856, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4856
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4856
```

```
Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 392 TTCGAAGCCAGCCAGAG 408
Db 1 UUCAAGCCAGCCAGAG 17

RESULT 227
US-10-156-306-4857
; Sequence 4857, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4857
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4857

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 393 TCCAAGCCAGCCAGAGG 409
Db 1 UCCAAGCCAGCCAGAGG 17

RESULT 228
US-10-156-306-4858
; Sequence 4858, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4858
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4858

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 396 AAGCCAGCCAGAGGGAG 412
Db 1 AAGCCAGCCAGAGGGAG 17

RESULT 229
US-10-156-306-4859
; Sequence 4859, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
```

```

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4859
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4859

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      397 AGCCAGCCAGGAGG 413
Db      1 AGCCAGCCAGGAGG 17

RESULT 230
US-10-156-306-4860
; Sequence 4860, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4860
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4860

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      417 AGGAGTTCCTCATGTGC 433
Db      1 AGGAGUCCUCAUGGUC 17

RESULT 231
US-10-156-306-4861
; Sequence 4861, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4861
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4861

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      417 AGGAGTTCCTCATGTGC 433
Db      1 AGGAGUCCUCAUGGUC 17

RESULT 232
US-10-156-306-4862
; Sequence 4862, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4862
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4862

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      420 AGTTCCTCATGTGCAAG 436
Db      1 AGUUCUCCUCAUGGCAAG 17

RESULT 233
US-10-156-306-4863
; Sequence 4863, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4863
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4863

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      426 TCATGTGCAAGTTCACG 442
Db      1 UCAUGUGCAAGUCCAG 17

RESULT 234
US-10-156-306-4864
; Sequence 4864, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
```

```

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      418 GGAGTTCTCATGTGCA 434
Db      1 GGAGUCCUCAUGGCA 17

RESULT 232
US-10-156-306-4862
; Sequence 4862, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4862
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4862

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      420 AGTTCCTCATGTGCAAG 436
Db      1 AGUUCUCCUCAUGGCAAG 17

RESULT 233
US-10-156-306-4863
; Sequence 4863, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4863
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4863

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      426 TCATGTGCAAGTTCACG 442
Db      1 UCAUGUGCAAGUCCAG 17

RESULT 234
US-10-156-306-4864
; Sequence 4864, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
```

```
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 4864
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4864

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 432 GCAAGTTCAGGAGGCC 448
      |||||:|||||
Db 1 GCAAGUCCAGGAGGCC 17

RESULT 235
US-10-156-306-4865
; Sequence 4865, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 4865
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4865

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 433 CAAGTTCAGGAGGCCA 449
      |||||:|||||
Db 1 CAAGUCCAGGAGGCCA 17

RESULT 236
US-10-156-306-4866
; Sequence 4866, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 4866
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4866

Query Match      2.3%; Score 17; DB 1; Length 17;
```

```
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 440 CAGGAGCCCGAGAAACT 456
      |||||:|||||
Db 1 CAGGAGCCCGAGAAACU 17

RESULT 237
US-10-156-306-4867
; Sequence 4867, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 4867
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4867

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 441 AGGAGCCCGAGAAACTG 457
      |||||:|||||
Db 1 AGGAGCCCGAGAAACUG 17

RESULT 238
US-10-156-306-4868
; Sequence 4868, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 4868
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4868

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 448 CAGGAAACTCGTGGAGA 464
      |||||:|||||
Db 1 CAGGAAACUGGUGGAGA 17

RESULT 239
US-10-156-306-4869
; Sequence 4869, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
```

```
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4869
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4869

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 460 GGAGAGACTCGGCTGG 476
Db 1 GGAGAGACUCGGCCUGG 17

RESULT 240
US-10-156-306-4870
; Sequence 4870, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4870
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4870

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 465 GACTCGGCTCGAGAG 481
Db 1 GACUCGGCCUGGAGAAG 17

RESULT 241
US-10-156-306-4871
; Sequence 4871, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4871
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4871

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 465 GACTCGGCTCGAGAG 481
Db 1 GACUCGGCCUGGAGAAG 17

RESULT 242
US-10-156-306-4872
; Sequence 4872, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4872
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4872

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 475 GGAGAGACTCGATCTGA 491
Db 1 GGAGAGACUCGAUCUGA 17

RESULT 243
US-10-156-306-4873
; Sequence 4873, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4873
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4873

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 481 GCTCGATCTGAAGAGGC 497
Db 1 GCUCGAUCUGAAGAGGC 17

RESULT 244
US-10-156-306-4874
; Sequence 4874, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4874
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4874

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
```

```
US-10-156-306-4871

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
```

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4874
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4874

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 490 GAAGAGCAGAGGAGC 506
Db 1 GAAGAGCAGAGGAGC 17

RESULT 245
US-10-156-306-4875
; Sequence 4875, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4875
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4875

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 499 GAAGGAGCAGGCTCGC 515
Db 1 GAAGGAGCAGGCUUCG 17

RESULT 246
US-10-156-306-4876
; Sequence 4876, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4876
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4876

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 503 GAGCAGGCTCTCGGGA 519
Db 1 GAGCAGGCTCTCGGGA 17

RESULT 247
US-10-156-306-4877
; Sequence 4877, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4877
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4877

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 505 GCAGGCTCTCGGAGG 521
Db 1 GCAGGCTCTCGGAGG 17

RESULT 248
US-10-156-306-4878
; Sequence 4878, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4878
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4878

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 520 GGTGAGCAGCCTGAAGA 536
Db 1 GGTGAGCAGCCTGAAGA 17

RESULT 249
US-10-156-306-4879
; Sequence 4879, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4879
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4879

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 522 TGGAGCACCCTGAAGAGA 538
Db 1 UGGAGCACCUAGAGAGA 17
:|||||:|||||

RESULT 250
US-10-156-306-4880
; Sequence 4880, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4880
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4880

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 523 GGAGCACCCTGAAGAGAT 539
Db 1 GGAGCACCUAGAGAGAU 17
:|||||:|||||

RESULT 251
US-10-156-306-4881
; Sequence 4881, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4881
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4881

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 534 AGAGATGCCAGCAGCAG 550
Db 1 AGAGAUGCCAGCAGCAG 17
:|||||:|||||

RESULT 252
US-10-156-306-4882
; Sequence 4882, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4882
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4882

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 535 GAGATGCCAGCAGCAGA 551
Db 1 GAGAUGCCAGCAGCAGA 17
:|||||:|||||

RESULT 253
US-10-156-306-4883
; Sequence 4883, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4883
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4883

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 538 ATGCCAGCAGCAGATGG 554
Db 1 AUGCCAGCAGCAGAU 17
:|||||:|||||

RESULT 254
US-10-156-306-4884
; Sequence 4884, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBHB01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4884
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4884

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 541 CCAGCAGCAGATGGCTG 557
|||||:|||||:|||||:
DB 1 CCAGCAGCAGAGUGGCU 17

RESULT 255
US-10-156-306-4885
; Sequence 4885, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4885
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4885

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 548 CAGATGGCTCAGGACAA 564
|||||:|||||:|||||:
DB 1 CAGAGGCTCAGGACAA 17

RESULT 256
US-10-156-306-4886
; Sequence 4886, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4886
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4886

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 555 CTGAGGACAGGCCTCT 571

DB 1 CUGAGGACCAAGGCCUCU 17
|:|||||:|||||:|:
RESULT 257
US-10-156-306-4887
; Sequence 4887, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4887
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4887

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 560 GACAAGGCCTCTGTGAA 576
|||||:|||||:|||||:
DB 1 GACAAGGCCUCUGUGAA 17

RESULT 258
US-10-156-306-4888
; Sequence 4888, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4888
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4888

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 561 ACAAGGCCTCTGTGAA 577
|||||:|||||:|||||:
DB 1 ACAAGGCCUCUGUGAA 17

RESULT 259
US-10-156-306-4889
; Sequence 4889, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4889
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4889

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 563 AAGCCTCTGGAAGC 579
|:|||||:|:|||||
Db 1 AAGCCUCUGAAGC 17

RESULT 260
US-10-156-306-4890
; Sequence 4890, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4890
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4890

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 572 GTGAAGCCCGAGTGAC 588
|:|||||:|:|||||
Db 1 GUGAAGCCCGAGGUGAC 17

RESULT 261
US-10-156-306-4891
; Sequence 4891, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4891
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4891

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 573 TGAAGCCCGAGTGACG 589
|:|||||:|:|||||

Db 1 UGAAAGCCCGAGGUGACG 17

RESULT 262
US-10-156-306-4892
; Sequence 4892, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4892
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4892

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 574 GAAAGCCCGAGTGACGT 590
|:|||||:|:|||||
Db 1 GAAAGCCCGAGGUGACGU 17

RESULT 263
US-10-156-306-4893
; Sequence 4893, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4893
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4893

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 584 GTGAGTCCTTGCTCGG 600
|:|||||:|:|||||
Db 1 GUGACGUCUUGCTCGG 17

RESULT 264
US-10-156-306-4894
; Sequence 4894, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4894
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4894

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.1%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 585 TGACGTCCTGTCGCGG 601
:||||:||||:||||
Db 1 UGAGGUCGUCGCGG 17

RESULT 265
US-10-156-306-4895
; Sequence 4895, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4895
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4895

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 589 GTCCTGCTCGGGGAGC 605
:||||:||||:||||
Db 1 GUCCUUGCUGGGGAGC 17

RESULT 266
US-10-156-306-4896
; Sequence 4896, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4896
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4896

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 598 CGGGAGCTGCAGGAGA 614
:||||:||||:||||
Db 1 CGGGAGCTGCAGGAGA 17

RESULT 267
US-10-156-306-4897
; Sequence 4897, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4897
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4897

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 601 GGAGCTGCAGGAGGCC 617
:||||:||||:||||
Db 1 GGAGCTGCAGGAGGCC 17

RESULT 268
US-10-156-306-4898
; Sequence 4898, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4898
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4898

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 609 AGGAGAGCCAGAGTCCG 625
:||||:||||:||||
Db 1 AGGAGAGCCAGAGTCCG 17

RESULT 269
US-10-156-306-4899
; Sequence 4899, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4899
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4899

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 609 AGGAGAGCCAGAGTCCG 625
:||||:||||:||||
Db 1 AGGAGAGCCAGAGTCCG 17

```
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4899
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4899

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      610 GGAGAGCCAGAGTCGCT 626
Db      1 GGAGAGCCAGAGUGCU 17
      |||||:|||||:|||||:
      |||||:|||||:|||||:

RESULT 270
US-10-156-306-4900
; Sequence 4900, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4900
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4900

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      618 AGAGTCGCTTGAGGCT 634
Db      1 AGAGUGCGUUGGAGGCU 17
      |||||:|||||:|||||:
      |||||:|||||:|||||:

RESULT 271
US-10-156-306-4901
; Sequence 4901, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4901
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4901

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      626 TTGAGGCTGCCACTAA 642
Db      1 UUGGAGGCGUCCACUAA 17
      ::|||:|||||:|||||:
      ::|||:|||||:|||||:
```

```
RESULT 272
US-10-156-306-4902
; Sequence 4902, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4902
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4902

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      629 GAGGCTGCCACTAAGGA 645
Db      1 GAGGCGUCCACUAAAGGA 17
      |||||:|||||:|||||:
      |||||:|||||:|||||:

RESULT 273
US-10-156-306-4903
; Sequence 4903, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4903
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4903

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      630 AGGCTGCCACTAAGGAA 646
Db      1 AGGCGUCCACUAAAGGAA 17
      |||||:|||||:|||||:
      |||||:|||||:|||||:

RESULT 274
US-10-156-306-4904
; Sequence 4904, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
```

; SEQ ID NO 4904
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4904

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 632 GCTGCCACTAAGGAATG 648
||:|||||:|||||:|
Db 1 GCUGCCACUAGGAUG 17

RESULT 275
US-10-156-306-4905
; Sequence 4905, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4905
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4905

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 642 AGGAATGCCAGGCTCTG 658
|||||:|||||:|
Db 1 AGGAUGCCAGGCUCUG 17

RESULT 276
US-10-156-306-4906
; Sequence 4906, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4906
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4906

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 643 GGAATGCCAGGCTCTGG 659
|||||:|||||:|
Db 1 GGAUGCCAGGCUCUG 17

RESULT 277
US-10-156-306-4907
; Sequence 4907, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4907
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4907

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 647 TGCCAGGCTCTGGAGGG 663
:|||||:|:|||||
Db 1 UGCCAGGCUCUGAGGG 17

RESULT 278
US-10-156-306-4908
; Sequence 4908, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4908
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4908

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 649 CCAGGCTCTGGAGGTC 665
|||||:|||||:|
Db 1 CCAGGCUCUGAGGGUC 17

RESULT 279
US-10-156-306-4909
; Sequence 4909, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4909

```
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4909

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 662 GGTGGGCGCCGGCGGC 678
Db 1 GGUCGGGCGCCGGCGGC 17

RESULT 280
US-10-156-306-4910
; Sequence 4910, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 4910
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4910

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 663 GTCGGGCGCCGGCGGC 679
Db 1 GUCGCGGCGCCGGCGGC 17

RESULT 281
US-10-156-306-4911
; Sequence 4911, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 4911
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4911

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 671 CGGCGGCGCCGAGCA 687
Db 1 CGGCGGCGCCGAGCA 17

RESULT 282
```

```
US-10-156-306-4912
; Sequence 4912, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 4912
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4912

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 672 GGGCGGCGCCGAGCAG 688
Db 1 GGGCGGCGCCGAGCAG 17

RESULT 283
US-10-156-306-4913
; Sequence 4913, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 4913
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4913

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 679 CAGCGAGCAGCGCGGC 695
Db 1 CAGCGAGCAGCGCGGC 17

RESULT 284
US-10-156-306-4914
; Sequence 4914, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 4914
; LENGTH: 17
```

```
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4914

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 688 GCGCGCGCAGCTGGAGA 704
      |||||:|||||
Db 1 GCGCGCGCAGCUGGAGA 17

RESULT 285
US-10-156-306-4915
; Sequence 4915, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4915
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4915

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 691 GCGCGCAGCTGGAGAGTG 707
      .|||||:|||||
Db 1 GCGCGCAGCUGGAGAGUG 17

RESULT 286
US-10-156-306-4916
; Sequence 4916, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4916
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4916

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 712 CGAGCGCTGCAGCAGC 728
      |||||:|||||
Db 1 CGAGCGCUGCAGCAGC 17

RESULT 287
US-10-156-306-4917
; Sequence 4917, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4917
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4917

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 715 GCGCGTCGACGACGACG 731
      |||||:|||||
Db 1 GCGCGCUGCAGCAGCAGC 17

RESULT 288
US-10-156-306-4918
; Sequence 4918, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4918
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4918

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 718 GCTGCAGCAGCAGCAGCA 734
      |||||:|||||
Db 1 GCUGCAGCAGCAGCAGCA 17

RESULT 289
US-10-156-306-4919
; Sequence 4919, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4919
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4919
```

```

; ORGANISM: Homo sapiens
US-10-156-306-4919

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 721 GCAGCAGCAGCAGCG 737
Db 1 GCAGCAGCAGCAGCG 17

RESULT 290
US-10-156-306-4920
; Sequence 4920, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4920
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4920

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 724 GCAGCAGCAGCAGCGTCG 740
Db 1 GCAGCAGCAGCAGCGTCG 17

RESULT 291
US-10-156-306-4921
; Sequence 4921, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4921
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4921

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 726 AGCAGCAGCAGCGTCGAG 742
Db 1 AGCAGCAGCAGCGTCGAG 17

RESULT 292
US-10-156-306-4922
; Sequence 4922, Application US/10156306

```

```

; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4922
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4922

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 733 CAGCGTGCGAGGTGGACC 749
Db 1 CAGCGTGCGAGGTGGACC 17

RESULT 293
US-10-156-306-4923
; Sequence 4923, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4923
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4923

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 741 AGGTGGACCGAGTGGCG 757
Db 1 AGGTGGACCGAGTGGCG 17

RESULT 294
US-10-156-306-4924
; Sequence 4924, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4924
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4924

```

US-10-156-306-4924

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 742 GGTGGACCACTGCCGA 758
||:|||||:|||||
Db 1 GGUGGACCACTGCCGA 17

RESULT 295

US-10-156-306-4925
; Sequence 4925, Application US/10156306
; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 4925

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-4925

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 745 GGACCACTGCCATGC 761
|||||:|||||:|
Db 1 GGACCACTGCCATGC 17

RESULT 296

US-10-156-306-4926
; Sequence 4926, Application US/10156306
; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 4926

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-4926

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 750 AGCTGCCATGCCGCGC 766
|||:|||||:|||||
Db 1 AGCTGCCATGCCGCGC 17

RESULT 297

US-10-156-306-4927
; Sequence 4927, Application US/10156306
; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 4927

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-4927

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 754 GCGCATGCCAGGCCAGA 770
|||||:|||||:|
Db 1 GCGCATGCCAGGCCAGA 17

RESULT 298

US-10-156-306-4928
; Sequence 4928, Application US/10156306
; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 4928

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-4928

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 759 TGCAGGCCAGCGGTG 775
:|||||:|||||:|
Db 1 UGCAGGCCAGCGGTG 17

RESULT 299

US-10-156-306-4929
; Sequence 4929, Application US/10156306
; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 4929

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-4929


```
Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 760 GCAGGGCCAGAGGCTGG 776
    |||||:|||||:|||||
Db 1 GCAGGGCCAGAGCGUGG 17

RESULT 300
US-10-156-306-4930
; Sequence 4930, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4930
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4930

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 773 GTGGAGGCGCGCTCCG 789
    :|||||:|||||:|||||
Db 1 GUGGAGGCGCGCUCCG 17

RESULT 301
US-10-156-306-4931
; Sequence 4931, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4931
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4931

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 778 GCGCGGCTCCGATGG 794
    |||||:|||||:|||||
Db 1 GCGCGGCTCCGCAUGG 17

RESULT 302
US-10-156-306-4932
; Sequence 4932, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4932
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4932
```

```
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4932
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4932

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 780 CCGCGCTCCGATGGAG 796
    |||||:|||||:|||||
Db 1 CCGCGCTCCGCAUGGAG 17

RESULT 303
US-10-156-306-4933
; Sequence 4933, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4933
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4933

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 783 CGCTCCGATGGAGCGC 799
    |||||:|||||:|||||
Db 1 CGCTCCGCAUGGAGCGC 17

RESULT 304
US-10-156-306-4934
; Sequence 4934, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4934
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4934
```

```

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 792 TGGAGCGCCAGGCGCCG 808
Db 1 UGGAGCGCCAGGCGCCG 17

RESULT 305
US-10-156-306-4935
; Sequence 4935, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4935
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4935

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 793 GGAGCGCCAGGCGCCCT 809
Db 1 GGAGCGCCAGGCGCCCT 17

RESULT 306
US-10-156-306-4936
; Sequence 4936, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4936
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4936

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 797 CGCAGCGCCGCTCGGA 813
Db 1 CGCAGCGCCGCTCGGA 17

RESULT 307
US-10-156-306-4937
; Sequence 4937, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

```

```

; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4937
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4937

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 800 CAGGCGCCCTCGGAGGA 816
Db 1 CAGGCGCCCTCGGAGGA 17

RESULT 308
US-10-156-306-4938
; Sequence 4938, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4938
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4938

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 801 AGCGCGCCCTCGGAGGAG 817
Db 1 AGCGCGCCCTCGGAGGAG 17

RESULT 309
US-10-156-306-4939
; Sequence 4939, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4939
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4939

Query Match          2.3%; Score 17; DB 1; Length 17;

```

Best Local Similarity 88.2%; Pred. No. 2.6e+02; Indels 0; Gaps 0;
Matches 15; Conservative 2; Mismatches 0;

Qy 820 GAGGAAGCTGCCAGT 836
|||||:|||||:
Db 1 GAGGAAGCTGCCAGU 17

RESULT 310
US-10-156-306-4940
; Sequence 4940, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4940
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4940

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 824 AAGCTGCCAGTTGCA 840
|||||:|||||:
Db 1 AAGCTGCCAGUUGCA 17

RESULT 311
US-10-156-306-4941
; Sequence 4941, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4941
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4941

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 825 AGCTGCCAGTTGCAG 841
|||||:|||||:
Db 1 AGCTGCCAGUUGCAG 17

RESULT 312
US-10-156-306-4942
; Sequence 4942, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4942
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4942

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 826 GCTGGCCAGTTGCAG 842
|||||:|||||:
Db 1 GCTGGCCAGUUGCAG 17

RESULT 313
US-10-156-306-4943
; Sequence 4943, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4943
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4943

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 832 CCAGTTGCAGTGGCCT 848
|||||:|||||:
Db 1 CCAGUUGCAGUUGCCU 17

RESULT 314
US-10-156-306-4944
; Sequence 4944, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4944
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4944

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;

Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 839 CAGGTGGCCTATCACCA 855
|||||:|:|:|:|:|:|
Db 1 CAGGUGCCUAUACCA 17

RESULT 315

US-10-156-306-4945
; Sequence 4945, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4945
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4945

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 840 AGGTGGCCTATCACCA 856
|||||:|:|:|:|:|:|
Db 1 AGGUGCCUAUACCA 17

RESULT 316

US-10-156-306-4946
; Sequence 4946, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4946
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4946

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 844 GGCTATCACCACTCT 860
|||||:|:|:|:|:|:|
Db 1 GGCCUAUACCACTCU 17

RESULT 317

US-10-156-306-4947
; Sequence 4947, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4947
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4947

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 846 CCTATCACCACTCTTC 862
||:|:|:|:|:|:|:|:|
Db 1 CCUAUACCACTCUUC 17

RESULT 318

US-10-156-306-4948
; Sequence 4948, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4948
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4948

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 847 CTATCACCACTCTTCC 863
|:|:|:|:|:|:|:|:|
Db 1 CUUACCACTCUUC 17

RESULT 319

US-10-156-306-4949
; Sequence 4949, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4949
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4949

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 850 TCACCAGCTTCCAAAG 866
 :|||||:|:|:|
 Db 1 UCACCAGCUCUCCAAG 17

RESULT 320
 US-10-156-306-4950
 ; Sequence 4950, Application US/10156306
 ; Publication No. US20030119017A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: McSwiggen, James
 ; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
 ; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
 ; FILE REFERENCE: MBH01-664-A (400/050)
 ; CURRENT APPLICATION NUMBER: US/10/156,306
 ; CURRENT FILING DATE: 2002-05-28
 ; NUMBER OF SEQ ID NOS: 8013
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 4950
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-156-306-4950

Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.6e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 852 ACCAGCTCTTCCAAGAA 868
 :|||||:|:|:|
 Db 1 ACCAGCUCUCCAAGAA 17

RESULT 321
 US-10-156-306-4951
 ; Sequence 4951, Application US/10156306
 ; Publication No. US20030119017A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: McSwiggen, James
 ; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
 ; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
 ; FILE REFERENCE: MBH01-664-A (400/050)
 ; CURRENT APPLICATION NUMBER: US/10/156,306
 ; CURRENT FILING DATE: 2002-05-28
 ; NUMBER OF SEQ ID NOS: 8013
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 4951
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-156-306-4951

Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 2.6e+02;
 Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 855 AGCTTCTCCAAGATAC 871
 :|||||:|:|:|
 Db 1 AGCUCUCCAAGAUAC 17

RESULT 322
 US-10-156-306-4952
 ; Sequence 4952, Application US/10156306
 ; Publication No. US20030119017A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: McSwiggen, James
 ; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
 ; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

; FILE REFERENCE: MBH01-664-A (400/050)
 ; CURRENT APPLICATION NUMBER: US/10/156,306
 ; CURRENT FILING DATE: 2002-05-28
 ; NUMBER OF SEQ ID NOS: 8013
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 4952
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-156-306-4952

Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 2.6e+02;
 Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 856 GCTCTCCAAGATACG 872
 :|||||:|:|:|
 Db 1 GCUCUCCAAGAUACG 17

RESULT 323
 US-10-156-306-4953
 ; Sequence 4953, Application US/10156306
 ; Publication No. US20030119017A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: McSwiggen, James
 ; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
 ; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
 ; FILE REFERENCE: MBH01-664-A (400/050)
 ; CURRENT APPLICATION NUMBER: US/10/156,306
 ; CURRENT FILING DATE: 2002-05-28
 ; NUMBER OF SEQ ID NOS: 8013
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 4953
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-156-306-4953

Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.6e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 867 AATACGACACCAACATC 883
 :|||||:|:|:|
 Db 1 AAUACGACACCAACAU 17

RESULT 324
 US-10-156-306-4954
 ; Sequence 4954, Application US/10156306
 ; Publication No. US20030119017A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: McSwiggen, James
 ; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
 ; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
 ; FILE REFERENCE: MBH01-664-A (400/050)
 ; CURRENT APPLICATION NUMBER: US/10/156,306
 ; CURRENT FILING DATE: 2002-05-28
 ; NUMBER OF SEQ ID NOS: 8013
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 4954
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-156-306-4954

Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.6e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 870 ACACAACCAATCAAG 886
|||||||:|||||
Db 1 ACACAACCAUCAAG 17

RESULT 325
US-10-156-306-4955
; Sequence 4955, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4955
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4955

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 871 CGACAACCAATCAAGA 887
|||||||:|||||
Db 1 CGACAACCAUCAAGA 17

RESULT 326
US-10-156-306-4956
; Sequence 4956, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4956
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4956

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 873 ACAACCAATCAAGGC 889
|||||||:|||||
Db 1 ACAACCAUCAAGGC 17

RESULT 327
US-10-156-306-4957
; Sequence 4957, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4957
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4957

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 876 ACCACATCAAGAGCAGC 892
|||||||:|||||
Db 1 ACCACATCAAGAGCAGC 17

RESULT 328
US-10-156-306-4958
; Sequence 4958, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4958
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4958

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 882 TCAAGAGCAGCGTGGTG 898
|||||||:|||||
Db 1 UCAAGAGCAGCGUGGUG 17

RESULT 329
US-10-156-306-4959
; Sequence 4959, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4959
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4959

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 894 TGGTGGCAGTCAGCGG 910

RESULT 330
US-10-156-306-4960
; Sequence 4960, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)

```
Db      1 UGGUGGCGAGGAGCG 17
      :||:|||||:|||||
RESULT 330
US-10-156-306-5772
; Sequence 5772, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5772
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5772

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      163 CTGAGAGGCGCACTGT 179
      :|||||:|||||:|
Db      1 CUGGAGAGCGCAACUG 17

RESULT 331
US-10-156-306-5773
; Sequence 5773, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5773
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5773

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      170 AGCCAACTGTGTGAGAT 186
      :|||||:|||||:|
Db      1 AGCCAAACUGUGAGAU 17

RESULT 332
US-10-156-306-5774
; Sequence 5774, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5774
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5774

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      172 CCAACTGTGTGAGATGG 188
      :|||||:|||||:|
Db      1 CCAACUGUGAGAGUGG 17
```

```
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5774
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5774

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      172 CCAACTGTGTGAGATGG 188
      :|||||:|||||:|
Db      1 CCAACUGUGAGAGUGG 17

RESULT 333
US-10-156-306-5775
; Sequence 5775, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5775
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5775

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      180 GTCAGATGTGTGAGCC 196
      :|||||:|||||:|
Db      1 GUGAGAGUGGAGAGCC 17

RESULT 334
US-10-156-306-5776
; Sequence 5776, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5776
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5776

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      182 GAGATGTGTGAGCCAG 198
      :|||||:|||||:|
```

```

; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5779
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5779

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy      193 GCCCAGTGGTGGCCCGG 209
      |||||:|||||
Db      1 GCCCAGUGGUGCCCGG 17

RESULT 338
US-10-156-306-5780
; Sequence 5780, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5780
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5780

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy      196 CAGTGGTGGCCCGGCAG 212
      ||||:|||||
Db      1 CAGUGUGGCGCCGCGAG 17

RESULT 339
US-10-156-306-5781
; Sequence 5781, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5781
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5781

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy      201 GTGGCCCGCGCAGCAT 217
      -||:|||||
Db      1 GUGGCCCGCGCAGCAU 17

```



```
RESULT 340
US-10-156-306-5782
; Sequence 5782, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5782
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5782

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      204 GCCCGGCGAGCATGAC 220
Db      1 GCCCGGCGAGCATGAC 17

RESULT 341
US-10-156-306-5783
; Sequence 5783, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5783
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5783

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy      216 ATCAGGACGTAAGGCG 232
Db      1 AUCAGGAGUAGUUGGC 17

RESULT 342
US-10-156-306-5784
; Sequence 5784, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
```

```
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5784
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5784

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy      223 CGTACTGGCGGAGAGT 239
Db      1 CGUACUGGCGGAGAGU 17

RESULT 343
US-10-156-306-5785
; Sequence 5785, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5785
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5785

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy      230 GGCGAAGAGTCTCTCT 246
Db      1 GGCGAAGAGUCCUCCU 17

RESULT 344
US-10-156-306-5786
; Sequence 5786, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5786
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5786

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy      245 CTGGGGAAGCGCAGCCAT 261
Db      1 CUGGGGAAGCGCAGCCAU 17
```

```
RESULT 345
US-10-156-306-5787
; Sequence 5787, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5787
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5787

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 249 GGAAGCCAGCCATGCTG 265
      |||||:|||||:|:|
Db 1 GGAAGCCAGCCAGCUG 17

RESULT 346
US-10-156-306-5788
; Sequence 5788, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5788
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5788

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 254 CCAGCCATGCTGCACCT 270
      |||||:|||||:|
Db 1 CCAGCCAGCUGCACCUC 17

RESULT 347
US-10-156-306-5789
; Sequence 5789, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5789
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5789

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 254 CCAGCCATGCTGCACCT 270
      |||||:|||||:|
Db 1 CCAGCCAGCUGCACCUC 17
```

```
; SEQ ID NO 5789
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5789

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 257 GCCATGCTGCACCTGCC 273
      |||||:|||||:|
Db 1 GCCAUGCUGCACCUGCC 17

RESULT 348
US-10-156-306-5790
; Sequence 5790, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5790
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5790

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 263 CTGCACCTGCCTTCAGA 279
      |||||:|||||:|
Db 1 CUGCACCUGCCUUCAGA 17

RESULT 349
US-10-156-306-5791
; Sequence 5791, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5791
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5791

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 277 AGAAGCCAGCGCTCCTG 293
      |||||:|||||:|
Db 1 AGAAGCCAGCGCCUCCUG 17
```

```
RESULT 350
US-10-156-306-5792
; Sequence 5792, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5792
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5792

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      279 AACAGGGCGCTCTCGAG 295
      |||||:|||||:|||||
Db      1 AACAGGGCGCUCUGAG 17

RESULT 351
US-10-156-306-5793
; Sequence 5793, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5793
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5793

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      296 ACCCTCAGCGCTCGCT 312
      |||||:|||||:|||||
Db      1 ACCUCCAGCGCUGCCU 17

RESULT 352
US-10-156-306-5794
; Sequence 5794, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5794
```

```
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5794

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      298 CCTCCAGCGCTGCTGG 314
      |||||:|||||:|||||
Db      1 CCUCCAGCGCUGCCUGG 17

RESULT 353
US-10-156-306-5795
; Sequence 5795, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5795
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5795

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      301 CCAGCGCTGCTGGAGG 317
      |||||:|||||:|||||
Db      1 CCAGCGCUGCCUGGAGG 17

RESULT 354
US-10-156-306-5796
; Sequence 5796, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5796
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5796

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      320 AATCAAGAGCTCCGAGA 336
      |||||:|||||:|||||
Db      1 AAUCAAGAGCUCGCGAGA 17

RESULT 355
```

```

US-10-156-306-5797
; Sequence 5797, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5797
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5797

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      330 TCCGAGATGCCATCCGG 346
Db      1 UCCGAGAUCCGCAUCCGG 17

RESULT 356
US-10-156-306-5798
; Sequence 5798, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5798
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5798

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      338 GCCATCCGCGCAGACCAA 354
Db      1 GCCAUCCGCGCAGACCAA 17

RESULT 357
US-10-156-306-5799
; Sequence 5799, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5799
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5799

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      338 GCCATCCGCGCAGACCAA 354
Db      1 GCCAUCCGCGCAGACCAA 17

RESULT 358
US-10-156-306-5800
; Sequence 5800, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5800
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5800

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      356 CAGATTCTCGCGGAGCG 372
Db      1 CAGAUUCUGCGGAGCG 17

RESULT 359
US-10-156-306-5801
; Sequence 5801, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5801
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5801

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      362 CTGCGGGAGCGTGGCA 378
Db      1 CUGCGGGAGCGCUGCGA 17

RESULT 360
US-10-156-306-5802

```

```

; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5799

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      343 CCGGCAGACCAACCAGA 359
Db      1 CCGGCAGACCAACCAGA 17

RESULT 358
US-10-156-306-5800
; Sequence 5800, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5800
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5800

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      356 CAGATTCTCGCGGAGCG 372
Db      1 CAGAUUCUGCGGAGCG 17

RESULT 359
US-10-156-306-5801
; Sequence 5801, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5801
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5801

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      362 CTGCGGGAGCGTGGCA 378
Db      1 CUGCGGGAGCGCUGCGA 17

RESULT 360
US-10-156-306-5802

```

; Sequence 5802, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5802
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5802

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 364 GCGGAGCGCTGCGAGG 380
Db 1 GCGGAGCGCUGCAGG 17

RESULT 361
US-10-156-306-5803
; Sequence 5803, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5803
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5803

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 367 GGAGCGCTGCGAGGAGC 383
Db 1 GGAGCGCUGCAGGAGC 17

RESULT 362
US-10-156-306-5804
; Sequence 5804, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5804
; LENGTH: 17
; TYPE: RNA

; ORGANISM: Homo sapiens
US-10-156-306-5804

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 374 TGCAGGAGCTTCTGCA 390
Db 1 UGCGAGGAGCUCUGCA 17

RESULT 363
US-10-156-306-5805
; Sequence 5805, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5805
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5805

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.6e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 380 GAGCTTCTGCATTTCGA 396
Db 1 GAGCUCUGCAUUCUCA 17

RESULT 364
US-10-156-306-5806
; Sequence 5806, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5806
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5806

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 390 ATTCCAGCCAGCCAG 406
Db 1 AUUCCAAGCCAGCCAG 17

RESULT 365
US-10-156-306-5807
; Sequence 5807, Application US/10156306

```
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5807
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5807

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 394 CCAAGCCAGCCAGG 410
Db 1 CCAAGCCAGCCAGG 17

RESULT 366
US-10-156-306-5808
; Sequence 5808, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5808
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5808

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 413 GAGAAGGAGTCTCAT 429
Db 1 GAGAAGGAGUCCAU 17

RESULT 367
US-10-156-306-5809
; Sequence 5809, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5809
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
```

```
US-10-156-306-5809

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 2.6e+02;
Matches 10; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 422 TTCCTCATGTGCAAGTT 438
Db 1 UUCUCAUGUGCAAGUU 17

RESULT 368
US-10-156-306-5810
; Sequence 5810, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5810
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5810

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 424 CCTCATGTGCAAGTTCC 440
Db 1 CCUCAUGUGCAAGUCC 17

RESULT 369
US-10-156-306-5811
; Sequence 5811, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5811
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5811

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 428 ATGTGCAAGTTCAGGA 444
Db 1 AUGUCAAGUCCAGGA 17

RESULT 370
US-10-156-306-5812
; Sequence 5812, Application US/10156306
; Publication No. US20030119017A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5812
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5812

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      438  TCACGAGGCGCAGGAAA 454
Db      1      UCCAGAGGCGCAGGAAA 17

RESULT 371
US-10-156-306-5813
; Sequence 5813, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5813
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5813

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy      450  GGAACCTGGTGGAGAGA 466
Db      1      GGAAACUGUGGAGAGA 17

RESULT 372
US-10-156-306-5814
; Sequence 5814, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5814
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5814
```

```
Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy      463  GAGACTCGCGCTGGAGA 479
Db      1      GAGACUGCGCCUGGAGA 17

RESULT 373
US-10-156-306-5815
; Sequence 5815, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5815
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5815

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy      473  CTGGAGAGCTCGATCT 489
Db      1      CUGGAGAGCUCGCAUCU 17

RESULT 374
US-10-156-306-5816
; Sequence 5816, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5816
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5816

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      488  CTGAAGAGCGCAGGAAGGA 504
Db      1      CUGAAGAGCGCAGGAAGGA 17

RESULT 375
US-10-156-306-5817
; Sequence 5817, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
```

```

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5817
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5817

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 497 CAGAAGCAGCAGCTCT 513
Db 1 CAGAAGCAGCAGCUCU 17

RESULT 376
US-10-156-306-5818
; Sequence 5818, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5818
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5818

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 501 AGGAGCAGCTCTGCGG 517
Db 1 AGGAGCAGCUCUCGCG 17

RESULT 377
US-10-156-306-5819
; Sequence 5819, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5819
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5819

```

```

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 506 CAGGCTCTCGGAGGT 522
Db 1 CAGGCTCTCGGAGGT 17

RESULT 378
US-10-156-306-5820
; Sequence 5820, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5820
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5820

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 513 TCGGGAGGTGGAGCAC 529
Db 1 UCGGGAGGTGGAGCAC 17

RESULT 379
US-10-156-306-5821
; Sequence 5821, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5821
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5821

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 518 GAGGTGAGCAGCTGAA 534
Db 1 GAGGTGAGCAGCTGAA 17

RESULT 380
US-10-156-306-5822
; Sequence 5822, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

```



```
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5822
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5822

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 532 GAAGAGATGCCAGCAGC 548
Db 1 GAAGAGAUGCAGCAGC 17

RESULT 381
US-10-156-306-5823
; Sequence 5823, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5823
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5823

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 536 AGATGCCAGCAGCAGAT 552
Db 1 AGAUGCCAGCAGCAGAU 17

RESULT 382
US-10-156-306-5824
; Sequence 5824, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5824
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5824

Query Match      2.3%; Score 17; DB 1; Length 17;
```

```
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 539 TGCCAGCAGCAGATGGC 555
Db 1 UGCCAGCAGCAGGAUGC 17

RESULT 383
US-10-156-306-5825
; Sequence 5825, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5825
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5825

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 546 AGCAGATGGCTGAGGAC 562
Db 1 AGCAGAUGCUCUGAGGAC 17

RESULT 384
US-10-156-306-5826
; Sequence 5826, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5826
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5826

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 558 AGGACAAGGCCTCTGTG 574
Db 1 AGGACAAGGCUCUGUG 17

RESULT 385
US-10-156-306-5827
; Sequence 5827, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
```

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5827
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5827

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 564 AGCCCTCTGTGAAGCC 580
|||||:|:|:|:|:|:|
Db 1 AGCCUCUGUGAAGCC 17

RESULT 386
US-10-156-306-5828
; Sequence 5828, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5828
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5828

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 570 CTGTGAAGCCAGGTG 586
|:|:|:|:|:|:|:|:|:|
Db 1 CUGUGAAGCCAGGUG 17

RESULT 387
US-10-156-306-5829
; Sequence 5829, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5829
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5829

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;

Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 576 AAGCCAGGTGAGTCC 592
|||||:|:|:|:|:|:|
Db 1 AAGCCAGGUGAGGUCC 17

RESULT 388
US-10-156-306-5830
; Sequence 5830, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5830
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5830

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 581 CAGGTGACGTCTTGCT 597
|||||:|:|:|:|:|:|
Db 1 CAGGUGAGGUCCUGCU 17

RESULT 389
US-10-156-306-5831
; Sequence 5831, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5831
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5831

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 587 ACGTCTTGCTCGGGA 603
|||||:|:|:|:|:|:|
Db 1 AGGUCCUGUCUGGGA 17

RESULT 390
US-10-156-306-5832
; Sequence 5832, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5832
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5832

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 596 CTCGGGAGCTGCAGGA 612
|:|||||:|||||:
Db 1 CUCGGGAGCGCAGGA 17

RESULT 391
US-10-156-306-5833
; Sequence 5833, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5833
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5833

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 599 GGGGAGCTGCAGGAGAG 615
|:|||||:|||||:
Db 1 GGGGAGCGCAGGAGAG 17

RESULT 392
US-10-156-306-5834
; Sequence 5834, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5834
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5834

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 607 GCAGGAGAGCCAGATC 623
|:|||||:|||||:
Db 1 GCAGGAGAGCCAGAGUC 17

RESULT 393
US-10-156-306-5835
; Sequence 5835, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5835
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5835

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 613 GAGCCAGAGTCGCTTGG 629
|:|||||:|||||:
Db 1 GAGCCAGAGUCGCUUGG 17

RESULT 394
US-10-156-306-5836
; Sequence 5836, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5836
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5836

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 616 CCAGAGTCGCTTCGAGG 632
|:|||||:|||||:
Db 1 CCAGAGUCGCUUGGAGG 17

RESULT 395
US-10-156-306-5837
; Sequence 5837, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5837
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5837

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 624 GCTTGAGGCTGCGCACT 640
DB 1 GCUUGGAGGCGGCCACU 17

RESULT 396
US-10-156-306-5838
; Sequence 5838, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5838
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5838

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 627 TGGAGGCTGCCACTAAG 643
DB 1 UGAGGCGCGCCCUAAG 17

RESULT 397
US-10-156-306-5839
; Sequence 5839, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5839
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5839

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 640 TAAGGAATGCCAGGCTC 656
DB 1 UAAAGGAUCCAGGCUC 17

RESULT 398
US-10-156-306-5840
; Sequence 5840, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5840
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5840

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 645 AATGCCAGGCTCTGGAG 661
DB 1 AAUGCCAGGCGUCUGGAG 17

RESULT 399
US-10-156-306-5841
; Sequence 5841, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5841
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5841

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 655 TCTGAGGCTCGGCCCC 671
DB 1 UCUGGAGGCGUCGGGCC 17

RESULT 400
US-10-156-306-5842
; Sequence 5842, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBHB01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5842
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5842

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 660 AGGTCGGGCCCGGGCG 676
|||||
Db 1 AGGUCGGGCCCGGGCG 17

RESULT 401

US-10-156-306-5843
; Sequence 5843, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MH801-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5843
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5843

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 666 GGGCCCGGGCGGCAGC 682
|||||
Db 1 GGGCCCGGGCGGCAGC 17

RESULT 402

US-10-156-306-5844
; Sequence 5844, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MH801-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5844
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5844

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 669 CCCGGGGCGGCAGCGAG 685

Db 1 CCCGGGGCGGCAGCGAG 17
|||||

RESULT 403

US-10-156-306-5845
; Sequence 5845, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MH801-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5845
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5845

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 673 GCGGCCGCGGCAGCG 689
|||||
Db 1 GCGGCCGCGGCAGCG 17

RESULT 404

US-10-156-306-5846
; Sequence 5846, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MH801-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5846
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5846

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 677 GCGGCCGCGGCAGCG 693
|||||
Db 1 GCGGCCGCGGCAGCG 17

RESULT 405

US-10-156-306-5847
; Sequence 5847, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MH801-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5847
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5847

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 681 GCGAGCAGCGCGGCAG 697
|||:|||||:|||||

Db 1 GCGAGCAGCGCGGCAG 17

RESULT 406

US-10-156-306-5848
; Sequence 5848, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5848
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5848

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 683 GAGCAGCGCGGCAGCT 699
|||:|||||:|||||

Db 1 GAGCAGCGCGGCAGCU 17

RESULT 407

US-10-156-306-5849
; Sequence 5849, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5849
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5849

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 686 CAGCGCGCGCAGCTGGA 702
|||:|||||:|||||

Db 1 CAGCGCGCGCAGCTUGGA 17

RESULT 408

US-10-156-306-5850
; Sequence 5850, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5850
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5850

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 689 GCGCGCGCAGCTGGAGAG 705
|||:|||||:|||||

Db 1 GCGCGCGCAGCTGGAGAG 17

RESULT 409

US-10-156-306-5851
; Sequence 5851, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5851
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5851

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 697 GCTGGCAGAGTGAGCGCG 713
|||:|||||:|||||

Db 1 GCUGGAGAGUGAGCGCG 17

RESULT 410

US-10-156-306-5852
; Sequence 5852, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5852
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5852

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 701 GAGAGTGGCGGCGGC 717
|||||:|||||
Db 1 GAGAGGAGCGCGAGGC 17

RESULT 411

US-10-156-306-5853
; Sequence 5853, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5853
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5853

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 703 GAGTGAGCGCGGCGGC 719
|||||:|||||
Db 1 GAGUGAGCGCGGCGGC 17

RESULT 412

US-10-156-306-5854
; Sequence 5854, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5854
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5854

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 708 AGCGGAGCGCGGCGGC 724
|||||:|||||
Db 1 AGCGGAGCGCGGCGGC 17

RESULT 413

US-10-156-306-5855
; Sequence 5855, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5855
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5855

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 710 CGCGAGCGCGCTGCAGCA 726
|||||:|||||
Db 1 CGCGAGCGCGCTGCAGCA 17

RESULT 414

US-10-156-306-5856
; Sequence 5856, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5856
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5856

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 713 GAGGCGCTGCAGCA 729
|||||:|||||
Db 1 GAGGCGCTGCAGCA 17

RESULT 415

US-10-156-306-5857
; Sequence 5857, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5857
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5857

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 716 GCGCTGCAGCAGCA 732
|||||:|||||:
Db 1 GCGCUGCAGCAGCA 17

RESULT 416
US-10-156-306-5858
; Sequence 5858, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5858
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5858

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 719 CTGCAGCAGCAGCAG 735
|:|||||:|||||:
Db 1 CUGCAGCAGCAGCAG 17

RESULT 417
US-10-156-306-5859
; Sequence 5859, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5859
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5859

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 722 CAGCAGCAGCAGCCT 738
|||||:|||||:
Db 1 CAGCAGCAGCAGCGU 17

RESULT 418

US-10-156-306-5860
; Sequence 5860, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5860
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5860

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 727 GCAGCAGCGTGCAGG 743
|||||:|||||:
Db 1 GCAGCAGCAGCGUGCAGG 17

RESULT 419
US-10-156-306-5861
; Sequence 5861, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5861
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5861

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 729 AGCAGCAGCGTGCAGTG 745
|||||:|||||:
Db 1 AGCAGCAGCGUGCAGGUG 17

RESULT 420
US-10-156-306-5862
; Sequence 5862, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0


```
; SEQ ID NO 5862
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5862

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 731 CACAGCGTGCAGTGGA 747
|||||:|||||:||||
Db 1 CACAGCGUGCAGGUGGA 17

RESULT 421
US-10-156-306-5863
; Sequence 5863, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5863
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5863

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 735 GCGTGCGAGGTGGACCAG 751
|||||:|||||:|||||
Db 1 GCGUGCAGGUGGUGCCAG 17

RESULT 422
US-10-156-306-5864
; Sequence 5864, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5864
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5864

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 743 GTGACCAAGTGGCGCAT 759
|||||:|||||:|||||
Db 1 GUGGACCAAGCUGGCCAU 17
```

```
RESULT 423
US-10-156-306-5865
; Sequence 5865, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5865
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5865

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 746 GACCAGCTGCGCATGCA 762
|||||:|||||:|||||
Db 1 GACCAGCUGCGCAUGCA 17

RESULT 424
US-10-156-306-5866
; Sequence 5866, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5866
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5866

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 748 CCAGCTGCCGATGCAGG 764
|||||:|||||:|||||
Db 1 CCAGCUGCGCAUGCAGG 17

RESULT 425
US-10-156-306-5867
; Sequence 5867, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5867
```

```
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5867

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 752 CTGCGCATGCGAGGCCA 768
   |||||:|||||
Db 1 CUGCGCAUGCAGGCGCCA 17

RESULT 426
US-10-156-306-5868
; Sequence 5868, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5868
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5868

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 757 CATGCGAGGCCAGAGCG 773
   ||:|||||
Db 1 CAUGCAGGCGCCAGAGCG 17

RESULT 427
US-10-156-306-5869
; Sequence 5869, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5869
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5869

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 763 GGGCCAGAGCGGTGGAGG 779
   |||||:|||||
Db 1 GGGCCAGAGCGGUGAGG 17

RESULT 428
```

```
US-10-156-306-5870
; Sequence 5870, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5870
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5870

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 765 GCCAGAGCGTGGAGGCC 781
   |||||:|||||
Db 1 GCCAGAGCGGUGAGGCC 17

RESULT 429
US-10-156-306-5871
; Sequence 5871, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5871
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5871

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 771 GCGTGGAGCGCGGCTC 787
   |||:|||||
Db 1 GCGUGAGGCGCGCGCUC 17

RESULT 430
US-10-156-306-5872
; Sequence 5872, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5872
; LENGTH: 17
```

```
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5872

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 774 TGGAGCGCGCTCCGC 790
Db 1 UGGAGCGCGCUCCGC 17

RESULT 431
US-10-156-306-5873
; Sequence 5873, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5873
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5873

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 776 GAGCGCGCGCTCCGCAT 792
Db 1 GAGCGCGCGCUCCCAU 17

RESULT 432
US-10-156-306-5874
; Sequence 5874, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5874
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5874

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 781 CGCGCTCCGCATGGAGC 797
Db 1 CGCGCUCCGCAUGGAGC 17

RESULT 433
US-10-156-306-5875
```

```
; Sequence 5875, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5875
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5875

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 788 CGCATGGAGCGCCAGGC 804
Db 1 CGCAUGGAGCGCCAGGC 17

RESULT 434
US-10-156-306-5876
; Sequence 5876, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5876
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5876

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 790 CATGGAGCGCCAGCGC 806
Db 1 CAUGGAGCGCCAGGCGC 17

RESULT 435
US-10-156-306-5877
; Sequence 5877, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5877
; LENGTH: 17
; TYPE: RNA
```

```

; ORGANISM: Homo sapiens
US-10-156-306-5877

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 795 AGCGCAGCGCCGCTCG 811
    |||||
Db 1 AGCGCAGCGCCGCUUG 17

RESULT 436
US-10-156-306-5878
; Sequence 5878, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5878
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5878

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 798 GCAGCGCCGCTCGGAG 814
    |||||
Db 1 GCAGCGCCGCTCGGAG 17

RESULT 437
US-10-156-306-5879
; Sequence 5879, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5879
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5879

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 818 AAGAGGAAGCTGCCCA 834
    |||||
Db 1 AAGAGGAAGCTGCCCA 17

RESULT 438
US-10-156-306-5880
; Sequence 5880, Application US/10156306

```

```

; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5880
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5880

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 822 GGAAGCTGCCCGAGTTG 838
    |||||
Db 1 GGAAGCTGCCCGAGUUG 17

RESULT 439
US-10-156-306-5881
; Sequence 5881, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5881
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5881

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 827 CTGGCCCGAGTTGCAGGT 843
    |||||
Db 1 CUGGCCCGAGUUGCAGGU 17

RESULT 440
US-10-156-306-5882
; Sequence 5882, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5882
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens

```

US-10-156-306-5882

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 830 GCCAGTTCGAGGTGGC 846
|||||:|||||:|||||
Db 1 GCCCAGUUGCAGGUGGC 17

RESULT 441

US-10-156-306-5883
; Sequence 5883, Application US/10156306
; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

; FILE REFERENCE: MBHB01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 5883

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-5883

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 834 AGTTCAGGTGGCCTAT 850
|||||:|||||:|||||
Db 1 AGUUGCAGGUGGCUAU 17

RESULT 442

US-10-156-306-5884
; Sequence 5884, Application US/10156306
; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

; FILE REFERENCE: MBHB01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 5884

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-5884

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 837 TGCAGGTGGCCTATCAC 853
|||||:|||||:|||||
Db 1 UGCAGGUGGCUAUAC 17

RESULT 443

US-10-156-306-5885
; Sequence 5885, Application US/10156306
; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

; FILE REFERENCE: MBHB01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 5885

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-5885

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 848 TATCACCAGCTCTTCCA 864
:|||||:|||||:|||||
Db 1 UAUCACCAGCUCUCCA 17

RESULT 444

US-10-156-306-5886

; Sequence 5886, Application US/10156306

; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

; FILE REFERENCE: MBHB01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 5886

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-5886

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 880 CATCAAGAGCAGCGTGG 896
|||:|||||:|||||:|||||
Db 1 CAUCAAGAGCAGCGUGG 17

RESULT 445

US-10-156-306-5887

; Sequence 5887, Application US/10156306

; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

; FILE REFERENCE: MBHB01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 5887

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-5887

```
Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      883 CAAGACGCGGTGG 899
      |||||:|||||:|||||
Db      1 CAAGACGCGGUGG 17

RESULT 446
US-10-156-306-5888
; Sequence 5888, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5888
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5888

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      885 AGAGCAGCGGTGGGCGC 901
      |||||:|||||:|||||
Db      1 AGAGCAGCGGUGGCGC 17

RESULT 447
US-10-156-306-5889
; Sequence 5889, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5889
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5889

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      888 GCAGCGGTGGGCGAGT 904
      |||||:|||||:|||||
Db      1 GCAGCGGUGGUGGCGAGU 17

RESULT 448
US-10-156-306-5890
; Sequence 5890, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5890
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5890

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      892 CGTGGCGGCGAGTGC 908
      |||||:|||||:|||||
Db      1 CGUGGCGGCGAGGAGC 17

RESULT 449
US-10-156-306-5891
; Sequence 5891, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5891
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5891

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      895 GGTGGCGGCGAGCGGA 911
      |||||:|||||:|||||
Db      1 CGUGGCGGCGAGGCGGA 17

RESULT 450
US-10-156-306-5892
; Sequence 5892, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5892
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5892
```

```

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 899 GGCAGTGCAGCGGAGCG 915
      |||||:|||||:|||||
Db 1 GGCAGUGAGCGGAGCG 17

RESULT 451
US-10-156-306-6318
; Sequence 6318, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6318
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6318

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 167 AAGAGCCAACTGTGTGA 183
      |||||:|||||:|||||
Db 1 AAGAGCCACUGUGUGA 17

RESULT 452
US-10-156-306-6319
; Sequence 6319, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6319
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6319

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 177 TGTGTGAGATGCTGCAG 193
      :||:|||||:|||||
Db 1 UGUGUGAGUGGUGCAG 17

RESULT 453
US-10-156-306-6320
; Sequence 6320, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

```

```

; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6320
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6320

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 208 GGCAGCAGATCAGGAGC 224
      |||||:|||||:|||||
Db 1 GGCAGCAGCAUCAGGAGC 17

RESULT 454
US-10-156-306-6321
; Sequence 6321, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6321
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6321

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 214 AGATCAGGAGCTACTGG 230
      |||||:|||||:|||||
Db 1 AGAUCAGGAGGAGUACUG 17

RESULT 455
US-10-156-306-6322
; Sequence 6322, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6322
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6322

Query Match      2.3%; Score 17; DB 1; Length 17;

```

```
Best Local Similarity 88.2%; Pred. No. 2.6e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 15; Conservative 2;

QY 272 CCTTCAGAACAGGGCCG 288
||:|||||
Db 1 CCUCAGAACAGGGCCG 17

RESULT 456
US-10-156-306-6323
; Sequence 6323, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6323
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6323

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 288 CTCCTGAGACCTCTCCAG 304
||:|||||
Db 1 CUCCUGAGACCUCCAG 17

RESULT 457
US-10-156-306-6324
; Sequence 6324, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6324
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6324

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 313 GGAGGAGAAATCAAGAGC 329
|||||
Db 1 GGAGGAGAAUCAAGAGC 17

RESULT 458
US-10-156-306-6325
; Sequence 6325, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
```

```
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6325
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6325

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 328 GCTCCGAGATCCATCC 344
||:|||||
Db 1 GCUCGAGAUCCAUCC 17

RESULT 459
US-10-156-306-6326
; Sequence 6326, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6326
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6326

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 346 GCAGAGCAACCATTC 362
|||||
Db 1 GCAGAGCAACCATTC 17

RESULT 460
US-10-156-306-6327
; Sequence 6327, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6327
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6327

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
```


QY 543 AGCAGCAGATGGCTGAG 559
|||||:||||:
Db 1 AGCAGCAGAUCCUGAG 17

RESULT 466
US-10-156-306-6333
; Sequence 6333, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6333
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6333

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02; Indels 0; Gaps 0;
Matches 15; Conservative 2; Mismatches 0;

QY 553 GGCTGAGGACAGGCCT 569
|||||:||||:
Db 1 GGCUGAGGACAGGCCT 17

RESULT 467
US-10-156-306-6334
; Sequence 6334, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6334
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6334

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02; Indels 0; Gaps 0;
Matches 13; Conservative 4; Mismatches 0;

QY 579 CCCAGGTGAGTCTTG 595
|||||:||||:
Db 1 CCCAGGAGGAGCUUG 17

RESULT 468
US-10-156-306-6335
; Sequence 6335, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6335
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6335

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02; Indels 0; Gaps 0;
Matches 15; Conservative 2; Mismatches 0;

QY 638 ACTAAGGAATGCCAGGC 654
|||||:||||:
Db 1 ACUAGGAUGCCAGGC 17

RESULT 469
US-10-156-306-6336
; Sequence 6336, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6336
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6336

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02; Indels 0; Gaps 0;
Matches 15; Conservative 2; Mismatches 0;

QY 739 GCAGGTGGACCACTGC 755
|||||:||||:
Db 1 GCAGGUGGACCACTGC 17

RESULT 470
US-10-156-306-6337
; Sequence 6337, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6337
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6337

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02; Indels 0; Gaps 0;
Matches 14; Conservative 3; Mismatches 0;

QY 860 TTCCAAGAAATACGACAA 876
:|||||:|||||
Db 1 UUCAAGAAUACGACAA 17

RESULT 471
US-10-156-306-6338
; Sequence 6338, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6338
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6338

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 865 AGAATACGACACACACA 881
:|||||:|||||
Db 1 AGAAUACGACACACACA 17

RESULT 472
US-10-156-306-6339
; Sequence 6339, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6339
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6339

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 868 ATACGACACACATCA 884
:|||||:|||||
Db 1 AUACGACACACCAUCA 17

RESULT 473
US-10-156-306-6814
; Sequence 6814, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6814
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6814

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 174 AACTGTGTGAGATGGTG 190
:|||||:|||||
Db 1 AACUGUGAGAGUGGUG 17

RESULT 474
US-10-156-306-6815
; Sequence 6815, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6815
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6815

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 176 CTGTGTGAGATGGTGCA 192
:|||||:|||||
Db 1 CUGUGAGAGUGGUGCA 17

RESULT 475
US-10-156-306-6816
; Sequence 6816, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6816
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6816

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 179 TGTGAGATGGTGACGCC 195

```

Db      1  UGUGAGUGGCGAGCC 17
          :|:||||:|:|:|||||
RESULT 476
US-10-156-306-6817
; Sequence 6817, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6817
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6817

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      192  AGCCGAGTGGTGGCCG 208
          |||||:|:|:|||||
Db      1  AGCCGAGUGGUGGCCG 17

RESULT 477
US-10-156-306-6818
; Sequence 6818, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6818
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6818

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      195  CCAGTGGTGGCCGGCA 211
          |||||:|:|:|||||
Db      1  CCAGUGGUGGCCGGCA 17

RESULT 478
US-10-156-306-6819
; Sequence 6819, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306

```

```

; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6819
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6819

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      200  GGTGGCCCGCAGCAGA 216
          .||:|||||:|||||
Db      1  GGUGGCCCGCAGCAGA 17

RESULT 479
US-10-156-306-6820
; Sequence 6820, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6820
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6820

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      207  CGGCAGCAGATCAGCAG 223
          |||||:|:|:|||||
Db      1  CGGCAGCAGCAUCAGGAC 17

RESULT 480
US-10-156-306-6821
; Sequence 6821, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6821
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6821

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      212  GCAGATCAGGACGTACT 228
          |||||:|:|:|||||:|:|:

```

```
Db      1 GCAGACAGGACGACU 17

RESULT 481
US-10-156-306-6822
; Sequence 6822, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6822
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6822

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      213 CAGATCAGGACGACTG 229
      |||||:|||||:|:|:|
Db      1 CAGACAGGACGACUG 17

RESULT 482
US-10-156-306-6823
; Sequence 6823, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6823
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6823

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      221 GAGCTACTGGCGGAAGA 237
      |||||:|||||:|:|:|
Db      1 GAGGACUGGCGGAG 17

RESULT 483
US-10-156-306-6824
; Sequence 6824, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
```

```
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6824
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6824

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      222 ACGTACTGGCGGAAGAG 238
      |||||:|||||:|:|:|
Db      1 ACGUACUGGCGGAAGAG 17

RESULT 484
US-10-156-306-6825
; Sequence 6825, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6825
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6825

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      225 TACTGGCGGAAGTCT 241
      :||:|||||:|:|:|
Db      1 UACUGGCGGAAGAGUCU 17

RESULT 485
US-10-156-306-6826
; Sequence 6826, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6826
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6826

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      228 TGGGCGGAAGTCTCT 244
      :|||||:|:|:|
Db      1 UGGGCGGAAGAGUCUCU 17
```

```
RESULT 486
US-10-156-306-6827
; Sequence 6827, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MEH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6827
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6827

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.3%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      239 TCCTCTCTGGGGAAGCC 255
      :|:|:|:|:|:|:|:|:|
Db      1 UCUCUCUGGGGAAGCC 17

RESULT 487
US-10-156-306-6828
; Sequence 6828, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MEH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6828
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6828

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      240 CTCCTCTGGGGAAGCCA 256
      |:|:|:|:|:|:|:|
Db      1 CUCCUCUGGGGAAGCCA 17

RESULT 488
US-10-156-306-6829
; Sequence 6829, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MEH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
```

```
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6829
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6829

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      241 TCCTCTGGGGAAGCCAG 257
      |:|:|:|:|:|:|:|
Db      1 UCCUCUGGGGAAGCCAG 17

RESULT 489
US-10-156-306-6830
; Sequence 6830, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MEH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6830
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6830

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      242 CCTCTGGGGAAGCCAGC 258
      |:|:|:|:|:|:|:|
Db      1 CCUCUGGGGAAGCCAGC 17

RESULT 490
US-10-156-306-6831
; Sequence 6831, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MEH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6831
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6831

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      270 TGCCTTCAGAACAGGCG 286
      |:|:|:|:|:|:|:|
Db      1 UGCCUUCAGAACAGGCG 17
```

RESULT 491

US-10-156-306-6832
; Sequence 6832, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6832
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6832

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 275 TCAGAACAGGGCGCTCC 291
:|||||:|||||:
Db 1 UCAGAACAGGGCGGUCC 17

RESULT 492

US-10-156-306-6833
; Sequence 6833, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6833
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6833

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 276 CAGAACAGGGCGTCTCT 292
:|||||:|||||:
Db 1 CAGAACAGGGCGGUCCU 17

RESULT 493

US-10-156-306-6834
; Sequence 6834, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 6834
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6834

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 285 GCGCTCCTGAGACCCCTC 301
|||||:|||||:
Db 1 GCGCUCCUGAGACCCUC 17

RESULT 494

US-10-156-306-6835
; Sequence 6835, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6835
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6835

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 287 GCTCCTGAGACCCCTCCA 303
:|||||:|||||:
Db 1 GCUCCUGAGACCCUCCA 17

RESULT 495

US-10-156-306-6836
; Sequence 6836, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6836
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6836

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 305 CGCTGCTGGAGGAGAA 321
|||||:|||||:
Db 1 CGCUGCCUGAGAGAA 17

```
RESULT 496
US-10-156-306-6837
; Sequence 6837, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6837
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6837

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 306 GCTGCTGGAGGAGAAAT 322
||:||||:||||:||||:
Db 1 GCUGCCUGGAGGAGAAU 17

RESULT 497
US-10-156-306-6838
; Sequence 6838, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6838
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6838

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 308 TGCTCGAGGAGAGAAATCA 324
||:||||:||||:||||:
Db 1 UGCGUGGAGGAGAAUCA 17

RESULT 498
US-10-156-306-6839
; Sequence 6839, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6839
```

```
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6839

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 309 GCCTGGAGGAGAAATCAA 325
||:||||:||||:||||:
Db 1 GCCUGGAGGAGAAUCA 17

RESULT 499
US-10-156-306-6840
; Sequence 6840, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6840
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6840

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 311 CTGGAGGAGAGAAATCAAGA 327
||:||||:||||:||||:
Db 1 CUGGAGGAGAGAAUCAAGA 17

RESULT 500
US-10-156-306-6841
; Sequence 6841, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6841
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6841

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 318 AGAATCAAGAGCTCCGA 334
||:||||:||||:||||:
Db 1 AGAAUCAAGAGCTCCGA 17

RESULT 501
```



```
US-10-156-306-6842
; Sequence 6842, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6842
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6842

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      325 AGAGCTCCGAGATGCCA 341
Db      1 AGAGCUCCGAGAGGCCA 17

RESULT 502
US-10-156-306-6843
; Sequence 6843, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6843
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6843

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      327 AGCTCCGAGATGCCATC 343
Db      1 AGCUCCGAGAGGCCAUC 17

RESULT 503
US-10-156-306-6844
; Sequence 6844, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6844
; LENGTH: 17
```

```
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6844

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      337 TGCCATCCGCGCAGACCA 353
Db      1 UGCCAUCCGCGCAGACCA 17

RESULT 504
US-10-156-306-6845
; Sequence 6845, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6845
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6845

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      341 ATCCGCGCAGACAACCA 357
Db      1 AUCCGCGCAGACAACCA 17

RESULT 505
US-10-156-306-6846
; Sequence 6846, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6846
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6846

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      350 AGCAACCAAGATTCTCGC 366
Db      1 AGCAACCAAGAUUCUGCG 17

RESULT 506
US-10-156-306-6847
```

```

; Sequence 6847, Application US/10156306
; Publication No. US20030111901/7A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCES: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6847
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-10-156-306-6847

```

Query Match	2.3%	Score 17	DB 1	Length 17
Best Local Similarity	76.5%	Pred. No. 2.6e+02		
Matches 13	Conservative	4	Mismatches 0	Indels 0
			Gaps	0

Qy	358	GATTCTGGGGAGCGCT	374
		: :	
D_b	1	GAUTUGGGGAGCGCU	17

```

RESULT 507
US-10-156-306-6848
; Sequence 6848, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6848
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6848

```

Query Match	2.3%	Score 17	DB 1	Length 17
Best Local Similarity	76.5%	Pred. No. 2.6e+02		
Matches 13	Conservative	4	Mismatches 0	Indels 0
			Gaps	0

Qy 359 ATTCTGCGGGAGCGCTG 375
| : | : | : | : | : | :
Dd 1 AUCUGCGGGAGCGCUG 17

RESULT 508
US-10-156-306-6849
; Sequence 6849, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: MCSwaggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 6849
; LENGTH: 17
; TYPE: RNA

; Sequence 6847, Application US/10156306
; Publication No. US20030119017A1

```

: APPLICANT: Ribozyme Pharmaceuticals, Inc.
:
: APPLICANT: McSwiggen, James
:
: TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
:
: TITLE OF INVENTION: Levels of IKK-Gamma and PKR
:
: FILE REFERENCE: MBHB01-664-A (400/050)
:
: CURRENT APPLICATION NUMBER: US/10/156,306
:
: CURRENT FILING DATE: 2002-05-28
:

```

```

; SOFTWARE: PATENTIN VERSION 3.0
; SEQ ID NO 6847
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens

```

```

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 358 GATTCTGCGGGAGCGCT 374
      ||:::|||||
Db 1 GAUUCUGCGGGAGGCGU 17

RESULT 507
US-10-156-306-6848
; Sequence 6848, Application US/10156306
; Publication No. US20030119017A1

```

, APPLICANT: Ribozyme Pharmaceuticals, Inc.
 , APPLICANT: McGraw-Hill
 , TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to HIV Infection
 , FILE REFERENCE: MBH01-664-A (400/050)
 , CURRENT APPLICATION NUMBER: US/10/156,306
 , CURRENT FILING DATE: 2002-05-28

```

; SOFTWARE: RACECLIN VERSION 3.0
; SEQ ID NO 6848
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens

```

```

US-10-156-306-6848
Query Match          2.3%;      Score 17;   DB 1;   Length 17;
Best Local Similarity 76.5%;    Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      359  ATTCTGCGGAGCGCTG  375
      ||::|||||||::|
Db       1  AUVUCGGGAGCGCUG  17

RESULT 508
US-10-156-306-6849
; Sequence 6849, Application US/10156306
; Publication No. US20030119017A1

```

/ CATION: Ribozyme Pharmaceuticals, Inc.
 / APPLICANT: Ribozyme Pharmaceuticals, Inc.
 / APPLICANT: McSwiggen, James
 / TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
 / TITLE OF INVENTION: Levels of IKK-Gamma and PKR
 / FILE REFERENCE: MBH01-664-A (400/050)
 / CURRENT APPLICATION NUMBER: US/10/156,306
 / CURRENT FILING DATE: 2002-05-28

```

? SOFTWARE: Patencin version 3.0
? SEQ ID NO 6849
? LENGTH: 17
? TYPE: RNA
?

```

```
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6852
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6852

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 372 GCTGCGAGGAGCTTCTG 388
Db 1 GCUGCGAGGAGCUUCUG 17

RESULT 512
US-10-156-306-6853
; Sequence 6853, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6853
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6853

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 398 GCCAGCCAGAGGGAGGA 414
Db 1 GCCAGCCAGAGGGAGGA 17

RESULT 513
US-10-156-306-6854
; Sequence 6854, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6854
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
```

```
US-10-156-306-6854

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 400 CAGCCAGAGGGAGGAGA 416
Db 1 CAGCCAGAGGGAGGAGA 17

RESULT 514
US-10-156-306-6855
; Sequence 6855, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6855
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6855

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 401 AGCCAGAGGGAGGAGAA 417
Db 1 AGCCAGAGGGAGGAGAA 17

RESULT 515
US-10-156-306-6856
; Sequence 6856, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6856
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6856

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 402 GCCAGAGGGAGGAGAAG 418
Db 1 GCCAGAGGGAGGAGAAG 17

RESULT 516
US-10-156-306-6857
; Sequence 6857, Application US/10156306
; Publication No. US20030119017A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6857
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6857

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 404 CAGAGGGAGGAGGAGGA 420
      |||||
Db 1 CAGAGGGAGGAGGAGGA 17

RESULT 517
US-10-156-306-6858
; Sequence 6858, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6858
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6858

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 405 AGAGGGAGGAGGAGGAG 421
      |||||
Db 1 AGAGGGAGGAGGAGGAG 17

RESULT 518
US-10-156-306-6859
; Sequence 6859, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6859
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6859
```

```
Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 407 AGGGAGGAGGAGGAGTT 423
      |||||
Db 1 AGGGAGGAGGAGGAGGUU 17

RESULT 519
US-10-156-306-6860
; Sequence 6860, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6860
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6860

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 410 GAGGAGGAGGAGGTTCT 426
      |||||
Db 1 GAGGAGGAGGAGGUCCU 17

RESULT 520
US-10-156-306-6861
; Sequence 6861, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6861
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6861

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 411 AGGAGAGGAGGTTCTC 427
      |||||
Db 1 AGGAGAGGAGGUCCUC 17

RESULT 521
US-10-156-306-6862
; Sequence 6862, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
```

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MH801-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6862
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6862

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 434 AAGTCCAGGAGGCCAG 450
|||:|||||
Db 1 AGUCCAGGAGGCCAG 17

RESULT 522

US-10-156-306-6863
; Sequence 6863, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MH801-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6863
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6863

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 435 AGTTCAGGAGGCCAGG 451
|||:|||||
Db 1 AGUCCAGGAGGCCAGG 17

RESULT 523

US-10-156-306-6864
; Sequence 6864, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MH801-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6864
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6864

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 437 TTCCAGGAGGCCAGGAA 453
|||:|||||
Db 1 UUCCAGGAGGCCAGGAA 17

RESULT 524

US-10-156-306-6865
; Sequence 6865, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MH801-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6865
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6865

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 442 GGAGGCCAGGAACTGG 458
|||:|||||
Db 1 GGAGGCCAGGAACTGG 17

RESULT 525

US-10-156-306-6866
; Sequence 6866, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MH801-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6866
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6866

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 443 GAGGCCAGGAACTGGT 459
|||:|||||
Db 1 GAGGCCAGGAACTGGT 17

RESULT 526

US-10-156-306-6867
; Sequence 6867, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

```
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6867
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6867

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 449 AGGAACTGCTGGAGAG 465
      |||||:|||||
Db 1 AGGAACTGCTGGAGAG 17

RESULT 527
US-10-156-306-6868
; Sequence 6868, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6868
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6868

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 452 AAACGTGCTGGAGACT 468
      |||||:|||||
Db 1 AAACGTGCTGGAGACT 17

RESULT 528
US-10-156-306-6869
; Sequence 6869, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6869
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6869

Query Match      2.3%; Score 17; DB 1; Length 17;
```

```
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 453 AACTGCTGGAGACTC 469
      |||||:|||||
Db 1 AACUGGUGGAGAGACUC 17

RESULT 529
US-10-156-306-6870
; Sequence 6870, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6870
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6870

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 455 CTGGTGGAGACTCGG 471
      |||||:|||||
Db 1 CUGGUGGAGAGACUCGG 17

RESULT 530
US-10-156-306-6871
; Sequence 6871, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6871
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6871

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 457 GGTGGAGAGACTCGGCC 473
      |||||:|||||
Db 1 GGUGGAGAGACUCGGCC 17

RESULT 531
US-10-156-306-6872
; Sequence 6872, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
```

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
 ; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
 ; FILE REFERENCE: MBHB01-664-A (400/050)
 ; CURRENT APPLICATION NUMBER: US/10/156,306
 ; CURRENT FILING DATE: 2002-05-28
 ; NUMBER OF SEQ ID NOS: 8013
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 6872
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-156-306-6872
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.6e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 Qy 462 AGAGACTCGGCTGGAG 478
 Db 1 AGAGACUCCGCGGAG 17
 RESULT 532
 US-10-156-306-6873
 ; Sequence 6873, Application US/10156306
 ; Publication No. US20030119017A1
 ; GENERAL INFORMATION:
 ; APPLICANT: McSwiggen, James
 ; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
 ; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
 ; FILE REFERENCE: MBHB01-664-A (400/050)
 ; CURRENT APPLICATION NUMBER: US/10/156,306
 ; CURRENT FILING DATE: 2002-05-28
 ; NUMBER OF SEQ ID NOS: 8013
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 6873
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-156-306-6873
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.6e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 Qy 467 CTCGGCTGGAGAGCT 483
 Db 1 CUCGGCCUGGAGAGCU 17
 RESULT 533
 US-10-156-306-6874
 ; Sequence 6874, Application US/10156306
 ; Publication No. US20030119017A1
 ; GENERAL INFORMATION:
 ; APPLICANT: McSwiggen, James
 ; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
 ; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
 ; FILE REFERENCE: MBHB01-664-A (400/050)
 ; CURRENT APPLICATION NUMBER: US/10/156,306
 ; CURRENT FILING DATE: 2002-05-28
 ; NUMBER OF SEQ ID NOS: 8013
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 6874
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-156-306-6874
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.6e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Matches	14;	Conservative	3;	Mismatches	0;	Indels	0;	Gaps	0;
Qy	468	TCGGCTGGAGAAGCTC	484						
		: :							
Db	1	UCGCCUGGAGAAGCUC	17						
RESULT 534									
US-10-156-306-6875									
; Sequence 6875, Application US/10156306									
; Publication No. US20030119017A1									
; GENERAL INFORMATION:									
; APPLICANT: Ribozyme Pharmaceuticals, Inc.									
; APPLICANT: McSwiggen, James									
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related									
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related									
; FILE REFERENCE: MH01-664-A (400/050)									
; CURRENT APPLICATION NUMBER: US/10/156,306									
; CURRENT FILING DATE: 2002-05-28									
; NUMBER OF SEQ ID NOS: 8013									
; SOFTWARE: PatentIn version 3.0									
; SEQ ID NO 6875									
; LENGTH: 17									
; TYPE: RNA									
; ORGANISM: Homo sapiens									
US-10-156-306-6875									
Query Match 2.3%; Score 17; DB 1; Length 17;									
Best Local Similarity 88.2%; Pred. No. 2.6e+02;									
Matches	15;	Conservative	2;	Mismatches	0;	Indels	0;	Gaps	0;
Qy	470	GGCCTGGAGAAGCTCGA	486						
		: :							
Db	1	GGCCUGGAGAAGCUGA	17						
RESULT 535									
US-10-156-306-6876									
; Sequence 6876, Application US/10156306									
; Publication No. US20030119017A1									
; GENERAL INFORMATION:									
; APPLICANT: Ribozyme Pharmaceuticals, Inc.									
; APPLICANT: McSwiggen, James									
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related									
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related									
; FILE REFERENCE: MH01-664-A (400/050)									
; CURRENT APPLICATION NUMBER: US/10/156,306									
; CURRENT FILING DATE: 2002-05-28									
; NUMBER OF SEQ ID NOS: 8013									
; SOFTWARE: PatentIn version 3.0									
; SEQ ID NO 6876									
; LENGTH: 17									
; TYPE: RNA									
; ORGANISM: Homo sapiens									
US-10-156-306-6876									
Query Match 2.3%; Score 17; DB 1; Length 17;									
Best Local Similarity 82.4%; Pred. No. 2.6e+02;									
Matches	14;	Conservative	3;	Mismatches	0;	Indels	0;	Gaps	0;
Qy	477	AGAAAGTCGATCTGAAG	493						
		: :							
Db	1	AGAAAGCUGAUCUGAAG	17						
RESULT 536									
US-10-156-306-6877									
; Sequence 6877, Application US/10156306									
; Publication No. US20030119017A1									
; GENERAL INFORMATION:									
; APPLICANT: Ribozyme Pharmaceuticals, Inc.									
; APPLICANT: McSwiggen, James									
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related									

Query Match	2.3%	Score 17;	DB 1;	Length 17;
Best Local Similarity	82.4%;	Pred. No. 2.6e+02;		

; AFFILIANT: KIDZYMED PHARMACEUTICALS, INC.
 ; APPLICANT: McSwiggen, James
 ; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels

Query Match	2.3%	Score 17;	DB 1;	Length 17;
Best Local Similarity	88.2%;	Pred. No. 2.6e+02;		
Matches 15;	Conservative	2;	Mismatches 0;	Indels 0;
			Gaps	0;

RESULT 541
US-10-136-306-6882
; Sequence 6882, Application US/10156306
; Publication No. US2003019017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid
; TITLE OF INVENTION: Levels of IKK-Gamma

; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6882
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6882

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 495 GCGAGGAGGAGGAGGCT 511
|||:|||||:|||||:
Db 1 GCGAGGAGGAGGAGGCU 17

RESULT 542
US-10-156-306-6883
; Sequence 6883, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6883
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6883

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 500 AAGGAGCAGGCTCTGGC 516
|||||:|||||:|||||:
Db 1 AAGGAGCAGGCTCTGGC 17

RESULT 543
US-10-156-306-6884
; Sequence 6884, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6884
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6884

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 508 GGCTCTCGGGAGGTGG 524
|||:|||||:|||||:
Db 1 GGCUCUGCGGAGGUGG 17

RESULT 544
US-10-156-306-6885
; Sequence 6885, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6885
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6885

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 509 GCTCTCGGGAGGTGGA 525
|||:|||||:|||||:
Db 1 GCUCUGCGGAGGUGGA 17

RESULT 545
US-10-156-306-6886
; Sequence 6886, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6886
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6886

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 510 CTCTCGGGAGGTGGAG 526
|||:|||||:|||||:
Db 1 CUCUGCGGAGGUGGAG 17

RESULT 546
US-10-156-306-6887
; Sequence 6887, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6887
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6887

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 512 CTGCGGAGGTGGAGCA 528
|:|||||:|||||:
Db 1 CUGCGGAGGUGGAGCA 17

RESULT 547
US-10-156-306-6888
; Sequence 6888, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6888
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6888

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 515 CGGAGGTGGAGCACT 531
|||||:|||||:
Db 1 CGGAGGUGGAGCACCU 17

RESULT 548
US-10-156-306-6889
; Sequence 6889, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6889
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6889

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 516 GGGAGGTGGAGCACTG 532

Db 1 GGGAGGUGGAGCACCU 17
|||||:|||||:|

RESULT 549
US-10-156-306-6890
; Sequence 6890, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6890
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6890

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 524 GAGCACTGAGAGATG 540
|||||:|||||:
Db 1 GAGCACCUAGAGAG 17

RESULT 550
US-10-156-306-6891
; Sequence 6891, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6891
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6891

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 527 CACCTGAGAGATGCCA 543
|||||:|||||:
Db 1 CACCUAGAGAGAGCCA 17

RESULT 551
US-10-156-306-6892
; Sequence 6892, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6892
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6892

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 529 CCTGAAGAGATGCCAGC 545
||:|||||:|||||
Db 1 CCUGAAGAGAUCCAGC 17

RESULT 552
US-10-156-306-6893
; Sequence 6893, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6893
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6893

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 542 CAGCAGCAGATGGCTGA 558
|||||||:|||||
Db 1 CAGCAGCAGAUCCUGA 17

RESULT 553
US-10-156-306-6894
; Sequence 6894, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6894
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6894

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 545 CAGCAGATGGCTGAGGA 561
|||||||:|||||

Db 1 CAGCAGAUCCUGAGGA 17
RESULT 554
US-10-156-306-6895
; Sequence 6895, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6895
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6895

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 549 AGATGGCTGAGGACAAG 565
|||||:|||||
Db 1 AGAUGGUGAGGACAAG 17

RESULT 555
US-10-156-306-6896
; Sequence 6896, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6896
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6896

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 551 ATGGCTGAGGACAAGGC 567
||:|||||:|||||
Db 1 AUGGUGAGGACAAGGC 17

RESULT 556
US-10-156-306-6897
; Sequence 6897, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6897
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6897

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 552 TGCCTGAGGACCAAGGCC 568
:||||:||||:||||:||||:
DB 1 UGCUGAGGACCAAGGCC 17

RESULT 557

US-10-156-306-6898
; Sequence 6898, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6898
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6898

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 557 GAGGACAAGCCCTCTCT 573
:||||:||||:||||:||||:
DB 1 GAGGACAAGCCUCUCU 17

RESULT 558

US-10-156-306-6899
; Sequence 6899, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6899
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6899

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 566 GCCTCTGTGAAGCCCA 582
:||||:||||:||||:||||:
DB 1 GCCUCUGAAGCCCA 17

RESULT 559

US-10-156-306-6900
; Sequence 6900, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6900
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6900

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 575 AAAGCCCAGGTGACGTC 591
:||||:||||:||||:||||:
DB 1 AAAGCCCAGGUGACGUC 17

RESULT 560

US-10-156-306-6901
; Sequence 6901, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6901
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6901

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 578 GCCCAGGTGACGTCCTT 594
:||||:||||:||||:||||:
DB 1 GCCCAGGUGACGUCU 17

RESULT 561

US-10-156-306-6902
; Sequence 6902, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6902
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6902

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 591 CCTGTCTCGGGAGCTG 607
||::||::||::||::||::||
Db 1 CCUUGCUCGGGAGCUG 17

RESULT 562
US-10-156-306-6903
; Sequence 6903, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6903
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6903

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 592 CTTGCTCGGGAGCTGC 608
||::||::||::||::||::||
Db 1 CUUGCUCGGGAGCUG 17

RESULT 563
US-10-156-306-6904
; Sequence 6904, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6904
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6904

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 593 TTGCTCGGGAGCTGCA 609
||::||::||::||::||::||
Db 1 UUGCUCGGGAGCUGCA 17

RESULT 564
US-10-156-306-6905
; Sequence 6905, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6905
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6905

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 594 TGCTCGGGAGCTGCAG 610
||::||::||::||::||::||
Db 1 UGCUCGGGAGCUGCAG 17

RESULT 565
US-10-156-306-6906
; Sequence 6906, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6906
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6906

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 602 GAGCTGCAGGAGGCCA 618
||::||::||::||::||::||
Db 1 GAGCUCGAGGAGGCCA 17

RESULT 566
US-10-156-306-6907
; Sequence 6907, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0

```
; SEQ ID NO 6907
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6907

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 603 AGCTGCAGGAGCCGAG 619
Db 1 AGCUGCAGGAGCCGAG 17

RESULT 567
US-10-156-306-6908
; Sequence 6908, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6908
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6908

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 605 CTGCAGGAGCCGAG 621
Db 1 CUGCAGGAGCCGAG 17

RESULT 568
US-10-156-306-6909
; Sequence 6909, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6909
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6909

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 611 GAGAGCCAGGCGCTT 627
Db 1 GAGAGCCAGGCGCTT 17
```

```
RESULT 569
US-10-156-306-6910
; Sequence 6910, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6910
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6910

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 620 AGTCGCTTGAGGCTGC 636
Db 1 AGUCGCUUGGAGGCTGC 17

RESULT 570
US-10-156-306-6911
; Sequence 6911, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6911
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6911

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 621 GTCGCTTGAGGCTGCC 637
Db 1 GUCGCUUGGAGGCTGCC 17

RESULT 571
US-10-156-306-6912
; Sequence 6912, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6912
```

```
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6912

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 623 CGCTGGAGGCTCCAC 639
    |||:|||||:|||||
Db 1 CGCUGGAGGCUGCCAC 17

RESULT 572
US-10-156-306-6913
; Sequence 6913, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6913
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6913

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 635 GCCACTAAGGAATGCCA 651
    |||:|||||:|||||
Db 1 GCCACUAGGAUGCCA 17

RESULT 573
US-10-156-306-6914
; Sequence 6914, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6914
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6914

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 650 CAGGCTCTGGAGGTCG 666
    |||:|||||:|||||
Db 1 CAGGCUCUGGAGGUGCG 17

RESULT 576
US-10-156-306-6917
; Sequence 6917, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6917
; LENGTH: 17
```

```
US-10-156-306-6915
; Sequence 6915, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6915
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6915

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 644 GAATGCCAGGCTCTCGA 660
    |||:|||||:|||||
Db 1 GAAUGCCAGGCUCUGGA 17

RESULT 575
US-10-156-306-6916
; Sequence 6916, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6916
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6916

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 650 CAGGCTCTGGAGGTCG 666
    |||:|||||:|||||
Db 1 CAGGCUCUGGAGGUGCG 17

RESULT 576
US-10-156-306-6917
; Sequence 6917, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6917
; LENGTH: 17
```

```
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6917

Query Match
Best Local Similarity 2.3%; Score 17; DB 1; Length 17;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 651 AGGCTCTGAGGTCGG 667
||||:|||||:||||
Db 1 AGGCUCGAGGGGCGGC 17

RESULT 577
US-10-156-306-6918
; Sequence 6918, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6918
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6918

Query Match
Best Local Similarity 2.3%; Score 17; DB 1; Length 17;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 653 GCTCTGAGGTCGGGC 669
|||:|||||:||||
Db 1 GCUCUGAGGGGCGGC 17

RESULT 578
US-10-156-306-6919
; Sequence 6919, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6919
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6919

Query Match
Best Local Similarity 2.3%; Score 17; DB 1; Length 17;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 654 CTCTGAGGTCGGGC 670
|:|||||:||||
Db 1 CUCUGAGGGGCGGC 17

RESULT 579
US-10-156-306-6920
```

```
; Sequence 6920, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6920
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6920

Query Match
Best Local Similarity 2.3%; Score 17; DB 1; Length 17;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 658 GGAGGTCGGGCCGGG 674
|||||:|||||:||||
Db 1 GGAGGUCGGGCCGGG 17

RESULT 580
US-10-156-306-6921
; Sequence 6921, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6921
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6921

Query Match
Best Local Similarity 2.3%; Score 17; DB 1; Length 17;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 659 GAGGTCGGGCCGGGC 675
|||||:|||||:||||
Db 1 GAGGUCGGGCCGGGC 17

RESULT 581
US-10-156-306-6922
; Sequence 6922, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6922
; LENGTH: 17
; TYPE: RNA
```



```
; ORGANISM: Homo sapiens
US-10-156-306-6922

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 17; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 664 TCGGGCCCGGGCGGCCA 680
      :|||||
Db 1 UCGGGCCCGGGCGGCCA 17

RESULT 582
US-10-156-306-6923
; Sequence 6923, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6923
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6923

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 665 CGGGCCCGGGCGGCCAG 681
      :|||||
Db 1 CGGGCCCGGGCGGCCAG 17

RESULT 583
US-10-156-306-6924
; Sequence 6924, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6924
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6924

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 668 GCCCGGGCGGCCAGCCA 684
      :|||||
Db 1 GCCCGGGCGGCCAGCCA 17

RESULT 584
US-10-156-306-6925
; Sequence 6925, Application US/10156306
```

```
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6925
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6925

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 675 CGGCCAGCGCAGCGCG 691
      :|||||
Db 1 CGGCCAGCGCAGCGCG 17

RESULT 585
US-10-156-306-6926
; Sequence 6926, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6926
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6926

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 680 AGCGAGCAGCGCGGCA 696
      :|||||
Db 1 AGCGAGCAGCGCGGCA 17

RESULT 586
US-10-156-306-6927
; Sequence 6927, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6927
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
```

US-10-156-306-6927

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 685 GCAGCGCGCGCAGCTGG 701
|||||:|||||:|||||
Db 1 GCAGGCGCGCAGCUGG 17

RESULT 587

US-10-156-306-6928
; Sequence 6928, Application US/10156306
; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 6928

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-6928

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 692 CGGCAGCTCGAGAGTGA 708
|||||:|||||:|||||
Db 1 CGGCAGCUGGAGAGUGA 17

RESULT 588

US-10-156-306-6929
; Sequence 6929, Application US/10156306
; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 6929

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-6929

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 693 GGCAGCTCGAGAGTGA 709
|||||:|||||:|||||
Db 1 GGCAGCUGGAGAGUGA 17

RESULT 589

US-10-156-306-6930
; Sequence 6930, Application US/10156306
; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 6930

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-6930

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 695 CAGCTGGAGAGTGAGCG 711
|||||:|||||:|||||
Db 1 CAGCUGGAGAGUGAGCG 17

RESULT 590

US-10-156-306-6931

; Sequence 6931, Application US/10156306

; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 6931

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-6931

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 699 TGGAGAGTGAGCGCGAG 715
|||||:|||||:|||||
Db 1 UGGAGAGUGAGCGCGAG 17

RESULT 591

US-10-156-306-6932

; Sequence 6932, Application US/10156306

; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 6932

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-6932

```
Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 705 GTGAGCGGAGGCGCTG 721
Db 1 GUGAGCGGAGGCGCUG 17

RESULT 592
US-10-156-306-6933
; Sequence 6933, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6933
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6933

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 707 GAGCGGAGGCGGTGCA 723
Db 1 GAGCGGAGGCGGUGCA 17

RESULT 593
US-10-156-306-6934
; Sequence 6934, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6934
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6934

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 734 AGCGTGCGAGTGACCA 750
Db 1 AGCGUGCAGGUGGACCA 17

RESULT 594
US-10-156-306-6935
; Sequence 6935, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6935
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6935

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 737 GTGCGAGTGGACCACTG 753
Db 1 GUGCAGGUGGACCACTG 17

RESULT 595
US-10-156-306-6936
; Sequence 6936, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6936
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6936

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 738 TGCAGGTGGACCACTG 754
Db 1 UGCAGGUGGACCACTG 17

RESULT 596
US-10-156-306-6937
; Sequence 6937, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6937
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6937
```

```

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 755 CGCATCGAGGCGCCAGAG 771
DB 1 CGCAUGCAGGCGCCAGAG 17

RESULT 597
US-10-156-306-6938
; Sequence 6938, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6938
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6938

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 756 GCATCGAGGCGCCAGAGC 772
DB 1 GCAUGCAGGCGCCAGAGC 17

RESULT 598
US-10-156-306-6939
; Sequence 6939, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6939
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6939

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 761 CAGGCGCCAGAGCGTGA 777
DB 1 CAGGCGCCAGAGCGUGA 17

RESULT 599
US-10-156-306-6940
; Sequence 6940, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

```

```

; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6940
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6940

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 767 CAGAGCGTGAGGCGCGC 783
DB 1 CAGAGCGUGAGGCGCGC 17

RESULT 600
US-10-156-306-6941
; Sequence 6941, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6941
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6941

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 768 AGAGCGTGAGGCGCGC 784
DB 1 AGAGCGUGAGGCGCGC 17

RESULT 601
US-10-156-306-6942
; Sequence 6942, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6942
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6942

Query Match          2.3%; Score 17; DB 1; Length 17;

```

Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 770 AGCGTGGAGCGCGCT 786
Db 1 AGCGUGGAGCGCGCU 17

RESULT 602

US-10-156-306-6943
; Sequence 6943, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6943
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6943

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 785 CTCGCATGGAGCGCCA 801
Db 1 CUCCGAUGGAGCGCCA 17

RESULT 603

US-10-156-306-6944
; Sequence 6944, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6944
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6944

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 786 TCCGCATGGAGCGCCAG 802
Db 1 UCCGCAUGGAGCGCCAG 17

RESULT 604

US-10-156-306-6945
; Sequence 6945, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6945
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6945

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 794 GAGCGCCAGCGCGCTC 810
Db 1 GAGCGCCAGCGCGCTC 17

RESULT 605

US-10-156-306-6946
; Sequence 6946, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6946
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6946

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 803 GCGCGCTCGAGGAGAA 819
Db 1 GCGCGCTCGAGGAGAA 17

RESULT 606

US-10-156-306-6947
; Sequence 6947, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6947
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6947

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;

```
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 804 CCGCTCGGAGGAGAG 820
      |||||:|||||
Db 1 CCGCCUGGAGGAGAG 17

RESULT 607
US-10-156-306-6948
; Sequence 6948, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6948
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6948

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 806 GCCTCGGAGGAGAGAG 822
      |||||:|||||
Db 1 GCUCUGGAGGAGAGAG 17

RESULT 608
US-10-156-306-6949
; Sequence 6949, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6949
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6949

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 807 CCTCGGAGGAGAGAGG 823
      |||||:|||||
Db 1 CCUCUGGAGGAGAGAGG 17

RESULT 609
US-10-156-306-6950
; Sequence 6950, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
```

```
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6950
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6950

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 809 TCGGAGGAGAGAGGAA 825
      |||||:|||||
Db 1 UCGGAGGAGAGAGGAA 17

RESULT 610
US-10-156-306-6951
; Sequence 6951, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6951
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6951

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 812 GAGGAGAGAGAGAGCT 828
      |||||:|||||
Db 1 GAGGAGAGAGAGAGCU 17

RESULT 611
US-10-156-306-6952
; Sequence 6952, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6952
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6952

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 813 GAGGAGAGAGAGAGCT 829
      |||||:|||||
Db 1 GAGGAGAGAGAGAGCU 17

RESULT 612
US-10-156-306-6953
; Sequence 6953, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6953
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6953

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

```

QY 814 GGAGAGGAGGAGCTGG 830
      |||||
Db 1 GGAGAGGAGGAGGCGG 17

RESULT 612
US-10-156-306-6953
; Sequence 6953, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6953
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6953

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 815 GAGAGGAGGAGCTGGC 831
      |||||
Db 1 GAGAGGAGGAGGCTGGC 17

RESULT 613
US-10-156-306-6954
; Sequence 6954, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6954
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6954

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 821 AGGAGCTGGCCGAGTT 837
      |||||
Db 1 AGGAGCTGGCCGAGUU 17

RESULT 614
US-10-156-306-6955
; Sequence 6955, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to

```

```

; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6955
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6955

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 833 CAGTTGCAGGTGGCCTA 849
      |||||
Db 1 CAGUUGCAGGUGGCCUA 17

RESULT 615
US-10-156-306-6956
; Sequence 6956, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6956
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6956

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 836 TTGCAGGTGGCCTATCA 852
      |||||
Db 1 UTGACAGGUGGCCUAUA 17

RESULT 616
US-10-156-306-6957
; Sequence 6957, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6957
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6957

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

```

QY 858 TCTTCAGACATACGAC 874
:|:|||||:|||||
DB 1 UCUUCCAAGAAUACGAC 17

RESULT 617

US-10-156-306-6958
; Sequence 6958, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 6958

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-6958

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 94.1%; Pred. No. 2.6e+02;

Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 864 AAGATACGACCAACCAC 880

|||||:|||||

DB 1 AAGAAUACGACCAACCAC 17

RESULT 618

US-10-156-306-6959
; Sequence 6959, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 6959

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-6959

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.6e+02;

Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 878 CACATCAGACGCGT 894

|||||:|||||

DB 1 CACAUCAGAGCGCGU 17

RESULT 619

US-10-156-306-6960
; Sequence 6960, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6960
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6960

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.6e+02;

Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 887 AGCAGCGTGGTGGCAG 903

|||||:|||||

DB 1 AGCAGCGUGGGCGAC 17

RESULT 620

US-10-156-306-6961
; Sequence 6961, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 6961

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-6961

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 2.6e+02;

Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 890 AGCGTGGTGGCAGTGA 906

|||||:|||||

DB 1 AGCGUGGUGGGCAGUGA 17

RESULT 621

US-10-156-306-6962
; Sequence 6962, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 6962

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-6962

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 2.6e+02;

Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 891 GCGTGGTGGCAGTGAG 907


```

Db      1 GCGUGGUGGCGAGGAG 17
||||:|:|||||:|:|
; PRIOR APPLICATION NUMBER: JP 2001-281992
; PRIOR FILING DATE: 2001-09-17
; PRIOR APPLICATION NUMBER: JP 2001-306873
; PRIOR FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: JP 2002-113279
; PRIOR FILING DATE: 2002-04-16
; NUMBER OF SEQ ID NOS: 42
; SEQ ID NO 12
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer F1 for sequencing
US-10-490-080-12

Query Match      2.2%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 3.6e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      423 TCCTCATGTGCAAGTTCAG 442
|||||:|:|||||:|:|
Db      20 TCCTCTTGTGCAGGTTCAG 1

RESULT 625
US-10-490-080-18
; Sequence 18, Application US/10490080
; Publication No. US20040253597A1
; GENERAL INFORMATION:
; APPLICANT: Takeda Chemical Industries, Ltd.
; TITLE OF INVENTION: Novel Protein and its DNA
; FILE REFERENCE: P02-0109PCT
; CURRENT APPLICATION NUMBER: US/10/490,080
; CURRENT FILING DATE: 2004-03-17
; PRIOR APPLICATION NUMBER: JP 2001-281992
; PRIOR FILING DATE: 2001-09-17
; PRIOR APPLICATION NUMBER: JP 2001-306873
; PRIOR FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: JP 2002-113279
; PRIOR FILING DATE: 2002-04-16
; NUMBER OF SEQ ID NOS: 42
; SEQ ID NO 18
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer R1 for sequencing
US-10-490-080-18

Query Match      2.2%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 3.6e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      423 TCCTCATGTGCAAGTTCAG 442
|||||:|:|||||:|:|
Db      2 TCCTCTTGTGCAGGTTCAG 21

RESULT 626
US-10-751-736-18624/c
; Sequence 18624, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000

```

```

Db      1 GCGUGGUGGCGAGGAG 17
||||:|:|||||:|:|
; PRIOR APPLICATION NUMBER: JP 2001-281992
; PRIOR FILING DATE: 2001-09-17
; PRIOR APPLICATION NUMBER: JP 2001-306873
; PRIOR FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: JP 2002-113279
; PRIOR FILING DATE: 2002-04-16
; NUMBER OF SEQ ID NOS: 42
; SEQ ID NO 12
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer F1 for sequencing
US-10-490-080-12

Query Match      2.2%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 3.6e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      423 TCCTCATGTGCAAGTTCAG 442
|||||:|:|||||:|:|
Db      20 TCCTCTTGTGCAGGTTCAG 1

RESULT 625
US-10-490-080-18
; Sequence 18, Application US/10490080
; Publication No. US20040253597A1
; GENERAL INFORMATION:
; APPLICANT: Takeda Chemical Industries, Ltd.
; TITLE OF INVENTION: Novel Protein and its DNA
; FILE REFERENCE: P02-0109PCT
; CURRENT APPLICATION NUMBER: US/10/490,080
; CURRENT FILING DATE: 2004-03-17
; PRIOR APPLICATION NUMBER: JP 2001-281992
; PRIOR FILING DATE: 2001-09-17
; PRIOR APPLICATION NUMBER: JP 2001-306873
; PRIOR FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: JP 2002-113279
; PRIOR FILING DATE: 2002-04-16
; NUMBER OF SEQ ID NOS: 42
; SEQ ID NO 18
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer R1 for sequencing
US-10-490-080-18

Query Match      2.2%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 3.6e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      423 TCCTCATGTGCAAGTTCAG 442
|||||:~|:|||||:~|:~|
Db      1 UCAGCCUGGAGAGCUGGAU 20

RESULT 624
US-10-490-080-12/c
; Sequence 12, Application US/10490080
; Publication No. US20040253597A1
; GENERAL INFORMATION:
; APPLICANT: Takeda Chemical Industries, Ltd.
; TITLE OF INVENTION: Novel Protein and its DNA
; FILE REFERENCE: P02-0109PCT
; CURRENT APPLICATION NUMBER: US/10/490,080
; CURRENT FILING DATE: 2004-03-17

```

```
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18624
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-18624

Query Match          2.2%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 3.6e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 166 GAAGACCAACTGTGTGAGA 185
DB 21 GAAGAGTCACCTGTGTGAGA 2

RESULT 627
US-10-751-736-49885
; Sequence 49885, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 49885
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-49885

Query Match          2.2%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 3.6e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 518 GAGGTGGAGCACTGAAGAG 537
DB 1 GAGGTGGAGCAGATGAAGAG 20

RESULT 628
US-10-751-736-9649/c
; Sequence 9649, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9649
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
```

```
US-10-751-736-9649

Query Match          2.2%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 4e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 377 GAGGAGCTTCTGCATTTC 394
DB 21 GAGGAACCTCTGCATTTC 4

RESULT 629
US-10-751-736-9650/c
; Sequence 9650, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9650
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-9650

Query Match          2.2%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 4e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 377 GAGGAGCTTCTGCATTTC 394
DB 19 GAGGAACCTCTGCATTTC 2

RESULT 630
US-10-786-720-11196/c
; Sequence 11196, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11196
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-antisense strand
US-10-786-720-11196

Query Match          2.1%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 4.2e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 466 ACTCGGCTCTGGAGAGCTCGA 486
DB 21 AATCAGCCTGGAGAGCTGGA 1
```

```
RESULT 631
US-10-751-736-39475/c
; Sequence 39475, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 39475
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-39475

Query Match      2.1%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 4.2e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 440 CAGAGCCGAGGAAGTGGTG 460
      ||||| | ||||| |||||
DB 21 CAGGAAGTGAGGAAGTGGTG 1

RESULT 632
US-10-751-736-39478/c
; Sequence 39478, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 39478
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-39478

Query Match      2.1%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 4.2e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 437 TTCAGGAGCCGAGGAACGTG 457
      ||||| | ||||| |||||
DB 21 TTCAGGAAGTGAGGAACGTG 1

RESULT 633
US-10-156-306-6813
; Sequence 6813, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
```

```
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6813
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6813

Query Match      2.1%; Score 16; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.4e+02;
Matches 13; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 162 TCTGGAAGAGCCAACT 177
      :||:||||| |||||
DB 2 UCUGGAAGAGCCAAACU 17

RESULT 634
US-10-156-306-6964
; Sequence 6964, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6964
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6964

Query Match      2.1%; Score 16; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3.4e+02;
Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 901 CAGTGAGCGGAAGCGA 916
      |||:||||| |||||
DB 1 CAGUGAGCGGAAGCGA 16

RESULT 635
US-10-224-836-290
; Sequence 290, Application US/10224836
; Publication No. US20030082598A1
; GENERAL INFORMATION:
; APPLICANT: Ecker, David J.
; TITLE OF INVENTION: Molecular Interaction Sites Of 23S Ribosomal RNA And Methods Of
; FILE REFERENCE: IBIS0402
; CURRENT APPLICATION NUMBER: US/10/224,836
; CURRENT FILING DATE: 2002-08-20
; PRIOR APPLICATION NUMBER: 60/314,251
; PRIOR FILING DATE: 2001-08-22
; NUMBER OF SEQ ID NOS: 327
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 290
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-224-836-290
```

```

Query Match          2.1%; Score 15.8; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.1e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 652 GGCTCTGGAGGTCGGGCC 670
Db 1 GGCGGAGGCGCGCGGCC 19

RESULT 636
US-10-670-011-56
; Sequence 56, Application US/10670011
; Publication No. US20040209832A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/132 (MEHB02-742-G)
; CURRENT APPLICATION NUMBER: US/10/670,011
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US60/440,129
; PRIOR FILING DATE: 2003-01-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 427
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 56
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense re
US-10-670-011-56

Query Match          2.1%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 701 GAGAGTGAGCGCGAGCGGC 719
Db 1 GAGAGGAGCGCGAGCGGC 19

RESULT 637
US-10-670-011-152/c
; Sequence 152, Application US/10670011
; Publication No. US20040209832A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela

```

```

; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/132 (MEHB02-742-G)
; CURRENT APPLICATION NUMBER: US/10/670,011
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US60/440,129
; PRIOR FILING DATE: 2003-01-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 427
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 152
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
US-10-670-011-152

Query Match          2.1%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 701 GAGAGTGAGCGCGAGCGGC 719
Db 19 GAGAGGAGCGCGAGCGGC 1

RESULT 638
US-10-764-957-56
; Sequence 56, Application US/10764957
; Publication No. US20050054596A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Pavco, Pamela
; APPLICANT: Beigelman, Leo
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/144 (MEHB02-742-O)
; CURRENT APPLICATION NUMBER: US/10/764,957
; CURRENT FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US60/386,782
; PRIOR FILING DATE: 2002-06-06

```

```
; PRIOR APPLICATION NUMBER: US60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US60/408,378
; PRIOR FILING DATE: 2002-09-05
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 473
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 56
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense region
US-10-764-957-56

Query Match      2.1%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 701 GAGAGTGCAGCGCGAGCGC 719
Db 1 GAGAGGAGCGCGAGCGCGC 19

RESULT 639
US-10-764-957-152/c
; Sequence 152, Application US/10764957
; Publication No. US20050054596A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; APPLICANT: Pavco, Pamela
; APPLICANT: Beigelman, Leo
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/144 (MBHB02-742-0)
; CURRENT APPLICATION NUMBER: US/10764,957
; CURRENT FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US60/408,378
; PRIOR FILING DATE: 2002-09-05
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 473
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 152
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-764-957-152
```

```
Query Match      2.1%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 701 GAGAGTGCAGCGCGAGCGC 719
Db 19 GAGAGGAGCGCGAGCGCGC 1

RESULT 640
US-10-083-720A-10
; Sequence 10, Application US/10083720A
; Publication No. US20030073199A1
; GENERAL INFORMATION:
; APPLICANT: de Waal Malefyt, Rene
; APPLICANT: Fickenscher, Helmut
; APPLICANT: Fleckenstein, Bernhard
; APPLICANT: Knappe, Andrea
; TITLE OF INVENTION: MAMMALIAN CYTOKINE; RELATED REAGENTS
; FILE REFERENCE: DX0644KBK
; CURRENT APPLICATION NUMBER: US/10/083,720A
; CURRENT FILING DATE: 2002-02-28
; PRIOR APPLICATION NUMBER: 09/363,993
; PRIOR FILING DATE: 1999-07-29
; PRIOR APPLICATION NUMBER: 08/934,959
; PRIOR FILING DATE: 1997-09-22
; PRIOR APPLICATION NUMBER: 60/345,690
; PRIOR FILING DATE: 2002-01-03
; PRIOR APPLICATION NUMBER: 60/302,176
; PRIOR FILING DATE: 2001-06-28
; PRIOR APPLICATION NUMBER: 60/027,368
; PRIOR FILING DATE: 1996-09-23
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 10
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: IL-10 forward.
; NAME/KEY: misc_feature
; LOCATION: (1)..(21)
; OTHER INFORMATION: IL-10 forward.
US-10-083-720A-10

Query Match      2.1%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 4.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 325 AGAGCTCCGAGATGCATC 343
Db 2 AGATCTCCGAGATGCCTTC 20

RESULT 641
US-10-186-180-20
; Sequence 20, Application US/10186180
; Publication No. US20030108958A1
; GENERAL INFORMATION:
; APPLICANT: De Waal Malefyt, Rene
; APPLICANT: Nagalakshmi, Marehalli
; APPLICANT: Moore, Kevin
; APPLICANT: Fickenscher, Helmut
; TITLE OF INVENTION: BIOLOGICAL ACTIVITY OF AK155
; FILE REFERENCE: DX01168
; CURRENT APPLICATION NUMBER: US/10/186,180
; CURRENT FILING DATE: 2002-06-27
; PRIOR APPLICATION NUMBER: U.S. Provisional 60/345,690
; PRIOR FILING DATE: 2002-01-03
; PRIOR APPLICATION NUMBER: U.S. Provisional 60/302,176
; PRIOR FILING DATE: 2001-06-28
```

; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 20
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Forward primer IL-10.
US-10-186-180-20

Query Match 2.1%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 4.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 325 AGAGTCCGAGATGCCATC 343
||| ||||| ||||| |||||
DB 2 AGATCTCCGAGATGCCATC 20

RESULT 642
US-10-005-956-1033/c
; Sequence 1033, Application US/10005956
; Publication No. US20030113726A1
; GENERAL INFORMATION:
; APPLICANT: Bristol-Myers Squibb Company
; TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS
; FILE REFERENCE: D0053NP
; CURRENT APPLICATION NUMBER: US/10/005,956
; CURRENT FILING DATE: 2001-12-03
; PRIOR APPLICATION NUMBER: 60/251,015
; PRIOR FILING DATE: 2000-12-04
; PRIOR APPLICATION NUMBER: 60/263,678
; PRIOR FILING DATE: 2001-01-23
; PRIOR APPLICATION NUMBER: 60/273,037
; PRIOR FILING DATE: 2001-03-02
; NUMBER OF SEQ ID NOS: 1579
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1033
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-005-956-1033

Query Match 2.1%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 4.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 390 ATTCTCAAGCCGACGAG 408
||| ||||| ||||| |||||
DB 20 ATCTCCAAGCCGACGAG 2

RESULT 643
US-10-786-720-11194
; Sequence 11194, Application US/10786720
; Publication No. US2004019181A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11194
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-786-720-11194

Query Match 2.1%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 4.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 468 TCGCCTGGAGAAGCTCGA 486
||| ||||| ||||| |||||
DB 3 TCAGCCTGGAGAGCTGGA 21

RESULT 644
US-10-683-990-202
; Sequence 202, Application US/10683990
; Publication No. US20040198682A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics
; APPLICANT: McSwiggen, James
; APPLICANT: Usman, Nassim
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
; FILE REFERENCE: 400/134 (02-742-H)
; CURRENT APPLICATION NUMBER: US/10/683,990
; CURRENT FILING DATE: 2003-10-10
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US 60/409,293
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 256
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 202
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-683-990-202

Query Match 2.1%; Score 15.8; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 4.6e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 303 AGCGCTGCCTGGAGAGAA 321
||| ||||| ||||| |||||
DB 1 AGAGCUGCCUGAUGAGAA 19

RESULT 645
US-10-683-990-206/c
; Sequence 206, Application US/10683990
; Publication No. US20040198682A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics

RESULT 646
US-10-683-990-210
; Sequence 210, Application US/10683990
; Publication No. US20040198682A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics
; APPLICANT: McSwiggen, James
; APPLICANT: Usman, Nassim
; APPLICANT: Favco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/134 (02-742-H)
; CURRENT APPLICATION NUMBER: US/10/683,990
; CURRENT FILING DATE: 2003-10-10
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782

```

Query Match      2.1%; Score 15.8; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 4.6e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy      303 AGCGCTGCCTGGAGGAGAA 321
      |||:||||:|||||
Db      1  AGAGCUCGCGGAGAGAA 19

RESULT 647
US-10-683-990-214/c
; Sequence 214, Application US/10683990
; Publication No. US20040198682A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics
; APPLICANT: McSwiggen, James
; APPLICANT: Usman, Nassim
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (s
; FILE REFERENCE: 400/134 (02-742-H)
; CURRENT APPLICATION NUMBER: US/10/683,990
; CURRENT FILING DATE: 2003-10-10
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20

```

```
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/440,129
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 256
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 214
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(5)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (7)..(9)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (13)..(13)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (16)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-683-990-214

Query Match      2.1%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 4.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 303 AGCGTGCCTGGAGGAGAA 321
DB 19 AGAGCTGCCTGGATGAGAA 1

RESULT 648
US-10-683-990-218
; Sequence 218, Application US/10683990
; Publication No. US20040198682A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics
; APPLICANT: McSwiggen, James
; APPLICANT: Usman, Nassim
; APPLICANT: Favco, Pamela
; TITLE OF INVENTION: Gene Expression Mediated Inhibition of Placental Growth Factor
; TITLE OF INVENTION: RNA Interference Using Short Interfering Nucleic Acid (siNA)
US-10-683-990-218

; FILE REFERENCE: 400/134 (02-742-H)
; CURRENT APPLICATION NUMBER: US/10/683,990
; CURRENT FILING DATE: 2003-10-10
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/440,129
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 256
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 218
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(4)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3' attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (5)..(6)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (7)..(7)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (8)..(10)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (11)..(13)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (14)..(14)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(19)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3' attached terminal deoxyabasic moiety
US-10-683-990-218
```



```

Query Match      2.1%; Score 15.8; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 4.6e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 303 AGCGTGCCTGGAGGAGAA 321
   |||:|||||:|||||
Db 1 AGAGCUGCCUGGAGGAGAA 19

RESULT 649
US-10-683-990-222/c
; Sequence 222, Application US/10683990
; Publication No. US20040198682A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics
; APPLICANT: McSwiggen, James
; APPLICANT: Usman, Nassim
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
; FILE REFERENCE: 400/134 (02-742-H)
; CURRENT APPLICATION NUMBER: US/10/683,990
; CURRENT FILING DATE: 2003-10-10
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US 60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 256
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 222
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(5)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (6)..(6)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (7)..(9)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (10)..(12)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (13)..(13)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro

```

```

; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (14)..(15)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (16)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-683-990-222

Query Match      2.1%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 4.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 303 AGCGTGCCTGGAGGAGAA 321
   |||:|||||:|||||
Db 19 AGAGTGCCTGGATGAGAA 1

RESULT 650
US-10-683-990-226
; Sequence 226, Application US/10683990
; Publication No. US20040198682A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics
; APPLICANT: McSwiggen, James
; APPLICANT: Usman, Nassim
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
; FILE REFERENCE: 400/134 (02-742-H)
; CURRENT APPLICATION NUMBER: US/10/683,990
; CURRENT FILING DATE: 2003-10-10
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US 60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 256
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 226
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc_feature
; LOCATION: (1)..(4)

```

OTHER INFORMATION: 2'-O-methyl
 FEATURE: misc feature
 NAME/KEY: (1)..(1)
 LOCATION: (1)..(1)
 OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
 FEATURE: misc feature
 NAME/KEY: (5)..(6)
 LOCATION: (5)..(6)
 OTHER INFORMATION: 2'-deoxy-2'-fluoro
 FEATURE: misc feature
 NAME/KEY: (7)..(7)
 LOCATION: (7)..(7)
 OTHER INFORMATION: 2'-O-methyl
 FEATURE: misc feature
 NAME/KEY: (8)..(10)
 LOCATION: (8)..(10)
 OTHER INFORMATION: 2'-deoxy-2'-fluoro
 FEATURE: misc feature
 NAME/KEY: (11)..(13)
 LOCATION: (11)..(13)
 OTHER INFORMATION: 2'-O-methyl
 FEATURE: misc feature
 NAME/KEY: (14)..(14)
 LOCATION: (14)..(14)
 OTHER INFORMATION: 2'-deoxy-2'-fluoro
 FEATURE: misc feature
 NAME/KEY: (15)..(19)
 LOCATION: (15)..(19)
 OTHER INFORMATION: 2'-O-methyl
 FEATURE: misc feature
 NAME/KEY: (20)..(21)
 LOCATION: (20)..(21)
 OTHER INFORMATION: n stands for thymidine
 FEATURE: misc feature
 NAME/KEY: (21)..(21)
 LOCATION: (21)..(21)
 OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety

US-10-683-990-226
 Query Match 2.1%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 78.5%; Pred No. 4.6e+02;
 Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 303 AGCGTCTGCTGGAGGAA 321
 |||||:|||||
 Db 1 AGAGCUGCCUGAUGAGAA 19

RESULT 651
 US-10-683-990-230/c
 ; Sequence 230, Application US/10683990
 ; Publication No. US20040198682A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Sirna Therapeutics
 ; APPLICANT: McSwiggen, James
 ; APPLICANT: Usman, Nassim
 ; APPLICANT: Pavco, Pamela
 ; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
 ; FILE REFERENCE: 400/134 (02-742-H)
 ; CURRENT APPLICATION NUMBER: US/10/683,990
 ; CURRENT FILING DATE: 2003-10-10
 ; PRIOR APPLICATION NUMBER: PCT/US03/05022
 ; PRIOR FILING DATE: 2003-02-20
 ; PRIOR APPLICATION NUMBER: US 60/358,580
 ; PRIOR FILING DATE: 2002-02-20
 ; PRIOR APPLICATION NUMBER: US 60/363,124
 ; PRIOR FILING DATE: 2002-03-11
 ; PRIOR APPLICATION NUMBER: US 60/386,782
 ; PRIOR FILING DATE: 2002-06-06
 ; PRIOR APPLICATION NUMBER: US 60/393,796
 ; PRIOR FILING DATE: 2002-07-03
 ; PRIOR APPLICATION NUMBER: US 60/399,348

OTHER INFORMATION: 2'-O-methyl
 FEATURE: misc feature
 NAME/KEY: (1)..(1)
 LOCATION: (1)..(1)
 OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
 FEATURE: misc feature
 NAME/KEY: (5)..(6)
 LOCATION: (5)..(6)
 OTHER INFORMATION: 2'-deoxy-2'-fluoro
 FEATURE: misc feature
 NAME/KEY: (7)..(7)
 LOCATION: (7)..(7)
 OTHER INFORMATION: 2'-O-methyl
 FEATURE: misc feature
 NAME/KEY: (8)..(10)
 LOCATION: (8)..(10)
 OTHER INFORMATION: 2'-deoxy-2'-fluoro
 FEATURE: misc feature
 NAME/KEY: (11)..(13)
 LOCATION: (11)..(13)
 OTHER INFORMATION: 2'-O-methyl
 FEATURE: misc feature
 NAME/KEY: (14)..(14)
 LOCATION: (14)..(14)
 OTHER INFORMATION: 2'-deoxy-2'-fluoro
 FEATURE: misc feature
 NAME/KEY: (15)..(19)
 LOCATION: (15)..(19)
 OTHER INFORMATION: 2'-O-methyl
 FEATURE: misc feature
 NAME/KEY: (20)..(21)
 LOCATION: (20)..(21)
 OTHER INFORMATION: n stands for thymidine
 FEATURE: misc feature
 NAME/KEY: (21)..(21)
 LOCATION: (21)..(21)
 OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety

US-10-683-990-226
 Query Match 2.1%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 78.5%; Pred No. 4.6e+02;
 Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 303 AGCGTCTGCTGGAGGAA 321
 |||||:|||||
 Db 1 AGAGCUGCCUGAUGAGAA 19

RESULT 651
 US-10-683-990-230/c
 ; Sequence 230, Application US/10683990
 ; Publication No. US20040198682A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Sirna Therapeutics
 ; APPLICANT: McSwiggen, James
 ; APPLICANT: Usman, Nassim
 ; APPLICANT: Pavco, Pamela
 ; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
 ; FILE REFERENCE: 400/134 (02-742-H)
 ; CURRENT APPLICATION NUMBER: US/10/683,990
 ; CURRENT FILING DATE: 2003-10-10
 ; PRIOR APPLICATION NUMBER: PCT/US03/05022
 ; PRIOR FILING DATE: 2003-02-20
 ; PRIOR APPLICATION NUMBER: US 60/358,580
 ; PRIOR FILING DATE: 2002-02-20
 ; PRIOR APPLICATION NUMBER: US 60/363,124
 ; PRIOR FILING DATE: 2002-03-11
 ; PRIOR APPLICATION NUMBER: US 60/386,782
 ; PRIOR FILING DATE: 2002-06-06
 ; PRIOR APPLICATION NUMBER: US 60/393,796
 ; PRIOR FILING DATE: 2002-07-03
 ; PRIOR APPLICATION NUMBER: US 60/399,348

OTHER INFORMATION: 2'-O-methyl
 FEATURE: misc feature
 NAME/KEY: (1)..(1)
 LOCATION: (1)..(1)
 OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
 FEATURE: misc feature
 NAME/KEY: (5)..(6)
 LOCATION: (5)..(6)
 OTHER INFORMATION: 2'-deoxy-2'-fluoro
 FEATURE: misc feature
 NAME/KEY: (7)..(7)
 LOCATION: (7)..(7)
 OTHER INFORMATION: 2'-O-methyl
 FEATURE: misc feature
 NAME/KEY: (8)..(10)
 LOCATION: (8)..(10)
 OTHER INFORMATION: 2'-deoxy-2'-fluoro
 FEATURE: misc feature
 NAME/KEY: (11)..(13)
 LOCATION: (11)..(13)
 OTHER INFORMATION: 2'-O-methyl
 FEATURE: misc feature
 NAME/KEY: (14)..(14)
 LOCATION: (14)..(14)
 OTHER INFORMATION: 2'-deoxy-2'-fluoro
 FEATURE: misc feature
 NAME/KEY: (15)..(19)
 LOCATION: (15)..(19)
 OTHER INFORMATION: 2'-O-methyl
 FEATURE: misc feature
 NAME/KEY: (20)..(21)
 LOCATION: (20)..(21)
 OTHER INFORMATION: n stands for thymidine
 FEATURE: misc feature
 NAME/KEY: (21)..(21)
 LOCATION: (21)..(21)
 OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety

US-10-683-990-226
 Query Match 2.1%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 78.5%; Pred No. 4.6e+02;
 Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

PRIOR FILING DATE: 2002-07-29
 PRIOR APPLICATION NUMBER: US 60/406,784
 PRIOR FILING DATE: 2002-08-29
 PRIOR APPLICATION NUMBER: US 60/408,378
 PRIOR FILING DATE: 2002-09-05
 PRIOR APPLICATION NUMBER: US 60/409,293
 PRIOR FILING DATE: 2002-09-09
 PRIOR APPLICATION NUMBER: US 60/440,129
 PRIOR FILING DATE: 2003-01-15
 Remaining Prior Application data removed - See File Wrapper or PALM.
 NUMBER OF SEQ ID NOS: 256
 SOFTWARE: PatentIn version 3.2
 SEQ ID NO 230
 LENGTH: 21
 TYPE: RNA
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: Description of Artificial Sequence: SINA antisense region
 FEATURE:
 NAME/KEY: misc feature
 LOCATION: (1)..(5)
 OTHER INFORMATION: 2'-deoxy-2'-fluoro
 FEATURE:
 NAME/KEY: misc feature
 LOCATION: (6)..(6)
 OTHER INFORMATION: 2'-O-methyl
 FEATURE:
 NAME/KEY: misc feature
 LOCATION: (7)..(9)
 OTHER INFORMATION: 2'-deoxy-2'-fluoro
 FEATURE:
 NAME/KEY: misc feature
 LOCATION: (10)..(12)
 OTHER INFORMATION: 2'-O-methyl
 FEATURE:
 NAME/KEY: misc feature
 LOCATION: (13)..(13)
 OTHER INFORMATION: 2'-deoxy-2'-fluoro
 FEATURE:
 NAME/KEY: misc feature
 LOCATION: (14)..(15)
 OTHER INFORMATION: 2'-O-methyl
 FEATURE:
 NAME/KEY: misc feature
 LOCATION: (16)..(19)
 OTHER INFORMATION: 2'-deoxy-2'-fluoro
 FEATURE:
 NAME/KEY: misc feature
 LOCATION: (20)..(21)
 OTHER INFORMATION: n stands for thymidine
 FEATURE:
 NAME/KEY: misc feature
 LOCATION: (20)..(20)
 OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
 US-10-683-990-230

Query Match 2.1%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 89.5%; Pred No. 4.6e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 303 AGCGTCTGCTGGAGGAA 321
 |||||:|||||
 Db 19 AGAGTCTGCTGGATGAGAA 1

RESULT 652
 US-10-683-990-234
 ; Sequence 234, Application US/10683990
 ; Publication No. US20040198682A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Sirna Therapeutics
 ; APPLICANT: McSwiggen, James
 ; APPLICANT: Usman, Nassim

```
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
; FILE REFERENCE: 400/134 (02-742-H)
; CURRENT APPLICATION NUMBER: US/10/683,990
; CURRENT FILING DATE: 2003-10-10
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US 60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 256
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 234
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA sense region
; NAME/KEY: misc feature
; LOCATION: (1)..(21)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-683-990-234

Query Match          2.1%; Score 15.8; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 4.6e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 303 AGCGTGCCTGGAGGAGAA 321
Db 1 AGAGCUGCCUGAUGAGAA 19

RESULT 653
US-10-683-990-238/c
; Sequence 238, Application US/10683990
; Publication No. US20040198682A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics
; APPLICANT: McSwiggen, James
; APPLICANT: Usgan, Naesim
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
; FILE REFERENCE: 400/134 (02-742-H)
; CURRENT APPLICATION NUMBER: US/10/683,990
; CURRENT FILING DATE: 2003-10-10
; PRIOR APPLICATION NUMBER: PCT/US03/05022
```

```
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US 60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 256
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 238
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-683-990-238

Query Match          2.1%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 4.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 303 AGCGTGCCTGGAGGAGAA 321
Db 19 AGAGCTGCCTGGATGAGAA 1

RESULT 654
US-10-751-736-16993
; Sequence 16993, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16993
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-16993

Query Match          2.1%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 4.6e+02;
```

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 543 AGCAGCAGTGGCTGAGGA 561
 ||||| |||||
 Db 2 AGCAGCAGGAGCTGAGGA 20

RESULT 655
 US-10-751-736-18963/c
 ; Sequence 18963, Application US/10751736
 ; Publication No. US20040265230A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Wyeth
 ; APPLICANT: Martinez, Robert
 ; APPLICANT: Brown, Eugene
 ; APPLICANT: Liu, Wei
 ; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
 ; FILE REFERENCE: AM100927 (031896-002000)
 ; CURRENT APPLICATION NUMBER: US/10/751,736
 ; CURRENT FILING DATE: 2003-01-06
 ; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
 ; PRIOR FILING DATE: 2003-01-06
 ; NUMBER OF SEQ ID NOS: 54873
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 18963
 ; LENGTH: 21
 ; TYPE: RNA
 ; ORGANISM: RNAi
 US-10-751-736-18963

Query Match 2.1%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 89.5%; Pred. No. 4.6e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 167 AAGAGCCACTGTGTGAGA 185
 ||||| |||||
 Db 21 AAGAGTCACCTGTGTGAGA 3

RESULT 656
 US-10-751-736-49882
 ; Sequence 49882, Application US/10751736
 ; Publication No. US20040265230A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Wyeth
 ; APPLICANT: Martinez, Robert
 ; APPLICANT: Brown, Eugene
 ; APPLICANT: Liu, Wei
 ; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
 ; FILE REFERENCE: AM100927 (031896-002000)
 ; CURRENT APPLICATION NUMBER: US/10/751,736
 ; CURRENT FILING DATE: 2003-01-06
 ; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
 ; PRIOR FILING DATE: 2003-01-06
 ; NUMBER OF SEQ ID NOS: 54873
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 49882
 ; LENGTH: 21
 ; TYPE: DNA
 ; ORGANISM: homo sapiens
 US-10-751-736-49882

Query Match 2.1%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 89.5%; Pred. No. 4.6e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 517 GGAGGTGGAGCCTCTGAAG 535
 ||||| |||||
 Db 3 GGAGGTGGAGCAGATGAAG 21

RESULT 657
 US-10-751-736-49883
 ; Sequence 49883, Application US/10751736
 ; Publication No. US20040265230A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Wyeth
 ; APPLICANT: Martinez, Robert
 ; APPLICANT: Brown, Eugene
 ; APPLICANT: Liu, Wei
 ; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
 ; FILE REFERENCE: AM100927 (031896-002000)
 ; CURRENT APPLICATION NUMBER: US/10/751,736
 ; CURRENT FILING DATE: 2003-01-06
 ; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
 ; PRIOR FILING DATE: 2003-01-06
 ; NUMBER OF SEQ ID NOS: 54873
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 49883
 ; LENGTH: 21
 ; TYPE: RNA
 ; ORGANISM: RNAi
 US-10-751-736-49883

Query Match 2.1%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 78.9%; Pred. No. 4.6e+02;
 Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 517 GGAGGTGGAGCCTCTGAAG 535
 ||||| |||||
 Db 1 GGAGGTGGAGCAGATGAAG 19

RESULT 658
 US-10-916-256-10
 ; Sequence 10, Application US/10916256
 ; Publication No. US20050009106A1
 ; GENERAL INFORMATION:
 ; APPLICANT: de Waal Malefyt, Rene
 ; APPLICANT: Fickenscher, Helmut
 ; APPLICANT: Fleckenstein, Bernhard
 ; APPLICANT: Knappe, Andrea
 ; TITLE OF INVENTION: MAMMALIAN CYTOKINE; RELATED REAGENTS
 ; FILE REFERENCE: DX0644KBK
 ; CURRENT APPLICATION NUMBER: US/10/916,256
 ; CURRENT FILING DATE: 2004-08-10
 ; PRIOR APPLICATION NUMBER: US/10/083,720
 ; PRIOR FILING DATE: 2002-02-28
 ; PRIOR APPLICATION NUMBER: 09/363,993
 ; PRIOR FILING DATE: 1999-07-29
 ; PRIOR APPLICATION NUMBER: 08/934,959
 ; PRIOR FILING DATE: 1997-09-22
 ; PRIOR APPLICATION NUMBER: 60/345,690
 ; PRIOR FILING DATE: 2002-01-03
 ; PRIOR APPLICATION NUMBER: 60/302,176
 ; PRIOR FILING DATE: 2001-06-28
 ; PRIOR APPLICATION NUMBER: 60/027,368
 ; PRIOR FILING DATE: 1996-09-23
 ; NUMBER OF SEQ ID NOS: 21
 ; SOFTWARE: PatentIn version 3.1
 ; SEQ ID NO 10
 ; LENGTH: 21
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURES:
 ; OTHER INFORMATION: IL-10 forward.
 ; FEATURE:
 ; NAME/KEY: misc feature
 ; LOCATION: (1)..(21)
 ; OTHER INFORMATION: IL-10 forward.
 US-10-916-256-10

Query Match 2.1%; Score 15.8; DB 1; Length 21;

```
Best Local Similarity 89.5%; Pred. No. 4.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 325 AGAGCTCCGAGATGCCATC 343
Db 2 AGATCTCGAGATGCCCTTC 20

RESULT 659
US-10-494-921-20/c
; Sequence 20, Application US/10494921
; Publication No. US20050059618A1
; GENERAL INFORMATION:
; APPLICANT: Eulenberg, Karsten
; APPLICANT: Steuernagel, Arnd
; APPLICANT: Haeder, Thomas
; APPLICANT: Broemer, Guenter
; TITLE OF INVENTION: Men Protein, GST2, Rab-RP1, Csp, F-box Protein Liliina/FBL7,
; TITLE OF INVENTION: ABC50, Coronin, Sec61 alpha, or Vhappal-1, or Homologous Protein
; TITLE OF INVENTION: Involved in the Regulation of Energy Homeostasis
; FILE REFERENCE: 2923-616
; CURRENT APPLICATION NUMBER: US/10/494,921
; CURRENT FILING DATE: 2004-05-07
; PRIOR APPLICATION NUMBER: PCT/EP02/12518
; PRIOR FILING DATE: 2002-11-08
; PRIOR APPLICATION NUMBER: EP 02 000 819.9
; PRIOR FILING DATE: 2002-01-14
; PRIOR APPLICATION NUMBER: EP 01 130 310.4
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: EP 01 129 727.2
; PRIOR FILING DATE: 2001-12-13
; PRIOR APPLICATION NUMBER: EP 01 128 254.8
; PRIOR FILING DATE: 2001-11-28
; PRIOR APPLICATION NUMBER: EP 01 127 959.3
; PRIOR FILING DATE: 2001-11-23
; PRIOR APPLICATION NUMBER: EP 01 127 960.1
; PRIOR FILING DATE: 2001-11-23
; PRIOR APPLICATION NUMBER: EP 01 127 669.8
; PRIOR FILING DATE: 2001-11-20
; PRIOR APPLICATION NUMBER: EP 01 126 967.7
; PRIOR FILING DATE: 2001-11-13
; PRIOR APPLICATION NUMBER: EP 01 126 804.2
; PRIOR FILING DATE: 2001-11-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 67
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Mus musculus
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: FAM reporter dye
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: TAMRA quencher dye
US-10-494-921-20

Query Match 2.1%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 4.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 839 CAGTGGCCCTATCACCAGC 857
Db 20 CAGTGGCCCTATCACCAGC 2

RESULT 660
US-09-866-108-7246
; Sequence 7246, Application US/09866108
; Patent No. US20020048800A1
```

```
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7246
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7246

Query Match 2.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 3.9e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 697 GCTGGAGAGTGAGCGCG 713
Db 1 GCTGGAGAGTGAGCGCG 17

RESULT 661
US-09-866-108-7450
; Sequence 7450, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
```

```

; PROR. FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 7450
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
;

```

US-10-723-361-7450

Query Match 2.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 3.9e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 412 GGAGAAGAGTCTCTCA 428
||||| |||||||
Db 1 GGAGAAGAGTCTCTCA 17

RESULT 664

US-10-454-246-336/c

; Sequence 336, Application US/10454246

; Publication No. US20050053930A1

; GENERAL INFORMATION:

; APPLICANT: Anderson, et al.

; TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHOD

; FILE REFERENCE: 21402-589 B

; CURRENT APPLICATION NUMBER: US/10/454,246

; CURRENT FILING DATE: 2003-06-03

; PRIOR APPLICATION NUMBER: 09/898,994

; PRIOR FILING DATE: 2001-07-03

; PRIOR APPLICATION NUMBER: 60/218,903

; PRIOR FILING DATE: 2000-07-18

; PRIOR APPLICATION NUMBER: 10/016,248

; PRIOR FILING DATE: 2001-12-10

; PRIOR APPLICATION NUMBER: 60/255,648

; PRIOR FILING DATE: 2000-12-14

; PRIOR APPLICATION NUMBER: 10/028,248

; PRIOR FILING DATE: 2001-12-19

; PRIOR APPLICATION NUMBER: 60/256,619

; PRIOR FILING DATE: 2000-12-19

; PRIOR APPLICATION NUMBER: 10/044,564

; PRIOR FILING DATE: 2002-01-11

; PRIOR APPLICATION NUMBER: 60/261,013

; PRIOR FILING DATE: 2001-01-11

; PRIOR APPLICATION NUMBER: 10/136,071

; PRIOR FILING DATE: 2002-05-01

; PRIOR APPLICATION NUMBER: 60/289,087

; PRIOR FILING DATE: 2001-05-07

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 339

; SOFTWARE: CuraSeqList version 0.1

; SEQ ID NO 336

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Primer/Probe

US-10-454-246-336

Query Match

2.0%; Score 15.4; DB 1; Length 17;

Best Local Similarity 94.1%; Pred. No. 3.9e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 556 TGAGGACAGGCTCTG 572
||||| |||||||
Db 17 TGAGGACAGGCTCTG 1

RESULT 665

US-09-146-157-3

; Sequence 3, Application US/09146157

; Patent No. US20010009760A1

; GENERAL INFORMATION:

; APPLICANT: HORN, Thomas

; APPLICANT: SCHROEDER, Hartmut R.

; APPLICANT: WARNER, Brian D.

; APPLICANT: FISS, Ellen

; APPLICANT: SELLS, Todd

; APPLICANT: LAW, Say-Jong

; TITLE OF INVENTION: OLIGONUCLEOTIDE PROBES BEARING QUENCHABLE FLUORESCENT LABELS,

; TITLE OF INVENTION: AND METHODS OF USE THEREOF

; FILE REFERENCE: 1411.002

; CURRENT APPLICATION NUMBER: US/09/146,157

; CURRENT FILING DATE: 1998-09-03

; EARLIER APPLICATION NUMBER: 60/057,810

; EARLIER FILING DATE: 1997-09-04

; NUMBER OF SEQ ID NOS: 8

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 3

; LENGTH: 18

; TYPE: DNA

; ORGANISM: Unknown

; FEATURE:

; OTHER INFORMATION: Description of Unknown Organism: This information

; OTHER INFORMATION: is not available.

US-09-146-157-3

Query Match

2.0%; Score 15.4; DB 1; Length 18;

Best Local Similarity 94.1%; Pred. No. 4.2e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 867 AATAGACACACATC 883
||||| |||||||
Db 2 AGTAGACACACATC 18

RESULT 666

US-09-412-947-2/c

; Sequence 2, Application US/09412947

; Publication No. US20030105035A1

; GENERAL INFORMATION:

; APPLICANT: AGRAWAL, Sudhir

; TITLE OF INVENTION: MODIFIED PROTEIN KINASE A-SPECIFIC OLIGONUCLEOTIDES AND

; FILE REFERENCE: HYZ-050CP2

; CURRENT APPLICATION NUMBER: US/09/412,947

; CURRENT FILING DATE: 1999-10-05

; PRIOR APPLICATION NUMBER: US 60/103,098

; PRIOR FILING DATE: 1998-10-05

; NUMBER OF SEQ ID NOS: 8

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 2

; LENGTH: 18

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: mismatched

; OTHER INFORMATION: control synthetic oligonucleotide

US-09-412-947-2

Query Match

2.0%; Score 15.4; DB 1; Length 18;

Best Local Similarity 94.1%; Pred. No. 4.2e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGAGCGCGCG 693
||||| |||||||
Db 18 GCCAGCGAGCGCGCG 2

RESULT 667

US-09-412-947-5/c

; Sequence 5, Application US/09412947

; Publication No. US20030105035A1

; GENERAL INFORMATION:

; APPLICANT: AGRAWAL, Sudhir

; TITLE OF INVENTION: MODIFIED PROTEIN KINASE A-SPECIFIC OLIGONUCLEOTIDES AND

; FILE REFERENCE: HYZ-050CP2

; CURRENT APPLICATION NUMBER: US/09/412,947

; CURRENT FILING DATE: 1999-10-05

; PRIOR APPLICATION NUMBER: US 60/103,098

; PRIOR FILING DATE: 1998-10-05

; NUMBER OF SEQ ID NOS: 8

```
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 5
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:single
; OTHER INFORMATION: stranded nucleic acid
; OTHER INFORMATION: Description of Artificial Sequence:mismatched
; OTHER INFORMATION: hybrid synthetic oligonucleotide
US-09-412-947-5

Query Match          2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 4.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGAGCAGCGCG 693
   ||||| ||||| |||||
Db 18 GCCAGCGAGGAGCGCG 2

RESULT 668
US-09-412-947-7/c
; Sequence 7, Application US/09412947
; Publication No. US20030105035A1
; GENERAL INFORMATION:
; APPLICANT: AGRAWAL, Sudhir
; TITLE OF INVENTION: MODIFIED PROTEIN KINASE A-SPECIFIC OLIGONUCLEOTIDES AND
; FILE REFERENCE: HYZ-050C2
; CURRENT APPLICATION NUMBER: US/09/412,947
; CURRENT FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: US 60/103,098
; PRIOR FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 7
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:single
; OTHER INFORMATION: stranded nucleic acid
; OTHER INFORMATION: Description of Artificial Sequence:mismatched
; OTHER INFORMATION: inverted hybrid synthetic oligonucleotide
US-09-412-947-7

Query Match          2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 4.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGAGCAGCGCG 693
   ||||| ||||| |||||
Db 18 GCCAGCGAGGAGCGCG 2

RESULT 669
US-10-641-521-2/c
; Sequence 2, Application US/10641521
; Publication No. US20040106570A1
; GENERAL INFORMATION:
; APPLICANT: AGRAWAL, SUDHIR
; TITLE OF INVENTION: MODIFIED PROTEIN KINASE A-SPECIFIC OLIGONUCLEOTIDES AND
; FILE REFERENCE: HYZ-050CIPDV-47508.766
; CURRENT APPLICATION NUMBER: US/10/641,521
; CURRENT FILING DATE: 2003-08-15
; PRIOR APPLICATION NUMBER: 09/022,965
; PRIOR FILING DATE: 1998-02-12
; PRIOR APPLICATION NUMBER: 60/040,740
; PRIOR FILING DATE: 1997-03-12
; PRIOR APPLICATION NUMBER: 08/532,979
; PRIOR FILING DATE: 1995-09-22
```

```
; PRIOR APPLICATION NUMBER: 08/516,454
; PRIOR FILING DATE: 1995-08-17
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 2
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-641-521-2

Query Match          2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 4.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGAGCAGCGCG 693
   ||||| ||||| |||||
Db 18 GCCAGCGAGGAGCGCG 2

RESULT 670
US-10-641-521-5/c
; Sequence 5, Application US/10641521
; Publication No. US20040106570A1
; GENERAL INFORMATION:
; APPLICANT: AGRAWAL, SUDHIR
; TITLE OF INVENTION: MODIFIED PROTEIN KINASE A-SPECIFIC OLIGONUCLEOTIDES AND
; FILE REFERENCE: HYZ-050CIPDV-47508.766
; CURRENT APPLICATION NUMBER: US/10/641,521
; CURRENT FILING DATE: 2003-08-15
; PRIOR APPLICATION NUMBER: 09/022,965
; PRIOR FILING DATE: 1998-02-12
; PRIOR APPLICATION NUMBER: 60/040,740
; PRIOR FILING DATE: 1997-03-12
; PRIOR APPLICATION NUMBER: 08/532,979
; PRIOR FILING DATE: 1995-09-22
; PRIOR APPLICATION NUMBER: 08/516,454
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 5
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-641-521-5

Query Match          2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 4.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGAGCAGCGCG 693
   ||||| ||||| |||||
Db 18 GCCAGCGAGGAGCGCG 2

RESULT 671
US-10-641-521-7/c
; Sequence 7, Application US/10641521
; Publication No. US20040106570A1
; GENERAL INFORMATION:
; APPLICANT: AGRAWAL, SUDHIR
; TITLE OF INVENTION: MODIFIED PROTEIN KINASE A-SPECIFIC OLIGONUCLEOTIDES AND
; FILE REFERENCE: HYZ-050CIPDV-47508.766
```


; CURRENT APPLICATION NUMBER: US/10/641,521
; CURRENT FILING DATE: 2003-08-15
; PRIOR APPLICATION NUMBER: 09/022,965
; PRIOR FILING DATE: 1998-02-12
; PRIOR APPLICATION NUMBER: 60/040,740
; PRIOR FILING DATE: 1997-03-12
; PRIOR APPLICATION NUMBER: 08/532,979
; PRIOR FILING DATE: 1995-09-22
; PRIOR APPLICATION NUMBER: 08/516,454
; PRIOR FILING DATE: 1995-08-17
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 7
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-641-521-7

Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 4.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGAGCGCGCG 693
Db 18 GCCAGCGAGCGCGCG 2

RESULT 672
US-10-854-989-2/c
; Sequence 2, Application US/10854989
; Publication No. US20050054600A1
; GENERAL INFORMATION:
; APPLICANT: AGRAWAL, SUDHIR
; TITLE OF INVENTION: MODIFIED PROTEIN KINASE A-SPECIFIC OLIGONUCLEOTIDES AND
; FILE REFERENCE: HYZ-050CP3 (47508.766)
; CURRENT APPLICATION NUMBER: US/10/854,989
; CURRENT FILING DATE: 2004-05-27
; PRIOR APPLICATION NUMBER: 09/708,786
; PRIOR FILING DATE: 2000-11-08
; PRIOR APPLICATION NUMBER: 09/412,947
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: 09/022,965
; PRIOR FILING DATE: 1998-02-12
; PRIOR APPLICATION NUMBER: 08/532,979
; PRIOR FILING DATE: 1995-09-22
; PRIOR APPLICATION NUMBER: 08/516,454
; PRIOR FILING DATE: 1995-08-17
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 2
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-854-989-2

Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 4.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGAGCGCGCG 693
Db 18 GCCAGCGAGCGCGCG 2

RESULT 673
US-10-854-989-5/c
; Sequence 5, Application US/10854989
; Publication No. US20050054600A1
; GENERAL INFORMATION:
; APPLICANT: AGRAWAL, SUDHIR
; TITLE OF INVENTION: MODIFIED PROTEIN KINASE A-SPECIFIC OLIGONUCLEOTIDES AND
; FILE REFERENCE: HYZ-050CP3 (47508.766)
; CURRENT APPLICATION NUMBER: US/10/854,989
; CURRENT FILING DATE: 2004-05-27
; PRIOR APPLICATION NUMBER: 09/708,786
; PRIOR FILING DATE: 2000-11-08
; PRIOR APPLICATION NUMBER: 09/412,947
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: 60/164,182
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/103,098
; PRIOR FILING DATE: 1998-10-05
; PRIOR APPLICATION NUMBER: 09/022,965
; PRIOR FILING DATE: 1998-02-12
; PRIOR APPLICATION NUMBER: 08/532,979
; PRIOR FILING DATE: 1995-09-22
; PRIOR APPLICATION NUMBER: 08/516,454
; PRIOR FILING DATE: 1995-08-17
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 5
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule: Synthetic
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-854-989-5

Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 4.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGAGCGCGCG 693
Db 18 GCCAGCGAGCGCGCG 2

RESULT 674
US-10-854-989-7/c
; Sequence 7, Application US/10854989
; Publication No. US20050054600A1
; GENERAL INFORMATION:
; APPLICANT: AGRAWAL, SUDHIR
; TITLE OF INVENTION: MODIFIED PROTEIN KINASE A-SPECIFIC OLIGONUCLEOTIDES AND
; FILE REFERENCE: HYZ-050CP3 (47508.766)
; CURRENT APPLICATION NUMBER: US/10/854,989
; CURRENT FILING DATE: 2004-05-27
; PRIOR APPLICATION NUMBER: 09/708,786
; PRIOR FILING DATE: 2000-11-08
; PRIOR APPLICATION NUMBER: 09/412,947
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: 60/164,182
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/103,098
; PRIOR FILING DATE: 1998-10-05
; PRIOR APPLICATION NUMBER: 09/022,965

; PRIOR FILING DATE: 1998-02-12
; PRIOR APPLICATION NUMBER: 08/532,979
; PRIOR FILING DATE: 1995-09-22
; PRIOR APPLICATION NUMBER: 08/516,454
; PRIOR FILING DATE: 1995-08-17
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 7
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-854-989-7

Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 4.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGAGCGCGG 593
DB 18 GCCAGCGAGCGCGG 2

RESULT 675
US-09-863-049A-13
; Sequence 13, Application US/09863049A
; Publication No. US20030032055A1
; GENERAL INFORMATION:
; APPLICANT: Kenrick, Sue J.
; APPLICANT: Nelson, David L.
; APPLICANT: Aradhyia, Swaroop
; APPLICANT: D'Urso, Michele
; APPLICANT: Woffendin, Hayley
; APPLICANT: Munnich, Arnold
; APPLICANT: Smahi, Aamae
; APPLICANT: Israel, Alain
; APPLICANT: Poustka, Annemarie
; APPLICANT: Lewis, Richard A
; APPLICANT: Levy, Meise
; APPLICANT: Heiss, Nina
; TITLE OF INVENTION: Diagnosis and Treatment of Medical Conditions Associated with Def
; FILE REFERENCE: HO-PO1961US1
; CURRENT APPLICATION NUMBER: US/09/863,049A
; PRIOR FILING DATE: 2001-05-22
; PRIOR APPLICATION NUMBER: US 60/206,223
; PRIOR FILING DATE: 2000-05-22
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 13
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Human
US-09-863-049A-13

Query Match 2.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 4.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 541 CCAGCAGCAGATGGCTG 557
DB 4 CCTGCAGCAGATGGCTG 20

RESULT 676
US-10-211-028-145/c
; Sequence 145, Application US/10211028
; Publication No. US20050027113A1

; GENERAL INFORMATION:
; APPLICANT: CUBIST PHARMACEUTICALS, INC.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS RELATING TO THE DAPTOMYCIN
; FILE REFERENCE: CUB-12 PCT CIP
; CURRENT APPLICATION NUMBER: US/10/211,028
; PRIOR FILING DATE: 2002-07-31
; PRIOR APPLICATION NUMBER: PCT/US02/24310
; PRIOR FILING DATE: 2002-10-25
; PRIOR APPLICATION NUMBER: PCT/US01/32354
; PRIOR FILING DATE: 2001-10-17
; PRIOR APPLICATION NUMBER: 60/310,385
; PRIOR FILING DATE: 2001-08-06
; PRIOR APPLICATION NUMBER: 60/379,866
; PRIOR FILING DATE: 2002-05-10
; NUMBER OF SEQ ID NOS: 170
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 145
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Streptomyces roseosporus
US-10-211-028-145

Query Match 2.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 4.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 546 AGCAGATGGCTGAGGAC 562
DB 18 AGGAGATGGCTGAGGAC 2

RESULT 677
US-09-752-639-131
; Sequence 131, Application US/09752639
; Patent No. US20020091243A1
; GENERAL INFORMATION:
; APPLICANT: Gatanaga, T.
; APPLICANT: Granger, G.A.
; TITLE OF INVENTION: Factors Altering Tumor Necrosis
; TITLE OF INVENTION: Factor Receptor Releasing Enzyme Activity, and Methods
; TITLE OF INVENTION: of Use Thereof
; NUMBER OF SEQUENCES: 154
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 755 PAGE MILL ROAD
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows
; SOFTWARE: FastSeq for Windows Version 2.0b
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/752,639
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US99/10793
; FILING DATE:
; APPLICATION NUMBER: 09/081,385
; FILING DATE:
; APPLICATION NUMBER: 08/964,747
; FILING DATE: 05-NOV-1997
; APPLICATION NUMBER: 60/030,761
; FILING DATE: 06-NOV-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Wu, Frank
; REGISTRATION NUMBER: 41,386
; REFERENCE/DOCKET NUMBER: 22000-20577.21
; TELECOMMUNICATION INFORMATION:

```

; TELEPHONE: 650-813-5600
; TELEFAX: 650-494-0792
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 131:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-752-639-131

Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 471 GCCTGGAGAGCTCGATCTG 490
Db 1 GCCTGGAGAGCCCGACTG 20

RESULT 678
US-09-984-198-131
; Sequence 131, Application US/09984198
; Patent No. US20020106679A1
; GENERAL INFORMATION:
; APPLICANT: Gatanaga, T.
; TITLE OF INVENTION: Factors Altering Tumor Necrosis
; TITLE OF INVENTION: Factor Receptor Releasing Enzyme Activity, and Methods
; TITLE OF INVENTION: of Use Thereof
; NUMBER OF SEQUENCES: 154
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 755 PAGE MILL ROAD
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows
; SOFTWARE: FastSeq for Windows Version 2.0b
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/984,198
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US99/10793
; FILING DATE:
; FILING DATE:
; APPLICATION NUMBER: 09/081,385
; FILING DATE:
; APPLICATION NUMBER: 08/964,747
; FILING DATE: 05-NOV-1997
; APPLICATION NUMBER: 60/030,761
; FILING DATE: 06-NOV-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Wu, Frank
; REGISTRATION NUMBER: 41,386
; REFERENCE/DOCKET NUMBER: 22000-20577.21
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-813-5600
; TELEFAX: 650-494-0792
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 131:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-984-198-131

Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 471 GCCTGGAGAGCTCGATCTG 490
Db 1 GCCTGGAGAGCCCGACTG 20

RESULT 679
US-09-836-697-3
; Sequence 3, Application US/09836697
; Patent No. US20020142311A1
; GENERAL INFORMATION:
; APPLICANT: Siffert, Winfried
; TITLE OF INVENTION: THE USE OF A GENETIC MODIFICATION IN THE GENE FOR HUMAN
; TITLE OF INVENTION: G PROTEIN b3 SUBUNIT FOR THE DIAGNOSIS OF DISEASES
; FILE REFERENCE: 1135-2
; CURRENT APPLICATION NUMBER: US/09/836,697
; CURRENT FILING DATE: 2001-04-16
; PRIOR APPLICATION NUMBER: 09/180,783
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: DE 19619362.1
; PRIOR FILING DATE: 1996-05-14
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-836-697-3

Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 513 TCGGGAGGTGAGCACCTG 532
Db 1 TGGGGAGATGAGCAACTG 20

RESULT 680
US-09-765-555-31
; Sequence 31, Application US/09765555
; Publication No. US20030037355A1
; GENERAL INFORMATION:
; APPLICANT: The Scripps Research Institute
; TITLE OF INVENTION: Methods and compositions to modulate
; TITLE OF INVENTION: expression in plants
; FILE REFERENCE: 27801-20014.40
; CURRENT APPLICATION NUMBER: US/09/765,555
; CURRENT FILING DATE: 2002-05-24
; PRIOR APPLICATION NUMBER: US 09/620,897
; PRIOR FILING DATE: 2000-01-21
; PRIOR APPLICATION NUMBER: US 60/177,468
; PRIOR FILING DATE: 2000-01-21
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer NZlib5'
US-09-765-555-31

Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 667 GCCTGGAGAGCTCGATCTG 686
Db 1 GCCTGGAGAGCCCGACTG 20

```

```
RESULT 681
US-10-160-807-122/c
; Sequence 122, Application US/10160807
; Publication No. US20030224514A1
; GENERAL INFORMATION:
; APPLICANT: William Gaarde
; APPLICANT: Susan M. Freier
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF PPAR-DELTA EXPRESSION
; FILE REFERENCE: RTS-0189
; CURRENT APPLICATION NUMBER: US/10/160,807
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 296
; SEQ ID NO 122
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-807-122

Query Match      2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      826  GGTGCCCGCCAGTTGCAGGTGG 845
          ||||| ||||| ||||| |||||
DB      20  GCTGGACACGCTGCAGATGG 1

RESULT 682
US-10-160-807-261
; Sequence 261, Application US/10160807
; Publication No. US20030224514A1
; GENERAL INFORMATION:
; APPLICANT: William Gaarde
; APPLICANT: Susan M. Freier
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF PPAR-DELTA EXPRESSION
; FILE REFERENCE: RTS-0189
; CURRENT APPLICATION NUMBER: US/10/160,807
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 296
; SEQ ID NO 261
; LENGTH: 20
; TYPE: DNA
; ORGANISM: M. musculus
; FEATURE:
US-10-160-807-261

Query Match      2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      826  GGTGCCCGCCAGTTGCAGGTGG 845
          ||||| ||||| ||||| |||||
DB      1  GCTGGACACGCTGCAGATGG 20

RESULT 683
US-10-161-983-15
; Sequence 15, Application US/10161983
; Publication No. US20030225015A1
; GENERAL INFORMATION:
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF RB2/PI30 EXPRESSION
; FILE REFERENCE: HTS-0020
; CURRENT APPLICATION NUMBER: US/10/161,983
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 74
; SEQ ID NO 15
```

```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-161-983-15

Query Match      2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      414  AGAAGGAGTTCTCTCATGTGC 433
          ||||| ||||| ||||| |||||
DB      1  AGTAGGAGTTTCTCTCTGTGC 20

RESULT 684
US-10-161-983-52/c
; Sequence 52, Application US/10161983
; Publication No. US20030225015A1
; GENERAL INFORMATION:
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF RB2/PI30 EXPRESSION
; FILE REFERENCE: HTS-0020
; CURRENT APPLICATION NUMBER: US/10/161,983
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 74
; SEQ ID NO 52
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-161-983-52

Query Match      2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      414  AGAAGGAGTTCTCTCATGTGC 433
          ||||| ||||| ||||| |||||
DB      20  AGTAGGAGTTTCTCTCTGTGC 1

RESULT 685
US-10-303-199A-7
; Sequence 7, Application US/10303199A
; Publication No. US20040023209A1
; GENERAL INFORMATION:
; APPLICANT: Pyrosequencing AB
; TITLE OF INVENTION: Method for Identifying Microorganisms based on Sequencing Gene Frag
; FILE REFERENCE: 27.7.76010/002
; CURRENT APPLICATION NUMBER: US/10/303,199A
; CURRENT FILING DATE: 2002-11-25
; NUMBER OF SEQ ID NOS: 87
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: ().T)
; OTHER INFORMATION: Primer: B-V3.AS
US-10-303-199A-7

Query Match      2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      251  AAGCCAGCCATGCTGCACCT 270
          ||||| ||||| ||||| |||||
DB      1  ACGACAGCCATGCGACGACCT 20
```

RESULT 686
 US-10-380-125-61/c
 ; Sequence 61, Application US/10380125
 ; Publication No. US20040048818A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Isis Pharmaceuticals, Inc.
 ; APPLICANT: Ian Popoff
 ; APPLICANT: Jacqueline Wyatt
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF E2F TRANSCRIPTION FACTOR 2 EXPRESSION
 ; FILE REFERENCE: R1SP-0176
 ; CURRENT APPLICATION NUMBER: US/10/380,125
 ; PRIOR FILING DATE: 2003-03-10
 ; PRIOR APPLICATION NUMBER: 09/658,679
 ; PRIOR FILING DATE: 2000-09-08
 ; NUMBER OF SEQ ID NOS: 87
 ; SEQ ID NO 61
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Antisense Oligonucleotide
 US-10-380-125-61

Query Match 2.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 5e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 548 CAGATGGCTGAGGACAGGC 567
 |||||
 Db 20 CACCTGACTGAGGACAGGC 1

RESULT 687
 US-10-655-847-122/c
 ; Sequence 122, Application US/10655847
 ; Publication No. US20040063129A1
 ; GENERAL INFORMATION:
 ; APPLICANT: William Gaarde
 ; APPLICANT: Susan M. Freier
 ; APPLICANT: Andrew T. Watt
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF PPAR-DELTA EXPRESSION
 ; FILE REFERENCE: RTS-0189
 ; CURRENT APPLICATION NUMBER: US/10/655,847
 ; CURRENT FILING DATE: 2003-09-05
 ; PRIOR APPLICATION NUMBER: US/10/160,807
 ; PRIOR FILING DATE: 2003-09-05
 ; NUMBER OF SEQ ID NOS: 296
 ; SEQ ID NO 122
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Antisense Oligonucleotide
 US-10-655-847-122

Query Match 2.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 5e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 826 GCTGGCCAGTTGCAGGTGG 845
 |||||
 Db 20 GCTGGACCAGCTGCAGATGG 1

RESULT 688
 US-10-655-847-261
 ; Sequence 261, Application US/10655847
 ; Publication No. US20040063129A1
 ; GENERAL INFORMATION:
 ; APPLICANT: William Gaarde
 ; APPLICANT: Susan M. Freier

; APPLICANT: Andrew T. Watt
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF PPAR-DELTA EXPRESSION
 ; FILE REFERENCE: RTS-0189
 ; CURRENT APPLICATION NUMBER: US/10/655,847
 ; CURRENT FILING DATE: 2003-09-05
 ; PRIOR APPLICATION NUMBER: US/10/160,807
 ; PRIOR FILING DATE: 2003-09-05
 ; NUMBER OF SEQ ID NOS: 296
 ; SEQ ID NO 261
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: M. musculus
 ; FEATURE:
 US-10-655-847-261

Query Match 2.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 5e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 826 GCTGGCCAGTTGCAGGTGG 845
 |||||
 Db 1 GCTGGACCAGCTGCAGATGG 20

RESULT 689
 US-10-688-706-2714
 ; Sequence 2714, Application US/10688706
 ; Publication No. US20040102412A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Pharmacia Corp.
 ; APPLICANT: Broschat, Kay
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF GFAT EXPRESSION
 ; FILE REFERENCE: 01393/1
 ; CURRENT APPLICATION NUMBER: US/10/688,706
 ; CURRENT FILING DATE: 2003-10-17
 ; PRIOR APPLICATION NUMBER: 60/419,268
 ; PRIOR FILING DATE: 2002-10-17
 ; NUMBER OF SEQ ID NOS: 3071
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 2714
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: artificial
 ; FEATURE:
 ; OTHER INFORMATION: human GFAT antisense
 US-10-688-706-2714

Query Match 2.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 5e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 162 TCTGGAAGAGCCCACTGTGT 181
 |||||
 Db 1 TATGGAACTGCCCACTGTGT 20

RESULT 690
 US-09-863-049A-62
 ; Sequence 62, Application US/09863049A
 ; Publication No. US20030032055A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Kenrick, Sue J.
 ; APPLICANT: Nelson, David L.
 ; APPLICANT: Aradhya, Swaroop
 ; APPLICANT: D'Urso, Michele
 ; APPLICANT: Woffendin, Hayley
 ; APPLICANT: Munnich, Arnold
 ; APPLICANT: Smahi, Asmae
 ; APPLICANT: Israel, Alain
 ; APPLICANT: Poustka, Annemarie
 ; APPLICANT: Lewis, Richard A
 ; APPLICANT: Levy, Moise
 ; APPLICANT: Heiss, Nina

```
; TITLE OF INVENTION: Diagnosis and Treatment of Medical Conditions Associated with Def
; TITLE OF INVENTION: NFKBPA B (NF-KB) Activation
; FILE REFERENCE: HO-P01961US1
; CURRENT APPLICATION NUMBER: US/09/863,049A
; CURRENT FILING DATE: 2001-05-22
; PRIOR APPLICATION NUMBER: US 60/206,223
; PRIOR FILING DATE: 2000-05-22
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 62
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Human
US-09-863-049A-62

Query Match          2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 269 CTGCCTTCAGAACAG 283
Db 1 CTGCCTTCAGAACAG 15

RESULT 691
US-10-156-306-7813
; Sequence 7813, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: MCSwiggan, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7813
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7813

Query Match          2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 3.7e+02;
Matches 10; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 420 AGTTCCTCATGTGCA 434
Db 1 AGUUCUCAUGUGCA 15

RESULT 692
US-10-156-306-7826
; Sequence 7826, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: MCSwiggan, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7826
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7826
```

```
Query Match          2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 3.7e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 317 GAGAAATCAAGAGCTC 331
Db 1 GAGAAUCAAAGAGCUC 15

RESULT 693
US-10-156-306-7828
; Sequence 7828, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: MCSwiggan, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7828
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7828

Query Match          2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 3.7e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 549 AGATGGCTGAGAGACA 563
Db 1 AGAUGGCUAGAGACA 15

RESULT 694
US-10-156-306-7829
; Sequence 7829, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: MCSwiggan, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7829
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7829

Query Match          2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3.7e+02;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 561 ACAAGGCCTCTGTGA 575
Db 1 ACNAGGCCUCUGUGA 15

RESULT 695
US-10-156-306-7831
; Sequence 7831, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
```

```

; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7831
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7831

Query Match      2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 3.7e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 573 TGAAGCCCGAGTGA 587
Db 1 UGAAAGCCCGAGGUA 15

RESULT 696
US-10-156-306-7847
; Sequence 7847, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7847
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7847

Query Match      2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 3.7e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 297 CCCTCAGCGCTGCC 311
Db 1 CCCUCCAGCGCCUGCC 15

RESULT 697
US-10-156-306-7848
; Sequence 7848, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7848
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7848

Query Match      2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 3.7e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 297 CCCTCAGCGCTGCC 311
Db 1 CCCUCCAGCGCCUGCC 15

```

```

Best Local Similarity 80.0%; Pred. No. 3.7e+02;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 299 CTCACAGCGCTGCTG 313
Db 1 CUCCAGCGCGCCUG 15

RESULT 698
US-10-156-306-7851
; Sequence 7851, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7851
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7851

Query Match      2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 3.7e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 321 ATCAAGAGCTCCGAG 335
Db 1 AUCRAAGAGCUCCGAG 15

RESULT 699
US-10-156-306-7853
; Sequence 7853, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7853
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7853

Query Match      2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3.7e+02;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 565 GGCCTCTGTGAAAGC 579
Db 1 GGCCUCUGUGAAAGC 15

RESULT 700
US-10-156-306-7861
; Sequence 7861, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James

```

```

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7861
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7861

Query Match      2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3.7e+02;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 431 TCGAAGTTCAGGAG 445
      :|||||:|||||
Db 1 UGCAAGUCCAGGAG 15

RESULT 701
US-10-156-306-7866
; Sequence 7866, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7866
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7866

Query Match      2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 3.7e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 734 AGCGTCAGGTGAG 748
      :|||||:|||||
Db 1 AGCGUCAGGUGGAC 15

RESULT 702
US-10-156-306-7876
; Sequence 7876, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7876
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7876

Query Match      2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 3.7e+02;
Matches 15; Conservative 0; Indels 0; Gaps 0;

```

```

Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 209 GCAGCAGATCAGGAC 223
      :|||||:|||||
Db 1 GCAGCAGAUCAGGAC 15

RESULT 703
US-10-156-306-7877
; Sequence 7877, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7877
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7877

Query Match      2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 3.7e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 531 TGAAGAGATGCCAGC 545
      :|||||:|||||
Db 1 UGAAGAGAUGCCAGC 15

RESULT 704
US-10-156-306-7878
; Sequence 7878, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7878
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7878

Query Match      2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 3.7e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 861 TCCAAGAATACGACA 875
      :|||||:|||||
Db 1 UCCAAGAAUACGACA 15

RESULT 705
US-10-156-306-7880
; Sequence 7880, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

```


; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; PCT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7880
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7880

Query Match 2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 3.7e+02;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 208 GGCAGCAGATCAGCA 222
|||||||:||||
Db 1 GGCAGCAGATCAGCA 15

RESULT 706

US-10-156-306-7881
; Sequence 7881, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; PCT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7881
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7881

Query Match 2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 810 CGGAGCAGAGAGGA 824
|||||||:||||
Db 1 CGGAGCAGAGAGGA 15

RESULT 707

US-09-866-108-7244
; Sequence 7244, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PCT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7244
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7244

Query Match 2.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 697 GCTGGAGAGTGAGCG 711
|||||||:||||
Db 3 GCTGGAGAGTGAGCG 17

RESULT 708

US-09-866-108-7245
; Sequence 7245, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PCT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7245
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7245

Query Match 2.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 697 GCTGGAGAGTGAGCG 711
||| ||||| ||||| |||||
Db 2 GCTGGAGAGTGAGCG 16

RESULT 709
US-10-156-306-6965
; Sequence 6965, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6965
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6965

Query Match 2.0%; Score 15; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 4.3e+02;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 902 AGTGAGCGGAAGCGA 916
||| ||||| ||||| |||||
Db 1 AGUGAGCGGAAGCGA 15

RESULT 710
US-10-723-361-7244
; Sequence 7244, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105

; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7244
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7244

Query Match 2.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 697 GCTGGAGAGTGAGCG 711
||| ||||| ||||| |||||
Db 3 GCTGGAGAGTGAGCG 17

RESULT 711
US-10-723-361-7245
; Sequence 7245, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 7245
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7245

Query Match          2.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 697 GCTGGAGAGTGAGCG 711
Db 2 GCTGGAGAGTGAGCG 16

RESULT 712
US-10-440-850-1112/c
; Sequence 1112, Application US/10440850
; Publication No. US20030207837A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Induction of Graft Tolerance and Reversal
; FILE REFERENCE: 250/130 (MBHB00-900-A)
; CURRENT APPLICATION NUMBER: US/10/440,850
; CURRENT FILING DATE: 2003-05-19
; PRIOR APPLICATION NUMBER: US/09/650,012
; PRIOR FILING DATE: 2000-08-28
; PRIOR APPLICATION NUMBER: US 08/585,684
; PRIOR FILING DATE: 1996-01-12
; PRIOR APPLICATION NUMBER: US 60/000,951
; PRIOR FILING DATE: 1995-07-07
; PRIOR APPLICATION NUMBER: US 09/038,073
; PRIOR FILING DATE: 1998-03-11
; NUMBER OF SEQ ID NOS: 2285
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1112
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-440-850-1112

Query Match          2.0%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 719 CTCGACGACGACGAC 733
Db 17 CTCGACGACGACGAC 3

RESULT 713
US-09-940-227-71/c
; Sequence 71, Application US/09940227
; Publication No. US20030017468A1
; GENERAL INFORMATION:
; APPLICANT: Chen, Sei Yu
; APPLICANT: Macina, Roberto
; APPLICANT: Sun, Yongming
; APPLICANT: Recipon, Hervé
; TITLE OF INVENTION: Compositions and Methods Relating to Lung Specific
; FILE REFERENCE: DEX-0230
; CURRENT APPLICATION NUMBER: US/09/940,227

```

```

; CURRENT FILING DATE: 2001-08-27
; PRIOR APPLICATION NUMBER: 60/228,378
; PRIOR FILING DATE: 2000-08-28
; NUMBER OF SEQ ID NOS: 84
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 71
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-940-227-71

Query Match          2.0%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 890 AGCGTGGTGGCAGT 904
Db 15 AGCGTGGTGGCAGT 1

RESULT 714
US-10-933-058-71/c
; Sequence 71, Application US/10933058
; Publication No. US20050026211A1
; GENERAL INFORMATION:
; APPLICANT: Chen, Sei Yu
; APPLICANT: Macina, Roberto
; APPLICANT: Sun, Yongming
; APPLICANT: Recipon, Hervé
; TITLE OF INVENTION: Compositions and Methods Relating to Lung Specific
; FILE REFERENCE: DEX-0230
; CURRENT APPLICATION NUMBER: US/10/933,058
; CURRENT FILING DATE: 2004-09-02
; PRIOR APPLICATION NUMBER: US/09/940,227
; PRIOR FILING DATE: 2001-08-27
; PRIOR APPLICATION NUMBER: 60/228,378
; PRIOR FILING DATE: 2000-08-28
; NUMBER OF SEQ ID NOS: 84
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 71
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-933-058-71

Query Match          2.0%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 890 AGCGTGGTGGCAGT 904
Db 15 AGCGTGGTGGCAGT 1

RESULT 715
US-09-863-777-3/c
; Sequence 3, Application US/09863777
; Patent No. US20020019359A1
; GENERAL INFORMATION:
; APPLICANT: Fett, James W.
; APPLICANT: Olson, Karen A.
; TITLE OF INVENTION: Antisense Inhibition of Angiogenin Expression
; FILE REFERENCE: 10498/05286
; CURRENT APPLICATION NUMBER: US/09/863,777
; CURRENT FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: 60/041182
; PRIOR FILING DATE: 1997-03-21
; NUMBER OF SEQ ID NOS: 10

```

; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: phosphorothioate oligodeoxynucleotide
US-09-863-777-3

Query Match 2.0%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 4.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 845 GCCTATCACGCTCTTC 862
||| ||||| |||||
DB 18 GCCCATCACGCTCTTC 1

RESULT 716
US-09-863-777-4
; Sequence 4, Application US/09863777
; Patent No. US20020019359A1
; GENERAL INFORMATION:
; APPLICANT: Fett, James W.
; APPLICANT: Olson, Karen A.
; TITLE OF INVENTION: Antisense Inhibition of Angiogenin Expression
; FILE REFERENCE: 10498/05286
; CURRENT APPLICATION NUMBER: US/09/863,777
; CURRENT FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: 60/041182
; PRIOR FILING DATE: 1997-03-21
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: phosphorothioate oligodeoxynucleotide
US-09-863-777-4

Query Match 2.0%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 4.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 845 GCCTATCACGCTCTTC 862
||| ||||| |||||
DB 1 GCCCATCACGCTCTTC 18

RESULT 717
US-10-349-143-8682
; Sequence 8682, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796

; SEQ ID NO 8682
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer 99-17522 for SEQ 817, in complemer
US-10-349-143-8682

Query Match 2.0%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 4.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 492 AGAGGCAGAGGAGCAGG 509
||| ||||| |||||
DB 1 AGAGGAGAGGAGCAGG 18

RESULT 718
US-10-297-068-880
; Sequence 880, Application US/10297068
; Publication No. US20030228585A1
; GENERAL INFORMATION:
; APPLICANT: INOKO, Hidetoshi
; APPLICANT: KAGIYA, Taeko
; APPLICANT: ICHIHARA, Tatsuo
; APPLICANT: Matsuura, Yoshiyuki
; APPLICANT: MORIYA, Shogo
; APPLICANT: NISHIDA, Michio
; TITLE OF INVENTION: KIT AND METHOD FOR DETERMINING HLA TYPES
; FILE REFERENCE: 13140P1174
; CURRENT APPLICATION NUMBER: US/10/297,068
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: JP 2000-164798
; PRIOR FILING DATE: 2000-06-01
; NUMBER OF SEQ ID NOS: 1298
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 880
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:capture
US-10-297-068-880

Query Match 2.0%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 310 CCTGGAGGAGGAGTCAAGA 327
||| ||||| |||||
DB 1 CCTGGAGGAGGAGTCAAGA 18

RESULT 719
US-10-444-795B-213/c
; Sequence 213, Application US/10444795B
; Publication No. US2004007574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; APPLICANT: Lewis, Stephen Patrick
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; TITLE OF INVENTION: TRANSDUCTION BY RNA INTERFERENCE
; FILE REFERENCE: 200125.449
; CURRENT APPLICATION NUMBER: US/10/444,795B
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 213
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence

```
; FEATURE:
; OTHER INFORMATION: Small interfering RNA
US-10-444-795B-213

Query Match      2.0%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 215 GATCAGGACGTACTGGGC 232
      ||||| || |||||
Db 19 GATCAGATGTACTGGGC 2

RESULT 720
US-10-665-951-1036
; Sequence 1036, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/131 (MBHB02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1036
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-665-951-1360

Query Match      2.0%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 811 GGAGGAGAGAGAGAGCT 828
      ||||| |||||
Db 19 GTAGAGAGAGAGAGAGCT 2

RESULT 722
US-09-866-108-7247
; Sequence 7247, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666

; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/131 (MBHB02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1036
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense x
US-10-665-951-1036

Query Match      2.0%; Score 14.8; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 5.2e+02;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 811 GGAGGAGAGAGAGAGCT 828
      ||||| |||||
Db 1 GUAGAGAGAGAGAGAGCU 18

RESULT 721
US-10-665-951-1360/c
; Sequence 1360, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
```

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7247
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7247

```

```

Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 698 CTGGAGAGTGAGCGG 713
Db 1 CTGGAGAGTGAGCGG 16

```

```

RESULT 723
US-09-866-108-7449
; Sequence 7449, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEWICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668

```

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7449
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7449

```

```

Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 412 GGAGAAGGAGTTCTTC 427
Db 2 GGAGAAGGAGTTCTTC 17

```

```

RESULT 724
US-09-866-108-7451
; Sequence 7451, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEWICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687

```

; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7451
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8970

Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 413 GAGAACGAGTCTCTCA 428
Db 1 GAGAACGAGTCTCTCA 16

RESULT 725

US-09-866-108-8970/c
; Sequence 8970, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8970
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8970

US-09-866-108-8970/c

Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 851 CACCAGCTCTTCCAAG 866
Db 17 CACCAGCTCTTCCATG 2

RESULT 726

US-09-866-108-8971/c
; Sequence 8971, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8971
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8971

US-09-866-108-8971/c

Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 851 CACCAGCTCTTCCAAG 866
Db 16 CACCAGCTCTTCCATG 1

RESULT 727

US-09-740-332-1362/c
; Sequence 1362, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1362
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1362

Query Match 1.9%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 5e+02; Mismatches 0; Gaps 0; Indels 1; Indels 0; Gaps 0;

QY 594 TGCTCGGGAGCTGCA 609

Db 16 TGCTCGGGAGCTGCA 1

RESULT 728

US-09-817-879-1362/c
; Sequence 1362, Application US/09817879
; Publication No. US2003017131A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: MBH900-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1362
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1362

Query Match 1.9%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 5e+02; Mismatches 0; Gaps 0; Indels 1; Indels 0; Gaps 0;

QY 594 TGCTCGGGAGCTGCA 609

Db 16 TGCTCGGGAGCTGCA 1

RESULT 729

US-10-669-841-3955/c
; Sequence 3955, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen

; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPATITIS C VIRUS
; FILE REFERENCE: 400/042US (MBH802-249-B)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3955
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-3955

Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 5e+02; Mismatches 0; Gaps 0; Indels 1; Indels 0; Gaps 0;

QY 594 TGCTCGGGAGCTGCA 609

Db 16 TGCTCGGGAGCTGCA 1

RESULT 730

US-10-723-361-7247
; Sequence 7247, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456


```
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7247
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7247
```

```
Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. NO. 5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 698 CTGAGAGTGCAGCG 713
DB 1 CTGAGAGTGCAGCG 16
```

```
RESULT 731
US-10-723-361-7449
; Sequence 7449, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10723,361
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
```

```
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7449
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7449
```

```
Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. NO. 5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 412 GGAGAGGAGTTCCTC 427
DB 2 GGAGAGGAGTTCCTC 17
```

```
RESULT 732
US-10-723-361-7451
; Sequence 7451, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10723,361
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7451
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7451
```

```
Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. NO. 5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 413 GAGAGGAGTTCCTCA 428
DB 1 GAGAGGAGTTCCTCA 16
```

```
RESULT 733
US-10-723-361-8970/c
; Sequence 8970, Application US/10723361
```

```

; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8970
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8970

Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 851 CACCAGCTCTTCCAG 866
Db 17 CACCAGCTCTTCCATG 2

RESULT 734
US-10-723-361-8971/c
; Sequence 8971, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04

```

```

; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8971
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8971

Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 851 CACCAGCTCTTCCAG 866
Db 16 CACCAGCTCTTCCATG 1

RESULT 735
US-09-995-529-188/c
; Sequence 188, Application US/09995529
; Publication No. US20030099655A1
; GENERAL INFORMATION:
; APPLICANT: Watkins, Jeffrey D.
; APPLICANT: Tang, Ying
; APPLICANT: Huse, William D.
; TITLE OF INVENTION: Humanized Collagen Antibodies and
; TITLE OF INVENTION: Related Methods
; FILE REFERENCE: P-IX 4976
; CURRENT APPLICATION NUMBER: US/09/995,529
; CURRENT FILING DATE: 2001-11-26
; NUMBER OF SEQ ID NOS: 358
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 188
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-09-995-529-188

Query Match 1.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 5.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 347 CAGAGCAACCAAGATTC 362
Db 17 CAGAGCAACCAAGATTC 2

RESULT 736
US-09-995-529-188/c
; Sequence 188, Application US/09995529
; Publication No. US20040091482A9
; GENERAL INFORMATION:
; APPLICANT: Watkins, Jeffrey D.
; APPLICANT: Huse, William D.
; APPLICANT: Tang, Ying
; TITLE OF INVENTION: Humanized Collagen Antibodies and

```

```

; TITLE OF INVENTION: Related Methods
; FILE REFERENCE: P-IX 4976
; CURRENT APPLICATION NUMBER: US/09/995,529
; CURRENT FILING DATE: 2001-11-26
; NUMBER OF SEQ ID NOS: 358
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 188
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-09-995-529-188

Query Match          1.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 5.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 347 CAGAGCAACGAGATTC 362
Db 17 CAGAGCAACGAGATTC 2

RESULT 737
US-10-440-850-1113/c
; Sequence 1113, Application US/10440850
; Publication No. US20030207837A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Stinchcomb, Dan
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Induction of Graft Tolerance and Reversal
; TITLE OF INVENTION: Immune Responses
; FILE REFERENCE: 250/130 (MHB00-900-A)
; CURRENT APPLICATION NUMBER: US/10/440,850
; CURRENT FILING DATE: 2003-05-19
; PRIOR FILING DATE: 2000-08-28
; PRIOR APPLICATION NUMBER: US 08/585,684
; PRIOR FILING DATE: 1996-01-12
; PRIOR APPLICATION NUMBER: US 60/000,951
; PRIOR FILING DATE: 1995-07-07
; PRIOR APPLICATION NUMBER: US 09/038,073
; PRIOR FILING DATE: 1998-03-11
; NUMBER OF SEQ ID NOS: 2285
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1113
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-440-850-1113

Query Match          1.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 5.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 717 CGCTGCAGCAGCAGCA 732
Db 16 CCTGCAGCAGCAGCA 1

RESULT 738
US-10-349-143-10970/c
; Sequence 10970, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET 020CP1
; CURRENT APPLICATION NUMBER: US/10/349,143
```

```

; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 10970
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer 99-23427 for SEQ 3105, in complement
US-10-349-143-10970

Query Match          1.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 5.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 811 GGAGGAGAGAGGAAG 826
Db 17 GGAGGAGAGAGATGAAG 2

RESULT 739
US-10-226-992-70
; Sequence 70, Application US/10226992
; Publication No. US20030148507A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Fosnaugh, Kathy
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Prostaglandin D2 Receptor
; TITLE OF INVENTION: and Prostaglandin D2 Synthetase (PTGDS) Gene Expression Using Sh
; FILE REFERENCE: 400/055 (MHB01-1110-B)
; CURRENT APPLICATION NUMBER: US/10/226,992
; CURRENT FILING DATE: 2003-02-24
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-21
; NUMBER OF SEQ ID NOS: 184
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 70
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense re
US-10-226-992-70

Query Match          1.9%; Score 14.4; DB 1; Length 19;
Best Local Similarity 81.2%; Pred. No. 5.7e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 487 TCTGAGAGCGCAGAAG 502
Db 3 UCUGAAGAGCAGAAG 18

RESULT 740
US-10-226-992-153/c
; Sequence 153, Application US/10226992
; Publication No. US20030148507A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Fosnaugh, Kathy
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Prostaglandin D2 Receptor
```

```
; TITLE OF INVENTION: and Prostaglandin D2 Synthetase (PTGDS) Gene Expression Using SH
; FILE REFERENCE: 400/055 (MBHB01-1110-B)
; CURRENT APPLICATION NUMBER: US/10/226,992
; CURRENT FILING DATE: 2003-02-24
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-21
; NUMBER OF SEQ ID NOS: 184
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 153
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-226-992-153

Query Match          1.9%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 5.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 487 TCTGAAGAGGACGAAG 502
      ||||| |||||
DB 17 TCTGAAGAGGACGAAG 2

RESULT 741
US-10-830-287A-8/c
; Sequence 8, Application US/10830287A
; Publication No. US20050038238A1
; GENERAL INFORMATION:
; APPLICANT: Kriesel, John D.
; APPLICANT: Jones, Brandt B.
; APPLICANT: Grissom, Charles B.
; APPLICANT: Herpin, Geoff
; APPLICANT: Glazer, Peter M.
; TITLE OF INVENTION: OLIGONUCLEOTIDE COMPLEXES FOR USE AS ANTI-VIRAL THERAPEUTICS
; FILE REFERENCE: 007180-19
; CURRENT APPLICATION NUMBER: US/10/830,287A
; CURRENT FILING DATE: 2004-04-21
; PRIOR APPLICATION NUMBER: 60/464,270
; PRIOR FILING DATE: 2003-04-21
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Variola virus
US-10-830-287A-8

Query Match          1.9%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 5.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 405 AGAGGAGGAGGAGGA 420
      ||||| |||||
DB 16 AGAGGAGGAGGAGGA 1

RESULT 742
US-09-866-108-7243
; Sequence 7243, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
```

```
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7243
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7243

Query Match          1.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 5.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 697 GCTGGAGAGTGAGC 710
      ||||| |||||
DB 4 GCTGGAGAGTGAGC 17

RESULT 743
US-09-866-108-8972/c
; Sequence 8972, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
```

; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8972
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8972

Query Match 1.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 5.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 851 CACCAGCTCTTCCA 864
|||||
Db 15 CACCAGCTCTTCCA 2

RESULT 744
US-09-866-108-8973/c
; Sequence 8973, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8973
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8973

Query Match 1.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 5.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 851 CACCAGCTCTTCCA 864
|||||
Db 14 CACCAGCTCTTCCA 1

RESULT 745
US-10-084-839-3739
; Sequence 3739, Application US/10084839
; Publication No. US20030186238A1
; GENERAL INFORMATION:
; APPLICANT: Third Wave Technologies
; APPLICANT: Allawi, Hatim
; APPLICANT: Argue, Brad T.
; APPLICANT: Bartholomay, Christian T.
; APPLICANT: Chehak, LuAnne
; APPLICANT: Curtis, Michelle L.
; APPLICANT: Eis, Peggy S.
; APPLICANT: Hall, Jeff G.
; APPLICANT: Ji, Lin
; APPLICANT: Kaiser, Michael
; APPLICANT: Kwiatkowski, Jr., Robert W.
; APPLICANT: Lukowiak, Andrew A.
; APPLICANT: Lyamichev, Victor
; APPLICANT: Lymaicheva, Natalie E.
; APPLICANT: Ma, WuPo
; APPLICANT: Neri, Bruce P.
; APPLICANT: Olson, Sarah M.
; APPLICANT: Olson-Munoz, Marilyn C.
; APPLICANT: Schaefer, James J.
; APPLICANT: Skrzypczynski, Zbigniew
; APPLICANT: Takova, Tssetska Y.
; APPLICANT: Thompson, Lisa C.
; APPLICANT: Vedvik, Kevin L.
; TITLE OF INVENTION: RNA Detection Assays
; FILE REFERENCE: FORS-06666
; CURRENT APPLICATION NUMBER: US/10/084,839
; CURRENT FILING DATE: 2002-02-26
; NUMBER OF SEQ ID NOS: 4004
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3739
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-084-839-3739

Query Match 1.9%; Score 14; DB 1; Length 17;

```

Best Local Similarity 100.0%; Pred. No. 5.5e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 14; Conservative 0;

QY 187 GGTGAGCCGAGTG 200
Db 1 GGTGAGCCGAGTG 14

RESULT 746
US-10-723-361-7243
; Sequence 7243, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7243
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7243

Query Match 1.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 5.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 697 GCTGGAGGTGAGC 710
Db 4 GCTGGAGGTGAGC 17

RESULT 747
US-10-723-361-8972/c
; Sequence 8972, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7243
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7243

```

```

; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8972
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8972

Query Match 1.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 5.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 851 CACCAGCTCTTCCA 864
Db 15 CACCAGCTCTTCCA 2

RESULT 748
US-10-723-361-8973/c
; Sequence 8973, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8972
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8972

```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8973
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8973

Query Match      1.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 5.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      851 CACCAGCTCTTCCA 864
Db      14 CACCAGCTCTTCCA 1

RESULT 749
US-09-866-108-6823/c
; Sequence 6823, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; CURRENT FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8973
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7698

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      266 CACCTGCCTTCAGACA 282
Db      17 CACCTGCCTTCAGAAAA 1

RESULT 750
US-09-866-108-7698/c
; Sequence 7698, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7698
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7698

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      827 CTGGCCCGTCAGTTCAGGT 843
```


Query Match	1.8%;	Score 13.8;	DB 1;	Length 17;
Best Local Similarity	64.7%;	Pred. No. 5.8e+02;		

Best Local Similarity 88.2%; Pred. NO. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 374 TGCAGGAGCTTCTGCA 390
 Db 17 TGCAGGCGCTTCTGCA 1

RESULT 757
 US-09-818-875-3455
 ; Sequence 3455, Application US/09818875
 ; Publication No. US20030051270A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Kmiec, Howard B.
 ; APPLICANT: Gamper, Howard B.
 ; APPLICANT: Rice, Michael C.
 ; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
 ; FILE REFERENCE: Napro-4
 ; CURRENT APPLICATION NUMBER: US/09/818,875
 ; CURRENT FILING DATE: 2001-03-27
 ; PRIOR APPLICATION NUMBER: US 60/192,176
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR APPLICATION NUMBER: US 60/192,179
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR APPLICATION NUMBER: US 60/208,538
 ; PRIOR FILING DATE: 2000-06-01
 ; PRIOR APPLICATION NUMBER: US 60/244,989
 ; PRIOR FILING DATE: 2000-10-30
 ; NUMBER OF SEQ ID NOS: 4385
 ; SOFTWARE: Friedman macro Napro4
 ; SEQ ID NO 3455
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-09-818-875-3455

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 374 TGCAGGAGCTTCTGCA 390
 Db 1 TGCAGGCGCTTCTGCA 17

RESULT 758
 US-09-927-046-478
 ; Sequence 478, Application US/09927046
 ; Publication No. US20030064946A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Thompson, Jim
 ; APPLICANT: McKenzie, Tim
 ; APPLICANT: Ayers, Dave
 ; APPLICANT: Grupe, Andrew
 ; APPLICANT: Szymkowski, Edmund
 ; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chlori
 ; FILE REFERENCE: 249/021
 ; CURRENT APPLICATION NUMBER: US/09/927,046
 ; CURRENT FILING DATE: 2001-08-09
 ; NUMBER OF SEQ ID NOS: 5450
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 478
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-09-927-046-478

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 70.6%; Pred. No. 5.8e+02;
 Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

OY 476 GAGAAGCTCGATCTGAA 492

Db 1 GAUAAGGUGCAUCUGAA 17

RESULT 759
 US-09-827-395A-168/c
 ; Sequence 168, Application US/09827395A
 ; Publication No. US20030113891A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Lawrence Blatt
 ; APPLICANT: James McSwiggen
 ; APPLICANT: Bharat Chowira
 ; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
 ; FILE REFERENCE: MBH00-878-C (400/017)
 ; CURRENT APPLICATION NUMBER: US/09/827,395A
 ; CURRENT FILING DATE: 2001-04-05
 ; PRIOR APPLICATION NUMBER: 09/780,533
 ; PRIOR FILING DATE: 2001-02-09
 ; PRIOR APPLICATION NUMBER: 60/181,797
 ; PRIOR FILING DATE: 2000-02-11
 ; NUMBER OF SEQ ID NOS: 2617
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 168
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-09-827-395A-168

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 685 GCAGGCGCGCAGCTGG 701
 Db 17 GCAGGCGCGGAGCTGG 1

RESULT 760
 US-09-827-395A-936/c
 ; Sequence 936, Application US/09827395A
 ; Publication No. US20030113891A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Lawrence Blatt
 ; APPLICANT: James McSwiggen
 ; APPLICANT: Bharat Chowira
 ; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
 ; FILE REFERENCE: MBH00-878-C (400/017)
 ; CURRENT APPLICATION NUMBER: US/09/827,395A
 ; CURRENT FILING DATE: 2001-04-05
 ; PRIOR APPLICATION NUMBER: 09/780,533
 ; PRIOR FILING DATE: 2001-02-09
 ; PRIOR APPLICATION NUMBER: 60/181,797
 ; PRIOR FILING DATE: 2000-02-11
 ; NUMBER OF SEQ ID NOS: 2617
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 936
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-09-827-395A-936

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 800 CAGGCGCCTCGAGGA 816
 Db 17 CAGGCGCCTCGAGGA 1

RESULT 761

	;	CURRENT APPLICATION NUMBER:	US/10/156.306	
	;	CURRENT FILING DATE:	2002-05-28	
	;	NUMBER OF SEQ ID NOS:	8013	
	;	SOFTWARE:	PatentIn version 3.0	
	;	SEQ ID NO	538	
	;	LENGTH:	17	
	;	TYPE:	RNA	
	;	ORGANISM:	Homo sapiens	
	;	US-10-156-306-538		

	Query Match	1.8%;	Score 13.8;	DB 1;	Length 17;
	Best Local Similarity	88.2%;	Pred. No. 5.8e+02;		
	Matches	15;	Conservative	0;	Mismatches 2; Indels 0; Gaps 0;

QY	492	AGAGGCAGAAGGACGAG	508	
Db	17	AGAGGCAGAAGTTGCAG	1	

	RESULT 764	
	US-10-156-306-539/c	
	; Sequence 539, Application US/10156306	
	; Publication No. US20030119017A1	
	; GENERAL INFORMATION:	
	; APPLICANT: Ribozyme Pharmaceuticals, Inc.	
	; TITLE OF INVENTION: McSwiggen, James	
	; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related	
	; FILE REFERENCE: MEHB01-664-A (400/050)	
	; CURRENT APPLICATION NUMBER: US/10/156.306	
	; CURRENT FILING DATE: 2002-05-28	
	; NUMBER OF SEQ ID NOS: 8013	
	; SOFTWARE: PatentIn version 3.0	
	; SEQ ID NO 539	
	LENGTH: 17	
	TYPE: RNA	
	ORGANISM: Homo sapiens	
	US-10-156-306-539	

	Query Match	1.8%;	Score 13.8;	DB 1;	Length 17;
	Best Local Similarity	88.2%;	Pred. No. 5.8e+02;		
	Matches	15;	Conservative	0;	Mismatches 2; Indels 0; Gaps 0;

QY	491	AAGAGGCAGAAGGACGA	507	
Db	17	AAGAGGCAGAAGTTGCA	1	

	RESULT 765	
	US-10-156-306-7018	
	; Sequence 7018, Application US/10156306	
	; Publication No. US20030119017A1	
	; GENERAL INFORMATION:	
	; APPLICANT: Ribozyme Pharmaceuticals, Inc.	
	; TITLE OF INVENTION: McSwiggen, James	
	; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related	
	; FILE REFERENCE: MEHB01-664-A (400/050)	
	; CURRENT APPLICATION NUMBER: US/10/156.306	
	; CURRENT FILING DATE: 2002-05-28	
	; NUMBER OF SEQ ID NOS: 8013	
	; SOFTWARE: PatentIn version 3.0	
	; SEQ ID NO 7018	
	LENGTH: 17	
	TYPE: RNA	
	ORGANISM: Homo sapiens	
	US-10-156-306-7018	

	Query Match	1.8%;	Score 13.8;	DB 1;	Length 17;
	Best Local Similarity	76.5%;	Pred. No. 5.8e+02;		
	Matches	13;	Conservative	2;	Mismatches 2; Indels 0; Gaps 0;

OY	410	GAGGAGAAGGAGTTCCT	426	
----	-----	-------------------	-----	--

Db 1 GAGAGAGAGGAGCUCCU 17
||||| :||:
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
RESULT 766
US-10-061-201-303
; Sequence 303, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 303
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-303

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 471 GCCTGAGAGCTCGAT 487
Db 1 GCTTTGAGAGCTCGAT 17
|||||
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

RESULT 767
US-10-230-006-2067/c
; Sequence 2067, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDI
; FILE REFERENCE: 400/056 (MBH01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2067
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-2067

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 705 GTGAGCGGCGAGCGCTG 721
Db 17 GTGAGCGGCTGGCGCTG 1
|||||
RESULT 768
US-10-430-882-168/c
; Sequence 168, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haerberli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 168
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-168

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 685 GCAGGCGGCGAGCTGG 701
Db 17 GCAGGCGGAGAGCTGG 1
|||||

RESULT 769
US-10-430-882-936/c
; Sequence 936, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haerberli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512

```

; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3455
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-3455

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 374 TGCAGGAGCGCTTCTGCA 390
DB 1 TGCAGGCGCTTCTGCA 17

RESULT 772
US-10-297-068-1063
; Sequence 1063, Application US/10297068
; Publication No. US20030228585A1
; GENERAL INFORMATION:
; APPLICANT: INOKO, Hidetoshi
; APPLICANT: KAGIYA, Taeko
; APPLICANT: ICHIHARA, Tatsuo
; APPLICANT: Matsumura, Yoshiyuki
; APPLICANT: MORIYA, Shogo
; APPLICANT: NISHIDA, Michio
; TITLE OF INVENTION: KIT AND METHOD FOR DETERMINING HLA TYPES
; FILE REFERENCE: 1314OP1174
; CURRENT APPLICATION NUMBER: US/10/297,068
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: JP 2000-164798
; PRIOR FILING DATE: 2000-06-01
; NUMBER OF SEQ ID NOS: 1298
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1063
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:capture
US-10-297-068-1063

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 760 GCAGGGCCGAGCGTGG 776
DB 1 GCAGGGCCGCGTGGTGG 17

RESULT 773
US-10-261-185-3454/c
; Sequence 3454, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261.185

```

; CURRENT FILING DATE: 2002-09-27
 ; PRIOR APPLICATION NUMBER: PCT/US01/09761
 ; PRIOR FILING DATE: 2001-03-27
 ; PRIOR APPLICATION NUMBER: US 60/192,176
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR APPLICATION NUMBER: US 60/192,179
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR APPLICATION NUMBER: US 60/208,538
 ; PRIOR FILING DATE: 2000-06-01
 ; PRIOR APPLICATION NUMBER: US 60/244,989
 ; PRIOR FILING DATE: 2000-10-30
 ; NUMBER OF SEQ ID NOS: 4385
 ; SOFTWARE: Friedman macro Napro4
 ; SEQ ID NO 3454
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-10-261-185-3454

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 374 TCGGAGGAGCTTCTGCA 390
 |||||
 Db 17 TCCAGGCGCTTCTGCA 1

RESULT 774
 US-10-261-185-3455
 ; Sequence 3455, Application US/10261185
 ; Publication No. US20040014057A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Kmiec, Eric B.
 ; APPLICANT: Gamper, Howard B.
 ; APPLICANT: Rice, Michael C.
 ; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
 ; FILE REFERENCE: Napro-4CON
 ; CURRENT APPLICATION NUMBER: US/10/261,185
 ; CURRENT FILING DATE: 2002-09-27
 ; PRIOR APPLICATION NUMBER: PCT/US01/09761
 ; PRIOR FILING DATE: 2001-03-27
 ; PRIOR APPLICATION NUMBER: US 60/192,176
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR APPLICATION NUMBER: US 60/192,179
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR APPLICATION NUMBER: US 60/208,538
 ; PRIOR FILING DATE: 2000-06-01
 ; PRIOR APPLICATION NUMBER: US 60/244,989
 ; PRIOR FILING DATE: 2000-10-30
 ; NUMBER OF SEQ ID NOS: 4385
 ; SOFTWARE: Friedman macro Napro4
 ; SEQ ID NO 3455
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-10-261-185-3455

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 374 TCGGAGGAGCTTCTGCA 390
 |||||
 Db 1 TCCAGGCGCTTCTGCA 17

RESULT 775
 US-10-138-674-2829/c
 ; Sequence 2829, Application US/10138674
 ; Publication No. US20040077565A1
 ; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Pavco, Pam
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Stinchcomb, Dan
 ; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
 ; FILE REFERENCE: MBH00-876-N (400/049)
 ; CURRENT APPLICATION NUMBER: US/10/138,674
 ; CURRENT FILING DATE: 2002-05-03
 ; NUMBER OF SEQ ID NOS: 20822
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 2829
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Mus musculus
 US-10-138-674-2829

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 457 GGTGAGAGACTCGGCC 473
 |||||
 Db 17 GTAGACAGACTCGGCC 1

RESULT 776
 US-10-138-674-4771
 ; Sequence 4771, Application US/10138674
 ; Publication No. US20040077565A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Pavco, Pam
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Stinchcomb, Dan
 ; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
 ; FILE REFERENCE: MBH00-876-N (400/049)
 ; CURRENT APPLICATION NUMBER: US/10/138,674
 ; CURRENT FILING DATE: 2002-05-03
 ; NUMBER OF SEQ ID NOS: 20822
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 4771
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-138-674-4771

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 5.8e+02;
 Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 874 CAACCACATCAAGAGCA 890
 |||||
 Db 1 CAACUACCUCAAGAGCA 17

RESULT 777
 US-10-138-674-6804/c
 ; Sequence 6804, Application US/10138674
 ; Publication No. US20040077565A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Pavco, Pam
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Stinchcomb, Dan
 ; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
 ; FILE REFERENCE: MBH00-876-N (400/049)
 ; CURRENT APPLICATION NUMBER: US/10/138,674

; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6804
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-6804

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 337 TGCCATCCGCGAGCA 353
Db 17 TGCCATCCTGCTGAGCA 1

RESULT 778

US-10-287-949A-2829/c
; Sequence 2829, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2829
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-2829

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 457 GGTGGAGAGACTCGGCC 473
Db 17 GGTAGACAGACTCGGCC 1

RESULT 779

US-10-287-949A-4771
; Sequence 4771, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4771
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-4771

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 874 CAACACATCAAGAGCA 890
Db 1 CAACUACCUCAAGAGCA 17

RESULT 780

US-10-287-949A-6804/c
; Sequence 6804, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6804
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-6804

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 337 TGCCATCCGCGAGCA 353
Db 17 TGCCATCCTGCTGAGCA 1

RESULT 781

US-10-712-672-60/c
; Sequence 60, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowirra, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBHB00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 60
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-60

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 810 CGGAGAGAGAGGAG 826

```
Db      17  CTGAGAGTAGAGGAAG 1
RESULT 782
US-10-712-672-508/c
; Sequence 508, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MHB00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 508
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-508

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      712  CGAGGCGCTGCAGCAGC 728
Db      17  CGCGGCGCAGCAGCAGC 1

RESULT 783
US-10-669-841-6933
; Sequence 6933, Application US/10669841
; Publication No. US2004012746A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
; FILE REFERENCE: 400/042US (MHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
```

```
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6933
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-6933

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 5.8e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY      180  GTGATGCTGCAGCCC 196
Db      1  GUGACAUGGUACAGCCC 17

RESULT 784
US-10-723-361-6823/c
; Sequence 6823, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 6823
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
```


US-10-723-361-6823

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 266 CACCTGCTTCAGAACCA 282
DB 17 CACCTGCTTCAGAAAA 1

RESULT 785

US-10-723-361-7698/c
Sequence 7698, Application US/10723361
Publication No. US20040137589A1

GENERAL INFORMATION:

APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark

TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN

FILE REFERENCE: PB0105
CURRENT APPLICATION NUMBER: US/10/723,361
CURRENT FILING DATE: 2003-11-26

PRIOR APPLICATION NUMBER: US 09/866,108

PRIOR FILING DATE: 2001-05-25

PRIOR APPLICATION NUMBER: US 60/207,456

PRIOR FILING DATE: 2000-05-26

PRIOR APPLICATION NUMBER: GB 24263.6

PRIOR FILING DATE: 2000-10-04

PRIOR APPLICATION NUMBER: US 60/236,359

PRIOR FILING DATE: 2000-09-27

PRIOR APPLICATION NUMBER: PCT/US01/00666

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00667

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00664

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00669

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00665

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00668

PRIOR FILING DATE: 2001-01-30

Remaining Prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 15755

SOFTWARE: Aeonica Sequence Listing Engine

SEQ ID NO 7698

LENGTH: 17

TYPE: DNA

ORGANISM: Homo sapiens

US-10-723-361-7698

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 827 CTGGCCAGTTCAGGT 843
DB 17 CTGGCCAGTTCAGGT 1

RESULT 786

US-10-723-361-7813
Sequence 7813, Application US/10723361
Publication No. US20040137589A1

GENERAL INFORMATION:

APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.

APPLICANT: HANZEL, David K.

APPLICANT: RANK, David R.

APPLICANT: CHEN, Wensheng

APPLICANT: SHANNON, Mark

TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN

FILE REFERENCE: PB0105

CURRENT APPLICATION NUMBER: US/10/723,361

CURRENT FILING DATE: 2003-11-26

PRIOR APPLICATION NUMBER: US 09/866,108

PRIOR FILING DATE: 2001-05-25

PRIOR APPLICATION NUMBER: US 60/207,456

PRIOR FILING DATE: 2000-05-26

PRIOR APPLICATION NUMBER: GB 24263.6

PRIOR FILING DATE: 2000-10-04

PRIOR APPLICATION NUMBER: US 60/236,359

PRIOR FILING DATE: 2000-09-27

PRIOR APPLICATION NUMBER: PCT/US01/00666

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00667

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00664

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00669

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00665

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00668

PRIOR FILING DATE: 2001-01-30

Remaining Prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 15755

SOFTWARE: Aeonica Sequence Listing Engine

SEQ ID NO 7813

LENGTH: 17

TYPE: DNA

ORGANISM: Homo sapiens

US-10-723-361-7813

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 493 GAGGAGAGGAGGAGG 509
DB 1 GAAGCAAAAGGAGCAGG 17

RESULT 787

US-10-723-361-8421

Sequence 8421, Application US/10723361

Publication No. US20040137589A1

GENERAL INFORMATION:

APPLICANT: GU, Yizhong

APPLICANT: JI, Yonggang

APPLICANT: PENN, Sharron G.

APPLICANT: HANZEL, David K.

APPLICANT: RANK, David R.

APPLICANT: CHEN, Wensheng

APPLICANT: SHANNON, Mark

TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN

FILE REFERENCE: PB0105

CURRENT APPLICATION NUMBER: US/10/723,361

CURRENT FILING DATE: 2003-11-26

PRIOR APPLICATION NUMBER: US 09/866,108

PRIOR FILING DATE: 2001-05-25

PRIOR APPLICATION NUMBER: US 60/207,456

PRIOR FILING DATE: 2000-05-26

PRIOR APPLICATION NUMBER: GB 24263.6

PRIOR FILING DATE: 2000-10-04

PRIOR APPLICATION NUMBER: US 60/236,359

PRIOR FILING DATE: 2000-09-27

PRIOR APPLICATION NUMBER: PCT/US01/00666

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00667

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8421
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8421

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 489 TGAAGAGCGCAGAGGAG 505
Db 1 TGAAGAGCGCAGAGGAG 17

RESULT 788
US-10-723-361-8422
; Sequence 8422, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8422
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8422

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 489 TGAAGAGCGCAGAGGAG 505
Db 1 TGAAGAGCGCAGAGGAG 17

RESULT 789
US-10-681-074-3454/c
; Sequence 3454, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEC, ERIC B.
; APPLICANT: VAN BRABANT, ANJA
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; FILE REFERENCE: NaPro-18 US
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3454
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-3454

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 374 TCCGAGGAGCTTCTGCA 390
Db 17 TCCGAGGAGCTTCTGCA 1

RESULT 790
US-10-681-074-3455
; Sequence 3455, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEC, ERIC B.
; APPLICANT: VAN BRABANT, ANJA
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; FILE REFERENCE: NaPro-18 US
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3455
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-3455

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 374 TCCGAGGAGCTTCTGCA 390
Db 1 TCCGAGGAGCTTCTGCA 17
```

```
RESULT 791
US-10-498-462-66
; Sequence 66, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; CURRENT FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 66
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-66

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      672 GGGCGCGCAGCGAGCAG 688
Db      1 GGGCTGCGAGCGAGCAG 17

RESULT 792
US-10-498-462-71
; Sequence 71, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; CURRENT FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 71
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-71

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      677 GCCAGCGAGCGAGCGCG 693
Db      1 GCGAGCGAGCGAGCGCG 17

RESULT 793
US-10-498-462-2025
; Sequence 2025, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; CURRENT FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2025
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-2025

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      413 GAGAGGAGGAGTTCTCAT 429
Db      1 GAGAGGAGGAGTCTCAT 17

RESULT 794
US-10-498-462-2112
; Sequence 2112, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; CURRENT FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2112
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-2112

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      413 GAGAGGAGGAGTTCTCAT 429
Db      1 GAGAGGAGGAGTCTCAT 17

RESULT 795
US-10-498-462-2113
; Sequence 2113, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; CURRENT FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2113
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-2113
```

```
Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 414 AGAAGGAGTTCTCATG 430
DB 1 AGAAGGAATGCTTCATG 17

RESULT 796
US-10-741-600-73509/c
; Sequence 73509, Application US/10741600
; Publication No. US20050026169A1
; GENERAL INFORMATION:
; APPLICANT: CARGILL, Michele et al.
; TITLE OF INVENTION: GENETIC POLYMORPHISMS ASSOCIATED WITH
; TITLE OF INVENTION: MYOCARDIAL INFARCTION, METHODS OF DETECTION AND USES THEREOF
; FILE REFERENCE: CL001499
; CURRENT APPLICATION NUMBER: US/10/741,600
; CURRENT FILING DATE: 2003-12-22
; NUMBER OF SEQ ID NOS: 73997
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 73509
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-741-600-73509

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 720 TGCAGCAGCAGCAGCAGC 736
DB 17 TGTACCAGCAGCAGCAGC 1

RESULT 797
US-09-901-484A-384
; Sequence 384, Application US/09901484A
; Patent No. US20020119460A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; APPLICANT: Bougueleret, Lydie
; TITLE OF INVENTION: Prostate Cancer Gene
; FILE REFERENCE: GEN-T11XC3D2
; CURRENT APPLICATION NUMBER: US/09/901,484A
; CURRENT FILING DATE: 2001-07-09
; PRIOR APPLICATION NUMBER: US 08/996,306
; PRIOR FILING DATE: 1997-12-22
; PRIOR APPLICATION NUMBER: US 60/099,658
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: US 09/218,207
; PRIOR FILING DATE: 1998-12-22
; PRIOR APPLICATION NUMBER: US 09/338,907
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: US 09/853,526
; PRIOR FILING DATE: 2001-05-11
; NUMBER OF SEQ ID NOS: 578
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 384
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer for SEQ 190, SEQ 267, SEQ 191,
US-09-901-484A-384
```

```
Query Match      1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 6.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 372 GCTGCGAGGAGCTTCTG 388
DB 2 GCTGAGAGGAGCTTTTG 18

RESULT 798
US-09-853-526-384
; Sequence 384, Application US/09853526
; Patent No. US20020165345A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Ilya, Chumakov
; APPLICANT: Bougueleret, Lydie
; TITLE OF INVENTION: PROSTATE CANCER GENE
; FILE REFERENCE: GENSET.18CP1CP
; CURRENT APPLICATION NUMBER: US/09/853,526
; CURRENT FILING DATE: 2001-05-11
; PRIOR APPLICATION NUMBER: 09/338,907
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: 08/996,306
; PRIOR FILING DATE: 1997-12-22
; PRIOR APPLICATION NUMBER: 60/099,658
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 09/218,207
; PRIOR FILING DATE: 1998-12-22
; NUMBER OF SEQ ID NOS: 578
; SOFTWARE: Patent.pm
; SEQ ID NO 384
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer for SEQ 190, SEQ 267, SEQ 191,
US-09-853-526-384

Query Match      1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 6.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 372 GCTGCGAGGAGCTTCTG 388
DB 2 GCTGAGAGGAGCTTTTG 18

RESULT 799
US-09-881-012-194
; Sequence 194, Application US/09881012
; Publication No. US20020192655A1
; GENERAL INFORMATION:
; APPLICANT: Ginns, Edward I.
; APPLICANT: Egeland, Janice A.
; APPLICANT: Paul, Steven M.
; APPLICANT: The Government of the United States of America
; APPLICANT: as represented by The Secretary of the
; APPLICANT: Department of Health and Human Services
; TITLE OF INVENTION: Susceptibility and Resistance Genes for
; FILE REFERENCE: 015280-248110US
; CURRENT APPLICATION NUMBER: US/09/881,012
; CURRENT FILING DATE: 2001-06-13
; PRIOR APPLICATION NUMBER: US/09/175,158
; PRIOR FILING DATE: 1998-10-19
; PRIOR APPLICATION NUMBER: US 60/062,924
; PRIOR FILING DATE: 1997-10-20
; NUMBER OF SEQ ID NOS: 240
```

; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 194
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: D6S1713 reverse primer
US-09-881-012-194

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 6.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 558 AGGCAAGGCTCTGTG 574
Db 1 AGGCAAGGCTCTGTG 17

RESULT 800

US-09-881-012-194
; Sequence 194, Application US/09881012
; Publication No. US20040248086A9
; GENERAL INFORMATION:
; APPLICANT: Ginn, Edward I.
; APPLICANT: Egeland, Janice A.
; APPLICANT: Paul, Steven M.
; APPLICANT: The Government of the United States of America
; APPLICANT: as represented by The Secretary of the
; APPLICANT: Department of Health and Human Services
; TITLE OF INVENTION: Susceptibility and Resistance Genes for
; TITLE OF INVENTION: Bipolar Affective Disorder
; FILE REFERENCE: 015280-248100US
; CURRENT APPLICATION NUMBER: US/09/881,012
; CURRENT FILING DATE: 2001-06-13
; PRIOR APPLICATION NUMBER: US/09/175,158
; PRIOR FILING DATE: 1998-10-19
; PRIOR APPLICATION NUMBER: US 60/062,924
; PRIOR FILING DATE: 1997-10-20
; NUMBER OF SEQ ID NOS: 240
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 194
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: D6S1713 reverse primer
US-09-881-012-194

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 6.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 558 AGGCAAGGCTCTGTG 574
Db 1 AGGCAAGGCTCTGTG 17

RESULT 801

US-09-998-027-104
; Sequence 104, Application US/09998027
; Publication No. US20030093819A1
; GENERAL INFORMATION:
; APPLICANT: D'Andrea et al.
; TITLE OF INVENTION: Methods and Compositions for the
; TITLE OF INVENTION: Diagnosis and Treatment of Cancers Associated with Defective
; TITLE OF INVENTION: DNA Repair Mechanisms
; FILE REFERENCE: 2486/101
; CURRENT APPLICATION NUMBER: US/09/998,027
; CURRENT FILING DATE: 2001-11-02
; NUMBER OF SEQ ID NOS: 191
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 104
; LENGTH: 18

; TYPE: DNA
; ORGANISM: MG476
US-09-998-027-104

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 6.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 647 TGCCAGGCTCTGGAGG 663
Db 2 TGCCAGGCTCTGGAGG 18

RESULT 802

US-10-314-657-204
; Sequence 204, Application US/10314657
; Publication No. US20030175888A1
; GENERAL INFORMATION:
; APPLICANT: SHEN, Ben
; APPLICANT: CHENG, Yi-Qiang
; APPLICANT: TANG, Gong-Li
; TITLE OF INVENTION: Discrete Acyltransferases Associated with Type I Polyketide
; TITLE OF INVENTION: Synthases and Methods of Use
; FILE REFERENCE: 054030-0021
; CURRENT APPLICATION NUMBER: US/10/314,657
; CURRENT FILING DATE: 2002-12-09
; PRIOR APPLICATION NUMBER: PCT/US02/08937
; PRIOR FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: US 60/278,935
; PRIOR FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 214
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 204
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Streptomyces atroolivaceus
US-10-314-657-204

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 6.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 275 TCAGACAGGCGGCTCC 291
Db 1 TCAGATCAGGCGGCGCC 17

RESULT 803

US-10-165-099-104
; Sequence 104, Application US/10165099
; Publication No. US20030188326A1
; GENERAL INFORMATION:
; APPLICANT: D'Andrea, Alan
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF CANCER SUSCEPTIBILITY
; TITLE OF INVENTION: DEFECTIVE DNA REPAIR MECHANISMS AND TREATMENT THEREOF
; FILE REFERENCE: 7032/2055
; CURRENT APPLICATION NUMBER: US/10/165,099
; CURRENT FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 09/998,027
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: US 60/245,756
; PRIOR FILING DATE: 2000-11-03
; NUMBER OF SEQ ID NOS: 352
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 104
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-165-099-104

Query Match 1.8%; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.2%; Pred. No. 6.2e+02; Mismatches 2; Indels 0; Gaps 0;
Matches 15; Conservative 0;

QY 647 TGCCAGGCTCTGGAGG 663
DB 2 TGCCAGACTCTGTTGG 18

RESULT 804
US-10-138-674-3980/c
; Sequence 380, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Epilepsy
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 3980
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-138-674-3980

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 6.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 688 GGCGCGGCAGCTGGAGA 704
DB 18 GGCGCGGCAGCTGTAGA 2

RESULT 805
US-10-664-422-334/c
; Sequence 334, Application US/10664422
; Publication No. US20040096885A1
; GENERAL INFORMATION:
; APPLICANT: Rouleau, Guy A.
; APPLICANT: Lafreniere, Ronald G.
; TITLE OF INVENTION: LOCI FOR IDIOPATHIC GENERALIZED EPILEPSY, MUTATIONS THEREOF AND METHODS OF TREATING EPILEPSY
; FILE REFERENCE: G00D:023USD3
; CURRENT APPLICATION NUMBER: US/10/664,422
; CURRENT FILING DATE: 2003-09-17
; PRIOR APPLICATION NUMBER: 09/718,355
; PRIOR FILING DATE: 2000-11-24
; PRIOR APPLICATION NUMBER: 60/167,623
; PRIOR FILING DATE: 1999-11-26
; NUMBER OF SEQ ID NOS: 408
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 334
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
US-10-664-422-334

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 6.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 617 CAGAGTCGCTTGGAGGC 633
DB 18 CAGAGTCGCTTGGAGGC 2

RESULT 806
US-10-287-949A-3980/c
; Sequence 3980, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Epilepsy
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 09/718,355
; PRIOR FILING DATE: 2000-11-24
; PRIOR APPLICATION NUMBER: 60/167,623
; PRIOR FILING DATE: 1999-11-26
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 3980
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-3980

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 6.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 688 GGCGCGGCAGCTGGAGA 704
DB 18 GGCGCGGCAGCTGTAGA 2

RESULT 808
US-10-765-500-57

DB 18 CAGAGTCGCTTGGAGGC 2

RESULT 806
US-10-664-423-334/c
; Sequence 334, Application US/10664423
; Publication No. US20040096886A1
; GENERAL INFORMATION:
; APPLICANT: Rouleau, Guy A.
; APPLICANT: Lafreniere, Ronald G.
; APPLICANT: Rochefort, Daniel
; TITLE OF INVENTION: LOCI FOR IDIOPATHIC GENERALIZED EPILEPSY, MUTATIONS THEREOF AND METHODS OF TREATING EPILEPSY
; FILE REFERENCE: G00D:023USD2
; CURRENT APPLICATION NUMBER: US/10/664,423
; CURRENT FILING DATE: 2003-09-17
; PRIOR APPLICATION NUMBER: 09/718,355
; PRIOR FILING DATE: 2000-11-24
; PRIOR APPLICATION NUMBER: 60/167,623
; PRIOR FILING DATE: 1999-11-26
; NUMBER OF SEQ ID NOS: 408
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 334
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic oligonucleotide
US-10-664-423-334

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 6.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 617 CAGAGTCGCTTGGAGGC 633
DB 18 CAGAGTCGCTTGGAGGC 2

RESULT 807
US-10-287-949A-3980/c
; Sequence 3980, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Epilepsy
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 09/718,355
; PRIOR FILING DATE: 2000-11-24
; PRIOR APPLICATION NUMBER: 60/167,623
; PRIOR FILING DATE: 1999-11-26
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 3980
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-3980

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 6.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 688 GGCGCGGCAGCTGGAGA 704
DB 18 GGCGCGGCAGCTGTAGA 2

RESULT 808
US-10-765-500-57

; Sequence 57, Application US/10765500
; Publication No. US20040137501A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia and Lex M. Cowseert
; TITLE OF INVENTION: ANTISENSE MODULATION OF TRADD EXPRESSION
; FILE REFERENCE: RISP-0100
; CURRENT APPLICATION NUMBER: US/10/765,500
; CURRENT FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US/09/763,748
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: 09/143,212
; PRIOR FILING DATE: 1998-08-28
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 57
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
; US-10-765-500-57

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 6.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 795 AGCGCCAGCGCGCTCG 811
||||| ||| |||||
Db 2 AGCGCCGCGAGCGCTCG 18

RESULT 809
US-10-664-603-334/c
; Sequence 334, Application US/10664603
; Publication No. US20040214195A1
; GENERAL INFORMATION:
; APPLICANT: Rouleau, Guy A.
; APPLICANT: Lafreniere, Ronald G.
; APPLICANT: Rochefort, Daniel
; TITLE OF INVENTION: LOCI FOR IDIOPATHIC GENERALIZED EPILEPSY, MUTATIONS THEREOF AND
; TITLE OF INVENTION: USING SAME TO ASSESS, DIAGNOSE, PROGNOSIS OR TREAT EPILEPSY
; FILE REFERENCE: G0UD:023USD1
; CURRENT APPLICATION NUMBER: US/10/664,603
; CURRENT FILING DATE: 2003-09-17
; PRIOR APPLICATION NUMBER: 09/718,355
; PRIOR FILING DATE: 2000-11-24
; PRIOR APPLICATION NUMBER: 60/167,623
; PRIOR FILING DATE: 1999-11-26
; NUMBER OF SEQ ID NOS: 408
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 334
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic oligonucleotide
; US-10-664-603-334

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 6.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 617 CAGAGTCGCTTGAGGC 633
||||| ||||| |||
Db 18 CAGAACTGCTTGGGGC 2

RESULT 810
US-10-660-122-143
; Sequence 143, Application US/10660122
; Publication No. US20040219517A1
; GENERAL INFORMATION:
; APPLICANT: Ecker, David J.
; APPLICANT: Griffey, Richard H.

; APPLICANT: Sampath, Rangarajan
; APPLICANT: Hofstadler, Steven
; APPLICANT: McNeil, John
; APPLICANT: Crooke, Stanley T.
; TITLE OF INVENTION: Methods For Rapid Identification Of Pathogens In Humans And Animals
; FILE REFERENCE: IBIS0061-100
; CURRENT APPLICATION NUMBER: US/10/660,122
; CURRENT FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 10/323,233
; PRIOR FILING DATE: 2002-12-18
; PRIOR APPLICATION NUMBER: 09/798,007
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/431,319
; PRIOR FILING DATE: 2002-12-06
; PRIOR APPLICATION NUMBER: 60/443,443
; PRIOR FILING DATE: 2003-01-29
; PRIOR APPLICATION NUMBER: 60/443,788
; PRIOR FILING DATE: 2003-01-30
; PRIOR APPLICATION NUMBER: 60/447,529
; PRIOR FILING DATE: 2003-02-14
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 143
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
; US-10-660-122-143

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 6.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 258 CCATGCTGCACCTGCCT 274
||||| ||||| |||
Db 1 CCATGAGCACCTGTCT 17

RESULT 811
US-10-806-793-38
; Sequence 38, Application US/10806793
; Publication No. US20040230043A1
; GENERAL INFORMATION:
; APPLICANT: Johansen, Teit E.
; APPLICANT: Blom, Nikolaj
; APPLICANT: Hansen, Claus
; TITLE OF INVENTION: Novel Neurotrophic Factors
; FILE REFERENCE: 19313-001 DIV
; CURRENT APPLICATION NUMBER: US/10/806,793
; CURRENT FILING DATE: 2004-03-22
; PRIOR APPLICATION NUMBER: US/09/662,183
; PRIOR FILING DATE: 2000-09-14
; PRIOR APPLICATION NUMBER: DANISH 1998 00904
; PRIOR FILING DATE: 1998-07-06
; PRIOR APPLICATION NUMBER: USSN 60/092,229
; PRIOR FILING DATE: 1998-07-09
; PRIOR APPLICATION NUMBER: DANISH 1998 01048
; PRIOR FILING DATE: 1998-08-19
; PRIOR APPLICATION NUMBER: USSN 60/097,774
; PRIOR FILING DATE: 1998-08-25
; PRIOR APPLICATION NUMBER: DANISH 1998 01260
; PRIOR FILING DATE: 1998-10-05
; PRIOR APPLICATION NUMBER: USSN 60/103,908
; PRIOR FILING DATE: 1998-10-13
; PRIOR APPLICATION NUMBER: DANISH 1998 01265
; PRIOR FILING DATE: 1998-10-06
; PRIOR APPLICATION NUMBER: 09/347,613
; PRIOR FILING DATE: 2000-07-02
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 38
; LENGTH: 18

```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-10-806-793-38

Query Match          1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 6.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 826 GCTGGCCCGAGTTGCAGG 842
DB 1 GCTGGCCCGCTGCAGG 17

RESULT 812
US-10-809-189-13872/c
; Sequence 13872, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 13872
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-809-189-13872

Query Match          1.8%; Score 13.8; DB 1; Length 25;
Best Local Similarity 72.0%; Pred. No. 8.4e+02;
Matches 18; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 823 GAAGCTGGCCCGAGTTGCAGTGGCC 847
DB 25 GCAGCTGGCCCGAGTTGCAGTGGC 1

RESULT 813
US-10-357-467-44
; Sequence 44, Application US/10357467
; Publication No. US20030194729A1
; GENERAL INFORMATION:
; APPLICANT: Abogadie, Fe C.
; APPLICANT: Cruz, Lourdes J.
; APPLICANT: Olivera, Baldomero M.
; APPLICANT: Walker, Craig
; APPLICANT: Colledge, Clark
; APPLICANT: Hillyard, David R.
; APPLICANT: Jimenez, Elsie
; TITLE OF INVENTION: Conantokins.
; NUMBER OF SEQUENCES: 71
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Rothwell, Figg, Ernst & Manbeck, P.C.
; STREET: 1425 K Street, N.W., Suite 800
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
```

```
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/357,467
; FILING DATE: 04-Feb-2003
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 09/142,080
; FILING DATE: 15-MAY-2000
; APPLICATION NUMBER: WO US97/12618
; FILING DATE: 21-JUL-1997
; APPLICATION NUMBER: US 08/684,742
; FILING DATE: 22-JUL-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Ihnen, Jeffrey L.
; REGISTRATION NUMBER: 28,957
; REFERENCE/DOCKET NUMBER: 2314-256.A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-783-6040
; TELEFAX: 202-783-6031
; INFORMATION FOR SEQ ID NO: 44:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "probe"
; SEQUENCE DESCRIPTION: SEQ ID NO: 44:
US-10-357-467-44

Query Match          1.8%; Score 13.6; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 6.1e+02;
Matches 10; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 315 AGGAGATCAAGAGCT 330
DB 2 ARGAAAYCARGAYT 17

RESULT 814
US-09-504-231A-988/c
; Sequence 988, Application US/09504231A
; Patent No. US20020013458A1
; GENERAL INFORMATION:
; APPLICANT: Blatt, Lawrence
; APPLICANT: McSwiggen, James
; APPLICANT: Roberts, Beth
; APPLICANT: Favco, Pamela
; APPLICANT: Macejak, Dennis
; TITLE OF INVENTION: ENZYMAIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATEI
; FILE REFERENCE: Ipi 247/282
; CURRENT APPLICATION NUMBER: US/09/504,231A
; CURRENT FILING DATE: 2000-02-15
; PRIOR APPLICATION NUMBER: 09/274,553
; PRIOR FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 09/257,608
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 60/100,842
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/083,217
; PRIOR FILING DATE: 1998-04-27
; NUMBER OF SEQ ID NOS: 3242
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 988
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target
US-09-504-231A-988

Query Match          1.8%; Score 13.4; DB 1; Length 15;
```


Best Local Similarity 93.3%; Pred. No. 5.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 595 GCTCGGGAGCTGCA 609
Db 15 GCTCGGGAGCTGCA 1

RESULT 815
US-09-274-553D-988/c
; Sequence 988, Application US/09274553D
; Patent No. US20020082225A1
; GENERAL INFORMATION:
; APPLICANT: Blatt, Lawrence
; APPLICANT: McSwiggen, James
; APPLICANT: Roberts, Beth
; APPLICANT: Pavco, Pamela
; APPLICANT: Macejak, Dennis
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE
; FILE REFERENCE: HEPATITIS C VIRUS INFECTION
; FILE REFERENCE: IP1 247/282
; CURRENT APPLICATION NUMBER: US/09/274,553D
; CURRENT FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 09/257,608
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 60/100,842
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/083,217
; PRIOR FILING DATE: 1998-04-27
; NUMBER OF SEQ ID NOS: 3148
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 988
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target

US-09-274-553D-988

Query Match 1.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 5.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 595 GCTCGGGAGCTGCA 609
Db 15 GCTCGGGAGCTGCA 1

RESULT 816
US-09-907-111-18
; Sequence 18, Application US/09907111
; Publication No. US20030003461A1
; GENERAL INFORMATION:
; APPLICANT: Pagratis, Nikos
; APPLICANT: Gold, Larry
; APPLICANT: Shtatland, Timur
; APPLICANT: Javornik, Brenda
; TITLE OF INVENTION: Truncation SELEX Method
; FILE REFERENCE: NEX 79
; CURRENT APPLICATION NUMBER: US/09/907,111
; CURRENT FILING DATE: 2001-07-17
; PRIOR APPLICATION NUMBER: 09/275,850
; PRIOR FILING DATE: 1999-03-24
; NUMBER OF SEQ ID NOS: 351
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 18
; LENGTH: 15
; TYPE: RNA
; ORGANISM: E. coli
US-09-907-111-18

Query Match 1.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 5.5e+02;

Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 720 TGCAGCAGCAGCACA 734
Db 1 UGCAGCAGCAGCGCA 15

RESULT 817
US-10-440-850-387/c
; Sequence 387, Application US/10440850
; Publication No. US20030207837A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Induction of Graft Tolerance and Revert
; FILE REFERENCE: Immune Responses
; FILE REFERENCE: 250/130 (MEHB00-900-A)
; CURRENT APPLICATION NUMBER: US/10/440,850
; CURRENT FILING DATE: 2003-05-19
; PRIOR APPLICATION NUMBER: US/09/650,012
; PRIOR FILING DATE: 2000-08-28
; PRIOR APPLICATION NUMBER: US 08/585,684
; PRIOR FILING DATE: 1996-01-12
; PRIOR APPLICATION NUMBER: US 60/000,951
; PRIOR FILING DATE: 1995-07-07
; PRIOR APPLICATION NUMBER: US 09/038,073
; PRIOR FILING DATE: 1998-03-11
; NUMBER OF SEQ ID NOS: 2285
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 387
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-440-850-387

Query Match 1.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 5.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 579 CCCAGGTGAGTCCT 593
Db 15 CCCAGGTGAGTCCT 1

RESULT 818
US-10-407-818-7/c
; Sequence 7, Application US/10407818
; Publication No. US20040198971A1
; GENERAL INFORMATION:
; APPLICANT: RABBANI, ELAZAR
; APPLICANT: STAVRIANPOULOS, JANNIS G.
; APPLICANT: DONEGAN, JAMES J.
; TITLE OF INVENTION: MULTISIGNAL LABELING REAGENTS, AND PROCESSES AND USES
; FILE REFERENCE: ENZ-65
; CURRENT APPLICATION NUMBER: US/10/407,818
; CURRENT FILING DATE: 2003-04-03
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-407-818-7

Query Match 1.8%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 5.5e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 718 GCTGACGACGACGACCA 732
 DB 15 GCAGCAGCAGCAGCA 1

RESULT 819

US-10-307-928A-36/c
 ; Sequence 36, Application US/10307928A
 ; Publication No. US2003029016A1

; GENERAL INFORMATION:
 ; APPLICANT: Alsobrook, John P.
 ; APPLICANT: Anderson, David W.
 ; APPLICANT: Boldog, Ferenc L.
 ; APPLICANT: Burgess, Catherine E.
 ; APPLICANT: Catterton, Elina
 ; APPLICANT: Edinger, Shlomit R.
 ; APPLICANT: Gorman, Linda
 ; APPLICANT: Guo, Xiaojia (Sasha)
 ; APPLICANT: Ji, Weizhen
 ; APPLICANT: Kekuda, Ramesh
 ; APPLICANT: Li, Li
 ; APPLICANT: Patturajan, Meera
 ; APPLICANT: Rieger, Daniel K.
 ; APPLICANT: Shenoy, Suresh G.
 ; APPLICANT: Spytek, Kimberly A.
 ; APPLICANT: Vernet, Corine A.M.
 ; APPLICANT: Voss, Edward Z.
 ; APPLICANT: Zhong, Mei

; TITLE OF INVENTION: NOVEL HUMAN PROTEINS, POLYNUCLEOTIDES ENCODING THEM AND METHODS

; FILE REFERENCE: 24102-502D
 ; CURRENT APPLICATION NUMBER: US/10/307,928A

; CURRENT FILING DATE: 2002-12-02
 ; PRIOR APPLICATION NUMBER: 60/341,477
 ; PRIOR FILING DATE: 2001-12-17
 ; PRIOR APPLICATION NUMBER: 60/341,540
 ; PRIOR FILING DATE: 2001-12-17
 ; PRIOR APPLICATION NUMBER: 60/342,592
 ; PRIOR FILING DATE: 2001-12-20
 ; PRIOR APPLICATION NUMBER: 60/344,903
 ; PRIOR FILING DATE: 2001-12-31
 ; PRIOR APPLICATION NUMBER: 60/373,288
 ; PRIOR FILING DATE: 2002-04-17
 ; PRIOR APPLICATION NUMBER: 60/380,981
 ; PRIOR FILING DATE: 2002-05-15
 ; PRIOR APPLICATION NUMBER: 60/381,495
 ; PRIOR FILING DATE: 2002-05-17
 ; PRIOR APPLICATION NUMBER: 60/383,744
 ; PRIOR FILING DATE: 2002-05-28
 ; PRIOR APPLICATION NUMBER: 60/384,024
 ; PRIOR FILING DATE: 2002-05-29
 ; PRIOR APPLICATION NUMBER: 60/401,788
 ; PRIOR FILING DATE: 2002-08-07
 ; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 53
 ; SOFTWARE: Curaseqlist version 0.1
 ; SEQ ID NO 36
 ; LENGTH: 16
 ; TYPE: DNA

; ORGANISM: Artificial Sequence
 ; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Primer/Probe
 US-10-307-928A-36

Query Match 1.8%; Score 13.4; DB 1; Length 16;
 Best Local Similarity 93.3%; Pred. No. 6e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 201 GTGGCCCGCAGCAGCA 215

DB 15 GTGGCCCTGCAGCAG 1

RESULT 820

US-09-866-108-6824/c
 ; Sequence 824, Application US/09866108
 ; Patent No. US20020048800A1

; GENERAL INFORMATION:
 ; APPLICANT: GU, Yizhong
 ; APPLICANT: Ji, Yonggang
 ; APPLICANT: PENN, Sharron G.
 ; APPLICANT: HANZEL, David K.
 ; APPLICANT: RANK, David R.
 ; APPLICANT: CHEN, Wensheng
 ; APPLICANT: SHANNON, Mark
 ; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
 ; FILE REFERENCE: AEWICA-7
 ; CURRENT APPLICATION NUMBER: US/09/866,108
 ; CURRENT FILING DATE: 2001-05-25
 ; PRIOR APPLICATION NUMBER: US 60/207,456
 ; PRIOR FILING DATE: 2000-05-26
 ; PRIOR APPLICATION NUMBER: GB 24263.6
 ; PRIOR FILING DATE: 2000-10-04
 ; PRIOR APPLICATION NUMBER: US 60/236,359
 ; PRIOR FILING DATE: 2000-09-27
 ; PRIOR APPLICATION NUMBER: PCT/US01/00666
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00667
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00663
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00662
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00661
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00670
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: US 60/234,687
 ; PRIOR FILING DATE: 2000-09-21
 ; PRIOR APPLICATION NUMBER: US 60/266,860
 ; PRIOR FILING DATE: 2001-02-05
 ; NUMBER OF SEQ ID NOS: 15752
 ; SOFTWARE: Aecomica Sequence Listing Engine
 ; SEQ ID NO 6824
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-09-866-108-6824

Query Match 1.8%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 6.4e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 266 CACCTGCCTTCAGAA 280

DB 16 CACCTGCCTTGAGAA 2

RESULT 821

US-09-866-108-6825/c
 ; Sequence 825, Application US/09866108
 ; Patent No. US20020048800A1

; GENERAL INFORMATION:
 ; APPLICANT: GU, Yizhong

/ APPLICANT: JI, Yonggang
/ APPLICANT: PENN, Sharron G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
/ FILE REFERENCE: AEOMICA-7
/ CURRENT APPLICATION NUMBER: US/09/866,108
/ PRIOR FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00663
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00662
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00661
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00670
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: US 60/234,687
/ PRIOR FILING DATE: 2000-09-21
/ PRIOR APPLICATION NUMBER: US 60/266,860
/ PRIOR FILING DATE: 2001-02-05
/ NUMBER OF SEQ ID NOS: 15752
/ SOFTWARE: Aeonica Sequence Listing Engine
/ SEQ ID NO 6825
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-09-866-108-6825

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 266 CACCTGCCTTCAGAA 280
Db 15 CACCTGCCTTCAGAA 1
|||||

RESULT 822
US-09-866-108-7248
/ Sequence 7248, Application US/09866108
/ Patent No. US20020048800A1
/ GENERAL INFORMATION:
/ APPLICANT: GU, Yizhong
/ APPLICANT: JI, Yonggang
/ APPLICANT: PENN, Sharron G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
/ FILE REFERENCE: AEOMICA-7
/ CURRENT APPLICATION NUMBER: US/09/866,108
/ CURRENT FILING DATE: 2001-05-25

/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00663
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00662
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00661
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00670
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: US 60/234,687
/ PRIOR FILING DATE: 2000-09-21
/ PRIOR APPLICATION NUMBER: US 60/266,860
/ PRIOR FILING DATE: 2001-02-05
/ NUMBER OF SEQ ID NOS: 15752
/ SOFTWARE: Aeonica Sequence Listing Engine
/ SEQ ID NO 7248
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-09-866-108-7248

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 699 TGGAGAGTGAGCGCG 713
Db 1 TGGAGAGTGAGCGGG 15
|||||

RESULT 823
US-09-866-108-7448
/ Sequence 7448, Application US/09866108
/ Patent No. US20020048800A1
/ GENERAL INFORMATION:
/ APPLICANT: GU, Yizhong
/ APPLICANT: JI, Yonggang
/ APPLICANT: PENN, Sharron G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
/ FILE REFERENCE: AEOMICA-7
/ CURRENT APPLICATION NUMBER: US/09/866,108
/ CURRENT FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30

```
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7448
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7448
```

```
Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 412 GGAGAGGAGTTCTCT 426
Db 3 GGAGAGGAGTTCTCT 17
||||| |||||||
```

```
RESULT 824
US-09-866-108-7452
; Sequence 7452, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7452
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7452
```

```
Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 414 AGAAGGAGTTCTCTCA 428
Db 1 AGAAGGAGTTCTCTCA 15
||||| |||||||
```

```
RESULT 825
US-09-866-108-8419
; Sequence 8419, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-02-05
```

; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 8419
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8419

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 489 TGAAGAGCGCAGAGG 503
Db 3 TGAAGAGCGCAGAGG 17

RESULT 826

US-09-866-108-8420
; Sequence 8420, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 8420
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8420

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 489 TGAAGAGCGCAGAGG 503
Db 2 TGAAGAGCGCAGAGG 16

RESULT 827

US-09-866-108-8969/c
; Sequence 8969, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 8969
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8969

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 852 ACCAGCTCTTCCAG 866
Db 17 ACCAGCTCTTCCATG 3

RESULT 828

US-09-864-785-124
; Sequence 124, Application US/09864785

```
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of NF-Kappa B
; FILE REFERENCE: 400/022 (MHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 124
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-124

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 6.4e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 884 AAGAGCAGCGTGGTG 898
Db 3 AAGAGCAGCGUGGG 17

RESULT 829
US-09-864-785-1475
; Sequence 1475, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of NF-Kappa B
; FILE REFERENCE: 400/022 (MHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1475
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-1475

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 6.4e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 884 AAGAGCAGCGTGGTG 898
Db 2 AAGAGCAGCGUGGG 16

RESULT 830
US-09-825-805-656/c
; Sequence 656, Application US/09825805
; Publication No. US20030004122A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
```

```
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleotides
; FILE REFERENCE: MBH00-831-F (400/009)
; CURRENT APPLICATION NUMBER: US/09/825,805
; CURRENT FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: 09/578,223
; PRIOR FILING DATE: 2000-05-23
; PRIOR APPLICATION NUMBER: 09/476,387
; PRIOR FILING DATE: 1999-12-30
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1558
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 656
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-825-805-656

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 642 AGGAATGCCAGCTC 656
Db 16 AGAATGCCAGGCTC 2

RESULT 831
US-09-740-332-3193
; Sequence 3193, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3193
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide subtrate
US-09-740-332-3193

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 6.4e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 594 TCCTCGGGGAGCTGC 608
Db 3 UGCUCGGCGAGCUGC 17

RESULT 832
US-09-817-879-3193
; Sequence 3193, Application US/09817879
; Publication No. US20030171311A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: MBHB00-801-P
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3193
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3193

Query Match      1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 6.4e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY      594 TGCTCGGGGAGCTGC 608
      :||:|||||:|:|
Db      3 UGCTCGCGGAGCGTC 17

RESULT 833
US-10-163-552-306/c
; Sequence 306, Application US/10163552
; Publication No. US2003010501A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
; TITLE OF INVENTION: HER2
; FILE REFERENCE: MBHB01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 306
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-306

Query Match      1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      642 AGGAATGCCAGGCTC 656
      ||| ||||| |||||
Db      16 AGAATGCCAGGCTC 2

RESULT 834
US-10-339-782-104/c
; Sequence 104, Application US/10339782
; Publication No. US20030166026A1
; GENERAL INFORMATION:
; APPLICANT: Lynx Therapeutics, Inc.
; APPLICANT: Goodman, Laurie J
; APPLICANT: Bowen, Benjamin A
; TITLE OF INVENTION: Identification of Specific Biomarkers for Breast Cancer Cells
; FILE REFERENCE: 37-000110US
; CURRENT APPLICATION NUMBER: US/10/339,782
; CURRENT FILING DATE: 2003-01-08
; NUMBER OF SEQ ID NOS: 495
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 104
; LENGTH: 17
```

```
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-339-782-104

Query Match      1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      492 AGAGGCAGAGGAGC 506
      ||||| ||||| |||||
Db      15 AGAGGCAGAGGATC 1

RESULT 835
US-10-339-782-127
; Sequence 127, Application US/10339782
; Publication No. US20030166026A1
; GENERAL INFORMATION:
; APPLICANT: Lynx Therapeutics, Inc.
; APPLICANT: Goodman, Laurie J
; APPLICANT: Bowen, Benjamin A
; TITLE OF INVENTION: Identification of Specific Biomarkers for Breast Cancer Cells
; FILE REFERENCE: 37-000110US
; CURRENT APPLICATION NUMBER: US/10/339,782
; CURRENT FILING DATE: 2003-01-08
; NUMBER OF SEQ ID NOS: 495
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 127
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-339-782-127

Query Match      1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      241 TCCTCTGGGGAGGCC 255
      ||||| ||||| |||||
Db      3 TCCTGTGGGGAGGCC 17

RESULT 836
US-10-230-006-1418
; Sequence 1418, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDIT
; FILE REFERENCE: 400/056 (MBHB01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1418
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-1418

Query Match      1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 6.4e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY      488 CTGAAGAGCGCAGAG 502
      |:||||| |||||
Db      1 CUGAAGAGCAGAG 15
```

```
RESULT 837
US-10-230-006-2221
; Sequence 2221, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDI
; FILE REFERENCE: 400/056 (MBH01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2221
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-2221

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 487 TCTGAAGAGGCGAAG 501
   :|:|||||
Db 3 UCUGAAGAGCGAAG 17

RESULT 838
US-10-307-005-975
; Sequence 975, Application US/10307005
; Publication No. US20030236208A1
; GENERAL INFORMATION:
; APPLICANT: University of Delaware
; APPLICANT: Eric B. Kmiec
; APPLICANT: Howard B. Gamper
; APPLICANT: Michael C. Rice
; APPLICANT: Jungsup Kim
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations in Plants
; FILE REFERENCE: Napro/009 PCT
; CURRENT APPLICATION NUMBER: US/10/307,005
; CURRENT FILING DATE: 2002-11-26
; PRIOR APPLICATION NUMBER: PCT/US01/17672
; PRIOR FILING DATE: 2001-06-01
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; NUMBER OF SEQ ID NOS: 2717
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 975
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Oryza sativa
US-10-307-005-975

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 899 GGCAGTGAGCGGAAG 913
   |||||
Db 17 GGCAGTGAGCGGAAG 3

RESULT 840
US-10-138-674-3805/c
; Sequence 3805, Application US/10138674
; Publication No. US2004007565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jalme
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3805
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-138-674-3805

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 696 AGCTGAGAGTGAGC 710
   |||||
Db 16 AGCTGAGAGTGAGC 2

RESULT 841
US-10-138-674-7939
; Sequence 7939, Application US/10138674
```



```
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MEH800-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7939
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-7939

Query Match      1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 6.4e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY      540 GCCAGCAGCAGATGG 554
Db      2 GCCAGGAGCAGAUGG 16

RESULT 842
US-10-412-672-3/c
; Sequence 3, Application US/10412672
; Publication No. US20040091488A1
; GENERAL INFORMATION:
; APPLICANT: SERMAN, GERHARD
; TITLE OF INVENTION: ANTIGENIC CONSTRUCTS OF MAJOR HISTOCOMPATIBILITY
; TITLE OF INVENTION: COMPLEX CLASS I ANTIGENS WITH SPECIFIC CARRIER
; FILE REFERENCE: SCH-1977D1
; CURRENT APPLICATION NUMBER: US/10/412,672
; CURRENT FILING DATE: 2003-04-14
; PRIOR APPLICATION NUMBER: 08/460,569
; PRIOR FILING DATE: 1995-06-02
; PRIOR FILING DATE: 07/912,677
; PRIOR FILING DATE: 1992-07-14
; PRIOR APPLICATION NUMBER: 07/385,532
; PRIOR FILING DATE: 1989-07-26
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-412-672-3

Query Match      1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      293 GAGACCCCTCCAGCGC 307
Db      17 GAGACGCTCCAGCGC 3

RESULT 843
US-10-287-949A-3805/c
; Sequence 3805, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
```

```
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MEH800-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3805
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-3805

Query Match      1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      696 AGCTGCGAGAGTGAGC 710
Db      16 AGCTGCGAGAGGAGC 2

RESULT 844
US-10-287-949A-7939
; Sequence 7939, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MEH800-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7939
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-7939

Query Match      1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 6.4e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY      540 GCCAGCAGCAGATGG 554
Db      2 GCCAGGAGCAGAUGG 16

RESULT 845
US-10-712-672-59/c
; Sequence 59, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MEH800-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
```

; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5886
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 59
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-59

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. NO. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 812 GAGGAGAGGAGGAG 826
||||| ||||| |||||
Db 17 GAGGAGTAGGAGGAG 3

RESULT 846

US-10-712-672-667/c
; Sequence 667, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan

; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH800-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5886
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 667
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-667

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. NO. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 812 GAGGAGAGGAGGAG 826
||||| ||||| |||||
Db 16 GAGGAGTAGGAGGAG 2

RESULT 847

US-10-669-841-5786
; Sequence 5786, Application US/10669841
; Publication No. US2004012746A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patricia, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
; TITLE OF INVENTION: VIRUS REPLICATION

; FILE REFERENCE: 400/042US (MBH802-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5786
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-5786

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. NO. 6.4e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 594 TGCTCGGGGAGCTGC 608
:||||| |||||
Db 3 UGCUCGGCGAGCUGC 17

RESULT 848

US-10-723-361-6824/c
; Sequence 6824, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; Remaining Prior Application data removed - See File Wrapper or PALM.
 ; NUMBER OF SEQ ID NOS: 15755
 ; SOFTWARE: Aeonica Sequence Listing Engine
 ; SEQ ID NO 6824
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-10-723-361-6824

Query Match 1.8%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 6.4e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 266 CACCTGCCTTCAGAA 280
 Db 16 CACCTGCCTTCAGAA 2

RESULT 849
 US-10-723-361-6825/c
 ; Sequence 6825, Application US/10723361
 ; Publication No. US20040137589A1
 ; GENERAL INFORMATION:
 ; APPLICANT: GU, Yizhong
 ; APPLICANT: JI, Yonggang
 ; APPLICANT: PENN, Sharron G.
 ; APPLICANT: HANZEL, David K.
 ; APPLICANT: RANK, David R.
 ; APPLICANT: CHEN, Wensheng
 ; APPLICANT: SHANNON, Mark
 ; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
 ; FILE REFERENCE: PB0105
 ; CURRENT APPLICATION NUMBER: US/10/723,361
 ; CURRENT FILING DATE: 2003-11-26
 ; PRIOR APPLICATION NUMBER: US 09/866,108
 ; PRIOR FILING DATE: 2001-05-25
 ; PRIOR APPLICATION NUMBER: US 60/207,456
 ; PRIOR FILING DATE: 2000-05-26
 ; PRIOR APPLICATION NUMBER: GB 24263.6
 ; PRIOR FILING DATE: 2000-10-04
 ; PRIOR APPLICATION NUMBER: US 60/236,359
 ; PRIOR FILING DATE: 2000-09-27
 ; PRIOR APPLICATION NUMBER: PCT/US01/00666
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00667
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; Remaining Prior Application data removed - See File Wrapper or PALM.
 ; NUMBER OF SEQ ID NOS: 15755
 ; SOFTWARE: Aeonica Sequence Listing Engine
 ; SEQ ID NO 6825
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-10-723-361-6825

Query Match 1.8%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 6.4e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 266 CACCTGCCTTCAGAA 280
 Db 15 CACCTGCCTTCAGAA 1

RESULT 850
 US-10-723-361-7248
 ; Sequence 7248, Application US/10723361
 ; Publication No. US20040137589A1
 ; GENERAL INFORMATION:
 ; APPLICANT: GU, Yizhong
 ; APPLICANT: JI, Yonggang
 ; APPLICANT: PENN, Sharron G.
 ; APPLICANT: HANZEL, David K.
 ; APPLICANT: RANK, David R.
 ; APPLICANT: CHEN, Wensheng
 ; APPLICANT: SHANNON, Mark
 ; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
 ; FILE REFERENCE: PB0105
 ; CURRENT APPLICATION NUMBER: US/10/723,361
 ; CURRENT FILING DATE: 2003-11-26
 ; PRIOR APPLICATION NUMBER: US 09/866,108
 ; PRIOR FILING DATE: 2001-05-25
 ; PRIOR APPLICATION NUMBER: US 60/207,456
 ; PRIOR FILING DATE: 2000-05-26
 ; PRIOR APPLICATION NUMBER: GB 24263.6
 ; PRIOR FILING DATE: 2000-10-04
 ; PRIOR APPLICATION NUMBER: US 60/236,359
 ; PRIOR FILING DATE: 2000-09-27
 ; PRIOR APPLICATION NUMBER: PCT/US01/00666
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00667
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; Remaining Prior Application data removed - See File Wrapper or PALM.
 ; NUMBER OF SEQ ID NOS: 15755
 ; SOFTWARE: Aeonica Sequence Listing Engine
 ; SEQ ID NO 7248
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-10-723-361-7248

Query Match 1.8%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 6.4e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 699 TGGAGAGTGGCGG 713
 Db 1 TGGAGAGTGGCGG 15

RESULT 851
 US-10-723-361-7448
 ; Sequence 7448, Application US/10723361
 ; Publication No. US20040137589A1
 ; GENERAL INFORMATION:
 ; APPLICANT: GU, Yizhong
 ; APPLICANT: JI, Yonggang
 ; APPLICANT: PENN, Sharron G.
 ; APPLICANT: HANZEL, David K.
 ; APPLICANT: RANK, David R.

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Ascomica Sequence Listing Engine
; SEQ ID NO 7452
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7452

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 414 AGAAGGAGTTCCTCA 428
|||||
Db 1 AGAACGAGTTCCTCA 15

RESULT 853
US-10-723-361-8419
; Sequence 8419, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.

```

```

; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN SKELETAL MUSCLE
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; REMINDER Prior Application data removed - See File Wrapper or PALM
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecmica Sequence Listing Engine
; SEQ ID NO 8419
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8419

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0;

```

```
QY 489 TGAAGAGCGCAGAAGG 503
||||| |||||||
Db 3 TGAAGAGCGCAGAAGG 17

RESULT 854
US-10-723-361-8420
; Sequence 8420, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8420
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8420

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred.No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 489 TGAAGAGCGCAGAAGG 503
||||| |||||||
Db 2 TGAAGAGCGCAGAAGG 16

RESULT 855
US-10-723-361-8969/c
; Sequence 8969, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
```

```
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8969
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8969

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred.No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 852 ACCAGCTCTTCCAAG 866
||||| |||||||
Db 17 ACCAGCTCTTCCATG 3

RESULT 856
US-10-712-633-1089
; Sequence 1089, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACT
; FILE REFERENCE: RECEPTOR FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND
; CURRENT APPLICATION NUMBER: US/10/712,633
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/708,690
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 09/870,161
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 60/334,461
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
```

; SEQ ID NO 1089
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-10-712-633-1089

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 6.4e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 540 GCAGCAGCAGTGG 554
||||| |||||:|
Db 2 GCCAGAGCAGG 16

RESULT 857

US-10-498-462-777
; Sequence 777, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; CURRENT FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 777
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-777

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 815 GAGAGAGGAGCTG 829
| | | | | | | | | |
Db 3 GTGAGAGGAGCTG 17

RESULT 858

US-10-156-306-7822
; Sequence 7822, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7822
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7822

Query Match 1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 5.1e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 189 TGCAGCCCGTGG 201
: | | | | | | | | | |
Db 1 UGCAGCCCGTGG 13

RESULT 859

US-10-156-306-7823
; Sequence 7823, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7823
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7823

Query Match 1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 5.1e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 190 GCAGCCCGTGGT 202
| | | | | | | | | |
Db 1 GCAGCCCGTGGU 13

RESULT 860

US-10-156-306-7824
; Sequence 7824, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7824
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7824

Query Match 1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 5.1e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 297 CCCTCCAGCGTGG 309
| | | | | | | | | |
Db 1 CCCUCCAGCGUG 13

RESULT 861

US-10-156-306-7825
; Sequence 7825, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013

```
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7825
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7825

Query Match      1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 5.1e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 318 AGAATCAAGAGCT 330
      |||||:|||||:
Db 1 AGAAUCAAGGCU 13

RESULT 862
US-10-156-306-7827
; Sequence 7827, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7827
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7827

Query Match      1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 5.1e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 550 GATGGCTGAGGAC 562
      |||||:|||||
Db 1 GAUGGUCGAGGAC 13

RESULT 863
US-10-156-306-7830
; Sequence 7830, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7830
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7830

Query Match      1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 76.9%; Pred. No. 5.1e+02;
Matches 10; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 565 GGCTCTGTGAAA 577
      |||||:|||||
Db 1 GGCCUCUGAGAA 13

RESULT 864
US-10-156-306-7832
; Sequence 7832, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7832
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7832

Query Match      1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 5.1e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 743 GTGGACCACTGC 755
      |:|||||:|
Db 1 GUGGACCACTGC 13

RESULT 865
US-10-156-306-7849
; Sequence 7849, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7849
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7849

Query Match      1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 5.1e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 303 AGCGTGCTGGA 315
      |||||:|||||
Db 1 AGCGTGCTGGA 13

RESULT 866
US-10-156-306-7850
; Sequence 7850, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
```

; SEQ ID NO 7850
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7850

Query Match 1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 5.1e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 322 TCAAGAGTCCGA 334
:|||||:||||
Db 1 UCAAGAGCUCCA 13

RESULT 867

US-10-156-306-7852
; Sequence 7852, Application US/10156306
; Publication No. US20030119017A1

; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7852
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7852

Query Match 1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 76.9%; Pred. No. 5.1e+02;
Matches 10; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 566 GCCTCTGTGAAAG 578
||||:|:||||
Db 1 GCCUCUGUGAAG 13

RESULT 868

US-10-156-306-7854
; Sequence 7854, Application US/10156306
; Publication No. US20030119017A1

; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7854
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7854

Query Match 1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 5.1e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 699 TCGAGAGTGAGCG 711
:|||||:||||
Db 1 UGGAGAGUGAGCG 13

RESULT 869

US-10-257-017B-129695/c
; Sequence 129695, Application US/10257017B
; Publication No. US20040241651A1

; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms (SNPs) and cytosine
; TITLE OF INVENTION: methylations
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 129695
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0032456

US-10-257-017B-129695

Query Match 1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 873 ACAACCATCAAA 885
|||||:||||
Db 13 ACAACCATCAAA 1

RESULT 870

US-10-257-017B-129696
; Sequence 129696, Application US/10257017B
; Publication No. US20040241651A1

; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms (SNPs) and cytosine
; TITLE OF INVENTION: methylations
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 129696
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0032456

US-10-257-017B-129696

Query Match 1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 873 ACAACCATCAAA 885
|||||:||||
Db 1 ACAACCATCAAA 13

RESULT 871

US-10-257-017B-130515
; Sequence 130515, Application US/10257017B
; Publication No. US20040241651A1

; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock


```
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 130515
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0032599
US-10-257-017B-130515

Query Match      1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      407 AGGAGGAGGAGG 419
Db      1 AGGAGGAGGAGG 13

RESULT 872
US-10-257-017B-130516/c
; Sequence 130516, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 130516
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0032599
US-10-257-017B-130516

Query Match      1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      407 AGGAGGAGGAGG 419
Db      13 AGGAGGAGGAGG 1

RESULT 873
US-09-811-286-11
; Sequence 11, Application US/09811286
; Patent No. US20010051712A1
; GENERAL INFORMATION:
; APPLICANT: Drysdale, Connie M
; APPLICANT: Judson, Richard S
; APPLICANT: Liggett, Stephen B
; APPLICANT: Nandabalan, Krishnan
; APPLICANT: Stack, Catherine B.
; APPLICANT: Stephens, J. Claiborne
; TITLE OF INVENTION: Association of beta2-adrenergic receptor haplotypes
; FILE REFERENCE: MMH-0303US1
```

```
; CURRENT APPLICATION NUMBER: US/09/811,286
; CURRENT FILING DATE: 2001-03-16
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 11
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-811-286-11

Query Match      1.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 6.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      196 CAGTGTGGCCCG 208
Db      3 CAGTGTGGCCCG 15

RESULT 874
US-09-979-593-20
; Sequence 20, Application US/09979593
; Publication No. US20030082555A1
; GENERAL INFORMATION:
; APPLICANT: Genaisance Pharmaceuticals, Inc.
; APPLICANT: Chew, Anne
; APPLICANT: Choi, Julie Y
; APPLICANT: Denton, R. Rex
; APPLICANT: Kliem, Stefanie E
; APPLICANT: Lee, Helen H
; APPLICANT: Nandabalan, Krishnan
; TITLE OF INVENTION: HAPLOTYPES OF THE ICAM2 GENE
; FILE REFERENCE: MMH-0425 PCT ICAM2
; CURRENT APPLICATION NUMBER: US/09/979,593
; CURRENT FILING DATE: 2001-11-14
; PRIOR APPLICATION NUMBER: PCT/US01/14714
; PRIOR FILING DATE: 2001-05-07
; PRIOR APPLICATION NUMBER: 60/201,946
; PRIOR FILING DATE: 2000-05-05
; NUMBER OF SEQ ID NOS: 83
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 20
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapien
US-09-979-593-20

Query Match      1.7%; Score 13; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 6.1e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY      210 CAGCAGATCAGGACG 224
Db      1 CAGCAGATCAGGGYG 15

RESULT 875
US-09-811-285-11
; Sequence 11, Application US/09811285
; Publication No. US20030091998A1
; GENERAL INFORMATION:
; APPLICANT: Drysdale, Connie M
; APPLICANT: Judson, Richard S
; APPLICANT: Liggett, Stephen B
; APPLICANT: Nandabalan, Krishnan
; APPLICANT: Stephens, J. Claiborne
; TITLE OF INVENTION: Association of beta2-adrenergic receptor haplotypes
; FILE REFERENCE: MMH-0303US2
; CURRENT APPLICATION NUMBER: US/09/811,285
; CURRENT FILING DATE: 2001-03-16
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: Patentin Ver. 2.1
```

```
; SEQ ID NO 11
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-811-285-11

Query Match          1.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 6.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 196 CAGTGGTGGCCCG 208
Db 3 CAGTGGTGGCCCG 15

RESULT 876
US-10-852-943-37
; Sequence 37, Application US/10852943
; Publication No. US20050037388A1
; GENERAL INFORMATION:
; APPLICANT: University of Geneva
; APPLICANT: Stylianos, Antonarakis
; APPLICANT: Deutch, Samuel
; TITLE OF INVENTION: METHOD FOR DETECTING DISEASES CAUSED BY CHROMOSOMAL IMBALANCES
; FILE REFERENCE: 27067/2005
; CURRENT APPLICATION NUMBER: US/10/852,943
; CURRENT FILING DATE: 2004-05-25
; PRIOR APPLICATION NUMBER: US 60/300,266
; PRIOR FILING DATE: 2001-06-21
; PRIOR APPLICATION NUMBER: US 10/177,063
; PRIOR FILING DATE: 2002-06-21
; NUMBER OF SEQ ID NOS: 98
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 37
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: PRIMER
US-10-852-943-37

Query Match          1.7%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 6.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 451 GAAACTGGTGGAG 463
Db 1 GAAACTGGTGGAG 13

RESULT 877
US-09-866-108-7242
; Sequence 7242, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7242
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7242

Query Match          1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 697 GCTGGAGAGTGAG 709
Db 5 GCTGGAGAGTGAG 17

RESULT 878
US-09-866-108-8974/c
; Sequence 8974, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 8974
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8974

Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 851 CACCAGCTCTCC 863
Db 13 CACCAGCTCTCC 1

RESULT 879

US-09-789-919-76/c
; Sequence 76, Application US/09789919
; Patent No. US20020064855A1
; GENERAL INFORMATION:
; APPLICANT: Lemischka, Ihor
; TITLE OF INVENTION: GENES THAT REGULATE HEMATOPOIETIC BLOOD FORMING STEM
; TITLE OF INVENTION: CELLS AND USES THEREOF
; FILE REFERENCE: 2275-1-005
; CURRENT APPLICATION NUMBER: US/09/789,919
; CURRENT FILING DATE: 2001-02-21
; NUMBER OF SEQ ID NOS: 96
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 76
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-789-919-76

Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 667 GGCCCGGGCGGCC 679
Db 17 GGCCCGGGCGGCC 5

RESULT 880

US-09-864-785-1474
; Sequence 1474, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of NF-Kappa B
; FILE REFERENCE: 400/022 (MBH00-812-D)

; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1474
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-1474

Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 7e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 884 AAAGCAGCGTGG 896
Db 5 AAAGCAGCGGUG 17

RESULT 881

US-09-740-332-1584/c
; Sequence 1584, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1584
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1584

Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 782 GCGCTCCGATGG 794
Db 17 GCGCTCCGATGG 5

RESULT 882

US-09-740-332-2971
; Sequence 2971, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2971
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:

; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-2971

Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 84.6%; Pred. No. 7e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 782 GGCCTCCGCATGG 794
||||:|||||:
Db 2 GCGCUCCGAUGG 14

RESULT 883

US-09-817-879-1584/c
; Sequence 1584, Application US/09817879
; Publication No. US20030171311A1

; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: MH800-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1584
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1584

Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 782 GGCCTCCGCATGG 794
||||:|||||:
Db 17 GCGCTCCGCATGG 5

RESULT 884

US-09-817-879-2971
; Sequence 2971, Application US/09817879
; Publication No. US20030171311A1

; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: MH800-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2971
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-2971

Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 84.6%; Pred. No. 7e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 782 GGCCTCCGCATGG 794
||||:|||||:

Db 2 GCGCUCCGAUGG 14

RESULT 885

US-10-156-306-6812
; Sequence 6812, Application US/10156306
; Publication No. US20030119017A1

; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6812
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6812

Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 84.6%; Pred. No. 7e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 162 TCTGGAAGAGCCA 174
||:|||||:
Db 5 UCUGGAAGAGCCA 17

RESULT 886

US-10-669-841-4177/c
; Sequence 4177, Application US/10669841
; Publication No. US20040127446A1

; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPATITIS
; FILE REFERENCE: 400/042US (MBH02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207

```
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4177
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-4177

Query Match      1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      782 GCGCTCCGCGATGG 794
Db      17 GCGCTCCGCGATGG 5

RESULT 887
US-10-669-841-5564
; Sequence 5564, Application US/10669841
; Publication No. US2004012746A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPATITIS B VIRUS AND HEPATITIS B VIRUS
; FILE REFERENCE: 400/04205 (MBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5564
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; LOCATION:
```

```
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-5564

Query Match      1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 84.6%; Pred. No. 7e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      782 GCGCTCCGCGATGG 794
Db      2 GCGCUCGCGAUGG 14

RESULT 888
US-10-723-361-7242
; Sequence 7242, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AND
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7242
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7242

Query Match      1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      697 GCTGGAGAGTGAG 709
Db      5 GCTGGAGAGTGAG 17

RESULT 889
US-10-723-361-8974/c
; Sequence 8974, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
```

APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
FILE REFERENCE: PB0105
CURRENT APPLICATION NUMBER: US/10/723,361
CURRENT FILING DATE: 2003-11-26
PRIOR APPLICATION NUMBER: US 09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aecomica Sequence Listing Engine
SEQ ID NO 8974
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-723-361-8974

Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 7e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 13; Conservative 0;

QY 851 CACCAGCTCTTCC 863
Db 13 CACCAGCTCTTCC 1

RESULT 890
US-10-227-719D-12/c
Sequence 12, Application US/10227719D
Publication No. US20030143578A1
GENERAL INFORMATION:
APPLICANT: Pruitt, Steven
TITLE OF INVENTION: A High Throughput Method for Identification of Sequence Tags
FILE REFERENCE: 03551.0108
CURRENT APPLICATION NUMBER: US/10/227,719D
CURRENT FILING DATE: 2002-08-26
PRIOR APPLICATION NUMBER: US/60/314,991
PRIOR FILING DATE: 2001-08-24
NUMBER OF SEQ ID NOS: 13
SEQ ID NO 12
LENGTH: 16
TYPE: DNA
ORGANISM: mus musculus
FEATURE:
OTHER INFORMATION: exon from actin binding protein
US-10-227-719D-12

Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 6.9e+02; Mismatches 2; Indels 0; Gaps 0;
Matches 14; Conservative 0;

QY 407 AGGAGGAGAGGAGT 422

Db 16 AGGAGGAGATGTAGT 1
RESULT 891
US-10-453-792-242/c
Sequence 242, Application US/10453792
Publication No. US20040029110A1
GENERAL INFORMATION:
APPLICANT: STUYVER, LIEVEN
ROSSAU, RUDI
MAERTENS, GEERT
TITLE OF INVENTION: METHOD FOR TYPING AND DETECTING HBV
NUMBER OF SEQUENCES: 313
CORRESPONDENCE ADDRESS:
ADDRESSEE: NIXON & VANDERHYE P.C.
STREET: 1100 NORTH GLEBE ROAD
CITY: ARLINGTON
STATE: VIRGINIA
COUNTRY: U.S.A.
ZIP: 22201-4714
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
CURRENT APPLICATION NUMBER: US/10/453,792
FILING DATE: 04-Jun-2003
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/155,885A
FILING DATE: 08-Oct-1998
APPLICATION NUMBER: PCT/EP97/02002
FILING DATE: 21-APR-1997
APPLICATION NUMBER: EP 96870053.4
FILING DATE: 19-APR-1996
ATTORNEY/AGENT INFORMATION:
NAME: SADOFF, B.J.
REGISTRATION NUMBER: 36,663
REFERENCE/DOCKET NUMBER: 2551-5
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 816-4000
TELEFAX: (703) 816-4100
INFORMATION FOR SEQ ID NO: 242:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
SEQUENCE DESCRIPTION: SEQ ID NO: 242:
US-10-453-792-242

Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 6.9e+02; Mismatches 2; Indels 0; Gaps 0;
Matches 14; Conservative 0;

QY 395 CAAGCCAGCCAGGG 410
Db 16 CAAGCCAGACAGTGGG 1

RESULT 892
US-10-712-672-1520/c
Sequence 1520, Application US/10712672
Publication No. US20040102413A1
GENERAL INFORMATION:
APPLICANT: Ribozyne Pharmaceuticals, Inc.
APPLICANT: Chowrira, Bharat
APPLICANT: McSwiggen, Jim

```
/ APPLICANT: Stinchcomb, Dan
/ TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
/ FILE REFERENCE: MEH800-882-C (400/019)
/ CURRENT APPLICATION NUMBER: US/10/712,672
/ CURRENT FILING DATE: 2003-11-13
/ PRIOR APPLICATION NUMBER: US/09/653,225
/ PRIOR FILING DATE: 2000-08-31
/ PRIOR APPLICATION NUMBER: 60/197,769
/ PRIOR FILING DATE: 2000-04-14
/ PRIOR APPLICATION NUMBER: 60/150,713
/ PRIOR FILING DATE: 1999-08-31
/ NUMBER OF SEQ ID NOS: 5586
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 1520
/ LENGTH: 16
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-10-712-672-1520

Query Match      1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 6.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      712 CGAGGCGCTGCAGCAG 727
Db      16 CGCGGCGCAGCAGCAG 1

RESULT 893
US-10-806-422-10
/ Sequence 10, Application US/10806422
/ Publication No. US20040170604A1
/ GENERAL INFORMATION:
/ APPLICANT: Tosoh Corporation
/ TITLE OF INVENTION: IL-6 RECEPTOR IL-6 DIRECT FUSION PROTEIN
/ FILE REFERENCE: Q62375
/ CURRENT APPLICATION NUMBER: US/10/806,422
/ CURRENT FILING DATE: 2004-03-23
/ PRIOR APPLICATION NUMBER: US/09/743,239
/ PRIOR FILING DATE: 2001-01-05
/ PRIOR APPLICATION NUMBER: JP Hei. No. 10-190597
/ PRIOR FILING DATE: 1998-07-06
/ PRIOR APPLICATION NUMBER: JP Hei. No. 11-21788
/ PRIOR FILING DATE: 1999-01-29
/ PRIOR APPLICATION NUMBER: JP Hei. No. 11-123411
/ PRIOR FILING DATE: 1999-04-30
/ NUMBER OF SEQ ID NOS: 60
/ SOFTWARE: PatentIn version 3.1
/ SEQ ID NO 10
/ LENGTH: 16
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Annealed Sequence
US-10-806-422-10

Query Match      1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 6.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      690 CGCGGCGCTGCAGAG 705
Db      1 CGCGGCGCTGCAGGG 16

RESULT 894
US-10-643-775-1137/c
/ Sequence 1137, Application US/10643775
/ Publication No. US20050026156A1
/ GENERAL INFORMATION:
/ APPLICANT: Lie, Oystein
/ APPLICANT: Slettan, Audun
/ APPLICANT: Hoyum, Morten
```

```
/ APPLICANT: Lingaas, Frode
/ TITLE OF INVENTION: Verification of Food Origin Based on
/ FILE REFERENCE: 66849-019
/ CURRENT APPLICATION NUMBER: US/10/643,775
/ CURRENT FILING DATE: 2003-08-18
/ PRIOR APPLICATION NUMBER: US 60/404,200
/ PRIOR FILING DATE: 2002-08-16
/ NUMBER OF SEQ ID NOS: 1377
/ SOFTWARE: FastSeq for Windows Version 4.0
/ SEQ ID NO 1137
/ LENGTH: 16
/ TYPE: DNA
/ ORGANISM: Oreochromis niloticus
US-10-643-775-1137

Query Match      1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 6.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      622 TCGCTTGGAGGTGCC 637
Db      16 TTGCTTGGAGACTGCC 1

RESULT 895
US-09-866-108-354/c
/ Sequence 354, Application US/09866108
/ Patent No. US20030048800A1
/ GENERAL INFORMATION:
/ APPLICANT: GU, Yizhong
/ APPLICANT: JI, Yonggang
/ APPLICANT: PENN, Sharron G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
/ FILE REFERENCE: AEOMICA-7
/ CURRENT APPLICATION NUMBER: US/09/866,108
/ CURRENT FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00663
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00662
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00661
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00670
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: US 60/234,687
/ PRIOR FILING DATE: 2000-09-21
/ PRIOR APPLICATION NUMBER: US 60/266,860
/ PRIOR FILING DATE: 2001-02-05
/ NUMBER OF SEQ ID NOS: 15752
/ SOFTWARE: Aeonica Sequence Listing Engine
```

; SEQ ID NO 354
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-09-866-108-354
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.3e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 482 CTCGATCTGAAGAGGC 497
 DB 17 CTCGTTCTGGAGAGC 2

RESULT 896
 US-09-866-108-355/c
 ; Sequence 355, Application US/09866108
 ; Patent No. US20020048800A1
 ; GENERAL INFORMATION:
 ; APPLICANT: GU, Yizhong
 ; APPLICANT: JI, Yonggang
 ; APPLICANT: PENN, Sharron G.
 ; APPLICANT: HANZEL, David K.
 ; APPLICANT: RANK, David R.
 ; APPLICANT: CHEN, Wensheng
 ; APPLICANT: SHANNON, Mark
 ; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
 ; FILE REFERENCE: AEOMICA-7
 ; CURRENT APPLICATION NUMBER: US/09/866,108
 ; CURRENT FILING DATE: 2001-05-25
 ; PRIOR APPLICATION NUMBER: US 60/207,456
 ; PRIOR FILING DATE: 2000-05-26
 ; PRIOR APPLICATION NUMBER: GB 24263.6
 ; PRIOR FILING DATE: 2000-10-04
 ; PRIOR APPLICATION NUMBER: US 60/236,359
 ; PRIOR FILING DATE: 2000-09-27
 ; PRIOR APPLICATION NUMBER: PCT/US01/00666
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00667
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00662
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00663
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00662
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00661
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00670
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: US 60/234,687
 ; PRIOR FILING DATE: 2000-09-21
 ; PRIOR APPLICATION NUMBER: US 60/266,860
 ; PRIOR FILING DATE: 2001-02-05
 ; NUMBER OF SEQ ID NOS: 15752
 ; SOFTWARE: Aecomica Sequence Listing Engine
 ; SEQ ID NO 355
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-09-866-108-355

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.3e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 482 CTCGATCTGAAGAGGC 497
 DB 16 CTCGTTCTGGAGAGC 1
 RESULT 897
 US-09-866-108-672/c
 ; Sequence 672, Application US/09866108
 ; Patent No. US20020048800A1
 ; GENERAL INFORMATION:
 ; APPLICANT: GU, Yizhong
 ; APPLICANT: JI, Yonggang
 ; APPLICANT: PENN, Sharron G.
 ; APPLICANT: HANZEL, David K.
 ; APPLICANT: RANK, David R.
 ; APPLICANT: CHEN, Wensheng
 ; APPLICANT: SHANNON, Mark
 ; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
 ; FILE REFERENCE: AEOMICA-7
 ; CURRENT APPLICATION NUMBER: US/09/866,108
 ; CURRENT FILING DATE: 2001-05-25
 ; PRIOR APPLICATION NUMBER: US 60/207,456
 ; PRIOR FILING DATE: 2000-05-26
 ; PRIOR APPLICATION NUMBER: GB 24263.6
 ; PRIOR FILING DATE: 2000-10-04
 ; PRIOR APPLICATION NUMBER: US 60/236,359
 ; PRIOR FILING DATE: 2000-09-27
 ; PRIOR APPLICATION NUMBER: PCT/US01/00666
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00667
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00663
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00662
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00661
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00670
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: US 60/234,687
 ; PRIOR FILING DATE: 2000-09-21
 ; PRIOR APPLICATION NUMBER: US 60/266,860
 ; PRIOR FILING DATE: 2001-02-05
 ; NUMBER OF SEQ ID NOS: 15752
 ; SOFTWARE: Aecomica Sequence Listing Engine
 ; SEQ ID NO 672
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-09-866-108-672

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.3e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 233 GAAGAGTCTCTCTCG 248
 DB 17 GATGAGTCTCTCTCG 2

RESULT 898
 US-09-866-108-673/c
 ; Sequence 673, Application US/09866108
 ; Patent No. US20020048800A1
 ; GENERAL INFORMATION:

APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 673
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-673

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 233 GAAGAGTCTCTCTGG 248
DB 16 GATGAGTCTCTCTGG 1

RESULT 899
US-09-866-108-1523/c
Sequence 1523, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108

CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 1523
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-1523

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 846 CCTATCACCGTCTT 861
DB 17 CCCATCACCTGCTCT 2

RESULT 900
US-09-866-108-1524/c
Sequence 1524, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667

```

RESULT 901
US-09-866-108-1720/c
: Sequence 1720, Application US/09866108
: Patent No. US20020048800A1
: GENERAL INFORMATION:
: APPLICANT: GU, Yizhong
: APPLICANT: JI, Yonggang
: APPLICANT: PENN, Sharron G.
: APPLICANT: HANZEL, David K.
: APPLICANT: RANK, David R.
: APPLICANT: CHEN, Wensheng
: APPLICANT: SHANNON, Mark
: TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRES
: FILE REFERENCE: AEMICA-7
: CURRENT APPLICATION NUMBER: US/09/866,108
: CURRENT FILING DATE: 2001-05-25
: PRIOR APPLICATION NUMBER: US 60/207,456
: PRIOR FILING DATE: 2000-05-26
: PRIOR APPLICATION NUMBER: GB 24263.6
: PRIOR FILING DATE: 2000-10-04
: PRIOR APPLICATION NUMBER: US 60/236,359
: PRIOR FILING DATE: 2000-09-27
: PRIOR APPLICATION NUMBER: PCT/US01/00666
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00667
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00664
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00669
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00665
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00668
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00663

```

RESULT 902

US-09-866-108-1721/c

Sequence 1721, Application US/09866108

Patent No. US20020048800A1

GENERAL INFORMATION:

APPLICANT: GU, Yizhong

APPLICANT: JI, Yonggang

APPLICANT: PENN, Sharron G.

APPLICANT: HANZEL, David K.

APPLICANT: RANK, David R.

APPLICANT: CHEN, Wensheng

APPLICANT: SHANNON, Mark

TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

FILE REFERENCE: AEWICA-7

CURRENT APPLICATION NUMBER: US/09/866,108

CURRENT FILING DATE: 2001-05-25

PRIOR APPLICATION NUMBER: US 60/207,456

PRIOR FILING DATE: 2000-05-26

PRIOR APPLICATION NUMBER: GB 24263.6

PRIOR FILING DATE: 2000-10-04

PRIOR APPLICATION NUMBER: US 60/236,359

PRIOR FILING DATE: 2000-09-27

PRIOR APPLICATION NUMBER: PCT/US01/00666

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00667

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00664

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00669

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00665

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00668

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00663

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00662

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00661

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00670

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: US 60/234,687

PRIOR FILING DATE: 2000-09-21

PRIOR APPLICATION NUMBER: US 60/266,860

```
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1721
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-1721

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 392 TTCCAAGCCAGCCAGA 407
Db 16 TTCTGAGCCAGCCAGA 1

RESULT 903
US-09-866-108-1996/c
; Sequence 1996, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1996
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-1997/c

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 309 GCCTGGAGGAGCAATCA 324
Db 16 GCCTGGAGGAGCAATCA 1

RESULT 904
US-09-866-108-1997/c
; Sequence 1997, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1997
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-1997/c

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 309 GCCTGGAGGAGCAATCA 324
Db 16 GCCTGGAGGAGCAATCA 1

RESULT 905
US-09-866-108-6822/c
```

; Sequence 6822, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6822
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6822

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 267 ACCTGCTTCAGACAA 282
||| ||||| ||||| |||||
DB 17 ACCTGCTTCAGAGAAA 2

RESULT 906
US-09-866-108-6890/c
; Sequence 6890, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6890
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6890

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 306 GCTGCTCGAGAGAA 321
||| ||||| ||||| |||||
DB 17 GCCGCTCGAGAGAA 2

RESULT 907
US-09-866-108-6891/c
; Sequence 6891, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27

```

, FILE REFERENCE: AEOMICA-7
, CURRENT APPLICATION NUMBER: US/09/866,108
, CURRENT FILING DATE: 2001-05-25
, PRIOR APPLICATION NUMBER: US 60/207,456
, PRIOR FILING DATE: 2000-05-26
, PRIOR APPLICATION NUMBER: GB 24263.6
, PRIOR FILING DATE: 2000-10-04
, PRIOR APPLICATION NUMBER: US 60/236,359
, PRIOR FILING DATE: 2000-09-27
, PRIOR APPLICATION NUMBER: PCT/US01/00665
, PRIOR FILING DATE: 2001-01-30
, PRIOR APPLICATION NUMBER: PCT/US01/00667
, PRIOR FILING DATE: 2001-01-30
, PRIOR APPLICATION NUMBER: PCT/US01/00664
, PRIOR FILING DATE: 2001-01-30
, PRIOR APPLICATION NUMBER: PCT/US01/00669
, PRIOR FILING DATE: 2001-01-30
, PRIOR APPLICATION NUMBER: PCT/US01/00665
, PRIOR FILING DATE: 2001-01-30
, PRIOR APPLICATION NUMBER: PCT/US01/00668
, PRIOR FILING DATE: 2001-01-30
, PRIOR APPLICATION NUMBER: PCT/US01/00663
, PRIOR FILING DATE: 2001-01-30
, PRIOR APPLICATION NUMBER: PCT/US01/00662
, PRIOR FILING DATE: 2001-01-30
, PRIOR APPLICATION NUMBER: PCT/US01/00661
, PRIOR FILING DATE: 2001-01-30
, PRIOR APPLICATION NUMBER: PCT/US01/00670
, PRIOR FILING DATE: 2001-01-30

```

; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 7678
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7678

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 490 GAAGAGCGCAGAGGAG 505
|||||
DB 1 GAAGAGCGCAGAGGAG 16
|||||

RESULT 910

; Sequence 7697, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 7697
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens

US-09-866-108-7697

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 828 TGGCCAGTTCAGGT 843
|||||
DB 17 TGGCCAGTTCAGGT 2
|||||

RESULT 911

; Sequence 7699, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 7699
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7699

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 827 CTGCGCCAGTTCAGG 842
|||||
DB 16 CTGCGCCAGTTCAGG 1
|||||

RESULT 912

US-09-866-108-7812
; Sequence 7812, Application US/09866108
; Patent No. US20020048800A1

GENERAL INFORMATION:

; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00662

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00661

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00670

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: US 60/234,687

; PRIOR FILING DATE: 2000-09-21

; PRIOR APPLICATION NUMBER: US 60/266,860

; PRIOR FILING DATE: 2001-02-05

; NUMBER OF SEQ ID NOS: 15752

; SOFTWARE: Aeomica Sequence Listing Engine

; SEQ ID NO 7812

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-866-108-7812

Query Match

Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 493 GAGCGAGAGGAGCAG 508

DB 2 GAAGCAAAAGGAGCAG 17

RESULT 913

US-09-866-108-7814

; Sequence 7814, Application US/09866108

; Patent No. US20020048800A1

GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

RESULT 914

US-09-866-108-8033

; Sequence 8033, Application US/09866108

; Patent No. US20020048800A1

GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108

; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108

; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00662

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00661

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00670

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: US 60/234,687

; PRIOR FILING DATE: 2000-09-21

; PRIOR APPLICATION NUMBER: US 60/266,860

; PRIOR FILING DATE: 2001-02-05

; NUMBER OF SEQ ID NOS: 15752

; SOFTWARE: Aeomica Sequence Listing Engine

; SEQ ID NO 7814

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-866-108-7814

Query Match

Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 494 AGGCGAGAGGAGCAGG 509

DB 1 AAGCAAAAGGAGCAGG 16

```
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8033
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8033
```

```
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 696 AGCTGAGAGTGCAGCG 711
DB 2 AGCTGAGATCGAGCG 17
|||||
```

RESULT 915

```
US-09-866-108-8034
; Sequence 8034, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8034
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8034
```

```
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 696 AGCTGAGAGTGCAGCG 711
DB 1 AGCTGAGATCGAGCG 16
|||||
```

RESULT 916

```
US-09-866-108-8423
; Sequence 8423, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
```


; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8423
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8423

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 491 AAGAGCGAGAGGAGCG 506
|||||
DB 1 AAGACGCGAAGGTGC 16

RESULT 917

US-09-864-785-404
; Sequence 404, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: 400/022 (MH800-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 404
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-404

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.3e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 713 GAGGCGCTGCAGCAGC 728
|||||
DB 2 GAGGCCUGCUGCAGC 17

RESULT 918

US-09-864-785-405
; Sequence 405, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: 400/022 (MH800-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 405
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-405

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 7.3e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 257 GCCATGCTGCACCTGC 272
|||||
DB 2 GCCCUGCUGCAGCUGC 17

RESULT 919

US-09-864-785-1589
; Sequence 1589, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: 400/022 (MH800-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1589
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-1589

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.3e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 713 GAGGCGCTGCAGCAGC 728
|||||
DB 1 GAGGCCUGCUGCAGC 16

RESULT 920

US-09-864-785-1590
; Sequence 1590, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: 400/022 (MH800-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1590
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-1590

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.5%; Pred. No. 7.3e+02; Indels 0; Gaps 0;
Matches 11; Conservative 3; Mismatches 2;

QY 257 GCCATGCTGCACCTGC 272
DB 1 GCCUCGUGCAGCUGC 16

RESULT 921
US-09-864-785-1704/c
; Sequence 1704, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: Levels of NF-Kappa B
; FILE REFERENCE: 400/022 (MBH00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1704
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-1704

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 2;

QY 530 CTGAGAGATGCCAGC 545
DB 17 CTGGAGAGCTGCCAGC 2

RESULT 922
US-09-864-785-2754
; Sequence 2754, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: Levels of NF-Kappa B
; FILE REFERENCE: 400/022 (MBH00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2754
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-2754

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 7.3e+02; Indels 0; Gaps 0;
Matches 10; Conservative 4; Mismatches 2;

QY 175 ACTGTGTGAGATGGT 190
DB 175 ACTGTGTGAGATGGT 190

Db 2 ACUGUGUGACAAGGUG 17

RESULT 923
US-09-825-805-477
; Sequence 477, Application US/09825805
; Publication No. US20030004122A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleotides
; FILE REFERENCE: MBH00-831-F (400/009)
; CURRENT APPLICATION NUMBER: US/09/825,805
; CURRENT FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: 09/578,223
; PRIOR FILING DATE: 2000-05-23
; PRIOR APPLICATION NUMBER: 09/476,387
; PRIOR FILING DATE: 1999-12-30
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1558
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 477
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-825-805-477

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 7.3e+02; Indels 0; Gaps 0;
Matches 10; Conservative 4; Mismatches 2;

QY 263 CTGCACCTGCCTTCAG 278
DB 1 CUCCUCGUGCCUUCAG 16

RESULT 924
US-09-825-805-604
; Sequence 604, Application US/09825805
; Publication No. US20030004122A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleotides
; FILE REFERENCE: MBH00-831-F (400/009)
; CURRENT APPLICATION NUMBER: US/09/825,805
; CURRENT FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: 09/578,223
; PRIOR FILING DATE: 2000-05-23
; PRIOR APPLICATION NUMBER: 09/476,387
; PRIOR FILING DATE: 1999-12-30
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511

; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
 ; FILE REFERENCE: Napro-4
 ; CURRENT APPLICATION NUMBER: US/09/818,875
 ; PRIOR FILING DATE: 2001-03-27
 ; PRIOR APPLICATION NUMBER: US 60/192,176
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR APPLICATION NUMBER: US 60/192,179
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR APPLICATION NUMBER: US 60/208,538
 ; PRIOR FILING DATE: 2000-06-01
 ; PRIOR APPLICATION NUMBER: US 60/244,989
 ; PRIOR FILING DATE: 2000-10-30
 ; NUMBER OF SEQ ID NOS: 4385
 ; SOFTWARE: Friedman macro Napro4
 ; SEQ ID NO 1376
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-09-818-875-1376

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.3e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 721 GCAGCAGCAGCAGC 736
 Db 1 GCAGCAGCAGCAGC 16

RESULT 929

US-09-818-875-3102
 ; Sequence 3102, Application US/09818875
 ; Publication No. US20030051270A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Kmiec, Eric B.
 ; APPLICANT: Gamper, Howard B.
 ; APPLICANT: Rice, Michael C.
 ; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
 ; FILE REFERENCE: Napro-4
 ; CURRENT APPLICATION NUMBER: US/09/818,875
 ; PRIOR FILING DATE: 2001-03-27
 ; PRIOR APPLICATION NUMBER: US 60/192,176
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR APPLICATION NUMBER: US 60/192,179
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR APPLICATION NUMBER: US 60/208,538
 ; PRIOR FILING DATE: 2000-06-01
 ; PRIOR APPLICATION NUMBER: US 60/244,989
 ; PRIOR FILING DATE: 2000-10-30
 ; NUMBER OF SEQ ID NOS: 4385
 ; SOFTWARE: Friedman macro Napro4
 ; SEQ ID NO 3102
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-09-818-875-3102

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.3e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 724 GCAGCAGCAGCAGC 739
 Db 1 GCAGCAGCAGCAGC 16

RESULT 930

US-09-818-875-3103/c
 ; Sequence 3103, Application US/09818875
 ; Publication No. US20030051270A1
 ; GENERAL INFORMATION:

; APPLICANT: Kmiec, Eric B.
 ; APPLICANT: Gamper, Howard B.
 ; APPLICANT: Rice, Michael C.
 ; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
 ; FILE REFERENCE: Napro-4
 ; CURRENT APPLICATION NUMBER: US/09/818,875
 ; PRIOR FILING DATE: 2001-03-27
 ; PRIOR APPLICATION NUMBER: US 60/192,176
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR APPLICATION NUMBER: US 60/192,179
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR APPLICATION NUMBER: US 60/208,538
 ; PRIOR FILING DATE: 2000-06-01
 ; PRIOR APPLICATION NUMBER: US 60/244,989
 ; PRIOR FILING DATE: 2000-10-30
 ; NUMBER OF SEQ ID NOS: 4385
 ; SOFTWARE: Friedman macro Napro4
 ; SEQ ID NO 3103
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-09-818-875-3103

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.3e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 724 GCAGCAGCAGCAGC 739
 Db 17 GCAGCAGCAGCAGC 2

RESULT 931

US-09-818-875-3414
 ; Sequence 3414, Application US/09818875
 ; Publication No. US20030051270A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Kmiec, Eric B.
 ; APPLICANT: Gamper, Howard B.
 ; APPLICANT: Rice, Michael C.
 ; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
 ; FILE REFERENCE: Napro-4
 ; CURRENT APPLICATION NUMBER: US/09/818,875
 ; PRIOR FILING DATE: 2001-03-27
 ; PRIOR APPLICATION NUMBER: US 60/192,176
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR APPLICATION NUMBER: US 60/192,179
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR APPLICATION NUMBER: US 60/208,538
 ; PRIOR FILING DATE: 2000-06-01
 ; PRIOR APPLICATION NUMBER: US 60/244,989
 ; PRIOR FILING DATE: 2000-10-30
 ; NUMBER OF SEQ ID NOS: 4385
 ; SOFTWARE: Friedman macro Napro4
 ; SEQ ID NO 3414
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-09-818-875-3414

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.3e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 757 CATGCTCGGCCAGAGC 772
 Db 1 CATGCTCGGCCAGAGC 16

RESULT 932

US-09-818-875-3415/c

```
; Sequence 3415, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Knitec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3415
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-818-875-3415

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 757 CATGCGGGCCAGAGC 772
Db 17 CATGCTGGCCAGAGC 2

RESULT 933
US-09-780-533A-15
; Sequence 15, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 15
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-780-533A-15

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 7.3e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 233 GAAGAGTCTCTCTGG 248
Db 2 GACGAGUCUCCUGG 17

RESULT 934
US-09-780-533A-785
; Sequence 785, Application US/09780533A
; Publication No. US20030060611A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 785
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-780-533A-785

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 7.3e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 233 GAAGAGTCTCTCTGG 248
Db 1 GACGAGUCUCCUGG 16

RESULT 935
US-09-780-533A-1938
; Sequence 1938, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1938
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-780-533A-1938

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.3e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 487 TCTGAAGAGGCAGAG 502
Db 1 UUGAGAGUCAGAG 16

RESULT 936
US-09-780-533A-2540
; Sequence 2540, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
```

; FILE REFERENCE: MBHB00.878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2540
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-2540

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 75.0%; Pred. No. 7.3e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 486 ATCTGAAGAGGAGGAG 501

Db | : ||||| |||||

2 AUUUGAAGAGUCAGAA 17

RESULT 937

US-09-927-046-1353

; Sequence 1353, Application US/09927046

; Publication No. US20030064946A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc

; APPLICANT: McSwiggen, Jim

; APPLICANT: Thompson, Jim

; APPLICANT: McKenzie, Tim

; APPLICANT: Ayers, Dave

; APPLICANT: Grupe, Andrew

; APPLICANT: Szymkowski, Edmund

; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chlori

; TITLE OF INVENTION: Channel-1

; FILE REFERENCE: 249/021

; CURRENT APPLICATION NUMBER: US/09/927,046

; CURRENT FILING DATE: 2001-08-09

; NUMBER OF SEQ ID NOS: 5450

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 1353

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-09-927-046-1353

Query Match

Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;

Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 477 AGAAGCTCGATCTGAA 492

Db | ||||| :|||

1 AUAAGUCGACUCAGAA 16

RESULT 938

US-09-877-478-687/c

; Sequence 687, Application US/09877478

; Publication No. US20030068301A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Draper, Kenneth

; APPLICANT: Blatt, Larry

; APPLICANT: McSwiggen, Jim

; APPLICANT: Morrissey, Dave

; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication

; FILE REFERENCE: MBHB00-845-H (400/029)

; CURRENT APPLICATION NUMBER: US/09/877,478

; CURRENT FILING DATE: 2001-12-31

; PRIOR APPLICATION NUMBER: US 07/882,712

; PRIOR FILING DATE: 1992-05-14

; PRIOR APPLICATION NUMBER: US 09/531,025

; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 687
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-687

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 406 GAGGAGGAGGAGGAG 421

Db ||||| ||||| |||||

16 GAGGAGGAGGAGGAG 1

RESULT 939

US-09-877-478-1416/c

; Sequence 1416, Application US/09877478

; Publication No. US20030068301A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Draper, Kenneth

; APPLICANT: Blatt, Larry

; APPLICANT: McSwiggen, Jim

; APPLICANT: Morrissey, Dave

; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication

; FILE REFERENCE: MBHB00-845-H (400/029)

; CURRENT APPLICATION NUMBER: US/09/877,478

; CURRENT FILING DATE: 2001-12-31

; PRIOR APPLICATION NUMBER: US 07/882,712

; PRIOR FILING DATE: 1992-05-14

; PRIOR APPLICATION NUMBER: US 09/531,025

; PRIOR FILING DATE: 2000-03-20

; PRIOR APPLICATION NUMBER: US 09/636,385

; PRIOR FILING DATE: 2000-08-09

; PRIOR APPLICATION NUMBER: US 09/696,347

; PRIOR FILING DATE: 2000-10-24

; PRIOR APPLICATION NUMBER: US 08/193,627

; PRIOR FILING DATE: 1994-02-07

; PRIOR APPLICATION NUMBER: US 08/433,993

; PRIOR FILING DATE: 1995-05-04

; PRIOR APPLICATION NUMBER: US 08/434,504

; PRIOR FILING DATE: 1995-05-04

; PRIOR APPLICATION NUMBER: US 09/436,430

; PRIOR FILING DATE: 1999-11-08

; NUMBER OF SEQ ID NOS: 6586

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 1416

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Hepatitis B virus

US-09-877-478-1416

Query Match

Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 406 GAGGAGGAGGAGGAG 421

Db 17 GAGCAGGAGGAGG 2

RESULT 940

US-09-848-754A-2408
; Sequence 2408, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Growth Factor Receptors
; FILE REFERENCE: MH800-958-1 (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2408
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-2408

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.3e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 600 GCGAGCTGCAGGAGG 615
Db 2 GCGUGUGCAGGAGG 17

RESULT 941

US-09-848-754A-3399
; Sequence 3399, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Growth Factor Receptors
; FILE REFERENCE: MH800-958-1 (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3399
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-3399

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.3e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 604 GCTGCAGGAGGAGCCAG 619
Db 2 GCUGCAGGAGGAGG 17

RESULT 942

US-09-776-474-126/c
; Sequence 126, Application US/09776474
; Publication No. US20030087847A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Boher, Robert
; APPLICANT: Holman, Patricia
; APPLICANT: Fattaey, Ali
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Checkpoint Kinase-1 (CHK-1)
; CURRENT APPLICATION NUMBER: US/09/827,395A

FILE REFERENCE: MH800-955-A (400/008)
; CURRENT APPLICATION NUMBER: US/09/776,474
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: US 60/179,983
; PRIOR FILING DATE: 2000-03-02
; NUMBER OF SEQ ID NOS: 2992
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 126
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-776-474-126

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 606 TGCAGGAGGCCAGAG 621
Db 16 TGCAGCAGAGCTAGAG 1

RESULT 943

US-09-776-474-479/c
; Sequence 479, Application US/09776474
; Publication No. US20030087847A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Boher, Robert
; APPLICANT: Holman, Patricia
; APPLICANT: Fattaey, Ali
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Checkpoint Kinase-1 (CHK-1)
; CURRENT APPLICATION NUMBER: US/09/776,474
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: US 60/179,983
; PRIOR FILING DATE: 2000-03-02
; NUMBER OF SEQ ID NOS: 2992
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 479
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-776-474-479

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 606 TGCAGGAGGCCAGAG 621
Db 17 TGCAGCAGAGCTAGAG 2

RESULT 944

US-09-827-395A-12/c
; Sequence 12, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MH800-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A

; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 12
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-12

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 686 CAGGCGGCGACGCTGG 701
Db 17 CAGGCGGCGGAGCTGG 2

RESULT 945
US-09-827-395A-19/c
; Sequence 19, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 19
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-19

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 604 GCTGCAGGAGGCCAG 619
Db 16 GCTCCAGGAGGCCAG 1

RESULT 946
US-09-827-395A-65/c
; Sequence 65, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11

; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 65
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-65

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 805 CCCTCGGAGGAGAG 820
Db 16 CACCTCGGAGGAGAG 1

RESULT 947
US-09-827-395A-195/c
; Sequence 195, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 195
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-195

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 604 GCTGCAGGAGGCCAG 619
Db 17 GCTCCAGGAGGCCAG 2

RESULT 948
US-09-827-395A-367/c
; Sequence 367, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 367
; LENGTH: 17
; TYPE: RNA


```

; ORGANISM: Homo sapiens
US-09-827-395A-367

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 805 CGCCTCGGAGGAGAG 820
Db 17 CACCTCGGAGGAGG 2

RESULT 949
US-09-827-395A-377/c
; Sequence 377, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 377
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-377

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 506 CAGCGTCTCGGAGG 521
Db 16 CAGCGTTCGGGAGG 1

RESULT 950
US-09-827-395A-596/c
; Sequence 596, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 596
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-596

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 685 GCAGGCGCGCAGCTG 700
Db 16 GCAGGCGCGGAGCTG 1

RESULT 951
US-09-827-395A-695/c
; Sequence 695, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 695
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-695

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 800 CAGGCGCGCTCGGAGG 815
Db 16 CAGGCGACCTCGGAGG 1

RESULT 952
US-09-827-395A-935/c
; Sequence 935, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 935
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-935

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 802 GCGCGCTCGGAGG 817
Db 17 GGCACCTCGGAGG 2

```

```

RESULT 953
US-09-740-332-215/c
; Sequence 215, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 215
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-215

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 181 TGAGATGGTGCAGCCC 196
    ||| ||||| |||||
Db 17 TGACATGGTACAGCCC 2

RESULT 954
US-09-740-332-1115
; Sequence 1115, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1115
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1115

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 7.3e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 383 CTTCTGCATTTCCAAG 398
    ||| ||| :|||
Db 1 CUUCUGCCAUAUCCAAG 16

RESULT 955
US-09-740-332-3567
; Sequence 3567, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3567
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3567

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 735 GCGTGCAGGTGGACCA 750
    ||| ||||| |||||
Db 1 GCGUGAGUGGGGCCA 16

```

```

; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3567
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3567

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.3e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 735 GCGTGCAGGTGGACCA 750
    ||| ||||| |||||
Db 1 GCGUGAGUGGGGCCA 16

RESULT 956
US-09-740-332-3831/c
; Sequence 3831, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3831
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3831

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 829 GGCCCAAGTTCAGGTG 844
    ||| ||||| |||||
Db 16 GGCCCAAGTTCAGGTG 1

RESULT 957
US-09-792-818-271
; Sequence 271, Application US/09792818
; Publication No. US20030134806A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Von Carlowitz, Ira
; APPLICANT: McSwiggen, Jim
; APPLICANT: Hamblin, Paul
; APPLICANT: Ellis, Jonathan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Insertion of a Specific Sequence into a Protein
; FILE REFERENCE: MEH00-901-A (400/013)
; CURRENT APPLICATION NUMBER: US/09/792,818
; CURRENT FILING DATE: 2001-02-23

```

US-09-792-818-361

3-09-792-818-361

QY 73I CACAGCGTGCAGGTGG 74I
|||||||

7 / 31 CACAGCGTGCAGGTGG / 46
||||| | | | |

```

Db      2  CACAGCGGGGAGGUGG 17

RESULT 962
US-09-792-818-874
; Sequence 874, Application US/09792818
; Publication No. US20030134806A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Von Carlowitz, Ira
; APPLICANT: McSwiggen, Jim
; APPLICANT: Hamblin, Paul
; APPLICANT: Ellis, Jonathan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Insertion
; FILE REFERENCE: MBH00-901-A (400/013)
; CURRENT APPLICATION NUMBER: US/09/792,818
; CURRENT FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 2304
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 874
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-792-818-874

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.3e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY      731  CACAGCGTGCAGGTGG 746
         ||||| |||||
Db      1  CACAGCGGGGAGGUGG 16

RESULT 963
US-09-817-879-215/c
; Sequence 215, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 215
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-215

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      181  TCAGATGGTGCAGCCC 196
         ||||| ||||| |||||
Db      17  TCAGATGGTGCAGCCC 2

RESULT 964
US-09-817-879-1115
; Sequence 1115, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:

```

```

; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1115
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1115

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 7.3e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY      383  CTTCTGTCATTCCCAAG 398
         |::||| :|||
Db      1  CUUCUGCAUCCCAAG 16

RESULT 965
US-09-817-879-3567
; Sequence 3567, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3567
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3567

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.3e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY      735  GCGTGCAGGTGCACCA 750
         ||| :||| |||
Db      1  GCGUGAGUGGCGCCA 16

RESULT 966
US-09-817-879-3831/c
; Sequence 3831, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3831

```

```
;
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3831

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      829  GGCCAGTTCAGGTG 844
Db      16  GGCCAGTTCAGGTG 1

RESULT 967
US-10-060-830-311
; Sequence 311, Application US/10060830
; Publication No. US20030032154A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: HUMAN LCCL DOMAIN CONTAINING PROTEIN
; FILE REFERENCE: PB0169
; CURRENT APPLICATION NUMBER: US/10/060,830
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/325,062
; PRIOR FILING DATE: 2001-09-25
; NUMBER OF SEQ ID NOS: 1123
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 311
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-830-311

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      500  AAGGAGCAGGCTCTGC 515
Db      2    AAGAGCAGGCTATGC 17

RESULT 968
US-10-060-830-312
; Sequence 312, Application US/10060830
; Publication No. US20030032154A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: HUMAN LCCL DOMAIN CONTAINING PROTEIN
; FILE REFERENCE: PB0169
; CURRENT APPLICATION NUMBER: US/10/060,830
; CURRENT FILING DATE: 2002-01-30
```

```
;
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/325,062
; PRIOR FILING DATE: 2001-09-25
; NUMBER OF SEQ ID NOS: 1123
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 312
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-830-312

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      500  AAGGAGCAGGCTCTGC 515
Db      1    AAGAAGCAGGCTATGC 16

RESULT 969
US-10-060-998-236
; Sequence 236, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
; FILE REFERENCE: PB01108
; CURRENT APPLICATION NUMBER: US/10/060,998
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/343,331
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 3056
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 236
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-236

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      448  CAGGAACCTGGTGGAG 463
Db      2    CATGAACCTGGAGGAG 17

RESULT 970
US-10-060-998-237
; Sequence 237, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
```

```

; FILE REFERENCE: PB01108
; CURRENT APPLICATION NUMBER: US/10/060,998
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/343,331
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 3056
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 237
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-237

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 448 CAGGAACCTGGTGGAG 463
|| ||||| |||||
Db 1 CATGAACCTGGAGGAG 16

RESULT 971
US-10-060-998-1476/c
; Sequence 1476, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
; FILE REFERENCE: PB01108
; CURRENT APPLICATION NUMBER: US/10/060,998
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/343,331
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 3056
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1476
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-1476

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 884 AAGACGACGCTGGTGG 899
|| ||||| |||||
Db 17 AGGAGCAGCGTAGTGG 2

RESULT 972
US-10-060-998-1477/c
; Sequence 1477, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
; FILE REFERENCE: PB01108
; CURRENT APPLICATION NUMBER: US/10/060,998
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23

```

```

; PRIOR APPLICATION NUMBER: US 60/343,331
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 3056
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1477
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-1477

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 884 AAGACGACGCTGGTGG 899
|| ||||| |||||
Db 16 AGGAGCAGCGTAGTGG 1

RESULT 973
US-10-163-552-135
; Sequence 135, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
; FILE REFERENCE: MBHB01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 135
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-135

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 512 CTGCGGAGCGTGGAGC 527
|| ||||| |||||
Db 1 CUGCGGAGCGUGCAGC 16

RESULT 974
US-10-163-552-870
; Sequence 870, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
; FILE REFERENCE: MBHB01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 870
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-870

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 263 CTGCACCTGCCTTCAG 278

```

```
Db      1 CUCCUCCUGCCUAC 16
      |.:|.:|.:|.:|.:|
RESULT 975
US-10-156-306-1663/c
; Sequence 1663, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1663
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-1663

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      493 GAGGCAGAGGAGCAG 508
      |||||
Db      17 GAGGCAGAGGAGCAG 2

RESULT 976
US-10-156-306-1664/c
; Sequence 1664, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1664
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-1664

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      491 AAGAGGCAGAGGAGC 506
      |||||
Db      16 AAGAGGCAGAGGAGTGC 1

RESULT 977
US-10-156-306-5007
; Sequence 5007, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
```

```
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5007
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5007
```

```
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.3e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY      694 GCAGCTGGAGAGTGAG 709
      |||||
Db      1 GCAGCUGCAGAGGGAG 16
```

```
RESULT 978
US-10-156-306-5121/c
; Sequence 5121, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5121
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5121
```

```
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      190 GCAGCCAGTGCTGTC 205
      |||||
Db      16 GCATCCCACTGCTGTC 1
```

```
RESULT 979
US-10-156-306-5922/c
; Sequence 5922, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5922
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5922
```

```
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      748 CCAGCTGGCAGTGCGAG 763
      |||||
```

```
Dbb 16 CCAGCTGCTCTGCAG 1

RESULT 980
US-10-156-306-5924
; Sequence 5924, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5924
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5924

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.3e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 740 CAGGTGGACGAGTGC 755
|||:|||||:|
Db 1 CAGCUGGACGACGUCG 16

RESULT 981
US-10-156-306-5925
; Sequence 5925, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5925
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5925

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.3e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 522 TGGAGCACCTGAAGAG 537
|||||:|:|
Db 2 USGAGCAGCUGCAGAG 17

RESULT 982
US-10-156-306-6361/c
; Sequence 6361, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
```

```
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6361
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6361

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 191 CAGCCCACTGTGGCC 206
|||:|||||:|
Db 17 CATCCCACTGTGGCC 2

RESULT 983
US-10-156-306-7019
; Sequence 7019, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7019
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7019

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.3e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 411 AGGAGAGGAGTCTCT 426
|||:|||||:|
Db 1 AGAGAGGAGGAGCUCU 16

RESULT 984
US-10-156-306-7021/c
; Sequence 7021, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7021
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7021

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 749 CAGCTGGCGATGCAGG 764
|||||:|:|
Db 17 CAGCTGCTCTCTGCAGG 2
```



```

RESULT 985
US-10-156-306-7023
; Sequence 7023, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Levels
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7023
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7023

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.8%; Pred. No. 7.3e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 739 GCAGGTGGACGAGCTG 754
      |||| :||| ||||:|
Db 2 GCACUGGAGCAGCUG 17

RESULT 986
US-10-156-306-7038
; Sequence 7038, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Levels
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7038
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7038

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.8%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 812 GAGGACAGGAGGAGC 827
      |||| | ||||| |||
Db 1 GAGGACAGGAGGAGC 16

RESULT 987
US-10-238-700-3318/c
; Sequence 3318, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Levels
; FILE REFERENCE: 400/057 (MBH01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29

```

```

; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3318
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-3318

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 571 TGTGAAGGCCAGGTG 586
      |||| | ||||| |||
Db 17 TGTGAAGGCCAGGAG 2

RESULT 988
US-10-238-700-3356/c
; Sequence 3356, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Levels
; FILE REFERENCE: 400/057 (MBH01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3356
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-3356

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 740 CAGGTGGACGAGCTGC 755
      |||| | ||||| |||
Db 17 CAGACGACGAGCTGC 2

RESULT 989
US-10-061-201-51
; Sequence 51, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30

```

US-10-061-201-51
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 51
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-51

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 617 CAGAGTCGCTTGAGG 632
||| |||||
Db 2 CAGCGCGCTTGAGG 17

RESULT 990
US-10-061-201-52
; Sequence 52, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 52
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-52

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 617 CAGAGTCGCTTGAGG 632
||| |||||
Db 1 CAGCGCGCTTGAGG 16

RESULT 991

US-10-061-201-302
; Sequence 302, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 302
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-302

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 471 GCTGCGAGAGCTCGA 486
||| |||||
Db 2 GCTTGAGAGCTCGA 17

RESULT 992
US-10-061-201-304
; Sequence 304, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 304
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-304

; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 304
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-304

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 472 CCTGGAAGCTCGAT 487
Db 1 CTTGGAAGCTCGAT 16

RESULT 993
US-10-061-201-305
; Sequence 305, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 305
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-305

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 474 TGGGAAGCTCGATCT 489
Db 2 TTGGAAGCTCGATGT 17

RESULT 994
US-10-061-201-306
; Sequence 306, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark

; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 306
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-306

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 474 TGGGAAGCTCGATCT 489
Db 1 TTGGAAGCTCGATGT 16

RESULT 995
US-10-061-201-307
; Sequence 307, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark

; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine

```
; SEQ ID NO 307
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-307

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 476 GAGAGCTCGATCTGA 491
Db 2 GAGAGCTCGATGTCA 17

RESULT 996
US-10-061-201-308
; Sequence 1046, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 308
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-308

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 476 GAGAGCTCGATCTGA 491
Db 1 GAGAGCTCGATGTCA 16

RESULT 997
US-10-061-201-1046
; Sequence 1046, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; PRIOR APPLICATION NUMBER: PCT/US01/00666
```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1046
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1046

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 253 GCCAGCCATGCTGCAC 268
Db 2 GCCAGTCATCTGCAC 17

RESULT 998
US-10-061-201-1047
; Sequence 1047, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1047
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1047
```

```
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 253 GCCAGCATGCTGCAC 268
      ||||| ||||| |||||
Db 1 GCCAGTCATCTGCAC 16

RESULT 999
US-10-084-839-3484
; Sequence 3484, Application US/10094839
; Publication No. US20030186238A1
; GENERAL INFORMATION:
; APPLICANT: Third Wave Technologies
; APPLICANT: Allawi, Hatim
; APPLICANT: Argue, Brad T.
; APPLICANT: Bartholomay, Christian T.
; APPLICANT: Chehak, LuAnne
; APPLICANT: Curtis, Michelle L.
; APPLICANT: Eis, Peggy S.
; APPLICANT: Hall, Jeff G.
; APPLICANT: Ip, Hon S.
; APPLICANT: Ji, Lin
; APPLICANT: Kaiser, Michael
; APPLICANT: Kwiatkowski, Jr., Robert W.
; APPLICANT: Lukowiak, Andrew A.
; APPLICANT: Lyamichev, Victor
; APPLICANT: Lyamacheva, Natalie E.
; APPLICANT: Ma, WuPo
; APPLICANT: Neri, Bruce P.
; APPLICANT: Olson, Sarah M.
; APPLICANT: Olson-Munoz, Marilyn C.
; APPLICANT: Schaefer, James J.
; APPLICANT: Skrzypczynski, Zbigniew
; APPLICANT: Takova, Tsetska Y.
; APPLICANT: Thompson, Lisa C.
; APPLICANT: Vedvik, Kevin L.
; TITLE OF INVENTION: RNA Detection Assays
; FILE REFERENCE: FORS-06666
; CURRENT APPLICATION NUMBER: US/10/084,839
; CURRENT FILING DATE: 2002-02-26
; NUMBER OF SEQ ID NOS: 4004
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3484
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-084-839-3484

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 784 GCTCCGCATGTCGCG 799
      ||||| ||||| |||||
Db 2 GATCCGCATGTCGCG 17

RESULT 1000
US-10-230-006-107/c
; Sequence 107, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDIT
; FILE REFERENCE: 400/056 (MHB01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 683
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-683
```

```
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 107
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-107

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 677 GCCAGCGAGCGCGC 692
      ||||| ||||| |||||
Db 17 GCCAGGAGAGCGCG 2

RESULT 1001
US-10-230-006-487/c
; Sequence 487, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDIT
; FILE REFERENCE: 400/056 (MHB01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 487
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-487

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 706 TGAGCGCGAGCGCTG 721
      ||||| ||||| |||||
Db 17 TGAGCGCTGCGCGCTG 2

RESULT 1002
US-10-230-006-683/c
; Sequence 683, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDIT
; FILE REFERENCE: 400/056 (MHB01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 683
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-683
```

```
Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 677 GCACGCGAGCGCGC 692
Db 16 GCCAGGAGAGCGCGC 1

RESULT 1003
US-10-230-006-1226/c
; Sequence 1226, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDIT
; FILE REFERENCE: 400/056 (MBH01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1226
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-1226

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 705 GTGAGCGCGAGCGCCT 720
Db 16 GTGAGCGCGCTGGCGCT 1

RESULT 1004
US-10-230-006-1316
; Sequence 1316, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDIT
; FILE REFERENCE: 400/056 (MBH01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1316
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-1316

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.3e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 353 AACCAAGTCTGCGGG 368
Db 2 AACCGAGUCUGCGGG 17

RESULT 1005
US-10-230-006-1403
```

```
; Sequence 1403, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDIT
; FILE REFERENCE: 400/056 (MBH01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1403
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-1403

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 7.3e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 473 CTGGAGAGCTCGATC 488
Db 1 CUGGAGGAGCUGGAUC 16

RESULT 1006
US-10-230-006-2205
; Sequence 2205, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDIT
; FILE REFERENCE: 400/056 (MBH01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2205
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-2205

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 7.3e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 472 CCTGGAGAGCTCGAT 487
Db 2 CCUGGAGGAGCUGGAU 17

RESULT 1007
US-10-430-882-12/c
; Sequence 12, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haerberli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
```

; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 12
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-12

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 686 CAGCGCGGCGAGCTGG 701
Db 17 CAGGCACGGAAGCTGG 2

RESULT 1008
US-10-430-882-19/c
; Sequence 19, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haerberli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 19
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-19

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 604 GCTCCAGGAGCGCAG 619
Db 16 GCTCCAGGAGCGCAG 1

RESULT 1009
US-10-430-882-65/c
; Sequence 65, Application US/10430882
; Publication No. US20030203870A1

; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haerberli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 65
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-65

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 805 CGCTCGGAGGAGAG 820
Db 16 CACCTCGGAGGAGAG 1

RESULT 1010
US-10-430-882-195/c
; Sequence 195, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haerberli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 195
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-195

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 604 GCTGCAGGAGGCCAG 619
 DB 17 GCTCCAGGAGGCCAG 2

RESULT 1011
 US-10-430-882-367/c
 ; Sequence 367, Application US/10430882
 ; Publication No. US20030203870A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Lawrence Blatt
 ; APPLICANT: James McSwiggen
 ; APPLICANT: Bharat Chowira
 ; APPLICANT: Peter Haerberli
 ; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
 ; FILE REFERENCE: MBH00-878-H (400/112)
 ; CURRENT APPLICATION NUMBER: US/10/430,882
 ; CURRENT FILING DATE: 2003-05-06
 ; PRIOR APPLICATION NUMBER: 09/827,395
 ; PRIOR FILING DATE: 2001-04-05
 ; PRIOR APPLICATION NUMBER: 09/780,533
 ; PRIOR FILING DATE: 2001-02-09
 ; PRIOR APPLICATION NUMBER: PCT/US01/04273
 ; PRIOR FILING DATE: 2001-02-09
 ; PRIOR APPLICATION NUMBER: 60/181,797
 ; PRIOR FILING DATE: 2000-02-11
 ; PRIOR APPLICATION NUMBER: PCT/US02/10512
 ; PRIOR FILING DATE: 2002-04-03
 ; NUMBER OF SEQ ID NOS: 2617
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 367
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-430-882-367

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.3e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 805 CGCTCGGAGGAGAG 820
 DB 17 CACCTCGGAGGAGG 2

RESULT 1012
 US-10-430-882-377/c
 ; Sequence 377, Application US/10430882
 ; Publication No. US20030203870A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Lawrence Blatt
 ; APPLICANT: James McSwiggen
 ; APPLICANT: Bharat Chowira
 ; APPLICANT: Peter Haerberli
 ; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
 ; FILE REFERENCE: MBH00-878-H (400/112)
 ; CURRENT APPLICATION NUMBER: US/10/430,882
 ; CURRENT FILING DATE: 2003-05-06
 ; PRIOR APPLICATION NUMBER: 09/827,395
 ; PRIOR FILING DATE: 2001-04-05
 ; PRIOR APPLICATION NUMBER: 09/780,533
 ; PRIOR FILING DATE: 2001-02-09
 ; PRIOR APPLICATION NUMBER: PCT/US01/04273
 ; PRIOR FILING DATE: 2001-02-09
 ; PRIOR APPLICATION NUMBER: 60/181,797
 ; PRIOR FILING DATE: 2000-02-11
 ; PRIOR APPLICATION NUMBER: PCT/US02/10512
 ; PRIOR FILING DATE: 2002-04-03
 ; NUMBER OF SEQ ID NOS: 2617
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 377

; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-430-882-377

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.3e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 506 CAGGCTCTGCGGAGG 521
 DB 16 CAGGCGTTGCGGAGG 1

RESULT 1013
 US-10-430-882-596/c
 ; Sequence 596, Application US/10430882
 ; Publication No. US20030203870A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Lawrence Blatt
 ; APPLICANT: James McSwiggen
 ; APPLICANT: Bharat Chowira
 ; APPLICANT: Peter Haerberli
 ; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
 ; FILE REFERENCE: MBH00-878-H (400/112)
 ; CURRENT APPLICATION NUMBER: US/10/430,882
 ; CURRENT FILING DATE: 2003-05-06
 ; PRIOR APPLICATION NUMBER: 09/827,395
 ; PRIOR FILING DATE: 2001-04-05
 ; PRIOR APPLICATION NUMBER: 09/780,533
 ; PRIOR FILING DATE: 2001-02-09
 ; PRIOR APPLICATION NUMBER: PCT/US01/04273
 ; PRIOR FILING DATE: 2001-02-09
 ; PRIOR APPLICATION NUMBER: 60/181,797
 ; PRIOR FILING DATE: 2000-02-11
 ; PRIOR APPLICATION NUMBER: PCT/US02/10512
 ; PRIOR FILING DATE: 2002-04-03
 ; NUMBER OF SEQ ID NOS: 2617
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 596
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-430-882-596

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.3e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 685 GCAGGCGGCGAGCTG 700
 DB 16 GCAGGCGAGGAGCTG 1

RESULT 1014
 US-10-430-882-695/c
 ; Sequence 695, Application US/10430882
 ; Publication No. US20030203870A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Lawrence Blatt
 ; APPLICANT: James McSwiggen
 ; APPLICANT: Bharat Chowira
 ; APPLICANT: Peter Haerberli
 ; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
 ; FILE REFERENCE: MBH00-878-H (400/112)
 ; CURRENT APPLICATION NUMBER: US/10/430,882
 ; CURRENT FILING DATE: 2003-05-06
 ; PRIOR APPLICATION NUMBER: 09/827,395
 ; PRIOR FILING DATE: 2001-04-05
 ; PRIOR APPLICATION NUMBER: 09/780,533
 ; PRIOR FILING DATE: 2001-02-09

; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; CURRENT APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 695
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-695

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 800 CAGGCCGCTCGAGG 815
||| |||||
Db 16 CAGGCACCTCGGAGG 1

RESULT 1015
US-10-430-882-935/c
; Sequence 935, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haeblerli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor
; FILE REFERENCE: MEH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 935
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-935

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 802 GCGCGCTCGAGG 817
||| |||||
Db 17 GGCACCTCGGAGG 2

RESULT 1016
US-10-209-787-351
; Sequence 351, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamber, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single

; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 351
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-351

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 364 GCGGAGCGCTCGAG 379
||| |||||
Db 2 GCGTGGCGCTTCGAG 17

RESULT 1017
US-10-209-787-352/c
; Sequence 352, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamber, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 352
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-352

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 364 GCGGAGCGCTCGAG 379
||| |||||
Db 16 GCGTGGCGCTTCGAG 1

RESULT 1018
US-10-209-787-1375/c

; Sequence 1375, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; PRIOR FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1375
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-1375

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 721 GCAGCAGCAGCAGCAGC 736
DB 17 GCAGCAGCAGCTCCGC 2

RESULT 1019
US-10-209-787-1376
; Sequence 1376, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; PRIOR FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1376
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-1376

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 721 GCAGCAGCAGCAGCAGC 736
DB 1 GCAGCAGCAGCTCCGC 16

RESULT 1020
US-10-209-787-3102
; Sequence 3102, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; PRIOR FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3102
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-3102

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 724 GCAGCAGCAGCAGCGTG 739
DB 1 GCAGCAGCAGCATCGAG 16

RESULT 1021
US-10-209-787-3103/c
; Sequence 3103, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; PRIOR FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3103
; LENGTH: 17
; TYPE: DNA

```
; ORGANISM: Homo sapiens
US-10-209-787-3103

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 724 GCAGCAGCACAGGCTG 739
Db 17 GCAGCAGCACATCGAG 2

RESULT 1022
US-10-209-787-3414
; Sequence 3414, Application US/10203787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3414
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-3414

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 757 CATCGAGGCCAGC 772
Db 1 CATGCTCGGCCAGC 16

RESULT 1023
US-10-209-787-3415/c
; Sequence 3415, Application US/10203787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
```

```
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3415
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-3415

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 757 CATCGAGGCCAGC 772
Db 17 CATGCTCGGCCAGC 2

RESULT 1024
US-10-307-005-1623
; Sequence 1623, Application US/10307005
; Publication No. US20030236208A1
; GENERAL INFORMATION:
; APPLICANT: University of Delaware
; APPLICANT: Eric B. Kmiec
; APPLICANT: Howard B. Gamper
; APPLICANT: Michael C. Rice
; APPLICANT: Jungsup Kim
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations in Plants
; TITLE OF INVENTION: Using Modified Single Stranded Oligonucleotides
; FILE REFERENCE: Napro/009 PCT
; CURRENT APPLICATION NUMBER: US/10/307,005
; CURRENT FILING DATE: 2002-11-26
; PRIOR APPLICATION NUMBER: PCT/US01/17672
; PRIOR FILING DATE: 2001-06-01
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; NUMBER OF SEQ ID NOS: 2717
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1623
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Oryza sativa
US-10-307-005-1623

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 409 GGAGGAGAGGAGTTC 424
Db 2 GGAGGAGAGGAGTTC 17

RESULT 1025
US-10-307-005-1624/c
; Sequence 1624, Application US/10307005
; Publication No. US20030236208A1
; GENERAL INFORMATION:
; APPLICANT: University of Delaware
; APPLICANT: Eric B. Kmiec
; APPLICANT: Howard B. Gamper
; APPLICANT: Michael C. Rice
; APPLICANT: Jungsup Kim
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations in Plants
; TITLE OF INVENTION: Using Modified Single Stranded Oligonucleotides
; FILE REFERENCE: Napro/009 PCT
; CURRENT APPLICATION NUMBER: US/10/307,005
```



```
RESULT 1029
US-10-261-185-1376
; Sequence 1376, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1376
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-1376

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 721 GCAGCAGCAGCAGC 736
Db 1 GCAGCAGCAGCTCCG 16

RESULT 1030
US-10-261-185-3102
; Sequence 3102, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3102
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-3102

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 721 GCAGCAGCAGCAGC 736
Db 1 GCAGCAGCAGCTCCG 16

RESULT 1031
US-10-261-185-3103/C
; Sequence 3103, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3103
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-3103

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 724 GCAGCAGCAGCAGCGTG 739
Db 1 GCAGCAGCAGCATCGAG 16

RESULT 1032
US-10-261-185-3414
; Sequence 3414, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3414
```

```
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 724 GCAGCAGCAGCAGCGTG 739
Db 1 GCAGCAGCAGCATCGAG 16

RESULT 1031
US-10-261-185-3103/C
; Sequence 3103, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3103
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-3103

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 724 GCAGCAGCAGCAGCGTG 739
Db 1 GCAGCAGCAGCATCGAG 2

RESULT 1032
US-10-261-185-3414
; Sequence 3414, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3414
```

```
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-3414

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 757 CATGCTCGCCGACG 772
Db 1 CATGCTCGCCGACG 16

RESULT 1033
US-10-261-185-3415/c
; Sequence 3415, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3415
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-3415

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 757 CATGCTCGCCGACG 772
Db 17 CATGCTCGCCGACG 2

RESULT 1034
US-10-342-902-687/c
; Sequence 687, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBH00-845-1)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/596,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1416
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-1416

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 406 GAGGCGAGGAGGAG 421
Db 17 GAGGCGAGGAGGAG 2

RESULT 1036
US-10-138-674-479
```

```
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 687
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-687

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 406 GAGGCGAGGAGGAG 421
Db 16 GAGGCGAGGAGGAG 1

RESULT 1035
US-10-342-902-1416/c
; Sequence 1416, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBH00-845-1)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/596,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1416
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-1416

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 406 GAGGCGAGGAGGAG 421
Db 17 GAGGCGAGGAGGAG 2

RESULT 1036
US-10-138-674-479
```

```
; Sequence 479, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 479
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-479

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.3e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 875 AACACATCAAGAGCA 890
    ||||| : |||||
Db 1 AACUACCUCAAGAGCA 16

RESULT 1037
US-10-138-674-3556/c
; Sequence 3556, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3556
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-138-674-3556

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 815 GAGAAGAGGAGGCTGG 830
    ||||| : |||||
Db 17 GAGAAGCAGAGGCTGG 2

RESULT 1038
US-10-138-674-4770
; Sequence 4770, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
```

```
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4770
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-4770

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.3e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 874 CAACACATCAAGAGC 889
    ||||| : |||||
Db 2 CAACUACCUCAAGAGC 17

RESULT 1039
US-10-676-154-648
; Sequence 648, Application US/10676154
; Publication No. US20040081996A1
; GENERAL INFORMATION:
; APPLICANT: John Landers
; APPLICANT: David Houseman
; APPLICANT: Barbara Jordan
; APPLICANT: Alain Charest
; TITLE OF INVENTION: Methods and Products Related to
; FILE REFERENCE: M0656/7045(HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/676,154
; CURRENT FILING DATE: 2003-09-29
; PRIOR APPLICATION NUMBER: US 60/101,757
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: PCT/US99/22283
; PRIOR FILING DATE: 1999-09-24
; NUMBER OF SEQ ID NOS: 691
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 648
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo Sapiens
US-10-676-154-648

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 397 AGCCAGCCAGAGGGAG 412
    ||||| : |||||
Db 1 AGGCAGCTAGAGGGAG 16

RESULT 1040
US-10-287-949A-479
; Sequence 479, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
```

; SEQ ID NO 479
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-479

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.3e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 875 AACACATCAAGGCA 890
DB 1 AACUACCUCAAGGCA 16

RESULT 1041
US-10-287-949A-3556/c
; Sequence 3556, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3556
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-3556

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 815 GAGAGGAGGAGCTGG 830
DB 17 GAGAGGAGGAGCTGG 2

RESULT 1042
US-10-287-949A-4770
; Sequence 4770, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4770
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-4770

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.3e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 874 CAACCATCAAGGAC 889
DB 2 CAACUACCUCAAGGAC 17

RESULT 1043
US-10-712-672-1992
; Sequence 1992, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1992
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-1992

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.3e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 624 GCTTGAGGCTGCCAC 639
DB 2 GCUCGGCGGCGGCCAC 17

RESULT 1044
US-10-669-841-687/c
; Sequence 687, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
; FILE REFERENCE: 400/042US (MBH02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11


```

; PRIOR APPLICATION NUMBER: US 09/817, 879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740, 332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611, 931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504, 321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 687
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-687

```

Query Match	1.7%	Score 12.8;	DB 1;	Length 17;
Best Local Similarity	87.5%;	Pred. No. 7.3e+02;		
Matches 14;	Conservative	0;	Mismatches 2;	Indels 0;
Gaps 0;				

QY 406 GAGGAGGAGAGGAG 421
|||
Db 16 GAGGAGGAGGAGGAG 1

RESIII.T 1045

```

RESUBMIT 10433
; Sequence 1416, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, MaceJakk
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavo
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIA
; TITLE OF INVENTION: VIRUS REPLICATION
; FILE REFERENCE: 400/04250 (NBH902-249-E)
; CURRENT APPLICATION NUMBER: US/10/669.941

```

Query Match	1.7%	Score 12.8;	DB 1;	Length 17;
Best Local Similarity	87.5%;	Pred. No. 7.3e+02;		
Matches 14;	Conservative	0;	Mismatches 2;	Indels

Qy 406 GAGGAGGAGGAAGGAG 421
|||
Db 17 GAGGAGGAGGAGGAG 2

RESULT 1046

US-10-669-841-2808/c
; Sequence 2808, Application US/10669841
; Publication No. US20040127446A1

```

GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Lawrence, Blatt
APPLICANT: Dennis, Macejak
APPLICANT: James, McSwiggen
APPLICANT: David, Morrissey
APPLICANT: Pamela, Pavco
APPLICANT: Patricia, Lee
APPLICANT: Kenneth, Draper
APPLICANT: Elisabeth, Roberts
TITLE OF INVENTION: OLIGONUCLEOTIDE-BINDING AGENTS
FILE REFERENCE: 400/042US (MRH02-26)
CURRENT APPLICATION NUMBER: US/10/6106
CURRENT FILING DATE: 2003-09-23
PRIOR APPLICATION NUMBER: PCT/US02/2
PRIOR FILING DATE: 2002-03-26
PRIOR APPLICATION NUMBER: US 60/2566
PRIOR FILING DATE: 2001-06-08
PRIOR APPLICATION NUMBER: US 60/33535
PRIOR FILING DATE: 2001-10-24
PRIOR APPLICATION NUMBER: US 60/33737
PRIOR FILING DATE: 2001-12-05
PRIOR APPLICATION NUMBER: US 60/358
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 09/817
PRIOR FILING DATE: 2001-03-26
PRIOR APPLICATION NUMBER: US 09/740
PRIOR FILING DATE: 2000-12-18
PRIOR APPLICATION NUMBER: US 09/611
PRIOR FILING DATE: 2000-07-07
PRIOR APPLICATION NUMBER: US 09/504
PRIOR FILING DATE: 2000-02-15
Remaining Prior Application data re
NUMBER OF SEQ ID NOS: 16207
SOFTWARE: PatentIn version 3.0
SEQ ID NO 2808
LENGTH: 17
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of
FEATURE:
NAME/KEY: misc_feature
LOCATION:
OTHER INFORMATION: oligonucleotide
US-10-669-841-2808

```

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels

Qy 181 TGAGATGGTGCAGCCC 196
||| ||||| |||||
Db 17 TGACATGGTACAGCCC 2

```

RESULT 1047
US-10-669-841-3708
; Sequence 3708, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
; TITLE OF INVENTION: VIRUS REPLICATION
; FILE REFERENCE: 400/042US (MBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3708
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; LOCATION:
; NAME/KEY: misc_feature
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-3708

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 7.3e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY    383   CTTCTGCAATTCCAAAG 398
      ||:||| ::|||
DB     1   CUUUGGCCAUUCCAAG 16

RESULT 1048
US-10-669-841-6160
; Sequence 6160, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey

```

```

; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
; TITLE OF INVENTION: VIRUS REPLICATION
; FILE REFERENCE: 400/042US (MBH02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6160
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
; US-10-669-841-6160

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.3e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 735 GCGTCAGGTGGACCA 750
|||:|||||
Db 1 GCGUGAGGUGGCCA 16

RESULT 1049
US-10-669-841-6424/c
; Sequence 6424, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
; TITLE OF INVENTION: VIRUS REPLICATION
; FILE REFERENCE: 400/042US (MBH02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187

```

```

; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/359,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6424
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-6424

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 829 GGCCGAGTTCAGGTG 844
   ||| ||||| |||
Db 16 GGCGCAGTTCAGGTG 1

RESULT 1050
US-10-723-361-354/c
; Sequence 354, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 355
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-355

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 354
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-354

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 482 CTCGATCTCGAGAGGC 497
   ||| ||||| |||
Db 17 CTCGTTCTGAGAGGC 2

RESULT 1051
US-10-723-361-355/c
; Sequence 355, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10723361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 355
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-355

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

QY 482 CTCGATCTCAAGAGGC 497
Db 16 CTCGTCTCGAGAGC 1

RESULT 1052

US-10-723-361-672/c
; Sequence 672, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 672
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-672

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 233 GAAGAGTCTCTCTGG 248
Db 17 GATGAGTCTCTCTGG 2

RESULT 1053

US-10-723-361-673/c
; Sequence 673, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105

; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 673
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-673

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 233 GAAGAGTCTCTCTGG 248
Db 16 GATGAGTCTCTCTGG 1

RESULT 1054

US-10-723-361-1523/c
; Sequence 1523, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 1523
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-1523

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      846 CCTATCACCGCTCTT 861
Db      17 CCCATCACCTGCTCTT 2

RESULT 1055
US-10-723-361-1524/c
; Sequence 1524, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 1524
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-1524

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      846 CCTATCACCGCTCTT 861
Db      16 CCCATCACCTGCTCTT 1
```

RESULT 1056

US-10-723-361-1720/c
; Sequence 1720, Application US/10723361
; Publication No. US20040137589A1

; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN

; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 1720
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-1720

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 392 TTCCAGCCAGCCAGCAGA 407
Db 17 TTCTGAGCCAGCCAGA 2

RESULT 1057

US-10-723-361-1721/c
; Sequence 1721, Application US/10723361
; Publication No. US20040137589A1

; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108

```
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1721
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-723-361-1721

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 392 TTCCAGCCAGCCAGCA 407
DB 16 TTCTGAGCCAGCCAGA 1

RESULT 1058
US-10-723-361-1996/c
; Sequence 1996, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
```

```
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1996
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-723-361-1996

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 309 GCCTGGAGGAGCAATCA 324
DB 17 GCCTGGAGGAGCAATCA 2

RESULT 1059
US-10-723-361-1997/c
; Sequence 1997, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1997
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-723-361-1997

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 309 GCCTGGAGGAGCAATCA 324
DB 16 GCCTGGAGGAGCAATCA 1

RESULT 1060
```

US-10-723-361-6822/c
; Sequence 6822, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6822
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-6822

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 267 ACCTGCTTCAGAAC 282
Db 17 ACCTGCTTCAGAAAA 2

RESULT 1061
US-10-723-361-6890/c
; Sequence 6890, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6890
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-6890

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 306 GCTGCTGAGAGAA 321
Db 17 GCGCGCTGAGAGAA 2

RESULT 1062

US-10-723-361-6891/c
; Sequence 6891, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine


```
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 7697
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7697

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 828 TGGCCCGAGTTCGAGGT 843
Db 17 TGGCCCGAGTTCGAGGT 2

RESULT 1066
US-10-723-361-7699/c
; Sequence 7699, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 7699
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7699/c
```

```
; ORGANISM: Homo sapiens
US-10-723-361-7699

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 827 CTGGCCCGAGTTCGAGG 842
Db 16 CTGGCCCGAGTTCGAGG 1

RESULT 1067
US-10-723-361-7812
; Sequence 7812, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 7812
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7812

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 493 GAGGCGAGGAGGAGCAG 508
Db 2 GAAGCAAGAGGAGCAG 17

RESULT 1068
US-10-723-361-7814
; Sequence 7814, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
```

```
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 7814
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7814

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 494 AGCGAGAGGAGCAGG 509
DB 1 AAGCAAAGGAGCAGG 16

RESULT 1069
US-10-723-361-8033
; Sequence 8033, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8034
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8034
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8033
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8033

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 696 AGCTGGAGATCGAGCG 711
DB 2 AGCTGGAGATCGAGCG 17

RESULT 1070
US-10-723-361-8034
; Sequence 8034, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8034
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8034
```

```
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 696 AGCTGGAGATGCGC 711
Db 1 AGCTGGAGATGCGC 16

RESULT 1071
US-10-723-361-8423
; Sequence 8423, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR FILING DATE: US 09/866,108
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8423
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8423

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 491 AAGACGAGAGGAGC 506
Db 1 AAGACGAGAGGAGC 16

RESULT 1072
US-10-645-471A-22
; Sequence 22, Application US/10645471A
; Publication No. US20040171022A1
; GENERAL INFORMATION:
; APPLICANT: Ebbinhaus, Scot W.
; APPLICANT: Hurley, Laurence H.
; APPLICANT: Siddiqui-Jain, Adam
; APPLICANT: Memmott, Regan
; TITLE OF INVENTION: METHODS FOR REGULATING TRANSCRIPTION BY
```

```
; TITLE OF INVENTION: TARGETING QUADRUPLIX DNA
; FILE REFERENCE: 532232000500
; CURRENT APPLICATION NUMBER: US/10/645,471A
; CURRENT FILING DATE: 2003-08-20
; PRIOR APPLICATION NUMBER: 60/404,965
; PRIOR FILING DATE: 2002-08-20
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: oligonucleotide
US-10-645-471A-22

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 490 GAAGGCGCAGAGGAG 505
Db 2 GAAGGCGCAGAGGAG 17

RESULT 1073
US-10-681-074-351
; Sequence 351, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEC, ERIC B.
; APPLICANT: VAN BRABANT, ANJA
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; FILE REFERENCE: NaPro-18 US
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 351
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-351

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 364 GCGGAGCGCTCGAG 379
Db 2 GCGTGAAGCGCTTCGAG 17

RESULT 1074
US-10-681-074-352/c
; Sequence 352, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEC, ERIC B.
; APPLICANT: VAN BRABANT, ANJA
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; FILE REFERENCE: NaPro-18 US
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
```

```
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 352
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-352

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 364 GCGGAGCGCTCCGAG 379
DB 16 GCGTGAGCGCTTCGAG 1

RESULT 1075
US-10-681-074-1375/c
; Sequence 1375, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEIC, ERIC B.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; FILE REFERENCE: NaPro-18 US
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1375
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-1375

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 721 GCAGCAGCAGCAGC 736
DB 17 GCAGCAGCAGCTCCG 2

RESULT 1076
US-10-681-074-1376
; Sequence 1376, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEIC, ERIC B.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; FILE REFERENCE: NaPro-18 US
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1376
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
```

```
US-10-681-074-1376

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 721 GCAGCAGCAGCAGC 736
DB 1 GCAGCAGCAGCTCCG 16

RESULT 1077
US-10-681-074-3102
; Sequence 3102, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEIC, ERIC B.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; FILE REFERENCE: NaPro-18 US
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3102
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-3102

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 724 GCAGCAGCAGCAGCTGTG 739
DB 1 GCAGCAGCAGCAGCTGAG 16

RESULT 1078
US-10-681-074-3103/c
; Sequence 3103, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEIC, ERIC B.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; FILE REFERENCE: NaPro-18 US
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3103
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-3103

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 724 GCAGCAGCAGCAGCTGTG 739
```

```
Db 17 GCAGCAGCACATCGAG 2
|||||
RESULT 1079
US-10-681-074-3414
; Sequence 3414, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEC, ERIC B.
; APPLICANT: VAN BRABANT, ANJA
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; FILE REFERENCE: OLIGONUCLEOTIDE-DIRECTED NUCLEIC ACID SEQUENCE ALTERATION
; CURRENT APPLICATION NUMBER: US/10/681.074
; PRIOR FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3414
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-3414

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 757 CATCGAGGGCCAGAGC 772
|||||
Db 1 CATGCTGGCCAGAGC 16
|||||

RESULT 1080
US-10-681-074-3415/c
; Sequence 3415, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEC, ERIC B.
; APPLICANT: VAN BRABANT, ANJA
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; FILE REFERENCE: OLIGONUCLEOTIDE-DIRECTED NUCLEIC ACID SEQUENCE ALTERATION
; CURRENT APPLICATION NUMBER: US/10/681.074
; PRIOR FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3415
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-3415

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 757 CATCGAGGGCCAGAGC 772
|||||
Db 17 CATGCTGGCCAGAGC 2
|||||

RESULT 1081
US-10-498-462-65
; Sequence 65, Application US/10498462
```

```
; Publication No. US20040259175A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; CURRENT FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 65
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-65

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 672 GCGCGCCGAGCAGCA 687
|||||
Db 2 GCGCTGCGAGCAGCA 17
|||||

RESULT 1082
US-10-498-462-67
; Sequence 67, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; CURRENT FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 67
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-67

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 673 GCGCGCCGAGCAGCA 688
|||||
Db 1 GCGCTGCGAGCAGCA 16
|||||

RESULT 1083
US-10-498-462-70
; Sequence 70, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; CURRENT FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
```

; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 70
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-70

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 677 GCAGGCGAGCGCGC 692
DB 2 GCGAGCGAGCAGCG 17
|||||

RESULT 1084

US-10-498-462-72
; Sequence 72, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:

; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; CURRENT FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 72
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-72

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 678 CCAGCGAGCAGCGCGC 693
DB 1 CGAGCGAGCAGCGCG 16
|||||

RESULT 1085

US-10-498-462-2024
; Sequence 2024, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:

; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; CURRENT FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2024
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-2024

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 333 GAGATGCCATCCGGCA 348
DB 2 GAGATGCCATCCGCA 17
|||||

RESULT 1086

US-10-498-462-2026
; Sequence 2026, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:

; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; CURRENT FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2026
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-2026

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 334 AGATGCCATCCGGCAG 349
DB 1 AGATGCCATCCGCGAG 16
|||||

RESULT 1087

US-10-498-462-2111
; Sequence 2111, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:

; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; CURRENT FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2111
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-2111

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 413 GAGAAGGAGTTCCTCA 428
DB 2 GAGAGGAATGCCTCA 17
|||||

RESULT 1088

US-10-498-462-2114
; Sequence 2114, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:

```
; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; CURRENT FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 2114
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-2114

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      415 GAAGGAGTTCCTCATG 430
Db      1 GAAGGATGCTCATG 16
|||||
|||||

RESULT 1089
US-10-741-600-73370
; Sequence 73370, Application US/10741600
; Publication No. US20050026169A1
; GENERAL INFORMATION:
; APPLICANT: CARGILL, Michele et al.
; TITLE OF INVENTION: GENETIC POLYMORPHISMS ASSOCIATED WITH
; TITLE OF INVENTION: MYOCARDIAL INFARCTION, METHODS OF DETECTION AND USES THEREOF
; FILE REFERENCE: CL001493
; CURRENT APPLICATION NUMBER: US/10/741,600
; CURRENT FILING DATE: 2003-12-22
; NUMBER OF SEQ ID NOS: 73997
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 73370
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-741-600-73370

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      601 GGAGCTGCAGGAGC 616
Db      2 GGAGCTGCAGGTGATC 17
|||||
|||||

RESULT 1090
US-10-845-667-390/c
; Sequence 390, Application US/10845667
; Publication No. US20050026183A1
; GENERAL INFORMATION:
; APPLICANT: Fan, Jian-Bing
; APPLICANT: Bibikova, Marina
; TITLE OF INVENTION: Methods and Compositions For Diagnosing
; TITLE OF INVENTION: Conditions Associated With Specific DNA Methylation Patterns
; FILE REFERENCE: 67234-091
; CURRENT APPLICATION NUMBER: US/10/845,667
; CURRENT FILING DATE: 2004-05-14
; PRIOR APPLICATION NUMBER: 60/471,488
; PRIOR FILING DATE: 2003-05-15
; NUMBER OF SEQ ID NOS: 1506
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 390
; LENGTH: 17
; TYPE: DNA
```

```
; ORGANISM: Homo sapiens
US-10-845-667-390

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      811 GGAGGAGAGAGGAAG 826
Db      16 GGAGGAGACGAGGAG 1
|||||
|||||

Search completed: April 8, 2005, 08:52:46
Job time : 12 secs
```